article_title,journal_title,journal_abbre,article_date,abstract,article_type,pub_days,citation,abstract_clean,Breast Cancer,Lung Cancer,Leukemia,Prostate Cancer,Colorectal Cancer,Lymphoma,Bone Cancer,Melanoma,Liver Cancer,Kidney Cancer,Ovarian Cancer,Pancreatic Cancer,Brain Tumor,Head and Neck Cancer,Acute Myeloid Leukemia (AML),Multiple Myeloma,Sarcoma,Bladder Cancer,Skin Cancer,Gastric Cancer,Gastrointestinal Tumor,Endometrial Cancer,Acute Lymphoblastic Leukemia (ALL),Chronic Lymphocytic Leukemia (CLL),Cardiac Tumors,Cervical Cancer,Esophageal Cancer,Thyroid Cancer,Rectal Cancer,text_clean_seq,text_length,pmid,title_clean,bert_similarity_rank_myeloproliferative_neoplasms,bert_similarity_rank_myeloproliferative_neoplasms_percentile
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients.,Blood,Blood,2002-02-01,"Chronic myelomonocytic leukemia (CMML) is a hematologic malignancy characterized by wide heterogeneity of clinical presentation and course. CMML shares myelodysplastic characteristics with features of myeloproliferative disorders. No treatment has proven effective in modifying the natural course of the disease. To improve the prognostic assessment of clinical outcome, the associations of patient and disease characteristics with survival times of 213 patients with CMML was investigated retrospectively. Median survival was 12 months. Univariate analysis identified low hemoglobin level; low platelet count; high white blood cell, monocyte, and lymphocyte counts; presence of circulating immature myeloid cells, high percentage of marrow blasts, low percentage of marrow erythroid cells, abnormal cytogenetics, and high levels of serum lactate dehydrogenase and beta(2)-microglobulin as characteristics associated with shorter survival. Hemoglobin level below 120 g/L (12 g/dL), presence of circulating immature myeloid cells, absolute lymphocyte count above 2.5 x 10(9)/L, and marrow blasts 10% or more were independently associated with shorter survival by multivariate analysis and were used to generate a prognostic score. The model identified 4 subgroups of patients with median survival of 24, 15, 8, and 5 months for low, intermediate-1, intermediate-2, and high risk, respectively. Researchers could not confer objective evidence suggesting that arbitrary divisions of CMML by white blood cell counts into ""dysplastic"" and ""proliferative"" categories reflect clinical entities differing in the risk of acute leukemia development, although a trend of shorter survival in patients with leukocytosis was observed. The prognostic model was compared with 6 previously published scoring systems for myelodysplastic syndrome/CMML. The reported results should provide an improved assessment of prognosis in CMML.",Journal Article,6563.0,261.0,Chronic myelomonocytic leukemia CMML hematologic malignancy characterized wide heterogeneity clinical presentation course CMML shares myelodysplastic characteristics features myeloproliferative disorders treatment proven effective modifying natural course disease improve prognostic assessment clinical outcome associations patient disease characteristics survival times 213 patients CMML investigated retrospectively Median survival 12 months Univariate identified low hemoglobin level low platelet count high white blood monocyte lymphocyte counts presence circulating immature myeloid high percentage marrow blasts low percentage marrow erythroid abnormal cytogenetics high levels serum lactate dehydrogenase beta 2 -microglobulin characteristics associated shorter survival Hemoglobin level 120 g/L 12 g/dL presence circulating immature myeloid absolute lymphocyte count 2.5 x 10 9 /L marrow blasts 10 independently associated shorter survival multivariate generate prognostic score model identified 4 subgroups patients median survival 24 15 8 5 months low intermediate-1 intermediate-2 high risk respectively Researchers confer objective evidence suggesting arbitrary divisions CMML white blood counts `` dysplastic '' `` proliferative '' categories reflect clinical entities differing risk acute leukemia development trend shorter survival patients leukocytosis observed prognostic model compared 6 previously published scoring systems myelodysplastic syndrome/CMML reported provide improved assessment prognosis CMML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 5451, 3382, 16, 8, 813, 710, 765, 20, 1019, 1144, 1, 38, 1031, 2, 906, 3382, 10641, 374, 5, 404, 1, 1997, 77, 24, 71, 1930, 323, 4, 4898, 3, 1504, 906, 1, 3, 34, 6, 401, 3, 177, 455, 1, 38, 228, 3, 685, 1, 69, 2, 34, 374, 5, 25, 1072, 1, 5833, 7, 5, 3382, 10, 565, 894, 52, 25, 10, 133, 53, 880, 65, 108, 154, 2222, 301, 154, 1596, 1276, 64, 886, 315, 31, 5231, 2, 1448, 1911, 463, 1, 1033, 5733, 533, 37, 64, 1150, 1, 581, 2438, 154, 1150, 1, 581, 7839, 37, 1668, 2510, 2, 64, 148, 1, 524, 3330, 2374, 2, 1090, 18, 5371, 22, 374, 41, 5, 985, 25, 2222, 301, 2736, 2031, 499, 805, 133, 499, 1826, 463, 1, 1033, 5733, 533, 37, 1766, 1448, 1276, 2090, 18, 33, 1006, 79, 83, 805, 2, 581, 2438, 79, 15, 80, 11, 1042, 41, 5, 985, 25, 20, 331, 65, 2, 11, 95, 6, 2562, 8, 177, 368, 3, 202, 108, 39, 1453, 1, 7, 5, 52, 25, 1, 259, 167, 66, 2, 33, 53, 9, 154, 919, 14, 919, 18, 2, 64, 43, 106, 4211, 359, 44, 2913, 461, 241, 802, 17, 16183, 30191, 1, 3382, 20, 886, 315, 31, 1911, 237, 6461, 522, 2, 2441, 522, 1996, 2694, 38, 4613, 5276, 4, 3, 43, 1, 286, 193, 242, 8, 853, 1, 985, 25, 4, 7, 5, 7463, 10, 164, 3, 177, 202, 10, 72, 5, 49, 373, 983, 2504, 1530, 9, 681, 3382, 3, 210, 99, 257, 377, 35, 231, 455, 1, 356, 4, 3382]",1816.0,11806985,Prognostic factors scoring systems chronic myelomonocytic leukemia retrospective 213 patients,0,0.0
"Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2002-02-01,"To investigate the activity of a novel dioxolane L-nucleoside analog, troxacitabine (L-(-)-OddC, BCH-4556), in patients with refractory leukemia. Study participants were patients with refractory or relapsed acute myeloid (AML) or lymphocytic (ALL) leukemia, myelodysplastic syndromes (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP). Troxacitabine was provided as an intravenous infusion for more than 30 minutes daily for 5 days at a dose of 8.0 mg/m(2)/d (40 mg/m(2) per course). Courses were given every 3 to 4 weeks according to antileukemic efficacy. Forty-two patients (AML, 18 patients; MDS, one patient; ALL, six patients; CML-BP, 17 patients) were treated. Median age was 51 years (range, 23 to 80 years); 22 patients were male. Stomatitis was the most significant adverse event, with three patients (7%) and two patients (5%), respectively, experiencing grade 3 or 4 toxicity. Ten patients (24%) had grade 3 hand-foot syndrome, and two patients (5%) had grade 3 skin rash. One patient (2%) had grade 3 fatigue and anorexia. Marrow hypoplasia occurred between days 14 and 28 in 12 (75%) of 16 assessable patients with AML. Two complete remissions and one partial remission (18%) were observed in 16 assessable patients with AML. None of six patients with ALL responded. Six (37%) of 16 assessable patients with CML-BP experienced a return to chronic-phase disease. Troxacitabine has significant antileukemic activity in patients with AML and CML-BP.",Clinical Trial,6563.0,69.0,investigate activity novel dioxolane L-nucleoside analog troxacitabine L- -OddC BCH-4556 patients refractory leukemia participants patients refractory relapsed acute myeloid AML lymphocytic leukemia myelodysplastic syndromes MDS chronic myelogenous leukemia blastic phase CML-BP Troxacitabine provided intravenous infusion 30 minutes daily 5 days dose 8.0 mg/m 2 /d 40 mg/m 2 course Courses given 3 4 weeks according antileukemic efficacy Forty-two patients AML 18 patients MDS patient patients CML-BP 17 patients treated Median age 51 years range 23 80 years 22 patients male Stomatitis significant adverse event patients 7 patients 5 respectively experiencing grade 3 4 toxicity patients 24 grade 3 hand-foot syndrome patients 5 grade 3 skin rash patient 2 grade 3 fatigue anorexia Marrow hypoplasia occurred days 14 28 12 75 16 assessable patients AML complete remissions partial remission 18 observed 16 assessable patients AML patients responded 37 16 assessable patients CML-BP experienced return chronic-phase disease Troxacitabine significant antileukemic activity patients AML CML-BP,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[6, 963, 3, 128, 1, 8, 229, 42835, 805, 4032, 3497, 10949, 805, 52719, 52720, 37077, 4, 7, 5, 430, 45, 776, 11, 7, 5, 430, 15, 591, 286, 533, 329, 15, 1193, 62, 2040, 1223, 15, 442, 2194, 4, 6529, 124, 903, 3044, 10949, 10, 1052, 22, 35, 1262, 904, 9, 80, 76, 201, 2511, 391, 9, 33, 162, 28, 8, 61, 1, 66, 13, 81, 188, 18, 427, 327, 81, 188, 18, 379, 906, 1993, 11, 447, 454, 27, 6, 39, 244, 768, 6, 4512, 209, 1213, 100, 7, 329, 203, 7, 1223, 104, 69, 62, 437, 7, 903, 3044, 269, 7, 11, 73, 52, 89, 10, 725, 60, 184, 382, 6, 493, 60, 350, 7, 11, 1045, 4486, 10, 3, 96, 93, 290, 774, 5, 169, 7, 67, 2, 100, 7, 33, 106, 2985, 88, 27, 15, 39, 155, 1618, 7, 259, 42, 88, 27, 2833, 4100, 681, 2, 100, 7, 33, 42, 88, 27, 1641, 104, 69, 18, 42, 88, 27, 613, 2, 3373, 581, 20991, 489, 59, 162, 213, 2, 339, 4, 133, 481, 1, 245, 3120, 7, 5, 329, 100, 236, 3166, 2, 104, 450, 734, 203, 11, 164, 4, 245, 3120, 7, 5, 329, 1292, 1, 437, 7, 5, 62, 2211, 437, 567, 1, 245, 3120, 7, 5, 903, 3044, 592, 8, 4656, 6, 442, 124, 34, 10949, 71, 93, 4512, 128, 4, 7, 5, 329, 2, 903, 3044]",1351.0,11821445,Phase II troxacitabine novel dioxolane nucleoside analog patients refractory leukemia,1,0.0017452006980802793
Therapy-related acute myeloid leukemia/myelodysplasia with balanced 21q22 translocations.,American journal of clinical pathology,Am. J. Clin. Pathol.,2002-02-01,"The morphologic and immunophenotypic findings of 36 cases of 21q22 acute myeloid leukemia (AML) and myelodysplasia (MDS) were compared, including 14 de novo t(8;21) AMLs, 11 t(8;21) therapy-related AML/MDS cases, and 11 therapy-related AML/MDS cases with other 21q22 balanced translocations [t(n;21)]. Cases were evaluated for the presence of Auer rods, distinct chunky cytoplasmic blast cell granules, promyelocyte increase, cytoplasmic perinuclear clearing (hofs) of blast cells, eosinophil increase, andfeatures of associated trilineage dysplasia. Results of immunophenotyping studies for CD19, CD34, and CD56 expression were compared. Cases of de novo and therapy-related t(8;21) disease shared common morphologic features of chunky cytoplasmic granules, perinuclear hofs, and promyelocyte increases that were not seen consistently in the t(n;21) group of t-AML/MDS cases. Immunophenotypic similarities also were observed between the 2 t(8;21) groups. De novo and therapy-related t(8;21) disease, however, differed by the frequent presence of associated dysplasia in both t-AML/MDS groups, which was infrequent in the de novo t(8;21) group. Therapy-related AMI/MDS with t(8;21) shares characteristic morphologic and immunophenotypic features with de novo t(8;21) AML, but frequently also occurs with associated myelodysplastic changes, similar to other therapy-related acute leukemias.",Comparative Study,6563.0,15.0,morphologic immunophenotypic findings 36 cases 21q22 acute myeloid leukemia AML myelodysplasia MDS compared including 14 novo 8 21 AMLs 11 8 21 therapy-related AML/MDS cases 11 therapy-related AML/MDS cases 21q22 balanced translocations n 21 Cases evaluated presence Auer rods distinct chunky cytoplasmic blast granules promyelocyte increase cytoplasmic perinuclear clearing hofs blast eosinophil increase andfeatures associated trilineage dysplasia immunophenotyping studies CD19 CD34 CD56 expression compared Cases novo therapy-related 8 21 disease shared common morphologic features chunky cytoplasmic granules perinuclear hofs promyelocyte increases seen consistently n 21 group t-AML/MDS cases Immunophenotypic similarities observed 2 8 21 groups novo therapy-related 8 21 disease differed frequent presence associated dysplasia t-AML/MDS groups infrequent novo 8 21 group Therapy-related AMI/MDS 8 21 shares characteristic morphologic immunophenotypic features novo 8 21 AML frequently occurs associated myelodysplastic changes similar therapy-related acute leukemias,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2815, 2, 6599, 272, 1, 511, 140, 1, 14402, 286, 533, 329, 2, 6128, 1223, 11, 72, 141, 213, 1566, 2018, 102, 66, 239, 9542, 175, 102, 66, 239, 36, 139, 329, 1223, 140, 2, 175, 36, 139, 329, 1223, 140, 5, 127, 14402, 4115, 3262, 102, 78, 239, 140, 11, 194, 9, 3, 463, 1, 37099, 25984, 834, 42856, 2828, 3112, 31, 13766, 30209, 344, 2828, 18756, 17090, 42857, 1, 3112, 37, 14738, 344, 52764, 1, 41, 21950, 2253, 99, 1, 9416, 94, 9, 3158, 2215, 2, 5803, 55, 11, 72, 140, 1, 1566, 2018, 2, 36, 139, 102, 66, 239, 34, 2664, 186, 2815, 404, 1, 42856, 2828, 13766, 18756, 42857, 2, 30209, 1106, 17, 11, 44, 527, 2433, 4, 3, 102, 78, 239, 87, 1, 102, 329, 1223, 140, 6599, 6089, 120, 11, 164, 59, 3, 18, 102, 66, 239, 271, 1566, 2018, 2, 36, 139, 102, 66, 239, 34, 137, 2512, 20, 3, 908, 463, 1, 41, 2253, 4, 110, 102, 329, 1223, 271, 92, 10, 4475, 4, 3, 1566, 2018, 102, 66, 239, 87, 36, 139, 18158, 1223, 5, 102, 66, 239, 10641, 2037, 2815, 2, 6599, 404, 5, 1566, 2018, 102, 66, 239, 329, 84, 746, 120, 1780, 5, 41, 400, 288, 6, 127, 36, 139, 286, 2792]",1322.0,11863228,Therapy-related acute myeloid leukemia/myelodysplasia balanced 21q22 translocations,47,0.08202443280977312
Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2002-02-26,"The translocation t(8;21)(q22;q22) is one of the most frequent chromosome translocations in acute myeloid leukemia (AML). AML1/RUNX1 at 21q22 is involved in t(8;21), t(3;21), and t(16;21) in de novo and therapy-related AML and myelodysplastic syndrome as well as in t(12;21) in childhood B cell acute lymphoblastic leukemia. Although DNA breakpoints in AML1 and ETO (at 8q22) cluster in a few introns, the mechanisms of DNA recombination resulting in t(8;21) are unknown. The correlation of specific chromatin structural elements, i.e., topoisomerase II (topo II) DNA cleavage sites, DNase I hypersensitive sites, and scaffold-associated regions, which have been implicated in chromosome recombination with genomic DNA breakpoints in AML1 and ETO in t(8;21) is unknown. The breakpoints in AML1 and ETO were clustered in the Kasumi 1 cell line and in 31 leukemia patients with t(8;21); all except one had de novo AML. Sequencing of the breakpoint junctions revealed no common DNA motif; however, deletions, duplications, microhomologies, and nontemplate DNA were found. Ten in vivo topo II DNA cleavage sites were mapped in AML1, including three in intron 5 and seven in intron 7a, and two were in intron 1b of ETO. All strong topo II sites colocalized with DNase I hypersensitive sites and thus represent open chromatin regions. These sites correlated with genomic DNA breakpoints in both AML1 and ETO, thus implicating them in the de novo 8;21 translocation.",Journal Article,6538.0,86.0,translocation 8 21 q22 q22 frequent chromosome translocations acute myeloid leukemia AML AML1/RUNX1 21q22 involved 8 21 3 21 16 21 novo therapy-related AML myelodysplastic syndrome 12 21 childhood B acute lymphoblastic leukemia DNA breakpoints AML1 ETO 8q22 cluster introns mechanisms DNA recombination resulting 8 21 unknown correlation specific chromatin structural elements i.e. topoisomerase II topo II DNA cleavage sites DNase hypersensitive sites scaffold-associated regions implicated chromosome recombination genomic DNA breakpoints AML1 ETO 8 21 unknown breakpoints AML1 ETO clustered Kasumi 1 line 31 leukemia patients 8 21 novo AML Sequencing breakpoint junctions revealed common DNA motif deletions duplications microhomologies nontemplate DNA vivo topo II DNA cleavage sites mapped AML1 including intron 5 seven intron 7a intron 1b ETO strong topo II sites colocalized DNase hypersensitive sites represent open chromatin regions sites correlated genomic DNA breakpoints AML1 ETO implicating novo 8 21 translocation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 2006, 102, 66, 239, 8026, 8026, 16, 104, 1, 3, 96, 908, 1170, 3262, 4, 286, 533, 329, 6535, 6092, 28, 14402, 16, 646, 4, 102, 66, 239, 102, 27, 239, 2, 102, 245, 239, 4, 1566, 2018, 2, 36, 139, 329, 2, 681, 22, 149, 22, 4, 102, 133, 239, 4, 864, 132, 31, 286, 1275, 242, 261, 7843, 4, 6535, 2, 8566, 28, 42858, 3132, 4, 8, 1021, 12491, 3, 483, 1, 261, 4017, 1113, 4, 102, 66, 239, 32, 860, 3, 816, 1, 112, 2287, 3281, 2531, 70, 563, 3999, 215, 7852, 215, 261, 3155, 633, 21951, 70, 14077, 633, 2, 11547, 41, 1374, 92, 47, 85, 1771, 4, 1170, 4017, 5, 572, 261, 7843, 4, 6535, 2, 8566, 4, 102, 66, 239, 16, 860, 3, 7843, 4, 6535, 2, 8566, 11, 6464, 4, 3, 18159, 14, 31, 328, 2, 4, 456, 7, 5, 102, 66, 239, 62, 2187, 104, 42, 1566, 2018, 329, 615, 1, 3, 8567, 10262, 553, 77, 186, 261, 5298, 137, 2439, 8910, 52765, 2, 52766, 261, 11, 204, 1618, 4, 386, 7852, 215, 261, 3155, 633, 11, 6224, 4, 6535, 141, 169, 4, 6259, 33, 2, 648, 4, 6259, 8730, 2, 100, 11, 4, 6259, 4693, 1, 8566, 62, 1082, 7852, 215, 633, 16625, 5, 21951, 70, 14077, 633, 2, 631, 1231, 1020, 2287, 1374, 46, 633, 438, 5, 572, 261, 7843, 4, 110, 6535, 2, 8566, 631, 7912, 1370, 4, 3, 1566, 2018, 66, 239, 2006]",1375.0,11867721,Genomic DNA breakpoints AML1/RUNX1 ETO cluster topoisomerase II DNA cleavage DNase hypersensitive sites 8 21 leukemia,18,0.031413612565445025
21q22 balanced chromosome aberrations in therapy-related hematopoietic disorders: report from an international workshop.,"Genes, chromosomes & cancer",Genes Chromosomes Cancer,2002-04-01,"The International Workshop on the relationship between prior therapy and balanced chromosome aberrations in therapy-related myelodysplastic syndromes (t-MDS) and therapy-related acute leukemia (t-AL) identified 79 of 511 (15.5%) patients with balanced 21q22 translocations. Patients were treated for their primary disease, including solid tumors (56%), hematologic malignancy (43%), and juvenile rheumatoid arthritis (single case), by radiation therapy (5 patients), chemotherapy (36 patients), or combined-modality therapy (38 patients). 21q translocations involved common partner chromosomes in 81% of cases: t(8;21) (n = 44; 56%), t(3;21) (n = 16; 20%), and t(16;21) (n = 4; 5%). Translocations involving 15 other partner chromosomes were also documented with involvement of AML1(CBFA2/RUNX1), identifying a total of 23 different 21q22/AML1 translocations. The data analysis was carried out on the basis of five subsets of 21q22 cases, that is, t(8;21) with and without additional aberrations, t(3;21), t(16;21), and other 21q22 translocations. Dysplastic features were present in all 21q22 cases. Therapy-related acute myeloid leukemia (t-AML) at presentation was highest in t(8;21) (82%) and lowest in t(3;21) (37.5%) patients. Cumulative drug dose exposure scores for alkylating agents (AAs) and topoisomerase II inhibitors indicated that t(3;21) patients received the most intensive therapy among the five 21q22 subsets, and the median AA score for patients with secondary chromosome 7 aberrations was double the AA score for the entire 21q22 group. All five patients who received only radiation therapy had t(8;21) t-AML. The median latency and overall survival (OS) for 21q22 patients were 39 and 14 months (mo), compared to 26 and 8 mo for 11q23 patients, 22 and 28 mo for inv(16), 69 and 7 mo for Rare recurring aberrations, and 59 and 7 mo for Unique (nonrecurring) balanced aberration (latency P < or = 0.016 for all pairwise comparisons; OS, P < or = 0.018 for all pairwise comparisons). The percentages of 21q22 patients surviving 1 year, 2 years, and 5 years were 58%, 33%, and 18%, respectively. Noticeable differences were observed in median OS between 21q22 patients (n = 7) receiving transplant (BMT) (31 mo) compared to 21q22 patients who received intensive non-BMT therapy (n = 46) (17 mo); however, this was nonsignificant because of the small sample size (log-rank, P = 0.33). t-MDS/t-AML with balanced 21q22 aberrations was associated with prior exposure to radiation, epipodophyllotoxins, and anthracyclines, dysplastic morphologic features, multiple partner chromosomes, and longer latency periods when compared to 11q23 and inv(16) t-MDS/AML Workshop subgroups. In general, patients could be divided into two prognostic risk groups, those with t(8;21) (median OS, 19 mo) and those without t(8;21) (median OS, 7 mo) leukemia (log-rank, P = 0.0007).",Congress,6504.0,76.0,International Workshop relationship prior therapy balanced chromosome aberrations therapy-related myelodysplastic syndromes t-MDS therapy-related acute leukemia t-AL identified 79 511 15.5 patients balanced 21q22 translocations Patients treated primary disease including solid 56 hematologic malignancy 43 juvenile rheumatoid arthritis single case radiation therapy 5 patients chemotherapy 36 patients combined-modality therapy 38 patients 21q translocations involved common partner chromosomes 81 cases 8 21 n 44 56 3 21 n 16 20 16 21 n 4 5 Translocations involving 15 partner chromosomes documented involvement AML1 CBFA2/RUNX1 identifying total 23 different 21q22/AML1 translocations carried basis subsets 21q22 cases 8 21 additional aberrations 3 21 16 21 21q22 translocations Dysplastic features present 21q22 cases Therapy-related acute myeloid leukemia t-AML presentation highest 8 21 82 lowest 3 21 37.5 patients Cumulative drug dose exposure scores alkylating agents AAs topoisomerase II inhibitors indicated 3 21 patients received intensive therapy 21q22 subsets median AA score patients secondary chromosome 7 aberrations double AA score entire 21q22 group patients received radiation therapy 8 21 t-AML median latency overall survival OS 21q22 patients 39 14 months mo compared 26 8 mo 11q23 patients 22 28 mo inv 16 69 7 mo Rare recurring aberrations 59 7 mo Unique nonrecurring balanced aberration latency P 0.016 pairwise comparisons OS P 0.018 pairwise comparisons percentages 21q22 patients surviving 1 year 2 years 5 years 58 33 18 respectively Noticeable differences observed median OS 21q22 patients n 7 receiving transplant BMT 31 mo compared 21q22 patients received intensive non-BMT therapy n 46 17 mo nonsignificant small size log-rank P 0.33 t-MDS/t-AML balanced 21q22 aberrations associated prior exposure radiation epipodophyllotoxins anthracyclines dysplastic morphologic features multiple partner chromosomes longer latency periods compared 11q23 inv 16 t-MDS/AML Workshop subgroups general patients divided prognostic risk groups 8 21 median OS 19 mo 8 21 median OS 7 mo leukemia log-rank P 0.0007,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 944, 4014, 23, 3, 858, 59, 324, 36, 2, 4115, 1170, 2152, 4, 36, 139, 2040, 102, 1223, 2, 36, 139, 286, 102, 2171, 108, 842, 1, 10532, 167, 33, 7, 5, 4115, 14402, 3262, 7, 11, 73, 9, 136, 86, 34, 141, 537, 57, 664, 813, 710, 601, 2, 7857, 12269, 8646, 226, 473, 20, 121, 36, 33, 7, 56, 511, 7, 15, 397, 1396, 36, 519, 7, 25998, 3262, 646, 186, 4852, 3560, 4, 865, 1, 140, 102, 66, 239, 78, 584, 664, 102, 27, 239, 78, 245, 179, 2, 102, 245, 239, 78, 39, 33, 3262, 1267, 167, 127, 4852, 3560, 11, 120, 1405, 5, 799, 1, 6535, 33205, 6092, 1386, 8, 181, 1, 382, 338, 14402, 6535, 3262, 3, 74, 65, 10, 2629, 1205, 23, 3, 877, 1, 365, 1890, 1, 14402, 140, 17, 16, 102, 66, 239, 5, 2, 187, 402, 2152, 102, 27, 239, 102, 245, 239, 2, 127, 14402, 3262, 6461, 404, 11, 364, 4, 62, 14402, 140, 36, 139, 286, 533, 102, 329, 28, 1031, 10, 1076, 4, 102, 66, 239, 878, 2, 2101, 4, 102, 27, 239, 567, 33, 7, 967, 234, 61, 645, 703, 9, 3410, 183, 7632, 2, 3999, 215, 222, 1103, 17, 102, 27, 239, 7, 103, 3, 96, 1686, 36, 107, 3, 365, 14402, 1890, 2, 3, 52, 1519, 368, 9, 7, 5, 568, 1170, 67, 2152, 10, 1627, 3, 1519, 368, 9, 3, 1797, 14402, 87, 62, 365, 7, 54, 103, 158, 121, 36, 42, 102, 66, 239, 102, 329, 3, 52, 5301, 2, 63, 25, 118, 9, 14402, 7, 11, 587, 2, 213, 53, 2035, 72, 6, 432, 2, 66, 2035, 9, 7975, 7, 350, 2, 339, 2035, 9, 6397, 245, 790, 2, 67, 2035, 9, 622, 6385, 2152, 2, 728, 2, 67, 2035, 9, 991, 37071, 4115, 7794, 5301, 19, 15, 13, 3820, 9, 62, 8716, 2213, 118, 19, 15, 13, 4047, 9, 62, 8716, 2213, 3, 5504, 1, 14402, 7, 3050, 14, 111, 18, 60, 2, 33, 60, 11, 717, 466, 2, 203, 106, 21011, 362, 11, 164, 4, 52, 118, 59, 14402, 7, 78, 67, 357, 941, 4611, 456, 2035, 72, 6, 14402, 7, 54, 103, 1686, 220, 4611, 36, 78, 641, 269, 2035, 137, 26, 10, 5542, 408, 1, 3, 302, 1000, 444, 1066, 1026, 19, 13, 466, 102, 1223, 102, 329, 5, 4115, 14402, 2152, 10, 41, 5, 324, 645, 6, 121, 25999, 2, 3597, 6461, 2815, 404, 232, 4852, 3560, 2, 589, 5301, 3338, 198, 72, 6, 7975, 2, 6397, 245, 102, 1223, 329, 4014, 1453, 4, 1083, 7, 359, 40, 2176, 237, 100, 177, 43, 271, 135, 5, 102, 66, 239, 52, 118, 326, 2035, 2, 135, 187, 102, 66, 239, 52, 118, 67, 2035, 1066, 1026, 19, 13, 6626]",2668.0,11921272,21q22 balanced chromosome aberrations therapy-related hematopoietic disorders report international workshop,22,0.038394415357766144
Balanced chromosome abnormalities inv(16) and t(15;17) in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop.,"Genes, chromosomes & cancer",Genes Chromosomes Cancer,2002-04-01,"The Workshop identified 48 unselected patients with therapy-related myelodysplastic syndrome or acute myeloid leukemia (t-MDS/t-AML) and inv(16), and 41 patients with t(15;17) after chemotherapy (CT) and/or radiotherapy (RT) for a malignant or nonmalignant disease. The primary diseases were: breast cancer, 33 patients; lymphomas, 24 patients; various other solid tumors, 30 patients; and nonmalignant diseases, 2 patients. The general type of previous therapy was RT only in 10 patients with an inv(16) and in 12 patients with a t(15;17), alkylating agents plus topoisomerase II inhibitors in 24 patients with an inv(16) and in 18 patients with a t(15;17), topoisomerase II inhibitors only in 5 patients with an inv(16) and in 2 patients with a t(15;17), alkylating agents only in 6 patients in each subgroup, and other types of chemotherapy in 3 patients in each subgroup. Most CT-treated patients (69%) also received RT. The latency period to development of t-MDS/t-AML was short: a median of 22 months in patients with inv(16) and 29 months in patients with t(15;17). Twenty-six patients (54%) with an inv(16) and 17 patients (41%) with a t(15;17) had additional cytogenetic abnormalities, which were unrelated to age and survival in both subgroups. Trisomy of chromosomes 8, 21, and 22 and del(7q) were the most frequent additional abnormalities in the inv(16) subgroup, whereas +8, -5, and del(16q) were most frequent in the t(15;17) subgroup. The disease was overt t-AML in 38/48 patients (79%) with an inv(16) and in 38/41 patients (93%) with a t(15;17). Thirty-three of 39 intensively treated patients (85%) with an inv(16) obtained a complete remission, whereas 24 of 35 intensively treated patients (69%) with a t(15;17) obtained a complete remission. The median overall survival of intensively treated patients was 29 months in both cytogenetic subgroups. In the inv(16) subgroup, patients younger than 55 years of age had a longer survival when compared with older patients (P = 0.006). The study supports the observation that t-MDS/t-AML with inv(16) and t(15;17) is often associated with prior therapy with topoisomerase II inhibitors; however, a notable finding was the high frequency of treatment with only radiotherapy, 29% of t(15;17) and 21% of inv(16). Response rates to intensive chemotherapy in this study were comparable to those of de novo disease.",Congress,6504.0,113.0,Workshop identified 48 unselected patients therapy-related myelodysplastic syndrome acute myeloid leukemia t-MDS/t-AML inv 16 41 patients 15 17 chemotherapy CT and/or radiotherapy RT malignant nonmalignant disease primary diseases breast 33 patients lymphomas 24 patients solid 30 patients nonmalignant diseases 2 patients general type previous therapy RT 10 patients inv 16 12 patients 15 17 alkylating agents plus topoisomerase II inhibitors 24 patients inv 16 18 patients 15 17 topoisomerase II inhibitors 5 patients inv 16 2 patients 15 17 alkylating agents 6 patients subgroup types chemotherapy 3 patients subgroup CT-treated patients 69 received RT latency period development t-MDS/t-AML short median 22 months patients inv 16 29 months patients 15 17 Twenty-six patients 54 inv 16 17 patients 41 15 17 additional cytogenetic abnormalities unrelated age survival subgroups Trisomy chromosomes 8 21 22 del 7q frequent additional abnormalities inv 16 subgroup +8 -5 del 16q frequent 15 17 subgroup disease overt t-AML 38/48 patients 79 inv 16 38/41 patients 93 15 17 Thirty-three 39 intensively treated patients 85 inv 16 obtained complete remission 24 35 intensively treated patients 69 15 17 obtained complete remission median overall survival intensively treated patients 29 months cytogenetic subgroups inv 16 subgroup patients younger 55 years age longer survival compared older patients P 0.006 supports observation t-MDS/t-AML inv 16 15 17 associated prior therapy topoisomerase II inhibitors notable finding high frequency treatment radiotherapy 29 15 17 21 inv 16 Response rates intensive chemotherapy comparable novo disease,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 4014, 108, 576, 3594, 7, 5, 36, 139, 681, 15, 286, 533, 102, 1223, 102, 329, 2, 6397, 245, 2, 605, 7, 5, 102, 167, 269, 50, 56, 425, 2, 15, 310, 240, 9, 8, 393, 15, 5967, 34, 3, 86, 1342, 11, 12, 466, 7, 1557, 259, 7, 747, 127, 537, 57, 201, 7, 2, 5967, 1342, 18, 7, 3, 1083, 267, 1, 698, 36, 10, 240, 158, 4, 79, 7, 5, 35, 6397, 245, 2, 4, 133, 7, 5, 8, 102, 167, 269, 3410, 183, 349, 3999, 215, 222, 4, 259, 7, 5, 35, 6397, 245, 2, 4, 203, 7, 5, 8, 102, 167, 269, 3999, 215, 222, 158, 4, 33, 7, 5, 35, 6397, 245, 2, 4, 18, 7, 5, 8, 102, 167, 269, 3410, 183, 158, 4, 49, 7, 4, 296, 1363, 2, 127, 630, 1, 56, 4, 27, 7, 4, 296, 1363, 96, 425, 73, 7, 790, 120, 103, 240, 3, 5301, 727, 6, 193, 1, 102, 1223, 102, 329, 10, 978, 8, 52, 1, 350, 53, 4, 7, 5, 6397, 245, 2, 462, 53, 4, 7, 5, 102, 167, 269, 737, 437, 7, 667, 5, 35, 6397, 245, 2, 269, 7, 605, 5, 8, 102, 167, 269, 42, 402, 1266, 1171, 92, 11, 2092, 6, 89, 2, 25, 4, 110, 1453, 6317, 1, 3560, 66, 239, 2, 350, 2, 3084, 9723, 11, 3, 96, 908, 402, 1171, 4, 3, 6397, 245, 1363, 547, 66, 33, 2, 3084, 14410, 11, 96, 908, 4, 3, 102, 167, 269, 1363, 3, 34, 10, 7192, 102, 329, 4, 519, 576, 7, 842, 5, 35, 6397, 245, 2, 4, 519, 605, 7, 966, 5, 8, 102, 167, 269, 977, 169, 1, 587, 13240, 73, 7, 772, 5, 35, 6397, 245, 683, 8, 236, 734, 547, 259, 1, 465, 13240, 73, 7, 790, 5, 8, 102, 167, 269, 683, 8, 236, 734, 3, 52, 63, 25, 1, 13240, 73, 7, 10, 462, 53, 4, 110, 1266, 1453, 4, 3, 6397, 245, 1363, 7, 773, 76, 614, 60, 1, 89, 42, 8, 589, 25, 198, 72, 5, 434, 7, 19, 13, 1861, 3, 45, 2304, 3, 1664, 17, 102, 1223, 102, 329, 5, 6397, 245, 2, 102, 167, 269, 16, 629, 41, 5, 324, 36, 5, 3999, 215, 222, 137, 8, 4090, 1567, 10, 3, 64, 675, 1, 24, 5, 158, 310, 462, 1, 102, 167, 269, 2, 239, 1, 6397, 245, 51, 151, 6, 1686, 56, 4, 26, 45, 11, 1279, 6, 135, 1, 1566, 2018, 34]",2246.0,11921273,Balanced chromosome abnormalities inv 16 15 17 therapy-related myelodysplastic syndromes acute leukemia report international workshop,40,0.06980802792321117
Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2002-04-01,"The aromatic fatty acid sodium phenylbutyrate (PB) promotes cytostasis and differentiation in a wide variety of tumor types; among several molecular activities, inhibition of histone deacetylase (HDAC) may account for many of its pharmacodynamic effects. A Phase I study demonstrated promising preliminary evidence of clinical activity in acute myeloid leukemia and myelodysplastic syndrome; however, plasma concentrations achieved at the maximum tolerated dose were less than those targeted based on in vitro studies. Because prolonged exposure to suboptimal concentrations of PB in vitro led to pharmacodynamic changes similar to a more brief exposure to higher concentrations, a study of the feasibility of prolonged administration of sodium PB was performed. Selected patients with acute myeloid leukemia and myelodysplastic syndrome were treated with sodium PB as a continuous i.v. infusion via ambulatory infusion pump. Sequential cohorts were treated for 7 consecutive days out of 14 or with 21 consecutive days out of 28. Prolonged infusions were well tolerated; dose-limiting central nervous system toxicity developed in 1 of 23 patients treated. End-of-infusion plasma concentrations were maintained within a range sufficient to inhibit HDAC. Two patients on the 21/28 schedule developed hematological improvement. Prolonged infusions of PB are well tolerated making this an attractive platform for the clinical investigation of HDAC inhibition.",Clinical Trial,6504.0,153.0,aromatic fatty acid sodium phenylbutyrate PB promotes cytostasis differentiation wide variety types molecular activities inhibition histone deacetylase HDAC account pharmacodynamic effects Phase demonstrated promising preliminary evidence clinical activity acute myeloid leukemia myelodysplastic syndrome plasma concentrations achieved maximum tolerated dose targeted based vitro studies prolonged exposure suboptimal concentrations PB vitro led pharmacodynamic changes similar brief exposure higher concentrations feasibility prolonged administration sodium PB performed Selected patients acute myeloid leukemia myelodysplastic syndrome treated sodium PB continuous i.v infusion ambulatory infusion pump Sequential cohorts treated 7 consecutive days 14 21 consecutive days 28 Prolonged infusions tolerated dose-limiting central nervous toxicity developed 1 23 patients treated End-of-infusion plasma concentrations maintained range sufficient inhibit HDAC patients 21/28 schedule developed hematological improvement Prolonged infusions PB tolerated making attractive platform clinical investigation HDAC inhibition,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 14060, 4038, 971, 4682, 21969, 3767, 2148, 27874, 2, 910, 4, 8, 1019, 1362, 1, 30, 630, 107, 392, 219, 2042, 297, 1, 1508, 2732, 2654, 68, 1967, 9, 445, 1, 211, 2424, 176, 8, 124, 70, 45, 264, 721, 1676, 241, 1, 38, 128, 4, 286, 533, 2, 681, 137, 554, 1003, 513, 28, 3, 689, 421, 61, 11, 299, 76, 135, 238, 90, 23, 4, 439, 94, 408, 1069, 645, 6, 3291, 1003, 1, 3767, 4, 439, 836, 6, 2424, 400, 288, 6, 8, 80, 3190, 645, 6, 142, 1003, 8, 45, 1, 3, 1437, 1, 1069, 634, 1, 4682, 3767, 10, 173, 715, 7, 5, 286, 533, 2, 681, 11, 73, 5, 4682, 3767, 22, 8, 1314, 70, 603, 904, 847, 4154, 904, 6320, 1787, 736, 11, 73, 9, 67, 935, 162, 1205, 1, 213, 15, 5, 239, 935, 162, 1205, 1, 339, 1069, 3435, 11, 149, 421, 61, 817, 854, 1880, 398, 155, 276, 4, 14, 1, 382, 7, 73, 396, 1, 904, 554, 1003, 11, 1955, 262, 8, 184, 1952, 6, 1433, 2654, 100, 7, 23, 3, 239, 339, 1055, 276, 2890, 767, 1069, 3435, 1, 3767, 32, 149, 421, 1079, 26, 35, 3059, 2243, 9, 3, 38, 940, 1, 2654, 297]",1385.0,11948101,Impact prolonged infusions putative differentiating agent sodium phenylbutyrate myelodysplastic syndromes acute myeloid leukemia,190,0.33158813263525305
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2002-05-01,"Patients with high-risk myelodysplastic syndrome (MDS) have high mortality from bone marrow failure or transformation to acute leukemia. Supportive care is standard therapy. We previously reported that azacitidine (Aza C) was active in patients with high-risk MDS. A randomized controlled trial was undertaken in 191 patients with MDS to compare Aza C (75 mg/m(2)/d subcutaneously for 7 days every 28 days) with supportive care. MDS was defined by French-American-British criteria. New rigorous response criteria were applied. Both arms received transfusions and antibiotics as required. Patients in the supportive care arm whose disease worsened were permitted to cross over to Aza C. Responses occurred in 60% of patients on the Aza C arm (7% complete response, 16% partial response, 37% improved) compared with 5% (improved) receiving supportive care (P <.001). Median time to leukemic transformation or death was 21 months for Aza C versus 13 months for supportive care (P =.007). Transformation to acute myelogenous leukemia occurred as the first event in 15% of patients on the Aza C arm and in 38% receiving supportive care (P =.001). Eliminating the confounding effect of early cross-over to Aza C, a landmark analysis after 6 months showed median survival of an additional 18 months for Aza C and 11 months for supportive care (P =.03). Quality-of-life assessment found significant major advantages in physical function, symptoms, and psychological state for patients initially randomized to Aza C. Aza C treatment results in significantly higher response rates, improved quality of life, reduced risk of leukemic transformation, and improved survival compared with supportive care. Aza C provides a new treatment option that is superior to supportive care for patients with the MDS subtypes and specific entry criteria treated in this study.",Clinical Trial,6474.0,1350.0,Patients high-risk myelodysplastic syndrome MDS high mortality bone marrow failure transformation acute leukemia Supportive care standard therapy previously reported azacitidine Aza C active patients high-risk MDS randomized controlled trial undertaken 191 patients MDS compare Aza C 75 mg/m 2 /d subcutaneously 7 days 28 days supportive care MDS defined French-American-British criteria New rigorous response criteria applied arms received transfusions antibiotics required Patients supportive care arm disease worsened permitted cross Aza C. Responses occurred 60 patients Aza C arm 7 complete response 16 partial response 37 improved compared 5 improved receiving supportive care P .001 Median time leukemic transformation death 21 months Aza C versus 13 months supportive care P =.007 Transformation acute myelogenous leukemia occurred event 15 patients Aza C arm 38 receiving supportive care P =.001 Eliminating confounding effect early cross-over Aza C landmark 6 months showed median survival additional 18 months Aza C 11 months supportive care P =.03 Quality-of-life assessment significant major advantages physical function symptoms psychological state patients initially randomized Aza C. Aza C treatment significantly higher response rates improved quality life reduced risk leukemic transformation improved survival compared supportive care Aza C provides new treatment option superior supportive care patients MDS subtypes specific entry criteria treated,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7, 5, 64, 43, 681, 1223, 47, 64, 282, 29, 581, 496, 15, 1392, 6, 286, 1877, 165, 16, 260, 36, 21, 373, 210, 17, 3752, 3924, 256, 10, 544, 4, 7, 5, 64, 43, 1223, 8, 384, 1149, 160, 10, 2789, 4, 6130, 7, 5, 1223, 6, 932, 3924, 256, 481, 81, 188, 18, 427, 3928, 9, 67, 162, 454, 339, 162, 5, 1877, 165, 1223, 10, 395, 20, 9254, 597, 11754, 371, 217, 6496, 51, 371, 11, 1498, 110, 1335, 103, 4987, 2, 5214, 22, 616, 7, 4, 3, 1877, 165, 475, 1310, 34, 5890, 11, 5449, 6, 1383, 252, 6, 3924, 256, 253, 489, 4, 335, 1, 7, 23, 3, 3924, 256, 475, 67, 236, 51, 245, 450, 51, 567, 231, 72, 5, 33, 231, 357, 1877, 165, 19, 144, 52, 98, 6, 2015, 1392, 15, 273, 10, 239, 53, 9, 3924, 256, 185, 233, 53, 9, 1877, 165, 19, 1999, 1392, 6, 286, 2194, 489, 22, 3, 157, 774, 4, 167, 1, 7, 23, 3, 3924, 256, 475, 2, 4, 519, 357, 1877, 165, 19, 144, 6923, 3, 4339, 254, 1, 191, 1383, 252, 6, 3924, 256, 8, 3829, 65, 50, 49, 53, 224, 52, 25, 1, 35, 402, 203, 53, 9, 3924, 256, 2, 175, 53, 9, 1877, 165, 19, 680, 372, 1, 358, 455, 204, 93, 458, 3126, 4, 900, 343, 507, 2, 2624, 1309, 9, 7, 1625, 384, 6, 3924, 256, 3924, 256, 24, 99, 4, 97, 142, 51, 151, 231, 372, 1, 358, 405, 43, 1, 2015, 1392, 2, 231, 25, 72, 5, 1877, 165, 3924, 256, 777, 8, 217, 24, 1501, 17, 16, 1123, 6, 1877, 165, 9, 7, 5, 3, 1223, 814, 2, 112, 3001, 371, 73, 4, 26, 45]",1765.0,12011120,Randomized controlled trial azacitidine patients myelodysplastic syndrome leukemia group B,26,0.04537521815008726
Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2002-05-01,"The impact of azacytidine (Aza C) on the quality of life of 191 patients with myelodysplastic syndrome was assessed in a phase III Cancer and Leukemia Group B trial (9221). One hundred ninety-one patients (mean age, 67.5 years; 69% male) were randomized to receive either Aza C (75 mg/m(2) subcutaneous for 7 days every 4 weeks) or supportive care, with supportive care patients crossing over to Aza C upon disease progression. Quality of life was assessed by centrally conducted telephone interviews at baseline and days 50, 106, and 182. Overall quality of life, psychological state, and social functioning were assessed by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire C30 and the Mental Health Inventory (MHI). Patients on the Aza C arm experienced significantly greater improvement in fatigue (EORTC, P =.001), dyspnea (EORTC, P =.0014), physical functioning (EORTC, P =.0002), positive affect (MHI, P =.0077), and psychological distress (MHI, P =.015) over the course of the study period than those in the supportive care arm. Particularly striking were improvements in fatigue and psychological state (MHI) in patients treated with Aza C compared with those receiving supportive care for patients who remained on study through at least day 106, corresponding to four cycles of Aza C. Significant differences between the two groups in quality of life were maintained even after controlling for the number of RBC transfusions. Improved quality of life for patients treated with Aza C coupled with significantly greater treatment response and delayed time to transformation to acute myeloid leukemia or death compared with patients on supportive care (P <.001) establishes Aza C as an important treatment option for myelodysplastic syndrome.",Clinical Trial,6474.0,312.0,impact azacytidine Aza C quality life 191 patients myelodysplastic syndrome assessed phase III Leukemia Group B trial 9221 ninety-one patients mean age 67.5 years 69 male randomized receive Aza C 75 mg/m 2 subcutaneous 7 days 4 weeks supportive care supportive care patients crossing Aza C disease progression Quality life assessed centrally conducted telephone interviews baseline days 50 106 182 Overall quality life psychological state social functioning assessed European Organization Research Treatment EORTC Quality Life Questionnaire C30 Mental Health Inventory MHI Patients Aza C arm experienced significantly greater improvement fatigue EORTC P =.001 dyspnea EORTC P =.0014 physical functioning EORTC P =.0002 positive affect MHI P =.0077 psychological distress MHI P =.015 course period supportive care arm Particularly striking improvements fatigue psychological state MHI patients treated Aza C compared receiving supportive care patients remained day 106 corresponding cycles Aza C. Significant differences groups quality life maintained controlling number RBC transfusions Improved quality life patients treated Aza C coupled significantly greater treatment response delayed time transformation acute myeloid leukemia death compared patients supportive care P .001 establishes Aza C important treatment option myelodysplastic syndrome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 345, 1, 11755, 3924, 256, 23, 3, 372, 1, 358, 1, 6130, 7, 5, 681, 10, 275, 4, 8, 124, 316, 12, 2, 87, 132, 160, 42926, 104, 1128, 2493, 104, 7, 313, 89, 598, 33, 60, 790, 1045, 11, 384, 6, 560, 361, 3924, 256, 481, 81, 188, 18, 2529, 9, 67, 162, 454, 39, 244, 15, 1877, 165, 5, 1877, 165, 7, 15117, 252, 6, 3924, 256, 1548, 34, 91, 372, 1, 358, 10, 275, 20, 4604, 426, 4258, 4053, 28, 330, 2, 162, 212, 3251, 2, 5160, 63, 372, 1, 358, 2624, 1309, 2, 2032, 2702, 11, 275, 20, 3, 1865, 2533, 9, 389, 2, 24, 1, 12, 4359, 372, 1, 358, 1770, 6273, 2, 3, 3031, 341, 3818, 15118, 7, 23, 3, 3924, 256, 475, 592, 97, 378, 767, 4, 613, 4359, 19, 144, 2923, 4359, 19, 11408, 900, 2702, 4359, 19, 3531, 109, 1158, 15118, 19, 18176, 2, 2624, 1462, 15118, 19, 3433, 252, 3, 906, 1, 3, 45, 727, 76, 135, 4, 3, 1877, 165, 475, 823, 5133, 11, 1474, 4, 613, 2, 2624, 1309, 15118, 4, 7, 73, 5, 3924, 256, 72, 5, 135, 357, 1877, 165, 9, 7, 54, 958, 23, 45, 298, 28, 506, 218, 3251, 1734, 6, 294, 410, 1, 3924, 256, 93, 362, 59, 3, 100, 271, 4, 372, 1, 358, 11, 1955, 871, 50, 1893, 9, 3, 207, 1, 7256, 4987, 231, 372, 1, 358, 9, 7, 73, 5, 3924, 256, 3332, 5, 97, 378, 24, 51, 2, 1612, 98, 6, 1392, 6, 286, 533, 15, 273, 72, 5, 7, 23, 1877, 165, 19, 144, 7410, 3924, 256, 22, 35, 305, 24, 1501, 9, 681]",1697.0,12011121,Impact azacytidine quality life patients myelodysplastic syndrome treated randomized phase III trial Leukemia Group B,1,0.0017452006980802793
"Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.",Blood,Blood,2002-06-01,"We investigated treatment with gemtuzumab ozogamicin (GO) in 51 patients aged 65 years or older with newly diagnosed acute myeloid leukemia (AML), refectory anemia (RA) with excess of blasts in transformation, or RA with excess blasts. GO was given in doses of 9 mg/m(2) of body-surface area on days 1 and 8 or, therapeutically equivalently, on days 1 and 15, with or without interleukin 11 (IL-11; 15 microg/kg per day on days 3 to 28), with assignment to IL-11 treatment made randomly. Complete remission (CR) rates were 2 of 26 (8%) for GO without IL-11 and 9 of 25 (36%) for GO with IL-11. Regression analyses indicated that IL-11 was independently predictive of CR but not survival. We compared GO with or without IL-11 with idarubicin plus cytosine arabinoside (IA), as previously administered, in similar patients. The CR rate with IA was 15 of 31 (48%), and survival was superior with IA compared with GO with or without IL-11 (P =.03). Besides accounting for possible covariate effects on outcome, we also accounted for possible trial effects (TEs) arising because IA and GO with or without IL-11 were not arms of a randomized trial. Bayesian posterior probabilities that GO with or without IL-11 produced longer survival than IA, after accounting for covariates and TEs, were less than 0.01 in patients with abnormal cytogenetic findings (AC) and less than 0.15 in patients with normal cytogenetic findings (NC). Regarding CR, the analogous probabilities were less than 0.02 for GO without IL-11 (all cytogenetic groups), and for GO with IL-11, less than 0.25 for AC groups and about 0.50 for NC groups. TEs 2 to 5 times the magnitude of those previously observed would be needed to conclude that survival with GO with or without IL-11 is likely longer than with IA. Thus, there is little evidence to suggest that GO with or without IL-11 should be used instead of IA in older patients with newly diagnosed AML or myelodysplastic syndrome.",Clinical Trial,6443.0,119.0,investigated treatment gemtuzumab ozogamicin 51 patients aged 65 years older newly diagnosed acute myeloid leukemia AML refectory anemia RA excess blasts transformation RA excess blasts given doses 9 mg/m 2 body-surface area days 1 8 therapeutically equivalently days 1 15 interleukin 11 IL-11 15 microg/kg day days 3 28 assignment IL-11 treatment randomly Complete remission CR rates 2 26 8 IL-11 9 25 36 IL-11 Regression indicated IL-11 independently predictive CR survival compared IL-11 idarubicin plus cytosine arabinoside IA previously administered similar patients CR rate IA 15 31 48 survival superior IA compared IL-11 P =.03 accounting possible covariate effects outcome accounted possible trial effects TEs arising IA IL-11 arms randomized trial Bayesian posterior probabilities IL-11 produced longer survival IA accounting covariates TEs 0.01 patients abnormal cytogenetic findings AC 0.15 patients normal cytogenetic findings NC CR analogous probabilities 0.02 IL-11 cytogenetic groups IL-11 0.25 AC groups 0.50 NC groups TEs 2 5 times magnitude previously observed needed conclude survival IL-11 likely longer IA little evidence suggest IL-11 instead IA older patients newly diagnosed AML myelodysplastic syndrome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 565, 24, 5, 7918, 5566, 3537, 4, 725, 7, 1032, 556, 60, 15, 434, 5, 732, 265, 286, 533, 329, 52935, 1545, 4631, 5, 2612, 1, 2438, 4, 1392, 15, 4631, 5, 2612, 2438, 3537, 10, 447, 4, 415, 1, 83, 81, 188, 18, 1, 642, 1255, 965, 23, 162, 14, 2, 66, 15, 4602, 27900, 23, 162, 14, 2, 167, 5, 15, 187, 1603, 175, 501, 175, 167, 2440, 503, 379, 218, 23, 162, 27, 6, 339, 5, 4392, 6, 501, 175, 24, 1229, 1108, 236, 734, 684, 151, 11, 18, 1, 432, 66, 9, 3537, 187, 501, 175, 2, 83, 1, 243, 511, 9, 3537, 5, 501, 175, 320, 318, 1103, 17, 501, 175, 10, 1042, 464, 1, 684, 84, 44, 25, 21, 72, 3537, 5, 15, 187, 501, 175, 5, 5684, 349, 6903, 11563, 3302, 22, 373, 468, 4, 288, 7, 3, 684, 116, 5, 3302, 10, 167, 1, 456, 576, 2, 25, 10, 1123, 5, 3302, 72, 5, 3537, 5, 15, 187, 501, 175, 19, 680, 7301, 3116, 9, 899, 6322, 176, 23, 228, 21, 120, 3688, 9, 899, 160, 176, 21037, 2635, 408, 3302, 2, 3537, 5, 15, 187, 501, 175, 11, 44, 1335, 1, 8, 384, 160, 5032, 3028, 3518, 17, 3537, 5, 15, 187, 501, 175, 1687, 589, 25, 76, 3302, 50, 3116, 9, 2489, 2, 21037, 11, 299, 76, 13, 355, 4, 7, 5, 1668, 1266, 272, 1948, 2, 299, 76, 13, 167, 4, 7, 5, 295, 1266, 272, 5480, 666, 684, 3, 8579, 3518, 11, 299, 76, 13, 588, 9, 3537, 187, 501, 175, 62, 1266, 271, 2, 9, 3537, 5, 501, 175, 299, 76, 13, 243, 9, 1948, 271, 2, 545, 13, 212, 9, 5480, 271, 21037, 18, 6, 33, 1072, 3, 3131, 1, 135, 373, 164, 688, 40, 575, 6, 2060, 17, 25, 5, 3537, 5, 15, 187, 501, 175, 16, 322, 589, 76, 5, 3302, 631, 125, 16, 1215, 241, 6, 309, 17, 3537, 5, 15, 187, 501, 175, 257, 40, 95, 3496, 1, 3302, 4, 434, 7, 5, 732, 265, 329, 15, 681]",1864.0,12036860,Gemtuzumab ozogamicin interleukin 11 patients 65 years age older untreated acute myeloid leukemia high-risk myelodysplastic syndrome comparison idarubicin plus continuous-infusion high-dose cytosine arabinoside,30,0.05235602094240838
Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.,British journal of haematology,Br. J. Haematol.,2002-07-01,"We have previously reported that high levels of cellular vascular endothelial growth factor (VEGF) protein correlated with short survival of patients with acute myeloid leukaemia (AML). As VEGF exerts its effects via two receptors, VEGF receptor 1 (VEGFR-1) and VEGFR-2, we evaluated the significance of VEGFR-1 and VEGFR-2 protein levels in AML and myelodysplastic syndrome (MDS), and their relationship to VEGF protein levels. Western blot analysis and radioimmunoassay confirmed and quantified specific protein levels in bone marrow samples from 41 MDS and 66 AML previously untreated patients. VEGFR-1 levels were significantly higher in AML than in MDS (P = 0.0004), but no significant difference was found in the VEGFR-2 levels (P = 0.5). No significant correlation between VEGFRs levels and duration of survival was found. VEGF protein levels were significantly higher in MDS than in AML (P < 0.0001). A Cox proportional-hazard regression model showed increasing VEGF levels to significantly correlate with shorter survival of patients with MDS (P = 0.008), a finding similar to our previous report of the inverse relationship between VEGF levels and survival of AML patients. We found a significant correlation between VEGF and VEGFR-2 levels in both AML and MDS (P < 0.0000001 andP < 0.0002 respectively) but not between VEGF and VEGFR-1 levels. These data suggest that VEGF expression, rather than the expression of its receptors, is the determining factor in the biological behaviour of AML and MDS, and that VEGFRs are differentially expressed in AML and MDS.",Journal Article,6413.0,54.0,previously reported high levels cellular vascular endothelial growth factor VEGF correlated short survival patients acute myeloid leukaemia AML VEGF exerts effects receptors VEGF receptor 1 VEGFR-1 VEGFR-2 evaluated significance VEGFR-1 VEGFR-2 levels AML myelodysplastic syndrome MDS relationship VEGF levels Western blot radioimmunoassay confirmed quantified specific levels bone marrow 41 MDS 66 AML previously untreated patients VEGFR-1 levels significantly higher AML MDS P 0.0004 significant difference VEGFR-2 levels P 0.5 significant correlation VEGFRs levels duration survival VEGF levels significantly higher MDS AML P 0.0001 Cox proportional-hazard regression model showed increasing VEGF levels significantly correlate shorter survival patients MDS P 0.008 finding similar previous report inverse relationship VEGF levels survival AML patients significant correlation VEGF VEGFR-2 levels AML MDS P 0.0000001 andP 0.0002 respectively VEGF VEGFR-1 levels suggest VEGF expression expression receptors determining factor behaviour AML MDS VEGFRs differentially expressed AML MDS,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 47, 373, 210, 17, 64, 148, 1, 763, 756, 845, 129, 161, 618, 178, 438, 5, 978, 25, 1, 7, 5, 286, 533, 2001, 329, 22, 618, 5685, 211, 176, 847, 100, 1186, 618, 153, 14, 2134, 14, 2, 2134, 18, 21, 194, 3, 724, 1, 2134, 14, 2, 2134, 18, 178, 148, 4, 329, 2, 681, 1223, 2, 136, 858, 6, 618, 178, 148, 1521, 2639, 65, 2, 18157, 557, 2, 2790, 112, 178, 148, 4, 581, 347, 29, 605, 1223, 2, 700, 329, 373, 1278, 7, 2134, 14, 148, 11, 97, 142, 4, 329, 76, 4, 1223, 19, 13, 5295, 84, 77, 93, 523, 10, 204, 4, 3, 2134, 18, 148, 19, 13, 33, 77, 93, 816, 59, 15864, 148, 2, 654, 1, 25, 10, 204, 618, 178, 148, 11, 97, 142, 4, 1223, 76, 4, 329, 19, 13, 488, 8, 418, 831, 360, 320, 202, 224, 602, 618, 148, 6, 97, 1513, 5, 985, 25, 1, 7, 5, 1223, 19, 13, 2155, 8, 1567, 288, 6, 114, 698, 414, 1, 3, 2931, 858, 59, 618, 148, 2, 25, 1, 329, 7, 21, 204, 8, 93, 816, 59, 618, 2, 2134, 18, 148, 4, 110, 329, 2, 1223, 19, 13, 37214, 53001, 13, 3531, 106, 84, 44, 59, 618, 2, 2134, 14, 148, 46, 74, 309, 17, 618, 55, 1832, 76, 3, 55, 1, 211, 1186, 16, 3, 2196, 161, 4, 3, 1037, 8173, 1, 329, 2, 1223, 2, 17, 15864, 32, 2478, 570, 4, 329, 2, 1223]",1503.0,12100142,Clinical relevance vascular endothelial growth factor receptors 1 2 acute myeloid leukaemia myelodysplastic syndrome,6,0.010471204188481676
The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution.,The hematology journal : the official journal of the European Haematology Association,Hematol. J.,2002-01-01,"Although retrospective analysis were frequently undertaken, and many prognostic systems for myelodysplastic syndromes (MDS) have been proposed worldwide, few such studies have been performed and the effectiveness of different scoring systems have not yet been verified in independent patient populations in China. The aim of this single center study was to evaluate the prognostic factors and compare the prognostic scoring systems in Chinese patients with MDS. One hundred and twenty-eight patients diagnosed as primary MDS in our Institution were studied retrospectively to identify significant prognostic factors and to assess the predictive value of 11 previously described prognostic systems, including French-American-British (FAB) classification, World Health Organization (WHO) classification, Mufti, Sanz, Morra, Aul, Oguma, Toyama, Morel and international prognostic scoring system (IPSS). The median age of the patients was 50 years (range 13-82). The 2- and 5-year survival rate of the patients were 55.22+/-4.90% and 26.09+/-6.36% respectively, with a median survival of 31 months (range 1-127 months). Fifty patients (39.1%) had progressed to acute leukemia (AL) with a median time of 8 months (range 1-43 months). Major independent variables indicated by multivariate analysis were the percentage of bone marrow (BM) blast cells and complex karyotype aberrations for survival (P=0.042 and 0.042, respectively) and only the percentage of BM blast cells for AL transformation (P=0.023). All the systems except Mufti scores successfully discriminated risk groups concerning both survival and AL evolution, especially in the high risk group, ranging from 10 to 20 months and from 4 to 7 months, respectively. The FAB and WHO classification, as well as Sanz, Oguma, Morel and IPSS possessed lower P value (P<0.0001) than that of the rest scoring systems. The patients in our study were younger than these of the Western population, whereas the survival and AL transformation ratio were comparable to these previous studies. The BM blast proportion and complex chromosomal defects were highly significant for predicting outcome in MDS patients. Most investigated systems effectively stratified patients into groups with different life expectancies and identified a subset of patients with poor clinical outcome. The FAB, WHO classification, as well as Sanz, Oguma, Morel and IPSS scoring systems were more applicable for predicting survival and leukemia progression.",Comparative Study,6594.0,16.0,retrospective frequently undertaken prognostic systems myelodysplastic syndromes MDS proposed worldwide studies performed effectiveness different scoring systems verified independent patient populations China aim single center evaluate prognostic factors compare prognostic scoring systems Chinese patients MDS twenty-eight patients diagnosed primary MDS Institution studied retrospectively identify significant prognostic factors assess predictive value 11 previously described prognostic systems including French-American-British FAB classification World Health Organization classification Mufti Sanz Morra Aul Oguma Toyama Morel international prognostic scoring IPSS median age patients 50 years range 13-82 2- 5-year survival rate patients 55.22+/-4.90 26.09+/-6.36 respectively median survival 31 months range 1-127 months patients 39.1 progressed acute leukemia median time 8 months range 1-43 months Major independent variables indicated multivariate percentage bone marrow BM blast complex karyotype aberrations survival P=0.042 0.042 respectively percentage BM blast transformation P=0.023 systems Mufti scores successfully discriminated risk groups concerning survival evolution especially high risk group ranging 10 20 months 4 7 months respectively FAB classification Sanz Oguma Morel IPSS possessed lower P value P 0.0001 rest scoring systems patients younger Western population survival transformation ratio comparable previous studies BM blast proportion complex chromosomal defects highly significant predicting outcome MDS patients investigated systems effectively stratified patients groups different life expectancies identified subset patients poor clinical outcome FAB classification Sanz Oguma Morel IPSS scoring systems applicable predicting survival leukemia progression,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[242, 459, 65, 11, 746, 2789, 2, 445, 177, 1530, 9, 2040, 1223, 47, 85, 1587, 2358, 1021, 225, 94, 47, 85, 173, 2, 3, 1236, 1, 338, 2504, 1530, 47, 44, 1145, 85, 4815, 4, 306, 69, 1184, 4, 5055, 3, 1130, 1, 26, 226, 574, 45, 10, 6, 376, 3, 177, 130, 2, 932, 3, 177, 2504, 1530, 4, 3656, 7, 5, 1223, 104, 1128, 2, 737, 659, 7, 265, 22, 86, 1223, 4, 114, 731, 11, 656, 894, 6, 255, 93, 177, 130, 2, 6, 423, 3, 464, 549, 1, 175, 373, 1027, 177, 1530, 141, 9254, 597, 11754, 9075, 947, 1956, 341, 2533, 54, 947, 42985, 37220, 53019, 53020, 37221, 53021, 37222, 2, 944, 177, 2504, 398, 8751, 3, 52, 89, 1, 3, 7, 10, 212, 60, 184, 233, 878, 3, 18, 2, 33, 111, 25, 116, 1, 3, 7, 11, 614, 350, 39, 424, 2, 432, 1730, 49, 511, 106, 5, 8, 52, 25, 1, 456, 53, 184, 14, 4080, 53, 1461, 7, 587, 14, 42, 1839, 6, 286, 2171, 5, 8, 52, 98, 1, 66, 53, 184, 14, 601, 53, 458, 306, 682, 1103, 20, 331, 65, 11, 3, 1150, 1, 581, 1246, 3112, 37, 2, 840, 3385, 2152, 9, 25, 19, 13, 5606, 2, 13, 5606, 106, 2, 158, 3, 1150, 1, 1246, 3112, 37, 9, 2171, 1392, 19, 13, 4482, 62, 3, 1530, 2187, 42985, 703, 1878, 8752, 43, 271, 4243, 110, 25, 2, 2171, 2554, 1093, 4, 3, 64, 43, 87, 2223, 29, 79, 6, 179, 53, 2, 29, 39, 6, 67, 53, 106, 3, 9075, 2, 54, 947, 22, 149, 22, 37220, 37221, 37222, 2, 8751, 10966, 280, 19, 549, 19, 13, 488, 76, 17, 1, 3, 3677, 2504, 1530, 3, 7, 4, 114, 45, 11, 773, 76, 46, 1, 3, 1521, 266, 547, 3, 25, 2, 2171, 1392, 197, 11, 1279, 6, 46, 698, 94, 3, 1246, 3112, 920, 2, 840, 1860, 2945, 11, 561, 93, 9, 1434, 228, 4, 1223, 7, 96, 565, 1530, 1856, 1173, 7, 237, 271, 5, 338, 358, 15505, 2, 108, 8, 697, 1, 7, 5, 334, 38, 228, 3, 9075, 54, 947, 22, 149, 22, 37220, 37221, 37222, 2, 8751, 2504, 1530, 11, 80, 3801, 9, 1434, 25, 2, 91]",2370.0,12111649,myelodysplastic syndromes prognostic factors comparison prognostic systems 128 Chinese patients single institution,0,0.0
TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies.,Expert review of anticancer therapy,Expert Rev Anticancer Ther,2002-06-01,"Tumor necrosis factor (TNF)-alpha is a major effector and regulatory cytokine with a pleiotropic role in the pathogenesis of several immune-regulated diseases, including graft versus host disease (GVHD) and hematologic malignancies, such as multiple myeloma (MM), myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Curative treatment for the above diseases are not currently available for most patients. Therapeutic approaches inactivating or blocking TNF-alpha are being evaluated in clinical trials. This review describes the development of the soluble TNF-alpha receptor (p75 TNF-R: Fc; etanercept) and other agents inactivating or blocking TNF-alpha in the management of patients with hematologic malignancies. The satisfactory safety profile of etanercept--as demonstrated in patients with autoimmune diseases--has been confirmed in patients with hematologic malignancies and GVHD. Studies to assess whether etanercept, either as a single agent or in combination with cytotoxic and/or immune therapy, may increase response rates and/or survival in patients with MM, MDS, AML and other hematologic malignancies are now warranted.",Journal Article,6443.0,26.0,necrosis factor TNF -alpha major effector regulatory cytokine pleiotropic role pathogenesis immune-regulated diseases including graft versus host disease GVHD hematologic malignancies multiple myeloma MM myelodysplastic syndrome MDS acute myelogenous leukemia AML Curative treatment diseases currently available patients Therapeutic approaches inactivating blocking TNF-alpha evaluated clinical trials review describes development soluble TNF-alpha receptor p75 TNF-R Fc etanercept agents inactivating blocking TNF-alpha management patients hematologic malignancies satisfactory safety profile etanercept -- demonstrated patients autoimmune diseases -- confirmed patients hematologic malignancies GVHD Studies assess etanercept single agent combination cytotoxic and/or immune therapy increase response rates and/or survival patients MM MDS AML hematologic malignancies warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[30, 1523, 161, 2254, 950, 16, 8, 458, 2070, 2, 1253, 1675, 5, 8, 7872, 200, 4, 3, 1384, 1, 392, 250, 1065, 1342, 141, 1599, 185, 1204, 34, 1562, 2, 813, 441, 225, 22, 232, 321, 681, 1223, 2, 286, 2194, 329, 1075, 24, 9, 3, 2090, 1342, 32, 44, 694, 390, 9, 96, 7, 189, 611, 6096, 15, 2521, 2254, 950, 32, 486, 194, 4, 38, 143, 26, 206, 2677, 3, 193, 1, 3, 2968, 2254, 950, 153, 22004, 2254, 668, 4127, 12527, 2, 127, 183, 6096, 15, 2521, 2254, 950, 4, 3, 284, 1, 7, 5, 813, 441, 3, 7972, 367, 800, 1, 12527, 22, 264, 4, 7, 5, 3445, 1342, 71, 85, 557, 4, 7, 5, 813, 441, 2, 1562, 94, 6, 423, 317, 12527, 361, 22, 8, 226, 420, 15, 4, 150, 5, 759, 2, 15, 250, 36, 68, 344, 51, 151, 2, 15, 25, 4, 7, 5, 321, 1223, 329, 2, 127, 813, 441, 32, 1134, 1197]",1096.0,12113051,TNF-alpha targeted therapeutic approaches patients hematologic malignancies,5,0.008726003490401396
"Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2002-07-01,"DX-8951f is a novel hexacyclic camptothecin-analogue topoisomerase I inhibitor with both in vitro antileukemic activity and myelosuppression as a dose-limiting toxicity in solid tumor Phase I studies. DX-8951f is active in a human acute myeloid leukemia (AML) severe combined immunodeficient mouse model. In a leukemia Phase I study, we investigated the toxicity profile and pharmacokinetics of DX-8951f in patients with primary refractory or relapsed AML or acute lymphocytic leukemia, myelodysplastic syndromes, or chronic myelogenous leukemia in blastic phase (CML-BP). DX-8951f was given as an i.v. infusion over 30 min daily for 5 or 7 days. The starting dose was 0.6 mg/m(2)/day for 5 days (3.0 mg/m(2)/course). Courses were given every 3-4 weeks according to toxicity and antileukemic efficacy. Twenty-five patients (AML, 21 patients; myelodysplastic syndrome, 1 patient; acute lymphocytic leukemia, 2 patients; CML-BP, 1 patient) were treated. Stomatitis was the dose-limiting toxicity, occurring in two of two patients treated at 1.35 mg/m(2)/day for 5 days, two of three treated at 1.2 mg/m(2)/day for 5 days, and one of six treated at 0.9 mg/m(2)/day for 7 days. The recommended Phase II dose was 0.9 mg/m(2)/day for 5 days. The pharmacokinetics of DX-8951 was linear and well fit by a two-compartment model. Phase II studies are warranted to further define the activity of DX-8951f in patients with hematological malignancies.",Clinical Trial,6413.0,24.0,DX-8951f novel hexacyclic camptothecin-analogue topoisomerase inhibitor vitro antileukemic activity myelosuppression dose-limiting toxicity solid Phase studies DX-8951f active human acute myeloid leukemia AML severe combined immunodeficient mouse model leukemia Phase investigated toxicity profile pharmacokinetics DX-8951f patients primary refractory relapsed AML acute lymphocytic leukemia myelodysplastic syndromes chronic myelogenous leukemia blastic phase CML-BP DX-8951f given i.v infusion 30 min daily 5 7 days starting dose 0.6 mg/m 2 /day 5 days 3.0 mg/m 2 /course Courses given 3-4 weeks according toxicity antileukemic efficacy Twenty-five patients AML 21 patients myelodysplastic syndrome 1 patient acute lymphocytic leukemia 2 patients CML-BP 1 patient treated Stomatitis dose-limiting toxicity occurring patients treated 1.35 mg/m 2 /day 5 days treated 1.2 mg/m 2 /day 5 days treated 0.9 mg/m 2 /day 7 days recommended Phase II dose 0.9 mg/m 2 /day 5 days pharmacokinetics DX-8951 linear fit two-compartment model Phase II studies warranted define activity DX-8951f patients hematological malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4946, 16242, 16, 8, 229, 37223, 6968, 4696, 3999, 70, 230, 5, 110, 4, 439, 4512, 128, 2, 2858, 22, 8, 61, 817, 155, 4, 537, 30, 124, 70, 94, 4946, 16242, 16, 544, 4, 8, 171, 286, 533, 329, 905, 397, 5031, 830, 202, 4, 8, 124, 70, 45, 21, 565, 3, 155, 800, 2, 1159, 1, 4946, 16242, 4, 7, 5, 86, 430, 15, 591, 329, 15, 286, 1193, 2040, 15, 442, 2194, 4, 6529, 124, 903, 3044, 4946, 16242, 10, 447, 22, 35, 70, 603, 904, 252, 201, 1538, 391, 9, 33, 15, 67, 162, 3, 1723, 61, 10, 13, 49, 81, 188, 18, 218, 9, 33, 162, 27, 13, 81, 188, 18, 906, 1993, 11, 447, 454, 27, 39, 244, 768, 6, 155, 2, 4512, 209, 737, 365, 7, 329, 239, 7, 681, 14, 69, 286, 1193, 18, 7, 903, 3044, 14, 69, 11, 73, 4486, 10, 3, 61, 817, 155, 1821, 4, 100, 1, 100, 7, 73, 28, 14, 465, 81, 188, 18, 218, 9, 33, 162, 100, 1, 169, 73, 28, 14, 18, 81, 188, 18, 218, 9, 33, 162, 2, 104, 1, 437, 73, 28, 13, 83, 81, 188, 18, 218, 9, 67, 162, 3, 793, 124, 215, 61, 10, 13, 83, 81, 188, 18, 218, 9, 33, 162, 3, 1159, 1, 4946, 24479, 10, 1646, 2, 149, 2975, 20, 8, 100, 3616, 202, 124, 215, 94, 32, 1197, 6, 195, 1107, 3, 128, 1, 4946, 16242, 4, 7, 5, 2890, 441]",1328.0,12114413,Phase pharmacokinetic DX-8951f exatecan mesylate hexacyclic camptothecin daily-times-five schedule patients advanced leukemia,0,0.0
"Myelodysplastic syndrome is not merely ""preleukemia"".",Blood,Blood,2002-08-01,"Myelodysplastic syndrome (MDS) is a disease characterized by ineffective hematopoiesis. There are significant biologic and clinical differences between MDS and acute myeloid leukemia (AML). We studied a cohort of 802 patients, 279 (35%) with newly diagnosed MDS and 523 (65%) with newly diagnosed AML, and compared clinical and biologic characteristics of the 2 groups. Complete clinical and cytogenetic data were available on all patients, and a subgroup of patients was studied for apoptosis, angiogenesis, proliferation, and growth factors. Our results demonstrate that MDS is a discrete entity that is different from AML and is characterized primarily by increased apoptosis in early and mature hematopoietic cells. Using cell sorting and loss of heterozygosity, we demonstrate that the leukemic cells from MDS patients are capable of differentiation into mature myeloid cells and monocytes. We also demonstrate that there is a significant overlap between AML and MDS when MDS is defined on the basis of an arbitrary percentage of blasts of 20% or 30%. These data suggest that despite similarities between AML and MDS in their responses to treatment and outcomes, MDS is biologically and clinically different from AML and should not be considered an early phase of AML. The data indicate that MDS must be better defined on the basis of its biology rather than the percentage of blasts; further, the data suggest that there is a need to develop therapeutic approaches that specifically address the biologic abnormalities of MDS.",Comparative Study,6382.0,109.0,Myelodysplastic syndrome MDS disease characterized ineffective hematopoiesis significant biologic clinical differences MDS acute myeloid leukemia AML studied cohort 802 patients 279 35 newly diagnosed MDS 523 65 newly diagnosed AML compared clinical biologic characteristics 2 groups Complete clinical cytogenetic available patients subgroup patients studied apoptosis angiogenesis proliferation growth factors demonstrate MDS discrete entity different AML characterized primarily increased apoptosis early mature hematopoietic sorting loss heterozygosity demonstrate leukemic MDS patients capable differentiation mature myeloid monocytes demonstrate significant overlap AML MDS MDS defined basis arbitrary percentage blasts 20 30 suggest despite similarities AML MDS responses treatment outcomes MDS biologically clinically different AML considered early phase AML indicate MDS better defined basis percentage blasts suggest need develop therapeutic approaches specifically address biologic abnormalities MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[681, 1223, 16, 8, 34, 765, 20, 3957, 5114, 125, 32, 93, 1283, 2, 38, 362, 59, 1223, 2, 286, 533, 329, 21, 656, 8, 180, 1, 15135, 7, 8562, 465, 5, 732, 265, 1223, 2, 10674, 556, 5, 732, 265, 329, 2, 72, 38, 2, 1283, 374, 1, 3, 18, 271, 236, 38, 2, 1266, 74, 11, 390, 23, 62, 7, 2, 8, 1363, 1, 7, 10, 656, 9, 351, 1056, 457, 2, 129, 130, 114, 99, 608, 17, 1223, 16, 8, 5447, 2983, 17, 16, 338, 29, 329, 2, 16, 765, 1561, 20, 101, 351, 4, 191, 2, 2908, 1007, 37, 75, 31, 6751, 2, 407, 1, 3963, 21, 608, 17, 3, 2015, 37, 29, 1223, 7, 32, 2787, 1, 910, 237, 2908, 533, 37, 2, 5078, 21, 120, 608, 17, 125, 16, 8, 93, 4526, 59, 329, 2, 1223, 198, 1223, 16, 395, 23, 3, 877, 1, 35, 16183, 1150, 1, 2438, 1, 179, 15, 201, 46, 74, 309, 17, 550, 6089, 59, 329, 2, 1223, 4, 136, 253, 6, 24, 2, 123, 1223, 16, 2665, 2, 505, 338, 29, 329, 2, 257, 44, 40, 515, 35, 191, 124, 1, 329, 3, 74, 1008, 17, 1223, 1642, 40, 380, 395, 23, 3, 877, 1, 211, 891, 1832, 76, 3, 1150, 1, 2438, 195, 3, 74, 309, 17, 125, 16, 8, 594, 6, 690, 189, 611, 17, 1225, 1539, 3, 1283, 1171, 1, 1223]",1475.0,12130488,Myelodysplastic syndrome merely `` preleukemia '',35,0.06108202443280977
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.,Haematologica,Haematologica,2002-08-01,"Early studies have suggested that increasing doses of anthracycline improve outcome in younger patients with acute myelogenous leukemia (AML), but dose escalation has been precluded by the acute and chronic toxicities of these agents. Amifostine is a cytoprotective compound that has been shown to protect against the acute cytotoxicities of anthracyclines in animal models. We report the results of a phase I study of dose escalation of idarubicin with amifostine and high-dose ara-C in patients with relapsed or refractory AML or myelodysplastic syndrome (MDS). The continuous reassessment method was used to predict the probability of toxicity. Five patients were treated at an idarubicin dose of 18 mg/m2/day x 3, three of whom developed grade 3 diarrhea or mucositis. Subsequently, three additional patients were treated at a dose of 15 mg/m2 x 3 days, all of whom experienced grade 3 diarrhea or mucositis. One patient achieved complete remission (CR rate 12.5%, 95% CI 0-0.52%). The addition of amifostine does not allow dose escalation of idarubicin when combined with high-dose ara-C.",Clinical Trial,6382.0,7.0,Early studies suggested increasing doses anthracycline improve outcome younger patients acute myelogenous leukemia AML dose escalation precluded acute chronic toxicities agents Amifostine cytoprotective compound shown protect acute cytotoxicities anthracyclines animal models report phase dose escalation idarubicin amifostine high-dose ara-C patients relapsed refractory AML myelodysplastic syndrome MDS continuous reassessment predict probability toxicity patients treated idarubicin dose 18 mg/m2/day x 3 developed grade 3 diarrhea mucositis Subsequently additional patients treated dose 15 mg/m2 x 3 days experienced grade 3 diarrhea mucositis patient achieved complete remission CR rate 12.5 95 CI 0-0.52 addition amifostine allow dose escalation idarubicin combined high-dose ara-C,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[191, 94, 47, 1148, 17, 602, 415, 1, 2044, 401, 228, 4, 773, 7, 5, 286, 2194, 329, 84, 61, 1125, 71, 85, 8035, 20, 3, 286, 2, 442, 385, 1, 46, 183, 5369, 16, 8, 10677, 2823, 17, 71, 85, 443, 6, 4869, 480, 3, 286, 33273, 1, 3597, 4, 2026, 274, 21, 414, 3, 99, 1, 8, 124, 70, 45, 1, 61, 1125, 1, 5684, 5, 5369, 2, 64, 61, 3899, 256, 4, 7, 5, 591, 15, 430, 329, 15, 681, 1223, 3, 1314, 8756, 596, 10, 95, 6, 678, 3, 1320, 1, 155, 365, 7, 11, 73, 28, 35, 5684, 61, 1, 203, 81, 821, 218, 1006, 27, 169, 1, 953, 276, 88, 27, 1172, 15, 2606, 1611, 169, 402, 7, 11, 73, 28, 8, 61, 1, 167, 81, 821, 1006, 27, 162, 62, 1, 953, 592, 88, 27, 1172, 15, 2606, 104, 69, 513, 236, 734, 684, 116, 133, 33, 48, 58, 13, 13, 653, 3, 352, 1, 5369, 1097, 44, 1700, 61, 1125, 1, 5684, 198, 397, 5, 64, 61, 3899, 256]",1046.0,12161355,phase idarubicin dose escalation amisfostine high-dose cytarabine patients relapsed acute myelogenous leukemia myelodysplastic syndromes,12,0.020942408376963352
The roles of FLT3 in hematopoiesis and leukemia.,Blood,Blood,2002-09-01,"FLT3 is a receptor tyrosine kinase expressed by immature hematopoietic cells and is important for the normal development of stem cells and the immune system. The ligand for FLT3 is expressed by marrow stromal cells and other cells and synergizes with other growth factors to stimulate proliferation of stem cells, progenitor cells, dendritic cells, and natural killer cells. Mutations of FLT3 have been detected in about 30% of patients with acute myelogenous leukemia and a small number of patients with acute lymphocytic leukemia or myelodysplastic syndrome. Patients with FLT3 mutations tend to have a poor prognosis. The mutations most often involve small tandem duplications of amino acids within the juxtamembrane domain of the receptor and result in constitutive tyrosine kinase activity. Expression of a mutant FLT3 receptor in murine marrow cells results in a lethal myeloproliferative syndrome and preliminary studies suggest that mutant FLT3 cooperates with other leukemia oncogenes to confer a more aggressive phenotype. Taken together, these results suggest that FLT3 is an attractive therapeutic target for kinase inhibitors or other approaches for patients with mutations of this gene.",Journal Article,6351.0,961.0,FLT3 receptor tyrosine kinase expressed immature hematopoietic important normal development stem immune ligand FLT3 expressed marrow stromal synergizes growth factors stimulate proliferation stem progenitor dendritic natural killer FLT3 detected 30 patients acute myelogenous leukemia small number patients acute lymphocytic leukemia myelodysplastic syndrome Patients FLT3 tend poor prognosis involve small tandem duplications amino acids juxtamembrane domain receptor constitutive tyrosine kinase activity Expression FLT3 receptor murine marrow lethal myeloproliferative syndrome preliminary studies suggest FLT3 cooperates leukemia oncogenes confer aggressive phenotype Taken suggest FLT3 attractive therapeutic target kinase inhibitors approaches patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[1224, 16, 8, 153, 564, 216, 570, 20, 5733, 1007, 37, 2, 16, 305, 9, 3, 295, 193, 1, 452, 37, 2, 3, 250, 398, 3, 1232, 9, 1224, 16, 570, 20, 581, 1126, 37, 2, 127, 37, 2, 10824, 5, 127, 129, 130, 6, 4223, 457, 1, 452, 37, 2520, 37, 2464, 37, 2, 1504, 3458, 37, 138, 1, 1224, 47, 85, 530, 4, 545, 201, 1, 7, 5, 286, 2194, 2, 8, 302, 207, 1, 7, 5, 286, 1193, 15, 681, 7, 5, 1224, 138, 5406, 6, 47, 8, 334, 356, 3, 138, 96, 629, 3882, 302, 2905, 8910, 1, 3078, 4562, 262, 3, 10541, 1398, 1, 3, 153, 2, 757, 4, 3178, 564, 216, 128, 55, 1, 8, 620, 1224, 153, 4, 1471, 581, 37, 99, 4, 8, 2266, 681, 2, 1676, 94, 309, 17, 620, 1224, 12535, 5, 127, 3326, 6, 2913, 8, 80, 571, 1005, 1633, 1162, 46, 99, 309, 17, 1224, 16, 35, 3059, 189, 283, 9, 216, 222, 15, 127, 611, 9, 7, 5, 138, 1, 26, 145]",1126.0,12176867,roles FLT3 hematopoiesis leukemia,10,0.017452006980802792
"Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2002-09-01,"Patients with chronic lymphocytic leukemia (CLL) may have disease transformation to non-Hodgkin's lymphoma or prolymphocytic leukemia; however, development of therapy-related acute myeloid leukemia (t-AML) is unusual. A series of patients enrolled onto an intergroup CLL trial were examined for this complication. A total of 544 previously untreated B-cell CLL patients were enrolled onto a randomized intergroup study comparing treatment with chlorambucil, fludarabine, or fludarabine plus chlorambucil. Case report forms from 521 patients were reviewed for t-AML. With a median follow-up of 4.2 years, six patients (1.2%) to date have developed therapy-related myelodysplastic syndrome (t-MDS; n = 3), t-AML (n = 2), or t-MDS evolving to t-AML (n = 1), from 27 to 53 months (median, 34 months) after study entry. This included five (3.5%) of 142 patients treated with fludarabine plus chlorambucil and one (0.5%) of 188 receiving fludarabine; no chlorambucil-treated patients developed t-MDS or t-AML (P =.007). At study entry, the median age among these six patients was 56 years (range, 44 to 72 years); three were male; the CLL Rai stage was I/II (n = 4) or III/IV (n = 2). Response to CLL therapy was complete (n = 4) or partial remission (n = 1) and stable disease (n = 1). Marrow cytogenetics, obtained in three of six cases at diagnosis of t-MDS or t-AML, were complex, with abnormalities in either or both chromosomes 5 and 7. Other abnormalities involved chromosomes X, 1, 8, 12, 17, and 19. Median survival after diagnosis of t-MDS/AML was 3.5 months (range, 0.5 to 10.1 months). Our findings raise the possibility that alkylator-purine analog combination therapy may increase the risk of therapy-related myeloid malignancies, which is of particular relevance with regard to ongoing trials using these combination therapies.",Clinical Trial,6351.0,147.0,Patients chronic lymphocytic leukemia CLL disease transformation non-Hodgkin 's lymphoma prolymphocytic leukemia development therapy-related acute myeloid leukemia t-AML unusual series patients enrolled intergroup CLL trial examined complication total 544 previously untreated B-cell CLL patients enrolled randomized intergroup comparing treatment chlorambucil fludarabine fludarabine plus chlorambucil Case report forms 521 patients reviewed t-AML median follow-up 4.2 years patients 1.2 date developed therapy-related myelodysplastic syndrome t-MDS n 3 t-AML n 2 t-MDS evolving t-AML n 1 27 53 months median 34 months entry included 3.5 142 patients treated fludarabine plus chlorambucil 0.5 188 receiving fludarabine chlorambucil-treated patients developed t-MDS t-AML P =.007 entry median age patients 56 years range 44 72 years male CLL Rai stage I/II n 4 III/IV n 2 Response CLL therapy complete n 4 partial remission n 1 stable disease n 1 Marrow cytogenetics obtained cases diagnosis t-MDS t-AML complex abnormalities chromosomes 5 7 abnormalities involved chromosomes X 1 8 12 17 19 Median survival diagnosis t-MDS/AML 3.5 months range 0.5 10.1 months findings raise possibility alkylator-purine analog combination therapy increase risk therapy-related myeloid malignancies particular relevance regard ongoing trials combination therapies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 442, 1193, 552, 68, 47, 34, 1392, 6, 292, 15, 14779, 137, 193, 1, 36, 139, 286, 533, 102, 329, 16, 4015, 8, 988, 1, 7, 346, 3301, 35, 4839, 552, 160, 11, 409, 9, 26, 1447, 8, 181, 1, 11770, 373, 1278, 132, 31, 552, 7, 11, 346, 3301, 8, 384, 4839, 45, 1430, 24, 5, 11585, 2027, 15, 2027, 349, 11585, 473, 414, 2377, 29, 11925, 7, 11, 446, 9, 102, 329, 5, 8, 52, 166, 126, 1, 39, 18, 60, 437, 7, 14, 18, 6, 1244, 47, 276, 36, 139, 681, 102, 1223, 78, 27, 102, 329, 78, 18, 15, 102, 1223, 3276, 6, 102, 329, 78, 14, 29, 428, 6, 699, 53, 52, 562, 53, 50, 45, 3001, 26, 159, 365, 27, 33, 1, 4785, 7, 73, 5, 2027, 349, 11585, 2, 104, 13, 33, 1, 5664, 357, 2027, 77, 11585, 73, 7, 276, 102, 1223, 15, 102, 329, 19, 1999, 28, 45, 3001, 3, 52, 89, 107, 46, 437, 7, 10, 664, 60, 184, 584, 6, 720, 60, 169, 11, 1045, 3, 552, 4121, 82, 10, 70, 215, 78, 39, 15, 316, 478, 78, 18, 51, 6, 552, 36, 10, 236, 78, 39, 15, 450, 734, 78, 14, 2, 585, 34, 78, 14, 581, 2510, 683, 4, 169, 1, 437, 140, 28, 147, 1, 102, 1223, 15, 102, 329, 11, 840, 5, 1171, 4, 361, 15, 110, 3560, 33, 2, 67, 127, 1171, 646, 3560, 1006, 14, 66, 133, 269, 2, 326, 52, 25, 50, 147, 1, 102, 1223, 329, 10, 27, 33, 53, 184, 13, 33, 6, 79, 14, 53, 114, 272, 5008, 3, 2526, 17, 9346, 5006, 3497, 150, 36, 68, 344, 3, 43, 1, 36, 139, 533, 441, 92, 16, 1, 1454, 2088, 5, 2539, 6, 942, 143, 75, 46, 150, 235]",1683.0,12228208,Therapy-related myeloid leukemias observed patients chronic lymphocytic leukemia treatment fludarabine chlorambucil intergroup leukemia group B 9011,0,0.0
Second malignant neoplasms in long-term survivors of osteosarcoma: Memorial Sloan-Kettering Cancer Center Experience.,Cancer,Cancer,2002-10-01,"The authors investigated the incidence and relative risk of secondary malignant neoplasms in long-term survivors of osteosarcoma. A comprehensive list of 509 patients with primary osteosarcoma treated at our institution between February 1973 and March 2000 was identified. All study patients received chemotherapy and/or surgery on one of six different protocols (T4, 5, 7, 10, 12, and CCG-7921/POG-9351). Chemotherapy was scheduled for up to 40 weeks with some variations in the actual treatment period and consisted of various combinations of the following agents: high-dose methotrexate, doxorubicin, bleomycin, cyclophosphamide, dactinomycin, vincristine, cisplatin, and ifosfamide. Secondary malignant neoplasms (SMN) occurred in 14 of 509 patients. Only one had pulmonary metastasis at diagnosis and subsequent multiple recurrences that required thoracotomies and further modification of the chemotherapy regimen. The median age at diagnosis for osteosarcoma was 16.6 years (range, 3.1-74.4 years). The median follow-up was 5.2 years (range, 0.1-25.0 years). The time interval from diagnosis of the primary osteosarcoma to the development of SMN was 1.3-13.1 years (median, 5.5; 95% confidence interval [CI], 3.6-9.6). The most common SMN occurred in the central nervous system (n = 4): anaplastic glioma, meningioma, high-grade glioma, and maxillary astrocytoma. There were two cases of acute myeloid leukemia and one case each of myelodysplastic syndrome, non-Hodgkin lymphoma, high-grade pleomorphic sarcoma, leiomyosarcoma, fibrosarcoma, breast carcinoma, and mucoepidermoid carcinoma. The overall 5 and 10-year cumulative incidences of SMNs were 1.4% +/- 1.1% and 3.1% +/- 1.8%. The standardized incidence ratio was 4.6 (95% CI, 2.53-7.78, P = 0.00001) for the cohort and 3.64 (95% CI, 1.82-6.52, P = 0.0007) when patients with a history of retinoblastoma or Rothmund-Thomson syndrome were excluded. The overall incidence of secondary malignancies in long-term survivors of osteosarcoma was significantly higher than the expected incidence of cancer in the general population. However, the standardized incidence ratios were much lower than those reported for Hodgkin disease and retinoblastoma. Although additional follow-up is warranted, the successes of current treatment regimens consisting of intensive, high-dose chemotherapy in combination with topoisomerase II inhibitors outweigh the risks.",Journal Article,6321.0,69.0,authors investigated incidence relative risk secondary malignant neoplasms long-term survivors osteosarcoma comprehensive list 509 patients primary osteosarcoma treated institution February 1973 March 2000 identified patients received chemotherapy and/or surgery different protocols T4 5 7 10 12 CCG-7921/POG-9351 Chemotherapy scheduled 40 weeks variations actual treatment period consisted combinations following agents high-dose methotrexate doxorubicin bleomycin cyclophosphamide dactinomycin vincristine cisplatin ifosfamide Secondary malignant neoplasms SMN occurred 14 509 patients pulmonary metastasis diagnosis subsequent multiple recurrences required thoracotomies modification chemotherapy regimen median age diagnosis osteosarcoma 16.6 years range 3.1-74.4 years median follow-up 5.2 years range 0.1-25.0 years time interval diagnosis primary osteosarcoma development SMN 1.3-13.1 years median 5.5 95 confidence interval CI 3.6-9.6 common SMN occurred central nervous n 4 anaplastic glioma meningioma high-grade glioma maxillary astrocytoma cases acute myeloid leukemia case myelodysplastic syndrome non-Hodgkin lymphoma high-grade pleomorphic sarcoma leiomyosarcoma fibrosarcoma breast carcinoma mucoepidermoid carcinoma overall 5 10-year cumulative incidences SMNs 1.4 +/- 1.1 3.1 +/- 1.8 standardized incidence ratio 4.6 95 CI 2.53-7.78 P 0.00001 cohort 3.64 95 CI 1.82-6.52 P 0.0007 patients history retinoblastoma Rothmund-Thomson syndrome excluded overall incidence secondary malignancies long-term survivors osteosarcoma significantly higher expected incidence general population standardized incidence ratios lower reported Hodgkin disease retinoblastoma additional follow-up warranted successes current treatment regimens consisting intensive high-dose chemotherapy combination topoisomerase II inhibitors outweigh risks,1,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 738, 565, 3, 287, 2, 580, 43, 1, 568, 393, 1179, 4, 319, 337, 332, 1, 8, 949, 4754, 1, 8727, 7, 5, 86, 73, 28, 114, 731, 59, 3010, 4756, 2, 2363, 1081, 10, 108, 62, 45, 7, 103, 56, 2, 15, 152, 23, 104, 1, 437, 338, 2189, 2463, 33, 67, 79, 133, 2, 9457, 53147, 17150, 53148, 56, 10, 4394, 9, 126, 6, 327, 244, 5, 476, 2293, 4, 3, 3480, 24, 727, 2, 1695, 1, 747, 1247, 1, 3, 366, 183, 64, 61, 2116, 856, 5213, 1112, 10295, 2132, 540, 2, 3157, 568, 393, 1179, 6474, 489, 4, 213, 1, 8727, 7, 158, 104, 42, 1087, 278, 28, 147, 2, 706, 232, 1593, 17, 616, 15525, 2, 195, 2437, 1, 3, 56, 477, 3, 52, 89, 28, 147, 9, 10, 245, 49, 60, 184, 27, 14, 794, 39, 60, 3, 52, 166, 126, 10, 33, 18, 60, 184, 13, 14, 243, 13, 60, 3, 98, 268, 29, 147, 1, 3, 86, 6, 3, 193, 1, 6474, 10, 14, 27, 233, 14, 60, 52, 33, 33, 48, 307, 268, 58, 27, 49, 83, 49, 3, 96, 186, 6474, 489, 4, 3, 854, 1880, 398, 78, 39, 1841, 945, 3944, 64, 88, 945, 2, 11399, 3822, 125, 11, 100, 140, 1, 286, 533, 2, 104, 473, 296, 1, 681, 64, 88, 4581, 3717, 8378, 134, 2, 10832, 134, 3, 63, 33, 2, 79, 111, 967, 3981, 1, 6580, 11, 14, 39, 14, 14, 2, 27, 14, 14, 66, 3, 1670, 287, 197, 10, 39, 49, 48, 58, 18, 699, 67, 833, 19, 13, 7868, 9, 3, 180, 2, 27, 660, 48, 58, 14, 878, 49, 653, 19, 13, 6626, 198, 7, 5, 8, 532, 1, 15, 43048, 33305, 681, 11, 1800, 3, 63, 287, 1, 568, 441, 4, 319, 337, 332, 1, 10, 97, 142, 76, 3, 1336, 287, 1, 12, 4, 3, 1083, 266, 137, 3, 1670, 287, 1137, 11, 1802, 280, 76, 135, 210, 9, 34, 2, 242, 402, 166, 126, 16, 1197, 3, 6697, 1, 291, 24, 472, 2273, 1, 1686, 64, 61, 56, 4, 150, 5, 3999, 215, 222, 11592, 3, 1098]",2164.0,12365021,Second malignant neoplasms long-term survivors osteosarcoma Memorial Sloan-Kettering Center Experience,2,0.0034904013961605585
Skeletal manifestations of pediatric acute megakaryoblastic leukemia.,Journal of pediatric hematology/oncology,J. Pediatr. Hematol. Oncol.,2002-10-01,"Once considered rare, acute megakaryoblastic leukemia (AMKL) now accounts for about 12% of all cases of de novo acute myeloid leukemia in children. Most cases of AMKL are difficult to diagnose because of their complex clinical presentation and unusual bone marrow morphologic features. In children, AMKL is often confused with metastatic solid tumors or myelodysplastic syndrome. Between January 1984 and December 1999, 43 patients were diagnosed with childhood AMKL at the authors' institution. Five of these presented with unusual skeletal lesions. These abnormalities (bilaterally symmetrical periostitis and osteolytic lesions) differed markedly from those commonly reported in association with pediatric acute leukemias. The authors present their experience and review the literature to define the spectrum of bony involvement associated with AMKL. This report will contribute to the evolving clinical characterization of this entity and increase clinicians' and radiologists' awareness of the manifestations of AMKL.",Case Reports,6321.0,22.0,considered rare acute megakaryoblastic leukemia AMKL accounts 12 cases novo acute myeloid leukemia children cases AMKL difficult diagnose complex clinical presentation unusual bone marrow morphologic features children AMKL confused metastatic solid myelodysplastic syndrome January 1984 December 1999 43 patients diagnosed childhood AMKL authors institution presented unusual skeletal lesions abnormalities bilaterally symmetrical periostitis osteolytic lesions differed markedly commonly reported association pediatric acute leukemias authors present experience review literature define spectrum bony involvement associated AMKL report contribute evolving clinical characterization entity increase clinicians radiologists awareness manifestations AMKL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1059, 515, 622, 286, 21056, 12742, 1134, 4162, 9, 545, 133, 1, 62, 140, 1, 1566, 2018, 286, 533, 4, 541, 96, 140, 1, 12742, 32, 1740, 6, 6073, 408, 1, 136, 840, 38, 1031, 2, 4015, 581, 2815, 404, 4, 541, 12742, 16, 629, 21075, 5, 113, 537, 57, 15, 681, 59, 1024, 6036, 2, 1397, 2043, 601, 7, 11, 265, 5, 864, 12742, 28, 3, 738, 731, 365, 1, 46, 917, 5, 4015, 2621, 406, 46, 1171, 17679, 30319, 53150, 2, 9570, 406, 2512, 2195, 29, 135, 841, 210, 4, 248, 5, 815, 286, 2792, 3, 738, 364, 136, 730, 2, 206, 3, 789, 6, 1107, 3, 1873, 1, 6552, 799, 41, 5, 12742, 26, 414, 303, 1248, 6, 3, 3276, 38, 2136, 1, 26, 2983, 2, 344, 1490, 2, 3915, 3310, 1, 3, 4282, 1, 12742]",964.0,12368696,Skeletal manifestations pediatric acute megakaryoblastic leukemia,2,0.0034904013961605585
"Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality.",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2002-01-01,"Hepatic venoocclusive disease (HVOD) is a complication of allogeneic hematopoietic stem cell transplantation (HSCT) and is a well-recognized dose-limiting toxicity of oral busulfan (Bu)-based preparative regimens. The unpredictable absorption of oral Bu from the gastrointestinal (GI) tract and hepatic first-pass effects have led to the development of an intravenous Bu preparation (i.v. Bu). The purpose of this retrospective comparison was to evaluate the incidence rate of HVOD and the 100-day mortality rate in patients treated with a busulfan/cyclophosphamide (BuCy2) regimen in which either oral Bu or i.v. Bu was administered. Data from 2 similar groups of patients treated between March 1995 and December 1997 were analyzed. Thirty patients were treated with oral Bu (1 mg/kg x 16 doses) at City of Hope and 61 patients were treated with i.v. Bu (0.8 mg/kg x 16 doses) in a multicenter trial involving 7 sites. Bu was followed by Cy (60 mg/kg x 2 days) and a histocompatible-sibling-donor HSCT. In the i.v. Bu treatment group, 48% of the patients were classified as heavily pretreated (> or = 3 prior chemotherapy regimens, prior radiation, or prior HSCT) with 13% having had a prior HSCT and 75% having active disease at the time of transplantation. According to the same classification criteria, 33% of the patients in the oral-Bu treatment group were considered heavily pretreated, with 23% having had a prior HSCT and 80% having active disease at the time of transplantation. The incidence rates of clinically diagnosed HVOD were 5/61 (8%) and 10/30 (33%) after i.v. and oral Bu, respectively. HVOD-related mortality occurred in 2 (3.3%) of 61 i.v. and 6 (20%) of 30 oral Bu patients. The (standardized) Jones criteria for HVOD were met by 4.9% of i.v. and 20% of oral Bu patients. Univariate logistic regression analysis identified oral versus i.v. Bu (P = .001) and a diagnosis of myelodysplastic syndrome (P = .04) as statistically significant factors in the development of HVOD, with prior extensive treatment identified as marginally significant (P = .25). No other demographic parameter was found to be significant. After adjustment for prior treatment, multivariate analyses showed that the use of oral versus i.v. Bu was the strongest predictor for development of HVOD (odds ratio, 7.5; 95% confidence interval, 2.1-27.2; P = .002). This study showed that the incidence rate of HVOD is significantly lower (P = .002) and the 100-day survival rate significantly higher (P = .002) in patients treated with i.v. Bu than in patients treated with oral Bu when Bu is used as part of a BuCy2 preparative regimen for allogeneic HSCT.",Clinical Trial,6594.0,183.0,Hepatic venoocclusive disease HVOD complication allogeneic hematopoietic stem transplantation HSCT well-recognized dose-limiting toxicity oral busulfan Bu -based preparative regimens unpredictable absorption oral Bu gastrointestinal GI tract hepatic first-pass effects led development intravenous Bu preparation i.v Bu purpose retrospective comparison evaluate incidence rate HVOD 100-day mortality rate patients treated busulfan/cyclophosphamide BuCy2 regimen oral Bu i.v Bu administered 2 similar groups patients treated March 1995 December 1997 Thirty patients treated oral Bu 1 mg/kg x 16 doses City Hope 61 patients treated i.v Bu 0.8 mg/kg x 16 doses multicenter trial involving 7 sites Bu followed Cy 60 mg/kg x 2 days histocompatible-sibling-donor HSCT i.v Bu treatment group 48 patients classified heavily pretreated 3 prior chemotherapy regimens prior radiation prior HSCT 13 prior HSCT 75 active disease time transplantation According classification criteria 33 patients oral-Bu treatment group considered heavily pretreated 23 prior HSCT 80 active disease time transplantation incidence rates clinically diagnosed HVOD 5/61 8 10/30 33 i.v oral Bu respectively HVOD-related mortality occurred 2 3.3 61 i.v 6 20 30 oral Bu patients standardized Jones criteria HVOD met 4.9 i.v 20 oral Bu patients Univariate logistic regression identified oral versus i.v Bu P .001 diagnosis myelodysplastic syndrome P .04 statistically significant factors development HVOD prior extensive treatment identified marginally significant P .25 demographic parameter significant adjustment prior treatment multivariate showed use oral versus i.v Bu strongest predictor development HVOD odds ratio 7.5 95 confidence interval 2.1-27.2 P .002 showed incidence rate HVOD significantly lower P .002 100-day survival rate significantly higher P .002 patients treated i.v Bu patients treated oral Bu Bu BuCy2 preparative regimen allogeneic HSCT,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[939, 20232, 34, 24519, 16, 8, 1447, 1, 1063, 1007, 452, 31, 497, 1703, 2, 16, 8, 149, 1904, 61, 817, 155, 1, 518, 3906, 3667, 90, 6085, 472, 3, 8907, 6125, 1, 518, 3667, 29, 3, 2104, 1696, 2, 939, 157, 10152, 176, 47, 836, 6, 3, 193, 1, 35, 1262, 3667, 4824, 70, 603, 3667, 3, 743, 1, 26, 459, 1155, 10, 6, 376, 3, 287, 116, 1, 24519, 2, 3, 394, 218, 282, 116, 4, 7, 73, 5, 8, 3906, 1112, 27967, 477, 4, 92, 361, 518, 3667, 15, 70, 603, 3667, 10, 468, 74, 29, 18, 288, 271, 1, 7, 73, 59, 2363, 2323, 2, 1397, 2341, 11, 311, 977, 7, 11, 73, 5, 518, 3667, 14, 81, 503, 1006, 245, 415, 28, 7235, 1, 3045, 2, 713, 7, 11, 73, 5, 70, 603, 3667, 13, 66, 81, 503, 1006, 245, 415, 4, 8, 1570, 160, 1267, 67, 633, 3667, 10, 370, 20, 5757, 335, 81, 503, 1006, 18, 162, 2, 8, 30254, 3684, 1488, 1703, 4, 3, 70, 603, 3667, 24, 87, 576, 1, 3, 7, 11, 1373, 22, 2447, 2193, 15, 27, 324, 56, 472, 324, 121, 15, 324, 1703, 5, 233, 1041, 42, 8, 324, 1703, 2, 481, 1041, 544, 34, 28, 3, 98, 1, 497, 768, 6, 3, 827, 947, 371, 466, 1, 3, 7, 4, 3, 518, 3667, 24, 87, 11, 515, 2447, 2193, 5, 382, 1041, 42, 8, 324, 1703, 2, 493, 1041, 544, 34, 28, 3, 98, 1, 497, 3, 287, 151, 1, 505, 265, 24519, 11, 33, 713, 66, 2, 79, 201, 466, 50, 70, 603, 2, 518, 3667, 106, 24519, 139, 282, 489, 4, 18, 27, 27, 1, 713, 70, 603, 2, 49, 179, 1, 201, 518, 3667, 7, 3, 1670, 21078, 371, 9, 24519, 11, 543, 20, 39, 83, 1, 70, 603, 2, 179, 1, 518, 3667, 7, 880, 812, 320, 65, 108, 518, 185, 70, 603, 3667, 19, 144, 2, 8, 147, 1, 681, 19, 755, 22, 712, 93, 130, 4, 3, 193, 1, 24519, 5, 324, 1344, 24, 108, 22, 5007, 93, 19, 243, 77, 127, 1540, 4219, 10, 204, 6, 40, 93, 50, 1852, 9, 324, 24, 331, 318, 224, 17, 3, 119, 1, 518, 185, 70, 603, 3667, 10, 3, 3311, 980, 9, 193, 1, 24519, 610, 197, 67, 33, 48, 307, 268, 18, 14, 428, 18, 19, 1111, 26, 45, 224, 17, 3, 287, 116, 1, 24519, 16, 97, 280, 19, 1111, 2, 3, 394, 218, 25, 116, 97, 142, 19, 1111, 4, 7, 73, 5, 70, 603, 3667, 76, 4, 7, 73, 5, 518, 3667, 198, 3667, 16, 95, 22, 760, 1, 8, 27967, 6085, 477, 9, 1063, 1703]",2506.0,12374454,Intravenous versus oral busulfan busulfan/cyclophosphamide preparative regimen allogeneic hematopoietic stem transplantation decreased incidence hepatic venoocclusive disease HVOD HVOD-related mortality overall 100-day mortality,52,0.09075043630017451
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.,Cancer,Cancer,2002-11-01,"Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are positive regulators of angiogenesis. Increased levels in urine, serum, plasma, or malignant tissue have been associated with an adverse prognosis in patients with solid tumors. The authors used an enzyme-linked immunosorbent assay to measure VEGF and bFGF levels in plasma samples from 99 patients with previously untreated myelodysplastic syndromes (MDS) (n = 41 patients; 42%) or acute myeloid leukemia (AML) (n = 58 patients; 58%) and compared the results with the results from a group of normal control participants. Increased expression levels of VEGF and bFGF were found in the plasma from patients with AML and MDS (P < 0.01) compared with the levels found in the control group. Plasma levels of VEGF in patients with AML or MDS were similar (median, 30.63 pg/mL and 34.41 pg/mL, respectively). There was no significant difference in bFGF levels between patients with AML and patients with MDS (median, 6.38 pg/mL and 6.98 pg/mL, respectively). Elevated levels of VEGF were associated with reduced survival (P = 0.02) in patients with AML as well as lower complete remission (CR) rates (P = 0.004). Elevated VEGF levels were not associated with reduced remission duration (CRD) in patients with AML. There was no correlation between VEGF levels and survival, CRD, or CR rates in patients with MDS. There was no correlation between bFGF levels and CR rates or survival in patients with either AML or MDS. Plasma VEGF levels have prognostic significance in patients with AML. The lack of clinical relevance of VEGF levels in patients with MDS suggests some biologic difference between AML and MDS.",Journal Article,6290.0,132.0,Vascular endothelial growth factor VEGF basic fibroblast growth factor bFGF positive regulators angiogenesis Increased levels urine serum plasma malignant tissue associated adverse prognosis patients solid authors enzyme-linked immunosorbent measure VEGF bFGF levels plasma 99 patients previously untreated myelodysplastic syndromes MDS n 41 patients 42 acute myeloid leukemia AML n 58 patients 58 compared group normal control participants Increased expression levels VEGF bFGF plasma patients AML MDS P 0.01 compared levels control group Plasma levels VEGF patients AML MDS similar median 30.63 pg/mL 34.41 pg/mL respectively significant difference bFGF levels patients AML patients MDS median 6.38 pg/mL 6.98 pg/mL respectively Elevated levels VEGF associated reduced survival P 0.02 patients AML lower complete remission CR rates P 0.004 Elevated VEGF levels associated reduced remission duration CRD patients AML correlation VEGF levels survival CRD CR rates patients MDS correlation bFGF levels CR rates survival patients AML MDS Plasma VEGF levels prognostic significance patients AML lack clinical relevance VEGF levels patients MDS suggests biologic difference AML MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[756, 845, 129, 161, 618, 2, 2795, 3758, 129, 161, 7964, 32, 109, 3196, 1, 1056, 101, 148, 4, 2646, 524, 554, 15, 393, 246, 47, 85, 41, 5, 35, 290, 356, 4, 7, 5, 537, 57, 3, 738, 95, 35, 1644, 1199, 5339, 719, 6, 1463, 618, 2, 7964, 148, 4, 554, 347, 29, 1058, 7, 5, 373, 1278, 2040, 1223, 78, 605, 7, 595, 15, 286, 533, 329, 78, 717, 7, 717, 2, 72, 3, 99, 5, 3, 99, 29, 8, 87, 1, 295, 182, 776, 101, 55, 148, 1, 618, 2, 7964, 11, 204, 4, 3, 554, 29, 7, 5, 329, 2, 1223, 19, 13, 355, 72, 5, 3, 148, 204, 4, 3, 182, 87, 554, 148, 1, 618, 4, 7, 5, 329, 15, 1223, 11, 288, 52, 201, 676, 3234, 542, 2, 562, 605, 3234, 542, 106, 125, 10, 77, 93, 523, 4, 7964, 148, 59, 7, 5, 329, 2, 7, 5, 1223, 52, 49, 519, 3234, 542, 2, 49, 1096, 3234, 542, 106, 804, 148, 1, 618, 11, 41, 5, 405, 25, 19, 13, 588, 4, 7, 5, 329, 22, 149, 22, 280, 236, 734, 684, 151, 19, 13, 1520, 804, 618, 148, 11, 44, 41, 5, 405, 734, 654, 9366, 4, 7, 5, 329, 125, 10, 77, 816, 59, 618, 148, 2, 25, 9366, 15, 684, 151, 4, 7, 5, 1223, 125, 10, 77, 816, 59, 7964, 148, 2, 684, 151, 15, 25, 4, 7, 5, 361, 329, 15, 1223, 554, 618, 148, 47, 177, 724, 4, 7, 5, 329, 3, 926, 1, 38, 2088, 1, 618, 148, 4, 7, 5, 1223, 844, 476, 1283, 523, 59, 329, 2, 1223]",1604.0,12404286,Plasma vascular endothelial growth factor levels prognostic significance patients acute myeloid leukemia patients myelodysplastic syndromes,4,0.006980802792321117
"The myelodysplastic syndromes: morphology, risk assessment, and clinical management (2002).",International journal of hematology,Int. J. Hematol.,2002-08-01,"The Myelodysplastic Syndromes (MDS) represent a group of potentially acute myeloid leukemic disorders. There exists a delicate balance between increased apoptosis and proliferation of the leukemic hematopoietic stem cell that permits many patients to survive for years. When the balance shifts towards proliferation AML develops with a poor outcome for most but not all patients. I will review the latest proposals from the W.H.O. in classification, including pediatric MDS, prognostic factors and response criteria. Then I will present a strategy for the management of low risk patients with supportive care or low intensity treatment (cytokines, Immune modulation, anti-VEGF agents) and finally chemotherapy and intensive therapy with auto and allo BMT.",Journal Article,6382.0,34.0,Myelodysplastic Syndromes MDS represent group potentially acute myeloid leukemic disorders exists delicate balance increased apoptosis proliferation leukemic hematopoietic stem permits patients survive years balance shifts proliferation AML develops poor outcome patients review latest proposals W.H.O classification including pediatric MDS prognostic factors response criteria present strategy management low risk patients supportive care low intensity treatment cytokines Immune modulation anti-VEGF agents finally chemotherapy intensive therapy auto allo BMT,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2040, 1223, 1231, 8, 87, 1, 751, 286, 533, 2015, 1997, 125, 2481, 8, 24476, 3459, 59, 101, 351, 2, 457, 1, 3, 2015, 1007, 452, 31, 17, 8504, 445, 7, 6, 4573, 9, 60, 198, 3, 3459, 5906, 3113, 457, 329, 4734, 5, 8, 334, 228, 9, 96, 84, 44, 62, 7, 70, 303, 206, 3, 5923, 11913, 29, 3, 5444, 555, 1990, 4, 947, 141, 815, 1223, 177, 130, 2, 51, 371, 818, 70, 303, 364, 8, 692, 9, 3, 284, 1, 154, 43, 7, 5, 1877, 165, 15, 154, 837, 24, 1886, 250, 2356, 312, 618, 183, 2, 1368, 56, 2, 1686, 36, 5, 3005, 2, 2564, 4611]",725.0,12430930,myelodysplastic syndromes morphology risk assessment clinical management 2002,1,0.0017452006980802793
"Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.",Pharmacogenetics,Pharmacogenetics,2002-11-01,"Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-ML) are serious complications that affect some patients after acute lymphoblastic leukemia (ALL) treatment. Genetic polymorphisms in the promoter of CYP3A4 (CYP3A4*1B) and in NAD(P)H:quinone oxidoreductase (NQO1609C-->T substitution) have been associated with the risk of t-ML. A polymorphism in CYP3A5 (CYP3A5*3) affects CYP3A activity and the wild-type allele (CYP3A5*1) is in partial linkage with the CYP3A4*1B allele. We compared the genotype frequencies for the CYP3A5*3, the CYP3A4*1B and the NQO1609C-->T substitution in 224 children with ALL who did not develop t-ML (controls) and in 53 children with ALL who did develop the complication. The allele frequencies differed significantly among whites, blacks and Hispanics (P < 0.001 for CYP3A5*3, P < 0.001 for CYP3A4*1B and P = 0.004 for NQO1609), thus we performed the comparisons between ALL controls and t-ML patients after accounting for race. We found no differences in the CYP3A4*1B allele distribution between ALL controls and t-ML patients in whites (P = 0.339, 6.6% vs. 9.8%), blacks (P = 0.498, 93.8% vs. 87.5%) or Hispanics (P = 0.523, 39.1% vs. 25.0%). The frequencies for the NQO1609C-->T allele did not differ between control and t-ML groups in whites (P = 0.191, 35.0% vs. 44.9%), blacks (P = 0.664, 37.5% vs. 37.5%) or Hispanics (P = 0.447, 65.2% vs. 50.0%). We found no differences between the control and t-ML group in the incidence of homozygous CYP3A5*3 genotypes: 82.0% vs. 85.4% in whites (P = 0.403), 6.5% vs. 12.5% in blacks (P = 0.508), and 69.6% vs. 75.0% in Hispanics (P= 0.663). Our data do not support an association between common CYP3A4, NQO1 or CYP3A5 polymorphisms and the risk of t-ML in children treated for ALL.",Journal Article,6290.0,94.0,Therapy-related acute myeloid leukemia myelodysplastic syndrome t-ML complications affect patients acute lymphoblastic leukemia treatment Genetic polymorphisms promoter CYP3A4 CYP3A4*1B NAD P H quinone oxidoreductase NQO1609C -- substitution associated risk t-ML polymorphism CYP3A5 CYP3A5*3 affects CYP3A activity wild-type allele CYP3A5*1 partial linkage CYP3A4*1B allele compared genotype frequencies CYP3A5*3 CYP3A4*1B NQO1609C -- substitution 224 children develop t-ML controls 53 children develop complication allele frequencies differed significantly whites blacks Hispanics P 0.001 CYP3A5*3 P 0.001 CYP3A4*1B P 0.004 NQO1609 performed comparisons controls t-ML patients accounting race differences CYP3A4*1B allele distribution controls t-ML patients whites P 0.339 6.6 vs. 9.8 blacks P 0.498 93.8 vs. 87.5 Hispanics P 0.523 39.1 vs. 25.0 frequencies NQO1609C -- allele differ control t-ML groups whites P 0.191 35.0 vs. 44.9 blacks P 0.664 37.5 vs. 37.5 Hispanics P 0.447 65.2 vs. 50.0 differences control t-ML group incidence homozygous CYP3A5*3 genotypes 82.0 vs. 85.4 whites P 0.403 6.5 vs. 12.5 blacks P 0.508 69.6 vs. 75.0 Hispanics P= 0.663 support association common CYP3A4 NQO1 CYP3A5 polymorphisms risk t-ML children treated,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[36, 139, 286, 533, 2, 681, 102, 542, 32, 1762, 521, 17, 1158, 476, 7, 50, 286, 1275, 62, 24, 336, 1203, 4, 3, 973, 1, 6208, 6208, 4693, 2, 4, 11597, 19, 555, 19517, 18836, 37322, 102, 5029, 47, 85, 41, 5, 3, 43, 1, 102, 542, 8, 1907, 4, 10071, 10071, 27, 2561, 12768, 128, 2, 3, 955, 267, 1254, 10071, 14, 16, 4, 450, 4820, 5, 3, 6208, 4693, 1254, 21, 72, 3, 1183, 2722, 9, 3, 10071, 27, 3, 6208, 4693, 2, 3, 37322, 102, 5029, 4, 5908, 541, 5, 62, 54, 205, 44, 690, 102, 542, 535, 2, 4, 699, 541, 5, 62, 54, 205, 690, 3, 1447, 3, 1254, 2722, 2512, 97, 107, 2556, 3544, 2, 3850, 19, 13, 144, 9, 10071, 27, 19, 13, 144, 9, 6208, 4693, 2, 19, 13, 1520, 9, 53231, 631, 21, 173, 3, 2213, 59, 62, 535, 2, 102, 542, 7, 50, 3116, 9, 1047, 21, 204, 77, 362, 4, 3, 6208, 4693, 1254, 1395, 59, 62, 535, 2, 102, 542, 7, 4, 2556, 19, 13, 7881, 49, 49, 105, 83, 66, 3544, 19, 13, 8928, 966, 66, 105, 912, 33, 15, 3850, 19, 13, 10674, 587, 14, 105, 243, 13, 3, 2722, 9, 3, 37322, 102, 1254, 205, 44, 1505, 59, 182, 2, 102, 542, 271, 4, 2556, 19, 13, 6130, 465, 13, 105, 584, 83, 3544, 19, 13, 13025, 567, 33, 105, 567, 33, 15, 3850, 19, 13, 9472, 556, 18, 105, 212, 13, 21, 204, 77, 362, 59, 3, 182, 2, 102, 542, 87, 4, 3, 287, 1, 3189, 10071, 27, 2071, 878, 13, 105, 772, 39, 4, 2556, 19, 13, 10836, 49, 33, 105, 133, 33, 4, 3544, 19, 13, 11598, 2, 790, 49, 105, 481, 13, 4, 3850, 19, 13, 10693, 114, 74, 1022, 44, 538, 35, 248, 59, 186, 6208, 10187, 15, 10071, 1203, 2, 3, 43, 1, 102, 542, 4, 541, 73, 9, 62]",1646.0,12439220,Genetic polymorphisms CYP3A5 CYP3A4 NQO1 children developed therapy-related myeloid malignancies,0,0.0
Acute myeloid leukemia.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2002-01-01,"In this chapter, Drs. Keating and Willman review recent advances in our understanding of the pathophysiology of acute myeloid leukemia (AML) and allied conditions, including the advanced myelodysplastic syndromes (MDS), while Drs. Goldstone, Avivi, Giles, and Kantarjian focus on therapeutic data with an emphasis on current patient care and future research studies. In Section I, Dr. Armand Keating reviews the role of the hematopoietic microenvironment in the initiation and progression of leukemia. He also discusses recent data on the stromal, or nonhematopoietic, marrow mesenchymal cell population and its possible role in AML. In Section II, Drs. Anthony Goldstone and Irit Avivi review the current role of stem cell transplantation as therapy for AML and MDS. They focus on data generated on recent Medical Research Council studies and promising investigation approaches. In Section III, Dr. Cheryl Willman reviews the current role of molecular genetics and gene expression analysis as tools to assist in AML disease classification systems, modeling of gene expression profiles associated with response or resistance to various interventions, and identifying novel therapeutic targets. In Section IV, Drs. Hagop Kantarjian and Francis Giles review some promising agents and strategies under investigation in the therapy of AML and MDS with an emphasis on novel delivery systems for cytotoxic therapy and on targeted biologic agents.",Journal Article,6594.0,79.0,chapter Drs Keating Willman review recent advances understanding pathophysiology acute myeloid leukemia AML allied conditions including advanced myelodysplastic syndromes MDS Drs Goldstone Avivi Giles Kantarjian focus therapeutic emphasis current patient care future research studies Section Dr. Armand Keating reviews role hematopoietic microenvironment initiation progression leukemia discusses recent stromal nonhematopoietic marrow mesenchymal population possible role AML Section II Drs Anthony Goldstone Irit Avivi review current role stem transplantation therapy AML MDS focus generated recent Medical Research Council studies promising investigation approaches Section III Dr. Cheryl Willman reviews current role molecular genetics expression tools assist AML disease classification systems modeling expression profiles associated response resistance interventions identifying novel therapeutic targets Section IV Drs Hagop Kantarjian Francis Giles review promising agents strategies investigation therapy AML MDS emphasis novel delivery systems cytotoxic therapy targeted biologic agents,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[4, 26, 6366, 9227, 43078, 2, 33329, 206, 435, 954, 4, 114, 612, 1, 3, 4320, 1, 286, 533, 329, 2, 18234, 1298, 141, 3, 131, 2040, 1223, 369, 9227, 43079, 43080, 43081, 2, 37325, 1222, 23, 189, 74, 5, 35, 3136, 23, 291, 69, 165, 2, 508, 389, 94, 4, 2917, 70, 3436, 53239, 43078, 2004, 3, 200, 1, 3, 1007, 995, 4, 3, 1118, 2, 91, 1, 3174, 120, 2759, 435, 74, 23, 3, 1126, 15, 19463, 581, 1569, 31, 266, 2, 211, 899, 200, 4, 329, 4, 2917, 215, 9227, 37326, 43079, 2, 53240, 43080, 206, 3, 291, 200, 1, 452, 31, 497, 22, 36, 9, 329, 2, 1223, 491, 1222, 23, 74, 1419, 23, 435, 484, 389, 9474, 94, 2, 721, 940, 611, 4, 2917, 316, 3436, 43082, 33329, 2004, 3, 291, 200, 1, 219, 2894, 2, 145, 55, 65, 22, 1896, 6, 3425, 4, 329, 34, 947, 1530, 2057, 1, 145, 55, 1241, 41, 5, 51, 15, 251, 6, 747, 1151, 2, 1386, 229, 189, 637, 4, 2917, 478, 9227, 53241, 37325, 2, 37327, 43081, 206, 476, 721, 183, 2, 422, 669, 940, 4, 3, 36, 1, 329, 2, 1223, 5, 35, 3136, 23, 229, 989, 1530, 9, 759, 36, 2, 23, 238, 1283, 183]",1377.0,12446420,Acute myeloid leukemia,310,0.5410122164048866
Advancing the treatment of hematologic malignancies through the development of targeted interventions.,Seminars in hematology,Semin. Hematol.,2002-10-01,"Significant advances have been made in the development of targeted interventions for hematologic malignancies. Progress has been made in defining the molecular pathogenesis of human leukemias. Data indicate that nonrandom, somatically acquired translocations, inversions, and other abnormalities occur in many acute leukemias. In the treatment of acute promyelocytic leukemia (APL), targeted therapy with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy leads to dramatic improvements in disease-free survival. Imatinib mesylate, a signal transduction inhibitor that inhibits tyrosine kinase activity, the protein product of the ABL proto-oncogene, has remarkable activity in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL). Farnesyltransferase inhibitors (FTIs), a promising class of agents that target multiple pathways including Ras proteins, are potential anticancer therapy for a wide range of malignancies, including leukemias and myelodysplastic syndromes (MDS). There also is evidence that recombinant human erythropoietin therapy (r-HuEPO) can benefit patients with chronic lymphocytic leukemia (CLL), multiple myeloma, and lymphomas. This supplement will discuss advances in our understanding of human leukemias, including the use of unconjugated monoclonal antibodies such as Campath-1H (Wellcome, Beckenham, UK, and Ilex Oncology, San Antonio, TX) and rituximab and immunoconjugates such as gemtuzumab ozogamicin and BL-22. Although these novel therapies are beginning to fulfill their promise, continued research efforts are needed to determine the optimal role of targeted therapy in acute and chronic leukemias.",Journal Article,6321.0,8.0,Significant advances development targeted interventions hematologic malignancies Progress defining molecular pathogenesis human leukemias indicate nonrandom somatically acquired translocations inversions abnormalities occur acute leukemias treatment acute promyelocytic leukemia APL targeted therapy all-trans retinoic acid ATRA anthracycline-based chemotherapy leads dramatic improvements disease-free survival Imatinib mesylate signal transduction inhibitor inhibits tyrosine kinase activity product ABL proto-oncogene remarkable activity patients chronic myeloid leukemia CML Philadelphia chromosome-positive Ph acute lymphoblastic leukemia Farnesyltransferase inhibitors FTIs promising class agents target multiple pathways including Ras potential anticancer therapy wide range malignancies including leukemias myelodysplastic syndromes MDS evidence recombinant human erythropoietin therapy r-HuEPO benefit patients chronic lymphocytic leukemia CLL multiple myeloma lymphomas supplement discuss advances understanding human leukemias including use unconjugated monoclonal antibodies Campath-1H Wellcome Beckenham UK Ilex Oncology San Antonio TX rituximab immunoconjugates gemtuzumab ozogamicin BL-22 novel therapies beginning fulfill promise continued research efforts needed determine optimal role targeted therapy acute chronic leukemias,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[93, 954, 47, 85, 1229, 4, 3, 193, 1, 238, 1151, 9, 813, 441, 1466, 71, 85, 1229, 4, 2847, 3, 219, 1384, 1, 171, 2792, 74, 1008, 17, 12480, 12293, 1294, 3262, 24544, 2, 127, 1171, 1271, 4, 445, 286, 2792, 4, 3, 24, 1, 286, 4300, 2578, 238, 36, 5, 62, 3437, 3887, 971, 2822, 2, 2044, 90, 56, 1940, 6, 3079, 1474, 4, 34, 115, 25, 577, 2347, 8, 1235, 2761, 230, 17, 1576, 564, 216, 128, 3, 178, 2821, 1, 3, 1425, 4976, 1836, 71, 3813, 128, 4, 7, 5, 442, 533, 903, 2, 3006, 1170, 109, 2058, 286, 1275, 62, 7480, 222, 8576, 8, 721, 1040, 1, 183, 17, 283, 232, 460, 141, 1102, 652, 32, 174, 1475, 36, 9, 8, 1019, 184, 1, 441, 141, 2792, 2, 2040, 1223, 125, 120, 16, 241, 17, 2835, 171, 6266, 36, 668, 21090, 122, 247, 7, 5, 442, 1193, 552, 232, 2, 1557, 26, 5836, 303, 1139, 954, 4, 114, 612, 1, 171, 2792, 141, 3, 119, 1, 11116, 848, 890, 225, 22, 16622, 10147, 37335, 43091, 6975, 2, 43092, 413, 6889, 20244, 6614, 2, 855, 2, 15109, 225, 22, 7918, 5566, 2, 6331, 350, 242, 46, 229, 235, 32, 2948, 6, 11246, 136, 1783, 1351, 389, 1413, 32, 575, 6, 223, 3, 665, 200, 1, 238, 36, 4, 286, 2, 442, 2792]",1611.0,12447845,Advancing treatment hematologic malignancies development targeted interventions,2,0.0034904013961605585
Epoetin alfa as a supportive measure in hematologic malignancies.,Seminars in hematology,Semin. Hematol.,2002-10-01,"Anemia is prevalent among cancer patients with hematologic malignancies, with fatigue and weakness, major symptoms of anemia, contributing to diminished quality of life (QOL). Data from several randomized, placebo-controlled clinical trials and three large community-based studies in patients with hematologic malignancies indicate that recombinant human erythropoietin (r-HuEPO, epoetin alfa) can correct anemia, reduce transfusion requirements, and improve QOL. Moreover, a positive relationship has been found between increased hemoglobin (Hb) levels and improvements in QOL assessments, regardless of disease state, with the greatest incremental improvement occurring when Hb increases from 11 g/dL to 12 g/dL (range, 11 to 13 g/dL). This suggests that patients with mild-to-moderate anemia may achieve the greatest QOL benefit from epoetin alfa therapy. Evidence from community-based studies suggests that epoetin alfa administered once weekly has a similar safety and efficacy profile as three-times-weekly administration. Further research is ongoing with less frequent dosing regimens. The beneficial effects of epoetin alfa therapy have been reported in studies involving patients with chronic lymphocytic leukemia (CLL), multiple myeloma, and lymphomas. Evidence also exists that epoetin alfa can benefit patients with myelodysplastic syndromes (MDS), although these results have not been as impressive. Combining epoetin alfa with other cytokine growth factors may confer some additional benefit in these patients, but more rigorous investigation is required.",Journal Article,6321.0,9.0,Anemia prevalent patients hematologic malignancies fatigue weakness major symptoms anemia contributing diminished quality life QOL randomized placebo-controlled clinical trials large community-based studies patients hematologic malignancies indicate recombinant human erythropoietin r-HuEPO epoetin alfa correct anemia reduce transfusion requirements improve QOL positive relationship increased hemoglobin Hb levels improvements QOL assessments regardless disease state greatest incremental improvement occurring Hb increases 11 g/dL 12 g/dL range 11 13 g/dL suggests patients mild-to-moderate anemia achieve greatest QOL benefit epoetin alfa therapy Evidence community-based studies suggests epoetin alfa administered weekly similar safety efficacy profile three-times-weekly administration research ongoing frequent dosing regimens beneficial effects epoetin alfa therapy reported studies involving patients chronic lymphocytic leukemia CLL multiple myeloma lymphomas Evidence exists epoetin alfa benefit patients myelodysplastic syndromes MDS impressive Combining epoetin alfa cytokine growth factors confer additional benefit patients rigorous investigation required,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1545, 16, 2485, 107, 12, 7, 5, 813, 441, 5, 613, 2, 6408, 458, 507, 1, 1545, 3156, 6, 2849, 372, 1, 358, 1001, 74, 29, 392, 384, 619, 1149, 38, 143, 2, 169, 375, 1714, 90, 94, 4, 7, 5, 813, 441, 1008, 17, 2835, 171, 6266, 668, 21090, 7305, 4443, 122, 4883, 1545, 969, 2785, 4230, 2, 401, 1001, 1393, 8, 109, 858, 71, 85, 204, 59, 101, 2222, 5753, 148, 2, 1474, 4, 1001, 2182, 1583, 1, 34, 1309, 5, 3, 2199, 3648, 767, 1821, 198, 5753, 1106, 29, 175, 499, 1826, 6, 133, 499, 1826, 184, 175, 6, 233, 499, 1826, 26, 844, 17, 7, 5, 1980, 6, 1163, 1545, 68, 1359, 3, 2199, 1001, 247, 29, 7305, 4443, 36, 241, 29, 1714, 90, 94, 844, 17, 7305, 4443, 468, 1059, 709, 71, 8, 288, 367, 2, 209, 800, 22, 169, 1072, 709, 634, 195, 389, 16, 942, 5, 299, 908, 1280, 472, 3, 2524, 176, 1, 7305, 4443, 36, 47, 85, 210, 4, 94, 1267, 7, 5, 442, 1193, 552, 232, 2, 1557, 241, 120, 2481, 17, 7305, 4443, 122, 247, 7, 5, 2040, 1223, 242, 46, 99, 47, 44, 85, 22, 5790, 1525, 7305, 4443, 5, 127, 1675, 129, 130, 68, 2913, 476, 402, 247, 4, 46, 7, 84, 80, 6496, 940, 16, 616]",1500.0,12447849,Epoetin alfa supportive measure hematologic malignancies,2,0.0034904013961605585
Acute leukemia: a pediatric perspective.,Cancer cell,Cancer Cell,2002-12-01,"The spectrum of hematological malignancies differs markedly between children and adults. Moreover, diseases such as acute lymphoblastic leukemia, acute myeloid leukemia, and myelodysplastic syndrome also demonstrate distinct biologic features and responses to treatment between these populations. In this review, we summarize our current understanding of the molecular pathology of acute leukemia and myelodysplastic syndrome, emphasizing areas in which studies in pediatric patients are providing unique insights into the hematopoietic malignancies of adults.",Comparative Study,6260.0,56.0,spectrum hematological malignancies differs markedly children adults diseases acute lymphoblastic leukemia acute myeloid leukemia myelodysplastic syndrome demonstrate distinct biologic features responses treatment populations review summarize current understanding molecular pathology acute leukemia myelodysplastic syndrome emphasizing areas studies pediatric patients providing unique insights hematopoietic malignancies adults,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1873, 1, 2890, 441, 4990, 2195, 59, 541, 2, 857, 1393, 1342, 225, 22, 286, 1275, 286, 533, 2, 681, 120, 608, 834, 1283, 404, 2, 253, 6, 24, 59, 46, 1184, 4, 26, 206, 21, 2479, 114, 291, 612, 1, 3, 219, 1117, 1, 286, 2, 681, 6826, 1361, 4, 92, 94, 4, 815, 7, 32, 1736, 991, 1957, 237, 3, 1007, 441, 1, 857]",493.0,12498712,Acute leukemia pediatric perspective,6,0.010471204188481676
Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2002-11-01,"Autoimmune paraneoplastic syndromes are commonly encountered in patients with myelodysplastic syndromes (MDS). A review of case reports and small series suggest as many as 10% of MDS patients may experience various autoimmune syndromes. Clinical manifestations of such phenomena may include an acute systemic vasculitic syndrome, skin vasculitis, fever, arthritis, pulmonary infiltrates, peripheral polyneuropathy, inflammatory bowel disease, glomerulonephritis, and even classical connective tissue disorders, such as relapsing polychondritis. On the other hand, asymptomatic immunologic abnormalities have also been reported in these patients. These autoimmune manifestations frequently respond to immunosuppressive agents including steroids and occasional hematologic responses to steroid therapy have also been reported. We report five patients with history of MDS who manifested different spectrums of autoimmune phenomena including: pyoderma gangrenosum (PG), vasculitis, Coombs negative hemolytic anemia, idiopathic thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy (CIDP). We also review the incidence, nature, course and response to therapy of these manifestations and discuss potential pathogenic mechanisms.",Case Reports,6290.0,111.0,Autoimmune paraneoplastic syndromes commonly encountered patients myelodysplastic syndromes MDS review case reports small series suggest 10 MDS patients experience autoimmune syndromes Clinical manifestations phenomena include acute systemic vasculitic syndrome skin vasculitis fever arthritis pulmonary infiltrates peripheral polyneuropathy inflammatory bowel disease glomerulonephritis classical connective tissue disorders relapsing polychondritis hand asymptomatic immunologic abnormalities reported patients autoimmune manifestations frequently respond immunosuppressive agents including steroids occasional hematologic responses steroid therapy reported report patients history MDS manifested different spectrums autoimmune phenomena including pyoderma gangrenosum PG vasculitis Coombs negative hemolytic anemia idiopathic thrombocytopenia chronic inflammatory demyelinating polyneuropathy CIDP review incidence nature course response therapy manifestations discuss potential pathogenic mechanisms,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[3445, 6544, 2040, 32, 841, 3903, 4, 7, 5, 2040, 1223, 8, 206, 1, 473, 1198, 2, 302, 988, 309, 22, 445, 22, 79, 1, 1223, 7, 68, 730, 747, 3445, 2040, 38, 4282, 1, 225, 11549, 68, 643, 35, 286, 403, 37370, 681, 18850, 2775, 8646, 1087, 5942, 672, 14469, 1291, 1659, 34, 26106, 2, 871, 3781, 10990, 246, 1997, 225, 22, 6758, 53332, 23, 3, 127, 2833, 2100, 3042, 1171, 47, 120, 85, 210, 4, 46, 7, 46, 3445, 4282, 746, 1892, 6, 2989, 183, 141, 4580, 2, 9753, 813, 253, 6, 3853, 36, 47, 120, 85, 210, 21, 414, 365, 7, 5, 532, 1, 1223, 54, 6023, 338, 37110, 1, 3445, 11549, 141, 43141, 43142, 3234, 18850, 43143, 199, 10425, 1545, 7540, 1340, 2, 442, 1291, 19540, 14469, 37371, 21, 120, 206, 3, 287, 2202, 906, 2, 51, 6, 36, 1, 46, 4282, 2, 1139, 174, 2806, 483]",1188.0,12533032,Autoimmune phenomena patients myelodysplastic syndromes chronic myelomonocytic leukemia,72,0.1256544502617801
Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2003-02-01,"In a series of trials, doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP/ABV) have been identified as effective treatments for Hodgkin's disease. We compared these regimens as initial chemotherapy for Hodgkin's disease. Adult patients (N = 856) with advanced Hodgkin's disease were randomly assigned to treatment with ABVD or MOPP/ABV. The major end points were failure-free and overall survival, life-threatening acute toxicities, and serious long-term toxicities, including cardiomyopathy, pulmonary toxicity, myelodysplastic syndromes (MDS), and secondary malignancies. The rates of complete remission (76% v 80%, P =.16), failure-free survival at 5 years (63% v 66%, P =.42), and overall survival at 5 years (82% v 81%, P =.82) were similar for ABVD and MOPP/ABV, respectively. Clinically significant acute pulmonary and hematologic toxicity were more common with MOPP/ABV (P =.060 and.001, respectively). There was no difference in cardiac toxicity. There were 24 deaths attributed to initial treatment: nine with ABVD and 15 with MOPP/ABV (P =.057). There have been 18 second malignancies associated with ABVD and 28 associated with MOPP/ABV (P =.13). Thirteen patients have developed MDS or acute leukemia: 11 were initially treated with MOPP/ABV, and two were initially treated with ABVD but subsequently received MOPP-containing regimens and radiotherapy before developing leukemia (P =.011). ABVD and the MOPP/ABV hybrid are effective therapies for Hodgkin's disease. MOPP/ABV is associated with a greater incidence of acute toxicity, MDS, and leukemia. ABVD should be considered the standard regimen for treatment of advanced Hodgkin's disease.",Clinical Trial,6198.0,391.0,series trials doxorubicin bleomycin vinblastine dacarbazine ABVD mechlorethamine vincristine procarbazine prednisone doxorubicin bleomycin vinblastine MOPP/ABV identified effective treatments Hodgkin 's disease compared regimens initial chemotherapy Hodgkin 's disease Adult patients N 856 advanced Hodgkin 's disease randomly assigned treatment ABVD MOPP/ABV major end points failure-free overall survival life-threatening acute toxicities long-term toxicities including cardiomyopathy pulmonary toxicity myelodysplastic syndromes MDS secondary malignancies rates complete remission 76 v 80 P =.16 failure-free survival 5 years 63 v 66 P =.42 overall survival 5 years 82 v 81 P =.82 similar ABVD MOPP/ABV respectively Clinically significant acute pulmonary hematologic toxicity common MOPP/ABV P =.060 and.001 respectively difference cardiac toxicity 24 deaths attributed initial treatment ABVD 15 MOPP/ABV P =.057 18 second malignancies associated ABVD 28 associated MOPP/ABV P =.13 Thirteen patients developed MDS acute leukemia 11 initially treated MOPP/ABV initially treated ABVD subsequently received MOPP-containing regimens radiotherapy developing leukemia P =.011 ABVD MOPP/ABV hybrid effective therapies Hodgkin 's disease MOPP/ABV associated greater incidence acute toxicity MDS leukemia ABVD considered standard regimen treatment advanced Hodgkin 's disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,"[4, 8, 988, 1, 143, 856, 5213, 5413, 2, 3404, 6316, 2, 15503, 2132, 8860, 1979, 856, 5213, 2, 5413, 15883, 15868, 47, 85, 108, 22, 323, 640, 9, 292, 34, 21, 72, 46, 472, 22, 388, 56, 9, 292, 34, 780, 7, 78, 13292, 5, 131, 292, 34, 11, 1108, 896, 6, 24, 5, 6316, 15, 15883, 15868, 3, 458, 396, 862, 11, 496, 115, 2, 63, 25, 358, 3691, 286, 385, 2, 1762, 319, 337, 385, 141, 6460, 1087, 155, 2040, 1223, 2, 568, 441, 3, 151, 1, 236, 734, 846, 603, 493, 19, 245, 496, 115, 25, 28, 33, 60, 676, 603, 700, 19, 595, 2, 63, 25, 28, 33, 60, 878, 603, 865, 19, 878, 11, 288, 9, 6316, 2, 15883, 15868, 106, 505, 93, 286, 1087, 2, 813, 155, 11, 80, 186, 5, 15883, 15868, 19, 9972, 2, 144, 106, 125, 10, 77, 523, 4, 155, 125, 11, 259, 1043, 3073, 6, 388, 24, 762, 5, 6316, 2, 167, 5, 15883, 15868, 19, 10807, 125, 47, 85, 203, 419, 441, 41, 5, 6316, 2, 339, 41, 5, 15883, 15868, 19, 233, 3170, 7, 47, 276, 1223, 15, 286, 175, 11, 1625, 73, 5, 15883, 15868, 2, 100, 11, 1625, 73, 5, 6316, 84, 1611, 103, 15883, 1101, 472, 2, 310, 348, 931, 19, 3651, 6316, 2, 3, 15883, 15868, 4542, 32, 323, 235, 9, 292, 34, 15883, 15868, 16, 41, 5, 8, 378, 287, 1, 286, 155, 1223, 2, 6316, 257, 40, 515, 3, 260, 477, 9, 24, 1, 131, 292, 34]",1614.0,12586796,Randomized comparison ABVD MOPP/ABV hybrid treatment advanced Hodgkin 's disease report intergroup trial,33,0.05759162303664921
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.,Cancer,Cancer,2003-03-01,"Because angiogenesis may play a role in the pathogenesis of acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), and thalidomide (Th) has shown significant anti-angiogenic activity, this study was designed to investigate the potential role of Th in the treatment of patients with AML and MDS and the possible role of a non-ara-C-containing regimen. Adults with AML or high-risk MDS and cytogenetic abnormalities other than inv (16), t(8;21), -Y or -X were randomized to receive liposomal daunorubicin (DNX) and ara-C (DA) or DNX and topotecan (DT). Within each arm, patients were randomized to receive chemotherapy alone (DA or DT) or with thalidomide (DATh or DTTh). Vascular endothelial growth factor (VEGF) plasma levels and microvascular density was measured before and after therapy. Eighty-four patients (median age, 65 years; range, 27-84 years) were treated. None of 11 patients treated with DT or DTTh responded and these arms were closed. Seventeen of 37 patients treated with DA and 15 of 36 treated with DATh achieved an early complete remission. Median complete response duration was 38 and 34 weeks (P = 0.57) and median survival 35 and 28 weeks (P = 0.15), respectively. Patients with high pretreatment VEGF levels had an inferior survival. There was no significant difference in the changes in VEGF levels or microvascular density after treatment in patients who did versus those who did not receive thalidomide. The authors concluded that thalidomide in combination with chemotherapy does not result in clinical benefit in patients with AML or high-risk MDS.",Clinical Trial,6170.0,38.0,angiogenesis play role pathogenesis acute myeloid leukemia AML high-risk myelodysplastic syndrome MDS thalidomide Th shown significant anti-angiogenic activity designed investigate potential role Th treatment patients AML MDS possible role non-ara-C-containing regimen Adults AML high-risk MDS cytogenetic abnormalities inv 16 8 21 -Y -X randomized receive liposomal daunorubicin DNX ara-C DA DNX topotecan DT arm patients randomized receive chemotherapy DA DT thalidomide DATh DTTh Vascular endothelial growth factor VEGF plasma levels microvascular density measured therapy Eighty-four patients median age 65 years range 27-84 years treated 11 patients treated DT DTTh responded arms closed Seventeen 37 patients treated DA 15 36 treated DATh achieved early complete remission Median complete response duration 38 34 weeks P 0.57 median survival 35 28 weeks P 0.15 respectively Patients high pretreatment VEGF levels inferior survival significant difference changes VEGF levels microvascular density treatment patients versus receive thalidomide authors concluded thalidomide combination chemotherapy clinical benefit patients AML high-risk MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[408, 1056, 68, 1343, 8, 200, 4, 3, 1384, 1, 286, 533, 329, 2, 64, 43, 681, 1223, 2, 2159, 4517, 71, 443, 93, 312, 2068, 128, 26, 45, 10, 1114, 6, 963, 3, 174, 200, 1, 4517, 4, 3, 24, 1, 7, 5, 329, 2, 1223, 2, 3, 899, 200, 1, 8, 220, 3899, 256, 1101, 477, 857, 5, 329, 15, 64, 43, 1223, 2, 1266, 1171, 127, 76, 6397, 245, 102, 66, 239, 2055, 15, 1006, 11, 384, 6, 560, 3275, 5247, 18861, 2, 3899, 256, 5424, 15, 18861, 2, 2129, 5281, 262, 296, 475, 7, 11, 384, 6, 560, 56, 279, 5424, 15, 5281, 15, 5, 2159, 43169, 15, 43170, 756, 845, 129, 161, 618, 554, 148, 2, 6466, 1263, 10, 644, 348, 2, 50, 36, 2207, 294, 7, 52, 89, 556, 60, 184, 428, 874, 60, 11, 73, 1292, 1, 175, 7, 73, 5, 5281, 15, 43170, 2211, 2, 46, 1335, 11, 3745, 3591, 1, 567, 7, 73, 5, 5424, 2, 167, 1, 511, 73, 5, 43169, 513, 35, 191, 236, 734, 52, 236, 51, 654, 10, 519, 2, 562, 244, 19, 13, 696, 2, 52, 25, 465, 2, 339, 244, 19, 13, 167, 106, 7, 5, 64, 1194, 618, 148, 42, 35, 1663, 25, 125, 10, 77, 93, 523, 4, 3, 400, 4, 618, 148, 15, 6466, 1263, 50, 24, 4, 7, 54, 205, 185, 135, 54, 205, 44, 560, 2159, 3, 738, 4724, 17, 2159, 4, 150, 5, 56, 1097, 44, 757, 4, 38, 247, 4, 7, 5, 329, 15, 64, 43, 1223]",1521.0,12599230,randomized trial liposomal daunorubicin cytarabine versus liposomal daunorubicin topotecan thalidomide initial therapy patients poor prognosis acute myelogenous leukemia myelodysplastic syndrome,84,0.14659685863874344
Acquired FANCA dysfunction and cytogenetic instability in adult acute myelogenous leukemia.,Blood,Blood,2003-03-13,"Myelodysplastic and leukemic stem cell clones that evolve in children and adults with Fanconi anemia universally bear complex cytogenetic abnormalities. The abnormalities are generally recurring deletions or chromosomal loss and involve precisely the same chromosomes with the same frequency as has been described in marrow cells from patients with secondary acute leukemia induced by alkylating agents. Reasoning that acquired Fanconi anemia protein dysfunction might contribute to cytogenetic instability in secondary acute myelogenous leukemia (AML) cells, we analyzed leukemic cells bearing characteristic complex cytogenetic defects obtained from a 68-year-old man whose lymphoblasts showed no evidence of Fanconi anemia. Unlike the lymphoblasts, this myeloid leukemia cell line (UoC-M1) was hypersensitive to mitomycin-C (MMC) and diepoxybutane (DEB) and exhibited a marked decrease in nuclear FANCA, FANCG, and FANCD2-L. Retroviral transduction of FANCA significantly reduced MMC sensitivity but FANCF, FANCG, and FANCC did not. Overexpression of FANCA restored levels of both FANCA and FANCG, whereas overexpression of FANCG or FANCC did not restore FANCA levels. The molecular mass of cytoplasmic FANCA, FANCG, FANCC, and nuclear FANCD2 were normal. All exons of FANCA and FANCG were sequenced, and no mutations were found. We conclude that perturbations of as yet unidentified factors that govern the binding activity or intracellular localization of FANCA may promote cytogenetic instability and clonal progression in patients with AML who do not have Fanconi anemia.",Journal Article,6158.0,39.0,Myelodysplastic leukemic stem clones evolve children adults Fanconi anemia universally bear complex cytogenetic abnormalities abnormalities generally recurring deletions chromosomal loss involve precisely chromosomes frequency described marrow patients secondary acute leukemia induced alkylating agents Reasoning acquired Fanconi anemia dysfunction contribute cytogenetic instability secondary acute myelogenous leukemia AML leukemic bearing characteristic complex cytogenetic defects obtained 68-year-old man lymphoblasts showed evidence Fanconi anemia Unlike lymphoblasts myeloid leukemia line UoC-M1 hypersensitive mitomycin-C MMC diepoxybutane DEB exhibited marked decrease nuclear FANCA FANCG FANCD2-L. Retroviral transduction FANCA significantly reduced MMC sensitivity FANCF FANCG FANCC Overexpression FANCA restored levels FANCA FANCG overexpression FANCG FANCC restore FANCA levels molecular mass cytoplasmic FANCA FANCG FANCC nuclear FANCD2 normal exons FANCA FANCG sequenced conclude perturbations unidentified factors govern binding activity intracellular localization FANCA promote cytogenetic instability clonal progression patients AML Fanconi anemia,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2, 2015, 452, 31, 2749, 17, 4800, 4, 541, 2, 857, 5, 8057, 1545, 6813, 10952, 840, 1266, 1171, 3, 1171, 32, 1228, 6385, 2439, 15, 1860, 407, 2, 3882, 7428, 3, 827, 3560, 5, 3, 827, 675, 22, 71, 85, 1027, 4, 581, 37, 29, 7, 5, 568, 286, 277, 20, 3410, 183, 15856, 17, 1294, 8057, 1545, 178, 1527, 822, 1248, 6, 1266, 1753, 4, 568, 286, 2194, 329, 37, 21, 311, 2015, 37, 1894, 2037, 840, 1266, 2945, 683, 29, 8, 806, 111, 1095, 3628, 1310, 10521, 224, 77, 241, 1, 8057, 1545, 4246, 3, 10521, 26, 533, 31, 328, 53427, 4445, 10, 14077, 6, 5837, 256, 6370, 2, 53428, 11131, 2, 1416, 8, 2003, 775, 4, 928, 15909, 20275, 2, 8949, 805, 8658, 2761, 1, 15909, 97, 405, 6370, 485, 84, 15910, 20275, 2, 17186, 205, 44, 851, 1, 15909, 4138, 148, 1, 110, 15909, 2, 20275, 547, 851, 1, 20275, 15, 17186, 205, 44, 6075, 15909, 148, 3, 219, 782, 1, 2828, 15909, 20275, 17186, 2, 928, 8949, 11, 295, 62, 3885, 1, 15909, 2, 20275, 11, 4040, 2, 77, 138, 11, 204, 21, 2060, 17, 7013, 1, 22, 1145, 10039, 130, 17, 13779, 3, 791, 128, 15, 2087, 2145, 1, 15909, 68, 1617, 1266, 1753, 2, 1946, 91, 4, 7, 5, 329, 54, 1022, 44, 47, 8057, 1545]",1508.0,12637330,Acquired FANCA dysfunction cytogenetic instability adult acute myelogenous leukemia,0,0.0
"Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2003-03-01,"Troxacitabine has significant single-agent activity. This study was conducted to define the dose-limiting toxicities (DLTs) of its combination with cytarabine (ara-C), idarubicin, or topotecan. Patients with refractory acute myeloid leukemia (AML), advanced myelodysplastic syndromes (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP) were initially randomly assigned to receive troxacitabine 5.0 mg/m(2) by intravenous (IV) infusion over 30 minutes on days 1 to 5 with ara-C 1.0 g/m(2)/d IV [DOSAGE ERROR CORRECTED] over 2 hours on days 1 to 5, idarubicin 12 mg/m(2) by 5 minute IV infusion on days 1 to 3, or topotecan 1.0 mg/m(2) as an continuous IV infusion on days 1 to 5. Doses were then adjusted to define DLT for each combination. Eighty-seven patients (68 AML, eight MDS, 11 CML-BP) were treated. DLTs were hepatic transaminitis, hyperbilirubinemia, and hand foot syndrome (HFS) on the troxacitabine plus ara-C combination. The recommended phase II doses were 6 mg/m(2) once a day for 5 days and 1.0g/m(2) once a day for 5 days, respectively. DLTs were diarrhea, rash, and mucositis on the troxacitabine plus topotecan combination. The recommended phase II doses were 4 mg/m(2) once a day for 5 days and 0.75 mg/m(2) once a day for 5 days, respectively. DLTs were HFS, rash, and mucositis on the troxacitabine plus idarubicin combination. The recommended phase II doses were 4 mg/m(2) once a day for 5 days and 9 mg/m(2) once a day for 3 days, respectively. Among 74 evaluable patients with AML or MDS, 10 (13%) achieved complete remission and four (5%) had hematologic improvement. Two of 11 (18%) evaluable patients with CML-BP returned to chronic phase. Troxacitabine-based combinations had significant antileukemic activity.",Clinical Trial,6170.0,29.0,Troxacitabine significant single-agent activity conducted define dose-limiting toxicities DLTs combination cytarabine ara-C idarubicin topotecan Patients refractory acute myeloid leukemia AML advanced myelodysplastic syndromes MDS chronic myelogenous leukemia blastic phase CML-BP initially randomly assigned receive troxacitabine 5.0 mg/m 2 intravenous IV infusion 30 minutes days 1 5 ara-C 1.0 g/m 2 /d IV DOSAGE ERROR CORRECTED 2 hours days 1 5 idarubicin 12 mg/m 2 5 minute IV infusion days 1 3 topotecan 1.0 mg/m 2 continuous IV infusion days 1 5 Doses adjusted define DLT combination Eighty-seven patients 68 AML MDS 11 CML-BP treated DLTs hepatic transaminitis hyperbilirubinemia hand foot syndrome HFS troxacitabine plus ara-C combination recommended phase II doses 6 mg/m 2 day 5 days 1.0g/m 2 day 5 days respectively DLTs diarrhea rash mucositis troxacitabine plus topotecan combination recommended phase II doses 4 mg/m 2 day 5 days 0.75 mg/m 2 day 5 days respectively DLTs HFS rash mucositis troxacitabine plus idarubicin combination recommended phase II doses 4 mg/m 2 day 5 days 9 mg/m 2 day 3 days respectively 74 evaluable patients AML MDS 10 13 achieved complete remission 5 hematologic improvement 11 18 evaluable patients CML-BP returned chronic phase Troxacitabine-based combinations significant antileukemic activity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[10949, 71, 93, 226, 420, 128, 26, 45, 10, 426, 6, 1107, 3, 61, 817, 385, 2506, 1, 211, 150, 5, 1855, 3899, 256, 5684, 15, 2129, 7, 5, 430, 286, 533, 329, 131, 2040, 1223, 15, 442, 2194, 4, 6529, 124, 903, 3044, 11, 1625, 1108, 896, 6, 560, 10949, 33, 13, 81, 188, 18, 20, 1262, 478, 904, 252, 201, 2511, 23, 162, 14, 6, 33, 5, 3899, 256, 14, 13, 499, 188, 18, 427, 478, 3323, 3444, 3848, 252, 18, 1459, 23, 162, 14, 6, 33, 5684, 133, 81, 188, 18, 20, 33, 3949, 478, 904, 23, 162, 14, 6, 27, 15, 2129, 14, 13, 81, 188, 18, 22, 35, 1314, 478, 904, 23, 162, 14, 6, 33, 415, 11, 818, 586, 6, 1107, 2059, 9, 296, 150, 2207, 648, 7, 806, 329, 659, 1223, 175, 903, 3044, 11, 73, 2506, 11, 939, 8181, 7236, 2, 2833, 4100, 681, 8597, 23, 3, 10949, 349, 3899, 256, 150, 3, 793, 124, 215, 415, 11, 49, 81, 188, 18, 1059, 8, 218, 9, 33, 162, 2, 14, 53429, 188, 18, 1059, 8, 218, 9, 33, 162, 106, 2506, 11, 1172, 1641, 2, 2606, 23, 3, 10949, 349, 2129, 150, 3, 793, 124, 215, 415, 11, 39, 81, 188, 18, 1059, 8, 218, 9, 33, 162, 2, 13, 481, 81, 188, 18, 1059, 8, 218, 9, 33, 162, 106, 2506, 11, 8597, 1641, 2, 2606, 23, 3, 10949, 349, 5684, 150, 3, 793, 124, 215, 415, 11, 39, 81, 188, 18, 1059, 8, 218, 9, 33, 162, 2, 83, 81, 188, 18, 1059, 8, 218, 9, 27, 162, 106, 107, 794, 859, 7, 5, 329, 15, 1223, 79, 233, 513, 236, 734, 2, 294, 33, 42, 813, 767, 100, 1, 175, 203, 859, 7, 5, 903, 3044, 5157, 6, 442, 124, 10949, 90, 1247, 42, 93, 4512, 128]",1649.0,12637470,Randomized phase I/II troxacitabine combined cytarabine idarubicin topotecan patients refractory myeloid leukemias,0,0.0
"SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.",Blood,Blood,2003-03-20,"Increased bone marrow angiogenesis and vascular endothelial growth factor (VEGF) levels are adverse prognostic features in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDSs). VEGF is a soluble circulating angiogenic molecule that stimulates signaling via receptor tyrosine kinases (RTKs), including VEGF receptor 2 (VEGFR-2). AML blasts may express VEGFR-2, c-kit, and FLT3. SU5416 is a small molecule RTK inhibitor (RTKI) of VEGFR-2, c-kit, and both wild-type and mutant FLT3. A multicenter phase 2 study of SU5416 was conducted in patients with refractory AML or MDS. For a median of 9 weeks (range, 1-55 weeks), 55 patients (33 AML: 10 [30%] primary refractory, 23 [70%] relapsed; 22 MDS: 15 [68%] relapsed) received 145 mg/m2 SU5416 twice weekly intravenously. Grade 3 or 4 drug-related toxicities included headaches (14%), infusion-related reactions (11%), dyspnea (14%), fatigue (7%), thrombotic episodes (7%), bone pain (5%), and gastrointestinal disturbance (4%). There were 11 patients (20%) who did not complete 4 weeks of therapy (10 progressive disease, 1 adverse event); 3 patients (5%) who achieved partial responses; and 1 (2%) who achieved hematologic improvement. Single agent SU5416 had biologic and modest clinical activity in refractory AML/MDS. Overall median survival was 12 weeks in AML patients (range, 4-41 weeks) and not reached in MDS patients. Most observed toxicities were attributable to drug formulation (polyoxyl 35 castor oil or hyperosmolarity of the SU5416 preparation). Studies of other RTKI and/or other antiangiogenic approaches, with correlative studies to examine biologic effects, may be warranted in patients with AML/MDS.",Clinical Trial,6151.0,174.0,Increased bone marrow angiogenesis vascular endothelial growth factor VEGF levels adverse prognostic features patients acute myeloid leukemia AML myelodysplastic syndromes MDSs VEGF soluble circulating angiogenic molecule stimulates signaling receptor tyrosine kinases RTKs including VEGF receptor 2 VEGFR-2 AML blasts express VEGFR-2 c-kit FLT3 SU5416 small molecule RTK inhibitor RTKI VEGFR-2 c-kit wild-type FLT3 multicenter phase 2 SU5416 conducted patients refractory AML MDS median 9 weeks range 1-55 weeks 55 patients 33 AML 10 30 primary refractory 23 70 relapsed 22 MDS 15 68 relapsed received 145 mg/m2 SU5416 twice weekly intravenously Grade 3 4 drug-related toxicities included headaches 14 infusion-related reactions 11 dyspnea 14 fatigue 7 thrombotic episodes 7 bone pain 5 gastrointestinal disturbance 4 11 patients 20 complete 4 weeks therapy 10 progressive disease 1 adverse event 3 patients 5 achieved partial responses 1 2 achieved hematologic improvement Single agent SU5416 biologic modest clinical activity refractory AML/MDS Overall median survival 12 weeks AML patients range 4-41 weeks reached MDS patients observed toxicities attributable drug formulation polyoxyl 35 castor oil hyperosmolarity SU5416 preparation Studies RTKI and/or antiangiogenic approaches correlative studies examine biologic effects warranted patients AML/MDS,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[101, 581, 1056, 2, 756, 845, 129, 161, 618, 148, 32, 290, 177, 404, 4, 7, 5, 286, 533, 329, 15, 2040, 13550, 618, 16, 8, 2968, 1033, 2068, 1354, 17, 6200, 314, 847, 153, 564, 1549, 6798, 141, 618, 153, 18, 2134, 18, 329, 2438, 68, 1669, 2134, 18, 256, 1164, 2, 1224, 7711, 16, 8, 302, 1354, 5261, 230, 33396, 1, 2134, 18, 256, 1164, 2, 110, 955, 267, 2, 620, 1224, 8, 1570, 124, 18, 45, 1, 7711, 10, 426, 4, 7, 5, 430, 329, 15, 1223, 9, 8, 52, 1, 83, 244, 184, 14, 614, 244, 614, 7, 466, 329, 79, 201, 86, 430, 382, 431, 591, 350, 1223, 167, 806, 591, 103, 4058, 81, 821, 7711, 936, 709, 1672, 88, 27, 15, 39, 234, 139, 385, 159, 9783, 213, 904, 139, 2428, 175, 2923, 213, 613, 67, 6108, 3750, 67, 559, 33, 2, 6663, 39, 125, 11, 175, 7, 179, 54, 205, 44, 236, 39, 244, 1, 36, 79, 1014, 34, 14, 290, 774, 27, 7, 33, 54, 513, 450, 253, 2, 14, 18, 54, 513, 813, 767, 226, 420, 7711, 42, 1283, 2, 1721, 38, 128, 4, 430, 329, 1223, 63, 52, 25, 10, 133, 244, 4, 329, 7, 184, 39, 605, 244, 2, 44, 1300, 4, 1223, 7, 96, 164, 385, 11, 2971, 6, 234, 3583, 53443, 465, 28031, 9481, 15, 30383, 1, 3, 7711, 4824, 94, 1, 127, 33396, 2, 15, 127, 2168, 611, 5, 3679, 94, 6, 1004, 1283, 176, 68, 40, 1197, 4, 7, 5, 329, 1223]",1544.0,12649163,SU5416 small molecule tyrosine kinase receptor inhibitor biologic activity patients refractory acute myeloid leukemia myelodysplastic syndromes,142,0.24781849912739964
New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2003-04-01,"To determine the incidence and risk factors for the development of new malignancies occurring after stem-cell transplantation (SCT). Between January 1, 1974, and March 31, 2001, 3,372 patients underwent SCT at the University of Minnesota. From these transplants, 147 posttransplant malignancies (PTMs) were identified in 137 patients. Excluding nonmelanoma skin cancers (n = 19) and carcinoma-in-situ (n = 5), the remaining 123 cases represented an 8.1-fold (95% confidence interval [CI], 6.7 to 9.6) increased risk of a PTM, an excess risk of 102.7 cases/10,000 persons/yr (age and sex adjusted). This includes a significantly elevated risk for developing myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML; standardized incidence ratio [SIR] = 300; 95% CI, 210 to 406), non-Hodgkin's lymphoma including posttransplant lymphoproliferative disorder (PTLD; SIR = 54.3; 95% CI, 39.5 to 41.1), Hodgkin's disease (SIR = 14.8; 95% CI, 3.9 to 32.9), or solid tumors overall (SIR = 2.8; CI, 2.0 to 3.7) and in specific for melanoma, brain, and oral cavity tumors. The cumulative incidence for the development of any PTM was 6.9% (95% CI, 5.2 to 8.6) at 20 years post-SCT. For PTLD (n = 43), the cumulative incidence plateaued at 1.4% (95% CI, 1.0 to 1.8) by 10 years post-SCT. For MDS or AML, the cumulative incidence plateaued at 1.4% (95% CI, 0.9 to 1.9) by 10 years post-SCT. The cumulative incidence of developing a solid tumor did not plateau and was 3.8% (95% CI, 2.2 to 5.4) at 20 years post-SCT. These data reveal that the risk of PTMs, especially solid tumors, continues to increase even 20 years after transplant, necessitating long-term close follow-up for these patients.",Journal Article,6139.0,221.0,"determine incidence risk factors development new malignancies occurring stem-cell transplantation SCT January 1 1974 March 31 2001 3,372 patients underwent SCT University Minnesota transplants 147 posttransplant malignancies PTMs identified 137 patients Excluding nonmelanoma skin n 19 carcinoma-in-situ n 5 remaining 123 cases represented 8.1-fold 95 confidence interval CI 6.7 9.6 increased risk PTM excess risk 102.7 cases/10,000 persons/yr age sex adjusted includes significantly elevated risk developing myelodysplastic syndrome MDS acute myeloid leukemia AML standardized incidence ratio SIR 300 95 CI 210 406 non-Hodgkin 's lymphoma including posttransplant lymphoproliferative disorder PTLD SIR 54.3 95 CI 39.5 41.1 Hodgkin 's disease SIR 14.8 95 CI 3.9 32.9 solid overall SIR 2.8 CI 2.0 3.7 specific melanoma brain oral cavity cumulative incidence development PTM 6.9 95 CI 5.2 8.6 20 years post-SCT PTLD n 43 cumulative incidence plateaued 1.4 95 CI 1.0 1.8 10 years post-SCT MDS AML cumulative incidence plateaued 1.4 95 CI 0.9 1.9 10 years post-SCT cumulative incidence developing solid plateau 3.8 95 CI 2.2 5.4 20 years post-SCT reveal risk PTMs especially solid continues increase 20 years transplant necessitating long-term close follow-up patients",0,0,1,0,0,1,0,1,0,0,0,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[6, 223, 3, 287, 2, 43, 130, 9, 3, 193, 1, 217, 441, 1821, 50, 452, 31, 497, 1988, 59, 1024, 14, 10201, 2, 2363, 456, 1758, 27, 10659, 7, 208, 1988, 28, 3, 1652, 1, 8297, 29, 46, 4016, 4961, 7346, 441, 33402, 11, 108, 4, 4352, 7, 3207, 7814, 163, 78, 326, 2, 134, 4, 957, 78, 33, 3, 1844, 2698, 140, 3324, 35, 66, 14, 1116, 48, 307, 268, 58, 49, 67, 6, 83, 49, 101, 43, 1, 8, 23207, 35, 2612, 43, 1, 2867, 67, 140, 79, 984, 4327, 2830, 89, 2, 1035, 586, 26, 1920, 8, 97, 804, 43, 9, 931, 681, 1223, 15, 286, 533, 329, 1670, 287, 197, 3636, 2036, 48, 58, 5376, 6, 8522, 292, 141, 7346, 4192, 2645, 10709, 3636, 667, 27, 48, 58, 587, 33, 6, 605, 14, 292, 34, 3636, 213, 66, 48, 58, 27, 83, 6, 531, 83, 15, 537, 57, 63, 3636, 18, 66, 58, 18, 13, 6, 27, 67, 2, 4, 112, 9, 342, 2, 518, 2405, 57, 3, 967, 287, 9, 3, 193, 1, 500, 23207, 10, 49, 83, 48, 58, 33, 18, 6, 66, 49, 28, 179, 60, 539, 1988, 9, 10709, 78, 601, 3, 967, 287, 13294, 28, 14, 39, 48, 58, 14, 13, 6, 14, 66, 20, 79, 60, 539, 1988, 9, 1223, 15, 329, 3, 967, 287, 13294, 28, 14, 39, 48, 58, 13, 83, 6, 14, 83, 20, 79, 60, 539, 1988, 3, 967, 287, 1, 931, 8, 537, 30, 205, 44, 6133, 2, 10, 27, 66, 48, 58, 18, 18, 6, 33, 39, 28, 179, 60, 539, 1988, 46, 74, 2396, 17, 3, 43, 1, 33402, 1093, 537, 57, 2274, 6, 344, 871, 179, 60, 50, 941, 8365, 319, 337, 2336, 166, 126, 9, 46, 7]",1517.0,12663726,New malignancies blood marrow stem-cell transplantation children adults incidence risk factors,35,0.06108202443280977
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.,Blood,Blood,2003-05-08,"Gemtuzumab ozogamicin (GO), a monoclonal antibody used in the treatment of acute myelogenous leukemia (AML) has been linked to the development of venoocclusive disease (VOD). We conducted a retrospective study of 62 patients with previously treated AML/MDS (myelodysplastic syndrome) who underwent allogeneic stem cell (SC) transplantation at our institution from December 2000 to October 2002 to determine whether GO exposure prior to allogeneic SC transplantation increases the risk of developing VOD. Fourteen patients received GO prior to SC transplantation. Of 62 patients, 13 (21%) developed VOD; 9 (64%) of 14 with prior GO exposure developed VOD compared with 4 (8%) of 48 without prior GO exposure (P <.0001). Logistic regression controlling for sex, disease status, donor type, and graft-versus-host disease prophylaxis identified prior treatment with GO as a significant risk factor for VOD (odds ratio [OR], 21.6; 95% confidence interval [CI], 4.2-112.2]. Nine of 10 patients who underwent SC transplantation 3.5 months or less following GO developed VOD compared with none of 4 patients who underwent SC transplantation more than 3.5 months from GO administration. Three of 14 patients who received GO prior to SC transplantation died of VOD. We conclude that patients undergoing SC transplantation within a short interval from GO administration are at increased risk of developing VOD.",Journal Article,6102.0,223.0,Gemtuzumab ozogamicin monoclonal antibody treatment acute myelogenous leukemia AML linked development venoocclusive disease VOD conducted retrospective 62 patients previously treated AML/MDS myelodysplastic syndrome underwent allogeneic stem SC transplantation institution December 2000 October 2002 determine exposure prior allogeneic SC transplantation increases risk developing VOD Fourteen patients received prior SC transplantation 62 patients 13 21 developed VOD 9 64 14 prior exposure developed VOD compared 4 8 48 prior exposure P .0001 Logistic regression controlling sex disease status donor type graft-versus-host disease prophylaxis identified prior treatment significant risk factor VOD odds ratio 21.6 95 confidence interval CI 4.2-112.2 10 patients underwent SC transplantation 3.5 months following developed VOD compared 4 patients underwent SC transplantation 3.5 months administration 14 patients received prior SC transplantation died VOD conclude patients undergoing SC transplantation short interval administration increased risk developing VOD,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7918, 5566, 3537, 8, 848, 548, 95, 4, 3, 24, 1, 286, 2194, 329, 71, 85, 1199, 6, 3, 193, 1, 20232, 34, 8768, 21, 426, 8, 459, 45, 1, 744, 7, 5, 373, 73, 329, 1223, 681, 54, 208, 1063, 452, 31, 2969, 497, 28, 114, 731, 29, 1397, 1081, 6, 2551, 1544, 6, 223, 317, 3537, 645, 324, 6, 1063, 2969, 497, 1106, 3, 43, 1, 931, 8768, 3225, 7, 103, 3537, 324, 6, 2969, 497, 1, 744, 7, 233, 239, 276, 8768, 83, 660, 1, 213, 5, 324, 3537, 645, 276, 8768, 72, 5, 39, 66, 1, 576, 187, 324, 3537, 645, 19, 488, 812, 320, 1893, 9, 1035, 34, 156, 1488, 267, 2, 1599, 185, 1204, 34, 2049, 108, 324, 24, 5, 3537, 22, 8, 93, 43, 161, 9, 8768, 610, 197, 15, 239, 49, 48, 307, 268, 58, 39, 18, 3726, 18, 762, 1, 79, 7, 54, 208, 2969, 497, 27, 33, 53, 15, 299, 366, 3537, 276, 8768, 72, 5, 1292, 1, 39, 7, 54, 208, 2969, 497, 80, 76, 27, 33, 53, 29, 3537, 634, 169, 1, 213, 7, 54, 103, 3537, 324, 6, 2969, 497, 1016, 1, 8768, 21, 2060, 17, 7, 479, 2969, 497, 262, 8, 978, 268, 29, 3537, 634, 32, 28, 101, 43, 1, 931, 8768]",1328.0,12738663,Prior gemtuzumab ozogamicin exposure significantly increases risk veno-occlusive disease patients undergo myeloablative allogeneic stem transplantation,0,0.0
"Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.",Cancer,Cancer,2003-06-01,"Imatinib mesylate is a selective tyrosine kinase inhibitor of c-abl, bcr/abl, c-kit, and platelet-derived growth factor-receptor (PDGF-R). c-kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated in the pathogenesis of myeloproliferative disorders (MPD). The authors investigated the efficacy of imatinib in patients with these disorders. Forty-eight patients with AML (n = 10), MDS (n = 8), myelofibrosis (n = 18), atypical chronic myeloid leukemia (CML; n = 7), chronic myelomonocytic leukemia (CMML; n = 3), or polycythemia vera (n = 2) were treated with imatinib 400 mg daily. None of the patients with AML or MDS responded. Among patients with myelofibrosis, 10 of 14 patients with splenomegaly (71%) had a 30% or greater reduction in spleen size, 1 patient had trilineage hematologic improvement, 2 had erythroid hematologic improvement, and 1 had improvement in platelet count. One patient with atypical CML had erythroid hematologic improvement. Both patients with polycythemia vera needed fewer phlebotomies (from 2-3 per year to none during the 8 months of therapy and from 3-6 per year to 1 during 9 months of therapy). None of the three patients with CMML responded. Treatment was well tolerated. The side effects were similar to those observed in patients with CML. Within these small subgroups of disease types, single-agent imatinib did not achieve a significant clinical response among patients with AML, MDS, atypical CML, or CMML without PDGF-R fusion genes. Preliminary data on polycythemia vera are promising and deserve further investigation. Responses among myelofibrosis patients were minor. Therefore, a combination treatment regimen including imatinib may be more effective.",Journal Article,6078.0,83.0,Imatinib mesylate selective tyrosine kinase inhibitor c-abl bcr/abl c-kit platelet-derived growth factor-receptor PDGF-R c-kit expressed patients acute myeloid leukemia AML myelodysplastic syndrome MDS PDGF implicated pathogenesis myeloproliferative disorders MPD authors investigated efficacy imatinib patients disorders Forty-eight patients AML n 10 MDS n 8 myelofibrosis n 18 atypical chronic myeloid leukemia CML n 7 chronic myelomonocytic leukemia CMML n 3 polycythemia vera n 2 treated imatinib 400 mg daily patients AML MDS responded patients myelofibrosis 10 14 patients splenomegaly 71 30 greater reduction spleen size 1 patient trilineage hematologic improvement 2 erythroid hematologic improvement 1 improvement platelet count patient atypical CML erythroid hematologic improvement patients polycythemia vera needed fewer phlebotomies 2-3 year 8 months therapy 3-6 year 1 9 months therapy patients CMML responded Treatment tolerated effects similar observed patients CML small subgroups disease types single-agent imatinib achieve significant clinical response patients AML MDS atypical CML CMML PDGF-R fusion Preliminary polycythemia vera promising deserve investigation Responses myelofibrosis patients minor combination treatment regimen including imatinib effective,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[577, 2347, 16, 8, 1094, 564, 216, 230, 1, 256, 1425, 1062, 1425, 256, 1164, 2, 1596, 526, 129, 161, 153, 4546, 668, 256, 1164, 16, 570, 4, 96, 7, 5, 286, 533, 329, 2, 681, 1223, 2, 4546, 71, 85, 1771, 4, 3, 1384, 1, 1997, 7712, 3, 738, 565, 3, 209, 1, 577, 4, 7, 5, 46, 1997, 1213, 659, 7, 5, 329, 78, 79, 1223, 78, 66, 4637, 78, 203, 1973, 442, 533, 903, 78, 67, 442, 5451, 3382, 78, 27, 15, 5755, 5756, 78, 18, 11, 73, 5, 577, 1524, 81, 391, 1292, 1, 3, 7, 5, 329, 15, 1223, 2211, 107, 7, 5, 4637, 79, 1, 213, 7, 5, 6364, 792, 42, 8, 201, 15, 378, 628, 4, 4071, 444, 14, 69, 42, 21950, 813, 767, 18, 42, 7839, 813, 767, 2, 14, 42, 767, 4, 1596, 1276, 104, 69, 5, 1973, 903, 42, 7839, 813, 767, 110, 7, 5, 5755, 5756, 575, 1497, 37459, 29, 18, 27, 379, 111, 6, 1292, 190, 3, 66, 53, 1, 36, 2, 29, 27, 49, 379, 111, 6, 14, 190, 83, 53, 1, 36, 1292, 1, 3, 169, 7, 5, 3382, 2211, 24, 10, 149, 421, 3, 1152, 176, 11, 288, 6, 135, 164, 4, 7, 5, 903, 262, 46, 302, 1453, 1, 34, 630, 226, 420, 577, 205, 44, 1359, 8, 93, 38, 51, 107, 7, 5, 329, 1223, 1973, 903, 15, 3382, 187, 4546, 668, 1212, 214, 1676, 74, 23, 5755, 5756, 32, 721, 2, 14825, 195, 940, 253, 107, 4637, 7, 11, 2278, 673, 8, 150, 24, 477, 141, 577, 68, 40, 80, 323]",1642.0,12767088,imatinib mesylate therapy patients refractory recurrent acute myeloid leukemia high-risk myelodysplastic syndrome myeloproliferative disorders,91,0.15881326352530542
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.,Blood,Blood,2003-06-05,"In a phase 2 study, 62 patients with relapsed and refractory acute myeloid leukemia (AML; n = 31), myelodysplastic syndrome (MDS; n = 8), chronic myeloid leukemia in blastic phase (CMLBP; n = 11), and acute lymphocytic leukemia (ALL; n = 12) received 40 mg/m2 clofarabine intravenously over 1 hour daily for 5 days, every 3 to 6 weeks. Twenty patients (32%) achieved complete response (CR), 1 had a partial response (PR), and 9 (15%) achieved CR but without platelet recovery (CRp), for an overall response rate of 48%. In AML, responses were noted in 2 (18%) of 11 patients in first salvage with short first CR (</= 12 months), in 7 (87%) of 8 patients with longer first CR, and in 8 (67%) of 12 patients in second or subsequent salvage. Responses were observed in 4 of 8 patients with high-risk MDS (50%), in 7 (64%) of 11 with CML-BP, and in 2 (17%) of 12 with ALL. Severe reversible liver dysfunction was noted in 15% to 25%. After the first clofarabine infusion, responders accumulated more clofarabine triphosphate in blasts compared with nonresponders (median 18 vs 10 microM; P =.03). This increased only in responders (median, 1.8-fold; P =.008) after the second clofarabine infusion. In summary, clofarabine is active in acute leukemias and MDS; cellular pharmacokinetics may have prognostic significance.",Clinical Trial,6074.0,255.0,phase 2 62 patients relapsed refractory acute myeloid leukemia AML n 31 myelodysplastic syndrome MDS n 8 chronic myeloid leukemia blastic phase CMLBP n 11 acute lymphocytic leukemia n 12 received 40 mg/m2 clofarabine intravenously 1 hour daily 5 days 3 6 weeks patients 32 achieved complete response CR 1 partial response PR 9 15 achieved CR platelet recovery CRp overall response rate 48 AML responses noted 2 18 11 patients salvage short CR /= 12 months 7 87 8 patients longer CR 8 67 12 patients second subsequent salvage Responses observed 4 8 patients high-risk MDS 50 7 64 11 CML-BP 2 17 12 Severe reversible liver dysfunction noted 15 25 clofarabine infusion responders accumulated clofarabine triphosphate blasts compared nonresponders median 18 vs 10 microM P =.03 increased responders median 1.8-fold P =.008 second clofarabine infusion summary clofarabine active acute leukemias MDS cellular pharmacokinetics prognostic significance,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[4, 8, 124, 18, 45, 744, 7, 5, 591, 2, 430, 286, 533, 329, 78, 456, 681, 1223, 78, 66, 442, 533, 4, 6529, 124, 53560, 78, 175, 2, 286, 1193, 62, 78, 133, 103, 327, 81, 821, 4149, 1672, 252, 14, 2583, 391, 9, 33, 162, 454, 27, 6, 49, 244, 737, 7, 531, 513, 236, 51, 684, 14, 42, 8, 450, 51, 998, 2, 83, 167, 513, 684, 84, 187, 1596, 1602, 3162, 9, 35, 63, 51, 116, 1, 576, 4, 329, 253, 11, 1051, 4, 18, 203, 1, 175, 7, 4, 157, 992, 5, 978, 157, 684, 133, 53, 4, 67, 912, 1, 66, 7, 5, 589, 157, 684, 2, 4, 66, 598, 1, 133, 7, 4, 419, 15, 706, 992, 253, 11, 164, 4, 39, 1, 66, 7, 5, 64, 43, 1223, 212, 4, 67, 660, 1, 175, 5, 903, 3044, 2, 4, 18, 269, 1, 133, 5, 62, 905, 2786, 1527, 10, 1051, 4, 167, 6, 243, 50, 3, 157, 4149, 904, 1983, 6664, 80, 4149, 7345, 4, 2438, 72, 5, 4498, 52, 203, 105, 79, 3550, 19, 680, 26, 101, 158, 4, 1983, 52, 14, 66, 1116, 19, 2155, 50, 3, 419, 4149, 904, 4, 1962, 4149, 16, 544, 4, 286, 2792, 2, 1223, 763, 1159, 68, 47, 177, 724]",1179.0,12791647,Phase 2 clinical pharmacologic clofarabine patients refractory relapsed acute leukemia,106,0.1849912739965096
Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome.,Leukemia research,Leuk. Res.,2003-09-01,"The syndrome of chronic myelomonocytic leukemia (CMML) includes a heterogeneous group of patients who exhibit both myelodysplastic and myeloproliferative clinicopathological features. Troublesome splenomegaly is uncommon in myelodysplastic syndrome (MDS), but when organomegaly occurs, this complication is more likely to be associated with myelodysplastic-myeloproliferative overlap syndromes such as CMML rather than ""dysplasia-only"" MDS types such as refractory anemia. We report a single-institution experience with splenectomy in CMML patients, including a detailed review of splenic histopathology. Twelve patients with CMML underwent splenectomy at the Mayo Clinic, primarily because of refractory thrombocytopenia and/or mechanical complications related to splenomegaly. Three of the 12 patients (25%) died as a direct result of surgery, and significant postoperative morbidity was seen in another 4 patients (33%). Thrombocytopenia improved in 4 of the 11 patients (36%) with low platelet counts before surgery. Three of the four responders had an abundance of CD68 (PGM1)-positive foamy histiocytes in the marginal zone surrounding the splenic white pulp-a pattern which can be seen in immune thrombocytopenia-and two of these three patients had thrombocytopenia out of proportion to the degree of anemia pre-operatively, suggestive of peripheral destruction of platelets. More consistent splenic pathological findings in the 12 patients included trilineage extramedullary hematopoiesis in splenic red pulp and expansion of splenic cords by a myelomonocytic infiltrate. This study underscores both the uniformity and diversity of splenic findings in CMML, highlights the potential dangers and benefits of splenectomy in this group, and suggests peripheral destruction of platelets as a mechanism contributing to thrombocytopenia in a subset of CMML patients.",Journal Article,5986.0,25.0,syndrome chronic myelomonocytic leukemia CMML includes heterogeneous group patients exhibit myelodysplastic myeloproliferative clinicopathological features Troublesome splenomegaly uncommon myelodysplastic syndrome MDS organomegaly occurs complication likely associated myelodysplastic-myeloproliferative overlap syndromes CMML `` dysplasia-only '' MDS types refractory anemia report single-institution experience splenectomy CMML patients including detailed review splenic histopathology patients CMML underwent splenectomy Mayo Clinic primarily refractory thrombocytopenia and/or mechanical complications related splenomegaly 12 patients 25 died direct surgery significant postoperative morbidity seen 4 patients 33 Thrombocytopenia improved 4 11 patients 36 low platelet counts surgery responders abundance CD68 PGM1 -positive foamy histiocytes marginal zone surrounding splenic white pulp-a pattern seen immune thrombocytopenia-and patients thrombocytopenia proportion degree anemia pre-operatively suggestive peripheral destruction platelets consistent splenic pathological findings 12 patients included trilineage extramedullary hematopoiesis splenic red pulp expansion splenic cords myelomonocytic infiltrate underscores uniformity diversity splenic findings CMML highlights potential dangers benefits splenectomy group suggests peripheral destruction platelets mechanism contributing thrombocytopenia subset CMML patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 681, 1, 442, 5451, 3382, 1920, 8, 1564, 87, 1, 7, 54, 2239, 110, 2, 2721, 404, 22115, 6364, 16, 2052, 4, 681, 1223, 84, 198, 16738, 1780, 26, 1447, 16, 80, 322, 6, 40, 41, 5, 10589, 10857, 4526, 2040, 225, 22, 3382, 1832, 76, 2253, 158, 522, 1223, 630, 225, 22, 430, 1545, 21, 414, 8, 226, 731, 730, 5, 6569, 4, 3382, 7, 141, 8, 2455, 206, 1, 5237, 3831, 2544, 7, 5, 3382, 208, 6569, 28, 3, 2486, 1188, 1561, 408, 1, 430, 1340, 2, 15, 6065, 521, 139, 6, 6364, 169, 1, 3, 133, 7, 243, 1016, 22, 8, 1196, 757, 1, 152, 2, 93, 573, 787, 10, 527, 4, 1809, 39, 7, 466, 1340, 231, 4, 39, 1, 3, 175, 7, 511, 5, 154, 1596, 1911, 348, 152, 169, 1, 3, 294, 1983, 42, 35, 4778, 1, 6439, 53579, 109, 30400, 16734, 4, 3, 3450, 3614, 2976, 3, 5237, 886, 23231, 8, 1177, 92, 122, 40, 527, 4, 250, 1340, 2, 100, 1, 46, 169, 7, 42, 1340, 1205, 1, 920, 6, 3, 1444, 1, 1545, 671, 9433, 3832, 1, 672, 4572, 1, 4407, 80, 925, 5237, 1301, 272, 4, 3, 133, 7, 159, 21950, 5508, 5114, 4, 5237, 3422, 23231, 2, 1422, 1, 5237, 17654, 20, 8, 5451, 5172, 26, 45, 6926, 110, 3, 9338, 2, 3653, 1, 5237, 272, 4, 3382, 2527, 3, 174, 43271, 2, 1141, 1, 6569, 4, 26, 87, 2, 844, 672, 4572, 1, 4407, 22, 8, 670, 3156, 6, 1340, 4, 8, 697, 1, 3382, 7]",1781.0,12804634,Splenic histopathological patterns chronic myelomonocytic leukemia clinical correlations reinforcement heterogeneity syndrome,11,0.019197207678883072
"Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2003-07-01,"To test the hypothesis that therapy of intermediate- and high-grade (excluding Burkitt lymphoblastic) lymphoma with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) could be safely dose-intensified with routine filgrastim support. Eligible patients were those who were previously untreated and who had either bulky stage II, or stage III or IV lymphoma with working formulation histology D, E, F, G, H, or J; performance status < or = 2; and acceptable end organ function. No upper age limit was specified. Therapy was dose-intensified CHOP (CHOP-DI) with filgrastim support. Each course was repeated every 14 days for six planned courses. Eighty-eight eligible patients were treated with CHOP-DI and had a median follow-up of 5.1 years on this phase II study, designated Southwest Oncology Group (SWOG) 9349. The progression-free survival was 51% at 2 years and 41% at 5 years. The overall survival was 60% at 5 years. Three fatal treatment-related events occurred. One patient with myelodysplastic syndrome was reported. Treatment with CHOP-DI can be safely administered in the cooperative group setting and results in improved survival. Estimated overall survival at 5 years was 14% better than that of patients treated with standard-dose CHOP in an earlier SWOG study, although progression-free survival of 60% at 2 years-the prespecified end point-was not achieved. CHOP-DI, given every 2 weeks at escalated doses, is a strategy that should be tested in a future randomized clinical trial in lymphoma.",Clinical Trial,6048.0,67.0,test hypothesis therapy intermediate- high-grade excluding Burkitt lymphoblastic lymphoma cyclophosphamide doxorubicin vincristine prednisone CHOP safely dose-intensified routine filgrastim support Eligible patients previously untreated bulky stage II stage III IV lymphoma working formulation histology E F G H J performance status 2 acceptable end organ function upper age limit specified Therapy dose-intensified CHOP CHOP-DI filgrastim support course repeated 14 days planned courses Eighty-eight eligible patients treated CHOP-DI median follow-up 5.1 years phase II designated Southwest Oncology Group SWOG 9349 progression-free survival 51 2 years 41 5 years overall survival 60 5 years fatal treatment-related events occurred patient myelodysplastic syndrome reported Treatment CHOP-DI safely administered cooperative group setting improved survival Estimated overall survival 5 years 14 better patients treated standard-dose CHOP earlier SWOG progression-free survival 60 2 years-the prespecified end point-was achieved CHOP-DI given 2 weeks escalated doses strategy tested future randomized clinical trial lymphoma,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 412, 3, 1492, 17, 36, 1, 919, 2, 64, 88, 3207, 1275, 5, 1112, 856, 2132, 2, 1979, 2907, 359, 40, 2268, 61, 7311, 5, 1311, 5552, 538, 625, 7, 11, 135, 54, 11, 373, 1278, 2, 54, 42, 361, 4112, 82, 215, 15, 82, 316, 15, 478, 5, 2644, 3583, 784, 427, 563, 1068, 499, 555, 15, 3543, 528, 156, 15, 18, 2, 1595, 396, 1259, 343, 77, 1726, 89, 2385, 10, 3575, 36, 10, 61, 7311, 2907, 2907, 6641, 5, 5552, 538, 296, 906, 10, 2113, 454, 213, 162, 9, 437, 1465, 1993, 2207, 659, 625, 7, 11, 73, 5, 2907, 6641, 2, 42, 8, 52, 166, 126, 1, 33, 14, 60, 23, 26, 124, 215, 45, 4107, 6625, 413, 87, 5462, 53600, 3, 91, 115, 25, 10, 725, 28, 18, 60, 2, 605, 28, 33, 60, 3, 63, 25, 10, 335, 28, 33, 60, 169, 3034, 24, 139, 281, 489, 104, 69, 5, 681, 10, 210, 24, 5, 2907, 6641, 122, 40, 2268, 468, 4, 3, 1690, 87, 546, 2, 99, 4, 231, 25, 661, 63, 25, 28, 33, 60, 10, 213, 380, 76, 17, 1, 7, 73, 5, 260, 61, 2907, 4, 35, 1677, 5462, 45, 242, 91, 115, 25, 1, 335, 28, 18, 60, 3, 4075, 396, 741, 10, 44, 513, 2907, 6641, 447, 454, 18, 244, 28, 2842, 415, 16, 8, 692, 17, 257, 40, 650, 4, 8, 508, 384, 38, 160, 4]",1427.0,12829664,Dose-intense chemotherapy 2 weeks dose-intense cyclophosphamide doxorubicin vincristine prednisone improve survival intermediate- high-grade lymphoma phase II Southwest Oncology Group SWOG 9349,9,0.015706806282722512
Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer.,The New England journal of medicine,N. Engl. J. Med.,2003-07-01,"The prognosis for women with primary breast cancer and 10 or more involved axillary lymph nodes is poor. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation has been reported to be effective in the adjuvant setting for patients at high risk for relapse. We randomly assigned 540 female patients with primary breast cancer and at least 10 involved ipsilateral axillary lymph nodes to receive either six cycles of adjuvant chemotherapy with cyclophosphamide, doxorubicin, and fluorouracil (CAF) or the same adjuvant chemotherapy followed by high-dose chemotherapy with cyclophosphamide and thiotepa and autologous hematopoietic stem-cell transplantation. Among the 511 eligible patients, there was no significant difference in disease-free survival, overall survival, or the time to recurrence between those who received CAF alone and those who received CAF plus high-dose chemotherapy and stem-cell transplantation. Among 417 patients fulfilling strict eligibility criteria, the time to recurrence was longer for patients who underwent stem-cell transplantation than for those who received CAF alone. In the transplantation group, nine patients died of transplantation-related complications and a myelodysplastic syndrome or acute myeloid leukemia developed in nine. The addition of high-dose chemotherapy and autologous hematopoietic stem-cell transplantation to six cycles of adjuvant chemotherapy with CAF may reduce the risk of relapse but does not improve the outcome among patients with primary breast cancer and at least 10 involved axillary lymph nodes. Conventional-dose adjuvant chemotherapy remains the standard of care for such patients.",Clinical Trial,6048.0,156.0,prognosis women primary breast 10 involved axillary lymph nodes poor High-dose chemotherapy autologous hematopoietic stem-cell transplantation reported effective adjuvant setting patients high risk relapse randomly assigned 540 female patients primary breast 10 involved ipsilateral axillary lymph nodes receive cycles adjuvant chemotherapy cyclophosphamide doxorubicin fluorouracil CAF adjuvant chemotherapy followed high-dose chemotherapy cyclophosphamide thiotepa autologous hematopoietic stem-cell transplantation 511 eligible patients significant difference disease-free survival overall survival time recurrence received CAF received CAF plus high-dose chemotherapy stem-cell transplantation 417 patients fulfilling strict eligibility criteria time recurrence longer patients underwent stem-cell transplantation received CAF transplantation group patients died transplantation-related complications myelodysplastic syndrome acute myeloid leukemia developed addition high-dose chemotherapy autologous hematopoietic stem-cell transplantation cycles adjuvant chemotherapy CAF reduce risk relapse improve outcome patients primary breast 10 involved axillary lymph nodes Conventional-dose adjuvant chemotherapy remains standard care patients,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 356, 9, 117, 5, 86, 12, 2, 79, 15, 80, 646, 1210, 263, 502, 16, 334, 64, 61, 56, 5, 1028, 1007, 452, 31, 497, 71, 85, 210, 6, 40, 323, 4, 3, 249, 546, 9, 7, 28, 64, 43, 9, 429, 21, 1108, 896, 9780, 1061, 7, 5, 86, 12, 2, 28, 506, 79, 646, 2880, 1210, 263, 502, 6, 560, 361, 437, 410, 1, 249, 56, 5, 1112, 856, 2, 1404, 7347, 15, 3, 827, 249, 56, 370, 20, 64, 61, 56, 5, 1112, 2, 8182, 2, 1028, 1007, 452, 31, 497, 107, 3, 10532, 625, 7, 125, 10, 77, 93, 523, 4, 34, 115, 25, 63, 25, 15, 3, 98, 6, 146, 59, 135, 54, 103, 7347, 279, 2, 135, 54, 103, 7347, 349, 64, 61, 56, 2, 452, 31, 497, 107, 9947, 7, 16200, 8043, 2317, 371, 3, 98, 6, 146, 10, 589, 9, 7, 54, 208, 452, 31, 497, 76, 9, 135, 54, 103, 7347, 279, 4, 3, 497, 87, 762, 7, 1016, 1, 497, 139, 521, 2, 8, 681, 15, 286, 533, 276, 4, 762, 3, 352, 1, 64, 61, 56, 2, 1028, 1007, 452, 31, 497, 6, 437, 410, 1, 249, 56, 5, 7347, 68, 969, 3, 43, 1, 429, 84, 1097, 44, 401, 3, 228, 107, 7, 5, 86, 12, 2, 28, 506, 79, 646, 1210, 263, 502, 809, 61, 249, 56, 469, 3, 260, 1, 165, 9, 225, 7]",1612.0,12840088,Conventional adjuvant chemotherapy high-dose chemotherapy autologous stem-cell transplantation high-risk breast,0,0.0
Phase I study of oral topotecan in hematological malignancies.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2003-09-01,"In this Phase I, dose-seeking study, we investigated the dose-limiting toxicities (DLTs) and maximal tolerated dose (MTD) of oral topotecan in patients with hematological malignancies. Patients with myelodysplastic syndromes, myeloproliferative disorders, or relapsed acute myelogenous leukemia were treated with 0.6-1.9 mg/m(2)/day oral topotecan for 5 consecutive days on and 2 days off, for 3 weeks (15 doses/course) followed by 2-4 weeks of rest. The DLTs occurring during the first course of treatment were considered for defining the MTD. Preliminary results of antitumor activity were assessed by examining bone marrow status and peripheral blood cell counts. All 26 patients enrolled in the study were evaluable for toxicity, and 24 patients were evaluable for response. A total of 54 courses were administered. The most frequently reported nonhematological toxicities (percentage of courses) were diarrhea (57%), nausea/vomiting (50%), fatigue (24%), and mucositis (9%). DLTs included grade 3 or 4 nausea/vomiting and diarrhea at 1.9 mg/m(2)/day. The MTD for oral topotecan in patients with hematological malignancies was defined at 1.4 mg/m(2)/day. Hematological toxicity was noted in all 26 patients and with all courses but was not considered dose-limiting. Four (17%) patients achieved a complete response, and six (25%) patients experienced hematological improvement. Protracted administration of oral topotecan is safe and well tolerated in patients with hematological malignancies. At the dose-schedule used, single-agent oral topotecan has a definite activity in patients with myelodysplastic syndrome and acute myelogenous leukemia and warrants further investigation alone or in combination with other agents.",Clinical Trial,5986.0,12.0,Phase dose-seeking investigated dose-limiting toxicities DLTs maximal tolerated dose MTD oral topotecan patients hematological malignancies Patients myelodysplastic syndromes myeloproliferative disorders relapsed acute myelogenous leukemia treated 0.6-1.9 mg/m 2 /day oral topotecan 5 consecutive days 2 days 3 weeks 15 doses/course followed 2-4 weeks rest DLTs occurring course treatment considered defining MTD Preliminary antitumor activity assessed examining bone marrow status peripheral blood counts 26 patients enrolled evaluable toxicity 24 patients evaluable response total 54 courses administered frequently reported nonhematological toxicities percentage courses diarrhea 57 nausea/vomiting 50 fatigue 24 mucositis 9 DLTs included grade 3 4 nausea/vomiting diarrhea 1.9 mg/m 2 /day MTD oral topotecan patients hematological malignancies defined 1.4 mg/m 2 /day Hematological toxicity noted 26 patients courses considered dose-limiting 17 patients achieved complete response 25 patients experienced hematological improvement Protracted administration oral topotecan safe tolerated patients hematological malignancies dose-schedule single-agent oral topotecan definite activity patients myelodysplastic syndrome acute myelogenous leukemia warrants investigation combination agents,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 26, 124, 70, 61, 5734, 45, 21, 565, 3, 61, 817, 385, 2506, 2, 2725, 421, 61, 961, 1, 518, 2129, 4, 7, 5, 2890, 441, 7, 5, 2040, 1997, 15, 591, 286, 2194, 11, 73, 5, 13, 49, 14, 83, 81, 188, 18, 218, 518, 2129, 9, 33, 935, 162, 23, 2, 18, 162, 1889, 9, 27, 244, 167, 415, 906, 370, 20, 18, 39, 244, 1, 3677, 3, 2506, 1821, 190, 3, 157, 906, 1, 24, 11, 515, 9, 2847, 3, 961, 1676, 99, 1, 579, 128, 11, 275, 20, 3282, 581, 156, 2, 672, 315, 31, 1911, 62, 432, 7, 346, 4, 3, 45, 11, 859, 9, 155, 2, 259, 7, 11, 859, 9, 51, 8, 181, 1, 667, 1993, 11, 468, 3, 96, 746, 210, 12494, 385, 1150, 1, 1993, 11, 1172, 696, 1218, 1966, 212, 613, 259, 2, 2606, 83, 2506, 159, 88, 27, 15, 39, 1218, 1966, 2, 1172, 28, 14, 83, 81, 188, 18, 218, 3, 961, 9, 518, 2129, 4, 7, 5, 2890, 441, 10, 395, 28, 14, 39, 81, 188, 18, 218, 2890, 155, 10, 1051, 4, 62, 432, 7, 2, 5, 62, 1993, 84, 10, 44, 515, 61, 817, 294, 269, 7, 513, 8, 236, 51, 2, 437, 243, 7, 592, 2890, 767, 7053, 634, 1, 518, 2129, 16, 1165, 2, 149, 421, 4, 7, 5, 2890, 441, 28, 3, 61, 1055, 95, 226, 420, 518, 2129, 71, 8, 8442, 128, 4, 7, 5, 681, 2, 286, 2194, 2, 2782, 195, 940, 279, 15, 4, 150, 5, 127, 183]",1603.0,14519630,Phase oral topotecan hematological malignancies,0,0.0
Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning.,Blood,Blood,2003-10-02,"This study retrospectively analyzed data from 446 patients given hematopoietic cell transplants from HLA-matched related or unrelated donors after conditioning with 2 Gy total body irradiation with or without fludarabine and postgrafting immunosuppression with mycophenolate mofetil and cyclosporine following grafting. Fifty-three of 446 patients received donor lymphocyte infusion (DLI) with a median CD3 dose of 1 x 10(7) cells/kg. Their diagnoses included myelodysplastic syndrome (n = 10), acute leukemia (n = 10), chronic leukemia (n = 11), multiple myeloma (n = 9), lymphoma (n = 9), and solid tumors (n = 4). Patients received DLI for persistent disease (n = 8), disease relapse (n = 17), progressive disease (n = 12), low donor chimerism with disease (n = 11), or low chimerism with disease remission (n = 5). Seventeen of the 53 patients (32%) are alive with a median follow-up of 30 months; 5 are in complete remission (CR), 2 are in partial remission (PR), and 10 have stable or progressive disease. Nine of 53 patients (17%) developed grades II to IV acute graft-versus-host disease. Of 48 patients receiving DLI for treatment of disease, 7 achieved CR and 5 PR, with an overall response rate of 25%. Six of 16 patients who received DLI for chimerism had increases in donor chimerism leading to sustained engraftment, whereas 10 eventually rejected their grafts. In conclusion, DLI is a potential treatment strategy, with acceptable toxicity, for patients with persistent, relapsed, or progressive disease after nonmyeloablative hematopoietic cell transplantation.",Clinical Trial,5955.0,110.0,retrospectively 446 patients given hematopoietic transplants HLA-matched related unrelated donors conditioning 2 Gy total body irradiation fludarabine postgrafting immunosuppression mycophenolate mofetil cyclosporine following grafting Fifty-three 446 patients received donor lymphocyte infusion DLI median CD3 dose 1 x 10 7 cells/kg diagnoses included myelodysplastic syndrome n 10 acute leukemia n 10 chronic leukemia n 11 multiple myeloma n 9 lymphoma n 9 solid n 4 Patients received DLI persistent disease n 8 disease relapse n 17 progressive disease n 12 low donor chimerism disease n 11 low chimerism disease remission n 5 Seventeen 53 patients 32 alive median follow-up 30 months 5 complete remission CR 2 partial remission PR 10 stable progressive disease 53 patients 17 developed grades II IV acute graft-versus-host disease 48 patients receiving DLI treatment disease 7 achieved CR 5 PR overall response rate 25 16 patients received DLI chimerism increases donor chimerism leading sustained engraftment 10 eventually rejected grafts DLI potential treatment strategy acceptable toxicity patients persistent relapsed progressive disease nonmyeloablative hematopoietic transplantation,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[26, 45, 894, 311, 74, 29, 9849, 7, 447, 1007, 31, 4016, 29, 1160, 655, 139, 15, 2092, 2344, 50, 1933, 5, 18, 381, 181, 642, 1104, 5, 15, 187, 2027, 2, 28085, 3646, 5, 11902, 13246, 2, 9112, 366, 13074, 1461, 169, 1, 9849, 7, 103, 1488, 1448, 904, 4676, 5, 8, 52, 3117, 61, 1, 14, 1006, 79, 67, 37, 503, 136, 2403, 159, 681, 78, 79, 286, 78, 79, 442, 78, 175, 232, 78, 83, 78, 83, 2, 537, 57, 78, 39, 7, 103, 4676, 9, 1882, 34, 78, 66, 34, 429, 78, 269, 1014, 34, 78, 133, 154, 1488, 6047, 5, 34, 78, 175, 15, 154, 6047, 5, 34, 734, 78, 33, 3591, 1, 3, 699, 7, 531, 32, 1701, 5, 8, 52, 166, 126, 1, 201, 53, 33, 32, 4, 236, 734, 684, 18, 32, 4, 450, 734, 998, 2, 79, 47, 585, 15, 1014, 34, 762, 1, 699, 7, 269, 276, 2276, 215, 6, 478, 286, 1599, 185, 1204, 34, 1, 576, 7, 357, 4676, 9, 24, 1, 34, 67, 513, 684, 2, 33, 998, 5, 35, 63, 51, 116, 1, 243, 437, 1, 245, 7, 54, 103, 4676, 9, 6047, 42, 1106, 4, 1488, 6047, 1049, 6, 2275, 2881, 547, 79, 3124, 11280, 136, 4713, 4, 1221, 4676, 16, 8, 174, 24, 692, 5, 1595, 155, 9, 7, 5, 1882, 591, 15, 1014, 34, 50, 6094, 1007, 31, 497]",1439.0,14525766,Adoptive immunotherapy donor lymphocyte infusions allogeneic hematopoietic transplantation following nonmyeloablative conditioning,2,0.0034904013961605585
DNA methylation in haematological malignancies: the role of decitabine.,Expert opinion on investigational drugs,Expert Opin Investig Drugs,2003-12-01,"Normal cell development and function is dependent upon controlled gene expression. DNA methylation is an epigenetic modification that can play an important role in the control of gene expression. DNA methylation at cytosine residues in gene promoter CpG sequences is known to inhibit gene transcription. Inappropriate inhibition of the transcription of tumour suppressor genes, genes that inhibit angiogenesis and metastasis and genes involved in DNA repair by uncontrolled methylation, can lead to unregulated growth and proliferation of a cell and carcinogenesis. Promoter hypermethylation affecting the p16 gene, resulting in gene silencing, has been shown to occur in many human solid tumours and a 'hypermethylation profile' in some leukaemias has been defined. The molecular mechanisms by which aberrant DNA methylation takes place during carcinogenesis are still not clear. However, the large number of target genes (involved in tumorigenesis) that are silenced by aberrant methylation suggests that inhibition of this process may have potential as cancer therapy. Decitabine (NSC-127716, Dacogen; SuperGen) is a potent and specific hypomethylating agent and an inhibitor of the DNA methyltransferase activity that mediates DNA methylation. Decitabine has been shown to have a broad range of antineoplastic activity in preclinical studies. This agent has exhibited significant activity in the treatment of patients with myelodysplastic syndrome, chronic myeloid leukaemia and acute myeloid leukaemia, although clinical Phase I and II studies with solid tumours have not been very promising. Phase II and III studies are currently ongoing to evaluate decitabine, both alone and in combination, in various stages of these haematological malignancies.",Journal Article,5895.0,28.0,Normal development function dependent controlled expression DNA methylation epigenetic modification play important role control expression DNA methylation cytosine residues promoter CpG sequences known inhibit transcription Inappropriate inhibition transcription tumour suppressor inhibit angiogenesis metastasis involved DNA repair uncontrolled methylation lead unregulated growth proliferation carcinogenesis Promoter hypermethylation affecting p16 resulting silencing shown occur human solid tumours 'hypermethylation profile leukaemias defined molecular mechanisms aberrant DNA methylation takes place carcinogenesis clear large number target involved tumorigenesis silenced aberrant methylation suggests inhibition process potential therapy Decitabine NSC-127716 Dacogen SuperGen potent specific hypomethylating agent inhibitor DNA methyltransferase activity mediates DNA methylation Decitabine shown broad range antineoplastic activity preclinical studies agent exhibited significant activity treatment patients myelodysplastic syndrome chronic myeloid leukaemia acute myeloid leukaemia clinical Phase II studies solid tumours promising Phase II III studies currently ongoing evaluate decitabine combination stages haematological malignancies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[295, 31, 193, 2, 343, 16, 470, 1548, 1149, 145, 55, 261, 569, 16, 35, 1418, 2437, 17, 122, 1343, 35, 305, 200, 4, 3, 182, 1, 145, 55, 261, 569, 28, 6903, 6418, 4, 145, 973, 2075, 2866, 16, 440, 6, 1433, 145, 866, 5148, 297, 1, 3, 866, 1, 770, 1245, 214, 214, 17, 1433, 1056, 2, 278, 2, 214, 646, 4, 261, 972, 20, 6180, 569, 122, 1122, 6, 17770, 129, 2, 457, 1, 8, 31, 2, 1719, 973, 2575, 2319, 3, 1932, 145, 1113, 4, 145, 2077, 71, 85, 443, 6, 1271, 4, 445, 171, 537, 1319, 2, 8, 53880, 800, 4, 476, 12160, 71, 85, 395, 3, 219, 483, 20, 92, 1898, 261, 569, 8512, 3536, 190, 1719, 32, 1234, 44, 885, 137, 3, 375, 207, 1, 283, 214, 646, 4, 1565, 17, 32, 5442, 20, 1898, 569, 844, 17, 297, 1, 26, 1129, 68, 47, 174, 22, 12, 36, 3004, 10073, 53881, 33559, 53882, 16, 8, 1157, 2, 112, 4931, 420, 2, 35, 230, 1, 3, 261, 3747, 128, 17, 3961, 261, 569, 3004, 71, 85, 443, 6, 47, 8, 2094, 184, 1, 3940, 128, 4, 693, 94, 26, 420, 71, 1416, 93, 128, 4, 3, 24, 1, 7, 5, 681, 442, 533, 2001, 2, 286, 533, 2001, 242, 38, 124, 70, 2, 215, 94, 5, 537, 1319, 47, 44, 85, 923, 721, 124, 215, 2, 316, 94, 32, 694, 942, 6, 376, 3004, 110, 279, 2, 4, 150, 4, 747, 1153, 1, 46, 5143, 441]",1712.0,14640942,DNA methylation haematological malignancies role decitabine,527,0.9197207678883071
Massive hyperdiploidy and tetraploidy in acute myelocytic leukemia and myelodysplastic syndrome.,Cancer genetics and cytogenetics,Cancer Genet. Cytogenet.,2004-01-01,"Massive hyperdiploidy (>50 chromosomes) and tetraploidy (4n) are rare cytogenetic abnormalities in myelocytic malignancies, and their significance is unknown. We report on 11 patients with acute myelocytic leukemia (AML) and two patients with a myelodysplastic syndrome (MDS) with massive hyperdiploidy (10 patients) or tetraploidy (3 patients) seen at our institution over a 12-year period. Eleven patients were male and two were female. Age range was 44-84 years (median, 70 years). Only one AML patient had a previous MDS, and no patient had therapy-related disease. One or more copies of chromosomes 8 and 19 were gained in eight patients each; other frequently gained chromosomes included 13, 15, and 21. Eight patients had structural abnormalities in addition to chromosome gain; del(5q) was most common (five patients). Eleven patients received induction chemotherapy, but only four achieved complete remission. Survival ranged from 1 to 22 months, with a median of 6 months. We conclude that massive hyperdiploidy and tetraploidy are infrequent abnormalities in AML and MDS, are seen primarily in de novo disease in older male patients and are associated with a low remission rate and short survival. Massive hyperdiploidy and tetraploidy define a prognostically unfavorable cytogenetic group in de novo AML.",Journal Article,5864.0,33.0,Massive hyperdiploidy 50 chromosomes tetraploidy 4n rare cytogenetic abnormalities myelocytic malignancies significance unknown report 11 patients acute myelocytic leukemia AML patients myelodysplastic syndrome MDS massive hyperdiploidy 10 patients tetraploidy 3 patients seen institution 12-year period patients male female Age range 44-84 years median 70 years AML patient previous MDS patient therapy-related disease copies chromosomes 8 19 gained patients frequently gained chromosomes included 13 15 21 patients structural abnormalities addition chromosome gain del 5q common patients patients received induction chemotherapy achieved complete remission Survival ranged 1 22 months median 6 months conclude massive hyperdiploidy tetraploidy infrequent abnormalities AML MDS seen primarily novo disease older male patients associated low remission rate short survival Massive hyperdiploidy tetraploidy define prognostically unfavorable cytogenetic group novo AML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7929, 11299, 212, 3560, 2, 17211, 22181, 32, 622, 1266, 1171, 4, 19446, 441, 2, 136, 724, 16, 860, 21, 414, 23, 175, 7, 5, 286, 19446, 329, 2, 100, 7, 5, 8, 681, 1223, 5, 7929, 11299, 79, 7, 15, 17211, 27, 7, 527, 28, 114, 731, 252, 8, 133, 111, 727, 2627, 7, 11, 1045, 2, 100, 11, 1061, 89, 184, 10, 584, 874, 60, 52, 431, 60, 158, 104, 329, 69, 42, 8, 698, 1223, 2, 77, 69, 42, 36, 139, 34, 104, 15, 80, 5127, 1, 3560, 66, 2, 326, 11, 3711, 4, 659, 7, 296, 127, 746, 3711, 3560, 159, 233, 167, 2, 239, 659, 7, 42, 3281, 1171, 4, 352, 6, 1170, 1803, 3084, 5460, 10, 96, 186, 365, 7, 2627, 7, 103, 504, 56, 84, 158, 294, 513, 236, 734, 25, 1869, 29, 14, 6, 350, 53, 5, 8, 52, 1, 49, 53, 21, 2060, 17, 7929, 11299, 2, 17211, 32, 4475, 1171, 4, 329, 2, 1223, 32, 527, 1561, 4, 1566, 2018, 34, 4, 434, 1045, 7, 2, 32, 41, 5, 8, 154, 734, 116, 2, 978, 25, 7929, 11299, 2, 17211, 1107, 8, 7848, 2483, 1266, 87, 4, 1566, 2018, 329]",1252.0,14697638,Massive hyperdiploidy tetraploidy acute myelocytic leukemia myelodysplastic syndrome,0,0.0
"RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.","Genes, chromosomes & cancer",Genes Chromosomes Cancer,2004-03-01,"Oncogenic mutations in the KRAS2, NRAS, or FLT3 gene are detected in more than 50% of patients with de novo acute myeloid leukemia (AML). RAS mutations are also prevalent in de novo myelodysplastic syndrome (MDS), especially chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia. However, few studies have examined these genetic lesions in therapy-related myeloid malignancies. Monosomy 7/del(7q) and monosomy 5/del(5q) represent the most common cytogenetic abnormalities in therapy-related MDS and AML (t-MDS/t-AML) and are strongly associated with prior exposure to alkylating agents. Mutational analysis of bone marrow specimens from a well-characterized cohort of 26 t-MDS/t-AML patients with abnormalities of chromosomes 5 and/or 7 revealed 3 with RAS mutations. Further analyses of 23 of these cases uncovered one FLT3 internal tandem duplication and five TP53 mutations. The four patients with RAS or FLT3 mutations had monosomy 7, including one with abnormalities of chromosomes 5 and 7. One specimen demonstrated mutations in both KRAS2 and TP53. RAS and FLT3 mutations, which are thought to stimulate the proliferation of leukemia cells, appear to be less common in t-MDS/t-AML than in de novo AML, whereas TP53 mutations are more frequent.",Journal Article,5804.0,53.0,Oncogenic KRAS2 NRAS FLT3 detected 50 patients novo acute myeloid leukemia AML RAS prevalent novo myelodysplastic syndrome MDS especially chronic myelomonocytic leukemia juvenile myelomonocytic leukemia studies examined genetic lesions therapy-related myeloid malignancies Monosomy 7/del 7q monosomy 5/del 5q represent common cytogenetic abnormalities therapy-related MDS AML t-MDS/t-AML strongly associated prior exposure alkylating agents bone marrow specimens well-characterized cohort 26 t-MDS/t-AML patients abnormalities chromosomes 5 and/or 7 revealed 3 RAS 23 cases uncovered FLT3 internal tandem duplication TP53 patients RAS FLT3 monosomy 7 including abnormalities chromosomes 5 7 specimen demonstrated KRAS2 TP53 RAS FLT3 thought stimulate proliferation leukemia appear common t-MDS/t-AML novo AML TP53 frequent,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1302, 138, 4, 3, 30530, 2845, 15, 1224, 145, 32, 530, 4, 80, 76, 212, 1, 7, 5, 1566, 2018, 286, 533, 329, 1102, 138, 32, 120, 2485, 4, 1566, 2018, 681, 1223, 1093, 442, 5451, 2, 7857, 5451, 137, 1021, 94, 47, 409, 46, 336, 406, 4, 36, 139, 533, 441, 7521, 67, 3084, 9723, 2, 7521, 33, 3084, 5460, 1231, 3, 96, 186, 1266, 1171, 4, 36, 139, 1223, 2, 329, 102, 1223, 102, 329, 2, 32, 1327, 41, 5, 324, 645, 6, 3410, 183, 1619, 65, 1, 581, 623, 29, 8, 149, 765, 180, 1, 432, 102, 1223, 102, 329, 7, 5, 1171, 1, 3560, 33, 2, 15, 67, 553, 27, 5, 1102, 138, 195, 318, 1, 382, 1, 46, 140, 5601, 104, 1224, 2329, 2905, 4616, 2, 365, 1206, 138, 3, 294, 7, 5, 1102, 15, 1224, 138, 42, 7521, 67, 141, 104, 5, 1171, 1, 3560, 33, 2, 67, 104, 2360, 264, 138, 4, 110, 30530, 2, 1206, 1102, 2, 1224, 138, 92, 32, 2739, 6, 4223, 3, 457, 1, 37, 1322, 6, 40, 299, 186, 4, 102, 1223, 102, 329, 76, 4, 1566, 2018, 329, 547, 1206, 138, 32, 80, 908]",1182.0,14732923,RAS FLT3 TP53 therapy-related myeloid malignancies abnormalities chromosomes 5 7,0,0.0
Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy.,Cancer,Cancer,2004-02-01,"The optimal antifungal prophylactic regimen for patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (MDS) undergoing induction chemotherapy has yet to be identified. A prospective historical control study evaluated the efficacy and safety of amphotericin B lipid complex (ABLC) in this patient population. Newly diagnosed patients with AML or high-risk MDS who were undergoing induction chemotherapy received prophylactic ABLC 2.5 mg/kg intravenously 3 times weekly. This treatment group was compared with a historical control group that had similar baseline characteristics and received prophylactic liposomal amphotericin B (L-AmB) 3 mg/kg 3 times weekly. The primary endpoint was the incidence of documented or suspected fungal infections during and up to 4 weeks after cessation of prophylaxis. Reported adverse events were used to assess tolerability. The overall efficacy of antifungal prophylaxis was similar in patients who received ABLC and patients who received L-AmB (P=0.95). Among 131 ABLC-treated patients and 70 L-AmB-treated patients who were assessed for efficacy and safety, 49% of patients in each group completed therapy without developing a documented or suspected fungal infection. Documented fungal infections occurred in 5% of ABLC-treated patients and in 4% of L-AmB-treated patients. Alternative antifungal strategies were required because of persistent fever or pneumonia of unknown pathogen in 28% and 32% of ABLC-treated and L-AmB-treated patients, respectively. Grade 3 and 4 adverse events, therapy discontinuations due to adverse events, and survival rates also were similar between treatment groups. ABLC and L-AmB appeared to have similar efficacy and were tolerated well as antifungal prophylaxis in patients with AML and high-risk MDS who were undergoing induction chemotherapy.",Clinical Trial,5833.0,36.0,optimal antifungal prophylactic regimen patients acute myelogenous leukemia AML high-risk myelodysplastic syndrome MDS undergoing induction chemotherapy identified prospective historical control evaluated efficacy safety amphotericin B lipid complex ABLC patient population Newly diagnosed patients AML high-risk MDS undergoing induction chemotherapy received prophylactic ABLC 2.5 mg/kg intravenously 3 times weekly treatment group compared historical control group similar baseline characteristics received prophylactic liposomal amphotericin B L-AmB 3 mg/kg 3 times weekly primary endpoint incidence documented suspected fungal infections 4 weeks cessation prophylaxis Reported adverse events assess tolerability overall efficacy antifungal prophylaxis similar patients received ABLC patients received L-AmB P=0.95 131 ABLC-treated patients 70 L-AmB-treated patients assessed efficacy safety 49 patients group completed therapy developing documented suspected fungal infection Documented fungal infections occurred 5 ABLC-treated patients 4 L-AmB-treated patients Alternative antifungal strategies required persistent fever pneumonia unknown pathogen 28 32 ABLC-treated L-AmB-treated patients respectively Grade 3 4 adverse events therapy discontinuations adverse events survival rates similar treatment groups ABLC L-AmB appeared similar efficacy tolerated antifungal prophylaxis patients AML high-risk MDS undergoing induction chemotherapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 665, 8606, 1862, 477, 9, 7, 5, 286, 2194, 329, 15, 64, 43, 681, 1223, 479, 504, 56, 71, 1145, 6, 40, 108, 8, 482, 2252, 182, 45, 194, 3, 209, 2, 367, 1, 22151, 132, 3121, 840, 26258, 4, 26, 69, 266, 732, 265, 7, 5, 329, 15, 64, 43, 1223, 54, 11, 479, 504, 56, 103, 1862, 26258, 18, 33, 81, 503, 1672, 27, 1072, 709, 26, 24, 87, 10, 72, 5, 8, 2252, 182, 87, 17, 42, 288, 330, 374, 2, 103, 1862, 3275, 22151, 132, 805, 22185, 27, 81, 503, 27, 1072, 709, 3, 86, 1138, 10, 3, 287, 1, 1405, 15, 2768, 7800, 1875, 190, 2, 126, 6, 39, 244, 50, 3345, 1, 2049, 210, 290, 281, 11, 95, 6, 423, 1543, 3, 63, 209, 1, 8606, 2049, 10, 288, 4, 7, 54, 103, 26258, 2, 7, 54, 103, 805, 22185, 19, 13, 48, 107, 2229, 26258, 73, 7, 2, 431, 805, 22185, 73, 7, 54, 11, 275, 9, 209, 2, 367, 739, 1, 7, 4, 296, 87, 781, 36, 187, 931, 8, 1405, 15, 2768, 7800, 930, 1405, 7800, 1875, 489, 4, 33, 1, 26258, 73, 7, 2, 4, 39, 1, 805, 22185, 73, 7, 1091, 8606, 422, 11, 616, 408, 1, 1882, 2775, 15, 3485, 1, 860, 15956, 4, 339, 2, 531, 1, 26258, 73, 2, 805, 22185, 73, 7, 106, 88, 27, 2, 39, 290, 281, 36, 8692, 520, 6, 290, 281, 2, 25, 151, 120, 11, 288, 59, 24, 271, 26258, 2, 805, 22185, 2121, 6, 47, 288, 209, 2, 11, 421, 149, 22, 8606, 2049, 4, 7, 5, 329, 2, 64, 43, 1223, 54, 11, 479, 504, 56]",1791.0,14745876,Amphotericin B lipid complex prophylaxis invasive fungal infections patients acute myelogenous leukemia myelodysplastic syndrome undergoing induction chemotherapy,1,0.0017452006980802793
Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia.,Human pathology,Hum. Pathol.,2004-02-01,"The nuclear transcription factor NF-kappa B regulates cell survival, proliferation, and differentiation. Little is known about NF-kappa B in myeloid malignancies. In this report, we assessed NF-kappa B in a group of myeloid neoplasms by using an electrophoretic mobility shift assay (EMSA) and immunofluorescence methods in freshly isolated leukemia cells. We analyzed 30 cases of acute myeloid leukemia (AML), 5 cases of myelodysplastic syndrome (MDS), 3 cases of chronic myelomonocytic leukemia (CMML), 15 cases of chronic myeloid leukemia in chronic phase (CML-CP), and 2 cases of chronic myeloid leukemia in blast crisis (CML-BC). Unstimulated cells (bone marrow and peripheral blood) from 17 normal donors and apheresis samples from 6 peripheral blood stem cell donors treated with granulocyte colony-stimulating factor (G-CSF) were used as controls. When EMSA was used, NF-kappa B was elevated in 14 of 30 (47%) cases of AML, in both cases of CML-BC, and in all reference donors treated with G-CSF, but it was at basal levels in all cases of MDS and CML-CP and in normal donors (P = <.01). Immunofluorescence analysis confirmed strong nuclear RelA/NF-kappa B immunoreactivity in AML blasts but not in normal bone marrow. Bcl-2, a downstream molecule, was expressed in cases with elevated NF-kappa B, but not in cases with basal levels of NF-kappa B, suggesting that NF-kappa B is active and provides the cells with survival advantages in vivo. These results suggest that suppression of NF-kappa B may be a useful therapeutic strategy for a subset of patients with AML.",Journal Article,5833.0,65.0,nuclear transcription factor NF-kappa B regulates survival proliferation differentiation Little known NF-kappa B myeloid malignancies report assessed NF-kappa B group myeloid neoplasms electrophoretic mobility shift EMSA immunofluorescence methods freshly isolated leukemia 30 cases acute myeloid leukemia AML 5 cases myelodysplastic syndrome MDS 3 cases chronic myelomonocytic leukemia CMML 15 cases chronic myeloid leukemia chronic phase CML-CP 2 cases chronic myeloid leukemia blast crisis CML-BC Unstimulated bone marrow peripheral blood 17 normal donors apheresis 6 peripheral blood stem donors treated granulocyte colony-stimulating factor G-CSF controls EMSA NF-kappa B elevated 14 30 47 cases AML cases CML-BC reference donors treated G-CSF basal levels cases MDS CML-CP normal donors P .01 Immunofluorescence confirmed strong nuclear RelA/NF-kappa B immunoreactivity AML blasts normal bone marrow Bcl-2 downstream molecule expressed cases elevated NF-kappa B cases basal levels NF-kappa B suggesting NF-kappa B active provides survival advantages vivo suggest suppression NF-kappa B useful therapeutic strategy subset patients AML,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 928, 866, 161, 1365, 3096, 132, 2468, 31, 25, 457, 2, 910, 1215, 16, 440, 545, 1365, 3096, 132, 4, 533, 441, 4, 26, 414, 21, 275, 1365, 3096, 132, 4, 8, 87, 1, 533, 1179, 20, 75, 35, 10980, 5717, 3024, 719, 15941, 2, 4130, 636, 4, 9957, 1355, 37, 21, 311, 201, 140, 1, 286, 533, 329, 33, 140, 1, 681, 1223, 27, 140, 1, 442, 5451, 3382, 167, 140, 1, 442, 533, 4, 442, 124, 903, 2541, 2, 18, 140, 1, 442, 533, 4, 3112, 6540, 903, 1402, 16781, 37, 581, 2, 672, 315, 29, 269, 295, 2344, 2, 9456, 347, 29, 49, 672, 315, 452, 31, 2344, 73, 5, 2764, 1975, 2122, 161, 499, 1211, 11, 95, 22, 535, 198, 15941, 10, 95, 1365, 3096, 132, 10, 804, 4, 213, 1, 201, 662, 140, 1, 329, 4, 110, 140, 1, 903, 1402, 2, 4, 62, 2482, 2344, 73, 5, 499, 1211, 84, 192, 10, 28, 2135, 148, 4, 62, 140, 1, 1223, 2, 903, 2541, 2, 4, 295, 2344, 19, 355, 4130, 65, 557, 1082, 928, 8672, 1365, 3096, 132, 4900, 4, 329, 2438, 84, 44, 4, 295, 581, 1044, 18, 8, 1489, 1354, 10, 570, 4, 140, 5, 804, 1365, 3096, 132, 84, 44, 4, 140, 5, 2135, 148, 1, 1365, 3096, 132, 802, 17, 1365, 3096, 132, 16, 544, 2, 777, 3, 37, 5, 25, 3126, 4, 386, 46, 99, 309, 17, 1332, 1, 1365, 3096, 132, 68, 40, 8, 999, 189, 692, 9, 8, 697, 1, 7, 5, 329]",1455.0,14991544,Expression constitutively active nuclear-kappa B RelA transcription factor blasts acute myeloid leukemia,0,0.0
Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma.,Blood,Blood,2004-03-09,"Adult-acquired Fanconi syndrome (FS) is a rare complication of monoclonal gammopathy. We retrospectively reviewed 32 patients diagnosed with adult-acquired FS between April 1968 and June 2002 at Mayo Clinic (Rochester, MN). At diagnosis, most patients had monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM), with a median creatinine level of 176.8 microM (2.0 mg/dL; range, 79.56-327.08 microM [0.9-3.7 mg/dL]) and evidence of osteomalacia. During the average 65 months (range, 2-238 months) of follow-up, 5 patients developed end-stage renal disease (ESRD) and only 1 of 14 patients with MGUS transformed to multiple myeloma (MM). Also, 14 deaths occurred, with only 1 from ESRD but 4 from alkylator-related leukemia or myelodysplastic syndrome. Chemotherapy offered little benefit on renal functions of MGUS or SMM patients. In conclusion, FS associated with monoclonal gammopathy does not appear to confer an additional risk of subsequent evolution to MM. ESRD occurs late in the disease process.",Journal Article,5796.0,82.0,Adult-acquired Fanconi syndrome FS rare complication monoclonal gammopathy retrospectively reviewed 32 patients diagnosed adult-acquired FS April 1968 June 2002 Mayo Clinic Rochester MN diagnosis patients monoclonal gammopathy undetermined significance MGUS smoldering multiple myeloma SMM median creatinine level 176.8 microM 2.0 mg/dL range 79.56-327.08 microM 0.9-3.7 mg/dL evidence osteomalacia average 65 months range 2-238 months follow-up 5 patients developed end-stage renal disease ESRD 1 14 patients MGUS transformed multiple myeloma MM 14 deaths occurred 1 ESRD 4 alkylator-related leukemia myelodysplastic syndrome Chemotherapy offered little benefit renal functions MGUS SMM patients FS associated monoclonal gammopathy appear confer additional risk subsequent evolution MM ESRD occurs late disease process,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[780, 1294, 8057, 681, 4110, 16, 8, 622, 1447, 1, 848, 5334, 21, 894, 446, 531, 7, 265, 5, 780, 1294, 4110, 59, 2292, 17767, 2, 1924, 1544, 28, 2486, 1188, 5801, 4691, 28, 147, 96, 7, 42, 848, 5334, 1, 5206, 724, 3226, 15, 7091, 232, 6049, 5, 8, 52, 3177, 301, 1, 5800, 66, 3550, 18, 13, 81, 1826, 184, 842, 664, 7749, 1592, 3550, 13, 83, 27, 67, 81, 1826, 2, 241, 1, 54052, 190, 3, 1011, 556, 53, 184, 18, 6883, 53, 1, 166, 126, 33, 7, 276, 396, 82, 34, 12350, 2, 158, 14, 1, 213, 7, 5, 3226, 2423, 6, 232, 321, 120, 213, 1043, 489, 5, 158, 14, 29, 12350, 84, 39, 29, 9346, 139, 15, 681, 56, 2216, 1215, 247, 23, 1681, 1, 3226, 15, 6049, 7, 4, 1221, 4110, 41, 5, 848, 5334, 1097, 44, 1322, 6, 2913, 35, 402, 43, 1, 706, 2554, 6, 321, 12350, 1780, 807, 4, 3, 34, 1129]",954.0,15010372,Acquired Fanconi syndrome indolent disorder absence overt multiple myeloma,6,0.010471204188481676
"Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.",Cancer,Cancer,2004-04-01,"OSI-211 is a low-clearance, unilamellar liposomal formulation of a water-soluble camptothecin analogue, lurtotecan. OSI-211 has significant activity in severe combined immunodeficient mouse models of human leukemia. This study was conducted to define the dose-limiting toxicities (DLT) and pharmacokinetics of OSI-211 in patients with refractory myeloid leukemias. Patients with refractory acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelogenous leukemia in blastic phase (CML-BP) were eligible. OSI-211 was given as an intravenous infusion over 30 minutes daily for 3 days. The starting dose was 1.5 mg/m2 per day (4.5 mg/m2 per course). The dose was escalated by 50% until Grade 2 toxicity was observed and then by 30-35% until the DLT was defined. Serial plasma and urine samples were collected, and drug levels were determined by high-performance liquid chromatography with fluorescence detection. Twenty patients (18 patients [90%] with AML, and 1 patient each [5%] with MDS and CML-BP) were treated. Mucositis and diarrhea were considered to be the DLTs. The maximum tolerated dose was 3.7 mg/m2 per day. Fourteen of 18 evaluable patients (78%) with AML or MDS achieved transient bone marrow aplasia. The mean systemic clearance of lurtotecan in plasma was 0.946 +/- 1.53 L/hour/m2. Urinary recovery of lurtotecan was 6.66% +/- 5.26% (range, 1.05-18.4%). Liposomal encapsulation of lurtotecan altered its metabolism significantly. There was no evident correlation between exposure, as measured by plasma pharmacokinetics of lurtotecan, and clinical response or toxicities. OSI-211 merits further study in hematologic malignancies.",Clinical Trial,5773.0,34.0,OSI-211 low-clearance unilamellar liposomal formulation water-soluble camptothecin analogue lurtotecan OSI-211 significant activity severe combined immunodeficient mouse models human leukemia conducted define dose-limiting toxicities DLT pharmacokinetics OSI-211 patients refractory myeloid leukemias Patients refractory acute myeloid leukemia AML myelodysplastic syndrome MDS chronic myelogenous leukemia blastic phase CML-BP eligible OSI-211 given intravenous infusion 30 minutes daily 3 days starting dose 1.5 mg/m2 day 4.5 mg/m2 course dose escalated 50 Grade 2 toxicity observed 30-35 DLT defined Serial plasma urine collected drug levels determined high-performance liquid chromatography fluorescence detection patients 18 patients 90 AML 1 patient 5 MDS CML-BP treated Mucositis diarrhea considered DLTs maximum tolerated dose 3.7 mg/m2 day Fourteen 18 evaluable patients 78 AML MDS achieved transient bone marrow aplasia mean systemic clearance lurtotecan plasma 0.946 +/- 1.53 L/hour/m2 Urinary recovery lurtotecan 6.66 +/- 5.26 range 1.05-18.4 Liposomal encapsulation lurtotecan altered metabolism significantly evident correlation exposure measured plasma pharmacokinetics lurtotecan clinical response toxicities OSI-211 merits hematologic malignancies,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6186, 5905, 16, 8, 154, 1960, 43548, 3275, 3583, 1, 8, 4388, 2968, 6968, 4696, 30568, 6186, 5905, 71, 93, 128, 4, 905, 397, 5031, 830, 274, 1, 171, 26, 45, 10, 426, 6, 1107, 3, 61, 817, 385, 2059, 2, 1159, 1, 6186, 5905, 4, 7, 5, 430, 533, 2792, 7, 5, 430, 286, 533, 329, 681, 1223, 15, 442, 2194, 4, 6529, 124, 903, 3044, 11, 625, 6186, 5905, 10, 447, 22, 35, 1262, 904, 252, 201, 2511, 391, 9, 27, 162, 3, 1723, 61, 10, 14, 33, 81, 821, 379, 218, 39, 33, 81, 821, 379, 906, 3, 61, 10, 2842, 20, 212, 1100, 88, 18, 155, 10, 164, 2, 818, 20, 201, 465, 1100, 3, 2059, 10, 395, 2108, 554, 2, 2646, 347, 11, 786, 2, 234, 148, 11, 509, 20, 64, 528, 3165, 5140, 5, 1591, 638, 737, 7, 203, 7, 424, 5, 329, 2, 14, 69, 296, 33, 5, 1223, 2, 903, 3044, 11, 73, 2606, 2, 1172, 11, 515, 6, 40, 3, 2506, 3, 689, 421, 61, 10, 27, 67, 81, 821, 379, 218, 3225, 1, 203, 859, 7, 833, 5, 329, 15, 1223, 513, 2473, 581, 12307, 3, 313, 403, 1960, 1, 30568, 4, 554, 10, 13, 17787, 14, 699, 805, 2583, 821, 1660, 1602, 1, 30568, 10, 49, 700, 33, 432, 184, 14, 474, 203, 39, 3275, 12784, 1, 30568, 1495, 211, 1600, 97, 125, 10, 77, 2853, 816, 59, 645, 22, 644, 20, 554, 1159, 1, 30568, 2, 38, 51, 15, 385, 6186, 5905, 4986, 195, 45, 4, 813, 441]",1563.0,15042679,Phase pharmacokinetic low-clearance unilamellar liposomal formulation lurtotecan topoisomerase 1 inhibitor patients advanced leukemia,0,0.0
"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS.",Blood,Blood,2004-04-08,"Postulating favorable antileukemic effect with improved safety, we used intravenous busulfan and fludarabine as conditioning therapy for allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). Fludarabine 40 mg/m2 and intravenous busulfan 130 mg/m2 were given once daily for 4 days, with tacrolimus-methotrexate as graft-versus-host disease (GVHD) prophylaxis. We treated 74 patients with AML and 22 patients with MDS; patients had a median age of 45 years (range, 19-66 years). Only 20% of the patients were in first complete remission (CR) at transplantation. Donors were HLA-compatible related (n = 60) or matched unrelated (n = 36). The CR rate for 54 patients with active disease was 85%. At a median follow-up of 12 months, 1-year regimen-related and treatment-related mortalities were 1% and 3%, respectively. Two patients had reversible hepatic veno-occlusive disease. Actuarial 1-year overall survival (OS) and event-free survival (EFS) were 65% and 52% for all patients, and 81% and 75% for patients receiving transplants in CR. Recipient age and donor type did not influence OS or EFS. Median busulfan clearance was 109 mL/min/m2 and median daily area-under-the-plasma-concentration-versus-time-curve was 4871 micromol-min, with negligible interdose variability in pharmacokinetic parameters. The results suggest that intravenous busulfan-fludarabine is an efficacious, reduced-toxicity, myeloablative-conditioning regimen for patients with AML or MDS undergoing HSCT.",Journal Article,5766.0,328.0,Postulating favorable antileukemic effect improved safety intravenous busulfan fludarabine conditioning therapy allogeneic hematopoietic stem transplantation HSCT acute myelogenous leukemia AML myelodysplastic syndrome MDS Fludarabine 40 mg/m2 intravenous busulfan 130 mg/m2 given daily 4 days tacrolimus-methotrexate graft-versus-host disease GVHD prophylaxis treated 74 patients AML 22 patients MDS patients median age 45 years range 19-66 years 20 patients complete remission CR transplantation Donors HLA-compatible related n 60 matched unrelated n 36 CR rate 54 patients active disease 85 median follow-up 12 months 1-year regimen-related treatment-related mortalities 1 3 respectively patients reversible hepatic veno-occlusive disease Actuarial 1-year overall survival OS event-free survival EFS 65 52 patients 81 75 patients receiving transplants CR Recipient age donor type influence OS EFS Median busulfan clearance 109 mL/min/m2 median daily area-under-the-plasma-concentration-versus-time-curve 4871 micromol-min negligible interdose variability pharmacokinetic parameters suggest intravenous busulfan-fludarabine efficacious reduced-toxicity myeloablative-conditioning regimen patients AML MDS undergoing HSCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[37668, 913, 4512, 254, 5, 231, 367, 21, 95, 1262, 3906, 2, 2027, 22, 1933, 36, 9, 1063, 1007, 452, 31, 497, 1703, 9, 286, 2194, 329, 2, 681, 1223, 2027, 327, 81, 821, 2, 1262, 3906, 3431, 81, 821, 11, 447, 1059, 391, 9, 39, 162, 5, 5643, 2116, 22, 1599, 185, 1204, 34, 1562, 2049, 21, 73, 794, 7, 5, 329, 2, 350, 7, 5, 1223, 7, 42, 8, 52, 89, 1, 512, 60, 184, 326, 700, 60, 158, 179, 1, 3, 7, 11, 4, 157, 236, 734, 684, 28, 497, 2344, 11, 1160, 7293, 139, 78, 335, 15, 655, 2092, 78, 511, 3, 684, 116, 9, 667, 7, 5, 544, 34, 10, 772, 28, 8, 52, 166, 126, 1, 133, 53, 14, 111, 477, 139, 2, 24, 139, 9743, 11, 14, 2, 27, 106, 100, 7, 42, 2786, 939, 10273, 8376, 34, 2361, 14, 111, 63, 25, 118, 2, 774, 115, 25, 1683, 11, 556, 2, 653, 9, 62, 7, 2, 865, 2, 481, 9, 7, 357, 4016, 4, 684, 5783, 89, 2, 1488, 267, 205, 44, 1054, 118, 15, 1683, 52, 3906, 1960, 10, 3486, 542, 1538, 821, 2, 52, 391, 965, 669, 3, 554, 1227, 185, 98, 1496, 10, 43576, 6297, 1538, 5, 6821, 37284, 1982, 4, 1456, 1038, 3, 99, 309, 17, 1262, 3906, 2027, 16, 35, 3289, 405, 155, 3246, 1933, 477, 9, 7, 5, 329, 15, 1223, 479, 1703]",1475.0,15073038,Once-daily intravenous busulfan fludarabine clinical pharmacokinetic myeloablative reduced-toxicity conditioning regimen allogeneic stem transplantation AML MDS,4,0.006980802792321117
"Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.",Cancer,Cancer,2004-05-01,"Vascular endothelial growth factor (VEGF) and its receptors (VEGFRs) are major regulators of angiogenesis, which plays a key role in the growth and dissemination of solid tumors and hematologic neoplasms. The authors measured the plasma concentrations of soluble VEGFR1 (sVEGFR1) and sVEGFR2 in 133 patients with acute myeloid leukemia (AML) and in 80 patients with myelodysplastic syndromes (MDS) at the time of initial presentation and compared clinical behaviors. A reverse correlation was observed between plasma sVEGFR1 levels and the rate of complete remission (CR) in patients with AML, but not in patients with MDS. In contrast, increased plasma levels of sVEGFR2 were correlated with a lower CR rate in patients with MDS, but not in patients with AML. Cox regression model analysis demonstrated that plasma levels of sVEGFR1, but not sVEGFR2, were independent prognostic factors in both patients with AML and patients with MDS. The findings suggest that different mechanisms are involved in the pathophysiology of AML and MDS. The concentration of sVEGFR1 and sVEGFR2 in plasma should be considered a significant factor in guiding antiangiogenic therapy for AML and MDS. They may play a role in the pharmacodynamics of therapeutic agents that are supposed to bind directly to these receptors.",Comparative Study,5743.0,62.0,Vascular endothelial growth factor VEGF receptors VEGFRs major regulators angiogenesis plays key role growth dissemination solid hematologic neoplasms authors measured plasma concentrations soluble VEGFR1 sVEGFR1 sVEGFR2 133 patients acute myeloid leukemia AML 80 patients myelodysplastic syndromes MDS time initial presentation compared clinical behaviors reverse correlation observed plasma sVEGFR1 levels rate complete remission CR patients AML patients MDS contrast increased plasma levels sVEGFR2 correlated lower CR rate patients MDS patients AML Cox regression model demonstrated plasma levels sVEGFR1 sVEGFR2 independent prognostic factors patients AML patients MDS findings suggest different mechanisms involved pathophysiology AML MDS concentration sVEGFR1 sVEGFR2 plasma considered significant factor guiding antiangiogenic therapy AML MDS play role pharmacodynamics therapeutic agents supposed bind directly receptors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[756, 845, 129, 161, 618, 2, 211, 1186, 15864, 32, 458, 3196, 1, 1056, 92, 1698, 8, 825, 200, 4, 3, 129, 2, 3430, 1, 537, 57, 2, 813, 1179, 3, 738, 644, 3, 554, 1003, 1, 2968, 7952, 17258, 2, 11484, 4, 5026, 7, 5, 286, 533, 329, 2, 4, 493, 7, 5, 2040, 1223, 28, 3, 98, 1, 388, 1031, 2, 72, 38, 3704, 8, 1772, 816, 10, 164, 59, 554, 17258, 148, 2, 3, 116, 1, 236, 734, 684, 4, 7, 5, 329, 84, 44, 4, 7, 5, 1223, 4, 748, 101, 554, 148, 1, 11484, 11, 438, 5, 8, 280, 684, 116, 4, 7, 5, 1223, 84, 44, 4, 7, 5, 329, 418, 320, 202, 65, 264, 17, 554, 148, 1, 17258, 84, 44, 11484, 11, 306, 177, 130, 4, 110, 7, 5, 329, 2, 7, 5, 1223, 3, 272, 309, 17, 338, 483, 32, 646, 4, 3, 4320, 1, 329, 2, 1223, 3, 1227, 1, 17258, 2, 11484, 4, 554, 257, 40, 515, 8, 93, 161, 4, 5972, 2168, 36, 9, 329, 2, 1223, 491, 68, 1343, 8, 200, 4, 3, 3587, 1, 189, 183, 17, 32, 30588, 6, 4060, 1606, 6, 46, 1186]",1250.0,15112269,Soluble vascular endothelial growth factor receptor 1 receptor 2 independent prognostic factor acute myeloid leukemia myelodysplastic syndromes,4,0.006980802792321117
"A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2004-05-01,"VNP40101M is a novel sulfonylhydrazine alkylating agent with broad antitumor activity in animal models. As alkylating agents are important antileukemia drugs, a Phase I and pharmacokinetic study of VNP40101M was conducted in patients with refractory or relapsed leukemias or poor-risk myelodysplastic syndromes (MDS). VNP40101M was given as a single i.v. infusion over 15-70 min on day 1. Courses were repeated every 4 weeks according to antileukemic activity. The starting dose of 220 mg/m(2) was escalated by approximately 33% in cohorts of 3-6 patients until a maximum-tolerated dose was established. One additional cohort was treated with the maximum-tolerated dose divided over days 1 and 8. Thirty-eight patients, including 28 with acute myeloid leukemia and 5 with MDS, received 52 courses of treatment. Nondose-limiting, reversible infusion-related toxicities were the most frequent adverse event, occurring in 24 (63%) patients on the first course. Dose escalation was terminated at 708 mg/m(2) for prolonged myelosuppression in 1 of 7 patients, and 600 mg/m(2) was selected as the recommended Phase II dose, with no significant extramedullary toxicity at this dose level. Two patients, 1 with MDS treated with 300 mg/m(2) and 1 with acute myeloid leukemia treated with 600 mg/m(2), achieved complete remission. VNP40101M had significant antileukemic activity and minimal extramedullary toxicity in patients with relapsed or refractory disease.",Clinical Trial,5743.0,47.0,VNP40101M novel sulfonylhydrazine alkylating agent broad antitumor activity animal models alkylating agents important antileukemia drugs Phase pharmacokinetic VNP40101M conducted patients refractory relapsed leukemias poor-risk myelodysplastic syndromes MDS VNP40101M given single i.v infusion 15-70 min day 1 Courses repeated 4 weeks according antileukemic activity starting dose 220 mg/m 2 escalated approximately 33 cohorts 3-6 patients maximum-tolerated dose established additional cohort treated maximum-tolerated dose divided days 1 8 Thirty-eight patients including 28 acute myeloid leukemia 5 MDS received 52 courses treatment Nondose-limiting reversible infusion-related toxicities frequent adverse event occurring 24 63 patients course Dose escalation terminated 708 mg/m 2 prolonged myelosuppression 1 7 patients 600 mg/m 2 selected recommended Phase II dose significant extramedullary toxicity dose level patients 1 MDS treated 300 mg/m 2 1 acute myeloid leukemia treated 600 mg/m 2 achieved complete remission VNP40101M significant antileukemic activity minimal extramedullary toxicity patients relapsed refractory disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[17260, 16, 8, 229, 30590, 3410, 420, 5, 2094, 579, 128, 4, 2026, 274, 22, 3410, 183, 32, 305, 9169, 600, 8, 124, 70, 2, 1456, 45, 1, 17260, 10, 426, 4, 7, 5, 430, 15, 591, 2792, 15, 334, 43, 2040, 1223, 17260, 10, 447, 22, 8, 226, 70, 603, 904, 252, 167, 431, 1538, 23, 218, 14, 1993, 11, 2113, 454, 39, 244, 768, 6, 4512, 128, 3, 1723, 61, 1, 6211, 81, 188, 18, 10, 2842, 20, 705, 466, 4, 736, 1, 27, 49, 7, 1100, 8, 689, 421, 61, 10, 635, 104, 402, 180, 10, 73, 5, 3, 689, 421, 61, 2176, 252, 162, 14, 2, 66, 977, 659, 7, 141, 339, 5, 286, 533, 2, 33, 5, 1223, 103, 653, 1993, 1, 24, 43604, 817, 2786, 904, 139, 385, 11, 3, 96, 908, 290, 774, 1821, 4, 259, 676, 7, 23, 3, 157, 906, 61, 1125, 10, 5640, 28, 9687, 81, 188, 18, 9, 1069, 2858, 4, 14, 1, 67, 7, 2, 2383, 81, 188, 18, 10, 715, 22, 3, 793, 124, 215, 61, 5, 77, 93, 5508, 155, 28, 26, 61, 301, 100, 7, 14, 5, 1223, 73, 5, 2036, 81, 188, 18, 2, 14, 5, 286, 533, 73, 5, 2383, 81, 188, 18, 513, 236, 734, 17260, 42, 93, 4512, 128, 2, 1048, 5508, 155, 4, 7, 5, 591, 15, 430, 34]",1387.0,15131024,Phase pharmacokinetic VNP40101M novel sulfonylhydrazine alkylating agent patients refractory leukemia,0,0.0
Management of thalidomide toxicity.,The journal of supportive oncology,J Support Oncol,,"Thalidomide has re-emerged as a novel antineoplastic agent with immunomodulatory and antiangiogenic activities. In the early sixties, it was withdrawn from the market after its infamous association with congenital abnormalities that left about 10,000 children affected world-wide. With strict regulations and precautions, thalidomide is now approved by the FDA for the treatment of erythema nodosum leprosum. Its role in cancer therapy is promising, with clinical trials in the past 5 years showing significant activity in multiple myeloma. Several trials are ongoing in other malignancies, such as myelodysplastic syndrome, agnogenic myeloid metaplasia, renal cell carcinoma, and prostate cancer. The major toxicities of thalidomide are birth defects, sensorimotor peripheral neuropathy, somnolence, rash, fatigue, and constipation. Less common side effects include deep venous thrombosis, Stevens-Johnson syndrome, elevated liver enzymes, malaise, and peripheral edema. The incidence and severity of adverse events are related to dose and duration of therapy. Doses of the drug of 200 mg/day or less are usually well tolerated. In this review, we will discuss the incidence and management of the side effects of thalidomide and the precautions and interventions needed to minimize the toxicities of this drug.",Journal Article,,119.0,"Thalidomide re-emerged novel antineoplastic agent immunomodulatory antiangiogenic activities early sixties withdrawn market infamous association congenital abnormalities left 10,000 children affected world-wide strict regulations precautions thalidomide approved FDA treatment erythema nodosum leprosum role therapy promising clinical trials past 5 years showing significant activity multiple myeloma trials ongoing malignancies myelodysplastic syndrome agnogenic myeloid metaplasia renal carcinoma prostate major toxicities thalidomide birth defects sensorimotor peripheral neuropathy somnolence rash fatigue constipation common effects include deep venous thrombosis Stevens-Johnson syndrome elevated liver enzymes malaise peripheral edema incidence severity adverse events related dose duration therapy Doses drug 200 mg/day usually tolerated review discuss incidence management effects thalidomide precautions interventions needed minimize toxicities drug",0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2159, 71, 1491, 2054, 22, 8, 229, 3940, 420, 5, 2555, 2, 2168, 2042, 4, 3, 191, 54328, 192, 10, 12107, 29, 3, 9763, 50, 211, 54329, 248, 5, 6711, 1171, 17, 1712, 545, 79, 984, 541, 1424, 1956, 1019, 5, 8043, 13608, 2, 15269, 2159, 16, 1134, 850, 20, 3, 2078, 9, 3, 24, 1, 9167, 30386, 33403, 211, 200, 4, 12, 36, 16, 721, 5, 38, 143, 4, 3, 1219, 33, 60, 2069, 93, 128, 4, 232, 392, 143, 32, 942, 4, 127, 441, 225, 22, 681, 26059, 533, 6054, 31, 134, 2, 12, 3, 458, 385, 1, 2159, 32, 3809, 2945, 18270, 672, 1751, 13823, 1641, 613, 2, 4532, 299, 186, 1152, 176, 643, 2369, 2167, 2839, 30481, 18915, 681, 804, 3039, 14734, 2, 672, 3306, 3, 287, 2, 1702, 1, 290, 281, 32, 139, 6, 61, 2, 654, 1, 36, 415, 1, 3, 234, 1, 1250, 81, 218, 15, 299, 32, 2082, 149, 421, 4, 26, 206, 21, 303, 1139, 3, 287, 2, 284, 1, 3, 1152, 176, 1, 2159, 2, 3, 15269, 2, 1151, 575, 6, 3241, 3, 385, 1, 26, 234]",1239.0,15334875,Management thalidomide toxicity,124,0.2164048865619546
"Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.",Blood,Blood,2004-09-02,"Leukemic cells from 30% of patients with acute myeloid leukemia (AML) have an activating mutation in the FLT3 (fms-like tyrosine kinase) gene, which represents a target for drug therapy. We treated 20 patients, each with mutant FLT3 relapsed/refractory AML or high-grade myelodysplastic syndrome and not believed to be candidates for chemotherapy, with an FLT3 tyrosine kinase inhibitor, PKC412 (N-benzoylstaurosporine), at a dose of 75 mg 3 times daily by mouth. The drug was generally well tolerated, although 2 patients developed fatal pulmonary events of unclear etiology. The peripheral blast count decreased by 50% in 14 patients (70%). Seven patients (35%) experienced a greater than 2-log reduction in peripheral blast count for at least 4 weeks (median response duration, 13 weeks; range, 9-47 weeks); PKC412 reduced bone marrow blast counts by 50% in 6 patients (2 of these to < 5%). FLT3 autophosphorylation was inhibited in most of the Corresponding patients, indicating in vivo target inhibition at the dose schedule used in this study. PKC412 is an oral tyrosine kinase inhibitor with clinical activity in patients with AML whose blasts have an activating mutation of FLT3, suggesting potential use in combination with active agents, such as chemotherapy.",Clinical Trial,5619.0,496.0,Leukemic 30 patients acute myeloid leukemia AML activating FLT3 fms-like tyrosine kinase represents target drug therapy treated 20 patients FLT3 relapsed/refractory AML high-grade myelodysplastic syndrome believed candidates chemotherapy FLT3 tyrosine kinase inhibitor PKC412 N-benzoylstaurosporine dose 75 mg 3 times daily mouth drug generally tolerated 2 patients developed fatal pulmonary events unclear etiology peripheral blast count decreased 50 14 patients 70 Seven patients 35 experienced greater 2-log reduction peripheral blast count 4 weeks median response duration 13 weeks range 9-47 weeks PKC412 reduced bone marrow blast counts 50 6 patients 2 5 FLT3 autophosphorylation inhibited Corresponding patients indicating vivo target inhibition dose schedule PKC412 oral tyrosine kinase inhibitor clinical activity patients AML blasts activating FLT3 suggesting potential use combination active agents chemotherapy,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2015, 37, 29, 201, 1, 7, 5, 286, 533, 329, 47, 35, 1616, 258, 4, 3, 1224, 5516, 733, 564, 216, 145, 92, 1449, 8, 283, 9, 234, 36, 21, 73, 179, 7, 296, 5, 620, 1224, 591, 430, 329, 15, 64, 88, 681, 2, 44, 3979, 6, 40, 1931, 9, 56, 5, 35, 1224, 564, 216, 230, 7154, 78, 54338, 28, 8, 61, 1, 481, 81, 27, 1072, 391, 20, 5831, 3, 234, 10, 1228, 149, 421, 242, 18, 7, 276, 3034, 1087, 281, 1, 1200, 2855, 3, 672, 3112, 1276, 340, 20, 212, 4, 213, 7, 431, 648, 7, 465, 592, 8, 378, 76, 18, 1066, 628, 4, 672, 3112, 1276, 9, 28, 506, 39, 244, 52, 51, 654, 233, 244, 184, 83, 662, 244, 7154, 405, 581, 3112, 1911, 20, 212, 4, 49, 7, 18, 1, 46, 6, 33, 1224, 8146, 10, 879, 4, 96, 1, 3, 1734, 7, 1716, 4, 386, 283, 297, 28, 3, 61, 1055, 95, 4, 26, 45, 7154, 16, 35, 518, 564, 216, 230, 5, 38, 128, 4, 7, 5, 329, 1310, 2438, 47, 35, 1616, 258, 1, 1224, 802, 174, 119, 4, 150, 5, 544, 183, 225, 22, 56]",1197.0,15345597,Patients acute myeloid leukemia activating FLT3 respond small-molecule FLT3 tyrosine kinase inhibitor PKC412,1,0.0017452006980802793
Acquired alpha-thalassemia in association with myelodysplastic syndrome and other hematologic malignancies.,Blood,Blood,2004-09-09,"Abnormalities of hemoglobin synthesis are usually inherited but may also arise as a secondary manifestation of another disease, most commonly hematologic neoplasia. Acquired hemoglobin disorders can be seen in any population and are not restricted to areas of the world with high incidences of inherited hemoglobinopathies. In fact, the acquired hemoglobinopathies may be more readily recognized where inherited hemoglobin abnormalities are rare and less likely to cause diagnostic confusion. Acquired alpha-thalassemia is the best characterized of the acquired red blood cell disorders in patients with hematologic malignancy, and it is almost always associated with a myelodysplastic syndrome (MDS). At least 2 molecular mechanisms for acquired alpha-thalassemia are now recognized: acquired deletion of the alpha-globin gene cluster limited to the neoplastic clone and, more commonly, inactivating somatic mutations of the trans-acting chromatin-associated factor ATRX, which cause dramatic down-regulation of alpha-globin gene expression. Here we review the clinical, hematologic, and molecular genetic features of alpha-thalassemia arising in a clonal myeloid disorder, and we discuss howATRX might affect gene expression in normal and abnormal hematopoiesis through epigenetic mechanisms.",Journal Article,5612.0,85.0,Abnormalities hemoglobin synthesis usually inherited arise secondary manifestation disease commonly hematologic neoplasia Acquired hemoglobin disorders seen population restricted areas world high incidences inherited hemoglobinopathies fact acquired hemoglobinopathies readily recognized inherited hemoglobin abnormalities rare likely cause diagnostic confusion Acquired alpha-thalassemia best characterized acquired red blood disorders patients hematologic malignancy associated myelodysplastic syndrome MDS 2 molecular mechanisms acquired alpha-thalassemia recognized acquired deletion alpha-globin cluster limited neoplastic clone commonly inactivating somatic trans-acting chromatin-associated factor ATRX cause dramatic down-regulation alpha-globin expression review clinical hematologic molecular genetic features alpha-thalassemia arising clonal myeloid disorder discuss howATRX affect expression normal abnormal hematopoiesis epigenetic mechanisms,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1171, 1, 2222, 2525, 32, 2082, 2986, 84, 68, 120, 3043, 22, 8, 568, 6746, 1, 1809, 34, 96, 841, 813, 2298, 1294, 2222, 1997, 122, 40, 527, 4, 500, 266, 2, 32, 44, 2016, 6, 1361, 1, 3, 1956, 5, 64, 3981, 1, 2986, 21271, 4, 1991, 3, 1294, 21271, 68, 40, 80, 3860, 1904, 1257, 2986, 2222, 1171, 32, 622, 2, 299, 322, 6, 708, 752, 7399, 1294, 950, 19662, 16, 3, 824, 765, 1, 3, 1294, 3422, 315, 31, 1997, 4, 7, 5, 813, 710, 2, 192, 16, 2214, 3763, 41, 5, 8, 681, 1223, 28, 506, 18, 219, 483, 9, 1294, 950, 19662, 32, 1134, 1904, 1294, 1528, 1, 3, 950, 16246, 145, 3132, 383, 6, 3, 2000, 3910, 2, 80, 841, 6096, 1119, 138, 1, 3, 3437, 5375, 2287, 41, 161, 7955, 92, 708, 3079, 1328, 863, 1, 950, 16246, 145, 55, 467, 21, 206, 3, 38, 813, 2, 219, 336, 404, 1, 950, 19662, 2635, 4, 8, 1946, 533, 2645, 2, 21, 1139, 54352, 822, 1158, 145, 55, 4, 295, 2, 1668, 5114, 298, 1418, 483]",1260.0,15358626,Acquired alpha-thalassemia association myelodysplastic syndrome hematologic malignancies,26,0.04537521815008726
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.,Blood,Blood,2004-10-14,"Clofarabine (2-chloro-2'-fluoro-deoxy-9-beta-D-arabinofuranosyladenine) is a second-generation nucleoside analog with activity in acute leukemias. As clofarabine is a potent inhibitor of ribonucleotide reductase (RnR), we hypothesized that clofarabine will modulate ara-c triphosphate accumulation and increase the antileukemic activity of cytarabine (ara-C). We conducted a phase 1-2 study of clofarabine plus ara-C in 32 patients with relapsed acute leukemia (25 acute myeloid leukemia [AML], 2 acute lymphoblastic leukemia [ALL]), 4 high-risk myelodysplastic syndrome (MDS), and 1 blast-phase chronic myeloid leukemia (CML).(1) Clofarabine was given as a 1-hour intravenous infusion for 5 days (days 2 through 6) followed 4 hours later by ara-C at 1 g/m(2) per day as a 2-hour intravenous infusion for 5 days (days 1 through 5). The phase 2 dose of clofarabine was 40 mg/m(2) per day for 5 days. Among all patients, 7 (22%) achieved complete remission (CR), and 5 (16%) achieved CR with incomplete platelet recovery (CRp), for an overall response rate of 38%. No responses occurred in 3 patients with ALL and CML. One patient (3%) died during induction. Adverse events were mainly less than or equal to grade 2, including transient liver test abnormalities, nausea/vomiting, diarrhea, skin rashes, mucositis, and palmoplantar erythrodysesthesias. Plasma clofarabine levels generated clofarabine triphosphate accumulation, which resulted in an increase in ara-CTP in the leukemic blasts. The combination of clofarabine with ara-C is safe and active. Cellular pharmacology data support the biochemical modulation strategy.",Clinical Trial,5577.0,176.0,Clofarabine 2-chloro-2'-fluoro-deoxy-9-beta-D-arabinofuranosyladenine second-generation nucleoside analog activity acute leukemias clofarabine potent inhibitor ribonucleotide reductase RnR hypothesized clofarabine modulate ara-c triphosphate accumulation increase antileukemic activity cytarabine ara-C conducted phase 1-2 clofarabine plus ara-C 32 patients relapsed acute leukemia 25 acute myeloid leukemia AML 2 acute lymphoblastic leukemia 4 high-risk myelodysplastic syndrome MDS 1 blast-phase chronic myeloid leukemia CML 1 Clofarabine given 1-hour intravenous infusion 5 days days 2 6 followed 4 hours later ara-C 1 g/m 2 day 2-hour intravenous infusion 5 days days 1 5 phase 2 dose clofarabine 40 mg/m 2 day 5 days patients 7 22 achieved complete remission CR 5 16 achieved CR incomplete platelet recovery CRp overall response rate 38 responses occurred 3 patients CML patient 3 died induction Adverse events mainly equal grade 2 including transient liver test abnormalities nausea/vomiting diarrhea skin rashes mucositis palmoplantar erythrodysesthesias Plasma clofarabine levels generated clofarabine triphosphate accumulation resulted increase ara-CTP leukemic blasts combination clofarabine ara-C safe active Cellular pharmacology support biochemical modulation strategy,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,"[4149, 18, 14778, 6135, 6231, 6149, 83, 1090, 427, 54408, 16, 8, 419, 914, 4032, 3497, 5, 128, 4, 286, 2792, 22, 4149, 16, 8, 1157, 230, 1, 7050, 4027, 18376, 21, 1237, 17, 4149, 303, 3319, 3899, 256, 7345, 1835, 2, 344, 3, 4512, 128, 1, 1855, 3899, 256, 21, 426, 8, 124, 14, 18, 45, 1, 4149, 349, 3899, 256, 4, 531, 7, 5, 591, 286, 243, 286, 533, 329, 18, 286, 1275, 62, 39, 64, 43, 681, 1223, 2, 14, 3112, 124, 442, 533, 903, 14, 4149, 10, 447, 22, 8, 14, 2583, 1262, 904, 9, 33, 162, 162, 18, 298, 49, 370, 39, 1459, 1559, 20, 3899, 256, 28, 14, 499, 188, 18, 379, 218, 22, 8, 18, 2583, 1262, 904, 9, 33, 162, 162, 14, 298, 33, 3, 124, 18, 61, 1, 4149, 10, 327, 81, 188, 18, 379, 218, 9, 33, 162, 107, 62, 7, 67, 350, 513, 236, 734, 684, 2, 33, 245, 513, 684, 5, 2610, 1596, 1602, 3162, 9, 35, 63, 51, 116, 1, 519, 77, 253, 489, 4, 27, 7, 5, 62, 2, 903, 104, 69, 27, 1016, 190, 504, 290, 281, 11, 2615, 299, 76, 15, 2997, 6, 88, 18, 141, 2473, 412, 1171, 1218, 1966, 1172, 11775, 2606, 2, 26275, 43678, 554, 4149, 148, 1419, 4149, 7345, 1835, 92, 627, 4, 35, 344, 4, 3899, 7107, 4, 3, 2015, 2438, 3, 150, 1, 4149, 5, 3899, 256, 16, 1165, 2, 544, 763, 6852, 74, 538, 3, 1487, 2356, 692]",1497.0,15486072,phase 1-2 clofarabine combination cytarabine ara-C relapsed refractory acute leukemias,210,0.36649214659685864
Platelet kinetics and decreased transfusion requirements after splenectomy for hematologic malignancy.,Annals of surgery,Ann. Surg.,2004-11-01,"Thrombocytopenia is a significant and morbid problem in patients with hematologic malignancy, resulting in frequent platelet transfusions and significant resource consumption. We undertook this study to determine the impact of splenectomy on transfusion requirements in patients with chronic leukemia, acute leukemia, myelodysplastic syndrome, and lymphoma. Records of 134 patients with hematologic malignancies who underwent splenectomy were reviewed. Results are reported as mean +/- standard error of the mean. Mean preoperative (preop) platelet count was 97 +/- 8 K/microL. A significant rise in platelets, compared with preop, was observed starting on postsplenectomy day 1 (141 +/- 8 K/microL, P < 0.001 versus preop) and persisted through day 7. Counts remained significantly elevated at 3 and 6 months and years 1-5. In profoundly thrombocytopenic patients (preop levels < 20 K/microL), preop count was 11 +/- 1 K/microL. A significant postsplenectomy platelet rise persisted for at least 1 year (137 +/- 52 K/microL, P < 0.05 versus preop). An increased platelet level was observed in all hematologic subgroups; in the chronic leukemias (n = 58, P < 0.01) and in lymphoma (n = 59, P < 0.001), this reached significance. Mean platelet transfusions were significantly decreased from preop (3 months preop: 8.6 +/- 2 units) compared with postsplenectomy (3 months postsplenectomy: 5.0 +/- 1 unit, P = 0.03). This decrease was even more pronounced in profoundly thrombocytopenic patients (31.6 +/- 10.6 units preop versus 8.9 +/- 4.8 units postoperative, P = 0.01). In the hematologic malignancies, splenectomy produces a significant and longlasting restoration of platelet levels and a resultant decrease in platelet transfusion requirements. These beneficial effects of splenectomy hold true even for the most profoundly thrombocytopenic patients.",Journal Article,5559.0,8.0,Thrombocytopenia significant morbid problem patients hematologic malignancy resulting frequent platelet transfusions significant resource consumption undertook determine impact splenectomy transfusion requirements patients chronic leukemia acute leukemia myelodysplastic syndrome lymphoma Records 134 patients hematologic malignancies underwent splenectomy reviewed reported mean +/- standard error mean Mean preoperative preop platelet count 97 +/- 8 K/microL significant rise platelets compared preop observed starting postsplenectomy day 1 141 +/- 8 K/microL P 0.001 versus preop persisted day 7 Counts remained significantly elevated 3 6 months years 1-5 profoundly thrombocytopenic patients preop levels 20 K/microL preop count 11 +/- 1 K/microL significant postsplenectomy platelet rise persisted 1 year 137 +/- 52 K/microL P 0.05 versus preop increased platelet level observed hematologic subgroups chronic leukemias n 58 P 0.01 lymphoma n 59 P 0.001 reached significance Mean platelet transfusions significantly decreased preop 3 months preop 8.6 +/- 2 units compared postsplenectomy 3 months postsplenectomy 5.0 +/- 1 unit P 0.03 decrease pronounced profoundly thrombocytopenic patients 31.6 +/- 10.6 units preop versus 8.9 +/- 4.8 units postoperative P 0.01 hematologic malignancies splenectomy produces significant longlasting restoration platelet levels resultant decrease platelet transfusion requirements beneficial effects splenectomy hold true profoundly thrombocytopenic patients,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1340, 16, 8, 93, 2, 8188, 2497, 4, 7, 5, 813, 710, 1113, 4, 908, 1596, 4987, 2, 93, 3069, 2421, 21, 5418, 26, 45, 6, 223, 3, 345, 1, 6569, 23, 2785, 4230, 4, 7, 5, 442, 286, 681, 2, 1064, 1, 4842, 7, 5, 813, 441, 54, 208, 6569, 11, 446, 99, 32, 210, 22, 313, 260, 3444, 1, 3, 313, 313, 498, 13526, 1596, 1276, 10, 1015, 66, 1634, 5128, 8, 93, 3693, 4, 4407, 72, 5, 13526, 10, 164, 1723, 23, 33749, 218, 14, 4379, 66, 1634, 5128, 19, 13, 144, 185, 13526, 2, 3760, 298, 218, 67, 1911, 958, 97, 804, 28, 27, 2, 49, 53, 2, 60, 14, 33, 4, 8802, 11908, 7, 13526, 148, 179, 1634, 5128, 13526, 1276, 10, 175, 14, 1634, 5128, 8, 93, 33749, 1596, 3693, 3760, 9, 28, 506, 14, 111, 4352, 653, 1634, 5128, 19, 13, 474, 185, 13526, 35, 101, 1596, 301, 10, 164, 4, 62, 813, 1453, 4, 3, 442, 2792, 78, 717, 19, 13, 355, 2, 4, 78, 728, 19, 13, 144, 26, 1300, 724, 313, 1596, 4987, 11, 97, 340, 29, 13526, 27, 53, 13526, 66, 49, 18, 2960, 72, 5, 33749, 27, 53, 33749, 33, 13, 14, 2712, 19, 13, 680, 26, 775, 10, 871, 80, 3517, 4, 8802, 11908, 7, 456, 49, 79, 49, 2960, 13526, 185, 66, 83, 39, 66, 2960, 573, 19, 13, 355, 4, 3, 813, 441, 6569, 4042, 8, 93, 2, 54419, 5194, 1, 1596, 148, 2, 8, 6099, 775, 4, 1596, 2785, 4230, 46, 2524, 176, 1, 6569, 4164, 2501, 871, 9, 3, 96, 8802, 11908, 7]",1734.0,15492568,Platelet kinetics decreased transfusion requirements splenectomy hematologic malignancy,0,0.0
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.,American journal of hematology,Am. J. Hematol.,2004-11-01,"Mastocytosis is characterized by mast cell proliferation that may be limited to the skin (cutaneous mastocytosis) or may involve one or more extracutaneous organs, e.g., the bone marrow (systemic mastocytosis; SM). This study objective is to evaluate the features and outcome of patients referred to M. D. Anderson Cancer Center (MDACC) with SM. A search of the MDACC database from 1944 to 2002 was conducted for patients with SM and review of their clinical charts. Eighteen patients with mastocytosis were identified in the MDACC database; 15 (11 males and 4 females) had SM and available information. Two had associated myelodysplastic syndrome (MDS), and one had acute myeloid leukemia (AML). The median age was 58 years (range 31-80). Nine patients were treated with subcutaneous interferon-alpha, and only 1 experienced temporary control of the disease. Three of these patients were then treated with imatinib mesylate: transient improvement was noted in two patients. One patient underwent stem cell transplantation as first therapy and achieved complete remission; this patient had associated MDS and is now in complete remission for 8 years. The patient with associated AML was treated with high-dose cytarabine and idarubicin; he has been in complete remission for 16 months. One patient was treated with induction chemotherapy consisting of high-dose cytarabine and 2CDA but expired due to sepsis. Three patients received symptomatic therapy only; these were the only 3 patients who presented with normal blood counts. SM is rare and has no effective standard of care. Collaboration among academic centers to accrue enough patients to evaluate novel therapeutic strategies is needed.",Journal Article,5559.0,40.0,Mastocytosis characterized mast proliferation limited skin cutaneous mastocytosis involve extracutaneous organs e.g. bone marrow systemic mastocytosis SM objective evaluate features outcome patients referred M. D. Anderson Center MDACC SM search MDACC database 1944 2002 conducted patients SM review clinical charts Eighteen patients mastocytosis identified MDACC database 15 11 males 4 females SM available information associated myelodysplastic syndrome MDS acute myeloid leukemia AML median age 58 years range 31-80 patients treated subcutaneous interferon-alpha 1 experienced temporary control disease patients treated imatinib mesylate transient improvement noted patients patient underwent stem transplantation therapy achieved complete remission patient associated MDS complete remission 8 years patient associated AML treated high-dose cytarabine idarubicin complete remission 16 months patient treated induction chemotherapy consisting high-dose cytarabine 2CDA expired sepsis patients received symptomatic therapy 3 patients presented normal blood counts SM rare effective standard care Collaboration academic centers accrue patients evaluate novel therapeutic strategies needed,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[7224, 16, 765, 20, 5563, 31, 457, 17, 68, 40, 383, 6, 3, 1486, 7224, 15, 68, 3882, 104, 15, 80, 18311, 2285, 563, 499, 3, 581, 403, 7224, 3635, 26, 45, 461, 16, 6, 376, 3, 404, 2, 228, 1, 7, 1995, 6, 188, 427, 1929, 12, 574, 7412, 5, 3635, 8, 1901, 1, 3, 7412, 609, 29, 30370, 6, 1544, 10, 426, 9, 7, 5, 3635, 2, 206, 1, 136, 38, 4413, 3195, 7, 5, 7224, 11, 108, 4, 3, 7412, 609, 167, 175, 2296, 2, 39, 2451, 42, 3635, 2, 390, 487, 100, 42, 41, 681, 1223, 2, 104, 42, 286, 533, 329, 3, 52, 89, 10, 717, 60, 184, 456, 493, 762, 7, 11, 73, 5, 2529, 1688, 950, 2, 158, 14, 592, 7579, 182, 1, 3, 34, 169, 1, 46, 7, 11, 818, 73, 5, 577, 2347, 2473, 767, 10, 1051, 4, 100, 7, 104, 69, 208, 452, 31, 497, 22, 157, 36, 2, 513, 236, 734, 26, 69, 42, 41, 1223, 2, 16, 1134, 4, 236, 734, 9, 66, 60, 3, 69, 5, 41, 329, 10, 73, 5, 64, 61, 1855, 2, 5684, 3174, 71, 85, 4, 236, 734, 9, 245, 53, 104, 69, 10, 73, 5, 504, 56, 2273, 1, 64, 61, 1855, 2, 28277, 84, 13758, 520, 6, 4227, 169, 7, 103, 1704, 36, 158, 46, 11, 3, 158, 27, 7, 54, 917, 5, 295, 315, 1911, 3635, 16, 622, 2, 71, 77, 323, 260, 1, 165, 4119, 107, 1916, 1168, 6, 17283, 5151, 7, 6, 376, 229, 189, 422, 16, 575]",1621.0,15495258,Management patients systemic mastocytosis review M. D. Anderson Center experience,0,0.0
Childhood and adolescent lymphoid and myeloid leukemia.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2004-01-01,"Remarkable progress has been made in the past decade in the treatment and in the understanding of the biology of childhood lymphoid and myeloid leukemias. With contemporary improved risk assessment, chemotherapy, hematopoietic stem cell transplantation and supportive care, approximately 80% of children with newly diagnosed acute lymphoblastic leukemia and 50% of those with myeloid neoplasm can be cured to date. Current emphasis is placed not only on increased cure rate but also on improved quality of life. In Section I, Dr. Ching-Hon Pui describes certain clinical and biologic features that still have prognostic and therapeutic relevance in the context of contemporary treatment programs. He emphasizes that treatment failure in some patients is not due to intrinsic drug resistance of leukemic cells but is rather caused by suboptimal drug dosing due to host compliance, pharmacodynamics, and pharmacogenetics. Hence, measurement of minimal residual disease, which accounts for both the genetic (primary and secondary) features of leukemic lymphoblasts and pharmacogenomic variables of the host, is the most reliable prognostic indicator. Finally, he contends that with optimal risk-directed systemic and intrathecal therapy, cranial irradiation may be omitted in all patients, regardless of the presenting features. In Section II, Dr. Martin Schrappe performs detailed analyses of the prognostic impact of presenting age, leukocyte count, sex, immunophenotype, genetic abnormality, early treatment response, and in vitro drug sensitivity/resistance in childhood acute lymphoblastic leukemia, based on the large database of the Berlin-Frankfurt-Mnster consortium. He also succinctly summarizes the important treatment components resulting in the improved outcome of children and young adolescents with this disease. He describes the treatment approach that led to the improved outcome of adolescent patients, a finding that may be applied to young adults in the second and third decade of life. Finally, he believes that treatment reduction under well-controlled clinical trials is feasible in a subgroup of patients with excellent early treatment response as evidenced by minimal residual disease measurement during induction and consolidation therapy. In Section III, Dr. Raul Ribeiro describes distinct morphologic and genetic subtypes of acute myeloid leukemia. The finding of essentially identical gene expression profiling by DNA microarray in certain specific genetic subtypes of childhood and adult acute myeloid leukemia suggests a shared leukemogenesis. He then describes the principles of treatment as well as the efficacy and toxicity of various forms of postremission therapy, emphasizing the need of tailoring therapy to both the disease and the age of the patient. Early results suggest that minimal residual disease measurement can also improve the risk assessment in acute myeloid leukemia, and that cranial irradiation can be omitted even in those with central-nervous-system leukemia at diagnosis. In Section IV, Dr. Charlotte Niemeyer describes a new classification of myelodysplastic and myeloproliferative diseases in childhood, which has greatly facilitated the diagnosis of myelodysplastic syndromes and juvenile myelomonocytic leukemia. The recent discovery of somatic mutations in PTPN11 has improved the understanding of the pathobiology and the diagnosis of juvenile myelomonocytic leukemia. Together with the findings of mutations in RAS and NF1 in the other patients, she suggests that pathological activation of RAS-dependent pathways plays a central role in the leukemogenesis of this disease. She then describes the various treatment approaches for both juvenile myelomonocytic leukemia and myelodysplastic syndromes in the US and Europe, emphasizing the differences between childhood and adult cases for the latter group of diseases. She also raises some controversial issues regarding treatment that will require well-controlled international clinical trials to address.",Journal Article,5864.0,115.0,Remarkable progress past decade treatment understanding childhood lymphoid myeloid leukemias contemporary improved risk assessment chemotherapy hematopoietic stem transplantation supportive care approximately 80 children newly diagnosed acute lymphoblastic leukemia 50 myeloid neoplasm cured date Current emphasis placed increased cure rate improved quality life Section Dr. Ching-Hon Pui describes certain clinical biologic features prognostic therapeutic relevance context contemporary treatment programs emphasizes treatment failure patients intrinsic drug resistance leukemic caused suboptimal drug dosing host compliance pharmacodynamics pharmacogenetics measurement minimal residual disease accounts genetic primary secondary features leukemic lymphoblasts pharmacogenomic variables host reliable prognostic indicator Finally contends optimal risk-directed systemic intrathecal therapy cranial irradiation omitted patients regardless presenting features Section II Dr. Martin Schrappe performs detailed prognostic impact presenting age leukocyte count sex immunophenotype genetic abnormality early treatment response vitro drug sensitivity/resistance childhood acute lymphoblastic leukemia based large database Berlin-Frankfurt-Mnster consortium succinctly summarizes important treatment components resulting improved outcome children young adolescents disease describes treatment approach led improved outcome adolescent patients finding applied young adults second decade life Finally believes treatment reduction well-controlled clinical trials feasible subgroup patients excellent early treatment response evidenced minimal residual disease measurement induction consolidation therapy Section III Dr. Raul Ribeiro describes distinct morphologic genetic subtypes acute myeloid leukemia finding essentially identical expression profiling DNA microarray certain specific genetic subtypes childhood adult acute myeloid leukemia suggests shared leukemogenesis describes principles treatment efficacy toxicity forms postremission therapy emphasizing need tailoring therapy disease age patient Early suggest minimal residual disease measurement improve risk assessment acute myeloid leukemia cranial irradiation omitted central-nervous-system leukemia diagnosis Section IV Dr. Charlotte Niemeyer describes new classification myelodysplastic myeloproliferative diseases childhood greatly facilitated diagnosis myelodysplastic syndromes juvenile myelomonocytic leukemia recent discovery somatic PTPN11 improved understanding pathobiology diagnosis juvenile myelomonocytic leukemia findings RAS NF1 patients suggests pathological activation RAS-dependent pathways plays central role leukemogenesis disease describes treatment approaches juvenile myelomonocytic leukemia myelodysplastic syndromes Europe emphasizing differences childhood adult cases group diseases raises controversial issues treatment require well-controlled international clinical trials address,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3813, 1466, 71, 85, 1229, 4, 3, 1219, 2025, 4, 3, 24, 2, 4, 3, 612, 1, 3, 891, 1, 864, 2303, 2, 533, 2792, 5, 2667, 231, 43, 455, 56, 1007, 452, 31, 497, 2, 1877, 165, 705, 493, 1, 541, 5, 732, 265, 286, 1275, 2, 212, 1, 135, 5, 533, 2131, 122, 40, 3733, 6, 1244, 291, 3136, 16, 3295, 44, 158, 23, 101, 1722, 116, 84, 120, 23, 231, 372, 1, 358, 4, 2917, 70, 3436, 37328, 43083, 43084, 2677, 1840, 38, 2, 1283, 404, 17, 1234, 47, 177, 2, 189, 2088, 4, 3, 1533, 1, 2667, 24, 2251, 3174, 7519, 17, 24, 496, 4, 476, 7, 16, 44, 520, 6, 2354, 234, 251, 1, 2015, 37, 84, 16, 1832, 1546, 20, 3291, 234, 1280, 520, 6, 1204, 3336, 3587, 2, 8759, 3665, 2204, 1, 1048, 753, 34, 92, 4162, 9, 110, 3, 336, 86, 2, 568, 404, 1, 2015, 10521, 2, 6971, 682, 1, 3, 1204, 16, 3, 96, 2450, 177, 3287, 1368, 3174, 54488, 17, 5, 665, 43, 1166, 403, 2, 5126, 36, 2565, 1104, 68, 40, 7138, 4, 62, 7, 1583, 1, 3, 1656, 404, 4, 2917, 215, 3436, 33556, 54489, 13491, 2455, 318, 1, 3, 177, 345, 1, 1656, 89, 3627, 1276, 1035, 5496, 336, 3698, 191, 24, 51, 2, 4, 439, 234, 485, 251, 4, 864, 286, 1275, 90, 23, 3, 375, 609, 1, 3, 20405, 23389, 26350, 2404, 3174, 120, 43090, 2869, 3, 305, 24, 1628, 1113, 4, 3, 231, 228, 1, 541, 2, 1169, 3101, 5, 26, 34, 3174, 2677, 3, 24, 353, 17, 836, 6, 3, 231, 228, 1, 3678, 7, 8, 1567, 17, 68, 40, 1498, 6, 1169, 857, 4, 3, 419, 2, 1282, 2025, 1, 358, 1368, 3174, 28311, 17, 24, 628, 669, 149, 1149, 38, 143, 16, 1313, 4, 8, 1363, 1, 7, 5, 1503, 191, 24, 51, 22, 4728, 20, 1048, 753, 34, 2204, 190, 504, 2, 2173, 36, 4, 2917, 316, 3436, 54490, 54491, 2677, 834, 2815, 2, 336, 814, 1, 286, 533, 3, 1567, 1, 7257, 3038, 145, 55, 1080, 20, 261, 1727, 4, 1840, 112, 336, 814, 1, 864, 2, 780, 286, 533, 844, 8, 2664, 5661, 3174, 818, 2677, 3, 4650, 1, 24, 22, 149, 22, 3, 209, 2, 155, 1, 747, 2377, 1, 8635, 36, 6826, 3, 594, 1, 7101, 36, 6, 110, 3, 34, 2, 3, 89, 1, 3, 69, 191, 99, 309, 17, 1048, 753, 34, 2204, 122, 120, 401, 3, 43, 455, 4, 286, 533, 2, 17, 2565, 1104, 122, 40, 7138, 871, 4, 135, 5, 854, 1880, 398, 28, 147, 4, 2917, 478, 3436, 54492, 54493, 2677, 8, 217, 947, 1, 2, 1342, 4, 864, 92, 71, 3510, 4667, 3, 147, 1, 2040, 2, 7857, 5451, 3, 435, 1574, 1, 1119, 138, 4, 8403, 71, 231, 3, 612, 1, 3, 8465, 2, 3, 147, 1, 7857, 5451, 1162, 5, 3, 272, 1, 138, 4, 1102, 2, 3474, 4, 3, 127, 7, 3109, 844, 17, 1301, 363, 1, 1102, 470, 460, 1698, 8, 854, 200, 4, 3, 5661, 1, 26, 34, 3109, 818, 2677, 3, 747, 24, 611, 9, 110, 7857, 5451, 2, 2040, 4, 3, 843, 2, 3934, 6826, 3, 362, 59, 864, 2, 780, 140, 9, 3, 3286, 87, 1, 1342, 3109, 120, 5789, 476, 2010, 1553, 666, 24, 17, 303, 1353, 149, 1149, 944, 38, 143, 6, 1539]",3814.0,15561680,Childhood adolescent lymphoid myeloid leukemia,52,0.09075043630017451
Arsenic trioxide as a treatment for myelodysplastic syndrome.,Current hematology reports,Curr. Hematol. Rep.,2005-01-01,"Myelodysplastic syndrome (MDS) is a heterogeneous bone marrow disorder primarily affecting older adults, for whom the only curative therapy, bone marrow transplantation, is rarely an option. New therapies, or novel applications of historical therapies, are desperately needed. Arsenic trioxide (ATO), which acts through pro-apoptotic, antiproliferative, and anti-angiogenesis mechanisms, has been used successfully to treat a variety of hematologic malignancies, including MDS. As monotherapy or in combination with other agents, it can effect hematologic improvement in 22% to 26% of patients, with tolerable side effects. MDS patients whose cells express the EVI1 mutation in particular may derive benefit from this therapy.",Journal Article,5498.0,3.0,Myelodysplastic syndrome MDS heterogeneous bone marrow disorder primarily affecting older adults curative therapy bone marrow transplantation rarely option New therapies novel applications historical therapies desperately needed Arsenic trioxide ATO acts pro-apoptotic antiproliferative anti-angiogenesis mechanisms successfully treat variety hematologic malignancies including MDS monotherapy combination agents effect hematologic improvement 22 26 patients tolerable effects MDS patients express EVI1 particular derive benefit therapy,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[681, 1223, 16, 8, 1564, 581, 2645, 1561, 2319, 434, 857, 9, 953, 3, 158, 1075, 36, 581, 497, 16, 2416, 35, 1501, 217, 235, 15, 229, 2911, 1, 2252, 235, 32, 11769, 575, 3217, 4574, 4021, 92, 4459, 298, 1805, 1631, 3669, 2, 312, 1056, 483, 71, 85, 95, 1878, 6, 943, 8, 1362, 1, 813, 441, 141, 1223, 22, 1411, 15, 4, 150, 5, 127, 183, 192, 122, 254, 813, 767, 4, 350, 6, 432, 1, 7, 5, 2668, 1152, 176, 1223, 7, 1310, 37, 1669, 3, 12188, 258, 4, 1454, 68, 3823, 247, 29, 26, 36]",677.0,15610661,Arsenic trioxide treatment myelodysplastic syndrome,2,0.0034904013961605585
Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2005-02-01,"Allogeneic progenitor cell transplantation is the only curative therapy for patients with refractory acute myelogenous leukemia or myelodysplastic syndromes. To identify prognostic factors in these patients, we performed a retrospective analysis of transplantation outcomes. Patients were selected if they had undergone an allogeneic transplantation between January 1988 and January 2002 and were not in remission or first untreated relapse at the time of transplantation. A total of 135 patients were identified. The median age was 49.5 years (range, 19-75 years). At the time of transplantation, 39.3% of patients had not responded to induction therapy, 37% had not responded to first salvage therapy, and 23.7% were beyond first salvage. Forty-one patients (30%) received unrelated donor progenitor cells. Eighty patients (59%) received either a reduced-intensity or a nonmyeloablative regimen. A total of 104 (77%) of 135 patients died, with a median survival time of 4.9 months (95% confidence interval, 3.9-6.6 months). The median progression-free survival was 2.9 months (95% confidence interval, 2.5-4.2 months). A Cox regression analysis showed that Karnofsky performance status, peripheral blood blasts, and tacrolimus exposure during the first 11 days after transplantation were predictive of survival. These data support the use of allogeneic transplantation for patients with relapsed or refractory acute myelogenous leukemia/myelodysplastic syndromes and suggest that optimal immune suppression early after transplantation is essential for long-term survival even in patients with refractory myeloid leukemias.",Journal Article,5467.0,86.0,Allogeneic progenitor transplantation curative therapy patients refractory acute myelogenous leukemia myelodysplastic syndromes identify prognostic factors patients performed retrospective transplantation outcomes Patients selected undergone allogeneic transplantation January 1988 January 2002 remission untreated relapse time transplantation total 135 patients identified median age 49.5 years range 19-75 years time transplantation 39.3 patients responded induction therapy 37 responded salvage therapy 23.7 salvage Forty-one patients 30 received unrelated donor progenitor Eighty patients 59 received reduced-intensity nonmyeloablative regimen total 104 77 135 patients died median survival time 4.9 months 95 confidence interval 3.9-6.6 months median progression-free survival 2.9 months 95 confidence interval 2.5-4.2 months Cox regression showed Karnofsky performance status peripheral blood blasts tacrolimus exposure 11 days transplantation predictive survival support use allogeneic transplantation patients relapsed refractory acute myelogenous leukemia/myelodysplastic syndromes suggest optimal immune suppression early transplantation essential long-term survival patients refractory myeloid leukemias,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1063, 2520, 31, 497, 16, 3, 158, 1075, 36, 9, 7, 5, 430, 286, 2194, 15, 2040, 6, 255, 177, 130, 4, 46, 7, 21, 173, 8, 459, 65, 1, 497, 123, 7, 11, 715, 492, 491, 42, 1989, 35, 1063, 497, 59, 1024, 3314, 2, 1024, 1544, 2, 11, 44, 4, 734, 15, 157, 1278, 429, 28, 3, 98, 1, 497, 8, 181, 1, 3978, 7, 11, 108, 3, 52, 89, 10, 739, 33, 60, 184, 326, 481, 60, 28, 3, 98, 1, 497, 587, 27, 1, 7, 42, 44, 2211, 6, 504, 36, 567, 42, 44, 2211, 6, 157, 992, 36, 2, 382, 67, 11, 1654, 157, 992, 1213, 104, 7, 201, 103, 2092, 1488, 2520, 37, 2207, 7, 728, 103, 361, 8, 405, 837, 15, 8, 6094, 477, 8, 181, 1, 3407, 849, 1, 3978, 7, 1016, 5, 8, 52, 25, 98, 1, 39, 83, 53, 48, 307, 268, 27, 83, 49, 49, 53, 3, 52, 91, 115, 25, 10, 18, 83, 53, 48, 307, 268, 18, 33, 39, 18, 53, 8, 418, 320, 65, 224, 17, 2857, 528, 156, 672, 315, 2438, 2, 5643, 645, 190, 3, 157, 175, 162, 50, 497, 11, 464, 1, 25, 46, 74, 538, 3, 119, 1, 1063, 497, 9, 7, 5, 591, 15, 430, 286, 2194, 2647, 10589, 2040, 2, 309, 17, 665, 250, 1332, 191, 50, 497, 16, 1452, 9, 319, 337, 25, 871, 4, 7, 5, 430, 533, 2792]",1557.0,15682071,Prognostic factors outcomes patients refractory relapsed acute myelogenous leukemia myelodysplastic syndromes undergoing allogeneic progenitor transplantation,24,0.041884816753926704
Cytoprotection in acute myelogenous leukemia (AML) therapy.,Seminars in oncology,Semin. Oncol.,2004-12-01,"Planning therapy for acute myelogenous leukemia (AML) is difficult because of the heterogeneous nature of the disease and varying patient age at presentation. Cytogenetics and patient age at the time of diagnosis are two major factors determining treatment outcome in AML. Patients with poor-risk cytogenetics have much lower complete remission rates than other groups. In addition, AML in patients greater than 55 to 60 years of age often exhibits a resistant phenotype, more akin to secondary AML or AML arising from myelodysplastic syndromes. This group is also characterized by lower complete remission rates, and often requires the delivery of intensive therapy to a patient population that is the least likely to tolerate it. At the Jefferson Health System (Philadelphia, PA), we wished to develop a regimen that was maximally intensive to treat stubborn disease, but gentle enough to be given to all patients regardless of age. Toward this end, 33 patients received a maximal dose of the cytoprotective agent, amifostine, before each infusion of idarubicin in the ""7 + 3"" regimen, escalating the dose of idarubicin in a phase I fashion to a maximum dose of 24 mg/m2 . The data indicate that the addition of amifostine to ""7 + 3"" AML induction therapy enables a substantial escalation of the idarubicin dose through the 21-mg/m2 dose level, without a concomitant increase in side effects, thus providing a regimen that is both intensive and applicable to patients of all ages. Currently, phase II studies are ongoing on a national basis to evaluate the efficacy of this regimen.",Clinical Trial,5529.0,4.0,Planning therapy acute myelogenous leukemia AML difficult heterogeneous nature disease varying patient age presentation Cytogenetics patient age time diagnosis major factors determining treatment outcome AML Patients poor-risk cytogenetics lower complete remission rates groups addition AML patients greater 55 60 years age exhibits resistant phenotype akin secondary AML AML arising myelodysplastic syndromes group characterized lower complete remission rates requires delivery intensive therapy patient population likely tolerate Jefferson Health Philadelphia PA wished develop regimen maximally intensive treat stubborn disease gentle given patients regardless age end 33 patients received maximal dose cytoprotective agent amifostine infusion idarubicin `` 7 3 '' regimen escalating dose idarubicin phase fashion maximum dose 24 mg/m2 indicate addition amifostine `` 7 3 '' AML induction therapy enables substantial escalation idarubicin dose 21-mg/m2 dose level concomitant increase effects providing regimen intensive applicable patients ages Currently phase II studies ongoing national basis evaluate efficacy regimen,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1349, 36, 9, 286, 2194, 329, 16, 1740, 408, 1, 3, 1564, 2202, 1, 3, 34, 2, 2990, 69, 89, 28, 1031, 2510, 2, 69, 89, 28, 3, 98, 1, 147, 32, 100, 458, 130, 2196, 24, 228, 4, 329, 7, 5, 334, 43, 2510, 47, 1802, 280, 236, 734, 151, 76, 127, 271, 4, 352, 329, 4, 7, 378, 76, 614, 6, 335, 60, 1, 89, 629, 4273, 8, 436, 1005, 80, 16693, 6, 568, 329, 15, 329, 2635, 29, 2040, 26, 87, 16, 120, 765, 20, 280, 236, 734, 151, 2, 629, 1706, 3, 989, 1, 1686, 36, 6, 8, 69, 266, 17, 16, 3, 506, 322, 6, 5010, 192, 28, 3, 24795, 341, 398, 3006, 3118, 21, 11382, 6, 690, 8, 477, 17, 10, 6402, 1686, 6, 943, 43865, 34, 84, 43866, 5151, 6, 40, 447, 6, 62, 7, 1583, 1, 89, 1317, 26, 396, 466, 7, 103, 8, 2725, 61, 1, 3, 10677, 420, 5369, 348, 296, 904, 1, 5684, 4, 3, 67, 27, 522, 477, 2922, 3, 61, 1, 5684, 4, 8, 124, 70, 3240, 6, 8, 689, 61, 1, 259, 81, 821, 3, 74, 1008, 17, 3, 352, 1, 5369, 6, 67, 27, 522, 329, 504, 36, 4843, 8, 1281, 1125, 1, 3, 5684, 61, 298, 3, 239, 81, 821, 61, 301, 187, 8, 1781, 344, 4, 1152, 176, 631, 1736, 8, 477, 17, 16, 110, 1686, 2, 3801, 6, 7, 1, 62, 2165, 694, 124, 215, 94, 32, 942, 23, 8, 657, 877, 6, 376, 3, 209, 1, 26, 477]",1536.0,15726527,Cytoprotection acute myelogenous leukemia AML therapy,227,0.3961605584642234
"Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2005-02-22,"To investigate the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of BMS-214662, a farnesyl transferase (FTase) inhibitor, in patients with acute leukemias and high-risk myelodysplastic syndromes (MDS). Patients with relapsed or refractory acute leukemias or MDS, or previously untreated but poor candidates for chemotherapy, were included in this phase I study with a 3 + 3 dose escalation design. BMS-214662 was administered as a 1-hour bolus once weekly at doses of 42 to 157 mg/m2. Once the MTD was identified, the schedule was changed to a 24-hour continuous infusion once weekly (starting dose, 300 mg/m2). Thirty patients were treated at a dose of 42 (n = 1), 56 (n = 3), 84 (n = 3), 118 (n = 13), 157 (n = 6) or 300 mg/m2 (n = 4). DLT occurred in 3 patients at 157 mg/m2, including nausea, vomiting, diarrhea, hypokalemia and cardiovascular problems. No DLT occurred with 24-hour continuous infusion. MTD with a 1-hour infusion was 118 mg/m2, with no MTD identified with the 24-hour infusion. Plasma concentrations of BMS-214662 correlated with the dose. Inhibition of FTase activity of approximately 60% occurred after the infusion with recovery to near baseline after 24 hours. Five patients had evidence of antileukemia activity, including two with complete remission with incomplete platelet recovery, one with hematologic improvement, and two with morphologic leukemia-free state. BMS-214662 is well tolerated at doses of up to 118 mg/m2 as a 1-hour infusion. The toxicity profile and efficacy may be improved with prolonged exposure. Further investigation of this agent in leukemia is warranted.",Clinical Trial,5446.0,44.0,investigate dose-limiting toxicity DLT maximum-tolerated dose MTD BMS-214662 farnesyl transferase FTase inhibitor patients acute leukemias high-risk myelodysplastic syndromes MDS Patients relapsed refractory acute leukemias MDS previously untreated poor candidates chemotherapy included phase 3 3 dose escalation design BMS-214662 administered 1-hour bolus weekly doses 42 157 mg/m2 MTD identified schedule changed 24-hour continuous infusion weekly starting dose 300 mg/m2 Thirty patients treated dose 42 n 1 56 n 3 84 n 3 118 n 13 157 n 6 300 mg/m2 n 4 DLT occurred 3 patients 157 mg/m2 including nausea vomiting diarrhea hypokalemia cardiovascular problems DLT occurred 24-hour continuous infusion MTD 1-hour infusion 118 mg/m2 MTD identified 24-hour infusion Plasma concentrations BMS-214662 correlated dose Inhibition FTase activity approximately 60 occurred infusion recovery near baseline 24 hours patients evidence antileukemia activity including complete remission incomplete platelet recovery hematologic improvement morphologic leukemia-free state BMS-214662 tolerated doses 118 mg/m2 1-hour infusion toxicity profile efficacy improved prolonged exposure investigation agent leukemia warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 963, 3, 61, 817, 155, 2059, 2, 689, 421, 61, 961, 1, 3502, 14561, 8, 8846, 4402, 14104, 230, 4, 7, 5, 286, 2792, 2, 64, 43, 2040, 1223, 7, 5, 591, 15, 430, 286, 2792, 15, 1223, 15, 373, 1278, 84, 334, 1931, 9, 56, 11, 159, 4, 26, 124, 70, 45, 5, 8, 27, 27, 61, 1125, 771, 3502, 14561, 10, 468, 22, 8, 14, 2583, 3604, 1059, 709, 28, 415, 1, 595, 6, 5311, 81, 821, 1059, 3, 961, 10, 108, 3, 1055, 10, 2368, 6, 8, 259, 2583, 1314, 904, 1059, 709, 1723, 61, 2036, 81, 821, 977, 7, 11, 73, 28, 8, 61, 1, 595, 78, 14, 664, 78, 27, 874, 78, 27, 4002, 78, 233, 5311, 78, 49, 15, 2036, 81, 821, 78, 39, 2059, 489, 4, 27, 7, 28, 5311, 81, 821, 141, 1218, 1966, 1172, 7799, 2, 2179, 2408, 77, 2059, 489, 5, 259, 2583, 1314, 904, 961, 5, 8, 14, 2583, 904, 10, 4002, 81, 821, 5, 77, 961, 108, 5, 3, 259, 2583, 904, 554, 1003, 1, 3502, 14561, 438, 5, 3, 61, 297, 1, 14104, 128, 1, 705, 335, 489, 50, 3, 904, 5, 1602, 6, 1829, 330, 50, 259, 1459, 365, 7, 42, 241, 1, 9169, 128, 141, 100, 5, 236, 734, 5, 2610, 1596, 1602, 104, 5, 813, 767, 2, 100, 5, 2815, 2647, 115, 1309, 3502, 14561, 16, 149, 421, 28, 415, 1, 126, 6, 4002, 81, 821, 22, 8, 14, 2583, 904, 3, 155, 800, 2, 209, 68, 40, 231, 5, 1069, 645, 195, 940, 1, 26, 420, 4, 16, 1197]",1530.0,15728224,Phase BMS-214662 farnesyl transferase inhibitor patients acute leukemias high-risk myelodysplastic syndromes,1,0.0017452006980802793
Complete remission following clofarabine treatment in refractory juvenile myelomonocytic leukemia.,Journal of pediatric hematology/oncology,J. Pediatr. Hematol. Oncol.,2005-03-01,"Juvenile myelomonocytic leukemia (JMML) is the most common myeloproliferative/myelodysplastic disorder seen in children. The treatment of choice, allogeneic stem cell transplantation, provides the only known cure for the disease, but relapse after transplant is common. The authors describe a 5-year-old boy diagnosed at age 34 months with JMML that evolved to acute myeloid leukemia. Initial treatment consisted of fludarabine and cis-retinoic acid therapy, followed by a matched sibling bone marrow transplant. After a relapse, he received a second transplant from the same donor, using peripheral blood stem cells, followed by repeated donor leukocyte infusions. After the second relapse, he received the farnesyltransferase inhibitor R115777 (tipifarnib, Zarnestra), but the leukemia persisted. When bone marrow blasts numbered 60% of the mononuclear cells, he received single-agent clofarabine induction (52 mg/m/d) for 5 days. After three courses, he attained a remission marrow with 5% blasts and disappearance of the 5q- and 9q- cytogenetic abnormalities.",Case Reports,5439.0,6.0,Juvenile myelomonocytic leukemia JMML common myeloproliferative/myelodysplastic disorder seen children treatment choice allogeneic stem transplantation provides known cure disease relapse transplant common authors 5-year-old boy diagnosed age 34 months JMML evolved acute myeloid leukemia Initial treatment consisted fludarabine cis-retinoic acid therapy followed matched sibling bone marrow transplant relapse received second transplant donor peripheral blood stem followed repeated donor leukocyte infusions second relapse received farnesyltransferase inhibitor R115777 tipifarnib Zarnestra leukemia persisted bone marrow blasts numbered 60 mononuclear received single-agent clofarabine induction 52 mg/m/d 5 days courses attained remission marrow 5 blasts disappearance 5q- 9q- cytogenetic abnormalities,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7857, 5451, 16768, 16, 3, 96, 186, 10857, 10589, 2645, 527, 4, 541, 3, 24, 1, 1866, 1063, 452, 31, 497, 777, 3, 158, 440, 1722, 9, 3, 34, 84, 429, 50, 941, 16, 186, 3, 738, 897, 8, 33, 111, 1095, 10802, 265, 28, 89, 562, 53, 5, 16768, 17, 3937, 6, 286, 533, 388, 24, 1695, 1, 2027, 2, 1927, 3887, 971, 36, 370, 20, 8, 655, 3684, 581, 941, 50, 8, 429, 3174, 103, 8, 419, 941, 29, 3, 827, 1488, 75, 672, 315, 452, 37, 370, 20, 2113, 1488, 3627, 3435, 50, 3, 419, 429, 3174, 103, 3, 7480, 230, 9645, 4781, 20218, 84, 3, 3760, 198, 581, 2438, 16778, 335, 1, 3, 3041, 37, 3174, 103, 226, 420, 4149, 504, 653, 81, 188, 427, 9, 33, 162, 50, 169, 1993, 3174, 5105, 8, 734, 581, 5, 33, 2438, 2, 13528, 1, 3, 5460, 2, 20998, 1266, 1171]",998.0,15750451,Complete remission following clofarabine treatment refractory juvenile myelomonocytic leukemia,21,0.03664921465968586
Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2005-03-07,"Although the risk of myelodysplastic syndrome (MDS) has been well-described following autologous bone marrow transplantation (ABMT), the risk of solid tumors has been poorly characterized. We report the incidence and outcome of solid tumors at 10-year follow-up in a large cohort of uniformly treated patients who underwent ABMT for non-Hodgkin's lymphoma (NHL). Between 1982 and 1997, 605 patients underwent ABMT for B-cell NHL, with uniform conditioning with cyclophosphamide and total-body irradiation followed by reinfusion of autologous bone marrow purged with anti-B-cell monoclonal antibodies. Current information on relapse of disease and second malignancies was obtained via an institutional review board-approved questionnaire sent to the referring oncologists. Forty-two solid tumors, six non-MDS hematologic malignancies, 39 nonmelanoma skin cancers, and 68 cases of MDS/acute myelogenous leukemia (AML) were observed at a median follow-up of 9.5 years. A cumulative incidence model using death as a competing risk found that the 10-year incidence of second malignancy is 21%, with 10.0% non-MDS malignancies. The projected incidence of all malignancies at 15 years is 29%. The principal risk factor for second malignancy is increased age at ABMT (P = .0002). In the entire cohort, 9.6% of patients have died of second malignancy. Lengthy follow-up demonstrates a significant incidence of second malignancies after ABMT for NHL. Although the incidence of MDS/AML starts to plateau, the incidence of solid tumors continues to rise. Second malignancies are responsible for a significant fraction of overall mortality following ABMT.",Journal Article,5433.0,91.0,risk myelodysplastic syndrome MDS well-described following autologous bone marrow transplantation ABMT risk solid poorly characterized report incidence outcome solid 10-year follow-up large cohort uniformly treated patients underwent ABMT non-Hodgkin 's lymphoma NHL 1982 1997 605 patients underwent ABMT B-cell NHL uniform conditioning cyclophosphamide total-body irradiation followed reinfusion autologous bone marrow purged anti-B-cell monoclonal antibodies Current information relapse disease second malignancies obtained institutional review board-approved questionnaire sent referring oncologists Forty-two solid non-MDS hematologic malignancies 39 nonmelanoma skin 68 cases MDS/acute myelogenous leukemia AML observed median follow-up 9.5 years cumulative incidence model death competing risk 10-year incidence second malignancy 21 10.0 non-MDS malignancies projected incidence malignancies 15 years 29 principal risk factor second malignancy increased age ABMT P .0002 entire cohort 9.6 patients died second malignancy Lengthy follow-up demonstrates significant incidence second malignancies ABMT NHL incidence MDS/AML starts plateau incidence solid continues rise Second malignancies responsible significant fraction overall mortality following ABMT,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[242, 3, 43, 1, 681, 1223, 71, 85, 149, 1027, 366, 1028, 581, 497, 14805, 3, 43, 1, 537, 57, 71, 85, 1240, 765, 21, 414, 3, 287, 2, 228, 1, 537, 57, 28, 79, 111, 166, 126, 4, 8, 375, 180, 1, 4254, 73, 7, 54, 208, 14805, 9, 292, 1176, 59, 6652, 2, 2341, 14247, 7, 208, 14805, 9, 132, 31, 1176, 5, 3490, 1933, 5, 1112, 2, 181, 642, 1104, 370, 20, 20145, 1, 1028, 581, 10546, 5, 312, 132, 31, 848, 890, 291, 487, 23, 429, 1, 34, 2, 419, 441, 10, 683, 847, 35, 1115, 206, 2620, 850, 1770, 6325, 6, 3, 8636, 1339, 1213, 100, 537, 57, 437, 220, 1223, 813, 441, 587, 7814, 163, 2, 806, 140, 1, 1223, 286, 2194, 329, 11, 164, 28, 8, 52, 166, 126, 1, 83, 33, 60, 8, 967, 287, 202, 75, 273, 22, 8, 2573, 43, 204, 17, 3, 79, 111, 287, 1, 419, 710, 16, 239, 5, 79, 13, 220, 1223, 441, 3, 5633, 287, 1, 62, 441, 28, 167, 60, 16, 462, 3, 4312, 43, 161, 9, 419, 710, 16, 101, 89, 28, 14805, 19, 3531, 4, 3, 1797, 180, 83, 49, 1, 7, 47, 1016, 1, 419, 710, 14487, 166, 126, 1902, 8, 93, 287, 1, 419, 441, 50, 14805, 9, 1176, 242, 3, 287, 1, 1223, 329, 23417, 6, 6133, 3, 287, 1, 537, 57, 2274, 6, 3693, 419, 441, 32, 2327, 9, 8, 93, 1509, 1, 63, 282, 366, 14805]",1545.0,15753460,Increasing incidence late second malignancies conditioning cyclophosphamide total-body irradiation autologous bone marrow transplantation non-Hodgkin 's lymphoma,9,0.015706806282722512
Expression of DLK1 in hematopoietic cells results in inhibition of differentiation and proliferation.,Oncogene,Oncogene,2005-06-01,"The Delta-like (DLK1) gene is overexpressed in CD34+ cells from myelodysplastic syndrome (MDS) patients. DLK1 encodes an EGF-like homeotic transmembrane protein homologous to the notch/delta/serrate family. Although exogenous DLK1 promotes maintenance of murine hematopoietic stem cells, the functional effects of DLK1 overexpression in hematopoietic cells are unknown. We show that ectopically expressed DLK1 significantly inhibits differentiation and proliferation of human promyelocytic HL-60 cells. Unlike preadipocytes, where proteolytic processing of membrane-bound protein and release of a soluble form mediates differentiation inhibition, proteolytic release of the extracellular domain was not required for inhibition of hematopoietic cell differentiation. However, intracellular domain interactions were critical to this DLK1 function. We conclude that DLK1 overexpression in hematopoietic cells has important functional consequences. Our studies identify novel molecular mechanisms and indicate that DLK1 has activity both as a soluble and a transmembrane expressed protein. Our results support further investigation of the role of DLK1 in abnormal hematopoiesis in MDS.",Journal Article,5347.0,60.0,Delta-like DLK1 overexpressed CD34+ myelodysplastic syndrome MDS patients DLK1 encodes EGF-like homeotic transmembrane homologous notch/delta/serrate family exogenous DLK1 promotes maintenance murine hematopoietic stem functional effects DLK1 overexpression hematopoietic unknown ectopically expressed DLK1 significantly inhibits differentiation proliferation human promyelocytic HL-60 Unlike preadipocytes proteolytic processing membrane-bound release soluble form mediates differentiation inhibition proteolytic release extracellular domain required inhibition hematopoietic differentiation intracellular domain interactions critical DLK1 function conclude DLK1 overexpression hematopoietic important functional consequences studies identify novel molecular mechanisms indicate DLK1 activity soluble transmembrane expressed support investigation role DLK1 abnormal hematopoiesis MDS,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 4305, 733, 19012, 145, 16, 1711, 4, 2215, 37, 29, 681, 1223, 7, 19012, 4322, 35, 3114, 733, 43917, 5527, 178, 3894, 6, 3, 3193, 4305, 54716, 607, 242, 4181, 19012, 2148, 1146, 1, 1471, 1007, 452, 37, 3, 583, 176, 1, 19012, 851, 4, 1007, 37, 32, 860, 21, 514, 17, 11744, 570, 19012, 97, 1576, 910, 2, 457, 1, 171, 4300, 1718, 335, 37, 4246, 28374, 1257, 8788, 3325, 1, 1905, 2951, 178, 2, 2008, 1, 8, 2968, 1297, 3961, 910, 297, 8788, 2008, 1, 3, 1976, 1398, 10, 44, 616, 9, 297, 1, 1007, 31, 910, 137, 2087, 1398, 1286, 11, 740, 6, 26, 19012, 343, 21, 2060, 17, 19012, 851, 4, 1007, 37, 71, 305, 583, 3255, 114, 94, 255, 229, 219, 483, 2, 1008, 17, 19012, 71, 128, 110, 22, 8, 2968, 2, 8, 5527, 570, 178, 114, 99, 538, 195, 940, 1, 3, 200, 1, 19012, 4, 1668, 5114, 4, 1223]",1148.0,15806146,Expression DLK1 hematopoietic inhibition differentiation proliferation,0,0.0
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.,Leukemia research,Leuk. Res.,2005-04-01,"A higher complete remission (CR) rate was observed in patients with acute myeloid leukemia (AML) who, on a prior randomized study of induction therapy, received gemtuzumab ozogamicin (GO) plus interleukin-11 (IL-11) rather than GO alone. An adaptive randomized phase III study of the addition of IL-11 to idarubicin and cytarabine (IA) induction in 100 patients >/=50 years of age with AML or high-risk myelodysplastic syndrome (MDS) was conducted. Median patient age was 67 years (range 50-82). Twenty-four of the 45 (53%) patients randomized to IA plus IL-11 achieved CR. Eight (33%) subsequently relapsed, 4 (17%) died in CR; median time to treatment failure (TTF) was 37 weeks. Twenty-nine of the 55 (53%) patients treated without IL-11 achieved CR. Eight (28%) subsequently relapsed, 2 (7%) died in CR; median TTF was 46 weeks. Median overall survivals were 21 and 59 weeks for the IA plus IL-11 and IA cohorts, respectively (p=0.271, log rank test; 0.435, Gehan-Breslow test). Ten episodes of the following grade 3 or 4 cardiopulmonary toxicities were observed in patients receiving IA plus IL-11, 12 such episodes in those receiving IA alone: atrial fibrillation, pleural effusions, myocardial infarction, bradycardia or hypotension. Two patients in each arm experienced grade 3 peripheral edema. There was no significant difference in incidence of any grade 3 or 4 adverse event, including thrombocytopenia, between treatment arms. There was no significant impact on CR rates, TTF, survival, or toxicity of adding an IL-11 regimen to IA induction in patients >/=50 years of age with AML.",Clinical Trial,5408.0,17.0,higher complete remission CR rate observed patients acute myeloid leukemia AML prior randomized induction therapy received gemtuzumab ozogamicin plus interleukin-11 IL-11 adaptive randomized phase III addition IL-11 idarubicin cytarabine IA induction 100 patients /=50 years age AML high-risk myelodysplastic syndrome MDS conducted Median patient age 67 years range 50-82 Twenty-four 45 53 patients randomized IA plus IL-11 achieved CR 33 subsequently relapsed 4 17 died CR median time treatment failure TTF 37 weeks Twenty-nine 55 53 patients treated IL-11 achieved CR 28 subsequently relapsed 2 7 died CR median TTF 46 weeks Median overall survivals 21 59 weeks IA plus IL-11 IA cohorts respectively p=0.271 log rank test 0.435 Gehan-Breslow test episodes following grade 3 4 cardiopulmonary toxicities observed patients receiving IA plus IL-11 12 episodes receiving IA atrial fibrillation pleural effusions myocardial infarction bradycardia hypotension patients arm experienced grade 3 peripheral edema significant difference incidence grade 3 4 adverse event including thrombocytopenia treatment arms significant impact CR rates TTF survival toxicity adding IL-11 regimen IA induction patients /=50 years age AML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[8, 142, 236, 734, 684, 116, 10, 164, 4, 7, 5, 286, 533, 329, 54, 23, 8, 324, 384, 45, 1, 504, 36, 103, 7918, 5566, 3537, 349, 1603, 175, 501, 175, 1832, 76, 3537, 279, 35, 2454, 384, 124, 316, 45, 1, 3, 352, 1, 501, 175, 6, 5684, 2, 1855, 3302, 504, 4, 394, 7, 212, 60, 1, 89, 5, 329, 15, 64, 43, 681, 1223, 10, 426, 52, 69, 89, 10, 598, 60, 184, 212, 878, 737, 294, 1, 3, 512, 699, 7, 384, 6, 3302, 349, 501, 175, 513, 684, 659, 466, 1611, 591, 39, 269, 1016, 4, 684, 52, 98, 6, 24, 496, 4583, 10, 567, 244, 737, 762, 1, 3, 614, 699, 7, 73, 187, 501, 175, 513, 684, 659, 339, 1611, 591, 18, 67, 1016, 4, 684, 52, 4583, 10, 641, 244, 52, 63, 3794, 11, 239, 2, 728, 244, 9, 3, 3302, 349, 501, 175, 2, 3302, 736, 106, 19, 13, 8957, 1066, 1026, 412, 13, 9002, 37901, 6931, 412, 1618, 3750, 1, 3, 366, 88, 27, 15, 39, 7744, 385, 11, 164, 4, 7, 357, 3302, 349, 501, 175, 133, 225, 3750, 4, 135, 357, 3302, 279, 7658, 9380, 2164, 5154, 5098, 6124, 16827, 15, 6577, 100, 7, 4, 296, 475, 592, 88, 27, 672, 3306, 125, 10, 77, 93, 523, 4, 287, 1, 500, 88, 27, 15, 39, 290, 774, 141, 1340, 59, 24, 1335, 125, 10, 77, 93, 345, 23, 684, 151, 4583, 25, 15, 155, 1, 2726, 35, 501, 175, 477, 6, 3302, 504, 4, 7, 212, 60, 1, 89, 5, 329]",1500.0,15863204,Adaptive randomized idarubicin cytarabine interleukin-11 induction therapy patients aged 50 acute myeloid leukemia high-risk myelodysplastic syndromes,11,0.019197207678883072
Myelodysplasic syndromes: a comprehensive review.,Blood reviews,Blood Rev.,2005-11-01,"Myelodysplastic syndromes (MDS) are a set of oligoclonal disorders of hematopoietic stem cells characterized by ineffective hematopoiesis that manifest clinically as anemia, neutropenia, and/or thrombocytopenia of variable severity. The result often is transfusion-dependent anemia, an increased risk of infection or hemorrhage, and a potential to progress to acute myelogenous leukemia (AML). Although progression to acute leukemia can lead to death in patients with MDS, many deaths are consequences of cytopenias and marrow failure in the absence of transformation. Approximately 2/3 of patients succumb to the disease within 3-4 years after presentation, and individuals with high-risk MDS generally survive about 1 year. Given that the disease is more prevalent in the elderly who often have comorbid conditions, the current treatment of MDS consists mainly of supportive care. Curative treatments are restricted to younger, healthy individuals with histocompatible (HLA)-matched donors for allogenic transplant or those able to undergo intensive chemotherapeutic regimens. However, understanding of the pathophysiology of MDS and identification of potential cellular and molecular targets in recent years has led to novel therapeutic approaches. Encouraging results using these heterogeneous therapeutic approaches alone or in combination in Phase I and II trials, have, in turn, called into question previous classification systems and have confirmed the need for an all-encompassing molecular, diagnostic and prognostic staging system.",Journal Article,5194.0,71.0,Myelodysplastic syndromes MDS set oligoclonal disorders hematopoietic stem characterized ineffective hematopoiesis manifest clinically anemia neutropenia and/or thrombocytopenia variable severity transfusion-dependent anemia increased risk infection hemorrhage potential progress acute myelogenous leukemia AML progression acute leukemia lead death patients MDS deaths consequences cytopenias marrow failure absence transformation Approximately 2/3 patients succumb disease 3-4 years presentation individuals high-risk MDS generally survive 1 year Given disease prevalent elderly comorbid conditions current treatment MDS consists mainly supportive care Curative treatments restricted younger healthy individuals histocompatible HLA -matched donors allogenic transplant able undergo intensive chemotherapeutic regimens understanding pathophysiology MDS identification potential cellular molecular targets recent years led novel therapeutic approaches Encouraging heterogeneous therapeutic approaches combination Phase II trials turn called question previous classification systems confirmed need all-encompassing molecular diagnostic prognostic staging,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2040, 1223, 32, 8, 916, 1, 18201, 1997, 1, 1007, 452, 37, 765, 20, 3957, 5114, 17, 7633, 505, 22, 1545, 778, 2, 15, 1340, 1, 1347, 1702, 3, 757, 629, 16, 2785, 470, 1545, 35, 101, 43, 1, 930, 15, 3599, 2, 8, 174, 6, 1466, 6, 286, 2194, 329, 242, 91, 6, 286, 122, 1122, 6, 273, 4, 7, 5, 1223, 445, 1043, 32, 3255, 1, 5635, 2, 581, 496, 4, 3, 1127, 1, 1392, 705, 18, 27, 1, 7, 9025, 6, 3, 34, 262, 27, 39, 60, 50, 1031, 2, 869, 5, 64, 43, 1223, 1228, 4573, 545, 14, 111, 447, 17, 3, 34, 16, 80, 2485, 4, 3, 1216, 54, 629, 47, 3952, 1298, 3, 291, 24, 1, 1223, 5132, 2615, 1, 1877, 165, 1075, 640, 32, 2016, 6, 773, 1331, 869, 5, 30254, 1160, 655, 2344, 9, 15122, 941, 15, 135, 1665, 6, 1251, 1686, 1573, 472, 137, 612, 1, 3, 4320, 1, 1223, 2, 911, 1, 174, 763, 2, 219, 637, 4, 435, 60, 71, 836, 6, 229, 189, 611, 2269, 99, 75, 46, 1564, 189, 611, 279, 15, 4, 150, 4, 124, 70, 2, 215, 143, 47, 4, 3854, 3472, 237, 2840, 698, 947, 1530, 2, 47, 557, 3, 594, 9, 35, 62, 6853, 219, 752, 2, 177, 632, 398]",1483.0,15885860,Myelodysplasic syndromes comprehensive review,216,0.3769633507853403
Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia.,American journal of hematology,Am. J. Hematol.,2005-06-01,"In a pilot study to reduce the duration of treatment and potential long-term toxicities, 39 patients with acute promyelocytic leukemia in remission received a single cycle of intensive consolidation therapy, followed by intermittent ATRA maintenance. Consolidation therapy required prolonged hospitalization and was associated with a high incidence of mucositis (43% grade II or greater) and documented infection (45%). No deaths occurred during consolidation. Seven patients have relapsed; all other patients are in molecular remission (median follow-up, 2.75 years). Kaplan-Meier estimate of 3 year disease-free survival is 73% (95% confidence interval 55-91%). The relapse rate (0.06 relapses/patient-year of follow-up) is well within the range of larger published series that administer more prolonged consolidation. One patient has developed secondary myelodysplastic syndrome. These pilot data suggest that decreasing the total duration of consolidation chemotherapy did not compromise disease-free survival for APL patients induced with ATRA/anthracycline and given intermittent ATRA maintenance. However, the toxicity of the consolidation module and the development of secondary myelodysplasia despite decreased total therapy emphasize the need to further improve and refine curative therapy for APL.",Journal Article,5347.0,2.0,pilot reduce duration treatment potential long-term toxicities 39 patients acute promyelocytic leukemia remission received single cycle intensive consolidation therapy followed intermittent ATRA maintenance Consolidation therapy required prolonged hospitalization associated high incidence mucositis 43 grade II greater documented infection 45 deaths occurred consolidation Seven patients relapsed patients molecular remission median follow-up 2.75 years Kaplan-Meier estimate 3 year disease-free survival 73 95 confidence interval 55-91 relapse rate 0.06 relapses/patient-year follow-up range larger published series administer prolonged consolidation patient developed secondary myelodysplastic syndrome pilot suggest decreasing total duration consolidation chemotherapy compromise disease-free survival APL patients induced ATRA/anthracycline given intermittent ATRA maintenance toxicity consolidation module development secondary myelodysplasia despite decreased total therapy emphasize need improve refine curative therapy APL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 8, 2281, 45, 6, 969, 3, 654, 1, 24, 2, 174, 319, 337, 385, 587, 7, 5, 286, 4300, 4, 734, 103, 8, 226, 417, 1, 1686, 2173, 36, 370, 20, 4102, 2822, 1146, 2173, 36, 616, 1069, 2826, 2, 10, 41, 5, 8, 64, 287, 1, 2606, 601, 88, 215, 15, 378, 2, 1405, 930, 512, 77, 1043, 489, 190, 2173, 648, 7, 47, 591, 62, 127, 7, 32, 4, 219, 734, 52, 166, 126, 18, 481, 60, 876, 882, 1191, 1, 27, 111, 34, 115, 25, 16, 803, 48, 307, 268, 614, 970, 3, 429, 116, 13, 1460, 3713, 69, 111, 1, 166, 126, 16, 149, 262, 3, 184, 1, 1077, 983, 988, 17, 6888, 80, 1069, 2173, 104, 69, 71, 276, 568, 681, 46, 2281, 74, 309, 17, 2777, 3, 181, 654, 1, 2173, 56, 205, 44, 4665, 34, 115, 25, 9, 2578, 7, 277, 5, 2822, 2044, 2, 447, 4102, 2822, 1146, 137, 3, 155, 1, 3, 2173, 5980, 2, 3, 193, 1, 568, 6128, 550, 340, 181, 36, 5560, 3, 594, 6, 195, 401, 2, 5003, 1075, 36, 9, 2578]",1254.0,15929100,Durable molecular remissions single cycle timed sequential consolidation chemotherapy acute promyelocytic leukemia,25,0.04363001745200698
"GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS.","Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2005-04-01,"Priming of leukemic cells with cytokines may enhance the efficacy of cell-cycle chemotherapy. In this study, we utilized these synergistic effects of granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim [Leukine]), hydroxyurea, and low-dose cytosine arabinoside to treat elderly patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). In a single-institution, retrospective study, we evaluated 94 treatments with concomitant hydroxyurea, cytosine arabinoside, and GM-CSF between the years of 1997 and 2003 in high-risk elderly patients with AML or MDS. A total of 80% of patients received all of the GM-CSF doses; 78% of patients received all of the cytosine arabinoside doses. Adverse events were minimal. No patient developed mucositis or alopecia. The most common adverse event was neutropenic fever, which was noted in 57% of patients. Twenty-one percent of patients remained neutropenic after treatment until death or relapse. Sixty-eight percent of patients reached an absolute neutrophil count of greater than 1000 microL in a median of 33.5 days. Our data show an overall response rate of 52%, with a complete response rate of 39% and a partial response rate of 13%. Overall, our study showed that low-dose cytosine arabinoside given by continuous infusion together with continuous infusion GM-CSF and hydroxyurea was well-tolerated and effective in treating elderly AML and MDS patients who were not eligible for standard induction therapy.",Journal Article,5408.0,3.0,Priming leukemic cytokines enhance efficacy cell-cycle chemotherapy utilized synergistic effects granulocyte-macrophage colony-stimulating factor GM-CSF sargramostim Leukine hydroxyurea low-dose cytosine arabinoside treat elderly patients acute myelogenous leukemia AML myelodysplastic syndrome MDS single-institution retrospective evaluated 94 treatments concomitant hydroxyurea cytosine arabinoside GM-CSF years 1997 2003 high-risk elderly patients AML MDS total 80 patients received GM-CSF doses 78 patients received cytosine arabinoside doses Adverse events minimal patient developed mucositis alopecia common adverse event neutropenic fever noted 57 patients Twenty-one percent patients remained neutropenic treatment death relapse Sixty-eight percent patients reached absolute neutrophil count greater 1000 microL median 33.5 days overall response rate 52 complete response rate 39 partial response rate 13 Overall showed low-dose cytosine arabinoside given continuous infusion continuous infusion GM-CSF hydroxyurea well-tolerated effective treating elderly AML MDS patients eligible standard induction therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4903, 1, 2015, 37, 5, 1886, 68, 1304, 3, 209, 1, 31, 417, 56, 4, 26, 45, 21, 2080, 46, 1806, 176, 1, 2764, 2674, 1975, 2122, 161, 2147, 1211, 15821, 43989, 5902, 2, 154, 61, 6903, 11563, 6, 943, 1216, 7, 5, 286, 2194, 329, 15, 681, 1223, 4, 8, 226, 731, 459, 45, 21, 194, 960, 640, 5, 1781, 5902, 6903, 11563, 2, 2147, 1211, 59, 3, 60, 1, 2341, 2, 1522, 4, 64, 43, 1216, 7, 5, 329, 15, 1223, 8, 181, 1, 493, 1, 7, 103, 62, 1, 3, 2147, 1211, 415, 833, 1, 7, 103, 62, 1, 3, 6903, 11563, 415, 290, 281, 11, 1048, 77, 69, 276, 2606, 15, 5691, 3, 96, 186, 290, 774, 10, 3659, 2775, 92, 10, 1051, 4, 696, 1, 7, 737, 104, 714, 1, 7, 958, 3659, 50, 24, 1100, 273, 15, 429, 1746, 659, 714, 1, 7, 1300, 35, 1766, 2595, 1276, 1, 378, 76, 2345, 5128, 4, 8, 52, 1, 466, 33, 162, 114, 74, 514, 35, 63, 51, 116, 1, 653, 5, 8, 236, 51, 116, 1, 587, 2, 8, 450, 51, 116, 1, 233, 63, 114, 45, 224, 17, 154, 61, 6903, 11563, 447, 20, 1314, 904, 1162, 5, 1314, 904, 2147, 1211, 2, 5902, 10, 149, 421, 2, 323, 4, 1367, 1216, 329, 2, 1223, 7, 54, 11, 44, 625, 9, 260, 504, 36]",1431.0,15934494,GM-CSF low-dose cytosine arabinoside high-risk elderly patients AML MDS,21,0.03664921465968586
Decitabine in chronic leukemias.,Seminars in hematology,Semin. Hematol.,2005-07-01,"5-Aza-2'-deoxycitidine (decitabine, Dacogen, Bloomington, MN) is a cytosine analogue that promotes hypomethylation of DNA and has documented efficacy in myeloid malignancies. Indeed, promising clinical results have been observed in acute myeloid leukemia (AML) and the myelodysplastic syndromes (MDS). Aberrant methylation has also been found in chronic leukemias, providing a rationale for investigating the use of decitabine in these diseases. There is clear evidence of molecular (hypomethylation) as well as hematologic and cytogenetic responses to decitabine in chronic myelogenous leukemia of all phases, including in patients resistant to imatinib mesylate. Clinical trials of decitabine in chronic lymphocytic leukemia are ongoing. There are many unanswered questions regarding optimizing this treatment for chronic leukemias, but successful proof-of-concept studies for hypomethylating agents move us closer to approaches that may have a significant impact on patient outcomes.",Journal Article,5317.0,15.0,5-Aza-2'-deoxycitidine decitabine Dacogen Bloomington MN cytosine analogue promotes hypomethylation DNA documented efficacy myeloid malignancies promising clinical observed acute myeloid leukemia AML myelodysplastic syndromes MDS Aberrant methylation chronic leukemias providing rationale investigating use decitabine diseases clear evidence molecular hypomethylation hematologic cytogenetic responses decitabine chronic myelogenous leukemia phases including patients resistant imatinib mesylate Clinical trials decitabine chronic lymphocytic leukemia ongoing unanswered questions optimizing treatment chronic leukemias successful proof-of-concept studies hypomethylating agents closer approaches significant impact patient outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[33, 3924, 6135, 44028, 3004, 33559, 37971, 4691, 16, 8, 6903, 4696, 17, 2148, 4441, 1, 261, 2, 71, 1405, 209, 4, 533, 441, 4462, 721, 38, 99, 47, 85, 164, 4, 286, 533, 329, 2, 3, 2040, 1223, 1898, 569, 71, 120, 85, 204, 4, 442, 2792, 1736, 8, 1728, 9, 3103, 3, 119, 1, 3004, 4, 46, 1342, 125, 16, 885, 241, 1, 219, 4441, 22, 149, 22, 813, 2, 1266, 253, 6, 3004, 4, 442, 2194, 1, 62, 3523, 141, 4, 7, 436, 6, 577, 2347, 38, 143, 1, 3004, 4, 442, 1193, 32, 942, 125, 32, 445, 7550, 1937, 666, 4336, 26, 24, 9, 442, 2792, 84, 1401, 3840, 1, 2545, 94, 9, 4931, 183, 6759, 843, 6576, 6, 611, 17, 68, 47, 8, 93, 345, 23, 69, 123]",922.0,16015505,Decitabine chronic leukemias,17,0.029668411867364748
"JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.",Blood,Blood,2005-07-21,"An activating 1849G>T mutation of JAK2 (Janus kinase 2) tyrosine kinase was recently described in chronic myeloproliferative disorders (MPDs). Its role in other hematologic neoplasms is unclear. We developed a quantitative pyrosequencing assay and analyzed 374 samples of hematologic neoplasms. The mutation was frequent in polycythemia vera (PV) (86%) and myelofibrosis (95%) but less prevalent in acute myeloid leukemia (AML) with an antecedent PV or myelofibrosis (5 [36%] of 14 patients). JAK2 mutation was also detected in 3 (19%) of 16 patients with Philadelphia-chromosome (Ph)-negative chronic myelogenous leukemia (CML), 2 (18%) of 11 patients with megakaryocytic AML, 7 (13%) of 52 patients with chronic myelomonocytic leukemia, and 1 (1%) of 68 patients with myelodysplastic syndromes. No mutation was found in Ph(+)CML (99 patients), AML M0-M6 (28 patients), or acute lymphoblastic leukemia (20 patients). We conclude that the JAK2 1849G>T mutation is common in Ph(-) MPD but not critical for transformation to the acute phase of these diseases and that it is generally rare in aggressive leukemias.",Journal Article,5297.0,302.0,activating 1849G JAK2 Janus kinase 2 tyrosine kinase recently described chronic myeloproliferative disorders MPDs role hematologic neoplasms unclear developed quantitative pyrosequencing 374 hematologic neoplasms frequent polycythemia vera PV 86 myelofibrosis 95 prevalent acute myeloid leukemia AML antecedent PV myelofibrosis 5 36 14 patients JAK2 detected 3 19 16 patients Philadelphia-chromosome Ph -negative chronic myelogenous leukemia CML 2 18 11 patients megakaryocytic AML 7 13 52 patients chronic myelomonocytic leukemia 1 1 68 patients myelodysplastic syndromes Ph CML 99 patients AML M0-M6 28 patients acute lymphoblastic leukemia 20 patients conclude JAK2 1849G common Ph MPD critical transformation acute phase diseases generally rare aggressive leukemias,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[35, 1616, 44054, 102, 258, 1, 2509, 6191, 216, 18, 564, 216, 10, 761, 1027, 4, 442, 1997, 24840, 211, 200, 4, 127, 813, 1179, 16, 1200, 21, 276, 8, 1156, 6031, 719, 2, 311, 10349, 347, 1, 813, 1179, 3, 258, 10, 908, 4, 5755, 5756, 3328, 868, 2, 4637, 48, 84, 299, 2485, 4, 286, 533, 329, 5, 35, 8775, 3328, 15, 4637, 33, 511, 1, 213, 7, 2509, 258, 10, 120, 530, 4, 27, 326, 1, 245, 7, 5, 3006, 1170, 2058, 199, 442, 2194, 903, 18, 203, 1, 175, 7, 5, 14385, 329, 67, 233, 1, 653, 7, 5, 442, 5451, 2, 14, 14, 1, 806, 7, 5, 2040, 77, 258, 10, 204, 4, 2058, 903, 1058, 7, 329, 4591, 30814, 339, 7, 15, 286, 1275, 179, 7, 21, 2060, 17, 3, 2509, 44054, 102, 258, 16, 186, 4, 2058, 7712, 84, 44, 740, 9, 1392, 6, 3, 286, 124, 1, 46, 1342, 2, 17, 192, 16, 1228, 622, 4, 571, 2792]",983.0,16037387,JAK2 1849G rare acute leukemias CMML Philadelphia chromosome-negative CML megakaryocytic leukemia,3,0.005235602094240838
"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.",Blood,Blood,2005-08-04,"Activating mutations in tyrosine kinases have been identified in hematopoietic and nonhematopoietic malignancies. Recently, we and others identified a single recurrent somatic activating mutation (JAK2V617F) in the Janus kinase 2 (JAK2) tyrosine kinase in the myeloproliferative disorders (MPDs) polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. We used direct sequence analysis to determine if the JAK2V617F mutation was present in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML)/atypical chronic myelogenous leukemia (aCML), myelodysplastic syndrome (MDS), B-lineage acute lymphoblastic leukemia (ALL), T-cell ALL, and chronic lymphocytic leukemia (CLL). Analysis of 222 patients with AML identified JAK2V617F mutations in 4 patients with AML, 3 of whom had a preceding MPD. JAK2V617F mutations were identified in 9 (7.8%) of 116 CMML/a CML samples, and in 2 (4.2%) of 48 MDS samples. We did not identify the JAK2V617F disease allele in B-lineage ALL (n = 83), T-cell ALL (n = 93), or CLL (n = 45). These data indicate that the JAK2V617F allele is present in acute and chronic myeloid malignancies but not in lymphoid malignancies.",Clinical Trial,5283.0,292.0,Activating tyrosine kinases identified hematopoietic nonhematopoietic malignancies Recently identified single recurrent somatic activating JAK2V617F Janus kinase 2 JAK2 tyrosine kinase myeloproliferative disorders MPDs polycythemia vera essential thrombocythemia myeloid metaplasia myelofibrosis direct sequence determine JAK2V617F present acute myeloid leukemia AML chronic myelomonocytic leukemia CMML /atypical chronic myelogenous leukemia aCML myelodysplastic syndrome MDS B-lineage acute lymphoblastic leukemia T-cell chronic lymphocytic leukemia CLL 222 patients AML identified JAK2V617F 4 patients AML 3 preceding MPD JAK2V617F identified 9 7.8 116 CMML/a CML 2 4.2 48 MDS identify JAK2V617F disease allele B-lineage n 83 T-cell n 93 CLL n 45 indicate JAK2V617F allele present acute chronic myeloid malignancies lymphoid malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[1616, 138, 4, 564, 1549, 47, 85, 108, 4, 1007, 2, 19463, 441, 761, 21, 2, 1749, 108, 8, 226, 387, 1119, 1616, 258, 9061, 4, 3, 6191, 216, 18, 2509, 564, 216, 4, 3, 1997, 24840, 5755, 5756, 1452, 8962, 2, 533, 6054, 5, 4637, 21, 95, 1196, 1532, 65, 6, 223, 492, 3, 9061, 258, 10, 364, 4, 286, 533, 329, 442, 5451, 3382, 1973, 442, 2194, 21345, 681, 1223, 132, 2542, 286, 1275, 62, 102, 31, 62, 2, 442, 1193, 552, 65, 1, 5647, 7, 5, 329, 108, 9061, 138, 4, 39, 7, 5, 329, 27, 1, 953, 42, 8, 5892, 7712, 9061, 138, 11, 108, 4, 83, 67, 66, 1, 3790, 3382, 8, 903, 347, 2, 4, 18, 39, 18, 1, 576, 1223, 347, 21, 205, 44, 255, 3, 9061, 34, 1254, 4, 132, 2542, 62, 78, 852, 102, 31, 62, 78, 966, 15, 552, 78, 512, 46, 74, 1008, 17, 3, 9061, 1254, 16, 364, 4, 286, 2, 442, 533, 441, 84, 44, 4, 2303, 441]",1059.0,16081687,JAK2V617F activating occurs chronic myelomonocytic leukemia acute myeloid leukemia acute lymphoblastic leukemia chronic lymphocytic leukemia,9,0.015706806282722512
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.,Blood,Blood,2005-08-25,"To characterize acute megakaryocytic leukemia (FAB M7 AML), we identified 37 patients with M7 AML treated at M.D. Anderson Cancer Center between 1987 and 2003 and compared them with 1800 patients with non-M7, non-M3 AML treated during the same period. The median age of the M7 AML group was 56 years (range, 21-78 years); 22 patients (59%) had an antecedent hematologic disorder or myelodysplastic syndrome or both, and 7 patients (19%) had previously received chemotherapy for other malignancies. Extensive bone marrow fibrosis was found in 23 patients (62%). Poor cytogenetic characteristics were observed in 49% of patients with M7 AML versus 33% of others (P < .001). Complete remission rates were 43% with M7 AML and 57% with non-M7 AML (P = .089). Median overall survival (OS) was 23 and 38 weeks, respectively (P = .006). Median disease-free survivals were 23 versus 52 weeks, respectively (P < .001). By multivariate analysis, M7 AML was an independent adverse prognostic factor for OS, independent of other factors including cytogenetic abnormalities (hazard ratio 1.51, P = .049). These results confirm the poor prognosis of M7 AML and indicate that other biologic characteristics beyond cytogenetic abnormalities likely play a role in this disease.",Comparative Study,5262.0,48.0,characterize acute megakaryocytic leukemia FAB M7 AML identified 37 patients M7 AML treated M.D Anderson Center 1987 2003 compared 1800 patients non-M7 non-M3 AML treated period median age M7 AML group 56 years range 21-78 years 22 patients 59 antecedent hematologic disorder myelodysplastic syndrome 7 patients 19 previously received chemotherapy malignancies Extensive bone marrow fibrosis 23 patients 62 Poor cytogenetic characteristics observed 49 patients M7 AML versus 33 P .001 Complete remission rates 43 M7 AML 57 non-M7 AML P .089 Median overall survival OS 23 38 weeks respectively P .006 Median disease-free survivals 23 versus 52 weeks respectively P .001 multivariate M7 AML independent adverse prognostic factor OS independent factors including cytogenetic abnormalities hazard ratio 1.51 P .049 confirm poor prognosis M7 AML indicate biologic characteristics cytogenetic abnormalities likely play role disease,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 1507, 286, 14385, 9075, 14730, 329, 21, 108, 567, 7, 5, 14730, 329, 73, 28, 188, 427, 1929, 12, 574, 59, 5450, 2, 1522, 2, 72, 1370, 5, 13507, 7, 5, 220, 14730, 220, 9852, 329, 73, 190, 3, 827, 727, 3, 52, 89, 1, 3, 14730, 329, 87, 10, 664, 60, 184, 239, 833, 60, 350, 7, 728, 42, 35, 8775, 813, 2645, 15, 681, 15, 110, 2, 67, 7, 326, 42, 373, 103, 56, 9, 127, 441, 1344, 581, 3000, 10, 204, 4, 382, 7, 744, 334, 1266, 374, 11, 164, 4, 739, 1, 7, 5, 14730, 329, 185, 466, 1, 1749, 19, 144, 236, 734, 151, 11, 601, 5, 14730, 329, 2, 696, 5, 220, 14730, 329, 19, 12877, 52, 63, 25, 118, 10, 382, 2, 519, 244, 106, 19, 1861, 52, 34, 115, 3794, 11, 382, 185, 653, 244, 106, 19, 144, 20, 331, 65, 14730, 329, 10, 35, 306, 290, 177, 161, 9, 118, 306, 1, 127, 130, 141, 1266, 1171, 360, 197, 14, 725, 19, 5121, 46, 99, 1843, 3, 334, 356, 1, 14730, 329, 2, 1008, 17, 127, 1283, 374, 1654, 1266, 1171, 322, 1343, 8, 200, 4, 26, 34]",1170.0,16123215,Adult acute megakaryocytic leukemia 37 patients treated M.D Anderson Center,3,0.005235602094240838
Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome.,Pediatric blood & cancer,Pediatr Blood Cancer,2006-12-01,"Therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) carry a poor prognosis. We analyzed the results of allogeneic HSCT in 38 children to determine which factors, if any, affected outcome. The effects of demographic, donor, and disease-related factors were analyzed to determine their effects on overall and disease-free survival (OS, DFS), relapse, and non-relapse mortality (NRM). OS and DFS for t-AML and t-MDS were similar. Three-year OS and EFS were the same (15.4 +/- 5.8%) and the 3-year NRM was 59.6 +/- 8.4%. The 1-year cumulative risk of grade III-IV acute graft-versus-host disease (GVHD) and relapse were 23.7 +/- 7.0% and 18.7 +/- 6.5%, respectively. The percentage of pre-transplant bone marrow (BM) blasts was positively associated with relapse (P = 0.05), while the percentage of BM blasts at diagnosis of therapy-related disease tended to associate with NRM (P = 0.07). Alternative donor and matched sibling donor grafts had similar outcomes. NRM was higher among patients who did not develop acute GVHD as compared to those with grade 1-2 acute GVHD (69.2 +/- 14.2% vs. +/- 12.7%, respectively), while NRM was 100% in patients with grade III-IV acute GVHD (P = 0.007). The percentage of BM blasts is associated with relapse in these disorders. High rates of NRM negatively impact the outcome of allogeneic HSCT for children with t-AML and t-MDS. Future studies should focus on reducing NRM.",Journal Article,4799.0,39.0,Therapy-related myelodysplastic syndrome t-MDS acute myeloid leukemia t-AML carry poor prognosis allogeneic HSCT 38 children determine factors affected outcome effects demographic donor disease-related factors determine effects overall disease-free survival OS DFS relapse non-relapse mortality NRM OS DFS t-AML t-MDS similar Three-year OS EFS 15.4 +/- 5.8 3-year NRM 59.6 +/- 8.4 1-year cumulative risk grade III-IV acute graft-versus-host disease GVHD relapse 23.7 +/- 7.0 18.7 +/- 6.5 respectively percentage pre-transplant bone marrow BM blasts positively associated relapse P 0.05 percentage BM blasts diagnosis therapy-related disease tended associate NRM P 0.07 Alternative donor matched sibling donor grafts similar outcomes NRM higher patients develop acute GVHD compared grade 1-2 acute GVHD 69.2 +/- 14.2 vs. +/- 12.7 respectively NRM 100 patients grade III-IV acute GVHD P 0.007 percentage BM blasts associated relapse disorders High rates NRM negatively impact outcome allogeneic HSCT children t-AML t-MDS Future studies focus reducing NRM,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[36, 139, 681, 102, 1223, 2, 286, 533, 102, 329, 3542, 8, 334, 356, 21, 311, 3, 99, 1, 1063, 1703, 4, 519, 541, 6, 223, 92, 130, 492, 500, 1424, 228, 3, 176, 1, 1540, 1488, 2, 34, 139, 130, 11, 311, 6, 223, 136, 176, 23, 63, 2, 34, 115, 25, 118, 1010, 429, 2, 220, 429, 282, 4296, 118, 2, 1010, 9, 102, 329, 2, 102, 1223, 11, 288, 169, 111, 118, 2, 1683, 11, 3, 827, 167, 39, 33, 66, 2, 3, 27, 111, 4296, 10, 728, 49, 66, 39, 3, 14, 111, 967, 43, 1, 88, 316, 478, 286, 1599, 185, 1204, 34, 1562, 2, 429, 11, 382, 67, 67, 13, 2, 203, 67, 49, 33, 106, 3, 1150, 1, 671, 941, 581, 1246, 2438, 10, 2375, 41, 5, 429, 19, 13, 474, 369, 3, 1150, 1, 1246, 2438, 28, 147, 1, 36, 139, 34, 3886, 6, 6446, 5, 4296, 19, 13, 1615, 1091, 1488, 2, 655, 3684, 1488, 4713, 42, 288, 123, 4296, 10, 142, 107, 7, 54, 205, 44, 690, 286, 1562, 22, 72, 6, 135, 5, 88, 14, 18, 286, 1562, 790, 18, 213, 18, 105, 133, 67, 106, 369, 4296, 10, 394, 4, 7, 5, 88, 316, 478, 286, 1562, 19, 13, 1999, 3, 1150, 1, 1246, 2438, 16, 41, 5, 429, 4, 46, 1997, 64, 151, 1, 4296, 2723, 345, 3, 228, 1, 1063, 1703, 9, 541, 5, 102, 329, 2, 102, 1223, 508, 94, 257, 1222, 23, 1818, 4296]",1351.0,16155933,Outcome hematopoietic stem transplantation pediatric patients therapy-related acute myeloid leukemia myelodysplastic syndrome,152,0.26527050610820246
"Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2005-09-01,"ABT-751 is an oral antimitotic agent that binds to the colchicine site on beta-tubulin. A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of ABT-751 in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias. Thirty-two patients were treated: nine with 100 (n = 3), 125 (n = 3), or 150 mg/m(2) (n = 3) of ABT-751 given orally once daily for 7 days every 3 weeks and 23 with 75 (n = 3), 100 (n = 3), 125 (n = 5), 150 (n = 5), 175 (n = 3), or 200 mg/m(2) (n = 4) of ABT-751 given orally once daily for 21 days every 4 weeks. Consenting patients had pharmacogenetic sampling and enumeration of circulating endothelial cells (CEC). Dose-limiting toxicity consisted of ileus in one patient at 200 mg/m(2), with a subsequent patient developing grade 2 constipation at the same dose level. One patient with relapsed acute myelogenous leukemia achieved a complete remission that was sustained for 2 months. Four other patients had transient hematologic improvements, consisting of a decrease in peripheral blood blasts and improvements in platelet counts. CEC number was reduced in three patients with a concomitant reduction in peripheral blasts. A previously undescribed nonsynonymous single nucleotide polymorphism, encoding Ala(185)Thr, was identified in exon 4 of the beta-tubulin gene, TUBB, in three other patients. The recommended phase 2 dose in hematologic malignancies is 175 mg/m(2) daily orally for 21 days every 4 weeks. Further assessment of ABT-751, especially in combination with other agents, in patients with acute leukemias is warranted.",Clinical Trial,5255.0,72.0,ABT-751 oral antimitotic agent binds colchicine site beta-tubulin phase 1 conducted determine maximum tolerated dose toxicities ABT-751 patients advanced myelodysplastic syndrome relapsed refractory acute leukemias Thirty-two patients treated 100 n 3 125 n 3 150 mg/m 2 n 3 ABT-751 given orally daily 7 days 3 weeks 23 75 n 3 100 n 3 125 n 5 150 n 5 175 n 3 200 mg/m 2 n 4 ABT-751 given orally daily 21 days 4 weeks Consenting patients pharmacogenetic sampling enumeration circulating endothelial CEC Dose-limiting toxicity consisted ileus patient 200 mg/m 2 subsequent patient developing grade 2 constipation dose level patient relapsed acute myelogenous leukemia achieved complete remission sustained 2 months patients transient hematologic improvements consisting decrease peripheral blood blasts improvements platelet counts CEC number reduced patients concomitant reduction peripheral blasts previously undescribed nonsynonymous single nucleotide polymorphism encoding Ala 185 Thr identified exon 4 beta-tubulin TUBB patients recommended phase 2 dose hematologic malignancies 175 mg/m 2 daily orally 21 days 4 weeks assessment ABT-751 especially combination agents patients acute leukemias warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3095, 6351, 16, 35, 518, 19035, 420, 17, 3333, 6, 3, 20416, 606, 23, 1090, 5303, 8, 124, 14, 45, 10, 426, 6, 223, 3, 689, 421, 61, 2, 385, 1, 3095, 6351, 4, 7, 5, 131, 681, 2, 591, 15, 430, 286, 2792, 977, 100, 7, 11, 73, 762, 5, 394, 78, 27, 1731, 78, 27, 15, 1577, 81, 188, 18, 78, 27, 1, 3095, 6351, 447, 1428, 1059, 391, 9, 67, 162, 454, 27, 244, 2, 382, 5, 481, 78, 27, 394, 78, 27, 1731, 78, 33, 1577, 78, 33, 3300, 78, 27, 15, 1250, 81, 188, 18, 78, 39, 1, 3095, 6351, 447, 1428, 1059, 391, 9, 239, 162, 454, 39, 244, 11932, 7, 42, 6578, 2874, 2, 7014, 1, 1033, 845, 37, 14569, 61, 817, 155, 1695, 1, 9843, 4, 104, 69, 28, 1250, 81, 188, 18, 5, 8, 706, 69, 931, 88, 18, 4532, 28, 3, 827, 61, 301, 104, 69, 5, 591, 286, 2194, 513, 8, 236, 734, 17, 10, 2275, 9, 18, 53, 294, 127, 7, 42, 2473, 813, 1474, 2273, 1, 8, 775, 4, 672, 315, 2438, 2, 1474, 4, 1596, 1911, 14569, 207, 10, 405, 4, 169, 7, 5, 8, 1781, 628, 4, 672, 2438, 8, 373, 13317, 10233, 226, 1579, 1907, 2362, 8497, 5805, 11105, 10, 108, 4, 1725, 39, 1, 3, 1090, 5303, 145, 55078, 4, 169, 127, 7, 3, 793, 124, 18, 61, 4, 813, 441, 16, 3300, 81, 188, 18, 391, 1428, 9, 239, 162, 454, 39, 244, 195, 455, 1, 3095, 6351, 1093, 4, 150, 5, 127, 183, 4, 7, 5, 286, 2792, 16, 1197]",1525.0,16166440,Phase 1 ABT-751 novel microtubule inhibitor patients refractory hematologic malignancies,17,0.029668411867364748
Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies.,Nature clinical practice. Oncology,Nat Clin Pract Oncol,2005-12-01,"A variety of epigenetic changes contribute to transcriptional dysregulation in myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML). DNA methyltransferase (DNMT) inhibitors--azacitidine and decitabine--have significant activity in the treatment of MDS. Despite marked activity in myeloid malignancy, monotherapy with DNMT inhibitors is limited by low complete and partial response rates (7-20%) and median response durations of 15 months. As with classical cytotoxic therapy, the targeting of biologic pathways and mechanisms may best be accomplished using a combination of agents offering complementary mechanisms and synergistic pharmacodynamic interactions. The goal of this approach is to improve response rates, quality, and duration, and to minimize adverse events. There are a number of new therapies under development for the management of MDS and AML. This review article touches on some of the more promising combination regimens in various phases of investigation. The treatment of MDS and AML is undergoing rapid evolution. Cytogenetic complete remission and prolonged survival represent important goals. Incremental improvements in disease state and quality-of-life issues are also important for patients. Given the overall failure of cytotoxic chemotherapy in the achievement of cures in MDS and MDS-related AML, the application of less toxic, biologically directed agents may represent a more promising approach to treatment. Combination therapies with DNMT inhibitors using optimal dosing regimens to focus on methylation reversal with lower doses over longer periods of time, rather than direct cytotoxic effects, are beginning to suggest promising results in MDS and AML.",Journal Article,5164.0,73.0,variety epigenetic changes contribute transcriptional dysregulation myelodysplastic syndromes MDSs acute myeloid leukemia AML DNA methyltransferase DNMT inhibitors -- azacitidine decitabine -- significant activity treatment MDS Despite marked activity myeloid malignancy monotherapy DNMT inhibitors limited low complete partial response rates 7-20 median response durations 15 months classical cytotoxic therapy targeting biologic pathways mechanisms best accomplished combination agents offering complementary mechanisms synergistic pharmacodynamic interactions goal approach improve response rates quality duration minimize adverse events number new therapies development management MDS AML review article touches promising combination regimens phases investigation treatment MDS AML undergoing rapid evolution Cytogenetic complete remission prolonged survival represent important goals Incremental improvements disease state quality-of-life issues important patients Given overall failure cytotoxic chemotherapy achievement cures MDS MDS-related AML application toxic biologically directed agents represent promising approach treatment Combination therapies DNMT inhibitors optimal dosing regimens focus methylation reversal lower doses longer periods time direct cytotoxic effects beginning suggest promising MDS AML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[8, 1362, 1, 1418, 400, 1248, 6, 1431, 3935, 4, 2040, 13550, 2, 286, 533, 329, 261, 3747, 10229, 222, 3752, 2, 3004, 47, 93, 128, 4, 3, 24, 1, 1223, 550, 2003, 128, 4, 533, 710, 1411, 5, 10229, 222, 16, 383, 20, 154, 236, 2, 450, 51, 151, 67, 179, 2, 52, 51, 4864, 1, 167, 53, 22, 5, 3781, 759, 36, 3, 529, 1, 1283, 460, 2, 483, 68, 824, 40, 5741, 75, 8, 150, 1, 183, 5846, 3380, 483, 2, 1806, 2424, 1286, 3, 1326, 1, 26, 353, 16, 6, 401, 51, 151, 372, 2, 654, 2, 6, 3241, 290, 281, 125, 32, 8, 207, 1, 217, 235, 669, 193, 9, 3, 284, 1, 1223, 2, 329, 26, 206, 946, 26114, 23, 476, 1, 3, 80, 721, 150, 472, 4, 747, 3523, 1, 940, 3, 24, 1, 1223, 2, 329, 16, 479, 1321, 2554, 1266, 236, 734, 2, 1069, 25, 1231, 305, 2802, 3648, 1474, 4, 34, 1309, 2, 372, 1, 358, 1553, 32, 120, 305, 9, 7, 447, 3, 63, 496, 1, 759, 56, 4, 3, 5088, 1, 9154, 4, 1223, 2, 1223, 139, 329, 3, 1581, 1, 299, 1812, 2665, 1166, 183, 68, 1231, 8, 80, 721, 353, 6, 24, 150, 235, 5, 10229, 222, 75, 665, 1280, 472, 6, 1222, 23, 569, 5933, 5, 280, 415, 252, 589, 3338, 1, 98, 1832, 76, 1196, 759, 176, 32, 2948, 6, 309, 721, 99, 4, 1223, 2, 329]",1651.0,16341238,Combination therapy DNA methyltransferase inhibitors hematologic malignancies,1,0.0017452006980802793
"Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.",Antimicrobial agents and chemotherapy,Antimicrob. Agents Chemother.,2006-01-01,"Invasive fungal infection remains the most common cause of infectious death in acute leukemia. In this open-label, randomized study, we compared the efficacy and safety of caspofungin with that of intravenous itraconazole for antifungal prophylaxis in patients undergoing induction chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Of 200 patients, 192 were evaluable for efficacy (86 for itraconazole, 106 for caspofungin). Duration of prophylaxis (median, 21 days [range, 1 to 38 days]), demographics, and prognostic factors were similar in both groups. Ninety-nine patients completed antifungal prophylaxis without developing fungal infection (44 [51%] with itraconazole, 55 [52%] with caspofungin). Twelve patients developed documented invasive fungal infections, five in the itraconazole group (four with candidemia and one with Aspergillus pneumonia), and seven in the caspofungin group (two with candidemia, two with disseminated trichosporon species, two with Aspergillus pneumonia, and one with disseminated Fusarium spp). Two patients in the itraconazole group and four in the caspofungin group died of fungal infection (P = 0.57). Grade 3 to 4 adverse event rates were comparable between groups; the most common event in both was reversible hyperbilirubinemia. No evidence of cardiovascular toxicity from intravenous itraconazole was noted among patients older than 60. In conclusion, intravenous itraconazole and caspofungin provided similar protection against invasive fungal infection during induction chemotherapy, and both drugs were well tolerated.",Journal Article,5133.0,121.0,Invasive fungal infection remains common cause infectious death acute leukemia open-label randomized compared efficacy safety caspofungin intravenous itraconazole antifungal prophylaxis patients undergoing induction chemotherapy acute myelogenous leukemia myelodysplastic syndrome 200 patients 192 evaluable efficacy 86 itraconazole 106 caspofungin Duration prophylaxis median 21 days range 1 38 days demographics prognostic factors similar groups Ninety-nine patients completed antifungal prophylaxis developing fungal infection 44 51 itraconazole 55 52 caspofungin patients developed documented invasive fungal infections itraconazole group candidemia Aspergillus pneumonia seven caspofungin group candidemia disseminated trichosporon species Aspergillus pneumonia disseminated Fusarium spp patients itraconazole group caspofungin group died fungal infection P 0.57 Grade 3 4 adverse event rates comparable groups common event reversible hyperbilirubinemia evidence cardiovascular toxicity intravenous itraconazole noted patients older 60 intravenous itraconazole caspofungin provided similar protection invasive fungal infection induction chemotherapy drugs tolerated,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[416, 7800, 930, 469, 3, 96, 186, 708, 1, 3398, 273, 4, 286, 4, 26, 1020, 1756, 384, 45, 21, 72, 3, 209, 2, 367, 1, 21366, 5, 17, 1, 1262, 10463, 9, 8606, 2049, 4, 7, 479, 504, 56, 9, 286, 2194, 15, 681, 1, 1250, 7, 5016, 11, 859, 9, 209, 868, 9, 10463, 3251, 9, 21366, 654, 1, 2049, 52, 239, 162, 184, 14, 6, 519, 162, 2221, 2, 177, 130, 11, 288, 4, 110, 271, 2493, 762, 7, 781, 8606, 2049, 187, 931, 7800, 930, 584, 725, 5, 10463, 614, 653, 5, 21366, 2544, 7, 276, 1405, 416, 7800, 1875, 365, 4, 3, 10463, 87, 294, 5, 26221, 2, 104, 5, 16675, 3485, 2, 648, 4, 3, 21366, 87, 100, 5, 26221, 100, 5, 3605, 55219, 2915, 100, 5, 16675, 3485, 2, 104, 5, 3605, 55220, 9918, 100, 7, 4, 3, 10463, 87, 2, 294, 4, 3, 21366, 87, 1016, 1, 7800, 930, 19, 13, 696, 88, 27, 6, 39, 290, 774, 151, 11, 1279, 59, 271, 3, 96, 186, 774, 4, 110, 10, 2786, 7236, 77, 241, 1, 2179, 155, 29, 1262, 10463, 10, 1051, 107, 7, 434, 76, 335, 4, 1221, 1262, 10463, 2, 21366, 1052, 288, 3525, 480, 416, 7800, 930, 190, 504, 56, 2, 110, 600, 11, 149, 421]",1505.0,16377679,Open-label randomized comparison itraconazole versus caspofungin prophylaxis patients hematologic malignancies,0,0.0
Current therapeutic uses of lenalidomide in multiple myeloma.,Expert opinion on investigational drugs,Expert Opin Investig Drugs,2006-02-01,"Thalidomide has demonstrated a broad spectrum of pharmacological and immunological effects, with potential therapeutic applications that span a wide spectrum of diseases: cancer and related conditions; infectious diseases; autoimmune diseases; dermatological diseases; and other disorders such as sarcoidosis, macular degeneration and diabetic retinopathy. Immunomodulatory derivative lenalidomide has more potent antitumour and anti-inflammatory effects. The molecular mechanisms of antitumour activity of lenalidomide have been extensively studied in multiple myeloma (MM). It directly induces growth arrest and/or apoptosis of even drug-resistant MM cells; inhibits binding of MM cells to bone marrow extracellular matrix proteins and stromal cells; modulates cytokine secretion and inhibits angiogenesis in the bone marrow milieu; and augments host antitumour immunity. Importantly, lenalidomide induces significant clinical responses even in patients with relapsed/refractory MM. Therefore, lenalidomide represents a new class of antitumour agents that is useful in the treatment of MM. Lenalidomide has received fast track designation from the FDA for the treatment of MM and myelodysplastic syndromes.",Journal Article,5102.0,30.0,Thalidomide demonstrated broad spectrum pharmacological immunological effects potential therapeutic applications span wide spectrum diseases related conditions infectious diseases autoimmune diseases dermatological diseases disorders sarcoidosis macular degeneration diabetic retinopathy Immunomodulatory derivative lenalidomide potent antitumour anti-inflammatory effects molecular mechanisms antitumour activity lenalidomide extensively studied multiple myeloma MM directly induces growth arrest and/or apoptosis drug-resistant MM inhibits binding MM bone marrow extracellular matrix stromal modulates cytokine secretion inhibits angiogenesis bone marrow milieu augments host antitumour immunity Importantly lenalidomide induces significant clinical responses patients relapsed/refractory MM lenalidomide represents new class antitumour agents useful treatment MM Lenalidomide received fast track designation FDA treatment MM myelodysplastic syndromes,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,"[2159, 71, 264, 8, 2094, 1873, 1, 3419, 2, 5073, 176, 5, 174, 189, 2911, 17, 7165, 8, 1019, 1873, 1, 1342, 12, 2, 139, 1298, 3398, 1342, 3445, 1342, 14906, 1342, 2, 127, 1997, 225, 22, 17877, 18253, 11298, 2, 5943, 12124, 2555, 4819, 1288, 71, 80, 1157, 5282, 2, 312, 1291, 176, 3, 219, 483, 1, 5282, 128, 1, 1288, 47, 85, 3576, 656, 4, 232, 321, 192, 1606, 1516, 129, 1854, 2, 15, 351, 1, 871, 234, 436, 321, 37, 1576, 791, 1, 321, 37, 6, 581, 1976, 2248, 652, 2, 1126, 37, 5259, 1675, 2935, 2, 1576, 1056, 4, 3, 581, 6795, 2, 8941, 1204, 5282, 1604, 1859, 1288, 1516, 93, 38, 253, 871, 4, 7, 5, 591, 430, 321, 673, 1288, 1449, 8, 217, 1040, 1, 5282, 183, 17, 16, 999, 4, 3, 24, 1, 321, 1288, 71, 103, 5830, 7446, 8402, 29, 3, 2078, 9, 3, 24, 1, 321, 2, 2040]",1153.0,16433596,Current therapeutic uses lenalidomide multiple myeloma,36,0.06282722513089005
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.,Cancer,Cancer,2006-03-01,"Elderly patients (age > or = 65 years) with acute myeloid leukemia (AML) generally have a poor prognosis. AML-type therapy results are often derived from studies in younger patients and may not apply to elderly AML. Many investigators and oncologists advocate, at times, only supportive care or frontline single agents, Phase I-II studies, low-intensity regimens, or 'targeted' therapies. However, baseline expectations for outcomes of elderly AML with 'standard' AML-type therapy are not well defined. The aim was to develop prognostic models for complete response (CR), induction (8-week) mortality, and survival rates in elderly AML, which would be used to advise oncologists and patients of expectations with standard AML type therapy, and to establish baseline therapy results against which novel strategies would be evaluated. A total of 998 patients age > or = 65 years with AML or high-risk myelodysplastic syndrome (> 10% blasts) treated with intensive chemotherapy between 1980 and 2004 were analyzed. Univariate and multivariate analyses of prognostic factors associated with CR, induction (8-week) mortality, and survival used standard methods. The overall CR rate was 45% and induction mortality 29%. Multivariate analysis of prognostic factors identified consistent independent poor prognostic factors for CR, 8-week mortality, and survival. These included age > or = 75 years, unfavorable karyotypes (often complex), poor performance (3-4 ECOG [Eastern Cooperative Oncology Group]), longer duration of antecedent hematologic disorder, treatment outside the laminar airflow room, and abnormal organ functions. Patients could be divided into: 1) a favorable group (about 20% of patients) with expected CR rates above 60%, induction mortality rates of 10%, and 1-year survival rates above 50%; 2) an intermediate group (about 50-55% of patients) with expected CR rates of 50%, induction mortality rates of 30%, and 1-year survival rates of 30%; and 3) an unfavorable risk group (about 25-30% of patients) with expected CR rates of less than 20%, induction mortality rates above 50%, and 1-year survival rates of less than 10%. Prognostic models, based on standard readily available baseline characteristics, were developed for elderly patients with AML, which may assist in therapeutic and investigational decisions. These predictive models, based on a retrospective analysis, will require validation in independent study groups.",Journal Article,5074.0,409.0,Elderly patients age 65 years acute myeloid leukemia AML generally poor prognosis AML-type therapy derived studies younger patients apply elderly AML investigators oncologists advocate times supportive care frontline single agents Phase I-II studies low-intensity regimens 'targeted therapies baseline expectations outcomes elderly AML 'standard AML-type therapy defined aim develop prognostic models complete response CR induction 8-week mortality survival rates elderly AML advise oncologists patients expectations standard AML type therapy establish baseline therapy novel strategies evaluated total 998 patients age 65 years AML high-risk myelodysplastic syndrome 10 blasts treated intensive chemotherapy 1980 2004 Univariate multivariate prognostic factors associated CR induction 8-week mortality survival standard methods overall CR rate 45 induction mortality 29 Multivariate prognostic factors identified consistent independent poor prognostic factors CR 8-week mortality survival included age 75 years unfavorable karyotypes complex poor performance 3-4 ECOG Eastern Cooperative Oncology Group longer duration antecedent hematologic disorder treatment outside laminar airflow room abnormal organ functions Patients divided 1 favorable group 20 patients expected CR rates 60 induction mortality rates 10 1-year survival rates 50 2 intermediate group 50-55 patients expected CR rates 50 induction mortality rates 30 1-year survival rates 30 3 unfavorable risk group 25-30 patients expected CR rates 20 induction mortality rates 50 1-year survival rates 10 Prognostic models based standard readily available baseline characteristics developed elderly patients AML assist therapeutic investigational decisions predictive models based retrospective require validation independent groups,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1216, 7, 89, 15, 556, 60, 5, 286, 533, 329, 1228, 47, 8, 334, 356, 329, 267, 36, 99, 32, 629, 526, 29, 94, 4, 773, 7, 2, 68, 44, 4930, 6, 1216, 329, 445, 2394, 2, 1339, 8912, 28, 1072, 158, 1877, 165, 15, 3171, 226, 183, 124, 70, 215, 94, 154, 837, 472, 15, 26474, 235, 137, 330, 5591, 9, 123, 1, 1216, 329, 5, 30905, 329, 267, 36, 32, 44, 149, 395, 3, 1130, 10, 6, 690, 177, 274, 9, 236, 51, 684, 504, 66, 647, 282, 2, 25, 151, 4, 1216, 329, 92, 688, 40, 95, 6, 12636, 1339, 2, 7, 1, 5591, 5, 260, 329, 267, 36, 2, 6, 1811, 330, 36, 99, 480, 92, 229, 422, 688, 40, 194, 8, 181, 1, 12970, 7, 89, 15, 556, 60, 5, 329, 15, 64, 43, 681, 79, 2438, 73, 5, 1686, 56, 59, 4376, 2, 1131, 11, 311, 880, 2, 331, 318, 1, 177, 130, 41, 5, 684, 504, 66, 647, 282, 2, 25, 95, 260, 636, 3, 63, 684, 116, 10, 512, 2, 504, 282, 462, 331, 65, 1, 177, 130, 108, 925, 306, 334, 177, 130, 9, 684, 66, 647, 282, 2, 25, 46, 159, 89, 15, 481, 60, 2483, 6809, 629, 840, 334, 528, 27, 39, 2351, 2118, 1690, 413, 87, 589, 654, 1, 8775, 813, 2645, 24, 2513, 3, 26067, 26475, 4698, 2, 1668, 1259, 1681, 7, 359, 40, 2176, 237, 14, 8, 913, 87, 545, 179, 1, 7, 5, 1336, 684, 151, 2090, 335, 504, 282, 151, 1, 79, 2, 14, 111, 25, 151, 2090, 212, 18, 35, 919, 87, 545, 212, 614, 1, 7, 5, 1336, 684, 151, 1, 212, 504, 282, 151, 1, 201, 2, 14, 111, 25, 151, 1, 201, 2, 27, 35, 2483, 43, 87, 545, 243, 201, 1, 7, 5, 1336, 684, 151, 1, 299, 76, 179, 504, 282, 151, 2090, 212, 2, 14, 111, 25, 151, 1, 299, 76, 79, 177, 274, 90, 23, 260, 3860, 390, 330, 374, 11, 276, 9, 1216, 7, 5, 329, 92, 68, 3425, 4, 189, 2, 3093, 1526, 46, 464, 274, 90, 23, 8, 459, 65, 303, 1353, 929, 4, 306, 45, 271]",2312.0,16435386,intensive chemotherapy 998 patients age 65 years older acute myeloid leukemia high-risk myelodysplastic syndrome predictive prognostic models outcome,249,0.43455497382198954
"Are myelodysplastic syndromes ""cancer""? Unexpected adverse consequences of linguistic ambiguity.",Leukemia research,Leuk. Res.,2006-01-26,"Myelodysplastic syndromes (MDS) are clonal, neoplastic disorders of hematopoietic tissue that convey a guarded prognosis, but physicians vary in whether they refer to MDS as a ""cancer"" when discussing the diagnosis with patients. Because of past ambiguity about whether MDS is truly a malignancy, confusion about MDS terminology is widespread. Additionally, patients who carry one of the dubious cancer-specific health insurance policies are usually not eligible for financial benefits when they receive a diagnosis of MDS. Likewise, patients with MDS who have been led to believe they do not have a form of cancer by their primary physician may become upset when seeing another health care provider who does refer to MDS in this way. Here, I discuss evidence supporting broader consideration of MDS as a form of malignant neoplasia - i.e., cancer - as well as some of the relevant practical issues.",Comparative Study,5108.0,18.0,Myelodysplastic syndromes MDS clonal neoplastic disorders hematopoietic tissue convey guarded prognosis physicians vary refer MDS `` '' discussing diagnosis patients past ambiguity MDS truly malignancy confusion MDS terminology widespread Additionally patients carry dubious cancer-specific health insurance policies usually eligible financial benefits receive diagnosis MDS Likewise patients MDS led believe form primary physician upset seeing health care provider refer MDS way discuss evidence supporting broader consideration MDS form malignant neoplasia i.e. relevant practical issues,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2040, 1223, 32, 1946, 2000, 1997, 1, 1007, 246, 17, 11415, 8, 21328, 356, 84, 1261, 2825, 4, 317, 491, 7851, 6, 1223, 22, 8, 12, 522, 198, 6003, 3, 147, 5, 7, 408, 1, 1219, 21375, 545, 317, 1223, 16, 7260, 8, 710, 7399, 545, 1223, 3462, 16, 3029, 1724, 7, 54, 3542, 104, 1, 3, 44229, 12, 112, 341, 1935, 7329, 32, 2082, 44, 625, 9, 3021, 1141, 198, 491, 560, 8, 147, 1, 1223, 6269, 7, 5, 1223, 54, 47, 85, 836, 6, 4629, 491, 1022, 44, 47, 8, 1297, 1, 12, 20, 136, 86, 1473, 68, 1417, 27998, 198, 13110, 1809, 341, 165, 3094, 54, 1097, 7851, 6, 1223, 4, 26, 2255, 467, 70, 1139, 241, 1912, 5410, 2415, 1, 1223, 22, 8, 1297, 1, 393, 2298, 70, 563, 12, 22, 149, 22, 476, 1, 3, 867, 3320, 1553]",869.0,16443272,myelodysplastic syndromes `` '' Unexpected adverse consequences linguistic ambiguity,0,0.0
Myelodysplasia: when to treat and how.,Best practice & research. Clinical haematology,Best Pract Res Clin Haematol,2006-01-01,"Myelodysplastic syndrome (MDS) is a disorder of hematopoietic stem cells characterized by ineffective hematopoiesis. The result is pancytopenia leading to transfusion-dependent anemia, an increased risk of infection or bleeding, and a potential to progress to acute myeloid leukemia (AML). MDS is most prevalent among older individuals, many of whom also suffer from other medical conditions. MDS is classified according to World Health Organization criteria and the International Prognostic Scoring System. Supportive care remains the mainstay of therapy. Those with low-risk MDS can often be monitored for an extended period of time without specific therapy, whereas those with intermediate- or high-risk MDS benefit from treatment. Currently, only azacitidine is approved for the treatment of MDS. Several new agents are being tested, including inhibitors of angiogenesis (thalidomide, lenalidomide), farnesyl transferase inhibitors (lonafarnib, tipifarnib), and DNA methyltransferase inhibitors (azacitidine, decitabine). Lenalidomide appears particularly effective in patients with low-risk MDS with the deletion of chromosome 5q31. Allogeneic stem cell transplantation is an alternative for high-risk MDS. With advances in transplantation techniques, this treatment can be offered to an increasing number of patients. However, it is necessary to assess each patient's disease individually and to evaluate prognostic factors, other treatment options, and the appropriateness and timing of transplantation.",Journal Article,5133.0,14.0,Myelodysplastic syndrome MDS disorder hematopoietic stem characterized ineffective hematopoiesis pancytopenia leading transfusion-dependent anemia increased risk infection bleeding potential progress acute myeloid leukemia AML MDS prevalent older individuals suffer medical conditions MDS classified according World Health Organization criteria International Prognostic Scoring Supportive care remains mainstay therapy low-risk MDS monitored extended period time specific therapy intermediate- high-risk MDS benefit treatment Currently azacitidine approved treatment MDS new agents tested including inhibitors angiogenesis thalidomide lenalidomide farnesyl transferase inhibitors lonafarnib tipifarnib DNA methyltransferase inhibitors azacitidine decitabine Lenalidomide appears particularly effective patients low-risk MDS deletion chromosome 5q31 Allogeneic stem transplantation alternative high-risk MDS advances transplantation techniques treatment offered increasing number patients necessary assess patient 's disease individually evaluate prognostic factors treatment options appropriateness timing transplantation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[681, 1223, 16, 8, 2645, 1, 1007, 452, 37, 765, 20, 3957, 5114, 3, 757, 16, 15154, 1049, 6, 2785, 470, 1545, 35, 101, 43, 1, 930, 15, 2294, 2, 8, 174, 6, 1466, 6, 286, 533, 329, 1223, 16, 96, 2485, 107, 434, 869, 445, 1, 953, 120, 6506, 29, 127, 484, 1298, 1223, 16, 1373, 768, 6, 1956, 341, 2533, 371, 2, 3, 944, 177, 2504, 398, 1877, 165, 469, 3, 4041, 1, 36, 135, 5, 154, 43, 1223, 122, 629, 40, 2909, 9, 35, 1747, 727, 1, 98, 187, 112, 36, 547, 135, 5, 919, 15, 64, 43, 1223, 247, 29, 24, 694, 158, 3752, 16, 850, 9, 3, 24, 1, 1223, 392, 217, 183, 32, 486, 650, 141, 222, 1, 1056, 2159, 1288, 8846, 4402, 222, 9388, 4781, 2, 261, 3747, 222, 3752, 3004, 1288, 1233, 823, 323, 4, 7, 5, 154, 43, 1223, 5, 3, 1528, 1, 1170, 22069, 1063, 452, 31, 497, 16, 35, 1091, 9, 64, 43, 1223, 5, 954, 4, 497, 1092, 26, 24, 122, 40, 2216, 6, 35, 602, 207, 1, 7, 137, 192, 16, 1493, 6, 423, 296, 69, 292, 34, 4257, 2, 6, 376, 177, 130, 127, 24, 838, 2, 3, 4473, 2, 1972, 1, 497]",1449.0,16516126,Myelodysplasia treat,19,0.03315881326352531
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.,Cancer,Cancer,2006-04-01,"Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy. Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters. A total of 170 patients with MDS were randomized to receive either decitabine at a dose of 15 mg/m2 given intravenously over 3 hours every 8 hours for 3 days (at a dose of 135 mg/m2 per course) and repeated every 6 weeks, or best supportive care. Response was assessed using the International Working Group criteria and required that response criteria be met for at least 8 weeks. Patients who were treated with decitabine achieved a significantly higher overall response rate (17%), including 9% complete responses, compared with supportive care (0%) (P < .001). An additional 12 patients who were treated with decitabine (13%) achieved hematologic improvement. Responses were durable (median, 10.3 mos) and were associated with transfusion independence. Patients treated with decitabine had a trend toward a longer median time to acute myelogenous leukemia (AML) progression or death compared with patients who received supportive care alone (all patients, 12.1 mos vs. 7.8 mos [P = 0.16]; those with International Prognostic Scoring System intermediate-2/high-risk disease, 12.0 mos vs. 6.8 mos [P = 0.03]; those with de novo disease, 12.6 mos vs. 9.4 mos [P = 0.04]; and treatment-naive patients, 12.3 mos vs. 7.3 mos [P = 0.08]). Decitabine was found to be clinically effective in the treatment of patients with MDS, provided durable responses, and improved time to AML transformation or death. The duration of decitabine therapy may improve these results further.","Clinical Trial, Phase III",5043.0,1063.0,Aberrant DNA methylation leukemogenesis frequent patients myelodysplastic syndromes MDS potential target pharmacologic therapy Decitabine indirectly depletes methylcytosine causes hypomethylation target promoters total 170 patients MDS randomized receive decitabine dose 15 mg/m2 given intravenously 3 hours 8 hours 3 days dose 135 mg/m2 course repeated 6 weeks best supportive care Response assessed International Working Group criteria required response criteria met 8 weeks Patients treated decitabine achieved significantly higher overall response rate 17 including 9 complete responses compared supportive care 0 P .001 additional 12 patients treated decitabine 13 achieved hematologic improvement Responses durable median 10.3 mos associated transfusion independence Patients treated decitabine trend longer median time acute myelogenous leukemia AML progression death compared patients received supportive care patients 12.1 mos vs. 7.8 mos P 0.16 International Prognostic Scoring intermediate-2/high-risk disease 12.0 mos vs. 6.8 mos P 0.03 novo disease 12.6 mos vs. 9.4 mos P 0.04 treatment-naive patients 12.3 mos vs. 7.3 mos P 0.08 Decitabine clinically effective treatment patients MDS provided durable responses improved time AML transformation death duration decitabine therapy improve,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1898, 261, 569, 92, 99, 4, 5661, 16, 908, 4, 7, 5, 2040, 1223, 2, 16, 8, 174, 283, 9, 2788, 36, 3004, 7792, 15243, 14943, 2, 1626, 4441, 1, 283, 145, 4347, 8, 181, 1, 5248, 7, 5, 1223, 11, 384, 6, 560, 361, 3004, 28, 8, 61, 1, 167, 81, 821, 447, 1672, 252, 27, 1459, 454, 66, 1459, 9, 27, 162, 28, 8, 61, 1, 3978, 81, 821, 379, 906, 2, 2113, 454, 49, 244, 15, 824, 1877, 165, 51, 10, 275, 75, 3, 944, 2644, 87, 371, 2, 616, 17, 51, 371, 40, 543, 9, 28, 506, 66, 244, 7, 54, 11, 73, 5, 3004, 513, 8, 97, 142, 63, 51, 116, 269, 141, 83, 236, 253, 72, 5, 1877, 165, 13, 19, 144, 35, 402, 133, 7, 54, 11, 73, 5, 3004, 233, 513, 813, 767, 253, 11, 1480, 52, 79, 27, 5166, 2, 11, 41, 5, 2785, 5773, 7, 73, 5, 3004, 42, 8, 853, 1317, 8, 589, 52, 98, 6, 286, 2194, 329, 91, 15, 273, 72, 5, 7, 54, 103, 1877, 165, 279, 62, 7, 133, 14, 5166, 105, 67, 66, 5166, 19, 13, 245, 135, 5, 944, 177, 2504, 398, 919, 18, 64, 43, 34, 133, 13, 5166, 105, 49, 66, 5166, 19, 13, 680, 135, 5, 1566, 2018, 34, 133, 49, 5166, 105, 83, 39, 5166, 19, 13, 755, 2, 24, 2462, 7, 133, 27, 5166, 105, 67, 27, 5166, 19, 13, 1592, 3004, 10, 204, 6, 40, 505, 323, 4, 3, 24, 1, 7, 5, 1223, 1052, 1480, 253, 2, 231, 98, 6, 329, 1392, 15, 273, 3, 654, 1, 3004, 36, 68, 401, 46, 99, 195]",1651.0,16532500,Decitabine improves patient outcomes myelodysplastic syndromes phase III randomized,106,0.1849912739965096
Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.,Seminars in hematology,Semin. Hematol.,2006-04-01,"Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) are diseases of the elderly. Allogeneic hematopoietic stem cell transplantation (HSCT) offers the possibility of cure for these malignancies, but until recently its use was restricted to younger patients due to prohibitive treatment-related mortality. Improvements in supportive care and development of reduced-intensity preparative regimens have allowed patients in the sixth, seventh, and to a lesser extent, eighth decade of life to be treated with allogeneic transplantation. Major obstacles to extending this form of treatment to older patients are lack of promptly available donors, graft-versus-host disease (GVHD), delayed immune recovery, and the high prevalence of refractory and relapsed disease intrinsic to the natural history of these myeloid malignancies. Here we review current results of allogeneic blood and marrow transplantation for AML and MDS in the elderly.",Journal Article,5043.0,30.0,Acute myelogenous leukemia AML myelodysplastic syndrome MDS diseases elderly Allogeneic hematopoietic stem transplantation HSCT offers possibility cure malignancies recently use restricted younger patients prohibitive treatment-related mortality Improvements supportive care development reduced-intensity preparative regimens allowed patients sixth seventh lesser extent eighth decade life treated allogeneic transplantation Major obstacles extending form treatment older patients lack promptly available donors graft-versus-host disease GVHD delayed immune recovery high prevalence refractory relapsed disease intrinsic natural history myeloid malignancies review current allogeneic blood marrow transplantation AML MDS elderly,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[286, 2194, 329, 2, 681, 1223, 32, 1342, 1, 3, 1216, 1063, 1007, 452, 31, 497, 1703, 2339, 3, 2526, 1, 1722, 9, 46, 441, 84, 1100, 761, 211, 119, 10, 2016, 6, 773, 7, 520, 6, 10784, 24, 139, 282, 1474, 4, 1877, 165, 2, 193, 1, 405, 837, 6085, 472, 47, 2313, 7, 4, 3, 7462, 8114, 2, 6, 8, 5191, 1039, 7732, 2025, 1, 358, 6, 40, 73, 5, 1063, 497, 458, 7140, 6, 4782, 26, 1297, 1, 24, 6, 434, 7, 32, 926, 1, 11396, 390, 2344, 1599, 185, 1204, 34, 1562, 1612, 250, 1602, 2, 3, 64, 1078, 1, 430, 2, 591, 34, 2354, 6, 3, 1504, 532, 1, 46, 533, 441, 467, 21, 206, 291, 99, 1, 1063, 315, 2, 581, 497, 9, 329, 2, 1223, 4, 3, 1216]",903.0,16616044,Allogeneic transplantation elderly patient acute myelogenous leukemia myelodysplastic syndrome,21,0.03664921465968586
Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.,Cancer,Cancer,2006-06-01,"The response to antifungal therapy alone often is suboptimal in patients with cancer who have therapy-refractory neutropenia, and even donor-derived granulocyte transfusions (GTX) are not always successful. The authors evaluated the safety and efficacy of immune enhancement using recombinant interferon gamma1b (rIFN-gamma1b) in patients with cancer who received GTX for refractory, systemic, opportunistic infections. Twenty recipients of high-dose donor GTX ( approximately 5.5 x 10(10) neutrophils per transfusion) who had received concurrent rIFN-gamma1b between October 2001 and December 2004 were evaluated retrospectively. The median age (+/- standard deviation [SD]) was 45 +/- 17 years. Ten patients (50%) were men, 17 patients (85%) had leukemia, and 3 patients (15%) had myelodysplastic syndrome. The median +/- SD Acute Physiology and Chronic Health Evaluation II score was 15 +/- 4 (range, 7-22). Most patients (n = 18 patients; 90%) had recurrent or refractory cancer. In 6 patients (30%) who received allogeneic hematopoietic stem cell transplantation, GTX plus rIFN-gamma1b was given a median +/- SD of 26 +/- 100 days (range, 12-372 days) after transplantation. Seventeen patients (85%) had neutropenia during GTX therapy. Five patients (25%) had possible invasive fungal infection, 3 patients (15%) had probable invasive fungal infection, and 11 patients (55%) had proven invasive fungal infection. One patient (5%) had refractory Pseudomonas aeruginosa sepsis. Eight patients (40%) received corticosteroids during GTX plus rIFN-gamma1b therapy. Patients received a median +/- SD of 8 +/- 7 GTX doses (range, 4-28 doses) and 9 +/- 7 rIFN-gamma1b doses (range, 1-28 doses), for a mean +/- SD cumulative dose (CD) of 400 +/- 2621 microg. Other concomitant cytokines were granulocyte-colony stimulating factor (12 +/- 3 doses; CD, 6720 +/- 4721 microg) in 15 patients (75%) and granulocyte-macrophage-colony stimulating factor (12 +/- 9 doses; CD, 4750 +/- 4410 microg) in 14 patients (70%). Four patients (20%) developed fever, and 2 patients (10%) developed skin rashes. Reversible liver dysfunction (n = 3 patients; 15%) and tachycardia (n = 1 patients; 5%) were considered rIFN-gamma1b-associated adverse reactions; whereas, in 1 patient (5%), transient dyspnea was attributed to GTX. Four weeks after therapy started, 9 patients (45%) had complete or partial resolution of infection; and, in another 3 patients (15%), the invasive fungal infection had become stable. The current results indicated that no serious adverse events were associated with rIFN-gamma1b immune enhancement in patients with systemic opportunistic infections who received donor GTX therapy.",Journal Article,4982.0,61.0,response antifungal therapy suboptimal patients therapy-refractory neutropenia donor-derived granulocyte transfusions GTX successful authors evaluated safety efficacy immune enhancement recombinant interferon gamma1b rIFN-gamma1b patients received GTX refractory systemic opportunistic infections recipients high-dose donor GTX approximately 5.5 x 10 10 neutrophils transfusion received concurrent rIFN-gamma1b October 2001 December 2004 evaluated retrospectively median age +/- standard deviation SD 45 +/- 17 years patients 50 men 17 patients 85 leukemia 3 patients 15 myelodysplastic syndrome median +/- SD Acute Physiology Chronic Health Evaluation II score 15 +/- 4 range 7-22 patients n 18 patients 90 recurrent refractory 6 patients 30 received allogeneic hematopoietic stem transplantation GTX plus rIFN-gamma1b given median +/- SD 26 +/- 100 days range 12-372 days transplantation Seventeen patients 85 neutropenia GTX therapy patients 25 possible invasive fungal infection 3 patients 15 probable invasive fungal infection 11 patients 55 proven invasive fungal infection patient 5 refractory Pseudomonas aeruginosa sepsis patients 40 received corticosteroids GTX plus rIFN-gamma1b therapy Patients received median +/- SD 8 +/- 7 GTX doses range 4-28 doses 9 +/- 7 rIFN-gamma1b doses range 1-28 doses mean +/- SD cumulative dose CD 400 +/- 2621 microg concomitant cytokines granulocyte-colony stimulating factor 12 +/- 3 doses CD 6720 +/- 4721 microg 15 patients 75 granulocyte-macrophage-colony stimulating factor 12 +/- 9 doses CD 4750 +/- 4410 microg 14 patients 70 patients 20 developed fever 2 patients 10 developed skin rashes Reversible liver dysfunction n 3 patients 15 tachycardia n 1 patients 5 considered rIFN-gamma1b-associated adverse reactions 1 patient 5 transient dyspnea attributed GTX weeks therapy started 9 patients 45 complete partial resolution infection 3 patients 15 invasive fungal infection stable current indicated adverse events associated rIFN-gamma1b immune enhancement patients systemic opportunistic infections received donor GTX therapy,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[3, 51, 6, 8606, 36, 279, 629, 16, 3291, 4, 7, 5, 12, 54, 47, 36, 430, 778, 2, 871, 1488, 526, 2764, 4987, 12203, 32, 44, 3763, 1401, 3, 738, 194, 3, 367, 2, 209, 1, 250, 2461, 75, 2835, 1688, 22364, 23521, 22364, 4, 7, 5, 12, 54, 103, 12203, 9, 430, 403, 10026, 1875, 737, 2190, 1, 64, 61, 1488, 12203, 705, 33, 33, 1006, 79, 79, 5700, 379, 2785, 54, 42, 103, 750, 23521, 22364, 59, 2551, 1758, 2, 1397, 1131, 11, 194, 894, 3, 52, 89, 260, 3348, 1270, 10, 512, 269, 60, 1618, 7, 212, 11, 325, 269, 7, 772, 42, 2, 27, 7, 167, 42, 681, 3, 52, 1270, 286, 7206, 2, 442, 341, 451, 215, 368, 10, 167, 39, 184, 67, 350, 96, 7, 78, 203, 7, 424, 42, 387, 15, 430, 12, 4, 49, 7, 201, 54, 103, 1063, 1007, 452, 31, 497, 12203, 349, 23521, 22364, 10, 447, 8, 52, 1270, 1, 432, 394, 162, 184, 133, 10659, 162, 50, 497, 3591, 7, 772, 42, 778, 190, 12203, 36, 365, 7, 243, 42, 899, 416, 7800, 930, 27, 7, 167, 42, 8782, 416, 7800, 930, 2, 175, 7, 614, 42, 1930, 416, 7800, 930, 104, 69, 33, 42, 430, 13538, 20506, 4227, 659, 7, 327, 103, 3876, 190, 12203, 349, 23521, 22364, 36, 7, 103, 8, 52, 1270, 1, 66, 67, 12203, 415, 184, 39, 339, 415, 2, 83, 67, 23521, 22364, 415, 184, 14, 339, 415, 9, 8, 313, 1270, 967, 61, 4420, 1, 1524, 55479, 2440, 127, 1781, 1886, 11, 2764, 1975, 2122, 161, 133, 27, 415, 4420, 44341, 44342, 2440, 4, 167, 7, 481, 2, 2764, 2674, 1975, 2122, 161, 133, 83, 415, 4420, 44343, 55480, 2440, 4, 213, 7, 431, 294, 7, 179, 276, 2775, 2, 18, 7, 79, 276, 11775, 2786, 1527, 78, 27, 7, 167, 2, 12177, 78, 14, 7, 33, 11, 515, 23521, 22364, 41, 290, 2428, 547, 4, 14, 69, 33, 2473, 2923, 10, 3073, 6, 12203, 294, 244, 50, 36, 3461, 83, 7, 512, 42, 236, 15, 450, 2125, 1, 930, 2, 4, 1809, 27, 7, 167, 3, 416, 7800, 930, 42, 1417, 585, 3, 291, 99, 1103, 17, 77, 1762, 290, 281, 11, 41, 5, 23521, 22364, 250, 2461, 4, 7, 5, 403, 10026, 1875, 54, 103, 1488, 12203, 36]",2510.0,16691620,Recombinant interferon gamma1b immune enhancement 20 patients hematologic malignancies systemic opportunistic infections treated donor granulocyte transfusions,0,0.0
Organizing pneumonia in patients with hematologic malignancies: a steroid-responsive lesion.,Respiratory medicine,Respir Med,2006-05-15,"Organizing pneumonia (OP) is a distinct histopathologic lesion that occurs in a variety of clinical contexts. There have been occasional reports of OP occurring in patients with hematologic malignancies. To examine the association of OP with hematologic malignancies and to assess the clinical course of affected patients. A retrospective review of our institutional experience of unexplained OP developing in patients with hematologic malignancies. Tertiary care, referral medical center. We identified 6 patients with a verified histopathologic diagnosis of OP and antecedent or concomitant diagnosis of a hematologic malignancy from the Mayo Clinic database (1995-2003). Clinical, radiologic, and outcome data were abstracted from records. Underlying hematologic disorders included lymphoma (2), acute leukemia (2), cutaneous T-cell lymphoma (1), and myelodysplastic syndrome (1). OP was diagnosed by surgical lung biopsy in 4 and bronchoscopic biopsy in 2. Four of the 6 patients had previously been exposed to chemotherapeutic agents, two had not. Three of the 6 patients had bone marrow transplantation prior to development of OP. Five patients were treated with prednisone and all experienced symptomatic improvement with documented radiologic resolution in 4. One patient experienced symptomatic and radiologic resolution with observation alone. Three patients ultimately died from complications of their underlying hematologic disorder and 1 patient died of unknown causes. Two patients were alive without respiratory complaints more than 1 year after lung biopsy. OP occurs in patients with underlying hematologic malignancies who may or may not have been treated with chemotherapy and responds favorably to corticosteroid therapy.",Journal Article,4999.0,25.0,Organizing pneumonia OP distinct histopathologic lesion occurs variety clinical contexts occasional reports OP occurring patients hematologic malignancies examine association OP hematologic malignancies assess clinical course affected patients retrospective review institutional experience unexplained OP developing patients hematologic malignancies Tertiary care referral medical center identified 6 patients verified histopathologic diagnosis OP antecedent concomitant diagnosis hematologic malignancy Mayo Clinic database 1995-2003 Clinical radiologic outcome abstracted records Underlying hematologic disorders included lymphoma 2 acute leukemia 2 cutaneous T-cell lymphoma 1 myelodysplastic syndrome 1 OP diagnosed surgical lung biopsy 4 bronchoscopic biopsy 2 6 patients previously exposed chemotherapeutic agents 6 patients bone marrow transplantation prior development OP patients treated prednisone experienced symptomatic improvement documented radiologic resolution 4 patient experienced symptomatic radiologic resolution observation patients ultimately died complications underlying hematologic disorder 1 patient died unknown causes patients alive respiratory complaints 1 year lung biopsy OP occurs patients underlying hematologic malignancies treated chemotherapy responds favorably corticosteroid therapy,0,1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[15917, 3485, 9209, 16, 8, 834, 2630, 1180, 17, 1780, 4, 8, 1362, 1, 38, 7875, 125, 47, 85, 9753, 1198, 1, 9209, 1821, 4, 7, 5, 813, 441, 6, 1004, 3, 248, 1, 9209, 5, 813, 441, 2, 6, 423, 3, 38, 906, 1, 1424, 7, 8, 459, 206, 1, 114, 1115, 730, 1, 8221, 9209, 931, 4, 7, 5, 813, 441, 2557, 165, 2096, 484, 574, 21, 108, 49, 7, 5, 8, 4815, 2630, 147, 1, 9209, 2, 8775, 15, 1781, 147, 1, 8, 813, 710, 29, 3, 2486, 1188, 609, 2323, 1522, 38, 2812, 2, 228, 74, 11, 4106, 29, 1064, 1181, 813, 1997, 159, 18, 286, 18, 1486, 102, 31, 14, 2, 681, 14, 9209, 10, 265, 20, 221, 411, 4, 39, 2, 18851, 411, 4, 18, 294, 1, 3, 49, 7, 42, 373, 85, 2234, 6, 1573, 183, 100, 42, 44, 169, 1, 3, 49, 7, 42, 581, 497, 324, 6, 193, 1, 9209, 365, 7, 11, 73, 5, 1979, 2, 62, 592, 1704, 767, 5, 1405, 2812, 2125, 4, 39, 104, 69, 592, 1704, 2, 2812, 2125, 5, 1664, 279, 169, 7, 2050, 1016, 29, 521, 1, 136, 1181, 813, 2645, 2, 14, 69, 1016, 1, 860, 1626, 100, 7, 11, 1701, 187, 2718, 6938, 80, 76, 14, 111, 50, 411, 9209, 1780, 4, 7, 5, 1181, 813, 441, 54, 68, 15, 68, 44, 47, 85, 73, 5, 56, 2, 7920, 5001, 6, 5654, 36]",1648.0,16704928,Organizing pneumonia patients hematologic malignancies steroid-responsive lesion,0,0.0
"SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice.",Blood,Blood,2006-06-08,"SALL4, a human homolog to Drosophila spalt, is a novel zinc finger transcriptional factor essential for development. We cloned SALL4 and its isoforms (SALL4A and SALL4B). Through immunohistochemistry and real-time reverse-transcription-polymerase chain reaction (RT-PCR), we demonstrated that SALL4 was constitutively expressed in human primary acute myeloid leukemia (AML, n = 81), and directly tested the leukemogenic potential of constitutive expression of SALL4 in a murine model. SALL4B transgenic mice developed myelodysplastic syndrome (MDS)-like features and subsequently AML that was transplantable. Increased apoptosis associated with dysmyelopoiesis was evident in transgenic mouse marrow and colony-formation (CFU) assays. Both isoforms could bind to beta-catenin and synergistically enhanced the Wnt/beta-catenin signaling pathway. Our data suggest that the constitutive expression of SALL4 causes MDS/AML, most likely through the Wnt/beta-catenin pathway. Our murine model provides a useful platform to study human MDS/AML transformation, as well as the Wnt/beta-catenin pathway's role in the pathogenesis of leukemia stem cells.",Journal Article,4975.0,155.0,SALL4 human homolog Drosophila spalt novel zinc finger transcriptional factor essential development cloned SALL4 isoforms SALL4A SALL4B immunohistochemistry real-time reverse-transcription-polymerase chain reaction RT-PCR demonstrated SALL4 constitutively expressed human primary acute myeloid leukemia AML n 81 directly tested leukemogenic potential constitutive expression SALL4 murine model SALL4B transgenic mice developed myelodysplastic syndrome MDS -like features subsequently AML transplantable Increased apoptosis associated dysmyelopoiesis evident transgenic mouse marrow colony-formation CFU isoforms bind beta-catenin synergistically enhanced Wnt/beta-catenin signaling pathway suggest constitutive expression SALL4 causes MDS/AML likely Wnt/beta-catenin pathway murine model provides useful platform human MDS/AML transformation Wnt/beta-catenin pathway 's role pathogenesis leukemia stem,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[16439, 8, 171, 3412, 6, 13003, 55557, 16, 8, 229, 5988, 8079, 1431, 161, 1452, 9, 193, 21, 8560, 16439, 2, 211, 3913, 55558, 2, 44382, 298, 888, 2, 1589, 98, 1772, 866, 1451, 1260, 1329, 240, 604, 21, 264, 17, 16439, 10, 2818, 570, 4, 171, 86, 286, 533, 329, 78, 865, 2, 1606, 650, 3, 13519, 174, 1, 3178, 55, 1, 16439, 4, 8, 1471, 202, 44382, 2862, 399, 276, 681, 1223, 733, 404, 2, 1611, 329, 17, 10, 11459, 101, 351, 41, 5, 44383, 10, 2853, 4, 2862, 830, 581, 2, 1975, 1264, 10388, 1013, 110, 3913, 359, 4060, 6, 1090, 1778, 2, 4240, 651, 3, 2112, 1090, 1778, 314, 308, 114, 74, 309, 17, 3, 3178, 55, 1, 16439, 1626, 1223, 329, 96, 322, 298, 3, 2112, 1090, 1778, 308, 114, 1471, 202, 777, 8, 999, 2243, 6, 45, 171, 1223, 329, 1392, 22, 149, 22, 3, 2112, 1090, 1778, 308, 292, 200, 4, 3, 1384, 1, 452, 37]",1084.0,16763212,SALL4 novel oncogene constitutively expressed human acute myeloid leukemia AML induces AML transgenic mice,5,0.008726003490401396
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.,Cancer research,Cancer Res.,2006-06-01,"Optimal reexpression of most genes silenced through promoter methylation requires the sequential application of DNA methyltransferase inhibitors followed by histone deacetylase inhibitors in tumor cell cultures. Patients with myelodysplastic syndrome or acute myeloid leukemia (AML) were treated with the methyltransferase inhibitor 5-azacitidine (aza-CR) followed by the histone deacetylase inhibitor sodium phenylbutyrate. Major responses associated with cytogenetic complete response developed in patients receiving prolonged dosing schedules of aza-CR. Bisulfite sequencing of the p15 promoter in marrow DNA during the first cycle of treatment showed heterogeneous allelic demethylation in three responding patients, suggesting ongoing demethylation within the tumor clone, but no demethylation in two nonresponders. Six of six responding patients with pretreatment methylation of p15 or CDH-1 promoters reversed methylation during the first cycle of therapy (methylation-specific PCR), whereas none of six nonresponders showed any demethylation. Gene demethylation correlated with the area under the aza-CR plasma concentration-time curve. Administration of both drugs was associated with induction of acetylation of histones H3 and H4. This study provides the first demonstration that molecular mechanisms responsible for responses to DNA methyltransferase/histone deacetylase inhibitor combinations may include reversal of aberrant epigenetic gene silencing. The promising percentage of major hematologic responses justifies the testing of such combinations in prospective randomized trials.",Journal Article,4982.0,415.0,Optimal reexpression silenced promoter methylation requires sequential application DNA methyltransferase inhibitors followed histone deacetylase inhibitors cultures Patients myelodysplastic syndrome acute myeloid leukemia AML treated methyltransferase inhibitor 5-azacitidine aza-CR followed histone deacetylase inhibitor sodium phenylbutyrate Major responses associated cytogenetic complete response developed patients receiving prolonged dosing schedules aza-CR Bisulfite sequencing p15 promoter marrow DNA cycle treatment showed heterogeneous allelic demethylation responding patients suggesting ongoing demethylation clone demethylation nonresponders responding patients pretreatment methylation p15 CDH-1 promoters reversed methylation cycle therapy methylation-specific PCR nonresponders showed demethylation demethylation correlated area aza-CR plasma concentration-time curve Administration drugs associated induction acetylation histones H3 H4 provides demonstration molecular mechanisms responsible responses DNA methyltransferase/histone deacetylase inhibitor combinations include reversal aberrant epigenetic silencing promising percentage major hematologic responses justifies testing combinations prospective randomized trials,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[665, 11120, 1, 96, 214, 5442, 298, 973, 569, 1706, 3, 1787, 1581, 1, 261, 3747, 222, 370, 20, 1508, 2732, 222, 4, 30, 31, 3231, 7, 5, 681, 15, 286, 533, 329, 11, 73, 5, 3, 3747, 230, 33, 3752, 3924, 684, 370, 20, 3, 1508, 2732, 230, 4682, 21969, 458, 253, 41, 5, 1266, 236, 51, 276, 4, 7, 357, 1069, 1280, 2314, 1, 3924, 684, 6181, 615, 1, 3, 8840, 973, 4, 581, 261, 190, 3, 157, 417, 1, 24, 224, 1564, 3861, 6800, 4, 169, 3261, 7, 802, 942, 6800, 262, 3, 30, 3910, 84, 77, 6800, 4, 100, 4498, 437, 1, 437, 3261, 7, 5, 1194, 569, 1, 8840, 15, 44385, 14, 4347, 3682, 569, 190, 3, 157, 417, 1, 36, 569, 112, 604, 547, 1292, 1, 437, 4498, 224, 500, 6800, 145, 6800, 438, 5, 3, 965, 669, 3, 3924, 684, 554, 1227, 98, 1496, 634, 1, 110, 600, 10, 41, 5, 504, 1, 4145, 1, 8457, 3739, 2, 7812, 26, 45, 777, 3, 157, 6533, 17, 219, 483, 2327, 9, 253, 6, 261, 3747, 1508, 2732, 230, 1247, 68, 643, 5933, 1, 1898, 1418, 145, 2077, 3, 721, 1150, 1, 458, 813, 253, 13299, 3, 471, 1, 225, 1247, 4, 482, 384, 143]",1555.0,16778214,Combined DNA methyltransferase histone deacetylase inhibition treatment myeloid neoplasms,0,0.0
Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined.,Best practice & research. Clinical haematology,Best Pract Res Clin Haematol,2006-01-01,"The World Health Organization (WHO) classification of myeloid disorders has provided updated parameters for the consistent diagnosis of two previously less than optimally defined chronic myeloid disorders, CNL and CMML. The classification of these disorders, which had been controversial, is now better defined and provides more clinically and biologically relevant disease definitions to enable uniform diagnosis and a framework to evaluate natural history and therapeutic interventions. CNL is now recognized as a distinct entity among the chronic myeloproliferative disorders and CMML is included within the new category of 'myelodysplastic/myeloproliferative diseases' (MDS/MPD). Predominant neutrophilia defines CNL whereas CMML is defined by predominant and monocytosis. In each case these defining features must be distinguished from reactive causes for the same in the absence of clear evidence of myeloid clonality (CNL and CMML) or dysplasia (CMML). The exclusion of underlying bcr/abl-driven oncogenesis is an essential component in the diagnosis of these chronic leukemic processes. The optimal therapy for both CNL and CMML remains uncertain. Current management decisions are based on small studies or extrapolated from therapeutic strategies that are effective in similar chronic, clonal myeloid disorders. Given the potential for evolution to acute leukemia or progressive refractory leucocytosis or cytopenias, allogeneic stem cell transplantation might be appropriate for younger patients. Continued reporting and investigation of specific therapeutic strategies and responses must be encouraged.",Journal Article,5133.0,34.0,World Health Organization classification myeloid disorders provided updated parameters consistent diagnosis previously optimally defined chronic myeloid disorders CNL CMML classification disorders controversial better defined provides clinically biologically relevant disease definitions enable uniform diagnosis framework evaluate natural history therapeutic interventions CNL recognized distinct entity chronic myeloproliferative disorders CMML included new category 'myelodysplastic/myeloproliferative diseases MDS/MPD Predominant neutrophilia defines CNL CMML defined predominant monocytosis case defining features distinguished reactive causes absence clear evidence myeloid clonality CNL CMML dysplasia CMML exclusion underlying bcr/abl-driven oncogenesis essential component diagnosis chronic leukemic processes optimal therapy CNL CMML remains uncertain Current management decisions based small studies extrapolated therapeutic strategies effective similar chronic clonal myeloid disorders Given potential evolution acute leukemia progressive refractory leucocytosis cytopenias allogeneic stem transplantation appropriate younger patients Continued reporting investigation specific therapeutic strategies responses encouraged,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1956, 341, 2533, 54, 947, 1, 533, 1997, 71, 1052, 2939, 1038, 9, 3, 925, 147, 1, 100, 373, 299, 76, 5074, 395, 442, 533, 1997, 17362, 2, 3382, 3, 947, 1, 46, 1997, 92, 42, 85, 2010, 16, 1134, 380, 395, 2, 777, 80, 505, 2, 2665, 867, 34, 3833, 6, 3047, 3490, 147, 2, 8, 2586, 6, 376, 1504, 532, 2, 189, 1151, 17362, 16, 1134, 1904, 22, 8, 834, 2983, 107, 3, 442, 1997, 2, 3382, 16, 159, 262, 3, 217, 2169, 1, 55575, 10857, 1342, 1223, 7712, 2750, 19770, 5849, 17362, 547, 3382, 16, 395, 20, 2750, 2, 16875, 4, 296, 473, 46, 2847, 404, 1642, 40, 4735, 29, 2163, 1626, 9, 3, 827, 4, 3, 1127, 1, 885, 241, 1, 533, 8905, 17362, 2, 3382, 15, 2253, 3382, 3, 4721, 1, 1181, 1062, 1425, 1621, 4503, 16, 35, 1452, 1249, 4, 3, 147, 1, 46, 442, 2015, 1849, 3, 665, 36, 9, 110, 17362, 2, 3382, 469, 2717, 291, 284, 1526, 32, 90, 23, 302, 94, 15, 10727, 29, 189, 422, 17, 32, 323, 4, 288, 442, 1946, 533, 1997, 447, 3, 174, 9, 2554, 6, 286, 15, 1014, 430, 44389, 15, 5635, 1063, 452, 31, 497, 822, 40, 870, 9, 773, 7, 1351, 1760, 2, 940, 1, 112, 189, 422, 2, 253, 1642, 40, 5865]",1561.0,16781489,Chronic neutrophilic leukemia chronic myelomonocytic leukemia defined,288,0.5026178010471204
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?,Hematological oncology,Hematol Oncol,2006-12-01,"The importance of arsenic trioxide (As2O3) has been underscored over the last decade due to its efficacy against acute promyelocytic leukemia (APL), a disease in which this agent has been associated with complete hematologic and molecular remission rates of 87% and 83%, respectively. The different molecular mechanisms of action of As2O3 suggest its applicability in hematologic malignancies other than APL. However, responses obtained thus far have consisted of improvements in signs and symptoms without the elimination of a given disease. Toxicities derived from As2O3 are significant but manageable and reversible. However, the risk/benefit ratio of As2O3 in hematologic malignancies other than APL is still unclear. The development of new generations of orally bioavailable inorganic, as well as new organic, arsenic compounds with improved toxicity profiles may bolster the therapeutic application of arsenic derivatives in hematologic malignancies such as leukemia, multiple myeloma and myelodysplastic syndromes.",Journal Article,4799.0,39.0,importance arsenic trioxide As2O3 underscored decade efficacy acute promyelocytic leukemia APL disease agent associated complete hematologic molecular remission rates 87 83 respectively different molecular mechanisms action As2O3 suggest applicability hematologic malignancies APL responses obtained far consisted improvements signs symptoms elimination given disease Toxicities derived As2O3 significant manageable reversible risk/benefit ratio As2O3 hematologic malignancies APL unclear development new generations orally bioavailable inorganic new organic arsenic compounds improved toxicity profiles bolster therapeutic application arsenic derivatives hematologic malignancies leukemia multiple myeloma myelodysplastic syndromes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1187, 1, 3217, 4574, 18209, 71, 85, 18466, 252, 3, 1060, 2025, 520, 6, 211, 209, 480, 286, 4300, 2578, 8, 34, 4, 92, 26, 420, 71, 85, 41, 5, 236, 813, 2, 219, 734, 151, 1, 912, 2, 852, 106, 3, 338, 219, 483, 1, 1578, 1, 18209, 309, 211, 5412, 4, 813, 441, 127, 76, 2578, 137, 253, 683, 631, 3272, 47, 1695, 1, 1474, 4, 3408, 2, 507, 187, 3, 3730, 1, 8, 447, 34, 385, 526, 29, 18209, 32, 93, 84, 2808, 2, 2786, 137, 3, 43, 247, 197, 1, 18209, 4, 813, 441, 127, 76, 2578, 16, 1234, 1200, 3, 193, 1, 217, 11083, 1, 1428, 6582, 9190, 22, 149, 22, 217, 9486, 3217, 2411, 5, 231, 155, 1241, 68, 23533, 3, 189, 1581, 1, 3217, 6490, 4, 813, 441, 225, 22, 232, 2, 2040]",960.0,16783836,Arsenic derivatives hematologic malignancies role acute promyelocytic leukemia,30,0.05235602094240838
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia.,Blood,Blood,2006-06-29,"During therapy with imatinib, some patients with chronic myeloid leukemia (CML) develop chromosomal abnormalities in Philadelphia chromosome (Ph)-negative cells. These abnormalities are frequently transient and their clinical consequence is unclear. Although some reports have suggested that the abnormalities might be associated with secondary myelodysplastic syndrome (MDS), the diagnosis has not always been established using standard criteria. We report 3 cases of patients treated with imatinib for CML who were subsequently found to have chromosomal abnormalities in Ph-negative cells. One of them developed acute myelogenous leukemia (AML) and the other 2 developed high-risk MDS that rapidly transformed to AML. These cases were identified in a total study group of 1701 patients. Although these occurrences are rare, the findings highlight the need for close monitoring of patients with CML treated with imatinib.",Case Reports,4954.0,123.0,therapy imatinib patients chronic myeloid leukemia CML develop chromosomal abnormalities Philadelphia chromosome Ph -negative abnormalities frequently transient clinical consequence unclear reports suggested abnormalities associated secondary myelodysplastic syndrome MDS diagnosis established standard criteria report 3 cases patients treated imatinib CML subsequently chromosomal abnormalities Ph-negative developed acute myelogenous leukemia AML 2 developed high-risk MDS rapidly transformed AML cases identified total group 1701 patients occurrences rare findings highlight need close monitoring patients CML treated imatinib,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[190, 36, 5, 577, 476, 7, 5, 442, 533, 903, 690, 1860, 1171, 4, 3006, 1170, 2058, 199, 37, 46, 1171, 32, 746, 2473, 2, 136, 38, 4177, 16, 1200, 242, 476, 1198, 47, 1148, 17, 3, 1171, 822, 40, 41, 5, 568, 681, 1223, 3, 147, 71, 44, 3763, 85, 635, 75, 260, 371, 21, 414, 27, 140, 1, 7, 73, 5, 577, 9, 903, 54, 11, 1611, 204, 6, 47, 1860, 1171, 4, 2058, 199, 37, 104, 1, 1370, 276, 286, 2194, 329, 2, 3, 127, 18, 276, 64, 43, 1223, 17, 1755, 2423, 6, 329, 46, 140, 11, 108, 4, 8, 181, 45, 87, 1, 38208, 7, 242, 46, 8781, 32, 622, 3, 272, 1817, 3, 594, 9, 2336, 1315, 1, 7, 5, 903, 73, 5, 577]",871.0,16809614,Myelodysplastic syndromes acute leukemia developing imatinib mesylate therapy chronic myeloid leukemia,71,0.12390924956369982
Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.,Haematologica,Haematologica,2006-07-25,"We determined mutations and promoter methylation status of NPM1 using pyrosequencing in 199 samples of myeloid neoplasia including myeloproliferative disorders (MPD). The mutations were present in 4% of chronic myelomonocytic leukemia, but not in other MPD or myelodysplastic syndromes. Promoter methylation was rare, and was found in only three samples of MPD.",Letter,4928.0,27.0,determined promoter methylation status NPM1 pyrosequencing 199 myeloid neoplasia including myeloproliferative disorders MPD present 4 chronic myelomonocytic leukemia MPD myelodysplastic syndromes Promoter methylation rare MPD,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 509, 138, 2, 973, 569, 156, 1, 4318, 75, 6031, 4, 5840, 347, 1, 533, 2298, 141, 1997, 7712, 3, 138, 11, 364, 4, 39, 1, 442, 5451, 84, 44, 4, 127, 7712, 15, 2040, 973, 569, 10, 622, 2, 10, 204, 4, 158, 169, 347, 1, 7712]",309.0,16870548,promoter methylation status NPM1 myeloproliferative disorders,0,0.0
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.,Blood,Blood,2006-08-01,"Epigenetic therapy with hypomethylating drugs is now the standard of care in myelodysplastic syndrome (MDS). Response rates remain low, and mechanism-based dose optimization has not been reported. We investigated the clinical and pharmacodynamic results of different dose schedules of decitabine. Adults with advanced MDS or chronic myelomonocytic leukemia (CMML) were randomized to 1 of 3 decitabine schedules: (1) 20 mg/m2 intravenously daily for 5 days; (2) 20 mg/m2 subcutaneously daily for 5 days; and (3) 10 mg/m2 intravenously daily for 10 days. Randomization followed a Bayesian adaptive design. Ninety-five patients were treated (77 with MDS, and 18 with CMML). Overall, 32 patients (34%) achieved a complete response (CR), and 69 (73%) had an objective response by the new modified International Working Group criteria. The 5-day intravenous schedule, which had the highest dose-intensity, was selected as optimal; the CR rate in that arm was 39%, compared with 21% in the 5-day subcutaneous arm and 24% in the 10-day intravenous arm (P < .05). The high dose-intensity arm was also superior at inducing hypomethylation at day 5 and at activating P15 expression at days 12 or 28 after therapy. We conclude that a low-dose, dose-intensity schedule of decitabine optimizes epigenetic modulation and clinical responses in MDS.",Comparative Study,4921.0,529.0,Epigenetic therapy hypomethylating drugs standard care myelodysplastic syndrome MDS Response rates remain low mechanism-based dose optimization reported investigated clinical pharmacodynamic different dose schedules decitabine Adults advanced MDS chronic myelomonocytic leukemia CMML randomized 1 3 decitabine schedules 1 20 mg/m2 intravenously daily 5 days 2 20 mg/m2 subcutaneously daily 5 days 3 10 mg/m2 intravenously daily 10 days Randomization followed Bayesian adaptive design Ninety-five patients treated 77 MDS 18 CMML Overall 32 patients 34 achieved complete response CR 69 73 objective response new modified International Working Group criteria 5-day intravenous schedule highest dose-intensity selected optimal CR rate arm 39 compared 21 5-day subcutaneous arm 24 10-day intravenous arm P .05 high dose-intensity arm superior inducing hypomethylation day 5 activating P15 expression days 12 28 therapy conclude low-dose dose-intensity schedule decitabine optimizes epigenetic modulation clinical responses MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1418, 36, 5, 4931, 600, 16, 1134, 3, 260, 1, 165, 4, 681, 1223, 51, 151, 918, 154, 2, 670, 90, 61, 3980, 71, 44, 85, 210, 21, 565, 3, 38, 2, 2424, 99, 1, 338, 61, 2314, 1, 3004, 857, 5, 131, 1223, 15, 442, 5451, 3382, 11, 384, 6, 14, 1, 27, 3004, 2314, 14, 179, 81, 821, 1672, 391, 9, 33, 162, 18, 179, 81, 821, 3928, 391, 9, 33, 162, 2, 27, 79, 81, 821, 1672, 391, 9, 79, 162, 3644, 370, 8, 5032, 2454, 771, 2493, 365, 7, 11, 73, 849, 5, 1223, 2, 203, 5, 3382, 63, 531, 7, 562, 513, 8, 236, 51, 684, 2, 790, 803, 42, 35, 461, 51, 20, 3, 217, 1230, 944, 2644, 87, 371, 3, 33, 218, 1262, 1055, 92, 42, 3, 1076, 61, 837, 10, 715, 22, 665, 3, 684, 116, 4, 17, 475, 10, 587, 72, 5, 239, 4, 3, 33, 218, 2529, 475, 2, 259, 4, 3, 79, 218, 1262, 475, 19, 474, 3, 64, 61, 837, 475, 10, 120, 1123, 28, 1958, 4441, 28, 218, 33, 2, 28, 1616, 8840, 55, 28, 162, 133, 15, 339, 50, 36, 21, 2060, 17, 8, 154, 61, 61, 837, 1055, 1, 3004, 16282, 1418, 2356, 2, 38, 253, 4, 1223]",1258.0,16882708,randomized 3 schedules low-dose decitabine higher-risk myelodysplastic syndrome chronic myelomonocytic leukemia,20,0.034904013961605584
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.,Blood,Blood,2006-08-01,"We conducted a phase 1/2 study of the combination of 5-aza-2'-deoxycytidine (decitabine) and the histone deacetylase inhibitor valproic acid (VPA) in patients with advanced leukemia, including older untreated patients. A group of 54 patients were treated with a fixed dose of decitabine (15 mg/m(2) by IV daily for 10 days) administered concomitantly with escalating doses of VPA orally for 10 days. A 50 mg/kg daily dose of VPA was found to be safe. Twelve (22%) patients had objective response, including 10 (19%) complete remissions (CRs), and 2 (3%) CRs with incomplete platelet recovery (CRp). Among 10 elderly patients with acute myelogenous leukemia or myelodysplastic syndrome, 5 (50%) had a response (4CRs, 1CRp's). Induction mortality was observed in 1 (2%) patient. Major cytogenetic response was documented in 6 of 8 responders. Remission duration was 7.2 months (range, 1.3-12.6+ months). Overall survival was 15.3 months (range, 4.6-20.2+ months) in responders. Transient DNA hypomethylation and global histone H3 and H4 acetylation were induced, and were associated with p15 reactivation. Patients with lower pretreatment levels of p15 methylation had a significantly higher response rate. In summary, this combination of epigenetic therapy in leukemia was safe and active, and was associated with transient reversal of aberrant epigenetic marks.","Clinical Trial, Phase I",4921.0,416.0,conducted phase 1/2 combination 5-aza-2'-deoxycytidine decitabine histone deacetylase inhibitor valproic acid VPA patients advanced leukemia including older untreated patients group 54 patients treated fixed dose decitabine 15 mg/m 2 IV daily 10 days administered concomitantly escalating doses VPA orally 10 days 50 mg/kg daily dose VPA safe 22 patients objective response including 10 19 complete remissions CRs 2 3 CRs incomplete platelet recovery CRp 10 elderly patients acute myelogenous leukemia myelodysplastic syndrome 5 50 response 4CRs 1CRp 's Induction mortality observed 1 2 patient Major cytogenetic response documented 6 8 responders Remission duration 7.2 months range 1.3-12.6+ months Overall survival 15.3 months range 4.6-20.2+ months responders Transient DNA hypomethylation global histone H3 H4 acetylation induced associated p15 reactivation Patients lower pretreatment levels p15 methylation significantly higher response rate summary combination epigenetic therapy leukemia safe active associated transient reversal aberrant epigenetic marks,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 426, 8, 124, 14, 18, 45, 1, 3, 150, 1, 33, 3924, 6135, 6750, 3004, 2, 3, 1508, 2732, 230, 11029, 971, 6770, 4, 7, 5, 131, 141, 434, 1278, 7, 8, 87, 1, 667, 7, 11, 73, 5, 8, 1959, 61, 1, 3004, 167, 81, 188, 18, 20, 478, 391, 9, 79, 162, 468, 6485, 5, 2922, 415, 1, 6770, 1428, 9, 79, 162, 8, 212, 81, 503, 391, 61, 1, 6770, 10, 204, 6, 40, 1165, 2544, 350, 7, 42, 461, 51, 141, 79, 326, 236, 3166, 3115, 2, 18, 27, 3115, 5, 2610, 1596, 1602, 3162, 107, 79, 1216, 7, 5, 286, 2194, 15, 681, 33, 212, 42, 8, 51, 55681, 55682, 292, 504, 282, 10, 164, 4, 14, 18, 69, 458, 1266, 51, 10, 1405, 4, 49, 1, 66, 1983, 734, 654, 10, 67, 18, 53, 184, 14, 27, 133, 49, 53, 63, 25, 10, 167, 27, 53, 184, 39, 49, 179, 18, 53, 4, 1983, 2473, 261, 4441, 2, 1648, 1508, 3739, 2, 7812, 4145, 11, 277, 2, 11, 41, 5, 8840, 3834, 7, 5, 280, 1194, 148, 1, 8840, 569, 42, 8, 97, 142, 51, 116, 4, 1962, 26, 150, 1, 1418, 36, 4, 10, 1165, 2, 544, 2, 10, 41, 5, 2473, 5933, 1, 1898, 1418, 8418]",1265.0,16882711,Phase 1/2 combination 5-aza-2'-deoxycytidine valproic acid patients leukemia,0,0.0
"A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2006-08-01,"LBH589 is a novel histone deacetylase inhibitor that inhibits proliferation and induces apoptosis in tumor cell lines. In this phase I study, LBH589 was administered i.v. as a 30-minute infusion on days 1 to 7 of a 21-day cycle. Fifteen patients (median age, 63 years; range, 42-87 years) with acute myeloid leukemia (13 patients), acute lymphocytic leukemia (1 patient), or myelodysplastic syndrome (1 patient) were treated with LBH589 at the following dose levels (mg/m(2)): 4.8 (3 patients), 7.2 (3 patients), 9.0 (1 patient), 11.5 (3 patient), and 14.0 (5 patients). The levels of histone acetylation were measured using quantitative flow cytometry and plasma LBH589 concentrations were assayed. Four dose-limiting toxicities (grade 3 QTcF prolongation) were observed, four at 14.0 mg/m(2) and one at 11.5 mg/m(2). QTcF prolongation was asymptomatic and reversed on LBH589 discontinuation. Other potentially LBH589-related toxicities included nausea (40%), diarrhea (33%), vomiting (33%), hypokalemia (27%), loss of appetite (13%), and thrombocytopenia (13%). In 8 of 11 patients with peripheral blasts, transient reductions occurred with a rebound following the 7-day treatment period. H3 acetylation increase was significant in B-cells (CD19(+); P = 0.02) and blasts (CD34(+); P = 0.04). The increase in H2B acetylation was highest in CD19(+) and CD34(+) cells [3.8-fold (P = 0.01) and 4.4-fold (P = 0.03), respectively]. The median acetylation of histones H2B and H3 in CD34(+) and CD19(+) cells significantly increased on therapy as did apoptosis in CD14(+) cells. Area under the curve increased proportionally with dose with a terminal half-life of approximately 11 hours. Intravenous administration of LBH589 was well tolerated at doses <11.5 mg/m(2) with consistent transient antileukemic and biological effects.","Clinical Trial, Phase I",4921.0,288.0,LBH589 novel histone deacetylase inhibitor inhibits proliferation induces apoptosis lines phase LBH589 administered i.v 30-minute infusion days 1 7 21-day cycle patients median age 63 years range 42-87 years acute myeloid leukemia 13 patients acute lymphocytic leukemia 1 patient myelodysplastic syndrome 1 patient treated LBH589 following dose levels mg/m 2 4.8 3 patients 7.2 3 patients 9.0 1 patient 11.5 3 patient 14.0 5 patients levels histone acetylation measured quantitative flow cytometry plasma LBH589 concentrations assayed dose-limiting toxicities grade 3 QTcF prolongation observed 14.0 mg/m 2 11.5 mg/m 2 QTcF prolongation asymptomatic reversed LBH589 discontinuation potentially LBH589-related toxicities included nausea 40 diarrhea 33 vomiting 33 hypokalemia 27 loss appetite 13 thrombocytopenia 13 8 11 patients peripheral blasts transient reductions occurred rebound following 7-day treatment period H3 acetylation increase significant B-cells CD19 P 0.02 blasts CD34 P 0.04 increase H2B acetylation highest CD19 CD34 3.8-fold P 0.01 4.4-fold P 0.03 respectively median acetylation histones H2B H3 CD34 CD19 significantly increased therapy apoptosis CD14 Area curve increased proportionally dose terminal half-life approximately 11 hours Intravenous administration LBH589 tolerated doses 11.5 mg/m 2 consistent transient antileukemic effects,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[11339, 16, 8, 229, 1508, 2732, 230, 17, 1576, 457, 2, 1516, 351, 4, 30, 31, 285, 4, 26, 124, 70, 45, 11339, 10, 468, 70, 603, 22, 8, 201, 3949, 904, 23, 162, 14, 6, 67, 1, 8, 239, 218, 417, 3057, 7, 52, 89, 676, 60, 184, 595, 912, 60, 5, 286, 533, 233, 7, 286, 1193, 14, 69, 15, 681, 14, 69, 11, 73, 5, 11339, 28, 3, 366, 61, 148, 81, 188, 18, 39, 66, 27, 7, 67, 18, 27, 7, 83, 13, 14, 69, 175, 33, 27, 69, 2, 213, 13, 33, 7, 3, 148, 1, 1508, 4145, 11, 644, 75, 1156, 1412, 1914, 2, 554, 11339, 1003, 11, 4499, 294, 61, 817, 385, 88, 27, 11340, 4464, 11, 164, 294, 28, 213, 13, 81, 188, 18, 2, 104, 28, 175, 33, 81, 188, 18, 11340, 4464, 10, 2100, 2, 3682, 23, 11339, 2007, 127, 751, 11339, 139, 385, 159, 1218, 327, 1172, 466, 1966, 466, 7799, 428, 407, 1, 4062, 233, 2, 1340, 233, 4, 66, 1, 175, 7, 5, 672, 2438, 2473, 2153, 489, 5, 8, 12309, 366, 3, 67, 218, 24, 727, 3739, 4145, 344, 10, 93, 4, 132, 37, 3158, 19, 13, 588, 2, 2438, 2215, 19, 13, 755, 3, 344, 4, 26465, 4145, 10, 1076, 4, 3158, 2, 2215, 37, 27, 66, 1116, 19, 13, 355, 2, 39, 39, 1116, 19, 13, 680, 106, 3, 52, 4145, 1, 8457, 26465, 2, 3739, 4, 2215, 2, 3158, 37, 97, 101, 23, 36, 22, 205, 351, 4, 7759, 37, 965, 669, 3, 1496, 101, 11142, 5, 61, 5, 8, 2158, 1303, 358, 1, 705, 175, 1459, 1262, 634, 1, 11339, 10, 149, 421, 28, 415, 175, 33, 81, 188, 18, 5, 925, 2473, 4512, 2, 1037, 176]",1670.0,16899611,phase intravenous LBH589 novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor patients refractory hematologic malignancies,27,0.04712041884816754
"Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.",Blood,Blood,2006-08-10,"Tandutinib (MLN518/CT53518) is a novel quinazoline-based inhibitor of the type III receptor tyrosine kinases: FMS-like tyrosine kinase 3 (FLT3), platelet-derived growth factor receptor (PDGFR), and KIT. Because of the correlation between FLT3 internal tandem duplication (ITD) mutations and poor prognosis in acute myelogenous leukemia (AML), we conducted a phase 1 trial of tandutinib in 40 patients with either AML or high-risk myelodysplastic syndrome (MDS). Tandutinib was given orally in doses ranging from 50 mg to 700 mg twice daily The principal dose-limiting toxicity (DLT) of tandutinib was reversible generalized muscular weakness, fatigue, or both, occurring at doses of 525 mg and 700 mg twice daily. Tandutinib's pharmacokinetics were characterized by slow elimination, with achievement of steady-state plasma concentrations requiring greater than 1 week of dosing. Western blotting showed that tandutinib inhibited phosphorylation of FLT3 in circulating leukemic blasts. Eight patients had FLT3-ITD mutations; 5 of these were evaluable for assessment of tandutinib's antileukemic effect. Two of the 5 patients, treated at 525 mg and 700 mg twice daily, showed evidence of antileukemic activity, with decreases in both peripheral and bone marrow blasts. Tandutinib at the MTD (525 mg twice daily) should be evaluated more extensively in patients with AML with FLT3-ITD mutations to better define its antileukemic activity.","Clinical Trial, Phase I",4912.0,203.0,Tandutinib MLN518/CT53518 novel quinazoline-based inhibitor type III receptor tyrosine kinases FMS-like tyrosine kinase 3 FLT3 platelet-derived growth factor receptor PDGFR KIT correlation FLT3 internal tandem duplication ITD poor prognosis acute myelogenous leukemia AML conducted phase 1 trial tandutinib 40 patients AML high-risk myelodysplastic syndrome MDS Tandutinib given orally doses ranging 50 mg 700 mg twice daily principal dose-limiting toxicity DLT tandutinib reversible generalized muscular weakness fatigue occurring doses 525 mg 700 mg twice daily Tandutinib 's pharmacokinetics characterized slow elimination achievement steady-state plasma concentrations requiring greater 1 week dosing Western blotting showed tandutinib inhibited phosphorylation FLT3 circulating leukemic blasts patients FLT3-ITD 5 evaluable assessment tandutinib 's antileukemic effect 5 patients treated 525 mg 700 mg twice daily showed evidence antileukemic activity decreases peripheral bone marrow blasts Tandutinib MTD 525 mg twice daily evaluated extensively patients AML FLT3-ITD better define antileukemic activity,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[15695, 38230, 55691, 16, 8, 229, 26185, 90, 230, 1, 3, 267, 316, 153, 564, 1549, 5516, 733, 564, 216, 27, 1224, 1596, 526, 129, 161, 153, 4103, 2, 1164, 408, 1, 3, 816, 59, 1224, 2329, 2905, 4616, 2837, 138, 2, 334, 356, 4, 286, 2194, 329, 21, 426, 8, 124, 14, 160, 1, 15695, 4, 327, 7, 5, 361, 329, 15, 64, 43, 681, 1223, 15695, 10, 447, 1428, 4, 415, 2223, 29, 212, 81, 6, 5692, 81, 936, 391, 3, 4312, 61, 817, 155, 2059, 1, 15695, 10, 2786, 4169, 8620, 6408, 613, 15, 110, 1821, 28, 415, 1, 10223, 81, 2, 5692, 81, 936, 391, 15695, 292, 1159, 11, 765, 20, 3645, 3730, 5, 5088, 1, 4152, 1309, 554, 1003, 1888, 378, 76, 14, 647, 1, 1280, 1521, 3661, 224, 17, 15695, 879, 982, 1, 1224, 4, 1033, 2015, 2438, 659, 7, 42, 1224, 2837, 138, 33, 1, 46, 11, 859, 9, 455, 1, 15695, 292, 4512, 254, 100, 1, 3, 33, 7, 73, 28, 10223, 81, 2, 5692, 81, 936, 391, 224, 241, 1, 4512, 128, 5, 2140, 4, 110, 672, 2, 581, 2438, 15695, 28, 3, 961, 10223, 81, 936, 391, 257, 40, 194, 80, 3576, 4, 7, 5, 329, 5, 1224, 2837, 138, 6, 380, 1107, 211, 4512, 128]",1372.0,16902153,Phase 1 clinical tandutinib MLN518 novel FLT3 antagonist patients acute myelogenous leukemia high-risk myelodysplastic syndrome safety pharmacokinetics pharmacodynamics,146,0.2547993019197208
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2006-09-01,"Everolimus (RAD001, Novartis), an oral derivative of rapamycin, inhibits the mammalian target of rapamycin (mTOR), which regulates many aspects of cell growth and division. A phase I/II study was done to determine safety and efficacy of everolimus in patients with relapsed or refractory hematologic malignancies. Two dose levels (5 and 10 mg orally once daily continuously) were evaluated in the phase I portion of this study to determine the maximum tolerated dose of everolimus to be used in the phase II study. Twenty-seven patients (9 acute myelogenous leukemia, 5 myelodysplastic syndrome, 6 B-chronic lymphocytic leukemia, 4 mantle cell lymphoma, 1 myelofibrosis, 1 natural killer cell/T-cell leukemia, and 1 T-cell prolymphocytic leukemia) received everolimus. No dose-limiting toxicities were observed. Grade 3 potentially drug-related toxicities included hyperglycemia (22%), hypophosphatemia (7%), fatigue (7%), anorexia (4%), and diarrhea (4%). One patient developed a cutaneous leukocytoclastic vasculitis requiring a skin graft. One patient with refractory anemia with excess blasts achieved a major platelet response of over 3-month duration. A second patient with refractory anemia with excess blasts showed a minor platelet response of 25-day duration. Phosphorylation of downstream targets of mTOR, eukaryotic initiation factor 4E-binding protein 1, and/or, p70 S6 kinase, was inhibited in six of nine patient samples, including those from the patient with a major platelet response. Everolimus is well tolerated at a daily dose of 10 mg daily and may have activity in patients with myelodysplastic syndrome. Studies of everolimus in combination with therapeutic agents directed against other components of the phosphatidylinositol 3-kinase/Akt/mTOR pathway are warranted.","Clinical Trial, Phase I",4890.0,262.0,Everolimus RAD001 Novartis oral derivative rapamycin inhibits mammalian target rapamycin mTOR regulates aspects growth division phase I/II determine safety efficacy everolimus patients relapsed refractory hematologic malignancies dose levels 5 10 mg orally daily continuously evaluated phase portion determine maximum tolerated dose everolimus phase II Twenty-seven patients 9 acute myelogenous leukemia 5 myelodysplastic syndrome 6 B-chronic lymphocytic leukemia 4 mantle lymphoma 1 myelofibrosis 1 natural killer cell/T-cell leukemia 1 T-cell prolymphocytic leukemia received everolimus dose-limiting toxicities observed Grade 3 potentially drug-related toxicities included hyperglycemia 22 hypophosphatemia 7 fatigue 7 anorexia 4 diarrhea 4 patient developed cutaneous leukocytoclastic vasculitis requiring skin graft patient refractory anemia excess blasts achieved major platelet response 3-month duration second patient refractory anemia excess blasts showed minor platelet response 25-day duration Phosphorylation downstream targets mTOR eukaryotic initiation factor 4E-binding 1 and/or p70 S6 kinase inhibited patient including patient major platelet response Everolimus tolerated daily dose 10 mg daily activity patients myelodysplastic syndrome Studies everolimus combination therapeutic agents directed components phosphatidylinositol 3-kinase/Akt/mTOR pathway warranted,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[1400, 7027, 7855, 35, 518, 4819, 1, 1620, 1576, 3, 2359, 283, 1, 1620, 873, 92, 2468, 445, 2695, 1, 31, 129, 2, 5750, 8, 124, 70, 215, 45, 10, 1822, 6, 223, 367, 2, 209, 1, 1400, 4, 7, 5, 591, 15, 430, 813, 441, 100, 61, 148, 33, 2, 79, 81, 1428, 1059, 391, 4285, 11, 194, 4, 3, 124, 70, 3206, 1, 26, 45, 6, 223, 3, 689, 421, 61, 1, 1400, 6, 40, 95, 4, 3, 124, 215, 45, 737, 648, 7, 83, 286, 2194, 33, 681, 49, 132, 442, 1193, 39, 2757, 31, 14, 4637, 14, 1504, 3458, 31, 102, 31, 2, 14, 102, 31, 14779, 103, 1400, 77, 61, 817, 385, 11, 164, 88, 27, 751, 234, 139, 385, 159, 3992, 350, 8021, 67, 613, 67, 3373, 39, 2, 1172, 39, 104, 69, 276, 8, 1486, 38242, 18850, 1888, 8, 1599, 104, 69, 5, 430, 1545, 5, 2612, 2438, 513, 8, 458, 1596, 51, 1, 252, 27, 811, 654, 8, 419, 69, 5, 430, 1545, 5, 2612, 2438, 224, 8, 2278, 1596, 51, 1, 243, 218, 654, 982, 1, 1489, 637, 1, 873, 8374, 1118, 161, 6726, 791, 178, 14, 2, 15, 9036, 4977, 216, 10, 879, 4, 437, 1, 762, 69, 347, 141, 135, 29, 3, 69, 5, 8, 458, 1596, 51, 1400, 16, 149, 421, 28, 8, 391, 61, 1, 79, 81, 391, 2, 68, 47, 128, 4, 7, 5, 681, 94, 1, 1400, 4, 150, 5, 189, 183, 1166, 480, 127, 1628, 1, 3, 3415, 27, 216, 649, 873, 308, 32, 1197]",1654.0,16951235,Phase I/II mammalian target rapamycin inhibitor everolimus RAD001 patients relapsed refractory hematologic malignancies,1,0.0017452006980802793
"Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.",Cancer,Cancer,2006-10-01,"Topoisomerase I inhibitors, like topotecan, have activity in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). 9-Nitro-camptothecin (9-NC) is a new oral topoisomerase inhibitor with a good safety profile. The aims of the current study were to evaluate the activity and safety of 9-NC in MDS and CMML. Adults with a diagnosis of MDS (n = 12) and CMML (n = 32) received 9-NC 2 mg/m(2) orally daily 5 days a week, every 4 to 6 weeks. Overall, 5 (11%) patients achieved complete response (CR), 7 (16%) had a partial response (PR), and 6 (14%) had hematologic improvement (HI), for an overall response rate of 41%. The response rate was similar in MDS and CMML. Severe (Grade 3-4) side effects included nausea and vomiting (7%), diarrhea (18%), other gastrointestinal toxicities (5%), and genitourinary toxicities (12%). 9-NC is active in MDS and CMML. The paucity of available therapies in CMML makes 9-NC a good candidate for further studies as a single agent, or in combination with decitabine, 5-azacitidine or cytarabine.",Clinical Trial,4860.0,18.0,Topoisomerase inhibitors like topotecan activity myelodysplastic syndrome MDS chronic myelomonocytic leukemia CMML 9-Nitro-camptothecin 9-NC new oral topoisomerase inhibitor good safety profile aims current evaluate activity safety 9-NC MDS CMML Adults diagnosis MDS n 12 CMML n 32 received 9-NC 2 mg/m 2 orally daily 5 days week 4 6 weeks Overall 5 11 patients achieved complete response CR 7 16 partial response PR 6 14 hematologic improvement HI overall response rate 41 response rate similar MDS CMML Severe Grade 3-4 effects included nausea vomiting 7 diarrhea 18 gastrointestinal toxicities 5 genitourinary toxicities 12 9-NC active MDS CMML paucity available therapies CMML makes 9-NC good candidate studies single agent combination decitabine 5-azacitidine cytarabine,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3999, 70, 222, 733, 2129, 47, 128, 4, 681, 1223, 2, 442, 5451, 3382, 83, 18962, 6968, 83, 5480, 16, 8, 217, 518, 3999, 230, 5, 8, 1178, 367, 800, 3, 2970, 1, 3, 291, 45, 11, 6, 376, 3, 128, 2, 367, 1, 83, 5480, 4, 1223, 2, 3382, 857, 5, 8, 147, 1, 1223, 78, 133, 2, 3382, 78, 531, 103, 83, 5480, 18, 81, 188, 18, 1428, 391, 33, 162, 8, 647, 454, 39, 6, 49, 244, 63, 33, 175, 7, 513, 236, 51, 684, 67, 245, 42, 8, 450, 51, 998, 2, 49, 213, 42, 813, 767, 5910, 9, 35, 63, 51, 116, 1, 605, 3, 51, 116, 10, 288, 4, 1223, 2, 3382, 905, 88, 27, 39, 1152, 176, 159, 1218, 2, 1966, 67, 1172, 203, 127, 385, 33, 2, 4109, 385, 133, 83, 5480, 16, 544, 4, 1223, 2, 3382, 3, 4832, 1, 390, 235, 4, 3382, 4677, 83, 5480, 8, 1178, 1609, 9, 195, 94, 22, 8, 226, 420, 15, 4, 150, 5, 3004, 33, 3752, 15, 1855]",938.0,16955510,Activity 9-nitro-camptothecin oral topoisomerase inhibitor myelodysplastic syndrome chronic myelomonocytic leukemia,2,0.0034904013961605585
Safety and efficacy of once-per-cycle pegfilgrastim in support of ABVD chemotherapy in patients with Hodgkin lymphoma.,"European journal of cancer (Oxford, England : 1990)",Eur. J. Cancer,2006-09-27,"The objective of this prospective study was to examine the safety and efficacy of pegfilgrastim in support of chemotherapy regimens that are administered every 14 d. Patients with Hodgkin lymphoma receiving standard ABVD (doxorubicin, bleomycin, vinblastine, and decarbazine) chemotherapy every 14 d were eligible for the study. All patients received one fixed dose of 6 mg pegfilgrastim approximately 24h after each ABVD infusion. Absolute neutrophil counts (ANCs) were measured weekly while on therapy. After completion of therapy, ANCs were measured every 3-4 months for 2 years, and every 6 months thereafter. Twenty-three patients received 115 courses (230 doses) of ABVD. Nadir ANC below 0.5 x 10(9)/L was observed only in two cases (1.1%), and ANC counts on the day of ABVD therapy below 1 x 10(9)/L was observed only once (0.4%). No neutropenic fever was observed. Two hundred and fifteen (93.5%) doses of ABVD were given on time as scheduled. Grade 3/4 bone pain was observed after 0.4% of ABVD doses, and bleomycin lung toxicity was observed in two patients. With a median follow-up of 29 months after completion of ABVD, no myelodysplastic syndrome was observed. Two patients relapsed and subsequently underwent successful stem cell collection and transplantation. Pegfilgrastim was found to be safe in support of ABVD chemotherapy that is administered every 14 d. Pegfilgrastim was also effective in maintaining ABVD dose intensity, and keeping planned dose of chemotherapy on schedule.",Journal Article,4864.0,24.0,objective prospective examine safety efficacy pegfilgrastim support chemotherapy regimens administered 14 d. Patients Hodgkin lymphoma receiving standard ABVD doxorubicin bleomycin vinblastine decarbazine chemotherapy 14 eligible patients received fixed dose 6 mg pegfilgrastim approximately 24h ABVD infusion Absolute neutrophil counts ANCs measured weekly therapy completion therapy ANCs measured 3-4 months 2 years 6 months Twenty-three patients received 115 courses 230 doses ABVD Nadir ANC 0.5 x 10 9 /L observed cases 1.1 ANC counts day ABVD therapy 1 x 10 9 /L observed 0.4 neutropenic fever observed 93.5 doses ABVD given time scheduled Grade 3/4 bone pain observed 0.4 ABVD doses bleomycin lung toxicity observed patients median follow-up 29 months completion ABVD myelodysplastic syndrome observed patients relapsed subsequently underwent successful stem collection transplantation Pegfilgrastim safe support ABVD chemotherapy administered 14 d. Pegfilgrastim effective maintaining ABVD dose intensity keeping planned dose chemotherapy schedule,0,1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 461, 1, 26, 482, 45, 10, 6, 1004, 3, 367, 2, 209, 1, 6005, 4, 538, 1, 56, 472, 17, 32, 468, 454, 213, 427, 7, 5, 357, 260, 6316, 856, 5213, 5413, 2, 55800, 56, 454, 213, 427, 11, 625, 9, 3, 45, 62, 7, 103, 104, 1959, 61, 1, 49, 81, 6005, 705, 12551, 50, 296, 6316, 904, 1766, 2595, 1911, 19084, 11, 644, 709, 369, 23, 36, 50, 1438, 1, 36, 19084, 11, 644, 454, 27, 39, 53, 9, 18, 60, 2, 454, 49, 53, 3972, 737, 169, 7, 103, 3670, 1993, 6136, 415, 1, 6316, 3686, 6486, 2736, 13, 33, 1006, 79, 83, 805, 10, 164, 158, 4, 100, 140, 14, 14, 2, 6486, 1911, 23, 3, 218, 1, 6316, 36, 2736, 14, 1006, 79, 83, 805, 10, 164, 158, 1059, 13, 39, 77, 3659, 2775, 10, 164, 100, 1128, 2, 3057, 966, 33, 415, 1, 6316, 11, 447, 23, 98, 22, 4394, 88, 27, 39, 559, 10, 164, 50, 13, 39, 1, 6316, 415, 2, 5213, 155, 10, 164, 4, 100, 7, 5, 8, 52, 166, 126, 1, 462, 53, 50, 1438, 1, 6316, 77, 681, 10, 164, 100, 7, 591, 2, 1611, 208, 1401, 452, 31, 2442, 2, 497, 6005, 10, 204, 6, 40, 1165, 4, 538, 1, 6316, 56, 17, 16, 468, 454, 213, 427, 6005, 10, 120, 323, 4, 3284, 6316, 61, 837, 2, 10991, 1465, 61, 1, 56, 23, 1055]",1418.0,17008093,Safety efficacy once-per-cycle pegfilgrastim support ABVD chemotherapy patients Hodgkin lymphoma,0,0.0
Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2006-10-01,"We reviewed 136 patients with advanced acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic transplantation to assess the impact of conditioning regimen intensity on outcome. Thirty-nine patients receiving nonmyeloablative stem cell transplantation (NST) were compared with 97 patients receiving myeloablative transplantation. Patients receiving NST were at high risk for treatment-related complications given that they were older, 57 vs 43 years (P < .001), and more likely had received previous or myeloablative transplantation (54% vs 2%; P < .0001). The cumulative risk of relapse was higher for patients after NST (61% vs 38%; P = .02). The 100-day mortality was less after NST (15% vs 32%) Overall survival (OS) at 2 years was 28% for NST and 34% for myeloablative transplantation (P = .89). Progression-free survival (PFS) at 2 years was 20% for NST and 31% for myeloablative transplantation (P = .31). Cox regression analysis showed that the intensity of the conditioning regimen had no effect on either OS or PFS. Despite the high-risk features of patients with advanced AML or MDS undergoing NST, OS and PFS in these patients was similar to those in patients receiving myeloablative transplantation. These results demonstrate that dose intensity plays a significant role in control of disease after transplantation, but that this benefit is negated by increasing treatment-related mortality. These results suggest that NST is a reasonable alternative for patients with advanced AML and MDS at high risk for complications after myeloablative transplantation.",Comparative Study,4860.0,148.0,reviewed 136 patients advanced acute myelogenous leukemia AML myelodysplastic syndrome MDS undergoing allogeneic transplantation assess impact conditioning regimen intensity outcome Thirty-nine patients receiving nonmyeloablative stem transplantation NST compared 97 patients receiving myeloablative transplantation Patients receiving NST high risk treatment-related complications given older 57 vs 43 years P .001 likely received previous myeloablative transplantation 54 vs 2 P .0001 cumulative risk relapse higher patients NST 61 vs 38 P .02 100-day mortality NST 15 vs 32 Overall survival OS 2 years 28 NST 34 myeloablative transplantation P .89 Progression-free survival PFS 2 years 20 NST 31 myeloablative transplantation P .31 Cox regression showed intensity conditioning regimen effect OS PFS Despite high-risk features patients advanced AML MDS undergoing NST OS PFS patients similar patients receiving myeloablative transplantation demonstrate dose intensity plays significant role control disease transplantation benefit negated increasing treatment-related mortality suggest NST reasonable alternative patients advanced AML MDS high risk complications myeloablative transplantation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 446, 4829, 7, 5, 131, 286, 2194, 329, 2, 681, 1223, 479, 1063, 497, 6, 423, 3, 345, 1, 1933, 477, 837, 23, 228, 977, 762, 7, 357, 6094, 452, 31, 497, 5976, 11, 72, 5, 1015, 7, 357, 3246, 497, 7, 357, 5976, 11, 28, 64, 43, 9, 24, 139, 521, 447, 17, 491, 11, 434, 696, 105, 601, 60, 19, 144, 2, 80, 322, 42, 103, 698, 15, 3246, 497, 667, 105, 18, 19, 488, 3, 967, 43, 1, 429, 10, 142, 9, 7, 50, 5976, 713, 105, 519, 19, 588, 3, 394, 218, 282, 10, 299, 50, 5976, 167, 105, 531, 63, 25, 118, 28, 18, 60, 10, 339, 9, 5976, 2, 562, 9, 3246, 497, 19, 887, 91, 115, 25, 300, 28, 18, 60, 10, 179, 9, 5976, 2, 456, 9, 3246, 497, 19, 456, 418, 320, 65, 224, 17, 3, 837, 1, 3, 1933, 477, 42, 77, 254, 23, 361, 118, 15, 300, 550, 3, 64, 43, 404, 1, 7, 5, 131, 329, 15, 1223, 479, 5976, 118, 2, 300, 4, 46, 7, 10, 288, 6, 135, 4, 7, 357, 3246, 497, 46, 99, 608, 17, 61, 837, 1698, 8, 93, 200, 4, 182, 1, 34, 50, 497, 84, 17, 26, 247, 16, 21413, 20, 602, 24, 139, 282, 46, 99, 309, 17, 5976, 16, 8, 3203, 1091, 9, 7, 5, 131, 329, 2, 1223, 28, 64, 43, 9, 521, 50, 3246, 497]",1521.0,17067911,Impact conditioning regimen intensity outcome allogeneic hematopoietic transplantation advanced acute myelogenous leukemia myelodysplastic syndrome,23,0.04013961605584642
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia.,Blood,Blood,2006-11-02,"Outcomes for older adults with acute myelogenous leukemia (AML) are poor due to both disease and host-related factors. In this phase 2 study, we tested the oral farnesyltransferase inhibitor tipifarnib in 158 older adults with previously untreated, poor-risk AML. The median age was 74 years, and a majority of patients had antecedent myelodysplastic syndrome. Complete remission (CR) was achieved in 22 patients (14%); partial remission or hematologic improvement occurred in 15 patients, for an overall response rate of 23%. The median duration of CR was 7.3 months and the median survival of complete responders was 18 months. Adverse karyotype, age 75 years or older, and poor performance status correlated negatively with survival. Early death in the absence of progressive disease was rare, and drug-related nonhematologic serious adverse events were observed in 74 patients (47%). Inhibition of farnesylation of the surrogate protein HDJ-2 occurred in the large majority of marrow samples tested. Baseline levels of phosphorylated mitogen-activated protein kinase and AKT did not correlate with clinical response. Tipifarnib is active and well tolerated in older adults with poor-risk AML and may impart a survival advantage in those patients who experience a clinical response.","Clinical Trial, Phase II",4828.0,155.0,Outcomes older adults acute myelogenous leukemia AML poor disease host-related factors phase 2 tested oral farnesyltransferase inhibitor tipifarnib 158 older adults previously untreated poor-risk AML median age 74 years majority patients antecedent myelodysplastic syndrome Complete remission CR achieved 22 patients 14 partial remission hematologic improvement occurred 15 patients overall response rate 23 median duration CR 7.3 months median survival complete responders 18 months Adverse karyotype age 75 years older poor performance status correlated negatively survival Early death absence progressive disease rare drug-related nonhematologic adverse events observed 74 patients 47 Inhibition farnesylation surrogate HDJ-2 occurred large majority marrow tested Baseline levels phosphorylated mitogen-activated kinase AKT correlate clinical response Tipifarnib active tolerated older adults poor-risk AML impart survival advantage patients experience clinical response,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[123, 9, 434, 857, 5, 286, 2194, 329, 32, 334, 520, 6, 110, 34, 2, 1204, 139, 130, 4, 26, 124, 18, 45, 21, 650, 3, 518, 7480, 230, 4781, 4, 5162, 434, 857, 5, 373, 1278, 334, 43, 329, 3, 52, 89, 10, 794, 60, 2, 8, 686, 1, 7, 42, 8775, 681, 236, 734, 684, 10, 513, 4, 350, 7, 213, 450, 734, 15, 813, 767, 489, 4, 167, 7, 9, 35, 63, 51, 116, 1, 382, 3, 52, 654, 1, 684, 10, 67, 27, 53, 2, 3, 52, 25, 1, 236, 1983, 10, 203, 53, 290, 3385, 89, 481, 60, 15, 434, 2, 334, 528, 156, 438, 2723, 5, 25, 191, 273, 4, 3, 1127, 1, 1014, 34, 10, 622, 2, 234, 139, 3534, 1762, 290, 281, 11, 164, 4, 794, 7, 662, 297, 1, 11905, 1, 3, 2592, 178, 26139, 18, 489, 4, 3, 375, 686, 1, 581, 347, 650, 330, 148, 1, 2365, 2625, 735, 178, 216, 2, 649, 205, 44, 1513, 5, 38, 51, 4781, 16, 544, 2, 149, 421, 4, 434, 857, 5, 334, 43, 329, 2, 68, 17138, 8, 25, 1874, 4, 135, 7, 54, 730, 8, 38, 51]",1231.0,17082323,phase 2 farnesyltransferase inhibitor tipifarnib poor-risk elderly patients previously untreated acute myelogenous leukemia,10,0.017452006980802792
"Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2006-12-04,"Cloretazine (VNP40101M) is a sulfonylhydrazine alkylating agent with significant antileukemia activity. A multicenter phase II study of cloretazine was conducted in patients 60 years of age or older with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Cloretazine 600 mg/m2 was administered as a single intravenous infusion. Patients were stratified by age, performance score, cytogenetic risk category, type of AML, and comorbidity. One hundred four patients, median age 72 years (range, 60 to 84 years), were treated on study. Performance status was 2 in 31 patients (30%) and no patient had a favorable karyotype. Forty-seven patients (45%) had cardiac disease, 25 patients (24%) had hepatic disease, and 19 patients (18%) had pulmonary disease, defined as per the Hematopoietic Cell Transplantation-Specific Comorbidity Index, at study entry. The overall response rate was 32%, with 29 patients (28%) achieving complete response (CR) and four patients (4%) achieving CR with incomplete platelet recovery. Response rates in 44 de novo AML patients, 45 secondary AML patients, and 15 high-risk MDS patients were 50%, 11%, and 40%, respectively. Response by cytogenetic risk category was 39% in 56 patients with intermediate cytogenetic risk and 24% in 46 patients with unfavorable cytogenetic risk. Nineteen (18%) patients died within 30 days of receiving cloretazine therapy. Median overall survival was 94 days, with a 1-year survival of 14%; the median duration of survival was 147 days, with a 1-year survival of 28% for those who achieved CR. Cloretazine has significant activity and modest extramedullary toxicity in elderly patients with AML or high-risk MDS. Response rates remain consistent despite increasing age and comorbidity.","Clinical Trial, Phase II",4796.0,66.0,Cloretazine VNP40101M sulfonylhydrazine alkylating agent significant antileukemia activity multicenter phase II cloretazine conducted patients 60 years age older previously untreated acute myeloid leukemia AML high-risk myelodysplastic syndrome MDS Cloretazine 600 mg/m2 administered single intravenous infusion Patients stratified age performance score cytogenetic risk category type AML comorbidity patients median age 72 years range 60 84 years treated Performance status 2 31 patients 30 patient favorable karyotype Forty-seven patients 45 cardiac disease 25 patients 24 hepatic disease 19 patients 18 pulmonary disease defined Hematopoietic Transplantation-Specific Comorbidity Index entry overall response rate 32 29 patients 28 achieving complete response CR patients 4 achieving CR incomplete platelet recovery Response rates 44 novo AML patients 45 secondary AML patients 15 high-risk MDS patients 50 11 40 respectively Response cytogenetic risk category 39 56 patients intermediate cytogenetic risk 24 46 patients unfavorable cytogenetic risk Nineteen 18 patients died 30 days receiving cloretazine therapy Median overall survival 94 days 1-year survival 14 median duration survival 147 days 1-year survival 28 achieved CR Cloretazine significant activity modest extramedullary toxicity elderly patients AML high-risk MDS Response rates remain consistent despite increasing age comorbidity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,"[13948, 17260, 16, 8, 30590, 3410, 420, 5, 93, 9169, 128, 8, 1570, 124, 215, 45, 1, 13948, 10, 426, 4, 7, 335, 60, 1, 89, 15, 434, 5, 373, 1278, 286, 533, 329, 15, 64, 43, 681, 1223, 13948, 2383, 81, 821, 10, 468, 22, 8, 226, 1262, 904, 7, 11, 1173, 20, 89, 528, 368, 1266, 43, 2169, 267, 1, 329, 2, 1879, 104, 1128, 294, 7, 52, 89, 720, 60, 184, 335, 6, 874, 60, 11, 73, 23, 45, 528, 156, 10, 18, 4, 456, 7, 201, 2, 77, 69, 42, 8, 913, 3385, 1213, 648, 7, 512, 42, 34, 243, 7, 259, 42, 939, 34, 2, 326, 7, 203, 42, 1087, 34, 395, 22, 379, 3, 1007, 31, 497, 112, 1879, 558, 28, 45, 3001, 3, 63, 51, 116, 10, 531, 5, 462, 7, 339, 1785, 236, 51, 684, 2, 294, 7, 39, 1785, 684, 5, 2610, 1596, 1602, 51, 151, 4, 584, 1566, 2018, 329, 7, 512, 568, 329, 7, 2, 167, 64, 43, 1223, 7, 11, 212, 175, 2, 327, 106, 51, 20, 1266, 43, 2169, 10, 587, 4, 664, 7, 5, 919, 1266, 43, 2, 259, 4, 641, 7, 5, 2483, 1266, 43, 3498, 203, 7, 1016, 262, 201, 162, 1, 357, 13948, 36, 52, 63, 25, 10, 960, 162, 5, 8, 14, 111, 25, 1, 213, 3, 52, 654, 1, 25, 10, 4961, 162, 5, 8, 14, 111, 25, 1, 339, 9, 135, 54, 513, 684, 13948, 71, 93, 128, 2, 1721, 5508, 155, 4, 1216, 7, 5, 329, 15, 64, 43, 1223, 51, 151, 918, 925, 550, 602, 89, 2, 1879]",1682.0,17146105,Cloretazine VNP40101M novel sulfonylhydrazine alkylating agent patients age 60 years older previously untreated acute myeloid leukemia,0,0.0
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation.,Nature medicine,Nat. Med.,2006-12-10,"Interstitial loss of all or part of the long arm of chromosome 5, or del(5q), is a frequent clonal chromosomal abnormality in human myelodysplastic syndrome (MDS, a preleukemic disorder) and acute myeloid leukemia (AML), and is thought to contribute to the pathogenesis of these diseases by deleting one or more tumor-suppressor genes. Although a major commonly deleted region (CDR) has been delineated on chromosome band 5q31.1 (refs. 3-7), attempts to identify tumor suppressors within this band have been unsuccessful. We focused our analysis of gene expression on RNA from primitive leukemia-initiating cells, which harbor 5q deletions, and analyzed 12 genes within the CDR that are expressed by normal hematopoietic stem cells. Here we show that the gene encoding alpha-catenin (CTNNA1) is expressed at a much lower level in leukemia-initiating stem cells from individuals with AML or MDS with a 5q deletion than in individuals with MDS or AML lacking a 5q deletion or in normal hematopoietic stem cells. Analysis of HL-60 cells, a myeloid leukemia line with deletion of the 5q31 region, showed that the CTNNA1 promoter of the retained allele is suppressed by both methylation and histone deacetylation. Restoration of CTNNA1 expression in HL-60 cells resulted in reduced proliferation and apoptotic cell death. Thus, loss of expression of the alpha-catenin tumor suppressor in hematopoietic stem cells may provide a growth advantage that contributes to human MDS or AML with del(5q).",Journal Article,4790.0,163.0,Interstitial loss long arm chromosome 5 del 5q frequent clonal chromosomal abnormality human myelodysplastic syndrome MDS preleukemic disorder acute myeloid leukemia AML thought contribute pathogenesis diseases deleting tumor-suppressor major commonly deleted region CDR delineated chromosome band 5q31.1 refs 3-7 attempts identify suppressors band unsuccessful focused expression RNA primitive leukemia-initiating harbor 5q deletions 12 CDR expressed normal hematopoietic stem encoding alpha-catenin CTNNA1 expressed lower level leukemia-initiating stem individuals AML MDS 5q deletion individuals MDS AML lacking 5q deletion normal hematopoietic stem HL-60 myeloid leukemia line deletion 5q31 region showed CTNNA1 promoter retained allele suppressed methylation histone deacetylation Restoration CTNNA1 expression HL-60 resulted reduced proliferation apoptotic death loss expression alpha-catenin suppressor hematopoietic stem provide growth advantage contributes human MDS AML del 5q,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4543, 407, 1, 62, 15, 760, 1, 3, 319, 475, 1, 1170, 33, 15, 3084, 5460, 16, 8, 908, 1946, 1860, 3698, 4, 171, 681, 1223, 8, 19788, 2645, 2, 286, 533, 329, 2, 16, 2739, 6, 1248, 6, 3, 1384, 1, 46, 1342, 20, 31039, 104, 15, 80, 30, 1245, 214, 242, 8, 458, 841, 4389, 1053, 13586, 71, 85, 5610, 23, 1170, 7679, 22069, 14, 22067, 27, 67, 4374, 6, 255, 30, 5704, 262, 26, 7679, 47, 85, 7581, 21, 1649, 114, 65, 1, 145, 55, 23, 893, 29, 5594, 2647, 2637, 37, 92, 2760, 5460, 2439, 2, 311, 133, 214, 262, 3, 13586, 17, 32, 570, 20, 295, 1007, 452, 37, 467, 21, 514, 17, 3, 145, 2362, 950, 1778, 17917, 16, 570, 28, 8, 1802, 280, 301, 4, 2647, 2637, 452, 37, 29, 869, 5, 329, 15, 1223, 5, 8, 5460, 1528, 76, 4, 869, 5, 1223, 15, 329, 1941, 8, 5460, 1528, 15, 4, 295, 1007, 452, 37, 65, 1, 1718, 335, 37, 8, 533, 328, 5, 1528, 1, 3, 22069, 1053, 224, 17, 3, 17917, 973, 1, 3, 3532, 1254, 16, 1908, 20, 110, 569, 2, 1508, 15191, 5194, 1, 17917, 55, 4, 1718, 335, 37, 627, 4, 405, 457, 2, 1631, 31, 273, 631, 407, 1, 55, 1, 3, 950, 1778, 30, 1245, 4, 1007, 452, 37, 68, 377, 8, 129, 1874, 17, 2444, 6, 171, 1223, 15, 329, 5, 3084, 5460]",1425.0,17159988,Chromosome 5q deletion epigenetic suppression encoding alpha-catenin CTNNA1 myeloid transformation,9,0.015706806282722512
Evaluation of recurring cytogenetic abnormalities in the treatment of myelodysplastic syndromes.,Leukemia research,Leuk. Res.,2006-12-11,"Myelodysplastic syndromes (MDS) are clinically heterogeneous, but the presence of specific cytogenetic abnormalities can predict disease manifestations, provide a basis for prognosis, and direct treatment. Conventional cytogenetic analysis is instrumental in identifying chromosomal abnormalities in MDS and novel genetic methods may provide supplementary information. Treatment with lenalidomide was recently shown to be effective in MDS, particularly in those cases with del(5q), resulting in durable cytogenetic remission and hematological responses. In this paradigm, diagnosis of the del(5q) abnormality would be essential to predicting response to therapy.",Journal Article,4789.0,40.0,Myelodysplastic syndromes MDS clinically heterogeneous presence specific cytogenetic abnormalities predict disease manifestations provide basis prognosis direct treatment Conventional cytogenetic instrumental identifying chromosomal abnormalities MDS novel genetic methods provide supplementary information Treatment lenalidomide recently shown effective MDS particularly cases del 5q resulting durable cytogenetic remission hematological responses paradigm diagnosis del 5q abnormality essential predicting response therapy,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2040, 1223, 32, 505, 1564, 84, 3, 463, 1, 112, 1266, 1171, 122, 678, 34, 4282, 377, 8, 877, 9, 356, 2, 1196, 24, 809, 1266, 65, 16, 8307, 4, 1386, 1860, 1171, 4, 1223, 2, 229, 336, 636, 68, 377, 14150, 487, 24, 5, 1288, 10, 761, 443, 6, 40, 323, 4, 1223, 823, 4, 135, 140, 5, 3084, 5460, 1113, 4, 1480, 1266, 734, 2, 2890, 253, 4, 26, 2431, 147, 1, 3, 3084, 5460, 3698, 688, 40, 1452, 6, 1434, 51, 6, 36]",632.0,17161457,Evaluation recurring cytogenetic abnormalities treatment myelodysplastic syndromes,5,0.008726003490401396
Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant.,American journal of clinical pathology,Am. J. Clin. Pathol.,2007-02-01,"In practice, cases of therapy-related myelodysplastic syndrome (t-MDS) are often classified according to morphologic schemes used for de novo MDS. However, there are few data addressing the appropriateness of such classification. We studied 155 patients with therapy-related acute myeloid leukemia (t-AML)/t-MDS to determine whether subclassification by the World Health Organization (WHO) criteria for de novo MDS provides prognostic information in t-MDS. In addition, we assessed whether cytogenetic stratification by the International Prognostic Scoring System (IPSS) guidelines or karyotypic complexity was prognostically important. We found no differences in median survival times among patients classified into the different WHO subgroup of MDS or according to their bone marrow blast percentage; our results indicate a uniformly poor outcome in t-MDS regardless of morphologic classification. However, significant survival differences correlated with cytogenetic stratification according to IPSS guidelines and/or karyotypic complexity. We found only a borderline difference in median survival of patients with an initial t-MDS diagnosis compared with patients with an initial t-AML diagnosis.",Journal Article,4737.0,66.0,practice cases therapy-related myelodysplastic syndrome t-MDS classified according morphologic schemes novo MDS addressing appropriateness classification studied 155 patients therapy-related acute myeloid leukemia t-AML /t-MDS determine subclassification World Health Organization criteria novo MDS provides prognostic information t-MDS addition assessed cytogenetic stratification International Prognostic Scoring IPSS guidelines karyotypic complexity prognostically important differences median survival times patients classified different subgroup MDS according bone marrow blast percentage indicate uniformly poor outcome t-MDS regardless morphologic classification significant survival differences correlated cytogenetic stratification according IPSS guidelines and/or karyotypic complexity borderline difference median survival patients initial t-MDS diagnosis compared patients initial t-AML diagnosis,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 758, 140, 1, 36, 139, 681, 102, 1223, 32, 629, 1373, 768, 6, 2815, 7103, 95, 9, 1566, 2018, 1223, 137, 125, 32, 1021, 74, 3432, 3, 4473, 1, 225, 947, 21, 656, 3735, 7, 5, 36, 139, 286, 533, 102, 329, 102, 1223, 6, 223, 317, 9341, 20, 3, 1956, 341, 2533, 54, 371, 9, 1566, 2018, 1223, 777, 177, 487, 4, 102, 1223, 4, 352, 21, 275, 317, 1266, 1541, 20, 3, 944, 177, 2504, 398, 8751, 677, 15, 9465, 3082, 10, 7848, 305, 21, 204, 77, 362, 4, 52, 25, 1072, 107, 7, 1373, 237, 3, 338, 54, 1363, 1, 1223, 15, 768, 6, 136, 581, 3112, 1150, 114, 99, 1008, 8, 4254, 334, 228, 4, 102, 1223, 1583, 1, 2815, 947, 137, 93, 25, 362, 438, 5, 1266, 1541, 768, 6, 8751, 677, 2, 15, 9465, 3082, 21, 204, 158, 8, 2932, 523, 4, 52, 25, 1, 7, 5, 35, 388, 102, 1223, 147, 72, 5, 7, 5, 35, 388, 102, 329, 147]",1151.0,17210514,Therapy-related myelodysplastic syndrome morphologic subclassification clinically relevant,0,0.0
"Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia.",Cancer,Cancer,2007-02-01,"Hypomethylating agents have activity in myelodysplastic syndrome (MDS) and have received approval for the treatment of both MDS and chronic myelomonocytic leukemia (CMML). The specific efficacy in CMML has not been detailed in a large number of patients. The aim of the study was to evaluate the activity and safety of decitabine in CMML. Nineteen adults with a diagnosis of CMML treated on decitabine studies were analyzed. Decitabine was given at 100 mg/m(2) per course every 4 weeks. The median number of courses given was 9 (range, 1-18). Overall, 11 patients (58%) achieved complete response (CR) and 2 (11%) had hematologic improvement (HI), for an overall response rate of 69% according to the modified International Working Group (IWG) criteria. Median survival was 19 months. Severe (grade 3-4) extramedullary side effects were rare. Decitabine is active in CMML. Studies of combinations of decitabine with topoisomerase I inhibitors or other active anti-CMML agents are indicated.",Journal Article,4737.0,84.0,Hypomethylating agents activity myelodysplastic syndrome MDS received approval treatment MDS chronic myelomonocytic leukemia CMML specific efficacy CMML detailed large number patients aim evaluate activity safety decitabine CMML Nineteen adults diagnosis CMML treated decitabine studies Decitabine given 100 mg/m 2 course 4 weeks median number courses given 9 range 1-18 Overall 11 patients 58 achieved complete response CR 2 11 hematologic improvement HI overall response rate 69 according modified International Working Group IWG criteria Median survival 19 months Severe grade 3-4 extramedullary effects rare Decitabine active CMML Studies combinations decitabine topoisomerase inhibitors active anti-CMML agents indicated,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4931, 183, 47, 128, 4, 681, 1223, 2, 47, 103, 1814, 9, 3, 24, 1, 110, 1223, 2, 442, 5451, 3382, 3, 112, 209, 4, 3382, 71, 44, 85, 2455, 4, 8, 375, 207, 1, 7, 3, 1130, 1, 3, 45, 10, 6, 376, 3, 128, 2, 367, 1, 3004, 4, 3382, 3498, 857, 5, 8, 147, 1, 3382, 73, 23, 3004, 94, 11, 311, 3004, 10, 447, 28, 394, 81, 188, 18, 379, 906, 454, 39, 244, 3, 52, 207, 1, 1993, 447, 10, 83, 184, 14, 203, 63, 175, 7, 717, 513, 236, 51, 684, 2, 18, 175, 42, 813, 767, 5910, 9, 35, 63, 51, 116, 1, 790, 768, 6, 3, 1230, 944, 2644, 87, 14620, 371, 52, 25, 10, 326, 53, 905, 88, 27, 39, 5508, 1152, 176, 11, 622, 3004, 16, 544, 4, 3382, 94, 1, 1247, 1, 3004, 5, 3999, 70, 222, 15, 127, 544, 312, 3382, 183, 32, 1103]",929.0,17219444,Activity decitabine hypomethylating agent chronic myelomonocytic leukemia,22,0.038394415357766144
Detrimental effect of natural killer cell alloreactivity in T-replete hematopoietic cell transplantation (HCT) for leukemia patients.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2007-02-01,"In hematopoietic cell transplantation (HCT), natural killer cell alloreactivity conferred by inhibitory ligands of killer immunoglobulin-like receptors (iKIRLs) may result in beneficial or detrimental outcomes. More data may contribute to resolution of this complex issue. We analyzed 378 primary allogeneic transplants with T-replete grafts for acute lymphoblastic leukemia (n = 101), acute myeloid leukemia and myelodysplastic syndrome (n = 149), and chronic myeloid leukemia (n = 128). The cohort was divided into 3 groups: in group 1, HLA class I matched at the antigen level (n = 260); in group 2, HLA class I mismatched at the antigen level (n = 57); and in group 3, HLA class I and iKIRLs mismatched (n = 61). One-year overall survival (OS) across groups 1 (59%), 2 (49%), and 3 (30%) was significantly different (P = .002). In contrast to group 2, group 3 had statistically lower OS (P = .05) and event-free survival (P = .01). Relapse and relapse-free mortality appeared to contribute to the low OS in group 3. The detrimental effect of natural killer alloreactivity was also evident when HLA-matched transplants were analyzed for patients lacking iKIRLs. One-year OS in patients lacking the HLA-Cw group 1 or 2 iKIRL was significantly lower than that in patients having the iKIRLs (55% vs 67%, n = 246, P = .01). Our observations indicate that, in T-replete unrelated HCT, iKIRL mismatches and the absence of iKIRLs confer higher risk to patients after HCT.",Journal Article,4737.0,24.0,hematopoietic transplantation HCT natural killer alloreactivity conferred inhibitory ligands killer immunoglobulin-like receptors iKIRLs beneficial detrimental outcomes contribute resolution complex issue 378 primary allogeneic transplants T-replete grafts acute lymphoblastic leukemia n 101 acute myeloid leukemia myelodysplastic syndrome n 149 chronic myeloid leukemia n 128 cohort divided 3 groups group 1 HLA class matched antigen level n 260 group 2 HLA class mismatched antigen level n 57 group 3 HLA class iKIRLs mismatched n 61 One-year overall survival OS groups 1 59 2 49 3 30 significantly different P .002 contrast group 2 group 3 statistically lower OS P .05 event-free survival P .01 Relapse relapse-free mortality appeared contribute low OS group 3 detrimental effect natural killer alloreactivity evident HLA-matched transplants patients lacking iKIRLs One-year OS patients lacking HLA-Cw group 1 2 iKIRL significantly lower patients iKIRLs 55 vs 67 n 246 P .01 observations indicate T-replete unrelated HCT iKIRL mismatches absence iKIRLs confer higher risk patients HCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 1007, 31, 497, 1085, 1504, 3458, 31, 22039, 3851, 20, 1810, 3123, 1, 3458, 2593, 733, 1186, 31051, 68, 757, 4, 2524, 15, 6227, 123, 80, 74, 68, 1248, 6, 2125, 1, 26, 840, 2537, 21, 311, 10084, 86, 1063, 4016, 5, 102, 11151, 4713, 9, 286, 1275, 78, 2338, 286, 533, 2, 681, 78, 4928, 2, 442, 533, 78, 3990, 3, 180, 10, 2176, 237, 27, 271, 4, 87, 14, 1160, 1040, 70, 655, 28, 3, 448, 301, 78, 6398, 4, 87, 18, 1160, 1040, 70, 5095, 28, 3, 448, 301, 78, 696, 2, 4, 87, 27, 1160, 1040, 70, 2, 31051, 5095, 78, 713, 104, 111, 63, 25, 118, 716, 271, 14, 728, 18, 739, 2, 27, 201, 10, 97, 338, 19, 1111, 4, 748, 6, 87, 18, 87, 27, 42, 712, 280, 118, 19, 474, 2, 774, 115, 25, 19, 355, 429, 2, 429, 115, 282, 2121, 6, 1248, 6, 3, 154, 118, 4, 87, 27, 3, 6227, 254, 1, 1504, 3458, 22039, 10, 120, 2853, 198, 1160, 655, 4016, 11, 311, 9, 7, 1941, 31051, 104, 111, 118, 4, 7, 1941, 3, 1160, 7198, 87, 14, 15, 18, 34209, 10, 97, 280, 76, 17, 4, 7, 1041, 3, 31051, 614, 105, 598, 78, 6907, 19, 355, 114, 2172, 1008, 17, 4, 102, 11151, 2092, 1085, 34209, 11828, 2, 3, 1127, 1, 31051, 2913, 142, 43, 6, 7, 50, 1085]",1339.0,17241925,Detrimental effect natural killer alloreactivity T-replete hematopoietic transplantation HCT leukemia patients,3,0.005235602094240838
"Intravenous busulfan and melphalan, tacrolimus, and short-course methotrexate followed by unmodified HLA-matched related or unrelated hematopoietic stem cell transplantation for the treatment of advanced hematologic malignancies.",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2007-02-01,"Results of allogeneic hematopoietic stem cell transplantation (HCT) to treat advanced leukemia or myelodysplastic syndrome (MDS) remain poor due to excessive relapse and transplant-related mortality. To improve transplant outcome in this patient population, 43 patients (median age, 46.1 years) with high-risk or advanced lymphoid (n = 5) or myeloid malignancy (n = 38) were prospectively enrolled on a pilot trial of cytoreduction with intravenous busulfan and melphalan followed by an unmodified HLA-A, -B, and -DRbeta1-matched related (n = 18) or unrelated (n = 25) HCT. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and methotrexate. Thirty-four patients had > or = 5% blasts at the time of HCT; 12 of these had > 20% blasts. Seventeen patients had unfavorable cytogenetics, 8 patients underwent transplantation for secondary MDS or acute myelogenous leukemia, and 4 patients had relapsed after a previous allogeneic transplantation. Although mucositis was the most significant regimen-related toxicity, requiring the addition of folinic acid rescue and failure to receive all 4 doses of methotrexate in 23 patients, the nonrelapse mortality at 30 and 100 days was low at 0% and 16%, respectively. The cumulative incidence of grade II-IV acute GVHD was 24%, and that of extensive chronic GVHD was 7%. With a minimum follow-up of 18 months, the estimated 3-year overall survival is 37% and the estimated disease-free survival (DFS) is 33%. For 18 patients with MDS (< or = RAEB-2) or high-risk myeloproliferative disorder, the estimated 3 year DFS is 61%. These data demonstrate the curative potential of this regimen in patients with high-risk myeloid malignancies.",Clinical Trial,4737.0,22.0,allogeneic hematopoietic stem transplantation HCT treat advanced leukemia myelodysplastic syndrome MDS remain poor excessive relapse transplant-related mortality improve transplant outcome patient population 43 patients median age 46.1 years high-risk advanced lymphoid n 5 myeloid malignancy n 38 prospectively enrolled pilot trial cytoreduction intravenous busulfan melphalan followed unmodified HLA-A -B -DRbeta1-matched related n 18 unrelated n 25 HCT Graft-versus-host disease GVHD prophylaxis consisted tacrolimus methotrexate Thirty-four patients 5 blasts time HCT 12 20 blasts Seventeen patients unfavorable cytogenetics 8 patients underwent transplantation secondary MDS acute myelogenous leukemia 4 patients relapsed previous allogeneic transplantation mucositis significant regimen-related toxicity requiring addition folinic acid rescue failure receive 4 doses methotrexate 23 patients nonrelapse mortality 30 100 days low 0 16 respectively cumulative incidence grade II-IV acute GVHD 24 extensive chronic GVHD 7 minimum follow-up 18 months estimated 3-year overall survival 37 estimated disease-free survival DFS 33 18 patients MDS RAEB-2 high-risk myeloproliferative disorder estimated 3 year DFS 61 demonstrate curative potential regimen patients high-risk myeloid malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[99, 1, 1063, 1007, 452, 31, 497, 1085, 6, 943, 131, 15, 681, 1223, 918, 334, 520, 6, 4529, 429, 2, 941, 139, 282, 6, 401, 941, 228, 4, 26, 69, 266, 601, 7, 52, 89, 641, 14, 60, 5, 64, 43, 15, 131, 2303, 78, 33, 15, 533, 710, 78, 519, 11, 1143, 346, 23, 8, 2281, 160, 1, 2844, 5, 1262, 3906, 2, 2370, 370, 20, 35, 10424, 1160, 8, 132, 2, 30379, 655, 139, 78, 203, 15, 2092, 78, 243, 1085, 1599, 185, 1204, 34, 1562, 2049, 1695, 1, 5643, 2, 2116, 977, 294, 7, 42, 15, 33, 2438, 28, 3, 98, 1, 1085, 133, 1, 46, 42, 179, 2438, 3591, 7, 42, 2483, 2510, 66, 7, 208, 497, 9, 568, 1223, 15, 286, 2194, 2, 39, 7, 42, 591, 50, 8, 698, 1063, 497, 242, 2606, 10, 3, 96, 93, 477, 139, 155, 1888, 3, 352, 1, 12175, 971, 4256, 2, 496, 6, 560, 62, 39, 415, 1, 2116, 4, 382, 7, 3, 4640, 282, 28, 201, 2, 394, 162, 10, 154, 28, 13, 2, 245, 106, 3, 967, 287, 1, 88, 215, 478, 286, 1562, 10, 259, 2, 17, 1, 1344, 442, 1562, 10, 67, 5, 8, 2499, 166, 126, 1, 203, 53, 3, 661, 27, 111, 63, 25, 16, 567, 2, 3, 661, 34, 115, 25, 1010, 16, 466, 9, 203, 7, 5, 1223, 15, 20273, 18, 15, 64, 43, 2645, 3, 661, 27, 111, 1010, 16, 713, 46, 74, 608, 3, 1075, 174, 1, 26, 477, 4, 7, 5, 64, 43, 533, 441]",1569.0,17241929,Intravenous busulfan melphalan tacrolimus short-course methotrexate followed unmodified HLA-matched related unrelated hematopoietic stem transplantation treatment advanced hematologic malignancies,3,0.005235602094240838
An MLL-SEPT9 fusion and t(11;17)(q23;q25) associated with de novo myelodysplastic syndrome.,Leukemia research,Leuk. Res.,2007-01-23,"Rearrangements of the MLL gene at chromosome 11q23 are uncommon in de novo myelodysplastic syndrome (MDS). Here, we describe molecular findings in a patient with multilineage dysplasia and t(11;17)(q23;q25) who responded to decitabine therapy. Fluorescent in situ hybridization (FISH) demonstrated rearrangement of MLL, while RT-PCR analysis and sequencing identified the transcript fusion partner as SEPT9, a member of the septin family of GTPases. MLL-SEPT9 fusion appears to be rare, having been described to date in only seven cases of AML and not, to our knowledge, in MDS. Analysis of MLL-septin family member fusion products such as the one seen here may provide further insights into the etiology of myeloid neoplasia, and MLL-SEPT9 fusion may be worth seeking in other cases of MLL rearrangements with a translocation partner on chromosome 17q.",Case Reports,4746.0,18.0,Rearrangements MLL chromosome 11q23 uncommon novo myelodysplastic syndrome MDS molecular findings patient multilineage dysplasia 11 17 q23 q25 responded decitabine therapy Fluorescent situ hybridization FISH demonstrated rearrangement MLL RT-PCR sequencing identified transcript fusion partner SEPT9 member septin family GTPases MLL-SEPT9 fusion appears rare described date seven cases AML knowledge MDS MLL-septin family member fusion products seen provide insights etiology myeloid neoplasia MLL-SEPT9 fusion worth seeking cases MLL rearrangements translocation partner chromosome 17q,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2072, 1, 3, 3049, 145, 28, 1170, 7975, 32, 2052, 4, 1566, 2018, 681, 1223, 467, 21, 897, 219, 272, 4, 8, 69, 5, 12471, 2253, 2, 102, 175, 269, 11423, 18837, 54, 2211, 6, 3004, 36, 2910, 4, 957, 1554, 1277, 264, 2675, 1, 3049, 369, 240, 604, 65, 2, 615, 108, 3, 3268, 1212, 4852, 22, 26568, 8, 2693, 1, 3, 44596, 607, 1, 13895, 3049, 26568, 1212, 1233, 6, 40, 622, 1041, 85, 1027, 6, 1244, 4, 158, 648, 140, 1, 329, 2, 44, 6, 114, 922, 4, 1223, 65, 1, 3049, 44596, 607, 2693, 1212, 2766, 225, 22, 3, 104, 527, 467, 68, 377, 195, 1957, 237, 3, 2855, 1, 533, 2298, 2, 3049, 26568, 1212, 68, 40, 9498, 5734, 4, 127, 140, 1, 3049, 2072, 5, 8, 2006, 4852, 23, 1170, 10529]",819.0,17250889,MLL-SEPT9 fusion 11 17 q23 q25 associated novo myelodysplastic syndrome,1,0.0017452006980802793
Risk-based management of myelodysplastic syndrome.,"Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2007-01-01,"Most adult patients with hematopoietic failure due to myelodysplastic syndrome (MDS) are treated with supportive care measures, including hematopoietic growth factors (epoetin alfa, darbepoetin alfa, filgrastim, pegfilgrastim, sargramostim), red blood cell or platelet transfusions, and antimicrobial agents. Allogeneic stem cell transplantation can be curative, but only a small subset of patients are eligible for transplantation, and until recently there were few options other than supportive care for transplant-ineligible patients. Since 2004, the US Food and Drug Administration (FDA) has approved three new therapies specifically for the indication of MDS: two DNA methyltransferase inhibitors (azacitidine and decitabine) and an immunomodulatory agent (lenalidomide). Several other drugs are used by clinicians for treatment of patients with MDS, but are not specifically FDA-approved for this indication. With several therapeutic options available, yet none of them effective in the majority of cases, it can be challenging for clinicians to choose the most appropriate treatment for an individual patient. Here we discuss a risk-based management approach to MDS that incorporates recent data regarding these new therapies. While many questions remain about the optimal use of newer agents, the long-standing perception of MDS as a syndrome where therapeutic nihilism is the only realistic approach is slowly beginning to change.",Journal Article,4768.0,18.0,adult patients hematopoietic failure myelodysplastic syndrome MDS treated supportive care measures including hematopoietic growth factors epoetin alfa darbepoetin alfa filgrastim pegfilgrastim sargramostim red blood platelet transfusions antimicrobial agents Allogeneic stem transplantation curative small subset patients eligible transplantation recently options supportive care transplant-ineligible patients 2004 Food Drug Administration FDA approved new therapies specifically indication MDS DNA methyltransferase inhibitors azacitidine decitabine immunomodulatory agent lenalidomide drugs clinicians treatment patients MDS specifically FDA-approved indication therapeutic options available effective majority cases challenging clinicians choose appropriate treatment individual patient discuss risk-based management approach MDS incorporates recent new therapies questions remain optimal use newer agents long-standing perception MDS syndrome therapeutic nihilism realistic approach slowly beginning change,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[96, 780, 7, 5, 1007, 496, 520, 6, 681, 1223, 32, 73, 5, 1877, 165, 1018, 141, 1007, 129, 130, 7305, 4443, 11502, 4443, 5552, 6005, 15821, 3422, 315, 31, 15, 1596, 4987, 2, 9816, 183, 1063, 452, 31, 497, 122, 40, 1075, 84, 158, 8, 302, 697, 1, 7, 32, 625, 9, 497, 2, 1100, 761, 125, 11, 1021, 838, 127, 76, 1877, 165, 9, 941, 3773, 7, 1192, 1131, 3, 843, 1773, 2, 234, 634, 2078, 71, 850, 169, 217, 235, 1225, 9, 3, 3607, 1, 1223, 100, 261, 3747, 222, 3752, 2, 3004, 2, 35, 2555, 420, 1288, 392, 127, 600, 32, 95, 20, 1490, 9, 24, 1, 7, 5, 1223, 84, 32, 44, 1225, 2078, 850, 9, 26, 3607, 5, 392, 189, 838, 390, 1145, 1292, 1, 1370, 323, 4, 3, 686, 1, 140, 192, 122, 40, 1950, 9, 1490, 6, 6009, 3, 96, 870, 24, 9, 35, 797, 69, 467, 21, 1139, 8, 43, 90, 284, 353, 6, 1223, 17, 6175, 435, 74, 666, 46, 217, 235, 369, 445, 1937, 918, 545, 3, 665, 119, 1, 2246, 183, 3, 319, 10909, 4886, 1, 1223, 22, 8, 681, 1257, 189, 21180, 16, 3, 158, 7661, 353, 16, 7681, 2948, 6, 707]",1391.0,17313156,Risk-based management myelodysplastic syndrome,515,0.8987783595113438
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience.,Cancer,Cancer,2007-03-01,"Decitabine, a hypomethylating agent, is active and has been approved for the treatment of myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia. Intensive chemotherapy is an accepted form of therapy for patients with higher risk MDS. The comparative efficacy of these 2 forms of treatment in MDS is unknown. The objective of the current study was to compare the efficacy and toxicity profiles of decitabine and intensive chemotherapy in MDS. The authors compared lower intensity decitabine therapy (n = 115 patients) with intensive chemotherapy (as it is used in acute myeloid leukemia [AML]) in patients with higher risk MDS. Two comparisons were made with a cohort of 376 historic patients (from 1995 to 2005): The first comparison included a subcohort of 115 patients (Group A) who matched the 115 decitabine study patients according to age, International Prognostic Scoring System, and cytogenetics; and the second comparison included the whole cohort of 376 patients without matching (Group B). A multivariate analysis was performed for outcome. The complete remission (CR) rate according to AML criteria was 43% with decitabine, 46% with intensive chemotherapy in Group A, and 52% with intensive chemotherapy in Group B. Compared with Group A, mortality at 6 weeks was 3% with decitabine versus 13% with intensive chemotherapy (P = .006) and, at 3 months, 7% with decitabine versus 23% with intensive chemotherapy (P = .001). Survival was better with decitabine versus intensive chemotherapy in Group A (median survival: 22 months vs 12 months; P < .001). A multivariate analysis of survival in all 491 patients who received decitabine or intensive chemotherapy (Group B) selected decitabine as an independent, favorable prognostic factor for survival (P = .006; hazard ratio, 0.74) after accounting for the independent prognostic effect of pretreatment factors. In this analysis, decitabine was associated with a survival advantage compared with intensive chemotherapy in patients with higher risk MDS. Future studies should evaluate prospectively the results of decitabine versus intensive chemotherapy in this setting.",Comparative Study,4709.0,139.0,Decitabine hypomethylating agent active approved treatment myelodysplastic syndrome MDS chronic myelomonocytic leukemia Intensive chemotherapy accepted form therapy patients higher risk MDS comparative efficacy 2 forms treatment MDS unknown objective current compare efficacy toxicity profiles decitabine intensive chemotherapy MDS authors compared lower intensity decitabine therapy n 115 patients intensive chemotherapy acute myeloid leukemia AML patients higher risk MDS comparisons cohort 376 historic patients 1995 2005 comparison included subcohort 115 patients Group matched 115 decitabine patients according age International Prognostic Scoring cytogenetics second comparison included cohort 376 patients matching Group B multivariate performed outcome complete remission CR rate according AML criteria 43 decitabine 46 intensive chemotherapy Group 52 intensive chemotherapy Group B Compared Group mortality 6 weeks 3 decitabine versus 13 intensive chemotherapy P .006 3 months 7 decitabine versus 23 intensive chemotherapy P .001 Survival better decitabine versus intensive chemotherapy Group median survival 22 months vs 12 months P .001 multivariate survival 491 patients received decitabine intensive chemotherapy Group B selected decitabine independent favorable prognostic factor survival P .006 hazard ratio 0.74 accounting independent prognostic effect pretreatment factors decitabine associated survival advantage compared intensive chemotherapy patients higher risk MDS Future studies evaluate prospectively decitabine versus intensive chemotherapy setting,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3004, 8, 4931, 420, 16, 544, 2, 71, 85, 850, 9, 3, 24, 1, 681, 1223, 2, 442, 5451, 1686, 56, 16, 35, 3058, 1297, 1, 36, 9, 7, 5, 142, 43, 1223, 3, 2352, 209, 1, 46, 18, 2377, 1, 24, 4, 1223, 16, 860, 3, 461, 1, 3, 291, 45, 10, 6, 932, 3, 209, 2, 155, 1241, 1, 3004, 2, 1686, 56, 4, 1223, 3, 738, 72, 280, 837, 3004, 36, 78, 3670, 7, 5, 1686, 56, 22, 192, 16, 95, 4, 286, 533, 329, 4, 7, 5, 142, 43, 1223, 100, 2213, 11, 1229, 5, 8, 180, 1, 9534, 6875, 7, 29, 2323, 6, 1242, 3, 157, 1155, 159, 8, 23582, 1, 3670, 7, 87, 8, 54, 655, 3, 3670, 3004, 45, 7, 768, 6, 89, 944, 177, 2504, 398, 2, 2510, 2, 3, 419, 1155, 159, 3, 902, 180, 1, 9534, 7, 187, 2616, 87, 132, 8, 331, 65, 10, 173, 9, 228, 3, 236, 734, 684, 116, 768, 6, 329, 371, 10, 601, 5, 3004, 641, 5, 1686, 56, 4, 87, 8, 2, 653, 5, 1686, 56, 4, 87, 132, 72, 5, 87, 8, 282, 28, 49, 244, 10, 27, 5, 3004, 185, 233, 5, 1686, 56, 19, 1861, 2, 28, 27, 53, 67, 5, 3004, 185, 382, 5, 1686, 56, 19, 144, 25, 10, 380, 5, 3004, 185, 1686, 56, 4, 87, 8, 52, 25, 350, 53, 105, 133, 53, 19, 144, 8, 331, 65, 1, 25, 4, 62, 10333, 7, 54, 103, 3004, 15, 1686, 56, 87, 132, 715, 3004, 22, 35, 306, 913, 177, 161, 9, 25, 19, 1861, 360, 197, 13, 794, 50, 3116, 9, 3, 306, 177, 254, 1, 1194, 130, 4, 26, 65, 3004, 10, 41, 5, 8, 25, 1874, 72, 5, 1686, 56, 4, 7, 5, 142, 43, 1223, 508, 94, 257, 376, 1143, 3, 99, 1, 3004, 185, 1686, 56, 4, 26, 546]",2033.0,17315156,Survival advantage decitabine versus intensive chemotherapy patients higher risk myelodysplastic syndrome comparison historical experience,9,0.015706806282722512
Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer.,Pharmacotherapy,Pharmacotherapy,2007-03-01,"Anemia is common in patients with cancer or myelodysplastic syndrome. Erythropoietic therapy offers an effective way to manage anemia by increasing hemoglobin levels, decreasing transfusion requirements, and alleviating symptoms. We reviewed data showing the feasibility and effectiveness of treatment with the erythropoiesis-stimulating protein darbepoetin alfa at extended dosing intervals to treat anemia in patients with cancer receiving multicycle chemotherapy. We also explored the darbepoetin alfa's potential for treating anemia in patients with myelodysplastic syndrome. Data from clinical studies and drug therapy evaluations confirm that darbepoetin alfa administered weekly, every 2 weeks, and every 3 weeks corrects and maintains hemoglobin levels in patients with chemotherapy-induced anemia. In addition, the data demonstrate that both weight-based and fixed dosing with darbepoetin alfa are effective, and that early intervention to treat anemia has clinical benefits. Darbepoetin alfa also is an effective treatment for anemia in patients with cancer not receiving chemotherapy, at extended dosing intervals of at least 3 weeks. Extended dosing for anemia treatment can provide benefits for patients, caregivers, and clinicians because it reduces the number of clinic visits needed and permits synchronizing anemia treatment with chemotherapy cycles. Data from recent studies suggest that darbepoetin alfa is effective for treating anemia in patients with myelodysplastic syndrome; this potential use is being investigated further in ongoing studies. Thus, darbepoetin alfa is an attractive therapy option for patients with chemotherapy or cancer-induced anemia. It allows increased flexibility and simplified dosing and may offer some benefit in the treatment of anemia in patients with myelodysplastic syndrome.",Journal Article,4709.0,3.0,Anemia common patients myelodysplastic syndrome Erythropoietic therapy offers effective way manage anemia increasing hemoglobin levels decreasing transfusion requirements alleviating symptoms reviewed showing feasibility effectiveness treatment erythropoiesis-stimulating darbepoetin alfa extended dosing intervals treat anemia patients receiving multicycle chemotherapy explored darbepoetin alfa 's potential treating anemia patients myelodysplastic syndrome clinical studies drug therapy evaluations confirm darbepoetin alfa administered weekly 2 weeks 3 weeks corrects maintains hemoglobin levels patients chemotherapy-induced anemia addition demonstrate weight-based fixed dosing darbepoetin alfa effective early intervention treat anemia clinical benefits Darbepoetin alfa effective treatment anemia patients receiving chemotherapy extended dosing intervals 3 weeks Extended dosing anemia treatment provide benefits patients caregivers clinicians reduces number clinic visits needed permits synchronizing anemia treatment chemotherapy cycles recent studies suggest darbepoetin alfa effective treating anemia patients myelodysplastic syndrome potential use investigated ongoing studies darbepoetin alfa attractive therapy option patients chemotherapy cancer-induced anemia allows increased flexibility simplified dosing offer benefit treatment anemia patients myelodysplastic syndrome,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1545, 16, 186, 4, 7, 5, 12, 15, 681, 14276, 36, 2339, 35, 323, 2255, 6, 4001, 1545, 20, 602, 2222, 148, 2777, 2785, 4230, 2, 12956, 507, 21, 446, 74, 2069, 3, 1437, 2, 1236, 1, 24, 5, 3, 10297, 2122, 178, 11502, 4443, 28, 1747, 1280, 1582, 6, 943, 1545, 4, 7, 5, 12, 357, 30515, 56, 21, 120, 1443, 3, 11502, 4443, 292, 174, 9, 1367, 1545, 4, 7, 5, 681, 74, 29, 38, 94, 2, 234, 36, 3816, 1843, 17, 11502, 4443, 468, 709, 454, 18, 244, 2, 454, 27, 244, 28233, 2, 8107, 2222, 148, 4, 7, 5, 56, 277, 1545, 4, 352, 3, 74, 608, 17, 110, 924, 90, 2, 1959, 1280, 5, 11502, 4443, 32, 323, 2, 17, 191, 788, 6, 943, 1545, 71, 38, 1141, 11502, 4443, 120, 16, 35, 323, 24, 9, 1545, 4, 7, 5, 12, 44, 357, 56, 28, 1747, 1280, 1582, 1, 28, 506, 27, 244, 1747, 1280, 9, 1545, 24, 122, 377, 1141, 9, 7, 2771, 2, 1490, 408, 192, 2389, 3, 207, 1, 1188, 2690, 575, 2, 8504, 31063, 1545, 24, 5, 56, 410, 74, 29, 435, 94, 309, 17, 11502, 4443, 16, 323, 9, 1367, 1545, 4, 7, 5, 681, 26, 174, 119, 16, 486, 565, 195, 4, 942, 94, 631, 11502, 4443, 16, 35, 3059, 36, 1501, 9, 7, 5, 56, 15, 12, 277, 1545, 192, 2333, 101, 9794, 2, 8087, 1280, 2, 68, 1918, 476, 247, 4, 3, 24, 1, 1545, 4, 7, 5, 681]",1745.0,17316154,Darbepoetin alfa effective treatment flexible simplified dosing anemia patients,0,0.0
Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?,Best practice & research. Clinical haematology,Best Pract Res Clin Haematol,2007-03-01,"Secondary leukemia is a poorly defined term that often refers to the development of acute myeloid leukemia (AML) following the history of a previous disease, such as a myelodysplastic syndrome or a chronic myeloproliferative disorder. Secondary leukemia can also be a consequence of treatment with chemotherapy, including alkylating agents and topoisomerase II inhibitors, and/or radiotherapy, or due to exposure to environmental carcinogens. Outcomes for this large and variable group of patients with secondary AML have been poor compared to people who develop AML de novo. The question arises whether a diagnosis of secondary leukemia per se indicates a poor prognosis or whether their bad outcomes result from an association with certain morphologic and biologic characteristics. Morphologic dysplasia in de novo AML is related to unfavorable cytogenetics, but has no independent prognostic relevance under the conditions of intensive chemotherapy. While there is no significant correlation between cytogenetic risk groups and dysplasia, cytogenetic features do have an impact on outcome among both de novo and secondary AML patients. In various subgroups of secondary AML, the spectrum of cytogenetic abnormalities is similar to de novo AML, but the frequency of abnormalities associated with unfavorable and intermediate risk cytogenetics, such as a complex karyotype, trisomy 8, monosomy 7, and others, is higher in secondary AML. The survival of patients with therapy-related myeloid leukemia (t-AML) is generally shorter than for those with de novo AML within the same cytogenetic risk group. Across the population of t-AML, however, survival varies according to cytogenetic risk group, with longer survival in patients with favorable-risk karyotypes. The term secondary AML is too broad and imprecise to be of importance and should not be used. These AML patients should be enrolled on front-line chemotherapy trials and should be stratified by pretreatment disease status and exposure history, if necessary. Most importantly, the molecular and genetic differences that appear to determine the phenotype and the outcome of these patients need to be investigated further.",Journal Article,4709.0,55.0,Secondary leukemia poorly defined term refers development acute myeloid leukemia AML following history previous disease myelodysplastic syndrome chronic myeloproliferative disorder Secondary leukemia consequence treatment chemotherapy including alkylating agents topoisomerase II inhibitors and/or radiotherapy exposure environmental carcinogens Outcomes large variable group patients secondary AML poor compared people develop AML novo question arises diagnosis secondary leukemia se indicates poor prognosis bad outcomes association certain morphologic biologic characteristics Morphologic dysplasia novo AML related unfavorable cytogenetics independent prognostic relevance conditions intensive chemotherapy significant correlation cytogenetic risk groups dysplasia cytogenetic features impact outcome novo secondary AML patients subgroups secondary AML spectrum cytogenetic abnormalities similar novo AML frequency abnormalities associated unfavorable intermediate risk cytogenetics complex karyotype trisomy 8 monosomy 7 higher secondary AML survival patients therapy-related myeloid leukemia t-AML generally shorter novo AML cytogenetic risk group population t-AML survival varies according cytogenetic risk group longer survival patients favorable-risk karyotypes term secondary AML broad imprecise importance AML patients enrolled front-line chemotherapy trials stratified pretreatment disease status exposure history necessary importantly molecular genetic differences appear determine phenotype outcome patients need investigated,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[568, 16, 8, 1240, 395, 337, 17, 629, 11312, 6, 3, 193, 1, 286, 533, 329, 366, 3, 532, 1, 8, 698, 34, 225, 22, 8, 681, 15, 8, 442, 2645, 568, 122, 120, 40, 8, 4177, 1, 24, 5, 56, 141, 3410, 183, 2, 3999, 215, 222, 2, 15, 310, 15, 520, 6, 645, 6, 3766, 8850, 123, 9, 26, 375, 2, 1347, 87, 1, 7, 5, 568, 329, 47, 85, 334, 72, 6, 3788, 54, 690, 329, 1566, 2018, 3, 2840, 6053, 317, 8, 147, 1, 568, 379, 3428, 2640, 8, 334, 356, 15, 317, 136, 5618, 123, 757, 29, 35, 248, 5, 1840, 2815, 2, 1283, 374, 2815, 2253, 4, 1566, 2018, 329, 16, 139, 6, 2483, 2510, 84, 71, 77, 306, 177, 2088, 669, 3, 1298, 1, 1686, 56, 369, 125, 16, 77, 93, 816, 59, 1266, 43, 271, 2, 2253, 1266, 404, 1022, 47, 35, 345, 23, 228, 107, 110, 1566, 2018, 2, 568, 329, 7, 4, 747, 1453, 1, 568, 329, 3, 1873, 1, 1266, 1171, 16, 288, 6, 1566, 2018, 329, 84, 3, 675, 1, 1171, 41, 5, 2483, 2, 919, 43, 2510, 225, 22, 8, 840, 3385, 6317, 66, 7521, 67, 2, 1749, 16, 142, 4, 568, 329, 3, 25, 1, 7, 5, 36, 139, 533, 102, 329, 16, 1228, 985, 76, 9, 135, 5, 1566, 2018, 329, 262, 3, 827, 1266, 43, 87, 716, 3, 266, 1, 102, 329, 137, 25, 4037, 768, 6, 1266, 43, 87, 5, 589, 25, 4, 7, 5, 913, 43, 6809, 3, 337, 568, 329, 16, 5044, 2094, 2, 18486, 6, 40, 1, 1187, 2, 257, 44, 40, 95, 46, 329, 7, 257, 40, 346, 23, 3007, 328, 56, 143, 2, 257, 40, 1173, 20, 1194, 34, 156, 2, 645, 532, 492, 1493, 96, 1859, 3, 219, 2, 336, 362, 17, 1322, 6, 223, 3, 1005, 2, 3, 228, 1, 46, 7, 594, 6, 40, 565, 195]",2066.0,17336252,secondary leukemia independent poor prognostic factor acute myeloid leukemia,94,0.16404886561954624
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.,Blood,Blood,2007-03-06,"Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis with potential for progression to acute myeloid leukemia (AML). We compared natural killer (NK) cytolytic function in 48 MDS patients with 37 healthy donors and found reduced activity in the patient population (K562 cytolysis, 19% +/- 21% SD versus 40% +/- 17%) (P < .001). NK cytotoxicity in MDS patients was reduced against 3 disparate tumor targets with differential activating receptor requirement, suggesting global defects in NK function. Reduced NK function in MDS was significantly associated with higher International Prognostic Score (P = .01), abnormal karyotype (P = .05), the presence of excess blasts (P = .01), and age-adjusted bone marrow hypercellularity (P = .04). MDS patients had a display of the activating receptor NKp30, and NKG2D down-regulation closely correlated with impaired NK function (P = .001). NKG2D ligands (MICA and MICB) were expressed on CD34(+) cells from bone marrow of 30% of MDS patients and a leukemic cell line derived from an MDS patient (MDS1). Collectively, these findings suggest that impairment of NK cytolytic function derives in part from reduced activating NK receptors such as NKG2D in association with disease progression. Evasion of NK immunosurveillance may have importance for MDS disease progression.",Journal Article,4704.0,131.0,Myelodysplastic syndromes MDS characterized ineffective hematopoiesis potential progression acute myeloid leukemia AML compared natural killer NK cytolytic function 48 MDS patients 37 healthy donors reduced activity patient population K562 cytolysis 19 +/- 21 SD versus 40 +/- 17 P .001 NK cytotoxicity MDS patients reduced 3 disparate targets differential activating receptor requirement suggesting global defects NK function Reduced NK function MDS significantly associated higher International Prognostic Score P .01 abnormal karyotype P .05 presence excess blasts P .01 age-adjusted bone marrow hypercellularity P .04 MDS patients display activating receptor NKp30 NKG2D down-regulation closely correlated impaired NK function P .001 NKG2D ligands MICA MICB expressed CD34 bone marrow 30 MDS patients leukemic line derived MDS patient MDS1 Collectively findings suggest impairment NK cytolytic function derives reduced activating NK receptors NKG2D association disease progression Evasion NK immunosurveillance importance MDS disease progression,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2040, 1223, 32, 765, 20, 3957, 5114, 5, 174, 9, 91, 6, 286, 533, 329, 21, 72, 1504, 3458, 1765, 6957, 343, 4, 576, 1223, 7, 5, 567, 1331, 2344, 2, 204, 405, 128, 4, 3, 69, 266, 5208, 18878, 326, 239, 1270, 185, 327, 269, 19, 144, 1765, 1408, 4, 1223, 7, 10, 405, 480, 27, 7985, 30, 637, 5, 1777, 1616, 153, 4701, 802, 1648, 2945, 4, 1765, 343, 405, 1765, 343, 4, 1223, 10, 97, 41, 5, 142, 944, 177, 368, 19, 355, 1668, 3385, 19, 474, 3, 463, 1, 2612, 2438, 19, 355, 2, 89, 586, 581, 21040, 19, 755, 1223, 7, 42, 8, 3640, 1, 3, 1616, 153, 38382, 2, 6677, 1328, 863, 3210, 438, 5, 2364, 1765, 343, 19, 144, 6677, 3123, 6804, 2, 21443, 11, 570, 23, 2215, 37, 29, 581, 1, 201, 1, 1223, 7, 2, 8, 2015, 31, 328, 526, 29, 35, 1223, 69, 38383, 2535, 46, 272, 309, 17, 2315, 1, 1765, 6957, 343, 17214, 4, 760, 29, 405, 1616, 1765, 1186, 225, 22, 6677, 4, 248, 5, 34, 91, 5351, 1, 1765, 15169, 68, 47, 1187, 9, 1223, 34, 91]",1242.0,17341666,Reduced natural killer NK function associated high-risk myelodysplastic syndrome MDS reduced expression activating NK receptors,0,0.0
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2007-02-08,"Reduced-intensity conditioning has extended the use of allogeneic hematopoietic stem cell transplantation (HSCT) to patients otherwise not eligible for this treatment due to older age or frailty. One hundred twelve acute myelogenous leukemia/myelodysplastic syndromes patients received fludarabine and melphalan (FM) conditioning with allogeneic HSCT. Most patients (73%) were not in remission. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus and mini-methotrexate. Median age was 55 years (range, 22-74). Donors were related (53%) and unrelated (47%). Median follow-up of surviving patients (n = 43) was 29.4 months (range, 13.1-87.7). The complete remission (CR) rate was 82%. Estimates of 2-year survival were 66%, 40%, and 23% for patients in CR, with active disease without and with circulating blasts at HSCT, respectively. In multivariate analysis, survival was negatively influenced by active disease at HSCT and development of grade II-IV acute GVHD. Presence of circulating blasts at HSCT negatively influenced freedom from disease progression. Incidence of nonrelapse mortality (NRM) was significantly higher for patients with active disease, but was not influenced by patient age. Patients in CR had a day-100 and 2-year NRM of 0% and 20%, respectively. Use of unrelated donors increased the risk of NRM only among patients with active disease. FM and HSCT elicited long-term disease control in a significant fraction of this high-risk cohort.",Clinical Trial,4730.0,91.0,Reduced-intensity conditioning extended use allogeneic hematopoietic stem transplantation HSCT patients eligible treatment older age frailty acute myelogenous leukemia/myelodysplastic syndromes patients received fludarabine melphalan FM conditioning allogeneic HSCT patients 73 remission Graft-versus-host disease GVHD prophylaxis consisted tacrolimus mini-methotrexate Median age 55 years range 22-74 Donors related 53 unrelated 47 Median follow-up surviving patients n 43 29.4 months range 13.1-87.7 complete remission CR rate 82 Estimates 2-year survival 66 40 23 patients CR active disease circulating blasts HSCT respectively multivariate survival negatively influenced active disease HSCT development grade II-IV acute GVHD Presence circulating blasts HSCT negatively influenced freedom disease progression Incidence nonrelapse mortality NRM significantly higher patients active disease influenced patient age Patients CR day-100 2-year NRM 0 20 respectively Use unrelated donors increased risk NRM patients active disease FM HSCT elicited long-term disease control significant fraction high-risk cohort,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[405, 837, 1933, 71, 1747, 3, 119, 1, 1063, 1007, 452, 31, 497, 1703, 6, 7, 2632, 44, 625, 9, 26, 24, 520, 6, 434, 89, 15, 5289, 104, 1128, 2544, 286, 2194, 2647, 10589, 2040, 7, 103, 2027, 2, 2370, 14228, 1933, 5, 1063, 1703, 96, 7, 803, 11, 44, 4, 734, 1599, 185, 1204, 34, 1562, 2049, 1695, 1, 5643, 2, 7313, 2116, 52, 89, 10, 614, 60, 184, 350, 794, 2344, 11, 139, 699, 2, 2092, 662, 52, 166, 126, 1, 3050, 7, 78, 601, 10, 462, 39, 53, 184, 233, 14, 912, 67, 3, 236, 734, 684, 116, 10, 878, 1423, 1, 18, 111, 25, 11, 700, 327, 2, 382, 9, 7, 4, 684, 5, 544, 34, 187, 2, 5, 1033, 2438, 28, 1703, 106, 4, 331, 65, 25, 10, 2723, 2574, 20, 544, 34, 28, 1703, 2, 193, 1, 88, 215, 478, 286, 1562, 463, 1, 1033, 2438, 28, 1703, 2723, 2574, 3060, 29, 34, 91, 287, 1, 4640, 282, 4296, 10, 97, 142, 9, 7, 5, 544, 34, 84, 10, 44, 2574, 20, 69, 89, 7, 4, 684, 42, 8, 218, 394, 2, 18, 111, 4296, 1, 13, 2, 179, 106, 119, 1, 2092, 2344, 101, 3, 43, 1, 4296, 158, 107, 7, 5, 544, 34, 14228, 2, 1703, 5179, 319, 337, 34, 182, 4, 8, 93, 1509, 1, 26, 64, 43, 180]",1419.0,17382251,Allogeneic hematopoietic stem transplantation treatment high-risk acute myelogenous leukemia myelodysplastic syndrome reduced-intensity conditioning fludarabine melphalan,1,0.0017452006980802793
"Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders.",Blood,Blood,2007-04-09,"Loss of a whole chromosome 5 or a deletion of the long arm, del(5q), is a recurring abnormality in myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML). To identify a leukemia-related gene on chromosome 5, we previously delineated a 970-kb segment of 5q31 that is deleted in all patients examined, and prepared a transcript map of this region. EGR1 is a candidate tumor suppressor gene within the commonly deleted segment of 5q, and encodes a zinc finger transcription factor. To test the hypothesis that loss of function of Egr1 is an initiating event in the pathogenesis of AML/MDS, Egr1-deficient mice were treated with a potent DNA alkylating agent, N-ethyl-nitrosourea (ENU), to induce secondary cooperating mutations. Egr1(+/-) and Egr1(-/-) mice treated with ENU developed immature T-cell lymphomas (CD4(+), CD8(+)) or a myeloproliferative disorder (MPD) at increased rates and with shorter latencies than that of wild-type littermates. The MPD was characterized by an elevated white blood cell count, anemia, and thrombocytopenia with ineffective erythropoiesis. Biallelic mutations of Egr1 were not observed in MPDs in Egr1(+/-) mice. Our data suggest that haploinsufficiency for Egr1 plays a role in murine leukemogenesis, and in the development of AML/MDS characterized by abnormalities of chromosome 5.",Journal Article,4670.0,169.0,Loss chromosome 5 deletion long arm del 5q recurring abnormality myelodysplastic syndromes MDSs acute myeloid leukemia AML identify leukemia-related chromosome 5 previously delineated 970-kb segment 5q31 deleted patients examined prepared transcript map region EGR1 candidate suppressor commonly deleted segment 5q encodes zinc finger transcription factor test hypothesis loss function Egr1 initiating event pathogenesis AML/MDS Egr1-deficient mice treated potent DNA alkylating agent N-ethyl-nitrosourea ENU induce secondary cooperating Egr1 +/- Egr1 -/- mice treated ENU developed immature T-cell lymphomas CD4 CD8 myeloproliferative disorder MPD increased rates shorter latencies wild-type littermates MPD characterized elevated white blood count anemia thrombocytopenia ineffective erythropoiesis Biallelic Egr1 observed MPDs Egr1 +/- mice suggest haploinsufficiency Egr1 plays role murine leukemogenesis development AML/MDS characterized abnormalities chromosome 5,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[407, 1, 8, 902, 1170, 33, 15, 8, 1528, 1, 3, 319, 475, 3084, 5460, 16, 8, 6385, 3698, 4, 2040, 13550, 2, 286, 533, 329, 6, 255, 8, 2647, 139, 145, 23, 1170, 33, 21, 373, 5610, 8, 14280, 5116, 4610, 1, 22069, 17, 16, 4389, 4, 62, 7, 409, 2, 4421, 8, 3268, 3771, 1, 26, 1053, 11258, 16, 8, 1609, 30, 1245, 145, 262, 3, 841, 4389, 4610, 1, 5460, 2, 4322, 8, 5988, 8079, 866, 161, 6, 412, 3, 1492, 17, 407, 1, 343, 1, 11258, 16, 35, 2637, 774, 4, 3, 1384, 1, 329, 1223, 11258, 1971, 399, 11, 73, 5, 8, 1157, 261, 3410, 420, 78, 10559, 8305, 23522, 6, 1290, 568, 11413, 138, 11258, 2, 11258, 399, 73, 5, 23522, 276, 5733, 102, 31, 1557, 1440, 968, 15, 8, 2645, 7712, 28, 101, 151, 2, 5, 985, 44691, 76, 17, 1, 955, 267, 17780, 3, 7712, 10, 765, 20, 35, 804, 886, 315, 31, 1276, 1545, 2, 1340, 5, 3957, 10297, 6435, 138, 1, 11258, 11, 44, 164, 4, 24840, 4, 11258, 399, 114, 74, 309, 17, 9292, 9, 11258, 1698, 8, 200, 4, 1471, 5661, 2, 4, 3, 193, 1, 329, 1223, 765, 20, 1171, 1, 1170, 33]",1243.0,17420284,Haploinsufficiency EGR1 candidate del 5q leads development myeloid disorders,0,0.0
Impact of cytogenetics on outcome of de novo and therapy-related AML and MDS after allogeneic transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2007-03-21,"Cytogenetics has an important impact on the prognosis of patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS). However, it is unclear whether currently accepted cytogenetic risk groups, which were established for patients treated mostly with standard therapy, are optimally discriminating for patients undergoing HSCT. Also, the impact of cytogenetics in the growing population of patients with therapy-related disease has not been completely elucidated. In this study, we retrospectively analyzed data on 556 patients with AML or MDS transplanted at our institution. We examined, in multivariate analyses, the contribution of cytogenetics to survival, relapse, and nonrelapse mortality for the 476 patients with de novo disease. We used these results to establish an optimal cytogenetic grouping scheme. We then applied this grouping scheme to the 80 patients with therapy-related disease. Our proposed 3-group cytogenetic classification outperformed the established grouping schemes for both de novo and therapy-related disease. When classified by this new scheme, cytogenetics was the strongest prognostic factor for overall survival in our cohort, through its impact on the risk of relapse (and not on nonrelapse mortality). After accounting for cytogenetics, patients with therapy-related AML or MDS had an equivalent outcome to those with de novo disease. This study demonstrates the impact of cytogenetics on the risk of relapse and death for patients with both de novo and therapy-related disease undergoing transplantation; it also emphasizes the necessity of using cytogenetics to stratify patients entering clinical trials, and provides a system for doing so, which can be validated in a multi-institutional database.",Journal Article,4689.0,111.0,Cytogenetics important impact prognosis patients undergoing allogeneic hematopoietic stem transplantation HSCT acute myelogenous leukemia AML myelodysplastic syndromes MDS unclear currently accepted cytogenetic risk groups established patients treated standard therapy optimally discriminating patients undergoing HSCT impact cytogenetics growing population patients therapy-related disease completely elucidated retrospectively 556 patients AML MDS transplanted institution examined multivariate contribution cytogenetics survival relapse nonrelapse mortality 476 patients novo disease establish optimal cytogenetic grouping scheme applied grouping scheme 80 patients therapy-related disease proposed 3-group cytogenetic classification outperformed established grouping schemes novo therapy-related disease classified new scheme cytogenetics strongest prognostic factor overall survival cohort impact risk relapse nonrelapse mortality accounting cytogenetics patients therapy-related AML MDS equivalent outcome novo disease demonstrates impact cytogenetics risk relapse death patients novo therapy-related disease undergoing transplantation emphasizes necessity cytogenetics stratify patients entering clinical trials provides validated multi-institutional database,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2510, 71, 35, 305, 345, 23, 3, 356, 1, 7, 479, 1063, 1007, 452, 31, 497, 1703, 9, 286, 2194, 329, 15, 2040, 1223, 137, 192, 16, 1200, 317, 694, 3058, 1266, 43, 271, 92, 11, 635, 9, 7, 73, 2754, 5, 260, 36, 32, 5074, 8059, 9, 7, 479, 1703, 120, 3, 345, 1, 2510, 4, 3, 1921, 266, 1, 7, 5, 36, 139, 34, 71, 44, 85, 2500, 3901, 4, 26, 45, 21, 894, 311, 74, 23, 12341, 7, 5, 329, 15, 1223, 4600, 28, 114, 731, 21, 409, 4, 331, 318, 3, 2925, 1, 2510, 6, 25, 429, 2, 4640, 282, 9, 3, 10652, 7, 5, 1566, 2018, 34, 21, 95, 46, 99, 6, 1811, 35, 665, 1266, 6946, 4633, 21, 818, 1498, 26, 6946, 4633, 6, 3, 493, 7, 5, 36, 139, 34, 114, 1587, 27, 87, 1266, 947, 9504, 3, 635, 6946, 7103, 9, 110, 1566, 2018, 2, 36, 139, 34, 198, 1373, 20, 26, 217, 4633, 2510, 10, 3, 3311, 177, 161, 9, 63, 25, 4, 114, 180, 298, 211, 345, 23, 3, 43, 1, 429, 2, 44, 23, 4640, 282, 50, 3116, 9, 2510, 7, 5, 36, 139, 329, 15, 1223, 42, 35, 2017, 228, 6, 135, 5, 1566, 2018, 34, 26, 45, 1902, 3, 345, 1, 2510, 23, 3, 43, 1, 429, 2, 273, 9, 7, 5, 110, 1566, 2018, 2, 36, 139, 34, 479, 497, 192, 120, 7519, 3, 7378, 1, 75, 2510, 6, 3570, 7, 7653, 38, 143, 2, 777, 8, 398, 9, 9647, 1743, 92, 122, 40, 938, 4, 8, 1414, 1115, 609]",1766.0,17531775,Impact cytogenetics outcome novo therapy-related AML MDS allogeneic transplantation,2,0.0034904013961605585
"Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.",Blood,Blood,2007-06-27,"The combination of a DNA hypomethylating agent with a histone deacetylase inhibitor has synergistic antileukemia activity and may restore sensitivity to all-trans retinoic acid (ATRA). We conducted a phase 1/2 study of the combination of 5-azacitidine (5-AZA), valproic acid (VPA), and ATRA in patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. 5-AZA was administered subcutaneously at a fixed dose of 75 mg/m(2) daily for 7 days. VPA was dose-escalated and given orally daily for 7 days concomitantly with 5-AZA. ATRA was given at 45 mg/m(2) orally daily for 5 days, starting on day 3. A total of 53 patients were treated. Their median age was 69 years (range, 5-84 years). The maximum tolerated dose of VPA in this combination was 50 mg/kg daily for 7 days. Dose-limiting toxicity was reversible neurotoxicity. The overall response rate was 42%. In previously untreated older patients, the response rate was 52%. Median number of courses to response was 1 (range, 1-3 courses). Median remission duration was 26 weeks, and median survival has not been reached. A significant decrease in global DNA methylation and induction of histone acetylation were achieved. VPA blood levels were higher in responders (P < .005). In conclusion, the combination studied is safe and has significant clinical activity. This clinical trial was registered at www.clinicaltrials.gov as no. NCT00326170.","Clinical Trial, Phase I",4591.0,330.0,combination DNA hypomethylating agent histone deacetylase inhibitor synergistic antileukemia activity restore sensitivity all-trans retinoic acid ATRA conducted phase 1/2 combination 5-azacitidine 5-AZA valproic acid VPA ATRA patients acute myeloid leukemia high-risk myelodysplastic syndrome 5-AZA administered subcutaneously fixed dose 75 mg/m 2 daily 7 days VPA dose-escalated given orally daily 7 days concomitantly 5-AZA ATRA given 45 mg/m 2 orally daily 5 days starting day 3 total 53 patients treated median age 69 years range 5-84 years maximum tolerated dose VPA combination 50 mg/kg daily 7 days Dose-limiting toxicity reversible neurotoxicity overall response rate 42 previously untreated older patients response rate 52 Median number courses response 1 range 1-3 courses Median remission duration 26 weeks median survival reached significant decrease global DNA methylation induction histone acetylation achieved VPA blood levels higher responders P .005 combination studied safe significant clinical activity clinical trial registered www.clinicaltrials.gov NCT00326170,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 150, 1, 8, 261, 4931, 420, 5, 8, 1508, 2732, 230, 71, 1806, 9169, 128, 2, 68, 6075, 485, 6, 62, 3437, 3887, 971, 2822, 21, 426, 8, 124, 14, 18, 45, 1, 3, 150, 1, 33, 3752, 33, 3924, 11029, 971, 6770, 2, 2822, 4, 7, 5, 286, 533, 15, 64, 43, 681, 33, 3924, 10, 468, 3928, 28, 8, 1959, 61, 1, 481, 81, 188, 18, 391, 9, 67, 162, 6770, 10, 61, 2842, 2, 447, 1428, 391, 9, 67, 162, 6485, 5, 33, 3924, 2822, 10, 447, 28, 512, 81, 188, 18, 1428, 391, 9, 33, 162, 1723, 23, 218, 27, 8, 181, 1, 699, 7, 11, 73, 136, 52, 89, 10, 790, 60, 184, 33, 874, 60, 3, 689, 421, 61, 1, 6770, 4, 26, 150, 10, 212, 81, 503, 391, 9, 67, 162, 61, 817, 155, 10, 2786, 3561, 3, 63, 51, 116, 10, 595, 4, 373, 1278, 434, 7, 3, 51, 116, 10, 653, 52, 207, 1, 1993, 6, 51, 10, 14, 184, 14, 27, 1993, 52, 734, 654, 10, 432, 244, 2, 52, 25, 71, 44, 85, 1300, 8, 93, 775, 4, 1648, 261, 569, 2, 504, 1, 1508, 4145, 11, 513, 6770, 315, 148, 11, 142, 4, 1983, 19, 1614, 4, 1221, 3, 150, 656, 16, 1165, 2, 71, 93, 38, 128, 26, 38, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 77, 56358]",1340.0,17596541,Safety clinical activity combination 5-azacytidine valproic acid all-trans retinoic acid acute myeloid leukemia myelodysplastic syndrome,0,0.0
Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2007-07-30,"The purpose of this study was to determine the risk of developing acute myeloid leukemia (AML) after adjuvant chemotherapy for breast cancer in older women. Data from the Surveillance, Epidemiology, and End Results-Medicare linked database were used for women diagnosed with nonmetastatic breast cancer from 1992 to 2002. The primary end point was a claim with an inpatient or outpatient diagnosis of AML (International Classification of Diseases ninth revision, codes 205 to 208), comparing patients treated with and without adjuvant chemotherapy, and by differing chemotherapy regimens. The cumulative hazard of AML was estimated using the Kaplan-Meier method. Cox proportional hazards models were used to determine factors independently associated with the development of AML. In this observational study, there were 64,715 patients: 10,130 received adjuvant chemotherapy and 54,585 did not. The median patient age was 75.6 years (range, 66 to 104 years). The mean follow-up was 54.8 months (range, 13 to 144 months). The absolute risk of developing AML at 10 years after any adjuvant chemotherapy for breast cancer was 1.8% versus 1.2% for women who had not received chemotherapy. The adjusted hazard ratio for AML with adjuvant chemotherapy versus none was 1.53 (95% CI, 1.14 to 2.06). Granulocyte colony-stimulating factor (G-CSF) within the first year of diagnosis did not convey a significantly increased risk of AML (hazard ratio, 1.14; 95% CI, 0.67 to 1.92). There is a small but real increase in AML after adjuvant chemotherapy for breast cancer in older women. This study may underestimate the true incidence because myelodysplastic syndrome cannot be identified through claims. G-CSF use within the first year of diagnosis does not convey an increased risk of AML in older women.",Journal Article,4558.0,111.0,"purpose determine risk developing acute myeloid leukemia AML adjuvant chemotherapy breast older women Surveillance Epidemiology End Results-Medicare linked database women diagnosed nonmetastatic breast 1992 2002 primary end point claim inpatient outpatient diagnosis AML International Classification Diseases ninth revision codes 205 208 comparing patients treated adjuvant chemotherapy differing chemotherapy regimens cumulative hazard AML estimated Kaplan-Meier Cox proportional hazards models determine factors independently associated development AML observational 64,715 patients 10,130 received adjuvant chemotherapy 54,585 median patient age 75.6 years range 66 104 years mean follow-up 54.8 months range 13 144 months absolute risk developing AML 10 years adjuvant chemotherapy breast 1.8 versus 1.2 women received chemotherapy adjusted hazard ratio AML adjuvant chemotherapy versus 1.53 95 CI 1.14 2.06 Granulocyte colony-stimulating factor G-CSF year diagnosis convey significantly increased risk AML hazard ratio 1.14 95 CI 0.67 1.92 small real increase AML adjuvant chemotherapy breast older women underestimate true incidence myelodysplastic syndrome identified claims G-CSF use year diagnosis convey increased risk AML older women",1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 223, 3, 43, 1, 931, 286, 533, 329, 50, 249, 56, 9, 12, 4, 434, 117, 74, 29, 3, 617, 1284, 2, 396, 99, 1378, 1199, 609, 11, 95, 9, 117, 265, 5, 2683, 12, 29, 2846, 6, 1544, 3, 86, 396, 741, 10, 8, 10429, 5, 35, 2420, 15, 2379, 147, 1, 329, 944, 947, 1, 1342, 13544, 5646, 5271, 5286, 6, 5920, 1430, 7, 73, 5, 2, 187, 249, 56, 2, 20, 5276, 56, 472, 3, 967, 360, 1, 329, 10, 661, 75, 3, 876, 882, 596, 418, 831, 1017, 274, 11, 95, 6, 223, 130, 1042, 41, 5, 3, 193, 1, 329, 4, 26, 2495, 45, 125, 11, 660, 14860, 7, 79, 3431, 103, 249, 56, 2, 667, 15351, 205, 44, 3, 52, 69, 89, 10, 481, 49, 60, 184, 700, 6, 3407, 60, 3, 313, 166, 126, 10, 667, 66, 53, 184, 233, 6, 4415, 53, 3, 1766, 43, 1, 931, 329, 28, 79, 60, 50, 500, 249, 56, 9, 12, 10, 14, 66, 185, 14, 18, 9, 117, 54, 42, 44, 103, 56, 3, 586, 360, 197, 9, 329, 5, 249, 56, 185, 1292, 10, 14, 699, 48, 58, 14, 213, 6, 18, 1460, 2764, 1975, 2122, 161, 499, 1211, 262, 3, 157, 111, 1, 147, 205, 44, 11415, 8, 97, 101, 43, 1, 329, 360, 197, 14, 213, 48, 58, 13, 598, 6, 14, 937, 125, 16, 8, 302, 84, 1589, 344, 4, 329, 50, 249, 56, 9, 12, 4, 434, 117, 26, 45, 68, 10397, 3, 2501, 287, 408, 681, 122, 44, 40, 108, 298, 2770, 499, 1211, 119, 262, 3, 157, 111, 1, 147, 1097, 44, 11415, 35, 101, 43, 1, 329, 4, 434, 117]",1695.0,17664457,Acute myeloid leukemia adjuvant breast therapy older women understanding risk,115,0.2006980802792321
Decitabine and its role in the treatment of hematopoietic malignancies.,Leukemia & lymphoma,Leuk. Lymphoma,2007-08-01,"DNA methylation is responsible for abnormal silencing of many genes, including tumor suppressor genes, in cancer. Decitabine, an S-phase specific inhibitor of DNA methyltransferase, has been shown to decrease levels of abnormal methylation in neoplasia. Though initially investigated at high doses as a cytotoxic agent, recent studies show that when administered at low doses, the hypomethylating activity of decitabine is increased with a demonstrated increase in activity in hematopoietic malignancies. Multiple clinical trials, both in the United States and in Europe, have demonstrated the efficacy of decitabine in acute myeloid leukemia, chronic myeloid leukemia, and myelodysplastic syndrome (MDS). Recently approved by the United States Food and Drug Administration for the treatment of (MDS), decitabine represents an effective and well-tolerated therapeutic option in this disease, for which treatment options were previously scarce. While the activity in MDS is promising, primary and secondary resistance remain a problem. Investigations of combinations of decitabine with other agents, including histone deacetylase inhibitors, are currently ongoing in the hope of substantially prolonging survival in patients with hematologic malignancies.",Journal Article,4556.0,84.0,DNA methylation responsible abnormal silencing including suppressor Decitabine S-phase specific inhibitor DNA methyltransferase shown decrease levels abnormal methylation neoplasia initially investigated high doses cytotoxic agent recent studies administered low doses hypomethylating activity decitabine increased demonstrated increase activity hematopoietic malignancies Multiple clinical trials United States Europe demonstrated efficacy decitabine acute myeloid leukemia chronic myeloid leukemia myelodysplastic syndrome MDS Recently approved United States Food Drug Administration treatment MDS decitabine represents effective well-tolerated therapeutic option disease treatment options previously scarce activity MDS promising primary secondary resistance remain problem Investigations combinations decitabine agents including histone deacetylase inhibitors currently ongoing hope substantially prolonging survival patients hematologic malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[261, 569, 16, 2327, 9, 1668, 2077, 1, 445, 214, 141, 30, 1245, 214, 4, 12, 3004, 35, 695, 124, 112, 230, 1, 261, 3747, 71, 85, 443, 6, 775, 148, 1, 1668, 569, 4, 2298, 2471, 1625, 565, 28, 64, 415, 22, 8, 759, 420, 435, 94, 514, 17, 198, 468, 28, 154, 415, 3, 4931, 128, 1, 3004, 16, 101, 5, 8, 264, 344, 4, 128, 4, 1007, 441, 232, 38, 143, 110, 4, 3, 1088, 907, 2, 4, 3934, 47, 264, 3, 209, 1, 3004, 4, 286, 533, 442, 533, 2, 681, 1223, 761, 850, 20, 3, 1088, 907, 1773, 2, 234, 634, 9, 3, 24, 1, 1223, 3004, 1449, 35, 323, 2, 149, 421, 189, 1501, 4, 26, 34, 9, 92, 24, 838, 11, 373, 8113, 369, 3, 128, 4, 1223, 16, 721, 86, 2, 568, 251, 918, 8, 2497, 2492, 1, 1247, 1, 3004, 5, 127, 183, 141, 1508, 2732, 222, 32, 694, 942, 4, 3, 3045, 1, 2109, 5559, 25, 4, 7, 5, 813, 441]",1194.0,17701577,Decitabine role treatment hematopoietic malignancies,59,0.10296684118673648
Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2007-08-01,"Older node-positive patients treated with newer adjuvant chemotherapy regimens have improvements in relapse-free and overall survival similar to younger patients. We compared toxicity of older and younger patients in three randomized trials of adjuvant chemotherapy. Toxicity data were available for 93% of 6,642 patients enrolled. The three trials included: Cancer and Leukemia Group B (CALGB) 8541, a comparison of cyclophosphamide, doxorubicin, and fluorouracil in three dose schedules; CALGB 9344: cyclophosphamide and doxorubicin with or without paclitaxel; and CALGB 9741: cyclophosphamide, doxorubicin, and paclitaxel every 2 versus every 3 weeks. National Cancer Institute grade 3 to 5 toxicities were compared among age groups. Seven percent of patients (n = 458) were age 65 or older, 3% were 70 or older, 38% were 51 to 64, and 55% were 50 or younger. Twenty-four deaths (0.4%) were attributed to treatment; seven (1.5%) of 486 in patients 65 or older, 10 (0.40%) of 2,480 in patients who were 51 to 64 years, and seven (0.19%) of 3,676 occurred in patients younger than 50. In multivariate analysis, older patients were significantly more likely to have grade 4 hematologic toxicity, to have discontinued treatment for toxicity, or to have died of acute myeloid leukemia/myelodysplastic syndrome. There were no significant differences in grade 3 to 4 nonhematologic toxicity. Healthy older patients who met the strict eligibility criteria for these trials had a higher rate of hematologic toxicity and treatment-related deaths than younger patients, but no increase in nonhematologic toxicity. Elderly patients treated with newer adjuvant chemotherapy regimens derive the same benefits from newer chemotherapy regimens as younger patients but should be cautioned about the increased risk of toxicity and treatment-related death.",Journal Article,4556.0,190.0,"Older node-positive patients treated newer adjuvant chemotherapy regimens improvements relapse-free overall survival similar younger patients compared toxicity older younger patients randomized trials adjuvant chemotherapy Toxicity available 93 6,642 patients enrolled trials included Leukemia Group B CALGB 8541 comparison cyclophosphamide doxorubicin fluorouracil dose schedules CALGB 9344 cyclophosphamide doxorubicin paclitaxel CALGB 9741 cyclophosphamide doxorubicin paclitaxel 2 versus 3 weeks National Institute grade 3 5 toxicities compared age groups Seven percent patients n 458 age 65 older 3 70 older 38 51 64 55 50 younger Twenty-four deaths 0.4 attributed treatment seven 1.5 486 patients 65 older 10 0.40 2,480 patients 51 64 years seven 0.19 3,676 occurred patients younger 50 multivariate older patients significantly likely grade 4 hematologic toxicity discontinued treatment toxicity died acute myeloid leukemia/myelodysplastic syndrome significant differences grade 3 4 nonhematologic toxicity Healthy older patients met strict eligibility criteria trials higher rate hematologic toxicity treatment-related deaths younger patients increase nonhematologic toxicity Elderly patients treated newer adjuvant chemotherapy regimens derive benefits newer chemotherapy regimens younger patients cautioned increased risk toxicity treatment-related death",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[434, 289, 109, 7, 73, 5, 2246, 249, 56, 472, 47, 1474, 4, 429, 115, 2, 63, 25, 288, 6, 773, 7, 21, 72, 155, 1, 434, 2, 773, 7, 4, 169, 384, 143, 1, 249, 56, 155, 74, 11, 390, 9, 966, 1, 49, 11994, 7, 346, 3, 169, 143, 159, 12, 2, 87, 132, 4077, 23076, 8, 1155, 1, 1112, 856, 2, 1404, 4, 169, 61, 2314, 4077, 22059, 1112, 2, 856, 5, 15, 187, 490, 2, 4077, 28474, 1112, 856, 2, 490, 454, 18, 185, 454, 27, 244, 657, 12, 1377, 88, 27, 6, 33, 385, 11, 72, 107, 89, 271, 648, 714, 1, 7, 78, 12072, 11, 89, 556, 15, 434, 27, 11, 431, 15, 434, 519, 11, 725, 6, 660, 2, 614, 11, 212, 15, 773, 737, 294, 1043, 13, 39, 11, 3073, 6, 24, 648, 14, 33, 1, 7582, 4, 7, 556, 15, 434, 79, 13, 327, 1, 18, 9108, 4, 7, 54, 11, 725, 6, 660, 60, 2, 648, 13, 326, 1, 27, 11010, 489, 4, 7, 773, 76, 212, 4, 331, 65, 434, 7, 11, 97, 80, 322, 6, 47, 88, 39, 813, 155, 6, 47, 2402, 24, 9, 155, 15, 6, 47, 1016, 1, 286, 533, 2647, 10589, 681, 125, 11, 77, 93, 362, 4, 88, 27, 6, 39, 3534, 155, 1331, 434, 7, 54, 543, 3, 8043, 2317, 371, 9, 46, 143, 42, 8, 142, 116, 1, 813, 155, 2, 24, 139, 1043, 76, 773, 7, 84, 77, 344, 4, 3534, 155, 1216, 7, 73, 5, 2246, 249, 56, 472, 3823, 3, 827, 1141, 29, 2246, 56, 472, 22, 773, 7, 84, 257, 40, 44819, 545, 3, 101, 43, 1, 155, 2, 24, 139, 273]",1778.0,17704418,Toxicity older younger patients treated adjuvant chemotherapy node-positive breast Leukemia Group B Experience,0,0.0
Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution.,Leukemia research,Leuk. Res.,2007-08-20,"The purpose of this study was to define the spectrum of hematologic neoplasms and chromosomal breakpoints associated with del(5q); separate analyses were performed to account for prior cytotoxic treatment. A total of 358 consecutive del(5q) cases were identified; specific diagnoses included myelodysplastic syndrome (MDS; 53%), acute myeloid leukemia (AML; 22%), plasma cell proliferative disorder (PCPD; 9%), myeloproliferative disorder (MPD; 7%), acute lymphoblastic leukemia (ALL; 2%), PCPD with MDS (2%), MDS/MPD (2%), and malignant lymphoma (ML; 2%). The corresponding figures in the absence/presence of prior cytotoxic treatment (n=250/108) were 61%/34% for MDS, 24%/19% for AML, 4%/20% for PCPD, 6%/8% for MPD, 1%/4% for ALL, and 2%/4% for ML. del(5q) occurred as the sole cytogenetic abnormality in 88 cases (25%) including 76 without prior cytotoxic therapy. Among the latter, 82% had MDS, 8% AML, 5% MPD, 4% PCPD, and 1% ML. Chromosome 5 breakpoints included q13q33 in 49% of the cases, q15q33 in 22%, q22q33 in 8%, and q13 in 3% and their distribution was not affected by specific diagnosis or treatment history. del(5q)-associated lymphoid disorders featured a higher prevalence of previous cytotoxic therapy and smaller number del(5q)-positive metaphases, when compared to their counterparts with myeloid neoplasms. We conclude that del(5q), although most prevalent in MDS, is seen across the spectrum of myeloid disorders including MPD and its occurrence in lymphoid disorders might signify, for the most part, an occult myeloid clone.",Journal Article,4537.0,13.0,purpose define spectrum hematologic neoplasms chromosomal breakpoints associated del 5q separate performed account prior cytotoxic treatment total 358 consecutive del 5q cases identified specific diagnoses included myelodysplastic syndrome MDS 53 acute myeloid leukemia AML 22 plasma proliferative disorder PCPD 9 myeloproliferative disorder MPD 7 acute lymphoblastic leukemia 2 PCPD MDS 2 MDS/MPD 2 malignant lymphoma ML 2 corresponding absence/presence prior cytotoxic treatment n=250/108 61 /34 MDS 24 /19 AML 4 /20 PCPD 6 /8 MPD 1 /4 2 /4 ML del 5q occurred sole cytogenetic abnormality 88 cases 25 including 76 prior cytotoxic therapy 82 MDS 8 AML 5 MPD 4 PCPD 1 ML Chromosome 5 breakpoints included q13q33 49 cases q15q33 22 q22q33 8 q13 3 distribution affected specific diagnosis treatment history del 5q -associated lymphoid disorders featured higher prevalence previous cytotoxic therapy smaller number del 5q -positive metaphases compared counterparts myeloid neoplasms conclude del 5q prevalent MDS seen spectrum myeloid disorders including MPD occurrence lymphoid disorders signify occult myeloid clone,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 1107, 3, 1873, 1, 813, 1179, 2, 1860, 7843, 41, 5, 3084, 5460, 2282, 318, 11, 173, 6, 1967, 9, 324, 759, 24, 8, 181, 1, 8396, 935, 3084, 5460, 140, 11, 108, 112, 2403, 159, 681, 1223, 699, 286, 533, 329, 350, 554, 31, 2441, 2645, 26626, 83, 2645, 7712, 67, 286, 1275, 62, 18, 26626, 5, 1223, 18, 1223, 7712, 18, 2, 393, 542, 18, 3, 1734, 9446, 4, 3, 1127, 463, 1, 324, 759, 24, 78, 2039, 3590, 11, 713, 562, 9, 1223, 259, 326, 9, 329, 39, 179, 9, 26626, 49, 66, 9, 7712, 14, 39, 9, 62, 2, 18, 39, 9, 542, 3084, 5460, 489, 22, 3, 4991, 1266, 3698, 4, 889, 140, 243, 141, 846, 187, 324, 759, 36, 107, 3, 3286, 878, 42, 1223, 66, 329, 33, 7712, 39, 26626, 2, 14, 542, 1170, 33, 7843, 159, 38527, 4, 739, 1, 3, 140, 56479, 4, 350, 56480, 4, 66, 2, 9938, 4, 27, 2, 136, 1395, 10, 44, 1424, 20, 112, 147, 15, 24, 532, 3084, 5460, 41, 2303, 1997, 11857, 8, 142, 1078, 1, 698, 759, 36, 2, 2170, 207, 3084, 5460, 109, 10653, 198, 72, 6, 136, 3953, 5, 533, 1179, 21, 2060, 17, 3084, 5460, 242, 96, 2485, 4, 1223, 16, 527, 716, 3, 1873, 1, 533, 1997, 141, 7712, 2, 211, 2291, 4, 2303, 1997, 822, 19016, 9, 3, 96, 760, 35, 2879, 533, 3910]",1399.0,17707907,Chromosome 5q deletion specific diagnoses cytogenetic details 358 consecutive cases single institution,30,0.05235602094240838
Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2007-08-20,"To investigate the incidence of treatment-related myelodysplastic syndrome (t-MDS) and treatment-related acute myelogenous leukemia (t-AML) after treatment with ibritumomab tiuxetan radioimmunotherapy. Analysis of the incidence of t-MDS and t-AML in 746 patients with non-Hodgkin's lymphoma (NHL) treated with the ibritumomab tiuxetan regimen in registration and compassionate-use trials between 1996 and 2002. Nineteen patients (2.5%) developed t-MDS or t-AML at a median follow-up of 4.4 years (range, 0 to 9.3). These malignancies were diagnosed at a median of 5.6 years (range, 1.4 to 13.9) after the diagnosis of NHL and 1.9 years (range, 0.4 to 6.3) after radioimmunotherapy. The annualized rates were 0.3% per year after the diagnosis of NHL and 0.7% per year after treatment. Most patients with t-MDS or t-AML had multiple cytogenetic aberrations, commonly on chromosomes 5 and 7, suggesting an association with previous exposure to chemotherapy. Analysis of data from patients in registration and compassionate-use trials suggests that the annualized incidences of t-MDS and t-AML are consistent with that expected in patients with NHL who have had extensive previous chemotherapy treatment and do not appear to be increased after treatment with the ibritumomab tiuxetan regimen. Cytogenetic testing before treatment with radioimmunotherapy may identify existing chromosomal abnormalities in previously treated patients, particularly those who have been treated with alkylating agents and purine nucleoside analogs and would be at higher risk for t-MDS or t-AML.",Journal Article,4537.0,107.0,investigate incidence treatment-related myelodysplastic syndrome t-MDS treatment-related acute myelogenous leukemia t-AML treatment ibritumomab tiuxetan radioimmunotherapy incidence t-MDS t-AML 746 patients non-Hodgkin 's lymphoma NHL treated ibritumomab tiuxetan regimen registration compassionate-use trials 1996 2002 Nineteen patients 2.5 developed t-MDS t-AML median follow-up 4.4 years range 0 9.3 malignancies diagnosed median 5.6 years range 1.4 13.9 diagnosis NHL 1.9 years range 0.4 6.3 radioimmunotherapy annualized rates 0.3 year diagnosis NHL 0.7 year treatment patients t-MDS t-AML multiple cytogenetic aberrations commonly chromosomes 5 7 suggesting association previous exposure chemotherapy patients registration compassionate-use trials suggests annualized incidences t-MDS t-AML consistent expected patients NHL extensive previous chemotherapy treatment appear increased treatment ibritumomab tiuxetan regimen Cytogenetic testing treatment radioimmunotherapy identify existing chromosomal abnormalities previously treated patients particularly treated alkylating agents purine nucleoside analogs higher risk t-MDS t-AML,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 963, 3, 287, 1, 24, 139, 681, 102, 1223, 2, 24, 139, 286, 2194, 102, 329, 50, 24, 5, 5251, 5294, 5862, 65, 1, 3, 287, 1, 102, 1223, 2, 102, 329, 4, 13595, 7, 5, 292, 1176, 73, 5, 3, 5251, 5294, 477, 4, 3169, 2, 9949, 119, 143, 59, 2648, 2, 1544, 3498, 7, 18, 33, 276, 102, 1223, 15, 102, 329, 28, 8, 52, 166, 126, 1, 39, 39, 60, 184, 13, 6, 83, 27, 46, 441, 11, 265, 28, 8, 52, 1, 33, 49, 60, 184, 14, 39, 6, 233, 83, 50, 3, 147, 1, 1176, 2, 14, 83, 60, 184, 13, 39, 6, 49, 27, 50, 5862, 3, 18519, 151, 11, 13, 27, 379, 111, 50, 3, 147, 1, 1176, 2, 13, 67, 379, 111, 50, 24, 96, 7, 5, 102, 1223, 15, 102, 329, 42, 232, 1266, 2152, 841, 23, 3560, 33, 2, 67, 802, 35, 248, 5, 698, 645, 6, 56, 65, 1, 74, 29, 7, 4, 3169, 2, 9949, 119, 143, 844, 17, 3, 18519, 3981, 1, 102, 1223, 2, 102, 329, 32, 925, 5, 17, 1336, 4, 7, 5, 1176, 54, 47, 42, 1344, 698, 56, 24, 2, 1022, 44, 1322, 6, 40, 101, 50, 24, 5, 3, 5251, 5294, 477, 1266, 471, 348, 24, 5, 5862, 68, 255, 1692, 1860, 1171, 4, 373, 73, 7, 823, 135, 54, 47, 85, 73, 5, 3410, 183, 2, 5006, 4032, 4063, 2, 688, 40, 28, 142, 43, 9, 102, 1223, 15, 102, 329]",1495.0,17709799,Treatment-related myelodysplastic syndrome acute myelogenous leukemia patients treated ibritumomab tiuxetan radioimmunotherapy,0,0.0
The use of hypomethylating agents in the treatment of hematologic malignancies.,Leukemia & lymphoma,Leuk. Lymphoma,2007-09-01,"Epigenetic alterations, such as DNA methylation and histone modifications, are abnormal in cancer cells, and the use of the hypomethylating agents 5-azacitidine and decitabine are important additions to our arsenal of active cancer drugs, especially for the treatment of the myelodysplastic syndromes and acute myeloid leukemia. Most effective are repeated cycles of the drugs given at doses much lower than originally tested. Typical overall response rates (complete responses + partial responses + hematologic improvement) for both drugs are in the range of 40 - 50%. These agents are generally very well tolerated, with myelosuppression being the major side effect. Postulated to work through hypomethylation of DNA causing induction of gene expression, the precise mechanism of action of these agents is not yet clear. Future studies are likely to combine these agents with other drugs like the histone deacetylase inhibitors that act in related pathways.",Journal Article,4525.0,27.0,Epigenetic alterations DNA methylation histone modifications abnormal use hypomethylating agents 5-azacitidine decitabine important additions arsenal active drugs especially treatment myelodysplastic syndromes acute myeloid leukemia effective repeated cycles drugs given doses lower originally tested Typical overall response rates complete responses partial responses hematologic improvement drugs range 40 50 agents generally tolerated myelosuppression major effect Postulated work hypomethylation DNA causing induction expression precise mechanism action agents clear Future studies likely combine agents drugs like histone deacetylase inhibitors act related pathways,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1418, 593, 225, 22, 261, 569, 2, 1508, 2916, 32, 1668, 4, 12, 37, 2, 3, 119, 1, 3, 4931, 183, 33, 3752, 2, 3004, 32, 305, 13267, 6, 114, 13325, 1, 544, 12, 600, 1093, 9, 3, 24, 1, 3, 2040, 2, 286, 533, 96, 323, 32, 2113, 410, 1, 3, 600, 447, 28, 415, 1802, 280, 76, 5045, 650, 3476, 63, 51, 151, 236, 253, 450, 253, 813, 767, 9, 110, 600, 32, 4, 3, 184, 1, 327, 212, 46, 183, 32, 1228, 923, 149, 421, 5, 2858, 486, 3, 458, 1152, 254, 6507, 6, 1357, 298, 4441, 1, 261, 3440, 504, 1, 145, 55, 3, 3260, 670, 1, 1578, 1, 46, 183, 16, 44, 1145, 885, 508, 94, 32, 322, 6, 4680, 46, 183, 5, 127, 600, 733, 3, 1508, 2732, 222, 17, 2559, 4, 139, 460]",913.0,17786703,use hypomethylating agents treatment hematologic malignancies,9,0.015706806282722512
"Clofarabine: past, present, and future.",Leukemia & lymphoma,Leuk. Lymphoma,2007-10-01,"Clofarabine is a good generation purine nucleoside analogue designed to overcome the limitations and to incorporate the best qualities of both cladribine and fludarabine. Clofarabine is thought to work via three mechanisms: inhibition of ribonucleotide reductase; incorporation to DNA; and induction of apoptosis. Given these mechanism of action, clofarabine would be predicted to act synergistically with other chemotherapeutic agents such as other purine nucleoside analogues and DNA damaging or cross linking agents such as anthracyclines and platinum-based compounds. Intravenous clofarabine showed significant efficacy in pediatric leukemias (specifically, acute lymphoblastic leukemia (ALL)) and, in 2004, it was approved by the United States Food and Drug Administration (FDA) for the treatment of pediatric relapsed/refractory ALL after at least two regimens. In adults, clofarabine has shown significant efficacy in hematologic malignancies including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) alone and in combinations. Ongoing and future studies will examine the use of clofarabine in elderly patients with AML for whom standard regimens are too toxic, and in MDS intravenous and oral forms of the drug.",Journal Article,4495.0,60.0,Clofarabine good generation purine nucleoside analogue designed overcome limitations incorporate best qualities cladribine fludarabine Clofarabine thought work mechanisms inhibition ribonucleotide reductase incorporation DNA induction apoptosis Given mechanism action clofarabine predicted act synergistically chemotherapeutic agents purine nucleoside analogues DNA damaging cross linking agents anthracyclines platinum-based compounds Intravenous clofarabine showed significant efficacy pediatric leukemias specifically acute lymphoblastic leukemia 2004 approved United States Food Drug Administration FDA treatment pediatric relapsed/refractory regimens adults clofarabine shown significant efficacy hematologic malignancies including acute myeloid leukemia AML myelodysplastic syndrome MDS combinations Ongoing future studies examine use clofarabine elderly patients AML standard regimens toxic MDS intravenous oral forms drug,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4149, 16, 8, 1178, 914, 5006, 4032, 4696, 1114, 6, 1768, 3, 1939, 2, 6, 3360, 3, 824, 15353, 1, 110, 8251, 2, 2027, 4149, 16, 2739, 6, 1357, 847, 169, 483, 297, 1, 7050, 4027, 2838, 6, 261, 2, 504, 1, 351, 447, 46, 670, 1, 1578, 4149, 688, 40, 783, 6, 2559, 4240, 5, 127, 1573, 183, 225, 22, 127, 5006, 4032, 4768, 2, 261, 4904, 15, 1383, 5806, 183, 225, 22, 3597, 2, 828, 90, 2411, 1262, 4149, 224, 93, 209, 4, 815, 2792, 1225, 286, 1275, 62, 2, 4, 1131, 192, 10, 850, 20, 3, 1088, 907, 1773, 2, 234, 634, 2078, 9, 3, 24, 1, 815, 591, 430, 62, 50, 28, 506, 100, 472, 4, 857, 4149, 71, 443, 93, 209, 4, 813, 441, 141, 286, 533, 329, 2, 681, 1223, 279, 2, 4, 1247, 942, 2, 508, 94, 303, 1004, 3, 119, 1, 4149, 4, 1216, 7, 5, 329, 9, 953, 260, 472, 32, 5044, 1812, 2, 4, 1223, 1262, 2, 518, 2377, 1, 3, 234]",1176.0,17852710,Clofarabine past present future,62,0.1082024432809773
Prevalence of erythrocyte haemoglobin H inclusions in unselected patients with clonal myeloid disorders.,British journal of haematology,Br. J. Haematol.,2007-11-01,"Patients with clonal myeloid disorders, especially myelodysplastic syndromes (MDS), may acquire alpha-thalassaemia. To estimate the prevalence of this erythrocyte phenotype, we examined brilliant cresyl blue-stained blood smears from 201 patients with neoplastic myeloid disorders and 282 controls (195 non-clonal anaemia, 62 with medical illnesses without anaemia and 25 healthy persons). Haemoglobin H inclusions were detected in 8/100 patients with MDS (8%) and 2/81 (2.5%) patients with myeloproliferative disorders, but in none of the acute leukaemia patients or controls. We conclude that the emergence of thalassaemic clones may be relatively common in the disordered marrow milieu of MDS.",Journal Article,4464.0,7.0,Patients clonal myeloid disorders especially myelodysplastic syndromes MDS acquire alpha-thalassaemia estimate prevalence erythrocyte phenotype examined brilliant cresyl blue-stained blood smears 201 patients neoplastic myeloid disorders 282 controls 195 non-clonal anaemia 62 medical illnesses anaemia 25 healthy persons Haemoglobin H inclusions detected 8/100 patients MDS 8 2/81 2.5 patients myeloproliferative disorders acute leukaemia patients controls conclude emergence thalassaemic clones relatively common disordered marrow milieu MDS,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7, 5, 1946, 533, 1997, 1093, 2040, 1223, 68, 6206, 950, 44885, 6, 1191, 3, 1078, 1, 26, 16470, 1005, 21, 409, 44886, 56592, 3352, 3386, 315, 8916, 29, 4766, 7, 5, 2000, 533, 1997, 2, 8219, 535, 5786, 220, 1946, 5712, 744, 5, 484, 8837, 187, 5712, 2, 243, 1331, 4327, 11820, 555, 16838, 11, 530, 4, 66, 394, 7, 5, 1223, 66, 2, 18, 865, 18, 33, 7, 5, 1997, 84, 4, 1292, 1, 3, 286, 2001, 7, 15, 535, 21, 2060, 17, 3, 3397, 1, 56593, 2749, 68, 40, 1352, 186, 4, 3, 16904, 581, 6795, 1, 1223]",642.0,17910635,Prevalence erythrocyte haemoglobin H inclusions unselected patients clonal myeloid disorders,0,0.0
"Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML.",Blood,Blood,2007-10-22,"Using metaphase cytogenetics (MC), chromosomal abnormalities are found in only a proportion of patients with myelodysplastic syndrome (MDS). We hypothesized that with new precise methods more cryptic karyotypic lesions can be uncovered that may show important clinical implications. We have applied 250K single nucleotide polymorphisms (SNP) arrays (SNP-A) to study chromosomal lesions in samples from 174 patients (94 MDS, 33 secondary acute myeloid leukemia [sAML], and 47 myelodysplastic/myeloproliferative disease [MDS/MPD]) and 76 controls. Using SNP-A, aberrations were found in around three-fourths of MDS, MDS/MPD, and sAML (vs 59%, 37%, 53% by MC; in 8% of patients MC was unsuccessful). Previously unrecognized lesions were detected in patients with normal MC and in those with known lesions. Moreover, segmental uniparental disomy (UPD) was found in 20% of MDS, 23% of sAML, and 35% of MDS/MPD patients, a lesion resulting in copy-neutral loss of heterozygosity undetectable by MC. The potential clinical significance of abnormalities detected by SNP-A, but not seen on MC, was demonstrated by their impact on overall survival. UPD involving chromosomes frequently affected by deletions may have prognostic implications similar to the deletions visible by MC. SNP-A-based karyotyping shows superior resolution for chromosomal defects, including UPD. This technique further complements MC to improve clinical prognosis and targeted therapies.",Journal Article,4474.0,262.0,metaphase cytogenetics MC chromosomal abnormalities proportion patients myelodysplastic syndrome MDS hypothesized new precise methods cryptic karyotypic lesions uncovered important clinical implications applied 250K single nucleotide polymorphisms SNP arrays SNP-A chromosomal lesions 174 patients 94 MDS 33 secondary acute myeloid leukemia sAML 47 myelodysplastic/myeloproliferative disease MDS/MPD 76 controls SNP-A aberrations three-fourths MDS MDS/MPD sAML vs 59 37 53 MC 8 patients MC unsuccessful Previously unrecognized lesions detected patients normal MC known lesions segmental uniparental disomy UPD 20 MDS 23 sAML 35 MDS/MPD patients lesion resulting copy-neutral loss heterozygosity undetectable MC potential clinical significance abnormalities detected SNP-A seen MC demonstrated impact overall survival UPD involving chromosomes frequently affected deletions prognostic implications similar deletions visible MC SNP-A-based karyotyping shows superior resolution chromosomal defects including UPD technique complements MC improve clinical prognosis targeted therapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[75, 10569, 2510, 4779, 1860, 1171, 32, 204, 4, 158, 8, 920, 1, 7, 5, 681, 1223, 21, 1237, 17, 5, 217, 3260, 636, 80, 10294, 9465, 406, 122, 40, 5601, 17, 68, 514, 305, 38, 1268, 21, 47, 1498, 34360, 226, 1579, 1203, 1845, 3923, 1845, 8, 6, 45, 1860, 406, 4, 347, 29, 5811, 7, 960, 1223, 466, 568, 286, 533, 8991, 2, 662, 10589, 10857, 34, 1223, 7712, 2, 846, 535, 75, 1845, 8, 2152, 11, 204, 4, 3337, 169, 17246, 1, 1223, 1223, 7712, 2, 8991, 105, 728, 567, 699, 20, 4779, 4, 66, 1, 7, 4779, 10, 7581, 373, 6055, 406, 11, 530, 4, 7, 5, 295, 4779, 2, 4, 135, 5, 440, 406, 1393, 7982, 17888, 13983, 19137, 10, 204, 4, 179, 1, 1223, 382, 1, 8991, 2, 465, 1, 1223, 7712, 7, 8, 1180, 1113, 4, 1337, 6338, 407, 1, 3963, 3920, 20, 4779, 3, 174, 38, 724, 1, 1171, 530, 20, 1845, 8, 84, 44, 527, 23, 4779, 10, 264, 20, 136, 345, 23, 63, 25, 19137, 1267, 3560, 746, 1424, 20, 2439, 68, 47, 177, 1268, 288, 6, 3, 2439, 4822, 20, 4779, 1845, 8, 90, 10406, 1949, 1123, 2125, 9, 1860, 2945, 141, 19137, 26, 1312, 195, 20576, 4779, 6, 401, 38, 356, 2, 238, 235]",1376.0,17954704,Chromosomal lesions uniparental disomy detected SNP arrays MDS MDS/MPD MDS-derived AML,2,0.0034904013961605585
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.,Blood,Blood,2007-10-25,"Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia. A phase 1 study was conducted to evaluate the safety and activity of oral vorinostat 100 to 300 mg twice or thrice daily for 14 days followed by 1-week rest. Patients with relapsed or refractory leukemias or myelodysplastic syndromes (MDS) and untreated patients who were not candidates for chemotherapy were eligible. Of 41 patients, 31 had acute myeloid leukemia (AML), 4 chronic lymphocytic leukemia, 3 MDS, 2 acute lymphoblastic leukemia, and 1 chronic myelocytic leukemia. The maximum tolerated dose (MTD) was 200 mg twice daily or 250 mg thrice daily. Dose-limiting toxicities were fatigue, nausea, vomiting, and diarrhea. Common drug-related adverse experiences were diarrhea, nausea, fatigue, and anorexia and were mild/moderate in severity. Grade 3/4 drug-related adverse experiences included fatigue (27%), thrombocytopenia (12%), and diarrhea (10%). There were no drug-related deaths; 7 patients had hematologic improvement response, including 2 complete responses and 2 complete responses with incomplete blood count recovery (all with AML treated at/below MTD). Increased histone acetylation was observed at all doses. Antioxidant gene expression may confer vorinostat resistance. Further evaluation of vorinostat in AML/MDS is warranted.","Clinical Trial, Phase I",4471.0,367.0,Vorinostat suberoylanilide hydroxamic acid SAHA histone deacetylase inhibitor active clinically cutaneous T-cell lymphoma preclinically leukemia phase 1 conducted evaluate safety activity oral vorinostat 100 300 mg twice thrice daily 14 days followed 1-week rest Patients relapsed refractory leukemias myelodysplastic syndromes MDS untreated patients candidates chemotherapy eligible 41 patients 31 acute myeloid leukemia AML 4 chronic lymphocytic leukemia 3 MDS 2 acute lymphoblastic leukemia 1 chronic myelocytic leukemia maximum tolerated dose MTD 200 mg twice daily 250 mg thrice daily Dose-limiting toxicities fatigue nausea vomiting diarrhea Common drug-related adverse experiences diarrhea nausea fatigue anorexia mild/moderate severity Grade 3/4 drug-related adverse experiences included fatigue 27 thrombocytopenia 12 diarrhea 10 drug-related deaths 7 patients hematologic improvement response including 2 complete responses 2 complete responses incomplete blood count recovery AML treated at/below MTD Increased histone acetylation observed doses Antioxidant expression confer vorinostat resistance evaluation vorinostat AML/MDS warranted,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[2371, 9258, 8856, 971, 5484, 16, 8, 1508, 2732, 230, 544, 505, 4, 1486, 102, 31, 2, 10838, 4, 8, 124, 14, 45, 10, 426, 6, 376, 3, 367, 2, 128, 1, 518, 2371, 394, 6, 2036, 81, 936, 15, 10058, 391, 9, 213, 162, 370, 20, 14, 647, 3677, 7, 5, 591, 15, 430, 2792, 15, 2040, 1223, 2, 1278, 7, 54, 11, 44, 1931, 9, 56, 11, 625, 1, 605, 7, 456, 42, 286, 533, 329, 39, 442, 1193, 27, 1223, 18, 286, 1275, 2, 14, 442, 19446, 3, 689, 421, 61, 961, 10, 1250, 81, 936, 391, 15, 2039, 81, 10058, 391, 61, 817, 385, 11, 613, 1218, 1966, 2, 1172, 186, 234, 139, 290, 4031, 11, 1172, 1218, 613, 2, 3373, 2, 11, 1980, 1163, 4, 1702, 88, 27, 39, 234, 139, 290, 4031, 159, 613, 428, 1340, 133, 2, 1172, 79, 125, 11, 77, 234, 139, 1043, 67, 7, 42, 813, 767, 51, 141, 18, 236, 253, 2, 18, 236, 253, 5, 2610, 315, 1276, 1602, 62, 5, 329, 73, 28, 2736, 961, 101, 1508, 4145, 10, 164, 28, 62, 415, 5536, 145, 55, 68, 2913, 2371, 251, 195, 451, 1, 2371, 4, 329, 1223, 16, 1197]",1298.0,17962510,Phase 1 histone deacetylase inhibitor vorinostat suberoylanilide hydroxamic acid SAHA patients advanced leukemias myelodysplastic syndromes,0,0.0
A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2007-11-26,"Allogeneic hematopoietic stem cell transplantation (SCT) has the potential to cure patients with acute leukemia or myelodysplastic syndromes (MDS), but a number of prognostic factors can influence the outcome of transplantation. At present, no transplantation-specific risk score exists for this patient population. We propose a simple scoring system for patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), or MDS, based on a retrospective analysis of 445 patients undergoing SCT at our institution (divided into training and validation subsets). The score depends on 5 variables: age, disease, stage at transplantation, cytogenetics, and pretransplantation ferritin. It divides patients into 3 groups of comparable size, with 5-year overall survival (OS) of 56% (low risk), 22% (intermediate risk), and 5% (high risk). This prognostic score could be useful in making treatment decisions for individual patients, in stratifying patients entering clinical trials, and in adjusting transplantation outcomes across centers under the new federal reporting rules.",Journal Article,4439.0,49.0,Allogeneic hematopoietic stem transplantation SCT potential cure patients acute leukemia myelodysplastic syndromes MDS number prognostic factors influence outcome transplantation present transplantation-specific risk score exists patient population propose simple scoring patients acute myelogenous leukemia AML acute lymphoblastic leukemia MDS based retrospective 445 patients undergoing SCT institution divided training validation subsets score depends 5 variables age disease stage transplantation cytogenetics pretransplantation ferritin divides patients 3 groups comparable size 5-year overall survival OS 56 low risk 22 intermediate risk 5 high risk prognostic score useful making treatment decisions individual patients stratifying patients entering clinical trials adjusting transplantation outcomes centers new federal reporting rules,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1063, 1007, 452, 31, 497, 1988, 71, 3, 174, 6, 1722, 7, 5, 286, 15, 2040, 1223, 84, 8, 207, 1, 177, 130, 122, 1054, 3, 228, 1, 497, 28, 364, 77, 497, 112, 43, 368, 2481, 9, 26, 69, 266, 21, 2548, 8, 2763, 2504, 398, 9, 7, 5, 286, 2194, 329, 286, 1275, 62, 15, 1223, 90, 23, 8, 459, 65, 1, 9398, 7, 479, 1988, 28, 114, 731, 2176, 237, 1741, 2, 929, 1890, 3, 368, 3828, 23, 33, 682, 89, 34, 82, 28, 497, 2510, 2, 9367, 9101, 192, 19735, 7, 237, 27, 271, 1, 1279, 444, 5, 33, 111, 63, 25, 118, 1, 664, 154, 43, 350, 919, 43, 2, 33, 64, 43, 26, 177, 368, 359, 40, 999, 4, 1079, 24, 1526, 9, 797, 7, 4, 5035, 7, 7653, 38, 143, 2, 4, 1358, 497, 123, 716, 1168, 669, 3, 217, 8536, 1760, 8679]",1005.0,18158958,prognostic score patients acute leukemia myelodysplastic syndromes undergoing allogeneic stem transplantation,0,0.0
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.,Seminars in hematology,Semin. Hematol.,2008-01-01,"The recently approved drugs 5-azacitidine (5AC) and 5-aza-2'-deoxyazacytidine (DAC) are in wide clinical use for the treatment of myelodysplastic syndrome (MDS) of all types and chronic myelomonocytic leukemia (CMML). These agents were developed based upon an understanding of the importance of epigenetic changes in malignancy, and they have been evaluated in randomized clinical trials, which demonstrate response rates between 20% and 40% in patients for whom no previous standard of care was available. As understanding of the epigenetic changes characteristic of the malignant phenotype improves, we are able to target other regulators of chromatin conformation that contribute to aberrant gene transcription and dysregulated cell growth. The histone deacetylase (HDAC) inhibitors belong to one class of therapeutics developed using this paradigm. Although responses using HDAC inhibitors alone in MDS have been modest, robust preclinical data drive clinical trials in which they are utilized in combination with DNA methyltransferase (DNMT) inhibitors. Combination therapy offers the possibility of hematologic improvement and remission to myelodysplastic patients with previously untreatable disease.",Journal Article,4403.0,161.0,recently approved drugs 5-azacitidine 5AC 5-aza-2'-deoxyazacytidine DAC wide clinical use treatment myelodysplastic syndrome MDS types chronic myelomonocytic leukemia CMML agents developed based understanding importance epigenetic changes malignancy evaluated randomized clinical trials demonstrate response rates 20 40 patients previous standard care available understanding epigenetic changes characteristic malignant phenotype improves able target regulators chromatin conformation contribute aberrant transcription dysregulated growth histone deacetylase HDAC inhibitors belong class therapeutics developed paradigm responses HDAC inhibitors MDS modest robust preclinical drive clinical trials utilized combination DNA methyltransferase DNMT inhibitors Combination therapy offers possibility hematologic improvement remission myelodysplastic patients previously untreatable disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 761, 850, 600, 33, 3752, 43863, 2, 33, 3924, 6135, 38588, 6140, 32, 4, 1019, 38, 119, 9, 3, 24, 1, 681, 1223, 1, 62, 630, 2, 442, 5451, 3382, 46, 183, 11, 276, 90, 1548, 35, 612, 1, 3, 1187, 1, 1418, 400, 4, 710, 2, 491, 47, 85, 194, 4, 384, 38, 143, 92, 608, 51, 151, 59, 179, 2, 327, 4, 7, 9, 953, 77, 698, 260, 1, 165, 10, 390, 22, 612, 1, 3, 1418, 400, 2037, 1, 3, 393, 1005, 1804, 21, 32, 1665, 6, 283, 127, 3196, 1, 2287, 7788, 17, 1248, 6, 1898, 145, 866, 2, 4288, 31, 129, 3, 1508, 2732, 2654, 222, 14795, 6, 104, 1040, 1, 1943, 276, 75, 26, 2431, 242, 253, 75, 2654, 222, 279, 4, 1223, 47, 85, 1721, 1922, 693, 74, 3279, 38, 143, 4, 92, 491, 32, 2080, 4, 150, 5, 261, 3747, 10229, 222, 150, 36, 2339, 3, 2526, 1, 813, 767, 2, 734, 6, 7, 5, 373, 20322, 34]",1142.0,18179966,DNA methyltransferase histone deacetylase inhibitors treatment myelodysplastic syndromes,46,0.08027923211169284
Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2008-02-01,"Allogeneic hematopoietic cell transplantation (HCT) is the only curative strategy for patients with myelodysplastic syndrome (MDS) and myeloproliferative disorders (MPD). We report the results of 148 patients (median age = 59 years old) with de novo MDS (n = 40), acute myelogenous leukemia (AML) after antecedent MDS/MPD (n = 49), treatment-related MDS (t-MDS) (n = 25), MPD (n = 27), and chronic myelomonocytic leukemia (CMML) (n = 7) who underwent allogeneic HCT using a conditioning regimen of low-dose total body irradiation (TBI) alone (200 cGy) on day 0 (n = 5) or with the addition of fludarabine (Flu) 30 mg/m(2)/day on days -4 to -2 (n = 143). Postgrafting immunosuppression consisted of cyclosporine and mycophenolate mofetil (MMF). Seventy-five patients (51%) received an allograft from a matched related donor (MRD), and 73 patients (49%) were recipients of unrelated donor (URD) grafts. There was no significant difference in the incidence of acute (gr II-IV) and chronic extensive graft-versus-host disease (aGVHD, cGVHD) between the recipients of related and unrelated donor grafts. By day +28, 75% of patients demonstrated mixed T cell chimerism. Graft rejection was seen in 15% of patients. With a median follow-up of 47 (range: 6-89) months, the 3-year relapse-free survival (RFS) and overall survival (OS) are both 27% for all patients, with a relapse incidence of 41%. The 3-year RFS for the patients with de novo MDS, AML after antecedent MDS/MPD, t-MDS, MPD, and CMML were 22%, 20%, 29%, 37%, and 43%, respectively, and the 3-year OS was 20%, 23%, 27%, 43%, and 43%, respectively. The 3-year nonrelapse mortality (NRM) was 32%. Factors associated with a lower risk of relapse were the development of extensive cGVHD and having a low risk or intermediate-1 risk International Prognostic Score for the de novo MDS patients. Nonmyeloablative HCT confers remissions in patients who otherwise were not eligible for conventional HCT but for whom relapse is the leading cause of treatment failure.",Clinical Trial,4372.0,106.0,Allogeneic hematopoietic transplantation HCT curative strategy patients myelodysplastic syndrome MDS myeloproliferative disorders MPD report 148 patients median age 59 years old novo MDS n 40 acute myelogenous leukemia AML antecedent MDS/MPD n 49 treatment-related MDS t-MDS n 25 MPD n 27 chronic myelomonocytic leukemia CMML n 7 underwent allogeneic HCT conditioning regimen low-dose total body irradiation TBI 200 cGy day 0 n 5 addition fludarabine Flu 30 mg/m 2 /day days -4 -2 n 143 Postgrafting immunosuppression consisted cyclosporine mycophenolate mofetil MMF Seventy-five patients 51 received allograft matched related donor MRD 73 patients 49 recipients unrelated donor URD grafts significant difference incidence acute gr II-IV chronic extensive graft-versus-host disease aGVHD cGVHD recipients related unrelated donor grafts day +28 75 patients demonstrated mixed chimerism Graft rejection seen 15 patients median follow-up 47 range 6-89 months 3-year relapse-free survival RFS overall survival OS 27 patients relapse incidence 41 3-year RFS patients novo MDS AML antecedent MDS/MPD t-MDS MPD CMML 22 20 29 37 43 respectively 3-year OS 20 23 27 43 43 respectively 3-year nonrelapse mortality NRM 32 Factors associated lower risk relapse development extensive cGVHD low risk intermediate-1 risk International Prognostic Score novo MDS patients Nonmyeloablative HCT confers remissions patients eligible conventional HCT relapse leading cause treatment failure,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1063, 1007, 31, 497, 1085, 16, 3, 158, 1075, 692, 9, 7, 5, 681, 1223, 2, 1997, 7712, 21, 414, 3, 99, 1, 4647, 7, 52, 89, 728, 60, 1095, 5, 1566, 2018, 1223, 78, 327, 286, 2194, 329, 50, 8775, 1223, 7712, 78, 739, 24, 139, 1223, 102, 1223, 78, 243, 7712, 78, 428, 2, 442, 5451, 3382, 78, 67, 54, 208, 1063, 1085, 75, 8, 1933, 477, 1, 154, 61, 181, 642, 1104, 4889, 279, 1250, 3071, 23, 218, 13, 78, 33, 15, 5, 3, 352, 1, 2027, 5119, 201, 81, 188, 18, 218, 23, 162, 39, 6, 18, 78, 4400, 28085, 3646, 1695, 1, 9112, 2, 11902, 13246, 9889, 2073, 365, 7, 725, 103, 35, 9568, 29, 8, 655, 139, 1488, 2029, 2, 803, 7, 739, 11, 2190, 1, 2092, 1488, 5847, 4713, 125, 10, 77, 93, 523, 4, 3, 287, 1, 286, 3845, 215, 478, 2, 442, 1344, 1599, 185, 1204, 34, 5873, 6670, 59, 3, 2190, 1, 139, 2, 2092, 1488, 4713, 20, 218, 339, 481, 1, 7, 264, 1739, 102, 31, 6047, 1599, 4772, 10, 527, 4, 167, 1, 7, 5, 8, 52, 166, 126, 1, 662, 184, 49, 887, 53, 3, 27, 111, 429, 115, 25, 1272, 2, 63, 25, 118, 32, 110, 428, 9, 62, 7, 5, 8, 429, 287, 1, 605, 3, 27, 111, 1272, 9, 3, 7, 5, 1566, 2018, 1223, 329, 50, 8775, 1223, 7712, 102, 1223, 7712, 2, 3382, 11, 350, 179, 462, 567, 2, 601, 106, 2, 3, 27, 111, 118, 10, 179, 382, 428, 601, 2, 601, 106, 3, 27, 111, 4640, 282, 4296, 10, 531, 130, 41, 5, 8, 280, 43, 1, 429, 11, 3, 193, 1, 1344, 6670, 2, 1041, 8, 154, 43, 15, 919, 14, 43, 944, 177, 368, 9, 3, 1566, 2018, 1223, 7, 6094, 1085, 4020, 3166, 4, 7, 54, 2632, 11, 44, 625, 9, 809, 1085, 84, 9, 953, 429, 16, 3, 1049, 708, 1, 24, 496]",1834.0,18215785,Reduced-intensity conditioning followed allogeneic hematopoietic transplantation adult patients myelodysplastic syndrome myeloproliferative disorders,114,0.19895287958115182
Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes.,Leukemia research,Leuk. Res.,2008-02-07,"Allogeneic blood and marrow transplantation (alloBMT) remains the only curative treatment for patients with myelodysplastic syndromes (MDS), but its application has been limited by the older age range of patients with this disease. T cell depletion decreases transplant-related toxicity related to graft-versus-host disease (GVHD), but does not improve overall survival because of increased risk for relapse and graft failure. Myeloid growth factors have been used to speed engraftment following alloBMT, but data suggest that they may also have anti-tumor properties. We treated 43 patients (median age 56) with MDS/AML with high-risk features using a myeloablative T cell depleted alloBMT followed by prolonged systemic GM-CSF. The current event-free survival at 1 and 3 years was 47% and 34%, respectively with a median follow-up of 22.8 months in surviving patients. The toxicities compared favorably with those seen using reduced intensity conditioning regimens and included grade III/IV GVHD (10%), graft failure (9%), and cumulative treatment-related mortality (28%). The cumulative incidence of relapse remained high at 38%; however, 3/10 patients receiving donor lymphocyte infusions achieved durable complete remissions. These results suggest that it is possible to maintain treatment intensity while minimizing toxicity in older, high-risk MDS patients.",Journal Article,4366.0,17.0,Allogeneic blood marrow transplantation alloBMT remains curative treatment patients myelodysplastic syndromes MDS application limited older age range patients disease depletion decreases transplant-related toxicity related graft-versus-host disease GVHD improve overall survival increased risk relapse graft failure Myeloid growth factors speed engraftment following alloBMT suggest anti-tumor properties treated 43 patients median age 56 MDS/AML high-risk features myeloablative depleted alloBMT followed prolonged systemic GM-CSF current event-free survival 1 3 years 47 34 respectively median follow-up 22.8 months surviving patients toxicities compared favorably seen reduced intensity conditioning regimens included grade III/IV GVHD 10 graft failure 9 cumulative treatment-related mortality 28 cumulative incidence relapse remained high 38 3/10 patients receiving donor lymphocyte infusions achieved durable complete remissions suggest possible maintain treatment intensity minimizing toxicity older high-risk MDS patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1063, 315, 2, 581, 497, 13051, 469, 3, 158, 1075, 24, 9, 7, 5, 2040, 1223, 84, 211, 1581, 71, 85, 383, 20, 3, 434, 89, 184, 1, 7, 5, 26, 34, 102, 31, 2286, 2140, 941, 139, 155, 139, 6, 1599, 185, 1204, 34, 1562, 84, 1097, 44, 401, 63, 25, 408, 1, 101, 43, 9, 429, 2, 1599, 496, 533, 129, 130, 47, 85, 95, 6, 5051, 2881, 366, 13051, 84, 74, 309, 17, 491, 68, 120, 47, 312, 30, 1571, 21, 73, 601, 7, 52, 89, 664, 5, 1223, 329, 5, 64, 43, 404, 75, 8, 3246, 102, 31, 4358, 13051, 370, 20, 1069, 403, 2147, 1211, 3, 291, 774, 115, 25, 28, 14, 2, 27, 60, 10, 662, 2, 562, 106, 5, 8, 52, 166, 126, 1, 350, 66, 53, 4, 3050, 7, 3, 385, 72, 5001, 5, 135, 527, 75, 405, 837, 1933, 472, 2, 159, 88, 316, 478, 1562, 79, 1599, 496, 83, 2, 967, 24, 139, 282, 339, 3, 967, 287, 1, 429, 958, 64, 28, 519, 137, 27, 79, 7, 357, 1488, 1448, 3435, 513, 1480, 236, 3166, 46, 99, 309, 17, 192, 16, 899, 6, 3040, 24, 837, 369, 4501, 155, 4, 434, 64, 43, 1223, 7]",1311.0,18261793,Myeloablative allogeneic bone marrow transplant depleted allografts followed post-transplant GM-CSF high-risk myelodysplastic syndromes,35,0.06108202443280977
Phase II study of azacitidine to restore responsiveness of prostate cancer to hormonal therapy.,Clinical genitourinary cancer,Clin Genitourin Cancer,2007-12-01,"Epigenetic alterations, including methylation of key tumor suppressor genes, may play a role in the progression of prostate cancer to a castration-refractory state. Azacitidine, an agent approved for the treatment of myelodysplastic syndromes, appears to exert its antineoplastic effects partly by hypomethylating DNA that leads to the reversal of gene silencing. It is hypothesized that the addition of azacitidine to complete androgen blockade may restore the responsiveness of progressive prostate cancer to hormonal therapy. A phase II trial was designed to evaluate the activity of azacitidine to primarily modulate PSA kinetics, with supportive secondary clinical endpoints. Correlative studies will be performed to detect the biologic activity of azacitidine (increased fetal hemoglobin, plasma DNA methylation) and examine any association with anti-tumor clinical activity.","Clinical Trial, Phase II",4434.0,11.0,Epigenetic alterations including methylation key suppressor play role progression prostate castration-refractory state Azacitidine agent approved treatment myelodysplastic syndromes appears exert antineoplastic effects partly hypomethylating DNA leads reversal silencing hypothesized addition azacitidine complete androgen blockade restore responsiveness progressive prostate hormonal therapy phase II trial designed evaluate activity azacitidine primarily modulate PSA kinetics supportive secondary clinical endpoints Correlative studies performed detect biologic activity azacitidine increased fetal hemoglobin plasma DNA methylation examine association anti-tumor clinical activity,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1418, 593, 141, 569, 1, 825, 30, 1245, 214, 68, 1343, 8, 200, 4, 3, 91, 1, 12, 6, 8, 1517, 430, 1309, 3752, 35, 420, 850, 9, 3, 24, 1, 2040, 1233, 6, 5448, 211, 3940, 176, 5180, 20, 4931, 261, 17, 1940, 6, 3, 5933, 1, 145, 2077, 192, 16, 1237, 17, 3, 352, 1, 3752, 6, 236, 687, 1189, 68, 6075, 3, 3642, 1, 1014, 12, 6, 1761, 36, 8, 124, 215, 160, 10, 1114, 6, 376, 3, 128, 1, 3752, 6, 1561, 3319, 534, 3839, 5, 1877, 568, 38, 1387, 3679, 94, 303, 40, 173, 6, 1426, 3, 1283, 128, 1, 3752, 101, 6698, 2222, 554, 261, 569, 2, 1004, 500, 248, 5, 312, 30, 38, 128]",834.0,18272030,Phase II azacitidine restore responsiveness prostate hormonal therapy,0,0.0
Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2008-03-01,"The lower morbidity and mortality of reduced-intensity conditioning (RIC) regimens have allowed allogeneic hematopoietic cell transplantation (HCT) in older patients. Unrelated umbilical cord blood (UCB) has been investigated as an alternative stem cell source to suitably HLA matched related (MRD) and adult volunteer unrelated donors. We hypothesized that RIC HCT using UCB would be safe and efficacious in older patients, and compared the treatment-related mortality (TRM) and overall survival (OS) of RIC HCT in patients older than 55 years using either MRD (n = 47) or, in patients with no 5 of 6 or 6 of 6 HLA compatible related donors, UCB (n = 43). RIC regimen consisted of total-body irradiation (TBI; 200 cGy) and either cyclophosphamide and fludarabine (n = 69), or busulfan and fludarabine (n = 16) or busulfan and cladribine (n = 5). The median age of MRD and UCB cohorts was 58 (range, 55-70) and 59 (range, 55-69) years, respectively. acute myelogenous leukemia/myelodysplastic syndrome (AML/MDS) (50%) was the most common diagnosis. All MRD grafts were 6 of 6 HLA matched to the recipient. Among patients undergoing UCB HCT, 88% received 2 UCB units to optimize cell dose and 93% received 1-2 HLA mismatched grafts. The median follow-up for survivors was 27 (range: 12-61) months. The 3-year probabilities of progression-free survival (PFS; 30% versus 34%, P = .98) and OS (43% versus 34%, P = .57) were similar for recipients of MRD and UCB. The cumulative incidence of grade II-IV acute graft-versus-host (aGVHD) disease (42% versus 49%, P = .20) and TRM at 180-days (23% versus 28%, P = .36) were comparable. However, UCB recipients had a lower incidence of chronic graft-versus-host disease (cGVHD) at 1 year (40% versus 17%, P = .02). On multivariate analysis, graft type had no impact on TRM or survival, and the HCT comorbidity index score was the only factor independently predictive for these endpoints. Our study supports the use of HLA mismatched UCB as an alternative graft source for older patients who need a transplant but do not have an MRD. The use of RIC and UCB extends the availability of transplant therapy to older patients previously excluded on the basis of age and lack of a suitable MRD. A careful review of existing comorbidities is necessary when considering older patients for HCT.",Clinical Trial,4343.0,96.0,lower morbidity mortality reduced-intensity conditioning RIC regimens allowed allogeneic hematopoietic transplantation HCT older patients Unrelated umbilical cord blood UCB investigated alternative stem source suitably HLA matched related MRD adult volunteer unrelated donors hypothesized RIC HCT UCB safe efficacious older patients compared treatment-related mortality TRM overall survival OS RIC HCT patients older 55 years MRD n 47 patients 5 6 6 6 HLA compatible related donors UCB n 43 RIC regimen consisted total-body irradiation TBI 200 cGy cyclophosphamide fludarabine n 69 busulfan fludarabine n 16 busulfan cladribine n 5 median age MRD UCB cohorts 58 range 55-70 59 range 55-69 years respectively acute myelogenous leukemia/myelodysplastic syndrome AML/MDS 50 common diagnosis MRD grafts 6 6 HLA matched recipient patients undergoing UCB HCT 88 received 2 UCB units optimize dose 93 received 1-2 HLA mismatched grafts median follow-up survivors 27 range 12-61 months 3-year probabilities progression-free survival PFS 30 versus 34 P .98 OS 43 versus 34 P .57 similar recipients MRD UCB cumulative incidence grade II-IV acute graft-versus-host aGVHD disease 42 versus 49 P .20 TRM 180-days 23 versus 28 P .36 comparable UCB recipients lower incidence chronic graft-versus-host disease cGVHD 1 year 40 versus 17 P .02 multivariate graft type impact TRM survival HCT comorbidity index score factor independently predictive endpoints supports use HLA mismatched UCB alternative graft source older patients need transplant MRD use RIC UCB extends availability transplant therapy older patients previously excluded basis age lack suitable MRD careful review existing comorbidities necessary considering older patients HCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 280, 787, 2, 282, 1, 405, 837, 1933, 3365, 472, 47, 2313, 1063, 1007, 31, 497, 1085, 4, 434, 7, 2092, 5998, 1885, 315, 4056, 71, 85, 565, 22, 35, 1091, 452, 31, 2353, 6, 33526, 1160, 655, 139, 2029, 2, 780, 15536, 2092, 2344, 21, 1237, 17, 3365, 1085, 75, 4056, 688, 40, 1165, 2, 3289, 4, 434, 7, 2, 72, 3, 24, 139, 282, 5064, 2, 63, 25, 118, 1, 3365, 1085, 4, 7, 434, 76, 614, 60, 75, 361, 2029, 78, 662, 15, 4, 7, 5, 77, 33, 1, 49, 15, 49, 1, 49, 1160, 7293, 139, 2344, 4056, 78, 601, 3365, 477, 1695, 1, 181, 642, 1104, 4889, 1250, 3071, 2, 361, 1112, 2, 2027, 78, 790, 15, 3906, 2, 2027, 78, 245, 15, 3906, 2, 8251, 78, 33, 3, 52, 89, 1, 2029, 2, 4056, 736, 10, 717, 184, 614, 431, 2, 728, 184, 614, 790, 60, 106, 286, 2194, 2647, 10589, 681, 329, 1223, 212, 10, 3, 96, 186, 147, 62, 2029, 4713, 11, 49, 1, 49, 1160, 655, 6, 3, 5783, 107, 7, 479, 4056, 1085, 889, 103, 18, 4056, 2960, 6, 2465, 31, 61, 2, 966, 103, 14, 18, 1160, 5095, 4713, 3, 52, 166, 126, 9, 332, 10, 428, 184, 133, 713, 53, 3, 27, 111, 3518, 1, 91, 115, 25, 300, 201, 185, 562, 19, 1096, 2, 118, 601, 185, 562, 19, 696, 11, 288, 9, 2190, 1, 2029, 2, 4056, 3, 967, 287, 1, 88, 215, 478, 286, 1599, 185, 1204, 5873, 34, 595, 185, 739, 19, 179, 2, 5064, 28, 3172, 162, 382, 185, 339, 19, 511, 11, 1279, 137, 4056, 2190, 42, 8, 280, 287, 1, 442, 1599, 185, 1204, 34, 6670, 28, 14, 111, 327, 185, 269, 19, 588, 23, 331, 65, 1599, 267, 42, 77, 345, 23, 5064, 15, 25, 2, 3, 1085, 1879, 558, 368, 10, 3, 158, 161, 1042, 464, 9, 46, 1387, 114, 45, 2304, 3, 119, 1, 1160, 5095, 4056, 22, 35, 1091, 1599, 2353, 9, 434, 7, 54, 594, 8, 941, 84, 1022, 44, 47, 35, 2029, 3, 119, 1, 3365, 2, 4056, 8464, 3, 2550, 1, 941, 36, 6, 434, 7, 373, 1800, 23, 3, 877, 1, 89, 2, 926, 1, 8, 2884, 2029, 8, 3465, 206, 1, 1692, 1909, 16, 1493, 198, 3075, 434, 7, 9, 1085]",2210.0,18275894,Reduced-intensity allogeneic transplant patients older 55 years unrelated umbilical cord blood safe effective patients matched related donor,0,0.0
New data with arsenic trioxide in leukemias and myelodysplastic syndromes.,Clinical lymphoma & myeloma,Clin Lymphoma Myeloma,2007-12-01,"Arsenic and its derivatives have been used for medicinal purposes for thousands of years. Arsenic trioxide has demonstrated remarkable activity in the treatment of acute promyelocytic leukemia (APL), for which it can bring about complete remissions (CR) in > 80% of patients with relapsed disease, and molecular remission in 90% of those who enter a CR. Clinical trials have explored its use in the first-line setting and as part of consolidation therapy for de novo APL, for which it appears to provide an event-free and overall survival advantage. Two multicenter trials have examined its use in the treatment of the myelodysplastic syndromes; as a single agent, it yields responses in 20% of patients, and smaller trials have provided evidence for its use in non-APL acute myeloid leukemia populations in combination with other drugs such as gemtuzumab ozogamicin, ascorbic acid, and cytarabine.",Journal Article,4434.0,12.0,Arsenic derivatives medicinal purposes thousands years Arsenic trioxide demonstrated remarkable activity treatment acute promyelocytic leukemia APL bring complete remissions CR 80 patients relapsed disease molecular remission 90 enter CR Clinical trials explored use first-line setting consolidation therapy novo APL appears provide event-free overall survival advantage multicenter trials examined use treatment myelodysplastic syndromes single agent yields responses 20 patients smaller trials provided evidence use non-APL acute myeloid leukemia populations combination drugs gemtuzumab ozogamicin ascorbic acid cytarabine,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3217, 2, 211, 6490, 47, 85, 95, 9, 17342, 4624, 9, 8505, 1, 60, 3217, 4574, 71, 264, 3813, 128, 4, 3, 24, 1, 286, 4300, 2578, 9, 92, 192, 122, 8798, 545, 236, 3166, 684, 4, 493, 1, 7, 5, 591, 34, 2, 219, 734, 4, 424, 1, 135, 54, 7058, 8, 684, 38, 143, 47, 1443, 211, 119, 4, 3, 157, 328, 546, 2, 22, 760, 1, 2173, 36, 9, 1566, 2018, 2578, 9, 92, 192, 1233, 6, 377, 35, 774, 115, 2, 63, 25, 1874, 100, 1570, 143, 47, 409, 211, 119, 4, 3, 24, 1, 3, 2040, 22, 8, 226, 420, 192, 4788, 253, 4, 179, 1, 7, 2, 2170, 143, 47, 1052, 241, 9, 211, 119, 4, 220, 2578, 286, 533, 1184, 4, 150, 5, 127, 600, 225, 22, 7918, 5566, 18841, 971, 2, 1855]",843.0,18282365,New arsenic trioxide leukemias myelodysplastic syndromes,24,0.041884816753926704
Involved-field radiotherapy before high-dose therapy and autologous stem-cell rescue in diffuse large-cell lymphoma: long-term disease control and toxicity.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2008-03-10,"To analyze outcome, prognostic factors, and toxicities in patients with diffuse large-cell lymphoma (DLCL) who received involved-field radiotherapy (IFRT) before high-dose chemotherapy with autologous stem-cell rescue (ASCR). Between January 1990 and August 2006, 164 patients with relapsed or refractory DLCL received IFRT at Memorial Sloan-Kettering Cancer Center (New York, NY) before high-dose chemotherapy and ASCR. IFRT was delivered to involved sites measuring more than 5 cm or to sites with residual disease more than 2 cm. Radiotherapy was administered in 1.5-Gy fractions twice daily to a total dose of 30 Gy. Progression-free survival and overall survival were calculated, and short- and long-term toxicity was assessed according to National Cancer Institute Common Toxicity Criteria (version 2.0). Median follow-up was 60 months (range, 2 to 187 months). Two- and 5-year progression-free survival was 62% and 53%; 2- and 5-year overall survival was 67% and 58%, respectively. Sixty-seven patients relapsed; only 10 patients relapsed completely within the radiotherapy field. There were seven early treatment-related mortalities and 11 secondary cancers (including four myelodysplastic syndromes), one of which occurred within the IFRT site and five after total-body irradiation. Minimal treatment-related mortality and morbidity resulted from short, intensive, involved-field radiotherapy before high-dose chemotherapy and ASCR, which was incorporated into a salvage regimen for patients with relapsed/refractory DLCL. This chemoradiotherapy salvage regimen resulted in a low local relapse rate that could potentially translate into an improved total outcome.",Clinical Trial,4334.0,29.0,outcome prognostic factors toxicities patients diffuse large-cell lymphoma DLCL received involved-field radiotherapy IFRT high-dose chemotherapy autologous stem-cell rescue ASCR January 1990 August 2006 164 patients relapsed refractory DLCL received IFRT Memorial Sloan-Kettering Center New York NY high-dose chemotherapy ASCR IFRT delivered involved sites measuring 5 cm sites residual disease 2 cm Radiotherapy administered 1.5-Gy fractions twice daily total dose 30 Gy Progression-free survival overall survival calculated short- long-term toxicity assessed according National Institute Common Toxicity Criteria version 2.0 Median follow-up 60 months range 2 187 months Two- 5-year progression-free survival 62 53 2- 5-year overall survival 67 58 respectively Sixty-seven patients relapsed 10 patients relapsed completely radiotherapy field seven early treatment-related mortalities 11 secondary including myelodysplastic syndromes occurred IFRT site total-body irradiation Minimal treatment-related mortality morbidity resulted short intensive involved-field radiotherapy high-dose chemotherapy ASCR incorporated salvage regimen patients relapsed/refractory DLCL chemoradiotherapy salvage regimen resulted low local relapse rate potentially translate improved total outcome,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 1992, 228, 177, 130, 2, 385, 4, 7, 5, 1388, 375, 31, 12770, 54, 103, 646, 1067, 310, 6375, 348, 64, 61, 56, 5, 1028, 452, 31, 4256, 10729, 59, 1024, 2289, 2, 2480, 1324, 5279, 7, 5, 591, 15, 430, 12770, 103, 6375, 28, 2563, 2783, 2784, 12, 574, 217, 5050, 2906, 348, 64, 61, 56, 2, 10729, 6375, 10, 1623, 6, 646, 633, 2978, 80, 76, 33, 494, 15, 6, 633, 5, 753, 34, 80, 76, 18, 494, 310, 10, 468, 4, 14, 33, 381, 1550, 936, 391, 6, 8, 181, 61, 1, 201, 381, 91, 115, 25, 2, 63, 25, 11, 981, 2, 978, 2, 319, 337, 155, 10, 275, 768, 6, 657, 12, 1377, 186, 155, 371, 2256, 18, 13, 52, 166, 126, 10, 335, 53, 184, 18, 6, 5568, 53, 100, 2, 33, 111, 91, 115, 25, 10, 744, 2, 699, 18, 2, 33, 111, 63, 25, 10, 598, 2, 717, 106, 1746, 648, 7, 591, 158, 79, 7, 591, 2500, 262, 3, 310, 1067, 125, 11, 648, 191, 24, 139, 9743, 2, 175, 568, 163, 141, 294, 2040, 104, 1, 92, 489, 262, 3, 6375, 606, 2, 365, 50, 181, 642, 1104, 1048, 24, 139, 282, 2, 787, 627, 29, 978, 1686, 646, 1067, 310, 348, 64, 61, 56, 2, 10729, 92, 10, 2449, 237, 8, 992, 477, 9, 7, 5, 591, 430, 12770, 26, 1464, 992, 477, 627, 4, 8, 154, 293, 429, 116, 17, 359, 751, 4509, 237, 35, 231, 181, 228]",1605.0,18332466,Involved-field radiotherapy high-dose therapy autologous stem-cell rescue diffuse large-cell lymphoma long-term disease control toxicity,1,0.0017452006980802793
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.,Leukemia research,Leuk. Res.,2008-03-19,"The addition of imatinib to high-intensity chemotherapy has improved the outcome of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the possible long-term side effects of this combination are not yet known. Development of new clonal abnormalities in complete cytogenetic remission after treatment with imatinib has been reported in patients with chronic myeloid leukemia but not in patients with Ph-positive ALL. Here, we present a patient with Ph-positive ALL who received hyperCVAD plus imatinib and achieved hematologic, cytogenetic, and major molecular responses. The patient then developed myelodysplastic syndrome and solitary central nervous system relapse of ALL.",Case Reports,4325.0,0.0,addition imatinib high-intensity chemotherapy improved outcome patients Philadelphia chromosome Ph -positive acute lymphoblastic leukemia possible long-term effects combination known Development new clonal abnormalities complete cytogenetic remission treatment imatinib reported patients chronic myeloid leukemia patients Ph-positive present patient Ph-positive received hyperCVAD plus imatinib achieved hematologic cytogenetic major molecular responses patient developed myelodysplastic syndrome solitary central nervous relapse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 352, 1, 577, 6, 64, 837, 56, 71, 231, 3, 228, 1, 7, 5, 3006, 1170, 2058, 109, 286, 1275, 62, 137, 3, 899, 319, 337, 1152, 176, 1, 26, 150, 32, 44, 1145, 440, 193, 1, 217, 1946, 1171, 4, 236, 1266, 734, 50, 24, 5, 577, 71, 85, 210, 4, 7, 5, 442, 533, 84, 44, 4, 7, 5, 2058, 109, 62, 467, 21, 364, 8, 69, 5, 2058, 109, 62, 54, 103, 13792, 349, 577, 2, 513, 813, 1266, 2, 458, 219, 253, 3, 69, 818, 276, 681, 2, 3144, 854, 1880, 398, 429, 1, 62]",674.0,18355919,Secondary myelodysplastic syndrome patient Philadelphia-positive acute lymphoblastic leukemia achieving major molecular response hyperCVAD plus imatinib mesylate,1,0.0017452006980802793
"A phase I biological study of MG98, an oligodeoxynucleotide antisense to DNA methyltransferase 1, in patients with high-risk myelodysplasia and acute myeloid leukemia.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2008-04-01,"Epigenetic silencing via aberrant promoter DNA hypermethylation of normal genes has been described as a leukemogenic mechanism in myelodysplastic syndromes (MDS) and acute myeloid leukemias (AML). We hypothesized that MG98, an oligonucleotide antisense to DNA methyltransferase 1 (DNMT1), could reverse malignant phenotypes by down-regulating DNMT1 and inducing reexpression of hypermethylated genes. This phase I study was conducted to determine a biologically effective dose and describe the safety of MG98 in MDS/AML. Twenty-three patients with MDS (n = 11) and AML (n = 12) were enrolled. Biologically effective dose was defined as the dose at which > or =50% of patients experienced >50% reduction in DNMT1 expression with acceptable toxicity. Escalating doses of MG98 were administered according to two schedules (2-hour i.v. bolus followed by 5-day continuous i.v. infusion every 14 days, or 14-day continuous i.v. infusion every 21 days). DNMT1 down-regulation was observed in 8 patients. However, biologically effective dose was not reached. Reexpression of target genes (P15, WIT1, and ER) was observed in 12 patients but did not correlate with DNMT1 down-regulation. Escalation was stopped due to dose-limiting toxicities (bone pain, nausea, and fever). No objective clinical response was observed. Disease stabilization occurred in 6 (26%) patients. No pharmacodynamic or clinical activity was observed at MG98 doses and schedules administered. Despite this, pursuing DNMT1 down-regulation remains a sound approach for targeting aberrant epigenetics in AML/MDS. Future studies with different formulation and/or doses and schedules will be required to ensure efficient MG98 intracellular uptake and fully evaluate its therapeutic potential.","Clinical Trial, Phase I",4312.0,67.0,Epigenetic silencing aberrant promoter DNA hypermethylation normal described leukemogenic mechanism myelodysplastic syndromes MDS acute myeloid leukemias AML hypothesized MG98 oligonucleotide antisense DNA methyltransferase 1 DNMT1 reverse malignant phenotypes down-regulating DNMT1 inducing reexpression hypermethylated phase conducted determine biologically effective dose safety MG98 MDS/AML Twenty-three patients MDS n 11 AML n 12 enrolled Biologically effective dose defined dose =50 patients experienced 50 reduction DNMT1 expression acceptable toxicity Escalating doses MG98 administered according schedules 2-hour i.v bolus followed 5-day continuous i.v infusion 14 days 14-day continuous i.v infusion 21 days DNMT1 down-regulation observed 8 patients biologically effective dose reached Reexpression target P15 WIT1 ER observed 12 patients correlate DNMT1 down-regulation Escalation stopped dose-limiting toxicities bone pain nausea fever objective clinical response observed Disease stabilization occurred 6 26 patients pharmacodynamic clinical activity observed MG98 doses schedules administered Despite pursuing DNMT1 down-regulation remains sound approach targeting aberrant epigenetics AML/MDS Future studies different formulation and/or doses schedules required ensure efficient MG98 intracellular uptake fully evaluate therapeutic potential,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1418, 2077, 847, 1898, 973, 261, 2575, 1, 295, 214, 71, 85, 1027, 22, 8, 13519, 670, 4, 2040, 1223, 2, 286, 533, 2792, 329, 21, 1237, 17, 31269, 35, 4727, 4645, 6, 261, 3747, 14, 7328, 359, 1772, 393, 2618, 20, 1328, 2681, 7328, 2, 1958, 11120, 1, 6936, 214, 26, 124, 70, 45, 10, 426, 6, 223, 8, 2665, 323, 61, 2, 897, 3, 367, 1, 31269, 4, 1223, 329, 737, 169, 7, 5, 1223, 78, 175, 2, 329, 78, 133, 11, 346, 2665, 323, 61, 10, 395, 22, 3, 61, 28, 92, 15, 212, 1, 7, 592, 212, 628, 4, 7328, 55, 5, 1595, 155, 2922, 415, 1, 31269, 11, 468, 768, 6, 100, 2314, 18, 2583, 70, 603, 3604, 370, 20, 33, 218, 1314, 70, 603, 904, 454, 213, 162, 15, 213, 218, 1314, 70, 603, 904, 454, 239, 162, 7328, 1328, 863, 10, 164, 4, 66, 7, 137, 2665, 323, 61, 10, 44, 1300, 11120, 1, 283, 214, 8840, 57003, 2, 516, 10, 164, 4, 133, 7, 84, 205, 44, 1513, 5, 7328, 1328, 863, 1125, 10, 4403, 520, 6, 61, 817, 385, 559, 1218, 2, 2775, 77, 461, 38, 51, 10, 164, 34, 3184, 489, 4, 49, 432, 7, 77, 2424, 15, 38, 128, 10, 164, 28, 31269, 415, 2, 2314, 468, 550, 26, 10692, 7328, 1328, 863, 469, 8, 11475, 353, 9, 529, 1898, 9706, 4, 329, 1223, 508, 94, 5, 338, 3583, 2, 15, 415, 2, 2314, 303, 40, 616, 6, 3478, 2547, 31269, 2087, 1135, 2, 1910, 376, 211, 189, 174]",1675.0,18413836,phase MG98 oligodeoxynucleotide antisense DNA methyltransferase 1 patients high-risk myelodysplasia acute myeloid leukemia,6,0.010471204188481676
Higher doses of lenalidomide are associated with unacceptable toxicity including life-threatening tumor flare in patients with chronic lymphocytic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2008-04-21,"Lenalidomide is a novel therapeutic agent with uncertain mechanism of action that is clinically active in myelodysplastic syndrome (MDS) and multiple myeloma (MM). Application of high (MM) and low (MDS) doses of lenalidomide has been reported to have clinical activity in CLL. Herein, we highlight life-threatening tumor flare when higher doses of lenalidomide are administered to patients with CLL and provide a potential mechanism for its occurrence. Four patients with relapsed CLL were treated with lenalidomide (25 mg/d for 21 days of a 28-day cycle). Serious adverse events including tumor flare and tumor lysis are summarized. In vitro studies examining drug-induced apoptosis and activation of CLL cells were also performed. Four consecutive patients were treated with lenalidomide; all had serious adverse events. Tumor flare was observed in three patients and was characterized by dramatic and painful lymph node enlargement resulting in hospitalization of two patients, with one fatal outcome. Another patient developed sepsis and renal failure. In vitro studies demonstrated lenalidomide-induced B-cell activation (upregulation of CD40 and CD86) corresponding to degree of tumor flare, possibly explaining the tumor flare observation. Lenalidomide administered at 25 mg/d in relapsed CLL is associated with unacceptable toxicity; the rapid onset and adverse clinical effects of tumor flare represent a significant limitation of lenalidomide use in CLL at this dose. Drug-associated B-cell activation may contribute to this adverse event. Future studies with lenalidomide in CLL should focus on understanding this toxicity, investigating patients at risk, and investigating alternative safer dosing schedules.",Case Reports,4292.0,135.0,Lenalidomide novel therapeutic agent uncertain mechanism action clinically active myelodysplastic syndrome MDS multiple myeloma MM Application high MM low MDS doses lenalidomide reported clinical activity CLL highlight life-threatening flare higher doses lenalidomide administered patients CLL provide potential mechanism occurrence patients relapsed CLL treated lenalidomide 25 mg/d 21 days 28-day cycle adverse events including flare lysis summarized vitro studies examining drug-induced apoptosis activation CLL performed consecutive patients treated lenalidomide adverse events flare observed patients characterized dramatic painful lymph node enlargement resulting hospitalization patients fatal outcome patient developed sepsis renal failure vitro studies demonstrated lenalidomide-induced B-cell activation upregulation CD40 CD86 corresponding degree flare possibly explaining flare observation Lenalidomide administered 25 mg/d relapsed CLL associated unacceptable toxicity rapid onset adverse clinical effects flare represent significant limitation lenalidomide use CLL dose Drug-associated B-cell activation contribute adverse event Future studies lenalidomide CLL focus understanding toxicity investigating patients risk investigating alternative safer dosing schedules,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1288, 16, 8, 229, 189, 420, 5, 2717, 670, 1, 1578, 17, 16, 505, 544, 4, 681, 1223, 2, 232, 321, 1581, 1, 64, 321, 2, 154, 1223, 415, 1, 1288, 71, 85, 210, 6, 47, 38, 128, 4, 552, 1986, 21, 1817, 358, 3691, 30, 6915, 198, 142, 415, 1, 1288, 32, 468, 6, 7, 5, 552, 2, 377, 8, 174, 670, 9, 211, 2291, 294, 7, 5, 591, 552, 11, 73, 5, 1288, 243, 81, 427, 9, 239, 162, 1, 8, 339, 218, 417, 1762, 290, 281, 141, 30, 6915, 2, 30, 4783, 32, 3989, 4, 439, 94, 3282, 234, 277, 351, 2, 363, 1, 552, 37, 11, 120, 173, 294, 935, 7, 11, 73, 5, 1288, 62, 42, 1762, 290, 281, 30, 6915, 10, 164, 4, 169, 7, 2, 10, 765, 20, 3079, 2, 7041, 263, 289, 9738, 1113, 4, 2826, 1, 100, 7, 5, 104, 3034, 228, 1809, 69, 276, 4227, 2, 496, 4, 439, 94, 264, 1288, 277, 132, 31, 363, 2218, 1, 5040, 2, 12514, 1734, 6, 1444, 1, 30, 6915, 2150, 8290, 3, 30, 6915, 1664, 1288, 468, 28, 243, 81, 427, 4, 591, 552, 16, 41, 5, 3215, 155, 3, 1321, 1707, 2, 290, 38, 176, 1, 30, 6915, 1231, 8, 93, 5039, 1, 1288, 119, 4, 552, 28, 26, 61, 234, 41, 132, 31, 363, 68, 1248, 6, 26, 290, 774, 508, 94, 5, 1288, 4, 552, 257, 1222, 23, 612, 26, 155, 3103, 7, 28, 43, 2, 3103, 1091, 9276, 1280, 2314]",1658.0,18427150,Higher doses lenalidomide associated unacceptable toxicity including life-threatening flare patients chronic lymphocytic leukemia,2,0.0034904013961605585
Adult Henoch-schnlein purpura in a patient with myelodysplastic syndrome and a history of follicular lymphoma.,Cutis,Cutis,2008-02-01,"To understand Henoch-Schnlein purpura (HSP) to better manage patients with the condition. Upon completion of this activity, dermatologists and general practitioners should be able to: 1. Describe the criteria for diagnosing HSP. 2. Explain the association of malignancy and HSP. 3. Discuss the prevalence of HSP in adults. Henoch-Schnlein purpura (HSP) is a systemic leukocytoclastic vasculitis involving arterioles and venules most commonly in the skin, glomeruli, and gastrointestinal tract. In skin, it is associated with IgA deposition around dermal blood vessels. While an exact cause of HSP has not been elucidated, several processes have been implicated in its development, including infections; drugs; and allergic, rheumatologic, and neoplastic diseases. We present a 57-year-old woman with a history of follicular lymphoma who developed HSP likely associated with myelodysplastic syndrome. This case is clinically significant because the patient was thought to be in remission of her hematologic disease until her skin findings prompted further evaluation. Her diagnosis of HSP was based on clinical presentation with palpable purpura and abdominal pain, and was confirmed with biopsy and immunohistochemical analyses of purpuric papules demonstrating leukocytoclastic vasculitis and strong anti-IgA labeling in the dermal endothelial cells consistent with immunocomplex deposition. The occurrence of vasculitis and malignant disease in the same patient often is difficult to interpret, as some patients may exhibit both diseases independently and by chance, while others may have vasculitis as a paraneoplastic syndrome. We review cases of adult HSP associated with malignancy in the literature.",Case Reports,4372.0,10.0,understand Henoch-Schnlein purpura HSP better manage patients condition completion activity dermatologists general practitioners able 1 criteria diagnosing HSP 2 Explain association malignancy HSP 3 Discuss prevalence HSP adults Henoch-Schnlein purpura HSP systemic leukocytoclastic vasculitis involving arterioles venules commonly skin glomeruli gastrointestinal tract skin associated IgA deposition dermal blood vessels exact cause HSP elucidated processes implicated development including infections drugs allergic rheumatologic neoplastic diseases present 57-year-old woman history follicular lymphoma developed HSP likely associated myelodysplastic syndrome case clinically significant patient thought remission hematologic disease skin findings prompted evaluation diagnosis HSP based clinical presentation palpable purpura abdominal pain confirmed biopsy immunohistochemical purpuric papules demonstrating leukocytoclastic vasculitis strong anti-IgA labeling dermal endothelial consistent immunocomplex deposition occurrence vasculitis malignant disease patient difficult interpret patients exhibit diseases independently chance vasculitis paraneoplastic syndrome review cases adult HSP associated malignancy literature,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[6, 1640, 45102, 45103, 14174, 7921, 6, 380, 4001, 7, 5, 3, 2850, 1548, 1438, 1, 26, 128, 15983, 2, 1083, 6323, 257, 40, 1665, 6, 14, 897, 3, 371, 9, 5798, 7921, 18, 2943, 3, 248, 1, 710, 2, 7921, 27, 1139, 3, 1078, 1, 7921, 4, 857, 45102, 45103, 14174, 7921, 16, 8, 403, 38242, 18850, 1267, 34456, 2, 28128, 96, 841, 4, 3, 57031, 2, 1696, 4, 192, 16, 41, 5, 9368, 6686, 3337, 6132, 315, 3102, 369, 35, 2472, 708, 1, 7921, 71, 44, 85, 3901, 392, 1849, 47, 85, 1771, 4, 211, 193, 141, 1875, 600, 2, 7465, 21444, 2, 2000, 1342, 21, 364, 8, 696, 111, 1095, 2854, 5, 8, 532, 1, 1974, 54, 276, 7921, 322, 41, 5, 681, 26, 473, 16, 505, 93, 408, 3, 69, 10, 2739, 6, 40, 4, 734, 1, 1084, 813, 34, 1100, 1084, 272, 4140, 195, 451, 1084, 147, 1, 7921, 10, 90, 23, 38, 1031, 5, 4880, 14174, 2, 1467, 559, 2, 10, 557, 5, 411, 2, 1382, 318, 1, 57032, 20577, 2219, 38242, 18850, 2, 1082, 312, 9368, 3383, 4, 3, 6132, 845, 37, 925, 5, 43135, 6686, 3, 2291, 1, 18850, 2, 393, 34, 4, 3, 827, 69, 629, 16, 1740, 6, 8048, 22, 476, 7, 68, 2239, 110, 1342, 1042, 2, 20, 3477, 369, 1749, 68, 47, 18850, 22, 8, 6544, 681, 21, 206, 140, 1, 780, 7921, 41, 5, 710, 4, 3, 789]",1618.0,18441766,Adult Henoch-schnlein purpura patient myelodysplastic syndrome history follicular lymphoma,24,0.041884816753926704
"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.",Blood,Blood,2008-04-28,"Reporting of myelodysplastic syndromes (MDSs) and chronic myeloproliferative disorders (CMDs) to population-based cancer registries in the United States was initiated in 2001. In this first analysis of data from the North American Association of Central Cancer Registries (NAACCR), encompassing 82% of the US population, we evaluated trends in MDS and CMD incidence, estimated case numbers for the entire United States, and assessed trends in diagnostic recognition and reporting. Based on more than 40 000 observations, average annual age-adjusted incidence rates of MDS and CMD for 2001 through 2003 were 3.3 and 2.1 per 100,000, respectively. Incidence rates increased with age for both MDS and CMD (P < .05) and were highest among whites and non-Hispanics. Based on follow-up data through 2004 from the Surveillance, Epidemiology, and End Results (SEER) Program, overall relative 3-year survival rates for MDS and CMD were 45% and 80%, respectively, with males experiencing poorer survival than females. Applying the observed age-specific incidence rates to US Census population estimates, approximately 9700 patients with MDS and 6300 patients with CMD were estimated for the entire United States in 2004. MDS incidence rates significantly increased with calendar year in 2001 through 2004, and only 4% of patients were reported to registries by physicians' offices. Thus, MDS disease burden in the United States may be underestimated.",Journal Article,4285.0,428.0,"Reporting myelodysplastic syndromes MDSs chronic myeloproliferative disorders CMDs population-based registries United States initiated 2001 North American Association Central Registries NAACCR encompassing 82 population evaluated trends MDS CMD incidence estimated case numbers entire United States assessed trends diagnostic recognition reporting Based 40 000 observations average annual age-adjusted incidence rates MDS CMD 2001 2003 3.3 2.1 100,000 respectively Incidence rates increased age MDS CMD P .05 highest whites non-Hispanics Based follow-up 2004 Surveillance Epidemiology End SEER Program overall relative 3-year survival rates MDS CMD 45 80 respectively males experiencing poorer survival females Applying observed age-specific incidence rates Census population estimates approximately 9700 patients MDS 6300 patients CMD estimated entire United States 2004 MDS incidence rates significantly increased calendar year 2001 2004 4 patients reported registries physicians offices MDS disease burden United States underestimated",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1760, 1, 2040, 13550, 2, 442, 1997, 57035, 6, 266, 90, 12, 3768, 4, 3, 1088, 907, 10, 1917, 4, 1758, 4, 26, 157, 65, 1, 74, 29, 3, 2669, 597, 248, 1, 854, 12, 3768, 38044, 6853, 878, 1, 3, 843, 266, 21, 194, 1963, 4, 1223, 2, 26697, 287, 661, 473, 1870, 9, 3, 1797, 1088, 907, 2, 275, 1963, 4, 752, 2335, 2, 1760, 90, 23, 80, 76, 327, 984, 2172, 1011, 2114, 89, 586, 287, 151, 1, 1223, 2, 26697, 9, 1758, 298, 1522, 11, 27, 27, 2, 18, 14, 379, 394, 984, 106, 287, 151, 101, 5, 89, 9, 110, 1223, 2, 26697, 19, 474, 2, 11, 1076, 107, 2556, 2, 220, 3850, 90, 23, 166, 126, 74, 298, 1131, 29, 3, 617, 1284, 2, 396, 99, 1605, 1243, 63, 580, 27, 111, 25, 151, 9, 1223, 2, 26697, 11, 512, 2, 493, 106, 5, 2296, 2985, 1769, 25, 76, 2451, 4798, 3, 164, 89, 112, 287, 151, 6, 843, 7319, 266, 1423, 705, 45104, 7, 5, 1223, 2, 45105, 7, 5, 26697, 11, 661, 9, 3, 1797, 1088, 907, 4, 1131, 1223, 287, 151, 97, 101, 5, 11236, 111, 4, 1758, 298, 1131, 2, 158, 39, 1, 7, 11, 210, 6, 3768, 20, 1261, 20424, 631, 1223, 34, 892, 4, 3, 1088, 907, 68, 40, 10585]",1366.0,18443215,Epidemiology myelodysplastic syndromes chronic myeloproliferative disorders United States 2001-2004 NAACCR SEER programs,0,0.0
"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2008-05-01,"Deforolimus (AP23573), a novel non-prodrug rapamycin analogue, inhibits the mammalian target of rapamycin, a downstream effector of the phosphatidylinositol 3-kinase/Akt and nutrient-sensing pathways. A phase 2 trial was conducted to determine the efficacy and safety of single-agent deforolimus in patients with relapsed or refractory hematologic malignancies. Eligible patients were assigned to one of five disease-specific, parallel cohorts and given 12.5 mg deforolimus as a 30-minute infusion once daily for 5 days every 2 weeks. A Simon two-stage design was used for each cohort. Safety, pharmacokinetics, pharmacodynamics, and antitumor response were assessed. Fifty-five patients received deforolimus as follows: cohort 1 23 acute myelogenous leukemia, two myelodysplastic syndrome and one chronic myelogenous leukemia in nonlymphoid blast phase; cohort 2, one acute lymphocytic leukemia; cohort 3, nine agnogenic myeloid metaplasia; cohort 4, eight chronic lymphocytic leukemia; cohort 5, nine mantle cell lymphoma and two T-cell leukemia/lymphoma. Most patients were heavily pretreated. Of the 52 evaluable patients, partial responses were noted in five (10%), two of seven agnogenic myeloid metaplasia and three of nine mantle cell lymphoma. Hematologic improvement/stable disease was observed in 21 (40%). Common treatment-related adverse events, which were generally mild and reversible, were mouth sores, fatigue, nausea, and thrombocytopenia. Decreased levels of phosphorylated 4E-BP1 in 9 of 11 acute myelogenous leukemia/myelodysplastic syndrome patients after therapy showed mammalian target of rapamycin inhibition by deforolimus. Deforolimus was well-tolerated in patients with heavily pretreated hematologic malignancies, and antitumor activity was observed. Further investigation of deforolimus alone and in combination with other therapeutic agents is warranted in patients with selected hematologic malignancies.","Clinical Trial, Phase II",4282.0,192.0,Deforolimus AP23573 novel non-prodrug rapamycin analogue inhibits mammalian target rapamycin downstream effector phosphatidylinositol 3-kinase/Akt nutrient-sensing pathways phase 2 trial conducted determine efficacy safety single-agent deforolimus patients relapsed refractory hematologic malignancies Eligible patients assigned disease-specific parallel cohorts given 12.5 mg deforolimus 30-minute infusion daily 5 days 2 weeks Simon two-stage design cohort Safety pharmacokinetics pharmacodynamics antitumor response assessed Fifty-five patients received deforolimus follows cohort 1 23 acute myelogenous leukemia myelodysplastic syndrome chronic myelogenous leukemia nonlymphoid blast phase cohort 2 acute lymphocytic leukemia cohort 3 agnogenic myeloid metaplasia cohort 4 chronic lymphocytic leukemia cohort 5 mantle lymphoma T-cell leukemia/lymphoma patients heavily pretreated 52 evaluable patients partial responses noted 10 seven agnogenic myeloid metaplasia mantle lymphoma Hematologic improvement/stable disease observed 21 40 Common treatment-related adverse events generally mild reversible mouth sores fatigue nausea thrombocytopenia Decreased levels phosphorylated 4E-BP1 9 11 acute myelogenous leukemia/myelodysplastic syndrome patients therapy showed mammalian target rapamycin inhibition deforolimus Deforolimus well-tolerated patients heavily pretreated hematologic malignancies antitumor activity observed investigation deforolimus combination therapeutic agents warranted patients selected hematologic malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[19848, 24680, 8, 229, 220, 5227, 1620, 4696, 1576, 3, 2359, 283, 1, 1620, 8, 1489, 2070, 1, 3, 3415, 27, 216, 649, 2, 8749, 8350, 460, 8, 124, 18, 160, 10, 426, 6, 223, 3, 209, 2, 367, 1, 226, 420, 19848, 4, 7, 5, 591, 15, 430, 813, 441, 625, 7, 11, 896, 6, 104, 1, 365, 34, 112, 2755, 736, 2, 447, 133, 33, 81, 19848, 22, 8, 201, 3949, 904, 1059, 391, 9, 33, 162, 454, 18, 244, 8, 7385, 100, 82, 771, 10, 95, 9, 296, 180, 367, 1159, 3587, 2, 579, 51, 11, 275, 1461, 365, 7, 103, 19848, 22, 2962, 180, 14, 382, 286, 2194, 100, 681, 2, 104, 442, 2194, 4, 20180, 3112, 124, 180, 18, 104, 286, 1193, 180, 27, 762, 26059, 533, 6054, 180, 39, 659, 442, 1193, 180, 33, 762, 2757, 31, 2, 100, 102, 31, 2647, 4763, 96, 7, 11, 2447, 2193, 1, 3, 653, 859, 7, 450, 253, 11, 1051, 4, 365, 79, 100, 1, 648, 26059, 533, 6054, 2, 169, 1, 762, 2757, 31, 813, 767, 585, 34, 10, 164, 4, 239, 327, 186, 24, 139, 290, 281, 92, 11, 1228, 1980, 2, 2786, 11, 5831, 45115, 613, 1218, 2, 1340, 340, 148, 1, 2365, 6726, 7949, 4, 83, 1, 175, 286, 2194, 2647, 10589, 681, 7, 50, 36, 224, 2359, 283, 1, 1620, 297, 20, 19848, 19848, 10, 149, 421, 4, 7, 5, 2447, 2193, 813, 441, 2, 579, 128, 10, 164, 195, 940, 1, 19848, 279, 2, 4, 150, 5, 127, 189, 183, 16, 1197, 4, 7, 5, 715, 813, 441]",1820.0,18451242,phase 2 clinical trial deforolimus AP23573 MK-8669 novel mammalian target rapamycin inhibitor patients relapsed refractory hematologic malignancies,0,0.0
"Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.",Cancer,Cancer,2008-07-01,"XL119 is a water-soluble derivative of rebeccamycin with dose-dependent myelosuppression as dose-limiting toxicity in phase 1 studies of solid tumors. A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of XL119 in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias. Thirty-one patients were treated at 7 dose levels ranging from 140 to 260 mg/m(2)/daily times 5 in a 21-day cycle. Consenting patients had correlative biologic parameters studied. Dose-limiting toxicity was grade 3/4 mucositis. The recommended phase 2 dose in hematologic malignancies is 240 mg/m(2)/daily times 5 in a 21-day cycle. Clinically significant reduction in bone marrow blasts were seen in 5 patients and additional patients had reductions in peripheral blood blasts. However, the responses were transient. Changes of plasma vascular endothelial growth factor levels from Day 1 to Day 7 correlated negatively with changes in peripheral blood blasts from Day 1 to Day 7. Further assessment of XL119 in combination with other agents in patients with acute leukemias and high-risk myelodysplastic syndrome is warranted.","Clinical Trial, Phase I",4221.0,6.0,XL119 water-soluble derivative rebeccamycin dose-dependent myelosuppression dose-limiting toxicity phase 1 studies solid phase 1 conducted determine maximum tolerated dose toxicities XL119 patients advanced myelodysplastic syndrome relapsed refractory acute leukemias Thirty-one patients treated 7 dose levels ranging 140 260 mg/m 2 /daily times 5 21-day cycle Consenting patients correlative biologic parameters studied Dose-limiting toxicity grade 3/4 mucositis recommended phase 2 dose hematologic malignancies 240 mg/m 2 /daily times 5 21-day cycle Clinically significant reduction bone marrow blasts seen 5 patients additional patients reductions peripheral blood blasts responses transient Changes plasma vascular endothelial growth factor levels Day 1 Day 7 correlated negatively changes peripheral blood blasts Day 1 Day 7 assessment XL119 combination agents patients acute leukemias high-risk myelodysplastic syndrome warranted,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[38720, 16, 8, 4388, 2968, 4819, 1, 22160, 5, 61, 470, 2858, 22, 61, 817, 155, 4, 124, 14, 94, 1, 537, 57, 8, 124, 14, 45, 10, 426, 6, 223, 3, 689, 421, 61, 2, 385, 1, 38720, 4, 7, 5, 131, 681, 2, 591, 15, 430, 286, 2792, 977, 104, 7, 11, 73, 28, 67, 61, 148, 2223, 29, 3304, 6, 6398, 81, 188, 18, 391, 1072, 33, 4, 8, 239, 218, 417, 11932, 7, 42, 3679, 1283, 1038, 656, 61, 817, 155, 10, 88, 27, 39, 2606, 3, 793, 124, 18, 61, 4, 813, 441, 16, 4263, 81, 188, 18, 391, 1072, 33, 4, 8, 239, 218, 417, 505, 93, 628, 4, 581, 2438, 11, 527, 4, 33, 7, 2, 402, 7, 42, 2153, 4, 672, 315, 2438, 137, 3, 253, 11, 2473, 400, 1, 554, 756, 845, 129, 161, 148, 29, 218, 14, 6, 218, 67, 438, 2723, 5, 400, 4, 672, 315, 2438, 29, 218, 14, 6, 218, 67, 195, 455, 1, 38720, 4, 150, 5, 127, 183, 4, 7, 5, 286, 2792, 2, 64, 43, 681, 16, 1197]",1119.0,18473351,Phase 1 XL119 rebeccamycin analog patients refractory hematologic malignancies,0,0.0
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.,Blood,Blood,2008-05-21,"MGCD0103 is an isotype-selective inhibitor of histone deacetylases (HDACs) targeted to isoforms 1, 2, 3, and 11. In a phase 1 study in patients with leukemia or myelodysplastic syndromes (MDS), MGCD0103 was administered orally 3 times weekly without interruption. Twenty-nine patients with a median age of 62 years (range, 32-84 years) were enrolled at planned dose levels (20, 40, and 80 mg/m(2)). The majority of patients (76%) had acute myelogenous leukemia (AML). In all, 24 (83%) of 29 patients had received 1 or more prior chemotherapies (range, 0-5), and 18 (62%) of 29 patients had abnormal cytogenetics. The maximum tolerated dose was determined to be 60 mg/m(2), with dose-limiting toxicities (DLTs) of fatigue, nausea, vomiting, and diarrhea observed at higher doses. Three patients achieved a complete bone marrow response (blasts <or= 5%). Pharmacokinetic analyses indicated absorption of MGCD0103 within 1 hour and an elimination half-life in plasma of 9 (+/- 2) hours. Exposure to MGCD0103 was proportional to dose up to 60 mg/m(2). Analysis of peripheral white cells demonstrated induction of histone acetylation and dose-dependent inhibition of HDAC enzyme activity. In summary, MGCD0103 was safe and had antileukemia activity that was mechanism based in patients with advanced leukemia.","Clinical Trial, Phase I",4262.0,202.0,MGCD0103 isotype-selective inhibitor histone deacetylases HDACs targeted isoforms 1 2 3 11 phase 1 patients leukemia myelodysplastic syndromes MDS MGCD0103 administered orally 3 times weekly interruption Twenty-nine patients median age 62 years range 32-84 years enrolled planned dose levels 20 40 80 mg/m 2 majority patients 76 acute myelogenous leukemia AML 24 83 29 patients received 1 prior chemotherapies range 0-5 18 62 29 patients abnormal cytogenetics maximum tolerated dose determined 60 mg/m 2 dose-limiting toxicities DLTs fatigue nausea vomiting diarrhea observed higher doses patients achieved complete bone marrow response blasts or= 5 Pharmacokinetic indicated absorption MGCD0103 1 hour elimination half-life plasma 9 +/- 2 hours Exposure MGCD0103 proportional dose 60 mg/m 2 peripheral white demonstrated induction histone acetylation dose-dependent inhibition HDAC enzyme activity summary MGCD0103 safe antileukemia activity mechanism based patients advanced leukemia,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[12421, 16, 35, 11420, 1094, 230, 1, 1508, 9758, 7803, 238, 6, 3913, 14, 18, 27, 2, 175, 4, 8, 124, 14, 45, 4, 7, 5, 15, 2040, 1223, 12421, 10, 468, 1428, 27, 1072, 709, 187, 4823, 737, 762, 7, 5, 8, 52, 89, 1, 744, 60, 184, 531, 874, 60, 11, 346, 28, 1465, 61, 148, 179, 327, 2, 493, 81, 188, 18, 3, 686, 1, 7, 846, 42, 286, 2194, 329, 4, 62, 259, 852, 1, 462, 7, 42, 103, 14, 15, 80, 324, 4203, 184, 13, 33, 2, 203, 744, 1, 462, 7, 42, 1668, 2510, 3, 689, 421, 61, 10, 509, 6, 40, 335, 81, 188, 18, 5, 61, 817, 385, 2506, 1, 613, 1218, 1966, 2, 1172, 164, 28, 142, 415, 169, 7, 513, 8, 236, 581, 51, 2438, 15, 33, 1456, 318, 1103, 6125, 1, 12421, 262, 14, 2583, 2, 35, 3730, 1303, 358, 4, 554, 1, 83, 18, 1459, 645, 6, 12421, 10, 831, 6, 61, 126, 6, 335, 81, 188, 18, 65, 1, 672, 886, 37, 264, 504, 1, 1508, 4145, 2, 61, 470, 297, 1, 2654, 1644, 128, 4, 1962, 12421, 10, 1165, 2, 42, 9169, 128, 17, 10, 670, 90, 4, 7, 5, 131]",1198.0,18495956,Phase 1 oral isotype specific histone deacetylase inhibitor MGCD0103 leukemia,0,0.0
"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2008-06-01,"Molecular characterization of Philadelphia chromosome-negative (Ph-) chronic myeloproliferative disorders, such as systemic mastocytosis (SM), has provided a clear rationale for investigating novel targeted therapies. The tyrosine kinase (TK) inhibitor dasatinib is 325-fold more potent against Bcr-Abl TK than imatinib in vitro, significantly inhibiting wild-type KIT and platelet-derived growth factor receptor beta TKs, and is active against cells carrying the mutant KIT-D816V gene. In this phase 2, open-label study, the efficacy of dasatinib (140 mg/d) was investigated in 67 patients with various Ph- myeloid disorders, including SM (n = 33; 28 KIT-D816V positive). The overall response rate to dasatinib in patients with SM was 33%. Only two patients, one with SM-myelofibrosis and one with SM-chronic eosinophilic leukemia, achieved complete response (elimination of mastocytosis) lasting for 5 and 16 months, respectively. Both patients were negative for KIT-D816V mutation, had low tryptase levels, abnormal WBC counts, and anemia, and had failed prior therapy with erythropoietin. Additional nine SM patients had symptomatic response, lasting 3 to 18+ months. Complete responses were achieved in two other patients (acute myeloid leukemia and hypereosinophilic syndrome). No responses were observed among patients with myelodysplastic syndromes and primary myelofibrosis. The majority of adverse events were grade 1/2. These data show that dasatinib therapy may benefit a selected group of SM patients, primarily by improving their symptoms, but it does not eliminate the disease in the patients with KIT-D816V mutation.","Clinical Trial, Phase II",4251.0,133.0,Molecular characterization Philadelphia chromosome-negative Ph- chronic myeloproliferative disorders systemic mastocytosis SM provided clear rationale investigating novel targeted therapies tyrosine kinase TK inhibitor dasatinib 325-fold potent Bcr-Abl TK imatinib vitro significantly inhibiting wild-type KIT platelet-derived growth factor receptor beta TKs active carrying KIT-D816V phase 2 open-label efficacy dasatinib 140 mg/d investigated 67 patients Ph- myeloid disorders including SM n 33 28 KIT-D816V positive overall response rate dasatinib patients SM 33 patients SM-myelofibrosis SM-chronic eosinophilic leukemia achieved complete response elimination mastocytosis lasting 5 16 months respectively patients negative KIT-D816V low tryptase levels abnormal WBC counts anemia failed prior therapy erythropoietin Additional SM patients symptomatic response lasting 3 18+ months Complete responses achieved patients acute myeloid leukemia hypereosinophilic syndrome responses observed patients myelodysplastic syndromes primary myelofibrosis majority adverse events grade 1/2 dasatinib therapy benefit selected group SM patients primarily improving symptoms eliminate disease patients KIT-D816V,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[219, 2136, 1, 3006, 1170, 199, 2058, 442, 1997, 225, 22, 403, 7224, 3635, 71, 1052, 8, 885, 1728, 9, 3103, 229, 238, 235, 3, 564, 216, 5067, 230, 1674, 16, 7139, 1116, 80, 1157, 480, 1062, 1425, 5067, 76, 577, 4, 439, 97, 2062, 955, 267, 1164, 2, 1596, 526, 129, 161, 153, 1090, 38624, 2, 16, 544, 480, 37, 2934, 3, 620, 1164, 12643, 145, 4, 26, 124, 18, 1020, 1756, 45, 3, 209, 1, 1674, 3304, 81, 427, 10, 565, 4, 598, 7, 5, 747, 2058, 533, 1997, 141, 3635, 78, 466, 339, 1164, 12643, 109, 3, 63, 51, 116, 6, 1674, 4, 7, 5, 3635, 10, 466, 158, 100, 7, 104, 5, 3635, 4637, 2, 104, 5, 3635, 442, 9757, 513, 236, 51, 3730, 1, 7224, 3443, 9, 33, 2, 245, 53, 106, 110, 7, 11, 199, 9, 1164, 12643, 258, 42, 154, 16910, 148, 1668, 4685, 1911, 2, 1545, 2, 42, 1551, 324, 36, 5, 6266, 402, 762, 3635, 7, 42, 1704, 51, 3443, 27, 6, 203, 53, 236, 253, 11, 513, 4, 100, 127, 7, 286, 533, 2, 13967, 681, 77, 253, 11, 164, 107, 7, 5, 2040, 2, 86, 4637, 3, 686, 1, 290, 281, 11, 88, 14, 18, 46, 74, 514, 17, 1674, 36, 68, 247, 8, 715, 87, 1, 3635, 7, 1561, 20, 1673, 136, 507, 84, 192, 1097, 44, 4964, 3, 34, 4, 3, 7, 5, 1164, 12643, 258]",1533.0,18559612,Phase II dasatinib Philadelphia chromosome-negative acute chronic myeloid diseases including systemic mastocytosis,75,0.13089005235602094
Recurrent metastatic neuroblastoma followed by myelodysplastic syndrome: possible leukemogenic role of temozolomide.,Pediatric blood & cancer,Pediatr Blood Cancer,2008-10-01,"An 8-year old child had a pelvic MYCN-nonamplified neuroblastoma (NB) with retroperitoneal nodal extension. Multi-modality therapy achieved complete remission (CR). Small recurrences confined to left supraclavicular nodes were treated with surgery alone at 4.9, 6.5, 7.5, 9.5, and 12.9 years from diagnosis. Monitoring through 12 months after the last resection showed CR. When she returned 34 months later (16.8 years from diagnosis), she had massive disease in the left neck and upper trunk, without osteomedullary metastases. Salvage therapy featured 11 cycles of temozolomide. She developed myelodysplastic syndrome with 45,XX,der(7)t(7;21) (p15;q11),-21 at age 24 and refused treatment; 19 months later she was transfusion-dependent but her NB remained in CR.",Case Reports,4129.0,11.0,8-year old child pelvic MYCN-nonamplified neuroblastoma NB retroperitoneal nodal extension Multi-modality therapy achieved complete remission CR Small recurrences confined left supraclavicular nodes treated surgery 4.9 6.5 7.5 9.5 12.9 years diagnosis Monitoring 12 months resection showed CR returned 34 months later 16.8 years diagnosis massive disease left neck upper trunk osteomedullary metastases Salvage therapy featured 11 cycles temozolomide developed myelodysplastic syndrome 45 XX der 7 7 21 p15 q11 -21 age 24 refused treatment 19 months later transfusion-dependent NB remained CR,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[35, 66, 111, 1095, 2566, 42, 8, 1110, 4068, 13339, 3446, 5, 2591, 779, 2401, 1414, 1396, 36, 513, 236, 734, 684, 302, 1593, 2902, 6, 1712, 5804, 502, 11, 73, 5, 152, 279, 28, 39, 83, 49, 33, 67, 33, 83, 33, 2, 133, 83, 60, 29, 147, 1315, 298, 133, 53, 50, 3, 1060, 170, 224, 684, 198, 3109, 5157, 562, 53, 1559, 245, 66, 60, 29, 147, 3109, 42, 7929, 34, 4, 3, 1712, 2, 1726, 5895, 187, 22489, 196, 992, 36, 11857, 175, 410, 1, 1537, 3109, 276, 681, 5, 512, 26720, 13324, 67, 102, 67, 239, 8840, 11532, 239, 28, 89, 259, 2, 8237, 24, 326, 53, 1559, 3109, 10, 2785, 470, 84, 1084, 3446, 958, 4, 684]",706.0,18570300,Recurrent metastatic neuroblastoma followed myelodysplastic syndrome possible leukemogenic role temozolomide,548,0.956369982547993
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.,Cancer,Cancer,2008-09-01,"Recent studies have highlighted issues with the International Prognostic Scoring System (IPSS) model in relation to the exclusion of many subgroups that now represent a large proportion of patients with myelodysplastic syndrome (MDS) (eg, secondary MDS, chronic myelomonocytic leukemia [CMML] with leukocytosis, prior therapy) and its lack of applicability to most patients on investigational programs, because many would have received prior therapies and would have had MDS for a significant length of time. The authors analyzed 1915 patients with MDS who were referred from 1993 to 2005 (including those with CMML, secondary MDS, and MDS with prior therapy). Only 507 patients (26%) had primary MDS without prior therapy (ie, classifiable by the IPSS). Patients were divided randomly into a study group (n = 958) and a test group (n = 957). RESULTS.: A multivariate analysis of prognostic factors in the study group identified the following adverse, independent factors as continuous and categoric values (P<.001): poor performance, older age, thrombocytopenia, anemia, increased bone marrow blasts, leukocytosis, chromosome 7 or complex (>or=3) abnormalities, and prior transfusions. Cutoffs for anemia, thrombocytopenia and blasts, and cytogenetic subsets were different according to the IPSS. The new MDS prognostic model divided patients into 4 prognostic groups with significantly different outcomes. The model was validated in the test group. Applying the prognostic score of the new model within the 4 IPSS risk groups, overall, and in patients who had primary MDS without prior therapy was found to be highly prognostic in each subset. Applying the IPSS within each of the 4 risk groups of the new MDS model was not found to be prognostic. The new model accounts for duration of MDS and prior therapy. It is applicable to any patient with MDS at any time during the course of MDS.",Journal Article,4159.0,363.0,Recent studies highlighted issues International Prognostic Scoring IPSS model relation exclusion subgroups represent large proportion patients myelodysplastic syndrome MDS secondary MDS chronic myelomonocytic leukemia CMML leukocytosis prior therapy lack applicability patients investigational programs received prior therapies MDS significant length time authors 1915 patients MDS referred 1993 2005 including CMML secondary MDS MDS prior therapy 507 patients 26 primary MDS prior therapy classifiable IPSS Patients divided randomly group n 958 test group n 957 multivariate prognostic factors group identified following adverse independent factors continuous categoric values P .001 poor performance older age thrombocytopenia anemia increased bone marrow blasts leukocytosis chromosome 7 complex or=3 abnormalities prior transfusions Cutoffs anemia thrombocytopenia blasts cytogenetic subsets different according IPSS new MDS prognostic model divided patients 4 prognostic groups significantly different outcomes model validated test group Applying prognostic score new model 4 IPSS risk groups overall patients primary MDS prior therapy highly prognostic subset Applying IPSS 4 risk groups new MDS model prognostic new model accounts duration MDS prior therapy applicable patient MDS time course MDS,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[435, 94, 47, 3681, 1553, 5, 3, 944, 177, 2504, 398, 8751, 202, 4, 2191, 6, 3, 4721, 1, 445, 1453, 17, 1134, 1231, 8, 375, 920, 1, 7, 5, 681, 1223, 2887, 568, 1223, 442, 5451, 3382, 5, 7463, 324, 36, 2, 211, 926, 1, 5412, 6, 96, 7, 23, 3093, 2251, 408, 445, 688, 47, 103, 324, 235, 2, 688, 47, 42, 1223, 9, 8, 93, 1318, 1, 98, 3, 738, 311, 28153, 7, 5, 1223, 54, 11, 1995, 29, 3343, 6, 1242, 141, 135, 5, 3382, 568, 1223, 2, 1223, 5, 324, 36, 158, 12257, 7, 432, 42, 86, 1223, 187, 324, 36, 2523, 38767, 20, 3, 8751, 7, 11, 2176, 1108, 237, 8, 45, 87, 78, 16493, 2, 8, 412, 87, 78, 15277, 99, 8, 331, 65, 1, 177, 130, 4, 3, 45, 87, 108, 3, 366, 290, 306, 130, 22, 1314, 2, 19511, 1030, 19, 144, 334, 528, 434, 89, 1340, 1545, 101, 581, 2438, 7463, 1170, 67, 15, 840, 15, 27, 1171, 2, 324, 4987, 8339, 9, 1545, 1340, 2, 2438, 2, 1266, 1890, 11, 338, 768, 6, 3, 8751, 3, 217, 1223, 177, 202, 2176, 7, 237, 39, 177, 271, 5, 97, 338, 123, 3, 202, 10, 938, 4, 3, 412, 87, 4798, 3, 177, 368, 1, 3, 217, 202, 262, 3, 39, 8751, 43, 271, 63, 2, 4, 7, 54, 42, 86, 1223, 187, 324, 36, 10, 204, 6, 40, 561, 177, 4, 296, 697, 4798, 3, 8751, 262, 296, 1, 3, 39, 43, 271, 1, 3, 217, 1223, 202, 10, 44, 204, 6, 40, 177, 3, 217, 202, 4162, 9, 654, 1, 1223, 2, 324, 36, 192, 16, 3801, 6, 500, 69, 5, 1223, 28, 500, 98, 190, 3, 906, 1, 1223]",1798.0,18618511,Proposal new risk model myelodysplastic syndrome accounts events considered original International Prognostic Scoring,19,0.03315881326352531
Myelodysplastic syndromes associated with interstitial deletion of chromosome 5q: clinicopathologic correlations and new insights from the pre-lenalidomide era.,American journal of hematology,Am. J. Hematol.,2008-09-01,"To better estimate prognosis for patients with myelodysplastic syndromes (MDS) associated with clonal interstitial deletions of the long arm of chromosome 5 (del(5q)), we reviewed the medical records of 130 adults with del(5q) MDS seen at our institution over a 15-year period. Overall median survival of this cohort was 9.5 months, shorter than reported in earlier series. The least favorable outcomes are associated with complex cytogenetics, lack of any normal metaphases, normocytic rather than macrocytic erythrocyte indices, and low baseline lymphocyte counts. Lymphopenia but not neutropenia at the time of diagnosis appears to be a new adverse prognostic indicator. Cytogenetic breakpoints defined by G-banded karyotyping correlate poorly with particular disease features. Surprisingly, survival of patients with treatment-related MDS was equivalent to that of de novo MDS with del(5q) in this series. Morphologic features associated with del(5q) are diverse. Most patients with del(5q) MDS do not meet criteria for WHO-defined 5q-syndrome, and the presence of del(5q) does not appear to modify the clinical phenotype otherwise risk-stratified by the International Prognostic Scoring System (IPSS). Additional important prognostic factors not taken into account by the IPSS include the baseline erythrocyte indices, lymphocyte count, and clonal burden.",Journal Article,4159.0,27.0,better estimate prognosis patients myelodysplastic syndromes MDS associated clonal interstitial deletions long arm chromosome 5 del 5q reviewed medical records 130 adults del 5q MDS seen institution 15-year period Overall median survival cohort 9.5 months shorter reported earlier series favorable outcomes associated complex cytogenetics lack normal metaphases normocytic macrocytic erythrocyte indices low baseline lymphocyte counts Lymphopenia neutropenia time diagnosis appears new adverse prognostic indicator Cytogenetic breakpoints defined G-banded karyotyping correlate poorly particular disease features Surprisingly survival patients treatment-related MDS equivalent novo MDS del 5q series Morphologic features associated del 5q diverse patients del 5q MDS meet criteria WHO-defined 5q-syndrome presence del 5q appear modify clinical phenotype risk-stratified International Prognostic Scoring IPSS Additional important prognostic factors taken account IPSS include baseline erythrocyte indices lymphocyte count clonal burden,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 380, 1191, 356, 9, 7, 5, 2040, 1223, 41, 5, 1946, 4543, 2439, 1, 3, 319, 475, 1, 1170, 33, 3084, 5460, 21, 446, 3, 484, 1064, 1, 3431, 857, 5, 3084, 5460, 1223, 527, 28, 114, 731, 252, 8, 167, 111, 727, 63, 52, 25, 1, 26, 180, 10, 83, 33, 53, 985, 76, 210, 4, 1677, 988, 3, 506, 913, 123, 32, 41, 5, 840, 2510, 926, 1, 500, 295, 10653, 38771, 1832, 76, 57247, 16470, 3824, 2, 154, 330, 1448, 1911, 3655, 84, 44, 778, 28, 3, 98, 1, 147, 1233, 6, 40, 8, 217, 290, 177, 3287, 1266, 7843, 395, 20, 499, 37072, 10406, 1513, 1240, 5, 1454, 34, 404, 5819, 25, 1, 7, 5, 24, 139, 1223, 10, 2017, 6, 17, 1, 1566, 2018, 1223, 5, 3084, 5460, 4, 26, 988, 2815, 404, 41, 5, 3084, 5460, 32, 1867, 96, 7, 5, 3084, 5460, 1223, 1022, 44, 3362, 371, 9, 54, 395, 5460, 681, 2, 3, 463, 1, 3084, 5460, 1097, 44, 1322, 6, 4289, 3, 38, 1005, 2632, 43, 1173, 20, 3, 944, 177, 2504, 398, 8751, 402, 305, 177, 130, 44, 1633, 237, 1967, 20, 3, 8751, 643, 3, 330, 16470, 3824, 1448, 1276, 2, 1946, 892]",1314.0,18634051,Myelodysplastic syndromes associated interstitial deletion chromosome 5q clinicopathologic correlations new insights pre-lenalidomide era,1,0.0017452006980802793
The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.,Cancer,Cancer,2008-10-01,"Tumor necrosis factor (TNF)-alpha and other cytokines are involved in the pathogenesis of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), but their prognostic significance in these diseases is unknown. In the current study, the authors assessed the association between serum levels of various cytokines and clinical outcomes in patients with untreated AML or high-risk MDS. Serum levels of TNF-alpha, interleukin (IL)-1 receptor antagonist, IL-6, IL-10, and endostatin were measured in patients with AML or high-risk MDS who presented for treatment at The University of Texas M. D. Anderson Cancer Center from September 1994 through January 2001. Univariate and multivariate analyses were performed to test for correlations with clinical outcomes. Higher TNF-alpha levels were found to correlate with poorer performance status; higher leukocyte counts; higher levels of beta2-microglobulin, creatinine, uric acid, and alkaline phosphatase; lower levels of creatinine clearance and albumin; baseline infection; and M4-M5 AML subtypes. TNF-alpha levels <10 pg/mL were associated with higher rates of complete remission (P = .003), survival (P = .0003), and event-free survival (EFS) (P = .0009). However, on multivariate analyses, TNF-alpha level > or =10 pg/mL was not found to be an independent factor predicting clinical outcomes, but became statistically significant when leukocyte count was excluded from the models. The other cytokines were not found to be predictive of clinical outcomes. High serum TNF-alpha level is an adverse prognostic factor for survival and EFS in patients with untreated AML or high-risk MDS.",Comparative Study,4129.0,74.0,necrosis factor TNF -alpha cytokines involved pathogenesis acute myeloid leukemia AML high-risk myelodysplastic syndromes MDS prognostic significance diseases unknown current authors assessed association serum levels cytokines clinical outcomes patients untreated AML high-risk MDS Serum levels TNF-alpha interleukin IL -1 receptor antagonist IL-6 IL-10 endostatin measured patients AML high-risk MDS presented treatment University Texas M. D. Anderson Center September 1994 January 2001 Univariate multivariate performed test correlations clinical outcomes Higher TNF-alpha levels correlate poorer performance status higher leukocyte counts higher levels beta2-microglobulin creatinine uric acid alkaline phosphatase lower levels creatinine clearance albumin baseline infection M4-M5 AML subtypes TNF-alpha levels 10 pg/mL associated higher rates complete remission P .003 survival P .0003 event-free survival EFS P .0009 multivariate TNF-alpha level =10 pg/mL independent factor predicting clinical outcomes statistically significant leukocyte count excluded models cytokines predictive clinical outcomes High serum TNF-alpha level adverse prognostic factor survival EFS patients untreated AML high-risk MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[30, 1523, 161, 2254, 950, 2, 127, 1886, 32, 646, 4, 3, 1384, 1, 286, 533, 329, 2, 64, 43, 2040, 1223, 84, 136, 177, 724, 4, 46, 1342, 16, 860, 4, 3, 291, 45, 3, 738, 275, 3, 248, 59, 524, 148, 1, 747, 1886, 2, 38, 123, 4, 7, 5, 1278, 329, 15, 64, 43, 1223, 524, 148, 1, 2254, 950, 1603, 501, 14, 153, 3137, 501, 49, 501, 79, 2, 6637, 11, 644, 4, 7, 5, 329, 15, 64, 43, 1223, 54, 917, 9, 24, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 29, 2636, 3023, 298, 1024, 1758, 880, 2, 331, 318, 11, 173, 6, 412, 9, 2553, 5, 38, 123, 142, 2254, 950, 148, 11, 204, 6, 1513, 5, 1769, 528, 156, 142, 3627, 1911, 142, 148, 1, 8911, 5371, 3177, 16387, 971, 2, 5355, 2577, 280, 148, 1, 3177, 1960, 2, 2799, 330, 930, 2, 11452, 10272, 329, 814, 2254, 950, 148, 79, 3234, 542, 11, 41, 5, 142, 151, 1, 236, 734, 19, 1421, 25, 19, 4418, 2, 774, 115, 25, 1683, 19, 7946, 137, 23, 331, 318, 2254, 950, 301, 15, 79, 3234, 542, 10, 44, 204, 6, 40, 35, 306, 161, 1434, 38, 123, 84, 3451, 712, 93, 198, 3627, 1276, 10, 1800, 29, 3, 274, 3, 127, 1886, 11, 44, 204, 6, 40, 464, 1, 38, 123, 64, 524, 2254, 950, 301, 16, 35, 290, 177, 161, 9, 25, 2, 1683, 4, 7, 5, 1278, 329, 15, 64, 43, 1223]",1574.0,18683214,prognostic significance cytokine levels newly diagnosed acute myeloid leukemia high-risk myelodysplastic syndromes,30,0.05235602094240838
Therapy-related myeloid leukemia.,Seminars in oncology,Semin. Oncol.,2008-08-01,"Therapy-related myelodysplastic syndrome and acute myeloid leukemia (t-MDS/t-AML) are thought to be the direct consequence of mutational events induced by chemotherapy, radiation therapy, immunosuppressive therapy, or a combination of these modalities, given for a pre-existing condition. The outcomes for these patients have been poor historically compared to people who develop de novo AML. The spectrum of cytogenetic abnormalities in t-AML is similar to de novo AML, but the frequency of unfavorable cytogenetics, such as a complex karyotype or deletion or loss of chromosomes 5 and/or 7, is considerably higher in t-AML. Survival varies according to cytogenetic risk group in t-AML patients, with better outcomes being observed in those with favorable-risk karyotypes. Treatment recommendations should be based on performance status and karyotype. A deeper understanding of the factors that predispose patients to the development of therapy-related myeloid leukemia would help clinicians monitor patients more carefully after treatment for a primary condition. Ultimately, this knowledge could influence initial treatment strategies with the goal of decreasing the incidence of this serious complication.",Journal Article,4190.0,176.0,Therapy-related myelodysplastic syndrome acute myeloid leukemia t-MDS/t-AML thought direct consequence events induced chemotherapy radiation therapy immunosuppressive therapy combination modalities given pre-existing condition outcomes patients poor historically compared people develop novo AML spectrum cytogenetic abnormalities t-AML similar novo AML frequency unfavorable cytogenetics complex karyotype deletion loss chromosomes 5 and/or 7 considerably higher t-AML Survival varies according cytogenetic risk group t-AML patients better outcomes observed favorable-risk karyotypes Treatment recommendations based performance status karyotype deeper understanding factors predispose patients development therapy-related myeloid leukemia help clinicians monitor patients carefully treatment primary condition Ultimately knowledge influence initial treatment strategies goal decreasing incidence complication,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[36, 139, 681, 2, 286, 533, 102, 1223, 102, 329, 32, 2739, 6, 40, 3, 1196, 4177, 1, 1619, 281, 277, 20, 56, 121, 36, 2989, 36, 15, 8, 150, 1, 46, 1558, 447, 9, 8, 671, 1692, 2850, 3, 123, 9, 46, 7, 47, 85, 334, 3578, 72, 6, 3788, 54, 690, 1566, 2018, 329, 3, 1873, 1, 1266, 1171, 4, 102, 329, 16, 288, 6, 1566, 2018, 329, 84, 3, 675, 1, 2483, 2510, 225, 22, 8, 840, 3385, 15, 1528, 15, 407, 1, 3560, 33, 2, 15, 67, 16, 5597, 142, 4, 102, 329, 25, 4037, 768, 6, 1266, 43, 87, 4, 102, 329, 7, 5, 380, 123, 486, 164, 4, 135, 5, 913, 43, 6809, 24, 883, 257, 40, 90, 23, 528, 156, 2, 3385, 8, 6029, 612, 1, 3, 130, 17, 6043, 7, 6, 3, 193, 1, 36, 139, 533, 688, 987, 1490, 3334, 7, 80, 3900, 50, 24, 9, 8, 86, 2850, 2050, 26, 922, 359, 1054, 388, 24, 422, 5, 3, 1326, 1, 2777, 3, 287, 1, 26, 1762, 1447]",1157.0,18692692,Therapy-related myeloid leukemia,59,0.10296684118673648
Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2008-09-01,"For more than 20 years the National Marrow Donor Program has facilitated unrelated donor hematopoietic cell transplants for adult recipients. In this time period, the volunteer donor pool has expanded to nearly 12 million adult donors worldwide, improvements have occurred in the understanding and technology of HLA matching, there have been many changes in clinical practice and supportive care, and the more common graft source has shifted from bone marrow (BM) to peripheral blood stem cells (PBSCs). The percentage of older patients who are receiving unrelated donor transplants is increasing; currently over 1 in 10 adult transplant recipients is over the age of 60 years. Chronic myelogenous leukemia (CML) was previously the most common diagnosis for unrelated donor transplantation, but it now comprises less than 10% of transplants for adult recipients. Transplants for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and myelodysplastic syndromes (MDS) all outnumber CML. Treatment-related mortality (TRM) has declined significantly over the years, particularly in association with myeloablative transplant preparative regimens. Correspondingly, survival within each disease category has improved. Particularly gratifying are the results in severe aplastic anemia (AA) where 2-year survival has doubled in just 10 years.",Historical Article,4159.0,91.0,20 years National Marrow Donor Program facilitated unrelated donor hematopoietic transplants adult recipients time period volunteer donor pool expanded nearly 12 million adult donors worldwide improvements occurred understanding technology HLA matching changes clinical practice supportive care common graft source shifted bone marrow BM peripheral blood stem PBSCs percentage older patients receiving unrelated donor transplants increasing currently 1 10 adult transplant recipients age 60 years Chronic myelogenous leukemia CML previously common diagnosis unrelated donor transplantation comprises 10 transplants adult recipients Transplants acute myelogenous leukemia AML acute lymphoblastic leukemia non-Hodgkin lymphoma NHL myelodysplastic syndromes MDS outnumber CML Treatment-related mortality TRM declined significantly years particularly association myeloablative transplant preparative regimens Correspondingly survival disease category improved Particularly gratifying severe aplastic anemia AA 2-year survival doubled 10 years,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[9, 80, 76, 179, 60, 3, 657, 581, 1488, 1243, 71, 4667, 2092, 1488, 1007, 31, 4016, 9, 780, 2190, 4, 26, 98, 727, 3, 15536, 1488, 6545, 71, 2064, 6, 1857, 133, 3346, 780, 2344, 2358, 1474, 47, 489, 4, 3, 612, 2, 2033, 1, 1160, 2616, 125, 47, 85, 445, 400, 4, 38, 758, 2, 1877, 165, 2, 3, 80, 186, 1599, 2353, 71, 7289, 29, 581, 1246, 6, 672, 315, 452, 37, 13620, 3, 1150, 1, 434, 7, 54, 32, 357, 2092, 1488, 4016, 16, 602, 694, 252, 14, 4, 79, 780, 941, 2190, 16, 252, 3, 89, 1, 335, 60, 442, 2194, 903, 10, 373, 3, 96, 186, 147, 9, 2092, 1488, 497, 84, 192, 1134, 6704, 299, 76, 79, 1, 4016, 9, 780, 2190, 4016, 9, 286, 2194, 329, 286, 1275, 62, 1176, 2, 2040, 1223, 62, 31036, 903, 24, 139, 282, 5064, 71, 3054, 97, 252, 3, 60, 823, 4, 248, 5, 3246, 941, 6085, 472, 11599, 25, 262, 296, 34, 2169, 71, 231, 823, 34530, 32, 3, 99, 4, 905, 16315, 1545, 1519, 1257, 18, 111, 25, 71, 8431, 4, 4673, 79, 60]",1273.0,18721775,years unrelated donor hematopoietic transplantation adult recipients facilitated National Marrow Donor Program,6,0.010471204188481676
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.,Cancer,Cancer,2008-10-01,"Major therapeutic progress has been accomplished in leukemia and myelodysplastic syndrome (MDS) over the past 40 years, which may not be fully appreciated by the larger medical community. The objective of this review was to briefly highlight the treatment breakthroughs in leukemia and MDS. Therapeutic progress happened through better understanding of disease pathophysiologies and rational development of targeted agents, like imatinib mesylate in chronic myeloid leukemia (CML), and through astute, empirical discoveries in the clinic, like all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia (APL) and chlorodeoxyadenosine in hairy cell leukemia (HCL). Today, the 5- to 10-year survival rates in patients with APL and HCL exceed 80%. In patients with CML, imatinib therapy has been associated with estimated 5- to 7-year survival rates from 85% to 90%. In patients with adult acute lymphocytic leukemia, modern intensive regimens have improved the 5-year survival rates from 20% up to 40%. In patients with chronic lymphocytic leukemia, chemoimmunotherapy recently produced high rates of quality responses and improved long-term outcome. In younger patients with acute myeloid leukemia (AML), the 5-year survival rates range from 40% to 50%, although elderly AML remains a therapeutic challenge. In patients with MDS, it was recently demonstrated that epigenetic therapy with hypomethylating agents improved survival. Much therapeutic progress has been witnessed in leukemia and MDS, and much more is expected to occur soon.",Journal Article,4129.0,74.0,Major therapeutic progress accomplished leukemia myelodysplastic syndrome MDS past 40 years fully appreciated larger medical community objective review briefly highlight treatment breakthroughs leukemia MDS Therapeutic progress happened better understanding disease pathophysiologies rational development targeted agents like imatinib mesylate chronic myeloid leukemia CML astute empirical discoveries clinic like all-trans retinoic acid arsenic trioxide acute promyelocytic leukemia APL chlorodeoxyadenosine hairy leukemia HCL Today 5- 10-year survival rates patients APL HCL exceed 80 patients CML imatinib therapy associated estimated 5- 7-year survival rates 85 90 patients adult acute lymphocytic leukemia modern intensive regimens improved 5-year survival rates 20 40 patients chronic lymphocytic leukemia chemoimmunotherapy recently produced high rates quality responses improved long-term outcome younger patients acute myeloid leukemia AML 5-year survival rates range 40 50 elderly AML remains therapeutic challenge patients MDS recently demonstrated epigenetic therapy hypomethylating agents improved survival therapeutic progress witnessed leukemia MDS expected occur soon,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[458, 189, 1466, 71, 85, 5741, 4, 2, 681, 1223, 252, 3, 1219, 327, 60, 92, 68, 44, 40, 1910, 7292, 20, 3, 1077, 484, 1714, 3, 461, 1, 26, 206, 10, 6, 6277, 1817, 3, 24, 9985, 4, 2, 1223, 189, 1466, 20566, 298, 380, 612, 1, 34, 44576, 2, 2696, 193, 1, 238, 183, 733, 577, 2347, 4, 442, 533, 903, 2, 298, 38816, 7273, 5012, 4, 3, 1188, 733, 62, 3437, 3887, 971, 2, 3217, 4574, 4, 286, 4300, 2578, 2, 23121, 4, 7152, 31, 4623, 5665, 3, 33, 6, 79, 111, 25, 151, 4, 7, 5, 2578, 2, 4623, 6818, 493, 4, 7, 5, 903, 577, 36, 71, 85, 41, 5, 661, 33, 6, 67, 111, 25, 151, 29, 772, 6, 424, 4, 7, 5, 780, 286, 1193, 2366, 1686, 472, 47, 231, 3, 33, 111, 25, 151, 29, 179, 126, 6, 327, 4, 7, 5, 442, 1193, 4438, 761, 1687, 64, 151, 1, 372, 253, 2, 231, 319, 337, 228, 4, 773, 7, 5, 286, 533, 329, 3, 33, 111, 25, 151, 184, 29, 327, 6, 212, 242, 1216, 329, 469, 8, 189, 1745, 4, 7, 5, 1223, 192, 10, 761, 264, 17, 1418, 36, 5, 4931, 183, 231, 25, 1802, 189, 1466, 71, 85, 10606, 4, 2, 1223, 2, 1802, 80, 16, 1336, 6, 1271, 6176]",1416.0,18798533,Therapeutic advances leukemia myelodysplastic syndrome past 40 years,1,0.0017452006980802793
Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.,Blood,Blood,2008-09-29,"Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity. Among older AML patients (age > 60 years), there are few long-term survivors. Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS), with the 5q- chromosomal abnormality. We report induction of sustained morphologic and cytogenetic complete remission in 2 older AML patients treated with high-dose, single-agent lenalidomide; each patient had trisomy 13 as the sole cytogenetic abnormality. We show for the first time that lenalidomide has clinical activity in this poor-risk cytogenetic subset of AML. The clinical trials described in this paper have been registered with www.clinicaltrials.gov under identifiers NCT00466895 and NCT00546897.",Case Reports,4131.0,58.0,Patients acute myeloid leukemia AML frequently fail chemotherapy refractory disease relapse toxicity older AML patients age 60 years long-term survivors Lenalidomide candidate AML based clinical activity related disorder myelodysplastic syndrome MDS 5q- chromosomal abnormality report induction sustained morphologic cytogenetic complete remission 2 older AML patients treated high-dose single-agent lenalidomide patient trisomy 13 sole cytogenetic abnormality time lenalidomide clinical activity poor-risk cytogenetic subset AML clinical trials described paper registered www.clinicaltrials.gov identifiers NCT00466895 NCT00546897,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7, 5, 286, 533, 329, 746, 4373, 56, 520, 6, 430, 34, 429, 15, 155, 107, 434, 329, 7, 89, 335, 60, 125, 32, 1021, 319, 337, 332, 1288, 16, 8, 1609, 9, 45, 4, 329, 90, 23, 211, 38, 128, 4, 8, 139, 2645, 681, 1223, 5, 3, 5460, 1860, 3698, 21, 414, 504, 1, 2275, 2815, 2, 1266, 236, 734, 4, 18, 434, 329, 7, 73, 5, 64, 61, 226, 420, 1288, 296, 69, 42, 6317, 233, 22, 3, 4991, 1266, 3698, 21, 514, 9, 3, 157, 98, 17, 1288, 71, 38, 128, 4, 26, 334, 43, 1266, 697, 1, 329, 3, 38, 143, 1027, 4, 26, 2817, 47, 85, 1653, 5, 3064, 1252, 1239, 669, 15877, 45273, 2, 57408]",793.0,18824593,Single-agent lenalidomide induces complete remission acute myeloid leukemia patients isolated trisomy 13,3,0.005235602094240838
Demethylating agents in myeloid malignancies.,Current opinion in oncology,Curr Opin Oncol,2008-11-01,"Two demethylating agents are approved in myelodysplastic syndromes (MDS): 5-azacitidine and 5-aza-2'-deoxycitidine (decitabine). These drugs are structurally related and induce DNA hypomethylation. Aberrant DNA methylation is associated with gene silencing. It is proposed that hypomethylating agents work by inducing reexpression of epigenetically silenced genes. Here, we provide an up-to-date summary of the clinical experience with these drugs. 5-Azacitidine and decitabine were approved in the United States based on clinical responses, but no effect on survival was documented. Recent results from a phase III study have indicated that treatment of patients with higher risk MDS with 5-azacitidine results in significant improvement in overall survival. Results of a randomized survival study of decitabine should be available in 2008. Reports of combination epigenetic therapies (a hypomethylating agent with a histone deacetylase inhibitor) indicate that these have significant activity in patients with MDS/acute myelogenous leukemia. Randomized studies are testing the concept that the combinations are superior to single-agent therapy. Demethylating agents are the standard of care for patients with higher risk MDS and the only agent known to improve the natural history of MDS. Further work in new combination therapies may result in further advances in the care of patients with MDS.",Journal Article,4098.0,94.0,demethylating agents approved myelodysplastic syndromes MDS 5-azacitidine 5-aza-2'-deoxycitidine decitabine drugs structurally related induce DNA hypomethylation Aberrant DNA methylation associated silencing proposed hypomethylating agents work inducing reexpression epigenetically silenced provide up-to-date summary clinical experience drugs 5-Azacitidine decitabine approved United States based clinical responses effect survival documented Recent phase III indicated treatment patients higher risk MDS 5-azacitidine significant improvement overall survival randomized survival decitabine available 2008 Reports combination epigenetic therapies hypomethylating agent histone deacetylase inhibitor indicate significant activity patients MDS/acute myelogenous leukemia Randomized studies testing concept combinations superior single-agent therapy Demethylating agents standard care patients higher risk MDS agent known improve natural history MDS work new combination therapies advances care patients MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[100, 8399, 183, 32, 850, 4, 2040, 1223, 33, 3752, 2, 33, 3924, 6135, 44028, 3004, 46, 600, 32, 8533, 139, 2, 1290, 261, 4441, 1898, 261, 569, 16, 41, 5, 145, 2077, 192, 16, 1587, 17, 4931, 183, 1357, 20, 1958, 11120, 1, 8976, 5442, 214, 467, 21, 377, 35, 126, 6, 1244, 1962, 1, 3, 38, 730, 5, 46, 600, 33, 3752, 2, 3004, 11, 850, 4, 3, 1088, 907, 90, 23, 38, 253, 84, 77, 254, 23, 25, 10, 1405, 435, 99, 29, 8, 124, 316, 45, 47, 1103, 17, 24, 1, 7, 5, 142, 43, 1223, 5, 33, 3752, 99, 4, 93, 767, 4, 63, 25, 99, 1, 8, 384, 25, 45, 1, 3004, 257, 40, 390, 4, 1375, 1198, 1, 150, 1418, 235, 8, 4931, 420, 5, 8, 1508, 2732, 230, 1008, 17, 46, 47, 93, 128, 4, 7, 5, 1223, 286, 2194, 384, 94, 32, 471, 3, 2545, 17, 3, 1247, 32, 1123, 6, 226, 420, 36, 8399, 183, 32, 3, 260, 1, 165, 9, 7, 5, 142, 43, 1223, 2, 3, 158, 420, 440, 6, 401, 3, 1504, 532, 1, 1223, 195, 1357, 4, 217, 150, 235, 68, 757, 4, 195, 954, 4, 3, 165, 1, 7, 5, 1223]",1351.0,18841054,Demethylating agents myeloid malignancies,57,0.09947643979057591
Long-term outcomes to fludarabine and rituximab in Waldenstrm macroglobulinemia.,Blood,Blood,2008-11-17,"We report the long-term outcome of a multicenter, prospective study examining fludarabine and rituximab in Waldenstrm macroglobulinemia (WM). WM patients with less than 2 prior therapies were eligible. Intended therapy consisted of 6 cycles (25 mg/m(2) per day for 5 days) of fludarabine and 8 infusions (375 mg/m(2) per week) of rituximab. A total of 43 patients were enrolled. Responses were: complete response (n = 2), very good partial response (n = 14), partial response (n = 21), and minor response (n = 4), for overall and major response rates of 95.3% and 86.0%, respectively. Median time to progression for all patients was 51.2 months and was longer for untreated patients (P = .017) and those achieving at least a very good partial response (P = .049). Grade 3 or higher toxicities included neutropenia (n = 27), thrombocytopenia (n = 7), and pneumonia (n = 6), including 2 patients who died of non-Pneumocystis carinii pneumonia. With a median follow-up of 40.3 months, we observed 3 cases of transformation to aggressive lymphoma and 3 cases of myelodysplastic syndrome/acute myeloid leukemia. The results of this study demonstrate that fludarabine and rituximab are highly active in WM, although short- and long-term toxicities need to be carefully weighed against other available treatment options. This study is registered at clinicaltrials.gov as NCT00020800.",Clinical Trial,4082.0,109.0,report long-term outcome multicenter prospective examining fludarabine rituximab Waldenstrm macroglobulinemia WM WM patients 2 prior therapies eligible Intended therapy consisted 6 cycles 25 mg/m 2 day 5 days fludarabine 8 infusions 375 mg/m 2 week rituximab total 43 patients enrolled Responses complete response n 2 good partial response n 14 partial response n 21 minor response n 4 overall major response rates 95.3 86.0 respectively Median time progression patients 51.2 months longer untreated patients P .017 achieving good partial response P .049 Grade 3 higher toxicities included neutropenia n 27 thrombocytopenia n 7 pneumonia n 6 including 2 patients died non-Pneumocystis carinii pneumonia median follow-up 40.3 months observed 3 cases transformation aggressive lymphoma 3 cases myelodysplastic syndrome/acute myeloid leukemia demonstrate fludarabine rituximab highly active WM short- long-term toxicities need carefully weighed available treatment options registered clinicaltrials.gov NCT00020800,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 414, 3, 319, 337, 228, 1, 8, 1570, 482, 45, 3282, 2027, 2, 855, 4, 3700, 3389, 1518, 1518, 7, 5, 299, 76, 18, 324, 235, 11, 625, 4081, 36, 1695, 1, 49, 410, 243, 81, 188, 18, 379, 218, 9, 33, 162, 1, 2027, 2, 66, 3435, 4175, 81, 188, 18, 379, 647, 1, 855, 8, 181, 1, 601, 7, 11, 346, 253, 11, 236, 51, 78, 18, 923, 1178, 450, 51, 78, 213, 450, 51, 78, 239, 2, 2278, 51, 78, 39, 9, 63, 2, 458, 51, 151, 1, 48, 27, 2, 868, 13, 106, 52, 98, 6, 91, 9, 62, 7, 10, 725, 18, 53, 2, 10, 589, 9, 1278, 7, 19, 3825, 2, 135, 1785, 28, 506, 8, 923, 1178, 450, 51, 19, 5121, 88, 27, 15, 142, 385, 159, 778, 78, 428, 1340, 78, 67, 2, 3485, 78, 49, 141, 18, 7, 54, 1016, 1, 220, 13243, 21967, 3485, 5, 8, 52, 166, 126, 1, 327, 27, 53, 21, 164, 27, 140, 1, 1392, 6, 571, 2, 27, 140, 1, 681, 286, 533, 3, 99, 1, 26, 45, 608, 17, 2027, 2, 855, 32, 561, 544, 4, 1518, 242, 978, 2, 319, 337, 385, 594, 6, 40, 3900, 10271, 480, 127, 390, 24, 838, 26, 45, 16, 1653, 28, 1252, 1239, 22, 57498]",1275.0,19015393,Long-term outcomes fludarabine rituximab Waldenstrm macroglobulinemia,0,0.0
Old and new cancers after hematopoietic-cell transplantation.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2008-01-01,"Relapse of primary disease and occurrence of new cancers can cause significant morbidity and mortality in recipients of autologous and allogeneic hematopoietic-cell transplantation (HCT). Treatment options for relapse are generally limited and can include disease-specific chemotherapy or targeted therapy. Additional relapse-directed therapies that are available for allogeneic HCT recipients include withdrawal of immunosuppression and donor lymphocyte infusion. Selected patients can be offered a second transplant procedure. Newer strategies to eliminate minimal residual disease and, in allogeneic HCT recipients, to augment the graft-versus-tumor effect are needed for patients who are at high risk for relapse after HCT. Second cancers after HCT include post-transplant lymphoproliferative disorder, hematologic malignancies and new solid cancers. The incidence of second solid cancers continues to rise without a plateau with increasing follow up of HCT survivors. Secondary myelodysplastic syndrome and acute leukemia are almost exclusively seen in autologous HCT recipients while post-transplant lymphoproliferative disorders complicate recipients of allogeneic HCT. Appropriate screening evaluations should be performed in HCT survivors to facilitate early detection and treatment of second cancers.",Journal Article,4403.0,30.0,Relapse primary disease occurrence new cause significant morbidity mortality recipients autologous allogeneic hematopoietic-cell transplantation HCT Treatment options relapse generally limited include disease-specific chemotherapy targeted therapy Additional relapse-directed therapies available allogeneic HCT recipients include withdrawal immunosuppression donor lymphocyte infusion Selected patients offered second transplant procedure Newer strategies eliminate minimal residual disease allogeneic HCT recipients augment graft-versus-tumor effect needed patients high risk relapse HCT Second HCT include post-transplant lymphoproliferative disorder hematologic malignancies new solid incidence second solid continues rise plateau increasing follow HCT survivors Secondary myelodysplastic syndrome acute leukemia exclusively seen autologous HCT recipients post-transplant lymphoproliferative disorders complicate recipients allogeneic HCT Appropriate screening evaluations performed HCT survivors facilitate early detection treatment second,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[429, 1, 86, 34, 2, 2291, 1, 217, 163, 122, 708, 93, 787, 2, 282, 4, 2190, 1, 1028, 2, 1063, 1007, 31, 497, 1085, 24, 838, 9, 429, 32, 1228, 383, 2, 122, 643, 34, 112, 56, 15, 238, 36, 402, 429, 1166, 235, 17, 32, 390, 9, 1063, 1085, 2190, 643, 3683, 1, 3646, 2, 1488, 1448, 904, 715, 7, 122, 40, 2216, 8, 419, 941, 1299, 2246, 422, 6, 4964, 1048, 753, 34, 2, 4, 1063, 1085, 2190, 6, 4369, 3, 1599, 185, 30, 254, 32, 575, 9, 7, 54, 32, 28, 64, 43, 9, 429, 50, 1085, 419, 163, 50, 1085, 643, 539, 941, 4192, 2645, 813, 441, 2, 217, 537, 163, 3, 287, 1, 419, 537, 163, 2274, 6, 3693, 187, 8, 6133, 5, 602, 166, 126, 1, 1085, 332, 568, 681, 2, 286, 32, 2214, 4437, 527, 4, 1028, 1085, 2190, 369, 539, 941, 4192, 1997, 11157, 2190, 1, 1063, 1085, 870, 453, 3816, 257, 40, 173, 4, 1085, 332, 6, 1876, 191, 638, 2, 24, 1, 419, 163]",1271.0,19074072,Old new hematopoietic-cell transplantation,12,0.020942408376963352
"Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.",Cancer,Cancer,2009-01-01,"Secondary malignancies including myeloid neoplasms occur infrequently in acute lymphoblastic leukemia (ALL) and to the authors' knowledge have not been as well documented in adults as in children. A total of 641 patients with de novo ALL who were treated with the hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen or its variants were analyzed. Sixteen patients (2.49%) developed secondary acute myelogenous leukemia (AML) (6 patients) or myelodysplastic syndrome (MDS) (10 patients). At the time of ALL diagnosis, the median age was 53 years; cytogenetics were normal in 11 patients, pseudo-diploidy with del(2) in 1 patient, t(9;22) in 1 patient, and unavailable in 3 patients. Frontline therapy included hyper-CVAD in 7 patients, hyper-CVAD with rituximab in 8 patients, and hyper-CVAD with imatinib in 1 patient. Karyotype at time of AML/MDS diagnosis was -5, -7 in 9 patients, normal in 1 patient, complex in 1 patient, inv(11) in 1 patient, t(4;11) in 1 patient, del(20) in 1 patient, and unavailable in 2 patients. Secondary AML/MDS developed at a median of 32 months after ALL diagnosis. Cytarabine plus anthracycline-based treatment was given to 12 patients with AML and high-risk MDS. One patient with MDS received arsenic trioxide, 1 received clofarabine, and 2 received decitabine. Response to treatment was complete remission in 3 patients, partial remission in 6 patients, and no response in 6 patients; 1 patient was untreated. Eight patients (1 with AML and 7 with MDS) underwent allogeneic stem cell transplantation, and all but 2 died at a median of 3 months (range, 0.5-11 months) after transplantation. The median overall survival after a diagnosis of secondary AML and MDS was 9.25 months (range, 1+ to 26+ months). Secondary AML and MDS occur infrequently in adult patients with de novo ALL treated with the hyper-CVAD regimens, and response to therapy is poor.",Journal Article,4037.0,13.0,Secondary malignancies including myeloid neoplasms occur infrequently acute lymphoblastic leukemia authors knowledge documented adults children total 641 patients novo treated hyper-CVAD hyperfractionated cyclophosphamide vincristine doxorubicin dexamethasone regimen Sixteen patients 2.49 developed secondary acute myelogenous leukemia AML 6 patients myelodysplastic syndrome MDS 10 patients time diagnosis median age 53 years cytogenetics normal 11 patients pseudo-diploidy del 2 1 patient 9 22 1 patient unavailable 3 patients Frontline therapy included hyper-CVAD 7 patients hyper-CVAD rituximab 8 patients hyper-CVAD imatinib 1 patient Karyotype time AML/MDS diagnosis -5 -7 9 patients normal 1 patient complex 1 patient inv 11 1 patient 4 11 1 patient del 20 1 patient unavailable 2 patients Secondary AML/MDS developed median 32 months diagnosis Cytarabine plus anthracycline-based treatment given 12 patients AML high-risk MDS patient MDS received arsenic trioxide 1 received clofarabine 2 received decitabine Response treatment complete remission 3 patients partial remission 6 patients response 6 patients 1 patient untreated patients 1 AML 7 MDS underwent allogeneic stem transplantation 2 died median 3 months range 0.5-11 months transplantation median overall survival diagnosis secondary AML MDS 9.25 months range 1+ 26+ months Secondary AML MDS occur infrequently adult patients novo treated hyper-CVAD regimens response therapy poor,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[568, 441, 141, 533, 1179, 1271, 6440, 4, 286, 1275, 62, 2, 6, 3, 738, 922, 47, 44, 85, 22, 149, 1405, 4, 857, 22, 4, 541, 8, 181, 1, 15599, 7, 5, 1566, 2018, 62, 54, 11, 73, 5, 3, 4855, 5574, 6201, 1112, 2132, 856, 2, 1217, 477, 15, 211, 839, 11, 311, 3228, 7, 18, 739, 276, 568, 286, 2194, 329, 49, 7, 15, 681, 1223, 79, 7, 28, 3, 98, 1, 62, 147, 3, 52, 89, 10, 699, 60, 2510, 11, 295, 4, 175, 7, 13337, 19586, 5, 3084, 18, 4, 14, 69, 102, 83, 350, 4, 14, 69, 2, 9098, 4, 27, 7, 3171, 36, 159, 4855, 5574, 4, 67, 7, 4855, 5574, 5, 855, 4, 66, 7, 2, 4855, 5574, 5, 577, 4, 14, 69, 3385, 28, 98, 1, 329, 1223, 147, 10, 33, 67, 4, 83, 7, 295, 4, 14, 69, 840, 4, 14, 69, 6397, 175, 4, 14, 69, 102, 39, 175, 4, 14, 69, 3084, 179, 4, 14, 69, 2, 9098, 4, 18, 7, 568, 329, 1223, 276, 28, 8, 52, 1, 531, 53, 50, 62, 147, 1855, 349, 2044, 90, 24, 10, 447, 6, 133, 7, 5, 329, 2, 64, 43, 1223, 104, 69, 5, 1223, 103, 3217, 4574, 14, 103, 4149, 2, 18, 103, 3004, 51, 6, 24, 10, 236, 734, 4, 27, 7, 450, 734, 4, 49, 7, 2, 77, 51, 4, 49, 7, 14, 69, 10, 1278, 659, 7, 14, 5, 329, 2, 67, 5, 1223, 208, 1063, 452, 31, 497, 2, 62, 84, 18, 1016, 28, 8, 52, 1, 27, 53, 184, 13, 33, 175, 53, 50, 497, 3, 52, 63, 25, 50, 8, 147, 1, 568, 329, 2, 1223, 10, 83, 243, 53, 184, 14, 6, 432, 53, 568, 329, 2, 1223, 1271, 6440, 4, 780, 7, 5, 1566, 2018, 62, 73, 5, 3, 4855, 5574, 472, 2, 51, 6, 36, 16, 334]",1834.0,19090005,Therapy-related acute myelogenous leukemia myelodysplastic syndrome patients acute lymphoblastic leukemia treated hyperfractionated cyclophosphamide vincristine doxorubicin dexamethasone regimens,2,0.0034904013961605585
Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies.,Haematologica,Haematologica,2009-01-14,"Because hepatitis C virus infection causes hepatic and immunological dysfunction, we hypothesized that seropositivity for this virus could be associated with increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. We performed a case-control study of the outcomes of patients who were hepatitis C virus seropositive at the time of allogeneic hematopoietic stem cell transplantation (N=31). Patients positive for hepatitis C virus were considered candidates for stem cell transplantation only if they had no significant evidence of hepatic dysfunction. Matched controls (N=31) were seronegative for viral hepatitides and were paired according to age, diagnosis, disease stage, conditioning regimen and donor type. We also compared the hepatitis C virus seropositive patients to all seronegative patients (all controls, N=1800) transplanted during the same period, to adjust for other confounding effects. The median age of the seropositive patients was 49 (range 26-72); 15 had acute myeloid leukemia/myelodysplastic syndrome, 6 had chronic myeloid leukemia/myeloproliferative disease, 6 non-Hodgkin's lymphoma, 2 myeloma, 1 acute lymphocytic leukemia and 1 Hodgkin's lymphoma; 61% had poor risk disease; 68% had related donors; 68% received reduced intensity conditioning; 7 patients had mildly abnormal alanine transaminase levels (all less than three times the upper limit of normal) and 1 patient had minimally elevated bilirubin. These characteristics were similar to those of the matched control group. Median overall survival was 3, 18 and 20 months, and 1-year survival was 29%, 56% and 56%, in the hepatitis C virus, matched and all controls groups, respectively (hazard ratio for death 3.1, 95% confidence interval 1.9-5.6, p<0.001 in multivariate analysis). Non-relapse mortality at 1 year was 43%, 24% and 23%, respectively (hazard ratio 3.3, 95% confidence interval 1.8-7.1, p<0.01). Disease progression and graft-versus-host disease rates were comparable. Hepatitis C virus seropositivity is a significant risk factor for non-relapse mortality after allogeneic hematopoietic stem cell transplantation even in patients with normal or minimally abnormal liver function tests.",Journal Article,4024.0,35.0,hepatitis C virus infection causes hepatic immunological dysfunction hypothesized seropositivity virus associated increased non-relapse mortality allogeneic hematopoietic stem transplantation performed case-control outcomes patients hepatitis C virus seropositive time allogeneic hematopoietic stem transplantation N=31 Patients positive hepatitis C virus considered candidates stem transplantation significant evidence hepatic dysfunction Matched controls N=31 seronegative viral hepatitides paired according age diagnosis disease stage conditioning regimen donor type compared hepatitis C virus seropositive patients seronegative patients controls N=1800 transplanted period adjust confounding effects median age seropositive patients 49 range 26-72 15 acute myeloid leukemia/myelodysplastic syndrome 6 chronic myeloid leukemia/myeloproliferative disease 6 non-Hodgkin 's lymphoma 2 myeloma 1 acute lymphocytic leukemia 1 Hodgkin 's lymphoma 61 poor risk disease 68 related donors 68 received reduced intensity conditioning 7 patients mildly abnormal alanine transaminase levels times upper limit normal 1 patient minimally elevated bilirubin characteristics similar matched control group Median overall survival 3 18 20 months 1-year survival 29 56 56 hepatitis C virus matched controls groups respectively hazard ratio death 3.1 95 confidence interval 1.9-5.6 p 0.001 multivariate Non-relapse mortality 1 year 43 24 23 respectively hazard ratio 3.3 95 confidence interval 1.8-7.1 p 0.01 Disease progression graft-versus-host disease rates comparable Hepatitis C virus seropositivity significant risk factor non-relapse mortality allogeneic hematopoietic stem transplantation patients normal minimally abnormal liver function tests,0,0,1,0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[408, 3002, 256, 1450, 930, 1626, 939, 2, 5073, 1527, 21, 1237, 17, 9525, 9, 26, 1450, 359, 40, 41, 5, 101, 220, 429, 282, 50, 1063, 1007, 452, 31, 497, 21, 173, 8, 473, 182, 45, 1, 3, 123, 1, 7, 54, 11, 3002, 256, 1450, 9909, 28, 3, 98, 1, 1063, 1007, 452, 31, 497, 78, 456, 7, 109, 9, 3002, 256, 1450, 11, 515, 1931, 9, 452, 31, 497, 158, 492, 491, 42, 77, 93, 241, 1, 939, 1527, 655, 535, 78, 456, 11, 14924, 9, 1667, 45397, 2, 11, 2355, 768, 6, 89, 147, 34, 82, 1933, 477, 2, 1488, 267, 21, 120, 72, 3, 3002, 256, 1450, 9909, 7, 6, 62, 14924, 7, 62, 535, 78, 13507, 4600, 190, 3, 827, 727, 6, 6611, 9, 127, 4339, 176, 3, 52, 89, 1, 3, 9909, 7, 10, 739, 184, 432, 720, 167, 42, 286, 533, 2647, 10589, 681, 49, 42, 442, 533, 2647, 10857, 34, 49, 292, 18, 14, 286, 1193, 2, 14, 292, 713, 42, 334, 43, 34, 806, 42, 139, 2344, 806, 103, 405, 837, 1933, 67, 7, 42, 9443, 1668, 5411, 6997, 148, 62, 299, 76, 169, 1072, 3, 1726, 2385, 1, 295, 2, 14, 69, 42, 2144, 804, 5009, 46, 374, 11, 288, 6, 135, 1, 3, 655, 182, 87, 52, 63, 25, 10, 27, 203, 2, 179, 53, 2, 14, 111, 25, 10, 462, 664, 2, 664, 4, 3, 3002, 256, 1450, 655, 2, 62, 535, 271, 106, 360, 197, 9, 273, 27, 14, 48, 307, 268, 14, 83, 33, 49, 19, 13, 144, 4, 331, 65, 220, 429, 282, 28, 14, 111, 10, 601, 259, 2, 382, 106, 360, 197, 27, 27, 48, 307, 268, 14, 66, 67, 14, 19, 13, 355, 34, 91, 2, 1599, 185, 1204, 34, 151, 11, 1279, 3002, 256, 1450, 9525, 16, 8, 93, 43, 161, 9, 220, 429, 282, 50, 1063, 1007, 452, 31, 497, 871, 4, 7, 5, 295, 15, 2144, 1668, 343, 895]",2098.0,19144658,Impact hepatitis C virus seropositivity survival allogeneic hematopoietic stem transplantation hematologic malignancies,0,0.0
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma.,Pediatric blood & cancer,Pediatr Blood Cancer,2009-07-01,"We report a prospective study of secondary leukemia (SL)/myelodysplastic syndrome (MDS) in neuroblastoma (NB) patients treated with > or =5 cycles of dose-intensive chemotherapy. NB patients received induction with high-dose cyclophosphamide (4,200 mg/m(2))-doxorubicin (75 mg/m(2))-vincristine (cycles 1, 2, 4, 6, 8), and high-dose cisplatin (200 mg/m(2))-etoposide (600 mg/m(2)) (cycles 3, 5, 7). Bone marrow was examined every 1-3 months for > or =36 months, with inclusion of extensive chromosomal studies 1-3 months post-induction and 1-2x/year thereafter. One hundred eight four patients received 5 (n = 76), 6 (n = 45), 7 (n = 59), or 8 (n = 4) cycles. Eight patients developed SL/MDS (only one each in the 5- and 6-cycle groups), at 12-50 months, including two cases detected in surveillance studies. Among 108 patients who received > or =6 cycles, the 5-year cumulative incidence was 7.1% (95% CI: 2%, 12.2%), versus 0% among 54 patients who received 5 cycles without maintenance oral etoposide. Five-year cumulative incidences were 1.46%, 2.28%, and 8.47% among patients in the 5-, 6-, and 7-cycle groups, with fewer cycles having a significantly lower risk (P = 0.048). There was no significant association of risk with potentially leukemogenic consolidative treatments (targeted radiotherapy, myeloablative therapy, and oral etoposide). Reducing the number of dose-intensive cycles significantly decreases the risk of SL/MDS, yielding 5-year rates matching the low range (0.4-2.2%) reported for moderate-dose combination chemotherapy regimens used against other pediatric solid tumors.",Journal Article,3856.0,26.0,"report prospective secondary leukemia SL /myelodysplastic syndrome MDS neuroblastoma NB patients treated =5 cycles dose-intensive chemotherapy NB patients received induction high-dose cyclophosphamide 4,200 mg/m 2 -doxorubicin 75 mg/m 2 -vincristine cycles 1 2 4 6 8 high-dose cisplatin 200 mg/m 2 -etoposide 600 mg/m 2 cycles 3 5 7 Bone marrow examined 1-3 months =36 months inclusion extensive chromosomal studies 1-3 months post-induction 1-2x/year patients received 5 n 76 6 n 45 7 n 59 8 n 4 cycles patients developed SL/MDS 5- 6-cycle groups 12-50 months including cases detected surveillance studies 108 patients received =6 cycles 5-year cumulative incidence 7.1 95 CI 2 12.2 versus 0 54 patients received 5 cycles maintenance oral etoposide Five-year cumulative incidences 1.46 2.28 8.47 patients 5- 6- 7-cycle groups fewer cycles significantly lower risk P 0.048 significant association risk potentially leukemogenic consolidative treatments targeted radiotherapy myeloablative therapy oral etoposide Reducing number dose-intensive cycles significantly decreases risk SL/MDS yielding 5-year rates matching low range 0.4-2.2 reported moderate-dose combination chemotherapy regimens pediatric solid",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 414, 8, 482, 45, 1, 568, 6570, 10589, 681, 1223, 4, 3446, 7, 73, 5, 15, 33, 410, 1, 61, 1686, 56, 3446, 7, 103, 504, 5, 64, 61, 1112, 39, 1250, 81, 188, 18, 856, 481, 81, 188, 18, 2132, 410, 14, 18, 39, 49, 66, 2, 64, 61, 540, 1250, 81, 188, 18, 1934, 2383, 81, 188, 18, 410, 27, 33, 67, 581, 10, 409, 454, 14, 27, 53, 9, 15, 511, 53, 5, 1680, 1, 1344, 1860, 94, 14, 27, 53, 539, 504, 2, 14, 38525, 111, 3972, 104, 1128, 659, 294, 7, 103, 33, 78, 846, 49, 78, 512, 67, 78, 728, 15, 66, 78, 39, 410, 659, 7, 276, 6570, 1223, 158, 104, 296, 4, 3, 33, 2, 49, 417, 271, 28, 133, 212, 53, 141, 100, 140, 530, 4, 617, 94, 107, 3590, 7, 54, 103, 15, 49, 410, 3, 33, 111, 967, 287, 10, 67, 14, 48, 58, 18, 133, 18, 185, 13, 107, 667, 7, 54, 103, 33, 410, 187, 1146, 518, 1934, 365, 111, 967, 3981, 11, 14, 641, 18, 339, 2, 66, 662, 107, 7, 4, 3, 33, 49, 2, 67, 417, 271, 5, 1497, 410, 1041, 8, 97, 280, 43, 19, 13, 4969, 125, 10, 77, 93, 248, 1, 43, 5, 751, 13519, 6618, 640, 238, 310, 3246, 36, 2, 518, 1934, 1818, 3, 207, 1, 61, 1686, 410, 97, 2140, 3, 43, 1, 6570, 1223, 4949, 33, 111, 151, 2616, 3, 154, 184, 13, 39, 18, 18, 210, 9, 1163, 61, 150, 56, 472, 95, 480, 127, 815, 537, 57]",1474.0,19148951,Reduced risk secondary leukemia fewer cycles dose-intensive induction chemotherapy patients neuroblastoma,307,0.5357766143106457
Therapy for older AML patients: the role of novel agents and allogeneic stem cell transplant.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2008-11-01,"The development of novel therapeutics in acute myeloid leukemia (AML) is driven by the need to improve efficacy and reduce toxicity. Clearly, elderly patients with AML represent a highly heterogeneous group, based on a wide array of disease- and patient-specific characteristics. Therefore, novel treatment strategies aimed at overcoming specific biologic modifiers of disease resistance will be paramount to successful therapy for some, whereas in others, the ability to administer a low-toxicity regimen on a chronic basis to achieve disease control may prove beneficial, perhaps even in the absence of complete responses. In addition, identifying genomic and proteomic expression patterns using an individual's unique neoplastic clone will likely optimize the ability to predict responders to novel therapies and identify new and relevant therapeutic targets. The development of reduced-intensity preparative regimens for allogeneic transplants has allowed physicians and patients to explore the option of long-term disease control. The risk-benefit ratio for this procedure will depend on the disease state, patient performance status, and comorbidities. However, current results underscore that age alone should no longer be a contraindication for allogeneic transplant with curative intent in these patients, and long-term disease control with good quality of life is possible and can be expected. Future trials combining the novel therapies described in this article and novel transplant technologies should allow more elderly patients with AML or myelodysplastic syndromes to experience long and productive lives.",Journal Article,4098.0,13.0,development novel therapeutics acute myeloid leukemia AML driven need improve efficacy reduce toxicity Clearly elderly patients AML represent highly heterogeneous group based wide array disease- patient-specific characteristics novel treatment strategies aimed overcoming specific biologic modifiers disease resistance paramount successful therapy ability administer low-toxicity regimen chronic basis achieve disease control prove beneficial absence complete responses addition identifying genomic proteomic expression patterns individual 's unique neoplastic clone likely optimize ability predict responders novel therapies identify new relevant therapeutic targets development reduced-intensity preparative regimens allogeneic transplants allowed physicians patients explore option long-term disease control risk-benefit ratio procedure depend disease state patient performance status comorbidities current underscore age longer contraindication allogeneic transplant curative intent patients long-term disease control good quality life possible expected Future trials combining novel therapies described article novel transplant technologies allow elderly patients AML myelodysplastic syndromes experience long productive lives,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 193, 1, 229, 1943, 4, 286, 533, 329, 16, 1621, 20, 3, 594, 6, 401, 209, 2, 969, 155, 2536, 1216, 7, 5, 329, 1231, 8, 561, 1564, 87, 90, 23, 8, 1019, 1926, 1, 34, 2, 69, 112, 374, 673, 229, 24, 422, 1295, 28, 5344, 112, 1283, 5663, 1, 34, 251, 303, 40, 7640, 6, 1401, 36, 9, 476, 547, 4, 1749, 3, 801, 6, 6888, 8, 154, 155, 477, 23, 8, 442, 877, 6, 1359, 34, 182, 68, 4361, 2524, 4434, 871, 4, 3, 1127, 1, 236, 253, 4, 352, 1386, 572, 2, 3784, 55, 764, 75, 35, 797, 292, 991, 2000, 3910, 303, 322, 2465, 3, 801, 6, 678, 1983, 6, 229, 235, 2, 255, 217, 2, 867, 189, 637, 3, 193, 1, 405, 837, 6085, 472, 9, 1063, 4016, 71, 2313, 1261, 2, 7, 6, 1645, 3, 1501, 1, 319, 337, 34, 182, 3, 43, 247, 197, 9, 26, 1299, 303, 4533, 23, 3, 34, 1309, 69, 528, 156, 2, 1909, 137, 291, 99, 5531, 17, 89, 279, 257, 77, 589, 40, 8, 8363, 9, 1063, 941, 5, 1075, 1697, 4, 46, 7, 2, 319, 337, 34, 182, 5, 1178, 372, 1, 358, 16, 899, 2, 122, 40, 1336, 508, 143, 1525, 3, 229, 235, 1027, 4, 26, 946, 2, 229, 941, 2590, 257, 1700, 80, 1216, 7, 5, 329, 15, 2040, 6, 730, 319, 2, 10110, 6407]",1576.0,19176199,Therapy older AML patients role novel agents allogeneic stem transplant,194,0.33856893542757416
T-cell large granular lymphocyte leukemia associated with myelodysplastic syndrome: a clinicopathologic study of nine cases.,American journal of clinical pathology,Am. J. Clin. Pathol.,2009-03-01,"We describe 9 patients with T-cell large granular lymphocyte leukemia (T-LGL) who also had a myelodysplastic syndrome (MDS). There were 6 men and 3 women with a median age of 60 years (range, 25-74 years). All patients had anemia at initial examination, 7 had neutropenia, and 5 had thrombocytopenia. The median absolute lymphocyte count was 1,300/microL (1.3 x 10(9)/L; range, 700-3,600/microL [0.7-3.6 x 10(9)/L]). Immunophenotypic analysis showed a CD8+ T-cell population, and molecular analysis showed monoclonal T-cell receptor gene rearrangement in every case. The MDS was classified as refractory cytopenia with multilineage dysplasia (RCMD, n = 5), refractory anemia (n = 2), RCMD with ringed sideroblasts (n = 1), and chronic myelomonocytic leukemia (n = 1). We compared the data for these patients with T-LGL/MDS with a group that had only T-LGL. The median hemoglobin level and absolute lymphocyte count were lower in patients with T-LGL/MDS (P < .05). The frequency of coexistent T-LGL and MDS at our institution suggests an etiologic relationship rather than simple coincidence.",Journal Article,3978.0,24.0,"9 patients T-cell large granular lymphocyte leukemia T-LGL myelodysplastic syndrome MDS 6 men 3 women median age 60 years range 25-74 years patients anemia initial examination 7 neutropenia 5 thrombocytopenia median absolute lymphocyte count 1,300/microL 1.3 x 10 9 /L range 700-3,600/microL 0.7-3.6 x 10 9 /L Immunophenotypic showed CD8+ T-cell population molecular showed monoclonal T-cell receptor rearrangement case MDS classified refractory cytopenia multilineage dysplasia RCMD n 5 refractory anemia n 2 RCMD ringed sideroblasts n 1 chronic myelomonocytic leukemia n 1 compared patients T-LGL/MDS group T-LGL median hemoglobin level absolute lymphocyte count lower patients T-LGL/MDS P .05 frequency coexistent T-LGL MDS institution suggests etiologic relationship simple coincidence",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 897, 83, 7, 5, 102, 31, 375, 7694, 1448, 102, 7816, 54, 120, 42, 8, 681, 1223, 125, 11, 49, 325, 2, 27, 117, 5, 8, 52, 89, 1, 335, 60, 184, 243, 794, 60, 62, 7, 42, 1545, 28, 388, 1385, 67, 42, 778, 2, 33, 42, 1340, 3, 52, 1766, 1448, 1276, 10, 14, 2036, 5128, 14, 27, 1006, 79, 83, 805, 184, 5692, 27, 2383, 5128, 13, 67, 27, 49, 1006, 79, 83, 805, 6599, 65, 224, 8, 968, 102, 31, 266, 2, 219, 65, 224, 848, 102, 31, 153, 145, 2675, 4, 454, 473, 3, 1223, 10, 1373, 22, 430, 8165, 5, 12471, 2253, 38929, 78, 33, 430, 1545, 78, 18, 38929, 5, 38930, 23740, 78, 14, 2, 442, 5451, 78, 14, 21, 72, 3, 74, 9, 46, 7, 5, 102, 7816, 1223, 5, 8, 87, 17, 42, 158, 102, 7816, 3, 52, 2222, 301, 2, 1766, 1448, 1276, 11, 280, 4, 7, 5, 102, 7816, 1223, 19, 474, 3, 675, 1, 12779, 102, 7816, 2, 1223, 28, 114, 731, 844, 35, 6604, 858, 1832, 76, 2763, 26006]",1008.0,19228641,T-cell large granular lymphocyte leukemia associated myelodysplastic syndrome clinicopathologic cases,12,0.020942408376963352
A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.,British journal of haematology,Br. J. Haematol.,2009-03-30,"The marginal zone lymphomas (MZLs) are a recently defined group of related diseases that probably arise from a common cell of origin, the marginal zone B cell. Data on therapy for subtypes other than gastric mucosa-associated lymphoid tissue (MALT) lymphoma has been largely limited to retrospective case series. This prospective phase 2 study of fludarabine and rituximab for the treatment of marginal zone lymphomas enrolled 26 patients, 14 with nodal MZL, eight with MALT lymphomas and four with splenic MZL; 81% were receiving initial systemic therapy. Only 58% [95% confidence interval (CI) 37-77%] of patients completed the planned six cycles, due to significant haematological, infectious and allergic toxicity. Four late toxic deaths occurred due to infections [15% (95% CI 4.3-35%)], two related to delayed bone marrow aplasia and two related to myelodysplastic syndrome. Nonetheless, the overall response rate was 85% (95% CI 65-96%), with 54% complete responses. The progression-free survival at 3.1 years of follow-up is 79.5% (95% CI 63-96%). We conclude that, although concurrent fludarabine and rituximab given at this dose and schedule is a highly effective regimen in the treatment of MZLs, the significant haematological and infectious toxicity observed both during and after therapy is prohibitive in this patient population, emphasizing the need to study MZLs as a separate entity.","Clinical Trial, Phase II",3949.0,62.0,marginal zone lymphomas MZLs recently defined group related diseases probably arise common origin marginal zone B therapy subtypes gastric mucosa-associated lymphoid tissue MALT lymphoma largely limited retrospective case series prospective phase 2 fludarabine rituximab treatment marginal zone lymphomas enrolled 26 patients 14 nodal MZL MALT lymphomas splenic MZL 81 receiving initial systemic therapy 58 95 confidence interval CI 37-77 patients completed planned cycles significant haematological infectious allergic toxicity late toxic deaths occurred infections 15 95 CI 4.3-35 related delayed bone marrow aplasia related myelodysplastic syndrome Nonetheless overall response rate 85 95 CI 65-96 54 complete responses progression-free survival 3.1 years follow-up 79.5 95 CI 63-96 conclude concurrent fludarabine rituximab given dose schedule highly effective regimen treatment MZLs significant haematological infectious toxicity observed therapy prohibitive patient population emphasizing need MZLs separate entity,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,"[3, 3450, 3614, 1557, 26803, 32, 8, 761, 395, 87, 1, 139, 1342, 17, 4061, 3043, 29, 8, 186, 31, 1, 1938, 3, 3450, 3614, 132, 31, 74, 23, 36, 9, 814, 127, 76, 2713, 41, 2303, 246, 8273, 71, 85, 1733, 383, 6, 459, 473, 988, 26, 482, 124, 18, 45, 1, 2027, 2, 855, 9, 3, 24, 1, 3450, 3614, 1557, 346, 432, 7, 213, 5, 779, 8277, 659, 5, 8273, 1557, 2, 294, 5, 5237, 8277, 865, 11, 357, 388, 403, 36, 158, 717, 48, 307, 268, 58, 567, 849, 1, 7, 781, 3, 1465, 437, 410, 520, 6, 93, 5143, 3398, 2, 7465, 155, 294, 807, 1812, 1043, 489, 520, 6, 1875, 167, 48, 58, 39, 27, 465, 100, 139, 6, 1612, 581, 12307, 2, 100, 139, 6, 681, 4648, 3, 63, 51, 116, 10, 772, 48, 58, 556, 921, 5, 667, 236, 253, 3, 91, 115, 25, 28, 27, 14, 60, 1, 166, 126, 16, 842, 33, 48, 58, 676, 921, 21, 2060, 17, 242, 750, 2027, 2, 855, 447, 28, 26, 61, 2, 1055, 16, 8, 561, 323, 477, 4, 3, 24, 1, 26803, 3, 93, 5143, 2, 3398, 155, 164, 110, 190, 2, 50, 36, 16, 10784, 4, 26, 69, 266, 6826, 3, 594, 6, 45, 26803, 22, 8, 2282, 2983]",1313.0,19344412,phase 2 concurrent fludarabine rituximab treatment marginal zone lymphomas,52,0.09075043630017451
Rapid transport and infusion of hematopoietic cells is associated with improved outcome after myeloablative therapy and unrelated donor transplant.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2009-05-01,"We evaluated effects of graft transport time on outcomes after transplantation of 938 unrelated donor bone marrow (BM) or 507 peripheral blood progenitor cells (PBPC) in patients with acute or chronic leukemia and myelodysplastic syndrome (MDS). BM grafts were collected at 107 centers and PBPC, 89 centers. Median time from end of collection to infusion was 14 hours for BM and 15 hours for PBPC. Platelet recovery was less likely in BM recipients when the interval from end of collection to receipt at transplant center was >or=20 hours (odds ratio 0.47, P = .010) and when the interval from receipt to infusion was >or=6 hours (odds ratio 0.57, P = .001). Mortality rates were higher in recipients of HLA-matched BM when the interval from end of collection to receipt at transplant center was >or=20 hours (relative risk 2.67, P < .001) after adjustment for other significant prognostic factors. Mortality after HLA-mismatched BM transplants was not associated with transport time. Transport times had no demonstrable effect on outcomes after PBPC transplants. These data support a general review of current transport procedures, especially for BM grafts requiring longer transport time and every effort made to minimize time from collection to infusion.",Journal Article,3917.0,20.0,evaluated effects graft transport time outcomes transplantation 938 unrelated donor bone marrow BM 507 peripheral blood progenitor PBPC patients acute chronic leukemia myelodysplastic syndrome MDS BM grafts collected 107 centers PBPC 89 centers Median time end collection infusion 14 hours BM 15 hours PBPC Platelet recovery likely BM recipients interval end collection receipt transplant center or=20 hours odds ratio 0.47 P .010 interval receipt infusion or=6 hours odds ratio 0.57 P .001 Mortality rates higher recipients HLA-matched BM interval end collection receipt transplant center or=20 hours relative risk 2.67 P .001 adjustment significant prognostic factors Mortality HLA-mismatched BM transplants associated transport time Transport times demonstrable effect outcomes PBPC transplants support general review current transport procedures especially BM grafts requiring longer transport time effort minimize time collection infusion,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 194, 176, 1, 1599, 4294, 98, 23, 123, 50, 497, 1, 13354, 2092, 1488, 581, 1246, 15, 12257, 672, 315, 2520, 37, 11537, 4, 7, 5, 286, 15, 442, 2, 681, 1223, 1246, 4713, 11, 786, 28, 3650, 1168, 2, 11537, 887, 1168, 52, 98, 29, 396, 1, 2442, 6, 904, 10, 213, 1459, 9, 1246, 2, 167, 1459, 9, 11537, 1596, 1602, 10, 299, 322, 4, 1246, 2190, 198, 3, 268, 29, 396, 1, 2442, 6, 1699, 28, 941, 574, 10, 15, 179, 1459, 610, 197, 13, 662, 19, 4873, 2, 198, 3, 268, 29, 1699, 6, 904, 10, 15, 49, 1459, 610, 197, 13, 696, 19, 144, 282, 151, 11, 142, 4, 2190, 1, 1160, 655, 1246, 198, 3, 268, 29, 396, 1, 2442, 6, 1699, 28, 941, 574, 10, 15, 179, 1459, 580, 43, 18, 598, 19, 144, 50, 1852, 9, 127, 93, 177, 130, 282, 50, 1160, 5095, 1246, 4016, 10, 44, 41, 5, 4294, 98, 4294, 1072, 42, 77, 11411, 254, 23, 123, 50, 11537, 4016, 46, 74, 538, 8, 1083, 206, 1, 291, 4294, 1369, 1093, 9, 1246, 4713, 1888, 589, 4294, 98, 2, 454, 2919, 1229, 6, 3241, 98, 29, 2442, 6, 904]",1193.0,19361751,Rapid transport infusion hematopoietic associated improved outcome myeloablative therapy unrelated donor transplant,35,0.06108202443280977
Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2009-05-01,"The purpose of this study was to determine the effect of alemtuzumab on treatment-related mortality (TRM), relapse, overall survival (OS), and disease-free survival (DSF) in patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS) undergoing reduced intensity conditioning (RIC). We compared the outcome of 95 patients treated at the University of Chicago with fludarabine melphalan (Flu + Mel) + alemtuzumab conditioning and 59 patients treated at the M.D. Anderson Cancer Center with Flu + Mel conditioning. Both groups had similar patient and donor characteristics. There were no significant differences in TRM, relapse, survival, and DFS between the 2 groups. The incidence of acute graft-versus-host disease (aGVHD) grade II-IV (relative risk [RR] 5.5, P < .01) and chronic GVHD (cGVHD) (RR 6.6, P < .01) were significantly lower in patients receiving alemtuzumab. The addition of alemtuzumab to an RIC regimen dramatically reduces the incidence of aGVHD and cGVHD in patients with AML and MDS undergoing allogeneic transplantation. TRM, relapse risk, OS and DFS are not affected.",Controlled Clinical Trial,3917.0,39.0,purpose determine effect alemtuzumab treatment-related mortality TRM relapse overall survival OS disease-free survival DSF patients acute myelogenous leukemia AML myelodysplastic syndromes MDS undergoing reduced intensity conditioning RIC compared outcome 95 patients treated University Chicago fludarabine melphalan Flu Mel alemtuzumab conditioning 59 patients treated M.D Anderson Center Flu Mel conditioning groups similar patient donor characteristics significant differences TRM relapse survival DFS 2 groups incidence acute graft-versus-host disease aGVHD grade II-IV relative risk RR 5.5 P .01 chronic GVHD cGVHD RR 6.6 P .01 significantly lower patients receiving alemtuzumab addition alemtuzumab RIC regimen dramatically reduces incidence aGVHD cGVHD patients AML MDS undergoing allogeneic transplantation TRM relapse risk OS DFS affected,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 223, 3, 254, 1, 3579, 23, 24, 139, 282, 5064, 429, 63, 25, 118, 2, 34, 115, 25, 16510, 4, 7, 5, 286, 2194, 329, 2, 2040, 1223, 479, 405, 837, 1933, 3365, 21, 72, 3, 228, 1, 48, 7, 73, 28, 3, 1652, 1, 9344, 5, 2027, 2370, 5119, 7383, 3579, 1933, 2, 728, 7, 73, 28, 3, 188, 427, 1929, 12, 574, 5, 5119, 7383, 1933, 110, 271, 42, 288, 69, 2, 1488, 374, 125, 11, 77, 93, 362, 4, 5064, 429, 25, 2, 1010, 59, 3, 18, 271, 3, 287, 1, 286, 1599, 185, 1204, 34, 5873, 88, 215, 478, 580, 43, 861, 33, 33, 19, 355, 2, 442, 1562, 6670, 861, 49, 49, 19, 355, 11, 97, 280, 4, 7, 357, 3579, 3, 352, 1, 3579, 6, 35, 3365, 477, 2729, 2389, 3, 287, 1, 5873, 2, 6670, 4, 7, 5, 329, 2, 1223, 479, 1063, 497, 5064, 429, 43, 118, 2, 1010, 32, 44, 1424]",1034.0,19361753,Fludarabine-melphalan conditioning AML MDS alemtuzumab reduces acute chronic GVHD affecting long-term outcomes,8,0.013961605584642234
Elevated AF1q expression is a poor prognostic marker for adult acute myeloid leukemia patients with normal cytogenetics.,American journal of hematology,Am. J. Hematol.,2009-05-01,"Nearly half of the patients with newly diagnosed acute myeloid leukemia have normal cytogenetics (NC-AML) and are classified as intermediate risk, but their 5-year overall survival (OS) ranges from 24 to 42%. Therefore, molecular biomarkers to identify poor-risk patients are needed. Elevated AF1q expression in the absence of specific poor cytogenetics is associated with poor outcomes in pediatric patients with AML and adult patients with myelodysplastic syndrome. We examined AF1q expression in 290 patients with NC-AML. We found that patients with low AF1q (n = 73) expression (AF1q(low)) have better OS (P = 0.026), disease-free survival (P = 0.1), and complete remission rate (P = 0.06) when compared with patients with high AF1q expression (AF1q(high) n = 217). The patients with AF1q(high) had significantly greater incidence of concurrent tyrosine kinase3 internal tandem duplication. A subgroup of the patients with AF1q(high) who received allogeneic stem cell transplantation (SCT) had a significant better relapse-free survival when compared with patients who received chemotherapy/autologous SCT (P = 0.04). This study suggests that high AF1q expression is a poor prognostic marker for adult patients with NC-AML.",Letter,3917.0,23.0,Nearly half patients newly diagnosed acute myeloid leukemia normal cytogenetics NC-AML classified intermediate risk 5-year overall survival OS ranges 24 42 molecular biomarkers identify poor-risk patients needed Elevated AF1q expression absence specific poor cytogenetics associated poor outcomes pediatric patients AML adult patients myelodysplastic syndrome examined AF1q expression 290 patients NC-AML patients low AF1q n 73 expression AF1q low better OS P 0.026 disease-free survival P 0.1 complete remission rate P 0.06 compared patients high AF1q expression AF1q high n 217 patients AF1q high significantly greater incidence concurrent tyrosine kinase3 internal tandem duplication subgroup patients AF1q high received allogeneic stem transplantation SCT significant better relapse-free survival compared patients received chemotherapy/autologous SCT P 0.04 suggests high AF1q expression poor prognostic marker adult patients NC-AML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1857, 1303, 1, 3, 7, 5, 732, 265, 286, 533, 47, 295, 2510, 5480, 329, 2, 32, 1373, 22, 919, 43, 84, 136, 33, 111, 63, 25, 118, 5632, 29, 259, 6, 595, 673, 219, 582, 6, 255, 334, 43, 7, 32, 575, 804, 23759, 55, 4, 3, 1127, 1, 112, 334, 2510, 16, 41, 5, 334, 123, 4, 815, 7, 5, 329, 2, 780, 7, 5, 681, 21, 409, 23759, 55, 4, 9027, 7, 5, 5480, 329, 21, 204, 17, 7, 5, 154, 23759, 78, 803, 55, 23759, 154, 47, 380, 118, 19, 13, 4554, 34, 115, 25, 19, 13, 14, 2, 236, 734, 116, 19, 13, 1460, 198, 72, 5, 7, 5, 64, 23759, 55, 23759, 64, 78, 6499, 3, 7, 5, 23759, 64, 42, 97, 378, 287, 1, 750, 564, 57850, 2329, 2905, 4616, 8, 1363, 1, 3, 7, 5, 23759, 64, 54, 103, 1063, 452, 31, 497, 1988, 42, 8, 93, 380, 429, 115, 25, 198, 72, 5, 7, 54, 103, 56, 1028, 1988, 19, 13, 755, 26, 45, 844, 17, 64, 23759, 55, 16, 8, 334, 177, 952, 9, 780, 7, 5, 5480, 329]",1153.0,19396856,Elevated AF1q expression poor prognostic marker adult acute myeloid leukemia patients normal cytogenetics,0,0.0
Targeting DNA methylation.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2009-06-09,"Two nucleoside inhibitors of DNA methylation, azacitidine and decitabine, are now standard of care for the treatment of the myelodysplastic syndrome, a deadly form of leukemia. These old drugs, developed as cytotoxic agents and nearly abandoned decades ago were resurrected by the renewed interest in DNA methylation. They have now provided proof of principle for epigenetic therapy, the final chapter in the long saga to provide legitimacy to the field of epigenetics in cancer. But challenges remain; we don't understand precisely how or why the drugs work or stop working after an initial response. Extending these promising findings to solid tumors faces substantial hurdles from drug uptake to clinical trial design. We do not know yet how to select patients for this therapy and how to move it from life extension to cure. The epigenetic potential of DNA methylation inhibitors may be limited by other epigenetic mechanisms that are also worth exploring as therapeutic targets. But the idea of stably changing gene expression in vivo has transformative potential in cancer therapy and beyond.",Journal Article,3878.0,283.0,nucleoside inhibitors DNA methylation azacitidine decitabine standard care treatment myelodysplastic syndrome deadly form leukemia old drugs developed cytotoxic agents nearly abandoned decades ago resurrected renewed DNA methylation provided proof principle epigenetic therapy final chapter long saga provide legitimacy field epigenetics challenges remain n't understand precisely drugs work stop working initial response Extending promising findings solid faces substantial hurdles drug uptake clinical trial design know select patients therapy life extension cure epigenetic potential DNA methylation inhibitors limited epigenetic mechanisms worth exploring therapeutic targets idea stably changing expression vivo transformative potential therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[100, 4032, 222, 1, 261, 569, 3752, 2, 3004, 32, 1134, 260, 1, 165, 9, 3, 24, 1, 3, 681, 8, 6610, 1297, 1, 46, 1095, 600, 276, 22, 759, 183, 2, 1857, 13015, 1968, 5028, 11, 57970, 20, 3, 8126, 1333, 4, 261, 569, 491, 47, 1134, 1052, 3840, 1, 4968, 9, 1418, 36, 3, 1457, 6366, 4, 3, 319, 33716, 6, 377, 39014, 6, 3, 1067, 1, 9706, 4, 12, 84, 1427, 918, 21, 1022, 12408, 1640, 7428, 832, 15, 5283, 3, 600, 1357, 15, 7142, 2644, 50, 35, 388, 51, 4782, 46, 721, 272, 6, 537, 57, 19786, 1281, 9583, 29, 234, 1135, 6, 38, 160, 771, 21, 1022, 44, 6572, 1145, 832, 6, 1717, 7, 9, 26, 36, 2, 832, 6, 6759, 192, 29, 358, 2401, 6, 1722, 3, 1418, 174, 1, 261, 569, 222, 68, 40, 383, 20, 127, 1418, 483, 17, 32, 120, 9498, 4378, 22, 189, 637, 84, 3, 8098, 1, 5834, 3600, 145, 55, 4, 386, 71, 16947, 174, 4, 12, 36, 2, 1654]",1060.0,19509174,Targeting DNA methylation,27,0.04712041884816754
Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies.,Blood,Blood,2009-06-22,"Sequential administration of DNA methyltransferase (DNMT) inhibitors and histone deacetylase (HDAC) inhibitors has demonstrated clinical efficacy in patients with hematologic malignancies. However, the mechanism behind their clinical efficacy remains controversial. In this study, the methylation dynamics of 4 TSGs (p15(INK4B), CDH-1, DAPK-1, and SOCS-1) were studied in sequential bone marrow samples from 30 patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) who completed a minimum of 4 cycles of therapy with 5-azacytidine and entinostat. Reversal of promoter methylation after therapy was observed in both clinical responders and nonresponders across all genes. There was no association between clinical response and either baseline methylation or methylation reversal in the bone marrow or purified CD34(+) population, nor was there an association with change in gene expression. Transient global hypomethylation was observed in samples after treatment but was not associated with clinical response. Induction of histone H3/H4 acetylation and the DNA damage-associated variant histone gamma-H2AX was observed in peripheral blood samples across all dose cohorts. In conclusion, methylation reversal of candidate TSGs during cycle 1 of therapy was not predictive of clinical response to combination ""epigenetic"" therapy. This trial is registered with http://www.clinicaltrials.gov under NCT00101179.","Clinical Trial, Phase I",3865.0,228.0,Sequential administration DNA methyltransferase DNMT inhibitors histone deacetylase HDAC inhibitors demonstrated clinical efficacy patients hematologic malignancies mechanism clinical efficacy remains controversial methylation dynamics 4 TSGs p15 INK4B CDH-1 DAPK-1 SOCS-1 studied sequential bone marrow 30 patients myelodysplastic syndrome MDS acute myeloid leukemia AML completed minimum 4 cycles therapy 5-azacytidine entinostat Reversal promoter methylation therapy observed clinical responders nonresponders association clinical response baseline methylation methylation reversal bone marrow purified CD34 population association change expression Transient global hypomethylation observed treatment associated clinical response Induction histone H3/H4 acetylation DNA damage-associated histone gamma-H2AX observed peripheral blood dose cohorts methylation reversal candidate TSGs cycle 1 therapy predictive clinical response combination `` epigenetic '' therapy trial registered http //www.clinicaltrials.gov NCT00101179,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1787, 634, 1, 261, 3747, 10229, 222, 2, 1508, 2732, 2654, 222, 71, 264, 38, 209, 4, 7, 5, 813, 441, 137, 3, 670, 5219, 136, 38, 209, 469, 2010, 4, 26, 45, 3, 569, 5193, 1, 39, 13876, 8840, 13536, 44385, 14, 22249, 14, 2, 26138, 14, 11, 656, 4, 1787, 581, 347, 29, 201, 7, 5, 681, 1223, 15, 286, 533, 329, 54, 781, 8, 2499, 1, 39, 410, 1, 36, 5, 33, 11755, 2, 7616, 5933, 1, 973, 569, 50, 36, 10, 164, 4, 110, 38, 1983, 2, 4498, 716, 62, 214, 125, 10, 77, 248, 59, 38, 51, 2, 361, 330, 569, 15, 569, 5933, 4, 3, 581, 15, 5963, 2215, 266, 2110, 10, 125, 35, 248, 5, 707, 4, 145, 55, 2473, 1648, 4441, 10, 164, 4, 347, 50, 24, 84, 10, 44, 41, 5, 38, 51, 504, 1, 1508, 3739, 7812, 4145, 2, 3, 261, 1350, 41, 1142, 1508, 1705, 6286, 10, 164, 4, 672, 315, 347, 716, 62, 61, 736, 4, 1221, 569, 5933, 1, 1609, 13876, 190, 417, 14, 1, 36, 10, 44, 464, 1, 38, 51, 6, 150, 1418, 522, 36, 26, 160, 16, 1653, 5, 5196, 3064, 1252, 1239, 669, 58009]",1369.0,19546476,Early epigenetic changes DNA damage predict clinical response overlapping schedule 5-azacytidine entinostat patients myeloid malignancies,75,0.13089005235602094
Reduced-toxicity conditioning therapy with allogeneic stem cell transplantation for acute leukemia.,Current opinion in oncology,Curr Opin Oncol,2009-06-01,"We hypothesized that standardized systemic drug delivery would improve treatment safety and provide better leukemia control. We therefore developed an intravenous busulfan formulation and combined it with fludarabine instead of cyclophosphamide in preparation for allogeneic stem cell transplantation (alloSCT). We used a Bayesian method to compare the outcomes of 67 acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) patients who received intravenous busulfan-cyclophosphamide (BuCy2) with 148 subsequent AML/MDS patients who received busulfan-fludarabine (Bu-Flu). The groups had comparable pretreatment characteristics, except that the Bu-Flu patients were older, more often had unrelated donors and had a shorter follow-up. A greatly improved outcome in the Bu-Flu group is unlikely to be explained by improved supportive care during this time period. Overall, the data support replacing BuCy2 with or without antithymocyte globulin (ATG) with Bu-Flu with or without rabbit-ATG for AML or MDS. We further suggest that the high level of safety and fast recovery from conditioning therapy-related side effects after the Bu-Flu regimen makes it a suitable platform technology for testing additional adjuncts for improved posttransplant immune recovery and long-term disease control in patients who are at high risk of rapidly recurrent disease after alloSCT. The extremely low one-year treatment-related mortality as well as high overall and event-free survival of patients in the Bu-Flu group indicate that it is time to revisit the value of alloSCT compared with conventional maintenance chemotherapy for patients in first complete remission of AML/MDS.",Comparative Study,3886.0,14.0,hypothesized standardized systemic drug delivery improve treatment safety provide better leukemia control developed intravenous busulfan formulation combined fludarabine instead cyclophosphamide preparation allogeneic stem transplantation alloSCT Bayesian compare outcomes 67 acute myeloid leukemia AML /myelodysplastic syndrome MDS patients received intravenous busulfan-cyclophosphamide BuCy2 148 subsequent AML/MDS patients received busulfan-fludarabine Bu-Flu groups comparable pretreatment characteristics Bu-Flu patients older unrelated donors shorter follow-up greatly improved outcome Bu-Flu group unlikely explained improved supportive care time period Overall support replacing BuCy2 antithymocyte globulin ATG Bu-Flu rabbit-ATG AML MDS suggest high level safety fast recovery conditioning therapy-related effects Bu-Flu regimen makes suitable platform technology testing additional adjuncts improved posttransplant immune recovery long-term disease control patients high risk rapidly recurrent disease alloSCT extremely low one-year treatment-related mortality high overall event-free survival patients Bu-Flu group indicate time revisit value alloSCT compared conventional maintenance chemotherapy patients complete remission AML/MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 1237, 17, 1670, 403, 234, 989, 688, 401, 24, 367, 2, 377, 380, 182, 21, 673, 276, 35, 1262, 3906, 3583, 2, 397, 192, 5, 2027, 3496, 1, 1112, 4, 4824, 9, 1063, 452, 31, 497, 7253, 21, 95, 8, 5032, 596, 6, 932, 3, 123, 1, 598, 286, 533, 329, 10589, 681, 1223, 7, 54, 103, 1262, 3906, 1112, 27967, 5, 4647, 706, 329, 1223, 7, 54, 103, 3906, 2027, 3667, 5119, 3, 271, 42, 1279, 1194, 374, 2187, 17, 3, 3667, 5119, 7, 11, 434, 80, 629, 42, 2092, 2344, 2, 42, 8, 985, 166, 126, 8, 3510, 231, 228, 4, 3, 3667, 5119, 87, 16, 3568, 6, 40, 3672, 20, 231, 1877, 165, 190, 26, 98, 727, 63, 3, 74, 538, 9574, 27967, 5, 15, 187, 11016, 7819, 7168, 5, 3667, 5119, 5, 15, 187, 11079, 7168, 9, 329, 15, 1223, 21, 195, 309, 17, 3, 64, 301, 1, 367, 2, 5830, 1602, 29, 1933, 36, 139, 1152, 176, 50, 3, 3667, 5119, 477, 4677, 192, 8, 2884, 2243, 2033, 9, 471, 402, 13885, 9, 231, 7346, 250, 1602, 2, 319, 337, 34, 182, 4, 7, 54, 32, 28, 64, 43, 1, 1755, 387, 34, 50, 7253, 3, 2938, 154, 104, 111, 24, 139, 282, 22, 149, 22, 64, 63, 2, 774, 115, 25, 1, 7, 4, 3, 3667, 5119, 87, 1008, 17, 192, 16, 98, 6, 26846, 3, 549, 1, 7253, 72, 5, 809, 1146, 56, 9, 7, 4, 157, 236, 734, 1, 329, 1223]",1626.0,19561406,Reduced-toxicity conditioning therapy allogeneic stem transplantation acute leukemia,25,0.04363001745200698
"Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose.",Blood,Blood,2009-07-16,"We report outcomes of 932 recipients of unrelated donor peripheral blood stem cell hematopoietic cell transplantation (URD-PBSC HCT) for acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome enrolled on a prospective National Marrow Donor Program trial from 1999 through 2003. Preparative regimens included myeloablative (MA; N = 611), reduced-intensity (RI; N = 160), and nonmyeloablative (NMA; N = 161). For MA recipients, CD34(+) counts greater than 3.8 x 10(6)/kg improved neutrophil and platelet engraftment, whereas improved overall survival (OS) and reduced transplant-related mortality (TRM) were seen for all preparative regimens when CD34(+) cell doses exceeded 4.5 x 10(6)/kg. Higher infused doses of CD34(+) cell dose did not result in increased rates of either acute or chronic graft-versus-host disease (GVHD). Three-year OS and disease-free survival (DFS) of recipients of MA, RI, and NMA approaches were similar (33%, 35%, and 32% OS; 33%, 30%, and 29% DFS, respectively). In summary, recipients of URD-PBSC HCT receiving preparative regimens differing in intensity experienced similar survival. Higher CD34(+) cell doses resulted in more rapid engraftment, less TRM, and better 3-year OS (39% versus 25%, MA, P = .004; 38% versus 21% RI/NMA, P = .004) but did not increase the risk of GVHD. This trial was registered at www.clinicaltrials.gov as #NCT00785525.",Clinical Trial,3841.0,91.0,report outcomes 932 recipients unrelated donor peripheral blood stem hematopoietic transplantation URD-PBSC HCT acute myeloid leukemia acute lymphoblastic leukemia chronic myelogenous leukemia myelodysplastic syndrome enrolled prospective National Marrow Donor Program trial 1999 2003 Preparative regimens included myeloablative N 611 reduced-intensity RI N 160 nonmyeloablative NMA N 161 recipients CD34 counts greater 3.8 x 10 6 /kg improved neutrophil platelet engraftment improved overall survival OS reduced transplant-related mortality TRM seen preparative regimens CD34 doses exceeded 4.5 x 10 6 /kg Higher infused doses CD34 dose increased rates acute chronic graft-versus-host disease GVHD Three-year OS disease-free survival DFS recipients RI NMA approaches similar 33 35 32 OS 33 30 29 DFS respectively summary recipients URD-PBSC HCT receiving preparative regimens differing intensity experienced similar survival Higher CD34 doses resulted rapid engraftment TRM better 3-year OS 39 versus 25 P .004 38 versus 21 RI/NMA P .004 increase risk GVHD trial registered www.clinicaltrials.gov NCT00785525,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 414, 123, 1, 15542, 2190, 1, 2092, 1488, 672, 315, 452, 31, 1007, 31, 497, 5847, 6368, 1085, 9, 286, 533, 286, 1275, 442, 2194, 2, 681, 346, 23, 8, 482, 657, 581, 1488, 1243, 160, 29, 2043, 298, 1522, 6085, 472, 159, 3246, 3687, 78, 10711, 405, 837, 9836, 78, 3457, 2, 6094, 10370, 78, 5377, 9, 3687, 2190, 2215, 1911, 378, 76, 27, 66, 1006, 79, 49, 503, 231, 2595, 2, 1596, 2881, 547, 231, 63, 25, 118, 2, 405, 941, 139, 282, 5064, 11, 527, 9, 62, 6085, 472, 198, 2215, 31, 415, 4726, 39, 33, 1006, 79, 49, 503, 142, 4524, 415, 1, 2215, 31, 61, 205, 44, 757, 4, 101, 151, 1, 361, 286, 15, 442, 1599, 185, 1204, 34, 1562, 169, 111, 118, 2, 34, 115, 25, 1010, 1, 2190, 1, 3687, 9836, 2, 10370, 611, 11, 288, 466, 465, 2, 531, 118, 466, 201, 2, 462, 1010, 106, 4, 1962, 2190, 1, 5847, 6368, 1085, 357, 6085, 472, 5276, 4, 837, 592, 288, 25, 142, 2215, 31, 415, 627, 4, 80, 1321, 2881, 299, 5064, 2, 380, 27, 111, 118, 587, 185, 243, 3687, 19, 1520, 519, 185, 239, 9836, 10370, 19, 1520, 84, 205, 44, 344, 3, 43, 1, 1562, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 58080]",1306.0,19608747,Donor recipient transplant characteristics risk factors unrelated donor PBSC transplantation beneficial effects higher CD34+ dose,488,0.8516579406631762
Vorinostat in solid and hematologic malignancies.,Journal of hematology & oncology,J Hematol Oncol,2009-07-27,"Vorinostat (Zolinza), a histone deacetylase inhibitor, was approved by the US Food and Drug Administration in October 2006 for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies. This review summarizes evidence on the use of vorinostat in solid and hematologic malignancies and collated tolerability data from the vorinostat clinical trial program. Pooled vorinostat clinical trial data from 498 patients with solid or hematologic malignancies show that vorinostat was well tolerated as monotherapy or combination therapy. The most commonly reported drug-related adverse events (AEs) associated with monotherapy (n = 341) were fatigue (61.9%), nausea (55.7%), diarrhea (49.3%), anorexia (48.1%), and vomiting (32.8%), and Grade 3/4 drug-related AEs included fatigue (12.0%), thrombocytopenia (10.6%), dehydration (7.3%), and decreased platelet count (5.3%). The most common drug-related AEs observed with vorinostat in combination therapy (n = 157, most of whom received vorinostat 400 mg qd for 14 days) were nausea (48.4%), diarrhea (40.8%), fatigue (34.4%), vomiting (31.2%), and anorexia (20.4%), with the majority of AEs being Grade 2 or less. In Phase I trials, combinations with vorinostat were generally well tolerated and preliminary evidence of anticancer activity as monotherapy or in combination with other systemic therapies has been observed across a range of malignancies. Ongoing and planned studies will further evaluate the potential of vorinostat in combination therapy, including combinations with radiation, in patients with diverse malignancy types, including non-small-cell lung cancer, glioblastoma multiforme, multiple myeloma, and myelodysplastic syndrome.",Evaluation Study,3830.0,108.0,Vorinostat Zolinza histone deacetylase inhibitor approved Food Drug Administration October 2006 treatment cutaneous manifestations patients cutaneous T-cell lymphoma progressive persistent recurrent disease following systemic therapies review summarizes evidence use vorinostat solid hematologic malignancies collated tolerability vorinostat clinical trial program Pooled vorinostat clinical trial 498 patients solid hematologic malignancies vorinostat tolerated monotherapy combination therapy commonly reported drug-related adverse events AEs associated monotherapy n 341 fatigue 61.9 nausea 55.7 diarrhea 49.3 anorexia 48.1 vomiting 32.8 Grade 3/4 drug-related AEs included fatigue 12.0 thrombocytopenia 10.6 dehydration 7.3 decreased platelet count 5.3 common drug-related AEs observed vorinostat combination therapy n 157 received vorinostat 400 mg qd 14 days nausea 48.4 diarrhea 40.8 fatigue 34.4 vomiting 31.2 anorexia 20.4 majority AEs Grade 2 Phase trials combinations vorinostat generally tolerated preliminary evidence anticancer activity monotherapy combination systemic therapies observed range malignancies Ongoing planned studies evaluate potential vorinostat combination therapy including combinations radiation patients diverse malignancy types including non-small-cell lung glioblastoma multiforme multiple myeloma myelodysplastic syndrome,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2371, 26641, 8, 1508, 2732, 230, 10, 850, 20, 3, 843, 1773, 2, 234, 634, 4, 2551, 1324, 9, 3, 24, 1, 1486, 4282, 4, 7, 5, 1486, 102, 31, 54, 47, 1014, 1882, 15, 387, 34, 23, 15, 366, 100, 403, 235, 26, 206, 2869, 241, 23, 3, 119, 1, 2371, 4, 537, 2, 813, 441, 2, 20341, 1543, 74, 29, 3, 2371, 38, 160, 1243, 1830, 2371, 38, 160, 74, 29, 8928, 7, 5, 537, 15, 813, 441, 514, 17, 2371, 10, 149, 421, 22, 1411, 15, 150, 36, 3, 96, 841, 210, 234, 139, 290, 281, 1477, 41, 5, 1411, 78, 4065, 11, 613, 713, 83, 1218, 614, 67, 1172, 739, 27, 3373, 576, 14, 2, 1966, 531, 66, 2, 88, 27, 39, 234, 139, 1477, 159, 613, 133, 13, 1340, 79, 49, 5414, 67, 27, 2, 340, 1596, 1276, 33, 27, 3, 96, 186, 234, 139, 1477, 164, 5, 2371, 4, 150, 36, 78, 5311, 96, 1, 953, 103, 2371, 1524, 81, 5419, 9, 213, 162, 11, 1218, 576, 39, 1172, 327, 66, 613, 562, 39, 1966, 456, 18, 2, 3373, 179, 39, 5, 3, 686, 1, 1477, 486, 88, 18, 15, 299, 4, 124, 70, 143, 1247, 5, 2371, 11, 1228, 149, 421, 2, 1676, 241, 1, 1475, 128, 22, 1411, 15, 4, 150, 5, 127, 403, 235, 71, 85, 164, 716, 8, 184, 1, 441, 942, 2, 1465, 94, 303, 195, 376, 3, 174, 1, 2371, 4, 150, 36, 141, 1247, 5, 121, 4, 7, 5, 1867, 710, 630, 141, 220, 302, 31, 12, 996, 3238, 232, 2, 681]",1686.0,19635146,Vorinostat solid hematologic malignancies,2,0.0034904013961605585
Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis.,Cancer,Cancer,2009-10-01,"Nucleophosmin (NPM1) gene mutations are reported to predict a favorable prognosis in acute myeloid leukemia (AML) patients. Aberrant cytoplasmic localization of nucleophosmin (NPM) protein is reported be a surrogate for NPM1 gene mutation. Using immunohistochemical (IHC) analysis, we assessed for NPM (clone 376) expression in formalin-fixed, formic acid-decalcified bone marrow biopsy specimens. DNA sequencing of exon 12 of NPM1 gene was performed in 104 patients. The study included 252 AML patients: 192 de novo AML, 33 AML preceded by either myelodysplastic syndrome or chronic myelomonocytic leukemia, and 27 therapy-related AML. The median age was 62 years and 115 patients were <or=60 years old. All patients received intensive chemotherapy. Cytoplasmic NPM was detected in 59 of 252 (23%) patients, including 48 of 192 (25%) de novo AML and 33 of 94 (35%) with a normal karyotype. DNA sequencing identified NPM1 mutations in 30 of 38 cases with cytoplasmic NPM and 10 of 66 cases with nuclear NPM. Cytoplasmic NPM was associated with young patient age (P=.024), FLT3/ITD (P=.005), CD34 negative blasts (P<.001), high peripheral blood blast count (P=.041), and high serum albumin level (P=.028). No statistical differences in overall or event-free survival were found on the basis of NPM localization. Similar results were obtained in patients<or=60 years old with normal karyotype and wild-type FLT3 (P=.768). IHC assessment for NPM localization did not predict prognosis in this patient cohort. The discordance between immunohistochemistry and DNA sequencing results indicates that DNA sequencing cannot be replaced by IHC assessment.",Journal Article,3764.0,31.0,Nucleophosmin NPM1 reported predict favorable prognosis acute myeloid leukemia AML patients Aberrant cytoplasmic localization nucleophosmin NPM reported surrogate NPM1 immunohistochemical IHC assessed NPM clone 376 expression formalin-fixed formic acid-decalcified bone marrow biopsy specimens DNA sequencing exon 12 NPM1 performed 104 patients included 252 AML patients 192 novo AML 33 AML preceded myelodysplastic syndrome chronic myelomonocytic leukemia 27 therapy-related AML median age 62 years 115 patients or=60 years old patients received intensive chemotherapy Cytoplasmic NPM detected 59 252 23 patients including 48 192 25 novo AML 33 94 35 normal karyotype DNA sequencing identified NPM1 30 38 cases cytoplasmic NPM 10 66 cases nuclear NPM Cytoplasmic NPM associated young patient age P=.024 FLT3/ITD P=.005 CD34 negative blasts P .001 high peripheral blood blast count P=.041 high serum albumin level P=.028 statistical differences overall event-free survival basis NPM localization Similar obtained patients or=60 years old normal karyotype wild-type FLT3 P=.768 IHC assessment NPM localization predict prognosis patient cohort discordance immunohistochemistry DNA sequencing indicates DNA sequencing replaced IHC assessment,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[13075, 4318, 145, 138, 32, 210, 6, 678, 8, 913, 356, 4, 286, 533, 329, 7, 1898, 2828, 2145, 1, 13075, 11111, 178, 16, 210, 40, 8, 2592, 9, 4318, 145, 258, 75, 1382, 1289, 65, 21, 275, 9, 11111, 3910, 9534, 55, 4, 3265, 1959, 20616, 971, 34728, 581, 411, 623, 261, 615, 1, 1725, 133, 1, 4318, 145, 10, 173, 4, 3407, 7, 3, 45, 159, 6951, 329, 7, 5016, 1566, 2018, 329, 466, 329, 6083, 20, 361, 681, 15, 442, 5451, 2, 428, 36, 139, 329, 3, 52, 89, 10, 744, 60, 2, 3670, 7, 11, 15, 335, 60, 1095, 62, 7, 103, 1686, 56, 2828, 11111, 10, 530, 4, 728, 1, 6951, 382, 7, 141, 576, 1, 5016, 243, 1566, 2018, 329, 2, 466, 1, 960, 465, 5, 8, 295, 3385, 261, 615, 108, 4318, 138, 4, 201, 1, 519, 140, 5, 2828, 11111, 2, 79, 1, 700, 140, 5, 928, 11111, 2828, 11111, 10, 41, 5, 1169, 69, 89, 19, 4247, 1224, 2837, 19, 1614, 2215, 199, 2438, 19, 144, 64, 672, 315, 3112, 1276, 19, 5937, 2, 64, 524, 2799, 301, 19, 4836, 77, 1050, 362, 4, 63, 15, 774, 115, 25, 11, 204, 23, 3, 877, 1, 11111, 2145, 288, 99, 11, 683, 4, 7, 15, 335, 60, 1095, 5, 295, 3385, 2, 955, 267, 1224, 19, 15188, 1289, 455, 9, 11111, 2145, 205, 44, 678, 356, 4, 26, 69, 180, 3, 5771, 59, 888, 2, 261, 615, 99, 2640, 17, 261, 615, 122, 44, 40, 6928, 20, 1289, 455]",1551.0,19637342,Cytoplasmic localization nucleophosmin bone marrow blasts acute myeloid leukemia patients completely concordant NPM1 predictive prognosis,5,0.008726003490401396
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.,Blood,Blood,2009-08-03,"Increasing evidence shows aberrant hypermethylation of genes occurring in and potentially contributing to pathogenesis of myeloid malignancies. Several of these diseases, such as myelodysplastic syndromes (MDSs), are responsive to DNA methyltransferase inhibitors. To determine the extent of promoter hypermethylation in such tumors, we compared the distribution of DNA methylation of 14 000 promoters in MDS and secondary acute myeloid leukemia (AML) patients enrolled in a phase 1 trial of 5-azacytidine and the histone deacetylase inhibitor entinostat against de novo AML patients and normal CD34(+) bone marrow cells. The MDS and secondary AML patients displayed more extensive aberrant DNA methylation involving thousands of genes than did the normal CD34(+) bone marrow cells or de novo AML blasts. Aberrant methylation in MDS and secondary AML tended to affect particular chromosomal regions, occurred more frequently in Alu-poor genes, and included prominent involvement of genes involved in the WNT and MAPK signaling pathways. DNA methylation was also measured at days 15 and 29 after the first treatment cycle. DNA methylation was reversed at day 15 in a uniform manner throughout the genome, and this effect persisted through day 29, even without continuous administration of the study drugs. This trial was registered at www.clinicaltrials.gov as J0443.",Clinical Trial,3823.0,244.0,Increasing evidence shows aberrant hypermethylation occurring potentially contributing pathogenesis myeloid malignancies diseases myelodysplastic syndromes MDSs responsive DNA methyltransferase inhibitors determine extent promoter hypermethylation compared distribution DNA methylation 14 000 promoters MDS secondary acute myeloid leukemia AML patients enrolled phase 1 trial 5-azacytidine histone deacetylase inhibitor entinostat novo AML patients normal CD34 bone marrow MDS secondary AML patients displayed extensive aberrant DNA methylation involving thousands normal CD34 bone marrow novo AML blasts Aberrant methylation MDS secondary AML tended affect particular chromosomal regions occurred frequently Alu-poor included prominent involvement involved WNT MAPK signaling pathways DNA methylation measured days 15 29 treatment cycle DNA methylation reversed day 15 uniform manner genome effect persisted day 29 continuous administration drugs trial registered www.clinicaltrials.gov J0443,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[602, 241, 1949, 1898, 2575, 1, 214, 1821, 4, 2, 751, 3156, 6, 1384, 1, 533, 441, 392, 1, 46, 1342, 225, 22, 2040, 13550, 32, 2443, 6, 261, 3747, 222, 6, 223, 3, 1039, 1, 973, 2575, 4, 225, 57, 21, 72, 3, 1395, 1, 261, 569, 1, 213, 984, 4347, 4, 1223, 2, 568, 286, 533, 329, 7, 346, 4, 8, 124, 14, 160, 1, 33, 11755, 2, 3, 1508, 2732, 230, 7616, 480, 1566, 2018, 329, 7, 2, 295, 2215, 581, 37, 3, 1223, 2, 568, 329, 7, 2507, 80, 1344, 1898, 261, 569, 1267, 8505, 1, 214, 76, 205, 3, 295, 2215, 581, 37, 15, 1566, 2018, 329, 2438, 1898, 569, 4, 1223, 2, 568, 329, 3886, 6, 1158, 1454, 1860, 1374, 489, 80, 746, 4, 15265, 334, 214, 2, 159, 3689, 799, 1, 214, 646, 4, 3, 2112, 2, 1748, 314, 460, 261, 569, 10, 120, 644, 28, 162, 167, 2, 462, 50, 3, 157, 24, 417, 261, 569, 10, 3682, 28, 218, 167, 4, 8, 3490, 1708, 2432, 3, 898, 2, 26, 254, 3760, 298, 218, 462, 871, 187, 1314, 634, 1, 3, 45, 600, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 58116]",1306.0,19652201,MDS secondary AML display unique patterns abundance aberrant DNA methylation,2,0.0034904013961605585
Moderate renal function impairment does not affect outcomes of reduced-intensity conditioning with fludarabine and melphalan for allogeneic hematopoietic stem cell transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2009-09-01,"Nonrelapse mortality (NRM) after reduced-intensity allogeneic transplants is likely to be influenced by abnormalities in renal function. We studied 141 patients diagnosed with acute myelogenous leukemia (AML) (n = 131) or high-risk myelodysplastic syndrome (MDS) (n = 10) who underwent allogeneic transplantation with fludarabine (Flu)/melphalan (Mel)-based regimens and hypothesized that moderate to mild renal function impairment increases NRM in this setting. Flu dose consisted of 25-30 mg/m(2) for 4 days and Mel dose was 100-180 mg/m(2). Donors were HLA-compatible siblings (n = 69) and matched unrelated donors (n = 72). Disease status at transplantation was complete remission (n = 56, 40%) or active disease (n = 85, 60%). The influence of the estimated glomerular filtration rate (GFR) measured before transplantation on outcomes was analyzed. GFR was estimated by both the Cockcroft-Gault (CG) and the modified diet in renal disease (MDRD) equations, using the creatinine value obtained prior to starting chemotherapy. Evaluated outcomes were overall survival (OS), NRM, and treatment-related mortality (TRM) at day 100 and 1-year posttransplantation. Median age was 55 years (range: 21-74 years); 59% of the patients were male. Estimated GFR by CG was > or =90 for 45 (32%), 60-89 for 78 (55%), and <60 for 18 (13%) patients. When estimated by MDRD, GFR was > or =90 for 65 (46%), 60-89 from 66 (47%), and <60 for 10 (7%) patients. The majority of patients by both estimations had a GFR between 60 and 89 (n = 78 by CG and n = 66 by MDRD) with no difference in the evaluated outcomes between this group and the subgroup of patients with a GFR <60 (P > .05). There were no differences in OS and NRM at day 100 and 1-year posttransplantation in the 3 groups by any GFR estimation method. In conclusion, a mild to moderate decrease in GFR was not associated with an increase in NRM.",Journal Article,3794.0,11.0,Nonrelapse mortality NRM reduced-intensity allogeneic transplants likely influenced abnormalities renal function studied 141 patients diagnosed acute myelogenous leukemia AML n 131 high-risk myelodysplastic syndrome MDS n 10 underwent allogeneic transplantation fludarabine Flu /melphalan Mel -based regimens hypothesized moderate mild renal function impairment increases NRM setting Flu dose consisted 25-30 mg/m 2 4 days Mel dose 100-180 mg/m 2 Donors HLA-compatible siblings n 69 matched unrelated donors n 72 Disease status transplantation complete remission n 56 40 active disease n 85 60 influence estimated glomerular filtration rate GFR measured transplantation outcomes GFR estimated Cockcroft-Gault CG modified diet renal disease MDRD equations creatinine value obtained prior starting chemotherapy Evaluated outcomes overall survival OS NRM treatment-related mortality TRM day 100 1-year posttransplantation Median age 55 years range 21-74 years 59 patients male Estimated GFR CG =90 45 32 60-89 78 55 60 18 13 patients estimated MDRD GFR =90 65 46 60-89 66 47 60 10 7 patients majority patients estimations GFR 60 89 n 78 CG n 66 MDRD difference evaluated outcomes group subgroup patients GFR 60 P .05 differences OS NRM day 100 1-year posttransplantation 3 groups GFR estimation mild moderate decrease GFR associated increase NRM,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4640, 282, 4296, 50, 405, 837, 1063, 4016, 16, 322, 6, 40, 2574, 20, 1171, 4, 343, 21, 656, 4379, 7, 265, 5, 286, 2194, 329, 78, 2229, 15, 64, 43, 681, 1223, 78, 79, 54, 208, 1063, 497, 5, 2027, 5119, 2370, 7383, 90, 472, 2, 1237, 17, 1163, 6, 1980, 343, 2315, 1106, 4296, 4, 26, 546, 5119, 61, 1695, 1, 243, 201, 81, 188, 18, 9, 39, 162, 2, 7383, 61, 10, 394, 3172, 81, 188, 18, 2344, 11, 1160, 7293, 2758, 78, 790, 2, 655, 2092, 2344, 78, 720, 34, 156, 28, 497, 10, 236, 734, 78, 664, 327, 15, 544, 34, 78, 772, 335, 3, 1054, 1, 3, 661, 6080, 5779, 116, 6644, 644, 348, 497, 23, 123, 10, 311, 6644, 10, 661, 20, 110, 3, 23473, 21349, 6773, 2, 3, 1230, 2453, 4, 34, 22556, 6799, 75, 3, 3177, 549, 683, 324, 6, 1723, 56, 194, 123, 11, 63, 25, 118, 4296, 2, 24, 139, 282, 5064, 28, 218, 394, 2, 14, 111, 8046, 52, 89, 10, 614, 60, 184, 239, 794, 60, 728, 1, 3, 7, 11, 1045, 661, 6644, 20, 6773, 10, 15, 424, 9, 512, 531, 335, 887, 9, 833, 614, 2, 335, 9, 203, 233, 7, 198, 661, 20, 22556, 6644, 10, 15, 424, 9, 556, 641, 335, 887, 29, 700, 662, 2, 335, 9, 79, 67, 7, 3, 686, 1, 7, 20, 110, 19200, 42, 8, 6644, 59, 335, 2, 887, 78, 833, 20, 6773, 2, 78, 700, 20, 22556, 5, 77, 523, 4, 3, 194, 123, 59, 26, 87, 2, 3, 1363, 1, 7, 5, 8, 6644, 335, 19, 474, 125, 11, 77, 362, 4, 118, 2, 4296, 28, 218, 394, 2, 14, 111, 8046, 4, 3, 27, 271, 20, 500, 6644, 4470, 596, 4, 1221, 8, 1980, 6, 1163, 775, 4, 6644, 10, 44, 41, 5, 35, 344, 4, 4296]",1737.0,19660722,Moderate renal function impairment affect outcomes reduced-intensity conditioning fludarabine melphalan allogeneic hematopoietic stem transplantation,7,0.012216404886561954
Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer.,Clinical breast cancer,Clin. Breast Cancer,2009-08-01,"Bone-targeted radiation therapy is an attractive strategy for addressing bone disease with minimal systemic toxicity. This pilot study was designed to determine the safety and efficacy of (166)Holmium (Ho)-DOTMP for irradiating malignant cells and adjacent marrow in women with bone-only metastatic breast cancer. Subjects included 6 women aged < or = 65 years with breast cancer and bone-only metastases at M. D. Anderson Cancer Center. The activity of (166)Ho-DOTMP was calculated to deliver a therapeutic absorbed dose of 22 Gy (n = 3) or 28 Gy (n = 3) to the marrow. Treatment was followed by autologous stem cell transplantation to circumvent the anticipated myelosuppresion. Median follow-up time was 40 months. All subjects showed prompt hematologic recovery. No patient experienced grade 3/4 acute toxicity aside from myelosuppression. Two patients developed hemorrhagic cystitis 2 years after therapy. One patient developed myelodysplastic syndrome but was found to have had pre-existing trisomy 8. Two patients remained progression free without evidence of disease for more than 6 years. Five women experienced disease relapse (4 at extraosseous sites) and died of progressive disease. Median time to progression was 10.4 months. The approach of bone-targeted radiation therapy with (166)Ho-DOTMP had an acceptable toxicity profile, and sustained complete response was obtained in 2 of 6 patients. We are conducting a phase II study to evaluate the efficacy of targeted skeletal radiation therapy for treating bone-only metastases.",Journal Article,3825.0,7.0,Bone-targeted radiation therapy attractive strategy addressing bone disease minimal systemic toxicity pilot designed determine safety efficacy 166 Holmium Ho -DOTMP irradiating malignant adjacent marrow women bone-only metastatic breast Subjects included 6 women aged 65 years breast bone-only metastases M. D. Anderson Center activity 166 Ho-DOTMP calculated deliver therapeutic absorbed dose 22 Gy n 3 28 Gy n 3 marrow Treatment followed autologous stem transplantation circumvent anticipated myelosuppresion Median follow-up time 40 months subjects showed prompt hematologic recovery patient experienced grade 3/4 acute toxicity aside myelosuppression patients developed hemorrhagic cystitis 2 years therapy patient developed myelodysplastic syndrome pre-existing trisomy 8 patients remained progression free evidence disease 6 years women experienced disease relapse 4 extraosseous sites died progressive disease Median time progression 10.4 months approach bone-targeted radiation therapy 166 Ho-DOTMP acceptable toxicity profile sustained complete response obtained 2 6 patients conducting phase II evaluate efficacy targeted skeletal radiation therapy treating bone-only metastases,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3417, 238, 121, 36, 16, 35, 3059, 692, 9, 3432, 34, 5, 1048, 403, 155, 26, 2281, 45, 10, 1114, 6, 223, 3, 367, 2, 209, 1, 5812, 21143, 11852, 17200, 9, 20248, 393, 37, 2, 2086, 581, 4, 117, 5, 3417, 158, 113, 12, 976, 159, 49, 117, 1032, 15, 556, 60, 5, 12, 2, 3417, 158, 196, 28, 188, 427, 1929, 12, 574, 3, 128, 1, 5812, 11852, 17200, 10, 981, 6, 3392, 8, 189, 5249, 61, 1, 350, 381, 78, 27, 15, 339, 381, 78, 27, 6, 3, 581, 24, 10, 370, 20, 1028, 452, 31, 497, 6, 8602, 3, 4078, 39065, 52, 166, 126, 98, 10, 327, 53, 62, 976, 224, 4776, 813, 1602, 77, 69, 592, 88, 27, 39, 286, 155, 11731, 29, 2858, 100, 7, 276, 6998, 13032, 18, 60, 50, 36, 104, 69, 276, 681, 84, 10, 204, 6, 47, 42, 671, 1692, 6317, 66, 100, 7, 958, 91, 115, 187, 241, 1, 34, 9, 80, 76, 49, 60, 365, 117, 592, 34, 429, 39, 28, 15459, 633, 2, 1016, 1, 1014, 34, 52, 98, 6, 91, 10, 79, 39, 53, 3, 353, 1, 3417, 238, 121, 36, 5, 5812, 11852, 17200, 42, 35, 1595, 155, 800, 2, 2275, 236, 51, 10, 683, 4, 18, 1, 49, 7, 21, 32, 6018, 8, 124, 215, 45, 6, 376, 3, 209, 1, 238, 2621, 121, 36, 9, 1367, 3417, 158, 196]",1472.0,19661041,Pilot targeted skeletal radiation therapy bone-only metastatic breast,0,0.0
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation.,International journal of hematology,Int. J. Hematol.,2009-08-29,"Cytogenetic abnormalities in patients with essential thrombocythemia (ET) are infrequent. Their role in survival of patients and disease transformation is not extensively studied. We describe cytogenetic abnormalities in 172 patients with ET at a single institution. At presentation nine (5.2%) patients had cytogenetic abnormality and three (1.7%) additional patients acquired them during follow-up. Survival of patients with cytogenetic changes at presentation did not differ when compared to the patients with normal karyotype. The more common were abnormalities of chromosome 9 (n = 4), 20 (n = 2), 5 (n = 2), and complex abnormalities (n = 2). Forty-one patients (23.8%) had additional cytogenetic tests performed for monitoring purposes during follow-up. Five patients (2.9%) with normal karyotype transformed to myelofibrosis (MF) without developing new cytogenetic changes at transformation. Two patients (1.2%) with normal karyotypes at presentation transformed to myelodysplastic syndrome and acute myeloid leukemia, respectively. Both acquired complex cytogenetic changes at the time of transformation. There is no rationale for repeating cytogenetic tests in ET patients on follow up, unless blood cell count changes suggest possible transformation.",Journal Article,3797.0,7.0,Cytogenetic abnormalities patients essential thrombocythemia infrequent role survival patients disease transformation extensively studied cytogenetic abnormalities 172 patients single institution presentation 5.2 patients cytogenetic abnormality 1.7 additional patients acquired follow-up Survival patients cytogenetic changes presentation differ compared patients normal karyotype common abnormalities chromosome 9 n 4 20 n 2 5 n 2 complex abnormalities n 2 Forty-one patients 23.8 additional cytogenetic tests performed monitoring purposes follow-up patients 2.9 normal karyotype transformed myelofibrosis MF developing new cytogenetic changes transformation patients 1.2 normal karyotypes presentation transformed myelodysplastic syndrome acute myeloid leukemia respectively acquired complex cytogenetic changes time transformation rationale repeating cytogenetic tests patients follow blood count changes suggest possible transformation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1266, 1171, 4, 7, 5, 1452, 8962, 2022, 32, 4475, 136, 200, 4, 25, 1, 7, 2, 34, 1392, 16, 44, 3576, 656, 21, 897, 1266, 1171, 4, 5312, 7, 5, 2022, 28, 8, 226, 731, 28, 1031, 762, 33, 18, 7, 42, 1266, 3698, 2, 169, 14, 67, 402, 7, 1294, 1370, 190, 166, 126, 25, 1, 7, 5, 1266, 400, 28, 1031, 205, 44, 1505, 198, 72, 6, 3, 7, 5, 295, 3385, 3, 80, 186, 11, 1171, 1, 1170, 83, 78, 39, 179, 78, 18, 33, 78, 18, 2, 840, 1171, 78, 18, 1213, 104, 7, 382, 66, 42, 402, 1266, 895, 173, 9, 1315, 4624, 190, 166, 126, 365, 7, 18, 83, 5, 295, 3385, 2423, 6, 4637, 2966, 187, 931, 217, 1266, 400, 28, 1392, 100, 7, 14, 18, 5, 295, 6809, 28, 1031, 2423, 6, 681, 2, 286, 533, 106, 110, 1294, 840, 1266, 400, 28, 3, 98, 1, 1392, 125, 16, 77, 1728, 9, 23652, 1266, 895, 4, 2022, 7, 23, 166, 126, 6179, 315, 31, 1276, 400, 309, 899, 1392]",1185.0,19728024,Cytogenetic abnormalities essential thrombocythemia presentation transformation,0,0.0
Advances in stem cell transplantation: making it better and safer.,Clinical lymphoma & myeloma,Clin Lymphoma Myeloma,2009-01-01,"The development of reduced-intensity regimens has allowed physicians and patients to explore this option even in older patients. Current results underscore that age by itself should no longer be a contraindication for allogeneic transplantation in these patients, and long-term disease control with good quality of life is possible. Future trials combining novel antileukemic therapies and novel transplantation technologies are being explored. These trials should allow more patients with acute myeloid leukemia or myelodysplastic syndromes to achieve long and productive lives.",Journal Article,4037.0,3.0,development reduced-intensity regimens allowed physicians patients explore option older patients Current underscore age longer contraindication allogeneic transplantation patients long-term disease control good quality life possible Future trials combining novel antileukemic therapies novel transplantation technologies explored trials allow patients acute myeloid leukemia myelodysplastic syndromes achieve long productive lives,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 193, 1, 405, 837, 472, 71, 2313, 1261, 2, 7, 6, 1645, 26, 1501, 871, 4, 434, 7, 291, 99, 5531, 17, 89, 20, 4045, 257, 77, 589, 40, 8, 8363, 9, 1063, 497, 4, 46, 7, 2, 319, 337, 34, 182, 5, 1178, 372, 1, 358, 16, 899, 508, 143, 1525, 229, 4512, 235, 2, 229, 497, 2590, 32, 486, 1443, 46, 143, 257, 1700, 80, 7, 5, 286, 533, 15, 2040, 6, 1359, 319, 2, 10110, 6407]",549.0,19778855,Advances stem transplantation making better safer,1,0.0017452006980802793
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities.,Cancer,Cancer,2009-12-01,"Outcome of patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) with chromosome 5 and 7 abnormalities (excluding del 5[q]) has been poor, with <10% of patients alive at 2 years. The authors investigated whether treatment with hypomethylating agents (5-azacytidine/decitabine) leads to an improved outcome. Between January 2004 and December 2007, 81 patients (37 [46%] with AML [>or=20% blasts]; 44 [54%] with high-risk MDS) with chromosome 5 and 7 abnormalities were treated with hypomethylating agents as their initial therapy. These included 68 patients with complex (>or=3) abnormalities and 13 with <3 aberrations. During the same period, 151 patients (126 with AML, 25 with MDS) with chromosome 5 and 7 abnormalities (128 complex, 23 noncomplex) were treated with intensive chemotherapy (including cytarabine-based regimens in 72% and other regimes in 28%). The median ages for the 2 groups were 66 years and 61 years, respectively (ranges, 37-85 years and 19-89 years). Thirty-three (41%) patients in the hypomethylating group achieved complete remission (CR) versus 53 (35%) in the chemotherapy group (P=.395). With a median follow-up of 51 weeks (range, 12-101 weeks) and 40 weeks (range, 5-128 weeks), 22 of 33 patients in the hypomethylating group and 33 of 53 patients in the chemotherapy group had developed disease recurrence. The median CR duration was 45 weeks and 23 weeks, respectively (P=.153). The overall survival was superior for the hypomethylating group compared with the chemotherapy group (P=.019). Treatment with hypomethylating agents may be superior to chemotherapy in patients with chromosome 5 and 7 abnormalities.",Evaluation Study,3703.0,86.0,Outcome patients acute myeloid leukemia AML high-risk myelodysplastic syndrome MDS chromosome 5 7 abnormalities excluding del 5 q poor 10 patients alive 2 years authors investigated treatment hypomethylating agents 5-azacytidine/decitabine leads improved outcome January 2004 December 2007 81 patients 37 46 AML or=20 blasts 44 54 high-risk MDS chromosome 5 7 abnormalities treated hypomethylating agents initial therapy included 68 patients complex or=3 abnormalities 13 3 aberrations period 151 patients 126 AML 25 MDS chromosome 5 7 abnormalities 128 complex 23 noncomplex treated intensive chemotherapy including cytarabine-based regimens 72 regimes 28 median ages 2 groups 66 years 61 years respectively ranges 37-85 years 19-89 years Thirty-three 41 patients hypomethylating group achieved complete remission CR versus 53 35 chemotherapy group P=.395 median follow-up 51 weeks range 12-101 weeks 40 weeks range 5-128 weeks 22 33 patients hypomethylating group 33 53 patients chemotherapy group developed disease recurrence median CR duration 45 weeks 23 weeks respectively P=.153 overall survival superior hypomethylating group compared chemotherapy group P=.019 Treatment hypomethylating agents superior chemotherapy patients chromosome 5 7 abnormalities,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[228, 1, 7, 5, 286, 533, 329, 2, 64, 43, 681, 1223, 5, 1170, 33, 2, 67, 1171, 3207, 3084, 33, 4170, 71, 85, 334, 5, 79, 1, 7, 1701, 28, 18, 60, 3, 738, 565, 317, 24, 5, 4931, 183, 33, 11755, 3004, 1940, 6, 35, 231, 228, 59, 1024, 1131, 2, 1397, 1307, 865, 7, 567, 641, 5, 329, 15, 179, 2438, 584, 667, 5, 64, 43, 1223, 5, 1170, 33, 2, 67, 1171, 11, 73, 5, 4931, 183, 22, 136, 388, 36, 46, 159, 806, 7, 5, 840, 15, 27, 1171, 2, 233, 5, 27, 2152, 190, 3, 827, 727, 5075, 7, 3927, 5, 329, 243, 5, 1223, 5, 1170, 33, 2, 67, 1171, 3990, 840, 382, 24903, 11, 73, 5, 1686, 56, 141, 1855, 90, 472, 4, 720, 2, 127, 18881, 4, 339, 3, 52, 2165, 9, 3, 18, 271, 11, 700, 60, 2, 713, 60, 106, 5632, 567, 772, 60, 2, 326, 887, 60, 977, 169, 605, 7, 4, 3, 4931, 87, 513, 236, 734, 684, 185, 699, 465, 4, 3, 56, 87, 19, 10300, 5, 8, 52, 166, 126, 1, 725, 244, 184, 133, 2338, 244, 2, 327, 244, 184, 33, 3990, 244, 350, 1, 466, 7, 4, 3, 4931, 87, 2, 466, 1, 699, 7, 4, 3, 56, 87, 42, 276, 34, 146, 3, 52, 684, 654, 10, 512, 244, 2, 382, 244, 106, 19, 4251, 3, 63, 25, 10, 1123, 9, 3, 4931, 87, 72, 5, 3, 56, 87, 19, 4049, 24, 5, 4931, 183, 68, 40, 1123, 6, 56, 4, 7, 5, 1170, 33, 2, 67, 1171]",1576.0,19795507,Superior outcome hypomethylating therapy patients acute myeloid leukemia high-risk myelodysplastic syndrome chromosome 5 7 abnormalities,1,0.0017452006980802793
Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the MD Anderson Cancer Center experience.,Journal of pediatric hematology/oncology,J. Pediatr. Hematol. Oncol.,2009-11-01,"Therapy-related myelodysplastic syndrome/acute myeloid leukemia (t-MDS/AML) is a long-term complication of pediatric cancer. We retrospectively studied pediatric t-MDS/AML patients treated at MD Anderson from 1975 to 2007. We also compared those patients to pediatric patients with de novo MDS/AML during this time interval. Among 2589 children with cancer treated at MD Anderson, we identified 22 patients with t-MDS/AML. Patients with t-MDS/AML had a median age of 14 years. There was a male and Hispanic predominance. The most common primary malignancies were osteosarcoma and Hodgkin lymphoma. The median latency period was 4.1 years. Three patients received supportive care only. Group 1 (n=5) underwent stem cell transplantation without induction chemotherapy. Group 2 (n=5) patients received AML-type chemotherapy and a stem cell transplant postremission (n=5). Group 3 (n=4) received a stem cell transplant as salvage therapy. The respective 2-year survival rates for groups 1, 2, and 3 were 20%, 40%, and 25% (P=0.85). Patients with de novo AML were younger (P=0.001) and higher rates of complete remission (P=0.03), and survival (P<0.0001). Independent factors predicting shorter survival were poor/intermediate-risk cytogenetics (P=0.01), lower hemoglobin level (P=0.0001), and t-MDS/AML (vs. de novo) (P=0.003). Childhood t-MDS/AML has a poor prognosis. Although patients benefited from AML-type induction chemotherapy followed by stem cell transplantation as postremission therapy, effective therapies, and prevention are needed.",Comparative Study,3733.0,34.0,Therapy-related myelodysplastic syndrome/acute myeloid leukemia t-MDS/AML long-term complication pediatric retrospectively studied pediatric t-MDS/AML patients treated MD Anderson 1975 2007 compared patients pediatric patients novo MDS/AML time interval 2589 children treated MD Anderson identified 22 patients t-MDS/AML Patients t-MDS/AML median age 14 years male Hispanic predominance common primary malignancies osteosarcoma Hodgkin lymphoma median latency period 4.1 years patients received supportive care Group 1 n=5 underwent stem transplantation induction chemotherapy Group 2 n=5 patients received AML-type chemotherapy stem transplant postremission n=5 Group 3 n=4 received stem transplant salvage therapy respective 2-year survival rates groups 1 2 3 20 40 25 P=0.85 Patients novo AML younger P=0.001 higher rates complete remission P=0.03 survival P 0.0001 Independent factors predicting shorter survival poor/intermediate-risk cytogenetics P=0.01 lower hemoglobin level P=0.0001 t-MDS/AML vs. novo P=0.003 Childhood t-MDS/AML poor prognosis patients benefited AML-type induction chemotherapy followed stem transplantation postremission therapy effective therapies prevention needed,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[36, 139, 681, 286, 533, 102, 1223, 329, 16, 8, 319, 337, 1447, 1, 815, 12, 21, 894, 656, 815, 102, 1223, 329, 7, 73, 28, 2244, 1929, 29, 7585, 6, 1307, 21, 120, 72, 135, 7, 6, 815, 7, 5, 1566, 2018, 1223, 329, 190, 26, 98, 268, 107, 58300, 541, 5, 12, 73, 28, 2244, 1929, 21, 108, 350, 7, 5, 102, 1223, 329, 7, 5, 102, 1223, 329, 42, 8, 52, 89, 1, 213, 60, 125, 10, 8, 1045, 2, 1776, 7593, 3, 96, 186, 86, 441, 11, 2, 3, 52, 5301, 727, 10, 39, 14, 60, 169, 7, 103, 1877, 165, 158, 87, 14, 78, 33, 208, 452, 31, 497, 187, 504, 56, 87, 18, 78, 33, 7, 103, 329, 267, 56, 2, 8, 452, 31, 941, 8635, 78, 33, 87, 27, 78, 39, 103, 8, 452, 31, 941, 22, 992, 36, 3, 3847, 18, 111, 25, 151, 9, 271, 14, 18, 2, 27, 11, 179, 327, 2, 243, 19, 13, 772, 7, 5, 1566, 2018, 329, 11, 773, 19, 13, 144, 2, 142, 151, 1, 236, 734, 19, 13, 680, 2, 25, 19, 13, 488, 306, 130, 1434, 985, 25, 11, 334, 919, 43, 2510, 19, 13, 355, 280, 2222, 301, 19, 13, 488, 2, 102, 1223, 329, 105, 1566, 2018, 19, 13, 1421, 864, 102, 1223, 329, 71, 8, 334, 356, 242, 7, 7067, 29, 329, 267, 504, 56, 370, 20, 452, 31, 497, 22, 8635, 36, 323, 235, 2, 1070, 32, 575]",1431.0,19801947,Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia MD Anderson Center experience,7,0.012216404886561954
Clonal hematopoiesis in Philadelphia chromosome-negative bone marrow cells of chronic myeloid leukemia patients receiving dasatinib.,Leukemia research,Leuk. Res.,2009-10-04,"A clonal cytogenetic abnormality was observed in Philadelphia chromosome-negative bone marrow cells of 6/27 chronic myeloid leukemia patients (+8 in 4, -7 in 1, and 20q- in 1) with dasatinib-induced remissions. The X-linked human androgen receptor gene assay demonstrated clonality in one additional patient. Single nucleotide polymorphism array analysis revealed somatic uniparental disomy involving chromosome 17(p12-pter) in another patient. The TP53 gene had a 5' splice site deletion of exon 6 that caused alternative splicing, frame shifting and introduction of a premature stop codon. After three years, no patient developed myelodysplastic syndrome or acute myeloid leukemia.",Journal Article,3761.0,6.0,clonal cytogenetic abnormality observed Philadelphia chromosome-negative bone marrow 6/27 chronic myeloid leukemia patients +8 4 -7 1 20q- 1 dasatinib-induced remissions X-linked human androgen receptor demonstrated clonality additional patient Single nucleotide polymorphism array revealed somatic uniparental disomy involving chromosome 17 p12-pter patient TP53 5 splice site deletion exon 6 caused alternative splicing frame shifting introduction premature stop codon years patient developed myelodysplastic syndrome acute myeloid leukemia,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[8, 1946, 1266, 3698, 10, 164, 4, 3006, 1170, 199, 581, 37, 1, 49, 428, 442, 533, 7, 66, 4, 39, 67, 4, 14, 2, 13887, 4, 14, 5, 1674, 277, 3166, 3, 1006, 1199, 171, 687, 153, 145, 719, 264, 8905, 4, 104, 402, 69, 226, 1579, 1907, 1926, 65, 553, 1119, 17888, 13983, 1267, 1170, 269, 25053, 26404, 4, 1809, 69, 3, 1206, 145, 42, 8, 33, 4371, 606, 1528, 1, 1725, 49, 17, 1546, 1091, 3895, 5331, 8964, 2, 2456, 1, 8, 5682, 7142, 3673, 50, 169, 60, 77, 69, 276, 681, 15, 286, 533]",631.0,19804904,Clonal hematopoiesis Philadelphia chromosome-negative bone marrow chronic myeloid leukemia patients receiving dasatinib,59,0.10296684118673648
Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies.,Cancer research,Cancer Res.,2009-10-13,"Complete loss or deletion of the long arm of chromosome 5 is frequent in myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). The putative gene(s) deleted and responsible for the pathogenesis of these poor prognosis hematologic disorders remain controversial. This study is a comprehensive analysis of previously implicated and novel genes for epigenetic inactivation in AML and MDS. In 146 AML cases, methylation of CTNNA1 was frequent, and more common in AML patients with 5q deletion (31%) than those without 5q deletion (14%), whereas no methylation of other 5q genes was observed. In 31 MDS cases, CTNNA1 methylation was only found in high-risk MDS (>or=RAEB2), but not in low-risk MDS (<RAEB2), indicating that CTNNA1 methylation might be important in the transformation of MDS to AML. CTNNA1 expression was lowest in AML/MDS patients with CTNNA1 methylation, although reduced expression was found in some patients without promoter methylation. Repressive chromatin marks (H3K27me3) at the promoter were identified in CTNNA1-repressed AML cell lines and primary leukemias, with the most repressive state correlating with DNA methylation. These results suggest progressive, acquired epigenetic inactivation at CTNNA1, including histone modifications and promoter CpG methylation, as a component of leukemia progression in patients with both 5q- and non-5q- myeloid malignancies.",Journal Article,3752.0,40.0,Complete loss deletion long arm chromosome 5 frequent myelodysplastic syndrome MDS acute myelogenous leukemia AML putative deleted responsible pathogenesis poor prognosis hematologic disorders remain controversial comprehensive previously implicated novel epigenetic inactivation AML MDS 146 AML cases methylation CTNNA1 frequent common AML patients 5q deletion 31 5q deletion 14 methylation 5q observed 31 MDS cases CTNNA1 methylation high-risk MDS or=RAEB2 low-risk MDS RAEB2 indicating CTNNA1 methylation important transformation MDS AML CTNNA1 expression lowest AML/MDS patients CTNNA1 methylation reduced expression patients promoter methylation Repressive chromatin marks H3K27me3 promoter identified CTNNA1-repressed AML lines primary leukemias repressive state correlating DNA methylation suggest progressive acquired epigenetic inactivation CTNNA1 including histone modifications promoter CpG methylation component leukemia progression patients 5q- non-5q- myeloid malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[236, 407, 15, 1528, 1, 3, 319, 475, 1, 1170, 33, 16, 908, 4, 681, 1223, 2, 286, 2194, 329, 3, 2743, 145, 695, 4389, 2, 2327, 9, 3, 1384, 1, 46, 334, 356, 813, 1997, 918, 2010, 26, 45, 16, 8, 949, 65, 1, 373, 1771, 2, 229, 214, 9, 1418, 2297, 4, 329, 2, 1223, 4, 4909, 329, 140, 569, 1, 17917, 10, 908, 2, 80, 186, 4, 329, 7, 5, 5460, 1528, 456, 76, 135, 187, 5460, 1528, 213, 547, 77, 569, 1, 127, 5460, 214, 10, 164, 4, 456, 1223, 140, 17917, 569, 10, 158, 204, 4, 64, 43, 1223, 15, 34782, 84, 44, 4, 154, 43, 1223, 34782, 1716, 17, 17917, 569, 822, 40, 305, 4, 3, 1392, 1, 1223, 6, 329, 17917, 55, 10, 2101, 4, 329, 1223, 7, 5, 17917, 569, 242, 405, 55, 10, 204, 4, 476, 7, 187, 973, 569, 9851, 2287, 8418, 9709, 28, 3, 973, 11, 108, 4, 17917, 6654, 329, 31, 285, 2, 86, 2792, 5, 3, 96, 9851, 1309, 5637, 5, 261, 569, 46, 99, 309, 1014, 1294, 1418, 2297, 28, 17917, 141, 1508, 2916, 2, 973, 2075, 569, 22, 8, 1249, 1, 91, 4, 7, 5, 110, 5460, 2, 220, 5460, 533, 441]",1327.0,19826047,Progressive chromatin repression promoter methylation CTNNA1 associated advanced myeloid malignancies,6,0.010471204188481676
Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome.,Cancer,Cancer,2010-01-01,"Acute pulmonary failure during remission induction therapy is a serious complication in patients with acute myeloid leukemia (AML). To the authors' knowledge, the course and prognosis of such patients is not well known. A total of 1541 patients referred for remission induction chemotherapy of AML or high-risk myelodysplastic syndrome were retrospectively reviewed. A total of 120 (8%) patients developed acute pulmonary failure within 2 weeks of the initiation of chemotherapy; 87 of these patients (73%) died during remission induction, whereas 17 (14%) achieved a complete response. The median survival among the 120 patients with early acute pulmonary failure was 3 weeks. Predictive factors for the development of early acute pulmonary failure by multivariate analysis were: male sex (P = .00038), acute promyelocytic leukemia (P = .00003), poor performance status (P = .001), lung infiltrates at diagnosis (P = .000001), and increased creatinine (P = .000005). Patients who had 0 to 1, 2, 3, or 4 to 5 adverse factors were found to have estimated predictive incidences of acute pulmonary failure of 3%, 13%, 23%, and 34%, respectively. Preventive approaches at the start of induction therapy in patients at high risk of pulmonary failure may improve the outcome of these patients.",Journal Article,3672.0,22.0,Acute pulmonary failure remission induction therapy complication patients acute myeloid leukemia AML authors knowledge course prognosis patients known total 1541 patients referred remission induction chemotherapy AML high-risk myelodysplastic syndrome retrospectively reviewed total 120 8 patients developed acute pulmonary failure 2 weeks initiation chemotherapy 87 patients 73 died remission induction 17 14 achieved complete response median survival 120 patients early acute pulmonary failure 3 weeks Predictive factors development early acute pulmonary failure multivariate male sex P .00038 acute promyelocytic leukemia P .00003 poor performance status P .001 lung infiltrates diagnosis P .000001 increased creatinine P .000005 Patients 0 1 2 3 4 5 adverse factors estimated predictive incidences acute pulmonary failure 3 13 23 34 respectively Preventive approaches start induction therapy patients high risk pulmonary failure improve outcome patients,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[286, 1087, 496, 190, 734, 504, 36, 16, 8, 1762, 1447, 4, 7, 5, 286, 533, 329, 6, 3, 738, 922, 3, 906, 2, 356, 1, 225, 7, 16, 44, 149, 440, 8, 181, 1, 39145, 7, 1995, 9, 734, 504, 56, 1, 329, 15, 64, 43, 681, 11, 894, 446, 8, 181, 1, 2031, 66, 7, 276, 286, 1087, 496, 262, 18, 244, 1, 3, 1118, 1, 56, 912, 1, 46, 7, 803, 1016, 190, 734, 504, 547, 269, 213, 513, 8, 236, 51, 3, 52, 25, 107, 3, 2031, 7, 5, 191, 286, 1087, 496, 10, 27, 244, 464, 130, 9, 3, 193, 1, 191, 286, 1087, 496, 20, 331, 65, 11, 1045, 1035, 19, 45747, 286, 4300, 19, 28585, 334, 528, 156, 19, 144, 5942, 28, 147, 19, 23568, 2, 101, 3177, 19, 45748, 7, 54, 42, 13, 6, 14, 18, 27, 15, 39, 6, 33, 290, 130, 11, 204, 6, 47, 661, 464, 3981, 1, 286, 1087, 496, 1, 27, 233, 382, 2, 562, 106, 3494, 611, 28, 3, 2435, 1, 504, 36, 4, 7, 28, 64, 43, 1, 1087, 496, 68, 401, 3, 228, 1, 46, 7]",1189.0,19862814,Acute pulmonary failure remission induction chemotherapy adults acute myeloid leukemia high-risk myelodysplastic syndrome,24,0.041884816753926704
Outcomes of hematologic malignancies after unrelated donor hematopoietic cell transplantation according to place of residence.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2009-10-30,"Studies suggest that patients who live in rural areas may have worse clinical outcomes compared with patients living in urban areas. We studied whether place of residence (rural versus urban) is associated with clinical outcomes of patients with leukemia or myelodysplastic syndrome (MDS) who received an unrelated donor hematopoietic cell transplantation (HCT). Patients' residential ZIP code at the time of transplant was used to determine rural or urban designation based on the Rural Urban Commuting Codes. The study included 6140 patients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 121 U.S. HCT centers: 1179 (19%) came from rural areas, whereas 4961 (81%) came from urban areas. Rural and urban patients were similar in patient-, disease-, and transplant-related characteristics aside from household income and distance traveled to the HCT center. After adjusting for income and other significant patient, disease, and transplant-related variables, the risk of overall mortality between patients residing in rural and urban areas were not statistically significant (relative risk 1.01, 95% confidence intervals 0.93-1.10, P = .74). Similar outcomes were noted for treatment-related mortality (TRM), disease-free survival (DFS), and relapse. Patient's income, derived from the U.S. Census and based on their residential ZIP code, was independently associated with outcomes. In summary, our study showed no differences in the clinical outcomes of patients from rural or urban areas after unrelated donor HCT.",Journal Article,3735.0,15.0,Studies suggest patients live rural areas worse clinical outcomes compared patients living urban areas studied place residence rural versus urban associated clinical outcomes patients leukemia myelodysplastic syndrome MDS received unrelated donor hematopoietic transplantation HCT Patients residential ZIP code time transplant determine rural urban designation based Rural Urban Commuting Codes included 6140 patients reported Center International Blood Marrow Transplant Research CIBMTR 121 U.S. HCT centers 1179 19 came rural areas 4961 81 came urban areas Rural urban patients similar patient- disease- transplant-related characteristics aside household income distance traveled HCT center adjusting income significant patient disease transplant-related variables risk overall mortality patients residing rural urban areas statistically significant relative risk 1.01 95 confidence intervals 0.93-1.10 P .74 Similar outcomes noted treatment-related mortality TRM disease-free survival DFS relapse Patient 's income derived U.S. Census based residential ZIP code independently associated outcomes summary showed differences clinical outcomes patients rural urban areas unrelated donor HCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[94, 309, 17, 7, 54, 3812, 4, 5291, 1361, 68, 47, 639, 38, 123, 72, 5, 7, 2798, 4, 5532, 1361, 21, 656, 317, 3536, 1, 5562, 5291, 185, 5532, 16, 41, 5, 38, 123, 1, 7, 5, 15, 681, 1223, 54, 103, 35, 2092, 1488, 1007, 31, 497, 1085, 7, 16304, 11458, 5853, 28, 3, 98, 1, 941, 10, 95, 6, 223, 5291, 15, 5532, 8402, 90, 23, 3, 5291, 5532, 58372, 5271, 3, 45, 159, 58373, 7, 210, 6, 3, 574, 9, 944, 315, 2, 581, 941, 389, 11203, 29, 4141, 1767, 695, 1085, 1168, 24966, 326, 8594, 29, 5291, 1361, 547, 58374, 865, 8594, 29, 5532, 1361, 5291, 2, 5532, 7, 11, 288, 4, 69, 34, 2, 941, 139, 374, 11731, 29, 7353, 2306, 2, 3019, 12590, 6, 3, 1085, 574, 50, 1358, 9, 2306, 2, 127, 93, 69, 34, 2, 941, 139, 682, 3, 43, 1, 63, 282, 59, 7, 8230, 4, 5291, 2, 5532, 1361, 11, 44, 712, 93, 580, 43, 14, 355, 48, 307, 1582, 13, 966, 14, 79, 19, 794, 288, 123, 11, 1051, 9, 24, 139, 282, 5064, 34, 115, 25, 1010, 2, 429, 69, 292, 2306, 526, 29, 3, 1767, 695, 7319, 2, 90, 23, 136, 16304, 11458, 5853, 10, 1042, 41, 5, 123, 4, 1962, 114, 45, 224, 77, 362, 4, 3, 38, 123, 1, 7, 29, 5291, 15, 5532, 1361, 50, 2092, 1488, 1085]",1490.0,19879951,Outcomes hematologic malignancies unrelated donor hematopoietic transplantation according place residence,11,0.019197207678883072
Evolving strategies in the treatment of MDS and AML.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2009-08-01,"Myelodysplastic syndrome (MDS) is a clonal hematopoietic disorder characterized by a hyperproliferative bone marrow, cellular dysplasia, and ineffective hematopoiesis. This heterogeneous malignancy is composed of several subtypes, the classification of which has evolved over several years. The treatment of MDS involves improving patient survival and quality of life while decreasing the likelihood of progression to acute myelogenous leukemia (AML). In addition to supportive care with transfusions and hematopoietic growth factors as well as stem cell transplantation, three chemotherapeutic agents have been approved to treat MDS--lenalidomide, azacitidine, and decitabine. In addition, multiple agents and novel combinations are currently in development to treat both MDS AML. Several clinical studies which have investigated these therapeutic approaches, as well as the incorporation of new tools used in the diagnosis of MDS, have been published since the 2008 American Society of Hematology (ASH) Annual Meeting and Exposition, and are discussed here. By becoming familiar with these studies, the physician will be better able to provide the optimal treatment for their patients, as well as become aware of novel therapeutic strategies to offer their patients in ongoing clinical trials.",Journal Article,3825.0,9.0,Myelodysplastic syndrome MDS clonal hematopoietic disorder characterized hyperproliferative bone marrow cellular dysplasia ineffective hematopoiesis heterogeneous malignancy composed subtypes classification evolved years treatment MDS involves improving patient survival quality life decreasing likelihood progression acute myelogenous leukemia AML addition supportive care transfusions hematopoietic growth factors stem transplantation chemotherapeutic agents approved treat MDS -- lenalidomide azacitidine decitabine addition multiple agents novel combinations currently development treat MDS AML clinical studies investigated therapeutic approaches incorporation new tools diagnosis MDS published 2008 American Society Hematology ASH Annual Meeting Exposition discussed familiar studies physician better able provide optimal treatment patients aware novel therapeutic strategies offer patients ongoing clinical trials,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[681, 1223, 16, 8, 1946, 1007, 2645, 765, 20, 8, 23524, 581, 763, 2253, 2, 3957, 5114, 26, 1564, 710, 16, 3317, 1, 392, 814, 3, 947, 1, 92, 71, 3937, 252, 392, 60, 3, 24, 1, 1223, 2921, 1673, 69, 25, 2, 372, 1, 358, 369, 2777, 3, 1420, 1, 91, 6, 286, 2194, 329, 4, 352, 6, 1877, 165, 5, 4987, 2, 1007, 129, 130, 22, 149, 22, 452, 31, 497, 169, 1573, 183, 47, 85, 850, 6, 943, 1223, 1288, 3752, 2, 3004, 4, 352, 232, 183, 2, 229, 1247, 32, 694, 4, 193, 6, 943, 110, 1223, 329, 392, 38, 94, 92, 47, 565, 46, 189, 611, 22, 149, 22, 3, 2838, 1, 217, 1896, 95, 4, 3, 147, 1, 1223, 47, 85, 983, 1192, 3, 1375, 597, 1174, 1, 6216, 14655, 2114, 2238, 2, 39170, 2, 32, 1588, 467, 20, 4009, 8381, 5, 46, 94, 3, 1473, 303, 40, 380, 1665, 6, 377, 3, 665, 24, 9, 136, 7, 22, 149, 22, 1417, 4749, 1, 229, 189, 422, 6, 1918, 136, 7, 4, 942, 38, 143]",1242.0,19927982,Evolving strategies treatment MDS AML,355,0.6195462478184991
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-11-23,"Sapacitabine is an oral deoxycytidine nucleoside analog with a unique mechanism of action that is different from cytarabine. To define the dose-limiting toxicities (DLT) and maximum-tolerated dose (MTD) of sapacitabine given orally twice daily for 7 days every 3 to 4 weeks, or twice daily for 3 days for 2 weeks (days 1 through 3 and days 8 through 10) every 3 to 4 weeks, in refractory-relapse acute leukemia and myelodysplastic syndrome (MDS). A total of 47 patients were treated in the phase I study that used a classical 3 + 3 design. Sapacitabine was escalated from 75 to 375 mg twice daily for 7 days (n = 35) and from 375 to 475 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. The DLTs with both schedules were gastrointestinal. The MTDs were 375 mg twice daily for 7 days and 425 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. The recommended phase II single-agent dose schedules were 325 mg twice daily for 7 days and 425 mg twice daily for 3 days on days 1 through 3 and days 8 through 10. Responses were observed in 13 patients (28%); four were complete responses, and nine were marrow complete responses. Sapacitabine is a new, safely administered, oral deoxycytidine analog that has encouraging activity in leukemia and MDS. Phase II studies are ongoing.","Clinical Trial, Phase I",3711.0,64.0,Sapacitabine oral deoxycytidine nucleoside analog unique mechanism action different cytarabine define dose-limiting toxicities DLT maximum-tolerated dose MTD sapacitabine given orally twice daily 7 days 3 4 weeks twice daily 3 days 2 weeks days 1 3 days 8 10 3 4 weeks refractory-relapse acute leukemia myelodysplastic syndrome MDS total 47 patients treated phase classical 3 3 design Sapacitabine escalated 75 375 mg twice daily 7 days n 35 375 475 mg twice daily 3 days days 1 3 days 8 10 DLTs schedules gastrointestinal MTDs 375 mg twice daily 7 days 425 mg twice daily 3 days days 1 3 days 8 10 recommended phase II single-agent dose schedules 325 mg twice daily 7 days 425 mg twice daily 3 days days 1 3 days 8 10 Responses observed 13 patients 28 complete responses marrow complete responses Sapacitabine new safely administered oral deoxycytidine analog encouraging activity leukemia MDS Phase II studies ongoing,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[20601, 16, 35, 518, 6750, 4032, 3497, 5, 8, 991, 670, 1, 1578, 17, 16, 338, 29, 1855, 6, 1107, 3, 61, 817, 385, 2059, 2, 689, 421, 61, 961, 1, 20601, 447, 1428, 936, 391, 9, 67, 162, 454, 27, 6, 39, 244, 15, 936, 391, 9, 27, 162, 9, 18, 244, 162, 14, 298, 27, 2, 162, 66, 298, 79, 454, 27, 6, 39, 244, 4, 430, 429, 286, 2, 681, 1223, 8, 181, 1, 662, 7, 11, 73, 4, 3, 124, 70, 45, 17, 95, 8, 3781, 27, 27, 771, 20601, 10, 2842, 29, 481, 6, 4175, 81, 936, 391, 9, 67, 162, 78, 465, 2, 29, 4175, 6, 9201, 81, 936, 391, 9, 27, 162, 23, 162, 14, 298, 27, 2, 162, 66, 298, 79, 3, 2506, 5, 110, 2314, 11, 3, 9375, 11, 4175, 81, 936, 391, 9, 67, 162, 2, 8544, 81, 936, 391, 9, 27, 162, 23, 162, 14, 298, 27, 2, 162, 66, 298, 79, 3, 793, 124, 215, 226, 420, 61, 2314, 11, 7139, 81, 936, 391, 9, 67, 162, 2, 8544, 81, 936, 391, 9, 27, 162, 23, 162, 14, 298, 27, 2, 162, 66, 298, 79, 253, 11, 164, 4, 233, 7, 339, 294, 11, 236, 253, 2, 762, 11, 581, 236, 253, 20601, 16, 8, 217, 2268, 468, 518, 6750, 3497, 17, 71, 2269, 128, 4, 2, 1223, 124, 215, 94, 32, 942]",1227.0,19933907,Phase clinical pharmacokinetic oral sapacitabine patients acute leukemia myelodysplastic syndrome,59,0.10296684118673648
Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.,Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,Support Care Cancer,2009-12-03,"To compare the efficacy and safety of voriconazole with itraconazole as prophylaxis in leukemia patients. Open-label, randomized study. Patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome undergoing induction chemotherapy or first salvage were eligible. Patients received voriconazole (400 mg intravenous (i.v.) every 12 h for two doses, followed by 300 mg BID) or itraconazole (200 mg i.v. twice daily for 2 days, followed by 200 mg i.v. daily). A total of 127 patients were enrolled. Four were excluded because they did not receive study drug (n=3) or received two antifungal agents during the first week on study (n=1), leaving 123 patients for analysis. None of the 71 patients receiving voriconazole developed proven or probable invasive fungal infection, compared to two (4%) of the 52 patients receiving itraconazole (P=0.17). Drug discontinuation because of adverse events occurred in 15 patients (21%) receiving voriconazole and six (11%) receiving itraconazole (P=0.23). Voriconazole is a good alternative for prophylaxis in patients with leukemia. Elevated baseline bilirubin levels were associated with a higher risk of side effects in patients receiving i.v. voriconazole or i.v. itraconazole. Monitoring of liver function and drug levels should be considered for some patients.",Comparative Study,3701.0,42.0,compare efficacy safety voriconazole itraconazole prophylaxis leukemia patients Open-label randomized Patients acute myelogenous leukemia high-risk myelodysplastic syndrome undergoing induction chemotherapy salvage eligible Patients received voriconazole 400 mg intravenous i.v 12 h doses followed 300 mg BID itraconazole 200 mg i.v twice daily 2 days followed 200 mg i.v daily total 127 patients enrolled excluded receive drug n=3 received antifungal agents week n =1 leaving 123 patients 71 patients receiving voriconazole developed proven probable invasive fungal infection compared 4 52 patients receiving itraconazole P=0.17 Drug discontinuation adverse events occurred 15 patients 21 receiving voriconazole 11 receiving itraconazole P=0.23 Voriconazole good alternative prophylaxis patients leukemia Elevated baseline bilirubin levels associated higher risk effects patients receiving i.v voriconazole i.v itraconazole Monitoring liver function drug levels considered patients,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 932, 3, 209, 2, 367, 1, 12916, 5, 10463, 22, 2049, 4, 7, 1020, 1756, 384, 45, 7, 5, 286, 2194, 15, 64, 43, 681, 479, 504, 56, 15, 157, 992, 11, 625, 7, 103, 12916, 1524, 81, 1262, 70, 603, 454, 133, 555, 9, 100, 415, 370, 20, 2036, 81, 2793, 15, 10463, 1250, 81, 70, 603, 936, 391, 9, 18, 162, 370, 20, 1250, 81, 70, 603, 391, 8, 181, 1, 4080, 7, 11, 346, 294, 11, 1800, 408, 491, 205, 44, 560, 45, 234, 78, 27, 15, 103, 100, 8606, 183, 190, 3, 157, 647, 23, 45, 78, 14, 7806, 2698, 7, 9, 65, 1292, 1, 3, 792, 7, 357, 12916, 276, 1930, 15, 8782, 416, 7800, 930, 72, 6, 100, 39, 1, 3, 653, 7, 357, 10463, 19, 13, 269, 234, 2007, 408, 1, 290, 281, 489, 4, 167, 7, 239, 357, 12916, 2, 437, 175, 357, 10463, 19, 13, 382, 12916, 16, 8, 1178, 1091, 9, 2049, 4, 7, 5, 804, 330, 5009, 148, 11, 41, 5, 8, 142, 43, 1, 1152, 176, 4, 7, 357, 70, 603, 12916, 15, 70, 603, 10463, 1315, 1, 343, 2, 234, 148, 257, 40, 515, 9, 476, 7]",1226.0,19956980,Efficacy safety intravenous voriconazole intravenous itraconazole antifungal prophylaxis patients acute myelogenous leukemia high-risk myelodysplastic syndrome,3,0.005235602094240838
Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia.,Chemico-biological interactions,Chem. Biol. Interact.,2009-12-01,"Therapy-related myelodysplastic syndrome and acute myeloid leukemia (t-MDS/t-AML) are late complications of cytotoxic therapy used in the treatment of malignant diseases. The most common subtype of t-AML ( approximately 75% of cases) develops after exposure to alkylating agents, and is characterized by loss or deletion of chromosome 5 and/or 7 [-5/del(5q), -7/del(7q)], and a poor outcome (median survival 8 months). In the University of Chicago's series of 386 patients with t-MDS/t-AML, 79 (20%) patients had abnormalities of chromosome 5, 95 (25%) patients had abnormalities of chromosome 7, and 85 (22%) patients had abnormalities of both chromosomes 5 and 7. t-MDS/t-AML with a -5/del(5q) is associated with a complex karyotype, characterized by trisomy 8, as well as loss of 12p, 13q, 16q22, 17p (TP53 locus), chromosome 18, and 20q. In addition, this subtype of t-AML is characterized by a unique expression profile (higher expression of genes) involved in cell cycle control (CCNA2, CCNE2, CDC2), checkpoints (BUB1), or growth (MYC), loss of expression of IRF8, and overexpression of FHL2. Haploinsufficiency of the RPS14, EGR1, APC, NPM1, and CTNNA1 genes on 5q has been implicated in the pathogenesis of MDS/AML. In previous studies, we determined that Egr1 acts by haploinsufficiency and cooperates with mutations induced by alkylating agents to induce myeloid leukemias in the mouse. To identify mutations that cooperate with Egr1 haploinsufficiency, we used retroviral insertional mutagenesis. To date, we have identified two common integration sites involving genes encoding transcription factors that play a critical role in hematopoiesis (Evi1 and Gfi1b loci). Of note is that the EVI1 transcription factor gene is deregulated in human AMLs, particularly those with -7, and abnormalities of 3q. Identifying the genetic pathways leading to t-AML will provide new insights into the underlying biology of this disease, and may facilitate the identification of new therapeutic targets.",Journal Article,3703.0,60.0,Therapy-related myelodysplastic syndrome acute myeloid leukemia t-MDS/t-AML late complications cytotoxic therapy treatment malignant diseases common subtype t-AML approximately 75 cases develops exposure alkylating agents characterized loss deletion chromosome 5 and/or 7 -5/del 5q -7/del 7q poor outcome median survival 8 months University Chicago 's series 386 patients t-MDS/t-AML 79 20 patients abnormalities chromosome 5 95 25 patients abnormalities chromosome 7 85 22 patients abnormalities chromosomes 5 7. t-MDS/t-AML -5/del 5q associated complex karyotype characterized trisomy 8 loss 12p 13q 16q22 17p TP53 locus chromosome 18 20q addition subtype t-AML characterized unique expression profile higher expression involved cycle control CCNA2 CCNE2 CDC2 checkpoints BUB1 growth MYC loss expression IRF8 overexpression FHL2 Haploinsufficiency RPS14 EGR1 APC NPM1 CTNNA1 5q implicated pathogenesis MDS/AML previous studies determined Egr1 acts haploinsufficiency cooperates induced alkylating agents induce myeloid leukemias mouse identify cooperate Egr1 haploinsufficiency retroviral insertional mutagenesis date identified common integration sites involving encoding transcription factors play critical role hematopoiesis Evi1 Gfi1b loci note EVI1 transcription factor deregulated human AMLs particularly -7 abnormalities 3q Identifying genetic pathways leading t-AML provide new insights underlying disease facilitate identification new therapeutic targets,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[36, 139, 681, 2, 286, 533, 102, 1223, 102, 329, 32, 807, 521, 1, 759, 36, 95, 4, 3, 24, 1, 393, 1342, 3, 96, 186, 875, 1, 102, 329, 705, 481, 1, 140, 4734, 50, 645, 6, 3410, 183, 2, 16, 765, 20, 407, 15, 1528, 1, 1170, 33, 2, 15, 67, 33, 3084, 5460, 67, 3084, 9723, 2, 8, 334, 228, 52, 25, 66, 53, 4, 3, 1652, 1, 9344, 292, 988, 1, 7567, 7, 5, 102, 1223, 102, 329, 842, 179, 7, 42, 1171, 1, 1170, 33, 48, 243, 7, 42, 1171, 1, 1170, 67, 2, 772, 350, 7, 42, 1171, 1, 110, 3560, 33, 2, 67, 102, 1223, 102, 329, 5, 8, 33, 3084, 5460, 16, 41, 5, 8, 840, 3385, 765, 20, 6317, 66, 22, 149, 22, 407, 1, 18936, 8453, 28136, 4135, 1206, 2474, 1170, 203, 2, 13887, 4, 352, 26, 875, 1, 102, 329, 16, 765, 20, 8, 991, 55, 800, 142, 55, 1, 214, 646, 4, 31, 417, 182, 23170, 33322, 8747, 4704, 27981, 15, 129, 1371, 407, 1, 55, 1, 12933, 2, 851, 1, 58451, 9292, 1, 3, 45786, 11258, 2528, 4318, 2, 17917, 214, 23, 5460, 71, 85, 1771, 4, 3, 1384, 1, 1223, 329, 4, 698, 94, 21, 509, 17, 11258, 4459, 20, 9292, 2, 12535, 5, 138, 277, 20, 3410, 183, 6, 1290, 533, 2792, 4, 3, 830, 6, 255, 138, 17, 8647, 5, 11258, 9292, 21, 95, 8658, 23271, 8595, 6, 1244, 21, 47, 108, 100, 186, 2676, 633, 1267, 214, 2362, 866, 130, 17, 1343, 8, 740, 200, 4, 5114, 12188, 2, 38820, 2012, 1, 5739, 16, 17, 3, 12188, 866, 161, 145, 16, 5415, 4, 171, 9542, 823, 135, 5, 67, 2, 1171, 1, 18200, 1386, 3, 336, 460, 1049, 6, 102, 329, 303, 377, 217, 1957, 237, 3, 1181, 891, 1, 26, 34, 2, 68, 1876, 3, 911, 1, 217, 189, 637]",1901.0,19958752,Cytogenetic genetic pathways therapy-related acute myeloid leukemia,108,0.18848167539267016
New agents for AML and MDS.,Best practice & research. Clinical haematology,Best Pract Res Clin Haematol,2009-12-01,"The heterogeneity of acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS) has led to a multiplicity of treatments, from cytotoxic agents to signal transduction modulators, cell-cycle inhibitors and epigenetic therapies. While some have shown promising initial results, the outlook for AML patients, particularly older and relapsed patients, as well as patients whose cells exhibit certain adverse chromosomal abnormalities or mutant oncoproteins, continues to be grim. Combination chemotherapy using new agents that act at a number of different levels may provide the greatest potential for successful future therapies. A select number of new agents, approaches and combinations are reviewed here.",Journal Article,3703.0,4.0,heterogeneity acute myeloid leukaemia AML myelodysplastic syndromes MDS led multiplicity treatments cytotoxic agents signal transduction modulators cell-cycle inhibitors epigenetic therapies shown promising initial outlook AML patients particularly older relapsed patients patients exhibit certain adverse chromosomal abnormalities oncoproteins continues grim Combination chemotherapy new agents act number different levels provide greatest potential successful future therapies select number new agents approaches combinations reviewed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1144, 1, 286, 533, 2001, 329, 2, 2040, 1223, 71, 836, 6, 8, 8641, 1, 640, 29, 759, 183, 6, 1235, 2761, 5014, 31, 417, 222, 2, 1418, 235, 369, 476, 47, 443, 721, 388, 99, 3, 8628, 9, 329, 7, 823, 434, 2, 591, 7, 22, 149, 22, 7, 1310, 37, 2239, 1840, 290, 1860, 1171, 15, 620, 8241, 2274, 6, 40, 11282, 150, 56, 75, 217, 183, 17, 2559, 28, 8, 207, 1, 338, 148, 68, 377, 3, 2199, 174, 9, 1401, 508, 235, 8, 1717, 207, 1, 217, 183, 611, 2, 1247, 32, 446, 467]",679.0,19959100,New agents AML MDS,276,0.4816753926701571
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-12-21,"In a phase III randomized trial, azacitidine significantly prolonged overall survival (OS) compared with conventional care regimens (CCRs) in patients with intermediate-2- and high-risk myelodysplastic syndromes. Approximately one third of these patients were classified as having acute myeloid leukemia (AML) under current WHO criteria. This analysis compared the effects of azacitidine versus CCR on OS in this subgroup. Patients were randomly assigned to receive subcutaneous azacitidine 75 mg/m(2)/d or CCR (best supportive care [BSC] only, low-dose cytarabine (LDAC), or intensive chemotherapy [IC]). Of the 113 elderly patients (median age, 70 years) randomly assigned to receive azacitidine (n = 55) or CCR (n = 58; 47% BSC, 34% LDAC, 19% IC), 86% were considered unfit for IC. At a median follow-up of 20.1 months, median OS for azacitidine-treated patients was 24.5 months compared with 16.0 months for CCR-treated patients (hazard ratio = 0.47; 95% CI, 0.28 to 0.79; P = .005), and 2-year OS rates were 50% and 16%, respectively (P = .001). Two-year OS rates were higher with azacitidine versus CCR in patients considered unfit for IC (P = .0003). Azacitidine was associated with fewer total days in hospital (P < .0001) than CCR. In older adult patients with low marrow blast count (20% to 30%) WHO-defined AML, azacitidine significantly prolongs OS and significantly improves several patient morbidity measures compared with CCR.","Clinical Trial, Phase III",3683.0,640.0,phase III randomized trial azacitidine significantly prolonged overall survival OS compared conventional care regimens CCRs patients intermediate-2- high-risk myelodysplastic syndromes Approximately patients classified acute myeloid leukemia AML current criteria compared effects azacitidine versus CCR OS subgroup Patients randomly assigned receive subcutaneous azacitidine 75 mg/m 2 /d CCR best supportive care BSC low-dose cytarabine LDAC intensive chemotherapy IC 113 elderly patients median age 70 years randomly assigned receive azacitidine n 55 CCR n 58 47 BSC 34 LDAC 19 IC 86 considered unfit IC median follow-up 20.1 months median OS azacitidine-treated patients 24.5 months compared 16.0 months CCR-treated patients hazard ratio 0.47 95 CI 0.28 0.79 P .005 2-year OS rates 50 16 respectively P .001 Two-year OS rates higher azacitidine versus CCR patients considered unfit IC P .0003 Azacitidine associated fewer total days hospital P .0001 CCR older adult patients low marrow blast count 20 30 WHO-defined AML azacitidine significantly prolongs OS significantly improves patient morbidity measures compared CCR,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 8, 124, 316, 384, 160, 3752, 97, 1069, 63, 25, 118, 72, 5, 809, 165, 472, 24579, 4, 7, 5, 919, 18, 2, 64, 43, 2040, 705, 104, 1282, 1, 46, 7, 11, 1373, 22, 1041, 286, 533, 329, 669, 291, 54, 371, 26, 65, 72, 3, 176, 1, 3752, 185, 4992, 23, 118, 4, 26, 1363, 7, 11, 1108, 896, 6, 560, 2529, 3752, 481, 81, 188, 18, 427, 15, 4992, 824, 1877, 165, 8472, 158, 154, 61, 1855, 10714, 15, 1686, 56, 2340, 1, 3, 4259, 1216, 7, 52, 89, 431, 60, 1108, 896, 6, 560, 3752, 78, 614, 15, 4992, 78, 717, 662, 8472, 562, 10714, 326, 2340, 868, 11, 515, 9681, 9, 2340, 28, 8, 52, 166, 126, 1, 179, 14, 53, 52, 118, 9, 3752, 73, 7, 10, 259, 33, 53, 72, 5, 245, 13, 53, 9, 4992, 73, 7, 360, 197, 13, 662, 48, 58, 13, 339, 6, 13, 842, 19, 1614, 2, 18, 111, 118, 151, 11, 212, 2, 245, 106, 19, 144, 100, 111, 118, 151, 11, 142, 5, 3752, 185, 4992, 4, 7, 515, 9681, 9, 2340, 19, 4418, 3752, 10, 41, 5, 1497, 181, 162, 4, 702, 19, 488, 76, 4992, 4, 434, 780, 7, 5, 154, 581, 3112, 1276, 179, 6, 201, 54, 395, 329, 3752, 97, 5613, 118, 2, 97, 1804, 392, 69, 787, 1018, 72, 5, 4992]",1339.0,20026804,Azacitidine prolongs overall survival compared conventional care regimens elderly patients low bone marrow blast count acute myeloid leukemia,8,0.013961605584642234
Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia.,Blood,Blood,2009-12-23,"Therapy-related myelodysplastic syndromes (t-MDSs) and acute myeloid leukemia (t-AML) have a poor prognosis with conventional therapy. Encouraging results are reported after allogeneic transplantation. We analyzed outcomes in 868 persons with t-AML (n = 545) or t-MDS (n = 323) receiving allogeneic transplants from 1990 to 2004. A myeloablative regimen was used for conditioning in 77%. Treatment-related mortality (TRM) and relapse were 41% (95% confidence interval [CI], 38-44) and 27% (24-30) at 1 year and 48% (44-51) and 31% (28-34) at 5 years, respectively. Disease-free (DFS) and overall survival (OS) were 32% (95% CI, 29-36) and 37% (34-41) at 1 year and 21% (18-24) and 22% (19-26) at 5 years, respectively. In multivariate analysis, 4 risk factors had adverse impacts on DFS and OS: (1) age older than 35 years; (2) poor-risk cytogenetics; (3) t-AML not in remission or advanced t-MDS; and (4) donor other than an HLA-identical sibling or a partially or well-matched unrelated donor. Five-year survival for subjects with none, 1, 2, 3, or 4 of these risk factors was 50% (95% CI, 38-61), 26% (20-31), 21% (16-26), 10% (5-15), and 4% (0-16), respectively (P < .001). These data permit a more precise prediction of outcome and identify subjects most likely to benefit from allogeneic transplantation.",Journal Article,3681.0,135.0,Therapy-related myelodysplastic syndromes t-MDSs acute myeloid leukemia t-AML poor prognosis conventional therapy Encouraging reported allogeneic transplantation outcomes 868 persons t-AML n 545 t-MDS n 323 receiving allogeneic transplants 1990 2004 myeloablative regimen conditioning 77 Treatment-related mortality TRM relapse 41 95 confidence interval CI 38-44 27 24-30 1 year 48 44-51 31 28-34 5 years respectively Disease-free DFS overall survival OS 32 95 CI 29-36 37 34-41 1 year 21 18-24 22 19-26 5 years respectively multivariate 4 risk factors adverse impacts DFS OS 1 age older 35 years 2 poor-risk cytogenetics 3 t-AML remission advanced t-MDS 4 donor HLA-identical sibling partially well-matched unrelated donor Five-year survival subjects 1 2 3 4 risk factors 50 95 CI 38-61 26 20-31 21 16-26 10 5-15 4 0-16 respectively P .001 permit precise prediction outcome identify subjects likely benefit allogeneic transplantation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[36, 139, 2040, 102, 13550, 2, 286, 533, 102, 329, 47, 8, 334, 356, 5, 809, 36, 2269, 99, 32, 210, 50, 1063, 497, 21, 311, 123, 4, 16697, 4327, 5, 102, 329, 78, 14204, 15, 102, 1223, 78, 10307, 357, 1063, 4016, 29, 2289, 6, 1131, 8, 3246, 477, 10, 95, 9, 1933, 4, 849, 24, 139, 282, 5064, 2, 429, 11, 605, 48, 307, 268, 58, 519, 584, 2, 428, 259, 201, 28, 14, 111, 2, 576, 584, 725, 2, 456, 339, 562, 28, 33, 60, 106, 34, 115, 1010, 2, 63, 25, 118, 11, 531, 48, 58, 462, 511, 2, 567, 562, 605, 28, 14, 111, 2, 239, 203, 259, 2, 350, 326, 432, 28, 33, 60, 106, 4, 331, 65, 39, 43, 130, 42, 290, 4719, 23, 1010, 2, 118, 14, 89, 434, 76, 465, 60, 18, 334, 43, 2510, 27, 102, 329, 44, 4, 734, 15, 131, 102, 1223, 2, 39, 1488, 127, 76, 35, 1160, 3038, 3684, 15, 8, 2995, 15, 149, 655, 2092, 1488, 365, 111, 25, 9, 976, 5, 1292, 14, 18, 27, 15, 39, 1, 46, 43, 130, 10, 212, 48, 58, 519, 713, 432, 179, 456, 239, 245, 432, 79, 33, 167, 2, 39, 13, 245, 106, 19, 144, 46, 74, 5634, 8, 80, 3260, 1590, 1, 228, 2, 255, 976, 96, 322, 6, 247, 29, 1063, 497]",1182.0,20032503,Allogeneic transplantation therapy-related myelodysplastic syndrome acute myeloid leukemia,18,0.031413612565445025
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification.,Blood,Blood,2009-12-29,"Acute erythroid leukemia (AEL) is a rare type of acute myeloid leukemia (AML) for which diagnostic criteria have been refined in the 2008 World Health Organization (WHO) classification of AML. The relationship of AEL to myelodysplastic syndromes (MDSs) and to AML with myelodysplasia-related changes (AML-MRC) is not clearly defined. We conducted a retrospective, multi-institutional study of patients with AEL and compared them with patients with MDS or AML-MRC with erythroid hyperplasia (> or = 50% erythroid cells). Among a total of 124 patients with AEL, 32% had a history of MDS or chronic cytopenia, 32% had therapy-related disease, and 35% had de novo disease. Sixty-four percent of patients had unfavorable AML risk-group karyotypes. FLT3 and RAS mutations were infrequent, occurring in 6% and 2%, respectively. The median overall survival (OS) of all AEL patients was 8 months, comparable with that of patients with MDS or AML-MRC with erythroid hyperplasia. The OS was related to cytogenetic risk group, but not blast count or morphologic dysplasia. Our findings suggest that AEL is in the continuum of MDS and AML with erythroid hyperplasia, where karyotype rather than an arbitrary blast cutoff represents the most important prognostic factor.",Evaluation Study,3675.0,79.0,Acute erythroid leukemia AEL rare type acute myeloid leukemia AML diagnostic criteria refined 2008 World Health Organization classification AML relationship AEL myelodysplastic syndromes MDSs AML myelodysplasia-related changes AML-MRC clearly defined conducted retrospective multi-institutional patients AEL compared patients MDS AML-MRC erythroid hyperplasia 50 erythroid total 124 patients AEL 32 history MDS chronic cytopenia 32 therapy-related disease 35 novo disease Sixty-four percent patients unfavorable AML risk-group karyotypes FLT3 RAS infrequent occurring 6 2 respectively median overall survival OS AEL patients 8 months comparable patients MDS AML-MRC erythroid hyperplasia OS related cytogenetic risk group blast count morphologic dysplasia findings suggest AEL continuum MDS AML erythroid hyperplasia karyotype arbitrary blast cutoff represents important prognostic factor,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[286, 7839, 19217, 16, 8, 622, 267, 1, 286, 533, 329, 9, 92, 752, 371, 47, 85, 5332, 4, 3, 1375, 1956, 341, 2533, 54, 947, 1, 329, 3, 858, 1, 19217, 6, 2040, 13550, 2, 6, 329, 5, 6128, 139, 400, 329, 10976, 16, 44, 2536, 395, 21, 426, 8, 459, 1414, 1115, 45, 1, 7, 5, 19217, 2, 72, 1370, 5, 7, 5, 1223, 15, 329, 10976, 5, 7839, 3176, 15, 212, 7839, 37, 107, 8, 181, 1, 2834, 7, 5, 19217, 531, 42, 8, 532, 1, 1223, 15, 442, 8165, 531, 42, 36, 139, 34, 2, 465, 42, 1566, 2018, 34, 1746, 294, 714, 1, 7, 42, 2483, 329, 43, 87, 6809, 1224, 2, 1102, 138, 11, 4475, 1821, 4, 49, 2, 18, 106, 3, 52, 63, 25, 118, 1, 62, 19217, 7, 10, 66, 53, 1279, 5, 17, 1, 7, 5, 1223, 15, 329, 10976, 5, 7839, 3176, 3, 118, 10, 139, 6, 1266, 43, 87, 84, 44, 3112, 1276, 15, 2815, 2253, 114, 272, 309, 17, 19217, 16, 4, 3, 7382, 1, 1223, 2, 329, 5, 7839, 3176, 1257, 3385, 1832, 76, 35, 16183, 3112, 2779, 1449, 3, 96, 305, 177, 161]",1180.0,20040759,Acute erythroid leukemia reassessment criteria refined 2008 classification,2,0.0034904013961605585
Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2010-01-01,"The use of nucleoside analog-based chemo-immunotherapeutic regimens over the last decade has significantly improved outcomes in patients with chronic lymphocytic leukemia (CLL). Nonetheless, virtually all patients with CLL relapse from chemoimmmunotherapy and current available therapies are not curative. Identifying therapies that effectively eliminate CLL cells and lack immunesuppression represent an exciting new therapeutic approach. IMiDs are a class of immunomodulating drugs that increase T-cell and NK-cell directed killing of tumor cells. The first generation molecule is thalidomide followed by a second generation molecule lenalidomide that lacks neurotoxicity and is being explored more extensively in clinical trials. Lenalidomide has been shown to benefit patients with multiple myeloma, myelodysplastic syndromes, and lymphoma. Initial reports in patients with relapsed and refractory CLL have shown promising responses. In a subset of patients with CLL complete responses have been noted. Subsequent studies, however, have suggested that this class of drug can also have serious and potentially life-threatening side effects including myelosuppression, tumor flare reaction and in a small subset of patients tumor lysis syndrome. Tumor flare with both thalidomide and lenalidomide appear to be disease specific to CLL and may reflect clinical manifestation of CLL tumor cell activation. As a consequence of these disease specific effects, the optimal safe dose of lenalidomide in CLL remains to be determined but appears to be lower than that tolerated in other B-cell malignancies. To date, biomarkers for response remain poorly defined and the relationship of clinical benefit to tumor flare is uncertain. This review examines the existing literature on the use of IMiDs in patients with CLL and provides suggestions for future research in this area.",Journal Article,3672.0,26.0,use nucleoside analog-based chemo-immunotherapeutic regimens decade significantly improved outcomes patients chronic lymphocytic leukemia CLL Nonetheless virtually patients CLL relapse chemoimmmunotherapy current available therapies curative Identifying therapies effectively eliminate CLL lack immunesuppression represent exciting new therapeutic approach IMiDs class immunomodulating drugs increase T-cell NK-cell directed killing generation molecule thalidomide followed second generation molecule lenalidomide lacks neurotoxicity explored extensively clinical trials Lenalidomide shown benefit patients multiple myeloma myelodysplastic syndromes lymphoma Initial reports patients relapsed refractory CLL shown promising responses subset patients CLL complete responses noted Subsequent studies suggested class drug potentially life-threatening effects including myelosuppression flare reaction small subset patients lysis syndrome flare thalidomide lenalidomide appear disease specific CLL reflect clinical manifestation CLL activation consequence disease specific effects optimal safe dose lenalidomide CLL remains determined appears lower tolerated B-cell malignancies date biomarkers response remain poorly defined relationship clinical benefit flare uncertain review examines existing literature use IMiDs patients CLL provides suggestions future research area,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 119, 1, 4032, 3497, 90, 3341, 3222, 472, 252, 3, 1060, 2025, 71, 97, 231, 123, 4, 7, 5, 442, 1193, 552, 4648, 5860, 62, 7, 5, 552, 429, 29, 58535, 2, 291, 390, 235, 32, 44, 1075, 1386, 235, 17, 1856, 4964, 552, 37, 2, 926, 58536, 1231, 35, 4963, 217, 189, 353, 7587, 32, 8, 1040, 1, 13861, 600, 17, 344, 102, 31, 2, 1765, 31, 1166, 3003, 1, 30, 37, 3, 157, 914, 1354, 16, 2159, 370, 20, 8, 419, 914, 1354, 1288, 17, 6856, 3561, 2, 16, 486, 1443, 80, 3576, 4, 38, 143, 1288, 71, 85, 443, 6, 247, 7, 5, 232, 2040, 2, 388, 1198, 4, 7, 5, 591, 2, 430, 552, 47, 443, 721, 253, 4, 8, 697, 1, 7, 5, 552, 236, 253, 47, 85, 1051, 706, 94, 137, 47, 1148, 17, 26, 1040, 1, 234, 122, 120, 47, 1762, 2, 751, 358, 3691, 1152, 176, 141, 2858, 30, 6915, 1329, 2, 4, 8, 302, 697, 1, 7, 30, 4783, 681, 30, 6915, 5, 110, 2159, 2, 1288, 1322, 6, 40, 34, 112, 6, 552, 2, 68, 2694, 38, 6746, 1, 552, 30, 31, 363, 22, 8, 4177, 1, 46, 34, 112, 176, 3, 665, 1165, 61, 1, 1288, 4, 552, 469, 6, 40, 509, 84, 1233, 6, 40, 280, 76, 17, 421, 4, 127, 132, 31, 441, 6, 1244, 582, 9, 51, 918, 1240, 395, 2, 3, 858, 1, 38, 247, 6, 30, 6915, 16, 2717, 26, 206, 4468, 3, 1692, 789, 23, 3, 119, 1, 7587, 4, 7, 5, 552, 2, 777, 9796, 9, 508, 389, 4, 26, 965]",1805.0,20055657,Thalidomide lenalidomide new therapeutics treatment chronic lymphocytic leukemia,49,0.08551483420593368
Reduced-intensity conditioning hematopoietic stem cell transplantation in patients over 60 years: hematologic malignancy outcomes are not impaired in advanced age.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-01-13,"Reduced-intensity-conditioning (RIC) hematopoietic stem cell transplantation (HSCT) is markedly underutilized in the elderly, in part because the impact of advanced age on outcomes is poorly understood. We retrospectively analyzed outcomes in 158 consecutive hematologic malignancy patients aged > or =60 years (median, 63 years; range: 60-71 years) undergoing fludarabine/busulfan-based RIC, with a median-follow-up of 34 months (range: 12.0-85.7). Multivariate analysis was undertaken for factors having an impact on outcome. For the patients aged > or =60 years, 2-year nonrelapse mortality (NRM) and relapse was 10% and 54.6%, respectively. Two-year overall and progression-free survival (OS, PFS) was 46% and 35%, respectively. Grade II-IV acute and chronic graft-versus-host disease (aGVHD, cGVHD) incidence was 19.6% and 45.9%, respectively. Comparing 110 patients aged 60-64 years versus 48 patients aged > or =65 years, 2-year NRM and relapse was 10.5% versus 8.3% (P = .84) and 53.5% versus 56.3% (P = .31), respectively. Grade II-IV aGVHD and cGVHD incidence was 19.1% versus 22.9% (P = .52) and 51.8% versus 32.5% (P = .01), respectively. Two-year OS and PFS was 49% versus 41% (P = .11) and 36% versus 35% (P = .24), respectively. In a multivariate Cox-model, high-risk disease associated with poorer PFS (hazard ratio [HR] = 2.1, P = .01) and OS (HR = 1.84, P = .03); acute myelogenous leukemia/myelodysplastic syndrome diagnosis (HR = 1.66, P = .03) and matched-related donor (HR = 1.62, P = .03) associated with poorer PFS. RIC HSCT is well tolerated, with reasonable survival in elderly patients. Age is not associated with impaired outcomes. HSCT should not be excluded solely based on advanced patient age.",Journal Article,3660.0,63.0,Reduced-intensity-conditioning RIC hematopoietic stem transplantation HSCT markedly underutilized elderly impact advanced age outcomes poorly understood retrospectively outcomes 158 consecutive hematologic malignancy patients aged =60 years median 63 years range 60-71 years undergoing fludarabine/busulfan-based RIC median-follow-up 34 months range 12.0-85.7 Multivariate undertaken factors impact outcome patients aged =60 years 2-year nonrelapse mortality NRM relapse 10 54.6 respectively Two-year overall progression-free survival OS PFS 46 35 respectively Grade II-IV acute chronic graft-versus-host disease aGVHD cGVHD incidence 19.6 45.9 respectively Comparing 110 patients aged 60-64 years versus 48 patients aged =65 years 2-year NRM relapse 10.5 versus 8.3 P .84 53.5 versus 56.3 P .31 respectively Grade II-IV aGVHD cGVHD incidence 19.1 versus 22.9 P .52 51.8 versus 32.5 P .01 respectively Two-year OS PFS 49 versus 41 P .11 36 versus 35 P .24 respectively multivariate Cox-model high-risk disease associated poorer PFS hazard ratio HR 2.1 P .01 OS HR 1.84 P .03 acute myelogenous leukemia/myelodysplastic syndrome diagnosis HR 1.66 P .03 matched-related donor HR 1.62 P .03 associated poorer PFS RIC HSCT tolerated reasonable survival elderly patients Age associated impaired outcomes HSCT excluded solely based advanced patient age,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[405, 837, 1933, 3365, 1007, 452, 31, 497, 1703, 16, 2195, 10398, 4, 3, 1216, 4, 760, 408, 3, 345, 1, 131, 89, 23, 123, 16, 1240, 1784, 21, 894, 311, 123, 4, 5162, 935, 813, 710, 7, 1032, 15, 335, 60, 52, 676, 60, 184, 335, 792, 60, 479, 2027, 3906, 90, 3365, 5, 8, 52, 166, 126, 1, 562, 53, 184, 133, 13, 772, 67, 331, 65, 10, 2789, 9, 130, 1041, 35, 345, 23, 228, 9, 3, 7, 1032, 15, 335, 60, 18, 111, 4640, 282, 4296, 2, 429, 10, 79, 2, 667, 49, 106, 100, 111, 63, 2, 91, 115, 25, 118, 300, 10, 641, 2, 465, 106, 88, 215, 478, 286, 2, 442, 1599, 185, 1204, 34, 5873, 6670, 287, 10, 326, 49, 2, 512, 83, 106, 1430, 3129, 7, 1032, 335, 660, 60, 185, 576, 7, 1032, 15, 556, 60, 18, 111, 4296, 2, 429, 10, 79, 33, 185, 66, 27, 19, 874, 2, 699, 33, 185, 664, 27, 19, 456, 106, 88, 215, 478, 5873, 2, 6670, 287, 10, 326, 14, 185, 350, 83, 19, 653, 2, 725, 66, 185, 531, 33, 19, 355, 106, 100, 111, 118, 2, 300, 10, 739, 185, 605, 19, 175, 2, 511, 185, 465, 19, 259, 106, 4, 8, 331, 418, 202, 64, 43, 34, 41, 5, 1769, 300, 360, 197, 168, 18, 14, 19, 355, 2, 118, 168, 14, 874, 19, 680, 286, 2194, 2647, 10589, 681, 147, 168, 14, 700, 19, 680, 2, 655, 139, 1488, 168, 14, 744, 19, 680, 41, 5, 1769, 300, 3365, 1703, 16, 149, 421, 5, 3203, 25, 4, 1216, 7, 89, 16, 44, 41, 5, 2364, 123, 1703, 257, 44, 40, 1800, 5558, 90, 23, 131, 69, 89]",1601.0,20074656,Reduced-intensity conditioning hematopoietic stem transplantation patients 60 years hematologic malignancy outcomes impaired advanced age,19,0.03315881326352531
Overexpression of human CAP10-like protein 46 KD in T-acute lymphoblastic leukemia and acute myelogenous leukemia.,Genetic testing and molecular biomarkers,Genet Test Mol Biomarkers,2010-02-01,"We earlier identified a novel gene human CAP10-like protein 46 KD (hCLP46) from human acute myelogenous leukemia (AML) transformed from myelodysplastic syndrome CD34(+) cells, but the function of this gene remains unclear. In this study, a real-time polymerase chain reaction-based assay was developed to quantify expression of hCLP46 in the peripheral blood of AML and T-acute lymphoblastic leukemia (T-ALL) primary samples and in six leukemic cell lines. Also, we investigated expression of CDKN2A/B and the apoptosis in U937 cells when hCLP46 is downregulated in vitro. Our findings showed that hCLP46 was overexpressed in AML, T-ALL, and the leukemic cell lines. Suppressing hCLP46 overexpression had no effect on expression of CDKN2A/B and apoptosis of U937 cells. Considering that hCLP46 has the capability of modifying the Notch pathway, our finding adds weight to the importance of Notch signaling in hematopoiesis and suggests that overexpression of hCLP46 might be an early event in the pathogenesis of AML and T-ALL.",Journal Article,3641.0,16.0,earlier identified novel human CAP10-like 46 KD hCLP46 human acute myelogenous leukemia AML transformed myelodysplastic syndrome CD34 function remains unclear real-time polymerase chain reaction-based developed quantify expression hCLP46 peripheral blood AML T-acute lymphoblastic leukemia T-ALL primary leukemic lines investigated expression CDKN2A/B apoptosis U937 hCLP46 downregulated vitro findings showed hCLP46 overexpressed AML T-ALL leukemic lines Suppressing hCLP46 overexpression effect expression CDKN2A/B apoptosis U937 Considering hCLP46 capability modifying Notch pathway finding adds weight importance Notch signaling hematopoiesis suggests overexpression hCLP46 early event pathogenesis AML T-ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 1677, 108, 8, 229, 145, 171, 58648, 733, 178, 641, 6271, 26912, 29, 171, 286, 2194, 329, 2423, 29, 681, 2215, 37, 84, 3, 343, 1, 26, 145, 469, 1200, 4, 26, 45, 8, 1589, 98, 1451, 1260, 1329, 90, 719, 10, 276, 6, 3091, 55, 1, 26912, 4, 3, 672, 315, 1, 329, 2, 102, 286, 1275, 102, 62, 86, 347, 2, 4, 437, 2015, 31, 285, 120, 21, 565, 55, 1, 3175, 132, 2, 3, 351, 4, 7000, 37, 198, 26912, 16, 3315, 4, 439, 114, 272, 224, 17, 26912, 10, 1711, 4, 329, 102, 62, 2, 3, 2015, 31, 285, 4669, 26912, 851, 42, 77, 254, 23, 55, 1, 3175, 132, 2, 351, 1, 7000, 37, 3075, 17, 26912, 71, 3, 6188, 1, 4898, 3, 3193, 308, 114, 1567, 6659, 924, 6, 3, 1187, 1, 3193, 314, 4, 5114, 2, 844, 17, 851, 1, 26912, 822, 40, 35, 191, 774, 4, 3, 1384, 1, 329, 2, 102, 62]",972.0,20143914,Overexpression human CAP10-like 46 KD T-acute lymphoblastic leukemia acute myelogenous leukemia,0,0.0
Characteristics of pericardial effusions in patients with leukemia.,Cancer,Cancer,2010-05-01,"Little information exists regarding the prevalence and natural history of pericardial disease in patients with leukemia. Recently, it has been reported that the use of histone deacetylase inhibitors is associated with an increased incidence of pericardial effusions (PEs). To study the characteristics and treatment relationships of PEs in patients with leukemia, the authors retrospectively analyzed a cohort of patients with leukemia evaluated at a single center. The authors reviewed 2592 patients with acute myeloid leukemia (AML, n = 1282, 49%), acute lymphocytic leukemia (ALL, n = 336, 13%), or myelodysplastic syndrome (MDS, n = 974, 38%), who were evaluated from August 2003 to July 2008. Electronic medical records were reviewed to select patients who had undergone at least 1 echocardiographic evaluation. Data regarding diagnosis, timing, effusion size, survival, and prior therapy were collected for the patients who had echocardiographic evidence of PEs. PEs were detected in 325 (20%) of the patients who had echocardiograms: 21% in AML, 23% in ALL, and 18% in MDS patients. Only a small portion of PEs were detected before the initiation of therapy: 26% in AML, 25% ALL, and 15% in MDS patients. Most PEs were of minimal size (70%) overall. No significant differences in effusion characteristics, including severity, were observed among different types of therapies. The presence of PEs had no impact on the survival of the patients evaluated. PEs are relatively common in patients with leukemia and do not appear to be related to specific types of therapy or to survival.",Journal Article,3552.0,19.0,Little information exists prevalence natural history pericardial disease patients leukemia Recently reported use histone deacetylase inhibitors associated increased incidence pericardial effusions PEs characteristics treatment relationships PEs patients leukemia authors retrospectively cohort patients leukemia evaluated single center authors reviewed 2592 patients acute myeloid leukemia AML n 1282 49 acute lymphocytic leukemia n 336 13 myelodysplastic syndrome MDS n 974 38 evaluated August 2003 July 2008 Electronic medical records reviewed select patients undergone 1 echocardiographic evaluation diagnosis timing effusion size survival prior therapy collected patients echocardiographic evidence PEs PEs detected 325 20 patients echocardiograms 21 AML 23 18 MDS patients small portion PEs detected initiation therapy 26 AML 25 15 MDS patients PEs minimal size 70 overall significant differences effusion characteristics including severity observed different types therapies presence PEs impact survival patients evaluated PEs relatively common patients leukemia appear related specific types therapy survival,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1215, 487, 2481, 666, 3, 1078, 2, 1504, 532, 1, 6657, 34, 4, 7, 5, 761, 192, 71, 85, 210, 17, 3, 119, 1, 1508, 2732, 222, 16, 41, 5, 35, 101, 287, 1, 6657, 5154, 11481, 6, 45, 3, 374, 2, 24, 2467, 1, 11481, 4, 7, 5, 3, 738, 894, 311, 8, 180, 1, 7, 5, 194, 28, 8, 226, 574, 3, 738, 446, 39264, 7, 5, 286, 533, 329, 78, 26918, 739, 286, 1193, 62, 78, 10047, 233, 15, 681, 1223, 78, 17847, 519, 54, 11, 194, 29, 2480, 1522, 6, 2066, 1375, 3098, 484, 1064, 11, 446, 6, 1717, 7, 54, 42, 1989, 28, 506, 14, 13220, 451, 74, 666, 147, 1972, 4433, 444, 25, 2, 324, 36, 11, 786, 9, 3, 7, 54, 42, 13220, 241, 1, 11481, 11481, 11, 530, 4, 7139, 179, 1, 3, 7, 54, 42, 15097, 239, 4, 329, 382, 4, 62, 2, 203, 4, 1223, 7, 158, 8, 302, 3206, 1, 11481, 11, 530, 348, 3, 1118, 1, 36, 432, 4, 329, 243, 62, 2, 167, 4, 1223, 7, 96, 11481, 11, 1, 1048, 444, 431, 63, 77, 93, 362, 4, 4433, 374, 141, 1702, 11, 164, 107, 338, 630, 1, 235, 3, 463, 1, 11481, 42, 77, 345, 23, 3, 25, 1, 3, 7, 194, 11481, 32, 1352, 186, 4, 7, 5, 2, 1022, 44, 1322, 6, 40, 139, 6, 112, 630, 1, 36, 15, 6, 25]",1454.0,20209609,Characteristics pericardial effusions patients leukemia,0,0.0
Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-03-08,"PURPOSE Acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) primarily afflict older individuals. Hematopoietic cell transplantation (HCT) is generally not offered because of concerns of excess morbidity and mortality. Reduced-intensity conditioning (RIC) regimens allow increased use of allogeneic HCT for older patients. To define prognostic factors impacting long-term outcomes of RIC regimens in patients older than age 40 years with AML in first complete remission or MDS and to determine the impact of age, we analyzed data from the Center for International Blood and Marrow Transplant Research (CIBMTR). PATIENTS AND METHODS We reviewed data reported to the CIBMTR (1995 to 2005) on 1,080 patients undergoing RIC HCT. Outcomes analyzed included neutrophil recovery, incidence of acute or chronic graft-versus-host disease (GVHD), nonrelapse mortality (NRM), relapse, disease-free survival (DFS), and overall survival (OS). RESULTS Univariate analyses demonstrated no age group differences in NRM, grade 2 to 4 acute GVHD, chronic GVHD, or relapse. Patients age 40 to 54, 55 to 59, 60 to 64, and > or = 65 years had 2-year survival rates as follows: 44% (95% CI, 37% to 52%), 50% (95% CI, 41% to 59%), 34% (95% CI, 25% to 43%), and 36% (95% CI, 24% to 49%), respectively, for patients with AML (P = .06); and 42% (95% CI, 35% to 49%), 35% (95% CI, 27% to 43%), 45% (95% CI, 36% to 54%), and 38% (95% CI, 25% to 51%), respectively, for patients with MDS (P = .37). Multivariate analysis revealed no significant impact of age on NRM, relapse, DFS, or OS (all P > .3). Greater HLA disparity adversely affected 2-year NRM, DFS, and OS. Unfavorable cytogenetics adversely impacted relapse, DFS, and OS. Better pre-HCT performance status predicted improved 2-year OS. CONCLUSION With these similar outcomes observed in older patients, we conclude that older age alone should not be considered a contraindication to HCT.",Journal Article,3606.0,312.0,"PURPOSE Acute myelogenous leukemia AML myelodysplastic syndrome MDS primarily afflict older individuals Hematopoietic transplantation HCT generally offered concerns excess morbidity mortality Reduced-intensity conditioning RIC regimens allow increased use allogeneic HCT older patients define prognostic factors impacting long-term outcomes RIC regimens patients older age 40 years AML complete remission MDS determine impact age Center International Blood Marrow Transplant Research CIBMTR PATIENTS METHODS reviewed reported CIBMTR 1995 2005 1,080 patients undergoing RIC HCT Outcomes included neutrophil recovery incidence acute chronic graft-versus-host disease GVHD nonrelapse mortality NRM relapse disease-free survival DFS overall survival OS Univariate demonstrated age group differences NRM grade 2 4 acute GVHD chronic GVHD relapse Patients age 40 54 55 59 60 64 65 years 2-year survival rates follows 44 95 CI 37 52 50 95 CI 41 59 34 95 CI 25 43 36 95 CI 24 49 respectively patients AML P .06 42 95 CI 35 49 35 95 CI 27 43 45 95 CI 36 54 38 95 CI 25 51 respectively patients MDS P .37 Multivariate revealed significant impact age NRM relapse DFS OS P .3 Greater HLA disparity adversely affected 2-year NRM DFS OS Unfavorable cytogenetics adversely impacted relapse DFS OS Better pre-HCT performance status predicted improved 2-year OS similar outcomes observed older patients conclude older age considered contraindication HCT",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[743, 286, 2194, 329, 2, 681, 1223, 1561, 31469, 434, 869, 1007, 31, 497, 1085, 16, 1228, 44, 2216, 408, 1, 2061, 1, 2612, 787, 2, 282, 405, 837, 1933, 3365, 472, 1700, 101, 119, 1, 1063, 1085, 9, 434, 7, 6, 1107, 177, 130, 8661, 319, 337, 123, 1, 3365, 472, 4, 7, 434, 76, 89, 327, 60, 5, 329, 4, 157, 236, 734, 15, 1223, 2, 6, 223, 3, 345, 1, 89, 21, 311, 74, 29, 3, 574, 9, 944, 315, 2, 581, 941, 389, 11203, 7, 2, 636, 21, 446, 74, 210, 6, 3, 11203, 2323, 6, 1242, 23, 14, 15490, 7, 479, 3365, 1085, 123, 311, 159, 2595, 1602, 287, 1, 286, 15, 442, 1599, 185, 1204, 34, 1562, 4640, 282, 4296, 429, 34, 115, 25, 1010, 2, 63, 25, 118, 99, 880, 318, 264, 77, 89, 87, 362, 4, 4296, 88, 18, 6, 39, 286, 1562, 442, 1562, 15, 429, 7, 89, 327, 6, 667, 614, 6, 728, 335, 6, 660, 2, 15, 556, 60, 42, 18, 111, 25, 151, 22, 2962, 584, 48, 58, 567, 6, 653, 212, 48, 58, 605, 6, 728, 562, 48, 58, 243, 6, 601, 2, 511, 48, 58, 259, 6, 739, 106, 9, 7, 5, 329, 19, 1460, 2, 595, 48, 58, 465, 6, 739, 465, 48, 58, 428, 6, 601, 512, 48, 58, 511, 6, 667, 2, 519, 48, 58, 243, 6, 725, 106, 9, 7, 5, 1223, 19, 567, 331, 65, 553, 77, 93, 345, 1, 89, 23, 4296, 429, 1010, 15, 118, 62, 19, 27, 378, 1160, 4326, 4311, 1424, 18, 111, 4296, 1010, 2, 118, 2483, 2510, 4311, 4619, 429, 1010, 2, 118, 380, 671, 1085, 528, 156, 783, 231, 18, 111, 118, 1221, 5, 46, 288, 123, 164, 4, 434, 7, 21, 2060, 17, 434, 89, 279, 257, 44, 40, 515, 8, 8363, 6, 1085]",1772.0,20212255,Effect age outcome reduced-intensity hematopoietic transplantation older patients acute myeloid leukemia complete remission myelodysplastic syndrome,21,0.03664921465968586
Phase I combination trial of lenalidomide and azacitidine in patients with higher-risk myelodysplastic syndromes.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-03-30,"Lenalidomide and azacitidine are active in patients with lower- and higher-risk myelodysplastic syndromes (MDS). These agents may complement each other by targeting both the bone marrow microenvironment and hypomethylating action on the malignant clone. This phase I trial explored the safety of combination therapy in patients with higher-risk MDS. Response and characterization of molecular and methylation status of responders were secondary objectives. Patients were enrolled using a 3 + 3 dose escalation. Cycles lasted 28 days, and patients received a maximum of seven cycles. Of 18 patients enrolled, median age was 68 years (range, 52 to 78 years), interval from diagnosis was 5 weeks (range, 2 to 106 weeks), and follow-up was 7 months (range, 1 to 26 months). International Prognostic Scoring System categories were intermediate 1 (n = 2), intermediate 2 (n = 10), and high (n = 6). No dose-limiting toxicities occurred, and a maximum-tolerated dose was not reached. Grades 3 to 4 nonhematologic toxicities (> 1) included febrile neutropenia (n = 5), cardiac (n = 2), and CNS hemorrhage (n = 2). Median absolute neutrophil count decrease was 26%, and platelet decrease was 1% (mean, 24%). The overall response rate was 67%: eight patients (44%) had a complete response (CR); three patients (17%) had hematologic improvement; one patient (6%) had marrow CR. Patients achieving CR were more likely to have normal cytogenetics and lower methylation levels. The combination of lenalidomide and azacitidine is well tolerated with encouraging clinical activity. The go-forward dose is azacitidine 75 mg/m(2) on days 1 through 5 and lenalidomide 10 mg on days 1 through 21.","Clinical Trial, Phase I",3584.0,102.0,Lenalidomide azacitidine active patients lower- higher-risk myelodysplastic syndromes MDS agents complement targeting bone marrow microenvironment hypomethylating action malignant clone phase trial explored safety combination therapy patients higher-risk MDS Response characterization molecular methylation status responders secondary objectives Patients enrolled 3 3 dose escalation Cycles lasted 28 days patients received maximum seven cycles 18 patients enrolled median age 68 years range 52 78 years interval diagnosis 5 weeks range 2 106 weeks follow-up 7 months range 1 26 months International Prognostic Scoring categories intermediate 1 n 2 intermediate 2 n 10 high n 6 dose-limiting toxicities occurred maximum-tolerated dose reached Grades 3 4 nonhematologic toxicities 1 included febrile neutropenia n 5 cardiac n 2 CNS hemorrhage n 2 Median absolute neutrophil count decrease 26 platelet decrease 1 mean 24 overall response rate 67 patients 44 complete response CR patients 17 hematologic improvement patient 6 marrow CR Patients achieving CR likely normal cytogenetics lower methylation levels combination lenalidomide azacitidine tolerated encouraging clinical activity go-forward dose azacitidine 75 mg/m 2 days 1 5 lenalidomide 10 mg days 1 21,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,"[1288, 2, 3752, 32, 544, 4, 7, 5, 280, 2, 142, 43, 2040, 1223, 46, 183, 68, 3731, 296, 127, 20, 529, 110, 3, 581, 995, 2, 4931, 1578, 23, 3, 393, 3910, 26, 124, 70, 160, 1443, 3, 367, 1, 150, 36, 4, 7, 5, 142, 43, 1223, 51, 2, 2136, 1, 219, 2, 569, 156, 1, 1983, 11, 568, 2409, 7, 11, 346, 75, 8, 27, 27, 61, 1125, 410, 6854, 339, 162, 2, 7, 103, 8, 689, 1, 648, 410, 1, 203, 7, 346, 52, 89, 10, 806, 60, 184, 653, 6, 833, 60, 268, 29, 147, 10, 33, 244, 184, 18, 6, 3251, 244, 2, 166, 126, 10, 67, 53, 184, 14, 6, 432, 53, 944, 177, 2504, 398, 1996, 11, 919, 14, 78, 18, 919, 18, 78, 79, 2, 64, 78, 49, 77, 61, 817, 385, 489, 2, 8, 689, 421, 61, 10, 44, 1300, 2276, 27, 6, 39, 3534, 385, 14, 159, 2498, 778, 78, 33, 78, 18, 2, 1025, 3599, 78, 18, 52, 1766, 2595, 1276, 775, 10, 432, 2, 1596, 775, 10, 14, 313, 259, 3, 63, 51, 116, 10, 598, 659, 7, 584, 42, 8, 236, 51, 684, 169, 7, 269, 42, 813, 767, 104, 69, 49, 42, 581, 684, 7, 1785, 684, 11, 80, 322, 6, 47, 295, 2510, 2, 280, 569, 148, 3, 150, 1, 1288, 2, 3752, 16, 149, 421, 5, 2269, 38, 128, 3, 3537, 4674, 61, 16, 3752, 481, 81, 188, 18, 23, 162, 14, 298, 33, 2, 1288, 79, 81, 23, 162, 14, 298, 239]",1559.0,20354132,Phase combination trial lenalidomide azacitidine patients higher-risk myelodysplastic syndromes,16,0.027923211169284468
"DNA methylation detection using MS-qFRET, a quantum dot-based nanoassay.","Methods (San Diego, Calif.)",Methods,2010-04-01,"Detection of aberrant promoter hypermethylation of tumor suppressor genes can be used as a prognostic or predictive marker for carcinogenesis. Since epigenetic modifying agents are FDA approved for treatment of patients with myelodysplastic syndrome, laboratory correlative tools to monitor response to this targeted therapy are important. Methylation specific quantum dot fluorescence resonance energy transfer (MS-qFRET) is a nanotechnology assay that enables the detection of methylation and its changes in a sensitive, quantifiable manner. It utilizes quantum dot-mediated fluorescence resonance energy transfer to achieve highly sensitive detection of DNA methylation. Template DNA is first treated with sodium bisulfite such that unmethylated cytosines are converted to uracil while methylated cytosines remain unconverted. Thereafter, the converted template is amplified using biotinylated methylation-specific primers. Quantum dots, functionalized with streptavidin, serve both as a scaffold to capture amplicons and as a donor for transferring energy to the Cy5 acceptor that is incorporated into the amplicons during PCR. Thus, the status of DNA methylation can be determined according to the level of FRET. In this report, MS-qFRET is validated in cell lines and then used to detect the status of p15(INK4B) methylation in clinical samples from eight patients with acute myeloid leukemia.",Journal Article,3582.0,31.0,Detection aberrant promoter hypermethylation suppressor prognostic predictive marker carcinogenesis epigenetic modifying agents FDA approved treatment patients myelodysplastic syndrome laboratory correlative tools monitor response targeted therapy important Methylation specific quantum dot fluorescence resonance energy transfer MS-qFRET nanotechnology enables detection methylation changes sensitive quantifiable manner utilizes quantum dot-mediated fluorescence resonance energy transfer achieve highly sensitive detection DNA methylation Template DNA treated sodium bisulfite unmethylated cytosines converted uracil methylated cytosines remain unconverted converted template amplified biotinylated methylation-specific primers Quantum dots functionalized streptavidin serve scaffold capture amplicons donor transferring energy Cy5 acceptor incorporated amplicons PCR status DNA methylation determined according level FRET report MS-qFRET validated lines detect status p15 INK4B methylation clinical patients acute myeloid leukemia,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[638, 1, 1898, 973, 2575, 1, 30, 1245, 214, 122, 40, 95, 22, 8, 177, 15, 464, 952, 9, 1719, 1192, 1418, 4898, 183, 32, 2078, 850, 9, 24, 1, 7, 5, 681, 1624, 3679, 1896, 6, 3334, 51, 6, 26, 238, 36, 32, 305, 569, 112, 14251, 13129, 1591, 1535, 2803, 2602, 2307, 45961, 16, 8, 8882, 719, 17, 4843, 3, 638, 1, 569, 2, 211, 400, 4, 8, 745, 11639, 1708, 192, 9639, 14251, 13129, 517, 1591, 1535, 2803, 2602, 6, 1359, 561, 745, 638, 1, 261, 569, 5932, 261, 16, 157, 73, 5, 4682, 6181, 225, 17, 8100, 23365, 32, 4764, 6, 11813, 369, 2963, 23365, 918, 58819, 3972, 3, 4764, 5932, 16, 2429, 75, 18353, 569, 112, 10031, 14251, 20435, 12962, 5, 17261, 1833, 110, 22, 8, 11547, 6, 2891, 15479, 2, 22, 8, 1488, 9, 18500, 2803, 6, 3, 8694, 19680, 17, 16, 2449, 237, 3, 15479, 190, 604, 631, 3, 156, 1, 261, 569, 122, 40, 509, 768, 6, 3, 301, 1, 39284, 4, 26, 414, 2307, 45961, 16, 938, 4, 31, 285, 2, 818, 95, 6, 1426, 3, 156, 1, 8840, 13536, 569, 4, 38, 347, 29, 659, 7, 5, 286, 533]",1355.0,20362674,DNA methylation detection MS-qFRET quantum dot-based nanoassay,0,0.0
Arsenic trioxide as a treatment for myelodysplastic syndrome.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2006-03-01,"Myelodysplastic syndrome (MDS) is a heterogeneous bone marrow disorder primarily affecting older adults, for whom the only curative therapy, bone marrow transplantation, is rarely an option. New therapies, or novel applications of historical therapies, are desperately needed. Arsenic trioxide (ATO), which acts through proapoptotic, antiproliferative, and antiangiogenesis mechanisms, has been used successfully to treat a variety of hematologic malignancies, including MDS. As monotherapy or in combination with other agents, it can effect hematologic improvement in 22% to 26% of patients, with tolerable side effects. MDS patients whose cells express the EVI1 mutation in particular may derive benefit from this therapy.",Journal Article,5074.0,3.0,Myelodysplastic syndrome MDS heterogeneous bone marrow disorder primarily affecting older adults curative therapy bone marrow transplantation rarely option New therapies novel applications historical therapies desperately needed Arsenic trioxide ATO acts proapoptotic antiproliferative antiangiogenesis mechanisms successfully treat variety hematologic malignancies including MDS monotherapy combination agents effect hematologic improvement 22 26 patients tolerable effects MDS patients express EVI1 particular derive benefit therapy,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[681, 1223, 16, 8, 1564, 581, 2645, 1561, 2319, 434, 857, 9, 953, 3, 158, 1075, 36, 581, 497, 16, 2416, 35, 1501, 217, 235, 15, 229, 2911, 1, 2252, 235, 32, 11769, 575, 3217, 4574, 4021, 92, 4459, 298, 4118, 3669, 2, 7351, 483, 71, 85, 95, 1878, 6, 943, 8, 1362, 1, 813, 441, 141, 1223, 22, 1411, 15, 4, 150, 5, 127, 183, 192, 122, 254, 813, 767, 4, 350, 6, 432, 1, 7, 5, 2668, 1152, 176, 1223, 7, 1310, 37, 1669, 3, 12188, 258, 4, 1454, 68, 3823, 247, 29, 26, 36]",675.0,20425329,Arsenic trioxide treatment myelodysplastic syndrome,3,0.005235602094240838
Arsenic trioxide - An old drug rediscovered.,Blood reviews,Blood Rev.,2010-05-15,"Over the last 17 years, clinical trials conducted worldwide have demonstrated the efficacy of arsenic trioxide (As(2)O(3)) in the treatment of relapsed acute promyelocytic leukemia (APL). Currently, the role of As(2)O(3) in front-line therapy is under investigation. Recent trials in the US have demonstrated that the addition of As(2)O(3) to standard treatment regimens improves survival outcomes in patients with APL and may allow a reduction in cytotoxic chemotherapy exposure. As(2)O(3) has also shown efficacy in other malignancies, particularly multiple myeloma and myelodysplastic syndromes. Therapeutic doses of As(2)O(3) are well tolerated, with no evidence of long-term toxicity. Adverse events include APL differentiation syndrome, electrocardiographic abnormalities, and mild elevations in liver enzymes. This review highlights trials investigating the role of As(2)O(3) in induction and consolidation for newly diagnosed APL, as well as its role in other hematologic malignancies. The chemistry, mechanisms of action, and clinical side effects of As(2)O(3) are also discussed.",Journal Article,3538.0,175.0,17 years clinical trials conducted worldwide demonstrated efficacy arsenic trioxide 2 3 treatment relapsed acute promyelocytic leukemia APL Currently role 2 3 front-line therapy investigation Recent trials demonstrated addition 2 3 standard treatment regimens improves survival outcomes patients APL allow reduction cytotoxic chemotherapy exposure 2 3 shown efficacy malignancies particularly multiple myeloma myelodysplastic syndromes Therapeutic doses 2 3 tolerated evidence long-term toxicity Adverse events include APL differentiation syndrome electrocardiographic abnormalities mild elevations liver enzymes review highlights trials investigating role 2 3 induction consolidation newly diagnosed APL role hematologic malignancies chemistry mechanisms action clinical effects 2 3 discussed,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[252, 3, 1060, 269, 60, 38, 143, 426, 2358, 47, 264, 3, 209, 1, 3217, 4574, 22, 18, 1990, 27, 4, 3, 24, 1, 591, 286, 4300, 2578, 694, 3, 200, 1, 22, 18, 1990, 27, 4, 3007, 328, 36, 16, 669, 940, 435, 143, 4, 3, 843, 47, 264, 17, 3, 352, 1, 22, 18, 1990, 27, 6, 260, 24, 472, 1804, 25, 123, 4, 7, 5, 2578, 2, 68, 1700, 8, 628, 4, 759, 56, 645, 22, 18, 1990, 27, 71, 120, 443, 209, 4, 127, 441, 823, 232, 2, 2040, 189, 415, 1, 22, 18, 1990, 27, 32, 149, 421, 5, 77, 241, 1, 319, 337, 155, 290, 281, 643, 2578, 910, 681, 24807, 1171, 2, 1980, 4712, 4, 3039, 26, 206, 2527, 143, 3103, 3, 200, 1, 22, 18, 1990, 27, 4, 504, 2, 2173, 9, 732, 265, 2578, 22, 149, 22, 211, 200, 4, 127, 813, 441, 3, 9352, 483, 1, 1578, 2, 38, 1152, 176, 1, 22, 18, 1990, 27, 32, 120, 1588]",1022.0,20471733,Arsenic trioxide old drug rediscovered,4,0.006980802792321117
Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease.,"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",Mod. Pathol.,2010-05-14,"The diagnostic criteria for acute erythroid leukemia have been controversial since this disease was initially described. Using the current World Health Organization classification criteria, we retrospectively reviewed cases of acute myeloid leukemia or myelodysplastic syndrome in which erythroid precursors were >or=50% of the bone marrow nucleated cell population and the diagnosis of erythroleukemia was considered using older classification schemes. We collected 90 cases and separated them into four diagnostic groups: acute erythroid leukemia, erythroleukemia or erythroid/myeloid type (n=20); acute myeloid leukemia with myelodysplasia-related changes (n=22); therapy-related acute myeloid leukemia (n=32); and refractory anemia with excess blasts and preceding or concurrent history of erythropoietin therapy for anemia (n=16). Patients with acute erythroid leukemia were the youngest patient group and had the best overall survival. There was a statistically significant difference in overall survival between patients with acute erythroid leukemia versus acute myeloid leukemia with myelodysplasia-related changes (P=0.003) and between patients with acute erythroid leukemia versus therapy-related acute myeloid leukemia (P<0.0001). The presence of complex cytogenetic abnormalities (>3) was the only statistically significant independent variable that adversely affected survival in the acute erythroid leukemia group. Monosomy 5/del(5q) and monosomy 7/del(7q) were overrepresented in the context of complex chromosomal abnormalities. Our data suggest that acute erythroid leukemia, as currently defined in the World Health Organization classification, has become a rare disease. A majority of the cases reported previously as erythroleukemia are now classified as other entities. In addition, our data suggest that the current definition of acute erythroid leukemia, erythroleukemia type remains heterogeneous. One subset of acute erythroid leukemia patients has relatively low blast counts and are diploid. The prognosis of this patient subset is relatively good. The other subset has cytogenetic abnormalities similar to those in myelodysplastic syndromes and a poor prognosis.",Journal Article,3539.0,26.0,diagnostic criteria acute erythroid leukemia controversial disease initially described current World Health Organization classification criteria retrospectively reviewed cases acute myeloid leukemia myelodysplastic syndrome erythroid precursors or=50 bone marrow nucleated population diagnosis erythroleukemia considered older classification schemes collected 90 cases separated diagnostic groups acute erythroid leukemia erythroleukemia erythroid/myeloid type n=20 acute myeloid leukemia myelodysplasia-related changes n=22 therapy-related acute myeloid leukemia n=32 refractory anemia excess blasts preceding concurrent history erythropoietin therapy anemia n=16 Patients acute erythroid leukemia youngest patient group best overall survival statistically significant difference overall survival patients acute erythroid leukemia versus acute myeloid leukemia myelodysplasia-related changes P=0.003 patients acute erythroid leukemia versus therapy-related acute myeloid leukemia P 0.0001 presence complex cytogenetic abnormalities 3 statistically significant independent variable adversely affected survival acute erythroid leukemia group Monosomy 5/del 5q monosomy 7/del 7q overrepresented context complex chromosomal abnormalities suggest acute erythroid leukemia currently defined World Health Organization classification rare disease majority cases reported previously erythroleukemia classified entities addition suggest current definition acute erythroid leukemia erythroleukemia type remains heterogeneous subset acute erythroid leukemia patients relatively low blast counts diploid prognosis patient subset relatively good subset cytogenetic abnormalities similar myelodysplastic syndromes poor prognosis,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 752, 371, 9, 286, 7839, 47, 85, 2010, 1192, 26, 34, 10, 1625, 1027, 75, 3, 291, 1956, 341, 2533, 947, 371, 21, 894, 446, 140, 1, 286, 533, 15, 681, 4, 92, 7839, 4881, 11, 15, 212, 1, 3, 581, 9862, 31, 266, 2, 3, 147, 1, 14661, 10, 515, 75, 434, 947, 7103, 21, 786, 424, 140, 2, 4910, 1370, 237, 294, 752, 271, 286, 7839, 14661, 15, 7839, 533, 267, 78, 179, 286, 533, 5, 6128, 139, 400, 78, 350, 36, 139, 286, 533, 78, 531, 2, 430, 1545, 5, 2612, 2438, 2, 5892, 15, 750, 532, 1, 6266, 36, 9, 1545, 78, 245, 7, 5, 286, 7839, 11, 3, 13042, 69, 87, 2, 42, 3, 824, 63, 25, 125, 10, 8, 712, 93, 523, 4, 63, 25, 59, 7, 5, 286, 7839, 185, 286, 533, 5, 6128, 139, 400, 19, 13, 1421, 2, 59, 7, 5, 286, 7839, 185, 36, 139, 286, 533, 19, 13, 488, 3, 463, 1, 840, 1266, 1171, 27, 10, 3, 158, 712, 93, 306, 1347, 17, 4311, 1424, 25, 4, 3, 286, 7839, 87, 7521, 33, 3084, 5460, 2, 7521, 67, 3084, 9723, 11, 13094, 4, 3, 1533, 1, 840, 1860, 1171, 114, 74, 309, 17, 286, 7839, 22, 694, 395, 4, 3, 1956, 341, 2533, 947, 71, 1417, 8, 622, 34, 8, 686, 1, 3, 140, 210, 373, 22, 14661, 32, 1134, 1373, 22, 127, 4613, 4, 352, 114, 74, 309, 17, 3, 291, 2470, 1, 286, 7839, 14661, 267, 469, 1564, 104, 697, 1, 286, 7839, 7, 71, 1352, 154, 3112, 1911, 2, 32, 6815, 3, 356, 1, 26, 69, 697, 16, 1352, 1178, 3, 127, 697, 71, 1266, 1171, 288, 6, 135, 4, 2040, 2, 8, 334, 356]",1986.0,20473273,Acute erythroid leukemia defined World Health Organization classification rare pathogenetically heterogeneous disease,0,0.0
Feasibility of therapy with hypomethylating agents in patients with renal insufficiency.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2010-06-01,"To our knowledge, the feasibility of therapy with hypomethylating agents (HAs) in patients with renal insufficiency (RI) has not been examined. We reviewed 41 patients with a diagnosis of acute myeloid leukemia (n = 17), myelodysplastic syndromes (n = 15), and chronic myelomonocytic leukemia (n = 9) who had RI and were receiving therapy with azacitidine or decitabine. The median number of administered cycles was 3. Most patients (39; 95%) received a standard dose of the drugs at the initiation of therapy. Nine patients (22%) required treatment interruptions or discontinuation, and 10 patients (24%) required dose reductions. The overall response rate was 63%, and 4 patients (10%) achieved a complete response. Twenty patients (51%) experienced grade 3 or 4 myelosuppression-related toxicities. Hospitalization was required in 68% of the patients. Among 12 patients with an estimated glomerular filtration rate of 29 mL per minute or less, 6 required dose reductions attributable to myelosuppression (n = 3) or to worsening renal function (n = 3). The overall survival (OS) at 18 months was 12%, and the median OS was 8.6 months. The use of HA in patients with RI is feasible, but is associated with a higher incidence of toxicity. Dose adjustments and the use of growth factor may be necessary for some patients.",Journal Article,3521.0,15.0,knowledge feasibility therapy hypomethylating agents patients renal insufficiency RI examined reviewed 41 patients diagnosis acute myeloid leukemia n 17 myelodysplastic syndromes n 15 chronic myelomonocytic leukemia n 9 RI receiving therapy azacitidine decitabine median number administered cycles 3 patients 39 95 received standard dose drugs initiation therapy patients 22 required treatment interruptions discontinuation 10 patients 24 required dose reductions overall response rate 63 4 patients 10 achieved complete response patients 51 experienced grade 3 4 myelosuppression-related toxicities Hospitalization required 68 patients 12 patients estimated glomerular filtration rate 29 mL minute 6 required dose reductions attributable myelosuppression n 3 worsening renal function n 3 overall survival OS 18 months 12 median OS 8.6 months use HA patients RI feasible associated higher incidence toxicity Dose adjustments use growth factor necessary patients,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 114, 922, 3, 1437, 1, 36, 5, 4931, 183, 71, 4, 7, 5, 4360, 9836, 71, 44, 85, 409, 21, 446, 605, 7, 5, 8, 147, 1, 286, 533, 78, 269, 2040, 78, 167, 2, 442, 5451, 78, 83, 54, 42, 9836, 2, 11, 357, 36, 5, 3752, 15, 3004, 3, 52, 207, 1, 468, 410, 10, 27, 96, 7, 587, 48, 103, 8, 260, 61, 1, 3, 600, 28, 3, 1118, 1, 36, 762, 7, 350, 616, 24, 7406, 15, 2007, 2, 79, 7, 259, 616, 61, 2153, 3, 63, 51, 116, 10, 676, 2, 39, 7, 79, 513, 8, 236, 51, 737, 7, 725, 592, 88, 27, 15, 39, 2858, 139, 385, 2826, 10, 616, 4, 806, 1, 3, 7, 107, 133, 7, 5, 35, 661, 6080, 5779, 116, 1, 462, 542, 379, 3949, 15, 299, 49, 616, 61, 2153, 2971, 6, 2858, 78, 27, 15, 6, 4323, 343, 78, 27, 3, 63, 25, 118, 28, 203, 53, 10, 133, 2, 3, 52, 118, 10, 66, 49, 53, 3, 119, 1, 4812, 4, 7, 5, 9836, 16, 1313, 84, 16, 41, 5, 8, 142, 287, 1, 155, 61, 6017, 2, 3, 119, 1, 129, 161, 68, 40, 1493, 9, 476, 7]",1209.0,20511166,Feasibility therapy hypomethylating agents patients renal insufficiency,24,0.041884816753926704
Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis.,Blood,Blood,2010-06-10,"We compared the outcomes of unrelated donor (URD, n = 358) with human leukocyte antigen (HLA)-matched sibling donor (MSD, n = 226) transplantations in patients with acute myeloid leukemia (AML) in first complete remission (CR1) having unfavorable cytogenetics at diagnosis. Unfavorable cytogenetic abnormalities were: complex ( 3 abnormalities), 32%; and noncomplex involving chromosome 7, 25%; chromosome 5, 9%; 11q or MLL rearrangements, 18%; t(6;9), 5%; and other noncomplex, 10%. URDs were HLA-well-matched (n = 254; 71%) or partially-matched (n = 104; 29%). Three-year leukemia-free survival (LFS) for MSD was 42% (95% confidence interval [CI], 35%-48%) compared with 34% (95% CI, 28%-41%) for HLA-well-matched URD and 29% (95% CI, 20%-39%) for partially-matched URD (P = .08). In multivariate analysis, HLA-well-matched URD and MSD yielded similar LFS (relative risk [RR] = 1.1, 95% CI, 0.86-1.40, P = .44) and overall survival (OS; RR = 1.06, 95% CI, 0.83-1.37, P = .63). LFS and OS were significantly inferior for HLA-partially-matched URD recipients, those with prior myelodysplastic syndrome, and those older than 50 years. All cytogenetic cohorts had similar outcomes. Patients with chronic graft-versus-host disease had a significantly lower risk of relapse (RR = 0.68, 95% CI, 0.47-0.99, P = .05). Hematopoietic cell transplantation (HCT) using HLA-well-matched URD and MSD resulted in similar LFS and OS in AML patients in CR1 with unfavorable cytogenetics. Outcomes of HCT from HLA-partially- matched URD were inferior.",Comparative Study,3512.0,124.0,compared outcomes unrelated donor URD n 358 human leukocyte antigen HLA -matched sibling donor MSD n 226 transplantations patients acute myeloid leukemia AML complete remission CR1 unfavorable cytogenetics diagnosis Unfavorable cytogenetic abnormalities complex  3 abnormalities 32 noncomplex involving chromosome 7 25 chromosome 5 9 11q MLL rearrangements 18 6 9 5 noncomplex 10 URDs HLA-well-matched n 254 71 partially-matched n 104 29 Three-year leukemia-free survival LFS MSD 42 95 confidence interval CI 35 -48 compared 34 95 CI 28 -41 HLA-well-matched URD 29 95 CI 20 -39 partially-matched URD P .08 multivariate HLA-well-matched URD MSD yielded similar LFS relative risk RR 1.1 95 CI 0.86-1.40 P .44 overall survival OS RR 1.06 95 CI 0.83-1.37 P .63 LFS OS significantly inferior HLA-partially-matched URD recipients prior myelodysplastic syndrome older 50 years cytogenetic cohorts similar outcomes Patients chronic graft-versus-host disease significantly lower risk relapse RR 0.68 95 CI 0.47-0.99 P .05 Hematopoietic transplantation HCT HLA-well-matched URD MSD resulted similar LFS OS AML patients CR1 unfavorable cytogenetics Outcomes HCT HLA-partially- matched URD inferior,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 72, 3, 123, 1, 2092, 1488, 5847, 78, 8396, 5, 171, 3627, 448, 1160, 655, 3684, 1488, 10751, 78, 7400, 6779, 4, 7, 5, 286, 533, 329, 4, 157, 236, 734, 4516, 1041, 2483, 2510, 28, 147, 2483, 1266, 1171, 11, 840, 749, 27, 1171, 531, 2, 24903, 1267, 1170, 67, 243, 1170, 33, 83, 7203, 15, 3049, 2072, 203, 102, 49, 83, 33, 2, 127, 24903, 79, 15979, 11, 1160, 149, 655, 78, 7691, 792, 15, 2995, 655, 78, 3407, 462, 169, 111, 2647, 115, 25, 5674, 9, 10751, 10, 595, 48, 307, 268, 58, 465, 576, 72, 5, 562, 48, 58, 339, 605, 9, 1160, 149, 655, 5847, 2, 462, 48, 58, 179, 587, 9, 2995, 655, 5847, 19, 1592, 4, 331, 65, 1160, 149, 655, 5847, 2, 10751, 2178, 288, 5674, 580, 43, 861, 14, 14, 48, 58, 13, 868, 14, 327, 19, 584, 2, 63, 25, 118, 861, 14, 1460, 48, 58, 13, 852, 14, 567, 19, 676, 5674, 2, 118, 11, 97, 1663, 9, 1160, 2995, 655, 5847, 2190, 135, 5, 324, 681, 2, 135, 434, 76, 212, 60, 62, 1266, 736, 42, 288, 123, 7, 5, 442, 1599, 185, 1204, 34, 42, 8, 97, 280, 43, 1, 429, 861, 13, 806, 48, 58, 13, 662, 13, 1058, 19, 474, 1007, 31, 497, 1085, 75, 1160, 149, 655, 5847, 2, 10751, 627, 4, 288, 5674, 2, 118, 4, 329, 7, 4, 4516, 5, 2483, 2510, 123, 1, 1085, 29, 1160, 2995, 655, 5847, 11, 1663]",1388.0,20538804,Comparable survival HLA-well-matched unrelated matched sibling donor transplantation acute myeloid leukemia remission unfavorable cytogenetics diagnosis,5,0.008726003490401396
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.,Cancer,Cancer,2010-08-01,"The prognosis of patients with myelodysplastic syndrome (MDS) after decitabine failure is not known. Data from 87 patients with MDS (n=67) and chronic myelomonocytic leukemia (n=.20) after failure of decitabine regimens were reviewed. After a median follow-up of 21 months from decitabine failure, 13 (15%) patients remained alive; the median survival was 4.3 months, and the estimated 12-month survival rate was 28%. The estimated 12-month survival rates were 27%, 33%, and 33%, respectively, for patients with high-risk, intermediate-2-risk, and intermediate-1-risk disease (P=.99) by the International Prognostic Scoring System. The estimated 12-month survival rates were 100%, 54%, 41%, and 18%, respectively, for patients with low-risk, intermediate-1-risk, intermediate-2-risk, and high-risk disease according to The University of Texas M. D. Anderson Cancer Center risk model (P=.01). The outcome of patients after decitabine failure is poor and appears to be predictable after decitabine failure.",Journal Article,3460.0,137.0,prognosis patients myelodysplastic syndrome MDS decitabine failure known 87 patients MDS n=67 chronic myelomonocytic leukemia n=.20 failure decitabine regimens reviewed median follow-up 21 months decitabine failure 13 15 patients remained alive median survival 4.3 months estimated 12-month survival rate 28 estimated 12-month survival rates 27 33 33 respectively patients high-risk intermediate-2-risk intermediate-1-risk disease P=.99 International Prognostic Scoring estimated 12-month survival rates 100 54 41 18 respectively patients low-risk intermediate-1-risk intermediate-2-risk high-risk disease according University Texas M. D. Anderson Center risk model P=.01 outcome patients decitabine failure poor appears predictable decitabine failure,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 356, 1, 7, 5, 681, 1223, 50, 3004, 496, 16, 44, 440, 74, 29, 912, 7, 5, 1223, 78, 598, 2, 442, 5451, 78, 179, 50, 496, 1, 3004, 472, 11, 446, 50, 8, 52, 166, 126, 1, 239, 53, 29, 3004, 496, 233, 167, 7, 958, 1701, 3, 52, 25, 10, 39, 27, 53, 2, 3, 661, 133, 811, 25, 116, 10, 339, 3, 661, 133, 811, 25, 151, 11, 428, 466, 2, 466, 106, 9, 7, 5, 64, 43, 919, 18, 43, 2, 919, 14, 43, 34, 19, 1058, 20, 3, 944, 177, 2504, 398, 3, 661, 133, 811, 25, 151, 11, 394, 667, 605, 2, 203, 106, 9, 7, 5, 154, 43, 919, 14, 43, 919, 18, 43, 2, 64, 43, 34, 768, 6, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 43, 202, 19, 355, 3, 228, 1, 7, 50, 3004, 496, 16, 334, 2, 1233, 6, 40, 7639, 50, 3004, 496]",935.0,20564137,Outcome patients myelodysplastic syndrome failure decitabine therapy,4,0.006980802792321117
Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.,Cancer,Cancer,2010-09-01,": Acute kidney injury (AKIis a common complication in the treatment of patients with acute myelogenous leukemia (AML) or high-risk myelodysplastic syndrome (HR-MDS), but, to the authors' knowledge, its clinical relevance has not been detailed to date. The objective of the current study was to identify the incidence, predictors, and outcome for AKI in patients with AML and HR-MDS. : Data were analyzed from 537 patients with AML or HR-MDS undergoing induction chemotherapy from 1999 to 2007. Predictors for AKI were identified by logistic regression. Eight-week mortality of patients was estimated by the Kaplan-Meier method stratified by the RIFLE criteria, a novel multilevel classification system for AKI based on the percent rise in serum creatinine from baseline (Risk, >50%; Injury, >100%; and Failure, >200% or requiring dialysis). : A total of 187 patients (36%) developed AKI. Significant independent risk factors for AKI included the following: age >/=55 years (odds ratio [OR], 1.8), mechanical ventilation (OR, 16), use of vancomycin (OR, 2.3), diuretics (OR, 3.0), amphotericin B lipid formulation (OR, 2.7), vasopressors (OR, 4.9), leukopenia (OR, 1.9), hypoalbuminemia (OR, 1.4), and use of non-fludarabine-based chemotherapy (OR, 2.7). The 8-week mortality rates were 3.8%, 13.6%, 19.6%, and 61.7% for the non-RIFLE, Risk, Injury, and Failure categories, respectively. Patients requiring dialysis (8%) had a median survival of 33 days. Survival of patients who achieved complete remission was favorable, regardless of degree of AKI. : The RIFLE classification for AKI appears to have prognostic utility in predicting mortality in patients with AML or HR-MDS. Relatively mild elevations in creatinine are associated with higher mortality. Strategies to avoid nephrotoxic drugs or fluid overload may be of benefit. Cancer 2010. (c) 2010 American Cancer Society.",Evaluation Study,3429.0,46.0,Acute kidney injury AKIis common complication treatment patients acute myelogenous leukemia AML high-risk myelodysplastic syndrome HR-MDS authors knowledge clinical relevance detailed date objective current identify incidence predictors outcome AKI patients AML HR-MDS 537 patients AML HR-MDS undergoing induction chemotherapy 1999 2007 Predictors AKI identified logistic regression Eight-week mortality patients estimated Kaplan-Meier stratified RIFLE criteria novel multilevel classification AKI based percent rise serum creatinine baseline Risk 50 Injury 100 Failure 200 requiring dialysis total 187 patients 36 developed AKI Significant independent risk factors AKI included following age /=55 years odds ratio 1.8 mechanical ventilation 16 use vancomycin 2.3 diuretics 3.0 amphotericin B lipid formulation 2.7 vasopressors 4.9 leukopenia 1.9 hypoalbuminemia 1.4 use non-fludarabine-based chemotherapy 2.7 8-week mortality rates 3.8 13.6 19.6 61.7 non-RIFLE Risk Injury Failure categories respectively Patients requiring dialysis 8 median survival 33 days Survival patients achieved complete remission favorable regardless degree AKI RIFLE classification AKI appears prognostic utility predicting mortality patients AML HR-MDS Relatively mild elevations creatinine associated higher mortality Strategies avoid nephrotoxic drugs fluid overload benefit 2010 c 2010 American Society,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[286, 2730, 59091, 8, 186, 1447, 4, 3, 24, 1, 7, 5, 286, 2194, 329, 15, 64, 43, 681, 168, 1223, 84, 6, 3, 738, 922, 211, 38, 2088, 71, 44, 85, 2455, 6, 1244, 3, 461, 1, 3, 291, 45, 10, 6, 255, 3, 287, 674, 2, 228, 9, 10019, 4, 7, 5, 329, 2, 168, 1223, 74, 11, 311, 29, 14449, 7, 5, 329, 15, 168, 1223, 479, 504, 56, 29, 2043, 6, 1307, 674, 9, 10019, 11, 108, 20, 812, 320, 659, 647, 282, 1, 7, 10, 661, 20, 3, 876, 882, 596, 1173, 20, 3, 34928, 371, 8, 229, 10913, 947, 398, 9, 10019, 90, 23, 3, 714, 3693, 4, 524, 3177, 29, 330, 43, 212, 2730, 394, 2, 496, 1250, 15, 1888, 7988, 8, 181, 1, 5568, 7, 511, 276, 10019, 93, 306, 43, 130, 9, 10019, 159, 3, 366, 89, 614, 60, 610, 197, 15, 14, 66, 6065, 7845, 15, 245, 119, 1, 9013, 15, 18, 27, 23137, 15, 27, 13, 22151, 132, 3121, 3583, 15, 18, 67, 28424, 15, 39, 83, 3904, 15, 14, 83, 11667, 15, 14, 39, 2, 119, 1, 220, 2027, 90, 56, 15, 18, 67, 3, 66, 647, 282, 151, 11, 27, 66, 233, 49, 326, 49, 2, 713, 67, 9, 3, 220, 34928, 43, 2730, 2, 496, 1996, 106, 7, 1888, 7988, 66, 42, 8, 52, 25, 1, 466, 162, 25, 1, 7, 54, 513, 236, 734, 10, 913, 1583, 1, 1444, 1, 10019, 3, 34928, 947, 9, 10019, 1233, 6, 47, 177, 1207, 4, 1434, 282, 4, 7, 5, 329, 15, 168, 1223, 1352, 1980, 4712, 4, 3177, 32, 41, 5, 142, 282, 422, 6, 3085, 16733, 600, 15, 2357, 13143, 68, 40, 1, 247, 12, 1120, 256, 1120, 597, 12, 1174]",1738.0,20564156,Predictors outcome acute kidney injury patients acute myelogenous leukemia high-risk myelodysplastic syndrome,23,0.04013961605584642
The molecular pathogenesis of myelodysplastic syndromes.,Cancer biology & therapy,Cancer Biol. Ther.,2010-08-05,"The myelodysplastic syndromes (MDS) are frequently associated with clonally restricted cytogenetic abnormalities, but until recently, the molecular pathobiology underlying this diverse group of neoplastic bone marrow disorders has been largely obscure. During the last 10 years, many investigative groups have applied the formidable power of new molecular biology techniques to hunt for recurrent genetic alterations in MDS primary cells. Several genetic abnormalities, including mutations in RUNX1 (AML1), TET2, ASXL1 and TP53, have been discovered in a substantial fraction of MDS cases; genes rearranged or mutated less commonly in MDS include IER3, ATRX, RAS and FLT3. Furthermore, haploinsufficiency and expression changes in RPS14, miR-145 and miR-146a, CDC25c, PP2A and SPARC in the absence of point mutations have also been implicated in MDS pathobiology. A major challenge will be to determine which of these mutations are causative ""drivers"" either in the development or progression of MDS, which might be therapeutically important because they predict response to treatment, and which are merely ""passengers"" along for the ride that alter phenotype but have no effect on the natural history of the disease. While the altered cellular biology of MDS is also increasingly well-understood, many mysteries remain. Abnormalities in iron regulation, microenvironment interactions, regulation of apoptosis and oxidative damage/DNA repair may all play an important pathobiological role. By gaining a deeper understanding of the mechanisms of these complex and heterogeneous diseases, we will hopefully improve our ability to treat our patients with MDS beyond the therapies with limited effectiveness that are available at present.",Journal Article,3456.0,35.0,myelodysplastic syndromes MDS frequently associated clonally restricted cytogenetic abnormalities recently molecular pathobiology underlying diverse group neoplastic bone marrow disorders largely obscure 10 years investigative groups applied formidable power new molecular techniques hunt recurrent genetic alterations MDS primary genetic abnormalities including RUNX1 AML1 TET2 ASXL1 TP53 discovered substantial fraction MDS cases rearranged commonly MDS include IER3 ATRX RAS FLT3 Furthermore haploinsufficiency expression changes RPS14 miR-145 miR-146a CDC25c PP2A SPARC absence point implicated MDS pathobiology major challenge determine causative `` drivers '' development progression MDS therapeutically important predict response treatment merely `` passengers '' ride alter phenotype effect natural history disease altered cellular MDS increasingly well-understood mysteries remain Abnormalities iron regulation microenvironment interactions regulation apoptosis oxidative damage/DNA repair play important pathobiological role gaining deeper understanding mechanisms complex heterogeneous diseases hopefully improve ability treat patients MDS therapies limited effectiveness available present,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2040, 1223, 32, 746, 41, 5, 9157, 2016, 1266, 1171, 84, 1100, 761, 3, 219, 8465, 1181, 26, 1867, 87, 1, 2000, 581, 1997, 71, 85, 1733, 12323, 190, 3, 1060, 79, 60, 445, 15504, 271, 47, 1498, 3, 11940, 2349, 1, 217, 219, 891, 1092, 6, 46101, 9, 387, 336, 593, 4, 1223, 86, 37, 392, 336, 1171, 141, 138, 4, 6092, 6535, 5038, 7782, 2, 1206, 47, 85, 2747, 4, 8, 1281, 1509, 1, 1223, 140, 214, 3201, 15, 1185, 299, 841, 4, 1223, 643, 59124, 7955, 1102, 2, 1224, 798, 9292, 2, 55, 400, 4, 45786, 722, 4058, 2, 722, 39365, 20292, 7890, 2, 9400, 4, 3, 1127, 1, 741, 138, 47, 120, 85, 1771, 4, 1223, 8465, 8, 458, 1745, 303, 40, 6, 223, 92, 1, 46, 138, 32, 8088, 3391, 522, 361, 4, 3, 193, 15, 91, 1, 1223, 92, 822, 40, 4602, 305, 408, 491, 678, 51, 6, 24, 2, 92, 32, 17187, 28971, 522, 1510, 9, 3, 37586, 17, 2688, 1005, 84, 47, 77, 254, 23, 3, 1504, 532, 1, 3, 34, 369, 3, 1495, 763, 891, 1, 1223, 16, 120, 1635, 149, 1784, 445, 26458, 918, 1171, 4, 4231, 863, 995, 1286, 863, 1, 351, 2, 3495, 1350, 261, 972, 68, 62, 1343, 35, 305, 22217, 200, 20, 7312, 8, 6029, 612, 1, 3, 483, 1, 46, 840, 2, 1564, 1342, 21, 303, 7464, 401, 114, 801, 6, 943, 114, 7, 5, 1223, 1654, 3, 235, 5, 383, 1236, 17, 32, 390, 28, 364]",1689.0,20592488,molecular pathogenesis myelodysplastic syndromes,13,0.02268760907504363
Non-small cell lung cancer resection in lymphoma patients.,The Annals of thoracic surgery,Ann. Thorac. Surg.,2010-07-01,"Lymphoma patients are at an increased risk of developing secondary malignancies, including lung cancer. It is unknown if these patients are at higher risk of dying from pulmonary resection due to lymphoma or if they have reasonable long-term survival. We identified 47 lymphoma patients, seven of which had active lymphoma and forty with a history of lymphoma, who underwent resection for lung cancer between 1998 and 2008. We matched lymphoma patients with lung cancer patients who had no lymphoma based on age, gender, surgery type, comorbidities, stage, and histology. We analyzed differences in the length of hospitalization, morbidity, mortality, and overall and lung cancer specific survival between the lymphoma group and the matched no lymphoma group. We found no significant difference in length of hospitalization, morbidity, or mortality between the lymphoma and matched no lymphoma group. The lymphoma group's 5-year overall survival rate (35%) was significantly lower than that of the no lymphoma group (67%; p = 0.04). However, the difference in lung cancer-specific survival between the groups was not significant. The cause-of-death analysis revealed that lymphoma patients also died from recurrent lymphoma or myelodysplastic syndrome-acute myeloid leukemia. Multivariate analysis revealed that older age, higher stage, and active lymphoma status were significant adverse predictors of survival. There is no significant increase in operative morbidity and mortality for lymphoma patients having pulmonary resection for lung cancer. The survival for lymphoma patients is decreased but still acceptable with no difference in lung cancer-specific survival.",Journal Article,3491.0,5.0,Lymphoma patients increased risk developing secondary malignancies including lung unknown patients higher risk dying pulmonary resection lymphoma reasonable long-term survival identified 47 lymphoma patients seven active lymphoma history lymphoma underwent resection lung 1998 2008 matched lymphoma patients lung patients lymphoma based age gender surgery type comorbidities stage histology differences length hospitalization morbidity mortality overall lung specific survival lymphoma group matched lymphoma group significant difference length hospitalization morbidity mortality lymphoma matched lymphoma group lymphoma group 's 5-year overall survival rate 35 significantly lower lymphoma group 67 p 0.04 difference lung cancer-specific survival groups significant cause-of-death revealed lymphoma patients died recurrent lymphoma myelodysplastic syndrome-acute myeloid leukemia Multivariate revealed older age higher stage active lymphoma status significant adverse predictors survival significant increase operative morbidity mortality lymphoma patients pulmonary resection lung survival lymphoma patients decreased acceptable difference lung cancer-specific survival,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7, 32, 28, 35, 101, 43, 1, 931, 568, 441, 141, 12, 192, 16, 860, 492, 46, 7, 32, 28, 142, 43, 1, 4536, 29, 1087, 170, 520, 6, 15, 492, 491, 47, 3203, 319, 337, 25, 21, 108, 662, 7, 648, 1, 92, 42, 544, 2, 1213, 5, 8, 532, 1, 54, 208, 170, 9, 12, 59, 1850, 2, 1375, 21, 655, 7, 5, 12, 7, 54, 42, 77, 90, 23, 89, 1632, 152, 267, 1909, 82, 2, 784, 21, 311, 362, 4, 3, 1318, 1, 2826, 787, 282, 2, 63, 2, 12, 112, 25, 59, 3, 87, 2, 3, 655, 77, 87, 21, 204, 77, 93, 523, 4, 1318, 1, 2826, 787, 15, 282, 59, 3, 2, 655, 77, 87, 3, 87, 292, 33, 111, 63, 25, 116, 465, 10, 97, 280, 76, 17, 1, 3, 77, 87, 598, 19, 13, 755, 137, 3, 523, 4, 12, 112, 25, 59, 3, 271, 10, 44, 93, 3, 708, 1, 273, 65, 553, 17, 7, 120, 1016, 29, 387, 15, 681, 286, 533, 331, 65, 553, 17, 434, 89, 142, 82, 2, 544, 156, 11, 93, 290, 674, 1, 25, 125, 16, 77, 93, 344, 4, 1208, 787, 2, 282, 9, 7, 1041, 1087, 170, 9, 12, 3, 25, 9, 7, 16, 340, 84, 1234, 1595, 5, 77, 523, 4, 12, 112, 25]",1412.0,20609777,Non-small lung resection lymphoma patients,0,0.0
Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-07-22,"Autologous blood or marrow transplantation (ABMT) for low-grade lymphomas can prolong event-free survival (EFS) but requires long-term follow-up. We report one of the longest follow-ups to a prospective transplantation study in such diseases. On a phase II study, 80 patients with low-grade, transformed, or mantle cell lymphoma received ABMT with 4-hydroperoxycyclophosphamide (4-HC) purging as part of initial or salvage therapy. Diagnoses included nontransformed follicular lymphoma in 63% and transformed lymphoma in 15%. With 16.6-year median follow-up for survival, actuarial 10-year EFS and overall survival (OS) were 34% (95% confidence interval [CI], 25%-46%) and 45% (35%-57%). Median EFS and OS were 3.0 and 8.0 years. Early nonrelapse mortality incidence was 8%; myelodysplastic syndrome or leukemia incidence was 4%. Most relapses occurred within 3 years, with a median time to diagnosis of relapse of 1.8 years (range: 0.1-15.6 years). On multivariate analysis, age >50 years, 3 prior chemotherapy regimens, and ABMT after relapse were associated with significantly inferior survival. Fifteen patients (19%) were event-free >15 years after transplantation, raising the possibility of a plateau in the progression-free survival curve. Thus, 4-HC-purged ABMT can produce extended remissions in a subgroup of patients with indolent lymphomas.","Clinical Trial, Phase II",3470.0,5.0,Autologous blood marrow transplantation ABMT low-grade lymphomas prolong event-free survival EFS requires long-term follow-up report longest follow-ups prospective transplantation diseases phase II 80 patients low-grade transformed mantle lymphoma received ABMT 4-hydroperoxycyclophosphamide 4-HC purging initial salvage therapy Diagnoses included nontransformed follicular lymphoma 63 transformed lymphoma 15 16.6-year median follow-up survival actuarial 10-year EFS overall survival OS 34 95 confidence interval CI 25 -46 45 35 -57 Median EFS OS 3.0 8.0 years Early nonrelapse mortality incidence 8 myelodysplastic syndrome leukemia incidence 4 relapses occurred 3 years median time diagnosis relapse 1.8 years range 0.1-15.6 years multivariate age 50 years 3 prior chemotherapy regimens ABMT relapse associated significantly inferior survival patients 19 event-free 15 years transplantation raising possibility plateau progression-free survival curve 4-HC-purged ABMT produce extended remissions subgroup patients indolent lymphomas,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1028, 315, 15, 581, 497, 14805, 9, 154, 88, 1557, 122, 3615, 774, 115, 25, 1683, 84, 1706, 319, 337, 166, 126, 21, 414, 104, 1, 3, 5683, 166, 6106, 6, 8, 482, 497, 45, 4, 225, 1342, 23, 8, 124, 215, 45, 493, 7, 5, 154, 88, 2423, 15, 2757, 31, 103, 14805, 5, 39, 37203, 39, 7487, 9441, 22, 760, 1, 388, 15, 992, 36, 2403, 159, 12264, 1974, 4, 676, 2, 2423, 4, 167, 5, 245, 49, 111, 52, 166, 126, 9, 25, 2361, 79, 111, 1683, 2, 63, 25, 118, 11, 562, 48, 307, 268, 58, 243, 641, 2, 512, 465, 696, 52, 1683, 2, 118, 11, 27, 13, 2, 66, 13, 60, 191, 4640, 282, 287, 10, 66, 681, 15, 287, 10, 39, 96, 3713, 489, 262, 27, 60, 5, 8, 52, 98, 6, 147, 1, 429, 1, 14, 66, 60, 184, 13, 14, 167, 49, 60, 23, 331, 65, 89, 212, 60, 2608, 324, 56, 472, 2, 14805, 50, 429, 11, 41, 5, 97, 1663, 25, 3057, 7, 326, 11, 774, 115, 167, 60, 50, 497, 6627, 3, 2526, 1, 8, 6133, 4, 3, 91, 115, 25, 1496, 631, 39, 7487, 10546, 14805, 122, 2410, 1747, 3166, 4, 8, 1363, 1, 7, 5, 2316, 1557]",1248.0,20655387,Extended follow-up autologous bone marrow transplantation 4-hydroperoxycyclophosphamide 4-HC purging indolent transformed non-Hodgkin lymphomas,0,0.0
Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-07-22,"Because patients who undergo allogeneic hematopoietic cell transplantation (allo-HCT) remain in the vicinity of the transplant center for approximately 90 days posttransplantation, identifying prognostic factors to determine those at immediate higher risk of mortality is essential. A normal serum albumin level generally denotes healthiness. We evaluated the prognostic significance of day 90 hypoalbuminemia (and other clinical, pharmacologic, and laboratory variables) in 163 patients, median age 48 years (range, 19-69 years), who underwent allo-HCT for acute myelogenous leukemia (n = 124) or myelodysplastic syndrome (n = 39). Day 90 hypoalbuminemia (serum albumin <3.0 g/dL) was associated with worse nonrelapse mortality (NRM) and poor overall survival (OS). The estimated 1- and 2-year cumulative incidence rates of NRM were 48% and 52%, respectively, and the corresponding OS rates were 7% and 3%. Serum albumin level <3.0 g/dL and Karnofsky score <80 at day 90 were strong independent predictors of worse NRM and OS in multivariate analysis. These results support day 90 hypoalbuminemia as an adverse prognostic marker for NRM and OS after allo-HCT for acute myelogenous leukemia and myelodysplastic syndrome.",Journal Article,3470.0,15.0,patients undergo allogeneic hematopoietic transplantation allo-HCT remain vicinity transplant center approximately 90 days posttransplantation identifying prognostic factors determine immediate higher risk mortality essential normal serum albumin level generally denotes healthiness evaluated prognostic significance day 90 hypoalbuminemia clinical pharmacologic laboratory variables 163 patients median age 48 years range 19-69 years underwent allo-HCT acute myelogenous leukemia n 124 myelodysplastic syndrome n 39 Day 90 hypoalbuminemia serum albumin 3.0 g/dL associated worse nonrelapse mortality NRM poor overall survival OS estimated 1- 2-year cumulative incidence rates NRM 48 52 respectively corresponding OS rates 7 3 Serum albumin level 3.0 g/dL Karnofsky score 80 day 90 strong independent predictors worse NRM OS multivariate support day 90 hypoalbuminemia adverse prognostic marker NRM OS allo-HCT acute myelogenous leukemia myelodysplastic syndrome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[408, 7, 54, 1251, 1063, 1007, 31, 497, 2564, 1085, 918, 4, 3, 19775, 1, 3, 941, 574, 9, 705, 424, 162, 8046, 1386, 177, 130, 6, 223, 135, 28, 2181, 142, 43, 1, 282, 16, 1452, 8, 295, 524, 2799, 301, 1228, 19535, 59184, 21, 194, 3, 177, 724, 1, 218, 424, 11667, 2, 127, 38, 2788, 2, 1624, 682, 4, 5409, 7, 52, 89, 576, 60, 184, 326, 790, 60, 54, 208, 2564, 1085, 9, 286, 2194, 78, 2834, 15, 681, 78, 587, 218, 424, 11667, 524, 2799, 27, 13, 499, 1826, 10, 41, 5, 639, 4640, 282, 4296, 2, 334, 63, 25, 118, 3, 661, 14, 2, 18, 111, 967, 287, 151, 1, 4296, 11, 576, 2, 653, 106, 2, 3, 1734, 118, 151, 11, 67, 2, 27, 524, 2799, 301, 27, 13, 499, 1826, 2, 2857, 368, 493, 28, 218, 424, 11, 1082, 306, 674, 1, 639, 4296, 2, 118, 4, 331, 65, 46, 99, 538, 218, 424, 11667, 22, 35, 290, 177, 952, 9, 4296, 2, 118, 50, 2564, 1085, 9, 286, 2194, 2, 681]",1128.0,20655389,Severe hypoalbuminemia day 90 predicts worse nonrelapse mortality overall survival allogeneic hematopoietic stem transplantation acute myelogenous leukemia myelodysplastic syndrome,46,0.08027923211169284
Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.,Cancer,Cancer,2010-07-29,"Recurrence is a major cause of treatment failure after allogeneic transplantation for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), and treatment options are very limited. Azacitidine is a DNA methyltransferase inhibitor with activity in myeloid disease. The authors hypothesized that low-dose azacitidine administered after transplant would reduce recurrence rates, and conducted a study to determine a safe dose/schedule combination. Forty-five high-risk patients were treated. Median age was 60 years; median number of comorbidities was 3; 67% were not in remission. By using a Bayesian adaptive method to determine the best dose/schedule combination based on time to toxicity, the authors investigated combinations of 5 daily azacitidine doses, 8, 16, 24, 32, and 40 mg/m2, and 4 schedules: 1, 2, 3, or 4 cycles, each with 5 days of drug and 25 days of rest. Cycle 1 started on Day +40. Reversible thrombocytopenia was the dose-limiting toxicity. The optimal combination was 32 mg/m2 given for 4 cycles. Median follow-up was 20.5 months. One-year event-free and overall survival were 58% and 77%, justifying further studies to estimate long-term clinical benefit. No dose significantly affected DNA global methylation. Azacitidine at 32 mg/m2 given for 5 days is safe and can be administered after allogeneic transplant for at least 4 cycles to heavily pretreated AML/MDS patients. The trial also suggested that this treatment may prolong event-free and overall survival, and that more cycles may be associated with greater benefit.","Clinical Trial, Phase I",3463.0,281.0,Recurrence major cause treatment failure allogeneic transplantation acute myelogenous leukemia AML myelodysplastic syndrome MDS treatment options limited Azacitidine DNA methyltransferase inhibitor activity myeloid disease authors hypothesized low-dose azacitidine administered transplant reduce recurrence rates conducted determine safe dose/schedule combination Forty-five high-risk patients treated Median age 60 years median number comorbidities 3 67 remission Bayesian adaptive determine best dose/schedule combination based time toxicity authors investigated combinations 5 daily azacitidine doses 8 16 24 32 40 mg/m2 4 schedules 1 2 3 4 cycles 5 days drug 25 days rest Cycle 1 started Day +40 Reversible thrombocytopenia dose-limiting toxicity optimal combination 32 mg/m2 given 4 cycles Median follow-up 20.5 months One-year event-free overall survival 58 77 justifying studies estimate long-term clinical benefit dose significantly affected DNA global methylation Azacitidine 32 mg/m2 given 5 days safe administered allogeneic transplant 4 cycles heavily pretreated AML/MDS patients trial suggested treatment prolong event-free overall survival cycles associated greater benefit,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[146, 16, 8, 458, 708, 1, 24, 496, 50, 1063, 497, 9, 286, 2194, 329, 2, 681, 1223, 2, 24, 838, 32, 923, 383, 3752, 16, 8, 261, 3747, 230, 5, 128, 4, 533, 34, 3, 738, 1237, 17, 154, 61, 3752, 468, 50, 941, 688, 969, 146, 151, 2, 426, 8, 45, 6, 223, 8, 1165, 61, 1055, 150, 1213, 365, 64, 43, 7, 11, 73, 52, 89, 10, 335, 60, 52, 207, 1, 1909, 10, 27, 598, 11, 44, 4, 734, 20, 75, 8, 5032, 2454, 596, 6, 223, 3, 824, 61, 1055, 150, 90, 23, 98, 6, 155, 3, 738, 565, 1247, 1, 33, 391, 3752, 415, 66, 245, 259, 531, 2, 327, 81, 821, 2, 39, 2314, 14, 18, 27, 15, 39, 410, 296, 5, 33, 162, 1, 234, 2, 243, 162, 1, 3677, 417, 14, 3461, 23, 218, 327, 2786, 1340, 10, 3, 61, 817, 155, 3, 665, 150, 10, 531, 81, 821, 447, 9, 39, 410, 52, 166, 126, 10, 179, 33, 53, 104, 111, 774, 115, 2, 63, 25, 11, 717, 2, 849, 13579, 195, 94, 6, 1191, 319, 337, 38, 247, 77, 61, 97, 1424, 261, 1648, 569, 3752, 28, 531, 81, 821, 447, 9, 33, 162, 16, 1165, 2, 122, 40, 468, 50, 1063, 941, 9, 28, 506, 39, 410, 6, 2447, 2193, 329, 1223, 7, 3, 160, 120, 1148, 17, 26, 24, 68, 3615, 774, 115, 2, 63, 25, 2, 17, 80, 410, 68, 40, 41, 5, 378, 247]",1495.0,20672358,Maintenance therapy low-dose azacitidine allogeneic hematopoietic stem transplantation recurrent acute myelogenous leukemia myelodysplastic syndrome dose schedule finding,61,0.10645724258289703
Chromatin remodeling is required for gene reactivation after decitabine-mediated DNA hypomethylation.,Cancer research,Cancer Res.,2010-08-16,"The DNA hypomethylating drug decitabine (DAC) reactivates silenced gene expression in cancer and is approved for the treatment of the myelodysplastic syndrome. Gene reactivation after DAC is variable and incompletely understood. Here, we established a cell line system (YB5) derived from the SW48 colon cancer cell line to study DAC-induced reactivation. YB5 contains a hypermethylated cytomegalovirus promoter driving green fluorescent protein (GFP), and the locus is transcriptionally silent. GFP reexpression can be achieved by DAC treatment, but the expression level of individual cells is heterogeneous. DAC-treated YB5 cells were separated into GFP-positive and GFP-negative subpopulations. By comparing DAC-treated sorted GFP-positive and GFP-negative cells, we found that their methylation levels were similarly decreased but that histone modifications and histone H3 densities were remarkably different. Despite a similar degree of (incomplete) DNA hypomethylation, GFP-positive cells reverted to an active chromatin structure marked by higher H3K9 acetylation, lower H3K27 trimethylation, and lower promoter nucleosome density. GFP-negative cells had histone modifications and promoter nucleosome density, similar to parental cells. On DAC withdrawal, gradual resilencing and remethylation occurred in both GFP-positive and GFP-negative cells, and the resilencing correlated with a gradual increase in nucleosome occupancy in GFP-positive cells. These data show that hypomethylation alone after DAC is insufficient for gene expression induction, and that chromatin resetting to an active state including nucleosome eviction is required for activation of protein expression. Our findings suggest that gene expression is the key in optimizing DAC treatment strategies in the clinic.",Journal Article,3445.0,51.0,DNA hypomethylating drug decitabine DAC reactivates silenced expression approved treatment myelodysplastic syndrome reactivation DAC variable incompletely understood established line YB5 derived SW48 colon line DAC-induced reactivation YB5 contains hypermethylated cytomegalovirus promoter driving green fluorescent GFP locus transcriptionally silent GFP reexpression achieved DAC treatment expression level individual heterogeneous DAC-treated YB5 separated GFP-positive GFP-negative subpopulations comparing DAC-treated sorted GFP-positive GFP-negative methylation levels similarly decreased histone modifications histone H3 densities remarkably different Despite similar degree incomplete DNA hypomethylation GFP-positive reverted active chromatin structure marked higher H3K9 acetylation lower H3K27 trimethylation lower promoter nucleosome density GFP-negative histone modifications promoter nucleosome density similar parental DAC withdrawal gradual resilencing remethylation occurred GFP-positive GFP-negative resilencing correlated gradual increase nucleosome occupancy GFP-positive hypomethylation DAC insufficient expression induction chromatin resetting active state including nucleosome eviction required activation expression findings suggest expression key optimizing DAC treatment strategies clinic,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 261, 4931, 234, 3004, 6140, 22447, 5442, 145, 55, 4, 12, 2, 16, 850, 9, 3, 24, 1, 3, 681, 145, 3834, 50, 6140, 16, 1347, 2, 5252, 1784, 467, 21, 635, 8, 31, 328, 398, 39403, 526, 29, 3, 18859, 12, 31, 328, 6, 45, 6140, 277, 3834, 39403, 4862, 8, 6936, 7314, 973, 4057, 4658, 2910, 178, 4687, 2, 3, 2474, 16, 6851, 9890, 4687, 11120, 122, 40, 513, 20, 6140, 24, 84, 3, 55, 301, 1, 797, 37, 16, 1564, 6140, 73, 39403, 37, 11, 4910, 237, 4687, 109, 2, 4687, 199, 4847, 20, 1430, 6140, 73, 8967, 4687, 109, 2, 4687, 199, 37, 21, 204, 17, 136, 569, 148, 11, 1813, 340, 84, 17, 1508, 2916, 2, 1508, 3739, 6908, 11, 4856, 338, 550, 8, 288, 1444, 1, 2610, 261, 4441, 4687, 109, 37, 23106, 6, 35, 544, 2287, 2772, 2003, 20, 142, 12917, 4145, 280, 14308, 13980, 2, 280, 973, 13921, 1263, 4687, 199, 37, 42, 1508, 2916, 2, 973, 13921, 1263, 288, 6, 3418, 37, 23, 6140, 3683, 11268, 46178, 2, 38338, 489, 4, 110, 4687, 109, 2, 4687, 199, 37, 2, 3, 46178, 438, 5, 8, 11268, 344, 4, 13921, 8509, 4, 4687, 109, 37, 46, 74, 514, 17, 4441, 279, 50, 6140, 16, 3027, 9, 145, 55, 504, 2, 17, 2287, 46179, 6, 35, 544, 1309, 141, 13921, 46180, 16, 616, 9, 363, 1, 178, 55, 114, 272, 309, 17, 145, 55, 16, 3, 825, 4, 4336, 6140, 24, 422, 4, 3, 1188]",1737.0,20713525,Chromatin remodeling required reactivation decitabine-mediated DNA hypomethylation,2,0.0034904013961605585
"Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999.",Blood,Blood,2010-08-17,"Zosuquidar, which modulates P-glycoprotein (P-gp) with minimal delay of anthracycline clearance, may reverse P-gp-mediated resistance in acute myeloid leukemia without increased toxicity. A total of 449 adults older than 60 years with acute myeloid leukemia or high-risk myelodysplastic syndrome enrolled in a randomized placebo-controlled double-blind trial (Eastern Cooperative Oncology Group 3999). Overall survival was compared between patients receiving conventional-dose cytarabine and daunorubicin and either zosuquidar (550 mg; 212 patients) or placebo (221 patients). Median and 2-year overall survival values were 7.2 months and 20% on zosuquidar and 9.4 months and 23% on placebo, respectively (P = .281). Remission rate was 51.9% on zosuquidar and 48.9% on placebo. All cause mortality to day 42 was not different (zosuquidar 22.2% vs placebo 16.3%; P = .158). In vitro modulation of P-gp activity by zosuquidar and expression of P-gp, multidrug resistance-related protein 1, lung resistance protein, and breast cancer resistance protein, were comparable in the 2 arms. Poor-risk cytogenetics were more common in P-gp(+) patients. P-gp expression and cytogenetics were correlated, though independent prognostic factors. We conclude that zosuquidar did not improve outcome in older acute myeloid leukemia, in part, because of the presence P-gp independent mechanisms of resistance. This trial is registered at www.clinicaltrials.gov as #NCT00046930.",Journal Article,3444.0,124.0,Zosuquidar modulates P-glycoprotein P-gp minimal delay anthracycline clearance reverse P-gp-mediated resistance acute myeloid leukemia increased toxicity total 449 adults older 60 years acute myeloid leukemia high-risk myelodysplastic syndrome enrolled randomized placebo-controlled double-blind trial Eastern Cooperative Oncology Group 3999 Overall survival compared patients receiving conventional-dose cytarabine daunorubicin zosuquidar 550 mg 212 patients placebo 221 patients Median 2-year overall survival values 7.2 months 20 zosuquidar 9.4 months 23 placebo respectively P .281 Remission rate 51.9 zosuquidar 48.9 placebo cause mortality day 42 different zosuquidar 22.2 vs placebo 16.3 P .158 vitro modulation P-gp activity zosuquidar expression P-gp multidrug resistance-related 1 lung resistance breast resistance comparable 2 arms Poor-risk cytogenetics common P-gp patients P-gp expression cytogenetics correlated independent prognostic factors conclude zosuquidar improve outcome older acute myeloid leukemia presence P-gp independent mechanisms resistance trial registered www.clinicaltrials.gov NCT00046930,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[11826, 92, 5259, 19, 4455, 19, 5407, 5, 1048, 1984, 1, 2044, 1960, 68, 1772, 19, 5407, 517, 251, 4, 286, 533, 187, 101, 155, 8, 181, 1, 8865, 857, 434, 76, 335, 60, 5, 286, 533, 15, 64, 43, 681, 346, 4, 8, 384, 619, 1149, 1627, 3142, 160, 2118, 1690, 413, 87, 34468, 63, 25, 10, 72, 59, 7, 357, 809, 61, 1855, 2, 5247, 2, 361, 11826, 7935, 81, 6586, 7, 15, 619, 5600, 7, 52, 2, 18, 111, 63, 25, 1030, 11, 67, 18, 53, 2, 179, 23, 11826, 2, 83, 39, 53, 2, 382, 23, 619, 106, 19, 8970, 734, 116, 10, 725, 83, 23, 11826, 2, 576, 83, 23, 619, 62, 708, 282, 6, 218, 595, 10, 44, 338, 11826, 350, 18, 105, 619, 245, 27, 19, 5162, 4, 439, 2356, 1, 19, 5407, 128, 20, 11826, 2, 55, 1, 19, 5407, 4814, 251, 139, 178, 14, 251, 178, 2, 12, 251, 178, 11, 1279, 4, 3, 18, 1335, 334, 43, 2510, 11, 80, 186, 4, 19, 5407, 7, 19, 5407, 55, 2, 2510, 11, 438, 2471, 306, 177, 130, 21, 2060, 17, 11826, 205, 44, 401, 228, 4, 434, 286, 533, 4, 760, 408, 1, 3, 463, 19, 5407, 306, 483, 1, 251, 26, 160, 16, 1653, 28, 3064, 1252, 1239, 22, 59258]",1356.0,20716770,Zosuquidar novel modulator P-glycoprotein improve outcome older patients newly diagnosed acute myeloid leukemia randomized placebo-controlled trial Eastern Cooperative Oncology Group 3999,0,0.0
"Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-08-23,"Mutations leading to constitutive activation of the FMS-like tyrosine kinase 3 receptor (FLT3) occur in blasts of 30% of patients with acute myeloid leukemia (AML). Midostaurin (PKC412; N-benzoylstaurosporin) is a multitargeted tyrosine kinase inhibitor, with demonstrated activity in patients with AML/myelodysplastic syndrome (MDS) with FLT3 mutations. Ninety-five patients with AML or MDS with either wild-type (n = 60) or mutated (n = 35) FLT3 were randomly assigned to receive oral midostaurin at 50 or 100 mg twice daily. The drug was discontinued in the absence of response at 2 months, disease progression, or unacceptable toxicity. Response was defined as complete response, partial response (PR), hematologic improvement, or reduction in peripheral blood or bone marrow blasts by  50% (BR). The rate of BR for the population in whom efficacy could be assessed (n = 92) was 71% in patients with FLT3-mutant and 42% in patients with FLT3 wild-type. One PR occurred in a patient with FLT3-mutant receiving the 100-mg dose regimen. Both doses were well-tolerated; there were no differences in toxicity or response rate according to the dose of midostaurin. These results suggest that midostaurin has hematologic activity in both patients with FLT3-mutant and wild-type. The degree of clinical activity observed supports additional studies that combine midostaurin and other agents such as chemotherapy especially in FLT3-mutant AML.","Clinical Trial, Phase II",3438.0,287.0,leading constitutive activation FMS-like tyrosine kinase 3 receptor FLT3 occur blasts 30 patients acute myeloid leukemia AML Midostaurin PKC412 N-benzoylstaurosporin multitargeted tyrosine kinase inhibitor demonstrated activity patients AML/myelodysplastic syndrome MDS FLT3 Ninety-five patients AML MDS wild-type n 60 n 35 FLT3 randomly assigned receive oral midostaurin 50 100 mg twice daily drug discontinued absence response 2 months disease progression unacceptable toxicity Response defined complete response partial response PR hematologic improvement reduction peripheral blood bone marrow blasts  50 BR rate BR population efficacy assessed n 92 71 patients FLT3-mutant 42 patients FLT3 wild-type PR occurred patient FLT3-mutant receiving 100-mg dose regimen doses well-tolerated differences toxicity response rate according dose midostaurin suggest midostaurin hematologic activity patients FLT3-mutant wild-type degree clinical activity observed supports additional studies combine midostaurin agents chemotherapy especially FLT3-mutant AML,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[138, 1049, 6, 3178, 363, 1, 3, 5516, 733, 564, 216, 27, 153, 1224, 1271, 4, 2438, 1, 201, 1, 7, 5, 286, 533, 329, 8824, 7154, 78, 59272, 16, 8, 5947, 564, 216, 230, 5, 264, 128, 4, 7, 5, 329, 10589, 681, 1223, 5, 1224, 138, 2493, 365, 7, 5, 329, 15, 1223, 5, 361, 955, 267, 78, 335, 15, 1185, 78, 465, 1224, 11, 1108, 896, 6, 560, 518, 8824, 28, 212, 15, 394, 81, 936, 391, 3, 234, 10, 2402, 4, 3, 1127, 1, 51, 28, 18, 53, 34, 91, 15, 3215, 155, 51, 10, 395, 22, 236, 51, 450, 51, 998, 813, 767, 15, 628, 4, 672, 315, 15, 581, 2438, 20, 749, 212, 5523, 3, 116, 1, 5523, 9, 3, 266, 4, 953, 209, 359, 40, 275, 78, 937, 10, 792, 4, 7, 5, 1224, 620, 2, 595, 4, 7, 5, 1224, 955, 267, 104, 998, 489, 4, 8, 69, 5, 1224, 620, 357, 3, 394, 81, 61, 477, 110, 415, 11, 149, 421, 125, 11, 77, 362, 4, 155, 15, 51, 116, 768, 6, 3, 61, 1, 8824, 46, 99, 309, 17, 8824, 71, 813, 128, 4, 110, 7, 5, 1224, 620, 2, 955, 267, 3, 1444, 1, 38, 128, 164, 2304, 402, 94, 17, 4680, 8824, 2, 127, 183, 225, 22, 56, 1093, 4, 1224, 620, 329]",1379.0,20733134,Phase IIB trial oral Midostaurin PKC412 FMS-like tyrosine kinase 3 receptor FLT3 multi-targeted kinase inhibitor patients acute myeloid leukemia high-risk myelodysplastic syndrome wild-type FLT3,0,0.0
Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-09-18,"Patients with hematologic malignancies undergoing allogeneic stem cell transplantation (HSCT) commonly have an elevated serum ferritin prior to HSCT, which has been associated with increased mortality after transplantation. This has led to the suggestion that iron overload is common and deleterious in this patient population. However, the relationship between serum ferritin and parenchymal iron overload in such patients is unknown. We report a prospective study of 48 patients with acute leukemia (AL) or myelodysplastic syndromes (MDS) undergoing myeloablative HSCT, using magnetic resonance imaging (MRI) to estimate liver iron content (LIC) and cardiac iron. The median (and range) pre-HSCT value of serum ferritin was 1549 ng/mL (20-6989); serum hepcidin, 59 ng/mL (10-468); labile plasma iron, 0 LPI units (0.0-0.9). Eighty-five percent of patients had hepatic iron overload (HIO), and 42% had significant HIO (LIC 5.0 mg/gdw). Only 1 patient had cardiac iron overload. There was a strong correlation between pre-HSCT serum ferritin and estimated LIC (r = .75), which was mostly dependent on prior transfusion history. Serum hepcidin was appropriately elevated in patients with HIO. Labile plasma iron elevation was rare. A regression calibration analysis supported the hypothesis that elevated pre-HSCT LIC is significantly associated with inferior post-HSCT survival. These results contribute to our understanding of the prevalence, mechanism, and consequences of iron overload in HSCT.",Journal Article,3412.0,61.0,Patients hematologic malignancies undergoing allogeneic stem transplantation HSCT commonly elevated serum ferritin prior HSCT associated increased mortality transplantation led suggestion iron overload common deleterious patient population relationship serum ferritin parenchymal iron overload patients unknown report prospective 48 patients acute leukemia myelodysplastic syndromes MDS undergoing myeloablative HSCT magnetic resonance imaging MRI estimate liver iron content LIC cardiac iron median range pre-HSCT value serum ferritin 1549 ng/mL 20-6989 serum hepcidin 59 ng/mL 10-468 labile plasma iron 0 LPI units 0.0-0.9 Eighty-five percent patients hepatic iron overload HIO 42 significant HIO LIC 5.0 mg/gdw 1 patient cardiac iron overload strong correlation pre-HSCT serum ferritin estimated LIC r .75 dependent prior transfusion history Serum hepcidin appropriately elevated patients HIO Labile plasma iron elevation rare regression calibration supported hypothesis elevated pre-HSCT LIC significantly associated inferior post-HSCT survival contribute understanding prevalence mechanism consequences iron overload HSCT,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,"[7, 5, 813, 441, 479, 1063, 452, 31, 497, 1703, 841, 47, 35, 804, 524, 9101, 324, 6, 1703, 92, 71, 85, 41, 5, 101, 282, 50, 497, 26, 71, 836, 6, 3, 8634, 17, 4231, 13143, 16, 186, 2, 3586, 4, 26, 69, 266, 137, 3, 858, 59, 524, 9101, 2, 5338, 4231, 13143, 4, 225, 7, 16, 860, 21, 414, 8, 482, 45, 1, 576, 7, 5, 286, 2171, 15, 2040, 1223, 479, 3246, 1703, 75, 1484, 1535, 270, 704, 6, 1191, 4231, 2457, 13960, 2, 4231, 3, 52, 2, 184, 671, 1703, 549, 1, 524, 9101, 10, 38888, 997, 542, 179, 59354, 524, 10250, 728, 997, 542, 79, 8279, 19462, 554, 4231, 13, 19157, 2960, 13, 13, 13, 83, 2207, 365, 714, 1, 7, 42, 939, 4231, 13143, 39420, 2, 595, 42, 93, 39420, 13960, 4126, 13, 81, 59355, 158, 14, 69, 42, 4231, 13143, 125, 10, 8, 1082, 816, 59, 671, 1703, 524, 9101, 2, 661, 13960, 668, 481, 92, 10, 2754, 470, 23, 324, 2785, 532, 524, 10250, 10, 4544, 804, 4, 7, 5, 39420, 19462, 554, 4231, 3292, 10, 622, 8, 320, 4821, 65, 2708, 3, 1492, 17, 804, 671, 1703, 13960, 16, 97, 41, 5, 1663, 539, 1703, 25, 46, 99, 1248, 6, 114, 612, 1, 3, 1078, 670, 2, 3255, 1, 4231, 13143, 4, 1703]",1401.0,20854920,Iron overload patients acute leukemia MDS undergoing myeloablative stem transplantation,5,0.008726003490401396
Clofarabine  fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-10-11,"Although a combination of i.v. busulfan (Bu) and fludarabine (Flu) is a safe, reduced-toxicity conditioning program for acute myelogenous leukemia/myelodysplastic syndromes (AML/MDS), recurrent leukemia posttransplantation remains a problem. To enhance the conditioning regimen's antileukemic effect, we decided to supplant Flu with clofarabine (Clo), and assayed the interactions of these nucleoside analogs alone and in combination with Bu in Bu-resistant human cell lines in vitro. We found pronounced synergy between each nucleoside and the alkylator but even more enhanced cytotoxic synergy when the nucleoside analogs were combined prior to exposing the cells to Bu. We then designed a 4-arm clinical trial in patients with myeloid leukemia undergoing allogeneic stem cell transplantation (allo-SCT). Patients were adaptively randomized as follows: Arm I-Clo:Flu 10:30 mg/m(2), Arm II-20:20 mg/m(2), Arm III-30:10 mg/m(2), and Arm IV-single-agent Clo at 40 mg/m(2). The nucleoside analog(s) were/was infused over 1 hour once daily for 4 days, followed on each day by Bu, infused over 3 hours to a pharmacokinetically targeted daily area under the curve (AUC) of 6000 Mol-min  10%. Fifty-one patients have been enrolled with a minimum follow-up exceeding 100 days. There were 32 males and 19 females, with a median age of 45 years (range: 6-59). Nine patients had chronic myeloid leukemia (CML) (BC: 2, second AP: 3, and tyrosine-kinase inhibitor refractory first chronic phase [CP]: 4). Forty-two patients had AML: 14 were induction failures, 8 in first chemotherapy-refractory relapse, 7 in untreated relapse, 3 in second or subsequent relapse, 4 were in second complete remission (CR), and 3 in second CR without platelet recovery (CRp), 2 were in high-risk CR1. Finally, 1 patient was in first CRp. Graft-versus-host disease (GVHD) prophylaxis was tacrolimus and mini-methorexate (MTX), and those who had an unrelated or 1 antigen-mismatched donor received low-dose rabbit-ATG (Thymoglobulin). All patients engrafted. Forty-one patients had active leukemia at the time of transplant, and 35 achieved CR (85%). Twenty of the 42 AML patients and 5 of 9 CML patients are alive with a projected median overall survival (OS) of 23 months. Marrow and blood (T cell) chimerism studies at day +100 revealed that both in the lower-dose Clo groups (groups 1+2) and the higher-dose Clo groups (groups 3+4), the patients had a median of 100% donor (T cell)-derived DNA. There has been no secondary graft failure. In the first 100 days, 1 patient died of pneumonia, and 1 of liver GVHD. We conclude that (1) Clo  Flu with i.v. Bu as pretransplant conditioning is safe in high-risk myeloid leukemia patients; (2) clofarabine is sufficiently immunosuppressive to support allo-SCT in myeloid leukemia; and (3) the median OS of 23 months in this high-risk patient population is encouraging. Additional studies to evaluate the antileukemic efficacy of Clo  Flu with i.v. Bu as pretransplant conditioning therapy are warranted.",Journal Article,3389.0,65.0,combination i.v busulfan Bu fludarabine Flu safe reduced-toxicity conditioning program acute myelogenous leukemia/myelodysplastic syndromes AML/MDS recurrent leukemia posttransplantation remains problem enhance conditioning regimen 's antileukemic effect decided supplant Flu clofarabine Clo assayed interactions nucleoside analogs combination Bu Bu-resistant human lines vitro pronounced synergy nucleoside alkylator enhanced cytotoxic synergy nucleoside analogs combined prior exposing Bu designed 4-arm clinical trial patients myeloid leukemia undergoing allogeneic stem transplantation allo-SCT Patients adaptively randomized follows Arm I-Clo Flu 10:30 mg/m 2 Arm II-20:20 mg/m 2 Arm III-30:10 mg/m 2 Arm IV-single-agent Clo 40 mg/m 2 nucleoside analog were/was infused 1 hour daily 4 days followed day Bu infused 3 hours pharmacokinetically targeted daily area curve AUC 6000 Mol-min  10 Fifty-one patients enrolled minimum follow-up exceeding 100 days 32 males 19 females median age 45 years range 6-59 patients chronic myeloid leukemia CML BC 2 second AP 3 tyrosine-kinase inhibitor refractory chronic phase CP 4 Forty-two patients AML 14 induction failures 8 chemotherapy-refractory relapse 7 untreated relapse 3 second subsequent relapse 4 second complete remission CR 3 second CR platelet recovery CRp 2 high-risk CR1 Finally 1 patient CRp Graft-versus-host disease GVHD prophylaxis tacrolimus mini-methorexate MTX unrelated 1 antigen-mismatched donor received low-dose rabbit-ATG Thymoglobulin patients engrafted Forty-one patients active leukemia time transplant 35 achieved CR 85 42 AML patients 5 9 CML patients alive projected median overall survival OS 23 months Marrow blood chimerism studies day +100 revealed lower-dose Clo groups groups 1+2 higher-dose Clo groups groups 3+4 patients median 100 donor -derived DNA secondary graft failure 100 days 1 patient died pneumonia 1 liver GVHD conclude 1 Clo  Flu i.v Bu pretransplant conditioning safe high-risk myeloid leukemia patients 2 clofarabine sufficiently immunosuppressive support allo-SCT myeloid leukemia 3 median OS 23 months high-risk patient population encouraging Additional studies evaluate antileukemic efficacy Clo  Flu i.v Bu pretransplant conditioning therapy warranted,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[242, 8, 150, 1, 70, 603, 3906, 3667, 2, 2027, 5119, 16, 8, 1165, 405, 155, 1933, 1243, 9, 286, 2194, 2647, 10589, 2040, 329, 1223, 387, 8046, 469, 8, 2497, 6, 1304, 3, 1933, 477, 292, 4512, 254, 21, 10561, 6, 20329, 5119, 5, 4149, 7676, 2, 4499, 3, 1286, 1, 46, 4032, 4063, 279, 2, 4, 150, 5, 3667, 4, 3667, 436, 171, 31, 285, 4, 439, 21, 204, 3517, 3439, 59, 296, 4032, 2, 3, 9346, 84, 871, 80, 651, 759, 3439, 198, 3, 4032, 4063, 11, 397, 324, 6, 14548, 3, 37, 6, 3667, 21, 818, 1114, 8, 39, 475, 38, 160, 4, 7, 5, 533, 479, 1063, 452, 31, 497, 2564, 1988, 7, 11, 17198, 384, 22, 2962, 475, 70, 7676, 5119, 79, 201, 81, 188, 18, 475, 215, 179, 179, 81, 188, 18, 475, 316, 201, 79, 81, 188, 18, 2, 475, 478, 226, 420, 7676, 28, 327, 81, 188, 18, 3, 4032, 3497, 695, 11, 10, 4524, 252, 14, 2583, 1059, 391, 9, 39, 162, 370, 23, 296, 218, 20, 3667, 4524, 252, 27, 1459, 6, 8, 14920, 238, 391, 965, 669, 3, 1496, 1376, 1, 16187, 7674, 1538, 810, 79, 1461, 104, 7, 47, 85, 346, 5, 8, 2499, 166, 126, 5178, 394, 162, 125, 11, 531, 2296, 2, 326, 2451, 5, 8, 52, 89, 1, 512, 60, 184, 49, 728, 762, 7, 42, 442, 533, 903, 1402, 18, 419, 2517, 27, 2, 564, 216, 230, 430, 157, 442, 124, 2541, 39, 1213, 100, 7, 42, 329, 213, 11, 504, 3368, 66, 4, 157, 56, 430, 429, 67, 4, 1278, 429, 27, 4, 419, 15, 706, 429, 39, 11, 4, 419, 236, 734, 684, 2, 27, 4, 419, 684, 187, 1596, 1602, 3162, 18, 11, 4, 64, 43, 4516, 1368, 14, 69, 10, 4, 157, 3162, 1599, 185, 1204, 34, 1562, 2049, 10, 5643, 2, 7313, 59449, 3453, 2, 135, 54, 42, 35, 2092, 15, 14, 448, 5095, 1488, 103, 154, 61, 11079, 7168, 59450, 62, 7, 6914, 1213, 104, 7, 42, 544, 28, 3, 98, 1, 941, 2, 465, 513, 684, 772, 737, 1, 3, 595, 329, 7, 2, 33, 1, 83, 903, 7, 32, 1701, 5, 8, 5633, 52, 63, 25, 118, 1, 382, 53, 581, 2, 315, 102, 31, 6047, 94, 28, 218, 394, 553, 17, 110, 4, 3, 280, 61, 7676, 271, 271, 14, 18, 2, 3, 142, 61, 7676, 271, 271, 27, 39, 3, 7, 42, 8, 52, 1, 394, 1488, 102, 31, 526, 261, 125, 71, 85, 77, 568, 1599, 496, 4, 3, 157, 394, 162, 14, 69, 1016, 1, 3485, 2, 14, 1, 1562, 21, 2060, 17, 14, 7676, 810, 5119, 5, 70, 603, 3667, 22, 7763, 1933, 16, 1165, 4, 64, 43, 533, 7, 18, 4149, 16, 5938, 2989, 6, 538, 2564, 1988, 4, 533, 2, 27, 3, 52, 118, 1, 382, 53, 4, 26, 64, 43, 69, 266, 16, 2269, 402, 94, 6, 376, 3, 4512, 209, 1, 7676, 810, 5119, 5, 70, 603, 3667, 22, 7763, 1933, 36, 32, 1197]",2853.0,20946966,Clofarabine  fludarabine daily i.v busulfan pretransplant conditioning therapy advanced myeloid leukemia MDS,3,0.005235602094240838
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.,Haematologica,Haematologica,2010-10-15,"Background Sorafenib is a multi-kinase inhibitor with activity against fms-like tyrosine kinase 3 with internal tandem duplication mutation and Raf kinase among others. A phase I dose escalation study of sorafenib was conducted in patients with advanced myelodysplastic syndrome and relapsed or refractory acute leukemias. Fifty patients received one of two different schedules; Schedule ""A"": once or twice daily, five days per week, every week for a 21 day cycle, and Schedule ""B"": once or twice daily, for 14 days every 21 days. Dose limiting toxicities were grade 3/4 hypertension, hyperbilirubinemia, and amylase elevation. The recommended phase II dose in hematologic malignancies is 400 mg twice daily for both schedules. Complete remissions or complete remissions with incomplete recovery of platelets were achieved in 5 (10%) patients (all with fms-like tyrosine kinase 3-internal tandem duplication). Significant reduction in bone marrow and/or peripheral blood blasts was seen in an additional 17 (34%) patients (all with fms-like tyrosine kinase 3-internal tandem duplication). Eleven of these responses (including 3 complete remissions/complete remissions with incomplete recovery) lasted for 2 cycles or beyond. In conclusion, sorafenib is active and well tolerated in acute myelogenous leukemia with fms-like tyrosine kinase 3 internal tandem duplication mutation. Conclusions Additional studies of sorafenib in patients with acute myelogenous leukemia, particularly those with fms-like tyrosine kinase 3 internal tandem duplication, are warranted, including sorafenib-based combinations. (ClinicalTrials.gov Identifier: NCT00217646).","Clinical Trial, Phase I",3385.0,116.0,Background Sorafenib multi-kinase inhibitor activity fms-like tyrosine kinase 3 internal tandem duplication Raf kinase phase dose escalation sorafenib conducted patients advanced myelodysplastic syndrome relapsed refractory acute leukemias patients received different schedules Schedule `` '' twice daily days week week 21 day cycle Schedule `` B '' twice daily 14 days 21 days Dose limiting toxicities grade 3/4 hypertension hyperbilirubinemia amylase elevation recommended phase II dose hematologic malignancies 400 mg twice daily schedules Complete remissions complete remissions incomplete recovery platelets achieved 5 10 patients fms-like tyrosine kinase 3-internal tandem duplication Significant reduction bone marrow and/or peripheral blood blasts seen additional 17 34 patients fms-like tyrosine kinase 3-internal tandem duplication responses including 3 complete remissions/complete remissions incomplete recovery lasted 2 cycles sorafenib active tolerated acute myelogenous leukemia fms-like tyrosine kinase 3 internal tandem duplication Conclusions Additional studies sorafenib patients acute myelogenous leukemia particularly fms-like tyrosine kinase 3 internal tandem duplication warranted including sorafenib-based combinations ClinicalTrials.gov Identifier NCT00217646,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2426, 1034, 16, 8, 1414, 216, 230, 5, 128, 480, 5516, 733, 564, 216, 27, 5, 2329, 2905, 4616, 258, 2, 2212, 216, 107, 1749, 8, 124, 70, 61, 1125, 45, 1, 1034, 10, 426, 4, 7, 5, 131, 681, 2, 591, 15, 430, 286, 2792, 1461, 7, 103, 104, 1, 100, 338, 2314, 1055, 8, 522, 1059, 15, 936, 391, 365, 162, 379, 647, 454, 647, 9, 8, 239, 218, 417, 2, 1055, 132, 522, 1059, 15, 936, 391, 9, 213, 162, 454, 239, 162, 61, 817, 385, 11, 88, 27, 39, 1824, 7236, 2, 11149, 3292, 3, 793, 124, 215, 61, 4, 813, 441, 16, 1524, 81, 936, 391, 9, 110, 2314, 236, 3166, 15, 236, 3166, 5, 2610, 1602, 1, 4407, 11, 513, 4, 33, 79, 7, 62, 5, 5516, 733, 564, 216, 27, 2329, 2905, 4616, 93, 628, 4, 581, 2, 15, 672, 315, 2438, 10, 527, 4, 35, 402, 269, 562, 7, 62, 5, 5516, 733, 564, 216, 27, 2329, 2905, 4616, 2627, 1, 46, 253, 141, 27, 236, 3166, 236, 3166, 5, 2610, 1602, 6854, 9, 18, 410, 15, 1654, 4, 1221, 1034, 16, 544, 2, 149, 421, 4, 286, 2194, 5, 5516, 733, 564, 216, 27, 2329, 2905, 4616, 258, 2130, 402, 94, 1, 1034, 4, 7, 5, 286, 2194, 823, 135, 5, 5516, 733, 564, 216, 27, 2329, 2905, 4616, 32, 1197, 141, 1034, 90, 1247, 1252, 1239, 3719, 59457]",1578.0,20952518,Phase sorafenib patients refractory relapsed acute leukemias,12,0.020942408376963352
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-10-18,"Lenalidomide is effective in myeloma and low-risk myelodysplastic syndromes with deletion 5q. We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute leukemia. Thirty-one adults with acute myeloid leukemia (AML) and four adults with acute lymphoblastic leukemia (ALL) were enrolled. Lenalidomide was given orally at escalating doses of 25 to 75 mg daily on days 1 through 21 of 28-day cycles to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD), as well as to provide pharmacokinetic and preliminary efficacy data. Patients had a median age of 63 years (range, 22 to 79 years) and a median of two prior therapies (range, one to four therapies). The DLT was fatigue; 50 mg/d was the MTD. Infectious complications were frequent. Plasma lenalidomide concentration increased proportionally with dose. In AML, five (16%) of 31 patients achieved complete remission (CR); three of three patients with cytogenetic abnormalities achieved cytogenetic CR (none with deletion 5q). Response duration ranged from 5.6 to 14 months. All responses occurred in AML with low presenting WBC count. No patient with ALL responded. Two of four patients who received lenalidomide as initial therapy for AML relapse after allogeneic transplantation achieved durable CR after development of cutaneous graft-versus-host disease, without donor leukocyte infusion. Lenalidomide was safely escalated to 50 mg daily for 21 days, every 4 weeks, and was active with relatively low toxicity in patients with relapsed/refractory AML. Remissions achieved after transplantation suggest a possible immunomodulatory effect of lenalidomide, and results provide enthusiasm for further studies in AML, either alone or in combination with conventional agents or other immunotherapies.","Clinical Trial, Phase I",3382.0,72.0,Lenalidomide effective myeloma low-risk myelodysplastic syndromes deletion 5q report phase dose-escalation trial lenalidomide relapsed refractory acute leukemia Thirty-one adults acute myeloid leukemia AML adults acute lymphoblastic leukemia enrolled Lenalidomide given orally escalating doses 25 75 mg daily days 1 21 28-day cycles determine dose-limiting toxicity DLT maximum-tolerated dose MTD provide pharmacokinetic preliminary efficacy Patients median age 63 years range 22 79 years median prior therapies range therapies DLT fatigue 50 mg/d MTD Infectious complications frequent Plasma lenalidomide concentration increased proportionally dose AML 16 31 patients achieved complete remission CR patients cytogenetic abnormalities achieved cytogenetic CR deletion 5q Response duration ranged 5.6 14 months responses occurred AML low presenting WBC count patient responded patients received lenalidomide initial therapy AML relapse allogeneic transplantation achieved durable CR development cutaneous graft-versus-host disease donor leukocyte infusion Lenalidomide safely escalated 50 mg daily 21 days 4 weeks active relatively low toxicity patients relapsed/refractory AML Remissions achieved transplantation suggest possible immunomodulatory effect lenalidomide provide enthusiasm studies AML combination conventional agents immunotherapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1288, 16, 323, 4, 2, 154, 43, 2040, 5, 1528, 5460, 21, 414, 99, 1, 8, 124, 70, 61, 1125, 160, 1, 1288, 4, 591, 15, 430, 286, 977, 104, 857, 5, 286, 533, 329, 2, 294, 857, 5, 286, 1275, 62, 11, 346, 1288, 10, 447, 1428, 28, 2922, 415, 1, 243, 6, 481, 81, 391, 23, 162, 14, 298, 239, 1, 339, 218, 410, 6, 223, 3, 61, 817, 155, 2059, 2, 689, 421, 61, 961, 22, 149, 22, 6, 377, 1456, 2, 1676, 209, 74, 7, 42, 8, 52, 89, 1, 676, 60, 184, 350, 6, 842, 60, 2, 8, 52, 1, 100, 324, 235, 184, 104, 6, 294, 235, 3, 2059, 10, 613, 212, 81, 427, 10, 3, 961, 3398, 521, 11, 908, 554, 1288, 1227, 101, 11142, 5, 61, 4, 329, 365, 245, 1, 456, 7, 513, 236, 734, 684, 169, 1, 169, 7, 5, 1266, 1171, 513, 1266, 684, 1292, 5, 1528, 5460, 51, 654, 1869, 29, 33, 49, 6, 213, 53, 62, 253, 489, 4, 329, 5, 154, 1656, 4685, 1276, 77, 69, 5, 62, 2211, 100, 1, 294, 7, 54, 103, 1288, 22, 388, 36, 9, 329, 429, 50, 1063, 497, 513, 1480, 684, 50, 193, 1, 1486, 1599, 185, 1204, 34, 187, 1488, 3627, 904, 1288, 10, 2268, 2842, 6, 212, 81, 391, 9, 239, 162, 454, 39, 244, 2, 10, 544, 5, 1352, 154, 155, 4, 7, 5, 591, 430, 329, 3166, 513, 50, 497, 309, 8, 899, 2555, 254, 1, 1288, 2, 99, 377, 8582, 9, 195, 94, 4, 329, 361, 279, 15, 4, 150, 5, 809, 183, 15, 127, 2811]",1716.0,20956622,Dose escalation lenalidomide relapsed refractory acute leukemias,0,0.0
Safety and efficacy of azacitidine in myelodysplastic syndromes.,"Drug design, development and therapy",Drug Des Devel Ther,2010-09-24,"The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are reviewed. Azacitidine is the first drug FDA-approved for the treatment of myelodysplastic syndromes that has demonstrated improvements in overall survival and delaying time to progression to acute myelogenous leukemia. The recommended dosage of azacitidine is 75 mg/m(2) daily for 7 days, with different treatment schedules validated. It appears to be well tolerated, with the most common adverse effects being myelosuppression. Several other off-label recommendations were also analyzed. Azacitidine is the first DNA hypomethylating agent approved by FDA for the treatment of myelodysplastic syndromes with demonstrated efficacy.",Journal Article,3406.0,20.0,clinical efficacy different dosages treatment schedules safety azacitidine reviewed Azacitidine drug FDA-approved treatment myelodysplastic syndromes demonstrated improvements overall survival delaying time progression acute myelogenous leukemia recommended dosage azacitidine 75 mg/m 2 daily 7 days different treatment schedules validated appears tolerated common adverse effects myelosuppression off-label recommendations Azacitidine DNA hypomethylating agent approved FDA treatment myelodysplastic syndromes demonstrated efficacy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 38, 209, 338, 7352, 24, 2314, 2, 367, 1, 3752, 32, 446, 3752, 16, 3, 157, 234, 2078, 850, 9, 3, 24, 1, 2040, 17, 71, 264, 1474, 4, 63, 25, 2, 7151, 98, 6, 91, 6, 286, 2194, 3, 793, 3323, 1, 3752, 16, 481, 81, 188, 18, 391, 9, 67, 162, 5, 338, 24, 2314, 938, 192, 1233, 6, 40, 149, 421, 5, 3, 96, 186, 290, 176, 486, 2858, 392, 127, 1889, 1756, 883, 11, 120, 311, 3752, 16, 3, 157, 261, 4931, 420, 850, 20, 2078, 9, 3, 24, 1, 2040, 5, 264, 209]",670.0,20957213,Safety efficacy azacitidine myelodysplastic syndromes,2,0.0034904013961605585
"A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.",Cancer,Cancer,2010-10-19,"The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome. Induction consisted of idarubicin 12 mg/m(2) a day on days 1-3, cytarabine 1.5 g/m(2) intravenously continuously daily on days 1-4 (days 1-3 if age 60 years), and tipifarnib, with the first cohort (n = 6) receiving 200 mg orally twice a day and all others receiving 300 mg twice a day for 21 days every 28 days. Consolidation consisted of 5 courses of idarubicin 8 mg/m(2) a day on days 1-2, cytarabine 0.75 g/m(2) a day on days 1-3, and tipifarnib 300 mg twice a day for 14 days every 4-6 weeks. Maintenance with tipifarnib 300 mg twice a day for 21 days every 4-6 weeks was continued for 6 months. With a median follow-up of 33 months, 61 patients achieved complete remission (CR) (64%), and 9 achieved complete remission with incomplete platelet recovery (CRp) (9%). The median duration of CR was not reached. Median overall survival was 17 months. The most common grade 3 adverse events were gastrointestinal toxicities, liver dysfunction, and skin rash. Compared with historical IA, IA and tipifarnib showed a better CR duration (P = .04) and a trend toward a higher CR rate in patients with chromosome 5/7 abnormalities. The combination of IA and tipifarnib is safe and active. Further studies exploring different dosages and schedules are warranted, particularly in patients with poor-risk AML.","Clinical Trial, Phase I",3381.0,28.0,authors conducted phase 1/2 tipifarnib combination idarubicin cytarabine IA 95 patients previously untreated acute myeloid leukemia AML high-risk myelodysplastic syndrome Induction consisted idarubicin 12 mg/m 2 day days 1-3 cytarabine 1.5 g/m 2 intravenously continuously daily days 1-4 days 1-3 age 60 years tipifarnib cohort n 6 receiving 200 mg orally twice day receiving 300 mg twice day 21 days 28 days Consolidation consisted 5 courses idarubicin 8 mg/m 2 day days 1-2 cytarabine 0.75 g/m 2 day days 1-3 tipifarnib 300 mg twice day 14 days 4-6 weeks Maintenance tipifarnib 300 mg twice day 21 days 4-6 weeks continued 6 months median follow-up 33 months 61 patients achieved complete remission CR 64 9 achieved complete remission incomplete platelet recovery CRp 9 median duration CR reached Median overall survival 17 months common grade 3 adverse events gastrointestinal toxicities liver dysfunction skin rash Compared historical IA IA tipifarnib showed better CR duration P .04 trend higher CR rate patients chromosome 5/7 abnormalities combination IA tipifarnib safe active studies exploring different dosages schedules warranted particularly patients poor-risk AML,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[3, 738, 426, 8, 124, 14, 18, 45, 1, 4781, 4, 150, 5, 5684, 2, 1855, 3302, 4, 48, 7, 5, 373, 1278, 286, 533, 329, 15, 64, 43, 681, 504, 1695, 1, 5684, 133, 81, 188, 18, 8, 218, 23, 162, 14, 27, 1855, 14, 33, 499, 188, 18, 1672, 4285, 391, 23, 162, 14, 39, 162, 14, 27, 492, 89, 6690, 60, 2, 4781, 5, 3, 157, 180, 78, 49, 357, 1250, 81, 1428, 936, 8, 218, 2, 62, 1749, 357, 2036, 81, 936, 8, 218, 9, 239, 162, 454, 339, 162, 2173, 1695, 1, 33, 1993, 1, 5684, 66, 81, 188, 18, 8, 218, 23, 162, 14, 18, 1855, 13, 481, 499, 188, 18, 8, 218, 23, 162, 14, 27, 2, 4781, 2036, 81, 936, 8, 218, 9, 213, 162, 454, 39, 49, 244, 1146, 5, 4781, 2036, 81, 936, 8, 218, 9, 239, 162, 454, 39, 49, 244, 10, 1351, 9, 49, 53, 5, 8, 52, 166, 126, 1, 466, 53, 713, 7, 513, 236, 734, 684, 660, 2, 83, 513, 236, 734, 5, 2610, 1596, 1602, 3162, 83, 3, 52, 654, 1, 684, 10, 44, 1300, 52, 63, 25, 10, 269, 53, 3, 96, 186, 88, 27, 290, 281, 11, 385, 1527, 2, 1641, 72, 5, 2252, 3302, 3302, 2, 4781, 224, 8, 380, 684, 654, 19, 755, 2, 8, 853, 1317, 8, 142, 684, 116, 4, 7, 5, 1170, 33, 67, 1171, 3, 150, 1, 3302, 2, 4781, 16, 1165, 2, 544, 195, 94, 4378, 338, 7352, 2, 2314, 32, 1197, 823, 4, 7, 5, 334, 43, 329]",1413.0,20960519,phase 1-2 farnesyltransferase inhibitor tipifarnib combined idarubicin cytarabine patients newly diagnosed acute myeloid leukemia high-risk myelodysplastic syndrome,6,0.010471204188481676
A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.,Cancer,Cancer,2010-10-19,"Higher-risk myelodysplastic syndromes (MDS) are similar pathobiologically to acute myeloid leukemia (AML), particularly in older adults. AML therapies thus may have activity in MDS. In the current study, phase 2 study data of arsenic trioxide (ATO) and gemtuzumab ozogamicin (GO) in CD33-positive patients with MDS and secondary AML (sAML) were presented. Between June 2004 and February 2006, 30 patients with higher-risk MDS or sAML received ATO (at a dose of 0.25 mg/kg intravenously for 5 days during Week 1, then twice weekly during Weeks 2-12) and GO (at a dose of 3 mg/m(2) on Day 8) for 1 or 2 cycles of 12 weeks each. The primary endpoint was response as per MDS or AML International Working Group (IWG) criteria. Adverse events were collected throughout treatment. Patients were followed for a minimum of 3 years for survival. The median patient age was 69 years. A total of 18 patients had MDS, 12 had sAML, and 19 had been previously treated. Seventeen patients (57%) completed 1 cycle, and 7 patients (23%) completed 2 cycles. IWG responses occurred in 9 patients (30%) according to IWG MDS criteria (including 2 of 7 patients who failed hypomethylating agents) and 3 of 12 AML patients (25%) according to IWG AML criteria. Grade 3/4 (according to National Cancer Institute Common Toxicity Criteria [version 3.0]) thrombocytopenia occurred in 47% of patients, neutropenia in 63%, and anemia in 37% of patients. The median overall survival was 9.7 months (28.6 months in responders and 7.6 months in nonresponders; P <.001). Patients who completed 2 cycles of therapy spent a median of 13 days in the hospital. Combination therapy with ATO and GO was found to have acceptable response rates and toxicity, and may be a viable treatment option to standard induction therapy, particularly for patients who fail therapy with hypomethylating agents.","Clinical Trial, Phase II",3381.0,27.0,Higher-risk myelodysplastic syndromes MDS similar pathobiologically acute myeloid leukemia AML particularly older adults AML therapies activity MDS current phase 2 arsenic trioxide ATO gemtuzumab ozogamicin CD33-positive patients MDS secondary AML sAML presented June 2004 February 2006 30 patients higher-risk MDS sAML received ATO dose 0.25 mg/kg intravenously 5 days Week 1 twice weekly Weeks 2-12 dose 3 mg/m 2 Day 8 1 2 cycles 12 weeks primary endpoint response MDS AML International Working Group IWG criteria Adverse events collected treatment Patients followed minimum 3 years survival median patient age 69 years total 18 patients MDS 12 sAML 19 previously treated Seventeen patients 57 completed 1 cycle 7 patients 23 completed 2 cycles IWG responses occurred 9 patients 30 according IWG MDS criteria including 2 7 patients failed hypomethylating agents 3 12 AML patients 25 according IWG AML criteria Grade 3/4 according National Institute Common Toxicity Criteria version 3.0 thrombocytopenia occurred 47 patients neutropenia 63 anemia 37 patients median overall survival 9.7 months 28.6 months responders 7.6 months nonresponders P .001 Patients completed 2 cycles therapy spent median 13 days hospital Combination therapy ATO acceptable response rates toxicity viable treatment option standard induction therapy particularly patients fail therapy hypomethylating agents,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[142, 43, 2040, 1223, 32, 288, 59462, 6, 286, 533, 329, 823, 4, 434, 857, 329, 235, 631, 68, 47, 128, 4, 1223, 4, 3, 291, 45, 124, 18, 45, 74, 1, 3217, 4574, 4021, 2, 7918, 5566, 3537, 4, 6353, 109, 7, 5, 1223, 2, 568, 329, 8991, 11, 917, 59, 1924, 1131, 2, 3010, 1324, 201, 7, 5, 142, 43, 1223, 15, 8991, 103, 4021, 28, 8, 61, 1, 13, 243, 81, 503, 1672, 9, 33, 162, 190, 647, 14, 818, 936, 709, 190, 244, 18, 133, 2, 3537, 28, 8, 61, 1, 27, 81, 188, 18, 23, 218, 66, 9, 14, 15, 18, 410, 1, 133, 244, 296, 3, 86, 1138, 10, 51, 22, 379, 1223, 15, 329, 944, 2644, 87, 14620, 371, 290, 281, 11, 786, 2432, 24, 7, 11, 370, 9, 8, 2499, 1, 27, 60, 9, 25, 3, 52, 69, 89, 10, 790, 60, 8, 181, 1, 203, 7, 42, 1223, 133, 42, 8991, 2, 326, 42, 85, 373, 73, 3591, 7, 696, 781, 3567, 417, 2, 67, 7, 382, 781, 18, 410, 14620, 253, 489, 4, 83, 7, 201, 768, 6, 14620, 1223, 371, 141, 18, 1, 67, 7, 54, 1551, 4931, 183, 2, 27, 1, 133, 329, 7, 243, 768, 6, 14620, 329, 371, 88, 27, 39, 768, 6, 657, 12, 1377, 186, 155, 371, 2256, 27, 13, 1340, 489, 4, 662, 1, 7, 778, 4, 676, 2, 1545, 4, 567, 1, 7, 3, 52, 63, 25, 10, 83, 67, 53, 339, 49, 53, 4, 1983, 2, 67, 49, 53, 4, 4498, 19, 144, 7, 54, 781, 18, 410, 1, 36, 9509, 8, 52, 1, 233, 162, 4, 3, 702, 150, 36, 5, 4021, 2, 3537, 10, 204, 6, 47, 1595, 51, 151, 2, 155, 2, 68, 40, 8, 2663, 24, 1501, 6, 260, 504, 36, 823, 9, 7, 54, 4373, 36, 5, 4931, 183]",1763.0,20960521,Phase 2 combination therapy arsenic trioxide gemtuzumab ozogamicin patients myelodysplastic syndromes secondary acute myeloid leukemia,26,0.04537521815008726
Very late recurrences of leukemia: why does leukemia awake after many years of dormancy?,Leukemia research,Leuk. Res.,2011-02-01,"We report a heterogeneous group of very late recurrences of leukemia occurring more than 10 years after initial treatment including 2 cases of childhood acute lymphoblastic leukemia (ALL) which recurred after more than 20 years of remission, 2 cases of donor cell leukemia which developed more than 10 years after allograft for acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) and 2 cases of chronic myeloid leukemia (CML) relapsing 13 and 17 years after allograft. Case descriptions are followed by a discussion regarding possible mechanisms leading to leukemia recurrence and a review of the literature.",Case Reports,3276.0,15.0,report heterogeneous group late recurrences leukemia occurring 10 years initial treatment including 2 cases childhood acute lymphoblastic leukemia recurred 20 years remission 2 cases donor leukemia developed 10 years allograft acute myeloid leukemia AML high risk myelodysplastic syndrome MDS 2 cases chronic myeloid leukemia CML relapsing 13 17 years allograft Case descriptions followed discussion possible mechanisms leading leukemia recurrence review literature,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 414, 8, 1564, 87, 1, 923, 807, 1593, 1, 1821, 80, 76, 79, 60, 50, 388, 24, 141, 18, 140, 1, 864, 286, 1275, 62, 92, 3363, 50, 80, 76, 179, 60, 1, 734, 18, 140, 1, 1488, 31, 92, 276, 80, 76, 79, 60, 50, 9568, 9, 286, 533, 329, 2, 64, 43, 681, 1223, 2, 18, 140, 1, 442, 533, 903, 6758, 233, 2, 269, 60, 50, 9568, 473, 11798, 32, 370, 20, 8, 2488, 666, 899, 483, 1049, 6, 146, 2, 8, 206, 1, 3, 789]",549.0,20970853,late recurrences leukemia leukemia awake years dormancy,4,0.006980802792321117
Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-11-01,"Reduced-intensity conditioning (RIC) extends the curative potential of allogeneic hematopoietic cell transplantation (HCT) to patients with hematologic malignancies unable to withstand myeloablative conditioning. We prospectively analyzed the outcomes of 123 patients (median age, 57 years; range, 23-70 years) with hematologic malignancies treated with a uniform RIC regimen of cyclophosphamide, fludarabine, and total-body irradiation (200 cGy) with or without antithymocyte globulin followed by related donor allogeneic HCT at the University of Minnesota between 2002 and 2008. The cohort included 45 patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS), 27 with aggressive non-Hodgkin lymphoma (NHL), 8 with indolent NHL, 10 with Hodgkin lymphoma (HL), 10 with myeloma, and 23 with acute lymphocytic leukemia, chronic myelogenous leukemia, other leukemias, or myeloproliferative disorders. The probability of 4-year overall survival was 73% for patients with indolent NHL, 58% for those with aggressive NHL, 67% for those with HL, 30% for those with AML/MDS, and only 10% for those with myeloma. Corresponding outcomes for relapse in these patients were 0%, 32%, 50%, 33%, and 38%, and those for progression-free survival were 73%, 45%, 27%, 27%, and 10%. The incidence of treatment-related mortality was 14% at day +100 and 22% at 1 year. The incidence of grade II-IV acute graft-versus-host disease was 38% at day +100, and that of chronic graft-versus-host disease was 50% at 2 years. Multivariate analysis revealed superior overall survival and progression-free survival in patients with both indolent and aggressive NHL compared with those with AML/MDS, HL, or myeloma. Worse 1-year treatment-related mortality was observed in patients with a Hematopoietic Cell Transplantation Comorbidity Index score  3 and in cytomegalovirus-seropositive recipients. These results suggest that (1) RIC conditioning was well tolerated by an older, heavily pretreated population; (2) patients with indolent and aggressive NHL respond well to RIC conditioning, highlighting the importance of the graft-versus-lymphoma effect; and (3) additional peri-transplantation manipulations are needed to improve outcomes for patients with AML/MDS or myeloma receiving RIC conditioning before HCT.",Clinical Trial,3368.0,27.0,Reduced-intensity conditioning RIC extends curative potential allogeneic hematopoietic transplantation HCT patients hematologic malignancies unable withstand myeloablative conditioning prospectively outcomes 123 patients median age 57 years range 23-70 years hematologic malignancies treated uniform RIC regimen cyclophosphamide fludarabine total-body irradiation 200 cGy antithymocyte globulin followed related donor allogeneic HCT University Minnesota 2002 2008 cohort included 45 patients acute myelogenous leukemia AML myelodysplastic syndrome MDS 27 aggressive non-Hodgkin lymphoma NHL 8 indolent NHL 10 Hodgkin lymphoma HL 10 myeloma 23 acute lymphocytic leukemia chronic myelogenous leukemia leukemias myeloproliferative disorders probability 4-year overall survival 73 patients indolent NHL 58 aggressive NHL 67 HL 30 AML/MDS 10 myeloma Corresponding outcomes relapse patients 0 32 50 33 38 progression-free survival 73 45 27 27 10 incidence treatment-related mortality 14 day +100 22 1 year incidence grade II-IV acute graft-versus-host disease 38 day +100 chronic graft-versus-host disease 50 2 years Multivariate revealed superior overall survival progression-free survival patients indolent aggressive NHL compared AML/MDS HL myeloma Worse 1-year treatment-related mortality observed patients Hematopoietic Transplantation Comorbidity Index score  3 cytomegalovirus-seropositive recipients suggest 1 RIC conditioning tolerated older heavily pretreated population 2 patients indolent aggressive NHL respond RIC conditioning highlighting importance graft-versus-lymphoma effect 3 additional peri-transplantation manipulations needed improve outcomes patients AML/MDS myeloma receiving RIC conditioning HCT,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[405, 837, 1933, 3365, 8464, 3, 1075, 174, 1, 1063, 1007, 31, 497, 1085, 6, 7, 5, 813, 441, 4253, 6, 21330, 3246, 1933, 21, 1143, 311, 3, 123, 1, 2698, 7, 52, 89, 696, 60, 184, 382, 431, 60, 5, 813, 441, 73, 5, 8, 3490, 3365, 477, 1, 1112, 2027, 2, 181, 642, 1104, 1250, 3071, 5, 15, 187, 11016, 7819, 370, 20, 139, 1488, 1063, 1085, 28, 3, 1652, 1, 8297, 59, 1544, 2, 1375, 3, 180, 159, 512, 7, 5, 286, 2194, 329, 15, 681, 1223, 428, 5, 571, 1176, 66, 5, 2316, 1176, 79, 5, 1718, 79, 5, 2, 382, 5, 286, 1193, 442, 2194, 127, 2792, 15, 1997, 3, 1320, 1, 39, 111, 63, 25, 10, 803, 9, 7, 5, 2316, 1176, 717, 9, 135, 5, 571, 1176, 598, 9, 135, 5, 1718, 201, 9, 135, 5, 329, 1223, 2, 158, 79, 9, 135, 5, 1734, 123, 9, 429, 4, 46, 7, 11, 13, 531, 212, 466, 2, 519, 2, 135, 9, 91, 115, 25, 11, 803, 512, 428, 428, 2, 79, 3, 287, 1, 24, 139, 282, 10, 213, 28, 218, 394, 2, 350, 28, 14, 111, 3, 287, 1, 88, 215, 478, 286, 1599, 185, 1204, 34, 10, 519, 28, 218, 394, 2, 17, 1, 442, 1599, 185, 1204, 34, 10, 212, 28, 18, 60, 331, 65, 553, 1123, 63, 25, 2, 91, 115, 25, 4, 7, 5, 110, 2316, 2, 571, 1176, 72, 5, 135, 5, 329, 1223, 1718, 15, 639, 14, 111, 24, 139, 282, 10, 164, 4, 7, 5, 8, 1007, 31, 497, 1879, 558, 368, 749, 27, 2, 4, 7314, 9909, 2190, 46, 99, 309, 17, 14, 3365, 1933, 10, 149, 421, 20, 35, 434, 2447, 2193, 266, 18, 7, 5, 2316, 2, 571, 1176, 1892, 149, 6, 3365, 1933, 4051, 3, 1187, 1, 3, 1599, 185, 4763, 254, 2, 27, 402, 6164, 497, 13775, 32, 575, 6, 401, 123, 9, 7, 5, 329, 1223, 15, 357, 3365, 1933, 348, 1085]",2091.0,21047561,Reduced-intensity conditioning followed related allografts hematologic malignancies long-term outcomes successful indolent aggressive non-Hodgkin lymphomas,14,0.02443280977312391
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.,BMC medical genetics,BMC Med. Genet.,2010-11-16,"Myelodysplastic syndrome (MDS) may be induced by certain mutagenic environmental or chemotherapeutic toxins; however, the role of susceptibility genes remains unclear. The G/G genotype of the single-nucleotide polymorphism (SNP) rs1617640 in the erythropoietin (EPO) promoter has been shown to be associated with decreased EPO expression. We examined the association of rs1617640 genotype with MDS. We genotyped the EPO rS1617640 SNP in 189 patients with MDS, 257 with acute myeloid leukemia (AML), 106 with acute lymphoblastic leukemia, 97 with chronic lymphocytic leukemia, 353 with chronic myeloid leukemia, and 95 healthy controls. The G/G genotype was significantly more common in MDS patients (47/187; 25.1%) than in controls (6/95; 6.3%) or in patients with other leukemias (101/813; 12.4%) (all P < 0.001). Individuals with the G/G genotype were more likely than those with other genotypes to have MDS (odd ratio = 4.98; 95% CI = 2.04-12.13). Clinical and follow up data were available for 112 MDS patients and 186 AML patients. There was no correlation between EPO promoter genotype and response to therapy or overall survival in MDS or AML. In the MDS group, the GG genotype was significantly associated with shorter complete remission duration, as compared with the TT genotype (P = 0.03). Time to neutrophils recovery after therapy was significantly longer in MDS patients with the G/G genotype (P = 0.02). These findings suggest a strong association between the rs1617640 G/G genotype and MDS. Further studies are warranted to investigate the utility of screening for this marker in individuals exposed to environmental toxins or chemotherapy.",Journal Article,3353.0,17.0,Myelodysplastic syndrome MDS induced certain mutagenic environmental chemotherapeutic toxins role susceptibility remains unclear G/G genotype single-nucleotide polymorphism SNP rs1617640 erythropoietin EPO promoter shown associated decreased EPO expression examined association rs1617640 genotype MDS genotyped EPO rS1617640 SNP 189 patients MDS 257 acute myeloid leukemia AML 106 acute lymphoblastic leukemia 97 chronic lymphocytic leukemia 353 chronic myeloid leukemia 95 healthy controls G/G genotype significantly common MDS patients 47/187 25.1 controls 6/95 6.3 patients leukemias 101/813 12.4 P 0.001 Individuals G/G genotype likely genotypes MDS odd ratio 4.98 95 CI 2.04-12.13 Clinical follow available 112 MDS patients 186 AML patients correlation EPO promoter genotype response therapy overall survival MDS AML MDS group GG genotype significantly associated shorter complete remission duration compared TT genotype P 0.03 Time neutrophils recovery therapy significantly longer MDS patients G/G genotype P 0.02 findings suggest strong association rs1617640 G/G genotype MDS studies warranted investigate utility screening marker individuals exposed environmental toxins chemotherapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[681, 1223, 68, 40, 277, 20, 1840, 14578, 3766, 15, 1573, 13820, 137, 3, 200, 1, 1432, 214, 469, 1200, 3, 499, 499, 1183, 1, 3, 226, 1579, 1907, 1845, 35006, 4, 3, 6266, 5423, 973, 71, 85, 443, 6, 40, 41, 5, 340, 5423, 55, 21, 409, 3, 248, 1, 35006, 1183, 5, 1223, 21, 3053, 3, 5423, 35006, 1845, 4, 5899, 7, 5, 1223, 7941, 5, 286, 533, 329, 3251, 5, 286, 1275, 1015, 5, 442, 1193, 10065, 5, 442, 533, 2, 48, 1331, 535, 3, 499, 499, 1183, 10, 97, 80, 186, 4, 1223, 7, 662, 5568, 243, 14, 76, 4, 535, 49, 48, 49, 27, 15, 4, 7, 5, 127, 2792, 2338, 15980, 133, 39, 62, 19, 13, 144, 869, 5, 3, 499, 499, 1183, 11, 80, 322, 76, 135, 5, 127, 2071, 6, 47, 1223, 12108, 197, 39, 1096, 48, 58, 18, 755, 133, 233, 38, 2, 166, 126, 74, 11, 390, 9, 3726, 1223, 7, 2, 5869, 329, 7, 125, 10, 77, 816, 59, 5423, 973, 1183, 2, 51, 6, 36, 15, 63, 25, 4, 1223, 15, 329, 4, 3, 1223, 87, 3, 4334, 1183, 10, 97, 41, 5, 985, 236, 734, 654, 22, 72, 5, 3, 3504, 1183, 19, 13, 680, 98, 6, 5700, 1602, 50, 36, 10, 97, 589, 4, 1223, 7, 5, 3, 499, 499, 1183, 19, 13, 588, 46, 272, 309, 8, 1082, 248, 59, 3, 35006, 499, 499, 1183, 2, 1223, 195, 94, 32, 1197, 6, 963, 3, 1207, 1, 453, 9, 26, 952, 4, 869, 2234, 6, 3766, 13820, 15, 56]",1543.0,21078205,Significant association polymorphism erythropoietin promoter myelodysplastic syndrome,0,0.0
Clofarabine in leukemia.,Expert review of hematology,Expert Rev Hematol,2010-02-01,"Clofarabine is a second-generation purine nucleoside analogue that has been synthesized to overcome the limitations and incorporate the best qualities of fludarabine and cladribine. Clofarabine acts by inhibiting ribonucleotide reductase and DNA polymerase, thereby depleting the amount of intracellular deoxynucleoside triphosphates available for DNA replication. Compared with its precursors, clofarabine has an increased resistance to deamination and phosphorolysis, hence better stability, as well as higher affinity to deoxycytidine kinase (dCyd), the rate-limiting step in nucleoside phosphorylation. In 1993, the first Phase I study was initiated in patients with hematologic and solid malignancies. Since then, clofarabine has demonstrated single-agent antitumor activity in pediatric and adult acute leukemia. Owing to its unique properties of biochemical modulation when used in combination with other established antileukemic drugs, mainly cytarabine, combination regimens containing clofarabine are being evaluated. A review of the English literature was performed that included original articles and related reviews from the MEDLINE (PubMed) database and from abstracts based on the publication of meeting materials. This article describes the development, pharmacology and clinical activity of clofarabine, as well as its emerging role in the treatment of acute leukemia, myelodysplastic syndrome and solid tumors.",Journal Article,3641.0,23.0,Clofarabine second-generation purine nucleoside analogue synthesized overcome limitations incorporate best qualities fludarabine cladribine Clofarabine acts inhibiting ribonucleotide reductase DNA polymerase depleting intracellular deoxynucleoside triphosphates available DNA replication Compared precursors clofarabine increased resistance deamination phosphorolysis better stability higher affinity deoxycytidine kinase dCyd rate-limiting step nucleoside phosphorylation 1993 Phase initiated patients hematologic solid malignancies clofarabine demonstrated single-agent antitumor activity pediatric adult acute leukemia Owing unique properties biochemical modulation combination established antileukemic drugs mainly cytarabine combination regimens containing clofarabine evaluated review English literature performed included original articles related reviews MEDLINE PubMed database abstracts based publication meeting materials article describes development pharmacology clinical activity clofarabine emerging role treatment acute leukemia myelodysplastic syndrome solid,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4149, 16, 8, 419, 914, 5006, 4032, 4696, 17, 71, 85, 5134, 6, 1768, 3, 1939, 2, 3360, 3, 824, 15353, 1, 2027, 2, 8251, 4149, 4459, 20, 2062, 7050, 4027, 2, 261, 1451, 2267, 9438, 3, 3108, 1, 2087, 30959, 28228, 390, 9, 261, 2079, 72, 5, 211, 4881, 4149, 71, 35, 101, 251, 6, 31701, 2, 46329, 3665, 380, 2769, 22, 149, 22, 142, 3601, 6, 6750, 216, 37878, 3, 116, 817, 2458, 4, 4032, 982, 4, 3343, 3, 157, 124, 70, 45, 10, 1917, 4, 7, 5, 813, 2, 537, 441, 1192, 818, 4149, 71, 264, 226, 420, 579, 128, 4, 815, 2, 780, 286, 3421, 6, 211, 991, 1571, 1, 1487, 2356, 198, 95, 4, 150, 5, 127, 635, 4512, 600, 2615, 1855, 150, 472, 1101, 4149, 32, 486, 194, 8, 206, 1, 3, 4201, 789, 10, 173, 17, 159, 2279, 2384, 2, 139, 2004, 29, 3, 3388, 3161, 609, 2, 29, 5159, 90, 23, 3, 4397, 1, 2238, 5102, 26, 946, 2677, 3, 193, 6852, 2, 38, 128, 1, 4149, 22, 149, 22, 211, 1478, 200, 4, 3, 24, 1, 286, 681, 2, 537, 57]",1370.0,21082931,Clofarabine leukemia,317,0.5532286212914486
Clinical activity of laromustine (Onrigin) in hematologic malignancies.,Expert review of hematology,Expert Rev Hematol,2009-10-01,"Laromustine (Onrigin), formerly known as Cloretazine() (VNP40101M), belongs to a novel class of alkylating agents--the sulfonylhydrazines--and was selected for clinical development based on its broad anti-tumor activity in preclinical models. Laromustine is metabolized to yield 90CE and methylisocyanate, the former rapidly produces an alkylating, chloroethylating species, similar to the chloroethylating species generated by carmustine. However, several features distinguish laromustine from carmustine and possibly account for their biological differences in vitro and in vivo. The chloroethylating species responsible for laromustine's alkylator effect is relatively specific for guanine and forms a crosslink after incorporation into DNA. Laromustine has significant activity in both older patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome, including those with very poor-risk disease, and in patients with relapsed disease. Further clinical studies are required with laromustine to evaluate its place as an anticancer agent in other hematological malignancies.",Journal Article,3764.0,2.0,Laromustine Onrigin known Cloretazine  VNP40101M belongs novel class alkylating agents -- sulfonylhydrazines -- selected clinical development based broad anti-tumor activity preclinical models Laromustine metabolized yield 90CE methylisocyanate rapidly produces alkylating chloroethylating species similar chloroethylating species generated carmustine features distinguish laromustine carmustine possibly account differences vitro vivo chloroethylating species responsible laromustine 's alkylator effect relatively specific guanine forms crosslink incorporation DNA Laromustine significant activity older patients previously untreated acute myeloid leukemia high-risk myelodysplastic syndrome including poor-risk disease patients relapsed disease clinical studies required laromustine evaluate place anticancer agent hematological malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[15013, 59548, 7350, 440, 22, 13948, 6081, 17260, 14815, 6, 8, 229, 1040, 1, 3410, 183, 3, 59549, 2, 10, 715, 9, 38, 193, 90, 23, 211, 2094, 312, 30, 128, 4, 693, 274, 15013, 16, 10523, 6, 2309, 59550, 2, 39475, 3, 3623, 1755, 4042, 35, 3410, 24492, 2915, 288, 6, 3, 24492, 2915, 1419, 20, 5818, 137, 392, 404, 3081, 15013, 29, 5818, 2, 2150, 1967, 9, 136, 1037, 362, 4, 439, 2, 4, 386, 3, 24492, 2915, 2327, 9, 15013, 292, 9346, 254, 16, 1352, 112, 9, 10079, 2, 2377, 8, 35009, 50, 2838, 237, 261, 15013, 71, 93, 128, 4, 110, 434, 7, 5, 373, 1278, 286, 533, 15, 64, 43, 681, 141, 135, 5, 923, 334, 43, 34, 2, 4, 7, 5, 591, 34, 195, 38, 94, 32, 616, 5, 15013, 6, 376, 211, 3536, 22, 35, 1475, 420, 4, 127, 2890, 441]",1076.0,21083013,Clinical activity laromustine Onrigin hematologic malignancies,358,0.62478184991274
Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-12-27,"As success of reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) relies primarily on graft-versus-leukemia (GVL) activity, increased minor HLA disparity in unrelated compared to related donors could have a significant impact on transplant outcomes. To assess whether use of unrelated donors (URD) engenders more potent GVL in RIC HSCT compared to matched related donors (MRD), we retrospectively studied 433 consecutive T-replete 6/6 HLA matched URD (n = 246) and MRD (n = 187) RIC HSCT for hematologic malignancies at our institution. Diseases included: acute myelogenous leukemia (AML) (127), non-Hodgkin lymphoma (NHL) (71), chronic lymphocytic leukemia (CLL) (68), myelodysplastic syndrome (MDS) (64), Hodgkin disease (HD) (40), chronic myeloid leukemia (CML) (25), multiple myeloma (MM) (23), myeloproliferative disorder (MPD) (12), acute lymphoblastic leukemia (ALL) (7), and other leukemia (1). All received uniform fludarabine and intravenous busulfan conditioning, and GVHD prophylaxis with tacrolimus/mini-methroxate (mini-MTX) or tacrolimus/sirolimus  mini-MTX. Unrelated donors were younger compared to MRD (median donor age: 33 years versus 52 years, P < .0001), and provided larger CD34(+) products (median CD34(+) cells infused: 8.7  10(6)/kg versus 7.5  10(6)/kg, P = .002). Distribution of diseases, disease risk, prior transplant, and cytomegalovirus (CMV) status was similar in both cohorts. Cumulative incidence of grade II-IV acute GVHD (at day +180), 2-year chronic GVHD, and 2-year nonrelapse mortality (NRM) were 20% versus 16%, 55% versus 50%, and 8% versus 6% in URD and MRD, respectively (P= NS). Cumulative incidence of relapse at 2 years was lower in URD, 52% versus 65% (P = .005). With median follow-up of 26.5 and 35.8 months, 2-year progression-free survival (PFS) was significantly better in unrelated donor transplants, 39.5% for URD, and 29% for MRD (P = .01). Overall survival (OS) at 2years were 56% for URD versus 50% for MRD (P = .53). In multivariable analysis, URD was associated with a lower risk of relapse (hazard ratio [HR] 0.67, P = .002) and superior PFS (HR 0.69, P = .002). These results suggest that URD is associated with greater GVL activity than MRD, and could have practice changing impact on future donor selection in RIC HSCT.",Comparative Study,3312.0,45.0,success reduced-intensity conditioning RIC hematopoietic stem transplantation HSCT relies primarily graft-versus-leukemia GVL activity increased minor HLA disparity unrelated compared related donors significant impact transplant outcomes assess use unrelated donors URD engenders potent GVL RIC HSCT compared matched related donors MRD retrospectively studied 433 consecutive T-replete 6/6 HLA matched URD n 246 MRD n 187 RIC HSCT hematologic malignancies institution Diseases included acute myelogenous leukemia AML 127 non-Hodgkin lymphoma NHL 71 chronic lymphocytic leukemia CLL 68 myelodysplastic syndrome MDS 64 Hodgkin disease HD 40 chronic myeloid leukemia CML 25 multiple myeloma MM 23 myeloproliferative disorder MPD 12 acute lymphoblastic leukemia 7 leukemia 1 received uniform fludarabine intravenous busulfan conditioning GVHD prophylaxis tacrolimus/mini-methroxate mini-MTX tacrolimus/sirolimus  mini-MTX Unrelated donors younger compared MRD median donor age 33 years versus 52 years P .0001 provided larger CD34 products median CD34 infused 8.7 10 6 /kg versus 7.5 10 6 /kg P .002 Distribution diseases disease risk prior transplant cytomegalovirus CMV status similar cohorts Cumulative incidence grade II-IV acute GVHD day +180 2-year chronic GVHD 2-year nonrelapse mortality NRM 20 versus 16 55 versus 50 8 versus 6 URD MRD respectively P NS Cumulative incidence relapse 2 years lower URD 52 versus 65 P .005 median follow-up 26.5 35.8 months 2-year progression-free survival PFS significantly better unrelated donor transplants 39.5 URD 29 MRD P .01 Overall survival OS 2 years 56 URD versus 50 MRD P .53 multivariable URD associated lower risk relapse hazard ratio HR 0.67 P .002 superior PFS HR 0.69 P .002 suggest URD associated greater GVL activity MRD practice changing impact future donor selection RIC HSCT,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[22, 1825, 1, 405, 837, 1933, 3365, 1007, 452, 31, 497, 1703, 6495, 1561, 23, 1599, 185, 2647, 8149, 128, 101, 2278, 1160, 4326, 4, 2092, 72, 6, 139, 2344, 359, 47, 8, 93, 345, 23, 941, 123, 6, 423, 317, 119, 1, 2092, 2344, 5847, 39508, 80, 1157, 8149, 4, 3365, 1703, 72, 6, 655, 139, 2344, 2029, 21, 894, 656, 13224, 935, 102, 11151, 49, 49, 1160, 655, 5847, 78, 6907, 2, 2029, 78, 5568, 3365, 1703, 9, 813, 441, 28, 114, 731, 1342, 159, 286, 2194, 329, 4080, 1176, 792, 442, 1193, 552, 806, 681, 1223, 660, 34, 2701, 327, 442, 533, 903, 243, 232, 321, 382, 2645, 7712, 133, 286, 1275, 62, 67, 2, 127, 14, 62, 103, 3490, 2027, 2, 1262, 3906, 1933, 2, 1562, 2049, 5, 5643, 7313, 59688, 7313, 3453, 15, 5643, 4519, 810, 7313, 3453, 2092, 2344, 11, 773, 72, 6, 2029, 52, 1488, 89, 466, 60, 185, 653, 60, 19, 488, 2, 1052, 1077, 2215, 2766, 52, 2215, 37, 4524, 66, 67, 79, 49, 503, 185, 67, 33, 79, 49, 503, 19, 1111, 1395, 1, 1342, 34, 43, 324, 941, 2, 7314, 3879, 156, 10, 288, 4, 110, 736, 967, 287, 1, 88, 215, 478, 286, 1562, 28, 218, 3172, 18, 111, 442, 1562, 2, 18, 111, 4640, 282, 4296, 11, 179, 185, 245, 614, 185, 212, 2, 66, 185, 49, 4, 5847, 2, 2029, 106, 19, 4044, 967, 287, 1, 429, 28, 18, 60, 10, 280, 4, 5847, 653, 185, 556, 19, 1614, 5, 52, 166, 126, 1, 432, 33, 2, 465, 66, 53, 18, 111, 91, 115, 25, 300, 10, 97, 380, 4, 2092, 1488, 4016, 587, 33, 9, 5847, 2, 462, 9, 2029, 19, 355, 63, 25, 118, 28, 18, 60, 11, 664, 9, 5847, 185, 212, 9, 2029, 19, 699, 4, 658, 65, 5847, 10, 41, 5, 8, 280, 43, 1, 429, 360, 197, 168, 13, 598, 19, 1111, 2, 1123, 300, 168, 13, 790, 19, 1111, 46, 99, 309, 17, 5847, 16, 41, 5, 378, 8149, 128, 76, 2029, 2, 359, 47, 758, 3600, 345, 23, 508, 1488, 881, 4, 3365, 1703]",2034.0,21193054,Use matched unrelated donors compared matched related donors associated lower relapse superior progression-free survival reduced-intensity conditioning hematopoietic stem transplantation,10,0.017452006980802792
Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignancies.,Blood,Blood,2011-02-01,"Single nucleotide polymorphism arrays (SNP-As) have emerged as an important tool in the identification of chromosomal defects undetected by metaphase cytogenetics (MC) in hematologic cancers, offering superior resolution of unbalanced chromosomal defects and acquired copy-neutral loss of heterozygosity. Myelodysplastic syndromes (MDSs) and related cancers share recurrent chromosomal defects and molecular lesions that predict outcomes. We hypothesized that combining SNP-A and MC could improve diagnosis/prognosis and further the molecular characterization of myeloid malignancies. We analyzed MC/SNP-A results from 430 patients (MDS = 250, MDS/myeloproliferative overlap neoplasm = 95, acute myeloid leukemia from MDS = 85). The frequency and clinical significance of genomic aberrations was compared between MC and MC plus SNP-A. Combined MC/SNP-A karyotyping lead to higher diagnostic yield of chromosomal defects (74% vs 44%, P < .0001), compared with MC alone, often through detection of novel lesions in patients with normal/noninformative (54%) and abnormal (62%) MC results. Newly detected SNP-A defects contributed to poorer prognosis for patients stratified by current morphologic and clinical risk schemes. The presence and number of new SNP-A detected lesions are independent predictors of overall and event-free survival. The significant diagnostic and prognostic contributions of SNP-A-detected defects in MDS and related diseases underscore the utility of SNP-A when combined with MC in hematologic malignancies.",Journal Article,3276.0,152.0,Single nucleotide polymorphism arrays SNP-As emerged important tool identification chromosomal defects undetected metaphase cytogenetics MC hematologic offering superior resolution unbalanced chromosomal defects acquired copy-neutral loss heterozygosity Myelodysplastic syndromes MDSs related share recurrent chromosomal defects molecular lesions predict outcomes hypothesized combining SNP-A MC improve diagnosis/prognosis molecular characterization myeloid malignancies MC/SNP-A 430 patients MDS 250 MDS/myeloproliferative overlap neoplasm 95 acute myeloid leukemia MDS 85 frequency clinical significance genomic aberrations compared MC MC plus SNP-A Combined MC/SNP-A karyotyping lead higher diagnostic yield chromosomal defects 74 vs 44 P .0001 compared MC detection novel lesions patients normal/noninformative 54 abnormal 62 MC Newly detected SNP-A defects contributed poorer prognosis patients stratified current morphologic clinical risk schemes presence number new SNP-A detected lesions independent predictors overall event-free survival significant diagnostic prognostic contributions SNP-A-detected defects MDS related diseases underscore utility SNP-A combined MC hematologic malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[226, 1579, 1907, 3923, 1845, 22, 47, 2054, 22, 35, 305, 1515, 4, 3, 911, 1, 1860, 2945, 11449, 20, 10569, 2510, 4779, 4, 813, 163, 5846, 1123, 2125, 1, 11947, 1860, 2945, 2, 1294, 1337, 6338, 407, 1, 3963, 2040, 13550, 2, 139, 163, 4349, 387, 1860, 2945, 2, 219, 406, 17, 678, 123, 21, 1237, 17, 1525, 1845, 8, 2, 4779, 359, 401, 147, 356, 2, 195, 3, 219, 2136, 1, 533, 441, 21, 311, 4779, 1845, 8, 99, 29, 10083, 7, 1223, 2039, 1223, 10857, 4526, 2131, 48, 286, 533, 29, 1223, 772, 3, 675, 2, 38, 724, 1, 572, 2152, 10, 72, 59, 4779, 2, 4779, 349, 1845, 8, 397, 4779, 1845, 8, 10406, 1122, 6, 142, 752, 2309, 1, 1860, 2945, 794, 105, 584, 19, 488, 72, 5, 4779, 279, 629, 298, 638, 1, 229, 406, 4, 7, 5, 295, 26057, 667, 2, 1668, 744, 4779, 99, 732, 530, 1845, 8, 2945, 3447, 6, 1769, 356, 9, 7, 1173, 20, 291, 2815, 2, 38, 43, 7103, 3, 463, 2, 207, 1, 217, 1845, 8, 530, 406, 32, 306, 674, 1, 63, 2, 774, 115, 25, 3, 93, 752, 2, 177, 5621, 1, 1845, 8, 530, 2945, 4, 1223, 2, 139, 1342, 5531, 3, 1207, 1, 1845, 8, 198, 397, 5, 4779, 4, 813, 441]",1464.0,21285439,Prognostic impact SNP array karyotyping myelodysplastic syndromes related myeloid malignancies,27,0.04712041884816754
Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes.,British journal of haematology,Br. J. Haematol.,2011-02-21,"The myelodysplastic syndromes (MDS) display both haematological and biological heterogeneity with variable leukaemia potential. MicroRNAs play an important role in tumour suppression and the regulation of self-renewal and differentiation of haematopoietic progenitors. Using a microarray platform, we evaluated microRNA expression from 44 patients with MDS and 17 normal controls. We identified a thirteen microRNA signature with statistically significant differential expression between normal and MDS specimens (P < 001), including down-regulation of members of the leukaemia-associated MIRLET7 family. A unique signature consisting of 10 microRNAs was closely associated with International Prognostic Scoring System (IPSS) risk category permitting discrimination between lower (Low/Intermediate-1) and higher risk (Intermediate-2/High) disease (P < 001). Selective overexpression of MIR181 family members was detected in higher risk MDS, indicating pathogenetic overlap with acute myeloid leukaemia. Survival analysis of an independent cohort of 22 IPSS lower risk MDS patients revealed a median survival of 35 years in patients with high expression of MIR181 family compared to 93 years in patients with low MIR181 expression (P = 0002). Our pilot study suggested that analysis of microRNA expression profile offers diagnostic utility, and provide pathogenetic and prognostic discrimination in MDS.",Journal Article,3256.0,50.0,myelodysplastic syndromes MDS display haematological heterogeneity variable leukaemia potential MicroRNAs play important role tumour suppression regulation self-renewal differentiation haematopoietic progenitors microarray platform evaluated microRNA expression 44 patients MDS 17 normal controls identified thirteen microRNA signature statistically significant differential expression normal MDS specimens P 001 including down-regulation members leukaemia-associated MIRLET7 family unique signature consisting 10 microRNAs closely associated International Prognostic Scoring IPSS risk category permitting discrimination lower Low/Intermediate-1 higher risk Intermediate-2/High disease P 001 Selective overexpression MIR181 family members detected higher risk MDS indicating pathogenetic overlap acute myeloid leukaemia Survival independent cohort 22 IPSS lower risk MDS patients revealed median survival 35 years patients high expression MIR181 family compared 93 years patients low MIR181 expression P 0002 pilot suggested microRNA expression profile offers diagnostic utility provide pathogenetic prognostic discrimination MDS,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2040, 1223, 3640, 110, 5143, 2, 1037, 1144, 5, 1347, 2001, 174, 3515, 1343, 35, 305, 200, 4, 770, 1332, 2, 3, 863, 1, 1074, 4495, 2, 910, 1, 7274, 4321, 75, 8, 1727, 2243, 21, 194, 3213, 55, 29, 584, 7, 5, 1223, 2, 269, 295, 535, 21, 108, 8, 3170, 3213, 1651, 5, 712, 93, 1777, 55, 59, 295, 2, 1223, 623, 19, 14670, 141, 1328, 863, 1, 1684, 1, 3, 2001, 41, 59855, 607, 8, 991, 1651, 2273, 1, 79, 3515, 10, 3210, 41, 5, 944, 177, 2504, 398, 8751, 43, 2169, 9621, 3520, 59, 280, 154, 919, 14, 2, 142, 43, 919, 18, 64, 34, 19, 14670, 1094, 851, 1, 25275, 607, 1684, 10, 530, 4, 142, 43, 1223, 1716, 10781, 4526, 5, 286, 533, 2001, 25, 65, 1, 35, 306, 180, 1, 350, 8751, 280, 43, 1223, 7, 553, 8, 52, 25, 1, 19259, 60, 4, 7, 5, 64, 55, 1, 25275, 607, 72, 6, 19934, 60, 4, 7, 5, 154, 25275, 55, 19, 22657, 114, 2281, 45, 1148, 17, 65, 1, 3213, 55, 800, 2339, 752, 1207, 2, 377, 10781, 2, 177, 3520, 4, 1223]",1359.0,21332710,Identification risk dependent microRNA expression signature myelodysplastic syndromes,0,0.0
Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.,Leukemia & lymphoma,Leuk. Lymphoma,2011-02-21,"Thalidomide possesses potent anti-inflammatory, immunomodulatory, and antiangiogenic properties. Thalidomide combined with corticosteroids is therapeutically active in multiple myeloma and myelofibrosis (MF). Lenalidomide and pomalidomide are second-generation immunomodulatory drugs (IMiDs) that were created by chemical modification of thalidomide with the intent to reduce toxicity and enhance therapeutic activity. Both drugs have also been shown to be active in the treatment of myeloma and MF. Thalidomide is US Food and Drug Administration (FDA)-approved for use in acute erythema nodosum leprosum and, in combination with dexamethasone, in newly diagnosed myeloma. Lenalidomide is approved for use in low/intermediate-1 risk myelodysplastic syndromes associated with transfusion-dependent anemia and a deletion 5q cytogenetic abnormality and, in combination with dexamethasone, in relapsed myeloma. Pomalidomide is currently not FDA-approved. Herein, we summarize what is currently known about the biologic and therapeutic effects of pomalidomide.",Journal Article,3256.0,13.0,Thalidomide possesses potent anti-inflammatory immunomodulatory antiangiogenic properties Thalidomide combined corticosteroids therapeutically active multiple myeloma myelofibrosis MF Lenalidomide pomalidomide second-generation immunomodulatory drugs IMiDs created chemical modification thalidomide intent reduce toxicity enhance therapeutic activity drugs shown active treatment myeloma MF Thalidomide Food Drug Administration FDA -approved use acute erythema nodosum leprosum combination dexamethasone newly diagnosed myeloma Lenalidomide approved use low/intermediate-1 risk myelodysplastic syndromes associated transfusion-dependent anemia deletion 5q cytogenetic abnormality combination dexamethasone relapsed myeloma Pomalidomide currently FDA-approved summarize currently known biologic therapeutic effects pomalidomide,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2159, 9857, 1157, 312, 1291, 2555, 2, 2168, 1571, 2159, 397, 5, 3876, 16, 4602, 544, 4, 232, 2, 4637, 2966, 1288, 2, 5385, 32, 419, 914, 2555, 600, 7587, 17, 11, 2466, 20, 3743, 2437, 1, 2159, 5, 3, 1697, 6, 969, 155, 2, 1304, 189, 128, 110, 600, 47, 120, 85, 443, 6, 40, 544, 4, 3, 24, 1, 2, 2966, 2159, 16, 843, 1773, 2, 234, 634, 2078, 850, 9, 119, 4, 286, 9167, 30386, 33403, 2, 4, 150, 5, 1217, 4, 732, 265, 1288, 16, 850, 9, 119, 4, 154, 919, 14, 43, 2040, 41, 5, 2785, 470, 1545, 2, 8, 1528, 5460, 1266, 3698, 2, 4, 150, 5, 1217, 4, 591, 5385, 16, 694, 44, 2078, 850, 1986, 21, 2479, 2067, 16, 694, 440, 545, 3, 1283, 2, 189, 176, 1, 5385]",987.0,21338284,Pomalidomide therapy multiple myeloma myelofibrosis update,1,0.0017452006980802793
Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2011-02-18,"The optimal pretransplant regimen for acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in patients  55 years of age remains to be determined. The myeloablative reduced-toxicity 4-day regimen i.v. busulfan (Bu) (130 mg/m(2)) and i.v. fludarabine (Flu) (40 mg/m(2)) is associated with low morbidity and mortality. We analyzed 79 patients  55 years of age (median, 58 years) with AML (n = 63) or MDS (n = 16) treated with i.v. Bu-Flu conditioning regimens between 2001 and 2009 (median follow-up, 24 months). The patients who received this regimen had a good performance status. The 2-year overall survival (OS) rates for patients in first complete remission (CR1), second CR (CR2), or refractory disease and for all patients at time of transplantation were 71%, 44%, 32%, and 46%, respectively; 2-year event-free survival (EFS) rates for patients in CR1, CR2, or refractory disease at time of transplantation and for all patients were 68%, 42%, 30%, and 44%, respectively. One-year transplant-related mortality (TRM) rates for patients who were in CR or who had active disease at the time of transplantation were 19% and 20%, respectively. Grade II-IV acute graft-versus-host (aGVHD) disease was diagnosed in 40% of the patients. Our results suggest that age alone should not be the primary reason for exclusion from receiving myeloablative reduced-toxicity conditioning with i.v. Bu-Flu preceding transplantation in patients with AML/MDS.",Clinical Trial,3259.0,75.0,optimal pretransplant regimen acute myeloid leukemia AML myelodysplastic syndrome MDS patients  55 years age remains determined myeloablative reduced-toxicity 4-day regimen i.v busulfan Bu 130 mg/m 2 i.v fludarabine Flu 40 mg/m 2 associated low morbidity mortality 79 patients  55 years age median 58 years AML n 63 MDS n 16 treated i.v Bu-Flu conditioning regimens 2001 2009 median follow-up 24 months patients received regimen good performance status 2-year overall survival OS rates patients complete remission CR1 second CR CR2 refractory disease patients time transplantation 71 44 32 46 respectively 2-year event-free survival EFS rates patients CR1 CR2 refractory disease time transplantation patients 68 42 30 44 respectively One-year transplant-related mortality TRM rates patients CR active disease time transplantation 19 20 respectively Grade II-IV acute graft-versus-host aGVHD disease diagnosed 40 patients suggest age primary reason exclusion receiving myeloablative reduced-toxicity conditioning i.v Bu-Flu preceding transplantation patients AML/MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 665, 7763, 477, 9, 286, 533, 329, 15, 681, 1223, 4, 7, 749, 614, 60, 1, 89, 469, 6, 40, 509, 3, 3246, 405, 155, 39, 218, 477, 70, 603, 3906, 3667, 3431, 81, 188, 18, 2, 70, 603, 2027, 5119, 327, 81, 188, 18, 16, 41, 5, 154, 787, 2, 282, 21, 311, 842, 7, 749, 614, 60, 1, 89, 52, 717, 60, 5, 329, 78, 676, 15, 1223, 78, 245, 73, 5, 70, 603, 3667, 5119, 1933, 472, 59, 1758, 2, 1238, 52, 166, 126, 259, 53, 3, 7, 54, 103, 26, 477, 42, 8, 1178, 528, 156, 3, 18, 111, 63, 25, 118, 151, 9, 7, 4, 157, 236, 734, 4516, 419, 684, 7865, 15, 430, 34, 2, 9, 62, 7, 28, 98, 1, 497, 11, 792, 584, 531, 2, 641, 106, 18, 111, 774, 115, 25, 1683, 151, 9, 7, 4, 4516, 7865, 15, 430, 34, 28, 98, 1, 497, 2, 9, 62, 7, 11, 806, 595, 201, 2, 584, 106, 104, 111, 941, 139, 282, 5064, 151, 9, 7, 54, 11, 4, 684, 15, 54, 42, 544, 34, 28, 3, 98, 1, 497, 11, 326, 2, 179, 106, 88, 215, 478, 286, 1599, 185, 1204, 5873, 34, 10, 265, 4, 327, 1, 3, 7, 114, 99, 309, 17, 89, 279, 257, 44, 40, 3, 86, 3852, 9, 4721, 29, 357, 3246, 405, 155, 1933, 5, 70, 603, 3667, 5119, 5892, 497, 4, 7, 5, 329, 1223]",1351.0,21338705,Myeloablative reduced-toxicity i.v busulfan-fludarabine allogeneic hematopoietic stem transplant patients acute myeloid leukemia myelodysplastic syndrome sixth eighth decades life,11,0.019197207678883072
Hypomethylating agents for urologic cancers.,"Future oncology (London, England)",Future Oncol,2011-03-01,"Silencing of tumor suppressor genes by promoter-region methylation as an epigenetic mechanism of gene regulation is increasingly recognized as beneficial in cancer. Initially developed as cytotoxic high-dose therapies, azacitidine and decitabine are now being reinvestigated in lower-dose cancer treatment regimens with a different paradigm - hypomethylation. Recent evidence for benefit in myelodysplastic syndromes and acute myeloid leukemias has renewed interest in hypomethylation as a therapeutic option in epithelial cancers. In this article, we describe the mechanistic aspects of DNA methylation, which alters gene expression, and review the evidence for hypomethylation as a therapeutic option in urologic cancers. Potential correlative studies that may assist in developing tailored therapy with hypomethylating agents are reviewed. Given that the population with urologic cancers is typically elderly with multiple comorbidities, the excellent tolerability of lower-dose hypomethylating agents provides a high therapeutic index and rational development is warranted, bearing in mind that the cytostatic and delayed activity present challenges in the choice of appropriate trial end points.",Journal Article,3248.0,3.0,Silencing suppressor promoter-region methylation epigenetic mechanism regulation increasingly recognized beneficial Initially developed cytotoxic high-dose therapies azacitidine decitabine reinvestigated lower-dose treatment regimens different paradigm hypomethylation Recent evidence benefit myelodysplastic syndromes acute myeloid leukemias renewed hypomethylation therapeutic option epithelial article mechanistic aspects DNA methylation alters expression review evidence hypomethylation therapeutic option urologic Potential correlative studies assist developing tailored therapy hypomethylating agents reviewed Given population urologic typically elderly multiple comorbidities excellent tolerability lower-dose hypomethylating agents provides high therapeutic index rational development warranted bearing mind cytostatic delayed activity present challenges choice appropriate trial end points,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2077, 1, 30, 1245, 214, 20, 973, 1053, 569, 22, 35, 1418, 670, 1, 145, 863, 16, 1635, 1904, 22, 2524, 4, 12, 1625, 276, 22, 759, 64, 61, 235, 3752, 2, 3004, 32, 1134, 486, 45274, 4, 280, 61, 12, 24, 472, 5, 8, 338, 2431, 4441, 435, 241, 9, 247, 4, 2040, 2, 286, 533, 2792, 71, 8126, 1333, 4, 4441, 22, 8, 189, 1501, 4, 701, 163, 4, 26, 946, 21, 897, 3, 2716, 2695, 1, 261, 569, 92, 6745, 145, 55, 2, 206, 3, 241, 9, 4441, 22, 8, 189, 1501, 4, 7178, 163, 174, 3679, 94, 17, 68, 3425, 4, 931, 3632, 36, 5, 4931, 183, 32, 446, 447, 17, 3, 266, 5, 7178, 163, 16, 1969, 1216, 5, 232, 1909, 3, 1503, 1543, 1, 280, 61, 4931, 183, 777, 8, 64, 189, 558, 2, 2696, 193, 16, 1197, 1894, 4, 8090, 17, 3, 8154, 2, 1612, 128, 364, 1427, 4, 3, 1866, 1, 870, 160, 396, 862]",1170.0,21417907,Hypomethylating agents urologic,1,0.0017452006980802793
Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome.,Cancer,Cancer,2010-11-08,"Secondary acute myeloid leukemia (AML) from an antecedent myelodysplastic syndrome (MDS)/myeloproliferative neoplasm is associated with a poor prognosis. The authors evaluated predictive factors in patients with secondary AML treated with anthracycline-based induction therapy. This was a retrospective review of secondary AML patients treated with induction therapy. Age, International Prognostic Scoring System, Eastern Cooperative Oncology Group performance status, cytogenetics, duration of MDS/myeloproliferative neoplasm, and prior MDS/myeloproliferative neoplasm treatment were evaluated for their impact on complete response (CR), CR with low platelets, and overall survival (OS). The authors evaluated 61 secondary AML patients who received induction chemotherapy; 59% (36 patients) achieved CR/CR with low platelets (95% confidence interval [CI], 46%-71%), and median OS was 6.5 (95% CI, 3.9-8.1) months. Three factors were associated with lower CR/CR with low platelets and OS: poor risk cytogenetics, prior treatment with hypomethylating agents or lenalidomide, and longer time to transformation to AML. Of those treated with hypomethylating agents or lenalidomide, 32% achieved CR/CR with low platelets versus 78% in the group not treated with a hypomethylating agent or lenalidomide (odds ratio [OR], 0.13; 95% CI, 0.04-0.42). Median OS for those treated with a hypomethylating agent or lenalidomide was 3.7 versus 10.5 months for those not treated with a hypomethylating agent or lenalidomide (P < .0001). The CR/CR with low platelets rate for those with intermediate risk cytogenetics was 70% versus 35% for those with poor risk (OR, 4.33; 95% CI, 1.38-13.6). Those with poor risk cytogenetics had a median OS of 2.8 versus 7.5 months for those with intermediate risk (P = .01). Prior treatment with hypomethylating agents or lenalidomide, poor risk cytogenetics, and longer time to transformation to AML are independent negative predictive factors for response and OS in patients with secondary AML after induction therapy.",Journal Article,3361.0,50.0,Secondary acute myeloid leukemia AML antecedent myelodysplastic syndrome MDS /myeloproliferative neoplasm associated poor prognosis authors evaluated predictive factors patients secondary AML treated anthracycline-based induction therapy retrospective review secondary AML patients treated induction therapy Age International Prognostic Scoring Eastern Cooperative Oncology Group performance status cytogenetics duration MDS/myeloproliferative neoplasm prior MDS/myeloproliferative neoplasm treatment evaluated impact complete response CR CR low platelets overall survival OS authors evaluated 61 secondary AML patients received induction chemotherapy 59 36 patients achieved CR/CR low platelets 95 confidence interval CI 46 -71 median OS 6.5 95 CI 3.9-8.1 months factors associated lower CR/CR low platelets OS poor risk cytogenetics prior treatment hypomethylating agents lenalidomide longer time transformation AML treated hypomethylating agents lenalidomide 32 achieved CR/CR low platelets versus 78 group treated hypomethylating agent lenalidomide odds ratio 0.13 95 CI 0.04-0.42 Median OS treated hypomethylating agent lenalidomide 3.7 versus 10.5 months treated hypomethylating agent lenalidomide P .0001 CR/CR low platelets rate intermediate risk cytogenetics 70 versus 35 poor risk 4.33 95 CI 1.38-13.6 poor risk cytogenetics median OS 2.8 versus 7.5 months intermediate risk P .01 Prior treatment hypomethylating agents lenalidomide poor risk cytogenetics longer time transformation AML independent negative predictive factors response OS patients secondary AML induction therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[568, 286, 533, 329, 29, 35, 8775, 681, 1223, 10857, 2131, 16, 41, 5, 8, 334, 356, 3, 738, 194, 464, 130, 4, 7, 5, 568, 329, 73, 5, 2044, 90, 504, 36, 26, 10, 8, 459, 206, 1, 568, 329, 7, 73, 5, 504, 36, 89, 944, 177, 2504, 398, 2118, 1690, 413, 87, 528, 156, 2510, 654, 1, 1223, 10857, 2131, 2, 324, 1223, 10857, 2131, 24, 11, 194, 9, 136, 345, 23, 236, 51, 684, 684, 5, 154, 4407, 2, 63, 25, 118, 3, 738, 194, 713, 568, 329, 7, 54, 103, 504, 56, 728, 511, 7, 513, 684, 684, 5, 154, 4407, 48, 307, 268, 58, 641, 792, 2, 52, 118, 10, 49, 33, 48, 58, 27, 83, 66, 14, 53, 169, 130, 11, 41, 5, 280, 684, 684, 5, 154, 4407, 2, 118, 334, 43, 2510, 324, 24, 5, 4931, 183, 15, 1288, 2, 589, 98, 6, 1392, 6, 329, 1, 135, 73, 5, 4931, 183, 15, 1288, 531, 513, 684, 684, 5, 154, 4407, 185, 833, 4, 3, 87, 44, 73, 5, 8, 4931, 420, 15, 1288, 610, 197, 15, 13, 233, 48, 58, 13, 755, 13, 595, 52, 118, 9, 135, 73, 5, 8, 4931, 420, 15, 1288, 10, 27, 67, 185, 79, 33, 53, 9, 135, 44, 73, 5, 8, 4931, 420, 15, 1288, 19, 488, 3, 684, 684, 5, 154, 4407, 116, 9, 135, 5, 919, 43, 2510, 10, 431, 185, 465, 9, 135, 5, 334, 43, 15, 39, 466, 48, 58, 14, 519, 233, 49, 135, 5, 334, 43, 2510, 42, 8, 52, 118, 1, 18, 66, 185, 67, 33, 53, 9, 135, 5, 919, 43, 19, 355, 324, 24, 5, 4931, 183, 15, 1288, 334, 43, 2510, 2, 589, 98, 6, 1392, 6, 329, 32, 306, 199, 464, 130, 9, 51, 2, 118, 4, 7, 5, 568, 329, 50, 504, 36]",1942.0,21425147,Outcomes induction chemotherapy patients acute myeloid leukemia arising myelodysplastic syndrome,0,0.0
Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival.,Blood,Blood,2011-03-30,"Survival in cytogenetically high-risk patients with acute myeloid leukemia or myelodysplastic syndromes is significantly worse in the presence of a monosomal karyotype (MK). The objective of the present study was to determine whether the same held true for primary myelofibrosis. Among 793 primary myelofibrosis patients seen at our institution, 62 displayed an unfavorable karyotype by way of complex karyotype (n = 41) or sole trisomy 8 (n = 21). Seventeen (41%) of the 41 patients with complex karyotype were classified as having an MK. Median survival was 6, 24, and 20 months in patients with MK, complex karyotype without monosomies, and sole trisomy 8, respectively (P < .0001). The corresponding 2-year leukemic transformation rates were 29.4%, 8.3%, and 0 (P < .0001); hazard ratios (95% confidence intervals) were 6.9 (1.3-37.3) and 14.8 (1.7-130.8). The prognostic relevance of MK was not accounted for by the Dynamic International Prognostic Scoring System. We conclude that MK in primary myelofibrosis is associated with extremely poor overall and leukemia-free survival.",Journal Article,3219.0,47.0,Survival cytogenetically high-risk patients acute myeloid leukemia myelodysplastic syndromes significantly worse presence monosomal karyotype MK objective present determine held true primary myelofibrosis 793 primary myelofibrosis patients seen institution 62 displayed unfavorable karyotype way complex karyotype n 41 sole trisomy 8 n 21 Seventeen 41 41 patients complex karyotype classified MK Median survival 6 24 20 months patients MK complex karyotype monosomies sole trisomy 8 respectively P .0001 corresponding 2-year leukemic transformation rates 29.4 8.3 0 P .0001 hazard ratios 95 confidence intervals 6.9 1.3-37.3 14.8 1.7-130.8 prognostic relevance MK accounted Dynamic International Prognostic Scoring conclude MK primary myelofibrosis associated extremely poor overall leukemia-free survival,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[25, 4, 7809, 64, 43, 7, 5, 286, 533, 15, 2040, 16, 97, 639, 4, 3, 463, 1, 8, 22660, 3385, 3558, 3, 461, 1, 3, 364, 45, 10, 6, 223, 317, 3, 827, 4033, 2501, 9, 86, 4637, 107, 12282, 86, 4637, 7, 527, 28, 114, 731, 744, 2507, 35, 2483, 3385, 20, 2255, 1, 840, 3385, 78, 605, 15, 4991, 6317, 66, 78, 239, 3591, 605, 1, 3, 605, 7, 5, 840, 3385, 11, 1373, 22, 1041, 35, 3558, 52, 25, 10, 49, 259, 2, 179, 53, 4, 7, 5, 3558, 840, 3385, 187, 31785, 2, 4991, 6317, 66, 106, 19, 488, 3, 1734, 18, 111, 2015, 1392, 151, 11, 462, 39, 66, 27, 2, 13, 19, 488, 360, 1137, 48, 307, 1582, 11, 49, 83, 14, 27, 567, 27, 2, 213, 66, 14, 67, 3431, 66, 3, 177, 2088, 1, 3558, 10, 44, 3688, 9, 20, 3, 2540, 944, 177, 2504, 398, 21, 2060, 17, 3558, 4, 86, 4637, 16, 41, 5, 2938, 334, 63, 2, 2647, 115, 25]",1012.0,21450904,Monosomal karyotype primary myelofibrosis detrimental overall leukemia-free survival,1,0.0017452006980802793
Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the Childhood Cancer Survivor Study.,Blood,Blood,2011-04-15,"Previous investigations of cancer survivors report that the cumulative incidence of subsequent leukemia plateaus between 10 and 15 years after primary therapy. Risk beyond 15 years has not been comprehensively assessed, primarily because of lack of long-term follow-up. Among 5-year survivors from the Childhood Cancer Survivor Study cohort, 13 pathologically confirmed cases of subsequent leukemia occurred  15 years after primary malignancy, with a mean latency of 21.6 years (range, 15-32 years). Seven were acute myeloid leukemia (2 acute promyelocytic leukemia with t(15;17), 2 with confirmed preceding myelodysplastic syndrome), 4 acute lymphoblastic leukemia (2 pre-B lineage, 1 T cell, 1 unknown), and 2 other. Two acute myeloid leukemia cases had the 7q- deletion. The standardized incidence ratio was 3.5 (95% confidence interval, 1.9-6.0). Median survival from diagnosis of subsequent leukemia was 2 years. This is the first description of a statistically significant increased risk of subsequent leukemia  15 years from primary diagnosis of childhood cancer.",Journal Article,3203.0,18.0,Previous investigations survivors report cumulative incidence subsequent leukemia plateaus 10 15 years primary therapy Risk 15 years comprehensively assessed primarily lack long-term follow-up 5-year survivors Childhood Survivor cohort 13 pathologically confirmed cases subsequent leukemia occurred  15 years primary malignancy mean latency 21.6 years range 15-32 years Seven acute myeloid leukemia 2 acute promyelocytic leukemia 15 17 2 confirmed preceding myelodysplastic syndrome 4 acute lymphoblastic leukemia 2 pre-B lineage 1 1 unknown 2 acute myeloid leukemia cases 7q- deletion standardized incidence ratio 3.5 95 confidence interval 1.9-6.0 Median survival diagnosis subsequent leukemia 2 years description statistically significant increased risk subsequent leukemia  15 years primary diagnosis childhood,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[698, 2492, 1, 12, 332, 414, 17, 3, 967, 287, 1, 706, 28925, 59, 79, 2, 167, 60, 50, 86, 36, 43, 1654, 167, 60, 71, 44, 85, 5627, 275, 1561, 408, 1, 926, 1, 319, 337, 166, 126, 107, 33, 111, 332, 29, 3, 864, 12, 2628, 45, 180, 233, 2998, 557, 140, 1, 706, 489, 749, 167, 60, 50, 86, 710, 5, 8, 313, 5301, 1, 239, 49, 60, 184, 167, 531, 60, 648, 11, 286, 533, 18, 286, 4300, 5, 102, 167, 269, 18, 5, 557, 5892, 681, 39, 286, 1275, 18, 671, 132, 2542, 14, 102, 31, 14, 860, 2, 18, 127, 100, 286, 533, 140, 42, 3, 9723, 1528, 3, 1670, 287, 197, 10, 27, 33, 48, 307, 268, 14, 83, 49, 13, 52, 25, 29, 147, 1, 706, 10, 18, 60, 26, 16, 3, 157, 5263, 1, 8, 712, 93, 101, 43, 1, 706, 749, 167, 60, 29, 86, 147, 1, 864, 12]",956.0,21498675,Long-term risk subsequent leukemia treatment childhood report Childhood Survivor,0,0.0
Pharmacokinetic evaluation of decitabine for the treatment of leukemia.,Expert opinion on drug metabolism & toxicology,Expert Opin Drug Metab Toxicol,2011-05-01,"Acute myeloid leukemia (AML) is a life-threatening malignancy that primarily afflicts an elderly population. Treatment of elderly patients with intensive chemotherapy is associated with high treatment-related morbidity and mortality. Therefore, less toxic approaches involving low-dose decitabine-based regimens are being explored in this patient population. This drug evaluation article discusses the rationale for targeting aberrant DNA methylation in hematologic malignancies, in particular the myelodysplastic syndromes (MDS) and AML. The authors review the pharmacokinetic data gained from low-dose decitabine, as well as the clinical progress of decitabine in the treatment of hematologic malignancies. Published manuscripts in English were selected from PubMed using a combination of the following search terms: acute myeloid leukemia, pharmacokinetics, decitabine, 5-aza-2'-deoxycytidine, DNA methylation, DNA methyltransferase, myelodysplastic syndrome and leukemia. Decitabine has established efficacy in MDS and shown promising activity in AML at low doses. Given decitabines favorable toxicity profile and emerging clinical efficacy, decitabine may be a low intensity therapeutic option for elderly patients with AML who are considered unfit for aggressive chemotherapy.",Journal Article,3187.0,16.0,Acute myeloid leukemia AML life-threatening malignancy primarily afflicts elderly population Treatment elderly patients intensive chemotherapy associated high treatment-related morbidity mortality toxic approaches involving low-dose decitabine-based regimens explored patient population drug evaluation article discusses rationale targeting aberrant DNA methylation hematologic malignancies particular myelodysplastic syndromes MDS AML authors review pharmacokinetic gained low-dose decitabine clinical progress decitabine treatment hematologic malignancies Published manuscripts English selected PubMed combination following search terms acute myeloid leukemia pharmacokinetics decitabine 5-aza-2'-deoxycytidine DNA methylation DNA methyltransferase myelodysplastic syndrome leukemia Decitabine established efficacy MDS shown promising activity AML low doses Given decitabine favorable toxicity profile emerging clinical efficacy decitabine low intensity therapeutic option elderly patients AML considered unfit aggressive chemotherapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[286, 533, 329, 16, 8, 358, 3691, 710, 17, 1561, 25347, 35, 1216, 266, 24, 1, 1216, 7, 5, 1686, 56, 16, 41, 5, 64, 24, 139, 787, 2, 282, 673, 299, 1812, 611, 1267, 154, 61, 3004, 90, 472, 32, 486, 1443, 4, 26, 69, 266, 26, 234, 451, 946, 2759, 3, 1728, 9, 529, 1898, 261, 569, 4, 813, 441, 4, 1454, 3, 2040, 1223, 2, 329, 3, 738, 206, 3, 1456, 74, 3711, 29, 154, 61, 3004, 22, 149, 22, 3, 38, 1466, 1, 3004, 4, 3, 24, 1, 813, 441, 983, 12827, 4, 4201, 11, 715, 29, 3161, 75, 8, 150, 1, 3, 366, 1901, 1794, 286, 533, 1159, 3004, 33, 3924, 6135, 6750, 261, 569, 261, 3747, 681, 2, 3004, 71, 635, 209, 4, 1223, 2, 443, 721, 128, 4, 329, 28, 154, 415, 447, 3004, 695, 913, 155, 800, 2, 1478, 38, 209, 3004, 68, 40, 8, 154, 837, 189, 1501, 9, 1216, 7, 5, 329, 54, 32, 515, 9681, 9, 571, 56]",1201.0,21500965,Pharmacokinetic evaluation decitabine treatment leukemia,87,0.1518324607329843
Association of JAK2 mutation status and cytogenetic abnormalities in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms.,American journal of clinical pathology,Am. J. Clin. Pathol.,2011-05-01,"Myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms are heterogeneous disorders. JAK2 mutation testing and karyotyping are routinely used for diagnosis but have not been incorporated into risk stratification in Philadelphia chromosome-negative myeloproliferative neoplasms. This study correlated cytogenetic abnormalities with disease stage and JAK2 status. A total of 179 cases were analyzed for the JAK2 mutation. Among them, cytogenetic data were available for 97 cases-45 of 106 JAK2+ and 52 of 73 JAK2-. The JAK2+ group showed a higher frequency of cytogenetic anomalies than the JAK2- group (23/45 [51%] vs 14/52 [27%]). Chromosome 9, chromosome 7, and 20q- were recurrent abnormalities in the JAK2+ group, whereas 13q- and trisomy 21 were common in the JAK2- group. In the JAK2+ group, chromosome 7 and complex cytogenetic abnormalities were associated with excess blasts/blastic transformation (P < .05), whereas no cases with 20q- underwent blastic transformation. Our results suggest that incorporation of JAK2 mutation testing and karyotyping allows for monitoring of disease progression with prognostic and therapeutic implications.",Journal Article,3187.0,7.0,Myeloproliferative neoplasms myelodysplastic/myeloproliferative neoplasms heterogeneous disorders JAK2 testing karyotyping routinely diagnosis incorporated risk stratification Philadelphia chromosome-negative myeloproliferative neoplasms correlated cytogenetic abnormalities disease stage JAK2 status total 179 cases JAK2 cytogenetic available 97 cases-45 106 JAK2+ 52 73 JAK2- JAK2+ group showed higher frequency cytogenetic anomalies JAK2- group 23/45 51 vs 14/52 27 Chromosome 9 chromosome 7 20q- recurrent abnormalities JAK2+ group 13q- trisomy 21 common JAK2- group JAK2+ group chromosome 7 complex cytogenetic abnormalities associated excess blasts/blastic transformation P .05 cases 20q- underwent blastic transformation suggest incorporation JAK2 testing karyotyping allows monitoring disease progression prognostic therapeutic implications,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1179, 2, 10589, 10857, 1179, 32, 1564, 1997, 2509, 258, 471, 2, 10406, 32, 3066, 95, 9, 147, 84, 47, 44, 85, 2449, 237, 43, 1541, 4, 3006, 1170, 199, 1179, 26, 45, 438, 1266, 1171, 5, 34, 82, 2, 2509, 156, 8, 181, 1, 5977, 140, 11, 311, 9, 3, 2509, 258, 107, 1370, 1266, 74, 11, 390, 9, 1015, 140, 512, 1, 3251, 2509, 2, 653, 1, 803, 2509, 3, 2509, 87, 224, 8, 142, 675, 1, 1266, 7623, 76, 3, 2509, 87, 382, 512, 725, 105, 213, 653, 428, 1170, 83, 1170, 67, 2, 13887, 11, 387, 1171, 4, 3, 2509, 87, 547, 8453, 2, 6317, 239, 11, 186, 4, 3, 2509, 87, 4, 3, 2509, 87, 1170, 67, 2, 840, 1266, 1171, 11, 41, 5, 2612, 2438, 6529, 1392, 19, 474, 547, 77, 140, 5, 13887, 208, 6529, 1392, 114, 99, 309, 17, 2838, 1, 2509, 258, 471, 2, 10406, 2333, 9, 1315, 1, 34, 91, 5, 177, 2, 189, 1268]",1105.0,21502425,Association JAK2 status cytogenetic abnormalities myeloproliferative neoplasms myelodysplastic/myeloproliferative neoplasms,0,0.0
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.,"European journal of cancer (Oxford, England : 1990)",Eur. J. Cancer,2011-04-20,"Dexrazoxane reduces the risk of anthracycline-related cardiotoxicity. In a study of children with Hodgkin lymphoma, the addition of dexrazoxane may have been associated with a higher risk for developing second malignant neoplasms (SMNs) including acute myelogenous leukaemia (AML) and myelodysplastic syndrome (MDS). We determined the incidence of SMNs in children and adolescents with acute lymphoblastic leukaemia (ALL) who were treated with dexrazoxane. Between 1996 and 2010, the Dana-Faber Cancer Institute ALL Consortium conducted three consecutive multicentre trials for children with newly diagnosed ALL. In the first (1996-2000), high risk patients were randomly assigned to receive doxorubicin (30mg/m(2)/dose, cumulative dose 300mg/m(2)) preceded by dexrazoxane (300mg/m(2)/dose, 10 doses), or the same dose of doxorubicin without dexrazoxane, during induction and intensification phases. In subsequent trials (2000-2005 and 2005-2010), all high risk and very high risk patients received doxorubicin preceded by dexrazoxane. Cases of SMNs were collected prospectively and were pooled for analysis. The frequency and 5-year cumulative incidence (CI) of SMNs were determined for patients who had received dexrazoxane. Among 553 patients treated with dexrazoxane (1996-2000, N=101; 2000-2005, N=196; and 2005-2010, N=256), the number of SMNs observed by protocol was 0 (median follow-up 9.6years), 0 (median follow-up 5.2years), and 1 (median follow-up 2.1years). The only SMN was a case of AML, which developed in a patient with MLL-rearranged ALL 2.14years after initial diagnosis. The overall 5-year CI of SMNs for all 553 patients was 0.240.24%. In a large population of children with high risk ALL who received dexrazoxane as a cardioprotectant drug, the occurrence of secondary AML was a rare event.",Journal Article,3198.0,84.0,Dexrazoxane reduces risk anthracycline-related cardiotoxicity children Hodgkin lymphoma addition dexrazoxane associated higher risk developing second malignant neoplasms SMNs including acute myelogenous leukaemia AML myelodysplastic syndrome MDS determined incidence SMNs children adolescents acute lymphoblastic leukaemia treated dexrazoxane 1996 2010 Dana-Faber Institute Consortium conducted consecutive multicentre trials children newly diagnosed 1996-2000 high risk patients randomly assigned receive doxorubicin 30mg/m 2 /dose cumulative dose 300mg/m 2 preceded dexrazoxane 300mg/m 2 /dose 10 doses dose doxorubicin dexrazoxane induction intensification phases subsequent trials 2000-2005 2005-2010 high risk high risk patients received doxorubicin preceded dexrazoxane Cases SMNs collected prospectively pooled frequency 5-year cumulative incidence CI SMNs determined patients received dexrazoxane 553 patients treated dexrazoxane 1996-2000 N=101 2000-2005 N=196 2005-2010 N=256 number SMNs observed protocol 0 median follow-up 9.6years 0 median follow-up 5.2years 1 median follow-up 2.1years SMN case AML developed patient MLL-rearranged 2.14years initial diagnosis overall 5-year CI SMNs 553 patients 0.240.24 large population children high risk received dexrazoxane cardioprotectant drug occurrence secondary AML rare event,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[8473, 2389, 3, 43, 1, 2044, 139, 4404, 4, 8, 45, 1, 541, 5, 3, 352, 1, 8473, 68, 47, 85, 41, 5, 8, 142, 43, 9, 931, 419, 393, 1179, 6580, 141, 286, 2194, 2001, 329, 2, 681, 1223, 21, 509, 3, 287, 1, 6580, 4, 541, 2, 3101, 5, 286, 1275, 2001, 62, 54, 11, 73, 5, 8473, 59, 2648, 2, 1120, 3, 4932, 60051, 12, 1377, 62, 2404, 426, 169, 935, 5761, 143, 9, 541, 5, 732, 265, 62, 4, 3, 157, 2648, 1081, 64, 43, 7, 11, 1108, 896, 6, 560, 856, 30285, 188, 18, 61, 967, 61, 21658, 188, 18, 6083, 20, 8473, 21658, 188, 18, 61, 79, 415, 15, 3, 827, 61, 1, 856, 187, 8473, 190, 504, 2, 5091, 3523, 4, 706, 143, 1081, 1242, 2, 1242, 1120, 62, 64, 43, 2, 923, 64, 43, 7, 103, 856, 6083, 20, 8473, 140, 1, 6580, 11, 786, 1143, 2, 11, 1830, 9, 65, 3, 675, 2, 33, 111, 967, 287, 58, 1, 6580, 11, 509, 9, 7, 54, 42, 103, 8473, 107, 11094, 7, 73, 5, 8473, 2648, 1081, 78, 2338, 1081, 1242, 78, 6369, 2, 1242, 1120, 78, 7162, 3, 207, 1, 6580, 164, 20, 1182, 10, 13, 52, 166, 126, 83, 27052, 13, 52, 166, 126, 33, 15766, 2, 14, 52, 166, 126, 18, 29147, 3, 158, 6474, 10, 8, 473, 1, 329, 92, 276, 4, 8, 69, 5, 3049, 3201, 62, 18, 60052, 50, 388, 147, 3, 63, 33, 111, 58, 1, 6580, 9, 62, 11094, 7, 10, 13, 60053, 259, 4, 8, 375, 266, 1, 541, 5, 64, 43, 62, 54, 103, 8473, 22, 8, 28769, 234, 3, 2291, 1, 568, 329, 10, 8, 622, 774]",1723.0,21514146,low incidence secondary acute myelogenous leukaemia children adolescents treated dexrazoxane acute lymphoblastic leukaemia report Dana-Farber Institute Consortium,0,0.0
"Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2011-04-25,"The International Prognostic Scoring System (IPSS) remains the most commonly used system for risk classification in myelodysplastic syndromes (MDSs). The IPSS gives more weight to blast count than to cytogenetics. However, previous publications suggested that cytogenetics are underweighted in the IPSS. Here we investigate the prognostic impact of cytogenetic subgroups compared with that of bone marrow blast count in a large, multicentric, international patient cohort. In total, 2,351 patients with MDS who have records in the German-Austrian and the MD Anderson Cancer Center databases were included and analyzed in univariate and multivariate models regarding overall survival and risk of transformation to acute myeloid leukemia (AML). The data were analyzed separately for patients treated with supportive care without specific therapy, with AML-like chemotherapy, or with other therapy regimens (low-dose chemotherapy, demethylating agents, immune modulating agents, valproic acid, and cyclosporine). The prognostic impact of poor-risk cytogenetic findings (as defined by the IPSS classification) on overall survival was as unfavorable as an increased (> 20%) blast count. The hazard ratio (compared with an abnormal karyotype or a bone marrow blast count < 5%) was 3.3 for poor-risk cytogenetics, 4.8 for complex abnormalities harboring chromosomes 5 and/or 7, and 3.1 for a blast count of 21% to 30% (P < .01 for all categories). The predictive power of the IPSS cytogenetic subgroups was unaffected by type of therapy given. The independent prognostic impact of poor-risk cytogenetics on overall survival is equivalent to the impact of high blast counts. This finding should be considered in the upcoming revision of the IPSS.",Journal Article,3193.0,121.0,"International Prognostic Scoring IPSS remains commonly risk classification myelodysplastic syndromes MDSs IPSS gives weight blast count cytogenetics previous publications suggested cytogenetics underweighted IPSS investigate prognostic impact cytogenetic subgroups compared bone marrow blast count large multicentric international patient cohort total 2,351 patients MDS records German-Austrian MD Anderson Center databases included univariate multivariate models overall survival risk transformation acute myeloid leukemia AML separately patients treated supportive care specific therapy AML-like chemotherapy therapy regimens low-dose chemotherapy demethylating agents immune modulating agents valproic acid cyclosporine prognostic impact poor-risk cytogenetic findings defined IPSS classification overall survival unfavorable increased 20 blast count hazard ratio compared abnormal karyotype bone marrow blast count 5 3.3 poor-risk cytogenetics 4.8 complex abnormalities harboring chromosomes 5 and/or 7 3.1 blast count 21 30 P .01 categories predictive power IPSS cytogenetic subgroups unaffected type therapy given independent prognostic impact poor-risk cytogenetics overall survival equivalent impact high blast counts finding considered upcoming revision IPSS",0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 944, 177, 2504, 398, 8751, 469, 3, 96, 841, 95, 398, 9, 43, 947, 4, 2040, 13550, 3, 8751, 7989, 80, 924, 6, 3112, 1276, 76, 6, 2510, 137, 698, 4463, 1148, 17, 2510, 32, 60058, 4, 3, 8751, 467, 21, 963, 3, 177, 345, 1, 1266, 1453, 72, 5, 17, 1, 581, 3112, 1276, 4, 8, 375, 8388, 944, 69, 180, 4, 181, 18, 7270, 7, 5, 1223, 54, 47, 1064, 4, 3, 10842, 22455, 2, 3, 2244, 1929, 12, 574, 2348, 11, 159, 2, 311, 4, 880, 2, 331, 274, 666, 63, 25, 2, 43, 1, 1392, 6, 286, 533, 329, 3, 74, 11, 311, 3582, 9, 7, 73, 5, 1877, 165, 187, 112, 36, 5, 329, 733, 56, 15, 5, 127, 36, 472, 154, 61, 56, 8399, 183, 250, 3712, 183, 11029, 971, 2, 9112, 3, 177, 345, 1, 334, 43, 1266, 272, 22, 395, 20, 3, 8751, 947, 23, 63, 25, 10, 22, 2483, 22, 35, 101, 179, 3112, 1276, 3, 360, 197, 72, 5, 35, 1668, 3385, 15, 8, 581, 3112, 1276, 33, 10, 27, 27, 9, 334, 43, 2510, 39, 66, 9, 840, 1171, 2105, 3560, 33, 2, 15, 67, 2, 27, 14, 9, 8, 3112, 1276, 1, 239, 6, 201, 19, 355, 9, 62, 1996, 3, 464, 2349, 1, 3, 8751, 1266, 1453, 10, 4585, 20, 267, 1, 36, 447, 3, 306, 177, 345, 1, 334, 43, 2510, 23, 63, 25, 16, 2017, 6, 3, 345, 1, 64, 3112, 1911, 26, 1567, 257, 40, 515, 4, 3, 11974, 5646, 1, 3, 8751]",1654.0,21519021,"Coalesced multicentric 2,351 patients myelodysplastic syndromes indicates underestimation poor-risk cytogenetics myelodysplastic syndromes international prognostic scoring",3,0.005235602094240838
A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.,Blood,Blood,2011-05-06,"Older acute myeloid leukemia (AML) patients with a chromosome 5q deletion have poor outcomes with conventional chemotherapy. This phase 2 study explored the safety and efficacy of single-agent lenalidomide in previously untreated older AML patients with del(5q) who declined standard chemotherapy. Patients were treated with lenalidomide 50 mg daily for 28 days as induction therapy and 10 mg daily for 21 days of a 28-day cycle as maintenance until disease progression or unacceptable toxicity. Among 37 evaluable patients, the median age was 74 years (range, 60-94), 21 (57%) were female, 19 (51%) had prior myelodysplastic syndrome, and 30 (81%) had pretreatment cytogenetic studies evaluated centrally. Six had isolated del(5q), 1 had del(5q) and +8, 23 had complex cytogenetics, and 7 others had del(5q) identified locally. Fourteen patients (38%) completed induction therapy: 7 patients died during induction therapy, 8 had disease progression, 7 had nonfatal adverse events, and 1 entered hospice. Eight patients started maintenance therapy. Five patients (14%) achieved a partial or complete response, 2 with isolated del(5q) and 3 with complex cytogenetics. Relapse-free survival was 5 months (range, 0-19). Median overall survival was 2 months for the entire population. In conclusion, lenalidomide as a single agent has modest activity in older del(5q) AML patients. Southwest Oncology Group Study S0605 is registered at www.clinicaltrials.gov as NCT00352365.","Clinical Trial, Phase II",3182.0,65.0,Older acute myeloid leukemia AML patients chromosome 5q deletion poor outcomes conventional chemotherapy phase 2 explored safety efficacy single-agent lenalidomide previously untreated older AML patients del 5q declined standard chemotherapy Patients treated lenalidomide 50 mg daily 28 days induction therapy 10 mg daily 21 days 28-day cycle maintenance disease progression unacceptable toxicity 37 evaluable patients median age 74 years range 60-94 21 57 female 19 51 prior myelodysplastic syndrome 30 81 pretreatment cytogenetic studies evaluated centrally isolated del 5q 1 del 5q +8 23 complex cytogenetics 7 del 5q identified locally Fourteen patients 38 completed induction therapy 7 patients died induction therapy 8 disease progression 7 nonfatal adverse events 1 entered hospice patients started maintenance therapy patients 14 achieved partial complete response 2 isolated del 5q 3 complex cytogenetics Relapse-free survival 5 months range 0-19 Median overall survival 2 months entire population lenalidomide single agent modest activity older del 5q AML patients Southwest Oncology Group S0605 registered www.clinicaltrials.gov NCT00352365,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[434, 286, 533, 329, 7, 5, 8, 1170, 5460, 1528, 47, 334, 123, 5, 809, 56, 26, 124, 18, 45, 1443, 3, 367, 2, 209, 1, 226, 420, 1288, 4, 373, 1278, 434, 329, 7, 5, 3084, 5460, 54, 3054, 260, 56, 7, 11, 73, 5, 1288, 212, 81, 391, 9, 339, 162, 22, 504, 36, 2, 79, 81, 391, 9, 239, 162, 1, 8, 339, 218, 417, 22, 1146, 1100, 34, 91, 15, 3215, 155, 107, 567, 859, 7, 3, 52, 89, 10, 794, 60, 184, 335, 960, 239, 696, 11, 1061, 326, 725, 42, 324, 681, 2, 201, 865, 42, 1194, 1266, 94, 194, 4604, 437, 42, 1355, 3084, 5460, 14, 42, 3084, 5460, 2, 66, 382, 42, 840, 2510, 2, 67, 1749, 42, 3084, 5460, 108, 795, 3225, 7, 519, 781, 504, 36, 67, 7, 1016, 190, 504, 36, 66, 42, 34, 91, 67, 42, 23412, 290, 281, 2, 14, 2836, 2490, 659, 7, 3461, 1146, 36, 365, 7, 213, 513, 8, 450, 15, 236, 51, 18, 5, 1355, 3084, 5460, 2, 27, 5, 840, 2510, 429, 115, 25, 10, 33, 53, 184, 13, 326, 52, 63, 25, 10, 18, 53, 9, 3, 1797, 266, 4, 1221, 1288, 22, 8, 226, 420, 71, 1721, 128, 4, 434, 3084, 5460, 329, 7, 6625, 413, 87, 45, 60098, 16, 1653, 28, 3064, 1252, 1239, 22, 46556]",1391.0,21551228,phase 2 lenalidomide monotherapy patients deletion 5q acute myeloid leukemia Southwest Oncology Group S0605,4,0.006980802792321117
"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2011-05-16,"To determine the maximum-tolerated dose (MTD), safety, pharmacokinetic and pharmacodynamic profiles, and clinical activity of an oral formulation of azacitidine in patients with myelodysplastic syndromes (MDSs), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). Patients received 1 cycle of subcutaneous (SC) azacitidine (75 mg/m2) on the first 7 days of cycle 1, followed by oral azacitidine daily (120 to 600 mg) on the first 7 days of each additional 28-day cycle. Pharmacokinetic and pharmacodynamic profiles were evaluated during cycles 1 and 2. Adverse events and hematologic responses were recorded. Cross-over to SC azacitidine was permitted for nonresponders who received  6 cycles of oral azacitidine. Overall, 41 patients received SC and oral azacitidine (MDSs, n = 29; CMML, n = 4; AML, n = 8). Dose-limiting toxicity (grade 3/4 diarrhea) occurred at the 600-mg dose and MTD was 480 mg. Most common grade 3/4 adverse events were diarrhea (12.2%), nausea (7.3%), vomiting (7.3%), febrile neutropenia (19.5%), and fatigue (9.8%). Azacitidine exposure increased with escalating oral doses. Mean relative oral bioavailability ranged from 6.3% to 20%. Oral and SC azacitidine decreased DNA methylation in blood, with maximum effect at day 15 of each cycle. Hematologic responses occurred in patients with MDSs and CMML. Overall response rate (i.e., complete remission, hematologic improvement, or RBC or platelet transfusion independence) was 35% in previously treated patients and 73% in previously untreated patients. Oral azacitidine was bioavailable and demonstrated biologic and clinical activity in patients with MDSs and CMML.","Clinical Trial, Phase I",3172.0,147.0,determine maximum-tolerated dose MTD safety pharmacokinetic pharmacodynamic profiles clinical activity oral formulation azacitidine patients myelodysplastic syndromes MDSs chronic myelomonocytic leukemia CMML acute myeloid leukemia AML Patients received 1 cycle subcutaneous SC azacitidine 75 mg/m2 7 days cycle 1 followed oral azacitidine daily 120 600 mg 7 days additional 28-day cycle Pharmacokinetic pharmacodynamic profiles evaluated cycles 1 2 Adverse events hematologic responses recorded Cross-over SC azacitidine permitted nonresponders received  6 cycles oral azacitidine Overall 41 patients received SC oral azacitidine MDSs n 29 CMML n 4 AML n 8 Dose-limiting toxicity grade 3/4 diarrhea occurred 600-mg dose MTD 480 mg common grade 3/4 adverse events diarrhea 12.2 nausea 7.3 vomiting 7.3 febrile neutropenia 19.5 fatigue 9.8 Azacitidine exposure increased escalating oral doses Mean relative oral bioavailability ranged 6.3 20 Oral SC azacitidine decreased DNA methylation blood maximum effect day 15 cycle Hematologic responses occurred patients MDSs CMML Overall response rate i.e. complete remission hematologic improvement RBC platelet transfusion independence 35 previously treated patients 73 previously untreated patients Oral azacitidine bioavailable demonstrated biologic clinical activity patients MDSs CMML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 223, 3, 689, 421, 61, 961, 367, 1456, 2, 2424, 1241, 2, 38, 128, 1, 35, 518, 3583, 1, 3752, 4, 7, 5, 2040, 13550, 442, 5451, 3382, 15, 286, 533, 329, 7, 103, 14, 417, 1, 2529, 2969, 3752, 481, 81, 821, 23, 3, 157, 67, 162, 1, 417, 14, 370, 20, 518, 3752, 391, 2031, 6, 2383, 81, 23, 3, 157, 67, 162, 1, 296, 402, 339, 218, 417, 1456, 2, 2424, 1241, 11, 194, 190, 410, 14, 2, 18, 290, 281, 2, 813, 253, 11, 1872, 1383, 252, 6, 2969, 3752, 10, 5449, 9, 4498, 54, 103, 749, 49, 410, 1, 518, 3752, 63, 605, 7, 103, 2969, 2, 518, 3752, 13550, 78, 462, 3382, 78, 39, 329, 78, 66, 61, 817, 155, 88, 27, 39, 1172, 489, 28, 3, 2383, 81, 61, 2, 961, 10, 9108, 81, 96, 186, 88, 27, 39, 290, 281, 11, 1172, 133, 18, 1218, 67, 27, 1966, 67, 27, 2498, 778, 326, 33, 2, 613, 83, 66, 3752, 645, 101, 5, 2922, 518, 415, 313, 580, 518, 5499, 1869, 29, 49, 27, 6, 179, 518, 2, 2969, 3752, 340, 261, 569, 4, 315, 5, 689, 254, 28, 218, 167, 1, 296, 417, 813, 253, 489, 4, 7, 5, 13550, 2, 3382, 63, 51, 116, 70, 563, 236, 734, 813, 767, 15, 7256, 15, 1596, 2785, 5773, 10, 465, 4, 373, 73, 7, 2, 803, 4, 373, 1278, 7, 518, 3752, 10, 6582, 2, 264, 1283, 2, 38, 128, 4, 7, 5, 13550, 2, 3382]",1551.0,21576646,Phase oral azacitidine myelodysplastic syndromes chronic myelomonocytic leukemia acute myeloid leukemia,5,0.008726003490401396
Clofarabine for myelodysplastic syndromes.,Expert opinion on investigational drugs,Expert Opin Investig Drugs,2011-05-19,"Treatment options in myelodysplastic syndromes (MDS) remain limited. The introduction of novel therapies that can improve response rates and survival outcomes in MDS remains a challenge. Clofarabine is a purine nucleoside analog that works primarily via inhibition of DNA biosynthesis and the ribonucleotide reductase enzyme with recent evidence suggesting that at low doses it may affect DNA methylation. It has been successfully used in the treatment of acute myeloid leukemia (AML) and is under investigation in MDS. A PubMed search for articles pertaining to clofarabine was conducted and streamlined to only include data on MDS or AML that evolved from MDS. Also included were clofarabine-related response and safety data from presentations at the 52(nd) Annual American Society of Hematology Meeting in Orlando, Florida, USA. Clinical trials using clofarabine in MDS and MDS/myeloproliferative neoplasms have produced overall response rates of 31 - 43% including complete responders. Although myelosuppression is an important side effect, clofarabine is generally well tolerated in MDS. Clofarabine is currently available in an intravenous form with an oral formulation presently under investigation, either as a single agent or in combination therapy in MDS. Larger studies may help clarify the viability of clofarabine in the treatment of MDS patients.",Journal Article,3169.0,1.0,Treatment options myelodysplastic syndromes MDS remain limited introduction novel therapies improve response rates survival outcomes MDS remains challenge Clofarabine purine nucleoside analog works primarily inhibition DNA biosynthesis ribonucleotide reductase enzyme recent evidence suggesting low doses affect DNA methylation successfully treatment acute myeloid leukemia AML investigation MDS PubMed search articles pertaining clofarabine conducted streamlined include MDS AML evolved MDS included clofarabine-related response safety presentations 52 nd Annual American Society Hematology Meeting Orlando Florida USA Clinical trials clofarabine MDS MDS/myeloproliferative neoplasms produced overall response rates 31 43 including complete responders myelosuppression important effect clofarabine generally tolerated MDS Clofarabine currently available intravenous form oral formulation presently investigation single agent combination therapy MDS Larger studies help clarify viability clofarabine treatment MDS patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[24, 838, 4, 2040, 1223, 918, 383, 3, 2456, 1, 229, 235, 17, 122, 401, 51, 151, 2, 25, 123, 4, 1223, 469, 8, 1745, 4149, 16, 8, 5006, 4032, 3497, 17, 10275, 1561, 847, 297, 1, 261, 6225, 2, 3, 7050, 4027, 1644, 5, 435, 241, 802, 17, 28, 154, 415, 192, 68, 1158, 261, 569, 192, 71, 85, 1878, 95, 4, 3, 24, 1, 286, 533, 329, 2, 16, 669, 940, 4, 1223, 8, 3161, 1901, 9, 2384, 6553, 6, 4149, 10, 426, 2, 18625, 6, 158, 643, 74, 23, 1223, 15, 329, 17, 3937, 29, 1223, 120, 159, 11, 4149, 139, 51, 2, 367, 74, 29, 4261, 28, 3, 653, 7175, 2114, 597, 1174, 1, 6216, 2238, 4, 60132, 10533, 2706, 38, 143, 75, 4149, 4, 1223, 2, 1223, 10857, 1179, 47, 1687, 63, 51, 151, 1, 456, 601, 141, 236, 1983, 242, 2858, 16, 35, 305, 1152, 254, 4149, 16, 1228, 149, 421, 4, 1223, 4149, 16, 694, 390, 4, 35, 1262, 1297, 5, 35, 518, 3583, 9083, 669, 940, 361, 22, 8, 226, 420, 15, 4, 150, 36, 4, 1223, 1077, 94, 68, 987, 3968, 3, 2120, 1, 4149, 4, 3, 24, 1, 1223, 7]",1313.0,21591997,Clofarabine myelodysplastic syndromes,2,0.0034904013961605585
Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2011-05-27,"Complete remission (CR) is the gold standard for assessing outcomes following chemotherapy for acute myelogenous leukemia (AML). ""CRp,"" a response criterion defined as fulfillment of all criteria for CR except platelet count recovery to 100  10(9)/L, is associated with inferior outcomes following chemotherapy. The prognostic importance of CRp before allogeneic stem cell transplantation (allo-SCT) remains unknown. We analyzed a cohort of AML (n = 334) and myelodysplastic syndrome (MDS; n = 10) patients to determine the prognostic significance of achieving CR versus CRp before allo-SCT. At time of transplantation, 266 patients were in CR (CR1 and CR2) and 78 in CRp (CR1p and CR2p). Median follow-up was 38 months (3-131 months). Overall survival, progression-free survival, and nonrelapse mortality (NRM) were most favorable in patients transplanted in CR (CR1 or CR2) compared with CRp (CR1p or CR2p). Achieving CR is therefore associated with improved posttransplantation outcomes compared with achieving CRp and is a significant prognostic factor that needs to be considered when evaluating AML/MDS patients for clinical trials and allo-SCT.",Journal Article,3161.0,10.0,Complete remission CR gold standard assessing outcomes following chemotherapy acute myelogenous leukemia AML `` CRp '' response criterion defined fulfillment criteria CR platelet count recovery 100 10 9 /L associated inferior outcomes following chemotherapy prognostic importance CRp allogeneic stem transplantation allo-SCT remains unknown cohort AML n 334 myelodysplastic syndrome MDS n 10 patients determine prognostic significance achieving CR versus CRp allo-SCT time transplantation 266 patients CR CR1 CR2 78 CRp CR1p CR2p Median follow-up 38 months 3-131 months Overall survival progression-free survival nonrelapse mortality NRM favorable patients transplanted CR CR1 CR2 compared CRp CR1p CR2p Achieving CR associated improved posttransplantation outcomes compared achieving CRp significant prognostic factor needs considered evaluating AML/MDS patients clinical trials allo-SCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[236, 734, 684, 16, 3, 4159, 260, 9, 1977, 123, 366, 56, 9, 286, 2194, 329, 3162, 522, 8, 51, 4643, 395, 22, 22136, 1, 62, 371, 9, 684, 2187, 1596, 1276, 1602, 6, 16138, 79, 83, 805, 16, 41, 5, 1663, 123, 366, 56, 3, 177, 1187, 1, 3162, 348, 1063, 452, 31, 497, 2564, 1988, 469, 860, 21, 311, 8, 180, 1, 329, 78, 9376, 2, 681, 1223, 78, 79, 7, 6, 223, 3, 177, 724, 1, 1785, 684, 185, 3162, 348, 2564, 1988, 28, 98, 1, 497, 8786, 7, 11, 4, 684, 4516, 2, 39688, 2, 833, 4, 3162, 46626, 2, 46627, 52, 166, 126, 10, 519, 53, 27, 2229, 53, 63, 25, 91, 115, 25, 2, 4640, 282, 4296, 11, 96, 913, 4, 7, 4600, 4, 684, 4516, 15, 39688, 72, 5, 3162, 46626, 15, 46627, 1785, 684, 16, 673, 41, 5, 231, 8046, 123, 72, 5, 1785, 3162, 2, 16, 8, 93, 177, 161, 17, 1891, 6, 40, 515, 198, 1435, 329, 1223, 7, 9, 38, 143, 2, 2564, 1988]",1094.0,21684343,Platelet recovery allogeneic stem transplantation predicts posttransplantation outcomes patients acute myelogenous leukemia myelodysplastic syndrome,27,0.04712041884816754
"Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.","Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2011-06-22,"We conducted a single-institution phase II clinical trial evaluating the safety and efficacy of combination chemoimmunotherapy followed by radioimmunotherapy consolidation and rituximab maintenance as front-line treatment in indolent lymphomas. We enrolled 20 patients with intermediate- to high-risk follicular lymphoma and 2 patients with marginal zone lymphoma. Treatment consisted of 4-6 cycles of FM (fludarabine 25 mg/m(2) on days 1-3, mitoxantrone 12 mg/m(2) on day 1 of each 28-day cycle). The protocol was amended after enrolling the first 4 patients to include rituximab 375 mg/m(2) on day 1. After 6-8 weeks, responders received (90)Y-ibritumomab tiuxetan (Zevalin) followed by maintenance rituximab (375 mg/m(2) weekly  4 doses, repeated every 6 months for 2 years). After R-FM, the overall response rate was 95% with a complete response rate (CR) of 45% (n = 10), a partial response (PR) rate of 50% (n = 11), and stable disease in 1 patient. Nineteen patients received (90)Y-ibritumomab tiuxetan with a 60% conversion rate of PR to CR, resulting in an improved CR of 79% (n = 15) and a PR of 21% (n = 4). Fifteen patients proceeded to rituximab maintenance resulting in 3 patients with PR converting to CR. At median follow-up of 49.6 months, median progression-free survival (PFS) was 47.2 months and median overall survival (OS) was not reached in an intent-to-treat analysis. The most common adverse effects were hematologic, with 2 patients experiencing treatment-related myelodysplastic syndrome (MDS), evolving to acute myelogenous leukemia (AML) in 1 patient. R-FM with (90)Y-ibritumomab tiuxetan consolidation and rituximab maintenance is well tolerated, improving CR rates and maintaining durable responses in patients with untreated indolent lymphomas.","Clinical Trial, Phase II",3135.0,,conducted single-institution phase II clinical trial evaluating safety efficacy combination chemoimmunotherapy followed radioimmunotherapy consolidation rituximab maintenance front-line treatment indolent lymphomas enrolled 20 patients intermediate- high-risk follicular lymphoma 2 patients marginal zone lymphoma Treatment consisted 4-6 cycles FM fludarabine 25 mg/m 2 days 1-3 mitoxantrone 12 mg/m 2 day 1 28-day cycle protocol amended enrolling 4 patients include rituximab 375 mg/m 2 day 1 6-8 weeks responders received 90 Y-ibritumomab tiuxetan Zevalin followed maintenance rituximab 375 mg/m 2 weekly 4 doses repeated 6 months 2 years R-FM overall response rate 95 complete response rate CR 45 n 10 partial response PR rate 50 n 11 stable disease 1 patient Nineteen patients received 90 Y-ibritumomab tiuxetan 60 conversion rate PR CR resulting improved CR 79 n 15 PR 21 n 4 patients proceeded rituximab maintenance resulting 3 patients PR converting CR median follow-up 49.6 months median progression-free survival PFS 47.2 months median overall survival OS reached intent-to-treat common adverse effects hematologic 2 patients experiencing treatment-related myelodysplastic syndrome MDS evolving acute myelogenous leukemia AML 1 patient R-FM 90 Y-ibritumomab tiuxetan consolidation rituximab maintenance tolerated improving CR rates maintaining durable responses patients untreated indolent lymphomas,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 426, 8, 226, 731, 124, 215, 38, 160, 1435, 3, 367, 2, 209, 1, 150, 4438, 370, 20, 5862, 2173, 2, 855, 1146, 22, 3007, 328, 24, 4, 2316, 1557, 21, 346, 179, 7, 5, 919, 6, 64, 43, 1974, 2, 18, 7, 5, 3450, 3614, 24, 1695, 1, 39, 49, 410, 1, 14228, 2027, 243, 81, 188, 18, 23, 162, 14, 27, 4419, 133, 81, 188, 18, 23, 218, 14, 1, 296, 339, 218, 417, 3, 1182, 10, 7595, 50, 6280, 3, 157, 39, 7, 6, 643, 855, 4175, 81, 188, 18, 23, 218, 14, 50, 49, 66, 244, 1983, 103, 424, 2055, 5251, 5294, 11392, 370, 20, 1146, 855, 4175, 81, 188, 18, 709, 39, 415, 2113, 454, 49, 53, 9, 18, 60, 50, 668, 14228, 3, 63, 51, 116, 10, 48, 5, 8, 236, 51, 116, 684, 1, 512, 78, 79, 8, 450, 51, 998, 116, 1, 212, 78, 175, 2, 585, 34, 4, 14, 69, 3498, 7, 103, 424, 2055, 5251, 5294, 5, 8, 335, 3111, 116, 1, 998, 6, 684, 1113, 4, 35, 231, 684, 1, 842, 78, 167, 2, 8, 998, 1, 239, 78, 39, 3057, 7, 6406, 6, 855, 1146, 1113, 4, 27, 7, 5, 998, 9369, 6, 684, 28, 52, 166, 126, 1, 739, 49, 53, 52, 91, 115, 25, 300, 10, 662, 18, 53, 2, 52, 63, 25, 118, 10, 44, 1300, 4, 35, 1697, 6, 943, 65, 3, 96, 186, 290, 176, 11, 813, 5, 18, 7, 2985, 24, 139, 681, 1223, 3276, 6, 286, 2194, 329, 4, 14, 69, 668, 14228, 5, 424, 2055, 5251, 5294, 2173, 2, 855, 1146, 16, 149, 421, 1673, 684, 151, 2, 3284, 1480, 253, 4, 7, 5, 1278, 2316, 1557]",1663.0,21700527,Safety efficacy combination therapy fludarabine mitoxantrone rituximab followed yttrium-90 ibritumomab tiuxetan maintenance rituximab front-line therapy patients follicular marginal zone lymphoma,2,0.0034904013961605585
"Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A.",Blood,Blood,2011-08-09,"Chronic myelomonocytic leukemia (CMML), a myelodysplastic/myeloproliferative neoplasm, is characterized by monocytic proliferation, dysplasia, and progression to acute myeloid leukemia. CMML has been associated with somatic mutations in diverse recently identified genes. We analyzed 72 well-characterized patients with CMML (N = 52) and CMML-derived acute myeloid leukemia (N = 20) for recurrent chromosomal abnormalities with the use of routine cytogenetics and single nucleotide polymorphism arrays along with comprehensive mutational screening. Cytogenetic aberrations were present in 46% of cases, whereas single nucleotide polymorphism array increased the diagnostic yield to 60%. At least 1 mutation was found in 86% of all cases; novel UTX, DNMT3A, and EZH2 mutations were found in 8%, 10%, and 5.5% of patients, respectively. TET2 mutations were present in 49%, ASXL1 in 43%, CBL in 14%, IDH1/2 in 4%, KRAS in 7%, NRAS in 4%, and JAK2 V617F in 1% of patients. Various mutant genotype combinations were observed, indicating molecular heterogeneity in CMML. Our results suggest that molecular defects affecting distinct pathways can lead to similar clinical phenotypes.",Journal Article,3087.0,229.0,Chronic myelomonocytic leukemia CMML myelodysplastic/myeloproliferative neoplasm characterized monocytic proliferation dysplasia progression acute myeloid leukemia CMML associated somatic diverse recently identified 72 well-characterized patients CMML N 52 CMML-derived acute myeloid leukemia N 20 recurrent chromosomal abnormalities use routine cytogenetics single nucleotide polymorphism arrays comprehensive screening Cytogenetic aberrations present 46 cases single nucleotide polymorphism array increased diagnostic yield 60 1 86 cases novel UTX DNMT3A EZH2 8 10 5.5 patients respectively TET2 present 49 ASXL1 43 CBL 14 IDH1/2 4 KRAS 7 NRAS 4 JAK2 V617F 1 patients genotype combinations observed indicating molecular heterogeneity CMML suggest molecular defects affecting distinct pathways lead similar clinical phenotypes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 5451, 3382, 8, 10589, 10857, 2131, 16, 765, 20, 9003, 457, 2253, 2, 91, 6, 286, 533, 3382, 71, 85, 41, 5, 1119, 138, 4, 1867, 761, 108, 214, 21, 311, 720, 149, 765, 7, 5, 3382, 78, 653, 2, 3382, 526, 286, 533, 78, 179, 9, 387, 1860, 1171, 5, 3, 119, 1, 1311, 2510, 2, 226, 1579, 1907, 3923, 1510, 5, 949, 1619, 453, 1266, 2152, 11, 364, 4, 641, 1, 140, 547, 226, 1579, 1907, 1926, 101, 3, 752, 2309, 6, 335, 28, 506, 14, 258, 10, 204, 4, 868, 1, 62, 140, 229, 23889, 6199, 2, 3755, 138, 11, 204, 4, 66, 79, 2, 33, 33, 1, 7, 106, 5038, 138, 11, 364, 4, 739, 7782, 4, 601, 6925, 4, 213, 2662, 18, 4, 39, 723, 4, 67, 2845, 4, 39, 2, 2509, 5657, 4, 14, 1, 7, 747, 620, 1183, 1247, 11, 164, 1716, 219, 1144, 4, 3382, 114, 99, 309, 17, 219, 2945, 2319, 834, 460, 122, 1122, 6, 288, 38, 2618]",1100.0,21828135,spectrum chronic myelomonocytic leukemia includes associated epigenetic regulation UTX EZH2 DNMT3A,19,0.03315881326352531
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.,Blood,Blood,2011-08-16,"Success of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) has given patients hope for a long disease-free-survival. A longer survival raises the question of late effects, including development of another malignancy. Records of 1445 patients with CML/myeloproliferative neoplasm or other hematologic malignancies treated with TKIs were reviewed to investigate frequency and characteristics of second malignancies (other than acute myeloid leukemia, acute lymphocytic leukemia, or myelodysplastic syndrome). The number of second cancers was compared with the number expected from the Surveillance, Epidemiology, and End Results database. After a median follow-up of 107 months (range, 13-362 months) after CML/myeloproliferative neoplasm diagnosis, 66 patients (4.6%) developed 80 second cancers, including skin (31%), prostate (15%), melanoma (13%), digestive system (10%), kidney (4%), thyroid (4%), breast (3%), chronic lymphocytic leukemia (3%), hepatobiliary (3%), and other cancers (14%). Excluding nonmelanoma skin cancers, 55 second cancers were seen in 51 (3.5%) of all patients treated. The risk of second cancer was lower than expected (observed-to-expected ratio, 0.6; 95% confidence interval, 0.44-0.81). Second cancers occur in a small percentage of patients receiving therapy with TKIs for hematologic malignancies, mostly CML. No evidence at the moment suggests that exposure to TKIs increases the risk of developing second cancers.",Journal Article,3080.0,66.0,Success tyrosine kinase inhibitors TKIs chronic myeloid leukemia CML given patients hope long disease-free-survival longer survival raises question late effects including development malignancy Records 1445 patients CML/myeloproliferative neoplasm hematologic malignancies treated TKIs reviewed investigate frequency characteristics second malignancies acute myeloid leukemia acute lymphocytic leukemia myelodysplastic syndrome number second compared number expected Surveillance Epidemiology End database median follow-up 107 months range 13-362 months CML/myeloproliferative neoplasm diagnosis 66 patients 4.6 developed 80 second including skin 31 prostate 15 melanoma 13 digestive 10 kidney 4 thyroid 4 breast 3 chronic lymphocytic leukemia 3 hepatobiliary 3 14 Excluding nonmelanoma skin 55 second seen 51 3.5 patients treated risk second lower expected observed-to-expected ratio 0.6 95 confidence interval 0.44-0.81 Second occur small percentage patients receiving therapy TKIs hematologic malignancies CML evidence moment suggests exposure TKIs increases risk developing second,1,0,1,1,0,0,0,1,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,1,0,"[1825, 1, 564, 216, 222, 1671, 4, 442, 533, 903, 71, 447, 7, 3045, 9, 8, 319, 34, 115, 25, 8, 589, 25, 5789, 3, 2840, 1, 807, 176, 141, 193, 1, 1809, 710, 1064, 1, 35181, 7, 5, 903, 10857, 2131, 15, 127, 813, 441, 73, 5, 1671, 11, 446, 6, 963, 675, 2, 374, 1, 419, 441, 127, 76, 286, 533, 286, 1193, 15, 681, 3, 207, 1, 419, 163, 10, 72, 5, 3, 207, 1336, 29, 3, 617, 1284, 2, 396, 99, 609, 50, 8, 52, 166, 126, 1, 3650, 53, 184, 233, 10530, 53, 50, 903, 10857, 2131, 147, 700, 7, 39, 49, 276, 493, 419, 163, 141, 456, 167, 233, 9117, 398, 79, 39, 39, 27, 442, 1193, 27, 4718, 27, 2, 127, 163, 213, 3207, 7814, 163, 614, 419, 163, 11, 527, 4, 725, 27, 33, 1, 62, 7, 73, 3, 43, 1, 419, 12, 10, 280, 76, 1336, 164, 6, 1336, 197, 13, 49, 48, 307, 268, 13, 584, 13, 865, 419, 163, 1271, 4, 8, 302, 1150, 1, 7, 357, 36, 5, 1671, 9, 813, 441, 2754, 903, 77, 241, 28, 3, 12854, 844, 17, 645, 6, 1671, 1106, 3, 43, 1, 931, 419, 163]",1287.0,21846902,Malignancies occurring therapy tyrosine kinase inhibitors TKIs chronic myeloid leukemia CML hematologic malignancies,0,0.0
"Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes.",Leukemia research,Leuk. Res.,2011-08-17,"Considering current reliance on cancer registry data, we sought to assess the potential for bias in myelodysplastic syndrome (MDS) registration using SEER-Medicare data 2001-2005. Using a validated claims-based algorithm, we identified and compared registered and non-registered MDS patients, and found that median cumulative survival was 18 and 28 months, 74% and 64% used erythropoiesis-stimulating agents (ESAs), and average 6-month health care cost was $24,249 and $21,750, respectively. While most non-registered MDS patients showed resource utilization and survival characteristics consistent with lower-risk MDS, a subset was registered as acute myeloid leukemia (7.6%) and accounted for early mortality.",Comparative Study,3079.0,11.0,"Considering current reliance registry sought assess potential bias myelodysplastic syndrome MDS registration SEER-Medicare 2001-2005 validated claims-based algorithm identified compared registered non-registered MDS patients median cumulative survival 18 28 months 74 64 erythropoiesis-stimulating agents ESAs average 6-month health care cost 24,249 21,750 respectively non-registered MDS patients showed resource utilization survival characteristics consistent lower-risk MDS subset registered acute myeloid leukemia 7.6 accounted early mortality",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3075, 291, 9007, 23, 12, 1608, 74, 21, 990, 6, 423, 3, 174, 9, 2947, 4, 681, 1223, 3169, 75, 1605, 1378, 74, 1758, 1242, 75, 8, 938, 2770, 90, 2124, 21, 108, 2, 72, 1653, 2, 220, 1653, 1223, 7, 2, 204, 17, 52, 967, 25, 10, 203, 2, 339, 53, 794, 2, 660, 95, 10297, 2122, 183, 3243, 2, 1011, 49, 811, 341, 165, 835, 10, 259, 7144, 2, 239, 4506, 106, 369, 96, 220, 1653, 1223, 7, 224, 3069, 1961, 2, 25, 374, 925, 5, 280, 43, 1223, 8, 697, 10, 1653, 22, 286, 533, 67, 49, 2, 3688, 9, 191, 282]",665.0,21851978,Diagnostic testing treatment cost care survival registered non-registered patients myelodysplastic syndromes,1,0.0017452006980802793
Treatment of acute promyelocytic leukemia without cytotoxic chemotherapy.,"Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2011-07-01,"The introduction of all-trans retinoic acid, or ATRA, in 1985, combined with anthracycline-based chemotherapy, has transformed acute promyelocytic leukemia (APL) from a fatal disease to one that is now highly curable. With appropriate contemporary therapy, more than 90% of patients achieve complete remission, and cure rates of approximately 80% and higher response and survival rates can be expected for patients at low and intermediate risk. The introduction of arsenic trioxide, or ATO, in 1994 has provided the opportunity to minimize and even eliminate standard cytotoxic chemotherapy from initial treatment regimens without compromising the excellent outcomes achieved by anthracycline-containing protocols. APL is a unique subtype of acute myeloid leukemia that is curable with targeted therapies and potentially without exposure to conventional DNA-damaging chemotherapy. The omission of conventional cytotoxic chemotherapy may reduce long-term complications such as cardiomyopathy and therapy-related myelodysplastic syndromes. Cure rates of APL may be further increased by adopting management strategies to reduce early hemorrhagic deaths, which now appear to be the major cause of treatment failure.",Journal Article,3126.0,26.0,introduction all-trans retinoic acid ATRA 1985 combined anthracycline-based chemotherapy transformed acute promyelocytic leukemia APL fatal disease highly curable appropriate contemporary therapy 90 patients achieve complete remission cure rates approximately 80 higher response survival rates expected patients low intermediate risk introduction arsenic trioxide ATO 1994 provided opportunity minimize eliminate standard cytotoxic chemotherapy initial treatment regimens compromising excellent outcomes achieved anthracycline-containing protocols APL unique subtype acute myeloid leukemia curable targeted therapies potentially exposure conventional DNA-damaging chemotherapy omission conventional cytotoxic chemotherapy reduce long-term complications cardiomyopathy therapy-related myelodysplastic syndromes Cure rates APL increased adopting management strategies reduce early hemorrhagic deaths appear major cause treatment failure,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2456, 1, 62, 3437, 3887, 971, 15, 2822, 4, 4675, 397, 5, 2044, 90, 56, 71, 2423, 286, 4300, 2578, 29, 8, 3034, 34, 6, 104, 17, 16, 1134, 561, 4151, 5, 870, 2667, 36, 80, 76, 424, 1, 7, 1359, 236, 734, 2, 1722, 151, 1, 705, 493, 2, 142, 51, 2, 25, 151, 122, 40, 1336, 9, 7, 28, 154, 2, 919, 43, 3, 2456, 1, 3217, 4574, 15, 4021, 4, 3023, 71, 1052, 3, 2666, 6, 3241, 2, 871, 4964, 260, 759, 56, 29, 388, 24, 472, 187, 6102, 3, 1503, 123, 513, 20, 2044, 1101, 2189, 2578, 16, 8, 991, 875, 1, 286, 533, 17, 16, 4151, 5, 238, 235, 2, 751, 187, 645, 6, 809, 261, 4904, 56, 3, 5736, 1, 809, 759, 56, 68, 969, 319, 337, 521, 225, 22, 6460, 2, 36, 139, 2040, 1722, 151, 1, 2578, 68, 40, 195, 101, 20, 10096, 284, 422, 6, 969, 191, 6998, 1043, 92, 1134, 1322, 6, 40, 3, 458, 708, 1, 24, 496]",1158.0,21874835,Treatment acute promyelocytic leukemia cytotoxic chemotherapy,301,0.525305410122164
Quantitative analyses of DAPK1 methylation in AML and MDS.,International journal of cancer,Int. J. Cancer,2011-11-28,"Aberrant DNA methylation and concomitant transcriptional silencing of death-associated protein kinase 1 (DAPK1) have been demonstrated to be key pathogenic events in chronic lymphocytic leukemia (CLL). In acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), however, the presence of elevated DNA methylation levels has been a matter of continued controversy. Several studies demonstrated highly variable frequencies of DAPK1 promoter methylation by the use of methylation-specific PCR (MSP). By quantitative high-resolution assessment, we demonstrate that aberrant DNA methylation is an extremely rare event in this region. We observed elevated levels just in one out of 246 (0.4%) AML patients, all 42 MDS patients were unmethylated. In conclusion, we present a refined DAPK1 methylation analysis in a large representative patient cohort of AML and MDS patients proofing almost complete absence of elevated DNA methylation. Our results highlight the importance of quantitative measurements for translational research questions on primary patient specimens, particularly.",Journal Article,2976.0,27.0,Aberrant DNA methylation concomitant transcriptional silencing death-associated kinase 1 DAPK1 demonstrated key pathogenic events chronic lymphocytic leukemia CLL acute myeloid leukemia AML myelodysplastic syndrome MDS presence elevated DNA methylation levels matter continued controversy studies demonstrated highly variable frequencies DAPK1 promoter methylation use methylation-specific PCR MSP quantitative high-resolution assessment demonstrate aberrant DNA methylation extremely rare event region observed elevated levels 246 0.4 AML patients 42 MDS patients unmethylated present refined DAPK1 methylation large representative patient cohort AML MDS patients proofing complete absence elevated DNA methylation highlight importance quantitative measurements translational research questions primary patient specimens particularly,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[1898, 261, 569, 2, 1781, 1431, 2077, 1, 273, 41, 178, 216, 14, 11503, 47, 85, 264, 6, 40, 825, 2806, 281, 4, 442, 1193, 552, 4, 286, 533, 329, 2, 681, 1223, 137, 3, 463, 1, 804, 261, 569, 148, 71, 85, 8, 5090, 1, 1351, 4089, 392, 94, 264, 561, 1347, 2722, 1, 11503, 973, 569, 20, 3, 119, 1, 569, 112, 604, 8858, 20, 1156, 64, 2125, 455, 21, 608, 17, 1898, 261, 569, 16, 35, 2938, 622, 774, 4, 26, 1053, 21, 164, 804, 148, 4673, 4, 104, 1205, 1, 6907, 13, 39, 329, 7, 62, 595, 1223, 7, 11, 8100, 4, 1221, 21, 364, 8, 5332, 11503, 569, 65, 4, 8, 375, 3724, 69, 180, 1, 329, 2, 1223, 7, 60548, 2214, 236, 1127, 1, 804, 261, 569, 114, 99, 1817, 3, 1187, 1, 1156, 1685, 9, 2460, 389, 1937, 23, 86, 69, 623, 823]",1023.0,21918973,Quantitative DAPK1 methylation AML MDS,0,0.0
Role of lenalidomide in the treatment of myelodysplastic syndromes.,Seminars in oncology,Semin. Oncol.,2011-10-01,"Lenalidomide is characterized as an immunomodulatory drug (IMiD), a second-generation drug in this proprietary drug class with greater potency and a toxicity profile that is distinct from the lead compound, thalidomide. Clinical trials exploring its role in treating patients with myelodysplastic syndrome (MDS) revealed unique karyotype-specific activity in patients with interstitial deletion of the long arm of chromosome 5 (del(5q)). This observation ultimately led the US Food and Drug Administration (FDA) to approve lenalidomide for the treatment of lower risk transfusion-dependent patients with del(5q) MDS. Herein we review the results of four clinical trials conducted with lenalidomide in lower risk MDS, summarizing the clinical efficacy and safety of the drug. We discuss the use of lenalidomide in non-del(5q) patients and efforts to optimize its activity, in addition to investigations exploring the role of lenalidomide in higher risk MDS and acute myeloid leukemia (AML). Finally, we highlight the current understanding of its mechanism of action, discussing the emerging insight into the underlying biology of del(5q) MDS and its linkage to potential targets of lenalidomide.",Journal Article,3034.0,19.0,Lenalidomide characterized immunomodulatory drug IMiD second-generation drug proprietary drug class greater potency toxicity profile distinct lead compound thalidomide Clinical trials exploring role treating patients myelodysplastic syndrome MDS revealed unique karyotype-specific activity patients interstitial deletion long arm chromosome 5 del 5q observation ultimately led Food Drug Administration FDA approve lenalidomide treatment lower risk transfusion-dependent patients del 5q MDS review clinical trials conducted lenalidomide lower risk MDS summarizing clinical efficacy safety drug discuss use lenalidomide non-del 5q patients efforts optimize activity addition investigations exploring role lenalidomide higher risk MDS acute myeloid leukemia AML Finally highlight current understanding mechanism action discussing emerging insight underlying del 5q MDS linkage potential targets lenalidomide,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1288, 16, 765, 22, 35, 2555, 234, 7597, 8, 419, 914, 234, 4, 26, 14950, 234, 1040, 5, 378, 3593, 2, 8, 155, 800, 17, 16, 834, 29, 3, 1122, 2823, 2159, 38, 143, 4378, 211, 200, 4, 1367, 7, 5, 681, 1223, 553, 991, 3385, 112, 128, 4, 7, 5, 4543, 1528, 1, 3, 319, 475, 1, 1170, 33, 3084, 5460, 26, 1664, 2050, 836, 3, 843, 1773, 2, 234, 634, 2078, 6, 34997, 1288, 9, 3, 24, 1, 280, 43, 2785, 470, 7, 5, 3084, 5460, 1223, 1986, 21, 206, 3, 99, 1, 294, 38, 143, 426, 5, 1288, 4, 280, 43, 1223, 15693, 3, 38, 209, 2, 367, 1, 3, 234, 21, 1139, 3, 119, 1, 1288, 4, 220, 3084, 5460, 7, 2, 1413, 6, 2465, 211, 128, 4, 352, 6, 2492, 4378, 3, 200, 1, 1288, 4, 142, 43, 1223, 2, 286, 533, 329, 1368, 21, 1817, 3, 291, 612, 1, 211, 670, 1, 1578, 6003, 3, 1478, 2670, 237, 3, 1181, 891, 1, 3084, 5460, 1223, 2, 211, 4820, 6, 174, 637, 1, 1288]",1143.0,21943671,Role lenalidomide treatment myelodysplastic syndromes,77,0.1343804537521815
"Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbilical-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis.",The Lancet. Oncology,Lancet Oncol.,2011-10-06,"The importance of matching at the HLA C locus has not been well defined for unrelated umbilical-cord blood transplantation. The selection algorithm for umbilical-cord blood units generally considers intermediate resolution HLA typing at A and B and allele-level typing at DRB1. We aimed to establish the relative importance of additional matching at HLA C. We used Cox regression to assess retrospectively the effect of donor-recipient HLA matching on outcomes of single umbilical-cord blood transplantations for leukaemia and myelodysplastic syndrome. Our primary endpoint was transplant-related mortality. HLA typing was done with molecular techniques with a minimum of intermediate resolution for HLA A, B, and C, and at the allele-level for DRB1. The median age of our study population was 10 years (range <1-62) and 552 (69%) of 803 patients were aged 16 years or younger at transplantation. Compared with transplantations matched at HLA A, B, C, and DRB1 (n=69), transplant-related mortality risk was higher after transplantations matched at HLA A, B, and DRB1 and mismatched at HLA C (n=23; HR 397, 95% CI 127-1240; p=0018). Transplant-related mortality risk was also higher after transplantations with a single mismatch at HLA A, B, or DRB1 and mismatched at HLA C (n=234; 170, 106-274; p=0029) compared with transplantations matched at HLA C with a single mismatch at HLA A, B, or DRB1 (n=127). Assessing the overall effect of HLA disparity on transplant-related mortality, risks were higher with units mismatched at two (n=259; 327, 142-754; p=0006), three (n=253; 334, 145-771; p=0005), or four (n=75; 351, 144-858; p=0006) loci compared with matched units (n=69). Our data suggest that the present strategy for umbilical-cord blood unit selection should be reassessed; matching at HLA C for units that are matched at HLA A, B, or DRB1 or in the presence of a single locus mismatch at HLA A, B, or DRB1 should be included to minimise mortality risks. National Cancer Institute, National Heart Lung and Blood Institute, National Institute for Allergy and Infectious Diseases, Leukemia and Lymphoma Society, US Department of the Navy, Children's Leukemia Research Association, and INSERM.",Journal Article,3029.0,129.0,importance matching HLA C locus defined unrelated umbilical-cord blood transplantation selection algorithm umbilical-cord blood units generally considers intermediate resolution HLA typing B allele-level typing DRB1 aimed establish relative importance additional matching HLA C. Cox regression assess retrospectively effect donor-recipient HLA matching outcomes single umbilical-cord blood transplantations leukaemia myelodysplastic syndrome primary endpoint transplant-related mortality HLA typing molecular techniques minimum intermediate resolution HLA B C allele-level DRB1 median age population 10 years range 1-62 552 69 803 patients aged 16 years younger transplantation Compared transplantations matched HLA B C DRB1 n=69 transplant-related mortality risk higher transplantations matched HLA B DRB1 mismatched HLA C n=23 HR 397 95 CI 127-1240 p=0018 Transplant-related mortality risk higher transplantations single mismatch HLA B DRB1 mismatched HLA C n=234 170 106-274 p=0029 compared transplantations matched HLA C single mismatch HLA B DRB1 n=127 Assessing overall effect HLA disparity transplant-related mortality risks higher units mismatched n=259 327 142-754 p=0006 n=253 334 145-771 p=0005 n=75 351 144-858 p=0006 loci compared matched units n=69 suggest present strategy umbilical-cord blood unit selection reassessed matching HLA C units matched HLA B DRB1 presence single locus mismatch HLA B DRB1 included minimise mortality risks National Institute National Heart Lung Blood Institute National Institute Allergy Infectious Diseases Leukemia Lymphoma Society Department Navy Children 's Leukemia Research Association INSERM,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,"[3, 1187, 1, 2616, 28, 3, 1160, 256, 2474, 71, 44, 85, 149, 395, 9, 2092, 5998, 1885, 315, 497, 3, 881, 2124, 9, 5998, 1885, 315, 2960, 1228, 9961, 919, 2125, 1160, 10656, 28, 8, 2, 132, 2, 1254, 301, 10656, 28, 8147, 21, 1295, 6, 1811, 3, 580, 1187, 1, 402, 2616, 28, 1160, 256, 21, 95, 418, 320, 6, 423, 894, 3, 254, 1, 1488, 5783, 1160, 2616, 23, 123, 1, 226, 5998, 1885, 315, 6779, 9, 2001, 2, 681, 114, 86, 1138, 10, 941, 139, 282, 1160, 10656, 10, 1822, 5, 219, 1092, 5, 8, 2499, 1, 919, 2125, 9, 1160, 8, 132, 2, 256, 2, 28, 3, 1254, 301, 9, 8147, 3, 52, 89, 1, 114, 45, 266, 10, 79, 60, 184, 14, 744, 2, 10097, 790, 1, 8341, 7, 11, 1032, 245, 60, 15, 773, 28, 497, 72, 5, 6779, 655, 28, 1160, 8, 132, 256, 2, 8147, 78, 790, 941, 139, 282, 43, 10, 142, 50, 6779, 655, 28, 1160, 8, 132, 2, 8147, 2, 5095, 28, 1160, 256, 78, 382, 168, 60633, 48, 58, 31872, 60634, 19, 31873, 941, 139, 282, 43, 10, 120, 142, 50, 6779, 5, 8, 226, 2617, 28, 1160, 8, 132, 15, 8147, 2, 5095, 28, 1160, 256, 78, 8049, 60635, 23926, 46815, 19, 25389, 72, 5, 6779, 655, 28, 1160, 256, 5, 8, 226, 2617, 28, 1160, 8, 132, 15, 8147, 78, 4080, 1977, 3, 63, 254, 1, 1160, 4326, 23, 941, 139, 282, 1098, 11, 142, 5, 2960, 5095, 28, 100, 78, 7696, 46816, 39754, 60636, 19, 19952, 169, 78, 8105, 60637, 25390, 60638, 19, 18638, 15, 294, 78, 481, 60639, 31874, 60640, 19, 19952, 2012, 72, 5, 655, 2960, 78, 790, 114, 74, 309, 17, 3, 364, 692, 9, 5998, 1885, 315, 2712, 881, 257, 40, 13523, 2616, 28, 1160, 256, 9, 2960, 17, 32, 655, 28, 1160, 8, 132, 15, 8147, 15, 4, 3, 463, 1, 8, 226, 2474, 2617, 28, 1160, 8, 132, 15, 8147, 257, 40, 159, 6, 21023, 282, 1098, 657, 12, 1377, 657, 2, 315, 1377, 657, 1377, 9, 9842, 2, 3398, 1342, 2, 1174, 843, 4271, 1, 3, 35210, 541, 292, 389, 248, 2, 60641]",2088.0,21982422,Effect donor-recipient HLA matching HLA B C DRB1 outcomes umbilical-cord blood transplantation leukaemia myelodysplastic syndrome retrospective,1,0.0017452006980802793
"Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.",Cancer,Cancer,2011-10-28,"Isolated isochromosome (17q) is a rare cytogenetic abnormality in Philadelphia chromosome-negative myeloid neoplasms, usually myelodysplastic and/or myeloproliferative neoplasms (MDS/MPN). De novo acute myeloid leukemia (AML) with isochromosome 17q has rarely been reported. The frequency of genetic mutations is unknown. The authors assessed clinicopathologic, immunophenotypic, and molecular genetic features of 22 myeloid neoplasms with isolated isochromosome 17q. Fourteen patients presented as MDS/MPN; 8 as de novo AML. Most presented with leukocytosis, anemia, thrombocytopenia, and splenomegaly. Morphologically, all showed myelodysplastic and myeloproliferative features, including pseudo-Pelger-Huet-like neutrophils, micromegakaryocytic hyperplasia, hypercellularity, fibrosis, and osteosclerosis. Blasts were increased (median, 40% in de novo AML; 9% in MDS/MPN). Immunohistochemical assessment of proliferation and apoptosis rates in AML were similar to a matched group without isochromosome 17q. In most patients, isochromosome 17q occurred at time of blast transformation or disease progression. DNA sequencing revealed no mutation in the uninvolved TP53 allele. Mutational analyses showed rare mutations in NRAS (3 of 10), FLT3 (2 of 16), and JAK2 (1 of 18), and no mutations in NPM1 (0 of 15), KIT (0 of 4), and CEBPA (0 of 4). The median overall survival was 14.5 months for de novo AML, and 11.0 months for MDS/MPN. With a median follow-up of 8.5 months (range, 1.5-107 months), 15 died of disease, 6 had persistent disease, and 1 was in remission after bone marrow transplantation. The authors conclude that myeloid neoplasms with isolated isochromosome 17q represent a distinct clinicopathologic entity with myelodysplastic and myeloproliferative features, high risk of leukemic transformation, and wild-type TP53.",Journal Article,3007.0,39.0,Isolated isochromosome 17q rare cytogenetic abnormality Philadelphia chromosome-negative myeloid neoplasms usually myelodysplastic and/or myeloproliferative neoplasms MDS/MPN novo acute myeloid leukemia AML isochromosome 17q rarely reported frequency genetic unknown authors assessed clinicopathologic immunophenotypic molecular genetic features 22 myeloid neoplasms isolated isochromosome 17q Fourteen patients presented MDS/MPN 8 novo AML presented leukocytosis anemia thrombocytopenia splenomegaly Morphologically showed myelodysplastic myeloproliferative features including pseudo-Pelger-Huet-like neutrophils micromegakaryocytic hyperplasia hypercellularity fibrosis osteosclerosis Blasts increased median 40 novo AML 9 MDS/MPN Immunohistochemical assessment proliferation apoptosis rates AML similar matched group isochromosome 17q patients isochromosome 17q occurred time blast transformation disease progression DNA sequencing revealed uninvolved TP53 allele showed rare NRAS 3 10 FLT3 2 16 JAK2 1 18 NPM1 0 15 KIT 0 4 CEBPA 0 4 median overall survival 14.5 months novo AML 11.0 months MDS/MPN median follow-up 8.5 months range 1.5-107 months 15 died disease 6 persistent disease 1 remission bone marrow transplantation authors conclude myeloid neoplasms isolated isochromosome 17q represent distinct clinicopathologic entity myelodysplastic myeloproliferative features high risk leukemic transformation wild-type TP53,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1355, 22366, 10529, 16, 8, 622, 1266, 3698, 4, 3006, 1170, 199, 533, 1179, 2082, 2, 15, 1179, 1223, 4125, 1566, 2018, 286, 533, 329, 5, 22366, 10529, 71, 2416, 85, 210, 3, 675, 1, 336, 138, 16, 860, 3, 738, 275, 1399, 6599, 2, 219, 336, 404, 1, 350, 533, 1179, 5, 1355, 22366, 10529, 3225, 7, 917, 22, 1223, 4125, 66, 22, 1566, 2018, 329, 96, 917, 5, 7463, 1545, 1340, 2, 6364, 6204, 62, 224, 2, 404, 141, 13337, 60742, 60743, 733, 5700, 60744, 3176, 21040, 3000, 2, 46177, 2438, 11, 101, 52, 327, 4, 1566, 2018, 329, 83, 4, 1223, 4125, 1382, 455, 1, 457, 2, 351, 151, 4, 329, 11, 288, 6, 8, 655, 87, 187, 22366, 10529, 4, 96, 7, 22366, 10529, 489, 28, 98, 1, 3112, 1392, 15, 34, 91, 261, 615, 553, 77, 258, 4, 3, 7377, 1206, 1254, 1619, 318, 224, 622, 138, 4, 2845, 27, 1, 79, 1224, 18, 1, 245, 2, 2509, 14, 1, 203, 2, 77, 138, 4, 4318, 13, 1, 167, 1164, 13, 1, 39, 2, 7667, 13, 1, 39, 3, 52, 63, 25, 10, 213, 33, 53, 9, 1566, 2018, 329, 2, 175, 13, 53, 9, 1223, 4125, 5, 8, 52, 166, 126, 1, 66, 33, 53, 184, 14, 33, 3650, 53, 167, 1016, 1, 34, 49, 42, 1882, 34, 2, 14, 10, 4, 734, 50, 581, 497, 3, 738, 2060, 17, 533, 1179, 5, 1355, 22366, 10529, 1231, 8, 834, 1399, 2983, 5, 2, 404, 64, 43, 1, 2015, 1392, 2, 955, 267, 1206]",1649.0,22038701,Myeloid neoplasms isolated isochromosome 17q represent clinicopathologic entity associated myelodysplastic/myeloproliferative features high risk leukemic transformation wild-type TP53,0,0.0
Relationship of race/ethnicity and survival after single umbilical cord blood transplantation for adults and children with leukemia and myelodysplastic syndromes.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2011-11-04,"The relationship of race/ethnicity with outcomes of umbilical cord blood transplantation (UCBT) is not well known. We analyzed the association between race/ethnicity and outcomes of unrelated single UCBT for leukemia and myelodysplastic syndromes. Our retrospective cohort study consisted of 885 adults and children (612 whites, 145 blacks, and 128 Hispanics) who received unrelated single UCBT for leukemia and myelodysplastic syndromes between 1995 and 2006 and were reported to the Center for International Blood and Marrow Transplant Research. A 5-6/6 HLA-matched unit with a total nucleated cell count infused of 2.5  10(7)/kg was given to 40% white and 42% Hispanic, but only 21% black patients. Overall survival at 2 years was 44% for whites, 34% for blacks, and 46% for Hispanics (P = .008). In multivariate analysis adjusting for patient, disease, and treatment factors (including HLA match and cell dose), blacks had inferior overall survival (relative risk of death, 1.31; P = .02), whereas overall survival of Hispanics was similar (relative risk, 1.03; P = .81) to that of whites. For all patients, younger age, early-stage disease, use of units with higher cell dose, and performance status 80 were independent predictors of improved survival. Black patients and white patients infused with well-matched cords had comparable survival; similarly, black and white patients receiving units with adequate cell dose had similar survival. These results suggest that blacks have inferior survival to whites after single UCBT, but outcomes are improved when units with a higher cell dose are used.",Journal Article,3000.0,24.0,relationship race/ethnicity outcomes umbilical cord blood transplantation UCBT known association race/ethnicity outcomes unrelated single UCBT leukemia myelodysplastic syndromes retrospective cohort consisted 885 adults children 612 whites 145 blacks 128 Hispanics received unrelated single UCBT leukemia myelodysplastic syndromes 1995 2006 reported Center International Blood Marrow Transplant Research 5-6/6 HLA-matched unit total nucleated count infused 2.5 10 7 /kg given 40 white 42 Hispanic 21 black patients Overall survival 2 years 44 whites 34 blacks 46 Hispanics P .008 multivariate adjusting patient disease treatment factors including HLA match dose blacks inferior overall survival relative risk death 1.31 P .02 overall survival Hispanics similar relative risk 1.03 P .81 whites patients younger age early-stage disease use units higher dose performance status 80 independent predictors improved survival Black patients white patients infused well-matched cords comparable survival similarly black white patients receiving units adequate dose similar survival suggest blacks inferior survival whites single UCBT outcomes improved units higher dose,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 858, 1, 1047, 2091, 5, 123, 1, 5998, 1885, 315, 497, 11305, 16, 44, 149, 440, 21, 311, 3, 248, 59, 1047, 2091, 2, 123, 1, 2092, 226, 11305, 9, 2, 2040, 114, 459, 180, 45, 1695, 1, 14962, 857, 2, 541, 11128, 2556, 4058, 3544, 2, 3990, 3850, 54, 103, 2092, 226, 11305, 9, 2, 2040, 59, 2323, 2, 1324, 2, 11, 210, 6, 3, 574, 9, 944, 315, 2, 581, 941, 389, 8, 33, 49, 49, 1160, 655, 2712, 5, 8, 181, 9862, 31, 1276, 4524, 1, 3107, 33, 79, 67, 503, 10, 447, 6, 327, 886, 2, 595, 1776, 84, 158, 239, 1445, 7, 63, 25, 28, 18, 60, 10, 584, 9, 2556, 562, 9, 3544, 2, 641, 9, 3850, 19, 2155, 4, 331, 65, 1358, 9, 69, 34, 2, 24, 130, 141, 1160, 5364, 2, 31, 61, 3544, 42, 1663, 63, 25, 580, 43, 1, 273, 14, 456, 19, 588, 547, 63, 25, 1, 3850, 10, 288, 580, 43, 14, 680, 19, 865, 6, 17, 1, 2556, 9, 62, 7, 773, 89, 191, 82, 34, 119, 1, 2960, 5, 142, 31, 61, 2, 528, 156, 9068, 11, 306, 674, 1, 231, 25, 1445, 7, 2, 886, 7, 4524, 5, 149, 655, 17654, 42, 1279, 25, 1813, 1445, 2, 886, 7, 357, 2960, 5, 1658, 31, 61, 42, 288, 25, 46, 99, 309, 17, 3544, 47, 1663, 25, 6, 2556, 50, 226, 11305, 84, 123, 32, 231, 198, 2960, 5, 8, 142, 31, 61, 32, 95]",1501.0,22062801,Relationship race/ethnicity survival single umbilical cord blood transplantation adults children leukemia myelodysplastic syndromes,0,0.0
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2011-11-09,"We conducted a phase I-II study of transplantation conditioning with clofarabine-melphalan-alemtuzumab for patients with advanced hematologic malignancies. Ten patients were accrued to the phase I portion, which utilized an accelerated titration design. No dose-limiting toxicity was observed, and clofarabine 40 mg/m(2)  5, melphalan 140 mg/m(2)  1, and alemtuzumab 20 mg  5 was adopted for the phase II study, which accrued 72 patients. Median age was 54 years. There were 44 patients with acute myelogenous leukemia or myelodysplastic syndromes, 27 with non-Hodgkin lymphoma, and nine patients with other hematologic malignancies. The largest subgroup of 35 patients had American Society for Blood and Marrow Transplantation high-risk, active disease. All evaluable patients engrafted with a median time to neutrophil and platelet recovery of 10 and 18 days, respectively. The cumulative incidence of treatment-related mortality was 26% at 1 year. Cumulative incidence of relapse was 29% at 1 year. Overall survival was 80% (95% confidence interval [CI], 71-89) at 100 days and 59% (95% CI, 47-71) at 1 year. Progression-free-survival was 45% (95% CI, 33-67) at 1 year. Rapid-onset renal failure was the main toxicity in the phase II study and more frequent in older patients and those with baseline decrease in glomerular filtration rate. Grade 3-5 renal toxicity was observed in 16 of 74 patients (21%) treated at the phase II doses. Clofarabine-melphalan-alemtuzumab conditioning yields promising response and duration of response, but renal toxicity poses a considerable risk particularly in older patients.","Clinical Trial, Phase I",2995.0,29.0,conducted phase I-II transplantation conditioning clofarabine-melphalan-alemtuzumab patients advanced hematologic malignancies patients accrued phase portion utilized accelerated titration design dose-limiting toxicity observed clofarabine 40 mg/m 2 5 melphalan 140 mg/m 2 1 alemtuzumab 20 mg 5 adopted phase II accrued 72 patients Median age 54 years 44 patients acute myelogenous leukemia myelodysplastic syndromes 27 non-Hodgkin lymphoma patients hematologic malignancies largest subgroup 35 patients American Society Blood Marrow Transplantation high-risk active disease evaluable patients engrafted median time neutrophil platelet recovery 10 18 days respectively cumulative incidence treatment-related mortality 26 1 year Cumulative incidence relapse 29 1 year Overall survival 80 95 confidence interval CI 71-89 100 days 59 95 CI 47-71 1 year Progression-free-survival 45 95 CI 33-67 1 year Rapid-onset renal failure main toxicity phase II frequent older patients baseline decrease glomerular filtration rate Grade 3-5 renal toxicity observed 16 74 patients 21 treated phase II doses Clofarabine-melphalan-alemtuzumab conditioning yields promising response duration response renal toxicity poses considerable risk particularly older patients,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 426, 8, 124, 70, 215, 45, 1, 497, 1933, 5, 4149, 2370, 3579, 9, 7, 5, 131, 813, 441, 1618, 7, 11, 3198, 6, 3, 124, 70, 3206, 92, 2080, 35, 2241, 8715, 771, 77, 61, 817, 155, 10, 164, 2, 4149, 327, 81, 188, 18, 33, 2370, 3304, 81, 188, 18, 14, 2, 3579, 179, 81, 33, 10, 4457, 9, 3, 124, 215, 45, 92, 3198, 720, 7, 52, 89, 10, 667, 60, 125, 11, 584, 7, 5, 286, 2194, 15, 2040, 428, 5, 2, 762, 7, 5, 127, 813, 441, 3, 2166, 1363, 1, 465, 7, 42, 597, 1174, 9, 315, 2, 581, 497, 64, 43, 544, 34, 62, 859, 7, 6914, 5, 8, 52, 98, 6, 2595, 2, 1596, 1602, 1, 79, 2, 203, 162, 106, 3, 967, 287, 1, 24, 139, 282, 10, 432, 28, 14, 111, 967, 287, 1, 429, 10, 462, 28, 14, 111, 63, 25, 10, 493, 48, 307, 268, 58, 792, 887, 28, 394, 162, 2, 728, 48, 58, 662, 792, 28, 14, 111, 91, 115, 25, 10, 512, 48, 58, 466, 598, 28, 14, 111, 1321, 1707, 496, 10, 3, 1895, 155, 4, 3, 124, 215, 45, 2, 80, 908, 4, 434, 7, 2, 135, 5, 330, 775, 4, 6080, 5779, 116, 88, 27, 33, 155, 10, 164, 4, 245, 1, 794, 7, 239, 73, 28, 3, 124, 215, 415, 4149, 2370, 3579, 1933, 4788, 721, 51, 2, 654, 1, 51, 84, 155, 7056, 8, 2658, 43, 823, 4, 434, 7]",1499.0,22079470,Phase I-II clofarabine-melphalan-alemtuzumab conditioning allogeneic hematopoietic transplantation,0,0.0
"Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.","Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",Mod. Pathol.,2011-11-11,"This study is focused on therapy-related myeloid neoplasms after the most promising frontline FCR (fludarabine, cyclophosphamide, and rituximab) therapy in previously untreated chronic lymphocytic leukemia patients. A total of 28 therapy-related myeloid neoplasm patients were identified, including 19 patients from 3 well-controlled FCR frontline trials (n=426 patients), giving an estimated frequency of 4.5% (1.9-8.3%) in a follow-up period of 44 months (range 5-122 months). Clinically, therapy-related myeloid neoplasms could emerge directly from 'prolonged myelosuppression' after FCR (10 patients), or after achieving complete hematological recovery (n=18). The overall latency was 35 months (range 3-118 months), with the former group of 23 months and the latter 42 months (P<0.001). In all, 10 cases presented as therapy-related acute myeloid leukemia and 18 as therapy-related myelodysplastic syndromes. Abnormal cytogenetics was present in 26 of 27 (96%) patients, with frequent chromosomes 5 and 7 abnormalities. The median survival was 7 months after therapy-related myeloid neoplasms. Our results indicate that the risk of therapy-related myeloid neoplasms secondary to frontline FCR therapy may not be as high as previously reported after removing the confounding factor of previous cytotoxic exposure, but this risk increased with older age and likely growth factor co-administration. Therapy-related myeloid neoplasms after FCR therapy shares clinicopathological features with therapy-related myeloid neoplasms secondary to other alkylating agents, but has a shorter latency interval indicating possible synergetic effects of the nucleotide analog fludarabine. The fact that therapy-related myeloid neoplasms can directly emerge from 'prolonged myelosuppression' warrants a bone marrow examination to rule out therapy-related myeloid neoplasms in this clinical setting.",Journal Article,2993.0,48.0,focused therapy-related myeloid neoplasms promising frontline FCR fludarabine cyclophosphamide rituximab therapy previously untreated chronic lymphocytic leukemia patients total 28 therapy-related myeloid neoplasm patients identified including 19 patients 3 well-controlled FCR frontline trials n=426 patients giving estimated frequency 4.5 1.9-8.3 follow-up period 44 months range 5-122 months Clinically therapy-related myeloid neoplasms emerge directly 'prolonged myelosuppression FCR 10 patients achieving complete hematological recovery n=18 overall latency 35 months range 3-118 months group 23 months 42 months P 0.001 10 cases presented therapy-related acute myeloid leukemia 18 therapy-related myelodysplastic syndromes Abnormal cytogenetics present 26 27 96 patients frequent chromosomes 5 7 abnormalities median survival 7 months therapy-related myeloid neoplasms indicate risk therapy-related myeloid neoplasms secondary frontline FCR therapy high previously reported removing confounding factor previous cytotoxic exposure risk increased older age likely growth factor co-administration Therapy-related myeloid neoplasms FCR therapy shares clinicopathological features therapy-related myeloid neoplasms secondary alkylating agents shorter latency interval indicating possible synergetic effects nucleotide analog fludarabine fact therapy-related myeloid neoplasms directly emerge 'prolonged myelosuppression warrants bone marrow examination rule therapy-related myeloid neoplasms clinical setting,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[26, 45, 16, 1649, 23, 36, 139, 533, 1179, 50, 3, 96, 721, 3171, 4953, 2027, 1112, 2, 855, 36, 4, 373, 1278, 442, 1193, 7, 8, 181, 1, 339, 36, 139, 533, 2131, 7, 11, 108, 141, 326, 7, 29, 27, 149, 1149, 4953, 3171, 143, 78, 12114, 7, 7375, 35, 661, 675, 1, 39, 33, 14, 83, 66, 27, 4, 8, 166, 126, 727, 1, 584, 53, 184, 33, 3285, 53, 505, 36, 139, 533, 1179, 359, 6371, 1606, 29, 46881, 2858, 50, 4953, 79, 7, 15, 50, 1785, 236, 2890, 1602, 78, 203, 3, 63, 5301, 10, 465, 53, 184, 27, 4002, 53, 5, 3, 3623, 87, 1, 382, 53, 2, 3, 3286, 595, 53, 19, 13, 144, 4, 62, 79, 140, 917, 22, 36, 139, 286, 533, 2, 203, 22, 36, 139, 2040, 1668, 2510, 10, 364, 4, 432, 1, 428, 921, 7, 5, 908, 3560, 33, 2, 67, 1171, 3, 52, 25, 10, 67, 53, 50, 36, 139, 533, 1179, 114, 99, 1008, 17, 3, 43, 1, 36, 139, 533, 1179, 568, 6, 3171, 4953, 36, 68, 44, 40, 22, 64, 22, 373, 210, 50, 9026, 3, 4339, 161, 1, 698, 759, 645, 84, 26, 43, 101, 5, 434, 89, 2, 322, 129, 161, 1269, 634, 36, 139, 533, 1179, 50, 4953, 36, 10641, 2721, 404, 5, 36, 139, 533, 1179, 568, 6, 127, 3410, 183, 84, 71, 8, 985, 5301, 268, 1716, 899, 31884, 176, 1, 3, 1579, 3497, 2027, 3, 1991, 17, 36, 139, 533, 1179, 122, 1606, 6371, 29, 46881, 2858, 2782, 8, 581, 1385, 6, 5340, 1205, 36, 139, 533, 1179, 4, 26, 38, 546]",1803.0,22080061,Therapy-related myeloid neoplasms following fludarabine cyclophosphamide rituximab FCR treatment patients chronic lymphocytic leukemia/small lymphocytic lymphoma,3,0.005235602094240838
"A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.",Cancer,Cancer,2011-12-02,"ARRY-520 selectively inhibits the mitotic kinesin spindle protein (KSP), which leads to abnormal monopolar spindle formation and apoptosis. A phase 1 trial was conducted to establish the safety and the maximum tolerated dose (MTD) of ARRY-520 given as a 1-hour infusion in either a single dose or on a day 1, 3, and 5 divided-dose schedule per cycle in patients with advanced or refractory myeloid leukemias. Additional objectives were to characterize pharmacokinetics, assess preliminary clinical activity, and explore biomarkers of KSP inhibition with ARRY-520. A total of 36 patients with acute myelogenous leukemia (n = 34) or myelodysplastic syndromes (n = 2) with a median age of 66 years (range, 21-88 years) were enrolled: 15 in the single-dose schedule (dose levels: 2.5, 3.75, 4.5, and 5.6 mg/m(2)) and 21 in the divided-dose schedule (dose levels: 0.8, 1.2, 1.5, and 1.8 mg/m(2)/day). The MTD was 4.5 mg/m(2) total dose per cycle for both dose schedules. Dose-limiting toxicities included mucositis, exfoliative rash, hand-foot syndrome, and hyperbilirubinemia. Grades 3 or 4 reversible drug-related myelosuppression were observed in 33 of 36 patients. Plasma pharmacokinetic analyses revealed low clearance of ARRY-520 (~3 L/hour), a volume of distribution of ~450 L, and a median terminal half-life of >90 hours. Monopolar spindles were observed in blood mononuclear cells, through use of 4',6-diamidino-2-phenylindole nucleic acid stain and antitubulin antibodies. On the basis of the relative lack of clinical activity, further development of ARRY-520 as an antileukemic agent was halted. (Clinicaltrials.gov identifier NCT00637052).","Clinical Trial, Phase I",2972.0,35.0,"ARRY-520 selectively inhibits mitotic kinesin spindle KSP leads abnormal monopolar spindle formation apoptosis phase 1 trial conducted establish safety maximum tolerated dose MTD ARRY-520 given 1-hour infusion single dose day 1 3 5 divided-dose schedule cycle patients advanced refractory myeloid leukemias Additional objectives characterize pharmacokinetics assess preliminary clinical activity explore biomarkers KSP inhibition ARRY-520 total 36 patients acute myelogenous leukemia n 34 myelodysplastic syndromes n 2 median age 66 years range 21-88 years enrolled 15 single-dose schedule dose levels 2.5 3.75 4.5 5.6 mg/m 2 21 divided-dose schedule dose levels 0.8 1.2 1.5 1.8 mg/m 2 /day MTD 4.5 mg/m 2 total dose cycle dose schedules Dose-limiting toxicities included mucositis exfoliative rash hand-foot syndrome hyperbilirubinemia Grades 3 4 reversible drug-related myelosuppression observed 33 36 patients Plasma pharmacokinetic revealed low clearance ARRY-520 ~3 L/hour volume distribution ~450 L median terminal half-life 90 hours Monopolar spindles observed blood mononuclear use 4',6-diamidino-2-phenylindole nucleic acid stain antitubulin antibodies basis relative lack clinical activity development ARRY-520 antileukemic agent halted Clinicaltrials.gov identifier NCT00637052",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[13412, 9158, 2382, 1576, 3, 2346, 14193, 4052, 178, 21532, 92, 1940, 6, 1668, 25116, 4052, 1264, 2, 351, 8, 124, 14, 160, 10, 426, 6, 1811, 3, 367, 2, 3, 689, 421, 61, 961, 1, 13412, 9158, 447, 22, 8, 14, 2583, 904, 4, 361, 8, 226, 61, 15, 23, 8, 218, 14, 27, 2, 33, 2176, 61, 1055, 379, 417, 4, 7, 5, 131, 15, 430, 533, 2792, 402, 2409, 11, 6, 1507, 1159, 423, 1676, 38, 128, 2, 1645, 582, 1, 21532, 297, 5, 13412, 9158, 8, 181, 1, 511, 7, 5, 286, 2194, 78, 562, 15, 2040, 78, 18, 5, 8, 52, 89, 1, 700, 60, 184, 239, 889, 60, 11, 346, 167, 4, 3, 226, 61, 1055, 61, 148, 18, 33, 27, 481, 39, 33, 2, 33, 49, 81, 188, 18, 2, 239, 4, 3, 2176, 61, 1055, 61, 148, 13, 66, 14, 18, 14, 33, 2, 14, 66, 81, 188, 18, 218, 3, 961, 10, 39, 33, 81, 188, 18, 181, 61, 379, 417, 9, 110, 61, 2314, 61, 817, 385, 159, 2606, 28036, 1641, 2833, 4100, 681, 2, 7236, 2276, 27, 15, 39, 2786, 234, 139, 2858, 11, 164, 4, 466, 1, 511, 7, 554, 1456, 318, 553, 154, 1960, 1, 13412, 9158, 27, 805, 2583, 8, 433, 1, 1395, 1, 5669, 805, 2, 8, 52, 2158, 1303, 358, 1, 424, 1459, 25116, 26747, 11, 164, 4, 315, 3041, 37, 298, 119, 1, 14401, 49, 19425, 18, 19426, 7895, 971, 8763, 2, 18860, 890, 23, 3, 877, 1, 3, 580, 926, 1, 38, 128, 195, 193, 1, 13412, 9158, 22, 35, 4512, 420, 10, 9473, 1252, 1239, 3719, 60848]",1565.0,22139909,phase 1 dose-escalation ARRY-520 kinesin spindle inhibitor patients advanced myeloid leukemias,3,0.005235602094240838
New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2011-01-01,"Ongoing analysis of the seminal AZA-001 study has taught many important lessons in the use of DNA methyltransferase (DNMT) inhibitors. The data emphasize the importance of patience in the use of these drugs, with several cycles required for the manifestations of hematologic responses. Improved survival in patients with high-risk myelodysplastic syndrome (MDS) treated with azacitidine extends to patients with any International Working Group-defined hematologic response; however, the benefit to patients with stable disease is less clear. A great deal remains to be learned about the optimal dosing and scheduling of the DNMT inhibitors, alone and in combination. New information on the impact of DNMT inhibitors on the immune system and on stem cells will likely lead to novel uses of these drugs in MDS and other hematologic and nonhematologic malignancies.",Journal Article,3307.0,23.0,Ongoing seminal AZA-001 taught important lessons use DNA methyltransferase DNMT inhibitors emphasize importance patience use drugs cycles required manifestations hematologic responses Improved survival patients high-risk myelodysplastic syndrome MDS treated azacitidine extends patients International Working Group-defined hematologic response benefit patients stable disease clear great deal remains learned optimal dosing scheduling DNMT inhibitors combination New information impact DNMT inhibitors immune stem likely lead novel uses drugs MDS hematologic nonhematologic malignancies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[942, 65, 1, 3, 4786, 3924, 144, 45, 71, 21242, 445, 305, 8268, 4, 3, 119, 1, 261, 3747, 10229, 222, 3, 74, 5560, 3, 1187, 1, 46934, 4, 3, 119, 1, 46, 600, 5, 392, 410, 616, 9, 3, 4282, 1, 813, 253, 231, 25, 4, 7, 5, 64, 43, 681, 1223, 73, 5, 3752, 8464, 6, 7, 5, 500, 944, 2644, 87, 395, 813, 51, 137, 3, 247, 6, 7, 5, 585, 34, 16, 299, 885, 8, 2797, 9081, 469, 6, 40, 6426, 545, 3, 665, 1280, 2, 8122, 1, 3, 10229, 222, 279, 2, 4, 150, 217, 487, 23, 3, 345, 1, 10229, 222, 23, 3, 250, 398, 2, 23, 452, 37, 303, 322, 1122, 6, 229, 4025, 1, 46, 600, 4, 1223, 2, 127, 813, 2, 3534, 441]",833.0,22160088,New ways use DNA methyltransferase inhibitors treatment myelodysplastic syndrome,4,0.006980802792321117
Underreporting of myeloid malignancies by United States cancer registries.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2012-01-11,"The recent decrease in myeloid leukemia incidence may be directly attributed to changes in the population-based cancer registries 2001 guidelines, which required the capture of only one malignancy in the myeloid lineage per person and the simultaneous adoption of myelodysplastic syndrome registration in the United States. We constructed four claims-based algorithms to assess myeloid leukemia incidence, applied the algorithms to the 1999-2008 Surveillance Epidemiology and End Results (SEER)-Medicare database, and assessed algorithm validity using SEER-registered cases. Each had moderate sensitivities (75%-94%) and high specificities (>99.0%), with the 2+BCBM algorithm showing the highest specificity. On the basis of the 2+BCBM algorithm, SEER registered only 50% of the acute myelogenous leukemia cases and a third of the chronic myelogenous leukemia (CML) cases. The annual incidence of myeloid leukemia in 2005 was 26 per 100,000 persons 66 years or older, much higher than the 15 per 100,000 reported by SEER using the same sample. Our findings suggest underreporting of myeloid leukemias in SEER by a magnitude of 50% to 70% as well as validate and support the use of the 2+BCBM claims algorithm in identifying myeloid leukemia cases. Use of this algorithm identified a high number of uncaptured myeloid leukemia cases, particularly CML cases. Our results call for the commitment of more resources for centralized cancer registries so that they may improve myeloid leukemia case ascertainment, which would empower policy makers with ability to properly allocate limited health care resources.",Journal Article,2932.0,47.0,"recent decrease myeloid leukemia incidence directly attributed changes population-based registries 2001 guidelines required capture malignancy myeloid lineage person simultaneous adoption myelodysplastic syndrome registration United States constructed claims-based algorithms assess myeloid leukemia incidence applied algorithms 1999-2008 Surveillance Epidemiology End SEER -Medicare database assessed algorithm validity SEER-registered cases moderate sensitivities 75 -94 high specificities 99.0 2+BCBM algorithm showing highest specificity basis 2+BCBM algorithm SEER registered 50 acute myelogenous leukemia cases chronic myelogenous leukemia CML cases annual incidence myeloid leukemia 2005 26 100,000 persons 66 years older higher 15 100,000 reported SEER findings suggest underreporting myeloid leukemias SEER magnitude 50 70 validate support use 2+BCBM claims algorithm identifying myeloid leukemia cases Use algorithm identified high number uncaptured myeloid leukemia cases particularly CML cases commitment resources centralized registries improve myeloid leukemia case ascertainment empower policy makers ability properly allocate limited health care resources",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 435, 775, 4, 533, 287, 68, 40, 1606, 3073, 6, 400, 4, 3, 266, 90, 12, 3768, 1758, 677, 92, 616, 3, 2891, 1, 158, 104, 710, 4, 3, 533, 2542, 379, 2719, 2, 3, 2824, 4350, 1, 681, 3169, 4, 3, 1088, 907, 21, 2776, 294, 2770, 90, 3529, 6, 423, 533, 287, 1498, 3, 3529, 6, 3, 2043, 1375, 617, 1284, 2, 396, 99, 1605, 1378, 609, 2, 275, 2124, 3099, 75, 1605, 1653, 140, 296, 42, 1163, 6202, 481, 960, 2, 64, 10571, 1058, 13, 5, 3, 18, 7517, 2124, 2069, 3, 1076, 1121, 23, 3, 877, 1, 3, 18, 7517, 2124, 1605, 1653, 158, 212, 1, 3, 286, 2194, 140, 2, 8, 1282, 1, 3, 442, 2194, 903, 140, 3, 2114, 287, 1, 533, 4, 1242, 10, 432, 379, 394, 984, 4327, 700, 60, 15, 434, 1802, 142, 76, 3, 167, 379, 394, 984, 210, 20, 1605, 75, 3, 827, 1000, 114, 272, 309, 25408, 1, 533, 2792, 4, 1605, 20, 8, 3131, 1, 212, 6, 431, 22, 149, 22, 2183, 2, 538, 3, 119, 1, 3, 18, 7517, 2770, 2124, 4, 1386, 533, 140, 119, 1, 26, 2124, 108, 8, 64, 207, 1, 60984, 533, 140, 823, 903, 140, 114, 99, 7715, 9, 3, 11082, 1, 80, 2892, 9, 10826, 12, 3768, 1743, 17, 491, 68, 401, 533, 473, 10798, 92, 688, 21138, 4196, 10888, 5, 801, 6, 6785, 22715, 383, 341, 165, 2892]",1488.0,22237987,Underreporting myeloid malignancies United States registries,1,0.0017452006980802793
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.,Cancer,Cancer,2012-01-17,"Although most patients with myelodysplastic syndrome (MDS) exhibit bone marrow hypercellularity, a subset of them present with a hypocellular bone marrow. Specific factors associated with poor prognosis have not been investigated in patients with hypocellular MDS. The authors studied a cohort of 253 patients with hypocellular MDS diagnosed at The University of Texas MD Anderson Cancer Center between 1993 and 2007 and a cohort of 1725 patients with hyper-/normocellular MDS diagnosed during the same time period. Patients with hypocellular MDS presented more frequently with thrombocytopenia (P < .019), neutropenia (P < .001), low serum -2 microglobulin (P < .001), increased transfusion dependency (P < .001), and intermediate-2/high-risk disease (57% vs 42%, P = .02) compared with patients with hyper-/normocellular MDS. However, no difference in overall survival was observed between the 2 groups (P = .28). Multivariate analysis identified poor performance status (Eastern Cooperative Oncology Group 2), low hemoglobin (<10 g/dL), unfavorable cytogenetics (-7/7q or complex), increased bone marrow blasts (5%), and high serum lactate dehydrogenase (>600 IU/L) as adverse independent factors for survival. A new prognostic model based on these factors was built that segregated patients into 3 distinct risk categories independent of International Prognostic Scoring System (IPSS) score. This model is independent from the IPSS, further refines IPSS-based prognostication, and may be used to develop of risk-adapted therapeutic approaches for patients with hypocellular MDS.",Journal Article,2926.0,29.0,patients myelodysplastic syndrome MDS exhibit bone marrow hypercellularity subset present hypocellular bone marrow Specific factors associated poor prognosis investigated patients hypocellular MDS authors studied cohort 253 patients hypocellular MDS diagnosed University Texas MD Anderson Center 1993 2007 cohort 1725 patients hyper-/normocellular MDS diagnosed time period Patients hypocellular MDS presented frequently thrombocytopenia P .019 neutropenia P .001 low serum -2 microglobulin P .001 increased transfusion dependency P .001 intermediate-2/high-risk disease 57 vs 42 P .02 compared patients hyper-/normocellular MDS difference overall survival observed 2 groups P .28 Multivariate identified poor performance status Eastern Cooperative Oncology Group 2 low hemoglobin 10 g/dL unfavorable cytogenetics -7/7q complex increased bone marrow blasts 5 high serum lactate dehydrogenase 600 IU/L adverse independent factors survival new prognostic model based factors built segregated patients 3 distinct risk categories independent International Prognostic Scoring IPSS score model independent IPSS refines IPSS-based prognostication develop risk-adapted therapeutic approaches patients hypocellular MDS,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[242, 96, 7, 5, 681, 1223, 2239, 581, 21040, 8, 697, 1, 1370, 364, 5, 8, 15724, 581, 112, 130, 41, 5, 334, 356, 47, 44, 85, 565, 4, 7, 5, 15724, 1223, 3, 738, 656, 8, 180, 1, 8105, 7, 5, 15724, 1223, 265, 28, 3, 1652, 1, 2738, 2244, 1929, 12, 574, 59, 3343, 2, 1307, 2, 8, 180, 1, 46993, 7, 5, 4855, 46994, 1223, 265, 190, 3, 827, 98, 727, 7, 5, 15724, 1223, 917, 80, 746, 5, 1340, 19, 4049, 778, 19, 144, 154, 524, 1458, 18, 5371, 19, 144, 101, 2785, 6359, 19, 144, 2, 919, 18, 64, 43, 34, 696, 105, 595, 19, 588, 72, 5, 7, 5, 4855, 46994, 1223, 137, 77, 523, 4, 63, 25, 10, 164, 59, 3, 18, 271, 19, 339, 331, 65, 108, 334, 528, 156, 2118, 1690, 413, 87, 3107, 154, 2222, 79, 499, 1826, 2483, 2510, 67, 9723, 15, 840, 101, 581, 2438, 4126, 2, 64, 524, 3330, 2374, 2383, 4588, 805, 22, 290, 306, 130, 9, 25, 8, 217, 177, 202, 90, 23, 46, 130, 10, 6859, 17, 11324, 7, 237, 27, 834, 43, 1996, 306, 1, 944, 177, 2504, 398, 8751, 368, 26, 202, 16, 306, 29, 3, 8751, 195, 25346, 8751, 90, 4260, 2, 68, 40, 95, 6, 690, 1, 43, 3716, 189, 611, 9, 7, 5, 15724, 1223]",1490.0,22252728,Predicting survival patients hypocellular myelodysplastic syndrome development disease-specific prognostic score,25,0.04363001745200698
"Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.",Blood,Blood,2012-02-09,"Myelodysplastic syndromes (MDSs) are chronic and often progressive myeloid neoplasms associated with remarkable heterogeneity in the histomorphology and clinical course. Various somatic mutations are involved in the pathogenesis of MDS. Recently, mutations in a gene encoding a spliceosomal protein, SF3B1, were discovered in a distinct form of MDS with ring sideroblasts. Whole exome sequencing of 15 patients with myeloid neoplasms was performed, and somatic mutations in spliceosomal genes were identified. Sanger sequencing of 310 patients was performed to assess phenotype/genotype associations. To determine the functional effect of spliceosomal mutations, we evaluated pre-mRNA splicing profiles by RNA deep sequencing. We identified additional somatic mutations in spliceosomal genes, including SF3B1, U2AF1, and SRSF2. These mutations alter pre-mRNA splicing patterns. SF3B1 mutations are prevalent in low-risk MDS with ring sideroblasts, whereas U2AF1 and SRSF2 mutations are frequent in chronic myelomonocytic leukemia and advanced forms of MDS. SF3B1 mutations are associated with a favorable prognosis, whereas U2AF1 and SRSF2 mutations are predictive for shorter survival. Mutations affecting spliceosomal genes that result in defective splicing are a new leukemogenic pathway. Spliceosomal genes are probably tumor suppressors, and their mutations may constitute diagnostic biomarkers that could potentially serve as therapeutic targets.",Journal Article,2903.0,248.0,Myelodysplastic syndromes MDSs chronic progressive myeloid neoplasms associated remarkable heterogeneity histomorphology clinical course somatic involved pathogenesis MDS Recently encoding spliceosomal SF3B1 discovered distinct form MDS ring sideroblasts exome sequencing 15 patients myeloid neoplasms performed somatic spliceosomal identified Sanger sequencing 310 patients performed assess phenotype/genotype associations determine functional effect spliceosomal evaluated pre-mRNA splicing profiles RNA deep sequencing identified additional somatic spliceosomal including SF3B1 U2AF1 SRSF2 alter pre-mRNA splicing patterns SF3B1 prevalent low-risk MDS ring sideroblasts U2AF1 SRSF2 frequent chronic myelomonocytic leukemia advanced forms MDS SF3B1 associated favorable prognosis U2AF1 SRSF2 predictive shorter survival affecting spliceosomal defective splicing new leukemogenic pathway Spliceosomal probably suppressors constitute diagnostic biomarkers potentially serve therapeutic targets,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2040, 13550, 32, 442, 2, 629, 1014, 533, 1179, 41, 5, 3813, 1144, 4, 3, 23400, 2, 38, 906, 747, 1119, 138, 32, 646, 4, 3, 1384, 1, 1223, 761, 138, 4, 8, 145, 2362, 8, 17448, 178, 10132, 11, 2747, 4, 8, 834, 1297, 1, 1223, 5, 4091, 23740, 902, 2865, 615, 1, 167, 7, 5, 533, 1179, 10, 173, 2, 1119, 138, 4, 17448, 214, 11, 108, 7285, 615, 1, 8292, 7, 10, 173, 6, 423, 1005, 1183, 685, 6, 223, 3, 583, 254, 1, 17448, 138, 21, 194, 671, 956, 3895, 1241, 20, 893, 2369, 615, 21, 108, 402, 1119, 138, 4, 17448, 214, 141, 10132, 11522, 2, 9830, 46, 138, 2688, 671, 956, 3895, 764, 10132, 138, 32, 2485, 4, 154, 43, 1223, 5, 4091, 23740, 547, 11522, 2, 9830, 138, 32, 908, 4, 442, 5451, 2, 131, 2377, 1, 1223, 10132, 138, 32, 41, 5, 8, 913, 356, 547, 11522, 2, 9830, 138, 32, 464, 9, 985, 25, 138, 2319, 17448, 214, 17, 757, 4, 4552, 3895, 32, 8, 217, 13519, 308, 17448, 214, 32, 4061, 30, 5704, 2, 136, 138, 68, 4999, 752, 582, 17, 359, 751, 1833, 22, 189, 637]",1402.0,22323480,spliceosome machinery novel ubiquitous pathway leukemogenesis,0,0.0
Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-02-13,"We hypothesized that surrogate markers of host immune response may predict survival in myeloid malignancies. Because of immediate practical applicability, we chose plasma immunoglobulin free light chain (FLC) concentration as the biomarker of interest. Two independent cohorts of patients with primary myelofibrosis (PMF) or myelodysplastic syndromes (MDS) were studied. Kappa () and lambda () FLCs were measured by a quantitative nephelometric assay. Patients with monoclonal FLC were excluded. Values that were above the upper limit of normal for  or  FLC were documented in 33% of 240 patients with PMF and 46% of 74 patients with MDS. Increased FLC was significantly associated with increased creatinine, and advanced age in PMF (P < .001) and hemoglobin less than 10 g/dL in MDS (P = .005). In multivariable analysis, increased FLC predicted shortened survival in both PMF and MDS, independent of age, creatinine, and other conventional risk factors. Cutoff levels based on receiver operating characteristic analysis for  plus  total FLCs delineated risk groups with highly significant differences in overall survival; International Prognostic Scoring System-adjusted hazard ratio in PMF was 1.9 (95% CI, 1.3 to 2.7), and was 6.3 (95% CI, 2.7 to 16.6) in MDS. No correlations were seen with leukemia-free survival, karyotype, or JAK2, MPL, or IDH mutations. In patients with PMF who were studied by cytokine profiling, the prognostic value of an increased FLC level was independent of that from circulating interleukin-2 receptor (IL-2R) or IL-8 levels. Increased plasma FLC concentration predicts inferior survival in both PMF and MDS. Its lack of correlation with leukemia-free survival and tumor-specific genetic markers suggests a primarily host-driven biologic phenomenon that might be more broadly applicable.",Journal Article,2899.0,22.0,hypothesized surrogate markers host immune response predict survival myeloid malignancies immediate practical applicability chose plasma immunoglobulin free light chain FLC concentration biomarker independent cohorts patients primary myelofibrosis PMF myelodysplastic syndromes MDS studied Kappa  lambda  FLCs measured quantitative nephelometric Patients monoclonal FLC excluded Values upper limit normal   FLC documented 33 240 patients PMF 46 74 patients MDS Increased FLC significantly associated increased creatinine advanced age PMF P .001 hemoglobin 10 g/dL MDS P .005 multivariable increased FLC predicted shortened survival PMF MDS independent age creatinine conventional risk factors Cutoff levels based receiver operating characteristic  plus  total FLCs delineated risk groups highly significant differences overall survival International Prognostic Scoring System-adjusted hazard ratio PMF 1.9 95 CI 1.3 2.7 6.3 95 CI 2.7 16.6 MDS correlations seen leukemia-free survival karyotype JAK2 MPL IDH patients PMF studied cytokine profiling prognostic value increased FLC level independent circulating interleukin-2 receptor IL-2R IL-8 levels Increased plasma FLC concentration predicts inferior survival PMF MDS lack correlation leukemia-free survival tumor-specific genetic markers suggests primarily host-driven biologic phenomenon broadly applicable,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 1237, 17, 2592, 525, 1, 1204, 250, 51, 68, 678, 25, 4, 533, 441, 408, 1, 2181, 3320, 5412, 21, 6177, 554, 2593, 115, 1691, 1260, 4266, 1227, 22, 3, 901, 1, 1333, 100, 306, 736, 1, 7, 5, 86, 4637, 7389, 15, 2040, 1223, 11, 656, 3096, 4627, 2, 8561, 12441, 17307, 11, 644, 20, 8, 1156, 38402, 719, 7, 5, 848, 4266, 11, 1800, 1030, 17, 11, 2090, 3, 1726, 2385, 1, 295, 9, 4627, 15, 12441, 4266, 11, 1405, 4, 466, 1, 4263, 7, 5, 7389, 2, 641, 1, 794, 7, 5, 1223, 101, 4266, 10, 97, 41, 5, 101, 3177, 2, 131, 89, 4, 7389, 19, 144, 2, 2222, 299, 76, 79, 499, 1826, 4, 1223, 19, 1614, 4, 658, 65, 101, 4266, 783, 6151, 25, 4, 110, 7389, 2, 1223, 306, 1, 89, 3177, 2, 127, 809, 43, 130, 2779, 148, 90, 23, 3185, 2584, 2037, 65, 9, 4627, 349, 12441, 181, 17307, 5610, 43, 271, 5, 561, 93, 362, 4, 63, 25, 944, 177, 2504, 398, 586, 360, 197, 4, 7389, 10, 14, 83, 48, 58, 14, 27, 6, 18, 67, 2, 10, 49, 27, 48, 58, 18, 67, 6, 245, 49, 4, 1223, 77, 2553, 11, 527, 5, 2647, 115, 25, 3385, 15, 2509, 16440, 15, 3056, 138, 4, 7, 5, 7389, 54, 11, 656, 20, 1675, 1080, 3, 177, 549, 1, 35, 101, 4266, 301, 10, 306, 1, 17, 29, 1033, 1603, 18, 153, 501, 8145, 15, 501, 66, 148, 101, 554, 4266, 1227, 2623, 1663, 25, 4, 110, 7389, 2, 1223, 211, 926, 1, 816, 5, 2647, 115, 25, 2, 30, 112, 336, 525, 844, 8, 1561, 1204, 1621, 1283, 3936, 17, 822, 40, 80, 5482, 3801]",1754.0,22331938,Polyclonal immunoglobulin free light chain levels predict survival myeloid neoplasms,0,0.0
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-02-13,"The karyotype is a strong independent prognostic factor in myelodysplastic syndromes (MDS). Since the implementation of the International Prognostic Scoring System (IPSS) in 1997, knowledge concerning the prognostic impact of abnormalities has increased substantially. The present study proposes a new and comprehensive cytogenetic scoring system based on an international data collection of 2,902 patients. Patients were included from the German-Austrian MDS Study Group (n = 1,193), the International MDS Risk Analysis Workshop (n = 816), the Spanish Hematological Cytogenetics Working Group (n = 849), and the International Working Group on MDS Cytogenetics (n = 44) databases. Patients with primary MDS and oligoblastic acute myeloid leukemia (AML) after MDS treated with supportive care only were evaluated for overall survival (OS) and AML evolution. Internal validation by bootstrap analysis and external validation in an independent patient cohort were performed to confirm the results. In total, 19 cytogenetic categories were defined, providing clear prognostic classification in 91% of all patients. The abnormalities were classified into five prognostic subgroups (P < .001): very good (median OS, 61 months; hazard ratio [HR], 0.5; n = 81); good (49 months; HR, 1.0 [reference category]; n = 1,809); intermediate (26 months; HR, 1.6; n = 529); poor (16 months; HR, 2.6; n = 148); and very poor (6 months; HR, 4.2; n = 187). The internal and external validations confirmed the results of the score. In conclusion, these data should contribute to the ongoing efforts to update the IPSS by refining the cytogenetic risk categories.",Journal Article,2899.0,400.0,"karyotype strong independent prognostic factor myelodysplastic syndromes MDS implementation International Prognostic Scoring IPSS 1997 knowledge concerning prognostic impact abnormalities increased substantially present proposes new comprehensive cytogenetic scoring based international collection 2,902 patients Patients included German-Austrian MDS Group n 1,193 International MDS Risk Workshop n 816 Spanish Hematological Cytogenetics Working Group n 849 International Working Group MDS Cytogenetics n 44 databases Patients primary MDS oligoblastic acute myeloid leukemia AML MDS treated supportive care evaluated overall survival OS AML evolution Internal validation bootstrap external validation independent patient cohort performed confirm total 19 cytogenetic categories defined providing clear prognostic classification 91 patients abnormalities classified prognostic subgroups P .001 good median OS 61 months hazard ratio HR 0.5 n 81 good 49 months HR 1.0 reference category n 1,809 intermediate 26 months HR 1.6 n 529 poor 16 months HR 2.6 n 148 poor 6 months HR 4.2 n 187 internal external validations confirmed score contribute ongoing efforts update IPSS refining cytogenetic risk categories",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 3385, 16, 8, 1082, 306, 177, 161, 4, 2040, 1223, 1192, 3, 2393, 1, 3, 944, 177, 2504, 398, 8751, 4, 2341, 922, 4243, 3, 177, 345, 1, 1171, 71, 101, 2109, 3, 364, 45, 9785, 8, 217, 2, 949, 1266, 2504, 398, 90, 23, 35, 944, 74, 2442, 1, 18, 13676, 7, 7, 11, 159, 29, 3, 10842, 22455, 1223, 45, 87, 78, 14, 5744, 3, 944, 1223, 43, 65, 4014, 78, 11501, 3, 8733, 2890, 2510, 2644, 87, 78, 16059, 2, 3, 944, 2644, 87, 23, 1223, 2510, 78, 584, 2348, 7, 5, 86, 1223, 2, 47053, 286, 533, 329, 50, 1223, 73, 5, 1877, 165, 158, 11, 194, 9, 63, 25, 118, 2, 329, 2554, 2329, 929, 20, 8086, 65, 2, 1455, 929, 4, 35, 306, 69, 180, 11, 173, 6, 1843, 3, 99, 4, 181, 326, 1266, 1996, 11, 395, 1736, 885, 177, 947, 4, 970, 1, 62, 7, 3, 1171, 11, 1373, 237, 365, 177, 1453, 19, 144, 923, 1178, 52, 118, 713, 53, 360, 197, 168, 13, 33, 78, 865, 1178, 739, 53, 168, 14, 13, 2482, 2169, 78, 14, 14494, 919, 432, 53, 168, 14, 49, 78, 14964, 334, 245, 53, 168, 18, 49, 78, 4647, 2, 923, 334, 49, 53, 168, 39, 18, 78, 5568, 3, 2329, 2, 1455, 23553, 557, 3, 99, 1, 3, 368, 4, 1221, 46, 74, 257, 1248, 6, 3, 942, 1413, 6, 2991, 3, 8751, 20, 10810, 3, 1266, 43, 1996]",1525.0,22331955,New comprehensive cytogenetic scoring primary myelodysplastic syndromes MDS oligoblastic acute myeloid leukemia MDS derived international database merge,187,0.3263525305410122
"Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-02-27,"Interstitial deletions of chromosome 5q are common in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), pointing toward the pathogenic role of this region in disease phenotype and clonal evolution. The higher level of resolution of single-nucleotide polymorphism array (SNP-A) karyotyping may be used to find cryptic abnormalities and to precisely define the topographic features of the genomic lesions, allowing for more accurate clinical correlations. We analyzed high-density SNP-A karyotyping at diagnosis for a cohort of 1,155 clinically well-annotated patients with malignant myeloid disorders. results: We identified chromosome 5q deletions in 142 (12%) of 1,155 patients and uniparental disomy segments (UPD) in four (0.35%) of 1,155 patients. Patients with deletions involving the centromeric and telomeric extremes of 5q have a more aggressive disease phenotype and additional chromosomal lesions. Lesions not involving the centromeric or telomeric extremes of 5q are not exclusive to 5q- syndrome but can be associated with other less aggressive forms of MDS. In addition, larger 5q deletions are associated with either del(17p) or UPD17p. In 31 of 33 patients with del(5q) AML, either a deletion involving the centromeric and/or telomeric regions or heterozygous mutations in NPM1 or MAML1 located in 5q35 were present. Our results suggest that the extent of the affected region on 5q determines clinical characteristics that can be further modified by heterozygous mutations present in the telomeric extreme.",Comparative Study,2885.0,69.0,"Interstitial deletions chromosome 5q common acute myeloid leukemia AML myelodysplastic syndromes MDS pointing pathogenic role region disease phenotype clonal evolution higher level resolution single-nucleotide polymorphism array SNP-A karyotyping cryptic abnormalities precisely define topographic features genomic lesions allowing accurate clinical correlations high-density SNP-A karyotyping diagnosis cohort 1,155 clinically well-annotated patients malignant myeloid disorders identified chromosome 5q deletions 142 12 1,155 patients uniparental disomy segments UPD 0.35 1,155 patients Patients deletions involving centromeric telomeric extremes 5q aggressive disease phenotype additional chromosomal lesions Lesions involving centromeric telomeric extremes 5q exclusive 5q- syndrome associated aggressive forms MDS addition larger 5q deletions associated del 17p UPD17p 31 33 patients del 5q AML deletion involving centromeric and/or telomeric regions heterozygous NPM1 MAML1 located 5q35 present suggest extent affected region 5q determines clinical characteristics modified heterozygous present telomeric extreme",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4543, 2439, 1, 1170, 5460, 32, 186, 4, 286, 533, 329, 2, 2040, 1223, 11548, 1317, 3, 2806, 200, 1, 26, 1053, 4, 34, 1005, 2, 1946, 2554, 3, 142, 301, 1, 2125, 1, 226, 1579, 1907, 1926, 1845, 8, 10406, 68, 40, 95, 6, 2469, 10294, 1171, 2, 6, 7428, 1107, 3, 35316, 404, 1, 3, 572, 406, 2952, 9, 80, 1481, 38, 2553, 21, 311, 64, 1263, 1845, 8, 10406, 28, 147, 9, 8, 180, 1, 14, 3735, 505, 149, 6196, 7, 5, 393, 533, 1997, 99, 21, 108, 1170, 5460, 2439, 4, 4785, 133, 1, 14, 3735, 7, 2, 17888, 13983, 5138, 19137, 4, 294, 13, 465, 1, 14, 3735, 7, 7, 5, 2439, 1267, 3, 15531, 2, 10944, 13107, 1, 5460, 47, 8, 80, 571, 34, 1005, 2, 402, 1860, 406, 406, 44, 1267, 3, 15531, 15, 10944, 13107, 1, 5460, 32, 44, 4804, 6, 5460, 681, 84, 122, 40, 41, 5, 127, 299, 571, 2377, 1, 1223, 4, 352, 1077, 5460, 2439, 32, 41, 5, 361, 3084, 4135, 15, 61180, 4, 456, 1, 466, 7, 5, 3084, 5460, 329, 361, 8, 1528, 1267, 3, 15531, 2, 15, 10944, 1374, 15, 4167, 138, 4, 4318, 15, 30356, 2308, 4, 31468, 11, 364, 114, 99, 309, 17, 3, 1039, 1, 3, 1424, 1053, 23, 5460, 9476, 38, 374, 17, 122, 40, 195, 1230, 20, 4167, 138, 364, 4, 3, 10944, 5611]",1482.0,22370328,Topography clinical genomic correlates 5q myeloid malignancies revisited,17,0.029668411867364748
"Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: results of a bone marrow failure consortium study.",Leukemia research,Leuk. Res.,2012-03-02,"Large granular lymphocyte (LGL) leukemia is characterized by clonal expansion of antigen-activated cytotoxic T cells (CTL). Patients frequently exhibit seroreactivity against a human T-cell leukemia virus (HTLV) epitope, BA21. Aplastic anemia, paroxysmal nocturnal hemoglobinuria and myelodysplastic syndrome are bone marrow failure diseases that can also be associated with similar aberrant CTL activation (LGL-BMF). We identified a BA21 peptide that was specifically reactive with LGL leukemia sera and found significantly elevated antibody reactivity against the same peptide in LGL-BMF sera. This finding of shared seroreactivity in LGL-BMF conditions and LGL leukemia suggests that these diseases might share a common pathogenesis.",Journal Article,2881.0,9.0,Large granular lymphocyte LGL leukemia characterized clonal expansion antigen-activated cytotoxic CTL Patients frequently exhibit seroreactivity human T-cell leukemia virus HTLV epitope BA21 Aplastic anemia paroxysmal nocturnal hemoglobinuria myelodysplastic syndrome bone marrow failure diseases associated similar aberrant CTL activation LGL-BMF identified BA21 peptide specifically reactive LGL leukemia sera significantly elevated antibody reactivity peptide LGL-BMF sera finding shared seroreactivity LGL-BMF conditions LGL leukemia suggests diseases share common pathogenesis,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[375, 7694, 1448, 7816, 16, 765, 20, 1946, 1422, 1, 448, 735, 759, 102, 37, 3872, 7, 746, 2239, 22268, 480, 8, 171, 102, 31, 1450, 15953, 4430, 30736, 16315, 1545, 38639, 20257, 38729, 2, 681, 32, 581, 496, 1342, 17, 122, 120, 40, 41, 5, 288, 1898, 3872, 363, 7816, 13680, 21, 108, 8, 30736, 1389, 17, 10, 1225, 2163, 5, 7816, 4210, 2, 204, 97, 804, 548, 4601, 480, 3, 827, 1389, 4, 7816, 13680, 4210, 26, 1567, 1, 2664, 22268, 4, 7816, 13680, 1298, 2, 7816, 844, 17, 46, 1342, 822, 4349, 8, 186, 1384]",664.0,22386729,Seroreactivity LGL leukemia-specific epitopes aplastic anemia myelodysplastic syndrome paroxysmal nocturnal hemoglobinuria bone marrow failure consortium,1,0.0017452006980802793
Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide.,Journal of hematology & oncology,J Hematol Oncol,2012-03-05,"While lenalidomide (LEN) shows high efficacy in myelodysplastic syndromes (MDS) with del[5q], responses can be also seen in patients presenting without del[5q]. We hypothesized that improved detection of chromosomal abnormalities with new karyotyping tools may better predict response to LEN. We have studied clinical, molecular and cytogenetic features of 42 patients with MDS, myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes and secondary acute myeloid leukemia (sAML) without del[5q] by metaphase cytogenetics (MC) who underwent therapy with LEN. Fluorescence in situ hybridization (FISH) or single nucleotide polymorphism array (SNP-A)-based karyotyping marginally increased the diagnostic yield over MC, detecting 2/42 (4.8%) additional cases with del[5q], one of whom were responded to LEN. Responses were more often observed in patients with a normal karyotype by MC (60% vs abnormal MC; 17%, p = .08) and those with gain of chromosome 8 material by either of all 3 karyotyping methods (83% vs all other chromosomal abnormalities; 44% p = .11). However, 5 out of those 6 patients received combined LEN/AZA therapy and it may also suggest those with gain of chromosome 8 material respond well to AZA. The addition of FISH or SNP-A did not improve the predictive value of normal cytogenetics by MC. Mutational analysis of TET2, UTX, CBL, EZH2, ASXL1, TP53, RAS, IDH1/2, and DNMT-3A was performed on 21 of 41 patients, and revealed 13 mutations in 11 patients, but did not show any molecular markers of responsiveness to LEN. Normal karyotype and gain of chromosome 8 material was predictive of response to LEN in non-del[5q] patients with myeloid malignancies.",Journal Article,2878.0,18.0,lenalidomide LEN shows high efficacy myelodysplastic syndromes MDS del 5q responses seen patients presenting del 5q hypothesized improved detection chromosomal abnormalities new karyotyping tools better predict response LEN studied clinical molecular cytogenetic features 42 patients MDS myeloproliferative neoplasms MPN MDS/MPN overlap syndromes secondary acute myeloid leukemia sAML del 5q metaphase cytogenetics MC underwent therapy LEN Fluorescence situ hybridization FISH single nucleotide polymorphism array SNP-A -based karyotyping marginally increased diagnostic yield MC detecting 2/42 4.8 additional cases del 5q responded LEN Responses observed patients normal karyotype MC 60 vs abnormal MC 17 p .08 gain chromosome 8 material 3 karyotyping methods 83 vs chromosomal abnormalities 44 p .11 5 6 patients received combined LEN/AZA therapy suggest gain chromosome 8 material respond AZA addition FISH SNP-A improve predictive value normal cytogenetics MC TET2 UTX CBL EZH2 ASXL1 TP53 RAS IDH1/2 DNMT-3A performed 21 41 patients revealed 13 11 patients molecular markers responsiveness LEN Normal karyotype gain chromosome 8 material predictive response LEN non-del 5q patients myeloid malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[369, 1288, 6841, 1949, 64, 209, 4, 2040, 1223, 5, 3084, 5460, 253, 122, 40, 120, 527, 4, 7, 1656, 187, 3084, 5460, 21, 1237, 17, 231, 638, 1, 1860, 1171, 5, 217, 10406, 1896, 68, 380, 678, 51, 6, 6841, 21, 47, 656, 38, 219, 2, 1266, 404, 1, 595, 7, 5, 1223, 1179, 4125, 1223, 4125, 4526, 2040, 2, 568, 286, 533, 8991, 187, 3084, 5460, 20, 10569, 2510, 4779, 54, 208, 36, 5, 6841, 1591, 4, 957, 1554, 1277, 15, 226, 1579, 1907, 1926, 1845, 8, 90, 10406, 5007, 101, 3, 752, 2309, 252, 4779, 2502, 18, 595, 39, 66, 402, 140, 5, 3084, 5460, 104, 1, 953, 11, 2211, 6, 6841, 253, 11, 80, 629, 164, 4, 7, 5, 8, 295, 3385, 20, 4779, 335, 105, 1668, 4779, 269, 19, 1592, 2, 135, 5, 1803, 1, 1170, 66, 3692, 20, 361, 1, 62, 27, 10406, 636, 852, 105, 62, 127, 1860, 1171, 584, 19, 175, 137, 33, 1205, 1, 135, 49, 7, 103, 397, 6841, 3924, 36, 2, 192, 68, 120, 309, 135, 5, 1803, 1, 1170, 66, 3692, 1892, 149, 6, 3924, 3, 352, 1, 1277, 15, 1845, 8, 205, 44, 401, 3, 464, 549, 1, 295, 2510, 20, 4779, 1619, 65, 1, 5038, 23889, 6925, 3755, 7782, 1206, 1102, 2662, 18, 2, 10229, 6981, 10, 173, 23, 239, 1, 605, 7, 2, 553, 233, 138, 4, 175, 7, 84, 205, 44, 514, 500, 219, 525, 1, 3642, 6, 6841, 295, 3385, 2, 1803, 1, 1170, 66, 3692, 10, 464, 1, 51, 6, 6841, 4, 220, 3084, 5460, 7, 5, 533, 441]",1573.0,22390313,Cytogenetic molecular predictors response patients myeloid malignancies del 5q treated lenalidomide,1,0.0017452006980802793
Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.,Cancer,Cancer,2012-03-05,"Children who are treated for myeloid leukemia associated with Down syndrome (DS) experience superior survival compared with children who have myeloid leukemia without DS. To maintain excellent outcomes while avoiding toxicity, the Children's Oncology Group (COG) conducted the phase 3 trial COG A2971, the first trial solely designed to provide uniform treatment of myeloid leukemia in North American children with DS. A2971 eliminated 2 induction drugs and 3 months of maintenance therapy from the standard-timing regimen of dexamethasone, cytarabine, 6-thioguanine, etoposide, and rubidomycin/daunomycin (DCTER) used in the previous study (Children's Cancer Group [CCG] 2891). COG A2971 was a multi-institutional, nonrandomized, clinical trial that enrolled 132 patients who had DS with either acute myeloid leukemia (n = 91) or myelodysplastic syndrome (n = 41). The median follow-up was 4.8 years (range, 0.8-8.6 years), the median age at diagnosis was 1.7 years (range, 0.3-13.6 years), and the median white blood cell count was 6200/L (range, 900-164,900/L). The remission rate (92.7%  6%) was similar to that reported in the CCG 2891 study (91.3%  5%; P = .679). The 5-year event free survival (EFS) rate was 79%  7% (vs 77%  7% in CCG 2891; P = .589), the disease-free survival (DFS) rate was 89%  6% (vs 85%  6% in CCG 2891; P = .337), and the overall survival rate was 84%  6% (vs 79%  7% in CCG 2891; P = .302). Induction day-14 bone marrow response trended toward a more favorable outcome (EFS: P = .12). Age >4 years was an adverse risk factor (5-year EFS rate: 33%  38% for children aged >4 years [median, 8.5 years; n = 6] vs 81%  7% for children ages 0-4 years [median, 1.7 years; n = 126]; P = .001). The COG A2971 trial reduced the chemotherapy dose and maintained survival to that achieved by the CCG 2891 trial in children who had myeloid leukemia associated with DS.","Clinical Trial, Phase III",2878.0,40.0,"Children treated myeloid leukemia associated syndrome DS experience superior survival compared children myeloid leukemia DS maintain excellent outcomes avoiding toxicity Children 's Oncology Group COG conducted phase 3 trial COG A2971 trial solely designed provide uniform treatment myeloid leukemia North American children DS A2971 eliminated 2 induction drugs 3 months maintenance therapy standard-timing regimen dexamethasone cytarabine 6-thioguanine etoposide rubidomycin/daunomycin DCTER previous Children 's Group CCG 2891 COG A2971 multi-institutional nonrandomized clinical trial enrolled 132 patients DS acute myeloid leukemia n 91 myelodysplastic syndrome n 41 median follow-up 4.8 years range 0.8-8.6 years median age diagnosis 1.7 years range 0.3-13.6 years median white blood count 6200/L range 900-164,900/L remission rate 92.7  6 similar reported CCG 2891 91.3  5 P .679 5-year event free survival EFS rate 79  7 vs 77  7 CCG 2891 P .589 disease-free survival DFS rate 89  6 vs 85  6 CCG 2891 P .337 overall survival rate 84  6 vs 79  7 CCG 2891 P .302 Induction day-14 bone marrow response trended favorable outcome EFS P .12 Age 4 years adverse risk factor 5-year EFS rate 33  38 children aged 4 years median 8.5 years n 6 vs 81  7 children ages 0-4 years median 1.7 years n 126 P .001 COG A2971 trial reduced chemotherapy dose maintained survival achieved CCG 2891 trial children myeloid leukemia associated DS",0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[541, 54, 32, 73, 9, 533, 41, 5, 1328, 681, 3602, 730, 1123, 25, 72, 5, 541, 54, 47, 533, 187, 3602, 6, 3040, 1503, 123, 369, 6048, 155, 3, 541, 292, 413, 87, 6377, 426, 3, 124, 27, 160, 6377, 35322, 3, 157, 160, 5558, 1114, 6, 377, 3490, 24, 1, 533, 4, 2669, 597, 541, 5, 3602, 35322, 6173, 18, 504, 600, 2, 27, 53, 1, 1146, 36, 29, 3, 260, 1972, 477, 1, 1217, 1855, 49, 17598, 1934, 2, 61203, 33534, 29038, 95, 4, 3, 698, 45, 541, 292, 12, 87, 9457, 23972, 6377, 35322, 10, 8, 1414, 1115, 5666, 38, 160, 17, 346, 4255, 7, 54, 42, 3602, 5, 361, 286, 533, 78, 970, 15, 681, 78, 605, 3, 52, 166, 126, 10, 39, 66, 60, 184, 13, 66, 66, 49, 60, 3, 52, 89, 28, 147, 10, 14, 67, 60, 184, 13, 27, 233, 49, 60, 2, 3, 52, 886, 315, 31, 1276, 10, 47102, 5513, 184, 5310, 5279, 5310, 5513, 3, 734, 116, 937, 67, 810, 49, 10, 288, 6, 17, 210, 4, 3, 9457, 23972, 45, 970, 27, 810, 33, 19, 12790, 3, 33, 111, 774, 115, 25, 1683, 116, 10, 842, 810, 67, 105, 849, 810, 67, 4, 9457, 23972, 19, 11858, 3, 34, 115, 25, 1010, 116, 10, 887, 810, 49, 105, 772, 810, 49, 4, 9457, 23972, 19, 8275, 2, 3, 63, 25, 116, 10, 874, 810, 49, 105, 842, 810, 67, 4, 9457, 23972, 19, 4952, 504, 218, 213, 581, 51, 6374, 1317, 8, 80, 913, 228, 1683, 19, 133, 89, 39, 60, 10, 35, 290, 43, 161, 33, 111, 1683, 116, 466, 810, 519, 9, 541, 1032, 39, 60, 52, 66, 33, 60, 78, 49, 105, 865, 810, 67, 9, 541, 2165, 13, 39, 60, 52, 14, 67, 60, 78, 3927, 19, 144, 3, 6377, 35322, 160, 405, 3, 56, 61, 2, 1955, 25, 6, 17, 513, 20, 3, 9457, 23972, 160, 4, 541, 54, 42, 533, 41, 5, 3602]",1715.0,22392565,Favorable survival maintained children myeloid leukemia associated syndrome reduced-dose chemotherapy Children 's Oncology Group trial A2971 report Children 's Oncology Group,0,0.0
Does iron overload really matter in stem cell transplantation?,American journal of hematology,Am. J. Hematol.,2012-04-04,"A growing body of evidence suggests that iron overload is associated with inferior outcomes after myeloablative allogeneic hematopoietic stem cell transplantation (HSCT). However, all of those studies used surrogate markers of iron overload, especially serum ferritin, and most had a retrospective design. We conducted a prospective observational study in patients with myelodysplastic syndrome or acute leukemia undergoing myeloablative HSCT. Forty-five patients who were followed for over 1 year, with serial measurements of serum iron parameters, as well as liver and cardiac magnetic resonance imaging. There was no significant increase in ferritin, liver or cardiac iron content in the 12 months following HSCT. Although serum ferritin still appeared to have prognostic significance, as previously reported, pre-HSCT iron overload (as reflected in liver iron content) was not associated with increased mortality, relapse, or graft-versus-host disease. These results raise the possibility that the adverse prognostic impact of pre-HSCT hyperferritinemia may be related to factors independent of iron overload.",Journal Article,2848.0,46.0,growing body evidence suggests iron overload associated inferior outcomes myeloablative allogeneic hematopoietic stem transplantation HSCT studies surrogate markers iron overload especially serum ferritin retrospective design conducted prospective observational patients myelodysplastic syndrome acute leukemia undergoing myeloablative HSCT Forty-five patients followed 1 year serial measurements serum iron parameters liver cardiac magnetic resonance imaging significant increase ferritin liver cardiac iron content 12 months following HSCT serum ferritin appeared prognostic significance previously reported pre-HSCT iron overload reflected liver iron content associated increased mortality relapse graft-versus-host disease raise possibility adverse prognostic impact pre-HSCT hyperferritinemia related factors independent iron overload,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,"[8, 1921, 642, 1, 241, 844, 17, 4231, 13143, 16, 41, 5, 1663, 123, 50, 3246, 1063, 1007, 452, 31, 497, 1703, 137, 62, 1, 135, 94, 95, 2592, 525, 1, 4231, 13143, 1093, 524, 9101, 2, 96, 42, 8, 459, 771, 21, 426, 8, 482, 2495, 45, 4, 7, 5, 681, 15, 286, 479, 3246, 1703, 1213, 365, 7, 54, 11, 370, 9, 252, 14, 111, 5, 2108, 1685, 1, 524, 4231, 1038, 22, 149, 22, 2, 1484, 1535, 270, 125, 10, 77, 93, 344, 4, 9101, 15, 4231, 2457, 4, 3, 133, 53, 366, 1703, 242, 524, 9101, 1234, 2121, 6, 47, 177, 724, 22, 373, 210, 671, 1703, 4231, 13143, 22, 4686, 4, 4231, 2457, 10, 44, 41, 5, 101, 282, 429, 15, 1599, 185, 1204, 34, 46, 99, 5008, 3, 2526, 17, 3, 290, 177, 345, 1, 671, 1703, 39944, 68, 40, 139, 6, 130, 306, 1, 4231, 13143]",1033.0,22473510,iron overload matter stem transplantation,1,0.0017452006980802793
"Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.","Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2012-04-24,"We evaluated the efficacy and safety of the combination of twice-daily fludarabine and cytarabine (BIDFA) in patients with refractory/relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and chronic myeloid leukemia in myeloid blast phase (CML-BP). One hundred seven patients were enrolled. Overall, 27 (26%) patients responded with a complete remission (CR) rate of 21% and CR without platelet recovery (CRp) of 5%. The overall 4-week mortality rate was 9%. In conclusion, BIDFA is active and safe in heavily pretreated patients with myeloid malignancies. The purpose of this study was to evaluate the efficacy and safety of the combination of twice-daily fludarabine and cytarabine (BIDFA) in patients with refractory/relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and chronic myeloid leukemia in myeloid blast phase (CML-BP). One hundred seven patients with refractory/relapsed AML, intermediate and high-risk MDS, and CML-BP, with a performance status of 3 or less and normal organ function were treated. Patients received fludarabine 15 mg/m(2) intravenously (IV) every 12 hours on days 1 to 5 and cytarabine 0.5 g/m(2) IV over 2 hours every 12 hours on days 1 to 5. Gemtuzumab ozogamicin (GO) was administered at 3 mg/m(2) IV on day 1 in the first 59 patients. Patients with CML-BP were allowed to receive concomitant tyrosine kinase inhibitors. Overall, 27 (26%) patients responded with a complete remission (CR) rate of 21% and CR without platelet recovery of 5%. The overall 4-week mortality rate was 9%. The CR rates for patients with relapsed AML with first CR duration greater than or equal to 12 months, relapsed AML with first CR duration less than 12 months, and refractory/relapsed AML beyond first salvage were 56%, 26%, and 11%, respectively. With a median follow-up of 7 months, the 6-month event-free survival, overall survival, and complete remission CR duration rates were 18%, 35%, and 70%, respectively. BIDFA is active with an overall response rate of 26% in a heavily pretreated population. This combination is safe with a low 4-week mortality rate of 9%.",Clinical Trial,2828.0,23.0,evaluated efficacy safety combination twice-daily fludarabine cytarabine BIDFA patients refractory/relapsed acute myeloid leukemia AML high-risk myelodysplastic syndromes MDS chronic myeloid leukemia myeloid blast phase CML-BP seven patients enrolled Overall 27 26 patients responded complete remission CR rate 21 CR platelet recovery CRp 5 overall 4-week mortality rate 9 BIDFA active safe heavily pretreated patients myeloid malignancies purpose evaluate efficacy safety combination twice-daily fludarabine cytarabine BIDFA patients refractory/relapsed acute myeloid leukemia AML high-risk myelodysplastic syndromes MDS chronic myeloid leukemia myeloid blast phase CML-BP seven patients refractory/relapsed AML intermediate high-risk MDS CML-BP performance status 3 normal organ function treated Patients received fludarabine 15 mg/m 2 intravenously IV 12 hours days 1 5 cytarabine 0.5 g/m 2 IV 2 hours 12 hours days 1 5 Gemtuzumab ozogamicin administered 3 mg/m 2 IV day 1 59 patients Patients CML-BP allowed receive concomitant tyrosine kinase inhibitors Overall 27 26 patients responded complete remission CR rate 21 CR platelet recovery 5 overall 4-week mortality rate 9 CR rates patients relapsed AML CR duration greater equal 12 months relapsed AML CR duration 12 months refractory/relapsed AML salvage 56 26 11 respectively median follow-up 7 months 6-month event-free survival overall survival complete remission CR duration rates 18 35 70 respectively BIDFA active overall response rate 26 heavily pretreated population combination safe low 4-week mortality rate 9,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 194, 3, 209, 2, 367, 1, 3, 150, 1, 936, 391, 2027, 2, 1855, 35353, 4, 7, 5, 430, 591, 286, 533, 329, 64, 43, 2040, 1223, 2, 442, 533, 4, 533, 3112, 124, 903, 3044, 104, 1128, 648, 7, 11, 346, 63, 428, 432, 7, 2211, 5, 8, 236, 734, 684, 116, 1, 239, 2, 684, 187, 1596, 1602, 3162, 1, 33, 3, 63, 39, 647, 282, 116, 10, 83, 4, 1221, 35353, 16, 544, 2, 1165, 4, 2447, 2193, 7, 5, 533, 441, 3, 743, 1, 26, 45, 10, 6, 376, 3, 209, 2, 367, 1, 3, 150, 1, 936, 391, 2027, 2, 1855, 35353, 4, 7, 5, 430, 591, 286, 533, 329, 64, 43, 2040, 1223, 2, 442, 533, 4, 533, 3112, 124, 903, 3044, 104, 1128, 648, 7, 5, 430, 591, 329, 919, 2, 64, 43, 1223, 2, 903, 3044, 5, 8, 528, 156, 1, 27, 15, 299, 2, 295, 1259, 343, 11, 73, 7, 103, 2027, 167, 81, 188, 18, 1672, 478, 454, 133, 1459, 23, 162, 14, 6, 33, 2, 1855, 13, 33, 499, 188, 18, 478, 252, 18, 1459, 454, 133, 1459, 23, 162, 14, 6, 33, 7918, 5566, 3537, 10, 468, 28, 27, 81, 188, 18, 478, 23, 218, 14, 4, 3, 157, 728, 7, 7, 5, 903, 3044, 11, 2313, 6, 560, 1781, 564, 216, 222, 63, 428, 432, 7, 2211, 5, 8, 236, 734, 684, 116, 1, 239, 2, 684, 187, 1596, 1602, 1, 33, 3, 63, 39, 647, 282, 116, 10, 83, 3, 684, 151, 9, 7, 5, 591, 329, 5, 157, 684, 654, 378, 76, 15, 2997, 6, 133, 53, 591, 329, 5, 157, 684, 654, 299, 76, 133, 53, 2, 430, 591, 329, 1654, 157, 992, 11, 664, 432, 2, 175, 106, 5, 8, 52, 166, 126, 1, 67, 53, 3, 49, 811, 774, 115, 25, 63, 25, 2, 236, 734, 684, 654, 151, 11, 203, 465, 2, 431, 106, 35353, 16, 544, 5, 35, 63, 51, 116, 1, 432, 4, 8, 2447, 2193, 266, 26, 150, 16, 1165, 5, 8, 154, 39, 647, 282, 116, 1, 83]",1991.0,22534616,Twice-daily fludarabine cytarabine combination gentuzumab ozogamicin effective patients relapsed/refractory acute myeloid leukemia high-risk myelodysplastic syndrome blast- phase chronic myeloid leukemia,0,0.0
Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2012-06-01,"A phase I-II study of bendamustine fractionated twice daily schedule for 4 days identified 75 mg/m(2) intravenously(IV) twice daily for 4 days as a phase II study schedule. Alkylating agents have shown activity in leukemia. Bendamustine, an active alkylating agent in lymphoma and chronic lymphocytic leukemia, was given in a fractionated twice daily schedule for 4 days to patients with acute leukemia and myelodysplastic syndrome (MDS) to define the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD). Adults with refractory acute leukemia or high-risk MDS were treated with bendamustine at a starting dose of 50 mg/m(2) IV over 1-2 hours twice daily for 4 days. Dose escalations were by 25 mg/m(2) in the 1st 3 levels. The study used the 3 + 3 design. A total of 25 patients were treated. Their median age was 57 years; the median salvage number was 3. Grade 2 creatinine elevations were observed in 1 of 6 patients at the 50 mg/m(2) dose, in 2 of 13 patients at the 75 mg/m(2) dose, and in 3 of 6 patients at the 100 mg/m(2) dose. This was considered significant, even though DLT was not reached. One patient achieved marrow complete remission. Significant reductions of marrow blasts (50% or more) were observed in 6 of 25 patients (24%). Bendamustine fractionated dose level of 100 mg/m(2) IV twice daily for 4 days (800 mg/m(2) per course) was associated with Grade 2 renal toxicity. The proposed phase II schedule is 75 mg/m(2) IV twice daily for 4 days. Future studies should evaluate this schedule in less heavily treated patients.","Clinical Trial, Phase I",2790.0,3.0,phase I-II bendamustine fractionated twice daily schedule 4 days identified 75 mg/m 2 intravenously IV twice daily 4 days phase II schedule Alkylating agents shown activity leukemia Bendamustine active alkylating agent lymphoma chronic lymphocytic leukemia given fractionated twice daily schedule 4 days patients acute leukemia myelodysplastic syndrome MDS define dose-limiting toxicities DLT maximum tolerated dose MTD Adults refractory acute leukemia high-risk MDS treated bendamustine starting dose 50 mg/m 2 IV 1-2 hours twice daily 4 days Dose escalations 25 mg/m 2 1st 3 levels 3 3 design total 25 patients treated median age 57 years median salvage number 3 Grade 2 creatinine elevations observed 1 6 patients 50 mg/m 2 dose 2 13 patients 75 mg/m 2 dose 3 6 patients 100 mg/m 2 dose considered significant DLT reached patient achieved marrow complete remission Significant reductions marrow blasts 50 observed 6 25 patients 24 Bendamustine fractionated dose level 100 mg/m 2 IV twice daily 4 days 800 mg/m 2 course associated Grade 2 renal toxicity proposed phase II schedule 75 mg/m 2 IV twice daily 4 days Future studies evaluate schedule heavily treated patients,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[8, 124, 70, 215, 45, 1, 4809, 3950, 936, 391, 1055, 9, 39, 162, 108, 481, 81, 188, 18, 1672, 478, 936, 391, 9, 39, 162, 22, 8, 124, 215, 45, 1055, 3410, 183, 47, 443, 128, 4, 4809, 35, 544, 3410, 420, 4, 2, 442, 1193, 10, 447, 4, 8, 3950, 936, 391, 1055, 9, 39, 162, 6, 7, 5, 286, 2, 681, 1223, 6, 1107, 3, 61, 817, 385, 2059, 2, 689, 421, 61, 961, 857, 5, 430, 286, 15, 64, 43, 1223, 11, 73, 5, 4809, 28, 8, 1723, 61, 1, 212, 81, 188, 18, 478, 252, 14, 18, 1459, 936, 391, 9, 39, 162, 61, 11388, 11, 20, 243, 81, 188, 18, 4, 3, 9524, 27, 148, 3, 45, 95, 3, 27, 27, 771, 8, 181, 1, 243, 7, 11, 73, 136, 52, 89, 10, 696, 60, 3, 52, 992, 207, 10, 27, 88, 18, 3177, 4712, 11, 164, 4, 14, 1, 49, 7, 28, 3, 212, 81, 188, 18, 61, 4, 18, 1, 233, 7, 28, 3, 481, 81, 188, 18, 61, 2, 4, 27, 1, 49, 7, 28, 3, 394, 81, 188, 18, 61, 26, 10, 515, 93, 871, 2471, 2059, 10, 44, 1300, 104, 69, 513, 581, 236, 734, 93, 2153, 1, 581, 2438, 212, 15, 80, 11, 164, 4, 49, 1, 243, 7, 259, 4809, 3950, 61, 301, 1, 394, 81, 188, 18, 478, 936, 391, 9, 39, 162, 2796, 81, 188, 18, 379, 906, 10, 41, 5, 88, 18, 155, 3, 1587, 124, 215, 1055, 16, 481, 81, 188, 18, 478, 936, 391, 9, 39, 162, 508, 94, 257, 376, 26, 1055, 4, 299, 2447, 73, 7]",1440.0,22578814,Phase I-II bendamustine patients acute leukemia high risk myelodysplastic syndrome,16,0.027923211169284468
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2012-05-10,"This phase II study assessed the efficacy and safety of lenalidomide in patients with relapsed/refractory acute myeloid leukemia (N = 18) and high-risk myelodysplastic syndrome (N = 9) with chromosome 5 abnormalities. The overall complete remission rate with or without platelet recovery was 7% (2/27). Activity of lenalidomide was limited to patients with noncomplex cytogenetics. Lenalidomide is effective in low-risk myelodysplastic syndromes (MDS) with deletion 5q. We conducted a phase II study to evaluate the safety and efficacy of lenalidomide in patients with relapsed/refractory acute myeloid leukemia (AML) and high-risk MDS with any chromosome 5 abnormality. Eighteen adults with AML and 9 with high-risk MDS were enrolled. Lenalidomide was given orally at doses 5 to 25 mg daily for 21 days of a 28-day cycle until disease progression or unacceptable adverse event. Median age for all 27 patients was 64 years (range, 39-88 years) with a median of 2 previous therapies (range, 1-6 lines). Two patients (7%) with AML and 5q deletion and +8 cytogenetic abnormality in 2 separate clones achieved complete remission (CR) or CR without platelet recovery (CRp). Response durations were 4 and 6 months, respectively. No responses were seen in patients with chromosome 5 abnormality in a complex cytogenetic background. Twenty patients (74%) developed neutropenic fever or infection requiring hospitalization. Clinical activity of lenalidomide as single agent in AML and high-risk MDS with chromosome 5 abnormalities appears to be limited to patients with noncomplex cytogenetics.","Clinical Trial, Phase II",2812.0,24.0,phase II assessed efficacy safety lenalidomide patients relapsed/refractory acute myeloid leukemia N 18 high-risk myelodysplastic syndrome N 9 chromosome 5 abnormalities overall complete remission rate platelet recovery 7 2/27 Activity lenalidomide limited patients noncomplex cytogenetics Lenalidomide effective low-risk myelodysplastic syndromes MDS deletion 5q conducted phase II evaluate safety efficacy lenalidomide patients relapsed/refractory acute myeloid leukemia AML high-risk MDS chromosome 5 abnormality Eighteen adults AML 9 high-risk MDS enrolled Lenalidomide given orally doses 5 25 mg daily 21 days 28-day cycle disease progression unacceptable adverse event Median age 27 patients 64 years range 39-88 years median 2 previous therapies range 1-6 lines patients 7 AML 5q deletion +8 cytogenetic abnormality 2 separate clones achieved complete remission CR CR platelet recovery CRp Response durations 4 6 months respectively responses seen patients chromosome 5 abnormality complex cytogenetic background patients 74 developed neutropenic fever infection requiring hospitalization Clinical activity lenalidomide single agent AML high-risk MDS chromosome 5 abnormalities appears limited patients noncomplex cytogenetics,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[26, 124, 215, 45, 275, 3, 209, 2, 367, 1, 1288, 4, 7, 5, 591, 430, 286, 533, 78, 203, 2, 64, 43, 681, 78, 83, 5, 1170, 33, 1171, 3, 63, 236, 734, 116, 5, 15, 187, 1596, 1602, 10, 67, 18, 428, 128, 1, 1288, 10, 383, 6, 7, 5, 24903, 2510, 1288, 16, 323, 4, 154, 43, 2040, 1223, 5, 1528, 5460, 21, 426, 8, 124, 215, 45, 6, 376, 3, 367, 2, 209, 1, 1288, 4, 7, 5, 591, 430, 286, 533, 329, 2, 64, 43, 1223, 5, 500, 1170, 33, 3698, 3195, 857, 5, 329, 2, 83, 5, 64, 43, 1223, 11, 346, 1288, 10, 447, 1428, 28, 415, 33, 6, 243, 81, 391, 9, 239, 162, 1, 8, 339, 218, 417, 1100, 34, 91, 15, 3215, 290, 774, 52, 89, 9, 62, 428, 7, 10, 660, 60, 184, 587, 889, 60, 5, 8, 52, 1, 18, 698, 235, 184, 14, 49, 285, 100, 7, 67, 5, 329, 2, 5460, 1528, 2, 66, 1266, 3698, 4, 18, 2282, 2749, 513, 236, 734, 684, 15, 684, 187, 1596, 1602, 3162, 51, 4864, 11, 39, 2, 49, 53, 106, 77, 253, 11, 527, 4, 7, 5, 1170, 33, 3698, 4, 8, 840, 1266, 2426, 737, 7, 794, 276, 3659, 2775, 15, 930, 1888, 2826, 38, 128, 1, 1288, 22, 226, 420, 4, 329, 2, 64, 43, 1223, 5, 1170, 33, 1171, 1233, 6, 40, 383, 6, 7, 5, 24903, 2510]",1490.0,22579233,phase II lenalidomide relapsed/refractory acute myeloid leukemia high-risk myelodysplastic syndromes chromosome 5 abnormalities,0,0.0
Lenalidomide in solid tumors.,Cancer chemotherapy and pharmacology,Cancer Chemother. Pharmacol.,2012-05-15,"Lenalidomide is a thalidomide analogue with immunomodulatory and anti-angiogenic properties that include altering cytokine production, activating T cells, and augmenting natural killer cell function. Lenalidomide is approved by the U.S. Food and Drug Administration (FDA) for single-agent treatment of myelodysplastic syndromes associated with a 5q deletion and as a combination therapy with dexamethasone for the treatment of multiple myeloma. All prospective phase I-III clinical trials and preclinical data published until October 2011 and relevant literature were reviewed. In phase I and/or II studies of single-agent lenalidomide in patients with advanced cancer, responses were reported in patients with prostate, thyroid, hepatocellular, pancreatic, and renal cancer and melanoma. The most common toxicities were hematologic, and in the first clinical trials, thrombotic events were noted. When anticoagulation prophylaxis and exclusion of patients with a history of thrombosis were implemented, thrombotic complications became uncommon. Monitoring of blood counts and for evidence of thromboembolic events is essential for patients treated with lenalidomide. Ongoing trials of lenalidomide combination therapy offer a treatment option for patients with advanced cancer and will better define the role of lenalidomide in solid tumors.",Journal Article,2807.0,19.0,Lenalidomide thalidomide analogue immunomodulatory anti-angiogenic properties include altering cytokine production activating augmenting natural killer function Lenalidomide approved U.S. Food Drug Administration FDA single-agent treatment myelodysplastic syndromes associated 5q deletion combination therapy dexamethasone treatment multiple myeloma prospective phase I-III clinical trials preclinical published October 2011 relevant literature reviewed phase and/or II studies single-agent lenalidomide patients advanced responses reported patients prostate thyroid hepatocellular pancreatic renal melanoma common toxicities hematologic clinical trials thrombotic events noted anticoagulation prophylaxis exclusion patients history thrombosis implemented thrombotic complications uncommon Monitoring blood counts evidence thromboembolic events essential patients treated lenalidomide Ongoing trials lenalidomide combination therapy offer treatment option patients advanced better define role lenalidomide solid,0,0,0,1,0,0,0,1,1,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,"[1288, 16, 8, 2159, 4696, 5, 2555, 2, 312, 2068, 1571, 17, 643, 4831, 1675, 1529, 1616, 102, 37, 2, 9015, 1504, 3458, 31, 343, 1288, 16, 850, 20, 3, 1767, 695, 1773, 2, 234, 634, 2078, 9, 226, 420, 24, 1, 2040, 41, 5, 8, 5460, 1528, 2, 22, 8, 150, 36, 5, 1217, 9, 3, 24, 1, 232, 62, 482, 124, 70, 316, 38, 143, 2, 693, 74, 983, 1100, 2551, 1132, 2, 867, 789, 11, 446, 4, 124, 70, 2, 15, 215, 94, 1, 226, 420, 1288, 4, 7, 5, 131, 12, 253, 11, 210, 4, 7, 5, 2, 12, 2, 3, 96, 186, 385, 11, 813, 2, 4, 3, 157, 38, 143, 6108, 281, 11, 1051, 198, 5361, 2049, 2, 4721, 1, 7, 5, 8, 532, 1, 2839, 11, 3426, 6108, 521, 3451, 2052, 1315, 1, 315, 1911, 2, 9, 241, 1, 4703, 281, 16, 1452, 9, 7, 73, 5, 1288, 942, 143, 1, 1288, 150, 36, 1918, 8, 24, 1501, 9, 7, 5, 131, 12, 2, 303, 380, 1107, 3, 200, 1, 1288, 4, 537, 57]",1240.0,22584909,Lenalidomide solid,2,0.0034904013961605585
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-05-14,"To evaluate the safety and efficacy of the combination of the histone deacetylase inhibitor vorinostat with idarubicin and ara-C (cytarabine) in patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). Patients with previously untreated AML or higher-risk MDS age 15 to 65 years with appropriate organ function and no core-binding factor abnormality were candidates. Induction therapy was vorinostat 500 mg orally three times a day (days 1 to 3), idarubin 12 mg/m(2) intravenously (IV) daily  3 (days 4 to 6), and cytarabine 1.5 g/m(2) IV as a continuous infusion daily for 3 or 4 days (days 4 to 7). Patients in remission could be treated with five cycles of consolidation therapy and up to 12 months of maintenance therapy with single-agent vorinostat. The study was designed to stop early if either excess toxicity or low probability of median event-free survival (EFS) of more than 28 weeks was likely. After a three-patient run-in phase, 75 patients were treated. Median age was 52 years (range, 19 to 65 years), 29 patients (39%) were cytogenetically normal, and 11 (15%) had FLT-3 internal tandem duplication (ITD). No excess vorinostat-related toxicity was observed. Induction mortality was 4%. EFS was 47 weeks (range, 3 to 134 weeks), and overall survival was 82 weeks (range, 3 to 134 weeks). Overall response rate (ORR) was 85%, including 76% complete response (CR) and 9% in CR with incomplete platelet recovery. ORR was 93% in diploid patients and 100% in FLT-3 ITD patients. Levels of NRF2 and CYBB were associated with longer survival. The combination of vorinostat with idarubicin and cytarabine is safe and active in AML.","Clinical Trial, Phase II",2808.0,110.0,evaluate safety efficacy combination histone deacetylase inhibitor vorinostat idarubicin ara-C cytarabine patients acute myelogenous leukemia AML myelodysplastic syndrome MDS Patients previously untreated AML higher-risk MDS age 15 65 years appropriate organ function core-binding factor abnormality candidates Induction therapy vorinostat 500 mg orally times day days 1 3 idarubin 12 mg/m 2 intravenously IV daily 3 days 4 6 cytarabine 1.5 g/m 2 IV continuous infusion daily 3 4 days days 4 7 Patients remission treated cycles consolidation therapy 12 months maintenance therapy single-agent vorinostat designed stop early excess toxicity low probability median event-free survival EFS 28 weeks likely three-patient run-in phase 75 patients treated Median age 52 years range 19 65 years 29 patients 39 cytogenetically normal 11 15 FLT-3 internal tandem duplication ITD excess vorinostat-related toxicity observed Induction mortality 4 EFS 47 weeks range 3 134 weeks overall survival 82 weeks range 3 134 weeks Overall response rate ORR 85 including 76 complete response CR 9 CR incomplete platelet recovery ORR 93 diploid patients 100 FLT-3 ITD patients Levels NRF2 CYBB associated longer survival combination vorinostat idarubicin cytarabine safe active AML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 376, 3, 367, 2, 209, 1, 3, 150, 1, 3, 1508, 2732, 230, 2371, 5, 5684, 2, 3899, 256, 1855, 4, 7, 5, 286, 2194, 329, 15, 681, 1223, 7, 5, 373, 1278, 329, 15, 142, 43, 1223, 89, 167, 6, 556, 60, 5, 870, 1259, 343, 2, 77, 1793, 791, 161, 3698, 11, 1931, 504, 36, 10, 2371, 1666, 81, 1428, 169, 1072, 8, 218, 162, 14, 6, 27, 61452, 133, 81, 188, 18, 1672, 478, 391, 27, 162, 39, 6, 49, 2, 1855, 14, 33, 499, 188, 18, 478, 22, 8, 1314, 904, 391, 9, 27, 15, 39, 162, 162, 39, 6, 67, 7, 4, 734, 359, 40, 73, 5, 365, 410, 1, 2173, 36, 2, 126, 6, 133, 53, 1, 1146, 36, 5, 226, 420, 2371, 3, 45, 10, 1114, 6, 7142, 191, 492, 361, 2612, 155, 15, 154, 1320, 1, 52, 774, 115, 25, 1683, 1, 80, 76, 339, 244, 10, 322, 50, 8, 169, 69, 7726, 4, 124, 481, 7, 11, 73, 52, 89, 10, 653, 60, 184, 326, 6, 556, 60, 462, 7, 587, 11, 7809, 295, 2, 175, 167, 42, 4368, 27, 2329, 2905, 4616, 2837, 77, 2612, 2371, 139, 155, 10, 164, 504, 282, 10, 39, 1683, 10, 662, 244, 184, 27, 6, 4842, 244, 2, 63, 25, 10, 878, 244, 184, 27, 6, 4842, 244, 63, 51, 116, 1735, 10, 772, 141, 846, 236, 51, 684, 2, 83, 4, 684, 5, 2610, 1596, 1602, 1735, 10, 966, 4, 6815, 7, 2, 394, 4, 4368, 27, 2837, 7, 148, 1, 5731, 2, 61453, 11, 41, 5, 589, 25, 3, 150, 1, 2371, 5, 5684, 2, 1855, 16, 1165, 2, 544, 4, 329]",1572.0,22585696,Phase II trial vorinostat idarubicin cytarabine patients newly diagnosed acute myelogenous leukemia myelodysplastic syndrome,2,0.0034904013961605585
Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-05-14,"Therapy-related myeloid neoplasms (t-MN) represent a unique clinical syndrome occurring in patients treated with chemotherapy and/or external-beam radiation (XRT) and are characterized by poorer prognosis compared with de novo disease. XRT techniques have evolved in recent years and are associated with significantly reduced bone marrow exposure. The characteristics of post-XRT t-MN in the current era have not been studied. We analyzed patients who developed acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) after XRT alone (47 patients) or cytotoxic chemotherapy/combined-modality therapy (C/CMT, 181 patients) and compared them with patients with de novo MDS or AML (222 patients). We estimated bone marrow exposure to radiation and compared the clinical, pathologic, and cytogenetic features and outcome of the XRT patients with the C/CMT patients and with patients with de novo MDS and AML. Patients with t-MN after XRT alone had superior overall survival (P = .006) and lower incidence of high-risk karyotypes (P = .01 for AML and < .001 for MDS) compared with patients in the C/CMT group. In contrast, there were no significant differences in survival or frequency of high-risk karyotypes between the XRT and de novo groups. AML and MDS diagnosed in the past decade in patients after receiving XRT alone differ from t-MN occurring after C/CMT and share genetic features and clinical behavior with de novo AML/MDS. Our results suggest that post-XRT MDS/AML may not represent a direct consequence of radiation toxicity and warrant a therapeutic approach similar to de novo disease.",Journal Article,2808.0,59.0,Therapy-related myeloid neoplasms t-MN represent unique clinical syndrome occurring patients treated chemotherapy and/or external-beam radiation XRT characterized poorer prognosis compared novo disease XRT techniques evolved recent years associated significantly reduced bone marrow exposure characteristics post-XRT t-MN current era studied patients developed acute myeloid leukemia AML myelodysplastic syndromes MDS XRT 47 patients cytotoxic chemotherapy/combined-modality therapy C/CMT 181 patients compared patients novo MDS AML 222 patients estimated bone marrow exposure radiation compared clinical pathologic cytogenetic features outcome XRT patients C/CMT patients patients novo MDS AML Patients t-MN XRT superior overall survival P .006 lower incidence high-risk karyotypes P .01 AML .001 MDS compared patients C/CMT group contrast significant differences survival frequency high-risk karyotypes XRT novo groups AML MDS diagnosed past decade patients receiving XRT differ t-MN occurring C/CMT share genetic features clinical behavior novo AML/MDS suggest post-XRT MDS/AML represent direct consequence radiation toxicity warrant therapeutic approach similar novo disease,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[36, 139, 533, 1179, 102, 4691, 1231, 8, 991, 38, 681, 1821, 4, 7, 73, 5, 56, 2, 15, 1455, 1345, 121, 3429, 2, 32, 765, 20, 1769, 356, 72, 5, 1566, 2018, 34, 3429, 1092, 47, 3937, 4, 435, 60, 2, 32, 41, 5, 97, 405, 581, 645, 3, 374, 1, 539, 3429, 102, 4691, 4, 3, 291, 1713, 47, 44, 85, 656, 21, 311, 7, 54, 276, 286, 533, 329, 15, 2040, 1223, 50, 3429, 279, 662, 7, 15, 759, 56, 397, 1396, 36, 256, 5380, 5540, 7, 2, 72, 1370, 5, 7, 5, 1566, 2018, 1223, 15, 329, 5647, 7, 21, 661, 581, 645, 6, 121, 2, 72, 3, 38, 510, 2, 1266, 404, 2, 228, 1, 3, 3429, 7, 5, 3, 256, 5380, 7, 2, 5, 7, 5, 1566, 2018, 1223, 2, 329, 7, 5, 102, 4691, 50, 3429, 279, 42, 1123, 63, 25, 19, 1861, 2, 280, 287, 1, 64, 43, 6809, 19, 355, 9, 329, 2, 144, 9, 1223, 72, 5, 7, 4, 3, 256, 5380, 87, 4, 748, 125, 11, 77, 93, 362, 4, 25, 15, 675, 1, 64, 43, 6809, 59, 3, 3429, 2, 1566, 2018, 271, 329, 2, 1223, 265, 4, 3, 1219, 2025, 4, 7, 50, 357, 3429, 279, 1505, 29, 102, 4691, 1821, 50, 256, 5380, 2, 4349, 336, 404, 2, 38, 1710, 5, 1566, 2018, 329, 1223, 114, 99, 309, 17, 539, 3429, 1223, 329, 68, 44, 1231, 8, 1196, 4177, 1, 121, 155, 2, 2946, 8, 189, 353, 288, 6, 1566, 2018, 34]",1531.0,22585703,Acute myeloid leukemia myelodysplastic syndromes radiation therapy similar novo disease differ therapy-related myeloid neoplasms,25,0.04363001745200698
Multi-color CD34 progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia.,Leukemia research,Leuk. Res.,2012-05-23,"Bone marrow assessment for myelodysplastic syndrome (MDS) in a patient who develops cytopenia(s) following cancer therapy is challenging. With recent advances in multi-color flow cytometry immunophenotypic analysis, a CD34(+) progenitor-focused 7-color assay was developed and tested in this clinical setting. This assay was first performed in 73 MDS patients and 53 non-MDS patients (developmental set). A number of immunophenotypic changes were differentially observed in these two groups. Based on the sensitivity, specificity and reproducibility, a core panel of markers was selected for final assessment that included increased total CD34(+) myeloblasts; decreased stage I hematogones; altered CD45/side scatter; altered expression of CD13, CD33, CD34, CD38, CD117, and CD123; aberrant expression of lymphoid or mature myelomonocytic antigens on CD34(+) myeloblasts; and several marked alterations in maturing myelomonocytic cells. The data were translated into a simplified scoring system which was then used in 120 patients with cytopenia(s) secondary to cancer therapy over a 2-year period (validation set). With a median follow-up of 11 months, this assay demonstrated 89% sensitivity, 94% specificity, and 92% accuracy in establishing or excluding a diagnosis of MDS.",Evaluation Study,2799.0,24.0,Bone marrow assessment myelodysplastic syndrome MDS patient develops cytopenia following therapy challenging recent advances multi-color flow cytometry immunophenotypic CD34 progenitor-focused 7-color developed tested clinical setting performed 73 MDS patients 53 non-MDS patients developmental set number immunophenotypic changes differentially observed groups Based sensitivity specificity reproducibility core panel markers selected final assessment included increased total CD34 myeloblasts decreased stage hematogones altered CD45/side scatter altered expression CD13 CD33 CD34 CD38 CD117 CD123 aberrant expression lymphoid mature myelomonocytic antigens CD34 myeloblasts marked alterations maturing myelomonocytic translated simplified scoring 120 patients cytopenia secondary therapy 2-year period validation set median follow-up 11 months demonstrated 89 sensitivity 94 specificity 92 accuracy establishing excluding diagnosis MDS,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[581, 455, 9, 681, 1223, 4, 8, 69, 54, 4734, 8165, 695, 366, 12, 36, 16, 1950, 5, 435, 954, 4, 1414, 6052, 1412, 1914, 6599, 65, 8, 2215, 2520, 1649, 67, 6052, 719, 10, 276, 2, 650, 4, 26, 38, 546, 26, 719, 10, 157, 173, 4, 803, 1223, 7, 2, 699, 220, 1223, 7, 4566, 916, 8, 207, 1, 6599, 400, 11, 2478, 164, 4, 46, 100, 271, 90, 23, 3, 485, 1121, 2, 4688, 8, 1793, 993, 1, 525, 10, 715, 9, 1457, 455, 17, 159, 101, 181, 2215, 14909, 340, 82, 70, 46534, 1495, 5280, 1152, 9411, 1495, 55, 1, 13518, 6353, 2215, 4469, 6999, 2, 8849, 1898, 55, 1, 2303, 15, 2908, 5451, 1575, 23, 2215, 14909, 2, 392, 2003, 593, 4, 17724, 5451, 37, 3, 74, 11, 5136, 237, 8, 8087, 2504, 398, 92, 10, 818, 95, 4, 2031, 7, 5, 8165, 695, 568, 6, 12, 36, 252, 8, 18, 111, 727, 929, 916, 5, 8, 52, 166, 126, 1, 175, 53, 26, 719, 264, 887, 485, 960, 1121, 2, 937, 1190, 4, 4431, 15, 3207, 8, 147, 1, 1223]",1213.0,22626984,Multi-color CD34 progenitor-focused flow cytometric evaluation myelodysplastic syndromes patients post therapy cytopenia,0,0.0
Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes.,Leukemia & lymphoma,Leuk. Lymphoma,2012-07-09,"As with most genetic cancer predisposition syndromes, inherited susceptibility to myelodysplastic syndrome (MDS) and acute leukemia (AL) is likely to be more common than previously appreciated. As next-generation sequencing technologies become integrated into clinical practice, we anticipate that the number of cases of familial MDS/AL identified will increase. Although the existence of syndromes predisposing to MDS/AL has been known for some time, clinical guidelines for the screening and management of suspected or confirmed cases do not exist. Based on our collective experience caring for families with these syndromes, we propose recommendations for genetic counseling, testing, and clinical management. We welcome discussion about these proposals and hope that they will catalyze an ongoing dialog leading to optimal medical and psychosocial care for these patients.",Journal Article,2752.0,48.0,genetic predisposition syndromes inherited susceptibility myelodysplastic syndrome MDS acute leukemia likely common previously appreciated next-generation sequencing technologies integrated clinical practice anticipate number cases familial MDS/AL identified increase existence syndromes predisposing MDS/AL known time clinical guidelines screening management suspected confirmed cases exist Based collective experience caring families syndromes propose recommendations genetic counseling testing clinical management welcome discussion proposals hope catalyze ongoing dialog leading optimal medical psychosocial care patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[22, 5, 96, 336, 12, 2863, 2040, 2986, 1432, 6, 681, 1223, 2, 286, 2171, 16, 322, 6, 40, 80, 186, 76, 373, 7292, 22, 1305, 914, 615, 2590, 1417, 2102, 237, 38, 758, 21, 8469, 17, 3, 207, 1, 140, 1, 2200, 1223, 2171, 108, 303, 344, 242, 3, 5335, 1, 2040, 6885, 6, 1223, 2171, 71, 85, 440, 9, 476, 98, 38, 677, 9, 3, 453, 2, 284, 1, 2768, 15, 557, 140, 1022, 44, 1923, 90, 23, 114, 9549, 730, 6571, 9, 1954, 5, 46, 2040, 21, 2548, 883, 9, 336, 2011, 471, 2, 38, 284, 21, 27895, 2488, 545, 46, 11913, 2, 3045, 17, 491, 303, 19669, 35, 942, 38999, 1049, 6, 665, 484, 2, 2322, 165, 9, 46, 7]",836.0,22691122,Proposal clinical detection management patients family members familial myelodysplastic syndrome/acute leukemia predisposition syndromes,13,0.02268760907504363
Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.,Blood,Blood,2012-06-21,"Cellular and interpatient heterogeneity and the involvement of different stem and progenitor compartments in leukemogenesis are challenges for the identification of common pathways contributing to the initiation and maintenance of acute myeloid leukemia (AML). Here we used a strategy of parallel transcriptional analysis of phenotypic long-term hematopoietic stem cells (HSCs), short-term HSCs, and granulocyte-monocyte progenitors from individuals with high-risk (-7/7q-) AML and compared them with the corresponding cell populations from healthy controls. This analysis revealed dysregulated expression of 11 genes, including IL-1 receptor accessory protein (IL1RAP), in all leukemic stem and progenitor cell compartments. IL1RAP protein was found to be overexpressed on the surface of HSCs of AML patients, and marked cells with the -7/7q- anomaly. IL1RAP was also overexpressed on HSCs of patients with normal karyotype AML and high-risk myelodysplastic syndrome, suggesting a pervasive role in different disease subtypes. High IL1RAP expression was independently associated with poor overall survival in 3 independent cohorts of AML patients (P = 2.2  10(-7)). Knockdown of IL1RAP decreased clonogenicity and increased cell death of AML cells. Our study identified genes dysregulated in stem and progenitor cells in -7/7q- AML, and suggests that IL1RAP may be a promising therapeutic and prognostic target in AML and high-risk myelodysplastic syndrome.",Journal Article,2770.0,84.0,Cellular interpatient heterogeneity involvement different stem progenitor compartments leukemogenesis challenges identification common pathways contributing initiation maintenance acute myeloid leukemia AML strategy parallel transcriptional phenotypic long-term hematopoietic stem HSCs short-term HSCs granulocyte-monocyte progenitors individuals high-risk -7/7q- AML compared corresponding populations healthy controls revealed dysregulated expression 11 including IL-1 receptor accessory IL1RAP leukemic stem progenitor compartments IL1RAP overexpressed surface HSCs AML patients marked -7/7q- anomaly IL1RAP overexpressed HSCs patients normal karyotype AML high-risk myelodysplastic syndrome suggesting pervasive role different disease subtypes High IL1RAP expression independently associated poor overall survival 3 independent cohorts AML patients P 2.2 10 -7 Knockdown IL1RAP decreased clonogenicity increased death AML identified dysregulated stem progenitor -7/7q- AML suggests IL1RAP promising therapeutic prognostic target AML high-risk myelodysplastic syndrome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[763, 2, 7423, 1144, 2, 3, 799, 1, 338, 452, 2, 2520, 6473, 4, 5661, 32, 1427, 9, 3, 911, 1, 186, 460, 3156, 6, 3, 1118, 2, 1146, 1, 286, 533, 329, 467, 21, 95, 8, 692, 1, 2755, 1431, 65, 1, 3290, 319, 337, 1007, 452, 37, 6185, 978, 337, 6185, 2, 2764, 5231, 4321, 29, 869, 5, 64, 43, 67, 9723, 329, 2, 72, 1370, 5, 3, 1734, 31, 1184, 29, 1331, 535, 26, 65, 553, 4288, 55, 1, 175, 214, 141, 501, 14, 153, 12082, 178, 29314, 4, 62, 2015, 452, 2, 2520, 31, 6473, 29314, 178, 10, 204, 6, 40, 1711, 23, 3, 1255, 1, 6185, 1, 329, 7, 2, 2003, 37, 5, 3, 67, 9723, 17085, 29314, 10, 120, 1711, 23, 6185, 1, 7, 5, 295, 3385, 329, 2, 64, 43, 681, 802, 8, 15130, 200, 4, 338, 34, 814, 64, 29314, 55, 10, 1042, 41, 5, 334, 63, 25, 4, 27, 306, 736, 1, 329, 7, 19, 18, 18, 79, 67, 1563, 1, 29314, 340, 9880, 2, 101, 31, 273, 1, 329, 37, 114, 45, 108, 214, 4288, 4, 452, 2, 2520, 37, 4, 67, 9723, 329, 2, 844, 17, 29314, 68, 40, 8, 721, 189, 2, 177, 283, 4, 329, 2, 64, 43, 681]",1388.0,22723552,Overexpression IL-1 receptor accessory stem progenitor outcome correlation AML MDS,22,0.038394415357766144
Pleural effusions in patients with acute leukemia and myelodysplastic syndrome.,Leukemia & lymphoma,Leuk. Lymphoma,2012-09-10,"Pleural effusions are rarely observed in patients with acute myelogenous leukemia (AML), acute lymphocytic leukemia (ALL) and myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN). Therefore the underlying etiology of pleural effusions and the efficacy and safety of pleural procedures in this population has not been well studied. In a retrospective review of cases from 1997 to 2007, we identified 111 patients with acute leukemia or MDS/MPN who underwent pleural procedures. Clinical characteristics were reviewed, and survival outcomes were estimated by Kaplan-Meier methods. A total of 270 pleural procedures were performed in 111 patients (69 AML, 27 ALL, 15 MDS/MPN). The main indications for pleural procedures were possible infection (49%) and respiratory symptoms (48%), and concomitant clinical symptoms included fever (34%), dyspnea (74%), chest pain (24%) and cough (37%). Most patients had active disease (61%). The most frequent etiology of pleural effusions was infection (47%), followed by malignancy (36%). Severe thrombocytopenia (platelet count < 20  10(3)/L) was present in 43% of the procedures, yet the procedural complication rate was only 1.9%. Multivariate analysis revealed that older age, AML, MDS/MPN and active disease status were associated with a shorter median overall survival. Infection and malignant involvement are the most common causes of pleural effusion in patients with acute leukemia or MDS. After optimizing platelet count and coagulopathy, thoracentesis may be performed safely and with high diagnostic yield in this population. Survival in these patients is determined by the response to treatment of the hematologic malignancy.",Journal Article,2689.0,15.0,Pleural effusions rarely observed patients acute myelogenous leukemia AML acute lymphocytic leukemia myelodysplastic syndrome MDS /myeloproliferative neoplasm MPN underlying etiology pleural effusions efficacy safety pleural procedures population studied retrospective review cases 1997 2007 identified 111 patients acute leukemia MDS/MPN underwent pleural procedures Clinical characteristics reviewed survival outcomes estimated Kaplan-Meier methods total 270 pleural procedures performed 111 patients 69 AML 27 15 MDS/MPN main indications pleural procedures possible infection 49 respiratory symptoms 48 concomitant clinical symptoms included fever 34 dyspnea 74 chest pain 24 cough 37 patients active disease 61 frequent etiology pleural effusions infection 47 followed malignancy 36 Severe thrombocytopenia platelet count 20 10 3 /L present 43 procedures procedural complication rate 1.9 Multivariate revealed older age AML MDS/MPN active disease status associated shorter median overall survival Infection malignant involvement common causes pleural effusion patients acute leukemia MDS optimizing platelet count coagulopathy thoracentesis performed safely high diagnostic yield population Survival patients determined response treatment hematologic malignancy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2164, 5154, 32, 2416, 164, 4, 7, 5, 286, 2194, 329, 286, 1193, 62, 2, 681, 1223, 10857, 2131, 4125, 673, 3, 1181, 2855, 1, 2164, 5154, 2, 3, 209, 2, 367, 1, 2164, 1369, 4, 26, 266, 71, 44, 85, 149, 656, 4, 8, 459, 206, 1, 140, 29, 2341, 6, 1307, 21, 108, 3167, 7, 5, 286, 15, 1223, 4125, 54, 208, 2164, 1369, 38, 374, 11, 446, 2, 25, 123, 11, 661, 20, 876, 882, 636, 8, 181, 1, 6666, 2164, 1369, 11, 173, 4, 3167, 7, 790, 329, 428, 62, 167, 1223, 4125, 3, 1895, 2406, 9, 2164, 1369, 11, 899, 930, 739, 2, 2718, 507, 576, 2, 1781, 38, 507, 159, 2775, 562, 2923, 794, 1662, 559, 259, 2, 6546, 567, 96, 7, 42, 544, 34, 713, 3, 96, 908, 2855, 1, 2164, 5154, 10, 930, 662, 370, 20, 710, 511, 905, 1340, 1596, 1276, 179, 79, 27, 17472, 10, 364, 4, 601, 1, 3, 1369, 1145, 3, 8492, 1447, 116, 10, 158, 14, 83, 331, 65, 553, 17, 434, 89, 329, 1223, 4125, 2, 544, 34, 156, 11, 41, 5, 8, 985, 52, 63, 25, 930, 2, 393, 799, 32, 3, 96, 186, 1626, 1, 2164, 4433, 4, 7, 5, 286, 15, 1223, 50, 4336, 1596, 1276, 2, 10029, 15328, 68, 40, 173, 2268, 2, 5, 64, 752, 2309, 4, 26, 266, 25, 4, 46, 7, 16, 509, 20, 3, 51, 6, 24, 1, 3, 813, 710]",1565.0,22812422,Pleural effusions patients acute leukemia myelodysplastic syndrome,0,0.0
Loss of the tumor suppressor BAP1 causes myeloid transformation.,"Science (New York, N.Y.)",Science,2012-08-09,"De-ubiquitinating enzyme BAP1 is mutated in a hereditary cancer syndrome with increased risk of mesothelioma and uveal melanoma. Somatic BAP1 mutations occur in various malignancies. We show that mouse Bap1 gene deletion is lethal during embryogenesis, but systemic or hematopoietic-restricted deletion in adults recapitulates features of human myelodysplastic syndrome (MDS). Knockin mice expressing BAP1 with a 3xFlag tag revealed that BAP1 interacts with host cell factor-1 (HCF-1), O-linked N-acetylglucosamine transferase (OGT), and the polycomb group proteins ASXL1 and ASXL2 in vivo. OGT and HCF-1 levels were decreased by Bap1 deletion, indicating a critical role for BAP1 in stabilizing these epigenetic regulators. Human ASXL1 is mutated frequently in chronic myelomonocytic leukemia (CMML) so an ASXL/BAP1 complex may suppress CMML. A BAP1 catalytic mutation found in a MDS patient implies that BAP1 loss of function has similar consequences in mice and humans.",Journal Article,2721.0,,De-ubiquitinating enzyme BAP1 hereditary syndrome increased risk mesothelioma uveal melanoma Somatic BAP1 occur malignancies mouse Bap1 deletion lethal embryogenesis systemic hematopoietic-restricted deletion adults recapitulates features human myelodysplastic syndrome MDS Knockin mice expressing BAP1 3xFlag tag revealed BAP1 interacts host factor-1 HCF-1 O-linked N-acetylglucosamine transferase OGT polycomb group ASXL1 ASXL2 vivo OGT HCF-1 levels decreased Bap1 deletion indicating critical role BAP1 stabilizing epigenetic regulators Human ASXL1 frequently chronic myelomonocytic leukemia CMML ASXL/BAP1 complex suppress CMML BAP1 catalytic MDS patient implies BAP1 loss function similar consequences mice humans,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1566, 61749, 1644, 5113, 16, 1185, 4, 8, 2305, 12, 681, 5, 101, 43, 1, 2, 4426, 1119, 5113, 138, 1271, 4, 747, 441, 21, 514, 17, 830, 5113, 145, 1528, 16, 2266, 190, 21285, 84, 403, 15, 1007, 2016, 1528, 4, 857, 11076, 404, 1, 171, 681, 1223, 26024, 399, 1046, 5113, 5, 8, 61750, 7479, 553, 17, 5113, 5528, 5, 1204, 31, 161, 14, 47332, 14, 1990, 1199, 78, 24600, 4402, 39587, 2, 3, 8666, 87, 652, 7782, 2, 40075, 4, 386, 39587, 2, 47332, 14, 148, 11, 340, 20, 5113, 1528, 1716, 8, 740, 200, 9, 5113, 4, 9116, 46, 1418, 3196, 171, 7782, 16, 1185, 746, 4, 442, 5451, 3382, 1743, 35, 61751, 5113, 840, 68, 3134, 3382, 8, 5113, 4784, 258, 204, 4, 8, 1223, 69, 10441, 17, 5113, 407, 1, 343, 71, 288, 3255, 4, 399, 2, 3218]",906.0,22878500,Loss suppressor BAP1 causes myeloid transformation,0,0.0
Clinical and cytogenetic characteristics of myelodysplastic syndrome in patients with HIV infection.,Leukemia research,Leuk. Res.,2012-08-21,"We report eight patients of myelodysplastic syndrome (MDS) with HIV infection. Compared to a historical cohort of HIV-uninfected MDS patients, HIV/MDS were younger (p=0.019), had more complex cytogenetics (p=0.015), and more often had 7q deletion or monosomy 7 (p=0.011). In five patients, HIV/MDS transformed to acute myeloid leukemia, with a median time to transformation of 7 months. Also, the median overall survival was shorter in the HIV/MDS than in their HIV-uninfected counterparts (8 vs. 22 months; p=0.003). These results suggest that HIV/MDS is a high-risk MDS necessitating thorough cytogenetic analysis and follow-up.",Journal Article,2709.0,7.0,report patients myelodysplastic syndrome MDS HIV infection Compared historical cohort HIV-uninfected MDS patients HIV/MDS younger p=0.019 complex cytogenetics p=0.015 7q deletion monosomy 7 p=0.011 patients HIV/MDS transformed acute myeloid leukemia median time transformation 7 months median overall survival shorter HIV/MDS HIV-uninfected counterparts 8 vs. 22 months p=0.003 suggest HIV/MDS high-risk MDS necessitating thorough cytogenetic follow-up,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 414, 659, 7, 1, 681, 1223, 5, 1942, 930, 72, 6, 8, 2252, 180, 1, 1942, 13599, 1223, 7, 1942, 1223, 11, 773, 19, 13, 4049, 42, 80, 840, 2510, 19, 13, 3433, 2, 80, 629, 42, 9723, 1528, 15, 7521, 67, 19, 13, 3651, 4, 365, 7, 1942, 1223, 2423, 6, 286, 533, 5, 8, 52, 98, 6, 1392, 1, 67, 53, 120, 3, 52, 63, 25, 10, 985, 4, 3, 1942, 1223, 76, 4, 136, 1942, 13599, 3953, 66, 105, 350, 53, 19, 13, 1421, 46, 99, 309, 17, 1942, 1223, 16, 8, 64, 43, 1223, 8365, 5506, 1266, 65, 2, 166, 126]",583.0,22917767,Clinical cytogenetic characteristics myelodysplastic syndrome patients HIV infection,34,0.059336823734729496
Epigenetic therapies in MDS and AML.,Advances in experimental medicine and biology,Adv. Exp. Med. Biol.,2013-01-01,"The use of low dose hypomethylating agents for patients with myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (AML) has had made a significant impact. In the past, therapies for these diseases were limited and patients who elected to receive treatment were subject to highly toxic, inpatient chemotherapeutics, which were often ineffective. In the era of hypomethylating agents (azacitidine and decitabine), a patient with high grade MDS or AML with multilineage dysplasia can be offered the alternative of outpatient, relatively low-toxicity therapy. Despite the fact that CR (CR) rates to such agents remain relatively low at 15-20%, a much larger percentage of patients will have clinically significant improvements in hemoglobin, platelet, and neutrophil counts while maintaining good outpatient quality of life. As our clinical experience with azanucleotides expands, questions regarding patient selection, optimal dosing strategy, latency to best response and optimal duration of therapy following disease progression remain, but there is no question that for some patients these agents offer, for a time, an almost miraculous clinical benefit. Ongoing clinical trials in combination and in sequence with conventional therapeutics, with other epigenetically active agents, or in conjunction with bone marrow transplantation continue to provide promise for optimization of these agents for patients with myeloid disease. Although the mechanism(s) responsible for the proven efficacy of these agents remain a matter of some controversy, activity is thought to stem from induction of DNA hypomethylation, direct DNA damage, or possibly even immune modulation; there is no question that they have become a permanent part of the armamentarium against myeloid neoplasms.",Journal Article,2576.0,46.0,use low dose hypomethylating agents patients myelodysplastic syndrome MDS secondary acute myeloid leukemia AML significant impact past therapies diseases limited patients elected receive treatment subject highly toxic inpatient chemotherapeutics ineffective era hypomethylating agents azacitidine decitabine patient high grade MDS AML multilineage dysplasia offered alternative outpatient relatively low-toxicity therapy Despite fact CR CR rates agents remain relatively low 15-20 larger percentage patients clinically significant improvements hemoglobin platelet neutrophil counts maintaining good outpatient quality life clinical experience azanucleotides expands questions patient selection optimal dosing strategy latency best response optimal duration therapy following disease progression remain question patients agents offer time miraculous clinical benefit Ongoing clinical trials combination sequence conventional therapeutics epigenetically active agents conjunction bone marrow transplantation continue provide promise optimization agents patients myeloid disease mechanism responsible proven efficacy agents remain matter controversy activity thought stem induction DNA hypomethylation direct DNA damage possibly immune modulation question permanent armamentarium myeloid neoplasms,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 119, 1, 154, 61, 4931, 183, 9, 7, 5, 681, 1223, 2, 568, 286, 533, 329, 71, 42, 1229, 8, 93, 345, 4, 3, 1219, 235, 9, 46, 1342, 11, 383, 2, 7, 54, 9164, 6, 560, 24, 11, 2974, 6, 561, 1812, 2420, 6097, 92, 11, 629, 3957, 4, 3, 1713, 1, 4931, 183, 3752, 2, 3004, 8, 69, 5, 64, 88, 1223, 15, 329, 5, 12471, 2253, 122, 40, 2216, 3, 1091, 1, 2379, 1352, 154, 155, 36, 550, 3, 1991, 17, 684, 684, 151, 6, 225, 183, 918, 1352, 154, 28, 167, 179, 8, 1802, 1077, 1150, 1, 7, 303, 47, 505, 93, 1474, 4, 2222, 1596, 2, 2595, 1911, 369, 3284, 1178, 2379, 372, 1, 358, 22, 114, 38, 730, 5, 61846, 9365, 1937, 666, 69, 881, 665, 1280, 692, 5301, 6, 824, 51, 2, 665, 654, 1, 36, 366, 34, 91, 918, 84, 125, 16, 77, 2840, 17, 9, 476, 7, 46, 183, 1918, 9, 8, 98, 35, 2214, 47385, 38, 247, 942, 38, 143, 4, 150, 2, 4, 1532, 5, 809, 1943, 5, 127, 8976, 544, 183, 15, 4, 3357, 5, 581, 497, 1906, 6, 377, 1783, 9, 3980, 1, 46, 183, 9, 7, 5, 533, 34, 242, 3, 670, 695, 2327, 9, 3, 1930, 209, 1, 46, 183, 918, 8, 5090, 1, 476, 4089, 128, 16, 2739, 6, 452, 29, 504, 1, 261, 4441, 1196, 261, 1350, 15, 2150, 871, 250, 2356, 125, 16, 77, 2840, 17, 491, 47, 1417, 8, 4377, 760, 1, 3, 5543, 480, 533, 1179]",1722.0,22956506,Epigenetic therapies MDS AML,84,0.14659685863874344
The role of clofarabine in acute myeloid leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2012-09-28,"Clofarabine is a second-generation purine nucleoside analog that has been synthesized to overcome the limitations and incorporate the best qualities of fludarabine and cladribine. Clofarabine acts by inhibiting ribonucleotide reductase and DNA polymerase, thereby depleting the amount of intracellular deoxynucleoside triphosphates available for DNA replication. Compared to its precursors, clofarabine has an increased resistance to deamination and phosphorolysis, and hence better stability as well as higher affinity to deoxycytidine kinase (dCyd), the rate-limiting step in nucleoside phosphorylation. Since the initiation of the first phase I study of clofarabine in 1993 in patients with hematologic and solid malignancies, clofarabine has demonstrated single-agent antitumor activity in adult acute leukemia, including acute myeloid leukemia (AML). Due to its unique properties of biochemical modulation when used in combination with other chemotherapy drugs, mainly cytarabine, combination regimens containing clofarabine have been evaluated. A review of the English literature was performed that included original articles and related reviews from the MEDLINE (PubMed) database and from abstracts based on the publication of meeting materials. This review describes the development, pharmacology and clinical activity of clofarabine, as well as its emerging role in the treatment of adult patients with AML and myelodysplastic syndrome.",Journal Article,2671.0,31.0,Clofarabine second-generation purine nucleoside analog synthesized overcome limitations incorporate best qualities fludarabine cladribine Clofarabine acts inhibiting ribonucleotide reductase DNA polymerase depleting intracellular deoxynucleoside triphosphates available DNA replication Compared precursors clofarabine increased resistance deamination phosphorolysis better stability higher affinity deoxycytidine kinase dCyd rate-limiting step nucleoside phosphorylation initiation phase clofarabine 1993 patients hematologic solid malignancies clofarabine demonstrated single-agent antitumor activity adult acute leukemia including acute myeloid leukemia AML unique properties biochemical modulation combination chemotherapy drugs mainly cytarabine combination regimens containing clofarabine evaluated review English literature performed included original articles related reviews MEDLINE PubMed database abstracts based publication meeting materials review describes development pharmacology clinical activity clofarabine emerging role treatment adult patients AML myelodysplastic syndrome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4149, 16, 8, 419, 914, 5006, 4032, 3497, 17, 71, 85, 5134, 6, 1768, 3, 1939, 2, 3360, 3, 824, 15353, 1, 2027, 2, 8251, 4149, 4459, 20, 2062, 7050, 4027, 2, 261, 1451, 2267, 9438, 3, 3108, 1, 2087, 30959, 28228, 390, 9, 261, 2079, 72, 6, 211, 4881, 4149, 71, 35, 101, 251, 6, 31701, 2, 46329, 2, 3665, 380, 2769, 22, 149, 22, 142, 3601, 6, 6750, 216, 37878, 3, 116, 817, 2458, 4, 4032, 982, 1192, 3, 1118, 1, 3, 157, 124, 70, 45, 1, 4149, 4, 3343, 4, 7, 5, 813, 2, 537, 441, 4149, 71, 264, 226, 420, 579, 128, 4, 780, 286, 141, 286, 533, 329, 520, 6, 211, 991, 1571, 1, 1487, 2356, 198, 95, 4, 150, 5, 127, 56, 600, 2615, 1855, 150, 472, 1101, 4149, 47, 85, 194, 8, 206, 1, 3, 4201, 789, 10, 173, 17, 159, 2279, 2384, 2, 139, 2004, 29, 3, 3388, 3161, 609, 2, 29, 5159, 90, 23, 3, 4397, 1, 2238, 5102, 26, 206, 2677, 3, 193, 6852, 2, 38, 128, 1, 4149, 22, 149, 22, 211, 1478, 200, 4, 3, 24, 1, 780, 7, 5, 329, 2, 681]",1388.0,22957815,role clofarabine acute myeloid leukemia,500,0.8726003490401396
T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2012-09-13,"Consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) provides a survival benefit to patients with acute lymphoblastic leukemia (ALL). We have previously reported comparable survival and relapse rates after T cell-depleted (TCD) allo-HSCT compared with unmodified transplantations for acute myelogenous leukemia, myelodysplastic syndrome, and non-Hodgkin lymphoma with significantly decreased graft-versus-host disease (GVHD). We performed a 56-patient retrospective study to evaluate TCD allo-HSCT for the treatment of ALL after myeloablative total body irradiation-based therapy. The 2-year and 5-year overall survival rates for patients with ALL after TCD allo-HSCT were 0.39 (95% confidence interval [CI], 0.26-0.52) and 0.32 (95% CI, 0.19-0.44), respectively, and the 2-year and 5-year disease-free survival rates were 0.38 (95% CI, 0.25-0.50) and 0.32 (95% CI, 0.20-0.44). There was a trend toward improved survival of patients who underwent TCD allo-HSCT in first complete remission compared with those who did so in other remission states. The cumulative incidence of grade II-IV acute GVHD at 1 year was 0.20 (95% CI, 0.10-0.31), and no patients developed grade IV acute GVHD. The cumulative incidence of chronic GVHD in 41 evaluable patients at 2 and 5 years was 0.15 (95% CI, 0.04-0.26), and that of extensive chronic GVHD at 2 and 5 years was 0.05 (95% CI, 0-11.6). We demonstrate OS and DFS rates that compare favorably to unmodified allo-HSCT with lower rates of GVHD.",Journal Article,2686.0,28.0,Consolidation allogeneic hematopoietic stem transplantation allo-HSCT provides survival benefit patients acute lymphoblastic leukemia previously reported comparable survival relapse rates cell-depleted TCD allo-HSCT compared unmodified transplantations acute myelogenous leukemia myelodysplastic syndrome non-Hodgkin lymphoma significantly decreased graft-versus-host disease GVHD performed 56-patient retrospective evaluate TCD allo-HSCT treatment myeloablative total body irradiation-based therapy 2-year 5-year overall survival rates patients TCD allo-HSCT 0.39 95 confidence interval CI 0.26-0.52 0.32 95 CI 0.19-0.44 respectively 2-year 5-year disease-free survival rates 0.38 95 CI 0.25-0.50 0.32 95 CI 0.20-0.44 trend improved survival patients underwent TCD allo-HSCT complete remission compared remission states cumulative incidence grade II-IV acute GVHD 1 year 0.20 95 CI 0.10-0.31 patients developed grade IV acute GVHD cumulative incidence chronic GVHD 41 evaluable patients 2 5 years 0.15 95 CI 0.04-0.26 extensive chronic GVHD 2 5 years 0.05 95 CI 0-11.6 demonstrate OS DFS rates compare favorably unmodified allo-HSCT lower rates GVHD,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2173, 5, 1063, 1007, 452, 31, 497, 2564, 1703, 777, 8, 25, 247, 6, 7, 5, 286, 1275, 62, 21, 47, 373, 210, 1279, 25, 2, 429, 151, 50, 102, 31, 4358, 8827, 2564, 1703, 72, 5, 10424, 6779, 9, 286, 2194, 681, 2, 5, 97, 340, 1599, 185, 1204, 34, 1562, 21, 173, 8, 664, 69, 459, 45, 6, 376, 8827, 2564, 1703, 9, 3, 24, 1, 62, 50, 3246, 181, 642, 1104, 90, 36, 3, 18, 111, 2, 33, 111, 63, 25, 151, 9, 7, 5, 62, 50, 8827, 2564, 1703, 11, 13, 587, 48, 307, 268, 58, 13, 432, 13, 653, 2, 13, 531, 48, 58, 13, 326, 13, 584, 106, 2, 3, 18, 111, 2, 33, 111, 34, 115, 25, 151, 11, 13, 519, 48, 58, 13, 243, 13, 212, 2, 13, 531, 48, 58, 13, 179, 13, 584, 125, 10, 8, 853, 1317, 231, 25, 1, 7, 54, 208, 8827, 2564, 1703, 4, 157, 236, 734, 72, 5, 135, 54, 205, 1743, 4, 127, 734, 907, 3, 967, 287, 1, 88, 215, 478, 286, 1562, 28, 14, 111, 10, 13, 179, 48, 58, 13, 79, 13, 456, 2, 77, 7, 276, 88, 478, 286, 1562, 3, 967, 287, 1, 442, 1562, 4, 605, 859, 7, 28, 18, 2, 33, 60, 10, 13, 167, 48, 58, 13, 755, 13, 432, 2, 17, 1, 1344, 442, 1562, 28, 18, 2, 33, 60, 10, 13, 474, 48, 58, 13, 175, 49, 21, 608, 118, 2, 1010, 151, 17, 932, 5001, 6, 10424, 2564, 1703, 5, 280, 151, 1, 1562]",1403.0,22982534,cell-depleted stem transplantation adults high-risk acute lymphoblastic leukemia long-term survival patients complete remission decreased risk graft-versus-host disease,0,0.0
Lenalidomide-mediated enhanced translation of C/EBP-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia.,Blood,Blood,2012-10-25,"Recently, we showed that increased miR-181a expression was associated with improved outcomes in cytogenetically normal acute myeloid leukemia (CN-AML). Interestingly, miR-181a expression was increased in CN-AML patients harboring CEBPA mutations, which are usually biallelic and associate with better prognosis. CEBPA encodes the C/EBP transcription factor. We demonstrate here that the presence of N-terminal CEBPA mutations and miR-181a expression are linked. Indeed, the truncated C/EBP-p30 isoform, which is produced from the N-terminal mutant CEBPA gene or from the differential translation of wild-type CEBPA mRNA and is commonly believed to have no transactivation activity, binds to the miR-181a-1 promoter and up-regulates the microRNA expression. Furthermore, we show that lenalidomide, a drug approved for myelodysplastic syndromes and multiple myeloma, enhances translation of the C/EBP-p30 isoform, resulting in higher miR-181a levels. In xenograft mouse models, ectopic miR-181a expression inhibits tumor growth. Similarly, lenalidomide exhibits antitumorigenic activity paralleled by increased miR-181a expression. This regulatory pathway may explain an increased sensitivity to apoptosis-inducing chemotherapy in subsets of AML patients. Altogether, our data provide a potential explanation for the improved clinical outcomes observed in CEBPA-mutated CN-AML patients, and suggest that lenalidomide treatment enhancing the C/EBP-p30 protein levels and in turn miR-181a may sensitize AML blasts to chemotherapy.",Journal Article,2644.0,49.0,Recently showed increased miR-181a expression associated improved outcomes cytogenetically normal acute myeloid leukemia CN-AML Interestingly miR-181a expression increased CN-AML patients harboring CEBPA usually biallelic associate better prognosis CEBPA encodes C/EBP transcription factor demonstrate presence N-terminal CEBPA miR-181a expression linked truncated C/EBP-p30 isoform produced N-terminal CEBPA differential translation wild-type CEBPA mRNA commonly believed transactivation activity binds miR-181a-1 promoter up-regulates microRNA expression Furthermore lenalidomide drug approved myelodysplastic syndromes multiple myeloma enhances translation C/EBP-p30 isoform resulting higher miR-181a levels xenograft mouse models ectopic miR-181a expression inhibits growth Similarly lenalidomide exhibits antitumorigenic activity paralleled increased miR-181a expression regulatory pathway explain increased sensitivity apoptosis-inducing chemotherapy subsets AML patients Altogether provide potential explanation improved clinical outcomes observed CEBPA-mutated CN-AML patients suggest lenalidomide treatment enhancing C/EBP-p30 levels turn miR-181a sensitize AML blasts chemotherapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[761, 21, 224, 17, 101, 722, 14652, 55, 10, 41, 5, 231, 123, 4, 7809, 295, 286, 533, 3183, 329, 2873, 722, 14652, 55, 10, 101, 4, 3183, 329, 7, 2105, 7667, 138, 92, 32, 2082, 6435, 2, 6446, 5, 380, 356, 7667, 4322, 3, 256, 12459, 866, 161, 21, 608, 467, 17, 3, 463, 1, 78, 2158, 7667, 138, 2, 722, 14652, 55, 32, 1199, 4462, 3, 6502, 256, 12459, 25023, 3995, 92, 16, 1687, 29, 3, 78, 2158, 620, 7667, 145, 15, 29, 3, 1777, 2691, 1, 955, 267, 7667, 956, 2, 16, 841, 3979, 6, 47, 77, 8355, 128, 3333, 6, 3, 722, 14652, 14, 973, 2, 126, 2468, 3, 3213, 55, 798, 21, 514, 17, 1288, 8, 234, 850, 9, 2040, 2, 232, 2519, 2691, 1, 3, 256, 12459, 25023, 3995, 1113, 4, 142, 722, 14652, 148, 4, 1330, 830, 274, 3647, 722, 14652, 55, 1576, 30, 129, 1813, 1288, 4273, 15958, 128, 10591, 20, 101, 722, 14652, 55, 26, 1253, 308, 68, 2943, 35, 101, 485, 6, 351, 1958, 56, 4, 1890, 1, 329, 7, 6767, 114, 74, 377, 8, 174, 6603, 9, 3, 231, 38, 123, 164, 4, 7667, 1185, 3183, 329, 7, 2, 309, 17, 1288, 24, 2430, 3, 256, 12459, 25023, 178, 148, 2, 4, 3854, 722, 14652, 68, 5745, 329, 2438, 6, 56]",1471.0,23100311,Lenalidomide-mediated enhanced translation C/EBP-p30 up-regulates expression antileukemic microRNA-181a acute myeloid leukemia,1,0.0017452006980802793
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia.,American journal of hematology,Am. J. Hematol.,2012-10-31,"FMS-like tyrosine kinase III (FLT3) mutations occur in one-third of acute myeloid leukemia (AML) patients and predict poor outcome. The incidence and impact of FLT3 in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) is unknown. We conducted a retrospective review to identify WHO MDS and CMML patients with FLT3 mutations at diagnosis. A total of 2,119 patients with MDS and 466 patients with CMML were evaluated at MD Anderson between 1997 and 2010. Of these, FLT3 mutation analysis was performed on 1,232 (58%) MDS and 302 (65%) CMML patients. FLT3 mutations were identified in 12 (0.95%) MDS patients: 9 (75%) had FLT3-ITD mutation and 3 had FLT3-tyrosine kinase domain (TKD) mutation. MDS patients with FLT3 mutations were younger (P = 0.02) and presented as RAEB (P = 0.03) more frequently. Median overall survival (OS) for FLT3-mutated MDS patients was 19.0 months versus 16.4 months for FLT3-nonmutated MDS patients (P = 0.08). FLT3 mutations were identified in 13 (4.3%) CMML patients: 8 had FLT3-ITD mutation and 5 had FLT3-TKD mutation. There were no significant differences in demographic and disease characteristics among CMML patients with and without FLT3 mutations. Median OS for FLT3-mutated CMML patients was 10.8 months versus 21.3 months for FLT3-nonmutated CMML patients (P = 0.12). FLT3 occurs in MDS and CMML at a lower frequency than AML and does not predict poor outcome.",Journal Article,2638.0,40.0,"FMS-like tyrosine kinase III FLT3 occur one-third acute myeloid leukemia AML patients predict poor outcome incidence impact FLT3 myelodysplastic syndrome MDS chronic myelomonocytic leukemia CMML unknown conducted retrospective review identify MDS CMML patients FLT3 diagnosis total 2,119 patients MDS 466 patients CMML evaluated MD Anderson 1997 2010 FLT3 performed 1,232 58 MDS 302 65 CMML patients FLT3 identified 12 0.95 MDS patients 9 75 FLT3-ITD 3 FLT3-tyrosine kinase domain TKD MDS patients FLT3 younger P 0.02 presented RAEB P 0.03 frequently Median overall survival OS FLT3-mutated MDS patients 19.0 months versus 16.4 months FLT3-nonmutated MDS patients P 0.08 FLT3 identified 13 4.3 CMML patients 8 FLT3-ITD 5 FLT3-TKD significant differences demographic disease characteristics CMML patients FLT3 Median OS FLT3-mutated CMML patients 10.8 months versus 21.3 months FLT3-nonmutated CMML patients P 0.12 FLT3 occurs MDS CMML lower frequency AML predict poor outcome",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[5516, 733, 564, 216, 316, 1224, 138, 1271, 4, 104, 1282, 1, 286, 533, 329, 7, 2, 678, 334, 228, 3, 287, 2, 345, 1, 1224, 4, 681, 1223, 2, 442, 5451, 3382, 16, 860, 21, 426, 8, 459, 206, 6, 255, 54, 1223, 2, 3382, 7, 5, 1224, 138, 28, 147, 8, 181, 1, 18, 4299, 7, 5, 1223, 2, 13638, 7, 5, 3382, 11, 194, 28, 2244, 1929, 59, 2341, 2, 1120, 1, 46, 1224, 258, 65, 10, 173, 23, 14, 7186, 717, 1223, 2, 4952, 556, 3382, 7, 1224, 138, 11, 108, 4, 133, 13, 48, 1223, 7, 83, 481, 42, 1224, 2837, 258, 2, 27, 42, 1224, 564, 216, 1398, 12415, 258, 1223, 7, 5, 1224, 138, 11, 773, 19, 13, 588, 2, 917, 22, 20273, 19, 13, 680, 80, 746, 52, 63, 25, 118, 9, 1224, 1185, 1223, 7, 10, 326, 13, 53, 185, 245, 39, 53, 9, 1224, 17210, 1223, 7, 19, 13, 1592, 1224, 138, 11, 108, 4, 233, 39, 27, 3382, 7, 66, 42, 1224, 2837, 258, 2, 33, 42, 1224, 12415, 258, 125, 11, 77, 93, 362, 4, 1540, 2, 34, 374, 107, 3382, 7, 5, 2, 187, 1224, 138, 52, 118, 9, 1224, 1185, 3382, 7, 10, 79, 66, 53, 185, 239, 27, 53, 9, 1224, 17210, 3382, 7, 19, 13, 133, 1224, 1780, 4, 1223, 2, 3382, 28, 8, 280, 675, 76, 329, 2, 1097, 44, 678, 334, 228]",1329.0,23115106,FLT3 myelodysplastic syndrome chronic myelomonocytic leukemia,7,0.012216404886561954
Frequency and reasons for return to acute care in patients with leukemia undergoing inpatient rehabilitation: a preliminary report.,American journal of physical medicine & rehabilitation,Am J Phys Med Rehabil,2013-03-01,"The aim of this study was to assess the frequency and reasons for return to the primary acute care service among patients with leukemia undergoing inpatient rehabilitation. This is a retrospective study of all patients with leukemia, myelodysplastic syndrome, aplastic anemia, or myelofibrosis admitted to inpatient rehabilitation at a tertiary referral-based cancer center between January 1, 2005, and April 10, 2012. Items analyzed from patient records included return to the primary acute care service with demographic information, leukemia characteristics, medications, hospital admission characteristics, and laboratory values. Two hundred twenty-five patients were admitted a total of 255 times. Ninety-three (37%) of the 255 leukemia inpatient rehabilitation admissions returned to the primary acute care service. Eighteen (19%) and 42 (45%) of the 93 patients died in the hospital and were discharged home, respectively. Statistically significant factors (P < 0.05) associated with return to the primary acute care service include peripheral blast percentage and the presence of an antifungal agent on the day of the inpatient rehabilitation transfer. Using additional two factors (platelet count and the presence of an antiviral agent, both P < 0.11), the Return to Primary-Leukemia Index was formulated. Patients with leukemia with the presence of circulating peripheral blasts and/or an antifungal agent may be at increased risk for return to the primary acute care service. The Return to Primary-Leukemia Index should be tested in prospective studies to determine its usefulness.",Journal Article,2517.0,11.0,aim assess frequency reasons return primary acute care service patients leukemia undergoing inpatient rehabilitation retrospective patients leukemia myelodysplastic syndrome aplastic anemia myelofibrosis admitted inpatient rehabilitation tertiary referral-based center January 1 2005 April 10 2012 Items patient records included return primary acute care service demographic information leukemia characteristics medications hospital admission characteristics laboratory values twenty-five patients admitted total 255 times Ninety-three 37 255 leukemia inpatient rehabilitation admissions returned primary acute care service Eighteen 19 42 45 93 patients died hospital discharged home respectively Statistically significant factors P 0.05 associated return primary acute care service include peripheral blast percentage presence antifungal agent day inpatient rehabilitation transfer additional factors platelet count presence antiviral agent P 0.11 Return Primary-Leukemia Index formulated Patients leukemia presence circulating peripheral blasts and/or antifungal agent increased risk return primary acute care service Return Primary-Leukemia Index tested prospective studies determine usefulness,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1130, 1, 26, 45, 10, 6, 423, 3, 675, 2, 2325, 9, 4656, 6, 3, 86, 286, 165, 3086, 107, 7, 5, 479, 2420, 4182, 26, 16, 8, 459, 45, 1, 62, 7, 5, 681, 16315, 1545, 15, 4637, 4319, 6, 2420, 4182, 28, 8, 2557, 2096, 90, 12, 574, 59, 1024, 14, 1242, 2, 2292, 79, 1195, 2980, 311, 29, 69, 1064, 159, 4656, 6, 3, 86, 286, 165, 3086, 5, 1540, 487, 374, 2679, 702, 3411, 374, 2, 1624, 1030, 100, 1128, 737, 365, 7, 11, 4319, 8, 181, 1, 7826, 1072, 2493, 169, 567, 1, 3, 7826, 2420, 4182, 5565, 5157, 6, 3, 86, 286, 165, 3086, 3195, 326, 2, 595, 512, 1, 3, 966, 7, 1016, 4, 3, 702, 2, 11, 6155, 3249, 106, 712, 93, 130, 19, 13, 474, 41, 5, 4656, 6, 3, 86, 286, 165, 3086, 643, 672, 3112, 1150, 2, 3, 463, 1, 35, 8606, 420, 23, 3, 218, 1, 3, 2420, 4182, 2602, 75, 402, 100, 130, 1596, 1276, 2, 3, 463, 1, 35, 6264, 420, 110, 19, 13, 175, 3, 4656, 6, 86, 2647, 558, 10, 7495, 7, 5, 5, 3, 463, 1, 1033, 672, 2438, 2, 15, 35, 8606, 420, 68, 40, 28, 101, 43, 9, 4656, 6, 3, 86, 286, 165, 3086, 3, 4656, 6, 86, 2647, 558, 257, 40, 650, 4, 482, 94, 6, 223, 211, 5235]",1490.0,23117267,Frequency reasons return acute care patients leukemia undergoing inpatient rehabilitation preliminary report,0,0.0
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-11-05,"The purpose of this study was to determine remission induction frequency when bortezomib was combined with daunorubicin and cytarabine in previously untreated older adults with acute myeloid leukemia (AML) and safety of bortezomib in combination with consolidation chemotherapy consisting of intermediate-dose cytarabine (Int-DAC). Ninety-five adults (age 60 to 75 years; median, 67 years) with previously untreated AML (including therapy-related and previous myelodysplastic syndrome) received bortezomib 1.3 mg/m(2) intravenously (IV) on days 1, 4, 8, and 11 with daunorubicin 60 mg/m(2) on days 1 through 3 and cytarabine 100 mg/m(2) by continuous IV infusion on days 1 through 7. Patients who achieved complete remission (CR) received up to two courses of consolidation chemotherapy with cytarabine 2 gm/m(2) on days 1 through 5 with bortezomib. Three cohorts with escalating dose levels of bortezomib were tested (0.7, 1.0, and 1.3 mg/m(2)). Dose-limiting toxicities were assessed during the first cycle of consolidation. The relationship between cell surface expression of CD74 and clinical outcome was assessed. Frequency of CR was 65% (62 of 95), and 4% of patients (four of 95) achieved CR with incomplete platelet recovery (CRp). Eleven patients developed grade 3 sensory neuropathy. Bortezomib plus Int-DAC proved tolerable at the highest dose tested. Lower CD74 expression was associated with CR/CRp (P = .04) but not with disease-free or overall survival. The addition of bortezomib to standard 3 + 7 daunorubicin and cytarabine induction chemotherapy for AML resulted in an encouraging remission rate. The maximum tested dose of bortezomib administered in combination with Int-DAC for remission consolidation was 1.3 mg/m(2) and proved tolerable. Further testing of this regimen is planned.",Clinical Trial,2633.0,63.0,purpose determine remission induction frequency bortezomib combined daunorubicin cytarabine previously untreated older adults acute myeloid leukemia AML safety bortezomib combination consolidation chemotherapy consisting intermediate-dose cytarabine Int-DAC Ninety-five adults age 60 75 years median 67 years previously untreated AML including therapy-related previous myelodysplastic syndrome received bortezomib 1.3 mg/m 2 intravenously IV days 1 4 8 11 daunorubicin 60 mg/m 2 days 1 3 cytarabine 100 mg/m 2 continuous IV infusion days 1 7 Patients achieved complete remission CR received courses consolidation chemotherapy cytarabine 2 gm/m 2 days 1 5 bortezomib cohorts escalating dose levels bortezomib tested 0.7 1.0 1.3 mg/m 2 Dose-limiting toxicities assessed cycle consolidation relationship surface expression CD74 clinical outcome assessed Frequency CR 65 62 95 4 patients 95 achieved CR incomplete platelet recovery CRp patients developed grade 3 sensory neuropathy Bortezomib plus Int-DAC proved tolerable highest dose tested Lower CD74 expression associated CR/CRp P .04 disease-free overall survival addition bortezomib standard 3 7 daunorubicin cytarabine induction chemotherapy AML resulted encouraging remission rate maximum tested dose bortezomib administered combination Int-DAC remission consolidation 1.3 mg/m 2 proved tolerable testing regimen planned,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 223, 734, 504, 675, 198, 819, 10, 397, 5, 5247, 2, 1855, 4, 373, 1278, 434, 857, 5, 286, 533, 329, 2, 367, 1, 819, 4, 150, 5, 2173, 56, 2273, 1, 919, 61, 1855, 7805, 6140, 2493, 365, 857, 89, 335, 6, 481, 60, 52, 598, 60, 5, 373, 1278, 329, 141, 36, 139, 2, 698, 681, 103, 819, 14, 27, 81, 188, 18, 1672, 478, 23, 162, 14, 39, 66, 2, 175, 5, 5247, 335, 81, 188, 18, 23, 162, 14, 298, 27, 2, 1855, 394, 81, 188, 18, 20, 1314, 478, 904, 23, 162, 14, 298, 67, 7, 54, 513, 236, 734, 684, 103, 126, 6, 100, 1993, 1, 2173, 56, 5, 1855, 18, 2147, 188, 18, 23, 162, 14, 298, 33, 5, 819, 169, 736, 5, 2922, 61, 148, 1, 819, 11, 650, 13, 67, 14, 13, 2, 14, 27, 81, 188, 18, 61, 817, 385, 11, 275, 190, 3, 157, 417, 1, 2173, 3, 858, 59, 31, 1255, 55, 1, 7780, 2, 38, 228, 10, 275, 675, 1, 684, 10, 556, 744, 1, 48, 2, 39, 1, 7, 294, 1, 48, 513, 684, 5, 2610, 1596, 1602, 3162, 2627, 7, 276, 88, 27, 4148, 1751, 819, 349, 7805, 6140, 4328, 2668, 28, 3, 1076, 61, 650, 280, 7780, 55, 10, 41, 5, 684, 3162, 19, 755, 84, 44, 5, 34, 115, 15, 63, 25, 3, 352, 1, 819, 6, 260, 27, 67, 5247, 2, 1855, 504, 56, 9, 329, 627, 4, 35, 2269, 734, 116, 3, 689, 650, 61, 1, 819, 468, 4, 150, 5, 7805, 6140, 9, 734, 2173, 10, 14, 27, 81, 188, 18, 2, 4328, 2668, 195, 471, 1, 26, 477, 16, 1465]",1724.0,23129738,Bortezomib added daunorubicin cytarabine induction therapy intermediate-dose cytarabine consolidation patients previously untreated acute myeloid leukemia age 60 75 years CALGB Alliance 10502,1,0.0017452006980802793
Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults.,Haematologica,Haematologica,2012-11-09,"Prior studies have investigated patients' characteristics, treatments, and outcomes for older adults with myelodysplastic syndromes, but most failed to distinguish chronic myelomonocytic leukemia. Recognizing potentially important differences between the diseases, we undertook a population-based comparison of baseline characteristics, treatments, and outcomes between older adults with chronic myelomonocytic leukemia and myelodysplastic syndromes. The patients' data were obtained from Surveillance Epidemiology and End Results registry data from 2001-2005, linked to Medicare claims. Baseline characteristics, treatment (red blood cell transfusions, hematopoietic growth factors, hypomethylating agents, chemotherapy or transplantation), progression to acute myeloid leukemia, and overall survival were compared using bivariate techniques. Multivariate logistic regression estimated differences in treatments received. Cox proportional hazard models estimated the effects of chronic myelomonocytic leukemia relative to myelodysplastic syndromes on progression-free survival. A larger proportion of patients with chronic myelomonocytic leukemia (n=792), compared to patients with myelodysplastic syndromes (n=7,385), failed to receive any treatment (25% versus 15%; P<0.0001), or only received red blood cell transfusions (19.8% versus 16.7%; P=0.037). A larger percentage of patients with chronic myelomonocytic leukemia progressed to acute myeloid leukemia (42.6% versus 15.5%, respectively; P<0.0001), with shorter time to progression. Chronic myelomonocytic leukemia patients had a shorter median survival (13.3 versus 23.3 months; P<0.0001) and lower 3-year survival rate (19% versus 36%; P<0.0001). Adjusted estimates, controlling for baseline characteristics and selected treatments, indicate that chronic myelomonocytic leukemia was associated with an increased risk of progression to acute myeloid leukemia or death (HR 2.22; P<0.0001), compared to myelodysplastic syndromes. In conclusion, chronic myelomonocytic leukemia is less frequently treated in older adults and is associated with worse outcomes, even after controlling for the patients' baseline characteristics and selected treatments. Our data suggest the need for continued evaluation of the biological differences between these diseases and clinical trials targeting chronic myelomonocytic leukemia.",Comparative Study,2629.0,9.0,"Prior studies investigated patients characteristics treatments outcomes older adults myelodysplastic syndromes failed distinguish chronic myelomonocytic leukemia Recognizing potentially important differences diseases undertook population-based comparison baseline characteristics treatments outcomes older adults chronic myelomonocytic leukemia myelodysplastic syndromes patients obtained Surveillance Epidemiology End registry 2001-2005 linked Medicare claims Baseline characteristics treatment red blood transfusions hematopoietic growth factors hypomethylating agents chemotherapy transplantation progression acute myeloid leukemia overall survival compared bivariate techniques Multivariate logistic regression estimated differences treatments received Cox proportional hazard models estimated effects chronic myelomonocytic leukemia relative myelodysplastic syndromes progression-free survival larger proportion patients chronic myelomonocytic leukemia n=792 compared patients myelodysplastic syndromes n=7,385 failed receive treatment 25 versus 15 P 0.0001 received red blood transfusions 19.8 versus 16.7 P=0.037 larger percentage patients chronic myelomonocytic leukemia progressed acute myeloid leukemia 42.6 versus 15.5 respectively P 0.0001 shorter time progression Chronic myelomonocytic leukemia patients shorter median survival 13.3 versus 23.3 months P 0.0001 lower 3-year survival rate 19 versus 36 P 0.0001 Adjusted estimates controlling baseline characteristics selected treatments indicate chronic myelomonocytic leukemia associated increased risk progression acute myeloid leukemia death HR 2.22 P 0.0001 compared myelodysplastic syndromes chronic myelomonocytic leukemia frequently treated older adults associated worse outcomes controlling patients baseline characteristics selected treatments suggest need continued evaluation differences diseases clinical trials targeting chronic myelomonocytic leukemia",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[324, 94, 47, 565, 7, 374, 640, 2, 123, 9, 434, 857, 5, 2040, 84, 96, 1551, 6, 3081, 442, 5451, 5842, 751, 305, 362, 59, 3, 1342, 21, 5418, 8, 266, 90, 1155, 1, 330, 374, 640, 2, 123, 59, 434, 857, 5, 442, 5451, 2, 2040, 3, 7, 74, 11, 683, 29, 617, 1284, 2, 396, 99, 1608, 74, 29, 1758, 1242, 1199, 6, 1378, 2770, 330, 374, 24, 3422, 315, 31, 4987, 1007, 129, 130, 4931, 183, 56, 15, 497, 91, 6, 286, 533, 2, 63, 25, 11, 72, 75, 7686, 1092, 331, 812, 320, 661, 362, 4, 640, 103, 418, 831, 360, 274, 661, 3, 176, 1, 442, 5451, 580, 6, 2040, 23, 91, 115, 25, 8, 1077, 920, 1, 7, 5, 442, 5451, 78, 13760, 72, 6, 7, 5, 2040, 78, 67, 11297, 1551, 6, 560, 500, 24, 243, 185, 167, 19, 13, 488, 15, 158, 103, 3422, 315, 31, 4987, 326, 66, 185, 245, 67, 19, 13, 5171, 8, 1077, 1150, 1, 7, 5, 442, 5451, 1839, 6, 286, 533, 595, 49, 185, 167, 33, 106, 19, 13, 488, 5, 985, 98, 6, 91, 442, 5451, 7, 42, 8, 985, 52, 25, 233, 27, 185, 382, 27, 53, 19, 13, 488, 2, 280, 27, 111, 25, 116, 326, 185, 511, 19, 13, 488, 586, 1423, 1893, 9, 330, 374, 2, 715, 640, 1008, 17, 442, 5451, 10, 41, 5, 35, 101, 43, 1, 91, 6, 286, 533, 15, 273, 168, 18, 350, 19, 13, 488, 72, 6, 2040, 4, 1221, 442, 5451, 16, 299, 746, 73, 4, 434, 857, 2, 16, 41, 5, 639, 123, 871, 50, 1893, 9, 3, 7, 330, 374, 2, 715, 640, 114, 74, 309, 3, 594, 9, 1351, 451, 1, 3, 1037, 362, 59, 46, 1342, 2, 38, 143, 529, 442, 5451]",2116.0,23144192,Treatment outcomes chronic myelomonocytic leukemia compared myelodysplastic syndromes older adults,3,0.005235602094240838
Translocation t(11;17) in de novo myelodysplastic syndrome not associated with acute myeloid or acute promyelocytic leukemia.,Acta haematologica,Acta Haematol.,2012-11-07,"Translocation t(11;17) is a well-recognized variant of acute promyelocytic leukemia (APL) and has also been identified in patients with mixed-lineage leukemia (MLL) non-APL acute myeloid leukemia. Here, we describe two patients bearing translocation t(11;17) presenting with a clinical diagnosis of de novo myelodysplastic syndrome (MDS): the first with sole karyotypic abnormality 46,XY,t(11;17)(p11.2; p13) and the second where it represented one of the two karyotypic abnormalities 46,XX,del(5)(q13q33)46,XX,del(5)(q13q33),t(11;17)(q24;q23). Molecular characterization of both cases failed to identify fusion transcripts involving MLL or PLZF-RARA and no collaborating somatic mutations commonly found among MDS patients were seen in either case, suggesting the presence of an as yet unidentified oncogenic fusion protein.",Case Reports,2631.0,2.0,Translocation 11 17 well-recognized acute promyelocytic leukemia APL identified patients mixed-lineage leukemia MLL non-APL acute myeloid leukemia patients bearing translocation 11 17 presenting clinical diagnosis novo myelodysplastic syndrome MDS sole karyotypic abnormality 46 XY 11 17 p11.2 p13 second represented karyotypic abnormalities 46 XX del 5 q13q33 46 XX del 5 q13q33 11 17 q24 q23 Molecular characterization cases failed identify fusion transcripts involving MLL PLZF-RARA collaborating somatic commonly MDS patients seen case suggesting presence unidentified oncogenic fusion,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2006, 102, 175, 269, 16, 8, 149, 1904, 1142, 1, 286, 4300, 2578, 2, 71, 120, 85, 108, 4, 7, 5, 1739, 2542, 3049, 220, 2578, 286, 533, 467, 21, 897, 100, 7, 1894, 2006, 102, 175, 269, 1656, 5, 8, 38, 147, 1, 1566, 2018, 681, 1223, 3, 157, 5, 4991, 9465, 3698, 641, 26388, 102, 175, 269, 11230, 18, 7914, 2, 3, 419, 1257, 192, 3324, 104, 1, 3, 100, 9465, 1171, 641, 26720, 3084, 33, 38527, 641, 26720, 3084, 33, 38527, 102, 175, 269, 13487, 11423, 219, 2136, 1, 110, 140, 1551, 6, 255, 1212, 2680, 1267, 3049, 15, 14682, 9847, 2, 77, 14977, 1119, 138, 841, 204, 107, 1223, 7, 11, 527, 4, 361, 473, 802, 3, 463, 1, 35, 22, 1145, 10039, 1302, 1212, 178]",760.0,23147462,Translocation 11 17 novo myelodysplastic syndrome associated acute myeloid acute promyelocytic leukemia,1,0.0017452006980802793
In vivo quantification of active decitabine-triphosphate metabolite: a novel pharmacoanalytical endpoint for optimization of hypomethylating therapy in acute myeloid leukemia.,The AAPS journal,AAPS J,2012-11-22,"Decitabine (DAC) is used for treatment of patients with myelodysplastic syndromes and acute myeloid leukemia (AML). Following cellular uptake, DAC is activated to DAC-triphosphate (TP) and incorporated into DNA. Once incorporated into the DNA, DAC-TP binds and inactivates DNA methyltransferases (DNMTs), thereby leading to hypomethylation and re-expression of epigenetically silenced tumor suppressor genes and ultimately antileukemia activity. However, direct evidence of in vivo DAC-TP occurrence in DAC-treated patients has been difficult to demonstrate due to a lack of suitable validated analytical methodology. Thus, we developed and validated a nonradioactive sensitive and specific LC-MS/MS assay for quantification of DAC-TP. The assay is linear from 50 to 1,000 nM and from 1 to 10 M and has a lower limit of quantitation of 50 nM and a coefficient of variation for both within- and between-day precision <20%. Following DAC treatment, we detected DAC-TP in parental and DAC-resistant AML cells (in vitro) and bone marrow (BM) and spleen of normal and leukemic mice (in vivo). Downregulation of DNMTs and correlation of DAC-TP concentration with proteins involved in mechanisms of DAC resistance were also demonstrated. The clinical applicability of this method was proven by measuring DAC-TP level in BM and blood mononuclear cells from DAC-treated AML patients. Higher levels are seemingly associated with clinical response. Monitoring the DAC-TP intracellular level may serve as a novel pharmacological endpoint for designing more effective DAC-based regimens.",Journal Article,2616.0,9.0,"Decitabine DAC treatment patients myelodysplastic syndromes acute myeloid leukemia AML Following cellular uptake DAC activated DAC-triphosphate TP incorporated DNA incorporated DNA DAC-TP binds inactivates DNA methyltransferases DNMTs leading hypomethylation re-expression epigenetically silenced suppressor ultimately antileukemia activity direct evidence vivo DAC-TP occurrence DAC-treated patients difficult demonstrate lack suitable validated analytical methodology developed validated nonradioactive sensitive specific LC-MS/MS quantification DAC-TP linear 50 1,000 nM 1 10 M lower limit quantitation 50 nM coefficient variation within- between-day precision 20 Following DAC treatment detected DAC-TP parental DAC-resistant AML vitro bone marrow BM spleen normal leukemic mice vivo Downregulation DNMTs correlation DAC-TP concentration involved mechanisms DAC resistance demonstrated clinical applicability proven measuring DAC-TP level BM blood mononuclear DAC-treated AML patients Higher levels seemingly associated clinical response Monitoring DAC-TP intracellular level serve novel pharmacological endpoint designing effective DAC-based regimens",0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3004, 6140, 16, 95, 9, 24, 1, 7, 5, 2040, 2, 286, 533, 329, 366, 763, 1135, 6140, 16, 735, 6, 6140, 7345, 5907, 2, 2449, 237, 261, 1059, 2449, 237, 3, 261, 6140, 5907, 3333, 2, 14521, 261, 11494, 16486, 2267, 1049, 6, 4441, 2, 1491, 55, 1, 8976, 5442, 30, 1245, 214, 2, 2050, 9169, 128, 137, 1196, 241, 1, 4, 386, 6140, 5907, 2291, 4, 6140, 73, 7, 71, 85, 1740, 6, 608, 520, 6, 8, 926, 1, 2884, 938, 5625, 3209, 631, 21, 276, 2, 938, 8, 31217, 745, 2, 112, 1837, 2307, 2307, 719, 9, 4752, 1, 6140, 5907, 3, 719, 16, 1646, 29, 212, 6, 14, 984, 2878, 2, 29, 14, 6, 79, 4810, 2, 71, 8, 280, 2385, 1, 7887, 1, 212, 2878, 2, 8, 3200, 1, 1380, 9, 110, 262, 2, 59, 218, 2720, 179, 366, 6140, 24, 21, 530, 6140, 5907, 4, 3418, 2, 6140, 436, 329, 37, 4, 439, 2, 581, 1246, 2, 4071, 1, 295, 2, 2015, 399, 4, 386, 2475, 1, 16486, 2, 816, 1, 6140, 5907, 1227, 5, 652, 646, 4, 483, 1, 6140, 251, 11, 120, 264, 3, 38, 5412, 1, 26, 596, 10, 1930, 20, 2978, 6140, 5907, 301, 4, 1246, 2, 315, 3041, 37, 29, 6140, 73, 329, 7, 142, 148, 32, 11405, 41, 5, 38, 51, 1315, 3, 6140, 5907, 2087, 301, 68, 1833, 22, 8, 229, 3419, 1138, 9, 5048, 80, 323, 6140, 90, 472]",1512.0,23180159,vivo quantification active decitabine-triphosphate metabolite novel pharmacoanalytical endpoint optimization hypomethylating therapy acute myeloid leukemia,31,0.05410122164048865
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2012-12-21,"Decitabine improves overall survival (OS) and reduces risk of progression to acute myeloid leukemia (AML) in myelodysplastic syndromes (MDS). In this retrospective analysis of data from 2 decitabine studies (n = 162), hemoglobin level  10 g/dL, platelet count  50 10(3)/L, and lack of chromosome 5 or 7 abnormalities predicted longer OS. Identifying potential prognostic factors for survival may guide decitabine treatment decisions and improve outcomes. Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30% of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions. We investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m(2) over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m(2) over 1 hour daily for 5 days every 4 weeks (n = 89). Multivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50  10(3)/L, and lack of chromosome 5 or 7 abnormalities were associated with longer OS. Patients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.",Journal Article,2587.0,11.0,Decitabine improves overall survival OS reduces risk progression acute myeloid leukemia AML myelodysplastic syndromes MDS retrospective 2 decitabine studies n 162 hemoglobin level  10 g/dL platelet count  50 10 3 /L lack chromosome 5 7 abnormalities predicted longer OS Identifying potential prognostic factors survival guide decitabine treatment decisions improve outcomes Myelodysplastic syndromes MDS progress acute myeloid leukemia AML approximately 30 patients Identification risk factors progression AML overall survival OS help guide treatment decisions investigated prognostic factors progression AML survival 163 patients MDS treated decitabine 15 mg/m 2 3 hours 8 hours 3 days 6 weeks n 74 20 mg/m 2 1 hour daily 5 days 4 weeks n 89 Multivariate pooled baseline revealed effect associated progression AML hemoglobin value 10 g/dL platelet count 50 10 3 /L lack chromosome 5 7 abnormalities associated longer OS Patients certain prognostic factors considered interventions addition decitabine treatment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3004, 1804, 63, 25, 118, 2, 2389, 43, 1, 91, 6, 286, 533, 329, 4, 2040, 1223, 4, 26, 459, 65, 1, 74, 29, 18, 3004, 94, 78, 5441, 2222, 301, 749, 79, 499, 1826, 1596, 1276, 749, 212, 79, 27, 5513, 2, 926, 1, 1170, 33, 15, 67, 1171, 783, 589, 118, 1386, 174, 177, 130, 9, 25, 68, 1597, 3004, 24, 1526, 2, 401, 123, 2040, 1223, 1466, 6, 286, 533, 329, 4, 705, 201, 1, 7, 911, 1, 43, 130, 9, 91, 6, 329, 2, 63, 25, 118, 688, 987, 1597, 24, 1526, 21, 565, 177, 130, 9, 91, 6, 329, 2, 25, 4, 5409, 7, 5, 1223, 73, 5, 3004, 167, 81, 188, 18, 252, 27, 1459, 454, 66, 1459, 9, 27, 162, 454, 49, 244, 78, 794, 15, 179, 81, 188, 18, 252, 14, 2583, 391, 9, 33, 162, 454, 39, 244, 78, 887, 331, 65, 1, 1830, 330, 74, 553, 17, 158, 45, 254, 10, 41, 5, 91, 6, 329, 8, 2222, 549, 28, 506, 79, 499, 1826, 1596, 1276, 28, 506, 212, 79, 27, 5513, 2, 926, 1, 1170, 33, 15, 67, 1171, 11, 41, 5, 589, 118, 7, 5, 1840, 177, 130, 257, 40, 515, 9, 127, 1151, 4, 352, 6, 3004, 24]",1241.0,23260600,Prognostic factors associated disease progression overall survival patients myelodysplastic syndromes treated decitabine,6,0.010471204188481676
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2013-01-03,"The cytidine analogs 5-azacytidine and decitabine, used to treat myelodysplastic syndromes (MDS), produce a molecular epigenetic effect, depletion of DNA-methyltransferase 1 (DNMT1). This action is S-phase dependent. Hence, genetic factors that decrease the half-lives of these drugs could impact efficacy. Documentation of such impact, and elucidation of underlying mechanisms, could lead to improved clinical application. Cytidine deaminase (CDA) rapidly inactivates 5-azacytidine/decitabine. The effect of CDA SNP A79C and gender on CDA expression, enzyme activity, and drug pharmacokinetics/pharmacodynamics was examined in mice and humans, and the impact on overall survival (OS) was evaluated in 5-azacytidine/decitabine-treated patients with MDS (n = 90) and cytarabine-treated patients with acute myeloid leukemia (AML) (n = 76). By high-performance liquid chromatography (HPLC), plasma CDA activity was decreased as expected in individuals with the SNP A79C. Interestingly and significantly, there was an even larger decrease in females than in males. Explaining this decrease, liver CDA expression was significantly lower in female versus male mice. As expected, decitabine plasma levels, measured by mass spectrometry, were significantly higher in females. In mathematical modeling, the detrimental impact of shorter drug half-life (e.g., in males) was greater in low compared with high S-phase fraction disease (e.g., MDS vs. AML), because in high S-phase fraction disease, even a short exposure treats a major portion of cells. Accordingly, in multivariate analysis, OS was significantly worse in male versus female patients with MDS treated with 5-azacytidine/decitabine. Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.",Journal Article,2574.0,69.0,cytidine analogs 5-azacytidine decitabine treat myelodysplastic syndromes MDS produce molecular epigenetic effect depletion DNA-methyltransferase 1 DNMT1 action S-phase dependent genetic factors decrease half-lives drugs impact efficacy Documentation impact elucidation underlying mechanisms lead improved clinical application Cytidine deaminase CDA rapidly inactivates 5-azacytidine/decitabine effect CDA SNP A79C gender CDA expression enzyme activity drug pharmacokinetics/pharmacodynamics examined mice humans impact overall survival OS evaluated 5-azacytidine/decitabine-treated patients MDS n 90 cytarabine-treated patients acute myeloid leukemia AML n 76 high-performance liquid chromatography HPLC plasma CDA activity decreased expected individuals SNP A79C Interestingly significantly larger decrease females males Explaining decrease liver CDA expression significantly lower female versus male mice expected decitabine plasma levels measured mass spectrometry significantly higher females mathematical modeling detrimental impact shorter drug half-life e.g. males greater low compared high S-phase fraction disease e.g. MDS vs. AML high S-phase fraction disease short exposure treats major portion Accordingly multivariate OS significantly worse male versus female patients MDS treated 5-azacytidine/decitabine Increased CDA expression/activity males contributes decreased cytidine analog half-life likely contributes worse outcomes 5-azacytidine decitabine therapy,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 12783, 4063, 33, 11755, 2, 3004, 95, 6, 943, 2040, 1223, 2410, 8, 219, 1418, 254, 2286, 1, 261, 3747, 14, 7328, 26, 1578, 16, 695, 124, 470, 3665, 336, 130, 17, 775, 3, 1303, 6407, 1, 46, 600, 359, 345, 209, 4965, 1, 225, 345, 2, 7481, 1, 1181, 483, 359, 1122, 6, 231, 38, 1581, 12783, 10197, 8174, 1755, 14521, 33, 11755, 3004, 3, 254, 1, 8174, 1845, 47555, 2, 1632, 23, 8174, 55, 1644, 128, 2, 234, 1159, 3587, 10, 409, 4, 399, 2, 3218, 2, 3, 345, 23, 63, 25, 118, 10, 194, 4, 33, 11755, 3004, 73, 7, 5, 1223, 78, 424, 2, 1855, 73, 7, 5, 286, 533, 329, 78, 846, 20, 64, 528, 3165, 5140, 10519, 554, 8174, 128, 10, 340, 22, 1336, 4, 869, 5, 3, 1845, 47555, 2873, 2, 97, 125, 10, 35, 871, 1077, 775, 4, 2451, 76, 4, 2296, 8290, 26, 775, 8174, 55, 10, 97, 280, 4, 1061, 185, 1045, 399, 22, 1336, 3004, 554, 148, 644, 20, 782, 3680, 11, 97, 142, 4, 2451, 4, 7419, 2057, 3, 6227, 345, 1, 985, 234, 1303, 358, 563, 499, 4, 2296, 10, 378, 4, 154, 72, 5, 64, 695, 124, 1509, 34, 563, 499, 1223, 105, 329, 408, 4, 64, 695, 124, 1509, 34, 871, 8, 978, 645, 15886, 8, 458, 3206, 1, 37, 4705, 4, 331, 65, 118, 10, 97, 639, 4, 1045, 185, 1061, 7, 5, 1223, 73, 5, 33, 11755, 3004, 101, 8174, 55, 128, 4, 2296, 2444, 6, 340, 12783, 3497, 1303, 358, 2, 322, 2444, 6, 639, 123, 5, 33, 11755, 15, 3004, 36]",1772.0,23287564,Increased CDA expression/activity males contributes decreased cytidine analog half-life likely contributes worse outcomes 5-azacytidine decitabine therapy,1,0.0017452006980802793
Outcome of azacitidine treatment in patients with therapy-related myeloid neoplasms with assessment of prognostic risk stratification models.,Leukemia research,Leuk. Res.,2013-01-16,"Azacitidine's efficacy in therapy-related myeloid neoplasms (t-MN) has not been well-studied. In our retrospective review of 84 t-MN patients treated with azacitidine, median overall survival (OS) was 14.5 months and overall response rate was 43%, including 11% complete remission, 4% marrow complete remission, and 11% partial remission. In patients who underwent allogeneic transplant (25%), median OS was 19.2 versus 12.8 months (P=0.023) for those who did not. Response rates were comparable to those reported for de novo myelodysplastic syndrome. When we analyzed outcomes according to five scoring systems, only the Global MD Anderson Risk Model predicted survival with statistical significance.",Clinical Trial,2561.0,16.0,Azacitidine 's efficacy therapy-related myeloid neoplasms t-MN well-studied retrospective review 84 t-MN patients treated azacitidine median overall survival OS 14.5 months overall response rate 43 including 11 complete remission 4 marrow complete remission 11 partial remission patients underwent allogeneic transplant 25 median OS 19.2 versus 12.8 months P=0.023 Response rates comparable reported novo myelodysplastic syndrome outcomes according scoring systems Global MD Anderson Risk Model predicted survival statistical significance,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3752, 292, 209, 4, 36, 139, 533, 1179, 102, 4691, 71, 44, 85, 149, 656, 4, 114, 459, 206, 1, 874, 102, 4691, 7, 73, 5, 3752, 52, 63, 25, 118, 10, 213, 33, 53, 2, 63, 51, 116, 10, 601, 141, 175, 236, 734, 39, 581, 236, 734, 2, 175, 450, 734, 4, 7, 54, 208, 1063, 941, 243, 52, 118, 10, 326, 18, 185, 133, 66, 53, 19, 13, 4482, 9, 135, 54, 205, 44, 51, 151, 11, 1279, 6, 135, 210, 9, 1566, 2018, 681, 198, 21, 311, 123, 768, 6, 365, 2504, 1530, 158, 3, 1648, 2244, 1929, 43, 202, 783, 25, 5, 1050, 724]",662.0,23332452,Outcome azacitidine treatment patients therapy-related myeloid neoplasms assessment prognostic risk stratification models,58,0.1012216404886562
"Defining incidence, risk factors, and impact on survival of central line-associated blood stream infections following hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome.",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2013-02-01,"Central line-associated blood stream infections (CLABSI) commonly complicate the care of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after allogeneic stem cell transplantation (HCT). We developed a modified CLABSI (MCLABSI) definition that attempts to exclude pathogens usually acquired because of disruption of mucosal barriers during the vulnerable neutropenic period following HCT that are generally included under the original definition (OCLABSI). We conducted a retrospective study of all AML and MDS patients undergoing HCT between August 2009 and December 2011 at the Cleveland Clinic (N=73), identifying both OCLABSI and MCLABSI incidence. The median age at transplantation was 52 years (range, 16 to 70); 34 had a high (3) HCT comorbidity index (HCT-CI); 34 received bone marrow (BM), 24 received peripheral stem cells (PSC), and 15 received umbilical cord blood cells (UCB). Among these 73 patients, 23 (31.5%) developed OCLABSI, of whom 16 (69.6%) died, and 8 (11%) developed MCLABSI, of whom 7 (87.5%) died. OCLABSI was diagnosed a median of 9 days from HCT: 5 days (range, 2 to 12) for UCB and 78 days (range, 7 to 211) for BM/PSC (P<.001). MCLABSI occurred a median of 12 days from HCT, with similar earlier UCB and later BM/PSC diagnosis (P=.030). Risk factors for OCLABSI in univariate analysis included CBC (P<.001), human leukocyte antigen (HLA)-mismatch (P=.005), low CD34(+) count (P=.007), low total nucleated cell dose (P=.016), and non-Caucasian race (P=.017). Risk factors for OCLABSI in multivariable analysis were UCB (P<.001) and high HCT-CI (P=.002). There was a significant increase in mortality for both OCLABSI (hazard ratio, 7.14; CI, 3.31 to 15.37; P<.001) and MCLABSI (hazard ratio, 6.44; CI, 2.28 to 18.18; P<.001). CLABSI is common and associated with high mortality in AML and MDS patients undergoing HCT, especially in UCB recipients and those with high HCT-CI. We propose the MCLABSI definition to replace the OCLABSI definition, given its greater precision for identifying preventable infection in HCT patients.",Journal Article,2545.0,25.0,Central line-associated blood stream infections CLABSI commonly complicate care patients acute myeloid leukemia AML myelodysplastic syndrome MDS allogeneic stem transplantation HCT developed modified CLABSI MCLABSI definition attempts exclude pathogens usually acquired disruption mucosal barriers vulnerable neutropenic period following HCT generally included original definition OCLABSI conducted retrospective AML MDS patients undergoing HCT August 2009 December 2011 Cleveland Clinic N 73 identifying OCLABSI MCLABSI incidence median age transplantation 52 years range 16 70 34 high 3 HCT comorbidity index HCT-CI 34 received bone marrow BM 24 received peripheral stem PSC 15 received umbilical cord blood UCB 73 patients 23 31.5 developed OCLABSI 16 69.6 died 8 11 developed MCLABSI 7 87.5 died OCLABSI diagnosed median 9 days HCT 5 days range 2 12 UCB 78 days range 7 211 BM/PSC P .001 MCLABSI occurred median 12 days HCT similar earlier UCB later BM/PSC diagnosis P .030 Risk factors OCLABSI univariate included CBC P .001 human leukocyte antigen HLA -mismatch P .005 low CD34 count P .007 low total nucleated dose P .016 non-Caucasian race P .017 Risk factors OCLABSI multivariable UCB P .001 high HCT-CI P .002 significant increase mortality OCLABSI hazard ratio 7.14 CI 3.31 15.37 P .001 MCLABSI hazard ratio 6.44 CI 2.28 18.18 P .001 CLABSI common associated high mortality AML MDS patients undergoing HCT especially UCB recipients high HCT-CI propose MCLABSI definition replace OCLABSI definition given greater precision identifying preventable infection HCT patients,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[854, 328, 41, 315, 14867, 1875, 20811, 841, 11157, 3, 165, 1, 7, 5, 286, 533, 329, 2, 681, 1223, 50, 1063, 452, 31, 497, 1085, 21, 276, 8, 1230, 20811, 29396, 2470, 17, 4374, 6, 6262, 9275, 2082, 1294, 408, 1, 3220, 1, 3068, 2160, 190, 3, 5017, 3659, 727, 366, 1085, 17, 32, 1228, 159, 669, 3, 2279, 2470, 25500, 21, 426, 8, 459, 45, 1, 62, 329, 2, 1223, 7, 479, 1085, 59, 2480, 1238, 2, 1397, 1132, 28, 3, 7317, 1188, 78, 803, 1386, 110, 25500, 2, 29396, 287, 3, 52, 89, 28, 497, 10, 653, 60, 184, 245, 6, 431, 562, 42, 8, 64, 2608, 1085, 1879, 558, 1085, 58, 562, 103, 581, 1246, 259, 103, 672, 452, 37, 5417, 2, 167, 103, 5998, 1885, 315, 37, 4056, 107, 46, 803, 7, 382, 456, 33, 276, 25500, 1, 953, 245, 790, 49, 1016, 2, 66, 175, 276, 29396, 1, 953, 67, 912, 33, 1016, 25500, 10, 265, 8, 52, 1, 83, 162, 29, 1085, 33, 162, 184, 18, 6, 133, 9, 4056, 2, 833, 162, 184, 67, 6, 5905, 9, 1246, 5417, 19, 144, 29396, 489, 8, 52, 1, 133, 162, 29, 1085, 5, 288, 1677, 4056, 2, 1559, 1246, 5417, 147, 19, 6542, 43, 130, 9, 25500, 4, 880, 65, 159, 5711, 19, 144, 171, 3627, 448, 1160, 2617, 19, 1614, 154, 2215, 1276, 19, 1999, 154, 181, 9862, 31, 61, 19, 3820, 2, 220, 3229, 1047, 19, 3825, 43, 130, 9, 25500, 4, 658, 65, 11, 4056, 19, 144, 2, 64, 1085, 58, 19, 1111, 125, 10, 8, 93, 344, 4, 282, 9, 110, 25500, 360, 197, 67, 213, 58, 27, 456, 6, 167, 567, 19, 144, 2, 29396, 360, 197, 49, 584, 58, 18, 339, 6, 203, 203, 19, 144, 20811, 16, 186, 2, 41, 5, 64, 282, 4, 329, 2, 1223, 7, 479, 1085, 1093, 4, 4056, 2190, 2, 135, 5, 64, 1085, 58, 21, 2548, 3, 29396, 2470, 6, 7195, 3, 25500, 2470, 447, 211, 378, 2720, 9, 1386, 7936, 930, 4, 1085, 7]",1949.0,23380342,Defining incidence risk factors impact survival central line-associated blood stream infections following hematopoietic transplantation acute myeloid leukemia myelodysplastic syndrome,16,0.027923211169284468
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.,The New England journal of medicine,N. Engl. J. Med.,2013-02-01,"Metastatic thyroid cancers that are refractory to radioiodine (iodine-131) are associated with a poor prognosis. In mouse models of thyroid cancer, selective mitogen-activated protein kinase (MAPK) pathway antagonists increase the expression of the sodium-iodide symporter and uptake of iodine. Their effects in humans are not known. We conducted a study to determine whether the MAPK kinase (MEK) 1 and MEK2 inhibitor selumetinib (AZD6244, ARRY-142886) could reverse refractoriness to radioiodine in patients with metastatic thyroid cancer. After stimulation with thyrotropin alfa, dosimetry with iodine-124 positron-emission tomography (PET) was performed before and 4 weeks after treatment with selumetinib (75 mg twice daily). If the second iodine-124 PET study indicated that a dose of iodine-131 of 2000 cGy or more could be delivered to the metastatic lesion or lesions, therapeutic radioiodine was administered while the patient was receiving selumetinib. Of 24 patients screened for the study, 20 could be evaluated. The median age was 61 years (range, 44 to 77), and 11 patients were men. Nine patients had tumors with BRAF mutations, and 5 patients had tumors with mutations of NRAS. Selumetinib increased the uptake of iodine-124 in 12 of the 20 patients (4 of 9 patients with BRAF mutations and 5 of 5 patients with NRAS mutations). Eight of these 12 patients reached the dosimetry threshold for radioiodine therapy, including all 5 patients with NRAS mutations. Of the 8 patients treated with radioiodine, 5 had confirmed partial responses and 3 had stable disease; all patients had decreases in serum thyroglobulin levels (mean reduction, 89%). No toxic effects of grade 3 or higher attributable by the investigators to selumetinib were observed. One patient received a diagnosis of myelodysplastic syndrome more than 51 weeks after radioiodine treatment, with progression to acute leukemia. Selumetinib produces clinically meaningful increases in iodine uptake and retention in a subgroup of patients with thyroid cancer that is refractory to radioiodine; the effectiveness may be greater in patients with RAS-mutant disease. (Funded by the American Thyroid Association and others; ClinicalTrials.gov number, NCT00970359.).",Clinical Trial,2545.0,,Metastatic thyroid refractory radioiodine iodine-131 associated poor prognosis mouse models thyroid selective mitogen-activated kinase MAPK pathway antagonists increase expression sodium-iodide symporter uptake iodine effects humans known conducted determine MAPK kinase MEK 1 MEK2 inhibitor selumetinib AZD6244 ARRY-142886 reverse refractoriness radioiodine patients metastatic thyroid stimulation thyrotropin alfa dosimetry iodine-124 positron-emission tomography PET performed 4 weeks treatment selumetinib 75 mg twice daily second iodine-124 PET indicated dose iodine-131 2000 cGy delivered metastatic lesion lesions therapeutic radioiodine administered patient receiving selumetinib 24 patients screened 20 evaluated median age 61 years range 44 77 11 patients men patients BRAF 5 patients NRAS Selumetinib increased uptake iodine-124 12 20 patients 4 9 patients BRAF 5 5 patients NRAS 12 patients reached dosimetry threshold radioiodine therapy including 5 patients NRAS 8 patients treated radioiodine 5 confirmed partial responses 3 stable disease patients decreases serum thyroglobulin levels mean reduction 89 toxic effects grade 3 higher attributable investigators selumetinib observed patient received diagnosis myelodysplastic syndrome 51 weeks radioiodine treatment progression acute leukemia Selumetinib produces clinically meaningful increases iodine uptake retention subgroup patients thyroid refractory radioiodine effectiveness greater patients RAS-mutant disease Funded American Thyroid Association ClinicalTrials.gov number NCT00970359,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[113, 163, 17, 32, 430, 6, 7211, 4287, 2229, 32, 41, 5, 8, 334, 356, 4, 830, 274, 1, 12, 1094, 2625, 735, 178, 216, 1748, 308, 4444, 344, 3, 55, 1, 3, 4682, 8456, 20641, 2, 1135, 1, 4287, 136, 176, 4, 3218, 32, 44, 440, 21, 426, 8, 45, 6, 223, 317, 3, 1748, 216, 1693, 14, 2, 12873, 230, 4626, 6590, 13412, 17958, 359, 1772, 12483, 6, 7211, 4, 7, 5, 113, 12, 50, 2503, 5, 16665, 4443, 4113, 5, 4287, 2834, 1900, 1799, 872, 495, 10, 173, 348, 2, 39, 244, 50, 24, 5, 4626, 481, 81, 936, 391, 492, 3, 419, 4287, 2834, 495, 45, 1103, 17, 8, 61, 1, 4287, 2229, 1, 1081, 3071, 15, 80, 359, 40, 1623, 6, 3, 113, 1180, 15, 406, 189, 7211, 10, 468, 369, 3, 69, 10, 357, 4626, 1, 259, 7, 2261, 9, 3, 45, 179, 359, 40, 194, 3, 52, 89, 10, 713, 60, 184, 584, 6, 849, 2, 175, 7, 11, 325, 762, 7, 42, 57, 5, 566, 138, 2, 33, 7, 42, 57, 5, 138, 1, 2845, 4626, 101, 3, 1135, 1, 4287, 2834, 4, 133, 1, 3, 179, 7, 39, 1, 83, 7, 5, 566, 138, 2, 33, 1, 33, 7, 5, 2845, 138, 659, 1, 46, 133, 7, 1300, 3, 4113, 2390, 9, 7211, 36, 141, 62, 33, 7, 5, 2845, 138, 1, 3, 66, 7, 73, 5, 7211, 33, 42, 557, 450, 253, 2, 27, 42, 585, 34, 62, 7, 42, 2140, 4, 524, 8978, 148, 313, 628, 887, 77, 1812, 176, 1, 88, 27, 15, 142, 2971, 20, 3, 2394, 6, 4626, 11, 164, 104, 69, 103, 8, 147, 1, 681, 80, 76, 725, 244, 50, 7211, 24, 5, 91, 6, 286, 4626, 4042, 505, 2538, 1106, 4, 4287, 1135, 2, 3947, 4, 8, 1363, 1, 7, 5, 12, 17, 16, 430, 6, 7211, 3, 1236, 68, 40, 378, 4, 7, 5, 1102, 620, 34, 3827, 20, 3, 597, 248, 2, 1749, 1252, 1239, 207, 62458]",2120.0,23406027,Selumetinib-enhanced radioiodine uptake advanced thyroid,1,0.0017452006980802793
Systemic mastocytosis with associated clonal hematological non-mast cell lineage disease: clinical significance and comparison of chomosomal abnormalities in SM and AHNMD components.,American journal of hematology,Am. J. Hematol.,2013-03-01,"Some patients with systemic mastocytosis have concurrent hematological neoplasms, designated in the World Health Organization (WHO) classification as systemic mastocytosis with associated clonal hematological non-mast cell lineage disease (SM-AHNMD). In this study, we analyzed 29 patients with SM-AHNMD and compared them to 40 patients with pure SM. The AHNMDs were classified as chronic myelomonocytic leukemia (CMML) (n = 10), myelodysplastic syndrome (MDS) (n = 7), myeloproliferative neoplasms (n = 4), B-cell lymphoma/leukemia/plasma cell neoplasms (n = 7), and acute myeloid leukemia (n = 1). Patients with SM-AHNMD were older, more frequently had constitutional symptoms and hematological abnormalities, less often had skin lesions, and had an inferior overall survival compared with pure SM patients (48 months vs. not-reached, P < 0.001). Karyotypic abnormalities were detected in 9/28 (32%) patients with SM-AHNMD but not in pure SM patients (P < 0.001). Combined imaging/ fluorescence-in-situ hybridization performed in four SM-AHNMD cases revealed shared abnormal signals in mast cells and myeloid cells in two patients with SM-CMML and one patient with SM-MDS, but not in the mast cells of a case SM-associated with chronic lymphocytic leukemia with ATM-deletion. Quantitative mutation analysis showed higher levels of mutant KIT D816V in SM-CMML and SM-MDS than in pure SM (P < 0.001). Our data indicate that the SM-AHNMD category in the WHO classification is heterogeneous, including clonally related and unrelated forms of AHNMD. The presentation, treatment, and outcome of patients with SM-AHNMD is often dictated by the type of AHNMD.",Comparative Study,2517.0,,patients systemic mastocytosis concurrent hematological neoplasms designated World Health Organization classification systemic mastocytosis associated clonal hematological non-mast lineage disease SM-AHNMD 29 patients SM-AHNMD compared 40 patients pure SM AHNMDs classified chronic myelomonocytic leukemia CMML n 10 myelodysplastic syndrome MDS n 7 myeloproliferative neoplasms n 4 B-cell lymphoma/leukemia/plasma neoplasms n 7 acute myeloid leukemia n 1 Patients SM-AHNMD older frequently constitutional symptoms hematological abnormalities skin lesions inferior overall survival compared pure SM patients 48 months vs. not-reached P 0.001 Karyotypic abnormalities detected 9/28 32 patients SM-AHNMD pure SM patients P 0.001 Combined imaging/ fluorescence-in-situ hybridization performed SM-AHNMD cases revealed shared abnormal signals mast myeloid patients SM-CMML patient SM-MDS mast case SM-associated chronic lymphocytic leukemia ATM-deletion Quantitative showed higher levels KIT D816V SM-CMML SM-MDS pure SM P 0.001 indicate SM-AHNMD category classification heterogeneous including clonally related unrelated forms AHNMD presentation treatment outcome patients SM-AHNMD dictated type AHNMD,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,"[476, 7, 5, 403, 7224, 47, 750, 2890, 1179, 4107, 4, 3, 1956, 341, 2533, 54, 947, 22, 403, 7224, 5, 41, 1946, 2890, 220, 5563, 31, 2542, 34, 3635, 21751, 4, 26, 45, 21, 311, 462, 7, 5, 3635, 21751, 2, 72, 1370, 6, 327, 7, 5, 3092, 3635, 3, 62493, 11, 1373, 22, 442, 5451, 3382, 78, 79, 681, 1223, 78, 67, 1179, 78, 39, 132, 31, 4763, 2647, 554, 31, 1179, 78, 67, 2, 286, 533, 78, 14, 7, 5, 3635, 21751, 11, 434, 80, 746, 42, 5962, 507, 2, 2890, 1171, 299, 629, 42, 406, 2, 42, 35, 1663, 63, 25, 72, 5, 3092, 3635, 7, 576, 53, 105, 44, 1300, 19, 13, 144, 9465, 1171, 11, 530, 4, 83, 339, 531, 7, 5, 3635, 21751, 84, 44, 4, 3092, 3635, 7, 19, 13, 144, 397, 270, 1591, 4, 957, 1554, 173, 4, 294, 3635, 21751, 140, 553, 2664, 1668, 2312, 4, 5563, 37, 2, 533, 37, 4, 100, 7, 5, 3635, 3382, 2, 104, 69, 5, 3635, 1223, 84, 44, 4, 3, 5563, 37, 1, 8, 473, 3635, 41, 5, 442, 1193, 5, 3552, 1528, 1156, 258, 65, 224, 142, 148, 1, 620, 1164, 12643, 4, 3635, 3382, 2, 3635, 1223, 76, 4, 3092, 3635, 19, 13, 144, 114, 74, 1008, 17, 3, 3635, 21751, 2169, 4, 3, 54, 947, 16, 1564, 141, 9157, 139, 2, 2092, 2377, 1, 21751, 3, 1031, 24, 2, 228, 1, 7, 5, 3635, 21751, 16, 629, 10575, 20, 3, 267, 1, 21751]",1520.0,23440662,Systemic mastocytosis associated clonal hematological non-mast lineage disease clinical significance comparison chomosomal abnormalities SM AHNMD components,0,0.0
Demethylation demystification.,Blood,Blood,2013-02-01,"The ability of the DNA methyltransferase inhibitors (DNMTi) to induce terminal differentiation in fibroblasts was first noted by Taylor and Jones in 1979; Silverman and Holland reported hematologic improvement in patients with myelodysplastic syndrome (MDS) in 1993. That azacitidine improves survival in patients with high-risk MDS and acute myeloid leukemia with MDS features compared with a combined comparator group of supportive care, low-dose cytarabine, and intensive cytarabine plus anthracycline, while inducing trilineage normalization in approximately 15% of patients makes the development of more potent, more specific drugs that behave like azacitidine imperative. The question is, how do the azanucleosides behave?",Journal Article,2545.0,3.0,ability DNA methyltransferase inhibitors DNMTi induce terminal differentiation fibroblasts noted Taylor Jones 1979 Silverman Holland reported hematologic improvement patients myelodysplastic syndrome MDS 1993 azacitidine improves survival patients high-risk MDS acute myeloid leukemia MDS features compared combined comparator group supportive care low-dose cytarabine intensive cytarabine plus anthracycline inducing trilineage normalization approximately 15 patients makes development potent specific drugs behave like azacitidine imperative question azanucleosides behave,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 801, 1, 3, 261, 3747, 222, 20004, 6, 1290, 2158, 910, 4, 3921, 10, 157, 1051, 20, 35537, 2, 21078, 4, 9444, 62506, 2, 44370, 210, 813, 767, 4, 7, 5, 681, 1223, 4, 3343, 17, 3752, 1804, 25, 4, 7, 5, 64, 43, 1223, 2, 286, 533, 5, 1223, 404, 72, 5, 8, 397, 8944, 87, 1, 1877, 165, 154, 61, 1855, 2, 1686, 1855, 349, 2044, 369, 1958, 21950, 5924, 4, 705, 167, 1, 7, 4677, 3, 193, 1, 80, 1157, 80, 112, 600, 17, 10403, 733, 3752, 6305, 3, 2840, 16, 832, 1022, 3, 40286, 10403]",689.0,23449614,Demethylation demystification,316,0.5514834205933682
Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.,The Lancet. Oncology,Lancet Oncol.,2013-02-28,"Tosedostat is a novel oral aminopeptidase inhibitor with clinical activity in a previous phase 1-2 study in elderly patients with relapsed or refractory acute myeloid leukaemia (AML). We aimed to compare two dosing regimens of tosedostat. In this randomised phase 2 study, patients aged 60 years or older with AML that had relapsed after a first complete remission lasting less than 12 months, or had achieved no previous complete remission, were randomly assigned (1:1) to receive as first salvage tosedostat 120 mg once daily for 6 months or 240 mg once daily for 2 months followed by 120 mg for 4 months. Randomisation was by block method via an interactive web response system using a randomisation schedule generated by an external vendor, with no stratification. The study was open label. The primary endpoint was the proportion of patients who obtained a complete remission or complete remission with incomplete platelet recovery. Analyses included all patients randomly assigned to treatment groups who received at least one oral dose of tosedostat. The study is registered with ClinicalTrials.gov, number NCT00780598. 38 patients were randomly assigned to receive tosedostat 120 mg and 38 to receive the tosedostat 240 mg to 120 mg regimen. 38 patients in the 120 mg group and 35 in the 240 mg to 120 mg group received tosedostat. Seven patients (10%) had complete remission or complete remission with incomplete platelet recovery: two (5%) in the 120 mg group and five (14%) in the 240 mg to 120 mg group. The most common grade 3 or worse adverse events were febrile neutropenia (11 [29%] patients in the 120 mg group and ten [29%] of the 240 mg to 120 mg group), thrombocytopenia (eight [21%] and eight [23%] patients), fatigue (seven [18%] and eight [23%] patients), dyspnoea (five [13%] and seven [20%] patients), and pneumonia (four [11%] and six [17%] patients). There were five fatal adverse events deemed to be treatment-related: three in the 120 mg group and two in the 240 mg to 120 mg group. The events were acute hepatitis, respiratory failure, pneumonia, atrial fibrillation, and left ventricular dysfunction. Tosedostat, at either dose schedule, has activity in older patients with relapsed or refractory AML. Additional studies of tosedostat including combination with hypomethylating agents and low-dose cytarabine in patients with high-risk myelodysplastic syndromes and AML are ongoing or planned. Chroma Therapeutics.","Clinical Trial, Phase II",2518.0,21.0,Tosedostat novel oral aminopeptidase inhibitor clinical activity previous phase 1-2 elderly patients relapsed refractory acute myeloid leukaemia AML aimed compare dosing regimens tosedostat randomised phase 2 patients aged 60 years older AML relapsed complete remission lasting 12 months achieved previous complete remission randomly assigned 1:1 receive salvage tosedostat 120 mg daily 6 months 240 mg daily 2 months followed 120 mg 4 months Randomisation block interactive web response randomisation schedule generated external vendor stratification open label primary endpoint proportion patients obtained complete remission complete remission incomplete platelet recovery included patients randomly assigned treatment groups received oral dose tosedostat registered ClinicalTrials.gov number NCT00780598 38 patients randomly assigned receive tosedostat 120 mg 38 receive tosedostat 240 mg 120 mg regimen 38 patients 120 mg group 35 240 mg 120 mg group received tosedostat Seven patients 10 complete remission complete remission incomplete platelet recovery 5 120 mg group 14 240 mg 120 mg group common grade 3 worse adverse events febrile neutropenia 11 29 patients 120 mg group 29 240 mg 120 mg group thrombocytopenia 21 23 patients fatigue seven 18 23 patients dyspnoea 13 seven 20 patients pneumonia 11 17 patients fatal adverse events deemed treatment-related 120 mg group 240 mg 120 mg group events acute hepatitis respiratory failure pneumonia atrial fibrillation left ventricular dysfunction Tosedostat dose schedule activity older patients relapsed refractory AML Additional studies tosedostat including combination hypomethylating agents low-dose cytarabine patients high-risk myelodysplastic syndromes AML ongoing planned Chroma Therapeutics,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21724, 16, 8, 229, 518, 18319, 230, 5, 38, 128, 4, 8, 698, 124, 14, 18, 45, 4, 1216, 7, 5, 591, 15, 430, 286, 533, 2001, 329, 21, 1295, 6, 932, 100, 1280, 472, 1, 21724, 4, 26, 2827, 124, 18, 45, 7, 1032, 335, 60, 15, 434, 5, 329, 17, 42, 591, 50, 8, 157, 236, 734, 3443, 299, 76, 133, 53, 15, 42, 513, 77, 698, 236, 734, 11, 1108, 896, 14, 14, 6, 560, 22, 157, 992, 21724, 2031, 81, 1059, 391, 9, 49, 53, 15, 4263, 81, 1059, 391, 9, 18, 53, 370, 20, 2031, 81, 9, 39, 53, 5204, 10, 20, 2381, 596, 847, 35, 4750, 3469, 51, 398, 75, 8, 5204, 1055, 1419, 20, 35, 1455, 16121, 5, 77, 1541, 3, 45, 10, 1020, 1756, 3, 86, 1138, 10, 3, 920, 1, 7, 54, 683, 8, 236, 734, 15, 236, 734, 5, 2610, 1596, 1602, 318, 159, 62, 7, 1108, 896, 6, 24, 271, 54, 103, 28, 506, 104, 518, 61, 1, 21724, 3, 45, 16, 1653, 5, 1252, 1239, 207, 62517, 519, 7, 11, 1108, 896, 6, 560, 21724, 2031, 81, 2, 519, 6, 560, 3, 21724, 4263, 81, 6, 2031, 81, 477, 519, 7, 4, 3, 2031, 81, 87, 2, 465, 4, 3, 4263, 81, 6, 2031, 81, 87, 103, 21724, 648, 7, 79, 42, 236, 734, 15, 236, 734, 5, 2610, 1596, 1602, 100, 33, 4, 3, 2031, 81, 87, 2, 365, 213, 4, 3, 4263, 81, 6, 2031, 81, 87, 3, 96, 186, 88, 27, 15, 639, 290, 281, 11, 2498, 778, 175, 462, 7, 4, 3, 2031, 81, 87, 2, 1618, 462, 1, 3, 4263, 81, 6, 2031, 81, 87, 1340, 659, 239, 2, 659, 382, 7, 613, 648, 203, 2, 659, 382, 7, 10489, 365, 233, 2, 648, 179, 7, 2, 3485, 294, 175, 2, 437, 269, 7, 125, 11, 365, 3034, 290, 281, 3779, 6, 40, 24, 139, 169, 4, 3, 2031, 81, 87, 2, 100, 4, 3, 4263, 81, 6, 2031, 81, 87, 3, 281, 11, 286, 3002, 2718, 496, 3485, 7658, 9380, 2, 1712, 4028, 1527, 21724, 28, 361, 61, 1055, 71, 128, 4, 434, 7, 5, 591, 15, 430, 329, 402, 94, 1, 21724, 141, 150, 5, 4931, 183, 2, 154, 61, 1855, 4, 7, 5, 64, 43, 2040, 2, 329, 32, 942, 15, 1465, 30615, 1943]",2342.0,23453583,dosing regimens tosedostat elderly patients relapsed refractory acute myeloid leukaemia OPAL randomised open-label phase 2,0,0.0
Significance of cytogenetic abnormalities in patients with polycythemia vera.,Leukemia & lymphoma,Leuk. Lymphoma,2013-04-17,"We analyzed 133 patients with polycythemia vera (PV) who were followed at our institution (median 7.5 years) and had adequate cytogenetics information. The 5-, 10- and 15-year survival rates were 93%, 79% and 64%, respectively, with a median projected overall survival of 24 years. Nineteen patients (14%) had abnormal cytogenetics at any time during the disease course (no survival difference). Sixteen patients (12%) underwent disease transformation during follow-up, after a median of 8.5 years, to myelofibrosis (n = 11), acute myeloid leukemia (n = 4) or myelodysplastic syndrome (n = 1); eight had cytogenetic abnormalities. Among 133 patients, 39 were newly diagnosed: 33 with normal and six with abnormal cytogenetics (no survival difference); nine underwent disease transformation (six with normal and three with abnormal cytogenetics at diagnosis). In keeping with other smaller series, the presence of chromosomal abnormalities may have had a role in disease transformation in patients with PV; survival was not affected likely due to short follow-up.",Journal Article,2470.0,16.0,133 patients polycythemia vera PV followed institution median 7.5 years adequate cytogenetics information 5- 10- 15-year survival rates 93 79 64 respectively median projected overall survival 24 years Nineteen patients 14 abnormal cytogenetics time disease course survival difference Sixteen patients 12 underwent disease transformation follow-up median 8.5 years myelofibrosis n 11 acute myeloid leukemia n 4 myelodysplastic syndrome n 1 cytogenetic abnormalities 133 patients 39 newly diagnosed 33 normal abnormal cytogenetics survival difference underwent disease transformation normal abnormal cytogenetics diagnosis keeping smaller series presence chromosomal abnormalities role disease transformation patients PV survival affected likely short follow-up,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 311, 5026, 7, 5, 5755, 5756, 3328, 54, 11, 370, 28, 114, 731, 52, 67, 33, 60, 2, 42, 1658, 2510, 487, 3, 33, 79, 2, 167, 111, 25, 151, 11, 966, 842, 2, 660, 106, 5, 8, 52, 5633, 63, 25, 1, 259, 60, 3498, 7, 213, 42, 1668, 2510, 28, 500, 98, 190, 3, 34, 906, 77, 25, 523, 3228, 7, 133, 208, 34, 1392, 190, 166, 126, 50, 8, 52, 1, 66, 33, 60, 6, 4637, 78, 175, 286, 533, 78, 39, 15, 681, 78, 14, 659, 42, 1266, 1171, 107, 5026, 7, 587, 11, 732, 265, 466, 5, 295, 2, 437, 5, 1668, 2510, 77, 25, 523, 762, 208, 34, 1392, 437, 5, 295, 2, 169, 5, 1668, 2510, 28, 147, 4, 10991, 5, 127, 2170, 988, 3, 463, 1, 1860, 1171, 68, 47, 42, 8, 200, 4, 34, 1392, 4, 7, 5, 3328, 25, 10, 44, 1424, 322, 520, 6, 978, 166, 126]",987.0,23488603,Significance cytogenetic abnormalities patients polycythemia vera,262,0.4572425828970332
Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia.,Blood,Blood,2013-04-02,"We investigated the predictive value of geriatric assessment (GA) on overall survival (OS) for older adults with acute myelogenous leukemia (AML). Consecutive patients  60 years with newly diagnosed AML and planned intensive chemotherapy were enrolled at a single institution. Pretreatment GA included evaluation of cognition, depression, distress, physical function (PF) (self-reported and objectively measured), and comorbidity. Objective PF was assessed using the Short Physical Performance Battery (SPPB, timed 4-m walk, chair stands, standing balance) and grip strength. Cox proportional hazards models were fit for each GA measure as a predictor of OS. Among 74 patients, the mean age was 70 years, and 78.4% had an Eastern Cooperative Oncology Group (ECOG) score  1. OS was significantly shorter for participants who screened positive for impairment in cognition and objectively measured PF. Adjusting for age, gender, ECOG score, cytogenetic risk group, myelodysplastic syndrome, and hemoglobin, impaired cognition (Modified Mini-Mental State Exam < 77) and impaired objective PF (SPPB < 9) were associated with worse OS. GA methods, with a focus on cognitive and PF, improve risk stratification and may inform interventions to improve outcomes for older AML patients.",Clinical Trial,2485.0,164.0,investigated predictive value geriatric assessment GA overall survival OS older adults acute myelogenous leukemia AML Consecutive patients  60 years newly diagnosed AML planned intensive chemotherapy enrolled single institution Pretreatment GA included evaluation cognition depression distress physical function PF self-reported objectively measured comorbidity Objective PF assessed Short Physical Performance Battery SPPB timed 4-m walk chair stands standing balance grip strength Cox proportional hazards models fit GA measure predictor OS 74 patients mean age 70 years 78.4 Eastern Cooperative Oncology Group ECOG score  1 OS significantly shorter participants screened positive impairment cognition objectively measured PF Adjusting age gender ECOG score cytogenetic risk group myelodysplastic syndrome hemoglobin impaired cognition Modified Mini-Mental State Exam 77 impaired objective PF SPPB 9 associated worse OS GA methods focus cognitive PF improve risk stratification inform interventions improve outcomes older AML patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 565, 3, 464, 549, 1, 3914, 455, 3414, 23, 63, 25, 118, 9, 434, 857, 5, 286, 2194, 329, 935, 7, 749, 335, 60, 5, 732, 265, 329, 2, 1465, 1686, 56, 11, 346, 28, 8, 226, 731, 1194, 3414, 159, 451, 1, 8130, 1774, 1462, 900, 343, 3313, 1074, 210, 2, 8731, 644, 2, 1879, 461, 3313, 10, 275, 75, 3, 978, 900, 528, 11665, 25520, 12200, 39, 188, 8200, 19069, 16270, 10909, 3459, 2, 16562, 3671, 418, 831, 1017, 274, 11, 2975, 9, 296, 3414, 1463, 22, 8, 980, 1, 118, 107, 794, 7, 3, 313, 89, 10, 431, 60, 2, 833, 39, 42, 35, 2118, 1690, 413, 87, 2351, 368, 1552, 14, 118, 10, 97, 985, 9, 776, 54, 2261, 109, 9, 2315, 4, 8130, 2, 8731, 644, 3313, 1358, 9, 89, 1632, 2351, 368, 1266, 43, 87, 681, 2, 2222, 2364, 8130, 1230, 7313, 3031, 1309, 6747, 849, 2, 2364, 461, 3313, 25520, 83, 11, 41, 5, 639, 118, 3414, 636, 5, 8, 1222, 23, 1863, 2, 3313, 401, 43, 1541, 2, 68, 2295, 1151, 6, 401, 123, 9, 434, 329, 7]",1204.0,23550038,Geriatric assessment predicts survival older adults receiving induction chemotherapy acute myelogenous leukemia,72,0.1256544502617801
Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2013-04-02,"Comparisons of myeloablative conditioning versus reduced-intensity conditioning (RIC) have demonstrated a tradeoff between relapse and toxicity. Dose intensity across RIC regimens vary and may affect treatment outcomes. In this retrospective analysis, we investigated the effect of i.v. busulfan dosing (total dose 3.2 mg/kg versus 6.4 mg/kg) in RIC regimens that combined fludarabine and busulfan on outcomes in patients who were undergoing hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). A total of 217 consecutive patients with MDS or AML underwent first busulfan and fludarabine RIC peripheral blood stem cell transplantation from well-matched related or unrelated donors at our institutions between 2004 and 2009. Of the 217 patients, 135 patients received Bu1 (3.2 mg/kg of busulfan) and 82 patients received Bu2 (6.4 mg/kg of busulfan), both with daily fludarabine (30 mg/m(2)/day for 4 days). The choice of RIC regimen was based on temporal institutional standard, enrollment on protocols, and physician choice. Patients had similar characteristics with a few notable differences: Patients who received Bu1 were younger (median age 61 versus 64 years, P < . 001), received more single-antigen mismatched unrelated grafts (14.1% versus 1.2%, P < . 001), received more sirolimus-based graft-versus-host disease (GVHD) prophylaxis regimens (63% versus 45%, P < .0001), received less antithymocyte globulin for GVHD prophylaxis (0% versus 22%, P < .001), and had less enrollment on a clinical trial that used prophylactic rituximab for the prevention of chronic GVHD (2.2% versus 11.0%, P = .011). Clinical disease status was similar between the groups. Median follow-up for survivors was 4.4 years for Bu1 and 3.2 years for Bu2. Because of the differences in characteristics, the 2 groups were compared with the adjustment of a propensity score that predicted Bu2 to account for measured differences. The day +200 cumulative incidence rates of grades II to IV acute GVHD (Bu1, 17%, versus Bu2, 8.5%; hazard ratio [HR], .56; 95% confidence interval [CI], .22 to 1.41; P = .22) or grades III to IV acute GVHD (Bu1, 6.7%, versus Bu2, 4.9%) were not different. The 2-year cumulative incidence of chronic GVHD was not significantly different between Bu1 and Bu2 (41.5% versus 28%, respectively; HR, .70; CI, .42 to 1.17; P = .09). Two-year nonrelapse mortality rates were similar for Bu1 and Bu2 (8.9% versus 9.8%, respectively; HR, .80; CI, .29 to 2.21; P = .67). Two-year progression-free survival and overall survival were also similar between Bu1 and Bu2 (progression-free survival: 40.6% versus 39.3%, respectively; HR, .82; CI, .57 to 1.30; P = .33; and overall survival: 47.4% versus 48.8%, respectively; HR, .96; CI, .64 to 1.44; P = .85). Subset analysis defined by clinical disease and cytogenetic risk with the propensity risk score applied suggest that in patients with high clinical disease risk and nonadverse cytogenetics, the higher dose busulfan RIC regimen may be of marginal benefit (2-year progression-free survival: HR, .54; CI, .29 to 1.03; P = .062). For the majority of patients with MDS or AML undergoing busulfan and fludarabine RIC peripheral blood stem cell transplantation, however, the dose of busulfan (3.2 mg/kg versus 6.4 mg/kg) is not associated with significant differences in overall outcomes.",Journal Article,2485.0,30.0,Comparisons myeloablative conditioning versus reduced-intensity conditioning RIC demonstrated tradeoff relapse toxicity Dose intensity RIC regimens vary affect treatment outcomes retrospective investigated effect i.v busulfan dosing total dose 3.2 mg/kg versus 6.4 mg/kg RIC regimens combined fludarabine busulfan outcomes patients undergoing hematopoietic stem transplantation HSCT myelodysplastic syndrome MDS acute myeloid leukemia AML total 217 consecutive patients MDS AML underwent busulfan fludarabine RIC peripheral blood stem transplantation well-matched related unrelated donors institutions 2004 2009 217 patients 135 patients received Bu1 3.2 mg/kg busulfan 82 patients received Bu2 6.4 mg/kg busulfan daily fludarabine 30 mg/m 2 /day 4 days choice RIC regimen based temporal institutional standard enrollment protocols physician choice Patients similar characteristics notable differences Patients received Bu1 younger median age 61 versus 64 years P 001 received single-antigen mismatched unrelated grafts 14.1 versus 1.2 P 001 received sirolimus-based graft-versus-host disease GVHD prophylaxis regimens 63 versus 45 P .0001 received antithymocyte globulin GVHD prophylaxis 0 versus 22 P .001 enrollment clinical trial prophylactic rituximab prevention chronic GVHD 2.2 versus 11.0 P .011 Clinical disease status similar groups Median follow-up survivors 4.4 years Bu1 3.2 years Bu2 differences characteristics 2 groups compared adjustment propensity score predicted Bu2 account measured differences day +200 cumulative incidence rates grades II IV acute GVHD Bu1 17 versus Bu2 8.5 hazard ratio HR .56 95 confidence interval CI .22 1.41 P .22 grades III IV acute GVHD Bu1 6.7 versus Bu2 4.9 different 2-year cumulative incidence chronic GVHD significantly different Bu1 Bu2 41.5 versus 28 respectively HR .70 CI .42 1.17 P .09 Two-year nonrelapse mortality rates similar Bu1 Bu2 8.9 versus 9.8 respectively HR .80 CI .29 2.21 P .67 Two-year progression-free survival overall survival similar Bu1 Bu2 progression-free survival 40.6 versus 39.3 respectively HR .82 CI .57 1.30 P .33 overall survival 47.4 versus 48.8 respectively HR .96 CI .64 1.44 P .85 Subset defined clinical disease cytogenetic risk propensity risk score applied suggest patients high clinical disease risk nonadverse cytogenetics higher dose busulfan RIC regimen marginal benefit 2-year progression-free survival HR .54 CI .29 1.03 P .062 majority patients MDS AML undergoing busulfan fludarabine RIC peripheral blood stem transplantation dose busulfan 3.2 mg/kg versus 6.4 mg/kg associated significant differences overall outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2213, 1, 3246, 1933, 185, 405, 837, 1933, 3365, 47, 264, 8, 24833, 59, 429, 2, 155, 61, 837, 716, 3365, 472, 2825, 2, 68, 1158, 24, 123, 4, 26, 459, 65, 21, 565, 3, 254, 1, 70, 603, 3906, 1280, 181, 61, 27, 18, 81, 503, 185, 49, 39, 81, 503, 4, 3365, 472, 17, 397, 2027, 2, 3906, 23, 123, 4, 7, 54, 11, 479, 1007, 452, 31, 497, 1703, 9, 681, 1223, 15, 286, 533, 329, 8, 181, 1, 6499, 935, 7, 5, 1223, 15, 329, 208, 157, 3906, 2, 2027, 3365, 672, 315, 452, 31, 497, 29, 149, 655, 139, 15, 2092, 2344, 28, 114, 1764, 59, 1131, 2, 1238, 1, 3, 6499, 7, 3978, 7, 103, 25522, 27, 18, 81, 503, 1, 3906, 2, 878, 7, 103, 25523, 49, 39, 81, 503, 1, 3906, 110, 5, 391, 2027, 201, 81, 188, 18, 218, 9, 39, 162, 3, 1866, 1, 3365, 477, 10, 90, 23, 3264, 1115, 260, 1798, 23, 2189, 2, 1473, 1866, 7, 42, 288, 374, 5, 8, 1021, 4090, 362, 7, 54, 103, 25522, 11, 773, 52, 89, 713, 185, 660, 60, 19, 144, 103, 80, 226, 448, 5095, 2092, 4713, 213, 14, 185, 14, 18, 19, 144, 103, 80, 4519, 90, 1599, 185, 1204, 34, 1562, 2049, 472, 676, 185, 512, 19, 488, 103, 299, 11016, 7819, 9, 1562, 2049, 13, 185, 350, 19, 144, 2, 42, 299, 1798, 23, 8, 38, 160, 17, 95, 1862, 855, 9, 3, 1070, 1, 442, 1562, 18, 18, 185, 175, 13, 19, 3651, 38, 34, 156, 10, 288, 59, 3, 271, 52, 166, 126, 9, 332, 10, 39, 39, 60, 9, 25522, 2, 27, 18, 60, 9, 25523, 408, 1, 3, 362, 4, 374, 3, 18, 271, 11, 72, 5, 3, 1852, 1, 8, 1925, 368, 17, 783, 25523, 6, 1967, 9, 644, 362, 3, 218, 1250, 967, 287, 151, 1, 2276, 215, 6, 478, 286, 1562, 25522, 269, 185, 25523, 66, 33, 360, 197, 168, 664, 48, 307, 268, 58, 350, 6, 14, 605, 19, 350, 15, 2276, 316, 6, 478, 286, 1562, 25522, 49, 67, 185, 25523, 39, 83, 11, 44, 338, 3, 18, 111, 967, 287, 1, 442, 1562, 10, 44, 97, 338, 59, 25522, 2, 25523, 605, 33, 185, 339, 106, 168, 431, 58, 595, 6, 14, 269, 19, 1730, 100, 111, 4640, 282, 151, 11, 288, 9, 25522, 2, 25523, 66, 83, 185, 83, 66, 106, 168, 493, 58, 462, 6, 18, 239, 19, 598, 100, 111, 91, 115, 25, 2, 63, 25, 11, 120, 288, 59, 25522, 2, 25523, 91, 115, 25, 327, 49, 185, 587, 27, 106, 168, 878, 58, 696, 6, 14, 201, 19, 466, 2, 63, 25, 662, 39, 185, 576, 66, 106, 168, 921, 58, 660, 6, 14, 584, 19, 772, 697, 65, 395, 20, 38, 34, 2, 1266, 43, 5, 3, 1925, 43, 368, 1498, 309, 17, 4, 7, 5, 64, 38, 34, 43, 2, 62683, 2510, 3, 142, 61, 3906, 3365, 477, 68, 40, 1, 3450, 247, 18, 111, 91, 115, 25, 168, 667, 58, 462, 6, 14, 680, 19, 12139, 9, 3, 686, 1, 7, 5, 1223, 15, 329, 479, 3906, 2, 2027, 3365, 672, 315, 452, 31, 497, 137, 3, 61, 1, 3906, 27, 18, 81, 503, 185, 49, 39, 81, 503, 16, 44, 41, 5, 93, 362, 4, 63, 123]",3199.0,23562738,Busulfan dose intensity outcomes reduced-intensity allogeneic peripheral blood stem transplantation myelodysplastic syndrome acute myeloid leukemia,40,0.06980802792321117
Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2013-05-20,"Second malignant neoplasms (SMNs) after diagnosis of childhood acute lymphoblastic leukemia (ALL) are rare events. We analyzed data on risk factors and outcomes of 642 children with SMNs occurring after treatment for ALL from 18 collaborative study groups between 1980 and 2007. Acute myeloid leukemia (AML; n = 186), myelodysplastic syndrome (MDS; n = 69), and nonmeningioma brain tumor (n = 116) were the most common types of SMNs and had the poorest outcome (5-year survival rate, 18.1%  2.9%, 31.1%  6.2%, and 18.3%  3.8%, respectively). Five-year survival estimates for AML were 11.2%  2.9% for 125 patients diagnosed before 2000 and 34.1%  6.3% for 61 patients diagnosed after 2000 (P < .001); 5-year survival estimates for MDS were 17.1%  6.4% (n = 36) and 48.2%  10.6% (n = 33; P = .005). Allogeneic stem-cell transplantation failed to improve outcome of secondary myeloid malignancies after adjusting for waiting time to transplantation. Five-year survival rates were above 90% for patients with meningioma, Hodgkin lymphoma, thyroid carcinoma, basal cell carcinoma, and parotid gland tumor, and 68.5%  6.4% for those with non-Hodgkin lymphoma. Eighty-nine percent of patients with brain tumors had received cranial irradiation. Solid tumors were associated with cyclophosphamide exposure, and myeloid malignancy was associated with topoisomerase II inhibitors and starting doses of methotrexate of at least 25 mg/m(2) per week and mercaptopurine of at least 75 mg/m(2) per day. Myeloid malignancies with monosomy 7/5q- were associated with high hyperdiploid ALL karyotypes, whereas 11q23/MLL-rearranged AML or MDS was associated with ALL harboring translocations of t(9;22), t(4;11), t(1;19), and t(12;21) (P = .03). SMNs, except for brain tumors, AML, and MDS, have outcomes similar to their primary counterparts.",Journal Article,2437.0,63.0,Second malignant neoplasms SMNs diagnosis childhood acute lymphoblastic leukemia rare events risk factors outcomes 642 children SMNs occurring treatment 18 collaborative groups 1980 2007 Acute myeloid leukemia AML n 186 myelodysplastic syndrome MDS n 69 nonmeningioma brain n 116 common types SMNs poorest outcome 5-year survival rate 18.1  2.9 31.1  6.2 18.3  3.8 respectively Five-year survival estimates AML 11.2  2.9 125 patients diagnosed 2000 34.1  6.3 61 patients diagnosed 2000 P .001 5-year survival estimates MDS 17.1  6.4 n 36 48.2  10.6 n 33 P .005 Allogeneic stem-cell transplantation failed improve outcome secondary myeloid malignancies adjusting waiting time transplantation Five-year survival rates 90 patients meningioma Hodgkin lymphoma thyroid carcinoma basal carcinoma parotid gland 68.5  6.4 non-Hodgkin lymphoma Eighty-nine percent patients brain received cranial irradiation Solid associated cyclophosphamide exposure myeloid malignancy associated topoisomerase II inhibitors starting doses methotrexate 25 mg/m 2 week mercaptopurine 75 mg/m 2 day Myeloid malignancies monosomy 7/5q- associated high hyperdiploid karyotypes 11q23/MLL-rearranged AML MDS associated harboring translocations 9 22 4 11 1 19 12 21 P .03 SMNs brain AML MDS outcomes similar primary counterparts,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,"[419, 393, 1179, 6580, 50, 147, 1, 864, 286, 1275, 62, 32, 622, 281, 21, 311, 74, 23, 43, 130, 2, 123, 1, 11994, 541, 5, 6580, 1821, 50, 24, 9, 62, 29, 203, 3737, 45, 271, 59, 4376, 2, 1307, 286, 533, 329, 78, 5869, 681, 1223, 78, 790, 2, 62818, 342, 30, 78, 3790, 11, 3, 96, 186, 630, 1, 6580, 2, 42, 3, 11136, 228, 33, 111, 25, 116, 203, 14, 810, 18, 83, 456, 14, 810, 49, 18, 2, 203, 27, 810, 27, 66, 106, 365, 111, 25, 1423, 9, 329, 11, 175, 18, 810, 18, 83, 9, 1731, 7, 265, 348, 1081, 2, 562, 14, 810, 49, 27, 9, 713, 7, 265, 50, 1081, 19, 144, 33, 111, 25, 1423, 9, 1223, 11, 269, 14, 810, 49, 39, 78, 511, 2, 576, 18, 810, 79, 49, 78, 466, 19, 1614, 1063, 452, 31, 497, 1551, 6, 401, 228, 1, 568, 533, 441, 50, 1358, 9, 7598, 98, 6, 497, 365, 111, 25, 151, 11, 2090, 424, 9, 7, 5, 3944, 134, 2135, 31, 134, 2, 5838, 2326, 30, 2, 806, 33, 810, 49, 39, 9, 135, 5, 2207, 762, 714, 1, 7, 5, 342, 57, 42, 103, 2565, 1104, 537, 57, 11, 41, 5, 1112, 645, 2, 533, 710, 10, 41, 5, 3999, 215, 222, 2, 1723, 415, 1, 2116, 1, 28, 506, 243, 81, 188, 18, 379, 647, 2, 9223, 1, 28, 506, 481, 81, 188, 18, 379, 218, 533, 441, 5, 7521, 67, 5460, 11, 41, 5, 64, 8847, 62, 6809, 547, 7975, 3049, 3201, 329, 15, 1223, 10, 41, 5, 62, 2105, 3262, 1, 102, 83, 350, 102, 39, 175, 102, 14, 326, 2, 102, 133, 239, 19, 680, 6580, 2187, 9, 342, 57, 329, 2, 1223, 47, 123, 288, 6, 136, 86, 3953]",1659.0,23690411,Second malignant neoplasms treatment childhood acute lymphoblastic leukemia,6,0.010471204188481676
A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance).,Investigational new drugs,Invest New Drugs,2013-05-23,"Angiogenesis is implicated in the pathophysiology and progression of myelodysplastic syndromes (MDS). Vatalanib (PTK787/ZK222584; Novartis and Schering AG) inhibits receptor tyrosine kinases of vascular endothelial growth factor, platelet derived growth factor and c-Kit. We examined whether vatalanib induces hematological responses in MDS and/or delays progression to acute myeloid leukemia (AML) or death. Two cohorts were studied. Vatalanib 1250 mg orally was given once daily (cohort 1) or 750-1250 mg once daily in an intra-patient dose escalating schedule (cohort 2) in 28-day cycles to 155 patients with MDS; 142 patients were evaluable for response and 153 for toxicity. The median age was 70.5 years; 51 % had low risk (International Prognostic Scoring System {IPSS} Low/Intermediate-1) and 32 % had high risk (IPSS Intermediate-2/High) MDS. Hematological improvement was achieved in 7/142 (5 %) patients; all 7 were among the 47 patients able to remain on vatalanib for at least 3 months (hematological improvement achieved in 15 % of these 47 patients). For patients with low risk and high risk MDS, respectively, median progression-free survivals were 15 and 6 months, median times to transformation to AML were 28 and 6 months, and median overall survivals were 36 and 10 months. The most frequent non-hematological adverse events grade  2 were fatigue, nausea or vomiting, dizziness, anorexia, ataxia, diarrhea, and pain. Two deaths (one intra-cerebral hemorrhage and one sudden death) were possibly related to vatalanib. Vatalanib induces improvement in blood counts in a small proportion of MDS patients. Clinical applicability is limited by side effects.","Clinical Trial, Phase II",2434.0,12.0,Angiogenesis implicated pathophysiology progression myelodysplastic syndromes MDS Vatalanib PTK787/ZK222584 Novartis Schering AG inhibits receptor tyrosine kinases vascular endothelial growth factor platelet derived growth factor c-Kit examined vatalanib induces hematological responses MDS and/or delays progression acute myeloid leukemia AML death cohorts studied Vatalanib 1250 mg orally given daily cohort 1 750-1250 mg daily intra-patient dose escalating schedule cohort 2 28-day cycles 155 patients MDS 142 patients evaluable response 153 toxicity median age 70.5 years 51 low risk International Prognostic Scoring IPSS Low/Intermediate-1 32 high risk IPSS Intermediate-2/High MDS Hematological improvement achieved 7/142 5 patients 7 47 patients able remain vatalanib 3 months hematological improvement achieved 15 47 patients patients low risk high risk MDS respectively median progression-free survivals 15 6 months median times transformation AML 28 6 months median overall survivals 36 10 months frequent non-hematological adverse events grade  2 fatigue nausea vomiting dizziness anorexia ataxia diarrhea pain deaths intra-cerebral hemorrhage sudden death possibly related vatalanib Vatalanib induces improvement blood counts small proportion MDS patients Clinical applicability limited effects,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1056, 16, 1771, 4, 3, 4320, 2, 91, 1, 2040, 1223, 15376, 12751, 26463, 7855, 2, 26175, 2741, 1576, 153, 564, 1549, 1, 756, 845, 129, 161, 1596, 526, 129, 161, 2, 256, 1164, 21, 409, 317, 15376, 1516, 2890, 253, 4, 1223, 2, 15, 3257, 91, 6, 286, 533, 329, 15, 273, 100, 736, 11, 656, 15376, 11551, 81, 1428, 10, 447, 1059, 391, 180, 14, 15, 4506, 11551, 81, 1059, 391, 4, 35, 2392, 69, 61, 2922, 1055, 180, 18, 4, 339, 218, 410, 6, 3735, 7, 5, 1223, 4785, 7, 11, 859, 9, 51, 2, 4251, 9, 155, 3, 52, 89, 10, 431, 33, 60, 725, 42, 154, 43, 944, 177, 2504, 398, 8751, 154, 919, 14, 2, 531, 42, 64, 43, 8751, 919, 18, 64, 1223, 2890, 767, 10, 513, 4, 67, 4785, 33, 7, 62, 67, 11, 107, 3, 662, 7, 1665, 6, 918, 23, 15376, 9, 28, 506, 27, 53, 2890, 767, 513, 4, 167, 1, 46, 662, 7, 9, 7, 5, 154, 43, 2, 64, 43, 1223, 106, 52, 91, 115, 3794, 11, 167, 2, 49, 53, 52, 1072, 6, 1392, 6, 329, 11, 339, 2, 49, 53, 2, 52, 63, 3794, 11, 511, 2, 79, 53, 3, 96, 908, 220, 2890, 290, 281, 88, 749, 18, 11, 613, 1218, 15, 1966, 11489, 3373, 8299, 1172, 2, 559, 100, 1043, 104, 2392, 3549, 3599, 2, 104, 10643, 273, 11, 2150, 139, 6, 15376, 15376, 1516, 767, 4, 315, 1911, 4, 8, 302, 920, 1, 1223, 7, 38, 5412, 16, 383, 20, 1152, 176]",1591.0,23700288,phase II oral VEGF receptor tyrosine kinase inhibitor vatalanib PTK787/ZK222584 myelodysplastic syndrome Leukemia Group B 10105 Alliance,0,0.0
"Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2013-05-28,"Over the past four decades, allogeneic hematopoietic cell transplantation (alloHCT) has evolved as a curative modality for patients with hematologic diseases. This study describes changes in use, technique, and survival in a population-based cohort. The study included 38,060 patients with hematologic malignancies or disorders who underwent first alloHCT in a US or Canadian center from 1994 to 2005 and were reported to the Center for International Blood and Marrow Transplant Research. AlloHCT as treatment for acute lymphoblastic (ALL) and myeloid leukemias (AML), myelodysplastic syndrome (MDS), and Hodgkin and non-Hodgkin lymphomas increased by 45%, from 2,520 to 3,668 patients annually. From 1994 to 2005, use of both peripheral (7% to 63%) [corrected] and cord blood increased (2% to 10%), whereas use of marrow decreased (90% to 27%). Despite a median age increase from 33 to 40 years and 165% [corrected] increase in unrelated donors for alloHCT, overall survival (OS) at day 100 significantly improved for patients with AML in first complete remission after myeloablative sibling alloHCT (85% to 94%; P < .001) and unrelated alloHCT (63% to 86%; P < .001); 1-year OS improved among those undergoing unrelated alloHCT (48% to 63%; P = .003) but not among those undergoing sibling alloHCT. Similar results were seen for ALL and MDS. Day-100 OS after cord blood alloHCT improved significantly from 60% to 78% (P < .001) for AML, ALL, MDS, and chronic myeloid leukemia. Use of reduced-intensity regimens increased, yielding OS rates similar to those of myeloablative regimens. Survival for those undergoing alloHCT has significantly improved over time. However, new approaches are needed to further improve 1-year OS.",Journal Article,2429.0,137.0,"past decades allogeneic hematopoietic transplantation alloHCT evolved curative modality patients hematologic diseases describes changes use technique survival population-based cohort included 38,060 patients hematologic malignancies disorders underwent alloHCT Canadian center 1994 2005 reported Center International Blood Marrow Transplant Research AlloHCT treatment acute lymphoblastic myeloid leukemias AML myelodysplastic syndrome MDS Hodgkin non-Hodgkin lymphomas increased 45 2,520 3,668 patients annually 1994 2005 use peripheral 7 63 corrected cord blood increased 2 10 use marrow decreased 90 27 Despite median age increase 33 40 years 165 corrected increase unrelated donors alloHCT overall survival OS day 100 significantly improved patients AML complete remission myeloablative sibling alloHCT 85 94 P .001 unrelated alloHCT 63 86 P .001 1-year OS improved undergoing unrelated alloHCT 48 63 P .003 undergoing sibling alloHCT Similar seen MDS Day-100 OS cord blood alloHCT improved significantly 60 78 P .001 AML MDS chronic myeloid leukemia Use reduced-intensity regimens increased yielding OS rates similar myeloablative regimens Survival undergoing alloHCT significantly improved time new approaches needed improve 1-year OS",0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[252, 3, 1219, 294, 1968, 1063, 1007, 31, 497, 5514, 71, 3937, 22, 8, 1075, 1396, 9, 7, 5, 813, 1342, 26, 45, 2677, 400, 4, 119, 1312, 2, 25, 4, 8, 266, 90, 180, 3, 45, 159, 519, 9972, 7, 5, 813, 441, 15, 1997, 54, 208, 157, 5514, 4, 8, 843, 15, 7170, 574, 29, 3023, 6, 1242, 2, 11, 210, 6, 3, 574, 9, 944, 315, 2, 581, 941, 389, 5514, 22, 24, 9, 286, 1275, 62, 2, 533, 2792, 329, 681, 1223, 2, 2, 1557, 101, 20, 512, 29, 18, 9158, 6, 27, 13642, 7, 4226, 29, 3023, 6, 1242, 119, 1, 110, 672, 67, 6, 676, 3848, 2, 1885, 315, 101, 18, 6, 79, 547, 119, 1, 581, 340, 424, 6, 428, 550, 8, 52, 89, 344, 29, 466, 6, 327, 60, 2, 4966, 3848, 344, 4, 2092, 2344, 9, 5514, 63, 25, 118, 28, 218, 394, 97, 231, 9, 7, 5, 329, 4, 157, 236, 734, 50, 3246, 3684, 5514, 772, 6, 960, 19, 144, 2, 2092, 5514, 676, 6, 868, 19, 144, 14, 111, 118, 231, 107, 135, 479, 2092, 5514, 576, 6, 676, 19, 1421, 84, 44, 107, 135, 479, 3684, 5514, 288, 99, 11, 527, 9, 62, 2, 1223, 218, 394, 118, 50, 1885, 315, 5514, 231, 97, 29, 335, 6, 833, 19, 144, 9, 329, 62, 1223, 2, 442, 533, 119, 1, 405, 837, 472, 101, 4949, 118, 151, 288, 6, 135, 1, 3246, 472, 25, 9, 135, 479, 5514, 71, 97, 231, 252, 98, 137, 217, 611, 32, 575, 6, 195, 401, 14, 111, 118]",1600.0,23715573,Significant improvement survival allogeneic hematopoietic transplantation period significantly increased use older recipient age use unrelated donors,0,0.0
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia.,American journal of hematology,Am. J. Hematol.,2013-07-23,"We hypothesized that the dynamic acquisition of cytogenetic abnormalities (ACA) during the follow up of myelodysplastic syndromes (MDS) could be associated with poor prognosis. We conducted a retrospective analysis of 365 patients with IPSS low or intermediate-1 risk MDS who had at least two consecutive cytogenetic analyses during the follow up. Acquisition of cytogenetic abnormalities was detected in 107 patients (29%). The most frequent alteration involved chromosome 7 in 21% of ACA cases. Median transformation-free and overall survival for patients with and without ACA were 13 vs. 52 months (P = 0.01) and 17 vs. 62 months (P = 0.01), respectively. By fitting ACA as a time-dependent covariate, multivariate Cox regression analysis showed that patients with ACA had increased risk of transformation (HR = 1.40; P = 0.03) or death (HR = 1.45; P = 0.02). Notably, female patients with therapy-related MDS (t-MDS) had an increased risk of developing ACA (OR = 5.26; P < 0.0001), although subgroup analysis showed that prognostic impact of ACA was not evident in t-MDS. In conclusion, ACA occurs in close to one third of patients with IPSS defined lower risk MDS, more common among patients with t-MDS, but has a significant prognostic impact on de novo MDS.",Clinical Trial,2373.0,30.0,hypothesized dynamic acquisition cytogenetic abnormalities ACA follow myelodysplastic syndromes MDS associated poor prognosis conducted retrospective 365 patients IPSS low intermediate-1 risk MDS consecutive cytogenetic follow Acquisition cytogenetic abnormalities detected 107 patients 29 frequent alteration involved chromosome 7 21 ACA cases Median transformation-free overall survival patients ACA 13 vs. 52 months P 0.01 17 vs. 62 months P 0.01 respectively fitting ACA time-dependent covariate multivariate Cox regression showed patients ACA increased risk transformation HR 1.40 P 0.03 death HR 1.45 P 0.02 Notably female patients therapy-related MDS t-MDS increased risk developing ACA 5.26 P 0.0001 subgroup showed prognostic impact ACA evident t-MDS ACA occurs close patients IPSS defined lower risk MDS common patients t-MDS significant prognostic impact novo MDS,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 1237, 17, 3, 2540, 3405, 1, 1266, 1171, 6285, 190, 3, 166, 126, 1, 2040, 1223, 359, 40, 41, 5, 334, 356, 21, 426, 8, 459, 65, 1, 7405, 7, 5, 8751, 154, 15, 919, 14, 43, 1223, 54, 42, 28, 506, 100, 935, 1266, 318, 190, 3, 166, 126, 3405, 1, 1266, 1171, 10, 530, 4, 3650, 7, 462, 3, 96, 908, 2611, 646, 1170, 67, 4, 239, 1, 6285, 140, 52, 1392, 115, 2, 63, 25, 9, 7, 5, 2, 187, 6285, 11, 233, 105, 653, 53, 19, 13, 355, 2, 269, 105, 744, 53, 19, 13, 355, 106, 20, 9748, 6285, 22, 8, 98, 470, 6322, 331, 418, 320, 65, 224, 17, 7, 5, 6285, 42, 101, 43, 1, 1392, 168, 14, 327, 19, 13, 680, 15, 273, 168, 14, 512, 19, 13, 588, 2552, 1061, 7, 5, 36, 139, 1223, 102, 1223, 42, 35, 101, 43, 1, 931, 6285, 15, 33, 432, 19, 13, 488, 242, 1363, 65, 224, 17, 177, 345, 1, 6285, 10, 44, 2853, 4, 102, 1223, 4, 1221, 6285, 1780, 4, 2336, 6, 104, 1282, 1, 7, 5, 8751, 395, 280, 43, 1223, 80, 186, 107, 7, 5, 102, 1223, 84, 71, 8, 93, 177, 345, 23, 1566, 2018, 1223]",1194.0,23760779,Acquisition cytogenetic abnormalities patients IPSS defined lower-risk myelodysplastic syndrome associated poor prognosis transformation acute myelogenous leukemia,23,0.04013961605584642
Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2013-06-13,"Lenalidomide is indicated for treatment of multiple myeloma in combination with dexamethasone and as a single agent in myelodysplastic syndromes. The incidence and risk of rash has been inconsistently reported. We conducted a systematic review and metaanalysis of the literature to determine the incidence and risk of developing rash. Relevant studies were identified from PubMed and abstracts presented at American Society of Clinical Oncology annual meetings. Incidence, relative risk, and 95% confidence intervals were calculated. Ten trials were available for analysis, and the overall incidence of all-grade and high-grade rash was 27.2% and 3.6%, respectively. Lenalidomide was associated with increased risk of all-grade rash (P< .001). Further studies for prevention and treatment of this toxicity are needed to minimize effect on quality of life and dose intensity.",Journal Article,2413.0,16.0,Lenalidomide indicated treatment multiple myeloma combination dexamethasone single agent myelodysplastic syndromes incidence risk rash inconsistently reported conducted systematic review metaanalysis literature determine incidence risk developing rash Relevant studies identified PubMed abstracts presented American Society Clinical Oncology annual meetings Incidence relative risk 95 confidence intervals calculated trials available overall incidence all-grade high-grade rash 27.2 3.6 respectively Lenalidomide associated increased risk all-grade rash P .001 studies prevention treatment toxicity needed minimize effect quality life dose intensity,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1288, 16, 1103, 9, 24, 1, 232, 4, 150, 5, 1217, 2, 22, 8, 226, 420, 4, 2040, 3, 287, 2, 43, 1, 1641, 71, 85, 12399, 210, 21, 426, 8, 1556, 206, 2, 19810, 1, 3, 789, 6, 223, 3, 287, 2, 43, 1, 931, 1641, 867, 94, 11, 108, 29, 3161, 2, 5159, 917, 28, 597, 1174, 1, 38, 413, 2114, 6941, 287, 580, 43, 2, 48, 307, 1582, 11, 981, 1618, 143, 11, 390, 9, 65, 2, 3, 63, 287, 1, 62, 88, 2, 64, 88, 1641, 10, 428, 18, 2, 27, 49, 106, 1288, 10, 41, 5, 101, 43, 1, 62, 88, 1641, 19, 144, 195, 94, 9, 1070, 2, 24, 1, 26, 155, 32, 575, 6, 3241, 254, 23, 372, 1, 358, 2, 61, 837]",832.0,23769670,Risk rash associated lenalidomide patients systematic review literature meta-analysis,0,0.0
Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?,Expert review of hematology,Expert Rev Hematol,2013-06-01,"High-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukemia (AML) with deletions of long arm of chromosome 5 (del[5q]) are characterized by rapid progression and poor survival. The majority of these patients are elderly with comorbidities, therefore limiting the use of intensive therapies which, even if used, unfortunately yield low responses. While azacitidine prolongs survival in patients with HR-MDS by a median of 9.5 months, responses only occur in less than half of the patients, and azacitidine therapy is not curative, with most patients relapsing within 2 years. Therefore, strategies to improve outcomes in these patients are needed. Azacitidine and lenalidomide both have meaningful single-agent clinical activity in HR-MDS and AML with del(5q). Early-phase trials in HR-MDS without del(5q) suggest increased activity with a concurrent azacitidine-lenalidomide combination. In this article, we review the results of a Phase I trial of a sequential azacitidine-lenalidomide combination approach in patients with HR-MDS and AML with del(5q) abnormality.",Journal Article,2425.0,18.0,High-risk myelodysplastic syndromes HR-MDS acute myeloid leukemia AML deletions long arm chromosome 5 del 5q characterized rapid progression poor survival majority patients elderly comorbidities limiting use intensive therapies unfortunately yield low responses azacitidine prolongs survival patients HR-MDS median 9.5 months responses occur half patients azacitidine therapy curative patients relapsing 2 years strategies improve outcomes patients needed Azacitidine lenalidomide meaningful single-agent clinical activity HR-MDS AML del 5q Early-phase trials HR-MDS del 5q suggest increased activity concurrent azacitidine-lenalidomide combination article review Phase trial sequential azacitidine-lenalidomide combination approach patients HR-MDS AML del 5q abnormality,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[64, 43, 2040, 168, 1223, 2, 286, 533, 329, 5, 2439, 1, 319, 475, 1, 1170, 33, 3084, 5460, 32, 765, 20, 1321, 91, 2, 334, 25, 3, 686, 1, 46, 7, 32, 1216, 5, 1909, 673, 817, 3, 119, 1, 1686, 235, 92, 871, 492, 95, 3869, 2309, 154, 253, 369, 3752, 5613, 25, 4, 7, 5, 168, 1223, 20, 8, 52, 1, 83, 33, 53, 253, 158, 1271, 4, 299, 76, 1303, 1, 3, 7, 2, 3752, 36, 16, 44, 1075, 5, 96, 7, 6758, 262, 18, 60, 673, 422, 6, 401, 123, 4, 46, 7, 32, 575, 3752, 2, 1288, 110, 47, 2538, 226, 420, 38, 128, 4, 168, 1223, 2, 329, 5, 3084, 5460, 191, 124, 143, 4, 168, 1223, 187, 3084, 5460, 309, 101, 128, 5, 8, 750, 3752, 1288, 150, 4, 26, 946, 21, 206, 3, 99, 1, 8, 124, 70, 160, 1, 8, 1787, 3752, 1288, 150, 353, 4, 7, 5, 168, 1223, 2, 329, 5, 3084, 5460, 3698]",1027.0,23782079,Higher-risk myelodysplastic syndromes del 5q sequential azacitidine-lenalidomide combination way,57,0.09947643979057591
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2013-06-18,"Allogeneic hematopoietic stem cell transplantation (HSCT) can achieve durable remissions in a number of patients with advanced hematologic malignancies. Little is known about the safety of HSCT in patients age 70 or older. Consecutive patients (n = 54) age 70 or older underwent HSCT between 2007 and 2012. Diseases included acute myelogenous leukemia (n = 25), myelodysplastic syndrome (n = 12), chronic lymphocytic leukemia (n = 5), non-Hodgkin lymphoma (n = 4), acute lymphoblastic leukemia (n = 3), myeloproliferative neoplasm (n = 4), and chronic myelogenous leukemia (n = 1). Median follow-up for survivors was 21 months. All patients received reduced-intensity conditioning regimens, primarily busulfan/fludarabine. All patients received unmanipulated peripheral blood stem cell grafts: 44 from 8/8 matched unrelated donors, 8 from matched related donors, and 2 from 7/8 matched unrelated donors. Graft-versus-host disease (GVHD) prophylaxis was calcineurin inhibitor-based in all patients. The median age at transplantation was 71 years (range, 70 to 76); the median HCT comorbidity index score was 1 (range, 0 to 5). Two patients died before hematopoietic recovery (1 with graft failure and 1 with disease progression), and 1 patient relapsed before hematopoietic recovery; otherwise, all engrafted with median donor chimerism of 94% at 1 month. Cumulative incidence of grades II to IV acute GVHD was 13% and of grades III to IV acute GVHD, 9.3%. At 2 years, the cumulative incidence of chronic GVHD was 36%, progression-free survival was 39%, overall survival was 39%, and relapse was 56%. Nonrelapse mortality was 3.7% at day +100 and 5.6% at 2 years. We conclude that allogeneic HSCT is a safe and effective option for carefully selected patients age 70 or older.",Journal Article,2408.0,46.0,Allogeneic hematopoietic stem transplantation HSCT achieve durable remissions number patients advanced hematologic malignancies Little known safety HSCT patients age 70 older Consecutive patients n 54 age 70 older underwent HSCT 2007 2012 Diseases included acute myelogenous leukemia n 25 myelodysplastic syndrome n 12 chronic lymphocytic leukemia n 5 non-Hodgkin lymphoma n 4 acute lymphoblastic leukemia n 3 myeloproliferative neoplasm n 4 chronic myelogenous leukemia n 1 Median follow-up survivors 21 months patients received reduced-intensity conditioning regimens primarily busulfan/fludarabine patients received unmanipulated peripheral blood stem grafts 44 8/8 matched unrelated donors 8 matched related donors 2 7/8 matched unrelated donors Graft-versus-host disease GVHD prophylaxis calcineurin inhibitor-based patients median age transplantation 71 years range 70 76 median HCT comorbidity index score 1 range 0 5 patients died hematopoietic recovery 1 graft failure 1 disease progression 1 patient relapsed hematopoietic recovery engrafted median donor chimerism 94 1 month Cumulative incidence grades II IV acute GVHD 13 grades III IV acute GVHD 9.3 2 years cumulative incidence chronic GVHD 36 progression-free survival 39 overall survival 39 relapse 56 Nonrelapse mortality 3.7 day +100 5.6 2 years conclude allogeneic HSCT safe effective option carefully selected patients age 70 older,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[1063, 1007, 452, 31, 497, 1703, 122, 1359, 1480, 3166, 4, 8, 207, 1, 7, 5, 131, 813, 441, 1215, 16, 440, 545, 3, 367, 1, 1703, 4, 7, 89, 431, 15, 434, 935, 7, 78, 667, 89, 431, 15, 434, 208, 1703, 59, 1307, 2, 1195, 1342, 159, 286, 2194, 78, 243, 681, 78, 133, 442, 1193, 78, 33, 78, 39, 286, 1275, 78, 27, 2131, 78, 39, 2, 442, 2194, 78, 14, 52, 166, 126, 9, 332, 10, 239, 53, 62, 7, 103, 405, 837, 1933, 472, 1561, 3906, 2027, 62, 7, 103, 14413, 672, 315, 452, 31, 4713, 584, 29, 66, 66, 655, 2092, 2344, 66, 29, 655, 139, 2344, 2, 18, 29, 67, 66, 655, 2092, 2344, 1599, 185, 1204, 34, 1562, 2049, 10, 12028, 230, 90, 4, 62, 7, 3, 52, 89, 28, 497, 10, 792, 60, 184, 431, 6, 846, 3, 52, 1085, 1879, 558, 368, 10, 14, 184, 13, 6, 33, 100, 7, 1016, 348, 1007, 1602, 14, 5, 1599, 496, 2, 14, 5, 34, 91, 2, 14, 69, 591, 348, 1007, 1602, 2632, 62, 6914, 5, 52, 1488, 6047, 1, 960, 28, 14, 811, 967, 287, 1, 2276, 215, 6, 478, 286, 1562, 10, 233, 2, 1, 2276, 316, 6, 478, 286, 1562, 83, 27, 28, 18, 60, 3, 967, 287, 1, 442, 1562, 10, 511, 91, 115, 25, 10, 587, 63, 25, 10, 587, 2, 429, 10, 664, 4640, 282, 10, 27, 67, 28, 218, 394, 2, 33, 49, 28, 18, 60, 21, 2060, 17, 1063, 1703, 16, 8, 1165, 2, 323, 1501, 9, 3900, 715, 7, 89, 431, 15, 434]",1597.0,23791626,Outcomes patients age 70 older undergoing allogeneic hematopoietic stem transplantation hematologic malignancies,0,0.0
Unrelated donor allogeneic hematopoietic cell transplantation is underused as a curative therapy in eligible patients from the United States.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2013-06-25,"Allogeneic hematopoietic cell transplantation (alloHCT) is a curative therapy for hematologic disorders including acute lymphoblastic and myeloid leukemia, chronic lymphocytic and myeloid leukemia, Hodgkin's and non-Hodgkin lymphoma, multiple myeloma, and myelodysplastic syndrome. To determine the utilization of alloHCT from unrelated donors (URDs) in the United States, we calculated the number of patients diagnosed with hematologic disorders age 20 to 74 years based on 2004 to 2008 Surveillance, Epidemiology and End Results and 2007 US Census data, estimated the percentage of patients who would be eligible for URD alloHCT after discounting the mortality rate during induction therapy and the rate of severe comorbidities, and compared these with the actual 2007 alloHCTs facilitated by the National Marrow Donor Program. We found that the number of URD alloHCT as a percentage of the estimated potential transplantations ranged from 11% for multiple myeloma to 54% for chronic myeloid leukemia, with an average percentage of 26% for all the disorders considered. In an analysis stratified by age groups (20 to 44, 45 to 64, and 65 to 74 years), the utilization of URD alloHCT was higher in younger patients than in older patients for all disorders. Of acute lymphoblastic and myeloid leukemia patients, approximately 66% underwent URD alloHCT later in the course of their disease (in second or greater complete remission). URD alloHCT is likely underused for potentially curable hematologic disorders, particularly in older patients. Understanding the reasons for low use of alloHCT may lead to strategies to expand the use of this curative therapy for more patients with hematologic disorders. ",Journal Article,2401.0,15.0,Allogeneic hematopoietic transplantation alloHCT curative therapy hematologic disorders including acute lymphoblastic myeloid leukemia chronic lymphocytic myeloid leukemia Hodgkin 's non-Hodgkin lymphoma multiple myeloma myelodysplastic syndrome determine utilization alloHCT unrelated donors URDs United States calculated number patients diagnosed hematologic disorders age 20 74 years based 2004 2008 Surveillance Epidemiology End 2007 Census estimated percentage patients eligible URD alloHCT discounting mortality rate induction therapy rate severe comorbidities compared actual 2007 alloHCTs facilitated National Marrow Donor Program number URD alloHCT percentage estimated potential transplantations ranged 11 multiple myeloma 54 chronic myeloid leukemia average percentage 26 disorders considered stratified age groups 20 44 45 64 65 74 years utilization URD alloHCT higher younger patients older patients disorders acute lymphoblastic myeloid leukemia patients approximately 66 underwent URD alloHCT later course disease second greater complete remission URD alloHCT likely underused potentially curable hematologic disorders particularly older patients Understanding reasons low use alloHCT lead strategies expand use curative therapy patients hematologic disorders,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[1063, 1007, 31, 497, 5514, 16, 8, 1075, 36, 9, 813, 1997, 141, 286, 1275, 2, 533, 442, 1193, 2, 533, 292, 2, 232, 2, 681, 6, 223, 3, 1961, 1, 5514, 29, 2092, 2344, 15979, 4, 3, 1088, 907, 21, 981, 3, 207, 1, 7, 265, 5, 813, 1997, 89, 179, 6, 794, 60, 90, 23, 1131, 6, 1375, 617, 1284, 2, 396, 99, 2, 1307, 843, 7319, 74, 661, 3, 1150, 1, 7, 54, 688, 40, 625, 9, 5847, 5514, 50, 34483, 3, 282, 116, 190, 504, 36, 2, 3, 116, 1, 905, 1909, 2, 72, 46, 5, 3, 3480, 1307, 63006, 4667, 20, 3, 657, 581, 1488, 1243, 21, 204, 17, 3, 207, 1, 5847, 5514, 22, 8, 1150, 1, 3, 661, 174, 6779, 1869, 29, 175, 9, 232, 6, 667, 9, 442, 533, 5, 35, 1011, 1150, 1, 432, 9, 62, 3, 1997, 515, 4, 35, 65, 1173, 20, 89, 271, 179, 6, 584, 512, 6, 660, 2, 556, 6, 794, 60, 3, 1961, 1, 5847, 5514, 10, 142, 4, 773, 7, 76, 4, 434, 7, 9, 62, 1997, 1, 286, 1275, 2, 533, 7, 705, 700, 208, 5847, 5514, 1559, 4, 3, 906, 1, 136, 34, 4, 419, 15, 378, 236, 734, 5847, 5514, 16, 322, 11166, 9, 751, 4151, 813, 1997, 823, 4, 434, 7, 612, 3, 2325, 9, 154, 119, 1, 5514, 68, 1122, 6, 422, 6, 4082, 3, 119, 1, 26, 1075, 36, 9, 80, 7, 5, 813, 1997]",1574.0,23811537,Unrelated donor allogeneic hematopoietic transplantation underused curative therapy eligible patients United States,33,0.05759162303664921
Somatic SETBP1 mutations in myeloid malignancies.,Nature genetics,Nat. Genet.,2013-07-07,"Here we report whole-exome sequencing of individuals with various myeloid malignancies and identify recurrent somatic mutations in SETBP1, consistent with a recent report on atypical chronic myeloid leukemia (aCML). Closely positioned somatic SETBP1 mutations encoding changes in Asp868, Ser869, Gly870, Ile871 and Asp880, which match germline mutations in Schinzel-Giedion syndrome (SGS), were detected in 17% of secondary acute myeloid leukemias (sAML) and 15% of chronic myelomonocytic leukemia (CMML) cases. These results from deep sequencing demonstrate a higher mutational detection rate than reported with conventional sequencing methodology. Mutant cases were associated with advanced age and monosomy 7/deletion 7q (-7/del(7q)) constituting poor prognostic factors. Analysis of serially collected samples indicated that SETBP1 mutations were acquired during leukemic evolution. Transduction with mutant Setbp1 led to the immortalization of mouse myeloid progenitors that showed enhanced proliferative capacity compared to cells transduced with wild-type Setbp1. Somatic mutations of SETBP1 seem to cause gain of function, are associated with myeloid leukemic transformation and convey poor prognosis in myelodysplastic syndromes (MDS) and CMML. ",Journal Article,2389.0,149.0,report whole-exome sequencing individuals myeloid malignancies identify recurrent somatic SETBP1 consistent recent report atypical chronic myeloid leukemia aCML Closely positioned somatic SETBP1 encoding changes Asp868 Ser869 Gly870 Ile871 Asp880 match germline Schinzel-Giedion syndrome SGS detected 17 secondary acute myeloid leukemias sAML 15 chronic myelomonocytic leukemia CMML cases deep sequencing demonstrate higher detection rate reported conventional sequencing methodology cases associated advanced age monosomy 7/deletion 7q -7/del 7q constituting poor prognostic factors serially collected indicated SETBP1 acquired leukemic evolution Transduction Setbp1 led immortalization mouse myeloid progenitors showed enhanced proliferative capacity compared transduced wild-type Setbp1 Somatic SETBP1 cause gain function associated myeloid leukemic transformation convey poor prognosis myelodysplastic syndromes MDS CMML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[467, 21, 414, 902, 2865, 615, 1, 869, 5, 747, 533, 441, 2, 255, 387, 1119, 138, 4, 16577, 925, 5, 8, 435, 414, 23, 1973, 442, 533, 21345, 3210, 14240, 1119, 16577, 138, 2362, 400, 4, 63040, 63041, 63042, 63043, 2, 63044, 92, 5364, 1009, 138, 4, 63045, 63046, 681, 23995, 11, 530, 4, 269, 1, 568, 286, 533, 2792, 8991, 2, 167, 1, 442, 5451, 3382, 140, 46, 99, 29, 2369, 615, 608, 8, 142, 1619, 638, 116, 76, 210, 5, 809, 615, 3209, 620, 140, 11, 41, 5, 131, 89, 2, 7521, 67, 1528, 9723, 67, 3084, 9723, 14122, 334, 177, 130, 65, 1, 6754, 786, 347, 1103, 17, 16577, 138, 11, 1294, 190, 2015, 2554, 2761, 5, 620, 16577, 836, 6, 3, 20169, 1, 830, 533, 4321, 17, 224, 651, 2441, 2162, 72, 6, 37, 5042, 5, 955, 267, 16577, 1119, 138, 1, 16577, 3233, 6, 708, 1803, 1, 343, 32, 41, 5, 533, 2015, 1392, 2, 11415, 334, 356, 4, 2040, 1223, 2, 3382]",1190.0,23832012,Somatic SETBP1 myeloid malignancies,79,0.13787085514834205
STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients.,Blood,Blood,2013-08-07,"Large granular lymphocyte leukemia (LGL) is often associated with immune cytopenias and can cooccur in the context of aplastic anemia (AA) and myelodysplastic syndromes (MDS). We took advantage of the recent description of signal transducer and activator of transcription 3 (STAT3) mutations in LGL clonal expansions to test, using sensitive methods, for the presence of these mutations in a large cohort of 367 MDS and 140 AA cases. STAT3 clones can be found not only in known LGL concomitant cases, but in a small proportion of unsuspected ones (7% AA and 2.5% MDS). In STAT3-mutated AA patients, an interesting trend toward better responses of immunosuppressive therapy and an association with the presence of human leukocyte antigen-DR15 were found. MDSs harboring a STAT3 mutant clone showed a lower degree of bone marrow cellularity and a higher frequency of developing chromosome 7 abnormalities. STAT3-mutant LGL clones may facilitate a persistently dysregulated autoimmune activation, responsible for the primary induction of bone marrow failure in a subset of AA and MDS patients. ",Journal Article,2358.0,62.0,Large granular lymphocyte leukemia LGL associated immune cytopenias cooccur context aplastic anemia AA myelodysplastic syndromes MDS took advantage recent description signal transducer activator transcription 3 STAT3 LGL clonal expansions test sensitive methods presence large cohort 367 MDS 140 AA cases STAT3 clones known LGL concomitant cases small proportion unsuspected ones 7 AA 2.5 MDS STAT3-mutated AA patients interesting trend better responses immunosuppressive therapy association presence human leukocyte antigen-DR15 MDSs harboring STAT3 clone showed lower degree bone marrow cellularity higher frequency developing chromosome 7 abnormalities STAT3-mutant LGL clones facilitate persistently dysregulated autoimmune activation responsible primary induction bone marrow failure subset AA MDS patients,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[375, 7694, 1448, 7816, 16, 629, 41, 5, 250, 5635, 2, 122, 47878, 4, 3, 1533, 1, 16315, 1545, 1519, 2, 2040, 1223, 21, 5060, 1874, 1, 3, 435, 5263, 1, 1235, 5182, 2, 3393, 1, 866, 27, 1439, 138, 4, 7816, 1946, 12384, 6, 412, 75, 745, 636, 9, 3, 463, 1, 46, 138, 4, 8, 375, 180, 1, 10720, 1223, 2, 3304, 1519, 140, 1439, 2749, 122, 40, 204, 44, 158, 4, 440, 7816, 1781, 140, 84, 4, 8, 302, 920, 1, 9073, 6737, 67, 1519, 2, 18, 33, 1223, 4, 1439, 1185, 1519, 7, 35, 6597, 853, 1317, 380, 253, 1, 2989, 36, 2, 35, 248, 5, 3, 463, 1, 171, 3627, 448, 20474, 11, 204, 13550, 2105, 8, 1439, 620, 3910, 224, 8, 280, 1444, 1, 581, 6363, 2, 8, 142, 675, 1, 931, 1170, 67, 1171, 1439, 620, 7816, 2749, 68, 1876, 8, 8684, 4288, 3445, 363, 2327, 9, 3, 86, 504, 1, 581, 496, 4, 8, 697, 1, 1519, 2, 1223, 7]",1032.0,23926297,STAT3 indicate presence subclinical T-cell clones subset aplastic anemia myelodysplastic syndrome patients,1,0.0017452006980802793
"TET2 mutations, myelodysplastic features, and a distinct immunoprofile characterize blastic plasmacytoid dendritic cell neoplasm in the bone marrow.",American journal of hematology,Am. J. Hematol.,2013-09-30,"Distinguishing blastic plasmacytoid dendritic cell neoplasm (BPDCN) from acute myeloid leukemia (AML) is gaining increased importance because of emerging differences in therapeutic approaches, and this distinction can be problematic in bone marrow specimens. We identified retrospectively 16 patients with bone marrow involvement by BPDCN: 11 men and 5 women with a median age of 62.5 years (range, 19-86 years). Myelodysplastic changes were observed in five patients. Immunophenotypic analysis showed that the neoplastic cells were positive for CD4, CD123, TCL-1, and HLA-DR and were negative for CD3, CD8, CD13, CD19, CD34, and myeloperoxidase. Other antigens expressed by subsets of BPDCN cases included the following: CD56 (13/15; 81%), CD33 (7/10; 70%), CD7 (11/14; 69%), TdT (5/15; 33%), CD2 (5/11; 31%), CD117 (2/9; 22%), and CD5 (2/13; 15%). Conventional cytogenetic analysis showed chromosomal abnormalities in 6 of 13 (46%) cases analyzed, of which 3 cases had -13/13q-. Targeted next-generation sequencing performed on five BPDCN cases identified TET2 (ten eleven translocation 2) mutations and no other AML-associated mutations. In conclusion, BPDCN in the bone marrow has a characteristic immunoprofile (CD4+, CD56+, CD123+, and TCL-1+) and appears to be commonly associated with myelodysplastic features and a high frequency of TET2 mutations in the absence of other mutations commonly observed in AML.",Journal Article,2304.0,58.0,Distinguishing blastic plasmacytoid dendritic neoplasm BPDCN acute myeloid leukemia AML gaining increased importance emerging differences therapeutic approaches distinction problematic bone marrow specimens identified retrospectively 16 patients bone marrow involvement BPDCN 11 men 5 women median age 62.5 years range 19-86 years Myelodysplastic changes observed patients Immunophenotypic showed neoplastic positive CD4 CD123 TCL-1 HLA-DR negative CD3 CD8 CD13 CD19 CD34 myeloperoxidase antigens expressed subsets BPDCN cases included following CD56 13/15 81 CD33 7/10 70 CD7 11/14 69 TdT 5/15 33 CD2 5/11 31 CD117 2/9 22 CD5 2/13 15 Conventional cytogenetic showed chromosomal abnormalities 6 13 46 cases 3 cases -13/13q- Targeted next-generation sequencing performed BPDCN cases identified TET2 translocation 2 AML-associated BPDCN bone marrow characteristic immunoprofile CD4+ CD56+ CD123+ TCL-1+ appears commonly associated myelodysplastic features high frequency TET2 absence commonly observed AML,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4508, 6529, 7978, 2464, 31, 2131, 8556, 29, 286, 533, 329, 16, 7312, 101, 1187, 408, 1, 1478, 362, 4, 189, 611, 2, 26, 6628, 122, 40, 6594, 4, 581, 623, 21, 108, 894, 245, 7, 5, 581, 799, 20, 8556, 175, 325, 2, 33, 117, 5, 8, 52, 89, 1, 744, 33, 60, 184, 326, 868, 60, 400, 11, 164, 4, 365, 7, 6599, 65, 224, 17, 3, 2000, 37, 11, 109, 9, 1440, 8849, 8885, 14, 2, 1160, 3436, 2, 11, 199, 9, 3117, 968, 13518, 3158, 2215, 2, 16722, 127, 1575, 570, 20, 1890, 1, 8556, 140, 159, 3, 366, 5803, 233, 167, 865, 6353, 67, 79, 431, 13217, 175, 213, 790, 10970, 33, 167, 466, 11048, 33, 175, 456, 6999, 18, 83, 350, 2, 6349, 18, 233, 167, 809, 1266, 65, 224, 1860, 1171, 4, 49, 1, 233, 641, 140, 311, 1, 92, 27, 140, 42, 233, 8453, 238, 1305, 914, 615, 173, 23, 365, 8556, 140, 108, 5038, 1618, 2627, 2006, 18, 138, 2, 77, 127, 329, 41, 138, 4, 1221, 8556, 4, 3, 581, 71, 8, 2037, 31332, 1440, 5803, 8849, 2, 8885, 14, 2, 1233, 6, 40, 841, 41, 5, 404, 2, 8, 64, 675, 1, 5038, 138, 4, 3, 1127, 1, 127, 138, 841, 164, 4, 329]",1288.0,23940084,TET2 myelodysplastic features distinct immunoprofile characterize blastic plasmacytoid dendritic neoplasm bone marrow,3,0.005235602094240838
BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.,Blood,Blood,2013-08-13,"Myelodysplastic syndrome (MDS) transforms into an acute myelogenous leukemia (AML) with associated increased bone marrow (BM) blast infiltration. Using a transgenic mouse model, MRP8[NRASD12/hBCL-2], in which the NRAS:BCL-2 complex at the mitochondria induces MDS progressing to AML with dysplastic features, we studied the therapeutic potential of a BCL-2 homology domain 3 mimetic inhibitor, ABT-737. Treatment significantly extended lifespan, increased survival of lethally irradiated secondary recipients transplanted with cells from treated mice compared with cells from untreated mice, with a reduction of BM blasts, Lin-/Sca-1(+)/c-Kit(+), and progenitor populations by increased apoptosis of infiltrating blasts of diseased mice assessed in vivo by technicium-labeled annexin V single photon emission computed tomography and ex vivo by annexin V/7-amino actinomycin D flow cytometry, terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling, caspase 3 cleavage, and re-localization of the NRAS:BCL-2 complex from mitochondria to plasma membrane. Phosphoprotein analysis showed restoration of wild-type (WT) AKT or protein kinase B, extracellular signal-regulated kinase 1/2 and mitogen-activated protein kinase patterns in spleen cells after treatment, which showed reduced mitochondrial membrane potential. Exon specific gene expression profiling corroborates the reduction of leukemic cells, with an increase in expression of genes coding for stem cell development and maintenance, myeloid differentiation, and apoptosis. Myelodysplastic features persist underscoring targeting of BCL-2-mediated effects on MDS-AML transformation and survival of leukemic cells. ",Journal Article,2352.0,27.0,Myelodysplastic syndrome MDS transforms acute myelogenous leukemia AML associated increased bone marrow BM blast infiltration transgenic mouse model MRP8 NRASD12/hBCL-2 NRAS BCL-2 complex mitochondria induces MDS progressing AML dysplastic features studied therapeutic potential BCL-2 homology domain 3 mimetic inhibitor ABT-737 Treatment significantly extended lifespan increased survival lethally irradiated secondary recipients transplanted treated mice compared untreated mice reduction BM blasts Lin-/Sca-1 /c-Kit progenitor populations increased apoptosis infiltrating blasts diseased mice assessed vivo technicium-labeled annexin V single photon emission computed tomography ex vivo annexin V/7-amino actinomycin flow cytometry terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling caspase 3 cleavage re-localization NRAS BCL-2 complex mitochondria plasma membrane Phosphoprotein showed restoration wild-type WT AKT kinase B extracellular signal-regulated kinase 1/2 mitogen-activated kinase patterns spleen treatment showed reduced mitochondrial membrane potential Exon specific expression profiling corroborates reduction leukemic increase expression coding stem development maintenance myeloid differentiation apoptosis Myelodysplastic features persist underscoring targeting BCL-2-mediated effects MDS-AML transformation survival leukemic,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[681, 1223, 22028, 237, 35, 286, 2194, 329, 5, 41, 101, 581, 1246, 3112, 2084, 75, 8, 2862, 830, 202, 25961, 63227, 63228, 18, 4, 92, 3, 2845, 1044, 18, 840, 28, 3, 5443, 1516, 1223, 4527, 6, 329, 5, 6461, 404, 21, 656, 3, 189, 174, 1, 8, 1044, 18, 7984, 1398, 27, 7343, 230, 3095, 4933, 24, 97, 1747, 11637, 101, 25, 1, 26772, 2398, 568, 2190, 4600, 5, 37, 29, 73, 399, 72, 5, 37, 29, 1278, 399, 5, 8, 628, 1, 1246, 2438, 12988, 19950, 14, 256, 1164, 2, 2520, 1184, 20, 101, 351, 1, 2097, 2438, 1, 10486, 399, 275, 4, 386, 20, 63229, 2841, 4850, 603, 226, 4216, 1799, 1220, 872, 2, 2581, 386, 20, 4850, 603, 67, 3078, 16226, 427, 1412, 1914, 2158, 30414, 517, 12716, 9547, 396, 3383, 1469, 27, 3155, 2, 1491, 2145, 1, 3, 2845, 1044, 18, 840, 29, 5443, 6, 554, 1905, 12302, 65, 224, 5194, 1, 955, 267, 1820, 649, 15, 178, 216, 132, 1976, 1235, 1065, 216, 14, 18, 2, 2625, 735, 178, 216, 764, 4, 4071, 37, 50, 24, 92, 224, 405, 2019, 1905, 174, 1725, 112, 145, 55, 1080, 24893, 3, 628, 1, 2015, 37, 5, 35, 344, 4, 55, 1, 214, 3097, 9, 452, 31, 193, 2, 1146, 533, 910, 2, 351, 404, 5589, 8369, 529, 1, 1044, 18, 517, 176, 23, 1223, 329, 1392, 2, 25, 1, 2015, 37]",1601.0,23943652,BCL-2 inhibition ABT-737 prolongs survival NRAS/BCL-2 mouse model AML targeting primitive LSK progenitor,0,0.0
Febrile neutropenia in hematologic malignancies.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2013-12-01,"Febrile neutropenia (FN) can occur at any time during the course of a malignancy, especially hematologic malignancies, from diagnosis to end-stage disease. The majority of FN episodes are typically confined to the period of initial diagnosis and active treatment. Because of suppressed inflammatory responses, fever is often the sole sign of infection. As FN is a true medical emergency, prompt identification of and intervention in FN can prolong survival and improve quality of life. This article reviews FN in the setting of hematologic malignancies, specifically myelodysplastic syndromes and acute leukemias, providing an overview of the definition of fever and neutropenia, diagnostic approach, categories of risk/risk assessment, management in patients at low and high risk, and prophylaxis of infections.",Journal Article,2242.0,16.0,Febrile neutropenia FN occur time course malignancy especially hematologic malignancies diagnosis end-stage disease majority FN episodes typically confined period initial diagnosis active treatment suppressed inflammatory responses fever sole sign infection FN true medical emergency prompt identification intervention FN prolong survival improve quality life article reviews FN setting hematologic malignancies specifically myelodysplastic syndromes acute leukemias providing overview definition fever neutropenia diagnostic approach categories risk/risk assessment management patients low high risk prophylaxis infections,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2498, 778, 5165, 122, 1271, 28, 500, 98, 190, 3, 906, 1, 8, 710, 1093, 813, 441, 29, 147, 6, 396, 82, 34, 3, 686, 1, 5165, 3750, 32, 1969, 2902, 6, 3, 727, 1, 388, 147, 2, 544, 24, 408, 1, 1908, 1291, 253, 2775, 16, 629, 3, 4991, 7636, 1, 930, 22, 5165, 16, 8, 2501, 484, 4605, 4776, 911, 1, 2, 788, 4, 5165, 122, 3615, 25, 2, 401, 372, 1, 358, 26, 946, 2004, 5165, 4, 3, 546, 1, 813, 441, 1225, 2040, 2, 286, 2792, 1736, 35, 2901, 1, 3, 2470, 1, 2775, 2, 778, 752, 353, 1996, 1, 43, 43, 455, 284, 4, 7, 28, 154, 2, 64, 43, 2, 2049, 1, 1875]",779.0,23990311,Febrile neutropenia hematologic malignancies,1,0.0017452006980802793
Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring.,Haematologica,Haematologica,2013-10-18,"Routine molecular testing in acute myeloid leukemia involves screening several genes of therapeutic and prognostic significance for mutations. A comprehensive analysis using single-gene assays requires large amounts of DNA, is cumbersome and timely consolidation of results for clinical reporting is challenging. High throughput, next-generation sequencing platforms widely used in research have not been tested vigorously for clinical application. Here we describe the clinical application of MiSeq, a next-generation sequencing platform to screen mutational hotspots in 54 cancer-related genes including genes relevant in acute myeloid leukemia (NRAS, KRAS, FLT3, NPM1, DNMT3A, IDH1/2, JAK2, KIT and EZH2). We sequenced 63 samples from patients with acute myeloid leukemia/myelodysplastic syndrome using MiSeq and compared the results with those obtained using another next-generation sequencing platform, Ion-Torrent Personal Genome Machine and other conventional testing platforms. MiSeq detected a total of 100 single nucleotide variants and 23 NPM1 insertions that were confirmed by Ion Torrent or conventional platforms, indicating complete concordance. FLT3-internal tandem duplications (n=10) were not detected; however, re-analysis of the MiSeq output by Pindel, an indel detection algorithm, did detect them. Dilution studies of cancer cell-line DNA showed that the quantitative accuracy of mutation detection was up to an allelic frequency of 1.5% with a high level of inter- and intra-run assay reproducibility, suggesting potential utility for monitoring response to therapy, clonal heterogeneity and evolution. Examples demonstrating the advantages of MiSeq over conventional platforms for disease monitoring are provided. Easy work-flow, high throughput multiplexing capability, 4-day turnaround time and simultaneous assessment of routinely tested and emerging markers make MiSeq highly applicable for clinical molecular testing in acute myeloid leukemia. ",Journal Article,2286.0,103.0,Routine molecular testing acute myeloid leukemia involves screening therapeutic prognostic significance comprehensive single-gene requires large amounts DNA cumbersome timely consolidation clinical reporting challenging High throughput next-generation sequencing platforms widely research tested vigorously clinical application clinical application MiSeq next-generation sequencing platform screen hotspots 54 cancer-related including relevant acute myeloid leukemia NRAS KRAS FLT3 NPM1 DNMT3A IDH1/2 JAK2 KIT EZH2 sequenced 63 patients acute myeloid leukemia/myelodysplastic syndrome MiSeq compared obtained next-generation sequencing platform Ion-Torrent Personal Genome Machine conventional testing platforms MiSeq detected total 100 single nucleotide 23 NPM1 insertions confirmed Ion Torrent conventional platforms indicating complete concordance FLT3-internal tandem duplications n=10 detected re-analysis MiSeq output Pindel indel detection algorithm detect Dilution studies cell-line DNA showed quantitative accuracy detection allelic frequency 1.5 high level inter- intra-run reproducibility suggesting potential utility monitoring response therapy clonal heterogeneity evolution Examples demonstrating advantages MiSeq conventional platforms disease monitoring provided Easy work-flow high throughput multiplexing capability 4-day turnaround time simultaneous assessment routinely tested emerging markers MiSeq highly applicable clinical molecular testing acute myeloid leukemia,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1311, 219, 471, 4, 286, 533, 2921, 453, 392, 214, 1, 189, 2, 177, 724, 9, 138, 8, 949, 65, 75, 226, 145, 1013, 1706, 375, 4939, 1, 261, 16, 20214, 2, 4225, 2173, 1, 99, 9, 38, 1760, 16, 1950, 64, 3643, 1305, 914, 615, 4364, 1792, 95, 4, 389, 47, 44, 85, 650, 23573, 9, 38, 1581, 467, 21, 897, 3, 38, 1581, 1, 17040, 8, 1305, 914, 615, 2243, 6, 2413, 1619, 11193, 4, 667, 12, 139, 214, 141, 214, 867, 4, 286, 533, 2845, 723, 1224, 4318, 6199, 2662, 18, 2509, 1164, 2, 3755, 21, 4040, 676, 347, 29, 7, 5, 286, 533, 2647, 10589, 681, 75, 17040, 2, 72, 3, 99, 5, 135, 683, 75, 1809, 1305, 914, 615, 2243, 7714, 20837, 3008, 898, 6555, 2, 127, 809, 471, 4364, 17040, 530, 8, 181, 1, 394, 226, 1579, 839, 2, 382, 4318, 6315, 17, 11, 557, 20, 7714, 20837, 15, 809, 4364, 1716, 236, 1827, 1224, 2329, 2905, 8910, 78, 79, 11, 44, 530, 137, 1491, 65, 1, 3, 17040, 6911, 20, 63534, 35, 24087, 638, 2124, 205, 1426, 1370, 10446, 94, 1, 12, 31, 328, 261, 224, 17, 3, 1156, 1190, 1, 258, 638, 10, 126, 6, 35, 3861, 675, 1, 14, 33, 5, 8, 64, 301, 1, 3606, 2, 2392, 7726, 719, 4688, 802, 174, 1207, 9, 1315, 51, 6, 36, 1946, 1144, 2, 2554, 4416, 2219, 3, 3126, 1, 17040, 252, 809, 4364, 9, 34, 1315, 32, 1052, 6261, 1357, 1412, 64, 3643, 27172, 6188, 39, 218, 14335, 98, 2, 2824, 455, 1, 3066, 650, 2, 1478, 525, 2378, 17040, 561, 3801, 9, 38, 219, 471, 4, 286, 533]",1910.0,24142997,Next-generation sequencing-based multigene screening acute myeloid leukemia MiSeq applicability diagnostics disease monitoring,0,0.0
The euphoria of hypomethylating agents in MDS and AML: is it justified?,Best practice & research. Clinical haematology,Best Pract Res Clin Haematol,2013-10-15,"While it is logical to use hypomethylating agents to treat patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), trial results with azacitidine and decitabine have been inconsistent. Azacitidine confers a survival benefit in higher-risk MDS patients, while decitabine does not. Neither agent has demonstrated a survival advantage in older AML patients in prospective studies. Reasons for this are explored here along with a recommendation to reconsider clinical trial design endpoints. ",Journal Article,2289.0,8.0,logical use hypomethylating agents treat patients myelodysplastic syndromes MDS acute myeloid leukemia AML trial azacitidine decitabine inconsistent Azacitidine confers survival benefit higher-risk MDS patients decitabine agent demonstrated survival advantage older AML patients prospective studies Reasons explored recommendation reconsider clinical trial design endpoints,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[369, 192, 16, 10405, 6, 119, 4931, 183, 6, 943, 7, 5, 2040, 1223, 2, 286, 533, 329, 160, 99, 5, 3752, 2, 3004, 47, 85, 4923, 3752, 4020, 8, 25, 247, 4, 142, 43, 1223, 7, 369, 3004, 1097, 44, 2174, 420, 71, 264, 8, 25, 1874, 4, 434, 329, 7, 4, 482, 94, 2325, 9, 26, 32, 1443, 467, 1510, 5, 8, 3347, 6, 35715, 38, 160, 771, 1387]",476.0,24309530,euphoria hypomethylating agents MDS AML justified,4,0.006980802792321117
Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.,Current opinion in hematology,Curr. Opin. Hematol.,2014-03-01,"Myelodysplastic/myeloproliferative neoplasms (MDS/MPNs), including chronic myelomonocytic leukemia, atypical chronic myeloid leukemia, MDS/MPN-Unclassifiable, ring sideroblasts associated with marked thrombocytosis, and juvenile myelomonocytic leukemia, are clonal hematologic diseases characterized by myeloid dysplasia, proliferation, and absence of the molecular lesions BCR/ABL, PDGFRA, PDGFRB, and FGFR1. There are currently no US Food and Drug Administration approved therapies for all MDS/MPN subtypes. Advances in the understanding of the biologic and molecular drivers of these diseases will help in diagnosis, prognosis, and therapeutics. This review article summarizes the molecular aspects of MDS/MPNs and provides an overview of classic and emerging therapies. Next generation sequencing has provided new insights into the genetic nature of MDS/MPNs. Molecular mutations such as TET2, CBL, SETBP1, CSF3R, and SF3B1 are relevant as diagnostic and prognostic biomarkers. Hematopoietic cell transplantation, although potentially curative, is applicable to only a small proportion of patients. Attempts to standardize response and outcomes criteria specific to MDS/MPN and clinical trials using novel agents focused on MDS/MPN patients are underway. MDS/MPNs have clinicopathologic features of both MDS and MPN diseases. Emerging molecular data support the distinctive disease biology of each of these morphologic entities, and will serve as the foundation to develop effective therapeutics that can ameliorate disease-related complications and lead to better outcomes.",Journal Article,2152.0,11.0,Myelodysplastic/myeloproliferative neoplasms MDS/MPNs including chronic myelomonocytic leukemia atypical chronic myeloid leukemia MDS/MPN-Unclassifiable ring sideroblasts associated marked thrombocytosis juvenile myelomonocytic leukemia clonal hematologic diseases characterized myeloid dysplasia proliferation absence molecular lesions BCR/ABL PDGFRA PDGFRB FGFR1 currently Food Drug Administration approved therapies MDS/MPN subtypes Advances understanding biologic molecular drivers diseases help diagnosis prognosis therapeutics review article summarizes molecular aspects MDS/MPNs provides overview classic emerging therapies generation sequencing provided new insights genetic nature MDS/MPNs Molecular TET2 CBL SETBP1 CSF3R SF3B1 relevant diagnostic prognostic biomarkers Hematopoietic transplantation potentially curative applicable small proportion patients Attempts standardize response outcomes criteria specific MDS/MPN clinical trials novel agents focused MDS/MPN patients underway MDS/MPNs clinicopathologic features MDS MPN diseases Emerging molecular support distinctive disease morphologic entities serve foundation develop effective therapeutics ameliorate disease-related complications lead better outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[10589, 10857, 1179, 1223, 6880, 141, 442, 5451, 1973, 442, 533, 1223, 4125, 14338, 4091, 23740, 41, 5, 2003, 7589, 2, 7857, 5451, 32, 1946, 813, 1342, 765, 20, 533, 2253, 457, 2, 1127, 1, 3, 219, 406, 1062, 1425, 4006, 10231, 2, 4549, 125, 32, 694, 77, 843, 1773, 2, 234, 634, 850, 235, 9, 62, 1223, 4125, 814, 954, 4, 3, 612, 1, 3, 1283, 2, 219, 3391, 1, 46, 1342, 303, 987, 4, 147, 356, 2, 1943, 26, 206, 946, 2869, 3, 219, 2695, 1, 1223, 6880, 2, 777, 35, 2901, 1, 3168, 2, 1478, 235, 1305, 914, 615, 71, 1052, 217, 1957, 237, 3, 336, 2202, 1, 1223, 6880, 219, 138, 225, 22, 5038, 6925, 16577, 15024, 2, 10132, 32, 867, 22, 752, 2, 177, 582, 1007, 31, 497, 242, 751, 1075, 16, 3801, 6, 158, 8, 302, 920, 1, 7, 4374, 6, 9211, 51, 2, 123, 371, 112, 6, 1223, 4125, 2, 38, 143, 75, 229, 183, 1649, 23, 1223, 4125, 7, 32, 3948, 1223, 6880, 47, 1399, 404, 1, 110, 1223, 2, 4125, 1342, 1478, 219, 74, 538, 3, 5049, 34, 891, 1, 296, 1, 46, 2815, 4613, 2, 303, 1833, 22, 3, 3247, 6, 690, 323, 1943, 17, 122, 9179, 34, 139, 521, 2, 1122, 6, 380, 123]",1519.0,24378705,Making sense myelodysplastic/myeloproliferative neoplasms overlap syndromes,572,0.9982547993019197
"Haploinsufficiency of del(5q) genes, Egr1 and Apc, cooperate with Tp53 loss to induce acute myeloid leukemia in mice.",Blood,Blood,2013-12-31,"An interstitial deletion of chromosome 5, del(5q), is the most common structural abnormality in primary myelodysplastic syndromes (MDS) and therapy-related myeloid neoplasms (t-MNs) after cytotoxic therapy. Loss of TP53 activity, through mutation or deletion, is highly associated with t-MNs with a del(5q). We previously demonstrated that haploinsufficiency of Egr1 and Apc, 2 genes lost in the 5q deletion, are key players in the progression of MDS with a del(5q). Using genetically engineered mice, we now show that reduction or loss of Tp53 expression, in combination with Egr1 haploinsufficiency, increased the rate of development of hematologic neoplasms and influenced the disease spectrum, but did not lead to overt myeloid leukemia, suggesting that altered function of additional gene(s) on 5q are likely required for myeloid leukemia development. Next, we demonstrated that cell intrinsic loss of Tp53 in hematopoietic stem and progenitor cells haploinsufficient for both Egr1 and Apc led to the development of acute myeloid leukemia (AML) in 17% of mice. The long latency (234-299 days) and clonal chromosomal abnormalities in the AMLs suggest that additional genetic changes may be required for full transformation. Thus, loss of Tp53 activity in cooperation with Egr1 and Apc haploinsufficiency creates an environment that is permissive for malignant transformation and the development of AML. ",Journal Article,2212.0,44.0,interstitial deletion chromosome 5 del 5q common structural abnormality primary myelodysplastic syndromes MDS therapy-related myeloid neoplasms t-MNs cytotoxic therapy Loss TP53 activity deletion highly associated t-MNs del 5q previously demonstrated haploinsufficiency Egr1 Apc 2 lost 5q deletion key players progression MDS del 5q genetically engineered mice reduction loss Tp53 expression combination Egr1 haploinsufficiency increased rate development hematologic neoplasms influenced disease spectrum lead overt myeloid leukemia suggesting altered function additional 5q likely required myeloid leukemia development demonstrated intrinsic loss Tp53 hematopoietic stem progenitor haploinsufficient Egr1 Apc led development acute myeloid leukemia AML 17 mice long latency 234-299 days clonal chromosomal abnormalities AMLs suggest additional genetic changes required transformation loss Tp53 activity cooperation Egr1 Apc haploinsufficiency creates environment permissive malignant transformation development AML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[35, 4543, 1528, 1, 1170, 33, 3084, 5460, 16, 3, 96, 186, 3281, 3698, 4, 86, 2040, 1223, 2, 36, 139, 533, 1179, 102, 17539, 50, 759, 36, 407, 1, 1206, 128, 298, 258, 15, 1528, 16, 561, 41, 5, 102, 17539, 5, 8, 3084, 5460, 21, 373, 264, 17, 9292, 1, 11258, 2, 2528, 18, 214, 3009, 4, 3, 5460, 1528, 32, 825, 10996, 4, 3, 91, 1, 1223, 5, 8, 3084, 5460, 75, 2301, 2794, 399, 21, 1134, 514, 17, 628, 15, 407, 1, 1206, 55, 4, 150, 5, 11258, 9292, 101, 3, 116, 1, 193, 1, 813, 1179, 2, 2574, 3, 34, 1873, 84, 205, 44, 1122, 6, 7192, 533, 802, 17, 1495, 343, 1, 402, 145, 695, 23, 5460, 32, 322, 616, 9, 533, 193, 1305, 21, 264, 17, 31, 2354, 407, 1, 1206, 4, 1007, 452, 2, 2520, 37, 15916, 9, 110, 11258, 2, 2528, 836, 6, 3, 193, 1, 286, 533, 329, 4, 269, 1, 399, 3, 319, 5301, 8049, 8769, 162, 2, 1946, 1860, 1171, 4, 3, 9542, 309, 17, 402, 336, 400, 68, 40, 616, 9, 1647, 1392, 631, 407, 1, 1206, 128, 4, 8323, 5, 11258, 2, 2528, 9292, 9803, 35, 3087, 17, 16, 11080, 9, 393, 1392, 2, 3, 193, 1, 329]",1330.0,24381225,Haploinsufficiency del 5q Egr1 Apc cooperate Tp53 loss induce acute myeloid leukemia mice,1,0.0017452006980802793
Patterns of hospice use in patients dying from hematologic malignancies.,Journal of palliative medicine,J Palliat Med,2014-01-02,"Hospice brings substantial clinical benefits to dying patients and families but is underutilized by patients dying of hematologic malignancies (HM); nationwide, only 2% of HM patients use hospice. There are 70,000 deaths among U.S. patients with hematologic malignancies yearly. We measured the use and length of stay (LOS) in hospice among patients with HMs at a large academic cancer center. This was a single center retrospective review of adult patients (18 years) with lymphoma, leukemia, myelodysplastic syndrome, aplastic anemia, and multiple myeloma referred for hospice. Information included demographics, transplant, hospice type, LOS, and use of ""expanded access"" services. Fifty-nine patients were referred to hospice, and 53 utilized hospice services, 25% of 209 HM decedents. Thirty-five received home hospice and 18 used inpatient hospice. The median home hospice LOS was nine days (SD 13) and inpatient hospice six days (SD 10). Nine patients with ""expanded access"" hospice received only a few blood transfusions, and none received radiation. HM patients are referred late or never for hospice services. Studies evaluating earlier integration of palliative and hospice care with usual HM care are warranted. We present a one-page negotiation form that we have found useful in negotiations among HM physicians, hospice medical directors, and payers.",Journal Article,2210.0,37.0,"Hospice brings substantial clinical benefits dying patients families underutilized patients dying hematologic malignancies HM nationwide 2 HM patients use hospice 70,000 deaths U.S. patients hematologic malignancies yearly measured use length stay LOS hospice patients HMs large academic center single center retrospective review adult patients 18 years lymphoma leukemia myelodysplastic syndrome aplastic anemia multiple myeloma referred hospice Information included demographics transplant hospice type LOS use `` expanded access '' services Fifty-nine patients referred hospice 53 utilized hospice services 25 209 HM decedents Thirty-five received home hospice 18 inpatient hospice median home hospice LOS days SD 13 inpatient hospice days SD 10 patients `` expanded access '' hospice received blood transfusions received radiation HM patients referred late hospice services Studies evaluating earlier integration palliative hospice care usual HM care warranted present one-page negotiation form useful negotiations HM physicians hospice medical directors payers",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2490, 15249, 1281, 38, 1141, 6, 4536, 7, 2, 1954, 84, 16, 10398, 20, 7, 4536, 1, 813, 441, 13440, 5405, 158, 18, 1, 13440, 7, 119, 2490, 125, 32, 431, 984, 1043, 107, 1767, 695, 7, 5, 813, 441, 9460, 21, 644, 3, 119, 2, 1318, 1, 2020, 3649, 4, 2490, 107, 7, 5, 25587, 28, 8, 375, 1916, 12, 574, 26, 10, 8, 226, 574, 459, 206, 1, 780, 7, 6624, 60, 5, 681, 16315, 1545, 2, 232, 1995, 9, 2490, 487, 159, 2221, 941, 2490, 267, 3649, 2, 119, 1, 2064, 1655, 522, 2142, 1461, 762, 7, 11, 1995, 6, 2490, 2, 699, 2080, 2490, 2142, 243, 1, 5941, 13440, 13722, 977, 365, 103, 3249, 2490, 2, 203, 95, 2420, 2490, 3, 52, 3249, 2490, 3649, 10, 762, 162, 1270, 233, 2, 2420, 2490, 437, 162, 1270, 79, 762, 7, 5, 2064, 1655, 522, 2490, 103, 158, 8, 1021, 315, 4987, 2, 1292, 103, 121, 13440, 7, 32, 1995, 807, 15, 1737, 9, 2490, 2142, 94, 1435, 1677, 2676, 1, 994, 2, 2490, 165, 5, 3521, 13440, 165, 32, 1197, 21, 364, 8, 104, 9430, 48124, 1297, 17, 21, 47, 204, 999, 4, 48125, 107, 13440, 1261, 2490, 484, 10173, 2, 9361]",1292.0,24383458,Patterns hospice use patients dying hematologic malignancies,0,0.0
Decitabine induces delayed reactive oxygen species (ROS) accumulation in leukemia cells and induces the expression of ROS generating enzymes.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2014-01-14,"Azanucleoside DNA methyltransferase (DNMT) inhibitors are currently approved by the U.S. Food and Drug Administration for treatment of myelodysplastic syndrome. The relative contributions of DNMT inhibition and other off-target effects to their clinical efficacy remain unclear. Data correlating DNA methylation reversal and clinical response have been conflicting. Consequently, it is necessary to investigate so-called off-target effects and their impact on cell survival and differentiation. Flow cytometry was used for cell cycle, apoptosis, and reactive oxygen species (ROS) accumulation analysis. Gene expression analysis was performed using real-time PCR. DNA methylation was detected by methylation-specific PCR. Mitochondrial membrane potential was analyzed using JC-1 dye staining. Western blotting was used for quantitative protein expression analysis. 5-Aza-2'-deoxycytidine (DAC) induced cell-cycle arrest and apoptosis in leukemia cells. p53 expression was dispensable for DAC-induced apoptosis. DAC induced delayed ROS accumulation in leukemia cells but not in solid tumor cells and p53 expression was dispensable for ROS increase. ROS increase was deoxycytidine kinase dependent, indicating that incorporation of DAC into nuclear DNA is required for ROS generation. ROS accumulation by DAC was caspase-independent and mediated the dissipation of the mitochondrial membrane potential. Concordantly, ROS scavengers diminished DAC-induced apoptosis. DAC induced the expression of different NADPH oxidase isoforms and upregulated Nox4 protein expression in an ATM-dependent manner, indicating the involvement of DNA damage signaling in Nox4 upregulation. These data highlight the importance of mechanisms other than DNA cytosine demethylation in modulating gene expression and suggest investigating the relevance of ROS accumulation to the clinical activity of DAC.",Journal Article,2198.0,35.0,Azanucleoside DNA methyltransferase DNMT inhibitors currently approved U.S. Food Drug Administration treatment myelodysplastic syndrome relative contributions DNMT inhibition off-target effects clinical efficacy remain unclear correlating DNA methylation reversal clinical response conflicting Consequently necessary investigate so-called off-target effects impact survival differentiation Flow cytometry cycle apoptosis reactive oxygen species ROS accumulation expression performed real-time PCR DNA methylation detected methylation-specific PCR Mitochondrial membrane potential JC-1 dye staining Western blotting quantitative expression 5-Aza-2'-deoxycytidine DAC induced cell-cycle arrest apoptosis leukemia p53 expression dispensable DAC-induced apoptosis DAC induced delayed ROS accumulation leukemia solid p53 expression dispensable ROS increase ROS increase deoxycytidine kinase dependent indicating incorporation DAC nuclear DNA required ROS generation ROS accumulation DAC caspase-independent mediated dissipation mitochondrial membrane potential Concordantly ROS scavengers diminished DAC-induced apoptosis DAC induced expression different NADPH oxidase isoforms upregulated Nox4 expression ATM-dependent manner indicating involvement DNA damage signaling Nox4 upregulation highlight importance mechanisms DNA cytosine demethylation modulating expression suggest investigating relevance ROS accumulation clinical activity DAC,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[32002, 261, 3747, 10229, 222, 32, 694, 850, 20, 3, 1767, 695, 1773, 2, 234, 634, 9, 24, 1, 681, 3, 580, 5621, 1, 10229, 297, 2, 127, 1889, 283, 176, 6, 136, 38, 209, 918, 1200, 74, 5637, 261, 569, 5933, 2, 38, 51, 47, 85, 4274, 3244, 192, 16, 1493, 6, 963, 1743, 3472, 1889, 283, 176, 2, 136, 345, 23, 31, 25, 2, 910, 1412, 1914, 10, 95, 9, 31, 417, 351, 2, 2163, 2848, 2915, 2609, 1835, 65, 145, 55, 65, 10, 173, 75, 1589, 98, 604, 261, 569, 10, 530, 20, 569, 112, 604, 2019, 1905, 174, 10, 311, 75, 13323, 14, 3796, 1029, 1521, 3661, 10, 95, 9, 1156, 178, 55, 65, 33, 3924, 6135, 6750, 6140, 277, 31, 417, 1854, 2, 351, 4, 37, 624, 55, 10, 15142, 9, 6140, 277, 351, 6140, 277, 1612, 2609, 1835, 4, 37, 84, 44, 4, 537, 30, 37, 2, 624, 55, 10, 15142, 9, 2609, 344, 2609, 344, 10, 6750, 216, 470, 1716, 17, 2838, 1, 6140, 237, 928, 261, 16, 616, 9, 2609, 914, 2609, 1835, 20, 6140, 10, 1469, 306, 2, 517, 3, 30734, 1, 3, 2019, 1905, 174, 21323, 2609, 26237, 2849, 6140, 277, 351, 6140, 277, 3, 55, 1, 338, 16029, 10447, 3913, 2, 2684, 22826, 178, 55, 4, 35, 3552, 470, 1708, 1716, 3, 799, 1, 261, 1350, 314, 4, 22826, 2218, 46, 74, 1817, 3, 1187, 1, 483, 127, 76, 261, 6903, 6800, 4, 3712, 145, 55, 2, 309, 3103, 3, 2088, 1, 2609, 1835, 6, 3, 38, 128, 1, 6140]",1814.0,24423613,Decitabine induces delayed reactive oxygen species ROS accumulation leukemia induces expression ROS generating enzymes,11,0.019197207678883072
Leukaemogenesis induced by an activating -catenin mutation in osteoblasts.,Nature,Nature,2014-01-15,"Cells of the osteoblast lineage affect the homing and the number of long-term repopulating haematopoietic stem cells, haematopoietic stem cell mobilization and lineage determination and B cell lymphopoiesis. Osteoblasts were recently implicated in pre-leukaemic conditions in mice. However, a single genetic change in osteoblasts that can induce leukaemogenesis has not been shown. Here we show that an activating mutation of -catenin in mouse osteoblasts alters the differentiation potential of myeloid and lymphoid progenitors leading to development of acute myeloid leukaemia with common chromosomal aberrations and cell autonomous progression. Activated -catenin stimulates expression of the Notch ligand jagged 1 in osteoblasts. Subsequent activation of Notch signalling in haematopoietic stem cell progenitors induces the malignant changes. Genetic or pharmacological inhibition of Notch signalling ameliorates acute myeloid leukaemia and demonstrates the pathogenic role of the Notch pathway. In 38% of patients with myelodysplastic syndromes or acute myeloid leukaemia, increased -catenin signalling and nuclear accumulation was identified in osteoblasts and these patients showed increased Notch signalling in haematopoietic cells. These findings demonstrate that genetic alterations in osteoblasts can induce acute myeloid leukaemia, identify molecular signals leading to this transformation and suggest a potential novel pharmacotherapeutic approach to acute myeloid leukaemia. ",Journal Article,2197.0,,osteoblast lineage affect homing number long-term repopulating haematopoietic stem haematopoietic stem mobilization lineage determination B lymphopoiesis Osteoblasts recently implicated pre-leukaemic conditions mice single genetic change osteoblasts induce leukaemogenesis shown activating -catenin mouse osteoblasts alters differentiation potential myeloid lymphoid progenitors leading development acute myeloid leukaemia common chromosomal aberrations autonomous progression Activated -catenin stimulates expression Notch ligand jagged 1 osteoblasts Subsequent activation Notch signalling haematopoietic stem progenitors induces malignant changes Genetic pharmacological inhibition Notch signalling ameliorates acute myeloid leukaemia demonstrates pathogenic role Notch pathway 38 patients myelodysplastic syndromes acute myeloid leukaemia increased -catenin signalling nuclear accumulation identified osteoblasts patients showed increased Notch signalling haematopoietic findings demonstrate genetic alterations osteoblasts induce acute myeloid leukaemia identify molecular signals leading transformation suggest potential novel pharmacotherapeutic approach acute myeloid leukaemia,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[37, 1, 3, 7418, 2542, 1158, 3, 5515, 2, 3, 207, 1, 319, 337, 24758, 7274, 452, 37, 7274, 452, 31, 4030, 2, 2542, 3104, 2, 132, 31, 30689, 5965, 11, 761, 1771, 4, 671, 8871, 1298, 4, 399, 137, 8, 226, 336, 707, 4, 5965, 17, 122, 1290, 21781, 71, 44, 85, 443, 467, 21, 514, 17, 35, 1616, 258, 1, 1458, 1778, 4, 830, 5965, 6745, 3, 910, 174, 1, 533, 2, 2303, 4321, 1049, 6, 193, 1, 286, 533, 2001, 5, 186, 1860, 2152, 2, 31, 12369, 91, 735, 1458, 1778, 6200, 55, 1, 3, 3193, 1232, 28886, 14, 4, 5965, 706, 363, 1, 3193, 3128, 4, 7274, 452, 31, 4321, 1516, 3, 393, 400, 336, 15, 3419, 297, 1, 3193, 3128, 19484, 286, 533, 2001, 2, 1902, 3, 2806, 200, 1, 3, 3193, 308, 4, 519, 1, 7, 5, 2040, 15, 286, 533, 2001, 101, 1458, 1778, 3128, 2, 928, 1835, 10, 108, 4, 5965, 2, 46, 7, 224, 101, 3193, 3128, 4, 7274, 37, 46, 272, 608, 17, 336, 593, 4, 5965, 122, 1290, 286, 533, 2001, 255, 219, 2312, 1049, 6, 26, 1392, 2, 309, 8, 174, 229, 26864, 353, 6, 286, 533, 2001]",1461.0,24429522,Leukaemogenesis induced activating -catenin osteoblasts,0,0.0
"Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.",Leukemia research,Leuk. Res.,2013-12-25,"For patients with acute myeloid leukemia from antecedent myelodysplastic syndrome particularly after azanucleoside treatment failure, outcome is poor. Here, we conducted a case-control study in these patients to compare the efficacy of CLAG-M induction (28 patients) versus standard 3+7 induction chemotherapy (24 patients). Response rates (P=0.014) and median overall survival (P=0.025) were 64% and 202 days (95% CI 37-367 days) versus 29% and 86 days (95% CI 36-136) in the CLAG-M and 3+7 cohorts, respectively. Median overall survival was 202 (95% CI 37-367 days) versus 86 days (95% CI 36-136) (P=0.025), respectively. CLAG-M has encouraging activity in this patient group. ",Journal Article,2218.0,21.0,patients acute myeloid leukemia antecedent myelodysplastic syndrome particularly azanucleoside treatment failure outcome poor conducted case-control patients compare efficacy CLAG-M induction 28 patients versus standard 3+7 induction chemotherapy 24 patients Response rates P=0.014 median overall survival P=0.025 64 202 days 95 CI 37-367 days versus 29 86 days 95 CI 36-136 CLAG-M 3+7 cohorts respectively Median overall survival 202 95 CI 37-367 days versus 86 days 95 CI 36-136 P=0.025 respectively CLAG-M encouraging activity patient group,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[9, 7, 5, 286, 533, 29, 8775, 681, 823, 50, 32002, 24, 496, 228, 16, 334, 467, 21, 426, 8, 473, 182, 45, 4, 46, 7, 6, 932, 3, 209, 1, 24106, 188, 504, 339, 7, 185, 260, 27, 67, 504, 56, 259, 7, 51, 151, 19, 13, 3618, 2, 52, 63, 25, 19, 13, 4067, 11, 660, 2, 5918, 162, 48, 58, 567, 10720, 162, 185, 462, 2, 868, 162, 48, 58, 511, 4829, 4, 3, 24106, 188, 2, 27, 67, 736, 106, 52, 63, 25, 10, 5918, 48, 58, 567, 10720, 162, 185, 868, 162, 48, 58, 511, 4829, 19, 13, 4067, 106, 24106, 188, 71, 2269, 128, 4, 26, 69, 87]",620.0,24439565,Cladribine cytarabine filgrastim mitoxantrone CLAG-M compared standard induction acute myeloid leukemia myelodysplastic syndrome azanucleoside failure,141,0.24607329842931938
Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2013-11-15,"We assessed the outcomes of 63 patients with acute myeloid leukemia (AML) arising from myelodysplastic syndrome (MDS) after hypomethylating agent failure. Their median age was 63 years. All 63 patients had received  1 salvage regimens for AML, and 35 patients (55%) had received  2. Of the 31 patients (49%) who had received high-dose cytarabine (HDAC) at first relapse, 2 (6%) achieved complete remission (CR) and 4 (13%) CR with incomplete platelet recovery (overall response rate, 19%). Of the 32 patients (51%) who had received other treatments, including investigational agents, 4 (12%) achieved CR and 4 (12%) CR with incomplete platelet recovery (overall response rate, 24%). The median response duration was 20 weeks. With a median follow-up of 42 months from the AML diagnosis, the median survival (21 weeks) was similar between the 2 groups. The 1- and 2-year survival rate was 19% and 8%, respectively. Multivariate analysis identified low albumin, HDAC treatment, and platelet count < 50  10(9)/L as independent adverse factors for CR and a platelet count < 50  10(9)/L and age > 65 years as independent adverse factors for survival. Thus, the outcome of AML evolving from MDS after hypomethylating agent failure is poor and not improved with HDAC. Novel therapies directed toward this emerging entity are urgently needed.",Journal Article,2258.0,8.0,assessed outcomes 63 patients acute myeloid leukemia AML arising myelodysplastic syndrome MDS hypomethylating agent failure median age 63 years 63 patients received  1 salvage regimens AML 35 patients 55 received  2 31 patients 49 received high-dose cytarabine HDAC relapse 2 6 achieved complete remission CR 4 13 CR incomplete platelet recovery overall response rate 19 32 patients 51 received treatments including investigational agents 4 12 achieved CR 4 12 CR incomplete platelet recovery overall response rate 24 median response duration 20 weeks median follow-up 42 months AML diagnosis median survival 21 weeks similar 2 groups 1- 2-year survival rate 19 8 respectively Multivariate identified low albumin HDAC treatment platelet count 50 10 9 /L independent adverse factors CR platelet count 50 10 9 /L age 65 years independent adverse factors survival outcome AML evolving MDS hypomethylating agent failure poor improved HDAC Novel therapies directed emerging entity urgently needed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 275, 3, 123, 1, 676, 7, 5, 286, 533, 329, 2635, 29, 681, 1223, 50, 4931, 420, 496, 136, 52, 89, 10, 676, 60, 62, 676, 7, 42, 103, 749, 14, 992, 472, 9, 329, 2, 465, 7, 614, 42, 103, 749, 18, 1, 3, 456, 7, 739, 54, 42, 103, 64, 61, 1855, 2654, 28, 157, 429, 18, 49, 513, 236, 734, 684, 2, 39, 233, 684, 5, 2610, 1596, 1602, 63, 51, 116, 326, 1, 3, 531, 7, 725, 54, 42, 103, 127, 640, 141, 3093, 183, 39, 133, 513, 684, 2, 39, 133, 684, 5, 2610, 1596, 1602, 63, 51, 116, 259, 3, 52, 51, 654, 10, 179, 244, 5, 8, 52, 166, 126, 1, 595, 53, 29, 3, 329, 147, 3, 52, 25, 239, 244, 10, 288, 59, 3, 18, 271, 3, 14, 2, 18, 111, 25, 116, 10, 326, 2, 66, 106, 331, 65, 108, 154, 2799, 2654, 24, 2, 1596, 1276, 212, 79, 83, 805, 22, 306, 290, 130, 9, 684, 2, 8, 1596, 1276, 212, 79, 83, 805, 2, 89, 556, 60, 22, 306, 290, 130, 9, 25, 631, 3, 228, 1, 329, 3276, 29, 1223, 50, 4931, 420, 496, 16, 334, 2, 44, 231, 5, 2654, 229, 235, 1166, 1317, 26, 1478, 2983, 32, 5354, 575]",1242.0,24447728,Acute myeloid leukemia myelodysplastic syndrome failure therapy hypomethylating agents emerging entity poor prognosis,125,0.2181500872600349
Familial myelodysplastic syndrome/acute leukemia syndromes: a review and utility for translational investigations.,Annals of the New York Academy of Sciences,Ann. N. Y. Acad. Sci.,2014-01-27,"The familial myelodysplastic (MDS)/acute leukemia (AL) predisposition syndromes are inherited disorders that lead to significantly increased lifetime risks of MDS and AL development. At present, four recognized syndromes have Clinical Laboratory Improvement Amendments--certified testing for their respective germ-line mutations: telomere biology disorders due to mutation of TERC or TERT, familial acute myeloid leukemia (AML) with mutated CEBPA, familial MDS/AML with mutated GATA2, and familial platelet disorder with propensity to myeloid malignancy. These disorders are heterogeneous with regard to their causative genetic mutations, clinical presentation, and progression to MDS/AL. However, as a group, they all share the unique requirement for a high index of clinical suspicion to allow appropriate genetic counseling, genetic testing, and mutation-specific clinical management. In addition, translational investigations of individuals and families with these syndromes provide a rare opportunity to understand key pathways underlying susceptibility and progression to MDS/AL and allow the possibility of novel strategies for the prevention and treatment of both familial and sporadic forms of MDS/AL.",Journal Article,2185.0,54.0,familial myelodysplastic MDS /acute leukemia predisposition syndromes inherited disorders lead significantly increased lifetime risks MDS development present recognized syndromes Clinical Laboratory Improvement Amendments -- certified testing respective germ-line telomere disorders TERC TERT familial acute myeloid leukemia AML CEBPA familial MDS/AML GATA2 familial platelet disorder propensity myeloid malignancy disorders heterogeneous regard causative genetic clinical presentation progression MDS/AL group share unique requirement high index clinical suspicion allow appropriate genetic counseling genetic testing mutation-specific clinical management addition translational investigations individuals families syndromes provide rare opportunity understand key pathways underlying susceptibility progression MDS/AL allow possibility novel strategies prevention treatment familial sporadic forms MDS/AL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2200, 1223, 286, 2171, 2863, 2040, 32, 2986, 1997, 17, 1122, 6, 97, 101, 2898, 1098, 1, 1223, 2, 2171, 193, 28, 364, 294, 1904, 2040, 47, 38, 1624, 767, 11877, 8972, 471, 9, 136, 3847, 2280, 328, 138, 4136, 891, 1997, 520, 6, 258, 1, 18432, 15, 3846, 2200, 286, 533, 329, 5, 1185, 7667, 2200, 1223, 329, 5, 1185, 12909, 2, 2200, 1596, 2645, 5, 1925, 6, 533, 710, 46, 1997, 32, 1564, 5, 2539, 6, 136, 8088, 336, 138, 38, 1031, 2, 91, 6, 1223, 2171, 137, 22, 8, 87, 491, 62, 4349, 3, 991, 4701, 9, 8, 64, 558, 1, 38, 5782, 6, 1700, 870, 336, 2011, 336, 471, 2, 258, 112, 38, 284, 4, 352, 2460, 2492, 1, 869, 2, 1954, 5, 46, 2040, 377, 8, 622, 2666, 6, 1640, 825, 460, 1181, 1432, 2, 91, 6, 1223, 2171, 2, 1700, 3, 2526, 1, 229, 422, 9, 3, 1070, 2, 24, 1, 110, 2200, 2, 1928, 2377, 1, 1223, 2171]",1156.0,24467820,Familial myelodysplastic syndrome/acute leukemia syndromes review utility translational investigations,246,0.4293193717277487
"The bone marrow niche, stem cells, and leukemia: impact of drugs, chemicals, and the environment.",Annals of the New York Academy of Sciences,Ann. N. Y. Acad. Sci.,2014-02-04,"Hematopoietic stem cells (HSCs) are a unique population of somatic stem cells that can both self-renew for long-term reconstitution of HSCs and differentiate into hematopoietic progenitor cells (HPCs), which in turn give rise, in a hierarchical manner, to the entire myeloid and lymphoid lineages. The differentiation and maturation of these lineages occurs in the bone marrow (BM) niche, a microenvironment that regulates self-renewal, survival, differentiation, and proliferation, with interactions among signaling pathways in the HSCs and the niche required to establish and maintain homeostasis. The accumulation of genetic mutations and cytogenetic abnormalities within cells of the partially differentiated myeloid lineage, particularly as a result of exposure to benzene or cytotoxic anticancer drugs, can give rise to malignancies like acute myeloid leukemia and myelodysplastic syndrome. Better understanding of the mechanisms driving these malignancies and susceptibility factors, both within HPCs and cells within the BM niche, may lead to the development of strategies for prevention of occupational and cancer therapy-induced disease. ",Introductory Journal Article,2177.0,21.0,Hematopoietic stem HSCs unique population somatic stem self-renew long-term reconstitution HSCs differentiate hematopoietic progenitor HPCs turn rise hierarchical manner entire myeloid lymphoid lineages differentiation maturation lineages occurs bone marrow BM niche microenvironment regulates self-renewal survival differentiation proliferation interactions signaling pathways HSCs niche required establish maintain homeostasis accumulation genetic cytogenetic abnormalities partially differentiated myeloid lineage particularly exposure benzene cytotoxic anticancer drugs rise malignancies like acute myeloid leukemia myelodysplastic syndrome Better understanding mechanisms driving malignancies susceptibility factors HPCs BM niche lead development strategies prevention occupational therapy-induced disease,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1007, 452, 37, 6185, 32, 8, 991, 266, 1, 1119, 452, 37, 17, 122, 110, 1074, 14931, 9, 319, 337, 5616, 1, 6185, 2, 3723, 237, 1007, 2520, 37, 21697, 92, 4, 3854, 4978, 3693, 4, 8, 4466, 1708, 6, 3, 1797, 533, 2, 2303, 7234, 3, 910, 2, 4537, 1, 46, 7234, 1780, 4, 3, 581, 1246, 4385, 8, 995, 17, 2468, 1074, 4495, 25, 910, 2, 457, 5, 1286, 107, 314, 460, 4, 3, 6185, 2, 3, 4385, 616, 6, 1811, 2, 3040, 4975, 3, 1835, 1, 336, 138, 2, 1266, 1171, 262, 37, 1, 3, 2995, 1442, 533, 2542, 823, 22, 8, 757, 1, 645, 6, 27070, 15, 759, 1475, 600, 122, 4978, 3693, 6, 441, 733, 286, 533, 2, 681, 380, 612, 1, 3, 483, 4057, 46, 441, 2, 1432, 130, 110, 262, 21697, 2, 37, 262, 3, 1246, 4385, 68, 1122, 6, 3, 193, 1, 422, 9, 1070, 1, 10318, 2, 12, 36, 277, 34]",1095.0,24495159,bone marrow niche stem leukemia impact drugs chemicals environment,26,0.04537521815008726
The evolving challenge of therapy-related myeloid neoplasms.,Best practice & research. Clinical haematology,Best Pract Res Clin Haematol,2013-10-01,"Therapy-related myelodysplastic syndrome (t-MDS) and therapy-related acute myeloid leukemia (t-AML) are late complications of cytotoxic therapies used to treat malignant, and increasingly, non-malignant conditions. Although distinct clinical, morphologic, and genetic features can be recognized, these disorders should be seen as part of a single disease spectrum recognized by the WHO in a singular classification, therapy-related myeloid neoplasms (t-MNs). Etiologic factors for t-MNs remain elusive, but ongoing research has characterized risk factors which vary between patient subgroups and exposures. Agents that damage DNA directly, interfere with DNA repair, and suppress the immune system's ability to detect malignant cells increase the risk of t-MNs. As in primary MDS and de novo AML, prognosis and treatment strategies rely on patient characteristics as well as cytogenetics. However, the overall outcome for patients with t-MNs remains poor. Here we review our current understanding of t-MNs as they are most often encountered by the practicing clinician. ",Journal Article,2303.0,41.0,Therapy-related myelodysplastic syndrome t-MDS therapy-related acute myeloid leukemia t-AML late complications cytotoxic therapies treat malignant increasingly non-malignant conditions distinct clinical morphologic genetic features recognized disorders seen single disease spectrum recognized singular classification therapy-related myeloid neoplasms t-MNs Etiologic factors t-MNs remain elusive ongoing research characterized risk factors vary patient subgroups exposures Agents damage DNA directly interfere DNA repair suppress immune 's ability detect malignant increase risk t-MNs primary MDS novo AML prognosis treatment strategies rely patient characteristics cytogenetics overall outcome patients t-MNs remains poor review current understanding t-MNs encountered practicing clinician,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[36, 139, 681, 102, 1223, 2, 36, 139, 286, 533, 102, 329, 32, 807, 521, 1, 759, 235, 95, 6, 943, 393, 2, 1635, 220, 393, 1298, 242, 834, 38, 2815, 2, 336, 404, 122, 40, 1904, 46, 1997, 257, 40, 527, 22, 760, 1, 8, 226, 34, 1873, 1904, 20, 3, 54, 4, 8, 17928, 947, 36, 139, 533, 1179, 102, 17539, 6604, 130, 9, 102, 17539, 918, 5327, 84, 942, 389, 71, 765, 43, 130, 92, 2825, 59, 69, 1453, 2, 3401, 183, 17, 1350, 261, 1606, 6178, 5, 261, 972, 2, 3134, 3, 250, 398, 292, 801, 6, 1426, 393, 37, 344, 3, 43, 1, 102, 17539, 22, 4, 86, 1223, 2, 1566, 2018, 329, 356, 2, 24, 422, 5533, 23, 69, 374, 22, 149, 22, 2510, 137, 3, 63, 228, 9, 7, 5, 102, 17539, 469, 334, 467, 21, 206, 114, 291, 612, 1, 102, 17539, 22, 491, 32, 96, 629, 3903, 20, 3, 6734, 3744]",1021.0,24507808,evolving challenge therapy-related myeloid neoplasms,33,0.05759162303664921
Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation.,Journal of the National Cancer Institute,J. Natl. Cancer Inst.,2014-02-27,"Exposure to ionizing radiation has been linked to myelodysplastic syndromes (MDS); it is not clear whether therapeutic radiation doses used for prostate cancer pose an increased MDS risk. We performed a retrospective cohort study of prostate cancer patients diagnosed between 1986 and 2011 at Cleveland Clinic, comparing those who underwent definitive treatment with radical prostatectomy (RP) to radiotherapy either external beam radiotherapy (EBRT) or prostate interstitial brachytherapy (PI) and to population-based registries. Competing risk regression analyses were used to determine the cumulative risk of developing MDS. All statistical tests were two-sided. Of 10924 patients, 5119 (47%) received radiation (n = 2183 [43%] in EBRT group and n = 2936 [57%] in PI group) and 5805 (53%) were treated with RP. Overall, 31 cases of MDS were observed, with age-adjusted incidence rates no higher than in population-based registries. In univariate analyses, advancing age (hazard ratio [HR] = 1.14; 95% confidence interval [CI] = 1.09 to 1.20; P < .001) and radiotherapy exposure (HR = 3.44; 95% CI = 1.41 to 8.37; P = .007) were statistically significantly associated with development of MDS. In multivariable analyses, although advanced age (HR = 1.13; 95% CI = 1.06 to 1.19; P < .001) remained statistically associated with MDS, radiation did not, although a small non-statistically significant trend existed for PI-treated patients. MDS rates were no higher than in population-based registries. With relatively short follow-up, prostate cancer patients definitively treated with radiation did not appear to have a statistically increased risk of subsequent MDS.",Journal Article,2154.0,16.0,Exposure ionizing radiation linked myelodysplastic syndromes MDS clear therapeutic radiation doses prostate pose increased MDS risk performed retrospective cohort prostate patients diagnosed 1986 2011 Cleveland Clinic comparing underwent definitive treatment radical prostatectomy RP radiotherapy external beam radiotherapy EBRT prostate interstitial brachytherapy PI population-based registries Competing risk regression determine cumulative risk developing MDS statistical tests two-sided 10924 patients 5119 47 received radiation n 2183 43 EBRT group n 2936 57 PI group 5805 53 treated RP Overall 31 cases MDS observed age-adjusted incidence rates higher population-based registries univariate advancing age hazard ratio HR 1.14 95 confidence interval CI 1.09 1.20 P .001 radiotherapy exposure HR 3.44 95 CI 1.41 8.37 P .007 statistically significantly associated development MDS multivariable advanced age HR 1.13 95 CI 1.06 1.19 P .001 remained statistically associated MDS radiation small non-statistically significant trend existed PI-treated patients MDS rates higher population-based registries relatively short follow-up prostate patients definitively treated radiation appear statistically increased risk subsequent MDS,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[645, 6, 4341, 121, 71, 85, 1199, 6, 2040, 1223, 192, 16, 44, 885, 317, 189, 121, 415, 95, 9, 12, 6015, 35, 101, 1223, 43, 21, 173, 8, 459, 180, 45, 1, 12, 7, 265, 59, 3751, 2, 1132, 28, 7317, 1188, 1430, 135, 54, 208, 1057, 24, 5, 711, 1202, 1622, 6, 310, 361, 1455, 1345, 310, 1883, 15, 4543, 1536, 2928, 2, 6, 266, 90, 3768, 2573, 43, 320, 318, 11, 95, 6, 223, 3, 967, 43, 1, 931, 1223, 62, 1050, 895, 11, 100, 1689, 1, 63998, 7, 39719, 662, 103, 121, 78, 48222, 601, 4, 1883, 87, 2, 78, 40627, 696, 4, 2928, 87, 2, 63999, 699, 11, 73, 5, 1622, 63, 456, 140, 1, 1223, 11, 164, 5, 89, 586, 287, 151, 77, 142, 76, 4, 266, 90, 3768, 4, 880, 318, 5155, 89, 360, 197, 168, 14, 213, 48, 307, 268, 58, 14, 1730, 6, 14, 179, 19, 144, 2, 310, 645, 168, 27, 584, 48, 58, 14, 605, 6, 66, 567, 19, 1999, 11, 712, 97, 41, 5, 193, 1, 1223, 4, 658, 318, 242, 131, 89, 168, 14, 233, 48, 58, 14, 1460, 6, 14, 326, 19, 144, 958, 712, 41, 5, 1223, 121, 205, 44, 242, 8, 302, 220, 712, 93, 853, 6810, 9, 2928, 73, 7, 1223, 151, 11, 77, 142, 76, 4, 266, 90, 3768, 5, 1352, 978, 166, 126, 12, 7, 6008, 73, 5, 121, 205, 44, 1322, 6, 47, 8, 712, 101, 43, 1, 706, 1223]",1531.0,24577815,Risk developing myelodysplastic syndromes prostate patients definitively treated radiation,9,0.015706806282722512
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.,Blood,Blood,2014-03-13,"Atypical chronic myeloid leukemia (aCML) is a rare subtype of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) largely defined morphologically. It is, unclear, however, whether aCML-associated features are distinctive enough to allow its separation from unclassifiable MDS/MPN (MDS/MPN-U). To study these 2 rare entities, 134 patient archives were collected from 7 large medical centers, of which 65 (49%) cases were further classified as aCML and the remaining 69 (51%) as MDS/MPN-U. Distinctively, aCML was associated with many adverse features and an inferior overall survival (12.4 vs 21.8 months, P = .004) and AML-free survival (11.2 vs 18.9 months, P = .003). The aCML defining features of leukocytosis and circulating myeloid precursors, but not dysgranulopoiesis, were independent negative predictors. Other factors, such as lactate dehydrogenase, circulating myeloblasts, platelets, and cytogenetics could further stratify MDS/MPN-U but not aCML patient risks. aCML appeared to have more mutated RAS (7/20 [35%] vs 4/29 [14%]) and less JAK2p.V617F (3/42 [7%] vs 10/52 [19%]), but was not statistically significant. Somatic CSF3R T618I (0/54) and CALR (0/30) mutations were not detected either in aCML or MDS/MPN-U. In conclusion, within MDS/MPN, the World Health Organization 2008 criteria for aCML identify a subgroup of patients with features clearly distinct from MDS/MPN-U. The MDS/MPN-U category is heterogeneous, and patient risk can be further stratified by a number of clinicopathological parameters.",Journal Article,2140.0,91.0,Atypical chronic myeloid leukemia aCML rare subtype myelodysplastic/myeloproliferative neoplasm MDS/MPN largely defined morphologically unclear aCML-associated features distinctive allow separation unclassifiable MDS/MPN MDS/MPN-U 2 rare entities 134 patient archives collected 7 large medical centers 65 49 cases classified aCML remaining 69 51 MDS/MPN-U Distinctively aCML associated adverse features inferior overall survival 12.4 vs 21.8 months P .004 AML-free survival 11.2 vs 18.9 months P .003 aCML defining features leukocytosis circulating myeloid precursors dysgranulopoiesis independent negative predictors factors lactate dehydrogenase circulating myeloblasts platelets cytogenetics stratify MDS/MPN-U aCML patient risks aCML appeared RAS 7/20 35 vs 4/29 14 JAK2p.V617F 3/42 7 vs 10/52 19 statistically significant Somatic CSF3R T618I 0/54 CALR 0/30 detected aCML MDS/MPN-U MDS/MPN World Health Organization 2008 criteria aCML identify subgroup patients features clearly distinct MDS/MPN-U MDS/MPN-U category heterogeneous patient risk stratified number clinicopathological parameters,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1973, 442, 533, 21345, 16, 8, 622, 875, 1, 10589, 10857, 2131, 1223, 4125, 1733, 395, 6204, 192, 16, 1200, 137, 317, 21345, 41, 404, 32, 5049, 5151, 6, 1700, 211, 5422, 29, 14338, 1223, 4125, 1223, 4125, 1767, 6, 45, 46, 18, 622, 4613, 4842, 69, 12810, 11, 786, 29, 67, 375, 484, 1168, 1, 92, 556, 739, 140, 11, 195, 1373, 22, 21345, 2, 3, 1844, 790, 725, 22, 1223, 4125, 1767, 26680, 21345, 10, 41, 5, 445, 290, 404, 2, 35, 1663, 63, 25, 133, 39, 105, 239, 66, 53, 19, 1520, 2, 329, 115, 25, 175, 18, 105, 203, 83, 53, 19, 1421, 3, 21345, 2847, 404, 1, 7463, 2, 1033, 533, 4881, 84, 44, 64067, 11, 306, 199, 674, 127, 130, 225, 22, 3330, 2374, 1033, 14909, 4407, 2, 2510, 359, 195, 3570, 1223, 4125, 1767, 84, 44, 21345, 69, 1098, 21345, 2121, 6, 47, 80, 1185, 1102, 67, 179, 465, 105, 39, 462, 213, 2, 299, 64068, 5657, 27, 595, 67, 105, 79, 653, 326, 84, 10, 44, 712, 93, 1119, 15024, 40647, 13, 667, 2, 11222, 13, 201, 138, 11, 44, 530, 361, 4, 21345, 15, 1223, 4125, 1767, 4, 1221, 262, 1223, 4125, 3, 1956, 341, 2533, 1375, 371, 9, 21345, 255, 8, 1363, 1, 7, 5, 404, 2536, 834, 29, 1223, 4125, 1767, 3, 1223, 4125, 1767, 2169, 16, 1564, 2, 69, 43, 122, 40, 195, 1173, 20, 8, 207, 1, 2721, 1038]",1446.0,24627528,Atypical chronic myeloid leukemia clinically distinct unclassifiable myelodysplastic/myeloproliferative neoplasms,4,0.006980802792321117
Subsequent malignant neoplasms in pediatric patients initially diagnosed with neuroblastoma.,Journal of pediatric hematology/oncology,J. Pediatr. Hematol. Oncol.,2015-01-01,"Most prior studies evaluating subsequent malignant neoplasms (SMNs) in patients with neuroblastoma are restricted to long-term survivors and/or their treatment exposures. This study investigates SMNs in patients diagnosed with neuroblastoma at our institution. Records of 646 patients treated for neuroblastoma at St Jude Children's Research Hospital between 1961 and 2005 were reviewed. Data from patients with SMNs were analyzed and the 20- and 30-year cumulative incidence of SMNs and standardized incidence ratio were calculated. Twenty-one patients had a SMN. The 20- and 30-year cumulative incidences of a SMN were 2.6%0.7% and 4.6%1.1%, respectively. The standardized incidence ratio was 8.3 (95% confidence interval, 5.0-13.0). Five patients developed a SMN within 5 years from diagnosis. The median latency for the development of acute myeloid leukemia/myelodysplastic syndrome (n=4), sarcomas (n=7), and carcinomas (n=5) were 3.6, 9, and 24.2 years, respectively. Nine patients died from their SMN, including all with acute myeloid leukemia/myelodysplastic syndrome. Patients with neuroblastoma have an increased risk of secondary neoplasia. Modification of risk-adapted therapies will likely alter the affected patient population and the incidence of SMNs. Future studies are necessary to link SMNs to treatment exposures and to evaluate the risk of SMNs beyond 30 years from diagnosis.",Journal Article,1846.0,11.0,prior studies evaluating subsequent malignant neoplasms SMNs patients neuroblastoma restricted long-term survivors and/or treatment exposures investigates SMNs patients diagnosed neuroblastoma institution Records 646 patients treated neuroblastoma St Jude Children 's Research Hospital 1961 2005 reviewed patients SMNs 20- 30-year cumulative incidence SMNs standardized incidence ratio calculated Twenty-one patients SMN 20- 30-year cumulative incidences SMN 2.6 0.7 4.6 1.1 respectively standardized incidence ratio 8.3 95 confidence interval 5.0-13.0 patients developed SMN 5 years diagnosis median latency development acute myeloid leukemia/myelodysplastic syndrome n=4 sarcomas n=7 carcinomas n=5 3.6 9 24.2 years respectively patients died SMN including acute myeloid leukemia/myelodysplastic syndrome Patients neuroblastoma increased risk secondary neoplasia Modification risk-adapted therapies likely alter affected patient population incidence SMNs Future studies necessary link SMNs treatment exposures evaluate risk SMNs 30 years diagnosis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[96, 324, 94, 1435, 706, 393, 1179, 6580, 4, 7, 5, 32, 2016, 6, 319, 337, 332, 2, 15, 136, 24, 3401, 26, 45, 7259, 6580, 4, 7, 265, 5, 28, 114, 731, 1064, 1, 14458, 7, 73, 9, 28, 3062, 4841, 541, 292, 389, 702, 59, 24688, 2, 1242, 11, 446, 74, 29, 7, 5, 6580, 11, 311, 2, 3, 179, 2, 201, 111, 967, 287, 1, 6580, 2, 1670, 287, 197, 11, 981, 737, 104, 7, 42, 8, 6474, 3, 179, 2, 201, 111, 967, 3981, 1, 8, 6474, 11, 18, 49, 18068, 67, 2, 39, 49, 18661, 14, 106, 3, 1670, 287, 197, 10, 66, 27, 48, 307, 268, 33, 13, 233, 13, 365, 7, 276, 8, 6474, 262, 33, 60, 29, 147, 3, 52, 5301, 9, 3, 193, 1, 286, 533, 2647, 10589, 681, 78, 39, 1479, 78, 67, 2, 826, 78, 33, 11, 27, 49, 83, 2, 259, 18, 60, 106, 762, 7, 1016, 29, 136, 6474, 141, 62, 5, 286, 533, 2647, 10589, 681, 7, 5, 47, 35, 101, 43, 1, 568, 2298, 2437, 1, 43, 3716, 235, 303, 322, 2688, 3, 1424, 69, 266, 2, 3, 287, 1, 6580, 508, 94, 32, 1493, 6, 3460, 6580, 6, 24, 3401, 2, 6, 376, 3, 43, 1, 6580, 1654, 201, 60, 29, 147]",1310.0,24633303,Subsequent malignant neoplasms pediatric patients initially diagnosed neuroblastoma,5,0.008726003490401396
Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma.,Pediatric blood & cancer,Pediatr Blood Cancer,2014-03-14,"Outcomes for high-risk neuroblastoma remain poor. Modern treatment protocols utilizing intense induction followed by myeloablative consolidation chemotherapy with autologous stem cell rescue (ASCR) have improved survival rates, but the long-term sequelae, including development of secondary malignant neoplasms (SMN), are just now surfacing. We retrospectively reviewed data from 87 patients with high-risk neuroblastoma who were treated with intensive induction chemotherapy followed by ASCR between January 1991 and July 2011 following one of two institutional protocols: Chicago Pilot 1 (CP1; n=12) and Chicago Pilot 2 (CP2; n=75). The 15-year overall survival rate for all 87 patients was 33.9% (95% confidence interval [CI], 23.1-45.0%). The 10- and 15-year cumulative incidence of SMN was 16.5% (95%CI, 7.2-38.0%) and 34.2% (95%CI, 18.6-63.1%), respectively, without evidence of a plateau at 15 years. Six of the 10 patients (n=2 in CP1 and n=8 in CP2) who developed SMN had hematologic malignancies including acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS). Solid tumors included thyroid papillary carcinoma, chondrosarcoma, hepatocellular carcinoma, and biliary adenocarcinoma. A significantly higher incidence of SMN, especially hematological malignancies, was observed in this cohort compared to older neuroblastoma studies, potentially due to exposure to epipodophyllotoxins and a high cumulative dose of alkylating agents these patients received. The risk of developing an SMN continued to increase with survival time and did not reach the plateau at 15 years. Although the number of the patients is relatively small, our study emphasizes the need for life-long follow-up of survivors who were treated using modern therapy.",Clinical Trial,2139.0,15.0,Outcomes high-risk neuroblastoma remain poor Modern treatment protocols utilizing intense induction followed myeloablative consolidation chemotherapy autologous stem rescue ASCR improved survival rates long-term sequelae including development secondary malignant neoplasms SMN surfacing retrospectively reviewed 87 patients high-risk neuroblastoma treated intensive induction chemotherapy followed ASCR January 1991 July 2011 following institutional protocols Chicago Pilot 1 CP1 n 12 Chicago Pilot 2 CP2 n 75 15-year overall survival rate 87 patients 33.9 95 confidence interval CI 23.1-45.0 10- 15-year cumulative incidence SMN 16.5 95 CI 7.2-38.0 34.2 95 CI 18.6-63.1 respectively evidence plateau 15 years 10 patients n 2 CP1 n 8 CP2 developed SMN hematologic malignancies including acute myeloid leukemia AML /myelodysplastic syndrome MDS Solid included thyroid papillary carcinoma chondrosarcoma hepatocellular carcinoma biliary adenocarcinoma significantly higher incidence SMN especially hematological malignancies observed cohort compared older neuroblastoma studies potentially exposure epipodophyllotoxins high cumulative dose alkylating agents patients received risk developing SMN continued increase survival time reach plateau 15 years number patients relatively small emphasizes need life-long follow-up survivors treated modern therapy,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,"[123, 9, 64, 43, 918, 334, 2366, 24, 2189, 2600, 3933, 504, 370, 20, 3246, 2173, 56, 5, 1028, 452, 31, 4256, 10729, 47, 231, 25, 151, 84, 3, 319, 337, 4156, 141, 193, 1, 568, 393, 1179, 6474, 32, 4673, 1134, 64078, 21, 894, 446, 74, 29, 912, 7, 5, 64, 43, 54, 11, 73, 5, 1686, 504, 56, 370, 20, 10729, 59, 1024, 3372, 2, 2066, 1132, 366, 104, 1, 100, 1115, 2189, 9344, 2281, 14, 22525, 78, 133, 2, 9344, 2281, 18, 48258, 78, 481, 3, 167, 111, 63, 25, 116, 9, 62, 912, 7, 10, 466, 83, 48, 307, 268, 58, 382, 14, 512, 13, 3, 79, 2, 167, 111, 967, 287, 1, 6474, 10, 245, 33, 48, 58, 67, 18, 519, 13, 2, 562, 18, 48, 58, 203, 49, 676, 14, 106, 187, 241, 1, 8, 6133, 28, 167, 60, 437, 1, 3, 79, 7, 78, 18, 4, 22525, 2, 78, 66, 4, 48258, 54, 276, 6474, 42, 813, 441, 141, 286, 533, 329, 10589, 681, 1223, 537, 57, 159, 1796, 134, 6116, 134, 2, 2532, 449, 8, 97, 142, 287, 1, 6474, 1093, 2890, 441, 10, 164, 4, 26, 180, 72, 6, 434, 94, 751, 520, 6, 645, 6, 25999, 2, 8, 64, 967, 61, 1, 3410, 183, 46, 7, 103, 3, 43, 1, 931, 35, 6474, 1351, 6, 344, 5, 25, 98, 2, 205, 44, 3690, 3, 6133, 28, 167, 60, 242, 3, 207, 1, 3, 7, 16, 1352, 302, 114, 45, 7519, 3, 594, 9, 358, 319, 166, 126, 1, 332, 54, 11, 73, 75, 2366, 36]",1617.0,24634399,Secondary malignant neoplasms high-dose chemotherapy autologous stem rescue high-risk neuroblastoma,0,0.0
"Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies.",Medical care,Med Care,2014-06-01,"In prior research, we developed a claims-based prediction model for poor patient disability status (DS), a proxy measure for performance status, commonly used by oncologists to summarize patient functional status and assess ability of a patient to tolerate aggressive treatment. In this study, we implemented and validated the DS measure in 4 cohorts of cancer patients: early and advanced non-small cell lung cancers (NSCLC), stage IV estrogen receptor-negative (ER-) breast cancer, and myelodysplastic syndromes (MDS). SEER-Medicare data (1999-2007) for the 4 cohorts of cancer patients. Bivariate and multivariate logistic regression tested the association of the DS measure with designated cancer-directed treatments: early NSCLC (surgery), advanced NSCLC (chemotherapy), stage IV ER- breast cancer (chemotherapy), and MDS (erythropoiesis-stimulating agents). Treatment model fit was compared across model iterations. In both unadjusted and adjusted results, predicted poor DS was strongly associated with a lower likelihood of cancer treatment receipt in all 4 cohorts [early NSCLC (N=20,280), advanced NSCLC (N=31,341), stage IV ER- breast cancer (N=1519), and MDS (N=6058)] independent of other patient, contextual, and disease characteristics, as well as the Charlson Comorbidity Index. Inclusion of the DS measure into models already controlling for other variables did not significantly improve model fit across the cohorts. The DS measure is a significant independent predictor of cancer-directed treatment. Small changes in model fit associated with both DS and the Charlson Comorbidity Index suggest that unobserved factors continue to play a role in determining cancer treatments.",Journal Article,2060.0,33.0,"prior research developed claims-based prediction model poor patient disability status DS proxy measure performance status commonly oncologists summarize patient functional status assess ability patient tolerate aggressive treatment implemented validated DS measure 4 cohorts patients early advanced non-small lung NSCLC stage IV estrogen receptor-negative ER- breast myelodysplastic syndromes MDS SEER-Medicare 1999-2007 4 cohorts patients Bivariate multivariate logistic regression tested association DS measure designated cancer-directed treatments early NSCLC surgery advanced NSCLC chemotherapy stage IV ER- breast chemotherapy MDS erythropoiesis-stimulating agents Treatment model fit compared model iterations unadjusted adjusted predicted poor DS strongly associated lower likelihood treatment receipt 4 cohorts early NSCLC N=20,280 advanced NSCLC N=31,341 stage IV ER- breast N=1519 MDS N=6058 independent patient contextual disease characteristics Charlson Comorbidity Index Inclusion DS measure models controlling variables significantly improve model fit cohorts DS measure significant independent predictor cancer-directed treatment Small changes model fit associated DS Charlson Comorbidity Index suggest unobserved factors continue play role determining treatments",1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 324, 389, 21, 276, 8, 2770, 90, 1590, 202, 9, 334, 69, 5868, 156, 3602, 8, 8806, 1463, 9, 528, 156, 841, 95, 20, 1339, 6, 2479, 69, 583, 156, 2, 423, 801, 1, 8, 69, 6, 5010, 571, 24, 4, 26, 45, 21, 3426, 2, 938, 3, 3602, 1463, 4, 39, 736, 1, 12, 7, 191, 2, 131, 31, 163, 304, 82, 478, 808, 153, 199, 516, 12, 2, 2040, 1223, 1605, 1378, 74, 2043, 1307, 9, 3, 39, 736, 1, 12, 7, 7686, 2, 331, 812, 320, 650, 3, 248, 1, 3, 3602, 1463, 5, 4107, 12, 1166, 640, 191, 304, 152, 131, 304, 56, 82, 478, 516, 12, 56, 2, 1223, 10297, 2122, 183, 24, 202, 2975, 10, 72, 716, 202, 15292, 4, 110, 4487, 2, 586, 99, 783, 334, 3602, 10, 1327, 41, 5, 8, 280, 1420, 1, 12, 24, 1699, 4, 62, 39, 736, 191, 304, 78, 179, 5775, 131, 304, 78, 456, 4065, 82, 478, 516, 12, 78, 31145, 2, 1223, 78, 64090, 306, 1, 127, 69, 19868, 2, 34, 374, 22, 149, 22, 3, 4670, 1879, 558, 1680, 1, 3, 3602, 1463, 237, 274, 3298, 1893, 9, 127, 682, 205, 44, 97, 401, 202, 2975, 716, 3, 736, 3, 3602, 1463, 16, 8, 93, 306, 980, 1, 12, 1166, 24, 302, 400, 4, 202, 2975, 41, 5, 110, 3602, 2, 3, 4670, 1879, 558, 309, 17, 24447, 130, 1906, 6, 1343, 8, 200, 4, 2196, 12, 640]",1587.0,24638118,Validation disability status claims-based measure functional status treatment outcomes studies,0,0.0
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2014-03-24,"Although azacitidine (AZA) improves survival in patients with high-risk myelodysplastic syndrome, the overall response remains approximately 50%. Entinostat is a histone deacetylase inhibitor that has been combined with AZA with significant clinical activity in a previous phase I dose finding study. Open label phase II randomized trial comparing AZA 50 mg/m(2)/d given for 10 days  entinostat 4 mg/m(2)/d day 3 and day 10. All subtypes of myelodysplasia, chronic myelomonocytic leukemia, and acute myeloid leukemia with myelodysplasia-related changes were eligible for the study. The primary objective was the rate of hematologic normalization (HN; complete remission + partial remission + trilineage hematological improvement). One hundred forty-nine patients were analyzed, including 97 patients with myelodysplastic syndrome and 52 patients with acute myeloid leukemia. In the AZA group, 32% (95% CI, 22% to 44%) experienced HN and 27% (95% CI, 17% to 39%) in the AZA + entinostat group. Both arms exceeded the HN rate of historical control (Cancer and Leukemia Group B 9221 trial), but only the AZA group fulfilled the primary objective of the study. Rates of overall hematologic response were 46% and 44%, respectively. Median overall survivals were 18 months for the AZA group and 13 months for the AZA + entinostat group. The combination arm led to less demethylation compared with the monotherapy arm, suggesting pharmacodynamic antagonism. Addition of entinostat to AZA did not increase clinical response as defined by the protocol and was associated with pharmacodynamic antagonism. However, the prolonged administration of AZA by itself seems to increase HN rate compared with standard dosing and warrants additional investigation.","Clinical Trial, Phase II",2129.0,145.0,azacitidine AZA improves survival patients high-risk myelodysplastic syndrome overall response remains approximately 50 Entinostat histone deacetylase inhibitor combined AZA significant clinical activity previous phase dose finding Open label phase II randomized trial comparing AZA 50 mg/m 2 /d given 10 days  entinostat 4 mg/m 2 /d day 3 day 10 subtypes myelodysplasia chronic myelomonocytic leukemia acute myeloid leukemia myelodysplasia-related changes eligible primary objective rate hematologic normalization HN complete remission partial remission trilineage hematological improvement forty-nine patients including 97 patients myelodysplastic syndrome 52 patients acute myeloid leukemia AZA group 32 95 CI 22 44 experienced HN 27 95 CI 17 39 AZA entinostat group arms exceeded HN rate historical control Leukemia Group B 9221 trial AZA group fulfilled primary objective Rates overall hematologic response 46 44 respectively Median overall survivals 18 months AZA group 13 months AZA entinostat group combination arm led demethylation compared monotherapy arm suggesting pharmacodynamic antagonism Addition entinostat AZA increase clinical response defined protocol associated pharmacodynamic antagonism prolonged administration AZA increase HN rate compared standard dosing warrants additional investigation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[242, 3752, 3924, 1804, 25, 4, 7, 5, 64, 43, 681, 3, 63, 51, 469, 705, 212, 7616, 16, 8, 1508, 2732, 230, 17, 71, 85, 397, 5, 3924, 5, 93, 38, 128, 4, 8, 698, 124, 70, 61, 1567, 45, 1020, 1756, 124, 215, 384, 160, 1430, 3924, 212, 81, 188, 18, 427, 447, 9, 79, 162, 810, 7616, 39, 81, 188, 18, 427, 218, 27, 2, 218, 79, 62, 814, 1, 6128, 442, 5451, 2, 286, 533, 5, 6128, 139, 400, 11, 625, 9, 3, 45, 3, 86, 461, 10, 3, 116, 1, 813, 5924, 9132, 236, 734, 450, 734, 21950, 2890, 767, 104, 1128, 1213, 762, 7, 11, 311, 141, 1015, 7, 5, 681, 2, 653, 7, 5, 286, 533, 4, 3, 3924, 87, 531, 48, 58, 350, 6, 584, 592, 9132, 2, 428, 48, 58, 269, 6, 587, 4, 3, 3924, 7616, 87, 110, 1335, 4726, 3, 9132, 116, 1, 2252, 182, 12, 2, 87, 132, 42926, 160, 84, 158, 3, 3924, 87, 9091, 3, 86, 461, 1, 3, 45, 151, 1, 63, 813, 51, 11, 641, 2, 584, 106, 52, 63, 3794, 11, 203, 53, 9, 3, 3924, 87, 2, 233, 53, 9, 3, 3924, 7616, 87, 3, 150, 475, 836, 6, 299, 6800, 72, 5, 3, 1411, 475, 802, 2424, 7537, 352, 1, 7616, 6, 3924, 205, 44, 344, 38, 51, 22, 395, 20, 3, 1182, 2, 10, 41, 5, 2424, 7537, 137, 3, 1069, 634, 1, 3924, 20, 4045, 2744, 6, 344, 9132, 116, 72, 5, 260, 1280, 2, 2782, 402, 940]",1623.0,24663049,Prolonged administration azacitidine entinostat myelodysplastic syndrome acute myeloid leukemia myelodysplasia-related changes Leukemia Intergroup trial E1905,59,0.10296684118673648
STAT3 inhibitors: finding a home in lymphoma and leukemia.,The oncologist,Oncologist,2014-04-04,"The Janus kinase (JAK) and signal transducer and activator of transcription (STAT) pathway is an active mediator of cytokine signaling in the pathogenesis of solid and hematologic malignancies. The seven-member STAT family is composed of latent cytoplasmic transcription factors that are activated by phosphorylation intertwined in a network with activation that ultimately leads to cell proliferation. An activated kinase enzyme phosphorylates one STAT factor or more, which shuttle to the nucleus to regulate gene expression, promoting cell survival. Somatic STAT3 mutations have been recently reported in large granular lymphocytic leukemia, aplastic anemia, and myelodysplastic syndrome. Furthermore, the relationship between BCL6 and STAT3 in diffuse large B-cell lymphomas, particularly on the activated B-cell subtype, needs to be further explored. The search for therapeutic STAT3 inhibitors that abrogate the JAK/STAT pathway is currently under way. Targeting the STAT pathway, which seems to be critical in tumorigenesis, is promising for multiple malignancies including lymphoma and leukemia. In this paper, we review mechanisms of action, failures, and successes of STAT3 inhibitors. ",Journal Article,2118.0,38.0,Janus kinase JAK signal transducer activator transcription STAT pathway active mediator cytokine signaling pathogenesis solid hematologic malignancies seven-member STAT family composed latent cytoplasmic transcription factors activated phosphorylation intertwined network activation ultimately leads proliferation activated kinase enzyme phosphorylates STAT factor shuttle nucleus regulate expression promoting survival Somatic STAT3 recently reported large granular lymphocytic leukemia aplastic anemia myelodysplastic syndrome Furthermore relationship BCL6 STAT3 diffuse large B-cell lymphomas particularly activated B-cell subtype needs explored search therapeutic STAT3 inhibitors abrogate JAK/STAT pathway currently way Targeting STAT pathway critical tumorigenesis promising multiple malignancies including lymphoma leukemia paper review mechanisms action failures successes STAT3 inhibitors,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 6191, 216, 4653, 2, 1235, 5182, 2, 3393, 1, 866, 4168, 308, 16, 35, 544, 3810, 1, 1675, 314, 4, 3, 1384, 1, 537, 2, 813, 441, 3, 648, 2693, 4168, 607, 16, 3317, 1, 6011, 2828, 866, 130, 17, 32, 735, 20, 982, 22377, 4, 8, 1801, 5, 363, 17, 2050, 1940, 6, 31, 457, 35, 735, 216, 1644, 12528, 104, 4168, 161, 15, 80, 92, 25610, 6, 3, 4262, 6, 2288, 145, 55, 2388, 31, 25, 1119, 1439, 138, 47, 85, 761, 210, 4, 375, 7694, 1193, 16315, 1545, 2, 681, 798, 3, 858, 59, 8148, 2, 1439, 4, 1388, 375, 132, 31, 1557, 823, 23, 3, 735, 132, 31, 875, 1891, 6, 40, 195, 1443, 3, 1901, 9, 189, 1439, 222, 17, 8581, 3, 4653, 4168, 308, 16, 694, 669, 2255, 529, 3, 4168, 308, 92, 2744, 6, 40, 740, 4, 1565, 16, 721, 9, 232, 441, 141, 2, 4, 26, 2817, 21, 206, 483, 1, 1578, 3368, 2, 6697, 1, 1439, 222]",1128.0,24705981,STAT3 inhibitors finding home lymphoma leukemia,270,0.4712041884816754
Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature.,Journal of hematology & oncology,J Hematol Oncol,2014-04-22,"A 50-year-old woman was diagnosed with acute myeloid leukemia (AML). She has history of thrombocytopenia for 25years and a significant family history of thrombocytopenia, affecting her mother, siblings and their children, as well as her own children. Both her mother and maternal aunt died from myelodysplastic syndrome (MDS). Additional genetic analysis was performed and identified two heterozygous missence mutations in the second zinc finger domain of GATA2 gene (p.Thr358Lys, and p.Leu359Val), occurring in cis on the same allele. Given the patient's family history and clinical manifestation, this was interpreted as an acute myeloid leukemia with heritable GATA2 mutations associated with familial AML-MDS. Germline GATA2 mutations are involved in a group of complex syndromes with overlapping clinical features of immune deficiency, lymphedema and propensity to acute myeloid leukemia or myelodysplastic syndrome (AML-MDS). Here we reported a case of familial AML-MDS with two novel GATA2 mutations. This case illustrates the importance of recognizing the clinical features for this rare category of AML-MDS and performing the appropriate molecular testing. The diagnosis of heritable gene mutations associated familial AML-MDS has significant clinical implication for the patients and affected families. Clinical trials are available to further investigate the role of allogeneic hematopoietic stem cell transplant in managing these patients. ",Case Reports,2100.0,18.0,50-year-old woman diagnosed acute myeloid leukemia AML history thrombocytopenia 25 years significant family history thrombocytopenia affecting mother siblings children children mother maternal aunt died myelodysplastic syndrome MDS Additional genetic performed identified heterozygous missence second zinc finger domain GATA2 p.Thr358Lys p.Leu359Val occurring cis allele Given patient 's family history clinical manifestation interpreted acute myeloid leukemia heritable GATA2 associated familial AML-MDS Germline GATA2 involved group complex syndromes overlapping clinical features immune deficiency lymphedema propensity acute myeloid leukemia myelodysplastic syndrome AML-MDS reported case familial AML-MDS novel GATA2 case illustrates importance recognizing clinical features rare category AML-MDS performing appropriate molecular testing diagnosis heritable associated familial AML-MDS significant clinical implication patients affected families Clinical trials available investigate role allogeneic hematopoietic stem transplant managing patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[8, 212, 111, 1095, 2854, 10, 265, 5, 286, 533, 329, 3109, 71, 532, 1, 1340, 9, 243, 60, 2, 8, 93, 607, 532, 1, 1340, 2319, 1084, 9733, 2758, 2, 136, 541, 22, 149, 22, 1084, 4165, 541, 110, 1084, 9733, 2, 6039, 37148, 1016, 29, 681, 1223, 402, 336, 65, 10, 173, 2, 108, 100, 4167, 64240, 138, 4, 3, 419, 5988, 8079, 1398, 1, 12909, 145, 19, 64241, 2, 19, 64242, 1821, 4, 1927, 23, 3, 827, 1254, 447, 3, 69, 292, 607, 532, 2, 38, 6746, 26, 10, 5047, 22, 35, 286, 533, 5, 6874, 12909, 138, 41, 5, 2200, 329, 1223, 1009, 12909, 138, 32, 646, 4, 8, 87, 1, 840, 2040, 5, 4551, 38, 404, 1, 250, 2299, 3063, 2, 1925, 6, 286, 533, 15, 681, 329, 1223, 467, 21, 210, 8, 473, 1, 2200, 329, 1223, 5, 100, 229, 12909, 138, 26, 473, 6342, 3, 1187, 1, 5842, 3, 38, 404, 9, 26, 622, 2169, 1, 329, 1223, 2, 3620, 3, 870, 219, 471, 3, 147, 1, 6874, 145, 138, 41, 2200, 329, 1223, 71, 93, 38, 8969, 9, 3, 7, 2, 1424, 1954, 38, 143, 32, 390, 6, 195, 963, 3, 200, 1, 1063, 1007, 452, 31, 941, 4, 3969, 46, 7]",1369.0,24754962,Heritable GATA2 associated familial AML-MDS case report review literature,0,0.0
Phase II clinical study of erlotinib for treatment of myelodysplastic syndromes.,American journal of hematology,Am. J. Hematol.,2014-05-16,"Outcome in patients with myelodysplastic syndrome (MDS) after azanucleoside failure is poor with unmet need for active novel agents. Preclinical data have suggested that erlotinib has in vivo and in vitro off epidermal growth factor receptor (EGFR)-target activity in MDS. We conducted a phase II study with single-agent erlotinib 150 mg/day orally in MDS patients following azanucleoside failure. All intermediate-2 or high-risk MDS patients by International Prognostic Scoring System and only those low/intermediate-1 patients with transfusion-dependent anemia or platelet counts <50  10(9) /L or a significant clinical hemorrhage requiring platelet transfusion or ANC <1  10(9) /L were eligible, with most of our patients being at high risk. In 35 eligible patients, overall best response was 14% (3 patients having marrow complete response and 2 hematological improvement). Four deaths occurred on study (sepsis, intracranial hemorrhage, sudden death, and acute myeloid leukemia (AML)). The most common observed grade 3/4 toxicities according to CTCAE v3 were diarrhea (17.1%), rash (17.1%), and infection (11.6%), accompanied by fatigue, thrombocytopenia, and anorexia at 5.7% each. Median overall survival was 6.8 months (95% CI 4.9-13.2), and leukemia-free survival was 5 months (95% CI 3.4-7.3). Erlotinib was generally well tolerated, with modest single-agent activity. Given these results and preclinical data suggesting synergistic effect with azanucleosides, the combination should be further explored.","Clinical Trial, Phase II",2076.0,13.0,Outcome patients myelodysplastic syndrome MDS azanucleoside failure poor unmet need active novel agents Preclinical suggested erlotinib vivo vitro epidermal growth factor receptor EGFR -target activity MDS conducted phase II single-agent erlotinib 150 mg/day orally MDS patients following azanucleoside failure intermediate-2 high-risk MDS patients International Prognostic Scoring low/intermediate-1 patients transfusion-dependent anemia platelet counts 50 10 9 /L significant clinical hemorrhage requiring platelet transfusion ANC 1 10 9 /L eligible patients high risk 35 eligible patients overall best response 14 3 patients marrow complete response 2 hematological improvement deaths occurred sepsis intracranial hemorrhage sudden death acute myeloid leukemia AML common observed grade 3/4 toxicities according CTCAE v3 diarrhea 17.1 rash 17.1 infection 11.6 accompanied fatigue thrombocytopenia anorexia 5.7 Median overall survival 6.8 months 95 CI 4.9-13.2 leukemia-free survival 5 months 95 CI 3.4-7.3 Erlotinib generally tolerated modest single-agent activity Given preclinical suggesting synergistic effect azanucleosides combination explored,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[228, 4, 7, 5, 681, 1223, 50, 32002, 496, 16, 334, 5, 3715, 594, 9, 544, 229, 183, 693, 74, 47, 1148, 17, 962, 71, 4, 386, 2, 4, 439, 1889, 829, 129, 161, 153, 227, 283, 128, 4, 1223, 21, 426, 8, 124, 215, 45, 5, 226, 420, 962, 1577, 81, 218, 1428, 4, 1223, 7, 366, 32002, 496, 62, 919, 18, 15, 64, 43, 1223, 7, 20, 944, 177, 2504, 398, 2, 158, 135, 154, 919, 14, 7, 5, 2785, 470, 1545, 15, 1596, 1911, 212, 79, 83, 805, 15, 8, 93, 38, 3599, 1888, 1596, 2785, 15, 6486, 14, 79, 83, 805, 11, 625, 5, 96, 1, 114, 7, 486, 28, 64, 43, 4, 465, 625, 7, 63, 824, 51, 10, 213, 27, 7, 1041, 581, 236, 51, 2, 18, 2890, 767, 294, 1043, 489, 23, 45, 4227, 2089, 3599, 10643, 273, 2, 286, 533, 329, 3, 96, 186, 164, 88, 27, 39, 385, 768, 6, 3898, 14296, 11, 1172, 269, 14, 1641, 269, 14, 2, 930, 175, 49, 2756, 20, 613, 1340, 2, 3373, 28, 33, 67, 296, 52, 63, 25, 10, 49, 66, 53, 48, 58, 39, 83, 233, 18, 2, 2647, 115, 25, 10, 33, 53, 48, 58, 27, 39, 67, 27, 962, 10, 1228, 149, 421, 5, 1721, 226, 420, 128, 447, 46, 99, 2, 693, 74, 802, 1806, 254, 5, 40286, 3, 150, 257, 40, 195, 1443]",1434.0,24764152,Phase II clinical erlotinib treatment myelodysplastic syndromes,7,0.012216404886561954
Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study.,Blood,Blood,2014-04-29,"Active cancer is the major predictor of venous thromboembolism (VTE) recurrence, but further stratification of recurrence risk is uncertain. In a population-based cohort study of all Olmsted County, Minnesota, residents with active cancer-related incident VTE during the 35-year period from 1966 to 2000 who survived 1 day or longer, we estimated VTE recurrence, bleeding on anticoagulant therapy, and survival and tested cancer and noncancer characteristics and secondary prophylaxis as predictors of VTE recurrence and bleeding, using Cox proportional hazards modeling. Of 477 patients, 139 developed recurrent VTE over the course of 1533 person-years of follow-up. The adjusted 10-year cumulative VTE recurrence rate was 28.6%. The adjusted 90-day cumulative incidence of major bleeding on anticoagulation was 1.9%. Survival was significantly worse for patients with cancer who had recurrent VTE (particularly pulmonary embolism) and with bleeding on anticoagulation. In a multivariable model, brain, lung, and ovarian cancer; myeloproliferative or myelodysplastic disorders; stage IV pancreatic cancer; other stage IV cancer; cancer stage progression; and leg paresis were associated with an increased hazard, and warfarin therapy was associated with a reduced hazard, of recurrent VTE. Recurrence rates were significantly higher for cancer patients with 1 or more vs no predictors of recurrence, suggesting these predictors may be useful for stratifying recurrence risk. ",Journal Article,2093.0,89.0,Active major predictor venous thromboembolism VTE recurrence stratification recurrence risk uncertain population-based cohort Olmsted County Minnesota residents active cancer-related incident VTE 35-year period 1966 2000 survived 1 day longer estimated VTE recurrence bleeding anticoagulant therapy survival tested noncancer characteristics secondary prophylaxis predictors VTE recurrence bleeding Cox proportional hazards modeling 477 patients 139 developed recurrent VTE course 1533 person-years follow-up adjusted 10-year cumulative VTE recurrence rate 28.6 adjusted 90-day cumulative incidence major bleeding anticoagulation 1.9 Survival significantly worse patients recurrent VTE particularly pulmonary embolism bleeding anticoagulation multivariable model brain lung ovarian myeloproliferative myelodysplastic disorders stage IV pancreatic stage IV stage progression leg paresis associated increased hazard warfarin therapy associated reduced hazard recurrent VTE Recurrence rates significantly higher patients 1 vs predictors recurrence suggesting predictors useful stratifying recurrence risk,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[544, 12, 16, 3, 458, 980, 1, 2167, 3501, 1779, 146, 84, 195, 1541, 1, 146, 43, 16, 2717, 4, 8, 266, 90, 180, 45, 1, 62, 12374, 5152, 8297, 5662, 5, 544, 12, 139, 2631, 1779, 190, 3, 465, 111, 727, 29, 11556, 6, 1081, 54, 2996, 14, 218, 15, 589, 21, 661, 1779, 146, 2294, 23, 8805, 36, 2, 25, 2, 650, 12, 2, 5994, 374, 2, 568, 2049, 22, 674, 1, 1779, 146, 2, 2294, 75, 418, 831, 1017, 2057, 1, 11810, 7, 4929, 276, 387, 1779, 252, 3, 906, 1, 27024, 2719, 60, 1, 166, 126, 3, 586, 79, 111, 967, 1779, 146, 116, 10, 339, 49, 3, 586, 424, 218, 967, 287, 1, 458, 2294, 23, 5361, 10, 14, 83, 25, 10, 97, 639, 9, 7, 5, 12, 54, 42, 387, 1779, 823, 1087, 5475, 2, 5, 2294, 23, 5361, 4, 8, 658, 202, 342, 2, 12, 15, 1997, 82, 478, 12, 127, 82, 478, 12, 12, 82, 91, 2, 10873, 20429, 11, 41, 5, 35, 101, 360, 2, 6748, 36, 10, 41, 5, 8, 405, 360, 1, 387, 1779, 146, 151, 11, 97, 142, 9, 12, 7, 5, 14, 15, 80, 105, 77, 674, 1, 146, 802, 46, 674, 68, 40, 999, 9, 5035, 146, 43]",1383.0,24782507,Predictors venous thromboembolism recurrence bleeding active patients population-based cohort,0,0.0
MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia.,Cancer cell,Cancer Cell,2014-05-01,"Recurring deletions of chromosome 7 and 7q [-7/del(7q)] occur in myelodysplastic syndromes and acute myeloid leukemia (AML) and are associated with poor prognosis. However, the identity of functionally relevant tumor suppressors on 7q remains unclear. Using RNAi and CRISPR/Cas9 approaches, we show that an 50% reduction in gene dosage of the mixed lineage leukemia 3 (MLL3) gene, located on 7q36.1, cooperates with other events occurring in -7/del(7q) AMLs to promote leukemogenesis. Mll3 suppression impairs the differentiation of HSPC. Interestingly, Mll3-suppressed leukemias, like human -7/del(7q) AMLs, are refractory to conventional chemotherapy but sensitive to the BET inhibitor JQ1. Thus, our mouse model functionally validates MLL3 as a haploinsufficient 7q tumor suppressor and suggests a therapeutic option for this aggressive disease. ",Journal Article,2091.0,145.0,Recurring deletions chromosome 7 7q -7/del 7q occur myelodysplastic syndromes acute myeloid leukemia AML associated poor prognosis identity functionally relevant suppressors 7q remains unclear RNAi CRISPR/Cas9 approaches 50 reduction dosage mixed lineage leukemia 3 MLL3 located 7q36.1 cooperates events occurring -7/del 7q AMLs promote leukemogenesis Mll3 suppression impairs differentiation HSPC Interestingly Mll3-suppressed leukemias like human -7/del 7q AMLs refractory conventional chemotherapy sensitive BET inhibitor JQ1 mouse model functionally validates MLL3 haploinsufficient 7q suppressor suggests therapeutic option aggressive disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6385, 2439, 1, 1170, 67, 2, 9723, 67, 3084, 9723, 1271, 4, 2040, 2, 286, 533, 329, 2, 32, 41, 5, 334, 356, 137, 3, 7710, 1, 3772, 867, 30, 5704, 23, 9723, 469, 1200, 75, 5881, 2, 7736, 9071, 611, 21, 514, 17, 35, 23911, 628, 4, 145, 3323, 1, 3, 1739, 2542, 27, 13433, 145, 2308, 23, 31772, 14, 12535, 5, 127, 281, 1821, 4, 67, 3084, 9723, 9542, 6, 1617, 5661, 13433, 1332, 8312, 3, 910, 1, 16490, 2873, 13433, 1908, 2792, 733, 171, 67, 3084, 9723, 9542, 32, 430, 6, 809, 56, 84, 745, 6, 3, 4661, 230, 10635, 631, 114, 830, 202, 3772, 11235, 13433, 22, 8, 15916, 9723, 30, 1245, 2, 844, 8, 189, 1501, 9, 26, 571, 34]",791.0,24794707,MLL3 haploinsufficient 7q suppressor acute myeloid leukemia,0,0.0
"Phase I trial of SAR103168, a novel multi-kinase inhibitor, in patients with refractory/relapsed acute leukemia or high-risk myelodysplastic syndrome.",Leukemia & lymphoma,Leuk. Lymphoma,2015-02-01,"There is no effective treatment for relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). We conducted a phase I dose escalation trial of SAR103168, a novel multi-targeted kinase inhibitor with activity against the Src kinase family, the BCR-Abl kinase and several angiogenic receptor kinases. Twenty-nine patients 18-83 years old were treated with SAR103168. Pharmacokinetics was characterized by plasma peak concentration (Cmax) at the end of the infusion, followed by a biphasic decline in the elimination profile. Adverse events were as expected for the patient population and there were no individual toxicities specific to SAR103168. Due to the unpredictable nature of drug exposure, the sponsor decided to discontinue the study prior to reaching the maximum tolerated dose.","Clinical Trial, Phase I",1815.0,2.0,effective treatment relapsed/refractory acute myeloid leukemia AML myelodysplastic syndrome MDS conducted phase dose escalation trial SAR103168 novel multi-targeted kinase inhibitor activity Src kinase family BCR-Abl kinase angiogenic receptor kinases Twenty-nine patients 18-83 years old treated SAR103168 Pharmacokinetics characterized plasma peak concentration Cmax end infusion followed biphasic decline elimination profile Adverse events expected patient population individual toxicities specific SAR103168 unpredictable nature drug exposure sponsor decided discontinue prior reaching maximum tolerated dose,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[125, 16, 77, 323, 24, 9, 591, 430, 286, 533, 329, 15, 681, 1223, 21, 426, 8, 124, 70, 61, 1125, 160, 1, 40717, 8, 229, 1414, 238, 216, 230, 5, 128, 480, 3, 2023, 216, 607, 3, 1062, 1425, 216, 2, 392, 2068, 153, 1549, 737, 762, 7, 203, 852, 60, 1095, 11, 73, 5, 40717, 1159, 10, 765, 20, 554, 2944, 1227, 9818, 28, 3, 396, 1, 3, 904, 370, 20, 8, 7739, 1858, 4, 3, 3730, 800, 290, 281, 11, 22, 1336, 9, 3, 69, 266, 2, 125, 11, 77, 797, 385, 112, 6, 40717, 520, 6, 3, 8907, 2202, 1, 234, 645, 3, 13677, 10561, 6, 7934, 3, 45, 324, 6, 6168, 3, 689, 421, 61]",769.0,24794806,Phase trial SAR103168 novel multi-kinase inhibitor patients refractory/relapsed acute leukemia high-risk myelodysplastic syndrome,4,0.006980802792321117
The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes.,Leukemia & lymphoma,Leuk. Lymphoma,2014-07-17,"Myelosuppression in myelodysplastic syndromes (MDS) is associated with the hypomethylating agent decitabine. A retrospective pooled analysis of two decitabine clinical trials in patients with MDS conducted Cox regression analyses of red blood cell or platelet dependence, myelosuppression, dose modification, cycle delay or dose reduction, and survival effects. In 182 patients, baseline platelet dependence was a predictor for dose modification, reduction or delay, and death (modification: p=0.006, hazard ratio [HR]=2.04; reduction/delay: p=0.011, HR=2.00; death: p=0.003, HR=1.94). Patients with dose modifications had significantly higher overall response rates versus those with none (22% vs. 10%; p=0.015). Patients with no dose modifications had faster progression to acute myeloid leukemia (AML) versus patients with dose modifications (p=0.004). Without dose modifications, patients tended to drop out due to disease progression or other reasons. Decitabine dose modifications on treatment may indicate response to treatment.",Journal Article,2014.0,6.0,Myelosuppression myelodysplastic syndromes MDS associated hypomethylating agent decitabine retrospective pooled decitabine clinical trials patients MDS conducted Cox regression red blood platelet dependence myelosuppression dose modification cycle delay dose reduction survival effects 182 patients baseline platelet dependence predictor dose modification reduction delay death modification p=0.006 hazard ratio HR =2.04 reduction/delay p=0.011 HR=2.00 death p=0.003 HR=1.94 Patients dose modifications significantly higher overall response rates versus 22 vs. 10 p=0.015 Patients dose modifications faster progression acute myeloid leukemia AML versus patients dose modifications p=0.004 dose modifications patients tended drop disease progression reasons Decitabine dose modifications treatment indicate response treatment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2858, 4, 2040, 1223, 16, 41, 5, 3, 4931, 420, 3004, 8, 459, 1830, 65, 1, 100, 3004, 38, 143, 4, 7, 5, 1223, 426, 418, 320, 318, 1, 3422, 315, 31, 15, 1596, 3721, 2858, 61, 2437, 417, 1984, 15, 61, 628, 2, 25, 176, 4, 5160, 7, 330, 1596, 3721, 10, 8, 980, 9, 61, 2437, 628, 15, 1984, 2, 273, 2437, 19, 13, 1861, 360, 197, 168, 18, 755, 628, 1984, 19, 13, 3651, 168, 18, 2038, 273, 19, 13, 1421, 168, 14, 960, 7, 5, 61, 2916, 42, 97, 142, 63, 51, 151, 185, 135, 5, 1292, 350, 105, 79, 19, 13, 3433, 7, 5, 77, 61, 2916, 42, 5308, 91, 6, 286, 533, 329, 185, 7, 5, 61, 2916, 19, 13, 1520, 187, 61, 2916, 7, 3886, 6, 7215, 1205, 520, 6, 34, 91, 15, 127, 2325, 3004, 61, 2916, 23, 24, 68, 1008, 51, 6, 24]",973.0,24844364,effect decitabine dose modification myelosuppression response survival patients myelodysplastic syndromes,3,0.005235602094240838
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2014-05-06,"We evaluated the characteristics of a cohort of patients with myelodysplastic syndrome (MDS) related to therapy (t-MDS) to create a prognostic model. We identified 281 patients with MDS who had received previous chemotherapy and/or radiotherapy for previous malignancy. Potential prognostic factors were determined using univariate and multivariate analyses. Multivariate Cox regression analysis identified 7 factors that independently predicted short survival in t-MDS: age 65 years (hazard ratio [HR], 1.63), Eastern Cooperative Oncology Group performance status 2-4 (HR, 1.86), poor cytogenetics (-7 and/or complex; HR, 2.47), World Health Organization MDS subtype (RARs or RAEB-1/2; HR, 1.92), hemoglobin (< 11 g/dL; HR, 2.24), platelets (< 50 10(9)/dL; HR, 2.01), and transfusion dependency (HR, 1.59). These risk factors were used to create a prognostic model that segregated patients into 3 groups with distinct median overall survival: good (0-2 risk factors; 34 months), intermediate (3-4 risk factors; 12 months), and poor (5-7 risk factors; 5 months) (P< .001) and 1-year leukemia-free survival (96%, 84%, and 72%, respectively, P= .003). This model also identified distinct survival groups according to t-MDS therapy. In summary, we devised a prognostic model specifically for patients with t-MDS that predicted overall survival and leukemia-free survival. This model might facilitate the development of risk-adapted therapeutic strategies.",Journal Article,2086.0,35.0,evaluated characteristics cohort patients myelodysplastic syndrome MDS related therapy t-MDS create prognostic model identified 281 patients MDS received previous chemotherapy and/or radiotherapy previous malignancy Potential prognostic factors determined univariate multivariate Multivariate Cox regression identified 7 factors independently predicted short survival t-MDS age  65 years hazard ratio HR 1.63 Eastern Cooperative Oncology Group performance status 2-4 HR 1.86 poor cytogenetics -7 and/or complex HR 2.47 World Health Organization MDS subtype RARs RAEB-1/2 HR 1.92 hemoglobin 11 g/dL HR 2.24 platelets 50 10 9 /dL HR 2.01 transfusion dependency HR 1.59 risk factors create prognostic model segregated patients 3 groups distinct median overall survival good 0-2 risk factors 34 months intermediate 3-4 risk factors 12 months poor 5-7 risk factors 5 months P .001 1-year leukemia-free survival 96 84 72 respectively P .003 model identified distinct survival groups according t-MDS therapy summary devised prognostic model specifically patients t-MDS predicted overall survival leukemia-free survival model facilitate development risk-adapted therapeutic strategies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 194, 3, 374, 1, 8, 180, 1, 7, 5, 681, 1223, 139, 6, 36, 102, 1223, 6, 3736, 8, 177, 202, 21, 108, 8970, 7, 5, 1223, 54, 42, 103, 698, 56, 2, 15, 310, 9, 698, 710, 174, 177, 130, 11, 509, 75, 880, 2, 331, 318, 331, 418, 320, 65, 108, 67, 130, 17, 1042, 783, 978, 25, 4, 102, 1223, 89, 749, 556, 60, 360, 197, 168, 14, 676, 2118, 1690, 413, 87, 528, 156, 18, 39, 168, 14, 868, 334, 2510, 67, 2, 15, 840, 168, 18, 662, 1956, 341, 2533, 1223, 875, 23114, 15, 20273, 14, 18, 168, 14, 937, 2222, 175, 499, 1826, 168, 18, 259, 4407, 212, 79, 83, 1826, 168, 18, 355, 2, 2785, 6359, 168, 14, 728, 46, 43, 130, 11, 95, 6, 3736, 8, 177, 202, 17, 11324, 7, 237, 27, 271, 5, 834, 52, 63, 25, 1178, 13, 18, 43, 130, 562, 53, 919, 27, 39, 43, 130, 133, 53, 2, 334, 33, 67, 43, 130, 33, 53, 19, 144, 2, 14, 111, 2647, 115, 25, 921, 874, 2, 720, 106, 19, 1421, 26, 202, 120, 108, 834, 25, 271, 768, 6, 102, 1223, 36, 4, 1962, 21, 10085, 8, 177, 202, 1225, 9, 7, 5, 102, 1223, 17, 783, 63, 25, 2, 2647, 115, 25, 26, 202, 822, 1876, 3, 193, 1, 43, 3716, 189, 422]",1362.0,24875590,prognostic model therapy-related myelodysplastic syndrome predicting survival transformation acute myeloid leukemia,161,0.28097731239092494
Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2014-06-02,"Reduced-intensity conditioning/nonmyeloablative conditioning regimens are increasingly used in allogeneic hematopoietic cell transplantation (HCT). Reports have shown CD34(+) dose to be important for transplantation outcome using myeloablative conditioning. The role of CD34(+) dose of peripheral blood progenitor cells (PBPC) has not been previously analyzed in a large population undergoing reduced-intensity conditioning/nonmyeloablative HCT. We studied 1054 patients, ages 45 to 75years, with acute myeloid leukemia or myelodysplastic syndrome who underwent transplantation between 2002 and 2011. Results of multivariate analysis showed that PBPC from HLA-matched siblings containing <410(6) CD34(+)/kg was associated with higher nonrelapse mortality (hazard ratio [HR], 2.03; P=.001), overall mortality (HR, 1.48; P=.008), and lower neutrophil (odds ratio [OR], .76; P=.03) and platelet (OR, .76; P=.03) recovery. PBPC from unrelated donors with CD34(+) dose < 610(6) CD34(+)/kg was also associated with higher nonrelapse (HR, 1.38; P=.02) and overall mortality (HR, 1.20; P=.05). In contrast to reports after myeloablative HCT, CD34(+) dose did not affect relapse or graft-versus-host disease with either donor type. An upper cell dose limit was not associated with adverse outcomes. These data suggest that PBPC CD34(+) doses >410(6) CD34(+)/kg and >610(6) CD34(+)/kg are optimal for HLA-matched sibling and unrelated donor HCT, respectively. ",Journal Article,2059.0,24.0,Reduced-intensity conditioning/nonmyeloablative conditioning regimens increasingly allogeneic hematopoietic transplantation HCT Reports shown CD34 dose important transplantation outcome myeloablative conditioning role CD34 dose peripheral blood progenitor PBPC previously large population undergoing reduced-intensity conditioning/nonmyeloablative HCT studied 1054 patients ages 45 75 years acute myeloid leukemia myelodysplastic syndrome underwent transplantation 2002 2011 multivariate showed PBPC HLA-matched siblings containing 4 10 6 CD34 /kg associated higher nonrelapse mortality hazard ratio HR 2.03 P .001 overall mortality HR 1.48 P .008 lower neutrophil odds ratio .76 P .03 platelet .76 P .03 recovery PBPC unrelated donors CD34 dose 6 10 6 CD34 /kg associated higher nonrelapse HR 1.38 P .02 overall mortality HR 1.20 P .05 contrast reports myeloablative HCT CD34 dose affect relapse graft-versus-host disease donor type upper dose limit associated adverse outcomes suggest PBPC CD34 doses 4 10 6 CD34 /kg 6 10 6 CD34 /kg optimal HLA-matched sibling unrelated donor HCT respectively,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[405, 837, 1933, 6094, 1933, 472, 32, 1635, 95, 4, 1063, 1007, 31, 497, 1085, 1198, 47, 443, 2215, 61, 6, 40, 305, 9, 497, 228, 75, 3246, 1933, 3, 200, 1, 2215, 61, 1, 672, 315, 2520, 37, 11537, 71, 44, 85, 373, 311, 4, 8, 375, 266, 479, 405, 837, 1933, 6094, 1085, 21, 656, 26764, 7, 2165, 512, 6, 481, 60, 5, 286, 533, 15, 681, 54, 208, 497, 59, 1544, 2, 1132, 99, 1, 331, 65, 224, 17, 11537, 29, 1160, 655, 2758, 1101, 39, 79, 49, 2215, 503, 10, 41, 5, 142, 4640, 282, 360, 197, 168, 18, 680, 19, 144, 63, 282, 168, 14, 576, 19, 2155, 2, 280, 2595, 610, 197, 15, 846, 19, 680, 2, 1596, 15, 846, 19, 680, 1602, 11537, 29, 2092, 2344, 5, 2215, 61, 49, 79, 49, 2215, 503, 10, 120, 41, 5, 142, 4640, 168, 14, 519, 19, 588, 2, 63, 282, 168, 14, 179, 19, 474, 4, 748, 6, 1198, 50, 3246, 1085, 2215, 61, 205, 44, 1158, 429, 15, 1599, 185, 1204, 34, 5, 361, 1488, 267, 35, 1726, 31, 61, 2385, 10, 44, 41, 5, 290, 123, 46, 74, 309, 17, 11537, 2215, 415, 39, 79, 49, 2215, 503, 2, 49, 79, 49, 2215, 503, 32, 665, 9, 1160, 655, 3684, 2, 2092, 1488, 1085, 106]",1350.0,24892261,Low CD34 dose associated poor survival reduced-intensity conditioning allogeneic transplantation acute myeloid leukemia myelodysplastic syndrome,9,0.015706806282722512
The clinical management of chronic myelomonocytic leukemia.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2014-03-01,"Chronic myelomonocytic leukemia (CMML) is an aggressive malignancy characterized by peripheral monocytosis and ineffective hematopoiesis. It has been historically classified as a subtype of the myelodysplastic syndromes (MDSs) but was recently demonstrated to be a distinct entity with a distinct natural history. Nonetheless, clinical practice guidelines for CMML have been inferred from studies designed for MDSs. It is imperative that clinicians understand which elements of MDS clinical practice are translatable to CMML, including which evidence has been generated from CMML-specific studies and which has not. This allows for an evidence-based approach to the treatment of CMML and identifies knowledge gaps in need of further study in a disease-specific manner. This review discusses the diagnosis, prognosis, and treatment of CMML, with the task of divorcing aspects of MDS practice that have not been demonstrated to be applicable to CMML and merging those that have been shown to be clinically similar. ",Journal Article,2152.0,14.0,Chronic myelomonocytic leukemia CMML aggressive malignancy characterized peripheral monocytosis ineffective hematopoiesis historically classified subtype myelodysplastic syndromes MDSs recently demonstrated distinct entity distinct natural history Nonetheless clinical practice guidelines CMML inferred studies designed MDSs imperative clinicians understand elements MDS clinical practice translatable CMML including evidence generated CMML-specific studies allows evidence-based approach treatment CMML identifies knowledge gaps need disease-specific manner review discusses diagnosis prognosis treatment CMML task divorcing aspects MDS practice demonstrated applicable CMML merging shown clinically similar,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 5451, 3382, 16, 35, 571, 710, 765, 20, 672, 16875, 2, 3957, 5114, 192, 71, 85, 3578, 1373, 22, 8, 875, 1, 3, 2040, 13550, 84, 10, 761, 264, 6, 40, 8, 834, 2983, 5, 8, 834, 1504, 532, 4648, 38, 758, 677, 9, 3382, 47, 85, 13782, 29, 94, 1114, 9, 13550, 192, 16, 6305, 17, 1490, 1640, 92, 2531, 1, 1223, 38, 758, 32, 19658, 6, 3382, 141, 92, 241, 71, 85, 1419, 29, 3382, 112, 94, 2, 92, 71, 44, 26, 2333, 9, 35, 241, 90, 353, 6, 3, 24, 1, 3382, 2, 2953, 922, 5287, 4, 594, 1, 195, 45, 4, 8, 34, 112, 1708, 26, 206, 2759, 3, 147, 356, 2, 24, 1, 3382, 5, 3, 3488, 1, 64512, 2695, 1, 1223, 758, 17, 47, 44, 85, 264, 6, 40, 3801, 6, 3382, 2, 20318, 135, 17, 47, 85, 443, 6, 40, 505, 288]",972.0,24927265,clinical management chronic myelomonocytic leukemia,30,0.05235602094240838
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.,British journal of haematology,Br. J. Haematol.,2014-07-04,"Reliable clinical or molecular predictors of benefit from azacitidine therapy in patients with myelodysplastic syndromes (MDS) are not defined. Doubling of platelet count at start of second cycle of azacitidine therapy compared to baseline was associated with achieving response and survival advantage in a Dutch cohort. To validate this observation, we analysed a larger cohort of North American patients, whose data was collected in a prospective clinical trial with a longer median follow-up. We found a significant association between platelet count doubling after first cycle of azacitidine therapy and probability of achieving objective response. Among patients with MDS or oligoblastic acute myeloid leukaemia (<30% bone marrow blasts, n = 102), there was a statistically significant reduction in risk of death for patients who achieved platelet count doubling (n = 23, median OS, 210 months) compared to those who did not (n = 79, median OS, 167 months, adjusted hazard ratio (no/yes)=188, 95% confidence interval, 103-340, P = 004). Nonetheless, the addition of this platelet count doubling variable did not improve the survival prediction provided by the revised International Prognostic Scoring System or the French Prognostic Scoring System. Identification of reliable and consistent predictors for clinical benefit for azacitidine therapy remains an unmet medical need and a top research priority.",Journal Article,2027.0,20.0,Reliable clinical molecular predictors benefit azacitidine therapy patients myelodysplastic syndromes MDS defined Doubling platelet count start second cycle azacitidine therapy compared baseline associated achieving response survival advantage Dutch cohort validate observation analysed larger cohort North American patients collected prospective clinical trial longer median follow-up significant association platelet count doubling cycle azacitidine therapy probability achieving objective response patients MDS oligoblastic acute myeloid leukaemia 30 bone marrow blasts n 102 statistically significant reduction risk death patients achieved platelet count doubling n 23 median OS 210 months compared n 79 median OS 167 months adjusted hazard ratio no/yes =188 95 confidence interval 103-340 P 004 Nonetheless addition platelet count doubling variable improve survival prediction provided revised International Prognostic Scoring French Prognostic Scoring Identification reliable consistent predictors clinical benefit azacitidine therapy remains unmet medical need research priority,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2450, 38, 15, 219, 674, 1, 247, 29, 3752, 36, 4, 7, 5, 2040, 1223, 32, 44, 395, 4342, 1, 1596, 1276, 28, 2435, 1, 419, 417, 1, 3752, 36, 72, 6, 330, 10, 41, 5, 1785, 51, 2, 25, 1874, 4, 8, 19120, 180, 6, 2183, 26, 1664, 21, 3141, 8, 1077, 180, 1, 2669, 597, 7, 1310, 74, 10, 786, 4, 8, 482, 38, 160, 5, 8, 589, 52, 166, 126, 21, 204, 8, 93, 248, 59, 1596, 1276, 4342, 50, 157, 417, 1, 3752, 36, 2, 1320, 1, 1785, 461, 51, 107, 7, 5, 1223, 15, 47053, 286, 533, 2001, 201, 581, 2438, 78, 2867, 125, 10, 8, 712, 93, 628, 4, 43, 1, 273, 9, 7, 54, 513, 1596, 1276, 4342, 78, 382, 52, 118, 40426, 53, 72, 6, 135, 54, 205, 44, 78, 842, 52, 118, 35836, 53, 586, 360, 197, 77, 7073, 48464, 48, 307, 268, 19351, 40772, 19, 22633, 4648, 3, 352, 1, 26, 1596, 1276, 4342, 1347, 205, 44, 401, 3, 25, 1590, 1052, 20, 3, 4218, 944, 177, 2504, 398, 15, 3, 9254, 177, 2504, 398, 911, 1, 2450, 2, 925, 674, 9, 38, 247, 9, 3752, 36, 469, 35, 3715, 484, 594, 2, 8, 3150, 389, 4690]",1355.0,24995683,Platelet count doubling cycle azacitidine therapy predicts eventual response survival patients myelodysplastic syndromes oligoblastic acute myeloid leukaemia add prognostic utility revised IPSS,10,0.017452006980802792
Genetic alterations of the cohesin complex genes in myeloid malignancies.,Blood,Blood,2014-07-08,"Somatic cohesin mutations have been reported in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). To account for the morphologic and cytogenetic diversity of these neoplasms, a well-annotated cohort of 1060 patients with myeloid malignancies including MDS (n = 386), myeloproliferative neoplasms (MPNs) (n = 55), MDS/MPNs (n = 169), and AML (n = 450) were analyzed for cohesin gene mutational status, gene expression, and therapeutic and survival outcomes. Somatic cohesin defects were detected in 12% of patients with myeloid malignancies, whereas low expression of these genes was present in an additional 15% of patients. Mutations of cohesin genes were mutually exclusive and mostly resulted in predicted loss of function. Patients with low cohesin gene expression showed similar expression signatures as those with somatic cohesin mutations. Cross-sectional deep-sequencing analysis for clonal hierarchy demonstrated STAG2, SMC3, and RAD21 mutations to be ancestral in 18%, 18%, and 47% of cases, respectively, and each expanded to clonal dominance concordant with disease transformation. Cohesin mutations were significantly associated with RUNX1, Ras-family oncogenes, and BCOR and ASXL1 mutations and were most prevalent in high-risk MDS and secondary AML. Cohesin defects were associated with poor overall survival (27.2 vs 40 months; P = .023), especially in STAG2 mutant MDS patients surviving >12 months (median survival 35 vs 50 months; P = .017). ",Clinical Trial,2023.0,100.0,Somatic cohesin reported myelodysplastic syndrome MDS acute myeloid leukemia AML account morphologic cytogenetic diversity neoplasms well-annotated cohort 1060 patients myeloid malignancies including MDS n 386 myeloproliferative neoplasms MPNs n 55 MDS/MPNs n 169 AML n 450 cohesin status expression therapeutic survival outcomes Somatic cohesin defects detected 12 patients myeloid malignancies low expression present additional 15 patients cohesin mutually exclusive resulted predicted loss function Patients low cohesin expression showed similar expression signatures somatic cohesin Cross-sectional deep-sequencing clonal hierarchy demonstrated STAG2 SMC3 RAD21 ancestral 18 18 47 cases respectively expanded clonal dominance concordant disease transformation Cohesin significantly associated RUNX1 Ras-family oncogenes BCOR ASXL1 prevalent high-risk MDS secondary AML Cohesin defects associated poor overall survival 27.2 vs 40 months P .023 especially STAG2 MDS patients surviving 12 months median survival 35 vs 50 months P .017,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1119, 17033, 138, 47, 85, 210, 4, 681, 1223, 2, 286, 533, 329, 6, 1967, 9, 3, 2815, 2, 1266, 3653, 1, 46, 1179, 8, 149, 6196, 180, 1, 31885, 7, 5, 533, 441, 141, 1223, 78, 7567, 1179, 6880, 78, 614, 1223, 6880, 78, 5436, 2, 329, 78, 5669, 11, 311, 9, 17033, 145, 1619, 156, 145, 55, 2, 189, 2, 25, 123, 1119, 17033, 2945, 11, 530, 4, 133, 1, 7, 5, 533, 441, 547, 154, 55, 1, 46, 214, 10, 364, 4, 35, 402, 167, 1, 7, 138, 1, 17033, 214, 11, 5575, 4804, 2, 2754, 627, 4, 783, 407, 1, 343, 7, 5, 154, 17033, 145, 55, 224, 288, 55, 2210, 22, 135, 5, 1119, 17033, 138, 1383, 2832, 2369, 615, 65, 9, 1946, 12517, 264, 15439, 40777, 2, 46579, 138, 6, 40, 15165, 4, 203, 203, 2, 662, 1, 140, 106, 2, 296, 2064, 6, 1946, 16402, 3610, 5, 34, 1392, 17033, 138, 11, 97, 41, 5, 6092, 1102, 607, 3326, 2, 8900, 2, 7782, 138, 2, 11, 96, 2485, 4, 64, 43, 1223, 2, 568, 329, 17033, 2945, 11, 41, 5, 334, 63, 25, 428, 18, 105, 327, 53, 19, 4482, 1093, 4, 15439, 620, 1223, 7, 3050, 133, 53, 52, 25, 465, 105, 212, 53, 19, 3825]",1369.0,25006131,Genetic alterations cohesin complex myeloid malignancies,55,0.09598603839441536
Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experience.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2014-06-10,"Cytogenetic abnormalities have a significant prognostic effect in many hematologic neoplasms. Monosomal karyotype (MK), a newly recognized cytogenetic category, has been reported to be a marker of poor prognosis in patients with myelodysplastic syndromes and myelofibrosis, but its effect in chronic myelomonocytic leukemia (CMML) remains relatively unknown. A retrospective study of cases diagnosed with CMML found a total of 262 patients. Patient characteristics, cytogenetic data, and survival were analyzed. Cytogenetic analysis found diploidy in 167 patients (64%). Trisomy 8 was the most frequent cytogenetic abnormality at 8% (22), followed by complex karyotype (CK) at 5% (14), (-)7 at 4% (10), and MK at 3% (7, of which 6 [86%] were also CK). Median overall survival was statistically significantly worse in MK-positive cases than in MK-negative cases (MK(+) vs. MK(-)). Patients with MK(+) only or CK(+)MK(+) did worse than any other group. MK is a rare entity but can predict statistically significantly shorter overall survival among all other cytogenetic categories.",Journal Article,2051.0,6.0,Cytogenetic abnormalities significant prognostic effect hematologic neoplasms Monosomal karyotype MK newly recognized cytogenetic category reported marker poor prognosis patients myelodysplastic syndromes myelofibrosis effect chronic myelomonocytic leukemia CMML remains relatively unknown retrospective cases diagnosed CMML total 262 patients Patient characteristics cytogenetic survival Cytogenetic diploidy 167 patients 64 Trisomy 8 frequent cytogenetic abnormality 8 22 followed complex karyotype CK 5 14 7 4 10 MK 3 7 6 86 CK Median overall survival statistically significantly worse MK-positive cases MK-negative cases MK vs. MK Patients MK CK MK worse group MK rare entity predict statistically significantly shorter overall survival cytogenetic categories,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1266, 1171, 47, 8, 93, 177, 254, 4, 445, 813, 1179, 22660, 3385, 3558, 8, 732, 1904, 1266, 2169, 71, 85, 210, 6, 40, 8, 952, 1, 334, 356, 4, 7, 5, 2040, 2, 4637, 84, 211, 254, 4, 442, 5451, 3382, 469, 1352, 860, 8, 459, 45, 1, 140, 265, 5, 3382, 204, 8, 181, 1, 7801, 7, 69, 374, 1266, 74, 2, 25, 11, 311, 1266, 65, 204, 19586, 4, 5431, 7, 660, 6317, 66, 10, 3, 96, 908, 1266, 3698, 28, 66, 350, 370, 20, 840, 3385, 4925, 28, 33, 213, 67, 28, 39, 79, 2, 3558, 28, 27, 67, 1, 92, 49, 868, 11, 120, 4925, 52, 63, 25, 10, 712, 97, 639, 4, 3558, 109, 140, 76, 4, 3558, 199, 140, 3558, 105, 3558, 7, 5, 3558, 158, 15, 4925, 3558, 205, 639, 76, 500, 127, 87, 3558, 16, 8, 622, 2983, 84, 122, 678, 712, 97, 985, 63, 25, 107, 62, 127, 1266, 1996]",993.0,25027568,Monosomal karyotype predicts adverse prognosis patients diagnosed chronic myelomonocytic leukemia single-institution experience,0,0.0
De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with 30% blasts in older adults: a Bone Marrow Pathology Group study.,American journal of hematology,Am. J. Hematol.,2014-07-31,"It is controversial whether acute myeloid leukemia (AML) patients with 20-29% bone marrow (BM) blasts, formerly referred to as refractory anemia with excess blasts in transformation (RAEBT), should be considered AML or myelodysplastic syndrome (MDS) for the purposes of treatment and prognostication. We retrospectively studied 571 de novo AML in patients aged >50 years, including 142 RAEBT and 429 with 30% blasts (AML30), as well as 151 patients with 10-19% BM blasts (RAEB2). RAEBT patients were older and had lower white blood count, but higher hemoglobin, platelet count, and karyotype risk scores compared to AML30, while these features were similar to RAEB2. FLT3 and NPM1 mutations and monocytic morphology occurred more commonly in AML30 than in RAEBT. RAEBT patients were treated less often with induction therapy than AML30, whereas allogeneic stem cell transplant frequency was similar. The median and 4-year OS of RAEBT patients were longer than those of AML30 patients (20.5 vs 12.0 months and 28.6% vs 20.4%, respectively, P=0.003); this difference in OS was manifested in patients in the intermediate UKMRC karyotype risk group, whereas OS of RAEBT patients and AML30 patients in the adverse karyotype risk group were not significantly different. Multivariable analysis showed that RAEBT (P<0.0001), hemoglobin (P=0.005), UKMRC karyotype risk group (P=0.002), normal BM karyotype (P=0.004), treatment with induction therapy (P<0.0001), and stem cell transplant (P<0.0001) were associated with longer OS. Our findings favor considering de novo RAEBT as a favorable prognostic subgroup of AML.",Comparative Study,2000.0,,controversial acute myeloid leukemia AML patients 20-29 bone marrow BM blasts referred refractory anemia excess blasts transformation RAEBT considered AML myelodysplastic syndrome MDS purposes treatment prognostication retrospectively studied 571 novo AML patients aged 50 years including 142 RAEBT 429 30 blasts AML30 151 patients 10-19 BM blasts RAEB2 RAEBT patients older lower white blood count higher hemoglobin platelet count karyotype risk scores compared AML30 features similar RAEB2 FLT3 NPM1 monocytic morphology occurred commonly AML30 RAEBT RAEBT patients treated induction therapy AML30 allogeneic stem transplant frequency similar median 4-year OS RAEBT patients longer AML30 patients 20.5 vs 12.0 months 28.6 vs 20.4 respectively P 0.003 difference OS manifested patients intermediate UKMRC karyotype risk group OS RAEBT patients AML30 patients adverse karyotype risk group significantly different Multivariable showed RAEBT P 0.0001 hemoglobin P 0.005 UKMRC karyotype risk group P 0.002 normal BM karyotype P 0.004 treatment induction therapy P 0.0001 stem transplant P 0.0001 associated longer OS findings favor considering novo RAEBT favorable prognostic subgroup AML,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[192, 16, 2010, 317, 286, 533, 329, 7, 5, 179, 462, 581, 1246, 2438, 7350, 1995, 6, 22, 430, 1545, 5, 2612, 2438, 4, 1392, 21123, 257, 40, 515, 329, 15, 681, 1223, 9, 3, 4624, 1, 24, 2, 4260, 21, 894, 656, 7846, 1566, 2018, 329, 4, 7, 1032, 212, 60, 141, 4785, 21123, 2, 8406, 5, 7783, 2438, 29589, 22, 149, 22, 5075, 7, 5, 79, 326, 1246, 2438, 34782, 21123, 7, 11, 434, 2, 42, 280, 886, 315, 1276, 84, 142, 2222, 1596, 1276, 2, 3385, 43, 703, 72, 6, 29589, 369, 46, 404, 11, 288, 6, 34782, 1224, 2, 4318, 138, 2, 9003, 2567, 489, 80, 841, 4, 29589, 76, 4, 21123, 21123, 7, 11, 73, 299, 629, 5, 504, 36, 76, 29589, 547, 1063, 452, 31, 941, 675, 10, 288, 3, 52, 2, 39, 111, 118, 1, 21123, 7, 11, 589, 76, 135, 1, 29589, 7, 179, 33, 105, 133, 13, 53, 2, 339, 49, 105, 179, 39, 106, 19, 13, 1421, 26, 523, 4, 118, 10, 6023, 4, 7, 4, 3, 919, 48483, 3385, 43, 87, 547, 118, 1, 21123, 7, 2, 29589, 7, 4, 3, 290, 3385, 43, 87, 11, 44, 97, 338, 658, 65, 224, 17, 21123, 19, 13, 488, 2222, 19, 13, 1614, 48483, 3385, 43, 87, 19, 13, 1111, 295, 1246, 3385, 19, 13, 1520, 24, 5, 504, 36, 19, 13, 488, 2, 452, 31, 941, 19, 13, 488, 11, 41, 5, 589, 118, 114, 272, 4283, 3075, 1566, 2018, 21123, 22, 8, 913, 177, 1363, 1, 329]",1521.0,25042343,novo acute myeloid leukemia 20-29 blasts aggressive acute myeloid leukemia 30 blasts older adults Bone Marrow Pathology Group,12,0.020942408376963352
Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2014-07-17,"We examined risk of second solid cancers after allogeneic hematopoietic cell transplantation (AHCT) using reduced-intensity/nonmyeloablative conditioning (RIC/NMC). RIC/NMC recipients with leukemia/myelodysplastic syndrome (MDS) (n = 2833) and lymphoma (n = 1436) between 1995 and 2006 were included. In addition, RIC/NMC recipients 40 to 60 years of age (n = 2138) were compared with patients of the same age receiving myeloablative conditioning (MAC, n = 6428). The cumulative incidence of solid cancers was 3.35% at 10 years. There was no increase in overall cancer risk compared with the general population (leukemia/MDS: standardized incidence ratio [SIR] .99, P = 1.00; lymphoma: SIR .92, P = .75). However, risks were significantly increased in leukemia/MDS patients for cancers of lip (SIR 14.28), tonsil (SIR 8.66), oropharynx (SIR 46.70), bone (SIR 23.53), soft tissue (SIR 12.92), and vulva (SIR 18.55) and skin melanoma (SIR 3.04). Lymphoma patients had significantly higher risks of oropharyngeal cancer (SIR 67.35) and skin melanoma (SIR 3.52). Among RIC/NMC recipients, age >50 years was the only independent risk factor for solid cancers (hazard ratio [HR] 3.02, P < .001). Among patients ages 40 to 60 years, when adjusted for other factors, there was no difference in cancer risks between RIC/NMC and MAC in leukemia/MDS patients (HR .98, P = .905). In lymphoma patients, risks were lower after RIC/NMC (HR .51, P = .047). In conclusion, the overall risks of second solid cancers in RIC/NMC recipients are similar to the general population, although there is an increased risk of cancer at some sites. Studies with longer follow-up are needed to realize the complete risks of solid cancers after RIC/NMC AHCT.",Journal Article,2014.0,31.0,examined risk second solid allogeneic hematopoietic transplantation AHCT reduced-intensity/nonmyeloablative conditioning RIC/NMC RIC/NMC recipients leukemia/myelodysplastic syndrome MDS n 2833 lymphoma n 1436 1995 2006 included addition RIC/NMC recipients 40 60 years age n 2138 compared patients age receiving myeloablative conditioning MAC n 6428 cumulative incidence solid 3.35 10 years increase overall risk compared general population leukemia/MDS standardized incidence ratio SIR .99 P 1.00 lymphoma SIR .92 P .75 risks significantly increased leukemia/MDS patients lip SIR 14.28 tonsil SIR 8.66 oropharynx SIR 46.70 bone SIR 23.53 soft tissue SIR 12.92 vulva SIR 18.55 skin melanoma SIR 3.04 Lymphoma patients significantly higher risks oropharyngeal SIR 67.35 skin melanoma SIR 3.52 RIC/NMC recipients age 50 years independent risk factor solid hazard ratio HR 3.02 P .001 patients ages 40 60 years adjusted factors difference risks RIC/NMC MAC leukemia/MDS patients HR .98 P .905 lymphoma patients risks lower RIC/NMC HR .51 P .047 overall risks second solid RIC/NMC recipients similar general population increased risk sites Studies longer follow-up needed realize complete risks solid RIC/NMC AHCT,0,0,1,0,0,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[21, 409, 43, 1, 419, 537, 163, 50, 1063, 1007, 31, 497, 5714, 75, 405, 837, 6094, 1933, 3365, 11526, 3365, 11526, 2190, 5, 2647, 10589, 681, 1223, 78, 48484, 2, 78, 35849, 59, 2323, 2, 1324, 11, 159, 4, 352, 3365, 11526, 2190, 327, 6, 335, 60, 1, 89, 78, 64636, 11, 72, 5, 7, 1, 3, 827, 89, 357, 3246, 1933, 7492, 78, 64637, 3, 967, 287, 1, 537, 163, 10, 27, 465, 28, 79, 60, 125, 10, 77, 344, 4, 63, 12, 43, 72, 5, 3, 1083, 266, 2647, 1223, 1670, 287, 197, 3636, 1058, 19, 14, 2038, 3636, 937, 19, 481, 137, 1098, 11, 97, 101, 4, 2647, 1223, 7, 9, 163, 1, 13489, 3636, 213, 339, 10226, 3636, 66, 700, 5333, 3636, 641, 431, 3636, 382, 699, 1214, 246, 3636, 133, 937, 2, 9263, 3636, 203, 614, 2, 3636, 27, 755, 7, 42, 97, 142, 1098, 1, 12, 3636, 598, 465, 2, 3636, 27, 653, 107, 3365, 11526, 2190, 89, 212, 60, 10, 3, 158, 306, 43, 161, 9, 537, 163, 360, 197, 168, 27, 588, 19, 144, 107, 7, 2165, 327, 6, 335, 60, 198, 586, 9, 127, 130, 125, 10, 77, 523, 4, 12, 1098, 59, 3365, 11526, 2, 7492, 4, 2647, 1223, 7, 168, 1096, 19, 13300, 4, 7, 1098, 11, 280, 50, 3365, 11526, 168, 725, 19, 5296, 4, 1221, 3, 63, 1098, 1, 419, 537, 163, 4, 3365, 11526, 2190, 32, 288, 6, 3, 1083, 266, 242, 125, 16, 35, 101, 43, 1, 12, 28, 476, 633, 94, 5, 589, 166, 126, 32, 575, 6, 13020, 3, 236, 1098, 1, 537, 163, 50, 3365, 11526, 5714]",1546.0,25042734,Second solid allogeneic hematopoietic transplantation reduced-intensity conditioning,25,0.04363001745200698
"Myeloid neoplasms after breast cancer: ""therapy-related"" not an independent poor prognostic factor.",Leukemia & lymphoma,Leuk. Lymphoma,2014-08-13,"Two hundred and thirty-five consecutive patients presenting to a single center with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after breast cancer treatment were compared with matched patients with de novo AML or MDS. There was no significant difference in median overall survival (OS) times between patients with therapy-related AML and those with de novo AML (8.7 months vs.10.2 months; p = 0.17). Patients with therapy-related MDS had slightly lower median baseline platelet counts and a higher frequency of poor cytogenetics than those with de novo MDS, but the two groups had similar OS times (13.6 months vs. 18.9 months; p = 0.06). Multivariate analysis revealed that cytogenetic risk, baseline white blood cell count, age and performance status were predictive for OS time in AML and that cytogenetic risk and performance status were predictive for OS time in MDS. Having therapy-related disease is not an independent risk factor in patients with myeloid neoplasms and with a history of breast cancer. Clinical trials should be designed to serve both populations. ",Journal Article,1987.0,10.0,thirty-five consecutive patients presenting single center acute myeloid leukemia AML myelodysplastic syndrome MDS breast treatment compared matched patients novo AML MDS significant difference median overall survival OS times patients therapy-related AML novo AML 8.7 months vs.10.2 months p 0.17 Patients therapy-related MDS slightly lower median baseline platelet counts higher frequency poor cytogenetics novo MDS groups similar OS times 13.6 months vs. 18.9 months p 0.06 Multivariate revealed cytogenetic risk baseline white blood count age performance status predictive OS time AML cytogenetic risk performance status predictive OS time MDS therapy-related disease independent risk factor patients myeloid neoplasms history breast Clinical trials designed serve populations,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[100, 1128, 2, 977, 365, 935, 7, 1656, 6, 8, 226, 574, 5, 286, 533, 329, 15, 681, 1223, 50, 12, 24, 11, 72, 5, 655, 7, 5, 1566, 2018, 329, 15, 1223, 125, 10, 77, 93, 523, 4, 52, 63, 25, 118, 1072, 59, 7, 5, 36, 139, 329, 2, 135, 5, 1566, 2018, 329, 66, 67, 53, 105, 79, 18, 53, 19, 13, 269, 7, 5, 36, 139, 1223, 42, 3223, 280, 52, 330, 1596, 1911, 2, 8, 142, 675, 1, 334, 2510, 76, 135, 5, 1566, 2018, 1223, 84, 3, 100, 271, 42, 288, 118, 1072, 233, 49, 53, 105, 203, 83, 53, 19, 13, 1460, 331, 65, 553, 17, 1266, 43, 330, 886, 315, 31, 1276, 89, 2, 528, 156, 11, 464, 9, 118, 98, 4, 329, 2, 17, 1266, 43, 2, 528, 156, 11, 464, 9, 118, 98, 4, 1223, 1041, 36, 139, 34, 16, 44, 35, 306, 43, 161, 4, 7, 5, 533, 1179, 2, 5, 8, 532, 1, 12, 38, 143, 257, 40, 1114, 6, 1833, 110, 1184]",1027.0,25048874,Myeloid neoplasms breast `` therapy-related '' independent poor prognostic factor,15,0.02617801047120419
Acute myeloid leukemia and myelodysplastic syndromes in older adults.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2014-08-01,"Treatment of older adults with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) is challenging because of disease morbidity and associated treatments. Both diseases represent a genetically heterogeneous group of disorders primarily affecting older adults, with treatment strategies ranging from supportive care to hematopoietic stem-cell transplantation. Although selected older adults can benefit from intensive therapies, as a group they experience increased treatment-related morbidity, are more likely to relapse, and have decreased survival. Age-related outcome disparities are attributed to both tumor and patient characteristics, requiring an individualized approach to treatment decision making beyond consideration of chronologic age alone. Selection of therapy for any individual requires consideration of both disease-specific risk factors and estimates of treatment tolerance and life expectancy derived from evaluation of functional status and comorbidity. Although treatment options for older adults are expanding, clinical trials accounting for the heterogeneity of tumor biology and aging are needed to define standard-of-care treatments for both disease groups. In addition, trials should include outcomes addressing quality of life, maintenance of independence, and use of health care services to assist in patient-centered decision making. This review will highlight available evidence in treatment of older adults with AML or MDS and unanswered clinical questions for older adults with these diseases.",Journal Article,1999.0,52.0,Treatment older adults acute myeloid leukemia AML myelodysplastic syndromes MDS challenging disease morbidity associated treatments diseases represent genetically heterogeneous group disorders primarily affecting older adults treatment strategies ranging supportive care hematopoietic stem-cell transplantation selected older adults benefit intensive therapies group experience increased treatment-related morbidity likely relapse decreased survival Age-related outcome disparities attributed patient characteristics requiring individualized approach treatment decision making consideration chronologic age Selection therapy individual requires consideration disease-specific risk factors estimates treatment tolerance life expectancy derived evaluation functional status comorbidity treatment options older adults expanding clinical trials accounting heterogeneity aging needed define standard-of-care treatments disease groups addition trials include outcomes addressing quality life maintenance independence use health care services assist patient-centered decision making review highlight available evidence treatment older adults AML MDS unanswered clinical questions older adults diseases,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[24, 1, 434, 857, 5, 286, 533, 329, 15, 2040, 1223, 16, 1950, 408, 1, 34, 787, 2, 41, 640, 110, 1342, 1231, 8, 2301, 1564, 87, 1, 1997, 1561, 2319, 434, 857, 5, 24, 422, 2223, 29, 1877, 165, 6, 1007, 452, 31, 497, 242, 715, 434, 857, 122, 247, 29, 1686, 235, 22, 8, 87, 491, 730, 101, 24, 139, 787, 32, 80, 322, 6, 429, 2, 47, 340, 25, 89, 139, 228, 2227, 32, 3073, 6, 110, 30, 2, 69, 374, 1888, 35, 2596, 353, 6, 24, 948, 1079, 1654, 2415, 1, 18435, 89, 279, 881, 1, 36, 9, 500, 797, 1706, 2415, 1, 110, 34, 112, 43, 130, 2, 1423, 1, 24, 2614, 2, 358, 3399, 526, 29, 451, 1, 583, 156, 2, 1879, 242, 24, 838, 9, 434, 857, 32, 4304, 38, 143, 3116, 9, 3, 1144, 1, 30, 891, 2, 4220, 32, 575, 6, 1107, 260, 1, 165, 640, 9, 110, 34, 271, 4, 352, 143, 257, 643, 123, 3432, 372, 1, 358, 1146, 1, 5773, 2, 119, 1, 341, 165, 2142, 6, 3425, 4, 69, 4846, 948, 1079, 26, 206, 303, 1817, 390, 241, 4, 24, 1, 434, 857, 5, 329, 15, 1223, 2, 7550, 38, 1937, 9, 434, 857, 5, 46, 1342]",1490.0,25071138,Acute myeloid leukemia myelodysplastic syndromes older adults,148,0.2582897033158813
"Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia.","Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2014-07-15,"Patients with multiple myeloma (MM) have had significant improvements in outcomes. An increased risk of therapy-related myeloid neoplasms (t-MNs) has also developed. Little is known about the characteristics and outcomes of these patients. Patients with MM treated at our institution from 1993 to 2011 were reviewed. Forty-seven patients were diagnosed with t-MN. Our primary objective was to evaluate the interval to t-MN, response to treatment, and overall survival (OS). The median patient age at the MM diagnosis was 65 years. Of the 47 patients, 32 (68.0%) initially received conventional chemotherapeutic agents, 7 (14.9%), novel agents (eg, lenalidomide, thalidomide, bortezomib), and 8 (17.0%), a combination. Twenty patients (42.6%) underwent high-dose chemotherapy and autologous hematopoietic stem cell transplantation. The median interval from the MM diagnosis to t-MN was 7 years (95% CI, 5.0-28.0). Of the 47 patients, 33 (70.2%) developed therapy-related myelodysplastic syndrome (t-MDS), 11 (23.4%) acute myeloid leukemia (t-AML), and 3 (6.4%) chronic myelomonocytic leukemia (t-CMML). The median age at the t-MN diagnosis was 65 years. Of the 47 patients, 26 (78.8%) with t-MDS, 9 (81.8%) with t-AML, and 1 (33.3%) with t-CMML had complex/high-risk cytogenetics. The median OS for all 47 patients after the t-MN diagnosis was 6.3 months (95% CI, 4.0-8.7). The development of t-MN in patients with MM is associated with poor outcomes. These patients, in general, have complex cytogenetic abnormalities and short complete remission and OS times. A better understanding of the disease biology and novel therapeutic approaches are warranted.",Journal Article,2016.0,18.0,Patients multiple myeloma MM significant improvements outcomes increased risk therapy-related myeloid neoplasms t-MNs developed Little known characteristics outcomes patients Patients MM treated institution 1993 2011 reviewed Forty-seven patients diagnosed t-MN primary objective evaluate interval t-MN response treatment overall survival OS median patient age MM diagnosis 65 years 47 patients 32 68.0 initially received conventional chemotherapeutic agents 7 14.9 novel agents lenalidomide thalidomide bortezomib 8 17.0 combination patients 42.6 underwent high-dose chemotherapy autologous hematopoietic stem transplantation median interval MM diagnosis t-MN 7 years 95 CI 5.0-28.0 47 patients 33 70.2 developed therapy-related myelodysplastic syndrome t-MDS 11 23.4 acute myeloid leukemia t-AML 3 6.4 chronic myelomonocytic leukemia t-CMML median age t-MN diagnosis 65 years 47 patients 26 78.8 t-MDS 9 81.8 t-AML 1 33.3 t-CMML complex/high-risk cytogenetics median OS 47 patients t-MN diagnosis 6.3 months 95 CI 4.0-8.7 development t-MN patients MM associated poor outcomes patients general complex cytogenetic abnormalities short complete remission OS times better understanding disease novel therapeutic approaches warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7, 5, 232, 321, 47, 42, 93, 1474, 4, 123, 35, 101, 43, 1, 36, 139, 533, 1179, 102, 17539, 71, 120, 276, 1215, 16, 440, 545, 3, 374, 2, 123, 1, 46, 7, 7, 5, 321, 73, 28, 114, 731, 29, 3343, 6, 1132, 11, 446, 1213, 648, 7, 11, 265, 5, 102, 4691, 114, 86, 461, 10, 6, 376, 3, 268, 6, 102, 4691, 51, 6, 24, 2, 63, 25, 118, 3, 52, 69, 89, 28, 3, 321, 147, 10, 556, 60, 1, 3, 662, 7, 531, 806, 13, 1625, 103, 809, 1573, 183, 67, 213, 83, 229, 183, 2887, 1288, 2159, 819, 2, 66, 269, 13, 8, 150, 737, 7, 595, 49, 208, 64, 61, 56, 2, 1028, 1007, 452, 31, 497, 3, 52, 268, 29, 3, 321, 147, 6, 102, 4691, 10, 67, 60, 48, 58, 33, 13, 339, 13, 1, 3, 662, 7, 466, 431, 18, 276, 36, 139, 681, 102, 1223, 175, 382, 39, 286, 533, 102, 329, 2, 27, 49, 39, 442, 5451, 102, 3382, 3, 52, 89, 28, 3, 102, 4691, 147, 10, 556, 60, 1, 3, 662, 7, 432, 833, 66, 5, 102, 1223, 83, 865, 66, 5, 102, 329, 2, 14, 466, 27, 5, 102, 3382, 42, 840, 64, 43, 2510, 3, 52, 118, 9, 62, 662, 7, 50, 3, 102, 4691, 147, 10, 49, 27, 53, 48, 58, 39, 13, 66, 67, 3, 193, 1, 102, 4691, 4, 7, 5, 321, 16, 41, 5, 334, 123, 46, 7, 4, 1083, 47, 840, 1266, 1171, 2, 978, 236, 734, 2, 118, 1072, 8, 380, 612, 1, 3, 34, 891, 2, 229, 189, 611, 32, 1197]",1525.0,25107338,Characteristics outcomes patients multiple myeloma develop therapy-related myelodysplastic syndrome chronic myelomonocytic leukemia acute myeloid leukemia,490,0.8551483420593369
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide.,Leukemia & lymphoma,Leuk. Lymphoma,2014-11-03,"The incidence and pattern of secondary neoplasms in patients with acute promyelocytic leukemia (APL) treated with all-trans retinoic acid (ATRA)-containing regimens is not well described. We compared 160 patients with APL treated with ATRA plus idarubicin (n = 54) or ATRA plus arsenic trioxide (ATO) (n = 106) for the incidence of secondary cancers per unit time of follow-up. Median follow-up times for the two cohorts were 136 and 29 months, respectively. Nine patients developed secondary cancers in the chemotherapy group. These included two breast cancers, three myelodysplastic syndromes/acute myeloid leukemia, one vulvar cancer, one prostate cancer, one colon cancer and one soft tissue sarcoma. A melanoma and one pancreatic cancer developed in the ATO group. We conclude that treatment of patients with APL using the non-chemotherapy regimen of ATRA plus ATO is not associated with a higher incidence of secondary cancers (p = 0.29) adjusted for unit time of exposure. ",Journal Article,1905.0,13.0,incidence pattern secondary neoplasms patients acute promyelocytic leukemia APL treated all-trans retinoic acid ATRA -containing regimens described compared 160 patients APL treated ATRA plus idarubicin n 54 ATRA plus arsenic trioxide ATO n 106 incidence secondary unit time follow-up Median follow-up times cohorts 136 29 months respectively patients developed secondary chemotherapy group included breast myelodysplastic syndromes/acute myeloid leukemia vulvar prostate colon soft tissue sarcoma melanoma pancreatic developed ATO group conclude treatment patients APL non-chemotherapy regimen ATRA plus ATO associated higher incidence secondary p 0.29 adjusted unit time exposure,1,0,1,1,1,0,0,1,0,0,0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 287, 2, 1177, 1, 568, 1179, 4, 7, 5, 286, 4300, 2578, 73, 5, 62, 3437, 3887, 971, 2822, 1101, 472, 16, 44, 149, 1027, 21, 72, 3457, 7, 5, 2578, 73, 5, 2822, 349, 5684, 78, 667, 15, 2822, 349, 3217, 4574, 4021, 78, 3251, 9, 3, 287, 1, 568, 163, 379, 2712, 98, 1, 166, 126, 52, 166, 126, 1072, 9, 3, 100, 736, 11, 4829, 2, 462, 53, 106, 762, 7, 276, 568, 163, 4, 3, 56, 87, 46, 159, 100, 163, 169, 2040, 286, 533, 104, 12, 104, 12, 104, 12, 2, 104, 1214, 246, 8, 2, 104, 12, 276, 4, 3, 4021, 87, 21, 2060, 17, 24, 1, 7, 5, 2578, 75, 3, 220, 56, 477, 1, 2822, 349, 4021, 16, 44, 41, 5, 8, 142, 287, 1, 568, 163, 19, 13, 462, 586, 9, 2712, 98, 1, 645]",859.0,25120050,Incidence secondary neoplasms patients acute promyelocytic leukemia treated all-trans retinoic acid plus chemotherapy all-trans retinoic acid plus arsenic trioxide,0,0.0
Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer.,Cancer,Cancer,2014-08-22,"Radiopharmaceutical use may improve the survival time of patients with castrate-resistant prostate cancer and bone metastases. Whether androgen-deprivation therapy (ADT) combined with bone-targeted therapy provides a clinical benefit to patients with advanced castrate-sensitive prostate cancer has not been investigated. Eighty male patients were enrolled, and 79 were randomized: 40 to the control arm and 39 to the strontium-89 (Sr-89) arm. After randomization, patients in both study arms received ADT, doxorubicin, and zoledronic acid. Kaplan-Meier methodology was used to evaluate the progression-free survival (PFS) time. Multivariate Cox proportional hazards regression was used to evaluate the effects of Sr-89 after controlling for the number of bone metastases. The median follow-up time for the 29 patients alive at the last follow-up was 76.9 months (range, 0.07-103.4 months). The median PFS time was 18.5 months (95% confidence interval, 9.7-49.4 months) for the control arm and 12.9 months (95% confidence interval, 8.9-72.5 months) for the Sr-89 arm (P=.86). No patient developed myelodysplastic syndrome or a hematologic malignancy. An unplanned subgroup analysis suggested increased efficacy of bone-targeted therapy with a greater extent of bone involvement (ie, >6 bone metastases vs 6 bone metastases on the bone scan). The data showed that bone-targeted therapy using 1 dose of Sr-89 combined with chemohormonal ablation therapy did not favorably affect the PFS of patients with castrate-sensitive prostate cancer. The combined therapy was feasible and safe. Whether such bone-targeted therapy provides a favorable outcome for those patients with a greater tumor burden in the bone warrants further investigation.","Clinical Trial, Phase II",1978.0,9.0,Radiopharmaceutical use improve survival time patients castrate-resistant prostate bone metastases androgen-deprivation therapy ADT combined bone-targeted therapy provides clinical benefit patients advanced castrate-sensitive prostate investigated Eighty male patients enrolled 79 randomized 40 control arm 39 strontium-89 Sr-89 arm randomization patients arms received ADT doxorubicin zoledronic acid Kaplan-Meier methodology evaluate progression-free survival PFS time Multivariate Cox proportional hazards regression evaluate effects Sr-89 controlling number bone metastases median follow-up time 29 patients alive follow-up 76.9 months range 0.07-103.4 months median PFS time 18.5 months 95 confidence interval 9.7-49.4 months control arm 12.9 months 95 confidence interval 8.9-72.5 months Sr-89 arm P .86 patient developed myelodysplastic syndrome hematologic malignancy unplanned subgroup suggested increased efficacy bone-targeted therapy greater extent bone involvement 6 bone metastases vs 6 bone metastases bone scan showed bone-targeted therapy 1 dose Sr-89 combined chemohormonal ablation therapy favorably affect PFS patients castrate-sensitive prostate combined therapy feasible safe bone-targeted therapy provides favorable outcome patients greater burden bone warrants investigation,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[10522, 119, 68, 401, 3, 25, 98, 1, 7, 5, 4435, 436, 12, 2, 196, 317, 687, 1868, 36, 1360, 397, 5, 3417, 238, 36, 777, 8, 38, 247, 6, 7, 5, 131, 4435, 745, 12, 71, 44, 85, 565, 2207, 1045, 7, 11, 346, 2, 842, 11, 384, 327, 6, 3, 182, 475, 2, 587, 6, 3, 15922, 887, 7460, 887, 475, 50, 3644, 7, 4, 110, 45, 1335, 103, 1360, 856, 2, 4055, 971, 876, 882, 3209, 10, 95, 6, 376, 3, 91, 115, 25, 300, 98, 331, 418, 831, 1017, 320, 10, 95, 6, 376, 3, 176, 1, 7460, 887, 50, 1893, 9, 3, 207, 1, 196, 3, 52, 166, 126, 98, 9, 3, 462, 7, 1701, 28, 3, 1060, 166, 126, 10, 846, 83, 53, 184, 13, 1615, 3283, 39, 53, 3, 52, 300, 98, 10, 203, 33, 53, 48, 307, 268, 83, 67, 739, 39, 53, 9, 3, 182, 475, 2, 133, 83, 53, 48, 307, 268, 66, 83, 720, 33, 53, 9, 3, 7460, 887, 475, 19, 868, 77, 69, 276, 681, 15, 8, 813, 710, 35, 5851, 1363, 65, 1148, 101, 209, 1, 3417, 238, 36, 5, 8, 378, 1039, 1, 799, 2523, 49, 196, 105, 10020, 196, 23, 3, 1657, 3, 74, 224, 17, 3417, 238, 36, 75, 14, 61, 1, 7460, 887, 397, 5, 14220, 1650, 36, 205, 44, 5001, 1158, 3, 300, 1, 7, 5, 4435, 745, 12, 3, 397, 36, 10, 1313, 2, 1165, 317, 225, 3417, 238, 36, 777, 8, 913, 228, 9, 135, 7, 5, 8, 378, 30, 892, 4, 3, 2782, 195, 940]",1618.0,25155428,Randomized phase 2 bone-targeted therapy containing strontium-89 advanced castrate-sensitive prostate,0,0.0
Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.,Blood,Blood,2014-08-26,"We examined current outcomes of unrelated donor allogeneic hematopoietic cell transplantation (HCT) to determine the clinical implications of donor-recipient HLA matching. Adult and pediatric patients who had first undergone myeloablative-unrelated bone marrow or peripheral blood HCT for acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome between 1999 and 2011 were included. All had high-resolution typing for HLA-A, -B, -C, and -DRB1. Of the total (n = 8003), cases were 8/8 (n = 5449), 7/8 (n = 2071), or 6/8 (n = 483) matched. HLA mismatch (6-7/8) conferred significantly increased risk for grades II to IV and III to IV acute graft vs host disease (GVHD), chronic GVHD, transplant-related mortality (TRM), and overall mortality compared with HLA-matched cases (8/8). Type (allele/antigen) and locus (HLA-A, -B, -C, and -DRB1) of mismatch were not associated with overall mortality. Among 8/8 matched cases, HLA-DPB1 and -DQB1 mismatch resulted in increased acute GVHD, and HLA-DPB1 mismatch had decreased relapse. Nonpermissive HLA-DPB1 allele mismatch was associated with higher TRM compared with permissive HLA-DPB1 mismatch or HLA-DPB1 match and increased overall mortality compared with permissive HLA-DPB1 mismatch in 8/8 (and 10/10) matched cases. Full matching at HLA-A, -B, -C, and -DRB1 is required for optimal unrelated donor HCT survival, and avoidance of nonpermissive HLA-DPB1 mismatches in otherwise HLA-matched pairs is indicated. ",Journal Article,1974.0,118.0,examined current outcomes unrelated donor allogeneic hematopoietic transplantation HCT determine clinical implications donor-recipient HLA matching Adult pediatric patients undergone myeloablative-unrelated bone marrow peripheral blood HCT acute myelogenous leukemia acute lymphoblastic leukemia chronic myelogenous leukemia myelodysplastic syndrome 1999 2011 included high-resolution typing HLA-A -B -C -DRB1 total n 8003 cases 8/8 n 5449 7/8 n 2071 6/8 n 483 matched HLA mismatch 6-7/8 conferred significantly increased risk grades II IV III IV acute graft vs host disease GVHD chronic GVHD transplant-related mortality TRM overall mortality compared HLA-matched cases 8/8 Type allele/antigen locus HLA-A -B -C -DRB1 mismatch associated overall mortality 8/8 matched cases HLA-DPB1 -DQB1 mismatch resulted increased acute GVHD HLA-DPB1 mismatch decreased relapse Nonpermissive HLA-DPB1 allele mismatch associated higher TRM compared permissive HLA-DPB1 mismatch HLA-DPB1 match increased overall mortality compared permissive HLA-DPB1 mismatch 8/8 10/10 matched cases matching HLA-A -B -C -DRB1 required optimal unrelated donor HCT survival avoidance nonpermissive HLA-DPB1 mismatches HLA-matched pairs indicated,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 409, 291, 123, 1, 2092, 1488, 1063, 1007, 31, 497, 1085, 6, 223, 3, 38, 1268, 1, 1488, 5783, 1160, 2616, 780, 2, 815, 7, 54, 42, 157, 1989, 3246, 2092, 581, 15, 672, 315, 1085, 9, 286, 2194, 286, 1275, 442, 2194, 2, 681, 59, 2043, 2, 1132, 11, 159, 62, 42, 64, 2125, 10656, 9, 1160, 8, 132, 256, 2, 8147, 1, 3, 181, 78, 64809, 140, 11, 66, 66, 78, 64810, 67, 66, 78, 48547, 15, 49, 66, 78, 10661, 655, 1160, 2617, 49, 67, 66, 3851, 97, 101, 43, 9, 2276, 215, 6, 478, 2, 316, 6, 478, 286, 1599, 105, 1204, 34, 1562, 442, 1562, 941, 139, 282, 5064, 2, 63, 282, 72, 5, 1160, 655, 140, 66, 66, 267, 1254, 448, 2, 2474, 1160, 8, 132, 256, 2, 8147, 1, 2617, 11, 44, 41, 5, 63, 282, 107, 66, 66, 655, 140, 1160, 13735, 2, 25301, 2617, 627, 4, 101, 286, 1562, 2, 1160, 13735, 2617, 42, 340, 429, 24146, 1160, 13735, 1254, 2617, 10, 41, 5, 142, 5064, 72, 5, 11080, 1160, 13735, 2617, 15, 1160, 13735, 5364, 2, 101, 63, 282, 72, 5, 11080, 1160, 13735, 2617, 4, 66, 66, 2, 79, 79, 655, 140, 1647, 2616, 28, 1160, 8, 132, 256, 2, 8147, 16, 616, 9, 665, 2092, 1488, 1085, 25, 2, 5863, 1, 24146, 1160, 13735, 11828, 4, 2632, 1160, 655, 2773, 16, 1103]",1407.0,25161269,Nonpermissive HLA-DPB1 mismatch increases mortality myeloablative unrelated allogeneic hematopoietic transplantation,1,0.0017452006980802793
"Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103).",Cancer chemotherapy and pharmacology,Cancer Chemother. Pharmacol.,2014-08-28,"Older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome have often been excluded from myeloablative-conditioning regimens containing busulfan because of non-disease-related morbidity and mortality. We hypothesized that busulfan clearance (BuCL) in older patients (>60 years) would be reduced compared to that in younger patients, potentially explaining observed differences in busulfan tolerability. AML patients in three CALGB hematopoietic cell transplantation studies were treated with a conditioning regimen using IV busulfan, dosed at 0.8 mg/kg. Plasma busulfan concentrations were determined by LC-MS and analyzed by non-compartmental methods. BuCL was normalized to actual (ABW), ideal (IBW), or corrected (CBW) body weight (kg). Differences in BuCL between age groups were examined using the Wilcoxon rank sum test. One hundred and eighty-five patients were accrued; 174 provided useable pharmacokinetic data. Twenty-nine patients  60 years old (median 66; range 60-74) had a significantly higher BuCL versus those <60 years old (median 50; range 18-60): BuCL 236 versus 168 mL/min, p = 0.0002; BuCL/ABW 3.0 versus 2.1 mL/min/kg, p = 0.0001; BuCL/IBW 3.8 versus 2.6 mL/min/kg, p = 0.0035; BuCL/CBW 3.4 versus 2.6 mL/min/kg, p = 0.0005. Inter-patient variability in clearance (CV %) was up to 48 % in both age groups. Phenytoin administration, a potential confounder, did not affect BuCL, regardless of weight normalization (p > 0.34). Contrary to our hypothesis, BuCL was significantly higher in older patients compared to younger patients in these studies and does not explain the previously reported increase in busulfan toxicity observed in older patients.",Clinical Trial,1972.0,11.0,Older patients acute myeloid leukemia AML myelodysplastic syndrome excluded myeloablative-conditioning regimens containing busulfan non-disease-related morbidity mortality hypothesized busulfan clearance BuCL older patients 60 years reduced compared younger patients potentially explaining observed differences busulfan tolerability AML patients CALGB hematopoietic transplantation studies treated conditioning regimen IV busulfan dosed 0.8 mg/kg Plasma busulfan concentrations determined LC-MS non-compartmental methods BuCL normalized actual ABW ideal IBW corrected CBW body weight Differences BuCL age groups examined Wilcoxon rank sum test eighty-five patients accrued 174 provided useable pharmacokinetic Twenty-nine patients  60 years old median 66 range 60-74 significantly higher BuCL versus 60 years old median 50 range 18-60 BuCL 236 versus 168 mL/min p 0.0002 BuCL/ABW 3.0 versus 2.1 mL/min/kg p 0.0001 BuCL/IBW 3.8 versus 2.6 mL/min/kg p 0.0035 BuCL/CBW 3.4 versus 2.6 mL/min/kg p 0.0005 Inter-patient variability clearance CV 48 age groups Phenytoin administration potential confounder affect BuCL regardless weight normalization p 0.34 Contrary hypothesis BuCL significantly higher older patients compared younger patients studies explain previously reported increase busulfan toxicity observed older patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[434, 7, 5, 286, 533, 329, 2, 681, 47, 629, 85, 1800, 29, 3246, 1933, 472, 1101, 3906, 408, 1, 220, 34, 139, 787, 2, 282, 21, 1237, 17, 3906, 1960, 22859, 4, 434, 7, 335, 60, 688, 40, 405, 72, 6, 17, 4, 773, 7, 751, 8290, 164, 362, 4, 3906, 1543, 329, 7, 4, 169, 4077, 1007, 31, 497, 94, 11, 73, 5, 8, 1933, 477, 75, 478, 3906, 6268, 28, 13, 66, 81, 503, 554, 3906, 1003, 11, 509, 20, 1837, 2307, 2, 311, 20, 220, 13522, 636, 22859, 10, 4207, 6, 3480, 25540, 3662, 26830, 15, 3848, 48548, 642, 924, 503, 362, 4, 22859, 59, 89, 271, 11, 409, 75, 3, 3896, 1026, 3216, 412, 104, 1128, 2, 2207, 365, 7, 11, 3198, 5811, 1052, 64813, 1456, 74, 737, 762, 7, 749, 335, 60, 1095, 52, 700, 184, 335, 794, 42, 8, 97, 142, 22859, 185, 135, 335, 60, 1095, 52, 212, 184, 203, 335, 22859, 6383, 185, 5359, 542, 1538, 19, 13, 3531, 22859, 25540, 27, 13, 185, 18, 14, 542, 1538, 503, 19, 13, 488, 22859, 26830, 27, 66, 185, 18, 49, 542, 1538, 503, 19, 13, 15569, 22859, 48548, 27, 39, 185, 18, 49, 542, 1538, 503, 19, 13, 4252, 3606, 69, 1982, 4, 1960, 6249, 10, 126, 6, 576, 4, 110, 89, 271, 14915, 634, 8, 174, 18166, 205, 44, 1158, 22859, 1583, 1, 924, 5924, 19, 13, 562, 7194, 6, 114, 1492, 22859, 10, 97, 142, 4, 434, 7, 72, 6, 773, 7, 4, 46, 94, 2, 1097, 44, 2943, 3, 373, 210, 344, 4, 3906, 155, 164, 4, 434, 7]",1597.0,25163570,Effect age pharmacokinetics busulfan patients undergoing hematopoietic transplantation alliance CALGB 10503 19808 100103,0,0.0
Favorable outcomes in elderly patients undergoing high-dose therapy and autologous stem cell transplantation for non-Hodgkin lymphoma.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2014-08-28,"High-dose therapy and autologous stem cell transplantation (HDT-ASCT) can offer potential long-term remission or cure in patients with non-Hodgkin lymphoma (NHL). Limited experience is available on the safety and efficacy of HDT-ASCT in elderly patients. This is a single-center, retrospective study examining outcomes of HDT-ASCT for 202 NHL patients, ages 60 years and older, between January 2001 and December 2012. Overall survival (OS) and progression-free survival (PFS) were analyzed according to age at HDT-ASCT, hematopoietic cell transplantation comorbidity index (HCT-CI), NHL histology, and remission status at the time of HDT-ASCT. The median age was 65 years (range, 60 to 74) and the majority had either diffuse large Bcell lymphoma (n= 73, 37%) or mantle cell lymphoma (n= 69, 34%). One hundred and fifteen patients (57%) had high HCT-CI scores at the time of HDT-ASCT. With a median follow-up of 3.6 years (range, 4 to 11.9 years) for survivors, PFS and OS at 3 years were 60% (95% confidence interval [CI], 53% to 68%) and 73% (95% CI, 67% to 80%), respectively. Transplantation-related mortality (TRM) was 4% both at 100 days and at 1 year after HDT-ASCT. Age and HCT-CI score were not associated with OS or PFS, and high HCT-CI did not correlate with TRM. Seven patients (4%) developed secondary myelodysplastic syndrome or acute myeloid leukemia at a median of 35 months (range, 6 to 48) after HDT-ASCT. In this single-center cohort of elderly patients with NHL undergoing HDT-ASCT, this intervention was proven tolerable and effective, with results similar to those of historic controls in younger patients. Our data suggest that age alone should not preclude HDT-ASCT in elderly patients. ",Clinical Trial,1972.0,28.0,High-dose therapy autologous stem transplantation HDT-ASCT offer potential long-term remission cure patients non-Hodgkin lymphoma NHL Limited experience available safety efficacy HDT-ASCT elderly patients single-center retrospective examining outcomes HDT-ASCT 202 NHL patients ages 60 years older January 2001 December 2012 Overall survival OS progression-free survival PFS according age HDT-ASCT hematopoietic transplantation comorbidity index HCT-CI NHL histology remission status time HDT-ASCT median age 65 years range 60 74 majority diffuse large B lymphoma n 73 37 mantle lymphoma n 69 34 patients 57 high HCT-CI scores time HDT-ASCT median follow-up 3.6 years range 4 11.9 years survivors PFS OS 3 years 60 95 confidence interval CI 53 68 73 95 CI 67 80 respectively Transplantation-related mortality TRM 4 100 days 1 year HDT-ASCT Age HCT-CI score associated OS PFS high HCT-CI correlate TRM Seven patients 4 developed secondary myelodysplastic syndrome acute myeloid leukemia median 35 months range 6 48 HDT-ASCT single-center cohort elderly patients NHL undergoing HDT-ASCT intervention proven tolerable effective similar historic controls younger patients suggest age preclude HDT-ASCT elderly patients,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[64, 61, 36, 2, 1028, 452, 31, 497, 5350, 1584, 122, 1918, 174, 319, 337, 734, 15, 1722, 4, 7, 5, 1176, 383, 730, 16, 390, 23, 3, 367, 2, 209, 1, 5350, 1584, 4, 1216, 7, 26, 16, 8, 226, 574, 459, 45, 3282, 123, 1, 5350, 1584, 9, 5918, 1176, 7, 2165, 335, 60, 2, 434, 59, 1024, 1758, 2, 1397, 1195, 63, 25, 118, 2, 91, 115, 25, 300, 11, 311, 768, 6, 89, 28, 5350, 1584, 1007, 31, 497, 1879, 558, 1085, 58, 1176, 784, 2, 734, 156, 28, 3, 98, 1, 5350, 1584, 3, 52, 89, 10, 556, 60, 184, 335, 6, 794, 2, 3, 686, 42, 361, 1388, 375, 132, 31, 78, 803, 567, 15, 2757, 31, 78, 790, 562, 104, 1128, 2, 3057, 7, 696, 42, 64, 1085, 58, 703, 28, 3, 98, 1, 5350, 1584, 5, 8, 52, 166, 126, 1, 27, 49, 60, 184, 39, 6, 175, 83, 60, 9, 332, 300, 2, 118, 28, 27, 60, 11, 335, 48, 307, 268, 58, 699, 6, 806, 2, 803, 48, 58, 598, 6, 493, 106, 497, 139, 282, 5064, 10, 39, 110, 28, 394, 162, 2, 28, 14, 111, 50, 5350, 1584, 89, 2, 1085, 58, 368, 11, 44, 41, 5, 118, 15, 300, 2, 64, 1085, 58, 205, 44, 1513, 5, 5064, 648, 7, 39, 276, 568, 681, 15, 286, 533, 28, 8, 52, 1, 465, 53, 184, 49, 6, 576, 50, 5350, 1584, 4, 26, 226, 574, 180, 1, 1216, 7, 5, 1176, 479, 5350, 1584, 26, 788, 10, 1930, 2668, 2, 323, 5, 99, 288, 6, 135, 1, 6875, 535, 4, 773, 7, 114, 74, 309, 17, 89, 279, 257, 44, 6064, 5350, 1584, 4, 1216, 7]",1570.0,25175794,Favorable outcomes elderly patients undergoing high-dose therapy autologous stem transplantation non-Hodgkin lymphoma,18,0.031413612565445025
Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2014-09-22,"We sought to determine whether differences in chronic graft-versus-host disease (GVHD) rates would lead to survival differences by comparing 2463 peripheral blood (PB) and 1713 bone marrow (BM) hematopoietic cell transplant recipients. Patients had acute leukemia, chronic myeloid leukemia (CML), or myelodysplastic syndrome, and they received myeloablative conditioning regimens and calcineurin-inhibitor GVHD prophylaxis. There were no significant differences in long-term survival after transplantation of PB and BM, except for patients in first chronic phase CML. For these patients, the 5-year rate of survival was lower after transplantation of PB compared with transplantation of BM (35% versus 56%, P = .001). Although mortality risks were higher in patients with chronic GVHD after both PB (hazard ratio [HR], 1.58; P < .001) and BM (HR 1.73; P < .001) transplantations, its effect on mortality did not differ by graft type (P = .42). BM is the preferred graft for first chronic phase CML, whereas as either graft is suitable for other leukemias.",Comparative Study,1947.0,19.0,sought determine differences chronic graft-versus-host disease GVHD rates lead survival differences comparing 2463 peripheral blood PB 1713 bone marrow BM hematopoietic transplant recipients Patients acute leukemia chronic myeloid leukemia CML myelodysplastic syndrome received myeloablative conditioning regimens calcineurin-inhibitor GVHD prophylaxis significant differences long-term survival transplantation PB BM patients chronic phase CML patients 5-year rate survival lower transplantation PB compared transplantation BM 35 versus 56 P .001 mortality risks higher patients chronic GVHD PB hazard ratio HR 1.58 P .001 BM HR 1.73 P .001 transplantations effect mortality differ graft type P .42 BM preferred graft chronic phase CML graft suitable leukemias,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 990, 6, 223, 317, 362, 4, 442, 1599, 185, 1204, 34, 1562, 151, 688, 1122, 6, 25, 362, 20, 1430, 44439, 672, 315, 3767, 2, 29354, 581, 1246, 1007, 31, 941, 2190, 7, 42, 286, 442, 533, 903, 15, 681, 2, 491, 103, 3246, 1933, 472, 2, 12028, 230, 1562, 2049, 125, 11, 77, 93, 362, 4, 319, 337, 25, 50, 497, 1, 3767, 2, 1246, 2187, 9, 7, 4, 157, 442, 124, 903, 9, 46, 7, 3, 33, 111, 116, 1, 25, 10, 280, 50, 497, 1, 3767, 72, 5, 497, 1, 1246, 465, 185, 664, 19, 144, 242, 282, 1098, 11, 142, 4, 7, 5, 442, 1562, 50, 110, 3767, 360, 197, 168, 14, 717, 19, 144, 2, 1246, 168, 14, 803, 19, 144, 6779, 211, 254, 23, 282, 205, 44, 1505, 20, 1599, 267, 19, 595, 1246, 16, 3, 2514, 1599, 9, 157, 442, 124, 903, 547, 22, 361, 1599, 16, 2884, 9, 127, 2792]",971.0,25255165,Long-term survival transplantation unrelated donor peripheral blood bone marrow hematopoietic hematologic malignancy,9,0.015706806282722512
Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2014-09-28,"Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) has been performed primarily with an HLA-matched donor. Outcomes of haploidentical transplantation have recently improved, and a comparison between donor sources in a uniform cohort of patients has not been performed. We evaluated outcomes of 227 patients with AML/MDS treated with melphalan-based conditioning. Donors were matched related (MRD) (n=87, 38%), matched unrelated (MUD) (n=108, 48%), or haploidentical (n=32, 14%). No significant differences were found between haploidentical and MUD transplantation outcomes; however, there was a trend for improved outcomes in the MRD group, with 3-year progression-free survival for patients in remission of 57%, 45%, and 41% for MRD, MUD, and haploidentical recipients, respectively (P=.417). Recovery of T cell subsets was similar for all groups. These results suggest that haploidentical donors can safely extend transplantation for AML/MDS patients without an HLA-matched donor. Prospective studies comparing haploidentical and MUD transplantation are warranted. ",Clinical Trial,1941.0,131.0,Allogeneic stem transplantation patients acute myeloid leukemia AML myelodysplastic syndromes MDS performed primarily HLA-matched donor Outcomes haploidentical transplantation recently improved comparison donor sources uniform cohort patients performed evaluated outcomes 227 patients AML/MDS treated melphalan-based conditioning Donors matched related MRD n 87 38 matched unrelated MUD n 108 48 haploidentical n 32 14 significant differences haploidentical MUD transplantation outcomes trend improved outcomes MRD group 3-year progression-free survival patients remission 57 45 41 MRD MUD haploidentical recipients respectively P .417 Recovery subsets similar groups suggest haploidentical donors safely extend transplantation AML/MDS patients HLA-matched donor Prospective studies comparing haploidentical MUD transplantation warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1063, 452, 31, 497, 9, 7, 5, 286, 533, 329, 2, 2040, 1223, 71, 85, 173, 1561, 5, 35, 1160, 655, 1488, 123, 1, 5802, 497, 47, 761, 231, 2, 8, 1155, 59, 1488, 3375, 4, 8, 3490, 180, 1, 7, 71, 44, 85, 173, 21, 194, 123, 1, 7132, 7, 5, 329, 1223, 73, 5, 2370, 90, 1933, 2344, 11, 655, 139, 2029, 78, 912, 519, 655, 2092, 7070, 78, 3590, 576, 15, 5802, 78, 531, 213, 77, 93, 362, 11, 204, 59, 5802, 2, 7070, 497, 123, 137, 125, 10, 8, 853, 9, 231, 123, 4, 3, 2029, 87, 5, 27, 111, 91, 115, 25, 9, 7, 4, 734, 1, 696, 512, 2, 605, 9, 2029, 7070, 2, 5802, 2190, 106, 19, 9947, 1602, 1, 102, 31, 1890, 10, 288, 9, 62, 271, 46, 99, 309, 17, 5802, 2344, 122, 2268, 4087, 497, 9, 329, 1223, 7, 187, 35, 1160, 655, 1488, 482, 94, 1430, 5802, 2, 7070, 497, 32, 1197]",1066.0,25263628,Similar transplantation outcomes acute myeloid leukemia myelodysplastic syndrome patients haploidentical versus 10/10 human leukocyte antigen-matched unrelated related donors,21,0.03664921465968586
Results of a prospective multicentre myeloablative double-unit cord blood transplantation trial in adult patients with acute leukaemia and myelodysplasia.,British journal of haematology,Br. J. Haematol.,2014-10-01,"Double-unit cord blood (CB) grafts may improve engraftment and relapse risk in adults with haematological malignancies. We performed a prospective high-dose myeloablative double-unit CB transplantation (CBT) trial in adults with high-risk acute leukaemia or myelodysplasia (MDS) between 2007 and 2011. The primary aim was to establish the 1-year overall survival in a multi-centre setting. Fifty-six patients (31 acute myeloid leukaemia, 19 acute lymphoblastic leukaemia, 4 other acute leukaemias, 2 myelodysplastic syndrome [MDS]) were transplanted at 10 centres. The median infused total nucleated cell doses were 262 (larger unit) and 202 (smaller unit)x10(7) /kg. The cumulative incidence of day 100 neutrophil engraftment was 89% (95% confidence interval [CI]: 80-96). Day 180 grade II-IV acute graft-versus-host disease (GVHD) incidence was 64% (95%CI: 51-76) and 36% (95%CI: 24-49) of patients had chronic GVHD by 3-years. At 3-years post-transplant, the transplant-related mortality (TRM) was 39% (95%CI: 26-52), and the 3-year relapse incidence was 11% (95%CI: 4-21). With a median 37-month (range 23-71) follow-up of survivors, the 3-year disease-free survival was 50% (95%CI: 37-63). Double-unit CBT is a viable alternative therapy for high-risk acute leukaemia/ MDS in patients lacking a matched unrelated donor. This is especially important for minority patients. The relapse incidence was low but strategies to ameliorate TRM are needed. ","Clinical Trial, Phase II",1938.0,18.0,Double-unit cord blood CB grafts improve engraftment relapse risk adults haematological malignancies performed prospective high-dose myeloablative double-unit CB transplantation CBT trial adults high-risk acute leukaemia myelodysplasia MDS 2007 2011 primary aim establish 1-year overall survival multi-centre setting Fifty-six patients 31 acute myeloid leukaemia 19 acute lymphoblastic leukaemia 4 acute leukaemias 2 myelodysplastic syndrome MDS transplanted 10 centres median infused total nucleated doses 262 larger unit 202 smaller unit x 10 7 /kg cumulative incidence day 100 neutrophil engraftment 89 95 confidence interval CI 80-96 Day 180 grade II-IV acute graft-versus-host disease GVHD incidence 64 95 CI 51-76 36 95 CI 24-49 patients chronic GVHD 3-years 3-years post-transplant transplant-related mortality TRM 39 95 CI 26-52 3-year relapse incidence 11 95 CI 4-21 median 37-month range 23-71 follow-up survivors 3-year disease-free survival 50 95 CI 37-63 Double-unit CBT viable alternative therapy high-risk acute leukaemia/ MDS patients lacking matched unrelated donor especially important minority patients relapse incidence low strategies ameliorate TRM needed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1627, 2712, 1885, 315, 4723, 4713, 68, 401, 2881, 2, 429, 43, 4, 857, 5, 5143, 441, 21, 173, 8, 482, 64, 61, 3246, 1627, 2712, 4723, 497, 7548, 160, 4, 857, 5, 64, 43, 286, 2001, 15, 6128, 1223, 59, 1307, 2, 1132, 3, 86, 1130, 10, 6, 1811, 3, 14, 111, 63, 25, 4, 8, 1414, 5931, 546, 1461, 437, 7, 456, 286, 533, 2001, 326, 286, 1275, 2001, 39, 127, 286, 12160, 18, 681, 1223, 11, 4600, 28, 79, 4496, 3, 52, 4524, 181, 9862, 31, 415, 11, 65007, 1077, 2712, 2, 40863, 2170, 2712, 1006, 79, 67, 503, 3, 967, 287, 1, 218, 394, 2595, 2881, 10, 887, 48, 307, 268, 58, 493, 921, 218, 3172, 88, 215, 478, 286, 1599, 185, 1204, 34, 1562, 287, 10, 660, 48, 58, 725, 846, 2, 511, 48, 58, 259, 739, 1, 7, 42, 442, 1562, 20, 27, 60, 28, 27, 60, 539, 941, 3, 941, 139, 282, 5064, 10, 587, 48, 58, 432, 653, 2, 3, 27, 111, 429, 287, 10, 175, 48, 58, 39, 239, 5, 8, 52, 567, 811, 184, 382, 792, 166, 126, 1, 332, 3, 27, 111, 34, 115, 25, 10, 212, 48, 58, 567, 676, 1627, 2712, 7548, 16, 8, 2663, 1091, 36, 9, 64, 43, 286, 2001, 1223, 4, 7, 1941, 8, 655, 2092, 1488, 26, 16, 1093, 305, 9, 2652, 7, 3, 429, 287, 10, 154, 84, 422, 6, 9179, 5064, 32, 575]",1373.0,25272241,prospective multicentre myeloablative double-unit cord blood transplantation trial adult patients acute leukaemia myelodysplasia,0,0.0
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.,Leukemia & lymphoma,Leuk. Lymphoma,2014-11-03,"Survival for patients with multiple myeloma has increased. Both melphalan and lenalidomide are associated with subsequent development of myelodysplasia. We reviewed the cases of all patients with multiple myeloma who had subsequent development of myelodysplastic syndrome (MDS) or acute non-lymphoblastic leukemia (ANLL) during a 12-year period in three centers. Of 55 patients identified, two received only lenalidomide before myelodysplasia developed. The median time between the diagnoses of multiple myeloma and MDS/ANLL was 52.7 months. Median survival after the diagnosis of MDS or ANLL was 6.7 months. Treatment of MDS comprised allogeneic stem cell transplant in eight patients (median survival, 219 days; one patient alive at 624 days) and a hypomethylating agent in 21 patients (response of stable or better in five patients). Myelodysplasia remains a devastating complication of therapy for multiple myeloma, with short survival and poor response rates to available modalities. ",Journal Article,1905.0,8.0,Survival patients multiple myeloma increased melphalan lenalidomide associated subsequent development myelodysplasia reviewed cases patients multiple myeloma subsequent development myelodysplastic syndrome MDS acute non-lymphoblastic leukemia ANLL 12-year period centers 55 patients identified received lenalidomide myelodysplasia developed median time diagnoses multiple myeloma MDS/ANLL 52.7 months Median survival diagnosis MDS ANLL 6.7 months Treatment MDS comprised allogeneic stem transplant patients median survival 219 days patient alive 624 days hypomethylating agent 21 patients response stable better patients Myelodysplasia remains devastating complication therapy multiple myeloma short survival poor response rates available modalities,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,"[25, 9, 7, 5, 232, 71, 101, 110, 2370, 2, 1288, 32, 41, 5, 706, 193, 1, 6128, 21, 446, 3, 140, 1, 62, 7, 5, 232, 54, 42, 706, 193, 1, 681, 1223, 15, 286, 220, 1275, 27864, 190, 8, 133, 111, 727, 4, 169, 1168, 1, 614, 7, 108, 100, 103, 158, 1288, 348, 6128, 276, 3, 52, 98, 59, 3, 2403, 1, 232, 2, 1223, 27864, 10, 653, 67, 53, 52, 25, 50, 3, 147, 1, 1223, 15, 27864, 10, 49, 67, 53, 24, 1, 1223, 2603, 1063, 452, 31, 941, 4, 659, 7, 52, 25, 6679, 162, 104, 69, 1701, 28, 10999, 162, 2, 8, 4931, 420, 4, 239, 7, 51, 1, 585, 15, 380, 4, 365, 7, 6128, 469, 8, 5778, 1447, 1, 36, 9, 232, 5, 978, 25, 2, 334, 51, 151, 6, 390, 1558]",911.0,25284489,Therapy-related myelodysplastic syndrome/acute leukemia multiple myeloma era novel agents,0,0.0
"Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes.",Leukemia & lymphoma,Leuk. Lymphoma,2014-11-19,"Patients with chronic lymphocytic leukemia (CLL) are known to have an increased incidence of second cancers, but the contribution of commonly used frontline therapies to the incidence of second cancers is unclear. We report on the characteristics, incidence, outcomes and factors associated with second cancers in 234 patients receiving fludarabine, cyclophosphamide and rituximab (FCR) based regimens in the frontline setting. The risk of second cancers was 2.38 times higher than the expected risk in the general population. Ninety-three patients (40%) had other cancers before and 66 patients (28%) after FCR. Rates of therapy related acute myeloid leukemia/myelodysplastic syndrome (t-AML/MDS) (5.1%) and Richter transformation (RT) (9%) were high, while solid tumors were not increased. Overall survival of patients with second cancers after frontline FCR was shorter (median of 4.5 years) compared to patients with and without prior cancers. Second cancer risk after frontline FCR is mainly due to high rates of t-AML/MDS and RT, and as speculated the survival of affected patients is shorter. ",Journal Article,1889.0,60.0,Patients chronic lymphocytic leukemia CLL known increased incidence second contribution commonly frontline therapies incidence second unclear report characteristics incidence outcomes factors associated second 234 patients receiving fludarabine cyclophosphamide rituximab FCR based regimens frontline setting risk second 2.38 times higher expected risk general population Ninety-three patients 40 66 patients 28 FCR Rates therapy related acute myeloid leukemia/myelodysplastic syndrome t-AML/MDS 5.1 Richter transformation RT 9 high solid increased Overall survival patients second frontline FCR shorter median 4.5 years compared patients prior Second risk frontline FCR mainly high rates t-AML/MDS RT speculated survival affected patients shorter,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[7, 5, 442, 1193, 552, 32, 440, 6, 47, 35, 101, 287, 1, 419, 163, 84, 3, 2925, 1, 841, 95, 3171, 235, 6, 3, 287, 1, 419, 163, 16, 1200, 21, 414, 23, 3, 374, 287, 123, 2, 130, 41, 5, 419, 163, 4, 8049, 7, 357, 2027, 1112, 2, 855, 4953, 90, 472, 4, 3, 3171, 546, 3, 43, 1, 419, 163, 10, 18, 519, 1072, 142, 76, 3, 1336, 43, 4, 3, 1083, 266, 2493, 169, 7, 327, 42, 127, 163, 348, 2, 700, 7, 339, 50, 4953, 151, 1, 36, 139, 286, 533, 2647, 10589, 681, 102, 329, 1223, 33, 14, 2, 8452, 1392, 240, 83, 11, 64, 369, 537, 57, 11, 44, 101, 63, 25, 1, 7, 5, 419, 163, 50, 3171, 4953, 10, 985, 52, 1, 39, 33, 60, 72, 6, 7, 5, 2, 187, 324, 163, 419, 12, 43, 50, 3171, 4953, 16, 2615, 520, 6, 64, 151, 1, 102, 329, 1223, 2, 240, 2, 22, 17812, 3, 25, 1, 1424, 7, 16, 985]",1055.0,25308294,Second patients chronic lymphocytic leukemia received frontline fludarabine cyclophosphamide rituximab therapy distribution clinical outcomes,22,0.038394415357766144
Inherited predisposition to acute myeloid leukemia.,Seminars in hematology,Semin. Hematol.,2014-08-12,"Germline testing for familial predisposition to myeloid malignancies is becoming more common with the recognition of multiple familial syndromes. Currently, Clinical Laboratory Improvement Amendments-approved testing exists for the following: familial platelet disorder with propensity to acute myeloid leukemia, caused by mutations in RUNX1; familial myelodysplastic syndrome/acute myeloid leukemia with mutated GATA2; familial acute myeloid leukemia with mutated CEBPA; and the inherited bone marrow failure syndromes, including dyskeratosis congenita, a disease of abnormal telomere maintenance. With the recognition of additional families with a genetic component to their myeloid diseases, new predisposition alleles are likely to be identified. Awareness of the existence of these syndromes will facilitate proper genetic counseling, appropriate testing, and clinical management of these cases. ",Journal Article,1988.0,38.0,Germline testing familial predisposition myeloid malignancies common recognition multiple familial syndromes Currently Clinical Laboratory Improvement Amendments-approved testing exists following familial platelet disorder propensity acute myeloid leukemia caused RUNX1 familial myelodysplastic syndrome/acute myeloid leukemia GATA2 familial acute myeloid leukemia CEBPA inherited bone marrow failure syndromes including dyskeratosis congenita disease abnormal telomere maintenance recognition additional families genetic component myeloid diseases new predisposition alleles likely identified Awareness existence syndromes facilitate proper genetic counseling appropriate testing clinical management cases,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1009, 471, 9, 2200, 2863, 6, 533, 441, 16, 4009, 80, 186, 5, 3, 2335, 1, 232, 2200, 2040, 694, 38, 1624, 767, 11877, 850, 471, 2481, 9, 3, 366, 2200, 1596, 2645, 5, 1925, 6, 286, 533, 1546, 20, 138, 4, 6092, 2200, 681, 286, 533, 5, 1185, 12909, 2200, 286, 533, 5, 1185, 7667, 2, 3, 2986, 581, 496, 2040, 141, 27182, 35908, 8, 34, 1, 1668, 4136, 1146, 5, 3, 2335, 1, 402, 1954, 5, 8, 336, 1249, 6, 136, 533, 1342, 217, 2863, 2558, 32, 322, 6, 40, 108, 3310, 1, 3, 5335, 1, 46, 2040, 303, 1876, 4576, 336, 2011, 870, 471, 2, 38, 284, 1, 46, 140]",837.0,25311743,Inherited predisposition acute myeloid leukemia,37,0.06457242582897033
Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2014-10-12,"We analyzed the outcomes of patients who survived disease-free for 1 year or more after a second allogeneic hematopoietic cell transplantation (HCT) for relapsed acute leukemia or myelodysplastic syndromes between 1980 and 2009. A total of 1285 patients received a second allogeneic transplant after disease relapse; among these, 325 were relapse free at 1 year after the second HCT. The median time from first to second HCT was 17 and 24 months for children and adults, respectively. A myeloablative preparative regimen was used in the second transplantation in 62% of children and 45% of adult patients. The overall 10-year conditional survival rates after second transplantation in this cohort of patients who had survived disease-free for at least 1 year was 55% in children and 39% in adults. Relapse was the leading cause of mortality (77% and 54% of deaths in children and adults, respectively). In multivariate analyses, only disease status before second HCT was significantly associated with higher risk for overall mortality (hazard ratio, 1.71 for patients with disease not in complete remission before second HCT, P < .01). Chronic graft-versus-host disease (GVHD) developed in 43% and 75% of children and adults after second transplantation. Chronic GVHD was the leading cause of nonrelapse mortality, followed by organ failure and infection. The cumulative incidence of developing at least 1 of the studied late effects within 10 years after second HCT was 63% in children and 55% in adults. The most frequent late effects in children were growth disturbance (10-year cumulative incidence, 22%) and cataracts (20%); in adults they were cataracts (20%) and avascular necrosis (13%). Among patients with acute leukemia and myelodysplastic syndromes who receive a second allogeneic HCT for relapse and survive disease free for at least 1 year, many can be expected to survive long term. However, they continue to be at risk for relapse and nonrelapse morbidity and mortality. Novel approaches are needed to minimize relapse risk and long-term transplantation morbidity in this population. ",Journal Article,1927.0,28.0,outcomes patients survived disease-free 1 year second allogeneic hematopoietic transplantation HCT relapsed acute leukemia myelodysplastic syndromes 1980 2009 total 1285 patients received second allogeneic transplant disease relapse 325 relapse free 1 year second HCT median time second HCT 17 24 months children adults respectively myeloablative preparative regimen second transplantation 62 children 45 adult patients overall 10-year conditional survival rates second transplantation cohort patients survived disease-free 1 year 55 children 39 adults Relapse leading cause mortality 77 54 deaths children adults respectively multivariate disease status second HCT significantly associated higher risk overall mortality hazard ratio 1.71 patients disease complete remission second HCT P .01 Chronic graft-versus-host disease GVHD developed 43 75 children adults second transplantation Chronic GVHD leading cause nonrelapse mortality followed organ failure infection cumulative incidence developing 1 studied late effects 10 years second HCT 63 children 55 adults frequent late effects children growth disturbance 10-year cumulative incidence 22 cataracts 20 adults cataracts 20 avascular necrosis 13 patients acute leukemia myelodysplastic syndromes receive second allogeneic HCT relapse survive disease free 1 year expected survive long term continue risk relapse nonrelapse morbidity mortality Novel approaches needed minimize relapse risk long-term transplantation morbidity population,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 311, 3, 123, 1, 7, 54, 2996, 34, 115, 9, 14, 111, 15, 80, 50, 8, 419, 1063, 1007, 31, 497, 1085, 9, 591, 286, 15, 2040, 59, 4376, 2, 1238, 8, 181, 1, 27987, 7, 103, 8, 419, 1063, 941, 50, 34, 429, 107, 46, 7139, 11, 429, 115, 28, 14, 111, 50, 3, 419, 1085, 3, 52, 98, 29, 157, 6, 419, 1085, 10, 269, 2, 259, 53, 9, 541, 2, 857, 106, 8, 3246, 6085, 477, 10, 95, 4, 3, 419, 497, 4, 744, 1, 541, 2, 512, 1, 780, 7, 3, 63, 79, 111, 3212, 25, 151, 50, 419, 497, 4, 26, 180, 1, 7, 54, 42, 2996, 34, 115, 9, 28, 506, 14, 111, 10, 614, 4, 541, 2, 587, 4, 857, 429, 10, 3, 1049, 708, 1, 282, 849, 2, 667, 1, 1043, 4, 541, 2, 857, 106, 4, 331, 318, 158, 34, 156, 348, 419, 1085, 10, 97, 41, 5, 142, 43, 9, 63, 282, 360, 197, 14, 792, 9, 7, 5, 34, 44, 4, 236, 734, 348, 419, 1085, 19, 355, 442, 1599, 185, 1204, 34, 1562, 276, 4, 601, 2, 481, 1, 541, 2, 857, 50, 419, 497, 442, 1562, 10, 3, 1049, 708, 1, 4640, 282, 370, 20, 1259, 496, 2, 930, 3, 967, 287, 1, 931, 28, 506, 14, 1, 3, 656, 807, 176, 262, 79, 60, 50, 419, 1085, 10, 676, 4, 541, 2, 614, 4, 857, 3, 96, 908, 807, 176, 4, 541, 11, 129, 6663, 79, 111, 967, 287, 350, 2, 13319, 179, 4, 857, 491, 11, 13319, 179, 2, 19455, 1523, 233, 107, 7, 5, 286, 2, 2040, 54, 560, 8, 419, 1063, 1085, 9, 429, 2, 4573, 34, 115, 9, 28, 506, 14, 111, 445, 122, 40, 1336, 6, 4573, 319, 337, 137, 491, 1906, 6, 40, 28, 43, 9, 429, 2, 4640, 787, 2, 282, 229, 611, 32, 575, 6, 3241, 429, 43, 2, 319, 337, 497, 787, 4, 26, 266]",1991.0,25316109,Long-term survival late effects one-year survivors second allogeneic hematopoietic transplantation relapsed acute leukemia myelodysplastic syndromes,3,0.005235602094240838
"Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.",Blood,Blood,2014-10-14,"High-dose, posttransplantation cyclophosphamide (PTCy) reduces severe graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (alloBMT), but the impact of PTCy on long-term, disease-specific outcomes is unclear. We conducted a retrospective study of 209 consecutive adult patients transplanted for acute myeloid leukemia (AML, n = 138), myelodysplastic syndrome (n = 28), or acute lymphoblastic leukemia (ALL, n = 43) using PTCy as sole GVHD prophylaxis after myeloablative conditioning and HLA-matched-related or -unrelated T-cell-replete allografting. At alloBMT, 30% of patients were not in morphologic complete remission. The cumulative incidences of grades II to IV and III to IV acute GVHD at 100 days and chronic GVHD at 2 years were 45%, 11%, and 13%, respectively. Forty-three percent of patients did not require immunosuppression for any reason beyond PTCy. At 3 years, relapse cumulative incidence was 36%, disease-free survival was 46%, survival free of disease and chronic GVHD was 39%, and overall survival was 58%. Lack of remission at alloBMT, adverse cytogenetics, and low allograft nucleated cell dose were associated with inferior survival for AML patients. Minimal residual disease but not t(9;22) was associated with inferior outcomes for ALL patients. The ability to limit posttransplantation immunosuppression makes PTCy a promising transplantation platform for the integration of postgrafting strategies to prevent relapse. ",Journal Article,1925.0,78.0,High-dose posttransplantation cyclophosphamide PTCy reduces severe graft-versus-host disease GVHD allogeneic blood marrow transplantation alloBMT impact PTCy long-term disease-specific outcomes unclear conducted retrospective 209 consecutive adult patients transplanted acute myeloid leukemia AML n 138 myelodysplastic syndrome n 28 acute lymphoblastic leukemia n 43 PTCy sole GVHD prophylaxis myeloablative conditioning HLA-matched-related -unrelated T-cell-replete allografting alloBMT 30 patients morphologic complete remission cumulative incidences grades II IV III IV acute GVHD 100 days chronic GVHD 2 years 45 11 13 respectively Forty-three percent patients require immunosuppression reason PTCy 3 years relapse cumulative incidence 36 disease-free survival 46 survival free disease chronic GVHD 39 overall survival 58 Lack remission alloBMT adverse cytogenetics low allograft nucleated dose associated inferior survival AML patients Minimal residual disease 9 22 associated inferior outcomes patients ability limit posttransplantation immunosuppression makes PTCy promising transplantation platform integration postgrafting strategies prevent relapse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[64, 61, 8046, 1112, 10932, 2389, 905, 1599, 185, 1204, 34, 1562, 50, 1063, 315, 15, 581, 497, 13051, 84, 3, 345, 1, 10932, 23, 319, 337, 34, 112, 123, 16, 1200, 21, 426, 8, 459, 45, 1, 5941, 935, 780, 7, 4600, 9, 286, 533, 329, 78, 4478, 681, 78, 339, 15, 286, 1275, 62, 78, 601, 75, 10932, 22, 4991, 1562, 2049, 50, 3246, 1933, 2, 1160, 655, 139, 15, 2092, 102, 31, 11151, 16181, 28, 13051, 201, 1, 7, 11, 44, 4, 2815, 236, 734, 3, 967, 3981, 1, 2276, 215, 6, 478, 2, 316, 6, 478, 286, 1562, 28, 394, 162, 2, 442, 1562, 28, 18, 60, 11, 512, 175, 2, 233, 106, 1213, 169, 714, 1, 7, 205, 44, 1353, 3646, 9, 500, 3852, 1654, 10932, 28, 27, 60, 429, 967, 287, 10, 511, 34, 115, 25, 10, 641, 25, 115, 1, 34, 2, 442, 1562, 10, 587, 2, 63, 25, 10, 717, 926, 1, 734, 28, 13051, 290, 2510, 2, 154, 9568, 9862, 31, 61, 11, 41, 5, 1663, 25, 9, 329, 7, 1048, 753, 34, 84, 44, 102, 83, 350, 10, 41, 5, 1663, 123, 9, 62, 7, 3, 801, 6, 2385, 8046, 3646, 4677, 10932, 8, 721, 497, 2243, 9, 3, 2676, 1, 28085, 422, 6, 1682, 429]",1386.0,25316679,Single-agent GVHD prophylaxis posttransplantation cyclophosphamide myeloablative HLA-matched BMT AML MDS,61,0.10645724258289703
Second cancer risk in childhood cancer survivors treated with intensity-modulated radiation therapy (IMRT).,Pediatric blood & cancer,Pediatr Blood Cancer,2014-10-18,"Treatment with radiotherapy (RT) is associated with an increased risk of second malignant neoplasms (SMNs) in childhood cancer survivors; it is unclear how treatment with intensity-modulated radiation therapy (IMRT) impacts this risk. We provide the first report of SMN risk in a cohort of childhood cancer survivors treated with IMRT. Retrospective review of patients 21 years of age treated with IMRT at Memorial Sloan Kettering Cancer Center between December 1998 and February 2009. Eligible patients survived at least 5 years from IMRT initiation. The risk of SMN was assessed via standardized incidence ratios (SIRs) and excess absolute risk (EAR). The cumulative incidence was estimated using methods for competing risks. Among 242 patients, six developed SMNs: four developed second solid cancers (all within the radiation field), and two developed myelodysplastic syndrome. Median time from IMRT initiation to a second solid cancer was 7.2 years (range, 6.8-9.5), with a 10-year cumulative incidence of 3.3% (95% confidence interval [CI], 1.0-7.8%), SIR of 11.4 (95% CI, 3.1-29.2) and EAR of 1.8 per 1,000 person-years (95% CI, -0.1 to 3.8). Longer follow-up is required to determine how the risk of SMN after IMRT compares to other modalities of radiation treatment, such as proton therapy. This study provides a preliminary report, which will serve as a baseline for future longitudinal analyses of SMN risk after IMRT. Pediatr Blood Cancer 2015;62:311-316.  2014 Wiley Periodicals, Inc.",Journal Article,1921.0,4.0,"Treatment radiotherapy RT associated increased risk second malignant neoplasms SMNs childhood survivors unclear treatment intensity-modulated radiation therapy IMRT impacts risk provide report SMN risk cohort childhood survivors treated IMRT Retrospective review patients 21 years age treated IMRT Memorial Sloan Kettering Center December 1998 February 2009 Eligible patients survived 5 years IMRT initiation risk SMN assessed standardized incidence ratios SIRs excess absolute risk EAR cumulative incidence estimated methods competing risks 242 patients developed SMNs developed second solid radiation field developed myelodysplastic syndrome Median time IMRT initiation second solid 7.2 years range 6.8-9.5 10-year cumulative incidence 3.3 95 confidence interval CI 1.0-7.8 SIR 11.4 95 CI 3.1-29.2 EAR 1.8 1,000 person-years 95 CI -0.1 3.8 Longer follow-up required determine risk SMN IMRT compares modalities radiation treatment proton therapy provides preliminary report serve baseline future longitudinal SMN risk IMRT Pediatr Blood 2015 62:311-316  2014 Wiley Periodicals",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[24, 5, 310, 240, 16, 41, 5, 35, 101, 43, 1, 419, 393, 1179, 6580, 4, 864, 12, 332, 192, 16, 1200, 832, 24, 5, 837, 1757, 121, 36, 964, 4719, 26, 43, 21, 377, 3, 157, 414, 1, 6474, 43, 4, 8, 180, 1, 864, 12, 332, 73, 5, 964, 459, 206, 1, 7, 22725, 60, 1, 89, 73, 5, 964, 28, 2563, 2783, 2784, 12, 574, 59, 1397, 1850, 2, 3010, 1238, 625, 7, 2996, 28, 506, 33, 60, 29, 964, 1118, 3, 43, 1, 6474, 10, 275, 847, 1670, 287, 1137, 7120, 2, 2612, 1766, 43, 7815, 3, 967, 287, 10, 661, 75, 636, 9, 2573, 1098, 107, 7722, 7, 437, 276, 6580, 294, 276, 419, 537, 163, 62, 262, 3, 121, 1067, 2, 100, 276, 681, 52, 98, 29, 964, 1118, 6, 8, 419, 537, 12, 10, 67, 18, 60, 184, 49, 66, 83, 33, 5, 8, 79, 111, 967, 287, 1, 27, 27, 48, 307, 268, 58, 14, 13, 67, 66, 3636, 1, 175, 39, 48, 58, 27, 14, 462, 18, 2, 7815, 1, 14, 66, 379, 14, 984, 2719, 60, 48, 58, 13, 14, 6, 27, 66, 589, 166, 126, 16, 616, 6, 223, 832, 3, 43, 1, 6474, 50, 964, 5815, 6, 127, 1558, 1, 121, 24, 225, 22, 2095, 36, 26, 45, 777, 8, 1676, 414, 92, 303, 1833, 22, 8, 330, 9, 508, 2380, 318, 1, 6474, 43, 50, 964, 24524, 315, 12, 1483, 744, 9521, 8500, 2206, 1409, 4692, 5493, 3479]",1431.0,25328040,Second risk childhood survivors treated intensity-modulated radiation therapy IMRT,0,0.0
A phase II study of AZD2171 (cediranib) in the treatment of patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.,Leukemia & lymphoma,Leuk. Lymphoma,2014-11-19,"Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) not fit for intensive treatment need novel therapy options. Vascular endothelial growth factor (VEGF) receptor inhibition is one potential mechanism by which AML and MDS could be treated. The receptor tyrosine kinase inhibitor AZD2171 (cediranib) has activity against VEGF receptors KDR and FLT-1. This multicenter phase II study was designed to test cediranib's activity in patients with AML or high-risk MDS. The primary endpoint was confirmed disease response defined as a composite of complete remission, partial remission or hematologic improvement. The study enrolled 23 subjects in the AML cohort and 16 subjects in the MDS cohort. There were no confirmed responses in either group. Since the study met the stopping rule after the first stage of enrollment, the trial was closed to further accrual. Common adverse events in both cohorts included thrombocytopenia, neutropenia, anemia, fatigue, dyspnea, diarrhea, nausea and dehydration. ","Clinical Trial, Phase II",1889.0,5.0,Patients acute myeloid leukemia AML myelodysplastic syndrome MDS fit intensive treatment need novel therapy options Vascular endothelial growth factor VEGF receptor inhibition potential mechanism AML MDS treated receptor tyrosine kinase inhibitor AZD2171 cediranib activity VEGF receptors KDR FLT-1 multicenter phase II designed test cediranib 's activity patients AML high-risk MDS primary endpoint confirmed disease response defined composite complete remission partial remission hematologic improvement enrolled 23 subjects AML cohort 16 subjects MDS cohort confirmed responses group met stopping rule stage enrollment trial closed accrual Common adverse events cohorts included thrombocytopenia neutropenia anemia fatigue dyspnea diarrhea nausea dehydration,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7, 5, 286, 533, 329, 2, 681, 1223, 44, 2975, 9, 1686, 24, 594, 229, 36, 838, 756, 845, 129, 161, 618, 153, 297, 16, 104, 174, 670, 20, 92, 329, 2, 1223, 359, 40, 73, 3, 153, 564, 216, 230, 14976, 5274, 71, 128, 480, 618, 1186, 8513, 2, 4368, 14, 26, 1570, 124, 215, 45, 10, 1114, 6, 412, 5274, 292, 128, 4, 7, 5, 329, 15, 64, 43, 1223, 3, 86, 1138, 10, 557, 34, 51, 395, 22, 8, 3308, 1, 236, 734, 450, 734, 15, 813, 767, 3, 45, 346, 382, 976, 4, 3, 329, 180, 2, 245, 976, 4, 3, 1223, 180, 125, 11, 77, 557, 253, 4, 361, 87, 1192, 3, 45, 543, 3, 6811, 5340, 50, 3, 157, 82, 1, 1798, 3, 160, 10, 3745, 6, 195, 2262, 186, 290, 281, 4, 110, 736, 159, 1340, 778, 1545, 613, 2923, 1172, 1218, 2, 5414]",972.0,25329007,phase II AZD2171 cediranib treatment patients acute myeloid leukemia high-risk myelodysplastic syndrome,20,0.034904013961605584
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.,Cancer,Cancer,2014-10-21,"Hypomethylating agents have demonstrated activity in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Preclinical and single-arm trials have suggested that adding histone deacetylase (HDAC) inhibitors may synergize the epigenetic modulation of hypomethylating agents and improve treatment results. The objective of this study was to evaluate the possible benefit of adding valproic acid, an HDAC inhibitor, to decitabine in the treatment of MDS and AML. Patients with higher risk MDS or with AML aged 60 years were eligible. Patients were randomized in a Bayesian response-adaptive design to receive intravenous decitabine 20 mg/m(2) daily for 5 days or decitabine plus oral valproic acid 50 mg/kg daily for 7 days. Courses were repeated every 4 to 6 weeks. A maximum of 150 patients were to be treated. In total, 149 patients were treated on study, including 87 patients with MDS and 62 patients with AML. The median patient age was 69 years (range, 20-89 years; 42% of patients were aged 70 years). Overall, 34% of patients achieved complete remission, and 55% had an objective response. The median survival was 11.9 months, and the estimated 2-year survival rate was 27%. Outcome was not different with the addition of valproic acid to decitabine versus decitabine alone in relation to the rates of complete remission, overall response, or survival. Subset analyses did not demonstrate a benefit within the MDS or AML categories. Toxicities-particularly neurotoxicities-were higher with the combination arm. Adding valproic acid to decitabine was not associated with improved outcome in the treatment of patients with MDS or elderly patients with AML. Future therapies may consider combining hypomethylating agents with better HDAC inhibitors and using different schedules.","Clinical Trial, Phase II",1918.0,88.0,Hypomethylating agents demonstrated activity patients myelodysplastic syndrome MDS acute myeloid leukemia AML Preclinical single-arm trials suggested adding histone deacetylase HDAC inhibitors synergize epigenetic modulation hypomethylating agents improve treatment objective evaluate possible benefit adding valproic acid HDAC inhibitor decitabine treatment MDS AML Patients higher risk MDS AML aged 60 years eligible Patients randomized Bayesian response-adaptive design receive intravenous decitabine 20 mg/m 2 daily 5 days decitabine plus oral valproic acid 50 mg/kg daily 7 days Courses repeated 4 6 weeks maximum 150 patients treated total 149 patients treated including 87 patients MDS 62 patients AML median patient age 69 years range 20-89 years 42 patients aged 70 years Overall 34 patients achieved complete remission 55 objective response median survival 11.9 months estimated 2-year survival rate 27 Outcome different addition valproic acid decitabine versus decitabine relation rates complete remission overall response survival Subset demonstrate benefit MDS AML categories Toxicities-particularly neurotoxicities-were higher combination arm Adding valproic acid decitabine associated improved outcome treatment patients MDS elderly patients AML Future therapies consider combining hypomethylating agents better HDAC inhibitors different schedules,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4931, 183, 47, 264, 128, 4, 7, 5, 681, 1223, 2, 286, 533, 329, 693, 2, 226, 475, 143, 47, 1148, 17, 2726, 1508, 2732, 2654, 222, 68, 8717, 3, 1418, 2356, 1, 4931, 183, 2, 401, 24, 99, 3, 461, 1, 26, 45, 10, 6, 376, 3, 899, 247, 1, 2726, 11029, 971, 35, 2654, 230, 6, 3004, 4, 3, 24, 1, 1223, 2, 329, 7, 5, 142, 43, 1223, 15, 5, 329, 1032, 6690, 60, 11, 625, 7, 11, 384, 4, 8, 5032, 51, 2454, 771, 6, 560, 1262, 3004, 179, 81, 188, 18, 391, 9, 33, 162, 15, 3004, 349, 518, 11029, 971, 212, 81, 503, 391, 9, 67, 162, 1993, 11, 2113, 454, 39, 6, 49, 244, 8, 689, 1, 1577, 7, 11, 6, 40, 73, 4, 181, 4928, 7, 11, 73, 23, 45, 141, 912, 7, 5, 1223, 2, 744, 7, 5, 329, 3, 52, 69, 89, 10, 790, 60, 184, 179, 887, 60, 595, 1, 7, 11, 1032, 6146, 60, 63, 562, 1, 7, 513, 236, 734, 2, 614, 42, 35, 461, 51, 3, 52, 25, 10, 175, 83, 53, 2, 3, 661, 18, 111, 25, 116, 10, 428, 228, 10, 44, 338, 5, 3, 352, 1, 11029, 971, 6, 3004, 185, 3004, 279, 4, 2191, 6, 3, 151, 1, 236, 734, 63, 51, 15, 25, 697, 318, 205, 44, 608, 8, 247, 262, 3, 1223, 15, 329, 1996, 385, 823, 20989, 11, 142, 5, 3, 150, 475, 2726, 11029, 971, 6, 3004, 10, 44, 41, 5, 231, 228, 4, 3, 24, 1, 7, 5, 1223, 15, 1216, 7, 5, 329, 508, 235, 68, 2419, 1525, 4931, 183, 5, 380, 2654, 222, 2, 75, 338, 2314]",1743.0,25336333,phase 2 randomized low-dose decitabine valproic acid patients myelodysplastic syndrome acute myelogenous leukemia,112,0.19546247818499127
Flow cytometry immunophenotypic findings in chronic myelomonocytic leukemia and its utility in monitoring treatment response.,European journal of haematology,Eur. J. Haematol.,2015-04-17,"Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative neoplasm, characterized by persistent monocytosis. Due to the lack of unique surface markers expressed by neoplastic monocytes and the frequent CD34-negative blast immunophenotype, the diagnostic value of flow cytometric immunophenotyping (FCI) in CMML is rarely studied. In this study, by using a multicolor FCI assay, we assessed bone marrow (BM) immunophenotypical alterations in 118 CMML patients and follow-up BM samples in 35 of these patients. The median BM monocytes as determined by FCI were 14% (1-63%), correlated with morphologic count (P = 0.0004). FCI alterations in monocytes were observed in 96% and granulocytes in 83% of cases. The percentage of CD34(+) myeloblasts by FCI was low [median 0.6% (0.02-12.6%)], but exhibiting frequent aberrancies [median 6 (2-12)]. CD34(+) B-cell precursors were absent in 93% of cases. In 35 patients with follow-up BM samples assessed, the CD34(+) myeloblasts showed persistent FCI aberrancies in all 29 patients treated with hypomethylating agents and 3 patients on observation, but became normal in 3 patients following stem cell transplant. In conclusion, CMML exhibit numerous FCI alterations in monocytes, granulocytes, and more profound/frequent in CD34(+) myeloblasts. These findings provide solid evidence for using FCI as an ancillary test in CMML diagnosis and also, in assessment of treatment responses.",Journal Article,1740.0,23.0,Chronic myelomonocytic leukemia CMML myelodysplastic/myeloproliferative neoplasm characterized persistent monocytosis lack unique surface markers expressed neoplastic monocytes frequent CD34-negative blast immunophenotype diagnostic value flow cytometric immunophenotyping FCI CMML rarely studied multicolor FCI assessed bone marrow BM immunophenotypical alterations 118 CMML patients follow-up BM 35 patients median BM monocytes determined FCI 14 1-63 correlated morphologic count P 0.0004 FCI alterations monocytes observed 96 granulocytes 83 cases percentage CD34 myeloblasts FCI low median 0.6 0.02-12.6 exhibiting frequent aberrancies median 6 2-12 CD34 B-cell precursors absent 93 cases 35 patients follow-up BM assessed CD34 myeloblasts showed persistent FCI aberrancies 29 patients treated hypomethylating agents 3 patients observation normal 3 patients following stem transplant CMML exhibit numerous FCI alterations monocytes granulocytes profound/frequent CD34 myeloblasts findings provide solid evidence FCI ancillary test CMML diagnosis assessment treatment responses,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 5451, 3382, 16, 8, 10589, 10857, 2131, 765, 20, 1882, 16875, 520, 6, 3, 926, 1, 991, 1255, 525, 570, 20, 2000, 5078, 2, 3, 908, 2215, 199, 3112, 5496, 3, 752, 549, 1, 1412, 6226, 9416, 18745, 4, 3382, 16, 2416, 656, 4, 26, 45, 20, 75, 8, 11920, 18745, 719, 21, 275, 581, 1246, 23613, 593, 4, 4002, 3382, 7, 2, 166, 126, 1246, 347, 4, 465, 1, 46, 7, 3, 52, 1246, 5078, 22, 509, 20, 18745, 11, 213, 14, 676, 438, 5, 2815, 1276, 19, 13, 5295, 18745, 593, 4, 5078, 11, 164, 4, 921, 2, 12695, 4, 852, 1, 140, 3, 1150, 1, 2215, 14909, 20, 18745, 10, 154, 52, 13, 49, 13, 588, 133, 49, 84, 4801, 908, 17158, 52, 49, 18, 133, 2215, 132, 31, 4881, 11, 3269, 4, 966, 1, 140, 4, 465, 7, 5, 166, 126, 1246, 347, 275, 3, 2215, 14909, 224, 1882, 18745, 17158, 4, 62, 462, 7, 73, 5, 4931, 183, 2, 27, 7, 23, 1664, 84, 3451, 295, 4, 27, 7, 366, 452, 31, 941, 4, 1221, 3382, 2239, 2331, 18745, 593, 4, 5078, 12695, 2, 80, 4399, 908, 4, 2215, 14909, 46, 272, 377, 537, 241, 9, 75, 18745, 22, 35, 8496, 412, 4, 3382, 147, 2, 120, 4, 455, 1, 24, 253]",1370.0,25354960,Flow cytometry immunophenotypic findings chronic myelomonocytic leukemia utility monitoring treatment response,0,0.0
MLL gene amplification in acute myeloid leukemia and myelodysplastic syndromes is associated with characteristic clinicopathological findings and TP53 gene mutation.,Human pathology,Hum. Pathol.,2014-10-02,"MLL gene rearrangements are well-recognized aberrations in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). In contrast, MLL gene amplification in AML/MDS remains poorly characterized. Here, we report a series of 21 patients with myeloid neoplasms associated with MLL gene amplification from 1 institution. This series included 13 men and 8 women, with a median age of 64 years. Eleven patients presented as AML with myelodysplasia-related changes, 6 as therapy-related AML, and 4 as therapy-related MDS. All patients had a highly complex karyotype, including frequent -5/del(5q), -18, and -17/del(17p) abnormalities; 16 patients were hypodiploid. TP53 mutations were detected in all 12 patients tested, and 3 patients showed TP53 mutation before MLL amplification. Morphologically, the leukemic cells frequently showed cytoplasmic vacuoles, bilobed nuclei, and were associated with background dyspoiesis. Immunophenotypically, 15 patients had a myeloid and 4 had myelomonocytic immunophenotype. Laboratory coagulopathies were common; 7 patients developed disseminated intravascular coagulopathy, and 3 died of intracranial bleeding. All patients were refractory to therapy; the median overall survival was 1 month, after MLL gene amplification was detected. We concluded that AML/MDS with MLL gene amplification is likely a subset of therapy-related AML/MDS or AML with myelodysplasia-related changes, associated with distinct clinicopathological features, frequent disseminated intravascular coagulopathy, a highly complex karyotype, TP53 deletion/mutation, and an aggressive clinical course. ",Journal Article,1937.0,16.0,MLL rearrangements well-recognized aberrations acute myeloid leukemia AML myelodysplastic syndromes MDS contrast MLL amplification AML/MDS remains poorly characterized report series 21 patients myeloid neoplasms associated MLL amplification 1 institution series included 13 men 8 women median age 64 years patients presented AML myelodysplasia-related changes 6 therapy-related AML 4 therapy-related MDS patients highly complex karyotype including frequent -5/del 5q -18 -17/del 17p abnormalities 16 patients hypodiploid TP53 detected 12 patients tested 3 patients showed TP53 MLL amplification Morphologically leukemic frequently showed cytoplasmic vacuoles bilobed nuclei associated background dyspoiesis Immunophenotypically 15 patients myeloid 4 myelomonocytic immunophenotype Laboratory coagulopathies common 7 patients developed disseminated intravascular coagulopathy 3 died intracranial bleeding patients refractory therapy median overall survival 1 month MLL amplification detected concluded AML/MDS MLL amplification likely subset therapy-related AML/MDS AML myelodysplasia-related changes associated distinct clinicopathological features frequent disseminated intravascular coagulopathy highly complex karyotype TP53 deletion/mutation aggressive clinical course,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3049, 145, 2072, 32, 149, 1904, 2152, 4, 286, 533, 329, 2, 2040, 1223, 4, 748, 3049, 145, 1073, 4, 329, 1223, 469, 1240, 765, 467, 21, 414, 8, 988, 1, 239, 7, 5, 533, 1179, 41, 5, 3049, 145, 1073, 29, 14, 731, 26, 988, 159, 233, 325, 2, 66, 117, 5, 8, 52, 89, 1, 660, 60, 2627, 7, 917, 22, 329, 5, 6128, 139, 400, 49, 22, 36, 139, 329, 2, 39, 22, 36, 139, 1223, 62, 7, 42, 8, 561, 840, 3385, 141, 908, 33, 3084, 5460, 203, 2, 269, 3084, 4135, 1171, 245, 7, 11, 12135, 1206, 138, 11, 530, 4, 62, 133, 7, 650, 2, 27, 7, 224, 1206, 258, 348, 3049, 1073, 6204, 3, 2015, 37, 746, 224, 2828, 22412, 65157, 4725, 2, 11, 41, 5, 2426, 65158, 24516, 167, 7, 42, 8, 533, 2, 39, 42, 5451, 5496, 1624, 40891, 11, 186, 67, 7, 276, 3605, 8741, 10029, 2, 27, 1016, 1, 2089, 2294, 62, 7, 11, 430, 6, 36, 3, 52, 63, 25, 10, 14, 811, 50, 3049, 145, 1073, 10, 530, 21, 4724, 17, 329, 1223, 5, 3049, 145, 1073, 16, 322, 8, 697, 1, 36, 139, 329, 1223, 15, 329, 5, 6128, 139, 400, 41, 5, 834, 2721, 404, 908, 3605, 8741, 10029, 8, 561, 840, 3385, 1206, 1528, 258, 2, 35, 571, 38, 906]",1545.0,25387813,MLL amplification acute myeloid leukemia myelodysplastic syndromes associated characteristic clinicopathological findings TP53,5,0.008726003490401396
A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution.,Acta haematologica,Acta Haematol.,2014-11-20,"Chronic myelomonocytic leukemia (CMML), a clonal hematopoietic stem cell disease, may be linked to immune-mediated processes and/or autoimmune disorders (AID), although the exact pathogens are still elusive. We retrospectively analyzed 123 CMML patients in our institution. Twenty-four CMML patients (19.5%) had at least one immune-mediated disorder, most commonly idiopathic thrombocytopenic purpura, gout and psoriasis. Four of these 24 patients (15%) had more than one AID. We found that, in contrast to the general population with a prevalence rate of 3.2-5.2%, newly diagnosed CMML patients demonstrated a high prevalence and variety of immune-mediated processes and/or AID. When we compared the results with those of myelodysplastic syndromes published in the literature, the prevalence of AID in these two groups of patients is similar. Our results also showed that the presence of cytogenetic abnormalities was less in CMML patients with AID (6 of 21; 28.6%) than in those without AID (37 of 94; 39.4%), although there was no statistical significance (p = 0.334). A multicenter large cohort study of CMML with AID is recommended to illustrate the molecular relationship between the two distinct groups.",Clinical Trial,1888.0,20.0,Chronic myelomonocytic leukemia CMML clonal hematopoietic stem disease linked immune-mediated processes and/or autoimmune disorders AID exact pathogens elusive retrospectively 123 CMML patients institution Twenty-four CMML patients 19.5 immune-mediated disorder commonly idiopathic thrombocytopenic purpura gout psoriasis 24 patients 15 AID contrast general population prevalence rate 3.2-5.2 newly diagnosed CMML patients demonstrated high prevalence variety immune-mediated processes and/or AID compared myelodysplastic syndromes published literature prevalence AID groups patients similar showed presence cytogenetic abnormalities CMML patients AID 6 21 28.6 AID 37 94 39.4 statistical significance p 0.334 multicenter large cohort CMML AID recommended illustrate molecular relationship distinct groups,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 5451, 3382, 8, 1946, 1007, 452, 31, 34, 68, 40, 1199, 6, 250, 517, 1849, 2, 15, 3445, 1997, 2427, 242, 3, 2472, 9275, 32, 1234, 5327, 21, 894, 311, 2698, 3382, 7, 4, 114, 731, 737, 294, 3382, 7, 326, 33, 42, 28, 506, 104, 250, 517, 2645, 96, 841, 7540, 11908, 14174, 34634, 2, 14648, 294, 1, 46, 259, 7, 167, 42, 80, 76, 104, 2427, 21, 204, 17, 4, 748, 6, 3, 1083, 266, 5, 8, 1078, 116, 1, 27, 18, 33, 18, 732, 265, 3382, 7, 264, 8, 64, 1078, 2, 1362, 1, 250, 517, 1849, 2, 15, 2427, 198, 21, 72, 3, 99, 5, 135, 1, 2040, 983, 4, 3, 789, 3, 1078, 1, 2427, 4, 46, 100, 271, 1, 7, 16, 288, 114, 99, 120, 224, 17, 3, 463, 1, 1266, 1171, 10, 299, 4, 3382, 7, 5, 2427, 49, 1, 239, 339, 49, 76, 4, 135, 187, 2427, 567, 1, 960, 587, 39, 242, 125, 10, 77, 1050, 724, 19, 13, 9376, 8, 1570, 375, 180, 45, 1, 3382, 5, 2427, 16, 793, 6, 4746, 3, 219, 858, 59, 3, 100, 834, 271]",1145.0,25413011,close association autoimmune-mediated processes autoimmune disorders chronic myelomonocytic leukemia observation single institution,0,0.0
Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2014-10-30,"Although transplant practices have changed over the last decades, no information is available on trends in incidence and outcome of chronic graft-versus-host disease (cGVHD) over time. This study used the central database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to describe time trends for cGVHD incidence, nonrelapse mortality, and risk factors for cGVHD. The 12-year period was divided into 3 intervals, 1995 to 1999, 2000 to 2003, and 2004 to 2007, and included 26,563 patients with acute leukemia, chronic myeloid leukemia, and myelodysplastic syndrome. Multivariate analysis showed an increased incidence of cGVHD in more recent years (odds ratio = 1.19, P < .0001), and this trend was still seen when adjusting for donor type, graft type, or conditioning intensity. In patients with cGVHD, nonrelapse mortality has decreased over time, but at 5 years there were no significant differences among different time periods. Risk factors for cGVHD were in line with previous studies. This is the first comprehensive characterization of the trends in cGVHD incidence and underscores the mounting need for addressing this major late complication of transplantation in future research.",Journal Article,1909.0,135.0,"transplant practices changed decades information available trends incidence outcome chronic graft-versus-host disease cGVHD time central database Center International Blood Marrow Transplant Research CIBMTR time trends cGVHD incidence nonrelapse mortality risk factors cGVHD 12-year period divided 3 intervals 1995 1999 2000 2003 2004 2007 included 26,563 patients acute leukemia chronic myeloid leukemia myelodysplastic syndrome Multivariate showed increased incidence cGVHD recent years odds ratio 1.19 P .0001 trend seen adjusting donor type graft type conditioning intensity patients cGVHD nonrelapse mortality decreased time 5 years significant differences different time periods Risk factors cGVHD line previous studies comprehensive characterization trends cGVHD incidence underscores mounting need addressing major late complication transplantation future research",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[242, 941, 2634, 47, 2368, 252, 3, 1060, 1968, 77, 487, 16, 390, 23, 1963, 4, 287, 2, 228, 1, 442, 1599, 185, 1204, 34, 6670, 252, 98, 26, 45, 95, 3, 854, 609, 1, 3, 574, 9, 944, 315, 2, 581, 941, 389, 11203, 6, 897, 98, 1963, 9, 6670, 287, 4640, 282, 2, 43, 130, 9, 6670, 3, 133, 111, 727, 10, 2176, 237, 27, 1582, 2323, 6, 2043, 1081, 6, 1522, 2, 1131, 6, 1307, 2, 159, 432, 13140, 7, 5, 286, 442, 533, 2, 681, 331, 65, 224, 35, 101, 287, 1, 6670, 4, 80, 435, 60, 610, 197, 14, 326, 19, 488, 2, 26, 853, 10, 1234, 527, 198, 1358, 9, 1488, 267, 1599, 267, 15, 1933, 837, 4, 7, 5, 6670, 4640, 282, 71, 340, 252, 98, 84, 28, 33, 60, 125, 11, 77, 93, 362, 107, 338, 98, 3338, 43, 130, 9, 6670, 11, 4, 328, 5, 698, 94, 26, 16, 3, 157, 949, 2136, 1, 3, 1963, 4, 6670, 287, 2, 6926, 3, 9183, 594, 9, 3432, 26, 458, 807, 1447, 1, 497, 4, 508, 389]",1154.0,25445023,Increasing incidence chronic graft-versus-host disease allogeneic transplantation report Center International Blood Marrow Transplant Research,7,0.012216404886561954
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome.,American journal of hematology,Am. J. Hematol.,2015-03-02,"We investigated the combination of midostaurin and azacitidine (AZA) in patients with acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS). Patients received AZA 75 mg m(-2) on days 1-7 and midostaurin 25 mg bid (in cohort 1 of phase I) or 50 mg bid (in cohort 2 of Phase I and in Phase II) orally on day 8-21 during the first cycle and continuously thereafter. Fourteen patients were enrolled in the phase I and 40 in the phase II. Overall response rate was 26%. The median remission duration (RD) was 20 weeks and was significantly longer in patients with FLT3 mutations not previously exposed to other FLT3 inhibitors (P = 0.05) and in patients not previously transplanted (P = 0.01). Thirty-two (59%) patients have died, all of complications related to disease progression. G3-4 nonhematological toxicity was reported in 38 (70%) patients, most frequently infections (56%), ejection fraction reduction (11%), and diarrhea or nausea/vomiting (9% each). The combination of midostaurin and AZA is an effective and safe regimen in patients with AML and high-risk MDS. Patients with FLT3 mutations but not previously exposed to other FLT3 inhibitors and patients not previously transplanted derived the greatest benefit. Further studies with this combination are warranted.","Clinical Trial, Phase I",1786.0,72.0,investigated combination midostaurin azacitidine AZA patients acute myeloid leukemia AML high risk myelodysplastic syndrome MDS Patients received AZA 75 mg -2 days 1-7 midostaurin 25 mg bid cohort 1 phase 50 mg bid cohort 2 Phase Phase II orally day 8-21 cycle continuously Fourteen patients enrolled phase 40 phase II Overall response rate 26 median remission duration RD 20 weeks significantly longer patients FLT3 previously exposed FLT3 inhibitors P 0.05 patients previously transplanted P 0.01 Thirty-two 59 patients died complications related disease progression G3-4 nonhematological toxicity reported 38 70 patients frequently infections 56 ejection fraction reduction 11 diarrhea nausea/vomiting 9 combination midostaurin AZA effective safe regimen patients AML high-risk MDS Patients FLT3 previously exposed FLT3 inhibitors patients previously transplanted derived greatest benefit studies combination warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 565, 3, 150, 1, 8824, 2, 3752, 3924, 4, 7, 5, 286, 533, 329, 2, 64, 43, 681, 1223, 7, 103, 3924, 481, 81, 188, 18, 23, 162, 14, 67, 2, 8824, 243, 81, 2793, 4, 180, 14, 1, 124, 70, 15, 212, 81, 2793, 4, 180, 18, 1, 124, 70, 2, 4, 124, 215, 1428, 23, 218, 66, 239, 190, 3, 157, 417, 2, 4285, 3972, 3225, 7, 11, 346, 4, 3, 124, 70, 2, 327, 4, 3, 124, 215, 63, 51, 116, 10, 432, 3, 52, 734, 654, 3089, 10, 179, 244, 2, 10, 97, 589, 4, 7, 5, 1224, 138, 44, 373, 2234, 6, 127, 1224, 222, 19, 13, 474, 2, 4, 7, 44, 373, 4600, 19, 13, 355, 977, 100, 728, 7, 47, 1016, 62, 1, 521, 139, 6, 34, 91, 5578, 39, 12494, 155, 10, 210, 4, 519, 431, 7, 96, 746, 1875, 664, 5420, 1509, 628, 175, 2, 1172, 15, 1218, 1966, 83, 296, 3, 150, 1, 8824, 2, 3924, 16, 35, 323, 2, 1165, 477, 4, 7, 5, 329, 2, 64, 43, 1223, 7, 5, 1224, 138, 84, 44, 373, 2234, 6, 127, 1224, 222, 2, 7, 44, 373, 4600, 526, 3, 2199, 247, 195, 94, 5, 26, 150, 32, 1197]",1217.0,25530214,Phase I/II trial combination midostaurin PKC412 5-azacytidine patients acute myeloid leukemia myelodysplastic syndrome,57,0.09947643979057591
Risk of marrow neoplasms after adjuvant breast cancer therapy: the national comprehensive cancer network experience.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2014-12-22,"Outcomes for early-stage breast cancer have improved. First-generation adjuvant chemotherapy trials reported a 0.27% 8-year cumulative incidence of myelodysplastic syndrome/acute myelogenous leukemia. Incomplete ascertainment and follow-up may have underestimated subsequent risk of treatment-associated marrow neoplasm (MN). We examined the MN frequency in 20,063 patients with stage I to III breast cancer treated at US academic centers between 1998 and 2007. Time-to-event analyses were censored at first date of new cancer event, last contact date, or death and considered competing risks. Cumulative incidence, hazard ratios (HRs), and comparisons with Surveillance, Epidemiology, and End Results estimates were obtained. Marrow cytogenetics data were reviewed. Fifty patients developed MN (myeloid, n = 42; lymphoid, n = 8) after breast cancer (median follow-up, 5.1 years). Patients who developed MN had similar breast cancer stage distribution, race, and chemotherapy exposure but were older compared with patients who did not develop MN (median age, 59.1 v 53.9 years, respectively; P = .03). Two thirds of patients had complex MN cytogenetics. Risk of MN was significantly increased after surgery plus chemotherapy (HR, 6.8; 95% CI, 1.3 to 36.1) or after all modalities (surgery, chemotherapy, and radiation; HR, 7.6; 95% CI, 1.6 to 35.8), compared with no treatment with chemotherapy. MN rates per 1,000 person-years were 0.16 (surgery), 0.43 (plus radiation), 0.46 (plus chemotherapy), and 0.54 (all three modalities). Cumulative incidence of MN doubled between years 5 and 10 (0.24% to 0.48%); 9% of patients were alive at 10 years. In this large early-stage breast cancer cohort, MN risk after radiation and/or adjuvant chemotherapy was low but higher than previously described. Risk continued to increase beyond 5 years. Individual risk of MN must be balanced against the absolute survival benefit of adjuvant chemotherapy.",Journal Article,1856.0,50.0,"Outcomes early-stage breast improved First-generation adjuvant chemotherapy trials reported 0.27 8-year cumulative incidence myelodysplastic syndrome/acute myelogenous leukemia Incomplete ascertainment follow-up underestimated subsequent risk treatment-associated marrow neoplasm MN examined MN frequency 20,063 patients stage III breast treated academic centers 1998 2007 Time-to-event censored date new event contact date death considered competing risks Cumulative incidence hazard ratios HRs comparisons Surveillance Epidemiology End estimates obtained Marrow cytogenetics reviewed patients developed MN myeloid n 42 lymphoid n 8 breast median follow-up 5.1 years Patients developed MN similar breast stage distribution race chemotherapy exposure older compared patients develop MN median age 59.1 v 53.9 years respectively P .03 thirds patients complex MN cytogenetics Risk MN significantly increased surgery plus chemotherapy HR 6.8 95 CI 1.3 36.1 modalities surgery chemotherapy radiation HR 7.6 95 CI 1.6 35.8 compared treatment chemotherapy MN rates 1,000 person-years 0.16 surgery 0.43 plus radiation 0.46 plus chemotherapy 0.54 modalities Cumulative incidence MN doubled years 5 10 0.24 0.48 9 patients alive 10 years large early-stage breast cohort MN risk radiation and/or adjuvant chemotherapy low higher previously described Risk continued increase 5 years Individual risk MN balanced absolute survival benefit adjuvant chemotherapy",1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[123, 9, 191, 82, 12, 47, 231, 157, 914, 249, 56, 143, 210, 8, 13, 428, 66, 111, 967, 287, 1, 681, 286, 2194, 2610, 10798, 2, 166, 126, 68, 47, 10585, 706, 43, 1, 24, 41, 581, 2131, 4691, 21, 409, 3, 4691, 675, 4, 179, 10592, 7, 5, 82, 70, 6, 316, 12, 73, 28, 843, 1916, 1168, 59, 1850, 2, 1307, 98, 6, 774, 318, 11, 7534, 28, 157, 1244, 1, 217, 12, 774, 1060, 4393, 1244, 15, 273, 2, 515, 2573, 1098, 967, 287, 360, 1137, 2733, 2, 2213, 5, 617, 1284, 2, 396, 99, 1423, 11, 683, 581, 2510, 74, 11, 446, 1461, 7, 276, 4691, 533, 78, 595, 2303, 78, 66, 50, 12, 52, 166, 126, 33, 14, 60, 7, 54, 276, 4691, 42, 288, 12, 82, 1395, 1047, 2, 56, 645, 84, 11, 434, 72, 5, 7, 54, 205, 44, 690, 4691, 52, 89, 728, 14, 603, 699, 83, 60, 106, 19, 680, 100, 5438, 1, 7, 42, 840, 4691, 2510, 43, 1, 4691, 10, 97, 101, 50, 152, 349, 56, 168, 49, 66, 48, 58, 14, 27, 6, 511, 14, 15, 50, 62, 1558, 152, 56, 2, 121, 168, 67, 49, 48, 58, 14, 49, 6, 465, 66, 72, 5, 77, 24, 5, 56, 4691, 151, 379, 14, 984, 2719, 60, 11, 13, 245, 152, 13, 601, 349, 121, 13, 641, 349, 56, 2, 13, 667, 62, 169, 1558, 967, 287, 1, 4691, 8431, 59, 60, 33, 2, 79, 13, 259, 6, 13, 576, 83, 1, 7, 11, 1701, 28, 79, 60, 4, 26, 375, 191, 82, 12, 180, 4691, 43, 50, 121, 2, 15, 249, 56, 10, 154, 84, 142, 76, 373, 1027, 43, 1351, 6, 344, 1654, 33, 60, 797, 43, 1, 4691, 1642, 40, 4115, 480, 3, 1766, 25, 247, 1, 249, 56]",1796.0,25534386,Risk marrow neoplasms adjuvant breast therapy national comprehensive network experience,0,0.0
Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2014-12-22,"There have been no randomized trials that have compared peripheral blood (PB) with bone marrow (BM) grafts in the setting of reduced-intensity conditioning (RIC) transplantations for hematologic malignancy. Because immune modulation plays a significant role in sustaining clinical remission after RIC, we hypothesize that higher graft-versus-host disease (GVHD) associated with PB transplantation may offer a survival advantage. The primary outcome evaluated was overall survival. Cox regression models were built to study outcomes after transplantation of PB (n = 887) relative to BM (n = 219) for patients with acute myeloid leukemia, myelodysplastic syndrome, or non-Hodgkin lymphoma, the three most common indications for unrelated RIC transplantation. Transplantations were performed in the United States between 2000 and 2008. Conditioning regimens consisted of an alkylating agent and fludarabine, and GVHD prophylaxis involved a calcineurin inhibitor (CNI) with either methotrexate (MTX) or mycophenolate mofetil (MMF). After adjusting for age, performance score, donor-recipient HLA-match, disease, and disease status at transplantation (factors associated with overall survival), there were no significant differences in 5-year rates of survival after transplantation of PB compared with BM: 34% versus 38% with CNI-MTX and 27% versus 20% with CNI-MMF GVHD prophylaxis. Survival after transplantation of PB and BM are comparable in the setting of nonirradiation RIC regimens for hematologic malignancy. The effect of GVHD prophylaxis on survival merits further evaluation.",Journal Article,1856.0,31.0,randomized trials compared peripheral blood PB bone marrow BM grafts setting reduced-intensity conditioning RIC transplantations hematologic malignancy immune modulation plays significant role sustaining clinical remission RIC hypothesize higher graft-versus-host disease GVHD associated PB transplantation offer survival advantage primary outcome evaluated overall survival Cox regression models built outcomes transplantation PB n 887 relative BM n 219 patients acute myeloid leukemia myelodysplastic syndrome non-Hodgkin lymphoma common indications unrelated RIC transplantation Transplantations performed United States 2000 2008 Conditioning regimens consisted alkylating agent fludarabine GVHD prophylaxis involved calcineurin inhibitor CNI methotrexate MTX mycophenolate mofetil MMF adjusting age performance score donor-recipient HLA-match disease disease status transplantation factors associated overall survival significant differences 5-year rates survival transplantation PB compared BM 34 versus 38 CNI-MTX 27 versus 20 CNI-MMF GVHD prophylaxis Survival transplantation PB BM comparable setting nonirradiation RIC regimens hematologic malignancy effect GVHD prophylaxis survival merits evaluation,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[125, 47, 85, 77, 384, 143, 17, 47, 72, 672, 315, 3767, 5, 581, 1246, 4713, 4, 3, 546, 1, 405, 837, 1933, 3365, 6779, 9, 813, 710, 408, 250, 2356, 1698, 8, 93, 200, 4, 10100, 38, 734, 50, 3365, 21, 4919, 17, 142, 1599, 185, 1204, 34, 1562, 41, 5, 3767, 497, 68, 1918, 8, 25, 1874, 3, 86, 228, 194, 10, 63, 25, 418, 320, 274, 11, 6859, 6, 45, 123, 50, 497, 1, 3767, 78, 23869, 580, 6, 1246, 78, 6679, 9, 7, 5, 286, 533, 681, 15, 3, 169, 96, 186, 2406, 9, 2092, 3365, 497, 6779, 11, 173, 4, 3, 1088, 907, 59, 1081, 2, 1375, 1933, 472, 1695, 1, 35, 3410, 420, 2, 2027, 2, 1562, 2049, 646, 8, 12028, 230, 16942, 5, 361, 2116, 3453, 15, 11902, 13246, 9889, 50, 1358, 9, 89, 528, 368, 1488, 5783, 1160, 5364, 34, 2, 34, 156, 28, 497, 130, 41, 5, 63, 25, 125, 11, 77, 93, 362, 4, 33, 111, 151, 1, 25, 50, 497, 1, 3767, 72, 5, 1246, 562, 185, 519, 5, 16942, 3453, 2, 428, 185, 179, 5, 16942, 9889, 1562, 2049, 25, 50, 497, 1, 3767, 2, 1246, 32, 1279, 4, 3, 546, 1, 65377, 3365, 472, 9, 813, 710, 3, 254, 1, 1562, 2049, 23, 25, 4986, 195, 451]",1483.0,25534391,Bone marrow peripheral blood reduced-intensity conditioning unrelated donor transplantation,30,0.05235602094240838
"G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.",American journal of hematology,Am. J. Hematol.,2015-01-30,"Prior study of the combination of clofarabine and high dose cytarabine with granulocyte colony-stimulating factor (G-CSF) priming (GCLAC) in relapsed or refractory acute myeloid leukemia resulted in a 46% rate of complete remission despite unfavorable risk cytogenetics. A multivariate analysis demonstrated that the remission rate and survival with GCLAC were superior to FLAG (fludarabine, cytarabine, G-CSF) in the relapsed setting. We therefore initiated a study of the GCLAC regimen in the upfront setting in a multicenter trial. The objectives were to evaluate the rates of complete remission (CR), overall and relapse-free survival (OS and RFS), and toxicity of GCLAC. Clofarabine was administered at 30 mg m(-2) day(-1)  5 and cytarabine at 2 g m(-2) day(-1)  5 after G-CSF priming in 50 newly-diagnosed patients ages 18-64 with AML or advanced myelodysplastic syndrome (MDS) or advanced myeloproliferative neoplasm (MPN). Responses were assessed in the different cytogenetic risk groups and in patients with antecedent hematologic disorder. The overall CR rate was 76% (95% confidence interval [CI] 64-88%) and the CR + CRp (CR with incomplete platelet count recovery) was 82% (95% CI 71-93%). The CR rate was 100% for patients with favorable, 84% for those with intermediate, and 62% for those with unfavorable risk cytogenetics. For patients with an antecedent hematologic disorder (AHD), the CR rate was 65%, compared to 85% for those without an AHD. The 60 day mortality was 2%. Thus, front line GCLAC is a well-tolerated, effective induction regimen for AML and advanced myelodysplastic or myeloproliferative disorders.",Clinical Trial,1817.0,7.0,Prior combination clofarabine high dose cytarabine granulocyte colony-stimulating factor G-CSF priming GCLAC relapsed refractory acute myeloid leukemia resulted 46 rate complete remission despite unfavorable risk cytogenetics multivariate demonstrated remission rate survival GCLAC superior FLAG fludarabine cytarabine G-CSF relapsed setting initiated GCLAC regimen upfront setting multicenter trial objectives evaluate rates complete remission CR overall relapse-free survival OS RFS toxicity GCLAC Clofarabine administered 30 mg -2 day -1 5 cytarabine 2 g -2 day -1 5 G-CSF priming 50 newly-diagnosed patients ages 18-64 AML advanced myelodysplastic syndrome MDS advanced myeloproliferative neoplasm MPN Responses assessed different cytogenetic risk groups patients antecedent hematologic disorder overall CR rate 76 95 confidence interval CI 64-88 CR CRp CR incomplete platelet count recovery 82 95 CI 71-93 CR rate 100 patients favorable 84 intermediate 62 unfavorable risk cytogenetics patients antecedent hematologic disorder AHD CR rate 65 compared 85 AHD 60 day mortality 2 line GCLAC well-tolerated effective induction regimen AML advanced myelodysplastic myeloproliferative disorders,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[324, 45, 1, 3, 150, 1, 4149, 2, 64, 61, 1855, 5, 2764, 1975, 2122, 161, 499, 1211, 4903, 19986, 4, 591, 15, 430, 286, 533, 627, 4, 8, 641, 116, 1, 236, 734, 550, 2483, 43, 2510, 8, 331, 65, 264, 17, 3, 734, 116, 2, 25, 5, 19986, 11, 1123, 6, 12546, 2027, 1855, 499, 1211, 4, 3, 591, 546, 21, 673, 1917, 8, 45, 1, 3, 19986, 477, 4, 3, 2941, 546, 4, 8, 1570, 160, 3, 2409, 11, 6, 376, 3, 151, 1, 236, 734, 684, 63, 2, 429, 115, 25, 118, 2, 1272, 2, 155, 1, 19986, 4149, 10, 468, 28, 201, 81, 188, 18, 218, 14, 33, 2, 1855, 28, 18, 499, 188, 18, 218, 14, 33, 50, 499, 1211, 4903, 4, 212, 732, 265, 7, 2165, 203, 660, 5, 329, 15, 131, 681, 1223, 15, 131, 2131, 4125, 253, 11, 275, 4, 3, 338, 1266, 43, 271, 2, 4, 7, 5, 8775, 813, 2645, 3, 63, 684, 116, 10, 846, 48, 307, 268, 58, 660, 889, 2, 3, 684, 3162, 684, 5, 2610, 1596, 1276, 1602, 10, 878, 48, 58, 792, 966, 3, 684, 116, 10, 394, 9, 7, 5, 913, 874, 9, 135, 5, 919, 2, 744, 9, 135, 5, 2483, 43, 2510, 9, 7, 5, 35, 8775, 813, 2645, 24163, 3, 684, 116, 10, 556, 72, 6, 772, 9, 135, 187, 35, 24163, 3, 335, 218, 282, 10, 18, 631, 3007, 328, 19986, 16, 8, 149, 421, 323, 504, 477, 9, 329, 2, 131, 15, 1997]",1488.0,25545153,G-CSF priming clofarabine high dose cytarabine GCLAC upfront treatment acute myeloid leukemia advanced myelodysplastic syndrome advanced myeloproliferative neoplasm,3,0.005235602094240838
Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.,Leukemia research,Leuk. Res.,2014-12-12,"Clofarabine, a second-generation nucleoside analog, has clinical activity in relapsed or refractory acute myelogenous leukemia (AML) and higher-risk myelodysplastic syndromes (MDS). However, there are few data evaluating performance of clofarabine in populations of patients not enrolled in clinical trials. We reviewed outcomes for 84 patients treated with clofarabine for relapsed or refractory AML or MDS, either with clofarabine as monotherapy (n=19) or in combination with cytarabine (n=65). Using International Working Group (IWG) response criteria, the overall response rate (ORR) of all treated patients was 21%, with a complete response rate with either complete or incomplete hematopoietic recovery (CRR=CR+CRi) of 14%. For combination therapy, ORR was 22% with CRR of 18%, and monotherapy patients had an ORR of 21% with CRR of 11%. Although limited by small numbers, subgroup analysis did not reveal variation in response rates when comparing different risk factors. The 30-day mortality was 21% and median survival was 3 months; a subset of 12 patients who were able to go to transplant had an 18-month median survival. Clofarabine's efficacy in a ""real-world"" setting appears to be less than has been reported in clinical trials, and treatment is associated with a high early mortality rate.",Clinical Trial,1866.0,11.0,Clofarabine second-generation nucleoside analog clinical activity relapsed refractory acute myelogenous leukemia AML higher-risk myelodysplastic syndromes MDS evaluating performance clofarabine populations patients enrolled clinical trials reviewed outcomes 84 patients treated clofarabine relapsed refractory AML MDS clofarabine monotherapy n=19 combination cytarabine n=65 International Working Group IWG response criteria overall response rate ORR treated patients 21 complete response rate complete incomplete hematopoietic recovery CRR=CR+CRi 14 combination therapy ORR 22 CRR 18 monotherapy patients ORR 21 CRR 11 limited small numbers subgroup reveal variation response rates comparing different risk factors 30-day mortality 21 median survival 3 months subset 12 patients able transplant 18-month median survival Clofarabine 's efficacy `` real-world '' setting appears reported clinical trials treatment associated high early mortality rate,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4149, 8, 419, 914, 4032, 3497, 71, 38, 128, 4, 591, 15, 430, 286, 2194, 329, 2, 142, 43, 2040, 1223, 137, 125, 32, 1021, 74, 1435, 528, 1, 4149, 4, 1184, 1, 7, 44, 346, 4, 38, 143, 21, 446, 123, 9, 874, 7, 73, 5, 4149, 9, 591, 15, 430, 329, 15, 1223, 361, 5, 4149, 22, 1411, 78, 326, 15, 4, 150, 5, 1855, 78, 556, 75, 944, 2644, 87, 14620, 51, 371, 3, 63, 51, 116, 1735, 1, 62, 73, 7, 10, 239, 5, 8, 236, 51, 116, 5, 361, 236, 15, 2610, 1007, 1602, 16134, 684, 6341, 1, 213, 9, 150, 36, 1735, 10, 350, 5, 16134, 1, 203, 2, 1411, 7, 42, 35, 1735, 1, 239, 5, 16134, 1, 175, 242, 383, 20, 302, 1870, 1363, 65, 205, 44, 2396, 1380, 4, 51, 151, 198, 1430, 338, 43, 130, 3, 201, 218, 282, 10, 239, 2, 52, 25, 10, 27, 53, 8, 697, 1, 133, 7, 54, 11, 1665, 6, 3537, 6, 941, 42, 35, 203, 811, 52, 25, 4149, 292, 209, 4, 8, 1589, 1956, 522, 546, 1233, 6, 40, 299, 76, 71, 85, 210, 4, 38, 143, 2, 24, 16, 41, 5, 8, 64, 191, 282, 116]",1245.0,25554239,Low efficacy high mortality associated clofarabine treatment relapsed/refractory acute myeloid leukemia myelodysplastic syndromes,0,0.0
"Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.",Leukemia research,Leuk. Res.,2014-12-20,"In this study we used a next generation sequencing-based approach to profile gene mutations in therapy-related myelodysplastic syndromes (t-MDS) and acute myeloid leukemia (t-AML); and compared these findings with de novo MDS/AML. Consecutive bone marrow samples of 498 patients, including 70 therapy-related (28 MDS and 42 AML) and 428 de novo (147 MDS and 281 AML) were analyzed using a modified-TruSeq Amplicon Cancer Panel (Illumina) covering mutation hotspots of 53 genes. Overall, mutation(s) were detected in 58.6% of t-MDS/AML and 56.8% of de novo MDS/AML. Of therapy-related cases, mutations were detected in 71.4% of t-AML versus 39.3% t-MDS (p=0.0127). TP53 was the most common mutated gene in t-MDS (35.7%) as well as t-AML (33.3%), significantly higher than de novo MDS (17.7%) (p=0.0410) and de novo AML (12.8%) (p=0.0020). t-AML showed more frequent PTPN11 but less NPM1 and FLT3 mutations than de novo AML. In summary, t-MDS/AML shows a mutation profile different from their de novo counterparts. TP53 mutations are highly and similarly prevalent in t-MDS and t-AML but mutations in genes other than TP53 were more frequent in t-AML than t-MDS. The molecular genetic profiling further expands our understanding in this group of clinically aggressive yet heterogeneous myeloid neoplasms. ",Comparative Study,1858.0,46.0,generation sequencing-based approach profile therapy-related myelodysplastic syndromes t-MDS acute myeloid leukemia t-AML compared findings novo MDS/AML Consecutive bone marrow 498 patients including 70 therapy-related 28 MDS 42 AML 428 novo 147 MDS 281 AML modified-TruSeq Amplicon Panel Illumina covering hotspots 53 Overall detected 58.6 t-MDS/AML 56.8 novo MDS/AML therapy-related cases detected 71.4 t-AML versus 39.3 t-MDS p=0.0127 TP53 common t-MDS 35.7 t-AML 33.3 significantly higher novo MDS 17.7 p=0.0410 novo AML 12.8 p=0.0020 t-AML showed frequent PTPN11 NPM1 FLT3 novo AML summary t-MDS/AML shows profile different novo counterparts TP53 highly similarly prevalent t-MDS t-AML TP53 frequent t-AML t-MDS molecular genetic profiling expands understanding group clinically aggressive heterogeneous myeloid neoplasms,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 26, 45, 21, 95, 8, 1305, 914, 615, 90, 353, 6, 800, 145, 138, 4, 36, 139, 2040, 102, 1223, 2, 286, 533, 102, 329, 2, 72, 46, 272, 5, 1566, 2018, 1223, 329, 935, 581, 347, 1, 8928, 7, 141, 431, 36, 139, 339, 1223, 2, 595, 329, 2, 10222, 1566, 2018, 4961, 1223, 2, 8970, 329, 11, 311, 75, 8, 1230, 48791, 9161, 12, 993, 7457, 9296, 258, 11193, 1, 699, 214, 63, 258, 695, 11, 530, 4, 717, 49, 1, 102, 1223, 329, 2, 664, 66, 1, 1566, 2018, 1223, 329, 1, 36, 139, 140, 138, 11, 530, 4, 792, 39, 1, 102, 329, 185, 587, 27, 102, 1223, 19, 13, 45359, 1206, 10, 3, 96, 186, 1185, 145, 4, 102, 1223, 465, 67, 22, 149, 22, 102, 329, 466, 27, 97, 142, 76, 1566, 2018, 1223, 269, 67, 19, 13, 39348, 2, 1566, 2018, 329, 133, 66, 19, 13, 28832, 102, 329, 224, 80, 908, 8403, 84, 299, 4318, 2, 1224, 138, 76, 1566, 2018, 329, 4, 1962, 102, 1223, 329, 1949, 8, 258, 800, 338, 29, 136, 1566, 2018, 3953, 1206, 138, 32, 561, 2, 1813, 2485, 4, 102, 1223, 2, 102, 329, 84, 138, 4, 214, 127, 76, 1206, 11, 80, 908, 4, 102, 329, 76, 102, 1223, 3, 219, 336, 1080, 195, 9365, 114, 612, 4, 26, 87, 1, 505, 571, 1145, 1564, 533, 1179]",1224.0,25573287,profiling therapy-related myelodysplastic syndromes acute myeloid leukemia generation sequencing comparison novo diseases,13,0.02268760907504363
Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.,Current opinion in hematology,Curr. Opin. Hematol.,2015-03-01,"Chronic myelomonocytic leukemia (CMML) is a troublesome hematologic malignancy characterized by peripheral blood monocytosis, marrow dysplasia, cytopenias, frequent extramedullary involvement by clonal cells, and a propensity for progression to acute myeloid leukemia. Although previously considered a subtype of the myelodysplastic syndromes (MDS), CMML is now recognized as a distinct entity with unique biologic and clinical features. This change has created a scientific and clinical research landscape that makes it difficult to discern CMML-specific validated conclusions versus speculative extrapolation from more general MDS data. Here, we review recent biologic observations that support the current CMML WHO classification, such as the high frequency of SRSF2 and ASXL1 mutations compared with MDS and critical dependence of CMML cells on granulocyte-macrophage colony-stimulating factor signaling. In addition, we discuss CMML-specific prognostic tools and therapeutic results of agents developed for MDS in patients with CMML. The present review focuses on evidence supporting CMML ontology and identifies key clinical differences in the management of CMML and that of MDS subtypes.",Journal Article,1787.0,18.0,Chronic myelomonocytic leukemia CMML troublesome hematologic malignancy characterized peripheral blood monocytosis marrow dysplasia cytopenias frequent extramedullary involvement clonal propensity progression acute myeloid leukemia previously considered subtype myelodysplastic syndromes MDS CMML recognized distinct entity unique biologic clinical features change created scientific clinical research landscape makes difficult discern CMML-specific validated conclusions versus speculative extrapolation general MDS review recent biologic observations support current CMML classification high frequency SRSF2 ASXL1 compared MDS critical dependence CMML granulocyte-macrophage colony-stimulating factor signaling addition discuss CMML-specific prognostic tools therapeutic agents developed MDS patients CMML present review focuses evidence supporting CMML ontology identifies key clinical differences management CMML MDS subtypes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 5451, 3382, 16, 8, 22115, 813, 710, 765, 20, 672, 315, 16875, 581, 2253, 5635, 908, 5508, 799, 20, 1946, 37, 2, 8, 1925, 9, 91, 6, 286, 533, 242, 373, 515, 8, 875, 1, 3, 2040, 1223, 3382, 16, 1134, 1904, 22, 8, 834, 2983, 5, 991, 1283, 2, 38, 404, 26, 707, 71, 2466, 8, 3138, 2, 38, 389, 2801, 17, 4677, 192, 1740, 6, 11643, 3382, 112, 938, 2130, 185, 28499, 14115, 29, 80, 1083, 1223, 74, 467, 21, 206, 435, 1283, 2172, 17, 538, 3, 291, 3382, 54, 947, 225, 22, 3, 64, 675, 1, 9830, 2, 7782, 138, 72, 5, 1223, 2, 740, 3721, 1, 3382, 37, 23, 2764, 2674, 1975, 2122, 161, 314, 4, 352, 21, 1139, 3382, 112, 177, 1896, 2, 189, 99, 1, 183, 276, 9, 1223, 4, 7, 5, 3382, 3, 364, 206, 3026, 23, 241, 1912, 3382, 11843, 2, 2953, 825, 38, 362, 4, 3, 284, 1, 3382, 2, 17, 1, 1223, 814]",1142.0,25575034,Cutting cord myelodysplastic syndromes chronic myelomonocytic leukemia-specific management strategies,3,0.005235602094240838
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.,Blood,Blood,2015-01-26,"Myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) are hematologically diverse stem cell malignancies sharing phenotypic features of both myelodysplastic syndromes and myeloproliferative neoplasms. There are currently no standard treatment recommendations for most adult patients with MDS/MPN. To optimize efforts to improve the management and disease outcomes, it is essential to identify meaningful clinical and biologic end points and standardized response criteria for clinical trials. The dual dysplastic and proliferative features in these stem cell malignancies define their uniqueness and challenges. We propose response assessment guidelines to harmonize future clinical trials with the principal objective of establishing suitable treatment algorithms. An international panel comprising laboratory and clinical experts in MDS/MPN was established involving 3 independent academic MDS/MPN workshops (March 2013, December 2013, and June 2014). These recommendations are the result of this collaborative project sponsored by the MDS Foundation. ",Journal Article,1821.0,66.0,Myelodysplastic syndromes MDS myeloproliferative neoplasms MPN hematologically diverse stem malignancies sharing phenotypic features myelodysplastic syndromes myeloproliferative neoplasms currently standard treatment recommendations adult patients MDS/MPN optimize efforts improve management disease outcomes essential identify meaningful clinical biologic end points standardized response criteria clinical trials dual dysplastic proliferative features stem malignancies define uniqueness challenges propose response assessment guidelines harmonize future clinical trials principal objective establishing suitable treatment algorithms international panel comprising laboratory clinical experts MDS/MPN established involving 3 independent academic MDS/MPN workshops March 2013 December 2013 June 2014 recommendations collaborative project sponsored MDS Foundation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2040, 1223, 2, 1179, 4125, 32, 37698, 1867, 452, 31, 441, 7436, 3290, 404, 1, 110, 2040, 2, 1179, 125, 32, 694, 77, 260, 24, 883, 9, 96, 780, 7, 5, 1223, 4125, 6, 2465, 1413, 6, 401, 3, 284, 2, 34, 123, 192, 16, 1452, 6, 255, 2538, 38, 2, 1283, 396, 862, 2, 1670, 51, 371, 9, 38, 143, 3, 1828, 6461, 2, 2441, 404, 4, 46, 452, 31, 441, 1107, 136, 32383, 2, 1427, 21, 2548, 51, 455, 677, 6, 27397, 508, 38, 143, 5, 3, 4312, 461, 1, 4431, 2884, 24, 3529, 35, 944, 993, 3538, 1624, 2, 38, 3186, 4, 1223, 4125, 10, 635, 1267, 27, 306, 1916, 1223, 4125, 16079, 2363, 1346, 1397, 1346, 2, 1924, 1409, 46, 883, 32, 3, 757, 1, 26, 3737, 3105, 5537, 20, 3, 1223, 3247]",984.0,25624319,international consortium proposal uniform response criteria myelodysplastic/myeloproliferative neoplasms MDS/MPN adults,0,0.0
More is better: combination therapies for myelodysplastic syndromes.,Best practice & research. Clinical haematology,Best Pract Res Clin Haematol,2014-11-11,"The myelodysplastic syndromes (MDS) are a heterogenous collection of clonal hematopoietic malignancies that exist as a subgroup of the myeloid neoplasms as classified by the World Health Organization (WHO). They are characterized by ineffective hematopoiesis, subsequent cytopenias, transformation to acute myeloid leukemia (AML), and poor overall survival. There are currently three FDA-approved medications for MDS; lenalidomide, azacitidine, and decitabine. The role of these agents is to diminish the clinical impact of MDS and delay its progression to AML. However, despite known results with these monotherapies, recent clinical trials with a variety of combinations for MDS have demonstrated promising results. These trials include combinations of hypomethylating agents, histone deacetylase inhibitors, growth factors, and chemotherapy among others. In this paper we review the current literature on combination therapies in MDS, analyze on-going and concluded trials, and suggest future possibilities for combination strategies in MDS. ",Journal Article,1897.0,18.0,myelodysplastic syndromes MDS heterogenous collection clonal hematopoietic malignancies exist subgroup myeloid neoplasms classified World Health Organization characterized ineffective hematopoiesis subsequent cytopenias transformation acute myeloid leukemia AML poor overall survival currently FDA-approved medications MDS lenalidomide azacitidine decitabine role agents diminish clinical impact MDS delay progression AML despite known monotherapies recent clinical trials variety combinations MDS demonstrated promising trials include combinations hypomethylating agents histone deacetylase inhibitors growth factors chemotherapy paper review current literature combination therapies MDS on-going concluded trials suggest future possibilities combination strategies MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2040, 1223, 32, 8, 8189, 2442, 1, 1946, 1007, 441, 17, 1923, 22, 8, 1363, 1, 3, 533, 1179, 22, 1373, 20, 3, 1956, 341, 2533, 54, 491, 32, 765, 20, 3957, 5114, 706, 5635, 1392, 6, 286, 533, 329, 2, 334, 63, 25, 125, 32, 694, 169, 2078, 850, 2679, 9, 1223, 1288, 3752, 2, 3004, 3, 200, 1, 46, 183, 16, 6, 8440, 3, 38, 345, 1, 1223, 2, 1984, 211, 91, 6, 329, 137, 550, 440, 99, 5, 46, 11670, 435, 38, 143, 5, 8, 1362, 1, 1247, 9, 1223, 47, 264, 721, 99, 46, 143, 643, 1247, 1, 4931, 183, 1508, 2732, 222, 129, 130, 2, 56, 107, 1749, 4, 26, 2817, 21, 206, 3, 291, 789, 23, 150, 235, 4, 1223, 1992, 23, 11587, 2, 4724, 143, 2, 309, 508, 10433, 9, 150, 422, 4, 1223]",993.0,25659727,better combination therapies myelodysplastic syndromes,32,0.055846422338568937
Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2015-02-07,"Graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (CY) after ablative HLA-matched bone marrow (BM) transplantation has been reported to have comparable rates of acute GVHD with an apparent reduction in chronic GVHD and infections when compared to historical prophylaxis with a calcineurin-inhibitor (CNI) and methotrexate (MTX). We conducted a phase II trial of post-transplantation CY (post-CY) after reduced-intensity conditioning (RIC) using intravenous busulfan (area under the curve of 4000 micromolar minute), fludarabine (40 mg/m(2)) for 4 days, and CY 50 mg/kg on days +3 and +4 after BM or peripheral blood (PB) transplantations from matched related (MRD) or unrelated donors (MUD). MUD recipients received antithymocyte globulin (ATG); however, a later amendment removed ATG. Forty-nine patients were treated (acute myeloid leukemia/myelodysplastic syndrome, 82%). Median age was 62 years (range, 39 to 72). Fifteen patients received an MRD (9 PB/6 BM); 34 had a MUD (2 PB/32 BM). The cumulative incidence of grade II to IV acute GVHD, III to IV acute GVHD, and chronic GVHD was 58%, 22%, and 18%, respectively. A matched cohort analysis compared outcomes to tacrolimus/methotrexate GVHD prophylaxis and indicated higher rates of acute GVHD grade II to IV (46% versus 19%; hazard ratio [HR], 2.8; P = .02) and treatment-related mortality (HR, 3.3; P = .035) and worse overall survival (HR, 1.9; P = .04) with post-CY. The incidence of chronic GVHD and CMV reactivation did not differ. This study suggests that post-CY should not be used as sole GVHD prophylaxis after a RIC transplantation from HLA-matched donors.","Clinical Trial, Phase II",1809.0,17.0,Graft-versus-host disease GVHD prophylaxis post-transplantation cyclophosphamide CY ablative HLA-matched bone marrow BM transplantation reported comparable rates acute GVHD apparent reduction chronic GVHD infections compared historical prophylaxis calcineurin-inhibitor CNI methotrexate MTX conducted phase II trial post-transplantation CY post-CY reduced-intensity conditioning RIC intravenous busulfan area curve 4000 micromolar minute fludarabine 40 mg/m 2 4 days CY 50 mg/kg days +3 +4 BM peripheral blood PB transplantations matched related MRD unrelated donors MUD MUD recipients received antithymocyte globulin ATG later amendment removed ATG Forty-nine patients treated acute myeloid leukemia/myelodysplastic syndrome 82 Median age 62 years range 39 72 patients received MRD 9 PB/6 BM 34 MUD 2 PB/32 BM cumulative incidence grade II IV acute GVHD III IV acute GVHD chronic GVHD 58 22 18 respectively matched cohort compared outcomes tacrolimus/methotrexate GVHD prophylaxis indicated higher rates acute GVHD grade II IV 46 versus 19 hazard ratio HR 2.8 P .02 treatment-related mortality HR 3.3 P .035 worse overall survival HR 1.9 P .04 post-CY incidence chronic GVHD CMV reactivation differ suggests post-CY sole GVHD prophylaxis RIC transplantation HLA-matched donors,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1599, 185, 1204, 34, 1562, 2049, 5, 539, 497, 1112, 5757, 50, 4504, 1160, 655, 581, 1246, 497, 71, 85, 210, 6, 47, 1279, 151, 1, 286, 1562, 5, 35, 2235, 628, 4, 442, 1562, 2, 1875, 198, 72, 6, 2252, 2049, 5, 8, 12028, 230, 16942, 2, 2116, 3453, 21, 426, 8, 124, 215, 160, 1, 539, 497, 5757, 539, 5757, 50, 405, 837, 1933, 3365, 75, 1262, 3906, 965, 669, 3, 1496, 1, 10660, 12174, 3949, 2027, 327, 81, 188, 18, 9, 39, 162, 2, 5757, 212, 81, 503, 23, 162, 27, 2, 39, 50, 1246, 15, 672, 315, 3767, 6779, 29, 655, 139, 2029, 15, 2092, 2344, 7070, 7070, 2190, 103, 11016, 7819, 7168, 137, 8, 1559, 11013, 2264, 7168, 1213, 762, 7, 11, 73, 286, 533, 2647, 10589, 681, 878, 52, 89, 10, 744, 60, 184, 587, 6, 720, 3057, 7, 103, 35, 2029, 83, 3767, 49, 1246, 562, 42, 8, 7070, 18, 3767, 531, 1246, 3, 967, 287, 1, 88, 215, 6, 478, 286, 1562, 316, 6, 478, 286, 1562, 2, 442, 1562, 10, 717, 350, 2, 203, 106, 8, 655, 180, 65, 72, 123, 6, 5643, 2116, 1562, 2049, 2, 1103, 142, 151, 1, 286, 1562, 88, 215, 6, 478, 641, 185, 326, 360, 197, 168, 18, 66, 19, 588, 2, 24, 139, 282, 168, 27, 27, 19, 4514, 2, 639, 63, 25, 168, 14, 83, 19, 755, 5, 539, 5757, 3, 287, 1, 442, 1562, 2, 3879, 3834, 205, 44, 1505, 26, 45, 844, 17, 539, 5757, 257, 44, 40, 95, 22, 4991, 1562, 2049, 50, 8, 3365, 497, 29, 1160, 655, 2344]",1573.0,25667989,Phase II Trial Graft-versus-Host Disease Prophylaxis Post-Transplantation Cyclophosphamide Reduced-Intensity Busulfan/Fludarabine Conditioning Hematological Malignancies,18,0.031413612565445025
Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2015-03-02,"Secondary acute myeloid leukemia (sAML), defined as AML arising after a prior myelodysplastic syndrome or after antineoplastic therapy, responds poorly to current therapies. It is often associated with adverse karyotypic abnormalities and overexpression of proteins that mediate drug resistance. We performed a phase III trial to determine whether induction therapy with cytarabine and amonafide L-malate, a DNA intercalator and non-ATP-dependent topoisomerase II inhibitor that evades drug resistance mechanisms, yielded a superior complete remission rate than standard therapy with cytarabine and daunorubicin in sAML. Patients with previously untreated sAML were randomly assigned at a one-to-one ratio to cytarabine 200 mg/m(2) continuous intravenous (IV) infusion once per day on days 1 to 7 plus either amonafide 600 mg/m(2) IV over 4 hours on days 1 to 5 (A + C arm) or daunorubicin 45 mg/m(2) IV over 30 minutes once per day on days 1 to 3 (D + C arm). The complete remission (CR) rate was 46% (99 of 216 patients) in A + C arm and 45% (97 of 217 patients) in D + C arm (P = .81). The 30- and 60-day mortality rates were 19% and 28% in A + C arm and 13% and 21% in D + C arm, respectively. Induction treatment with A + C did not improve the CR rate compared with D + C in patients with sAML.","Clinical Trial, Phase III",1786.0,33.0,Secondary acute myeloid leukemia sAML defined AML arising prior myelodysplastic syndrome antineoplastic therapy responds poorly current therapies associated adverse karyotypic abnormalities overexpression mediate drug resistance performed phase III trial determine induction therapy cytarabine amonafide L-malate DNA intercalator non-ATP-dependent topoisomerase II inhibitor evades drug resistance mechanisms yielded superior complete remission rate standard therapy cytarabine daunorubicin sAML Patients previously untreated sAML randomly assigned one-to-one ratio cytarabine 200 mg/m 2 continuous intravenous IV infusion day days 1 7 plus amonafide 600 mg/m 2 IV 4 hours days 1 5 C arm daunorubicin 45 mg/m 2 IV 30 minutes day days 1 3 C arm complete remission CR rate 46 99 216 patients C arm 45 97 217 patients C arm P .81 30- 60-day mortality rates 19 28 C arm 13 21 C arm respectively Induction treatment C improve CR rate compared C patients sAML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[568, 286, 533, 8991, 395, 22, 329, 2635, 50, 8, 324, 681, 15, 50, 3940, 36, 7920, 1240, 6, 291, 235, 192, 16, 629, 41, 5, 290, 9465, 1171, 2, 851, 1, 652, 17, 3367, 234, 251, 21, 173, 8, 124, 316, 160, 6, 223, 317, 504, 36, 5, 1855, 2, 35976, 805, 10617, 8, 261, 65710, 2, 220, 3918, 470, 3999, 215, 230, 17, 33758, 234, 251, 483, 2178, 8, 1123, 236, 734, 116, 76, 260, 36, 5, 1855, 2, 5247, 4, 8991, 7, 5, 373, 1278, 8991, 11, 1108, 896, 28, 8, 104, 6, 104, 197, 6, 1855, 1250, 81, 188, 18, 1314, 1262, 478, 904, 1059, 379, 218, 23, 162, 14, 6, 67, 349, 361, 35976, 2383, 81, 188, 18, 478, 252, 39, 1459, 23, 162, 14, 6, 33, 8, 256, 475, 15, 5247, 512, 81, 188, 18, 478, 252, 201, 2511, 1059, 379, 218, 23, 162, 14, 6, 27, 427, 256, 475, 3, 236, 734, 684, 116, 10, 641, 1058, 1, 6287, 7, 4, 8, 256, 475, 2, 512, 1015, 1, 6499, 7, 4, 427, 256, 475, 19, 865, 3, 201, 2, 335, 218, 282, 151, 11, 326, 2, 339, 4, 8, 256, 475, 2, 233, 2, 239, 4, 427, 256, 475, 106, 504, 24, 5, 8, 256, 205, 44, 401, 3, 684, 116, 72, 5, 427, 256, 4, 7, 5, 8991]",1219.0,25732165,Phase III open-label randomized cytarabine combination amonafide L-malate daunorubicin induction therapy patients secondary acute myeloid leukemia,48,0.08376963350785341
"Pevonedistat (MLN4924), a First-in-Class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study.",British journal of haematology,Br. J. Haematol.,2015-03-02,"This trial was conducted to determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the first in class NEDD8-activating enzyme (NAE) inhibitor, pevonedistat, and to investigate pevonedistat pharmacokinetics and pharmacodynamics in patients with acute myeloid leukaemia (AML) and myelodysplastic syndromes (MDS). Pevonedistat was administered via a 60-min intravenous infusion on days 1, 3 and 5 (schedule A, n=27), or days 1, 4, 8 and 11 (schedule B, n=26) every 21-days. Dose escalation proceeded using a standard '3+3' design. Responses were assessed according to published guidelines. The MTD for schedules A and B were 59 and 83mg/m(2) , respectively. On schedule A, hepatotoxicity was dose limiting. Multi-organ failure (MOF) was dose limiting on schedule B. The overall complete (CR) and partial (PR) response rate in patients treated at or below the MTD was 17% (4/23, 2 CRs, 2 PRs) for schedule A and 10% (2/19, 2 PRs) for schedule B. Pevonedistat plasma concentrations peaked after infusion followed by elimination in a biphasic pattern. Pharmacodynamic studies of biological correlates of NAE inhibition demonstrated target-specific activity of pevonedistat. In conclusion, administration of the first-in-class agent, pevonedistat, was feasible in patients with MDS and AML and modest clinical activity was observed. ","Clinical Trial, Phase I",1786.0,107.0,trial conducted determine dose-limiting toxicities DLTs maximum tolerated dose MTD class NEDD8-activating enzyme NAE inhibitor pevonedistat investigate pevonedistat pharmacokinetics pharmacodynamics patients acute myeloid leukaemia AML myelodysplastic syndromes MDS Pevonedistat administered 60-min intravenous infusion days 1 3 5 schedule n 27 days 1 4 8 11 schedule B n 26 21-days Dose escalation proceeded standard 3 3 design Responses assessed according published guidelines MTD schedules B 59 83 mg/m 2 respectively schedule hepatotoxicity dose limiting Multi-organ failure MOF dose limiting schedule B overall complete CR partial PR response rate patients treated MTD 17 4/23 2 CRs 2 PRs schedule 10 2/19 2 PRs schedule B. Pevonedistat plasma concentrations peaked infusion followed elimination biphasic pattern Pharmacodynamic studies correlates NAE inhibition demonstrated target-specific activity pevonedistat administration first-in-class agent pevonedistat feasible patients MDS AML modest clinical activity observed,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[26, 160, 10, 426, 6, 223, 3, 61, 817, 385, 2506, 2, 689, 421, 61, 961, 1, 3, 157, 4, 1040, 15031, 1616, 1644, 17052, 230, 9833, 2, 6, 963, 9833, 1159, 2, 3587, 4, 7, 5, 286, 533, 2001, 329, 2, 2040, 1223, 9833, 10, 468, 847, 8, 335, 1538, 1262, 904, 23, 162, 14, 27, 2, 33, 1055, 8, 78, 428, 15, 162, 14, 39, 66, 2, 175, 1055, 132, 78, 432, 454, 239, 162, 61, 1125, 6406, 75, 8, 260, 27, 27, 771, 253, 11, 275, 768, 6, 983, 677, 3, 961, 9, 2314, 8, 2, 132, 11, 728, 2, 852, 81, 188, 18, 106, 23, 1055, 8, 6667, 10, 61, 817, 1414, 1259, 496, 35977, 10, 61, 817, 23, 1055, 132, 3, 63, 236, 684, 2, 450, 998, 51, 116, 4, 7, 73, 28, 15, 2736, 3, 961, 10, 269, 39, 382, 18, 3115, 18, 4018, 9, 1055, 8, 2, 79, 18, 326, 18, 4018, 9, 1055, 132, 9833, 554, 1003, 11095, 50, 904, 370, 20, 3730, 4, 8, 7739, 1177, 2424, 94, 1, 1037, 1871, 1, 17052, 297, 264, 283, 112, 128, 1, 9833, 4, 1221, 634, 1, 3, 157, 4, 1040, 420, 9833, 10, 1313, 4, 7, 5, 1223, 2, 329, 2, 1721, 38, 128, 10, 164]",1281.0,25733005,Pevonedistat MLN4924 First-in-Class NEDD8-activating enzyme inhibitor patients acute myeloid leukaemia myelodysplastic syndromes phase 1,24,0.041884816753926704
Speaking a common language in MDS/MPNs.,Blood,Blood,2015-03-01,"In this issue of Blood, Savona and an international consortium of clinical investigators propose uniform response criteria for treatment trials enrolling adult patients with myelodysplastic/myeloproliferative neoplasms (MDS/MPNs). Such a proposal is needed because new drugs are finally being tested in these rare overlap syndromes that have both dysplastic and proliferative pathological features, and neither the International Working Group (IWG) response criteria for myelodysplastic syndromes nor the IWG Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) response criteria for myelofibrosis or for other myeloproliferative neoplasms fit such patients well.",Journal Article,1787.0,0.0,issue Blood Savona international consortium clinical investigators propose uniform response criteria treatment trials enrolling adult patients myelodysplastic/myeloproliferative neoplasms MDS/MPNs proposal needed new drugs finally tested rare overlap syndromes dysplastic proliferative pathological features International Working Group IWG response criteria myelodysplastic syndromes IWG Myeloproliferative Neoplasms Research Treatment IWG-MRT response criteria myelofibrosis myeloproliferative neoplasms fit patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 26, 2537, 1, 315, 65788, 2, 35, 944, 2404, 1, 38, 2394, 2548, 3490, 51, 371, 9, 24, 143, 6280, 780, 7, 5, 10589, 10857, 1179, 1223, 6880, 225, 8, 13383, 16, 575, 408, 217, 600, 32, 1368, 486, 650, 4, 46, 622, 4526, 2040, 17, 47, 110, 6461, 2, 2441, 1301, 404, 2, 2174, 3, 944, 2644, 87, 14620, 51, 371, 9, 2040, 2110, 3, 14620, 1179, 389, 2, 24, 14620, 11848, 51, 371, 9, 4637, 15, 9, 127, 1179, 2975, 225, 7, 149]",608.0,25792730,Speaking common language MDS/MPNs,151,0.26352530541012215
"Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies.","Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2015-02-19,"Rat sarcoma (RAS)/rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase activation (mutational or nonmutational) is a key pathway for survival and proliferative advantage of leukemic cells. Salirasib (Concordia Pharmaceuticals) is an oral RAS inhibitor that causes dislocation of RAS by competing directly with farnesylated RAS in binding to its putative membrane-binding proteins. Salirasib does not inhibit farnesyl transferase enzyme. We report on a phase I study of Salirasib in patients with relapsed/refractory hematologic malignancies. Salirasib was administered orally twice daily on days 1 to 21 of a 28-day cycle in a ""3+3"" dose escalation design. Seventeen patients with relapsed/refractory leukemia were treated for a median of 4 cycles (range, 1-29). Three patients each were enrolled at a dose level of 100, 200, 400, 600, and 800 mg twice daily and 2 patients at a dose level of 900 mg twice daily. No dose-limiting toxicities were encountered. Grade 1/2 diarrhea was the only frequent nonhematologic toxicity observed in 14 of 17 (82%) patients and was resolved with oral antidiarrheal agents. Eight (47%) patients (4 with myelodysplastic syndrome, 2 with acute myeloid leukemia, 1 with chronic myelomonocytic leukemia, and 1 with chronic myeloid leukemia) had hematological improvement; 1 in 3 lineages, 1 in 2 lineages, and 6 in 1 lineage. None of the patients achieved complete remission. The responses lasted for a median of 10 weeks (range, 5-115). The study was discontinued because of financial constraints. Salirasib was well tolerated and showed modest activity in relapsed/refractory hematological malignancies. The safety profile of Salirasib and its hematological malignancy relevant target makes it a potential drug to be used in combination therapy.","Clinical Trial, Phase I",1797.0,16.0,Rat sarcoma RAS /rapidly accelerated fibrosarcoma RAF /mitogen-activated kinase activation nonmutational key pathway survival proliferative advantage leukemic Salirasib Concordia Pharmaceuticals oral RAS inhibitor causes dislocation RAS competing directly farnesylated RAS binding putative membrane-binding Salirasib inhibit farnesyl transferase enzyme report phase Salirasib patients relapsed/refractory hematologic malignancies Salirasib administered orally twice daily days 1 21 28-day cycle `` 3+3 '' dose escalation design Seventeen patients relapsed/refractory leukemia treated median 4 cycles range 1-29 patients enrolled dose level 100 200 400 600 800 mg twice daily 2 patients dose level 900 mg twice daily dose-limiting toxicities encountered Grade 1/2 diarrhea frequent nonhematologic toxicity observed 14 17 82 patients resolved oral antidiarrheal agents 47 patients 4 myelodysplastic syndrome 2 acute myeloid leukemia 1 chronic myelomonocytic leukemia 1 chronic myeloid leukemia hematological improvement 1 3 lineages 1 2 lineages 6 1 lineage patients achieved complete remission responses lasted median 10 weeks range 5-115 discontinued financial constraints Salirasib tolerated showed modest activity relapsed/refractory hematological malignancies safety profile Salirasib hematological malignancy relevant target makes potential drug combination therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[4008, 1102, 1755, 2241, 8378, 2212, 2625, 735, 178, 216, 363, 1619, 15, 37067, 16, 8, 825, 308, 9, 25, 2, 2441, 1874, 1, 2015, 37, 12668, 65797, 5888, 16, 35, 518, 1102, 230, 17, 1626, 48920, 1, 1102, 20, 2573, 1606, 5, 28870, 1102, 4, 791, 6, 211, 2743, 1905, 791, 652, 12668, 1097, 44, 1433, 8846, 4402, 1644, 21, 414, 23, 8, 124, 70, 45, 1, 12668, 4, 7, 5, 591, 430, 813, 441, 12668, 10, 468, 1428, 936, 391, 23, 162, 14, 6, 239, 1, 8, 339, 218, 417, 4, 8, 27, 27, 522, 61, 1125, 771, 3591, 7, 5, 591, 430, 11, 73, 9, 8, 52, 1, 39, 410, 184, 14, 462, 169, 7, 296, 11, 346, 28, 8, 61, 301, 1, 394, 1250, 1524, 2383, 2, 2796, 81, 936, 391, 2, 18, 7, 28, 8, 61, 301, 1, 5310, 81, 936, 391, 77, 61, 817, 385, 11, 3903, 88, 14, 18, 1172, 10, 3, 158, 908, 3534, 155, 164, 4, 213, 1, 269, 878, 7, 2, 10, 3862, 5, 518, 26911, 183, 659, 662, 7, 39, 5, 681, 18, 5, 286, 533, 14, 5, 442, 5451, 2, 14, 5, 442, 533, 42, 2890, 767, 14, 4, 27, 7234, 14, 4, 18, 7234, 2, 49, 4, 14, 2542, 1292, 1, 3, 7, 513, 236, 734, 3, 253, 6854, 9, 8, 52, 1, 79, 244, 184, 33, 3670, 3, 45, 10, 2402, 408, 1, 3021, 4879, 12668, 10, 149, 421, 2, 224, 1721, 128, 4, 591, 430, 2890, 441, 3, 367, 800, 1, 12668, 2, 211, 2890, 710, 867, 283, 4677, 192, 8, 174, 234, 6, 40, 95, 4, 150, 36]",1696.0,25795639,Phase S-trans trans-farnesylthiosalicylic acid salirasib novel oral RAS inhibitor patients refractory hematologic malignancies,93,0.16230366492146597
WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.,American journal of hematology,Am. J. Hematol.,2015-05-03,"Peptide vaccines are capable of eliciting immune responses targeting tumor-associated antigens such as the Wilms' Tumor 1 (WT1) antigen, often overexpressed in myeloid malignancies. Here, we assessed the safety, tolerability, and immunogenicity of a polyvalent WT1 peptide vaccine. Individuals with WT1-positive acute myeloid leukemia (AML) in first (CR1) or second (CR2) remission or with higher-risk myelodysplastic syndrome (MDS) following at least 1 prior line of therapy were vaccinated with a mixture of peptides derived from the WT1 protein, with sargramostim injections before vaccination to amplify immunogenicity. Six vaccinations were delivered biweekly, continuing then monthly until patients received 12 vaccinations or showed disease relapse or progression. Therapeutic efficacy was evaluated by progression-free and overall survival. Immune responses were evaluated by delayed-type hypersensitivity testing and T-cell IFN ELISPOT at specified intervals. In 16 patients who received at least one vaccination, 10 completed the planned course of six vaccinations and six continued for up to six additional monthly vaccinations. Vaccinations were well tolerated, with no patients discontinuing due to toxicity. One of two patients with high-risk MDS experienced a prolonged decrease in transfusion dependence. Two of 14 AML patients demonstrated relapse-free survival >1 year. Both patients were in CR2 at time of vaccination, with duration of their remission exceeding duration of their first remission, suggesting a potential benefit. Our WT1 vaccine was well-tolerated. The clinical benefit that we observed in several patients suggests engagement of a protective immune response, indicating a need for further trials.","Clinical Trial, Phase I",1724.0,25.0,Peptide vaccines capable eliciting immune responses targeting tumor-associated antigens Wilms 1 WT1 antigen overexpressed myeloid malignancies assessed safety tolerability immunogenicity polyvalent WT1 peptide vaccine Individuals WT1-positive acute myeloid leukemia AML CR1 second CR2 remission higher-risk myelodysplastic syndrome MDS following 1 prior line therapy vaccinated mixture peptides derived WT1 sargramostim injections vaccination amplify immunogenicity vaccinations delivered biweekly continuing monthly patients received 12 vaccinations showed disease relapse progression Therapeutic efficacy evaluated progression-free overall survival Immune responses evaluated delayed-type hypersensitivity testing T-cell IFN ELISPOT specified intervals 16 patients received vaccination 10 completed planned course vaccinations continued additional monthly vaccinations Vaccinations tolerated patients discontinuing toxicity patients high-risk MDS experienced prolonged decrease transfusion dependence 14 AML patients demonstrated relapse-free survival 1 year patients CR2 time vaccination duration remission exceeding duration remission suggesting potential benefit WT1 vaccine well-tolerated clinical benefit observed patients suggests engagement protective immune response indicating need trials,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1389, 1842, 32, 2787, 1, 10299, 250, 253, 529, 30, 41, 1575, 225, 22, 3, 30, 14, 3722, 448, 629, 1711, 4, 533, 441, 467, 21, 275, 3, 367, 1543, 2, 4050, 1, 8, 23304, 3722, 1389, 1274, 869, 5, 3722, 109, 286, 533, 329, 4, 157, 4516, 15, 419, 7865, 734, 15, 5, 142, 43, 681, 1223, 366, 28, 506, 14, 324, 328, 1, 36, 11, 5130, 5, 8, 6972, 1, 2491, 526, 29, 3, 3722, 178, 5, 15821, 4344, 348, 1915, 6, 13868, 4050, 437, 7318, 11, 1623, 7551, 4346, 818, 3889, 1100, 7, 103, 133, 7318, 15, 224, 34, 429, 15, 91, 189, 209, 10, 194, 20, 91, 115, 2, 63, 25, 250, 253, 11, 194, 20, 1612, 267, 4034, 471, 2, 102, 31, 6062, 7662, 28, 3575, 1582, 4, 245, 7, 54, 103, 28, 506, 104, 1915, 79, 781, 3, 1465, 906, 1, 437, 7318, 2, 437, 1351, 9, 126, 6, 437, 402, 3889, 7318, 7318, 11, 149, 421, 5, 77, 7, 7971, 520, 6, 155, 104, 1, 100, 7, 5, 64, 43, 1223, 592, 8, 1069, 775, 4, 2785, 3721, 100, 1, 213, 329, 7, 264, 429, 115, 25, 14, 111, 110, 7, 11, 4, 7865, 28, 98, 1, 1915, 5, 654, 1, 136, 734, 5178, 654, 1, 136, 157, 734, 802, 8, 174, 247, 114, 3722, 1274, 10, 149, 421, 3, 38, 247, 17, 21, 164, 4, 392, 7, 844, 5103, 1, 8, 2864, 250, 51, 1716, 8, 594, 9, 195, 143]",1666.0,25802083,WT1 vaccination AML MDS pilot trial synthetic analog peptides,0,0.0
IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells.,Blood,Blood,2015-03-25,"Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are associated with disease-initiating stem cells that are not eliminated by conventional therapies. Novel therapeutic targets against preleukemic stem cells need to be identified for potentially curative strategies. We conducted parallel transcriptional analysis of highly fractionated stem and progenitor populations in MDS, AML, and control samples and found interleukin 8 (IL8) to be consistently overexpressed in patient samples. The receptor for IL8, CXCR2, was also significantly increased in MDS CD34(+) cells from a large clinical cohort and was predictive of increased transfusion dependence. High CXCR2 expression was also an adverse prognostic factor in The Cancer Genome Atlas AML cohort, further pointing to the critical role of the IL8-CXCR2 axis in AML/MDS. Functionally, CXCR2 inhibition by knockdown and pharmacologic approaches led to a significant reduction in proliferation in several leukemic cell lines and primary MDS/AML samples via induction of G0/G1 cell cycle arrest. Importantly, inhibition of CXCR2 selectively inhibited immature hematopoietic stem cells from MDS/AML samples without an effect on healthy controls. CXCR2 knockdown also impaired leukemic growth in vivo. Together, these studies demonstrate that the IL8 receptor CXCR2 is an adverse prognostic factor in MDS/AML and is a potential therapeutic target against immature leukemic stem cell-enriched cell fractions in MDS and AML. ",Journal Article,1763.0,68.0,Acute myeloid leukemia AML myelodysplastic syndromes MDS associated disease-initiating stem eliminated conventional therapies Novel therapeutic targets preleukemic stem need identified potentially curative strategies conducted parallel transcriptional highly fractionated stem progenitor populations MDS AML control interleukin 8 IL8 consistently overexpressed patient receptor IL8 CXCR2 significantly increased MDS CD34 large clinical cohort predictive increased transfusion dependence High CXCR2 expression adverse prognostic factor Genome Atlas AML cohort pointing critical role IL8-CXCR2 axis AML/MDS Functionally CXCR2 inhibition knockdown pharmacologic approaches led significant reduction proliferation leukemic lines primary MDS/AML induction G0/G1 cycle arrest Importantly inhibition CXCR2 selectively inhibited immature hematopoietic stem MDS/AML effect healthy controls CXCR2 knockdown impaired leukemic growth vivo studies demonstrate IL8 receptor CXCR2 adverse prognostic factor MDS/AML potential therapeutic target immature leukemic stem cell-enriched fractions MDS AML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[286, 533, 329, 2, 2040, 1223, 32, 41, 5, 34, 2637, 452, 37, 17, 32, 44, 6173, 20, 809, 235, 229, 189, 637, 480, 19788, 452, 37, 594, 6, 40, 108, 9, 751, 1075, 422, 21, 426, 2755, 1431, 65, 1, 561, 3950, 452, 2, 2520, 1184, 4, 1223, 329, 2, 182, 347, 2, 204, 1603, 66, 9798, 6, 40, 2433, 1711, 4, 69, 347, 3, 153, 9, 9798, 8201, 10, 120, 97, 101, 4, 1223, 2215, 37, 29, 8, 375, 38, 180, 2, 10, 464, 1, 101, 2785, 3721, 64, 8201, 55, 10, 120, 35, 290, 177, 161, 4, 3, 12, 898, 2643, 329, 180, 195, 11548, 6, 3, 740, 200, 1, 3, 9798, 8201, 2310, 4, 329, 1223, 3772, 8201, 297, 20, 1563, 2, 2788, 611, 836, 6, 8, 93, 628, 4, 457, 4, 392, 2015, 31, 285, 2, 86, 1223, 329, 347, 847, 504, 1, 8588, 3344, 31, 417, 1854, 1859, 297, 1, 8201, 2382, 879, 5733, 1007, 452, 37, 29, 1223, 329, 347, 187, 35, 254, 23, 1331, 535, 8201, 1563, 120, 2364, 2015, 129, 4, 386, 1162, 46, 94, 608, 17, 3, 9798, 153, 8201, 16, 35, 290, 177, 161, 4, 1223, 329, 2, 16, 8, 174, 189, 283, 480, 5733, 2015, 452, 31, 2220, 31, 1550, 4, 1223, 2, 329]",1434.0,25810490,IL8-CXCR2 pathway inhibition therapeutic strategy MDS AML stem,1,0.0017452006980802793
Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.,Leukemia research,Leuk. Res.,2015-03-20,"Hypomethylating agents (HMA), such as 5-azacitidine or decitabine, are currently used to treat patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) until treatment failure. However, the outcomes for patients who discontinue therapy after achieving partial response (PR) or complete remission (CR) but before treatment failure have not been reported. We present a series of 16 patients with higher-risk MDS (n=5; 31%) or AML (n=11; 69%) who achieved PR (n=1) or CR (n=15) and stopped HMA therapy while in response in the context of clinical trials. They received a median of 12 courses (range 1-24) and achieved response after a median of 1 course of therapy (1-4). Loss of response after discontinuation of therapy was rapid, with a median progression-free survival of 4 months (95% CI: 2-6). Median overall survival (OS) from the time of therapy discontinuation was 15 months (95% CI: 6-24). Patients who received 12 cycles of therapy or more had significantly better OS (median: 20 months [95% CI: 12-27]) than those who received fewer than 12 cycles (median: 4 months [95% CI: 1-8]) (p=0.043). Poor-risk cytogenetics were also associated with lower 1-year OS (33% versus 69%; p=0.046). According to these results and considering the poor prognosis after HMA failure, HMA interruption should be avoided once a sustained response has been achieved. ","Clinical Trial, Phase I",1768.0,28.0,Hypomethylating agents HMA 5-azacitidine decitabine currently treat patients myelodysplastic syndromes MDS acute myeloid leukemia AML treatment failure outcomes patients discontinue therapy achieving partial response PR complete remission CR treatment failure reported present series 16 patients higher-risk MDS n=5 31 AML n=11 69 achieved PR n=1 CR n=15 stopped HMA therapy response context clinical trials received median 12 courses range 1-24 achieved response median 1 course therapy 1-4 Loss response discontinuation therapy rapid median progression-free survival 4 months 95 CI 2-6 Median overall survival OS time therapy discontinuation 15 months 95 CI 6-24 Patients received 12 cycles therapy significantly better OS median 20 months 95 CI 12-27 received fewer 12 cycles median 4 months 95 CI 1-8 p=0.043 Poor-risk cytogenetics associated lower 1-year OS 33 versus 69 p=0.046 According considering poor prognosis HMA failure HMA interruption avoided sustained response achieved,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4931, 183, 7518, 225, 22, 33, 3752, 15, 3004, 32, 694, 95, 6, 943, 7, 5, 2040, 1223, 15, 286, 533, 329, 1100, 24, 496, 137, 3, 123, 9, 7, 54, 7934, 36, 50, 1785, 450, 51, 998, 15, 236, 734, 684, 84, 348, 24, 496, 47, 44, 85, 210, 21, 364, 8, 988, 1, 245, 7, 5, 142, 43, 1223, 78, 33, 456, 15, 329, 78, 175, 790, 54, 513, 998, 78, 14, 15, 684, 78, 167, 2, 4403, 7518, 36, 369, 4, 51, 4, 3, 1533, 1, 38, 143, 491, 103, 8, 52, 1, 133, 1993, 184, 14, 259, 2, 513, 51, 50, 8, 52, 1, 14, 906, 1, 36, 14, 39, 407, 1, 51, 50, 2007, 1, 36, 10, 1321, 5, 8, 52, 91, 115, 25, 1, 39, 53, 48, 58, 18, 49, 52, 63, 25, 118, 29, 3, 98, 1, 36, 2007, 10, 167, 53, 48, 58, 49, 259, 7, 54, 103, 133, 410, 1, 36, 15, 80, 42, 97, 380, 118, 52, 179, 53, 48, 58, 133, 428, 76, 135, 54, 103, 1497, 76, 133, 410, 52, 39, 53, 48, 58, 14, 66, 19, 13, 5653, 334, 43, 2510, 11, 120, 41, 5, 280, 14, 111, 118, 466, 185, 790, 19, 13, 4902, 768, 6, 46, 99, 2, 3075, 3, 334, 356, 50, 7518, 496, 7518, 4823, 257, 40, 5617, 1059, 8, 2275, 51, 71, 85, 513]",1278.0,25828745,Discontinuation hypomethylating agent therapy patients myelodysplastic syndromes acute myelogenous leukemia complete remission partial response retrospective survival long-term follow-up,6,0.010471204188481676
The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality.,The Journal of antimicrobial chemotherapy,J. Antimicrob. Chemother.,2015-04-07,"The epidemiology and clinical course of candidaemia in patients with acute leukaemia, a population frequently exposed to antifungals, have not been extensively studied. In the present contemporary series of acute leukaemia patients, we describe patient characteristics, Candida species and MIC distributions and investigate the association between antifungal resistance and all-cause mortality. We performed a retrospective review of medical records and microbiological data of adult patients with acute leukaemia or high-risk myelodysplastic syndrome with at least one positive blood culture for Candida species at the MD Anderson Cancer Center between January 2008 and October 2012. Susceptibility was defined according to the 2012 epidemiological cut-off values and clinical breakpoints. We identified 67 episodes of candidaemia in 65 patients. Almost all episodes (94%) occurred in patients who were receiving antifungal agents, 71% in patients receiving an echinocandin. Almost all isolates (99%) were of non-albicans Candida species [most frequently Candida parapsilosis (32%), Candida tropicalis (23%) and Candida glabrata (20%)]. Caspofungin non-susceptibility was significantly associated with fluconazole resistance (P<0.001). Non-susceptibility to caspofungin and multidrug resistance were associated with excess 14 day [adjusted HR (aHR) 3.02 (95% CI 1.28-7.09), P=0.011 and aHR 3.02 (95% CI 1.27-7.14), P=0.012, respectively] and 30 day [aHR 2.96 (95% CI 1.38-6.37), P=0.005 and aHR 2.86 (95% CI 1.31-6.21), P=0.008, respectively] all-cause mortality. In patients with acute leukaemia, a shift in candidaemia epidemiology was noted with a 99% predominance of non-albicans species. Non-susceptibility of Candida strains to caspofungin or multidrug resistance were independent markers of poor outcome in this patient population.",Journal Article,1750.0,40.0,epidemiology clinical course candidaemia patients acute leukaemia population frequently exposed antifungals extensively studied present contemporary series acute leukaemia patients patient characteristics Candida species MIC distributions investigate association antifungal resistance all-cause mortality performed retrospective review medical records microbiological adult patients acute leukaemia high-risk myelodysplastic syndrome positive blood culture Candida species MD Anderson Center January 2008 October 2012 Susceptibility defined according 2012 epidemiological cut-off values clinical breakpoints identified 67 episodes candidaemia 65 patients episodes 94 occurred patients receiving antifungal agents 71 patients receiving echinocandin isolates 99 non-albicans Candida species frequently Candida parapsilosis 32 Candida tropicalis 23 Candida glabrata 20 Caspofungin non-susceptibility significantly associated fluconazole resistance P 0.001 Non-susceptibility caspofungin multidrug resistance associated excess 14 day adjusted HR aHR 3.02 95 CI 1.28-7.09 P 0.011 aHR 3.02 95 CI 1.27-7.14 P 0.012 respectively 30 day aHR 2.96 95 CI 1.38-6.37 P 0.005 aHR 2.86 95 CI 1.31-6.21 P 0.008 respectively all-cause mortality patients acute leukaemia shift candidaemia epidemiology noted 99 predominance non-albicans species Non-susceptibility Candida strains caspofungin multidrug resistance independent markers poor outcome patient population,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1284, 2, 38, 906, 1, 41059, 4, 7, 5, 286, 2001, 8, 266, 746, 2234, 6, 24512, 47, 44, 85, 3576, 656, 4, 3, 364, 2667, 988, 1, 286, 2001, 7, 21, 897, 69, 374, 13321, 2915, 2, 9216, 4477, 2, 963, 3, 248, 59, 8606, 251, 2, 62, 708, 282, 21, 173, 8, 459, 206, 1, 484, 1064, 2, 27055, 74, 1, 780, 7, 5, 286, 2001, 15, 64, 43, 681, 5, 28, 506, 104, 109, 315, 2099, 9, 13321, 2915, 28, 3, 2244, 1929, 12, 574, 59, 1024, 1375, 2, 2551, 1195, 1432, 10, 395, 768, 6, 3, 1195, 4614, 3554, 1889, 1030, 2, 38, 7843, 21, 108, 598, 3750, 1, 41059, 4, 556, 7, 2214, 62, 3750, 960, 489, 4, 7, 54, 11, 357, 8606, 183, 792, 4, 7, 357, 35, 46910, 2214, 62, 9274, 1058, 11, 1, 220, 24644, 13321, 2915, 96, 746, 13321, 43387, 531, 13321, 43388, 382, 2, 13321, 43386, 179, 21366, 220, 1432, 10, 97, 41, 5, 22152, 251, 19, 13, 144, 220, 1432, 6, 21366, 2, 4814, 251, 11, 41, 5, 2612, 213, 218, 586, 168, 3657, 27, 588, 48, 58, 14, 339, 67, 1730, 19, 13, 3651, 2, 3657, 27, 588, 48, 58, 14, 428, 67, 213, 19, 13, 3499, 106, 2, 201, 218, 3657, 18, 921, 48, 58, 14, 519, 49, 567, 19, 13, 1614, 2, 3657, 18, 868, 48, 58, 14, 456, 49, 239, 19, 13, 2155, 106, 62, 708, 282, 4, 7, 5, 286, 2001, 8, 3024, 4, 41059, 1284, 10, 1051, 5, 8, 1058, 7593, 1, 220, 24644, 2915, 220, 1432, 1, 13321, 5175, 6, 21366, 15, 4814, 251, 11, 306, 525, 1, 334, 228, 4, 26, 69, 266]",1760.0,25855759,ever-evolving landscape candidaemia patients acute leukaemia non-susceptibility caspofungin multidrug resistance associated increased mortality,0,0.0
Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation.,Bone marrow transplantation,Bone Marrow Transplant.,2015-04-13,"We hypothesized that during conditioning chemotherapy for allogeneic stem cell transplant (allo-SCT), the disruption of stromal-leukemia interactions using G-CSF in combination with the CXCR4-specific inhibitor, plerixafor, may promote the release of leukemic cells from the niche and increase tumor elimination. In a phase 1/2 investigation, we treated 45 AML/myelodysplastic syndrome (MDS)/CML patients (34 AML, 7 MDS and 4 CML) with G-CSF (10 g/kg daily for 6 days starting on day -9) plus plerixafor (doses of 0, 80, 160 or 240 g/kg daily for 4 days starting on day -7) along with the busulfan-fludarabine (Bu-Flu) conditioning regimen. In the phase 1 part, we determined that G-CSF plus plerixafor is safe in this setting. We compared the clinical effects and outcomes of AML/MDS study patients (n=40) with 164 patients from a historical data set who received Bu-Flu alone before allo-SCT by stratifying on cytogenetics and disease status to correct for bias. Study patients had increased myeloid chimerism and lower rates of GvHD. There was no significant difference in relapse-free survival or overall survival. The G-CSF plus plerixafor combination increased circulating WBCs, CD34+ cells and CXCR4+ cells, and preferentially mobilized FISH+ leukemic cells.",Journal Article,1744.0,16.0,hypothesized conditioning chemotherapy allogeneic stem transplant allo-SCT disruption stromal-leukemia interactions G-CSF combination CXCR4-specific inhibitor plerixafor promote release leukemic niche increase elimination phase 1/2 investigation treated 45 AML/myelodysplastic syndrome MDS /CML patients 34 AML 7 MDS 4 CML G-CSF 10 g/kg daily 6 days starting day -9 plus plerixafor doses 0 80 160 240 g/kg daily 4 days starting day -7 busulfan-fludarabine Bu-Flu conditioning regimen phase 1 determined G-CSF plus plerixafor safe setting compared clinical effects outcomes AML/MDS patients n=40 164 patients historical set received Bu-Flu allo-SCT stratifying cytogenetics disease status correct bias patients increased myeloid chimerism lower rates GvHD significant difference relapse-free survival overall survival G-CSF plus plerixafor combination increased circulating WBCs CD34+ CXCR4+ preferentially mobilized FISH+ leukemic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[21, 1237, 17, 190, 1933, 56, 9, 1063, 452, 31, 941, 2564, 1988, 3, 3220, 1, 1126, 2647, 1286, 75, 499, 1211, 4, 150, 5, 3, 2318, 112, 230, 5583, 68, 1617, 3, 2008, 1, 2015, 37, 29, 3, 4385, 2, 344, 30, 3730, 4, 8, 124, 14, 18, 940, 21, 73, 512, 329, 10589, 681, 1223, 903, 7, 562, 329, 67, 1223, 2, 39, 903, 5, 499, 1211, 79, 3802, 503, 391, 9, 49, 162, 1723, 23, 218, 83, 349, 5583, 415, 1, 13, 493, 3457, 15, 4263, 3802, 503, 391, 9, 39, 162, 1723, 23, 218, 67, 1510, 5, 3, 3906, 2027, 3667, 5119, 1933, 477, 4, 3, 124, 14, 760, 21, 509, 17, 499, 1211, 349, 5583, 16, 1165, 4, 26, 546, 21, 72, 3, 38, 176, 2, 123, 1, 329, 1223, 45, 7, 78, 327, 5, 5279, 7, 29, 8, 2252, 74, 916, 54, 103, 3667, 5119, 279, 348, 2564, 1988, 20, 5035, 23, 2510, 2, 34, 156, 6, 4883, 9, 2947, 45, 7, 42, 101, 533, 6047, 2, 280, 151, 1, 1562, 125, 10, 77, 93, 523, 4, 429, 115, 25, 15, 63, 25, 3, 499, 1211, 349, 5583, 150, 101, 1033, 17238, 2215, 37, 2, 2318, 37, 2, 3509, 7695, 1277, 2015, 37]",1237.0,25867648,Leukemia mobilization G-CSF plus plerixafor busulfan-fludarabine conditioning allogeneic stem transplantation,16,0.027923211169284468
Chronic myelomonocytic leukemia: Forefront of the field in 2015.,Critical reviews in oncology/hematology,Crit. Rev. Oncol. Hematol.,2015-03-14,"Chronic myelomonocytic leukemia (CMML) includes components of both myelodysplastic syndrome and myeloproliferative neoplasms and is associated with a characteristic peripheral monocytosis. CMML is caused by the proliferation of an abnormal hematopoietic stem cell clone and may be influenced by microenvironmental changes. The disease is rare and has undergone revisions in its classification. We review the recent classification strategies as well as diagnostic criteria, focusing on CMML's genetic alterations and unique pathophysiology. We also discuss the latest molecular characterization of the disease, including how molecular factors affect current prognostic models. Finally, we focus on available treatment strategies, with a special emphasis on experimental and forthcoming therapies. ",Journal Article,1774.0,16.0,Chronic myelomonocytic leukemia CMML includes components myelodysplastic syndrome myeloproliferative neoplasms associated characteristic peripheral monocytosis CMML caused proliferation abnormal hematopoietic stem clone influenced microenvironmental changes disease rare undergone revisions classification review recent classification strategies diagnostic criteria focusing CMML 's genetic alterations unique pathophysiology discuss latest molecular characterization disease including molecular factors affect current prognostic models Finally focus available treatment strategies special emphasis experimental forthcoming therapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 5451, 3382, 1920, 1628, 1, 110, 681, 2, 1179, 2, 16, 41, 5, 8, 2037, 672, 16875, 3382, 16, 1546, 20, 3, 457, 1, 35, 1668, 1007, 452, 31, 3910, 2, 68, 40, 2574, 20, 9300, 400, 3, 34, 16, 622, 2, 71, 1989, 8935, 4, 211, 947, 21, 206, 3, 435, 947, 422, 22, 149, 22, 752, 371, 3312, 23, 3382, 292, 336, 593, 2, 991, 4320, 21, 120, 1139, 3, 5923, 219, 2136, 1, 3, 34, 141, 832, 219, 130, 1158, 291, 177, 274, 1368, 21, 1222, 23, 390, 24, 422, 5, 8, 3714, 3136, 23, 1560, 2, 16039, 235]",740.0,25869097,Chronic myelomonocytic leukemia Forefront field 2015,2,0.0034904013961605585
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes.,Blood,Blood,2015-04-30,"Recent genetic analyses of large populations have revealed that somatic mutations in hematopoietic cells leading to clonal expansion are commonly acquired during human aging. Clonally restricted hematopoiesis is associated with an increased risk of subsequent diagnosis of myeloid or lymphoid neoplasia and increased all-cause mortality. Although myelodysplastic syndromes (MDS) are defined by cytopenias, dysplastic morphology of blood and marrow cells, and clonal hematopoiesis, most individuals who acquire clonal hematopoiesis during aging will never develop MDS. Therefore, acquisition of somatic mutations that drive clonal expansion in the absence of cytopenias and dysplastic hematopoiesis can be considered clonal hematopoiesis of indeterminate potential (CHIP), analogous to monoclonal gammopathy of undetermined significance and monoclonal B-cell lymphocytosis, which are precursor states for hematologic neoplasms but are usually benign and do not progress. Because mutations are frequently observed in healthy older persons, detection of an MDS-associated somatic mutation in a cytopenic patient without other evidence of MDS may cause diagnostic uncertainty. Here we discuss the nature and prevalence of CHIP, distinction of this state from MDS, and current areas of uncertainty regarding diagnostic criteria for myeloid malignancies. ",Journal Article,1727.0,524.0,Recent genetic large populations revealed somatic hematopoietic leading clonal expansion commonly acquired human aging Clonally restricted hematopoiesis associated increased risk subsequent diagnosis myeloid lymphoid neoplasia increased all-cause mortality myelodysplastic syndromes MDS defined cytopenias dysplastic morphology blood marrow clonal hematopoiesis individuals acquire clonal hematopoiesis aging develop MDS acquisition somatic drive clonal expansion absence cytopenias dysplastic hematopoiesis considered clonal hematopoiesis indeterminate potential CHIP analogous monoclonal gammopathy undetermined significance monoclonal B-cell lymphocytosis precursor states hematologic neoplasms usually benign progress frequently observed healthy older persons detection MDS-associated somatic cytopenic patient evidence MDS cause diagnostic uncertainty discuss nature prevalence CHIP distinction state MDS current areas uncertainty diagnostic criteria myeloid malignancies,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[435, 336, 318, 1, 375, 1184, 47, 553, 17, 1119, 138, 4, 1007, 37, 1049, 6, 1946, 1422, 32, 841, 1294, 190, 171, 4220, 9157, 2016, 5114, 16, 41, 5, 35, 101, 43, 1, 706, 147, 1, 533, 15, 2303, 2298, 2, 101, 62, 708, 282, 242, 2040, 1223, 32, 395, 20, 5635, 6461, 2567, 1, 315, 2, 581, 37, 2, 1946, 5114, 96, 869, 54, 6206, 1946, 5114, 190, 4220, 303, 1737, 690, 1223, 673, 3405, 1, 1119, 138, 17, 3279, 1946, 1422, 4, 3, 1127, 1, 5635, 2, 6461, 5114, 122, 40, 515, 1946, 5114, 1, 5167, 174, 4222, 8579, 6, 848, 5334, 1, 5206, 724, 2, 848, 132, 31, 8125, 92, 32, 2765, 907, 9, 813, 1179, 84, 32, 2082, 1002, 2, 1022, 44, 1466, 408, 138, 32, 746, 164, 4, 1331, 434, 4327, 638, 1, 35, 1223, 41, 1119, 258, 4, 8, 32164, 69, 187, 127, 241, 1, 1223, 68, 708, 752, 4004, 467, 21, 1139, 3, 2202, 2, 1078, 1, 4222, 6628, 1, 26, 1309, 29, 1223, 2, 291, 1361, 1, 4004, 666, 752, 371, 9, 533, 441]",1313.0,25931582,Clonal hematopoiesis indeterminate potential distinction myelodysplastic syndromes,12,0.020942408376963352
"Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.",Investigational new drugs,Invest New Drugs,2015-05-02,"Ilorasertib (ABT-348) is a novel inhibitor of Aurora kinase, vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptors, and the Src families of tyrosine kinases. Ilorasertib alone or in combination with azacitidine demonstrated activity in preclinical models in various hematological malignancies, indicating that pan-Aurora kinase and multiple kinase inhibition may have preferential antileukemic activity. This phase 1 trial determined the safety, pharmacokinetics, and preliminary antitumor activity of ilorasertib alone or combined with azacitidine in advanced hematologic malignancies. Fifty-two patients (median age, 67 years; 35 % with >4 prior regimens) with acute myelogenous leukaemia (AML; n=38), myelodysplastic syndrome (n=12), or chronic myelomonocytic leukaemia (n=2) received 3 or 6 doses of ilorasertib per 28-day cycle and were assigned to arm A (once-weekly oral), B (twice-weekly oral), C (once-weekly oral plus azacitidine), or D (once-weekly intravenous) treatment. Maximum tolerated doses were not determined; the recommended phase 2 oral monotherapy doses were 540 mg once weekly and 480 mg twice weekly. The most common grade 3/4 adverse events were hypertension (28.8 %), hypokalemia (15.4 %), anemia (13.5 %), and hypophosphatemia (11.5 %). Oral ilorasertib pharmacokinetics appeared dose proportional, with a 15-hour half-life and no interaction with azacitidine. Ilorasertib inhibited biomarkers for Aurora kinase and VEGF receptors, and demonstrated clinical responses in 3 AML patients. Ilorasertib exhibited acceptable safety and pharmacokinetics at or below the recommended phase 2 dose, displayed evidence of dual Aurora kinase and VEGF receptor kinase inhibition, and activity in AML.","Clinical Trial, Phase I",1725.0,12.0,Ilorasertib ABT-348 novel inhibitor Aurora kinase vascular endothelial growth factor VEGF platelet-derived growth factor receptors Src families tyrosine kinases Ilorasertib combination azacitidine demonstrated activity preclinical models hematological malignancies indicating pan-Aurora kinase multiple kinase inhibition preferential antileukemic activity phase 1 trial determined safety pharmacokinetics preliminary antitumor activity ilorasertib combined azacitidine advanced hematologic malignancies Fifty-two patients median age 67 years 35 4 prior regimens acute myelogenous leukaemia AML n 38 myelodysplastic syndrome n 12 chronic myelomonocytic leukaemia n 2 received 3 6 doses ilorasertib 28-day cycle assigned arm once-weekly oral B twice-weekly oral C once-weekly oral plus azacitidine once-weekly intravenous treatment Maximum tolerated doses determined recommended phase 2 oral monotherapy doses 540 mg weekly 480 mg twice weekly common grade 3/4 adverse events hypertension 28.8 hypokalemia 15.4 anemia 13.5 hypophosphatemia 11.5 Oral ilorasertib pharmacokinetics appeared dose proportional 15-hour half-life interaction azacitidine Ilorasertib inhibited biomarkers Aurora kinase VEGF receptors demonstrated clinical responses 3 AML patients Ilorasertib exhibited acceptable safety pharmacokinetics recommended phase 2 dose displayed evidence dual Aurora kinase VEGF receptor kinase inhibition activity AML,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[20889, 3095, 9935, 16, 8, 229, 230, 1, 4095, 216, 756, 845, 129, 161, 618, 2, 1596, 526, 129, 161, 1186, 2, 3, 2023, 1954, 1, 564, 1549, 20889, 279, 15, 4, 150, 5, 3752, 264, 128, 4, 693, 274, 4, 747, 2890, 441, 1716, 17, 3055, 4095, 216, 2, 232, 216, 297, 68, 47, 6629, 4512, 128, 26, 124, 14, 160, 509, 3, 367, 1159, 2, 1676, 579, 128, 1, 20889, 279, 15, 397, 5, 3752, 4, 131, 813, 441, 1461, 100, 7, 52, 89, 598, 60, 465, 5, 39, 324, 472, 5, 286, 2194, 2001, 329, 78, 519, 681, 78, 133, 15, 442, 5451, 2001, 78, 18, 103, 27, 15, 49, 415, 1, 20889, 379, 339, 218, 417, 2, 11, 896, 6, 475, 8, 1059, 709, 518, 132, 936, 709, 518, 256, 1059, 709, 518, 349, 3752, 15, 427, 1059, 709, 1262, 24, 689, 421, 415, 11, 44, 509, 3, 793, 124, 18, 518, 1411, 415, 11, 9780, 81, 1059, 709, 2, 9108, 81, 936, 709, 3, 96, 186, 88, 27, 39, 290, 281, 11, 1824, 339, 66, 7799, 167, 39, 1545, 233, 33, 2, 8021, 175, 33, 518, 20889, 1159, 2121, 61, 831, 5, 8, 167, 2583, 1303, 358, 2, 77, 915, 5, 3752, 20889, 879, 582, 9, 4095, 216, 2, 618, 1186, 2, 264, 38, 253, 4, 27, 329, 7, 20889, 1416, 1595, 367, 2, 1159, 28, 15, 2736, 3, 793, 124, 18, 61, 2507, 241, 1, 1828, 4095, 216, 2, 618, 153, 216, 297, 2, 128, 4, 329]",1663.0,25933833,Phase 1 dose escalation trial ilorasertib dual Aurora/VEGF receptor kinase inhibitor patients hematologic malignancies,0,0.0
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.,Journal of hematology & oncology,J Hematol Oncol,2015-05-08,"TP53 mutation is more prevalent in therapy-related myeloid neoplasms (t-MN) than their de novo counterparts; however, the pattern of mutations involving TP53 gene in t-MN versus de novo diseases is largely unknown. We collected 108 consecutive patients with therapy-related myelodysplastic syndrome (t-MDS)/acute myeloid leukemia (t-AML). Clinical, hematological, and cytogenetic data were collected by searching the electronic medical record. TP53 sequencing was performed in all patients using a clinically validated next-generation sequencing-based gene panel assay. A previously published patient cohort consisting of 428 patients with de novo MDS/AML was included for comparison. We assessed 108 patients with t-MN, in which 40 patients (37%) had TP53 mutations. The mutation frequency was similar between t-MDS and t-AML; but significantly higher than de novo MDS/AML (62/428 patients, 14.5%) (p<0.0001). TP53 mutations in t-MN were mainly clustered in DNA-binding domains, with an allelic frequency of 37.0% (range, 7.1 to 98.8). Most mutations involved single nucleotide changes, of which, transitions (65.9%) were more common than transversions (34.1%). Missense mutations were the most frequent, followed by frameshift and nonsense mutations. This TP53 mutation pattern was strikingly similar to that observed in de novo MDS/AML. TP53 mutations in t-MN were associated with a complex karyotype (p<0.0001), a higher number of chromosomal abnormalities (p<0.0001), and an inferior overall survival in affected patients (6.1 vs 14.1 months) by univariate (p<0.0001) and multivariate analyses (p=0.0020). Our findings support the recent notion that heterozygous TP53 mutation may be a function of normal aging and that mutated cells are subject to selection upon exposure to cytotoxic therapy. t-MN carrying TP53 mutation have an aggressive clinical course independent of other confounding factors.",Journal Article,1719.0,46.0,TP53 prevalent therapy-related myeloid neoplasms t-MN novo counterparts pattern involving TP53 t-MN versus novo diseases largely unknown collected 108 consecutive patients therapy-related myelodysplastic syndrome t-MDS /acute myeloid leukemia t-AML Clinical hematological cytogenetic collected searching electronic medical record TP53 sequencing performed patients clinically validated next-generation sequencing-based panel previously published patient cohort consisting 428 patients novo MDS/AML included comparison assessed 108 patients t-MN 40 patients 37 TP53 frequency similar t-MDS t-AML significantly higher novo MDS/AML 62/428 patients 14.5 p 0.0001 TP53 t-MN mainly clustered DNA-binding domains allelic frequency 37.0 range 7.1 98.8 involved single nucleotide changes transitions 65.9 common transversions 34.1 Missense frequent followed frameshift nonsense TP53 pattern strikingly similar observed novo MDS/AML TP53 t-MN associated complex karyotype p 0.0001 higher number chromosomal abnormalities p 0.0001 inferior overall survival affected patients 6.1 vs 14.1 months univariate p 0.0001 multivariate p=0.0020 findings support recent notion heterozygous TP53 function normal aging subject selection exposure cytotoxic therapy t-MN carrying TP53 aggressive clinical course independent confounding factors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1206, 258, 16, 80, 2485, 4, 36, 139, 533, 1179, 102, 4691, 76, 136, 1566, 2018, 3953, 137, 3, 1177, 1, 138, 1267, 1206, 145, 4, 102, 4691, 185, 1566, 2018, 1342, 16, 1733, 860, 21, 786, 3590, 935, 7, 5, 36, 139, 681, 102, 1223, 286, 533, 102, 329, 38, 2890, 2, 1266, 74, 11, 786, 20, 10082, 3, 3098, 484, 3237, 1206, 615, 10, 173, 4, 62, 7, 75, 8, 505, 938, 1305, 914, 615, 90, 145, 993, 719, 8, 373, 983, 69, 180, 2273, 1, 10222, 7, 5, 1566, 2018, 1223, 329, 10, 159, 9, 1155, 21, 275, 3590, 7, 5, 102, 4691, 4, 92, 327, 7, 567, 42, 1206, 138, 3, 258, 675, 10, 288, 59, 102, 1223, 2, 102, 329, 84, 97, 142, 76, 1566, 2018, 1223, 329, 744, 10222, 7, 213, 33, 19, 13, 488, 1206, 138, 4, 102, 4691, 11, 2615, 6464, 4, 261, 791, 2703, 5, 35, 3861, 675, 1, 567, 13, 184, 67, 14, 6, 1096, 66, 96, 138, 646, 226, 1579, 400, 1, 92, 7738, 556, 83, 11, 80, 186, 76, 24398, 562, 14, 4007, 138, 11, 3, 96, 908, 370, 20, 9425, 2, 9168, 138, 26, 1206, 258, 1177, 10, 6787, 288, 6, 17, 164, 4, 1566, 2018, 1223, 329, 1206, 138, 4, 102, 4691, 11, 41, 5, 8, 840, 3385, 19, 13, 488, 8, 142, 207, 1, 1860, 1171, 19, 13, 488, 2, 35, 1663, 63, 25, 4, 1424, 7, 49, 14, 105, 213, 14, 53, 20, 880, 19, 13, 488, 2, 331, 318, 19, 13, 28832, 114, 272, 538, 3, 435, 6691, 17, 4167, 1206, 258, 68, 40, 8, 343, 1, 295, 4220, 2, 17, 1185, 37, 32, 2974, 6, 881, 1548, 645, 6, 759, 36, 102, 4691, 2934, 1206, 258, 47, 35, 571, 38, 906, 306, 1, 127, 4339, 130]",1819.0,25952993,TP53 characteristics therapy-related myelodysplastic syndromes acute myeloid leukemia similar novo diseases,2,0.0034904013961605585
Impact of KIR and HLA Genotypes on Outcomes after Reduced-Intensity Conditioning Hematopoietic Cell Transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2015-05-08,"Natural killer cells are regulated by killer cell immunoglobulin-like receptor (KIR) interactions with HLA class I ligands. Several models of natural killer cell reactivity have been associated with improved outcomes after myeloablative allogeneic hematopoietic cell transplantation (HCT), but this issue has not been rigorously addressed in reduced-intensity conditioning (RIC) unrelated donor (URD) HCT. We studied 909 patients undergoing RIC-URD HCT. Patients with acute myeloid leukemia (AML, n = 612) lacking  1 KIR ligands experienced higher grade III to IV acute graft-versus-host disease (GVHD) (HR, 1.6; 95% CI, 1.16 to 2.28; P = .005) compared to those with all ligands present. Absence of HLA-C2 for donor KIR2DL1 was associated with higher grade II to IV (HR, 1.4; P = .002) and III to IV acute GVHD (HR, 1.5; P = .01) compared with HLA-C2(+) patients. AML patients with KIR2DS1(+), HLA-C2 homozygous donors had greater treatment-related mortality compared with others (HR, 2.4; 95% CI, 1.4 to 4.2; P = .002) but did not experience lower relapse. There were no significant associations with outcomes for AML when assessing donor-activating KIRs or centromeric KIR content or for any donor-recipient KIR-HLA assessments in patients with myelodysplastic syndrome (n = 297). KIR-HLA combinations in RIC-URD HCT recapitulate some but not all KIR-HLA effects observed in myeloablative HCT.",Journal Article,1719.0,17.0,Natural killer regulated killer immunoglobulin-like receptor KIR interactions HLA class ligands models natural killer reactivity associated improved outcomes myeloablative allogeneic hematopoietic transplantation HCT issue rigorously addressed reduced-intensity conditioning RIC unrelated donor URD HCT studied 909 patients undergoing RIC-URD HCT Patients acute myeloid leukemia AML n 612 lacking  1 KIR ligands experienced higher grade III IV acute graft-versus-host disease GVHD HR 1.6 95 CI 1.16 2.28 P .005 compared ligands present Absence HLA-C2 donor KIR2DL1 associated higher grade II IV HR 1.4 P .002 III IV acute GVHD HR 1.5 P .01 compared HLA-C2 patients AML patients KIR2DS1 HLA-C2 homozygous donors greater treatment-related mortality compared HR 2.4 95 CI 1.4 4.2 P .002 experience lower relapse significant associations outcomes AML assessing donor-activating KIRs centromeric KIR content donor-recipient KIR-HLA assessments patients myelodysplastic syndrome n 297 KIR-HLA combinations RIC-URD HCT recapitulate KIR-HLA effects observed myeloablative HCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1504, 3458, 37, 32, 1065, 20, 3458, 31, 2593, 733, 153, 6989, 1286, 5, 1160, 1040, 70, 3123, 392, 274, 1, 1504, 3458, 31, 4601, 47, 85, 41, 5, 231, 123, 50, 3246, 1063, 1007, 31, 497, 1085, 84, 26, 2537, 71, 44, 85, 10347, 2814, 4, 405, 837, 1933, 3365, 2092, 1488, 5847, 1085, 21, 656, 16804, 7, 479, 3365, 5847, 1085, 7, 5, 286, 533, 329, 78, 11128, 1941, 749, 14, 6989, 3123, 592, 142, 88, 316, 6, 478, 286, 1599, 185, 1204, 34, 1562, 168, 14, 49, 48, 58, 14, 245, 6, 18, 339, 19, 1614, 72, 6, 135, 5, 62, 3123, 364, 1127, 1, 1160, 6706, 9, 1488, 26842, 10, 41, 5, 142, 88, 215, 6, 478, 168, 14, 39, 19, 1111, 2, 316, 6, 478, 286, 1562, 168, 14, 33, 19, 355, 72, 5, 1160, 6706, 7, 329, 7, 5, 66094, 1160, 6706, 3189, 2344, 42, 378, 24, 139, 282, 72, 5, 1749, 168, 18, 39, 48, 58, 14, 39, 6, 39, 18, 19, 1111, 84, 205, 44, 730, 280, 429, 125, 11, 77, 93, 685, 5, 123, 9, 329, 198, 1977, 1488, 1616, 24000, 15, 15531, 6989, 2457, 15, 9, 500, 1488, 5783, 6989, 1160, 2182, 4, 7, 5, 681, 78, 8526, 6989, 1160, 1247, 4, 3365, 5847, 1085, 7746, 476, 84, 44, 62, 6989, 1160, 176, 164, 4, 3246, 1085]",1307.0,25960307,Impact KIR HLA Genotypes Outcomes Reduced-Intensity Conditioning Hematopoietic Transplantation,1,0.0017452006980802793
Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2015-05-29,"Clinical trials commonly use adjudication committees to refine endpoints, but observational research or genome-wide association studies rarely do. Our goals were to establish definitions of cause-specific death after unrelated-donor allogeneic hematopoietic cell transplantation (URD-HCT), to estimate discordance between reported and adjudicated cause-specific death, and to identify factors contributing to inconsistency in cause-specific death determination. A consensus panel adjudicated cause-specific death in 1484 patients who died within 1 year after HCT, derived from 3532 acute leukemia or myelodysplasia patients after URD-HCT from 2000 to 2011 reported by 151 US transplant centers to the Center for International Blood and Marrow Transplant Research. Deaths were classified as disease-related or transplant-related. The panel agreed with >99% of deaths reported by centers as disease-related and 80% reported as transplant-related. Year of transplant (cohort effect) and disease status significantly influenced agreement between the panel and centers. Sensitivity analysis of deaths < 100 days post-transplant yielded the lowest agreement between the panel and centers for myelodysplastic syndrome patients. Standard predefined criteria for adjudicating cause-specific death led to consistent application to similar clinical scenarios and clearer delineation of cause-specific death categories. Other studies of competing events such as cancer-specific versus treatment-related mortality would benefit from our results. Our detailed algorithm should result in more consistent reporting of cause-specific death by centers. ",Clinical Trial,1698.0,11.0,Clinical trials commonly use adjudication committees refine endpoints observational research genome-wide association studies rarely goals establish definitions cause-specific death unrelated-donor allogeneic hematopoietic transplantation URD-HCT estimate discordance reported adjudicated cause-specific death identify factors contributing inconsistency cause-specific death determination consensus panel adjudicated cause-specific death 1484 patients died 1 year HCT derived 3532 acute leukemia myelodysplasia patients URD-HCT 2000 2011 reported 151 transplant centers Center International Blood Marrow Transplant Research Deaths classified disease-related transplant-related panel agreed 99 deaths reported centers disease-related 80 reported transplant-related Year transplant cohort effect disease status significantly influenced agreement panel centers Sensitivity deaths 100 days post-transplant yielded lowest agreement panel centers myelodysplastic syndrome patients Standard predefined criteria adjudicating cause-specific death led consistent application similar clinical scenarios clearer delineation cause-specific death categories studies competing events cancer-specific versus treatment-related mortality benefit detailed algorithm consistent reporting cause-specific death centers,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[38, 143, 841, 119, 23648, 16045, 6, 5003, 1387, 84, 2495, 389, 15, 898, 1019, 248, 94, 2416, 1022, 114, 2802, 11, 6, 1811, 3833, 1, 708, 112, 273, 50, 2092, 1488, 1063, 1007, 31, 497, 5847, 1085, 6, 1191, 5771, 59, 210, 2, 11506, 708, 112, 273, 2, 6, 255, 130, 3156, 6, 17453, 4, 708, 112, 273, 3104, 8, 1391, 993, 11506, 708, 112, 273, 4, 41106, 7, 54, 1016, 262, 14, 111, 50, 1085, 526, 29, 41107, 286, 15, 6128, 7, 50, 5847, 1085, 29, 1081, 6, 1132, 210, 20, 5075, 843, 941, 1168, 6, 3, 574, 9, 944, 315, 2, 581, 941, 389, 1043, 11, 1373, 22, 34, 139, 15, 941, 139, 3, 993, 4681, 5, 1058, 1, 1043, 210, 20, 1168, 22, 34, 139, 2, 493, 210, 22, 941, 139, 111, 1, 941, 180, 254, 2, 34, 156, 97, 2574, 2024, 59, 3, 993, 2, 1168, 485, 65, 1, 1043, 394, 162, 539, 941, 2178, 3, 2101, 2024, 59, 3, 993, 2, 1168, 9, 681, 7, 260, 5944, 371, 9, 66222, 708, 112, 273, 836, 6, 925, 1581, 6, 288, 38, 3964, 2, 15960, 5529, 1, 708, 112, 273, 1996, 127, 94, 1, 2573, 281, 225, 22, 12, 112, 185, 24, 139, 282, 688, 247, 29, 114, 99, 114, 2455, 2124, 257, 757, 4, 80, 925, 1760, 1, 708, 112, 273, 20, 1168]",1586.0,26028504,Establishment Definitions Review Process Consistent Adjudication Cause-specific Mortality Allogeneic Unrelated-donor Hematopoietic Transplantation,0,0.0
Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2015-06-06,"Jumping translocations (JT) are uncommon cytogenetic abnormalities involving nonreciprocal translocations of a single donor chromosome onto 2 or more chromosomes. The clinical characteristics and prognosis of JTs in patients with myeloid malignancies are not well described. We searched our cytogenetic database from 2003 to 2014 to identify cases of myeloid malignancies associated with a JT. These cases were cross-referenced with our clinical databases to determine patient characteristics, response to treatment and overall survival. We identified 10 patients with myeloid malignancies and a JT: 4 cases of acute myeloid leukemia with myelodysplastic syndrome-related changes, 4 cases of myelodysplastic syndrome, and 2 cases of postpolycythemia myelofibrosis. The donor segment was derived from chromosome 1 in every case. The acquisition of a JT was a late occurrence, with a median time to JT development of 24.9 months (range, 0-248 months) from diagnosis. The overall response to treatment was poor, with no patients experiencing a response to conventional chemotherapy or hypomethylating agents. The median overall survival for the group was 9 months (95% confidence interval, 2.5-15.5) after identification of a JT. The acquisition of a JT in patients with myeloid malignancies appears to be a late event and is associated with myelodysplasia. In our series, this was associated with a poor prognosis with a poor response to treatment, disease transformation to acute myeloid leukemia, and short overall survival.",Journal Article,1690.0,5.0,Jumping translocations JT uncommon cytogenetic abnormalities involving nonreciprocal translocations single donor chromosome 2 chromosomes clinical characteristics prognosis JTs patients myeloid malignancies described searched cytogenetic database 2003 2014 identify cases myeloid malignancies associated JT cases cross-referenced clinical databases determine patient characteristics response treatment overall survival identified 10 patients myeloid malignancies JT 4 cases acute myeloid leukemia myelodysplastic syndrome-related changes 4 cases myelodysplastic syndrome 2 cases postpolycythemia myelofibrosis donor segment derived chromosome 1 case acquisition JT late occurrence median time JT development 24.9 months range 0-248 months diagnosis overall response treatment poor patients experiencing response conventional chemotherapy hypomethylating agents median overall survival group 9 months 95 confidence interval 2.5-15.5 identification JT acquisition JT patients myeloid malignancies appears late event associated myelodysplasia series associated poor prognosis poor response treatment disease transformation acute myeloid leukemia short overall survival,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[49168, 3262, 24191, 32, 2052, 1266, 1171, 1267, 43997, 3262, 1, 8, 226, 1488, 1170, 3301, 18, 15, 80, 3560, 3, 38, 374, 2, 356, 1, 32452, 4, 7, 5, 533, 441, 32, 44, 149, 1027, 21, 3080, 114, 1266, 609, 29, 1522, 6, 1409, 6, 255, 140, 1, 533, 441, 41, 5, 8, 24191, 46, 140, 11, 1383, 13365, 5, 114, 38, 2348, 6, 223, 69, 374, 51, 6, 24, 2, 63, 25, 21, 108, 79, 7, 5, 533, 441, 2, 8, 24191, 39, 140, 1, 286, 533, 5, 681, 139, 400, 39, 140, 1, 681, 2, 18, 140, 1, 40558, 4637, 3, 1488, 4610, 10, 526, 29, 1170, 14, 4, 454, 473, 3, 3405, 1, 8, 24191, 10, 8, 807, 2291, 5, 8, 52, 98, 6, 24191, 193, 1, 259, 83, 53, 184, 13, 7100, 53, 29, 147, 3, 63, 51, 6, 24, 10, 334, 5, 77, 7, 2985, 8, 51, 6, 809, 56, 15, 4931, 183, 3, 52, 63, 25, 9, 3, 87, 10, 83, 53, 48, 307, 268, 18, 33, 167, 33, 50, 911, 1, 8, 24191, 3, 3405, 1, 8, 24191, 4, 7, 5, 533, 441, 1233, 6, 40, 8, 807, 774, 2, 16, 41, 5, 6128, 4, 114, 988, 26, 10, 41, 5, 8, 334, 356, 5, 8, 334, 51, 6, 24, 34, 1392, 6, 286, 533, 2, 978, 63, 25]",1445.0,26141213,Jumping Translocations Myeloid Malignancies Associated Treatment Resistance Poor Survival,4,0.006980802792321117
Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse ofAcute Myeloid Leukemia and Myelodysplastic Syndromes.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2015-07-14,"Chimerism testing after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) represents a promising tool for predicting disease relapse, although its precise role in this setting remains unclear. We investigated the predictive value of T lymphocyte chimerism analysis at 90 to 120days after allo-HSCT in 378 patients with AML/MDS who underwent busulfan/fludarabine-based myeloablative preparative regimens. Of 265 (70%) patients with available T lymphocyte chimerism data, 43% of patients in first or second complete remission (CR1/CR2) at the time of transplantation had complete (100%) donor T lymphocytes at day+90 to+120 compared with 60% of patients in the non-CR1/CR2 cohort (P=.005). In CR1/CR2 patients, donor T lymphocyte chimerism  85% at day+90 to+120 was associated with a higher frequency of 3-year disease progression (29%; 95% confidence interval [CI], 18% to 46% versus 15%; 95% CI, 9% to 23%; hazard ratio [HR], 2.1; P=.04). However, in the more advanced, non-CR1/CR2 cohort, mixed T lymphocyte chimerism was not associated with relapse (37%; 95% CI, 20% to 66% versus 34%; 95% CI, 25% to 47%; HR, 1.3; P=.60). These findings demonstrate that early T lymphocyte chimerism testing at day+90 to+120 is a useful approach for predicting AML/MDS disease recurrence in patients in CR1/CR2 at the time of transplantation. ",Journal Article,1652.0,23.0,Chimerism testing allogeneic hematopoietic stem transplantation allo-HSCT patients acute myeloid leukemia AML myelodysplastic syndromes MDS represents promising tool predicting disease relapse precise role setting remains unclear investigated predictive value lymphocyte chimerism 90 120 days allo-HSCT 378 patients AML/MDS underwent busulfan/fludarabine-based myeloablative preparative regimens 265 70 patients available lymphocyte chimerism 43 patients second complete remission CR1/CR2 time transplantation complete 100 donor lymphocytes day +90 +120 compared 60 patients non-CR1/CR2 cohort P .005 CR1/CR2 patients donor lymphocyte chimerism  85 day +90 +120 associated higher frequency 3-year disease progression 29 95 confidence interval CI 18 46 versus 15 95 CI 9 23 hazard ratio HR 2.1 P .04 advanced non-CR1/CR2 cohort mixed lymphocyte chimerism associated relapse 37 95 CI 20 66 versus 34 95 CI 25 47 HR 1.3 P .60 findings demonstrate early lymphocyte chimerism testing day +90 +120 useful approach predicting AML/MDS disease recurrence patients CR1/CR2 time transplantation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6047, 471, 50, 1063, 1007, 452, 31, 497, 2564, 1703, 4, 7, 5, 286, 533, 329, 2, 2040, 1223, 1449, 8, 721, 1515, 9, 1434, 34, 429, 242, 211, 3260, 200, 4, 26, 546, 469, 1200, 21, 565, 3, 464, 549, 1, 102, 1448, 6047, 65, 28, 424, 6, 2031, 162, 50, 2564, 1703, 4, 10084, 7, 5, 329, 1223, 54, 208, 3906, 2027, 90, 3246, 6085, 472, 1, 7298, 431, 7, 5, 390, 102, 1448, 6047, 74, 601, 1, 7, 4, 157, 15, 419, 236, 734, 4516, 7865, 28, 3, 98, 1, 497, 42, 236, 394, 1488, 102, 1594, 28, 218, 424, 6, 2031, 72, 5, 335, 1, 7, 4, 3, 220, 4516, 7865, 180, 19, 1614, 4, 4516, 7865, 7, 1488, 102, 1448, 6047, 1552, 772, 28, 218, 424, 6, 2031, 10, 41, 5, 8, 142, 675, 1, 27, 111, 34, 91, 462, 48, 307, 268, 58, 203, 6, 641, 185, 167, 48, 58, 83, 6, 382, 360, 197, 168, 18, 14, 19, 755, 137, 4, 3, 80, 131, 220, 4516, 7865, 180, 1739, 102, 1448, 6047, 10, 44, 41, 5, 429, 567, 48, 58, 179, 6, 700, 185, 562, 48, 58, 243, 6, 662, 168, 14, 27, 19, 335, 46, 272, 608, 17, 191, 102, 1448, 6047, 471, 28, 218, 424, 6, 2031, 16, 8, 999, 353, 9, 1434, 329, 1223, 34, 146, 4, 7, 4, 4516, 7865, 28, 3, 98, 1, 497]",1337.0,26183077,Mixed Lymphocyte Chimerism Allogeneic Hematopoietic Transplantation Predictive Relapse Acute Myeloid Leukemia Myelodysplastic Syndromes,1,0.0017452006980802793
"Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.",Cancer,Cancer,2015-07-28,"Fludarabine, cyclophosphamide, and rituximab (FCR) result in durable responses in patients with previously untreated chronic lymphocytic leukemia (CLL). Previous reports have suggested that in patients with relapsed CLL, a dose-intensified rituximab regimen increases response rates in comparison with standard-dose rituximab. It is unknown whether rituximab intensification of the FCR regimen will result in improved response rates and patient outcomes in patients with previously untreated CLL. A single-arm study was conducted to evaluate the safety and efficacy of a modified FCR regimen with multiple-dose rituximab (FCR3) in 65 patients with previously untreated CLL. The results were compared with those for a historical cohort treated with FCR. The overall response rate to FCR3 was 97%, with 75% of the patients achieving a complete remission. Minimal residual disease negativity was achieved for 62% of the patients according to flow cytometry. The median time to progression (TTP) was 81 months, and the median overall survival (OS) was not reached, with 58% of the patients still alive at a median survivor follow-up of 9.7 years. Grade 3 or 4 neutropenia, grade 3 or 4 thrombocytopenia, and major infections were observed with 45%, 5%, and 1.9% of the FCR3 courses, respectively. Therapy-related myelodysplastic syndrome (t-MDS) or therapy-related acute myelogenous leukemia (t-AML) developed in 7 patients (11%; P < .01 vs the historical FCR cohort). In patients with previously untreated CLL, FCR3 resulted in response rates, TTP, and OS similar to those of a historical cohort of patients treated with FCR. FCR3 was associated with an increased incidence of t-MDS/t-AML.","Clinical Trial, Phase II",1638.0,8.0,Fludarabine cyclophosphamide rituximab FCR durable responses patients previously untreated chronic lymphocytic leukemia CLL Previous reports suggested patients relapsed CLL dose-intensified rituximab regimen increases response rates comparison standard-dose rituximab unknown rituximab intensification FCR regimen improved response rates patient outcomes patients previously untreated CLL single-arm conducted evaluate safety efficacy modified FCR regimen multiple-dose rituximab FCR3 65 patients previously untreated CLL compared historical cohort treated FCR overall response rate FCR3 97 75 patients achieving complete remission Minimal residual disease negativity achieved 62 patients according flow cytometry median time progression TTP 81 months median overall survival OS reached 58 patients alive median survivor follow-up 9.7 years Grade 3 4 neutropenia grade 3 4 thrombocytopenia major infections observed 45 5 1.9 FCR3 courses respectively Therapy-related myelodysplastic syndrome t-MDS therapy-related acute myelogenous leukemia t-AML developed 7 patients 11 P .01 vs historical FCR cohort patients previously untreated CLL FCR3 resulted response rates TTP OS similar historical cohort patients treated FCR FCR3 associated increased incidence t-MDS/t-AML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[2027, 1112, 2, 855, 4953, 757, 4, 1480, 253, 4, 7, 5, 373, 1278, 442, 1193, 552, 698, 1198, 47, 1148, 17, 4, 7, 5, 591, 552, 8, 61, 7311, 855, 477, 1106, 51, 151, 4, 1155, 5, 260, 61, 855, 192, 16, 860, 317, 855, 5091, 1, 3, 4953, 477, 303, 757, 4, 231, 51, 151, 2, 69, 123, 4, 7, 5, 373, 1278, 552, 8, 226, 475, 45, 10, 426, 6, 376, 3, 367, 2, 209, 1, 8, 1230, 4953, 477, 5, 232, 61, 855, 32471, 4, 556, 7, 5, 373, 1278, 552, 3, 99, 11, 72, 5, 135, 9, 8, 2252, 180, 73, 5, 4953, 3, 63, 51, 116, 6, 32471, 10, 1015, 5, 481, 1, 3, 7, 1785, 8, 236, 734, 1048, 753, 34, 6014, 10, 513, 9, 744, 1, 3, 7, 768, 6, 1412, 1914, 3, 52, 98, 6, 91, 2422, 10, 865, 53, 2, 3, 52, 63, 25, 118, 10, 44, 1300, 5, 717, 1, 3, 7, 1234, 1701, 28, 8, 52, 2628, 166, 126, 1, 83, 67, 60, 88, 27, 15, 39, 778, 88, 27, 15, 39, 1340, 2, 458, 1875, 11, 164, 5, 512, 33, 2, 14, 83, 1, 3, 32471, 1993, 106, 36, 139, 681, 102, 1223, 15, 36, 139, 286, 2194, 102, 329, 276, 4, 67, 7, 175, 19, 355, 105, 3, 2252, 4953, 180, 4, 7, 5, 373, 1278, 552, 32471, 627, 4, 51, 151, 2422, 2, 118, 288, 6, 135, 1, 8, 2252, 180, 1, 7, 73, 5, 4953, 32471, 10, 41, 5, 35, 101, 287, 1, 102, 1223, 102, 329]",1599.0,26218678,Fludarabine cyclophosphamide multiple-dose rituximab frontline therapy chronic lymphocytic leukemia,0,0.0
"Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia, Myelodysplastic Syndromes, and Acute Lymphoid Leukemia.",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2015-08-07,"Clofarabine has potent antileukemia activity and its inclusion in reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (HSCT) for acute leukemia could potentially improve outcomes. We conducted a phase II study of busulfan (.8 mg/kg i.v. twice daily on days-5,-4,-3, and-2) with clofarabine (40 mg/m(2) i.v. daily on days-5,-4,-3, and-2) conditioning before allogeneic 8/8 HLA-matched related or unrelated HSCT. The primary endpoint was donor neutrophil engraftment by day+40. Secondary endpoints included nonrelapse mortality (NRM), acute and chronic graft-versus-host disease (GVHD), progression-free survival (PFS), and overall survival (OS). Thirty-four patients (acute myeloid leukemia [AML], n= 25; myelodysplastic syndromes, n= 5; and acute lymphoid leukemia, n= 4) were enrolled. Day 40+ engraftment with donor chimerism was achieved in 33 of 34 patients with 1 patient dying before count recovery. Day 100 and 1-year NRM were 5.9% (95% confidence interval [CI], 1.0 to 17.4) and 24% (95% CI, 11 to 39), respectively. The 2-year relapse rate was 26% (95% CI, 13 to 42). Cumulative incidences of acute and chronic GVHD were 21% and 44%, respectively. The 2-year PFS was 50% (95% CI, 32 to 65) and OS was 56% (95% CI, 38 to 71). For patients with AML in first complete remission, 2-year PFS and OS were both 82% (95% CI, 55 to 94). RIC with busulfan and clofarabine leads to successful engraftment with acceptable rates of NRM and GVHD. ","Clinical Trial, Phase II",1628.0,10.0,Clofarabine potent antileukemia activity inclusion reduced-intensity conditioning RIC allogeneic hematopoietic stem transplantation HSCT acute leukemia potentially improve outcomes conducted phase II busulfan .8 mg/kg i.v twice daily days -5 -4 -3 -2 clofarabine 40 mg/m 2 i.v daily days -5 -4 -3 -2 conditioning allogeneic 8/8 HLA-matched related unrelated HSCT primary endpoint donor neutrophil engraftment day +40 Secondary endpoints included nonrelapse mortality NRM acute chronic graft-versus-host disease GVHD progression-free survival PFS overall survival OS Thirty-four patients acute myeloid leukemia AML n 25 myelodysplastic syndromes n 5 acute lymphoid leukemia n 4 enrolled Day 40+ engraftment donor chimerism achieved 33 34 patients 1 patient dying count recovery Day 100 1-year NRM 5.9 95 confidence interval CI 1.0 17.4 24 95 CI 11 39 respectively 2-year relapse rate 26 95 CI 13 42 Cumulative incidences acute chronic GVHD 21 44 respectively 2-year PFS 50 95 CI 32 65 OS 56 95 CI 38 71 patients AML complete remission 2-year PFS OS 82 95 CI 55 94 RIC busulfan clofarabine leads successful engraftment acceptable rates NRM GVHD,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4149, 71, 1157, 9169, 128, 2, 211, 1680, 4, 405, 837, 1933, 3365, 1063, 1007, 452, 31, 497, 1703, 9, 286, 359, 751, 401, 123, 21, 426, 8, 124, 215, 45, 1, 3906, 66, 81, 503, 70, 603, 936, 391, 23, 162, 33, 39, 27, 2, 18, 5, 4149, 327, 81, 188, 18, 70, 603, 391, 23, 162, 33, 39, 27, 2, 18, 1933, 348, 1063, 66, 66, 1160, 655, 139, 15, 2092, 1703, 3, 86, 1138, 10, 1488, 2595, 2881, 20, 218, 327, 568, 1387, 159, 4640, 282, 4296, 286, 2, 442, 1599, 185, 1204, 34, 1562, 91, 115, 25, 300, 2, 63, 25, 118, 977, 294, 7, 286, 533, 329, 78, 243, 2040, 78, 33, 2, 286, 2303, 78, 39, 11, 346, 218, 327, 2881, 5, 1488, 6047, 10, 513, 4, 466, 1, 562, 7, 5, 14, 69, 4536, 348, 1276, 1602, 218, 394, 2, 14, 111, 4296, 11, 33, 83, 48, 307, 268, 58, 14, 13, 6, 269, 39, 2, 259, 48, 58, 175, 6, 587, 106, 3, 18, 111, 429, 116, 10, 432, 48, 58, 233, 6, 595, 967, 3981, 1, 286, 2, 442, 1562, 11, 239, 2, 584, 106, 3, 18, 111, 300, 10, 212, 48, 58, 531, 6, 556, 2, 118, 10, 664, 48, 58, 519, 6, 792, 9, 7, 5, 329, 4, 157, 236, 734, 18, 111, 300, 2, 118, 11, 110, 878, 48, 58, 614, 6, 960, 3365, 5, 3906, 2, 4149, 1940, 6, 1401, 2881, 5, 1595, 151, 1, 4296, 2, 1562]",1354.0,26260679,Phase II Trial Reduced-Intensity Busulfan/Clofarabine Conditioning Allogeneic Hematopoietic Stem Transplantation Patients Acute Myeloid Leukemia Myelodysplastic Syndromes Acute Lymphoid Leukemia,189,0.3298429319371728
Accessibility and Quality of Online Cancer-Related Clinical Trial Information for Nave Searchers.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2015-08-11,"Although the Internet may help to increase cancer patients' awareness of clinical trials, little is known about the accessibility and quality of online clinical trial information. We simulated the experience of a nave cancer patient without clinical trial knowledge by searching three popular search engines for treatment information for breast, lung, and prostate cancer, and myelodysplastic syndromes (MDS). Two coders independently evaluated website content for accessibility and quality. We screened 120 websites and identified 40 unique sites for analysis. Overall, 85% [95% confidence interval (CI), 70%-94%] of sites mentioned clinical trials on the landing page and 68% (51%-81%) included links to specific trials. Overall readability was poor. Approximately half of websites (36%-68%) included information on the potential benefits and risks of clinical trials and 40% provided information about when the site had been updated (25%-57%). Among sites with links to specific clinical trials, only 44% (25%-65%) provided an interactive interface that would allow patients to customize search results; breast (100%) and prostate (50%) sites were more interactive than lung (25%) and MDS (14%; P = 0.007). Although cancer clinical trial information is widely available on the Internet, its quality is highly variable. Given the fact that many emerging cancer therapeutics are personalized based on disease or genomic characteristics, interactive web-based interfaces could serve as powerful vehicles to help patients locate appropriate clinical trials. Without enhanced efforts to ensure greater interactivity of cancer treatment websites, patient awareness of relevant clinical trials may remain low.",Journal Article,1624.0,6.0,Internet help increase patients awareness clinical trials little known accessibility quality online clinical trial information simulated experience nave patient clinical trial knowledge searching popular search engines treatment information breast lung prostate myelodysplastic syndromes MDS coders independently evaluated website content accessibility quality screened 120 websites identified 40 unique sites Overall 85 95 confidence interval CI 70 -94 sites mentioned clinical trials landing page 68 51 -81 included links specific trials Overall readability poor Approximately half websites 36 -68 included information potential benefits risks clinical trials 40 provided information site updated 25 -57 sites links specific clinical trials 44 25 -65 provided interactive interface allow patients customize search breast 100 prostate 50 sites interactive lung 25 MDS 14 P 0.007 clinical trial information widely available Internet quality highly variable Given fact emerging therapeutics personalized based disease genomic characteristics interactive web-based interfaces serve powerful vehicles help patients locate appropriate clinical trials enhanced efforts ensure greater interactivity treatment websites patient awareness relevant clinical trials remain low,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[242, 3, 5912, 68, 987, 6, 344, 12, 7, 3310, 1, 38, 143, 1215, 16, 440, 545, 3, 9571, 2, 372, 1, 4123, 38, 160, 487, 21, 5872, 3, 730, 1, 8, 2809, 12, 69, 187, 38, 160, 922, 20, 10082, 169, 8298, 1901, 14883, 9, 24, 487, 9, 2, 12, 2, 2040, 1223, 100, 35021, 1042, 194, 8262, 2457, 9, 9571, 2, 372, 21, 2261, 2031, 12706, 2, 108, 327, 991, 633, 9, 65, 63, 772, 48, 307, 268, 58, 431, 960, 1, 633, 11402, 38, 143, 23, 3, 33828, 9430, 2, 806, 725, 865, 159, 6491, 6, 112, 143, 63, 27215, 10, 334, 705, 1303, 1, 12706, 511, 806, 159, 487, 23, 3, 174, 1141, 2, 1098, 1, 38, 143, 2, 327, 1052, 487, 545, 198, 3, 606, 42, 85, 2939, 243, 696, 107, 633, 5, 6491, 6, 112, 38, 143, 158, 584, 243, 556, 1052, 35, 4750, 7074, 17, 688, 1700, 7, 6, 22144, 1901, 99, 394, 2, 212, 633, 11, 80, 4750, 76, 243, 2, 1223, 213, 19, 13, 1999, 242, 12, 38, 160, 487, 16, 1792, 390, 23, 3, 5912, 211, 372, 16, 561, 1347, 447, 3, 1991, 17, 445, 1478, 12, 1943, 32, 2175, 90, 23, 34, 15, 572, 374, 4750, 3469, 90, 29246, 359, 1833, 22, 3757, 11327, 6, 987, 7, 15124, 870, 38, 143, 187, 651, 1413, 6, 3478, 378, 66628, 1, 12, 24, 12706, 69, 3310, 1, 867, 38, 143, 68, 918, 154]",1586.0,26265204,Accessibility Quality Online Cancer-Related Clinical Trial Information Nave Searchers,0,0.0
Myelodysplastic syndromes following therapy with hypomethylating agents (HMAs): development of acute erythroleukemia may not influence assessment of treatment response.,Leukemia & lymphoma,Leuk. Lymphoma,2016-03-04,"This study followed 28 patients with myelodysplastic syndromes (MDS) who showed a rise of bone marrow (BM) erythroids to50% following three cycles (1-60) of hypomethylating agent (HMA) therapy. If BM blasts were calculated as a percentage of non-erythroids, 12 (42.9%) patients met the diagnostic criteria for acute erythroleukemia, erythroid/myeloid (AEL). However, none of the patients showed clonal cytogenetic evolution or new mutations. When compared to 47 de novo AEL patients, these 12 patients were less anemic and thrombocytopenic, had less complex karyotypes (p=0.044) and showed a longer survival, either calculated from diagnosis (p<0.001) or from the time of AEL (p=0.005). These findings illustrate that50% erythroids may appear in BM post-HMA therapy, likely a combination of reduction of BM granulocytes (p<0.001) and promotion of normal or abnormal erythroid proliferation. Enumeration of blasts as a percentage of non-erythroid cells may lead to a diagnosis of AEL and mis-interpretation as disease progression.",Journal Article,1418.0,5.0,followed 28 patients myelodysplastic syndromes MDS showed rise bone marrow BM erythroids  50 following cycles 1-60 hypomethylating agent HMA therapy BM blasts calculated percentage non-erythroids 12 42.9 patients met diagnostic criteria acute erythroleukemia erythroid/myeloid AEL patients showed clonal cytogenetic evolution new compared 47 novo AEL patients 12 patients anemic thrombocytopenic complex karyotypes p 0.044 showed longer survival calculated diagnosis p 0.001 time AEL p 0.005 findings illustrate  50 erythroids appear BM post-HMA therapy likely combination reduction BM granulocytes p 0.001 promotion normal abnormal erythroid proliferation Enumeration blasts percentage non-erythroid lead diagnosis AEL mis-interpretation disease progression,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[26, 45, 370, 339, 7, 5, 2040, 1223, 54, 224, 8, 3693, 1, 581, 1246, 41194, 6, 749, 212, 366, 169, 410, 14, 335, 1, 4931, 420, 7518, 36, 492, 1246, 2438, 11, 981, 22, 8, 1150, 1, 220, 41194, 133, 595, 83, 7, 543, 3, 752, 371, 9, 286, 14661, 7839, 533, 19217, 137, 1292, 1, 3, 7, 224, 1946, 1266, 2554, 15, 217, 138, 198, 72, 6, 662, 1566, 2018, 19217, 7, 46, 133, 7, 11, 299, 16224, 2, 11908, 42, 299, 840, 6809, 19, 13, 6194, 2, 224, 8, 589, 25, 361, 981, 29, 147, 19, 13, 144, 15, 29, 3, 98, 1, 19217, 19, 13, 1614, 46, 272, 4746, 17, 749, 212, 41194, 68, 1322, 4, 1246, 539, 7518, 36, 322, 8, 150, 1, 628, 1, 1246, 12695, 19, 13, 144, 2, 5478, 1, 295, 15, 1668, 7839, 457, 7014, 1, 2438, 22, 8, 1150, 1, 220, 7839, 37, 68, 1122, 6, 8, 147, 1, 19217, 2, 4386, 3037, 22, 34, 91]",978.0,26293512,Myelodysplastic syndromes following therapy hypomethylating agents HMAs development acute erythroleukemia influence assessment treatment response,5,0.008726003490401396
"Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.",American journal of hematology,Am. J. Hematol.,2015-09-01,"The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older males and in individuals with prior exposure to cytotoxic therapy. Diagnosis of MDS is based on morphological evidence of dysplasia upon visual examination of a bone marrow aspirate and biopsy. Information obtained from additional studies such as karyotype, flow cytometry, or molecular genetics is complementary but not diagnostic. Risk-stratification: Prognosis of patients with MDS can be calculated using a number of scoring systems. In general, all these scoring systems include analysis of peripheral cytopenias, percentage of blasts in the bone marrow, and cytogenetic characteristics. The most commonly used system still is probably the International Prognostic Scoring System (IPSS). IPSS is being replaced by the new revised score IPSS-R. Therapy is selected based on risk, transfusion needs, percent of bone marrow blasts, and more recently cytogenetic and mutational profiles. Goals of therapy are different in lower risk patients than in higher risk. In lower risk, the goal is to decrease transfusion needs and transformation to higher risk disease or AML, as well as to improve survival. In higher risk, the goal is to prolong survival. Current available therapies include growth factor support, lenalidomide, hypomethylating agents, intensive chemotherapy, and allogeneic stem cell transplantation. The use of lenalidomide has significant clinical activity in patients with lower risk disease, anemia, and a chromosome 5 alteration. 5-Azacitidine and decitabine have activity in higher risk MDS. 5-Azacitidine has been shown to improve survival in higher risk MDS. A number of new molecular lesions have been described in MDS that may serve as new therapeutic targets or aid in the selection of currently available agents. Additional supportive care measures may include the use of prophylactic antibiotics and iron chelation. Management of progressive or refractory disease: At the present time there are no approved interventions for patients with progressive or refractory disease particularly after hypomethylating based therapy. Options include participation in a clinical trial or cytarabine based therapy and stem cell transplantation.",Journal Article,1603.0,66.0,myelodysplastic syndromes MDS heterogeneous group myeloid disorders characterized peripheral blood cytopenias increased risk transformation acute myelogenous leukemia AML MDS occurs frequently older males individuals prior exposure cytotoxic therapy Diagnosis MDS based morphological evidence dysplasia visual examination bone marrow aspirate biopsy Information obtained additional studies karyotype flow cytometry molecular genetics complementary diagnostic Risk-stratification Prognosis patients MDS calculated number scoring systems general scoring systems include peripheral cytopenias percentage blasts bone marrow cytogenetic characteristics commonly probably International Prognostic Scoring IPSS IPSS replaced new revised score IPSS-R Therapy selected based risk transfusion needs percent bone marrow blasts recently cytogenetic profiles Goals therapy different lower risk patients higher risk lower risk goal decrease transfusion needs transformation higher risk disease AML improve survival higher risk goal prolong survival Current available therapies include growth factor support lenalidomide hypomethylating agents intensive chemotherapy allogeneic stem transplantation use lenalidomide significant clinical activity patients lower risk disease anemia chromosome 5 alteration 5-Azacitidine decitabine activity higher risk MDS 5-Azacitidine shown improve survival higher risk MDS number new molecular lesions described MDS serve new therapeutic targets aid selection currently available agents Additional supportive care measures include use prophylactic antibiotics iron chelation Management progressive refractory disease present time approved interventions patients progressive refractory disease particularly hypomethylating based therapy Options include participation clinical trial cytarabine based therapy stem transplantation,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2040, 1223, 32, 8, 923, 1564, 87, 1, 533, 1997, 765, 20, 672, 315, 5635, 2, 101, 43, 1, 1392, 6, 286, 2194, 329, 1223, 1780, 80, 746, 4, 434, 2296, 2, 4, 869, 5, 324, 645, 6, 759, 36, 147, 1, 1223, 16, 90, 23, 4268, 241, 1, 2253, 1548, 3046, 1385, 1, 8, 581, 8022, 2, 411, 487, 683, 29, 402, 94, 225, 22, 3385, 1412, 1914, 15, 219, 2894, 16, 3380, 84, 44, 752, 43, 1541, 356, 1, 7, 5, 1223, 122, 40, 981, 75, 8, 207, 1, 2504, 1530, 4, 1083, 62, 46, 2504, 1530, 643, 65, 1, 672, 5635, 1150, 1, 2438, 4, 3, 581, 2, 1266, 374, 3, 96, 841, 95, 398, 1234, 16, 4061, 3, 944, 177, 2504, 398, 8751, 8751, 16, 486, 6928, 20, 3, 217, 4218, 368, 8751, 668, 36, 16, 715, 90, 23, 43, 2785, 1891, 714, 1, 581, 2438, 2, 80, 761, 1266, 2, 1619, 1241, 2802, 1, 36, 32, 338, 4, 280, 43, 7, 76, 4, 142, 43, 4, 280, 43, 3, 1326, 16, 6, 775, 2785, 1891, 2, 1392, 6, 142, 43, 34, 15, 329, 22, 149, 22, 6, 401, 25, 4, 142, 43, 3, 1326, 16, 6, 3615, 25, 291, 390, 235, 643, 129, 161, 538, 1288, 4931, 183, 1686, 56, 2, 1063, 452, 31, 497, 3, 119, 1, 1288, 71, 93, 38, 128, 4, 7, 5, 280, 43, 34, 1545, 2, 8, 1170, 33, 2611, 33, 3752, 2, 3004, 47, 128, 4, 142, 43, 1223, 33, 3752, 71, 85, 443, 6, 401, 25, 4, 142, 43, 1223, 8, 207, 1, 217, 219, 406, 47, 85, 1027, 4, 1223, 17, 68, 1833, 22, 217, 189, 637, 15, 2427, 4, 3, 881, 1, 694, 390, 183, 402, 1877, 165, 1018, 68, 643, 3, 119, 1, 1862, 5214, 2, 4231, 19709, 284, 1, 1014, 15, 430, 34, 28, 3, 364, 98, 125, 32, 77, 850, 1151, 9, 7, 5, 1014, 15, 430, 34, 823, 50, 4931, 90, 36, 838, 643, 2599, 4, 8, 38, 160, 15, 1855, 90, 36, 2, 452, 31, 497]",2316.0,26294090,Myelodysplastic syndromes 2015 Update diagnosis risk-stratification management,49,0.08551483420593368
Pharmacokinetics and Pharmacodynamics with Extended Dosing of CC-486 in Patients with Hematologic Malignancies.,PloS one,PLoS ONE,2015-08-21,"CC-486 (oral azacitidine) is an epigenetic modifier in development for patients with myelodysplastic syndromes and acute myeloid leukemia. In part 1 of this two-part study, a 7-day CC-486 dosing schedule showed clinical activity, was generally well tolerated, and reduced DNA methylation. Extending dosing of CC-486 beyond 7 days would increase duration of azacitidine exposure. We hypothesized that extended dosing would therefore provide more sustained epigenetic activity. Reported here are the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of CC-486 extended dosing schedules in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) from part 2 of this study. PK and/or PD data were available for 59 patients who were sequentially assigned to 1 of 4 extended CC-486 dosing schedules: 300mg once-daily or 200mg twice-daily for 14 or 21 days per 28-day cycle. Both 300mg once-daily schedules and the 200mg twice-daily 21-day schedule significantly (all P < .05) reduced global DNA methylation in whole blood at all measured time points (days 15, 22, and 28 of the treatment cycle), with sustained hypomethylation at cycle end compared with baseline. CC-486 exposures and reduced DNA methylation were significantly correlated. Patients who had a hematologic response had significantly greater methylation reductions than non-responding patients. These data demonstrate that extended dosing of CC-486 sustains epigenetic effects through the treatment cycle. ClinicalTrials.gov NCT00528983.",Clinical Trial,1614.0,14.0,CC-486 oral azacitidine epigenetic modifier development patients myelodysplastic syndromes acute myeloid leukemia 1 two-part 7-day CC-486 dosing schedule showed clinical activity generally tolerated reduced DNA methylation Extending dosing CC-486 7 days increase duration azacitidine exposure hypothesized extended dosing provide sustained epigenetic activity Reported pharmacokinetic PK pharmacodynamic PD profiles CC-486 extended dosing schedules patients myelodysplastic syndromes MDS chronic myelomonocytic leukemia CMML acute myeloid leukemia AML 2 PK and/or PD available 59 patients sequentially assigned 1 4 extended CC-486 dosing schedules 300mg once-daily 200mg twice-daily 14 21 days 28-day cycle 300mg once-daily schedules 200mg twice-daily 21-day schedule significantly P .05 reduced global DNA methylation blood measured time points days 15 22 28 treatment cycle sustained hypomethylation cycle end compared baseline CC-486 exposures reduced DNA methylation significantly correlated Patients hematologic response significantly greater methylation reductions non-responding patients demonstrate extended dosing CC-486 sustains epigenetic effects treatment cycle ClinicalTrials.gov NCT00528983,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1951, 7582, 518, 3752, 16, 35, 1418, 8833, 4, 193, 9, 7, 5, 2040, 2, 286, 533, 4, 760, 14, 1, 26, 100, 760, 45, 8, 67, 218, 1951, 7582, 1280, 1055, 224, 38, 128, 10, 1228, 149, 421, 2, 405, 261, 569, 4782, 1280, 1, 1951, 7582, 1654, 67, 162, 688, 344, 654, 1, 3752, 645, 21, 1237, 17, 1747, 1280, 688, 673, 377, 80, 2275, 1418, 128, 210, 467, 32, 3, 1456, 2395, 2, 2424, 333, 1241, 1, 1951, 7582, 1747, 1280, 2314, 4, 7, 5, 2040, 1223, 442, 5451, 3382, 15, 286, 533, 329, 29, 760, 18, 1, 26, 45, 2395, 2, 15, 333, 74, 11, 390, 9, 728, 7, 54, 11, 5455, 896, 6, 14, 1, 39, 1747, 1951, 7582, 1280, 2314, 21658, 1059, 391, 15, 15316, 936, 391, 9, 213, 15, 239, 162, 379, 339, 218, 417, 110, 21658, 1059, 391, 2314, 2, 3, 15316, 936, 391, 239, 218, 1055, 97, 62, 19, 474, 405, 1648, 261, 569, 4, 902, 315, 28, 62, 644, 98, 862, 162, 167, 350, 2, 339, 1, 3, 24, 417, 5, 2275, 4441, 28, 417, 396, 72, 5, 330, 1951, 7582, 3401, 2, 405, 261, 569, 11, 97, 438, 7, 54, 42, 8, 813, 51, 42, 97, 378, 569, 2153, 76, 220, 3261, 7, 46, 74, 608, 17, 1747, 1280, 1, 1951, 7582, 19039, 1418, 176, 298, 3, 24, 417, 1252, 1239, 66682]",1466.0,26296092,Pharmacokinetics Pharmacodynamics Extended Dosing CC-486 Patients Hematologic Malignancies,27,0.04712041884816754
"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study.",The Lancet. Oncology,Lancet Oncol.,2015-08-19,"Hypomethylating agents are used to treat cancers driven by aberrant DNA methylation, but their short half-life might limit their activity, particularly in patients with less proliferative diseases. Guadecitabine (SGI-110) is a novel hypomethylating dinucleotide of decitabine and deoxyguanosine resistant to degradation by cytidine deaminase. We aimed to assess the safety and clinical activity of subcutaneously given guadecitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. In this multicentre, open-label, phase 1 study, patients from nine North American medical centres with myelodysplastic syndrome or acute myeloid leukaemia that was refractory to or had relapsed after standard treatment were randomly assigned (1:1) to receive subcutaneous guadecitabine, either once-daily for 5 consecutive days (daily  5), or once-weekly for 3 weeks, in a 28-day treatment cycle. Patients were stratified by disease. A 3 + 3 dose-escalation design was used in which we treated patients with guadecitabine doses of 3-125 mg/m(2) in separate dose-escalation cohorts. A twice-weekly treatment schedule was added to the study after a protocol amendment. The primary objective was to assess safety and tolerability of guadecitabine, determine the maximum tolerated and biologically effective dose, and identify the recommended phase 2 dose of guadecitabine. Safety analyses included all patients who received at least one dose of guadecitabine. Pharmacokinetic and pharmacodynamic analyses to determine the biologically effective dose included all patients for whom samples were available. This study is registered with ClinicalTrials.gov, number NCT01261312. Between Jan 4, 2011, and April 11, 2014, we enrolled and treated 93 patients: 35 patients with acute myeloid leukaemia and nine patients with myelodysplastic syndrome in the daily  5 dose-escalation cohorts, 28 patients with acute myeloid leukaemia and six patients with myelodysplastic syndrome in the once-weekly dose-escalation cohorts, and 11 patients with acute myeloid leukaemia and four patients with myelodysplastic syndrome in the twice-weekly dose-escalation cohorts. The most common grade 3 or higher adverse events were febrile neutropenia (38 [41%] of 93 patients), pneumonia (27 [29%] of 93 patients), thrombocytopenia (23 [25%] of 93 patients), anaemia (23 [25%] of 93 patients), and sepsis (16 [17%] of 93 patients). The most common serious adverse events were febrile neutropenia (29 [31%] of 93 patients), pneumonia (26 [28%] of 93 patients), and sepsis (16 [17%] of 93 patients). Six of the 74 patients with acute myeloid leukaemia and six of the 19 patients with myelodysplastic syndrome had a clinical response to treatment. Two dose-limiting toxicities were noted in patients with myelodysplastic syndrome at 125 mg/m(2) daily  5, thus the maximum tolerated dose in patients with myelodysplastic syndrome was 90 mg/m(2) daily  5. The maximum tolerated dose was not reached in patients with acute myeloid leukaemia. Potent dose-related DNA demethylation occurred on the daily  5 regimen, reaching a plateau at 60 mg/m(2) (designated as the biologically effective dose). Guadecitabine given subcutaneously at 60 mg/m(2) daily  5 is well tolerated and is clinically and biologically active in patients with myelodysplastic syndrome and acute myeloid leukaemia. Guadecitabine 60 mg/m(2) daily  5 is the recommended phase 2 dose, and these findings warrant further phase 2 studies. Astex Pharmaceuticals, Stand Up To Cancer.","Clinical Trial, Phase I",1616.0,149.0,Hypomethylating agents treat driven aberrant DNA methylation short half-life limit activity particularly patients proliferative diseases Guadecitabine SGI-110 novel hypomethylating dinucleotide decitabine deoxyguanosine resistant degradation cytidine deaminase aimed assess safety clinical activity subcutaneously given guadecitabine patients acute myeloid leukaemia myelodysplastic syndrome multicentre open-label phase 1 patients North American medical centres myelodysplastic syndrome acute myeloid leukaemia refractory relapsed standard treatment randomly assigned 1:1 receive subcutaneous guadecitabine once-daily 5 consecutive days daily 5 once-weekly 3 weeks 28-day treatment cycle Patients stratified disease 3 3 dose-escalation design treated patients guadecitabine doses 3-125 mg/m 2 separate dose-escalation cohorts twice-weekly treatment schedule added protocol amendment primary objective assess safety tolerability guadecitabine determine maximum tolerated biologically effective dose identify recommended phase 2 dose guadecitabine Safety included patients received dose guadecitabine Pharmacokinetic pharmacodynamic determine biologically effective dose included patients available registered ClinicalTrials.gov number NCT01261312 Jan 4 2011 April 11 2014 enrolled treated 93 patients 35 patients acute myeloid leukaemia patients myelodysplastic syndrome daily 5 dose-escalation cohorts 28 patients acute myeloid leukaemia patients myelodysplastic syndrome once-weekly dose-escalation cohorts 11 patients acute myeloid leukaemia patients myelodysplastic syndrome twice-weekly dose-escalation cohorts common grade 3 higher adverse events febrile neutropenia 38 41 93 patients pneumonia 27 29 93 patients thrombocytopenia 23 25 93 patients anaemia 23 25 93 patients sepsis 16 17 93 patients common adverse events febrile neutropenia 29 31 93 patients pneumonia 26 28 93 patients sepsis 16 17 93 patients 74 patients acute myeloid leukaemia 19 patients myelodysplastic syndrome clinical response treatment dose-limiting toxicities noted patients myelodysplastic syndrome 125 mg/m 2 daily 5 maximum tolerated dose patients myelodysplastic syndrome 90 mg/m 2 daily 5 maximum tolerated dose reached patients acute myeloid leukaemia Potent dose-related DNA demethylation occurred daily 5 regimen reaching plateau 60 mg/m 2 designated biologically effective dose Guadecitabine given subcutaneously 60 mg/m 2 daily 5 tolerated clinically biologically active patients myelodysplastic syndrome acute myeloid leukaemia Guadecitabine 60 mg/m 2 daily 5 recommended phase 2 dose findings warrant phase 2 studies Astex Pharmaceuticals Stand,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4931, 183, 32, 95, 6, 943, 163, 1621, 20, 1898, 261, 569, 84, 136, 978, 1303, 358, 822, 2385, 136, 128, 823, 4, 7, 5, 299, 2441, 1342, 10779, 10768, 3129, 16, 8, 229, 4931, 11816, 1, 3004, 2, 17863, 436, 6, 2373, 20, 12783, 10197, 21, 1295, 6, 423, 3, 367, 2, 38, 128, 1, 3928, 447, 10779, 4, 7, 5, 286, 533, 2001, 15, 681, 4, 26, 5761, 1020, 1756, 124, 14, 45, 7, 29, 762, 2669, 597, 484, 4496, 5, 681, 15, 286, 533, 2001, 17, 10, 430, 6, 15, 42, 591, 50, 260, 24, 11, 1108, 896, 14, 14, 6, 560, 2529, 10779, 361, 1059, 391, 9, 33, 935, 162, 391, 33, 15, 1059, 709, 9, 27, 244, 4, 8, 339, 218, 24, 417, 7, 11, 1173, 20, 34, 8, 27, 27, 61, 1125, 771, 10, 95, 4, 92, 21, 73, 7, 5, 10779, 415, 1, 27, 1731, 81, 188, 18, 4, 2282, 61, 1125, 736, 8, 936, 709, 24, 1055, 10, 1953, 6, 3, 45, 50, 8, 1182, 11013, 3, 86, 461, 10, 6, 423, 367, 2, 1543, 1, 10779, 223, 3, 689, 421, 2, 2665, 323, 61, 2, 255, 3, 793, 124, 18, 61, 1, 10779, 367, 318, 159, 62, 7, 54, 103, 28, 506, 104, 61, 1, 10779, 1456, 2, 2424, 318, 6, 223, 3, 2665, 323, 61, 159, 62, 7, 9, 953, 347, 11, 390, 26, 45, 16, 1653, 5, 1252, 1239, 207, 49257, 59, 7555, 39, 1132, 2, 2292, 175, 1409, 21, 346, 2, 73, 966, 7, 465, 7, 5, 286, 533, 2001, 2, 762, 7, 5, 681, 4, 3, 391, 33, 61, 1125, 736, 339, 7, 5, 286, 533, 2001, 2, 437, 7, 5, 681, 4, 3, 1059, 709, 61, 1125, 736, 2, 175, 7, 5, 286, 533, 2001, 2, 294, 7, 5, 681, 4, 3, 936, 709, 61, 1125, 736, 3, 96, 186, 88, 27, 15, 142, 290, 281, 11, 2498, 778, 519, 605, 1, 966, 7, 3485, 428, 462, 1, 966, 7, 1340, 382, 243, 1, 966, 7, 5712, 382, 243, 1, 966, 7, 2, 4227, 245, 269, 1, 966, 7, 3, 96, 186, 1762, 290, 281, 11, 2498, 778, 462, 456, 1, 966, 7, 3485, 432, 339, 1, 966, 7, 2, 4227, 245, 269, 1, 966, 7, 437, 1, 3, 794, 7, 5, 286, 533, 2001, 2, 437, 1, 3, 326, 7, 5, 681, 42, 8, 38, 51, 6, 24, 100, 61, 817, 385, 11, 1051, 4, 7, 5, 681, 28, 1731, 81, 188, 18, 391, 33, 631, 3, 689, 421, 61, 4, 7, 5, 681, 10, 424, 81, 188, 18, 391, 33, 3, 689, 421, 61, 10, 44, 1300, 4, 7, 5, 286, 533, 2001, 1157, 61, 139, 261, 6800, 489, 23, 3, 391, 33, 477, 6168, 8, 6133, 28, 335, 81, 188, 18, 4107, 22, 3, 2665, 323, 61, 10779, 447, 3928, 28, 335, 81, 188, 18, 391, 33, 16, 149, 421, 2, 16, 505, 2, 2665, 544, 4, 7, 5, 681, 2, 286, 533, 2001, 10779, 335, 81, 188, 18, 391, 33, 16, 3, 793, 124, 18, 61, 2, 46, 272, 2946, 195, 124, 18, 94, 49258, 5888, 9959, 126, 6, 12]",3260.0,26296954,Safety tolerability guadecitabine SGI-110 patients myelodysplastic syndrome acute myeloid leukaemia multicentre randomised dose-escalation phase 1,74,0.12914485165794065
"An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.",Haematologica,Haematologica,2015-09-01,"In the 2008 WHO classification, chronic myeloid malignancies that share both myelodysplastic and myeloproliferative features define the myelodysplastic/myeloproliferative group, which includes chronic myelomonocytic leukemia, juvenile myelomonocytic leukemia, atypical chronic myeloid leukemia, refractory anemia with ring sideroblasts and thrombocytosis, and myelodysplastic/myeloproliferative unclassified. With the notable exception of refractory anemia with ring sideroblasts and thrombocytosis, there is much overlap among the various subtypes at the molecular and clinical levels, and a better definition of these entities, an understanding of their biology and an identification of subtype-specific molecular or cellular markers are needed. To address some of these challenges, a panel comprised of laboratory and clinical experts in myelodysplastic/myeloproliferative was established, and four independent academic MDS/MPN workshops were held on: 9(th) March 2013, in Miami, Florida, USA; 6(th) December 2013, in New Orleans, Louisiana, USA; 13(th) June 2014 in Milan, Italy; and 5(th) December 2014 in San Francisco, USA. During these meetings, the current understanding of these malignancies and matters of biology, diagnosis and management were discussed. This perspective and the recommendations on molecular pathogenesis, diagnosis and clinical characterization for adult onset myelodysplastic/myeloproliferative is the result of a collaborative project endorsed and supported by the MDS Foundation. ",Journal Article,1603.0,53.0,2008 classification chronic myeloid malignancies share myelodysplastic myeloproliferative features define myelodysplastic/myeloproliferative group includes chronic myelomonocytic leukemia juvenile myelomonocytic leukemia atypical chronic myeloid leukemia refractory anemia ring sideroblasts thrombocytosis myelodysplastic/myeloproliferative unclassified notable exception refractory anemia ring sideroblasts thrombocytosis overlap subtypes molecular clinical levels better definition entities understanding identification subtype-specific molecular cellular markers needed address challenges panel comprised laboratory clinical experts myelodysplastic/myeloproliferative established independent academic MDS/MPN workshops held 9 th March 2013 Miami Florida USA 6 th December 2013 New Orleans Louisiana USA 13 th June 2014 Milan Italy 5 th December 2014 San Francisco USA meetings current understanding malignancies matters diagnosis management discussed perspective recommendations molecular pathogenesis diagnosis clinical characterization adult onset myelodysplastic/myeloproliferative collaborative project endorsed supported MDS Foundation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 3, 1375, 54, 947, 442, 533, 441, 17, 4349, 110, 2, 404, 1107, 3, 10589, 10857, 87, 92, 1920, 442, 5451, 7857, 5451, 1973, 442, 533, 430, 1545, 5, 4091, 23740, 2, 7589, 2, 10589, 10857, 7096, 5, 3, 4090, 4188, 1, 430, 1545, 5, 4091, 23740, 2, 7589, 125, 16, 1802, 4526, 107, 3, 747, 814, 28, 3, 219, 2, 38, 148, 2, 8, 380, 2470, 1, 46, 4613, 35, 612, 1, 136, 891, 2, 35, 911, 1, 875, 112, 219, 15, 763, 525, 32, 575, 6, 1539, 476, 1, 46, 1427, 8, 993, 2603, 1, 1624, 2, 38, 3186, 4, 10589, 10857, 10, 635, 2, 294, 306, 1916, 1223, 4125, 16079, 11, 4033, 23, 83, 4517, 2363, 1346, 4, 22507, 10533, 2706, 49, 4517, 1397, 1346, 4, 217, 31644, 22620, 2706, 233, 4517, 1924, 1409, 4, 10610, 11300, 2, 33, 4517, 1397, 1409, 4, 6889, 9732, 2706, 190, 46, 6941, 3, 291, 612, 1, 46, 441, 2, 25029, 1, 891, 147, 2, 284, 11, 1588, 26, 3727, 2, 3, 883, 23, 219, 1384, 147, 2, 38, 2136, 9, 780, 1707, 10589, 10857, 16, 3, 757, 1, 8, 3737, 3105, 6864, 2, 2708, 20, 3, 1223, 3247]",1415.0,26341525,International MDS/MPN Working Group 's perspective recommendations molecular pathogenesis diagnosis clinical characterization myelodysplastic/myeloproliferative neoplasms,195,0.3403141361256545
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.,Leukemia & lymphoma,Leuk. Lymphoma,2015-10-13,"The outcome of sequential azacitidine with lenalidomide has not been reported in previously treated patients with acute myeloid leukemia (AML) and higher risk myelodysplastic syndrome (MDS). This study describes a phase 2 study evaluating the safety and efficacy of this combination in elderly patients with AML and MDS with prior hypomethylating agent (HMA) and/or immunomodulatory agent exposure. Patients were treated on a 42-day cycle with azacitidine at 75mg/m2 SQ/IV daily on days 1-7, followed by lenalidomide 50mg orally daily on days 8-28. The median number of treatment cycles on study was two (range=1-11). Of 32 evaluable patients, the overall response rate was 25%. Neutropenic fever was the most common serious adverse event, but overall the combination was well-tolerated. The median overall survival (OS) for responders vs non-responders was 9.8 vs 4.0 months, respectively (HR=0.36, p=0.016). In conclusion, this combination demonstrated modest clinical activity in this poor risk population.","Clinical Trial, Phase II",1561.0,15.0,outcome sequential azacitidine lenalidomide reported previously treated patients acute myeloid leukemia AML higher risk myelodysplastic syndrome MDS describes phase 2 evaluating safety efficacy combination elderly patients AML MDS prior hypomethylating agent HMA and/or immunomodulatory agent exposure Patients treated 42-day cycle azacitidine 75 mg/m2 SQ/IV daily days 1-7 followed lenalidomide 50 mg orally daily days 8-28 median number treatment cycles range 1-11 32 evaluable patients overall response rate 25 Neutropenic fever common adverse event overall combination well-tolerated median overall survival OS responders vs non-responders 9.8 vs 4.0 months respectively HR 0.36 p 0.016 combination demonstrated modest clinical activity poor risk population,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 228, 1, 1787, 3752, 5, 1288, 71, 44, 85, 210, 4, 373, 73, 7, 5, 286, 533, 329, 2, 142, 43, 681, 1223, 26, 45, 2677, 8, 124, 18, 45, 1435, 3, 367, 2, 209, 1, 26, 150, 4, 1216, 7, 5, 329, 2, 1223, 5, 324, 4931, 420, 7518, 2, 15, 2555, 420, 645, 7, 11, 73, 23, 8, 595, 218, 417, 5, 3752, 28, 481, 81, 821, 13318, 478, 391, 23, 162, 14, 67, 370, 20, 1288, 212, 81, 1428, 391, 23, 162, 66, 339, 3, 52, 207, 1, 24, 410, 23, 45, 10, 100, 184, 14, 175, 1, 531, 859, 7, 3, 63, 51, 116, 10, 243, 3659, 2775, 10, 3, 96, 186, 1762, 290, 774, 84, 63, 3, 150, 10, 149, 421, 3, 52, 63, 25, 118, 9, 1983, 105, 220, 1983, 10, 83, 66, 105, 39, 13, 53, 106, 168, 13, 511, 19, 13, 3820, 4, 1221, 26, 150, 264, 1721, 38, 128, 4, 26, 334, 43, 266]",959.0,26374199,Sequential azacitidine plus lenalidomide previously treated elderly patients acute myeloid leukemia higher risk myelodysplastic syndrome,0,0.0
ABO blood group incompatibility as an adverse risk factor for outcomes in patients with myelodysplastic syndromes and acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic cell transplantation after reduced-intensity conditioning.,Transfusion,Transfusion,2015-10-07,"ABO incompatibility is not a contraindication to hematopoietic cell transplantation (HCT), but it has been associated with additional risks including delayed engraftment, pure red cell aplasia (PRCA), and higher transfusion needs. Data on these events and on patient survival after reduced-intensity conditioning (RIC) HCT are limited. A total of 127 consecutive patients, 86 with acute myeloid leukemia and 41 with myelodysplastic syndromes, who underwent HLA-matched peripheral blood RIC allogenic HCT between 2005 and 2014 were retrospectively analyzed. Eighty ABO-compatible, 26 major/bidirectional, and 21 minor-ABO-mismatch HCT were identified. Compared to the ABO-compatible group, major/bidirectional mismatches had increased red blood cell (RBC) transfusion requirement during the first 100 days (p=0.009), delayed RBC and PLT engraftment (p=0.0011 and p=0.005, respectively), and higher incidence of grade II to IV acute graft-versus-host disease (aGVHD; p=0.037). In multivariable analysis, major/bidirectional mismatches had significantly higher non-relapse mortality (NRM) and inferior disease-free survival (DFS) and overall survival (OS) compared with ABO-compatible patients (p=0.01, p=0.04, and p=0.035, respectively). Minor ABO mismatch had no impact on survival (p = 0.99). Four (15%) of 26 major/bidirectional mismatches developed PRCA. There was a significant association between fludarabine plus busulfan conditioning and PRCA (p=0.0046). Major/bidirectional ABO mismatch is associated with higher NRM and shortened DFS and OS in the setting of RIC HCT. Increased transfusion need, delayed RBC and platelet engraftment, PRCA, and increased severity of aGVHD are additional complications contributing to the morbidity.",Clinical Trial,1567.0,8.0,ABO incompatibility contraindication hematopoietic transplantation HCT associated additional risks including delayed engraftment pure red aplasia PRCA higher transfusion needs events patient survival reduced-intensity conditioning RIC HCT limited total 127 consecutive patients 86 acute myeloid leukemia 41 myelodysplastic syndromes underwent HLA-matched peripheral blood RIC allogenic HCT 2005 2014 retrospectively Eighty ABO-compatible 26 major/bidirectional 21 minor-ABO-mismatch HCT identified Compared ABO-compatible group major/bidirectional mismatches increased red blood RBC transfusion requirement 100 days p 0.009 delayed RBC PLT engraftment p 0.0011 p 0.005 respectively higher incidence grade II IV acute graft-versus-host disease aGVHD p 0.037 multivariable major/bidirectional mismatches significantly higher non-relapse mortality NRM inferior disease-free survival DFS overall survival OS compared ABO-compatible patients p 0.01 p 0.04 p 0.035 respectively Minor ABO mismatch impact survival p 0.99 15 26 major/bidirectional mismatches developed PRCA significant association fludarabine plus busulfan conditioning PRCA p 0.0046 Major/bidirectional ABO mismatch associated higher NRM shortened DFS OS setting RIC HCT Increased transfusion need delayed RBC platelet engraftment PRCA increased severity aGVHD additional complications contributing morbidity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[8623, 38961, 16, 44, 8, 8363, 6, 1007, 31, 497, 1085, 84, 192, 71, 85, 41, 5, 402, 1098, 141, 1612, 2881, 3092, 3422, 31, 12307, 7861, 2, 142, 2785, 1891, 74, 23, 46, 281, 2, 23, 69, 25, 50, 405, 837, 1933, 3365, 1085, 32, 383, 8, 181, 1, 4080, 935, 7, 868, 5, 286, 533, 2, 605, 5, 2040, 54, 208, 1160, 655, 672, 315, 3365, 15122, 1085, 59, 1242, 2, 1409, 11, 894, 311, 2207, 8623, 7293, 432, 458, 10953, 2, 239, 2278, 8623, 2617, 1085, 11, 108, 72, 6, 3, 8623, 7293, 87, 458, 10953, 11828, 42, 101, 3422, 315, 31, 7256, 2785, 4701, 190, 3, 157, 394, 162, 19, 13, 2376, 1612, 7256, 2, 15620, 2881, 19, 13, 13046, 2, 19, 13, 1614, 106, 2, 142, 287, 1, 88, 215, 6, 478, 286, 1599, 185, 1204, 34, 5873, 19, 13, 5171, 4, 658, 65, 458, 10953, 11828, 42, 97, 142, 220, 429, 282, 4296, 2, 1663, 34, 115, 25, 1010, 2, 63, 25, 118, 72, 5, 8623, 7293, 7, 19, 13, 355, 19, 13, 755, 2, 19, 13, 4514, 106, 2278, 8623, 2617, 42, 77, 345, 23, 25, 19, 13, 1058, 294, 167, 1, 432, 458, 10953, 11828, 276, 7861, 125, 10, 8, 93, 248, 59, 2027, 349, 3906, 1933, 2, 7861, 19, 13, 21259, 458, 10953, 8623, 2617, 16, 41, 5, 142, 4296, 2, 6151, 1010, 2, 118, 4, 3, 546, 1, 3365, 1085, 101, 2785, 594, 1612, 7256, 2, 1596, 2881, 7861, 2, 101, 1702, 1, 5873, 32, 402, 521, 3156, 6, 3, 787]",1653.0,26446051,ABO blood group incompatibility adverse risk factor outcomes patients myelodysplastic syndromes acute myeloid leukemia undergoing HLA-matched peripheral blood hematopoietic transplantation reduced-intensity conditioning,3,0.005235602094240838
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.,The oncologist,Oncologist,2015-10-13,"The myelodysplastic syndromes (MDS) comprise a heterogeneous group of clonal myeloid malignancies characterized by multilineage cytopenias, recurrent cytogenetic abnormalities, and risk of progression to acute myeloid leukemia (AML). AML, which can occur de novo as well as secondary to MDS, is characterized by malignant clones of myeloid lineage in the bone marrow and peripheral blood, with dissemination into tissues. The cytidine nucleoside analog and epigenetic modifier azacitidine is approved in the U.S. for the treatment of all French-American-British subtypes of MDS and in many countries for the treatment of AML with 20%-30% blasts and multilineage dysplasia according to the World Health Organization classification. Benefits of azacitidine treatment of patients with AML with >30% blasts have also been shown in a recent phase III trial. Oral administration of azacitidine may enhance patient convenience, eliminate injection-site reactions, allow for alternative dosing and scheduling, and enable long-term treatment. Phase I studies with oral azacitidine (CC-486) have shown biological activity, clinical responses, and tolerability in patients with MDS and AML. Extended dosing schedules of oral azacitidine (for 14 or 21 days of 28-day cycles) are currently under investigation as frontline therapy in patients with lower risk MDS, as maintenance therapy for patients with AML not eligible for stem cell transplant, and as maintenance therapy for patients with MDS or AML following stem cell transplant. This review presents clinical data supporting the use of injectable azacitidine in MDS and AML and examines the rationale for and results of the clinical development of oral azacitidine.",Journal Article,1561.0,19.0,myelodysplastic syndromes MDS comprise heterogeneous group clonal myeloid malignancies characterized multilineage cytopenias recurrent cytogenetic abnormalities risk progression acute myeloid leukemia AML AML occur novo secondary MDS characterized malignant clones myeloid lineage bone marrow peripheral blood dissemination tissues cytidine nucleoside analog epigenetic modifier azacitidine approved U.S. treatment French-American-British subtypes MDS countries treatment AML 20 -30 blasts multilineage dysplasia according World Health Organization classification Benefits azacitidine treatment patients AML 30 blasts shown recent phase III trial Oral administration azacitidine enhance patient convenience eliminate injection-site reactions allow alternative dosing scheduling enable long-term treatment Phase studies oral azacitidine CC-486 shown activity clinical responses tolerability patients MDS AML Extended dosing schedules oral azacitidine 14 21 days 28-day cycles currently investigation frontline therapy patients lower risk MDS maintenance therapy patients AML eligible stem transplant maintenance therapy patients MDS AML following stem transplant review presents clinical supporting use injectable azacitidine MDS AML examines rationale clinical development oral azacitidine,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2040, 1223, 5238, 8, 1564, 87, 1, 1946, 533, 441, 765, 20, 12471, 5635, 387, 1266, 1171, 2, 43, 1, 91, 6, 286, 533, 329, 329, 92, 122, 1271, 1566, 2018, 22, 149, 22, 568, 6, 1223, 16, 765, 20, 393, 2749, 1, 533, 2542, 4, 3, 581, 2, 672, 315, 5, 3430, 237, 742, 3, 12783, 4032, 3497, 2, 1418, 8833, 3752, 16, 850, 4, 3, 1767, 695, 9, 3, 24, 1, 62, 9254, 597, 11754, 814, 1, 1223, 2, 4, 445, 2115, 9, 3, 24, 1, 329, 5, 179, 201, 2438, 2, 12471, 2253, 768, 6, 3, 1956, 341, 2533, 947, 1141, 1, 3752, 24, 1, 7, 5, 329, 5, 201, 2438, 47, 120, 85, 443, 4, 8, 435, 124, 316, 160, 518, 634, 1, 3752, 68, 1304, 69, 8184, 4964, 1754, 606, 2428, 1700, 9, 1091, 1280, 2, 8122, 2, 3047, 319, 337, 24, 124, 70, 94, 5, 518, 3752, 1951, 7582, 47, 443, 1037, 128, 38, 253, 2, 1543, 4, 7, 5, 1223, 2, 329, 1747, 1280, 2314, 1, 518, 3752, 9, 213, 15, 239, 162, 1, 339, 218, 410, 32, 694, 669, 940, 22, 3171, 36, 4, 7, 5, 280, 43, 1223, 22, 1146, 36, 9, 7, 5, 329, 44, 625, 9, 452, 31, 941, 2, 22, 1146, 36, 9, 7, 5, 1223, 15, 329, 366, 452, 31, 941, 26, 206, 2740, 38, 74, 1912, 3, 119, 1, 11652, 3752, 4, 1223, 2, 329, 2, 4468, 3, 1728, 9, 2, 99, 1, 3, 38, 193, 1, 518, 3752]",1648.0,26463870,Oral Azacitidine CC-486 Treatment Myelodysplastic Syndromes Acute Myeloid Leukemia,76,0.13263525305410123
"Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial.",The Lancet. Oncology,Lancet Oncol.,2015-10-22,"New options are needed for patients with heavily pretreated breast cancer. Etirinotecan pegol is a long-acting topoisomerase-I inhibitor that prolongs exposure to, but reduces the toxicity of, SN38 (the active metabolite of irinotecan). We assessed whether etirinotecan pegol is superior to currently available treatments for patients with previously treated, locally recurrent or metastatic breast cancer. In this open-label, multicentre, randomised phase 3 study (BEACON; BrEAst Cancer Outcomes with NKTR-102), conducted at 135 sites in 11 countries, patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine (and two to five previous regimens for advanced disease) were randomly assigned (1:1) centrally via an interactive response system to etirinotecan pegol (145 mg/m(2) as a 90-min intravenous infusion every 3 weeks) or single-drug treatment of physician's choice. Patients with stable brain metastases and an Eastern Cooperative Oncology Group performance status of 0-1 were eligible. Randomisation was stratified with a permuted block scheme by region, previous eribulin, and receptor status. After randomisation, patients and investigators were aware of treatment assignments. The primary endpoint was overall survival in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01492101. Between Dec 19, 2011, and Aug 20, 2013, 852 patients were randomly assigned; 429 to etirinotecan pegol and 423 to treatment of physician's choice. There was no significant difference in overall survival between groups (median 124 months [95% CI 110-136] for the etirinotecan pegol group vs 103 months [90-113] for the treatment of physician's choice group; hazard ratio 087 [95% CI 075-102]; p=0084). The safety population includes the 831 patients who received at least one dose of assigned treatment (425 assigned to etirinotecan pegol and 406 to treatment of physician's choice). Serious adverse events were recorded for 128 (30%) patients treated with etirinotecan pegol and 129 (32%) treated with treatment of physician's choice. Fewer patients in the etirinotecan pegol group had grade 3 or worse toxicity than those in the treatment of physician's choice group (204 [48%] vs 256 [63%]; p<00001). The most common grade 3 or worse adverse events were diarrhoea (41 [10%] in the experimental group vs five [1%] in the control group), neutropenia (41 [10%] vs 125 [31%]), and peripheral neuropathy (two [<1%] vs 15 [4%]). Three patients in the etirinotecan pegol group died of treatment-related adverse events (pneumonia, myelodysplastic syndrome, and acute renal failure) and two in the treatment of physician's choice group (neutropenic sepsis and septic shock). This trial did not demonstrate an improvement in overall survival for etirinotecan pegol compared to treatment of physician's choice in patients with heavily pre-treated advanced breast cancer. The toxicity profile noted in the etirinotecan pegol group differed from that in the control group. In view of the frequency of cross-resistance and overlapping toxicities noted with many available drugs and the need for effective drugs in highly refractory disease, etirinotecan pegol may warrant further research in some subgroups of patients. Nektar Therapeutics.","Clinical Trial, Phase III",1552.0,46.0,New options needed patients heavily pretreated breast Etirinotecan pegol long-acting topoisomerase-I inhibitor prolongs exposure reduces toxicity SN38 active metabolite irinotecan assessed etirinotecan pegol superior currently available treatments patients previously treated locally recurrent metastatic breast open-label multicentre randomised phase 3 BEACON BrEAst Outcomes NKTR-102 conducted 135 sites 11 countries patients locally recurrent metastatic breast previously treated anthracycline taxane capecitabine previous regimens advanced disease randomly assigned 1:1 centrally interactive response etirinotecan pegol 145 mg/m 2 90-min intravenous infusion 3 weeks single-drug treatment physician 's choice Patients stable brain metastases Eastern Cooperative Oncology Group performance status 0-1 eligible Randomisation stratified permuted block scheme region previous eribulin receptor status randomisation patients investigators aware treatment assignments primary endpoint overall survival intention-to-treat population registered ClinicalTrials.gov number NCT01492101 Dec 19 2011 Aug 20 2013 852 patients randomly assigned 429 etirinotecan pegol 423 treatment physician 's choice significant difference overall survival groups median 124 months 95 CI 110-136 etirinotecan pegol group vs 103 months 90-113 treatment physician 's choice group hazard ratio 087 95 CI 075-102 p=0084 safety population includes 831 patients received dose assigned treatment 425 assigned etirinotecan pegol 406 treatment physician 's choice adverse events recorded 128 30 patients treated etirinotecan pegol 129 32 treated treatment physician 's choice Fewer patients etirinotecan pegol group grade 3 worse toxicity treatment physician 's choice group 204 48 vs 256 63 p 00001 common grade 3 worse adverse events diarrhoea 41 10 experimental group vs 1 control group neutropenia 41 10 vs 125 31 peripheral neuropathy 1 vs 15 4 patients etirinotecan pegol group died treatment-related adverse events pneumonia myelodysplastic syndrome acute renal failure treatment physician 's choice group neutropenic sepsis septic shock trial demonstrate improvement overall survival etirinotecan pegol compared treatment physician 's choice patients heavily pre-treated advanced breast toxicity profile noted etirinotecan pegol group differed control group view frequency cross-resistance overlapping toxicities noted available drugs need effective drugs highly refractory disease etirinotecan pegol warrant research subgroups patients Nektar Therapeutics,1,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[217, 838, 32, 575, 9, 7, 5, 2447, 2193, 12, 12461, 12462, 16, 8, 319, 5375, 3999, 70, 230, 17, 5613, 645, 6, 84, 2389, 3, 155, 1, 10557, 3, 544, 3379, 1, 1071, 21, 275, 317, 12461, 12462, 16, 1123, 6, 694, 390, 640, 9, 7, 5, 373, 73, 795, 387, 15, 113, 12, 4, 26, 1020, 1756, 5761, 2827, 124, 27, 45, 20280, 12, 123, 5, 49351, 2867, 426, 28, 3978, 633, 4, 175, 2115, 7, 5, 795, 387, 15, 113, 12, 373, 73, 5, 35, 2044, 8, 1715, 2, 1629, 2, 100, 6, 365, 698, 472, 9, 131, 34, 11, 1108, 896, 14, 14, 4604, 847, 35, 4750, 51, 398, 6, 12461, 12462, 4058, 81, 188, 18, 22, 8, 424, 1538, 1262, 904, 454, 27, 244, 15, 226, 234, 24, 1, 1473, 292, 1866, 7, 5, 585, 342, 196, 2, 35, 2118, 1690, 413, 87, 528, 156, 1, 13, 14, 11, 625, 5204, 10, 1173, 5, 8, 10496, 2381, 4633, 20, 1053, 698, 5659, 2, 153, 156, 50, 5204, 7, 2, 2394, 11, 4749, 1, 24, 16433, 3, 86, 1138, 10, 63, 25, 4, 3, 3205, 6, 943, 266, 26, 45, 16, 1653, 5, 1252, 1239, 207, 49352, 59, 8702, 326, 1132, 2, 10497, 179, 1346, 15563, 7, 11, 1108, 896, 8406, 6, 12461, 12462, 2, 11310, 6, 24, 1, 1473, 292, 1866, 125, 10, 77, 93, 523, 4, 63, 25, 59, 271, 52, 36120, 53, 48, 58, 21796, 25485, 9, 3, 12461, 12462, 87, 105, 23893, 53, 19972, 23940, 9, 3, 24, 1, 1473, 292, 1866, 87, 360, 197, 18008, 48, 58, 16992, 18650, 19, 41240, 3, 367, 266, 1920, 3, 13962, 7, 54, 103, 28, 506, 104, 61, 1, 896, 24, 8544, 896, 6, 12461, 12462, 2, 8522, 6, 24, 1, 1473, 292, 1866, 1762, 290, 281, 11, 1872, 9, 3990, 201, 7, 73, 5, 12461, 12462, 2, 4649, 531, 73, 5, 24, 1, 1473, 292, 1866, 1497, 7, 4, 3, 12461, 12462, 87, 42, 88, 27, 15, 639, 155, 76, 135, 4, 3, 24, 1, 1473, 292, 1866, 87, 5996, 576, 105, 7162, 676, 19, 4599, 3, 96, 186, 88, 27, 15, 639, 290, 281, 11, 4959, 605, 79, 4, 3, 1560, 87, 105, 365, 14, 4, 3, 182, 87, 778, 605, 79, 105, 1731, 456, 2, 672, 1751, 100, 14, 105, 167, 39, 169, 7, 4, 3, 12461, 12462, 87, 1016, 1, 24, 139, 290, 281, 3485, 681, 2, 286, 496, 2, 100, 4, 3, 24, 1, 1473, 292, 1866, 87, 3659, 4227, 2, 12526, 3971, 26, 160, 205, 44, 608, 35, 767, 4, 63, 25, 9, 12461, 12462, 72, 6, 24, 1, 1473, 292, 1866, 4, 7, 5, 2447, 671, 73, 131, 12, 3, 155, 800, 1051, 4, 3, 12461, 12462, 87, 2512, 29, 17, 4, 3, 182, 87, 4, 3811, 1, 3, 675, 1, 1383, 251, 2, 4551, 385, 1051, 5, 445, 390, 600, 2, 3, 594, 9, 323, 600, 4, 561, 430, 34, 12461, 12462, 68, 2946, 195, 389, 4, 476, 1453, 1, 7, 67003, 1943]",3186.0,26482278,Etirinotecan pegol NKTR-102 versus treatment physician 's choice women advanced breast previously treated anthracycline taxane capecitabine BEACON randomised open-label multicentre phase 3 trial,0,0.0
The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.,Journal of hematology & oncology,J Hematol Oncol,2015-10-20,"Therapy and outcome for elderly acute myeloid leukemia (AML) patients has not improved for many years. Similarly, there remains a clinical need to improve response rates in advanced myelodysplastic syndrome (MDS) patients treated with hypomethylating agents, and few combination regimens have shown clinical benefit. We conducted a 5-azacytidine (5-Aza) RNA-interference (RNAi) sensitizer screen to identify gene targets within the commonly deleted regions (CDRs) of chromosomes 5 and 7, whose silencing enhances the activity of 5-Aza. An RNAi silencing screen of 270 genes from the CDRs of chromosomes 5 and 7 was performed in combination with 5-Aza treatment in four AML cell lines (TF-1, THP-1, MDS-L, and HEL). Several genes within the hedgehog pathway (HhP), specifically SHH, SMO, and GLI3, were identified as 5-Aza sensitizing hits. The smoothened (SMO) inhibitors LDE225 (erismodegib) and GDC0449 (vismodegib) showed moderate single-agent activity in AML cell lines. Further studies with erismodegib in combination with 5-Aza demonstrated synergistic activity with combination index (CI) values of 0.48 to 0.71 in seven AML lines. Clonogenic growth of primary patient samples was inhibited to a greater extent in the combination than with single-agent erismodegib or 5-Aza in 55% (6 of 11) primary patient samples examined. There was no association of the 5-Aza/erismodegib sensitization potential to clinical-cytogenetic features or common myeloid mutations. Activation of the HhP, as determined by greater expression of HhP-related genes, showed less responsiveness to single-agent SMO inhibition, while synergy between both agents was similar regardless of HhP gene expression. In vitro experiments suggested that concurrent dosing showed stronger synergy than sequential dosing. Inhibition of the HhP with SMO inhibitors in combination with the hypomethylating agent 5-Aza demonstrates synergy in vitro and inhibits long-term repopulation capacity ex vivo in AML and MDS. A clinical trial combining 5-Aza with LDE225 (erismodegib) in MDS and AML is ongoing based on these results as well as additional publications suggesting a role for HhP signaling in myeloid disease.",Journal Article,1554.0,20.0,Therapy outcome elderly acute myeloid leukemia AML patients improved years Similarly remains clinical need improve response rates advanced myelodysplastic syndrome MDS patients treated hypomethylating agents combination regimens shown clinical benefit conducted 5-azacytidine 5-Aza RNA-interference RNAi sensitizer screen identify targets commonly deleted regions CDRs chromosomes 5 7 silencing enhances activity 5-Aza RNAi silencing screen 270 CDRs chromosomes 5 7 performed combination 5-Aza treatment AML lines TF-1 THP-1 MDS-L HEL hedgehog pathway HhP specifically SHH SMO GLI3 identified 5-Aza sensitizing hits smoothened SMO inhibitors LDE225 erismodegib GDC0449 vismodegib showed moderate single-agent activity AML lines studies erismodegib combination 5-Aza demonstrated synergistic activity combination index CI values 0.48 0.71 seven AML lines Clonogenic growth primary patient inhibited greater extent combination single-agent erismodegib 5-Aza 55 6 11 primary patient examined association 5-Aza/erismodegib sensitization potential clinical-cytogenetic features common myeloid Activation HhP determined greater expression HhP-related showed responsiveness single-agent SMO inhibition synergy agents similar regardless HhP expression vitro experiments suggested concurrent dosing showed stronger synergy sequential dosing Inhibition HhP SMO inhibitors combination hypomethylating agent 5-Aza demonstrates synergy vitro inhibits long-term repopulation capacity ex vivo AML MDS clinical trial combining 5-Aza LDE225 erismodegib MDS AML ongoing based additional publications suggesting role HhP signaling myeloid disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[36, 2, 228, 9, 1216, 286, 533, 329, 7, 71, 44, 231, 9, 445, 60, 1813, 125, 469, 8, 38, 594, 6, 401, 51, 151, 4, 131, 681, 1223, 7, 73, 5, 4931, 183, 2, 1021, 150, 472, 47, 443, 38, 247, 21, 426, 8, 33, 11755, 33, 3924, 893, 3182, 5881, 13806, 2413, 6, 255, 145, 637, 262, 3, 841, 4389, 1374, 28850, 1, 3560, 33, 2, 67, 1310, 2077, 2519, 3, 128, 1, 33, 3924, 35, 5881, 2077, 2413, 1, 6666, 214, 29, 3, 28850, 1, 3560, 33, 2, 67, 10, 173, 4, 150, 5, 33, 3924, 24, 4, 294, 329, 31, 285, 4641, 14, 10186, 14, 1223, 805, 2, 23517, 392, 214, 262, 3, 4097, 308, 15058, 1225, 5170, 7229, 2, 25181, 11, 108, 22, 33, 3924, 5979, 12397, 3, 11990, 7229, 222, 27362, 29728, 2, 67008, 6035, 224, 1163, 226, 420, 128, 4, 329, 31, 285, 195, 94, 5, 29728, 4, 150, 5, 33, 3924, 264, 1806, 128, 5, 150, 558, 58, 1030, 1, 13, 576, 6, 13, 792, 4, 648, 329, 285, 3798, 129, 1, 86, 69, 347, 10, 879, 6, 8, 378, 1039, 4, 3, 150, 76, 5, 226, 420, 29728, 15, 33, 3924, 4, 614, 49, 1, 175, 86, 69, 347, 409, 125, 10, 77, 248, 1, 3, 33, 3924, 29728, 6272, 174, 6, 38, 1266, 404, 15, 186, 533, 138, 363, 1, 3, 15058, 22, 509, 20, 378, 55, 1, 15058, 139, 214, 224, 299, 3642, 6, 226, 420, 7229, 297, 369, 3439, 59, 110, 183, 10, 288, 1583, 1, 15058, 145, 55, 4, 439, 2332, 1148, 17, 750, 1280, 224, 3355, 3439, 76, 1787, 1280, 297, 1, 3, 15058, 5, 7229, 222, 4, 150, 5, 3, 4931, 420, 33, 3924, 1902, 3439, 4, 439, 2, 1576, 319, 337, 17148, 2162, 2581, 386, 4, 329, 2, 1223, 8, 38, 160, 1525, 33, 3924, 5, 27362, 29728, 4, 1223, 2, 329, 16, 942, 90, 23, 46, 99, 22, 149, 22, 402, 4463, 802, 8, 200, 9, 15058, 314, 4, 533, 34]",2104.0,26483188,Hedgehog pathway targetable vulnerability 5-azacytidine myelodysplastic syndrome acute myeloid leukemia,35,0.06108202443280977
Clinical validation of a multipurpose assay for detection and genotyping of CALR mutations in myeloproliferative neoplasms.,American journal of clinical pathology,Am. J. Clin. Pathol.,2015-11-01,"To develop a polymerase chain reaction (PCR)-based approach to detect CALR mutations in myeloproliferative neoplasms (MPNs) in a clinical laboratory. DNA was extracted from bone marrow aspirate samples of 67 JAK2 wild-type MPNs (22 with matched peripheral blood), 54 cases of unclassifiable myelodysplastic syndrome/MPN, and 16 cases of atypical chronic myeloid leukemia. We used genomic DNA to detect somatic mutations in exon 9 of CALR and PCR with fluorescently labeled and M13-tagged primers and subjected the products to capillary electrophoresis (CE) followed by Sanger sequencing. Detailed assay performance characteristics were established. We identified CALR mutations in 19 (28.4%) of 67 JAK2-negative MPNs, including 14 type I (52-base pair [bp] deletion), four type II (5-bp insertions), and one type III (18-bp deletion). All mutations were confirmed by Sanger sequencing. Sensitivity studies showed 2.5% and 5% mutation detection levels by CE and Sanger sequencing, respectively, with high reproducibility. This assay allows for rapid, convenient screening for CALR mutations in MPNs, thereby reducing the number of cases that require assessment by Sanger sequencing, reducing labor and improving turnaround time.",Journal Article,1542.0,8.0,develop polymerase chain reaction PCR -based approach detect CALR myeloproliferative neoplasms MPNs clinical laboratory DNA extracted bone marrow aspirate 67 JAK2 wild-type MPNs 22 matched peripheral blood 54 cases unclassifiable myelodysplastic syndrome/MPN 16 cases atypical chronic myeloid leukemia genomic DNA detect somatic exon 9 CALR PCR fluorescently labeled M13-tagged primers subjected products capillary electrophoresis CE followed Sanger sequencing Detailed performance characteristics established identified CALR 19 28.4 67 JAK2-negative MPNs including 14 type 52-base pair bp deletion type II 5-bp insertions type III 18-bp deletion confirmed Sanger sequencing Sensitivity studies showed 2.5 5 detection levels CE Sanger sequencing respectively high reproducibility allows rapid convenient screening CALR MPNs reducing number cases require assessment Sanger sequencing reducing labor improving turnaround time,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 690, 8, 1451, 1260, 1329, 604, 90, 353, 6, 1426, 11222, 138, 4, 1179, 6880, 4, 8, 38, 1624, 261, 10, 2484, 29, 581, 8022, 347, 1, 598, 2509, 955, 267, 6880, 350, 5, 655, 672, 315, 667, 140, 1, 14338, 681, 4125, 2, 245, 140, 1, 1973, 442, 533, 21, 95, 572, 261, 6, 1426, 1119, 138, 4, 1725, 83, 1, 11222, 2, 604, 5, 12496, 2841, 2, 67011, 9874, 10031, 2, 4325, 3, 2766, 6, 8943, 6777, 7065, 370, 20, 7285, 615, 2455, 719, 528, 374, 11, 635, 21, 108, 11222, 138, 4, 326, 339, 39, 1, 598, 2509, 199, 6880, 141, 213, 267, 70, 653, 1782, 4767, 3044, 1528, 294, 267, 215, 33, 3044, 6315, 2, 104, 267, 316, 203, 3044, 1528, 62, 138, 11, 557, 20, 7285, 615, 485, 94, 224, 18, 33, 2, 33, 258, 638, 148, 20, 7065, 2, 7285, 615, 106, 5, 64, 4688, 26, 719, 2333, 9, 1321, 7048, 453, 9, 11222, 138, 4, 6880, 2267, 1818, 3, 207, 1, 140, 17, 1353, 455, 20, 7285, 615, 1818, 9557, 2, 1673, 14335, 98]",1140.0,26486739,Clinical validation multipurpose detection genotyping CALR myeloproliferative neoplasms,0,0.0
Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia.,Blood,Blood,2015-10-22,"Familial clustering of myelodysplastic syndromes (MDSs) and acute myeloid leukemia (AML) can be caused by inherited factors. We screened 59 individuals from 17 families with 2 or more biological relatives with MDS/AML for variants in 12 genes with established roles in predisposition to MDS/AML, and identified a pathogenic germ line variant in 5 families (29%). Extending the screen with a panel of 264 genes that are recurrently mutated in de novo AML, we identified rare, nonsynonymous germ line variants in 4 genes, each segregating with MDS/AML in 2 families. Somatic mutations are required for progression to MDS/AML in these familial cases. Using a combination of targeted and exome sequencing of tumor and matched normal samples from 26 familial MDS/AML cases and asymptomatic carriers, we identified recurrent frameshift mutations in the cohesin-associated factor PDS5B, co-occurrence of somatic ASXL1 mutations with germ line GATA2 mutations, and recurrent mutations in other known MDS/AML drivers. Mutations in genes that are recurrently mutated in de novo AML were underrepresented in the familial MDS/AML cases, although the total number of somatic mutations per exome was the same. Lastly, clonal skewing of hematopoiesis was detected in 67% of young, asymptomatic RUNX1 carriers, providing a potential biomarker that could be used for surveillance in these high-risk families. ",Clinical Trial,1552.0,91.0,Familial clustering myelodysplastic syndromes MDSs acute myeloid leukemia AML caused inherited factors screened 59 individuals 17 families 2 relatives MDS/AML 12 established roles predisposition MDS/AML identified pathogenic germ line 5 families 29 Extending screen panel 264 recurrently novo AML identified rare nonsynonymous germ line 4 segregating MDS/AML 2 families Somatic required progression MDS/AML familial cases combination targeted exome sequencing matched normal 26 familial MDS/AML cases asymptomatic carriers identified recurrent frameshift cohesin-associated factor PDS5B co-occurrence somatic ASXL1 germ line GATA2 recurrent known MDS/AML drivers recurrently novo AML underrepresented familial MDS/AML cases total number somatic exome Lastly clonal skewing hematopoiesis detected 67 young asymptomatic RUNX1 carriers providing potential biomarker surveillance high-risk families,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2200, 3147, 1, 2040, 13550, 2, 286, 533, 329, 122, 40, 1546, 20, 2986, 130, 21, 2261, 728, 869, 29, 269, 1954, 5, 18, 15, 80, 1037, 3335, 5, 1223, 329, 9, 839, 4, 133, 214, 5, 635, 1790, 4, 2863, 6, 1223, 329, 2, 108, 8, 2806, 2280, 328, 1142, 4, 33, 1954, 462, 4782, 3, 2413, 5, 8, 993, 1, 6528, 214, 17, 32, 8820, 1185, 4, 1566, 2018, 329, 21, 108, 622, 10233, 2280, 328, 839, 4, 39, 214, 296, 23435, 5, 1223, 329, 4, 18, 1954, 1119, 138, 32, 616, 9, 91, 6, 1223, 329, 4, 46, 2200, 140, 75, 8, 150, 1, 238, 2, 2865, 615, 1, 30, 2, 655, 295, 347, 29, 432, 2200, 1223, 329, 140, 2, 2100, 1316, 21, 108, 387, 9425, 138, 4, 3, 17033, 41, 161, 67025, 1269, 2291, 1, 1119, 7782, 138, 5, 2280, 328, 12909, 138, 2, 387, 138, 4, 127, 440, 1223, 329, 3391, 138, 4, 214, 17, 32, 8820, 1185, 4, 1566, 2018, 329, 11, 9900, 4, 3, 2200, 1223, 329, 140, 242, 3, 181, 207, 1, 1119, 138, 379, 2865, 10, 3, 827, 6354, 1946, 23650, 1, 5114, 10, 530, 4, 598, 1, 1169, 2100, 6092, 1316, 1736, 8, 174, 901, 17, 359, 40, 95, 9, 617, 4, 46, 64, 43, 1954]",1340.0,26492932,Genomic germ line somatic familial myelodysplasia/acute myeloid leukemia,24,0.041884816753926704
Optimal Threshold and Time of Absolute Lymphocyte CountAssessment for Outcome Prediction after Bone MarrowTransplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2015-10-31,"The recovery pace of absolute lymphocyte count (ALC) is prognostic after hematopoietic stem cell transplantation. Previous studies have evaluated a wide range of ALC cutoffs and time points for predicting outcomes. We aimed to determine the optimal ALC value for outcome prediction after bone marrow transplantation (BMT). A total of 518 patients who underwent BMT for acute leukemia or myelodysplastic syndrome between 1999 and 2010 were divided into a training set and a test set to assess the prognostic value of ALC on days 30, 60, 90, 120, 180, as well as the first post-transplantation day of an ALC of 100, 200, 300, 400, 500, and 1000/L. In the training set, the best predictor of overall survival (OS), relapse-free survival (RFS), and nonrelapse mortality (NRM) was ALC on day 60. In the entire patient cohort, multivariable analyses demonstrated significantly better OS, RFS, and NRM and lower incidence of graft-versus-host disease (GVHD) in patients with an ALC >300/L on day 60 post-BMT, both including and excluding patients who developed GVHD before day 60. Among the patient-, disease-, and transplant-related factors assessed, only busulfan-based conditioning was significantly associated with higher ALC values on day 60 in both cohorts. The optimal ALC cutoff for predicting outcomes after BMT is 300/L on day 60 post-transplantation. ",Journal Article,1543.0,10.0,recovery pace absolute lymphocyte count ALC prognostic hematopoietic stem transplantation Previous studies evaluated wide range ALC cutoffs time points predicting outcomes aimed determine optimal ALC value outcome prediction bone marrow transplantation BMT total 518 patients underwent BMT acute leukemia myelodysplastic syndrome 1999 2010 divided training set test set assess prognostic value ALC days 30 60 90 120 180 post-transplantation day ALC 100 200 300 400 500 1000/L training set best predictor overall survival OS relapse-free survival RFS nonrelapse mortality NRM ALC day 60 entire patient cohort multivariable demonstrated significantly better OS RFS NRM lower incidence graft-versus-host disease GVHD patients ALC 300/L day 60 post-BMT including excluding patients developed GVHD day 60 patient- disease- transplant-related factors assessed busulfan-based conditioning significantly associated higher ALC values day 60 cohorts optimal ALC cutoff predicting outcomes BMT 300/L day 60 post-transplantation,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1602, 7265, 1, 1766, 1448, 1276, 3749, 16, 177, 50, 1007, 452, 31, 497, 698, 94, 47, 194, 8, 1019, 184, 1, 3749, 8339, 2, 98, 862, 9, 1434, 123, 21, 1295, 6, 223, 3, 665, 3749, 549, 9, 228, 1590, 50, 581, 497, 4611, 8, 181, 1, 10978, 7, 54, 208, 4611, 9, 286, 15, 681, 59, 2043, 2, 1120, 11, 2176, 237, 8, 1741, 916, 2, 8, 412, 916, 6, 423, 3, 177, 549, 1, 3749, 23, 162, 201, 335, 424, 2031, 3172, 22, 149, 22, 3, 157, 539, 497, 218, 1, 35, 3749, 1, 394, 1250, 2036, 1524, 1666, 2, 2345, 5513, 4, 3, 1741, 916, 3, 824, 980, 1, 63, 25, 118, 429, 115, 25, 1272, 2, 4640, 282, 4296, 10, 3749, 23, 218, 335, 4, 3, 1797, 69, 180, 658, 318, 264, 97, 380, 118, 1272, 2, 4296, 2, 280, 287, 1, 1599, 185, 1204, 34, 1562, 4, 7, 5, 35, 3749, 2036, 5513, 23, 218, 335, 539, 4611, 110, 141, 2, 3207, 7, 54, 276, 1562, 348, 218, 335, 107, 3, 69, 34, 2, 941, 139, 130, 275, 158, 3906, 90, 1933, 10, 97, 41, 5, 142, 3749, 1030, 23, 218, 335, 4, 110, 736, 3, 665, 3749, 2779, 9, 1434, 123, 50, 4611, 16, 2036, 5513, 23, 218, 335, 539, 497]",1286.0,26524730,Optimal Threshold Time Absolute Lymphocyte Count Assessment Outcome Prediction Bone Marrow Transplantation,0,0.0
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.,Leukemia research,Leuk. Res.,2015-10-19,"The molecular events that drive the transformation from myelodysplastic syndromes (MDS) to acute myeloid leukemia (AML) have yet to be fully characterized. We hypothesized that detection of these mutations at the time of transformation from MDS to AML may lead to poorer outcomes. We analyzed 102 MDS patients who were admitted to our institution between 2004 and 2013, had wild-type (wt) FLT3-ITD and RAS at diagnosis, progressed to AML, and had serial mutation testing at both the MDS and AML stages. We detected FLT3-ITD and/or RAS mutations in twenty-seven (26%) patients at the time of transformation to AML. Twenty-two patients (81%) had RAS mutations and five (19%) had FLT3-ITD mutations. The median survival after leukemia transformation in patients who had detectable RAS and/or FLT3-ITD mutations was 2.4 months compared to 7.5 months in patients who retained wt RAS and FLT3-ITD (hazard ratio [HR]: 3.08, 95% confidence interval [CI]: 1.9-5.0, p<0.0001). In multivariate analysis, FLT3-ITD and RAS mutations had independent prognostic significance for poor outcome.",Journal Article,1555.0,22.0,molecular events drive transformation myelodysplastic syndromes MDS acute myeloid leukemia AML fully characterized hypothesized detection time transformation MDS AML lead poorer outcomes 102 MDS patients admitted institution 2004 2013 wild-type wt FLT3-ITD RAS diagnosis progressed AML serial testing MDS AML stages detected FLT3-ITD and/or RAS twenty-seven 26 patients time transformation AML Twenty-two patients 81 RAS 19 FLT3-ITD median survival leukemia transformation patients detectable RAS and/or FLT3-ITD 2.4 months compared 7.5 months patients retained wt RAS FLT3-ITD hazard ratio HR 3.08 95 confidence interval CI 1.9-5.0 p 0.0001 multivariate FLT3-ITD RAS independent prognostic significance poor outcome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 219, 281, 17, 3279, 3, 1392, 29, 2040, 1223, 6, 286, 533, 329, 47, 1145, 6, 40, 1910, 765, 21, 1237, 17, 638, 1, 46, 138, 28, 3, 98, 1, 1392, 29, 1223, 6, 329, 68, 1122, 6, 1769, 123, 21, 311, 2867, 1223, 7, 54, 11, 4319, 6, 114, 731, 59, 1131, 2, 1346, 42, 955, 267, 1820, 1224, 2837, 2, 1102, 28, 147, 1839, 6, 329, 2, 42, 2108, 258, 471, 28, 110, 3, 1223, 2, 329, 1153, 21, 530, 1224, 2837, 2, 15, 1102, 138, 4, 737, 648, 432, 7, 28, 3, 98, 1, 1392, 6, 329, 737, 100, 7, 865, 42, 1102, 138, 2, 365, 326, 42, 1224, 2837, 138, 3, 52, 25, 50, 1392, 4, 7, 54, 42, 2083, 1102, 2, 15, 1224, 2837, 138, 10, 18, 39, 53, 72, 6, 67, 33, 53, 4, 7, 54, 3532, 1820, 1102, 2, 1224, 2837, 360, 197, 168, 27, 1592, 48, 307, 268, 58, 14, 83, 33, 13, 19, 13, 488, 4, 331, 65, 1224, 2837, 2, 1102, 138, 42, 306, 177, 724, 9, 334, 228]",1006.0,26547258,Detectable FLT3-ITD RAS time transformation MDS AML predicts poor outcomes,0,0.0
Polo-like kinase inhibitors in hematologic malignancies.,Critical reviews in oncology/hematology,Crit. Rev. Oncol. Hematol.,2015-11-04,"Polo-like kinases (Plk) are key regulators of the cell cycle and multiple aspects of mitosis. Two agents that inhibit the Plk signaling pathway have shown promising activity in patients with hematologic malignancies and are currently in phase III trials. Volasertib is a Plk inhibitor under evaluation combined with low-dose cytarabine in older patients with acute myeloid leukemia (AML) ineligible for intensive induction therapy. Rigosertib, a dual inhibitor of the Plk and phosphatidylinositol 3-kinase pathways, is under investigation in patients with myelodysplastic syndrome (MDS) who have failed azacitidine or decitabine treatment. The prognosis for patients with AML, who are ineligible for intensive induction therapy, and for those with MDS refractory/relapsed after a hypomethylating agent, remains poor. Novel approaches, such as Plk inhibitors, are urgently needed for these patients. Here, we provide a comprehensive overview of the current state of development of Plk inhibitors for the treatment of hematologic malignancies. ",Journal Article,1539.0,20.0,Polo-like kinases Plk key regulators cycle multiple aspects mitosis agents inhibit Plk signaling pathway shown promising activity patients hematologic malignancies currently phase III trials Volasertib Plk inhibitor evaluation combined low-dose cytarabine older patients acute myeloid leukemia AML ineligible intensive induction therapy Rigosertib dual inhibitor Plk phosphatidylinositol 3-kinase pathways investigation patients myelodysplastic syndrome MDS failed azacitidine decitabine treatment prognosis patients AML ineligible intensive induction therapy MDS refractory/relapsed hypomethylating agent remains poor Novel approaches Plk inhibitors urgently needed patients provide comprehensive overview current state development Plk inhibitors treatment hematologic malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[12635, 733, 1549, 13177, 32, 825, 3196, 1, 3, 31, 417, 2, 232, 2695, 1, 5624, 100, 183, 17, 1433, 3, 13177, 314, 308, 47, 443, 721, 128, 4, 7, 5, 813, 441, 2, 32, 694, 4, 124, 316, 143, 17041, 16, 8, 13177, 230, 669, 451, 397, 5, 154, 61, 1855, 4, 434, 7, 5, 286, 533, 329, 3773, 9, 1686, 504, 36, 17505, 8, 1828, 230, 1, 3, 13177, 2, 3415, 27, 216, 460, 16, 669, 940, 4, 7, 5, 681, 1223, 54, 47, 1551, 3752, 15, 3004, 24, 3, 356, 9, 7, 5, 329, 54, 32, 3773, 9, 1686, 504, 36, 2, 9, 135, 5, 1223, 430, 591, 50, 8, 4931, 420, 469, 334, 229, 611, 225, 22, 13177, 222, 32, 5354, 575, 9, 46, 7, 467, 21, 377, 8, 949, 2901, 1, 3, 291, 1309, 1, 193, 1, 13177, 222, 9, 3, 24, 1, 813, 441]",995.0,26597019,Polo-like kinase inhibitors hematologic malignancies,2,0.0034904013961605585
Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly.,Clinics in geriatric medicine,Clin. Geriatr. Med.,2016-02-01,"Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are hematologic diseases that frequently affect older adults. Treatment is challenging. Management of older adults with MDS and AML needs to be individualized, accounting for both the heterogeneity of disease biology and patient characteristics, which can influence life expectancy and treatment tolerance. Clinical trials accounting for the heterogeneity of tumor biology and physiologic changes of aging are needed to define optimal standards of care. This article highlights key evidence related to the management of older adults with MDS and AML and highlights future directions for research. ",Journal Article,1450.0,12.0,Myelodysplastic syndromes MDS acute myeloid leukemia AML hematologic diseases frequently affect older adults Treatment challenging Management older adults MDS AML needs individualized accounting heterogeneity disease patient characteristics influence life expectancy treatment tolerance Clinical trials accounting heterogeneity physiologic changes aging needed define optimal standards care article highlights key evidence related management older adults MDS AML highlights future directions research,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2040, 1223, 2, 286, 533, 329, 32, 813, 1342, 17, 746, 1158, 434, 857, 24, 16, 1950, 284, 1, 434, 857, 5, 1223, 2, 329, 1891, 6, 40, 2596, 3116, 9, 110, 3, 1144, 1, 34, 891, 2, 69, 374, 92, 122, 1054, 358, 3399, 2, 24, 2614, 38, 143, 3116, 9, 3, 1144, 1, 30, 891, 2, 4628, 400, 1, 4220, 32, 575, 6, 1107, 665, 3371, 1, 165, 26, 946, 2527, 825, 241, 139, 6, 3, 284, 1, 434, 857, 5, 1223, 2, 329, 2, 2527, 508, 3540, 9, 389]",625.0,26614866,Myelodysplastic Syndromes Acute Myeloid Leukemia Elderly,240,0.418848167539267
Donor Lymphocyte Infusion in Hematologic Malignancies--Good to be Fresh?,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2015-11-03,"Donor lymphocyte infusion (DLI) has been used with variable success in a variety of hematologic malignancies. We conducted a retrospective analysis of all patients who were treated with DLI for persistent or relapsed disease at the Temple University Bone Marrow Transplant Unit from July 1, 1993 to December 31, 2013 to evaluate the effect of the type of DLI (fresh vs. cryopreserved) on event-free survival (EFS) and overall survival (OS). Median follow-up was 64.8 months (range, 0.3-142.6 months). We found that EFS and OS were similar between patients receiving cryopreserved cells and those receiving fresh DLI (median OS for cryopreserved cells, 0.39 years; median OS for fresh cells, 0.32 years; P = .793; median EFS for cryopreserved cells, 0.410 years; median EFS for fresh cells, 0.420 years; P = .4264). In the setting of relapsed disease, treatment with any chemotherapy regimen before receiving DLI did not significantly impact OS (n = 63; P = .2203) or EFS (n = 40; P = .542). A subgroup analysis limited to patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) (32 patients) showed that differences in OS and EFS between cryopreserved and fresh DLI approached significance (median OS for cryopreserved cells, 0.34 years; median OS for fresh cells, 0.17 years; P = .16; median EFS for cryopreserved cells, 0.37 years; median EFS for fresh cells, 0.094 years; P = 0.11). We conclude that the use of fresh cells versus cryopreserved cells does not have an impact on outcomes, and selected patients can achieve long-term survival with DLI for treatment of relapse after transplantation, although the overall outcomes remain dismal.",Journal Article,1540.0,4.0,Donor lymphocyte infusion DLI variable success variety hematologic malignancies conducted retrospective patients treated DLI persistent relapsed disease Temple University Bone Marrow Transplant Unit July 1 1993 December 31 2013 evaluate effect type DLI fresh vs. cryopreserved event-free survival EFS overall survival OS Median follow-up 64.8 months range 0.3-142.6 months EFS OS similar patients receiving cryopreserved receiving fresh DLI median OS cryopreserved 0.39 years median OS fresh 0.32 years P .793 median EFS cryopreserved 0.410 years median EFS fresh 0.420 years P .4264 setting relapsed disease treatment chemotherapy regimen receiving DLI significantly impact OS n 63 P .2203 EFS n 40 P .542 subgroup limited patients acute myeloid leukemia AML /myelodysplastic syndrome MDS 32 patients showed differences OS EFS cryopreserved fresh DLI approached significance median OS cryopreserved 0.34 years median OS fresh 0.17 years P .16 median EFS cryopreserved 0.37 years median EFS fresh 0.094 years P 0.11 conclude use fresh versus cryopreserved impact outcomes selected patients achieve long-term survival DLI treatment relapse transplantation overall outcomes remain dismal,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1488, 1448, 904, 4676, 71, 85, 95, 5, 1347, 1825, 4, 8, 1362, 1, 813, 441, 21, 426, 8, 459, 65, 1, 62, 7, 54, 11, 73, 5, 4676, 9, 1882, 15, 591, 34, 28, 3, 40233, 1652, 581, 941, 2712, 29, 2066, 14, 3343, 6, 1397, 456, 1346, 6, 376, 3, 254, 1, 3, 267, 1, 4676, 4329, 105, 10432, 23, 774, 115, 25, 1683, 2, 63, 25, 118, 52, 166, 126, 10, 660, 66, 53, 184, 13, 27, 4785, 49, 53, 21, 204, 17, 1683, 2, 118, 11, 288, 59, 7, 357, 10432, 37, 2, 135, 357, 4329, 4676, 52, 118, 9, 10432, 37, 13, 587, 60, 52, 118, 9, 4329, 37, 13, 531, 60, 19, 12282, 52, 1683, 9, 10432, 37, 13, 7690, 60, 52, 1683, 9, 4329, 37, 13, 5401, 60, 19, 49438, 4, 3, 546, 1, 591, 34, 24, 5, 500, 56, 477, 348, 357, 4676, 205, 44, 97, 345, 118, 78, 676, 19, 67265, 15, 1683, 78, 327, 19, 10895, 8, 1363, 65, 383, 6, 7, 5, 286, 533, 329, 10589, 681, 1223, 531, 7, 224, 17, 362, 4, 118, 2, 1683, 59, 10432, 2, 4329, 4676, 5738, 724, 52, 118, 9, 10432, 37, 13, 562, 60, 52, 118, 9, 4329, 37, 13, 269, 60, 19, 245, 52, 1683, 9, 10432, 37, 13, 567, 60, 52, 1683, 9, 4329, 37, 13, 13877, 60, 19, 13, 175, 21, 2060, 17, 3, 119, 1, 4329, 37, 185, 10432, 37, 1097, 44, 47, 35, 345, 23, 123, 2, 715, 7, 122, 1359, 319, 337, 25, 5, 4676, 9, 24, 1, 429, 50, 497, 242, 3, 63, 123, 918, 3929]",1576.0,26632076,Donor Lymphocyte Infusion Hematologic Malignancies -- Good Fresh,15,0.02617801047120419
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center.,British journal of haematology,Br. J. Haematol.,2015-12-09,"Intensive chemotherapy regimens containing cytarabine have substantially improved remission durability and overall survival in younger adults with mantle cell lymphoma (MCL). However, there have been no long-term follow-up results for patients treated with these regimens. We present long-term survival outcomes from a pivotal phase II trial of rituximab, hyper-fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with methotrexate and cytarabine (R-HCVAD/MA). At 15 years of follow-up (median: 134 years), the median failure-free survival (FFS) and overall survival (OS) for all patients was 48 years and 107 years, respectively. The FFS seems to have plateaued after 10 years, with an estimated 15-year FFS of 30% in younger patients (65 years). Patients who achieved complete response (CR) after 2 cycles had a favourable median FFS of 88 years. Six patients developed myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML) whilst in first CR. The 10-year cumulative incidence of MDS/AML of patients in first remission was 62% (95% confidence interval: 25-122%). In patients with newly diagnosed MCL, R-HCVAD/MA showed sustained efficacy, with a median OS exceeding 10 years in all patients and freedom from disease recurrence of nearly 15 years in almost one-third of the younger patients (65 years).","Clinical Trial, Phase II",1504.0,42.0,Intensive chemotherapy regimens containing cytarabine substantially improved remission durability overall survival younger adults mantle lymphoma MCL long-term follow-up patients treated regimens present long-term survival outcomes pivotal phase II trial rituximab hyper-fractionated cyclophosphamide vincristine doxorubicin dexamethasone alternating methotrexate cytarabine R-HCVAD/MA 15 years follow-up median 134 years median failure-free survival FFS overall survival OS patients 48 years 107 years respectively FFS plateaued 10 years estimated 15-year FFS 30 younger patients 65 years Patients achieved complete response CR 2 cycles favourable median FFS 88 years patients developed myelodysplastic syndrome/acute myeloid leukaemia MDS/AML whilst CR 10-year cumulative incidence MDS/AML patients remission 62 95 confidence interval 25-122 patients newly diagnosed MCL R-HCVAD/MA showed sustained efficacy median OS exceeding 10 years patients freedom disease recurrence nearly 15 years one-third younger patients 65 years,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1686, 56, 472, 1101, 1855, 47, 2109, 231, 734, 6867, 2, 63, 25, 4, 773, 857, 5, 2757, 31, 1308, 137, 125, 47, 85, 77, 319, 337, 166, 126, 99, 9, 7, 73, 5, 46, 472, 21, 364, 319, 337, 25, 123, 29, 8, 3754, 124, 215, 160, 1, 855, 4855, 3950, 1112, 2132, 856, 2, 1217, 5181, 5, 2116, 2, 1855, 668, 14372, 3687, 28, 167, 60, 1, 166, 126, 52, 35995, 60, 3, 52, 496, 115, 25, 5058, 2, 63, 25, 118, 9, 62, 7, 10, 17500, 60, 2, 22738, 60, 106, 3, 5058, 2744, 6, 47, 13294, 50, 79, 60, 5, 35, 661, 167, 111, 5058, 1, 201, 4, 773, 7, 25391, 60, 7, 54, 513, 236, 51, 684, 50, 18, 410, 42, 8, 6816, 52, 5058, 1, 25695, 60, 437, 7, 276, 681, 286, 533, 2001, 1223, 329, 16427, 4, 157, 684, 3, 79, 111, 967, 287, 1, 1223, 329, 1, 7, 4, 157, 734, 10, 25423, 48, 307, 268, 17499, 27374, 4, 7, 5, 732, 265, 1308, 668, 14372, 3687, 224, 2275, 209, 5, 8, 52, 118, 5178, 79, 60, 4, 62, 7, 2, 3060, 29, 34, 146, 1, 1857, 167, 60, 4, 2214, 104, 1282, 1, 3, 773, 7, 25391, 60]",1282.0,26648336,Rituximab plus hyper-CVAD alternating MTX/Ara-C patients newly diagnosed mantle lymphoma 15-year follow-up phase II MD Anderson Center,5,0.008726003490401396
"Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.",The Lancet. Haematology,Lancet Haematol,2014-12-22,"The standard of care for myelodysplastic syndromes is hypomethylating agents such as azacitidine. However, responses to azacitidine are generally temporary, and outcomes after hypomethylating agent failure are dismal. Therefore, the development of more effective treatments is crucial to improve outcomes in patients with myelodysplastic syndromes. We aimed to assess azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia. We did this single-arm phase 1/2 study at the University of Texas MD Anderson Cancer Center, TX, USA. Patients of any age were eligible for phase 1 and 2a if they had relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome with bone marrow blasts more than 10%. For phase 2b, eligible participants were previously untreated with myelodysplastic syndrome with an International Prognostic Scoring System (IPSS) score of intermediate-1 or higher with up to 30% blasts. All participants received 75 mg/m(2) azacitidine once a day for days 1-5 for each 28 day cycle. We gave patients oral lenalidomide for 5 or 10 days starting on day 6. We assessed seven lenalidomide doses in a 3+3 phase 1 design (n=28). The primary endpoint in phase 1 was the maximum tolerated dose, and the primary endpoint in phase 2 was overall survival. Outcome analyses were by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01038635. Between Dec 30, 2009, and June, 17, 2013, we enrolled 88 patients (28 in phase 1 and 60 in phase 2). One patient unexpectedly died in the phase 1 study at the highest dose level, six more patients were recruited with no further serious adverse events. We recorded no dose-limiting toxic effects, and the maximum tolerated dose of lenalidomide in combination with azacitidine in patients with acute myeloid leukaemia and myelodysplastic syndrome was initially established at 50 mg per day for 10 days. In the first 20 patients in phase 2, we noted a high rate of myelosuppression and myelosuppression-related toxic effects; therefore, we amended the lenalidomide dose to 25 mg per day for 5 days. We also adjusted the inclusion criteria to include patients with less than 30% blasts to focus mainly on patients with myelodysplastic syndromes. Median overall survival was 75 weeks (IQR 25-not reached) for the 40 patients in phase 2b. The most common grade 3-4 adverse events overall were neutropenic fever (n=27) and pneumonia (n=18). We have identified a safe and active sequential treatment combination of azacitidine and lenalidomide for patient with myelodysplastic syndrome and have preliminary evidence that this dose is also safe for patients with acute myeloid leukaemia. MD Anderson Cancer Center and Celgene.","Clinical Trial, Phase I",1856.0,20.0,standard care myelodysplastic syndromes hypomethylating agents azacitidine responses azacitidine generally temporary outcomes hypomethylating agent failure dismal development effective treatments crucial improve outcomes patients myelodysplastic syndromes aimed assess azacitidine lenalidomide patients high-risk myelodysplastic syndromes acute myeloid leukaemia single-arm phase 1/2 University Texas MD Anderson Center TX USA Patients age eligible phase 1 2a relapsed refractory acute myeloid leukaemia myelodysplastic syndrome bone marrow blasts 10 phase 2b eligible participants previously untreated myelodysplastic syndrome International Prognostic Scoring IPSS score intermediate-1 higher 30 blasts participants received 75 mg/m 2 azacitidine day days 1-5 28 day cycle gave patients oral lenalidomide 5 10 days starting day 6 assessed seven lenalidomide doses 3 3 phase 1 design n=28 primary endpoint phase 1 maximum tolerated dose primary endpoint phase 2 overall survival Outcome intention treat registered ClinicalTrials.gov number NCT01038635 Dec 30 2009 June 17 2013 enrolled 88 patients 28 phase 1 60 phase 2 patient unexpectedly died phase 1 highest dose level patients recruited adverse events recorded dose-limiting toxic effects maximum tolerated dose lenalidomide combination azacitidine patients acute myeloid leukaemia myelodysplastic syndrome initially established 50 mg day 10 days 20 patients phase 2 noted high rate myelosuppression myelosuppression-related toxic effects amended lenalidomide dose 25 mg day 5 days adjusted inclusion criteria include patients 30 blasts focus mainly patients myelodysplastic syndromes Median overall survival 75 weeks IQR 25-not reached 40 patients phase 2b common grade 3-4 adverse events overall neutropenic fever n=27 pneumonia n=18 identified safe active sequential treatment combination azacitidine lenalidomide patient myelodysplastic syndrome preliminary evidence dose safe patients acute myeloid leukaemia MD Anderson Center Celgene,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 260, 1, 165, 9, 2040, 16, 4931, 183, 225, 22, 3752, 137, 253, 6, 3752, 32, 1228, 7579, 2, 123, 50, 4931, 420, 496, 32, 3929, 673, 3, 193, 1, 80, 323, 640, 16, 2653, 6, 401, 123, 4, 7, 5, 2040, 21, 1295, 6, 423, 3752, 2, 1288, 4, 7, 5, 64, 43, 2040, 2, 286, 533, 2001, 21, 205, 26, 226, 475, 124, 14, 18, 45, 28, 3, 1652, 1, 2738, 2244, 1929, 12, 574, 6614, 2706, 7, 1, 500, 89, 11, 625, 9, 124, 14, 2, 4707, 492, 491, 42, 591, 15, 430, 286, 533, 2001, 15, 681, 5, 581, 2438, 80, 76, 79, 9, 124, 3381, 625, 776, 11, 373, 1278, 5, 681, 5, 35, 944, 177, 2504, 398, 8751, 368, 1, 919, 14, 15, 142, 5, 126, 6, 201, 2438, 62, 776, 103, 481, 81, 188, 18, 3752, 1059, 8, 218, 9, 162, 14, 33, 9, 296, 339, 218, 417, 21, 6421, 7, 518, 1288, 9, 33, 15, 79, 162, 1723, 23, 218, 49, 21, 275, 648, 1288, 415, 4, 8, 27, 27, 124, 14, 771, 78, 339, 3, 86, 1138, 4, 124, 14, 10, 3, 689, 421, 61, 2, 3, 86, 1138, 4, 124, 18, 10, 63, 25, 228, 318, 11, 20, 3205, 6, 943, 26, 45, 16, 1653, 5, 1252, 1239, 207, 67348, 59, 8702, 201, 1238, 2, 1924, 269, 1346, 21, 346, 889, 7, 339, 4, 124, 14, 2, 335, 4, 124, 18, 104, 69, 6016, 1016, 4, 3, 124, 14, 45, 28, 3, 1076, 61, 301, 437, 80, 7, 11, 2619, 5, 77, 195, 1762, 290, 281, 21, 1872, 77, 61, 817, 1812, 176, 2, 3, 689, 421, 61, 1, 1288, 4, 150, 5, 3752, 4, 7, 5, 286, 533, 2001, 2, 681, 10, 1625, 635, 28, 212, 81, 379, 218, 9, 79, 162, 4, 3, 157, 179, 7, 4, 124, 18, 21, 1051, 8, 64, 116, 1, 2858, 2, 2858, 139, 1812, 176, 673, 21, 7595, 3, 1288, 61, 6, 243, 81, 379, 218, 9, 33, 162, 21, 120, 586, 3, 1680, 371, 6, 643, 7, 5, 299, 76, 201, 2438, 6, 1222, 2615, 23, 7, 5, 2040, 52, 63, 25, 10, 481, 244, 2245, 243, 44, 1300, 9, 3, 327, 7, 4, 124, 3381, 3, 96, 186, 88, 27, 39, 290, 281, 63, 11, 3659, 2775, 78, 428, 2, 3485, 78, 203, 21, 47, 108, 8, 1165, 2, 544, 1787, 24, 150, 1, 3752, 2, 1288, 9, 69, 5, 681, 2, 47, 1676, 241, 17, 26, 61, 16, 120, 1165, 9, 7, 5, 286, 533, 2001, 2244, 1929, 12, 574, 2, 16002]",2565.0,26687423,Sequential azacitidine lenalidomide patients high-risk myelodysplastic syndromes acute myeloid leukaemia single-arm phase 1/2,7,0.012216404886561954
"Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.",The Lancet. Haematology,Lancet Haematol,2015-07-26,"Activation of the Hedgehog signalling pathway contributes to cancer progression and the development of myeloid leukaemia stem cell therapeutic resistance. We aimed to identify the maximum tolerated dose (MTD) and the recommended phase 2 dose of the selective Hedgehog antagonist PF-04449913 in myeloid malignancies. We undertook an open-label, dose-finding, standard 3+3 design phase 1 study of PF-04449913 in adult patients with acute myeloid leukaemia, chronic myeloid leukaemia, chronic myelomonocytic leukaemia, myelodysplastic syndrome, or myelofibrosis who were refractory, resistant, or intolerant to previous treatments, at three centres in the USA and one in Italy. Patients who had newly diagnosed, untreated disease were included if they were not eligible for standard treatment options or if standard treatments were not deemed appropriate. Patients received PF-04449913 once daily continuously until disease progression, unacceptable toxic effects, or patient withdrawal for up to 12 28-day cycles. Additional cycles were given if patients showed evidence of clinical benefit. The starting dose was 5 mg and was increased by 100% until the first dose-limiting toxic effect (DLT) and by 50% thereafter, in keeping with a 3+3 clinical trial statistical design. The primary endpoint was first-cycle DLTs. Secondary endpoints were safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity. This trial is registered with ClinicalTrials.gov, number NCT00953758. Between March 24, 2010, and Sept 7, 2012, 47 patients were enrolled and included in the study: 28 with acute myeloid leukaemia, six with myelodysplastic syndrome, five with chronic myeloid leukaemia (two with chronic-phase and three with blast-phase disease), one with chronic myelomonocytic leukaemia, and seven with myelofibrosis. Patients received PF-04449913 once daily at 5 mg (n=3), 10 mg (n=3), 20 mg (n=4), 40 mg (n=4), 80 mg (n=8), 120 mg (n=3), 180 mg (n=3), 270 mg (n=5), 400 mg (n=9), and 600 mg (n=5). Two patients experienced DLTs (one each in the 80 mg and 600 mg dose groups). The MTD for PF-04449913 was established to be 400 mg once daily. Of the 47 patients enrolled, 28 (60%) experienced treatment-related adverse events, three of which were grade 4 in severity. The most common treatment-related adverse events included dysgeusia (13 [28%] patients), decreased appetite (nine [19%]), and alopecia (seven [15%]). None of the 15 deaths reported were treatment related. Pharmacokinetics seemed to be dose proportional. The mean half-life was 239 h (SD 140) in the MTD group. Some suggestion of clinical activity was noted in 23 (49%) of 47 patients with haematological malignancies. Based on these results, the recommended phase 2 dose was 200 mg or lower once daily. Based on these findings, PF-04449913 is being tested in phase 2 studies in patients with myelodysplastic syndrome, acute myeloid leukaemia, and myelofibrosis. Pfizer.","Clinical Trial, Phase I",1640.0,51.0,Activation Hedgehog signalling pathway contributes progression development myeloid leukaemia stem therapeutic resistance aimed identify maximum tolerated dose MTD recommended phase 2 dose selective Hedgehog antagonist PF-04449913 myeloid malignancies undertook open-label dose-finding standard 3+3 design phase 1 PF-04449913 adult patients acute myeloid leukaemia chronic myeloid leukaemia chronic myelomonocytic leukaemia myelodysplastic syndrome myelofibrosis refractory resistant intolerant previous treatments centres USA Italy Patients newly diagnosed untreated disease included eligible standard treatment options standard treatments deemed appropriate Patients received PF-04449913 daily continuously disease progression unacceptable toxic effects patient withdrawal 12 28-day cycles Additional cycles given patients showed evidence clinical benefit starting dose 5 mg increased 100 dose-limiting toxic effect DLT 50 keeping 3+3 clinical trial statistical design primary endpoint first-cycle DLTs Secondary endpoints safety tolerability pharmacokinetics pharmacodynamics preliminary clinical activity trial registered ClinicalTrials.gov number NCT00953758 March 24 2010 Sept 7 2012 47 patients enrolled included 28 acute myeloid leukaemia myelodysplastic syndrome chronic myeloid leukaemia chronic-phase blast-phase disease chronic myelomonocytic leukaemia seven myelofibrosis Patients received PF-04449913 daily 5 mg n=3 10 mg n=3 20 mg n=4 40 mg n=4 80 mg n=8 120 mg n=3 180 mg n=3 270 mg n=5 400 mg n=9 600 mg n=5 patients experienced DLTs 80 mg 600 mg dose groups MTD PF-04449913 established 400 mg daily 47 patients enrolled 28 60 experienced treatment-related adverse events grade 4 severity common treatment-related adverse events included dysgeusia 13 28 patients decreased appetite 19 alopecia seven 15 15 deaths reported treatment related Pharmacokinetics dose proportional mean half-life 239 h SD 140 MTD group suggestion clinical activity noted 23 49 47 patients haematological malignancies Based recommended phase 2 dose 200 mg lower daily Based findings PF-04449913 tested phase 2 studies patients myelodysplastic syndrome acute myeloid leukaemia myelofibrosis Pfizer,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[363, 1, 3, 4097, 3128, 308, 2444, 6, 12, 91, 2, 3, 193, 1, 533, 2001, 452, 31, 189, 251, 21, 1295, 6, 255, 3, 689, 421, 61, 961, 2, 3, 793, 124, 18, 61, 1, 3, 1094, 4097, 3137, 3313, 20054, 4, 533, 441, 21, 5418, 35, 1020, 1756, 61, 1567, 260, 27, 27, 771, 124, 14, 45, 1, 3313, 20054, 4, 780, 7, 5, 286, 533, 2001, 442, 533, 2001, 442, 5451, 2001, 681, 15, 4637, 54, 11, 430, 436, 15, 4944, 6, 698, 640, 28, 169, 4496, 4, 3, 2706, 2, 104, 4, 11300, 7, 54, 42, 732, 265, 1278, 34, 11, 159, 492, 491, 11, 44, 625, 9, 260, 24, 838, 15, 492, 260, 640, 11, 44, 3779, 870, 7, 103, 3313, 20054, 1059, 391, 4285, 1100, 34, 91, 3215, 1812, 176, 15, 69, 3683, 9, 126, 6, 133, 339, 218, 410, 402, 410, 11, 447, 492, 7, 224, 241, 1, 38, 247, 3, 1723, 61, 10, 33, 81, 2, 10, 101, 20, 394, 1100, 3, 157, 61, 817, 1812, 254, 2059, 2, 20, 212, 3972, 4, 10991, 5, 8, 27, 27, 38, 160, 1050, 771, 3, 86, 1138, 10, 157, 417, 2506, 568, 1387, 11, 367, 1543, 1159, 3587, 2, 1676, 38, 128, 26, 160, 16, 1653, 5, 1252, 1239, 207, 67352, 59, 2363, 259, 1120, 2, 8708, 67, 1195, 662, 7, 11, 346, 2, 159, 4, 3, 45, 339, 5, 286, 533, 2001, 437, 5, 681, 365, 5, 442, 533, 2001, 100, 5, 442, 124, 2, 169, 5, 3112, 124, 34, 104, 5, 442, 5451, 2001, 2, 648, 5, 4637, 7, 103, 3313, 20054, 1059, 391, 28, 33, 81, 78, 27, 79, 81, 78, 27, 179, 81, 78, 39, 327, 81, 78, 39, 493, 81, 78, 66, 2031, 81, 78, 27, 3172, 81, 78, 27, 6666, 81, 78, 33, 1524, 81, 78, 83, 2, 2383, 81, 78, 33, 100, 7, 592, 2506, 104, 296, 4, 3, 493, 81, 2, 2383, 81, 61, 271, 3, 961, 9, 3313, 20054, 10, 635, 6, 40, 1524, 81, 1059, 391, 1, 3, 662, 7, 346, 339, 335, 592, 24, 139, 290, 281, 169, 1, 92, 11, 88, 39, 4, 1702, 3, 96, 186, 24, 139, 290, 281, 159, 13905, 233, 339, 7, 340, 4062, 762, 326, 2, 5691, 648, 167, 1292, 1, 3, 167, 1043, 210, 11, 24, 139, 1159, 5025, 6, 40, 61, 831, 3, 313, 1303, 358, 10, 36009, 555, 1270, 27317, 4, 3, 961, 87, 476, 8634, 1, 38, 128, 10, 1051, 4, 382, 739, 1, 662, 7, 5, 5143, 441, 90, 23, 46, 99, 3, 793, 124, 18, 61, 10, 1250, 81, 15, 280, 1059, 391, 90, 23, 46, 272, 3313, 20054, 16, 486, 650, 4, 124, 18, 94, 4, 7, 5, 681, 286, 533, 2001, 2, 4637, 8982]",2789.0,26688487,Treatment PF-04449913 oral smoothened antagonist patients myeloid malignancies phase 1 safety pharmacokinetics,0,0.0
Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies.,Blood,Blood,2015-12-28,"Recently our group and others have identified DDX41 mutations both as germ line and acquired somatic mutations in families with multiple cases of late onset myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML), suggesting that DDX41 acts as a tumor suppressor. To determine whether novel DDX41 mutations could be identified in families with additional types of hematologic malignancies, our group screened two cohorts of families with a diverse range of hematologic malignancy subtypes. Among 289 families, we identified nine (3%) with DDX41 mutations. As previously observed, MDS and AML were the most common malignancies, often of the erythroblastic subtype, and 1 family displayed early-onset follicular lymphoma. Five novel mutations were identified, including missense mutations within important functional domains and start-loss and splicing mutations predicted to result in truncated proteins. We also show that most asymptomatic mutation carriers have normal blood counts until malignancy develops. This study expands both the mutation and phenotypic spectra observed in families with germ line DDX41 mutations. With an increasing number of both inherited and acquired mutations in this gene being identified, further study of how DDX41 disruption leads to hematologic malignancies is critical. ",Journal Article,1485.0,70.0,Recently group identified DDX41 germ line acquired somatic families multiple cases late onset myelodysplastic syndrome MDS and/or acute myeloid leukemia AML suggesting DDX41 acts suppressor determine novel DDX41 identified families additional types hematologic malignancies group screened cohorts families diverse range hematologic malignancy subtypes 289 families identified 3 DDX41 previously observed MDS AML common malignancies erythroblastic subtype 1 family displayed early-onset follicular lymphoma novel identified including missense important functional domains start-loss splicing predicted truncated asymptomatic carriers normal blood counts malignancy develops expands phenotypic spectra observed families germ line DDX41 increasing number inherited acquired identified DDX41 disruption leads hematologic malignancies critical,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[761, 114, 87, 2, 1749, 47, 108, 16588, 138, 110, 22, 2280, 328, 2, 1294, 1119, 138, 4, 1954, 5, 232, 140, 1, 807, 1707, 681, 1223, 2, 15, 286, 533, 329, 802, 17, 16588, 4459, 22, 8, 30, 1245, 6, 223, 317, 229, 16588, 138, 359, 40, 108, 4, 1954, 5, 402, 630, 1, 813, 441, 114, 87, 2261, 100, 736, 1, 1954, 5, 8, 1867, 184, 1, 813, 710, 814, 107, 9080, 1954, 21, 108, 762, 27, 5, 16588, 138, 22, 373, 164, 1223, 2, 329, 11, 3, 96, 186, 441, 629, 1, 3, 25240, 875, 2, 14, 607, 2507, 191, 1707, 1974, 365, 229, 138, 11, 108, 141, 4007, 138, 262, 305, 583, 2703, 2, 2435, 407, 2, 3895, 138, 783, 6, 757, 4, 6502, 652, 21, 120, 514, 17, 96, 2100, 258, 1316, 47, 295, 315, 1911, 1100, 710, 4734, 26, 45, 9365, 110, 3, 258, 2, 3290, 7683, 164, 4, 1954, 5, 2280, 328, 16588, 138, 5, 35, 602, 207, 1, 110, 2986, 2, 1294, 138, 4, 26, 145, 486, 108, 195, 45, 1, 832, 16588, 3220, 1940, 6, 813, 441, 16, 740]",1259.0,26712909,Novel germ line DDX41 define families lower age MDS/AML onset lymphoid malignancies,1,0.0017452006980802793
Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2015-12-29,"We defined associations among immune cell subsets in granulocyte colony-stimulating factor (G-CSF)-mobilized allografts and clinical outcomes after allogeneic hematopoietic cell transplantation (alloHCT). Fresh peripheral blood stem cell (PBSC) aliquots from 238 G-CSF-mobilized allografts were extensively characterized by immunophenotype. Subset-specific transplanted cells were correlated with acute graft-versus-host disease (aGVHD), chronic GVHD (cGVHD), malignant disease relapse, nonrelapse mortality, and overall survival. Of 238 assessable alloHCT recipients, 185 patients (78%) received reduced-intensity conditioning and 152 (64%) antithymocyte globulin-based serotherapy. Incidences of aGVHD and cGVHD were 58% and 48%, respectively. Median follow-up was 21months (range, 1.4 to 41.1). In multivariable analyses adjusted for relevant clinical factors, allograft activated natural killer (NK) cells (CD56(+)CD16(+)CD69(+)CD158b(+)) were associated with a significantly lower risk of aGVHD (P=.0016; HR, .51; 95% confidence interval, .33 to .78), whereas late-activated HLA-DR(+) CD3(+) cells were associated with significantly higher aGVHD (P<.0005; HR, 2.31; 95% confidence interval, 1.55 to 3.43). In a subgroup of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), receipt of an allograft from an older donor (40years) was associated with a higher incidence of relapse (P=.0042; HR, 2.99); allograft content of early activated CD3(+) cells (CD3(+)CD69(+); P=.0024; HR, .4) and NKT cells (CD3(+)CD56(+); P=.0006; HR, .54) were associated with a lower incidence of relapse. Presence of HLA-Bw4-80Ile(+) genotype was associated with lower relapse incidence. In conclusion, activated NK cells within PBSC allografts associate with lower aGVHD risk, whereas HLA-DR(+) Tcells associate with higher aGVHD and cGVHD risk. NKT cells and early activated Tcells are associated with lower relapse risk in AML and MDS patients. These findings may have implications in therapeutic targeting of select populations in the allograft to minimize incidence of GVHD.",Journal Article,1484.0,12.0,defined associations immune subsets granulocyte colony-stimulating factor G-CSF -mobilized allografts clinical outcomes allogeneic hematopoietic transplantation alloHCT Fresh peripheral blood stem PBSC aliquots 238 G-CSF-mobilized allografts extensively characterized immunophenotype Subset-specific transplanted correlated acute graft-versus-host disease aGVHD chronic GVHD cGVHD malignant disease relapse nonrelapse mortality overall survival 238 assessable alloHCT recipients 185 patients 78 received reduced-intensity conditioning 152 64 antithymocyte globulin-based serotherapy Incidences aGVHD cGVHD 58 48 respectively Median follow-up 21 months range 1.4 41.1 multivariable adjusted relevant clinical factors allograft activated natural killer NK CD56 CD16 CD69 CD158b associated significantly lower risk aGVHD P .0016 HR .51 95 confidence interval .33 .78 late-activated HLA-DR CD3 associated significantly higher aGVHD P .0005 HR 2.31 95 confidence interval 1.55 3.43 subgroup patients acute myeloid leukemia AML myelodysplastic syndrome MDS receipt allograft older donor 40 years associated higher incidence relapse P .0042 HR 2.99 allograft content early activated CD3 CD3 CD69 P .0024 HR .4 NKT CD3 CD56 P .0006 HR .54 associated lower incidence relapse Presence HLA-Bw4-80Ile genotype associated lower relapse incidence activated NK PBSC allografts associate lower aGVHD risk HLA-DR associate higher aGVHD cGVHD risk NKT early activated associated lower relapse risk AML MDS patients findings implications therapeutic targeting select populations allograft minimize incidence GVHD,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 395, 685, 107, 250, 31, 1890, 4, 2764, 1975, 2122, 161, 499, 1211, 7695, 10586, 2, 38, 123, 50, 1063, 1007, 31, 497, 5514, 4329, 672, 315, 452, 31, 6368, 16390, 29, 6883, 499, 1211, 7695, 10586, 11, 3576, 765, 20, 5496, 697, 112, 4600, 37, 11, 438, 5, 286, 1599, 185, 1204, 34, 5873, 442, 1562, 6670, 393, 34, 429, 4640, 282, 2, 63, 25, 1, 6883, 3120, 5514, 2190, 5805, 7, 833, 103, 405, 837, 1933, 2, 5370, 660, 11016, 7819, 90, 37444, 3981, 1, 5873, 2, 6670, 11, 717, 2, 576, 106, 52, 166, 126, 10, 239, 53, 184, 14, 39, 6, 605, 14, 4, 658, 318, 586, 9, 867, 38, 130, 9568, 735, 1504, 3458, 1765, 37, 5803, 11287, 16337, 40616, 11, 41, 5, 8, 97, 280, 43, 1, 5873, 19, 13230, 168, 725, 48, 307, 268, 466, 6, 833, 547, 807, 735, 1160, 3436, 3117, 37, 11, 41, 5, 97, 142, 5873, 19, 4252, 168, 18, 456, 48, 307, 268, 14, 614, 6, 27, 601, 4, 8, 1363, 1, 7, 5, 286, 533, 329, 2, 681, 1223, 1699, 1, 35, 9568, 29, 35, 434, 1488, 8483, 60, 10, 41, 5, 8, 142, 287, 1, 429, 19, 21111, 168, 18, 1058, 9568, 2457, 1, 191, 735, 3117, 37, 3117, 16337, 19, 14804, 168, 39, 2, 15761, 37, 3117, 5803, 19, 6013, 168, 667, 11, 41, 5, 8, 280, 287, 1, 429, 463, 1, 1160, 41315, 67454, 1183, 10, 41, 5, 280, 429, 287, 4, 1221, 735, 1765, 37, 262, 6368, 10586, 6446, 5, 280, 5873, 43, 547, 1160, 3436, 102, 37, 6446, 5, 142, 5873, 2, 6670, 43, 15761, 37, 2, 191, 735, 102, 37, 32, 41, 5, 280, 429, 43, 4, 329, 2, 1223, 7, 46, 272, 68, 47, 1268, 4, 189, 529, 1, 1717, 1184, 4, 3, 9568, 6, 3241, 287, 1, 1562]",1952.0,26743340,Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Subsets Associated Risk Acute Chronic Graft-versus-Host Disease,0,0.0
Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2016-01-06,"We conducted a phase 2 study to determine the efficacy of HLA-haploidentical related donor natural killer (NK) cells after cyclophosphamide-based lymphodepletion in patients with relapsed or progressive acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS) following allogeneic hematopoietic cell transplantation (HCT). Eight patients (2 with MDS and 6 with AML) were treated with cyclophosphamide 50 mg/kg on day -3 and day -2 before infusion of NK cells isolated from a haploidentical related donor. One patient also received fludarabine 25 mg/m2/day for 4 days. Six doses of 1 million units of interleukin-2 (IL-2) were administered on alternating days beginning on day -1. The median number of NK cells infused was 10.6  10(6)/kg (range, 4.3 to 22.4  10(6)/kg), and the median number of CD3 cells infused was 2.1  10(3)/kg (range, 1.9 to 40  10(3)/kg). NK infusions were well tolerated, with a median time to neutrophil recovery of 19 days (range, 7 days to not achieved) and no incidence of graft-versus-host disease after NK infusion. One patient with AML and 1 patient with MDS achieved a complete response, but relapsed at 1.7 and 1.8 months, respectively. One patient with MDS experienced resolution of dysplastic features but persistence of clonal karyotype abnormalities; this patient was stable at 65 months after NK cell therapy. The median duration of survival was 12.9 months (range, 0.8 to 65.3 months). Chimerism analysis of CD3(-)/CD56(+) peripheral blood cells did not detect any circulating haploidentical NK cells after infusion. NK phenotyping was performed in 7 patients during and after IL-2 infusion. We found a slight trend toward greater expression of KIR2DL2/2DL3/2DS2 (5% versus 28%; P = .03) at 14 days in patients who survived longer than 6 months from NK cell infusion (n = 4) compared with those who died within 6 months of NK cell therapy (n = 3). In summary, our data support the safety of haploidentical NK cell infusion after allogeneic HCT.","Clinical Trial, Phase II",1476.0,40.0,conducted phase 2 determine efficacy HLA-haploidentical related donor natural killer NK cyclophosphamide-based lymphodepletion patients relapsed progressive acute myelogenous leukemia AML myelodysplastic syndrome MDS following allogeneic hematopoietic transplantation HCT patients 2 MDS 6 AML treated cyclophosphamide 50 mg/kg day -3 day -2 infusion NK isolated haploidentical related donor patient received fludarabine 25 mg/m2/day 4 days doses 1 million units interleukin-2 IL-2 administered alternating days beginning day -1 median number NK infused 10.6 10 6 /kg range 4.3 22.4 10 6 /kg median number CD3 infused 2.1 10 3 /kg range 1.9 40 10 3 /kg NK infusions tolerated median time neutrophil recovery 19 days range 7 days achieved incidence graft-versus-host disease NK infusion patient AML 1 patient MDS achieved complete response relapsed 1.7 1.8 months respectively patient MDS experienced resolution dysplastic features persistence clonal karyotype abnormalities patient stable 65 months NK therapy median duration survival 12.9 months range 0.8 65.3 months Chimerism CD3 /CD56 peripheral blood detect circulating haploidentical NK infusion NK phenotyping performed 7 patients IL-2 infusion slight trend greater expression KIR2DL2/2DL3/2DS2 5 versus 28 P .03 14 days patients survived longer 6 months NK infusion n 4 compared died 6 months NK therapy n 3 summary support safety haploidentical NK infusion allogeneic HCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 426, 8, 124, 18, 45, 6, 223, 3, 209, 1, 1160, 5802, 139, 1488, 1504, 3458, 1765, 37, 50, 1112, 90, 16876, 4, 7, 5, 591, 15, 1014, 286, 2194, 329, 15, 681, 1223, 366, 1063, 1007, 31, 497, 1085, 659, 7, 18, 5, 1223, 2, 49, 5, 329, 11, 73, 5, 1112, 212, 81, 503, 23, 218, 27, 2, 218, 18, 348, 904, 1, 1765, 37, 1355, 29, 8, 5802, 139, 1488, 104, 69, 120, 103, 2027, 243, 81, 821, 218, 9, 39, 162, 437, 415, 1, 14, 3346, 2960, 1, 1603, 18, 501, 18, 11, 468, 23, 5181, 162, 2948, 23, 218, 14, 3, 52, 207, 1, 1765, 37, 4524, 10, 79, 49, 79, 49, 503, 184, 39, 27, 6, 350, 39, 79, 49, 503, 2, 3, 52, 207, 1, 3117, 37, 4524, 10, 18, 14, 79, 27, 503, 184, 14, 83, 6, 327, 79, 27, 503, 1765, 3435, 11, 149, 421, 5, 8, 52, 98, 6, 2595, 1602, 1, 326, 162, 184, 67, 162, 6, 44, 513, 2, 77, 287, 1, 1599, 185, 1204, 34, 50, 1765, 904, 104, 69, 5, 329, 2, 14, 69, 5, 1223, 513, 8, 236, 51, 84, 591, 28, 14, 67, 2, 14, 66, 53, 106, 104, 69, 5, 1223, 592, 2125, 1, 6461, 404, 84, 4108, 1, 1946, 3385, 1171, 26, 69, 10, 585, 28, 556, 53, 50, 1765, 31, 36, 3, 52, 654, 1, 25, 10, 133, 83, 53, 184, 13, 66, 6, 556, 27, 53, 6047, 65, 1, 3117, 5803, 672, 315, 37, 205, 44, 1426, 500, 1033, 5802, 1765, 37, 50, 904, 1765, 16526, 10, 173, 4, 67, 7, 190, 2, 50, 501, 18, 904, 21, 204, 8, 8041, 853, 1317, 378, 55, 1, 31546, 67490, 67491, 33, 185, 339, 19, 680, 28, 213, 162, 4, 7, 54, 2996, 589, 76, 49, 53, 29, 1765, 31, 904, 78, 39, 72, 5, 135, 54, 1016, 262, 49, 53, 1, 1765, 31, 36, 78, 27, 4, 1962, 114, 74, 538, 3, 367, 1, 5802, 1765, 31, 904, 50, 1063, 1085]",1899.0,26772158,Phase II Haploidentical Natural Killer Infusion Treatment Relapsed Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Transplantation,0,0.0
Prior hypomethylating agent use lacks impact on clinical outcome in patients with secondary acute myeloid leukemia arising from myelodysplastic syndromes treated with standard induction chemotherapy.,International journal of hematology,Int. J. Hematol.,2016-01-18,"Patients with secondary acute myeloid leukemia (sAML) arising from prior myelodysplastic syndromes have poor prognosis. Anthracycline plus cytarabine (7 + 3) is a standard treatment option for patients who are fit for intensive therapy. In the present study, 22 of 96 sAML patients (23 %) were treated with 7 + 3 and achieved median overall survival (OS) of 9.8 months. Hypomethylating agents (HMA) were given for MDS in 6/22 (28 %) of the patients. When evaluating the prior HMA group, CR/CRi was 50 % for those with prior HMA exposure and 63 % for those without HMA exposure (P = 0.6). Median OS was 14 months for prior HMA exposure vs 10 months for no prior HMA (P = 0.9). The outcome of sAML patients who were treated with 7 + 3 continues to be poor. No statistical significant difference was found between response rates and mOS between prior HMA exposure or not. Additional larger studies are needed to confirm our results.",Journal Article,1464.0,0.0,Patients secondary acute myeloid leukemia sAML arising prior myelodysplastic syndromes poor prognosis Anthracycline plus cytarabine 7 3 standard treatment option patients fit intensive therapy present 22 96 sAML patients 23 treated 7 3 achieved median overall survival OS 9.8 months Hypomethylating agents HMA given MDS 6/22 28 patients evaluating prior HMA group CR/CRi 50 prior HMA exposure 63 HMA exposure P 0.6 Median OS 14 months prior HMA exposure vs 10 months prior HMA P 0.9 outcome sAML patients treated 7 3 continues poor statistical significant difference response rates mOS prior HMA exposure Additional larger studies needed confirm,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7, 5, 568, 286, 533, 8991, 2635, 29, 324, 2040, 47, 334, 356, 2044, 349, 1855, 67, 27, 16, 8, 260, 24, 1501, 9, 7, 54, 32, 2975, 9, 1686, 36, 4, 3, 364, 45, 350, 1, 921, 8991, 7, 382, 11, 73, 5, 67, 27, 2, 513, 52, 63, 25, 118, 1, 83, 66, 53, 4931, 183, 7518, 11, 447, 9, 1223, 4, 49, 350, 339, 1, 3, 7, 198, 1435, 3, 324, 7518, 87, 684, 6341, 10, 212, 9, 135, 5, 324, 7518, 645, 2, 676, 9, 135, 187, 7518, 645, 19, 13, 49, 52, 118, 10, 213, 53, 9, 324, 7518, 645, 105, 79, 53, 9, 77, 324, 7518, 19, 13, 83, 3, 228, 1, 8991, 7, 54, 11, 73, 5, 67, 27, 2274, 6, 40, 334, 77, 1050, 93, 523, 10, 204, 59, 51, 151, 2, 5166, 59, 324, 7518, 645, 15, 44, 402, 1077, 94, 32, 575, 6, 1843, 114, 99]",859.0,26781617,Prior hypomethylating agent use lacks impact clinical outcome patients secondary acute myeloid leukemia arising myelodysplastic syndromes treated standard induction chemotherapy,106,0.1849912739965096
Thoracolumbar spinal cord tolerance to high dose conformal proton-photon radiation therapy.,Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology,Radiother Oncol,2016-01-11,"To evaluate and understand the tolerance of the thoracolumbar spinal cord using equivalent uniform dose (EUD) and dose volume histogram (DVH) analysis after combined high dose photon-proton radiotherapy. A total of 68 patients were identified as having high dose radiotherapy, 5900cGy (RBE) in the region of the thoracolumbar spinal cord, defined as extending inferiorly to L2. Pathological diagnosis for patients in this review included chordoma (50 patients, 53.1%), chondrosarcoma (28 patients, 29.8%), osteosarcoma (3 patients, 3.2%), other sarcoma (11 patients, 11.7%), and other (2 patients, 2.1%). Patient data were reviewed retrospectively, detailed dose volume histogram data (DVH) were available for 23 patients. Composite plans and DVH were constructed for both pre-operative and post-operative radiation therapy courses in MIM-Vista software, as available. Dose constraints to the center and surface of the cord were 5400cGy (RBE), and 6300cGy (RBE) respectively, and patients receiving concurrent chemotherapy received an eight percent dose reduction. Spinal cord toxicity was recorded using the RTOG/EORTC late effects scoring system. Clinical and dosimetric data for each patient were analyzed. Median prescription dose was 7020cGy (RBE), range (5940-7820cGy (RBE)). Median follow-up was 12.9months. Five-year overall survival for all patients in this group was 88.7%, 95%CI (74.7-95.2). One patient suffered from transient paralysis following stem cell transplant for treatment of myelodysplastic syndrome. Other reasons for spinal cord injury following treatment included: local disease progression, noted in 7 patients (10.3%), and direct result of surgery, noted in 8 patients (11.8%). Freedom from neurological injury (RTOG Grade 2 or higher) at 5years was 92.9%(95%CI: 74.6-98.2), at 6years was 80.9%(95%CI: 55.3-92.7), and at 8years 80.9%(95%CI: 55.3-92.7). Our clinical and dosimetric data suggest that the noted dose constraints are safe and acceptable with regard to spinal cord complications. Pre-existing disease characteristics, surgical complications, as well as tumor progression, appear to be more important factors when it comes to spinal cord toxicity.",Journal Article,1471.0,3.0,evaluate understand tolerance thoracolumbar spinal cord equivalent uniform dose EUD dose volume histogram DVH combined high dose photon-proton radiotherapy total 68 patients identified high dose radiotherapy 5900cGy RBE region thoracolumbar spinal cord defined extending inferiorly L2 Pathological diagnosis patients review included chordoma 50 patients 53.1 chondrosarcoma 28 patients 29.8 osteosarcoma 3 patients 3.2 sarcoma 11 patients 11.7 2 patients 2.1 Patient reviewed retrospectively detailed dose volume histogram DVH available 23 patients Composite plans DVH constructed pre-operative post-operative radiation therapy courses MIM-Vista software available Dose constraints center surface cord 5400cGy RBE 6300cGy RBE respectively patients receiving concurrent chemotherapy received percent dose reduction Spinal cord toxicity recorded RTOG/EORTC late effects scoring Clinical dosimetric patient Median prescription dose 7020cGy RBE range 5940-7820cGy RBE Median follow-up 12.9months Five-year overall survival patients group 88.7 95 CI 74.7-95.2 patient suffered transient paralysis following stem transplant treatment myelodysplastic syndrome reasons spinal cord injury following treatment included local disease progression noted 7 patients 10.3 direct surgery noted 8 patients 11.8 Freedom neurological injury RTOG Grade 2 higher 5years 92.9 95 CI 74.6-98.2 6years 80.9 95 CI 55.3-92.7 8years 80.9 95 CI 55.3-92.7 clinical dosimetric suggest noted dose constraints safe acceptable regard spinal cord complications Pre-existing disease characteristics surgical complications progression appear important factors comes spinal cord toxicity,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 376, 2, 1640, 3, 2614, 1, 3, 41330, 1499, 1885, 75, 2017, 3490, 61, 17299, 2, 61, 433, 8261, 8255, 65, 50, 397, 64, 61, 4216, 2095, 310, 8, 181, 1, 806, 7, 11, 108, 22, 1041, 64, 61, 310, 67518, 7037, 4, 3, 1053, 1, 3, 41330, 1499, 1885, 395, 22, 4782, 25313, 6, 5111, 1301, 147, 9, 7, 4, 26, 206, 159, 3911, 212, 7, 699, 14, 6116, 339, 7, 462, 66, 27, 7, 27, 18, 127, 175, 7, 175, 67, 2, 127, 18, 7, 18, 14, 69, 74, 11, 446, 894, 2455, 61, 433, 8261, 74, 8255, 11, 390, 9, 382, 7, 3308, 1853, 2, 8255, 11, 2776, 9, 110, 671, 1208, 2, 539, 1208, 121, 36, 1993, 4, 9752, 10503, 3639, 22, 390, 61, 4879, 6, 3, 574, 2, 1255, 1, 3, 1885, 11, 67519, 7037, 2, 67520, 7037, 106, 2, 7, 357, 750, 56, 103, 35, 659, 714, 61, 628, 1499, 1885, 155, 10, 1872, 75, 3, 3931, 4359, 807, 176, 2504, 398, 38, 2, 3187, 74, 9, 296, 69, 11, 311, 52, 3584, 61, 10, 67521, 7037, 184, 41331, 67522, 7037, 52, 166, 126, 10, 133, 16988, 365, 111, 63, 25, 9, 62, 7, 4, 26, 87, 10, 889, 67, 48, 58, 794, 67, 48, 18, 104, 69, 6388, 29, 2473, 11737, 366, 452, 31, 941, 9, 24, 1, 681, 127, 2325, 9, 1499, 1885, 2730, 366, 24, 159, 293, 34, 91, 1051, 4, 67, 7, 79, 27, 2, 1196, 757, 1, 152, 1051, 4, 66, 7, 175, 66, 3060, 29, 3622, 2730, 3931, 88, 18, 15, 142, 28, 18577, 10, 937, 83, 48, 58, 794, 49, 1096, 18, 28, 27052, 10, 493, 83, 48, 58, 614, 27, 937, 67, 2, 28, 29418, 493, 83, 48, 58, 614, 27, 937, 67, 114, 38, 2, 3187, 74, 309, 17, 3, 1051, 61, 4879, 32, 1165, 2, 1595, 5, 2539, 6, 1499, 1885, 521, 671, 1692, 34, 374, 221, 521, 22, 149, 22, 30, 91, 1322, 6, 40, 80, 305, 130, 198, 192, 10705, 6, 1499, 1885, 155]",2054.0,26791929,Thoracolumbar spinal cord tolerance high dose conformal proton-photon radiation therapy,0,0.0
Impact of allogeneic hematopoietic cell transplant in patients with myeloid neoplasms carrying spliceosomal mutations.,American journal of hematology,Am. J. Hematol.,2016-03-14,"Molecular predictors of outcome are increasingly important in determining optimal therapy for myeloid neoplasms. Mutations in the spliceosomal genes (U2AF1 and SRSF2) predict for poor outcomes in myelodysplastic syndromes (MDS) and related diseases. We investigated the effect of hematopoietic cell transplant (HCT) on the negative prognostic impact of U2AF1 and SRSF2 mutations. In total, 122 patients with MDS (30%), acute myeloid leukemia (51%), myeloproliferative neoplasms (MPN) (11%), and MDS/MPN (8%) receiving a HCT from 2003 to 2012 were evaluated for mutations in U2AF1 and SRSF2 by direct sequencing. Median time of follow up was 24 months (range 0.46-110). SRSF2 mutations were detected in 11 (10%) patients and U2AF1 in 3 (3%) patients. There were no significant differences in baseline characteristics between mutated and wild-type (WT) patients. Patients carrying SRSF2 and U2AF1 mutations had similar overall survival (P=0.84), relapse mortality (P=0.50), and non-relapse mortality (P=0.72) compared to WT patients. However, taking into account disease status and cytogenetics in a subset of AML patients, SRSF2 and U2AF1 mutations were associated with worse survival (HR 3.71, P=0.035).",Journal Article,1408.0,6.0,Molecular predictors outcome increasingly important determining optimal therapy myeloid neoplasms spliceosomal U2AF1 SRSF2 predict poor outcomes myelodysplastic syndromes MDS related diseases investigated effect hematopoietic transplant HCT negative prognostic impact U2AF1 SRSF2 total 122 patients MDS 30 acute myeloid leukemia 51 myeloproliferative neoplasms MPN 11 MDS/MPN 8 receiving HCT 2003 2012 evaluated U2AF1 SRSF2 direct sequencing Median time follow 24 months range 0.46-110 SRSF2 detected 11 10 patients U2AF1 3 3 patients significant differences baseline characteristics wild-type WT patients Patients carrying SRSF2 U2AF1 similar overall survival P 0.84 relapse mortality P 0.50 non-relapse mortality P 0.72 compared WT patients taking account disease status cytogenetics subset AML patients SRSF2 U2AF1 associated worse survival HR 3.71 P 0.035,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[219, 674, 1, 228, 32, 1635, 305, 4, 2196, 665, 36, 9, 533, 1179, 138, 4, 3, 17448, 214, 11522, 2, 9830, 678, 9, 334, 123, 4, 2040, 1223, 2, 139, 1342, 21, 565, 3, 254, 1, 1007, 31, 941, 1085, 23, 3, 199, 177, 345, 1, 11522, 2, 9830, 138, 4, 181, 3285, 7, 5, 1223, 201, 286, 533, 725, 1179, 4125, 175, 2, 1223, 4125, 66, 357, 8, 1085, 29, 1522, 6, 1195, 11, 194, 9, 138, 4, 11522, 2, 9830, 20, 1196, 615, 52, 98, 1, 166, 126, 10, 259, 53, 184, 13, 641, 3129, 9830, 138, 11, 530, 4, 175, 79, 7, 2, 11522, 4, 27, 27, 7, 125, 11, 77, 93, 362, 4, 330, 374, 59, 1185, 2, 955, 267, 1820, 7, 7, 2934, 9830, 2, 11522, 138, 42, 288, 63, 25, 19, 13, 874, 429, 282, 19, 13, 212, 2, 220, 429, 282, 19, 13, 720, 72, 6, 1820, 7, 137, 2727, 237, 1967, 34, 156, 2, 2510, 4, 8, 697, 1, 329, 7, 9830, 2, 11522, 138, 11, 41, 5, 639, 25, 168, 27, 792, 19, 13, 4514]",1103.0,26799334,Impact allogeneic hematopoietic transplant patients myeloid neoplasms carrying spliceosomal,14,0.02443280977312391
Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).,American journal of hematology,Am. J. Hematol.,2016-02-01,"Acute myeloid leukemia (AML) is defined as 20% myeloblasts, representing a change from original guidelines where 30% blasts were considered as myelodysplastic syndromes (MDS), and 20-29% blasts classified as refractory anemia with excess blasts in transformation (RAEB-T). Whether the diagnostic bone marrow blast percentage has current value with regards to patient prognostication or identification of optimal treatment strategies is unclear. We retrospectively studied 1652 treatment-nave adults with MDS or AML and 10% blasts from January 2000 to April 2014. Patients with 20-29% blasts were more similar to MDS patients in terms of advanced age, increased frequency of poor-risk cytogenetics, lower WBC count, and less frequent NPM1 and FLT3-ITD mutations. Median overall survival of MDS and RAEB-T were similar, 16.0 and 16.0 months, compared to 13.5 months for AML with 30% blasts (P=0.045). Multivariate analysis showed inferior survival with increased age (HR 1.81 age 60-69, HR 2.68 age 70, P<0.0005); poor-risk cytogenetics (HR 2.25, P<0.0005); therapy-related disease (HR 1.44, P<0.0005); and markers of proliferative disease including WBC 25  10(9) /L (HR 1.35, P = 0.0003), elevated LDH count (HR 1.24, P=0.0015), and peripheral blasts (HR 1.25, P=0.004). Among younger patients (60 years), intensive AML-type therapy resulted in similar outcomes regardless of blast percentage, suggesting this to be optimal therapy in this context. Among older patients (70 years), patients with 20-29% blasts had similar outcomes to patients with <20% blasts, and better than those with 30% blasts. In addition, among older patients, epigenetic therapy provided at least equivalent outcome to intensive chemotherapy.",Journal Article,1450.0,13.0,Acute myeloid leukemia AML defined 20 myeloblasts representing change original guidelines 30 blasts considered myelodysplastic syndromes MDS 20-29 blasts classified refractory anemia excess blasts transformation RAEB-T diagnostic bone marrow blast percentage current value regards patient prognostication identification optimal treatment strategies unclear retrospectively studied 1652 treatment-nave adults MDS AML 10 blasts January 2000 April 2014 Patients 20-29 blasts similar MDS patients terms advanced age increased frequency poor-risk cytogenetics lower WBC count frequent NPM1 FLT3-ITD Median overall survival MDS RAEB-T similar 16.0 16.0 months compared 13.5 months AML 30 blasts P 0.045 Multivariate showed inferior survival increased age HR 1.81 age 60-69 HR 2.68 age 70 P 0.0005 poor-risk cytogenetics HR 2.25 P 0.0005 therapy-related disease HR 1.44 P 0.0005 markers proliferative disease including WBC 25 10 9 /L HR 1.35 P 0.0003 elevated LDH count HR 1.24 P 0.0015 peripheral blasts HR 1.25 P 0.004 younger patients 60 years intensive AML-type therapy resulted similar outcomes regardless blast percentage suggesting optimal therapy context older patients 70 years patients 20-29 blasts similar outcomes patients 20 blasts better 30 blasts addition older patients epigenetic therapy provided equivalent outcome intensive chemotherapy,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[286, 533, 329, 16, 395, 22, 8076, 14909, 2861, 8, 707, 29, 2279, 677, 1257, 15401, 2438, 11, 515, 22, 2040, 1223, 2, 179, 462, 2438, 1373, 22, 430, 1545, 5, 2612, 2438, 4, 1392, 20273, 102, 317, 3, 752, 581, 3112, 1150, 71, 291, 549, 5, 8930, 6, 69, 4260, 15, 911, 1, 665, 24, 422, 16, 1200, 21, 894, 656, 49536, 24, 2809, 857, 5, 1223, 15, 329, 2, 4556, 2438, 29, 1024, 1081, 6, 2292, 1409, 7, 5, 179, 462, 2438, 11, 80, 288, 6, 1223, 7, 4, 1794, 1, 131, 89, 101, 675, 1, 334, 43, 2510, 280, 4685, 1276, 2, 299, 908, 4318, 2, 1224, 2837, 138, 52, 63, 25, 1, 1223, 2, 20273, 102, 11, 288, 245, 13, 2, 245, 13, 53, 72, 6, 233, 33, 53, 9, 329, 5, 7783, 2438, 19, 13, 4918, 331, 65, 224, 1663, 25, 5, 101, 89, 168, 14, 865, 89, 335, 790, 168, 18, 806, 89, 6146, 19, 13, 4252, 334, 43, 2510, 168, 18, 243, 19, 13, 4252, 36, 139, 34, 168, 14, 584, 19, 13, 4252, 2, 525, 1, 2441, 34, 141, 4685, 11056, 79, 83, 805, 168, 14, 465, 19, 13, 4418, 804, 4592, 1276, 168, 14, 259, 19, 13, 9490, 2, 672, 2438, 168, 14, 243, 19, 13, 1520, 107, 773, 7, 12236, 60, 1686, 329, 267, 36, 627, 4, 288, 123, 1583, 1, 3112, 1150, 802, 26, 6, 40, 665, 36, 4, 26, 1533, 107, 434, 7, 6146, 60, 7, 5, 179, 462, 2438, 42, 288, 123, 6, 7, 5, 179, 2438, 2, 380, 76, 135, 5, 7783, 2438, 4, 352, 107, 434, 7, 1418, 36, 1052, 28, 506, 2017, 228, 6, 1686, 56]",1624.0,26799610,Interactions relevance blast percentage treatment strategy younger older patients acute myeloid leukemia AML myelodysplastic syndrome MDS,8,0.013961605584642234
Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.,Expert opinion on investigational drugs,Expert Opin Investig Drugs,2016-01-01,"Epigenetic changes and mutations in epigenetic modifiers characterize and likely drive many cases of acute myeloid leukemia and myelodysplastic syndrome. Development of DNA methyltransferase inhibitors has been most successful in these diseases. While many epigenetic marks are potential targets of cancer therapies, histone deacetylase inhibitors (HDACi) have undergone the most advanced development to date. In this review, the authors describe and discuss the biology and the clinical results of HDAC inhibitors in the settings of myeloid malignancies. While significant results have been achieved in lymphoma and myeloma, efficacy remains limited in myeloid malignancies for both single agent and HDACi based combination regimens. The redundancy and the pleiotropic activity of HDACi (on both histone and non-histone proteins) are key factors that have limited to date the selection of patients and the design of robust biomarkers. Recent advances in biology (mechanisms of resistance, immunology) and the design of a more specific third generation of HDACi are two important features that will drive the future clinical development of HDACi in myeloid malignancies.",Journal Article,1481.0,29.0,Epigenetic changes epigenetic modifiers characterize likely drive cases acute myeloid leukemia myelodysplastic syndrome Development DNA methyltransferase inhibitors successful diseases epigenetic marks potential targets therapies histone deacetylase inhibitors HDACi undergone advanced development date review authors discuss clinical HDAC inhibitors settings myeloid malignancies significant achieved lymphoma myeloma efficacy remains limited myeloid malignancies single agent HDACi based combination regimens redundancy pleiotropic activity HDACi histone non-histone key factors limited date selection patients design robust biomarkers Recent advances mechanisms resistance immunology design specific generation HDACi important features drive future clinical development HDACi myeloid malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1418, 400, 2, 138, 4, 1418, 5663, 1507, 2, 322, 3279, 445, 140, 1, 286, 533, 2, 681, 193, 1, 261, 3747, 222, 71, 85, 96, 1401, 4, 46, 1342, 369, 445, 1418, 8418, 32, 174, 637, 1, 12, 235, 1508, 2732, 222, 4265, 47, 1989, 3, 96, 131, 193, 6, 1244, 4, 26, 206, 3, 738, 897, 2, 1139, 3, 891, 2, 3, 38, 99, 1, 2654, 222, 4, 3, 1947, 1, 533, 441, 369, 93, 99, 47, 85, 513, 4, 2, 209, 469, 383, 4, 533, 441, 9, 110, 226, 420, 2, 4265, 90, 150, 472, 3, 12589, 2, 3, 7872, 128, 1, 4265, 23, 110, 1508, 2, 220, 1508, 652, 32, 825, 130, 17, 47, 383, 6, 1244, 3, 881, 1, 7, 2, 3, 771, 1, 1922, 582, 435, 954, 4, 891, 483, 1, 251, 6534, 2, 3, 771, 1, 8, 80, 112, 1282, 914, 1, 4265, 32, 100, 305, 404, 17, 303, 3279, 3, 508, 38, 193, 1, 4265, 4, 533, 441]",1111.0,26807602,Lost translation years development histone deacetylase inhibitors acute myeloid leukemia myelodysplastic syndromes,1,0.0017452006980802793
The NAE inhibitor pevonedistat interacts with the HDAC inhibitor belinostat to target AML cells by disrupting the DDR.,Blood,Blood,2016-02-05,"Two classes of novel agents, NEDD8-activating enzyme (NAE) and histone deacetylase (HDAC) inhibitors, have shown single-agent activity in acute myelogenous leukemia (AML)/myelodysplastic syndrome (MDS). Here we examined mechanisms underlying interactions between the NAE inhibitor pevonedistat (MLN4924) and the approved HDAC inhibitor belinostat in AML/MDS cells. MLN4924/belinostat coadministration synergistically induced AML cell apoptosis with or without p53 deficiency or FLT3-internal tandem duplication (ITD), whereas p53 short hairpin RNA (shRNA) knockdown or enforced FLT3-ITD expression significantly sensitized cells to the regimen. MLN4924 blocked belinostat-induced antiapoptotic gene expression through nuclear factor-B inactivation. Each agent upregulated Bim, and Bim knockdown significantly attenuated apoptosis. Microarrays revealed distinct DNA damage response (DDR) genetic profiles between individual vs combined MLN4924/belinostat exposure. Whereas belinostat abrogated the MLN4924-activated intra-S checkpoint through Chk1 and Wee1 inhibition/downregulation, cotreatment downregulated multiple homologous recombination and nonhomologous end-joining repair proteins, triggering robust double-stranded breaks, chromatin pulverization, and apoptosis. Consistently, Chk1 or Wee1 shRNA knockdown significantly sensitized AML cells to MLN4924. MLN4924/belinostat displayed activity against primary AML or MDS cells, including those carrying next-generation sequencing-defined poor-prognostic cancer hotspot mutations, and CD34(+)/CD38(-)/CD123(+) populations, but not normal CD34(+) progenitors. Finally, combined treatment markedly reduced tumor burden and significantly prolonged animal survival (P < .0001) in AML xenograft models with negligible toxicity, accompanied by pharmacodynamic effects observed in vitro. Collectively, these findings argue that MLN4924 and belinostat interact synergistically by reciprocally disabling the DDR in AML/MDS cells. This strategy warrants further consideration in AML/MDS, particularly in disease with unfavorable genetic aberrations.",Journal Article,1446.0,17.0,classes novel agents NEDD8-activating enzyme NAE histone deacetylase HDAC inhibitors shown single-agent activity acute myelogenous leukemia AML /myelodysplastic syndrome MDS examined mechanisms underlying interactions NAE inhibitor pevonedistat MLN4924 approved HDAC inhibitor belinostat AML/MDS MLN4924/belinostat coadministration synergistically induced AML apoptosis p53 deficiency FLT3-internal tandem duplication ITD p53 short hairpin RNA shRNA knockdown enforced FLT3-ITD expression significantly sensitized regimen MLN4924 blocked belinostat-induced antiapoptotic expression nuclear factor-B inactivation agent upregulated Bim Bim knockdown significantly attenuated apoptosis Microarrays revealed distinct DNA damage response DDR genetic profiles individual vs combined MLN4924/belinostat exposure belinostat abrogated MLN4924-activated intra-S checkpoint Chk1 Wee1 inhibition/downregulation cotreatment downregulated multiple homologous recombination nonhomologous end-joining repair triggering robust double-stranded breaks chromatin pulverization apoptosis Consistently Chk1 Wee1 shRNA knockdown significantly sensitized AML MLN4924 MLN4924/belinostat displayed activity primary AML MDS including carrying next-generation sequencing-defined poor-prognostic hotspot CD34 /CD38 /CD123 populations normal CD34 progenitors Finally combined treatment markedly reduced burden significantly prolonged animal survival P .0001 AML xenograft models negligible toxicity accompanied pharmacodynamic effects observed vitro Collectively findings argue MLN4924 belinostat interact synergistically reciprocally disabling DDR AML/MDS strategy warrants consideration AML/MDS particularly disease unfavorable genetic aberrations,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[100, 3211, 1, 229, 183, 15031, 1616, 1644, 17052, 2, 1508, 2732, 2654, 222, 47, 443, 226, 420, 128, 4, 286, 2194, 329, 10589, 681, 1223, 467, 21, 409, 483, 1181, 1286, 59, 3, 17052, 230, 9833, 11716, 2, 3, 850, 2654, 230, 6842, 4, 329, 1223, 37, 11716, 6842, 5777, 4240, 277, 329, 31, 351, 5, 15, 187, 624, 2299, 15, 1224, 2329, 2905, 4616, 2837, 547, 624, 978, 5957, 893, 3976, 1563, 15, 7807, 1224, 2837, 55, 97, 4242, 37, 6, 3, 477, 11716, 2582, 6842, 277, 4176, 145, 55, 298, 928, 161, 2448, 2297, 296, 420, 2684, 3595, 2, 3595, 1563, 97, 2656, 351, 2774, 553, 834, 261, 1350, 51, 5630, 336, 1241, 59, 797, 105, 397, 11716, 6842, 645, 547, 6842, 3728, 3, 11716, 735, 2392, 695, 986, 298, 4638, 2, 10382, 297, 2475, 10066, 3315, 232, 3894, 4017, 2, 16858, 396, 10690, 972, 652, 8867, 1922, 1627, 9021, 4492, 2287, 67595, 2, 351, 2433, 4638, 15, 10382, 3976, 1563, 97, 4242, 329, 37, 6, 11716, 11716, 6842, 2507, 128, 480, 86, 329, 15, 1223, 37, 141, 135, 2934, 1305, 914, 615, 395, 334, 177, 12, 5991, 138, 2, 2215, 4469, 8849, 1184, 84, 44, 295, 2215, 4321, 1368, 397, 24, 2195, 405, 30, 892, 2, 97, 1069, 2026, 25, 19, 488, 4, 329, 1330, 274, 5, 6821, 155, 2756, 20, 2424, 176, 164, 4, 439, 2535, 46, 272, 7004, 17, 11716, 2, 6842, 4491, 4240, 20, 18316, 12492, 3, 5630, 4, 329, 1223, 37, 26, 692, 2782, 195, 2415, 4, 329, 1223, 823, 4, 34, 5, 2483, 336, 2152]",2029.0,26851293,NAE inhibitor pevonedistat interacts HDAC inhibitor belinostat target AML disrupting DDR,1,0.0017452006980802793
Autoimmune diseases and myelodysplastic syndromes.,American journal of hematology,Am. J. Hematol.,2016-04-04,"Immune dysregulation and altered T-cell hemostasis play important roles in the pathogenesis of myelodysplastic syndromes (MDS). Recent studies suggest an increased risk of MDS among patients with autoimmune diseases. Here, we investigated the prevalence of autoimmune diseases among MDS patients, comparing characteristics and outcomes in those with and without autoimmune diseases. From our study group of 1408 MDS patients, 391 (28%) had autoimmune disease, with hypothyroidism being the most common type, accounting for 44% (n=171) of patients (12% among all MDS patients analyzed). Other autoimmune diseases with 5% prevalence included idiopathic thrombocytopenic purpura in 12% (n=46), rheumatoid arthritis in 10% (n=41), and psoriasis in 7% (n=28) of patients. Autoimmune diseases were more common in female MDS patients, those with RA or RCMD WHO subtype, and those who were less dependent on red blood cell transfusion. Median overall survival (OS) was 60 months (95% CI, 50-70) for patients with autoimmune diseases versus 45 months (95% CI, 40-49) for those without (log-rank test, P=0.006). By multivariate analysis adjusting for revised IPSS and age >60 years, autoimmune diseases were a statistically significant independent factor for OS (HR 0.78; 95% CI, 0.66-0.92; P=0.004). The rate of acute myeloid leukemia (AML) transformation was 23% (n=89) in MDS patients with autoimmune disease versus 30% (n=301) in those without (P=0.011). Patient groups did not differ in response to azacitidine or lenalidomide treatment. Autoimmune diseases are prevalent among MDS patients. MDS patients with autoimmune diseases have better OS and less AML transformation.",Comparative Study,1387.0,33.0,Immune dysregulation altered T-cell hemostasis play important roles pathogenesis myelodysplastic syndromes MDS Recent studies suggest increased risk MDS patients autoimmune diseases investigated prevalence autoimmune diseases MDS patients comparing characteristics outcomes autoimmune diseases group 1408 MDS patients 391 28 autoimmune disease hypothyroidism common type accounting 44 n 171 patients 12 MDS patients autoimmune diseases 5 prevalence included idiopathic thrombocytopenic purpura 12 n 46 rheumatoid arthritis 10 n 41 psoriasis 7 n 28 patients Autoimmune diseases common female MDS patients RA RCMD subtype dependent red blood transfusion Median overall survival OS 60 months 95 CI 50-70 patients autoimmune diseases versus 45 months 95 CI 40-49 log-rank test P 0.006 multivariate adjusting revised IPSS age 60 years autoimmune diseases statistically significant independent factor OS HR 0.78 95 CI 0.66-0.92 P 0.004 rate acute myeloid leukemia AML transformation 23 n 89 MDS patients autoimmune disease versus 30 n 301 P 0.011 Patient groups differ response azacitidine lenalidomide treatment Autoimmune diseases prevalent MDS patients MDS patients autoimmune diseases better OS AML transformation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[250, 3935, 2, 1495, 102, 31, 16020, 1343, 305, 1790, 4, 3, 1384, 1, 2040, 1223, 435, 94, 309, 35, 101, 43, 1, 1223, 107, 7, 5, 3445, 1342, 467, 21, 565, 3, 1078, 1, 3445, 1342, 107, 1223, 7, 1430, 374, 2, 123, 4, 135, 5, 2, 187, 3445, 1342, 29, 114, 45, 87, 1, 46287, 1223, 7, 10881, 339, 42, 3445, 34, 5, 4147, 486, 3, 96, 186, 267, 3116, 9, 584, 78, 5702, 1, 7, 133, 107, 62, 1223, 7, 311, 127, 3445, 1342, 5, 4126, 1078, 159, 7540, 11908, 14174, 4, 133, 78, 641, 12269, 8646, 4, 79, 78, 605, 2, 14648, 4, 67, 78, 339, 1, 7, 3445, 1342, 11, 80, 186, 4, 1061, 1223, 7, 135, 5, 4631, 15, 38929, 54, 875, 2, 135, 54, 11, 299, 470, 23, 3422, 315, 31, 2785, 52, 63, 25, 118, 10, 335, 53, 48, 58, 212, 431, 9, 7, 5, 3445, 1342, 185, 512, 53, 48, 58, 327, 739, 9, 135, 187, 1066, 1026, 412, 19, 13, 1861, 20, 331, 65, 1358, 9, 4218, 8751, 2, 89, 335, 60, 3445, 1342, 11, 8, 712, 93, 306, 161, 9, 118, 168, 13, 833, 48, 58, 13, 700, 13, 937, 19, 13, 1520, 3, 116, 1, 286, 533, 329, 1392, 10, 382, 78, 887, 4, 1223, 7, 5, 3445, 34, 185, 201, 78, 5721, 4, 135, 187, 19, 13, 3651, 69, 271, 205, 44, 1505, 4, 51, 6, 3752, 15, 1288, 24, 3445, 1342, 32, 2485, 107, 1223, 7, 1223, 7, 5, 3445, 1342, 47, 380, 118, 2, 299, 329, 1392]",1571.0,26875020,Autoimmune diseases myelodysplastic syndromes,8,0.013961605584642234
Clinical prognostic factors and outcomes of essential thrombocythemia when transformed to myelodysplastic syndromes and acute myeloid leukemia.,Leukemia research,Leuk. Res.,2016-02-02,"Transformation of essential thrombocythemia (ET) to myelodysplastic syndromes or acute myeloid leukemia is infrequent, comprising 1-5% of cases with dismal clinical outcome. Studies on prognosis in ET patients with leukemic transformation are limited. The large cohort included 40 patients (1990-2014) with ET transformation (median age of 59 years, M:F of 1:1). Median time from ET diagnosis to transformation was 76 months (26-481) with median follow-up time of 15 years. Advanced age, myelofibrosis (grade 2-3), and leukocytosis at the time of transformation were associated with inferior OS from transformation (p<0.05). Given rarity of the clinical scenario, multicenter efforts are encouraged. ",Journal Article,1449.0,4.0,Transformation essential thrombocythemia myelodysplastic syndromes acute myeloid leukemia infrequent comprising 1-5 cases dismal clinical outcome Studies prognosis patients leukemic transformation limited large cohort included 40 patients 1990-2014 transformation median age 59 years F 1:1 Median time diagnosis transformation 76 months 26-481 median follow-up time 15 years Advanced age myelofibrosis grade 2-3 leukocytosis time transformation associated inferior OS transformation p 0.05 Given rarity clinical scenario multicenter efforts encouraged,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1392, 1, 1452, 8962, 2022, 6, 2040, 15, 286, 533, 16, 4475, 3538, 14, 33, 1, 140, 5, 3929, 38, 228, 94, 23, 356, 4, 2022, 7, 5, 2015, 1392, 32, 383, 3, 375, 180, 159, 327, 7, 2289, 1409, 5, 2022, 1392, 52, 89, 1, 728, 60, 188, 1068, 1, 14, 14, 52, 98, 29, 2022, 147, 6, 1392, 10, 846, 53, 432, 12178, 5, 52, 166, 126, 98, 1, 167, 60, 131, 89, 4637, 88, 18, 27, 2, 7463, 28, 3, 98, 1, 1392, 11, 41, 5, 1663, 118, 29, 1392, 19, 13, 474, 447, 4989, 1, 3, 38, 5456, 1570, 1413, 32, 5865]",650.0,26894965,Clinical prognostic factors outcomes essential thrombocythemia transformed myelodysplastic syndromes acute myeloid leukemia,183,0.3193717277486911
Myelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 Therapy.,Cancer immunology research,Cancer Immunol Res,2016-03-10,"Antibodies aimed at blocking the interaction between programmed cell death-1 (PD-1) and its ligands have shown impressive efficacy in a variety of malignancies and are generally well tolerated. Research has focused intensely on T cells and their interaction with cells within melanoma tumors, while relatively little is understood about the systems immunology of the cells in the blood during checkpoint inhibitor therapy. Longitudinal cytomic analysis using mass cytometry can characterize all the cells in a small sample of blood and has the potential to reveal key shifts in the cellular milieu occurring during treatment. We report a case of advanced melanoma in which mass cytometry detected abnormal myeloid cells resulting from myelodysplastic syndrome (MDS) in the blood following treatment with an anti-PD-1 agent. Myeloid blasts comprised <1% of peripheral blood mononuclear cells (PBMC) 1 month after the start of treatment. Six months after starting therapy, myeloid blasts comprised 5% of PBMCs, and a bone marrow biopsy confirmed refractory anemia with excess blasts-2 (RAEB-2). Longitudinal mass cytometry immunophenotyping comprehensively characterized blast phenotype evolution and revealed elevated PD-1 expression on the surface of nonblast myeloid cells. These findings highlight the clinical significance of cytomic monitoring, indicate that the myeloid compartment should be monitored during checkpoint inhibitor therapy, and emphasize the value of systems immunology in medicine. Cancer Immunol Res; 4(6); 474-80. 2016 AACR.",Case Reports,1412.0,10.0,Antibodies aimed blocking interaction programmed death-1 PD-1 ligands shown impressive efficacy variety malignancies generally tolerated Research focused intensely interaction melanoma relatively little understood systems immunology blood checkpoint inhibitor therapy Longitudinal cytomic mass cytometry characterize small blood potential reveal key shifts cellular milieu occurring treatment report case advanced melanoma mass cytometry detected abnormal myeloid resulting myelodysplastic syndrome MDS blood following treatment anti-PD-1 agent Myeloid blasts comprised 1 peripheral blood mononuclear PBMC 1 month start treatment months starting therapy myeloid blasts comprised 5 PBMCs bone marrow biopsy confirmed refractory anemia excess blasts-2 RAEB-2 Longitudinal mass cytometry immunophenotyping comprehensively characterized blast phenotype evolution revealed elevated PD-1 expression surface nonblast myeloid findings highlight clinical significance cytomic monitoring indicate myeloid compartment monitored checkpoint inhibitor therapy emphasize value systems immunology medicine Immunol Res 4 6 474-80 2016 AACR,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[890, 1295, 28, 2521, 3, 915, 59, 1846, 31, 273, 14, 333, 14, 2, 211, 3123, 47, 443, 5790, 209, 4, 8, 1362, 1, 441, 2, 32, 1228, 149, 421, 389, 71, 1649, 20549, 23, 102, 37, 2, 136, 915, 5, 37, 262, 57, 369, 1352, 1215, 16, 1784, 545, 3, 1530, 6534, 1, 3, 37, 4, 3, 315, 190, 986, 230, 36, 2380, 49611, 65, 75, 782, 1914, 122, 1507, 62, 3, 37, 4, 8, 302, 1000, 1, 315, 2, 71, 3, 174, 6, 2396, 825, 5906, 4, 3, 763, 6795, 1821, 190, 24, 21, 414, 8, 473, 1, 131, 4, 92, 782, 1914, 530, 1668, 533, 37, 1113, 29, 681, 1223, 4, 3, 315, 366, 24, 5, 35, 312, 333, 14, 420, 533, 2438, 2603, 14, 1, 672, 315, 3041, 37, 5063, 14, 811, 50, 3, 2435, 1, 24, 437, 53, 50, 1723, 36, 533, 2438, 2603, 33, 1, 4617, 2, 8, 581, 411, 557, 430, 1545, 5, 2612, 2438, 18, 20273, 18, 2380, 782, 1914, 9416, 5627, 765, 3112, 1005, 2554, 2, 553, 804, 333, 14, 55, 23, 3, 1255, 1, 67771, 533, 37, 46, 272, 1817, 3, 38, 724, 1, 49611, 1315, 1008, 17, 3, 533, 3616, 257, 40, 2909, 190, 986, 230, 36, 2, 5560, 3, 549, 1, 1530, 6534, 4, 1807, 12, 8557, 1936, 39, 49, 10282, 493, 3456, 1630]",1480.0,26966176,Myelodysplastic Syndrome Revealed Systems Immunology Melanoma Patient Undergoing Anti-PD-1 Therapy,122,0.21291448516579406
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.,Cancer,Cancer,2016-03-18,"RAS/RAF/mitogen-activated protein kinase activation is common in myeloid malignancies. Trametinib, a mitogen-activated protein kinase kinase 1 (MEK1)/MEK2 inhibitor with activity against multiple myeloid cell lines at low nanomolar concentrations, was evaluated for safety and clinical activity in patients with relapsed/refractory leukemias. This phase 1/2 study accrued patients with any relapsed/refractory leukemia in phase 1. In phase 2, this study accrued patients with relapsed/refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) with NRAS or KRAS mutations (cohort 1); patients with AML, MDS, or chronic myelomonocytic leukemia (CMML) with a RAS wild-type mutation or an unknown mutation status (cohort 2); and patients with CMML with an NRAS or KRAS mutation (cohorts 3). The most commonly reported treatment-related adverse events were diarrhea, rash, nausea, and increased alanine aminotransferase levels. The phase 2 recommended dose for Trametinib was 2 mg orally daily. The overall response rates were 20%, 3%, and 27% for cohorts 1, 2, and 3, respectively, and this indicated preferential activity among RAS-mutated myeloid malignancies. Repeated cycles of trametinib were well tolerated with manageable or reversible toxicities; these results were similar to those of other trametinib studies. The selective, single-agent activity of trametinib against RAS-mutated myeloid malignancies validates its therapeutic potential. Combination strategies based on a better understanding of the hierarchical role of mutations and signaling in myeloid malignancies are likely to improve the response rate and duration. Cancer 2016;122:1871-9.  2016 American Cancer Society.","Clinical Trial, Phase I",1404.0,43.0,RAS/RAF/mitogen-activated kinase activation common myeloid malignancies Trametinib mitogen-activated kinase kinase 1 MEK1 /MEK2 inhibitor activity multiple myeloid lines low nanomolar concentrations evaluated safety clinical activity patients relapsed/refractory leukemias phase 1/2 accrued patients relapsed/refractory leukemia phase 1 phase 2 accrued patients relapsed/refractory acute myeloid leukemia AML high-risk myelodysplastic syndromes MDS NRAS KRAS cohort 1 patients AML MDS chronic myelomonocytic leukemia CMML RAS wild-type unknown status cohort 2 patients CMML NRAS KRAS cohorts 3 commonly reported treatment-related adverse events diarrhea rash nausea increased alanine aminotransferase levels phase 2 recommended dose Trametinib 2 mg orally daily overall response rates 20 3 27 cohorts 1 2 3 respectively indicated preferential activity RAS-mutated myeloid malignancies Repeated cycles trametinib tolerated manageable reversible toxicities similar trametinib studies selective single-agent activity trametinib RAS-mutated myeloid malignancies validates therapeutic potential Combination strategies based better understanding hierarchical role signaling myeloid malignancies likely improve response rate duration 2016 122:1871-9  2016 American Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1102, 2212, 2625, 735, 178, 216, 363, 16, 186, 4, 533, 441, 3858, 8, 2625, 735, 178, 216, 216, 14, 3893, 12873, 230, 5, 128, 480, 232, 533, 31, 285, 28, 154, 7927, 1003, 10, 194, 9, 367, 2, 38, 128, 4, 7, 5, 591, 430, 2792, 26, 124, 14, 18, 45, 3198, 7, 5, 500, 591, 430, 4, 124, 14, 4, 124, 18, 26, 45, 3198, 7, 5, 591, 430, 286, 533, 329, 15, 64, 43, 2040, 1223, 5, 2845, 15, 723, 138, 180, 14, 7, 5, 329, 1223, 15, 442, 5451, 3382, 5, 8, 1102, 955, 267, 258, 15, 35, 860, 258, 156, 180, 18, 2, 7, 5, 3382, 5, 35, 2845, 15, 723, 258, 736, 27, 3, 96, 841, 210, 24, 139, 290, 281, 11, 1172, 1641, 1218, 2, 101, 5411, 4597, 148, 3, 124, 18, 793, 61, 9, 3858, 10, 18, 81, 1428, 391, 3, 63, 51, 151, 11, 179, 27, 2, 428, 9, 736, 14, 18, 2, 27, 106, 2, 26, 1103, 6629, 128, 107, 1102, 1185, 533, 441, 2113, 410, 1, 3858, 11, 149, 421, 5, 2808, 15, 2786, 385, 46, 99, 11, 288, 6, 135, 1, 127, 3858, 94, 3, 1094, 226, 420, 128, 1, 3858, 480, 1102, 1185, 533, 441, 11235, 211, 189, 174, 150, 422, 90, 23, 8, 380, 612, 1, 3, 4466, 200, 1, 138, 2, 314, 4, 533, 441, 32, 322, 6, 401, 3, 51, 116, 2, 654, 12, 1390, 3285, 49633, 83, 2206, 1390, 597, 12, 1174]",1623.0,26990290,Activity oral mitogen-activated kinase kinase inhibitor trametinib RAS-mutant relapsed refractory myeloid malignancies,0,0.0
Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2016-04-16,"Allogeneic stem cell transplantation is an effective treatment for high-risk myeloid malignancies, but relapse remains the major post-transplantation cause of treatment failure. Alloreactive natural killer (NK) cells mediate a potent antileukemic effect and may also enhance engraftment and reduce graft-versus-host disease (GVHD). Haploidentical transplantations provide a setting in which NK cell alloreactivity can be manipulated, but they are associated with high rates of GVHD. We performed a phase I study infusing escalating doses of NK cells from an HLA haploidentical-related donor-selected for alloreactivity when possible-as a component of the preparative regimen for allotransplantation from a separate HLA-identical donor. The goal of infusing third-party alloreactive NK cells was to augment the antileukemic effect of the transplantation without worsening GVHD and, thus, improve the overall outcome of hematopoietic transplantation. Twenty-one patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelogenous leukemia refractory or beyond first remission received a preparative regimen with busulfan and fludarabine followed by infusion of apheresis-derived, antibody-selected, and IL-2-activated NK cells. Doses were initially based on total nucleated cell (TNC) content and later based on CD56(+) cells to reduce variability. CD56(+) content ranged from .02 to 8.3210(6)/kg. IL-2, .510(6) units/m(2) subcutaneously was administered daily for 5days in the final cohort (n=10). CD3(+) cells in the NK cell product were required to be<10(5)/kg. Median relapse-free, overall, and GVHD-free/relapse-free survival for all patients enrolled was 102, 233, and 89days, respectively. Five patients are alive, 5 patients died of transplantation-related causes, and 11 patients died of relapse. Despite the small sample size, survival was highly associated with CD56(+) cells delivered (P= .022) and development of  grade 3 GVHD (P= .006). There were nonsignificant trends toward higher survival rates in those receiving NK cells from KIR ligand-mismatched donors and KIR-B haplotype donors. There was no association with disease type, remission at time of transplantation, or KIR content. GVHD was not associated with TNC, CD56(+), or CD3(+) cells infused in the NK cell product or the stem cell product. This trial demonstrates a lack of major toxicity attributable to third-party NK cell infusions delivered in combination with an HLA-compatible allogeneic transplantation. The infusion of haploidentical alloreactive NK cells was well tolerated and did not interfere with engraftment or increase the rate of GVHD after allogeneic hematopoietic transplantation. Durable complete remissions occurred in 5 patients at high risk for disease recurrence. This approach is being further developed in a phase I/II trial with exvivo-expanded NK cells to increase the NK cell dose with the objective of reducing relapse and improving the outcome of allogeneic hematopoietic transplantation for AML/MDS.","Clinical Trial, Phase I",1375.0,41.0,Allogeneic stem transplantation effective treatment high-risk myeloid malignancies relapse remains major post-transplantation cause treatment failure Alloreactive natural killer NK mediate potent antileukemic effect enhance engraftment reduce graft-versus-host disease GVHD Haploidentical transplantations provide setting NK alloreactivity manipulated associated high rates GVHD performed phase infusing escalating doses NK HLA haploidentical-related donor-selected alloreactivity possible-as component preparative regimen allotransplantation separate HLA-identical donor goal infusing third-party alloreactive NK augment antileukemic effect transplantation worsening GVHD improve overall outcome hematopoietic transplantation Twenty-one patients high-risk acute myeloid leukemia AML myelodysplastic syndrome MDS chronic myelogenous leukemia refractory remission received preparative regimen busulfan fludarabine followed infusion apheresis-derived antibody-selected IL-2-activated NK Doses initially based total nucleated TNC content later based CD56 reduce variability CD56 content ranged .02 8.32 10 6 /kg IL-2 .5 10 6 units/m 2 subcutaneously administered daily 5 days final cohort n 10 CD3 NK product required 10 5 /kg Median relapse-free overall GVHD-free/relapse-free survival patients enrolled 102 233 89 days respectively patients alive 5 patients died transplantation-related causes 11 patients died relapse Despite small size survival highly associated CD56 delivered P .022 development  grade 3 GVHD P .006 nonsignificant trends higher survival rates receiving NK KIR ligand-mismatched donors KIR-B haplotype donors association disease type remission time transplantation KIR content GVHD associated TNC CD56 CD3 infused NK product stem product trial demonstrates lack major toxicity attributable third-party NK infusions delivered combination HLA-compatible allogeneic transplantation infusion haploidentical alloreactive NK tolerated interfere engraftment increase rate GVHD allogeneic hematopoietic transplantation Durable complete remissions occurred 5 patients high risk disease recurrence approach developed phase I/II trial ex vivo-expanded NK increase NK dose objective reducing relapse improving outcome allogeneic hematopoietic transplantation AML/MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1063, 452, 31, 497, 16, 35, 323, 24, 9, 64, 43, 533, 441, 84, 429, 469, 3, 458, 539, 497, 708, 1, 24, 496, 13831, 1504, 3458, 1765, 37, 3367, 8, 1157, 4512, 254, 2, 68, 120, 1304, 2881, 2, 969, 1599, 185, 1204, 34, 1562, 5802, 6779, 377, 8, 546, 4, 92, 1765, 31, 22039, 122, 40, 13222, 84, 491, 32, 41, 5, 64, 151, 1, 1562, 21, 173, 8, 124, 70, 45, 21343, 2922, 415, 1, 1765, 37, 29, 35, 1160, 5802, 139, 1488, 715, 9, 22039, 198, 899, 22, 8, 1249, 1, 3, 6085, 477, 9, 37175, 29, 8, 2282, 1160, 3038, 1488, 3, 1326, 1, 21343, 1282, 11429, 13831, 1765, 37, 10, 6, 4369, 3, 4512, 254, 1, 3, 497, 187, 4323, 1562, 2, 631, 401, 3, 63, 228, 1, 1007, 497, 737, 104, 7, 5, 64, 43, 286, 533, 329, 681, 1223, 15, 442, 2194, 430, 15, 1654, 157, 734, 103, 8, 6085, 477, 5, 3906, 2, 2027, 370, 20, 904, 1, 9456, 526, 548, 715, 2, 501, 18, 735, 1765, 37, 415, 11, 1625, 90, 23, 181, 9862, 31, 20000, 2457, 2, 1559, 90, 23, 5803, 37, 6, 969, 1982, 5803, 2457, 1869, 29, 588, 6, 66, 531, 79, 49, 503, 501, 18, 33, 79, 49, 2960, 188, 18, 3928, 10, 468, 391, 9, 33, 162, 4, 3, 1457, 180, 78, 79, 3117, 37, 4, 3, 1765, 31, 2821, 11, 616, 6, 40, 79, 33, 503, 52, 429, 115, 63, 2, 1562, 115, 429, 115, 25, 9, 62, 7, 346, 10, 2867, 7005, 2, 887, 162, 106, 365, 7, 32, 1701, 33, 7, 1016, 1, 497, 139, 1626, 2, 175, 7, 1016, 1, 429, 550, 3, 302, 1000, 444, 25, 10, 561, 41, 5, 5803, 37, 1623, 19, 4773, 2, 193, 1, 749, 88, 27, 1562, 19, 1861, 125, 11, 5542, 1963, 1317, 142, 25, 151, 4, 135, 357, 1765, 37, 29, 6989, 1232, 5095, 2344, 2, 6989, 132, 4179, 2344, 125, 10, 77, 248, 5, 34, 267, 734, 28, 98, 1, 497, 15, 6989, 2457, 1562, 10, 44, 41, 5, 20000, 5803, 15, 3117, 37, 4524, 4, 3, 1765, 31, 2821, 15, 3, 452, 31, 2821, 26, 160, 1902, 8, 926, 1, 458, 155, 2971, 6, 1282, 11429, 1765, 31, 3435, 1623, 4, 150, 5, 35, 1160, 7293, 1063, 497, 3, 904, 1, 5802, 13831, 1765, 37, 10, 149, 421, 2, 205, 44, 6178, 5, 2881, 15, 344, 3, 116, 1, 1562, 50, 1063, 1007, 497, 1480, 236, 3166, 489, 4, 33, 7, 28, 64, 43, 9, 34, 146, 26, 353, 16, 486, 195, 276, 4, 8, 124, 70, 215, 160, 5, 2581, 386, 2064, 1765, 37, 6, 344, 3, 1765, 31, 61, 5, 3, 461, 1, 1818, 429, 2, 1673, 3, 228, 1, 1063, 1007, 497, 9, 329, 1223]",2939.0,27090958,Haploidentical Natural Killer Infused Allogeneic Stem Transplantation Myeloid Malignancies Phase Trial,20,0.034904013961605584
miR-22 has a potent anti-tumour role with therapeutic potential in acute myeloid leukaemia.,Nature communications,Nat Commun,2016-04-26,"MicroRNAs are subject to precise regulation and have key roles in tumorigenesis. In contrast to the oncogenic role of miR-22 reported in myelodysplastic syndrome (MDS) and breast cancer, here we show that miR-22 is an essential anti-tumour gatekeeper in de novo acute myeloid leukaemia (AML) where it is significantly downregulated. Forced expression of miR-22 significantly suppresses leukaemic cell viability and growth in vitro, and substantially inhibits leukaemia development and maintenance in vivo. Mechanistically, miR-22 targets multiple oncogenes, including CRTC1, FLT3 and MYCBP, and thus represses the CREB and MYC pathways. The downregulation of miR-22 in AML is caused by TET1/GFI1/EZH2/SIN3A-mediated epigenetic repression and/or DNA copy-number loss. Furthermore, nanoparticles carrying miR-22 oligos significantly inhibit leukaemia progression in vivo. Together, our study uncovers a TET1/GFI1/EZH2/SIN3A/miR-22/CREB-MYC signalling circuit and thereby provides insights into epigenetic/genetic mechanisms underlying the pathogenesis of AML, and also highlights the clinical potential of miR-22-based AML therapy.",Journal Article,1365.0,56.0,MicroRNAs subject precise regulation key roles tumorigenesis contrast oncogenic role miR-22 reported myelodysplastic syndrome MDS breast miR-22 essential anti-tumour gatekeeper novo acute myeloid leukaemia AML significantly downregulated Forced expression miR-22 significantly suppresses leukaemic viability growth vitro substantially inhibits leukaemia development maintenance vivo Mechanistically miR-22 targets multiple oncogenes including CRTC1 FLT3 MYCBP represses CREB MYC pathways downregulation miR-22 AML caused TET1/GFI1/EZH2/SIN3A-mediated epigenetic repression and/or DNA copy-number loss Furthermore nanoparticles carrying miR-22 oligos significantly inhibit leukaemia progression vivo uncovers TET1/GFI1/EZH2/SIN3A/miR-22/CREB-MYC signalling circuit provides insights epigenetic/genetic mechanisms underlying pathogenesis AML highlights clinical potential miR-22-based AML therapy,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3515, 32, 2974, 6, 3260, 863, 2, 47, 825, 1790, 4, 1565, 4, 748, 6, 3, 1302, 200, 1, 722, 350, 210, 4, 681, 1223, 2, 12, 467, 21, 514, 17, 722, 350, 16, 35, 1452, 312, 770, 10899, 4, 1566, 2018, 286, 533, 2001, 329, 1257, 192, 16, 97, 3315, 5216, 55, 1, 722, 350, 97, 4079, 8871, 31, 2120, 2, 129, 4, 439, 2, 2109, 1576, 2001, 193, 2, 1146, 4, 386, 4187, 722, 350, 637, 232, 3326, 141, 16594, 1224, 2, 68055, 2, 631, 10946, 3, 8764, 2, 1371, 460, 3, 2475, 1, 722, 350, 4, 329, 16, 1546, 20, 20655, 39930, 3755, 21855, 517, 1418, 5255, 2, 15, 261, 1337, 207, 407, 798, 2889, 2934, 722, 350, 26256, 97, 1433, 2001, 91, 4, 386, 1162, 114, 45, 18562, 8, 20655, 39930, 3755, 21855, 722, 350, 8764, 1371, 3128, 14944, 2, 2267, 777, 1957, 237, 1418, 336, 483, 1181, 3, 1384, 1, 329, 2, 120, 2527, 3, 38, 174, 1, 722, 350, 90, 329, 36]",1086.0,27116251,miR-22 potent anti-tumour role therapeutic potential acute myeloid leukaemia,0,0.0
Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.,Cancer genetics,Cancer Genet,2016-04-06,"Der(5;17)(p10;q10) is a recurrent but rare aberration reported in myeloid neoplasms (MNs). We report 48 such patients including 19 acute myeloid leukemia (AML) and 29 myelodysplastic syndrome (MDS), to characterize their clinicopathological features. There were 29 men and 19 women, with a median age of 61 years (range, 18-80). 62.5% patients had therapy-related diseases (t-MNs), 70.8% had multilineage dysplasia and 83.3% showed complex karyotypes. In 39 patients tested, FLT3, NPM1, CEBPA, KIT were all wild type and NRAS, KRAS, IDH1, APC, TET2 mutations were detected in single case(s) respectively. TP53 mutations were identified in 8 of 10 cases (80%) tested. Median disease-free survival (DFS) and overall survival (OS) were 3 and 10 months, respectively and did not differ between AML or MDS cases, or between de novo versus therapy-related cases, or between the groups with or without complex karyotypes. In 19 patients who achieved complete remission after chemotherapy, and in 9 patients who underwent stem cell transplantation, the OS was better (14 and 17.5 months, P=0.0128 and P=0.0086, respectively). The der(5;17)(p10;q10) represents a unique molecular-cytogenetic subgroup in t-MNs and, associated with complex karyotypes. TP53 inactivation, resulting from 17p deletion coupled with TP53 mutation, likely contributes to the poor clinical outcome of these patients.",Journal Article,1385.0,2.0,Der 5 17 p10 q10 recurrent rare aberration reported myeloid neoplasms MNs report 48 patients including 19 acute myeloid leukemia AML 29 myelodysplastic syndrome MDS characterize clinicopathological features 29 men 19 women median age 61 years range 18-80 62.5 patients therapy-related diseases t-MNs 70.8 multilineage dysplasia 83.3 showed complex karyotypes 39 patients tested FLT3 NPM1 CEBPA KIT wild type NRAS KRAS IDH1 APC TET2 detected single case respectively TP53 identified 8 10 cases 80 tested Median disease-free survival DFS overall survival OS 3 10 months respectively differ AML MDS cases novo versus therapy-related cases groups complex karyotypes 19 patients achieved complete remission chemotherapy 9 patients underwent stem transplantation OS better 14 17.5 months P 0.0128 P 0.0086 respectively der 5 17 p10 q10 represents unique molecular-cytogenetic subgroup t-MNs associated complex karyotypes TP53 inactivation resulting 17p deletion coupled TP53 likely contributes poor clinical outcome patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[13324, 33, 269, 16536, 19649, 16, 8, 387, 84, 622, 7794, 210, 4, 533, 1179, 17539, 21, 414, 576, 225, 7, 141, 326, 286, 533, 329, 2, 462, 681, 1223, 6, 1507, 136, 2721, 404, 125, 11, 462, 325, 2, 326, 117, 5, 8, 52, 89, 1, 713, 60, 184, 203, 493, 744, 33, 7, 42, 36, 139, 1342, 102, 17539, 431, 66, 42, 12471, 2253, 2, 852, 27, 224, 840, 6809, 4, 587, 7, 650, 1224, 4318, 7667, 1164, 11, 62, 955, 267, 2, 2845, 723, 2662, 2528, 5038, 138, 11, 530, 4, 226, 473, 695, 106, 1206, 138, 11, 108, 4, 66, 1, 79, 140, 493, 650, 52, 34, 115, 25, 1010, 2, 63, 25, 118, 11, 27, 2, 79, 53, 106, 2, 205, 44, 1505, 59, 329, 15, 1223, 140, 15, 59, 1566, 2018, 185, 36, 139, 140, 15, 59, 3, 271, 5, 15, 187, 840, 6809, 4, 326, 7, 54, 513, 236, 734, 50, 56, 2, 4, 83, 7, 54, 208, 452, 31, 497, 3, 118, 10, 380, 213, 2, 269, 33, 53, 19, 13, 31347, 2, 19, 13, 21308, 106, 3, 13324, 33, 269, 16536, 19649, 1449, 8, 991, 219, 1266, 1363, 4, 102, 17539, 2, 41, 5, 840, 6809, 1206, 2297, 1113, 29, 4135, 1528, 3332, 5, 1206, 258, 322, 2444, 6, 3, 334, 38, 228, 1, 46, 7]",1299.0,27134073,Whole-arm translocation der 5 17 p10 q10 concurrent TP53 acute myeloid leukemia AML myelodysplastic syndrome MDS unique molecular-cytogenetic subgroup,11,0.019197207678883072
"High Expression of Human Homologue of Murine Double Minute 4 and the Short SplicingVariant, HDM4-S, in Bone Marrow inPatients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.","Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2016-04-01,"The human homologue of murine double minute 2 (HDM2) and HDM4 negatively regulate p53. HDM4 has not been assessed in acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). We examined the expression of HDM4 and the short splicing variant, HDM4-S, in bone marrow samples obtained from 85 and 23 patients with AMLand MDS, respectively, and 18 negative tumor staging bone marrow samples (used as the control). Immunohistochemical staining showed that HDM4 was overexpressed in 78 AML cases (92%) and 12 MDS cases (52%) compared with 1 stressed bone marrow sample (6%). Quantitative reverse transcriptase-polymerase chain reaction analysis of 8 AML and 11 low-grade (LG)-MDS cases confirmed that HDM4 and HDM4-S mRNA expression were also elevated in all AML cases. HDM4 and HDM4-S mRNA expression was elevated in 3 (27%) and 10 (91%) LG-MDS cases, respectively. HDM4 and HDM4-S mRNA levels were higher in those with AML than in those with LG-MDS. In leukemia cell lines, HEL and U937 predominantly expressed HDM4-S. In contrast, NALM6 expressed HDM4 and HDM4-S. Downregulation of HDM4 expression by treatment with small interfering RNA in NALM6 and HEL cells induced p21 expression but not increased apoptotic activity. Our results indicate that HDM4 is a potential therapeutic target in patients with AML or MDS.",Journal Article,1390.0,3.0,human homologue murine double minute 2 HDM2 HDM4 negatively regulate p53 HDM4 assessed acute myeloid leukemia AML myelodysplastic syndrome MDS examined expression HDM4 short splicing HDM4-S bone marrow obtained 85 23 patients AML MDS respectively 18 negative staging bone marrow control Immunohistochemical staining showed HDM4 overexpressed 78 AML cases 92 12 MDS cases 52 compared 1 stressed bone marrow 6 Quantitative reverse transcriptase-polymerase chain reaction 8 AML 11 low-grade LG -MDS cases confirmed HDM4 HDM4-S mRNA expression elevated AML cases HDM4 HDM4-S mRNA expression elevated 3 27 10 91 LG-MDS cases respectively HDM4 HDM4-S mRNA levels higher AML LG-MDS leukemia lines HEL U937 predominantly expressed HDM4-S contrast NALM6 expressed HDM4 HDM4-S. Downregulation HDM4 expression treatment small interfering RNA NALM6 HEL induced p21 expression increased apoptotic activity indicate HDM4 potential therapeutic target patients AML MDS,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 171, 7907, 1, 1471, 1627, 3949, 18, 11466, 2, 11507, 2723, 2288, 624, 11507, 71, 44, 85, 275, 4, 286, 533, 329, 15, 681, 1223, 21, 409, 3, 55, 1, 11507, 2, 3, 978, 3895, 1142, 11507, 695, 4, 581, 347, 683, 29, 772, 2, 382, 7, 5, 329, 2, 1223, 106, 2, 203, 199, 30, 632, 581, 347, 95, 22, 3, 182, 1382, 1029, 224, 17, 11507, 10, 1711, 4, 833, 329, 140, 937, 2, 133, 1223, 140, 653, 72, 5, 14, 15330, 581, 1000, 49, 1156, 1772, 4456, 1451, 1260, 1329, 65, 1, 66, 329, 2, 175, 154, 88, 12034, 1223, 140, 557, 17, 11507, 2, 11507, 695, 956, 55, 11, 120, 804, 4, 62, 329, 140, 11507, 2, 11507, 695, 956, 55, 10, 804, 4, 27, 428, 2, 79, 970, 12034, 1223, 140, 106, 11507, 2, 11507, 695, 956, 148, 11, 142, 4, 135, 5, 329, 76, 4, 135, 5, 12034, 1223, 4, 31, 285, 23517, 2, 7000, 2117, 570, 11507, 695, 4, 748, 40068, 570, 11507, 2, 11507, 695, 2475, 1, 11507, 55, 20, 24, 5, 302, 3449, 893, 4, 40068, 2, 23517, 37, 277, 2657, 55, 84, 44, 101, 1631, 128, 114, 99, 1008, 17, 11507, 16, 8, 174, 189, 283, 4, 7, 5, 329, 15, 1223]",1229.0,27155969,High Expression Human Homologue Murine Double Minute 4 Short Splicing HDM4-S Bone Marrow Patients Acute Myeloid Leukemia Myelodysplastic Syndrome,0,0.0
Chronic myelomoncytic leukemia: Are we finally solving the identity crisis?,Blood reviews,Blood Rev.,2016-04-25,"Chronic myelomonocytic leukemia (CMML) is a unique disease entity with overlap components of both myelodysplastic syndrome and myeloproliferative neoplasms. CMML is a clonal hematopoietic stem cell neoplasm characterized by monocytosis, cytopenias, and extramedullary manifestations such as splenomegaly. The disease is rare and has undergone revisions in its classification. We review the recent classification strategies as well as diagnostic criteria, focusing on the new insights into the genetic alterations and unique pathophysiology of the disease. We also discuss the latest molecular characterization of the disease, including how molecular factors affect current prognostic models. Finally, we focus on available treatment strategies, with a special emphasis on experimental and forthcoming therapies.",Journal Article,1366.0,3.0,Chronic myelomonocytic leukemia CMML unique disease entity overlap components myelodysplastic syndrome myeloproliferative neoplasms CMML clonal hematopoietic stem neoplasm characterized monocytosis cytopenias extramedullary manifestations splenomegaly disease rare undergone revisions classification review recent classification strategies diagnostic criteria focusing new insights genetic alterations unique pathophysiology disease discuss latest molecular characterization disease including molecular factors affect current prognostic models Finally focus available treatment strategies special emphasis experimental forthcoming therapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 5451, 3382, 16, 8, 991, 34, 2983, 5, 4526, 1628, 1, 110, 681, 2, 1179, 3382, 16, 8, 1946, 1007, 452, 31, 2131, 765, 20, 16875, 5635, 2, 5508, 4282, 225, 22, 6364, 3, 34, 16, 622, 2, 71, 1989, 8935, 4, 211, 947, 21, 206, 3, 435, 947, 422, 22, 149, 22, 752, 371, 3312, 23, 3, 217, 1957, 237, 3, 336, 593, 2, 991, 4320, 1, 3, 34, 21, 120, 1139, 3, 5923, 219, 2136, 1, 3, 34, 141, 832, 219, 130, 1158, 291, 177, 274, 1368, 21, 1222, 23, 390, 24, 422, 5, 8, 3714, 3136, 23, 1560, 2, 16039, 235]",753.0,27162201,Chronic myelomoncytic leukemia finally solving identity crisis,7,0.012216404886561954
Fludarabine-Busulfan Reduced-Intensity Conditioning in Comparison with Fludarabine-Melphalan Is Associated with Increased Relapse Risk In Spite of Pharmacokinetic Dosing.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2016-05-07,"Fludarabine with busulfan (FB) and fludarabine with melphalan (FM) are commonly used reduced-intensity conditioning (RIC) regimens. Pharmacokinetic dosing of busulfan (Bu) is frequently done for myeloablative conditioning, but evidence for its use is limited in RIC transplants. We compared transplant outcomes of FB versus FM using i.v. Bu targeted to the area under the curve (AUC). A total of 134 RIC transplants (47 FB and 87 FM) for acute myelogenous leukemia and myelodysplastic syndrome were identified, and median follow-up of the cohort was 40months (range, 0 to 63.3). A significantly higher 2-year cumulative incidence of relapse (CIR) was associated with FB versus FM at 35.6% versus 17.3%, respectively (P=.0058). Furthermore, 2-year progression-free survival rates were higher for FM versus FB at 60.5% versus 48.7%, respectively (P=.04). However, 2-year rates of nonrelapse mortality (NRM) and overall survival (OS) were similar. The need for dose adjustment based on AUC did not alter relapse risk or NRM. Patients with Karnofsky performance status  90 who received FM had a 2-year OS rate of 74.8% versus 48.3% for FB (P=.03). FB use remained prognostic forrelapse in multivariable analysis (hazard ratio, 2.75; 95% confidence interval, 1.28 to 5.89; P=.0097). Insummary, in spite of AUC-directed dosing, FB compared with FM was associated with a significantly higherCIR.",Comparative Study,1354.0,7.0,Fludarabine busulfan FB fludarabine melphalan FM commonly reduced-intensity conditioning RIC regimens Pharmacokinetic dosing busulfan Bu frequently myeloablative conditioning evidence use limited RIC transplants compared transplant outcomes FB versus FM i.v Bu targeted area curve AUC total 134 RIC transplants 47 FB 87 FM acute myelogenous leukemia myelodysplastic syndrome identified median follow-up cohort 40 months range 0 63.3 significantly higher 2-year cumulative incidence relapse CIR associated FB versus FM 35.6 versus 17.3 respectively P .0058 Furthermore 2-year progression-free survival rates higher FM versus FB 60.5 versus 48.7 respectively P .04 2-year rates nonrelapse mortality NRM overall survival OS similar need dose adjustment based AUC alter relapse risk NRM Patients Karnofsky performance status  90 received FM 2-year OS rate 74.8 versus 48.3 FB P .03 FB use remained prognostic relapse multivariable hazard ratio 2.75 95 confidence interval 1.28 5.89 P .0097 summary spite AUC-directed dosing FB compared FM associated significantly higher CIR,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2027, 5, 3906, 8136, 2, 2027, 5, 2370, 14228, 32, 841, 95, 405, 837, 1933, 3365, 472, 1456, 1280, 1, 3906, 3667, 16, 746, 1822, 9, 3246, 1933, 84, 241, 9, 211, 119, 16, 383, 4, 3365, 4016, 21, 72, 941, 123, 1, 8136, 185, 14228, 75, 70, 603, 3667, 238, 6, 3, 965, 669, 3, 1496, 1376, 8, 181, 1, 4842, 3365, 4016, 662, 8136, 2, 912, 14228, 9, 286, 2194, 2, 681, 11, 108, 2, 52, 166, 126, 1, 3, 180, 10, 327, 53, 184, 13, 6, 676, 27, 8, 97, 142, 18, 111, 967, 287, 1, 429, 6757, 10, 41, 5, 8136, 185, 14228, 28, 465, 49, 185, 269, 27, 106, 19, 21380, 798, 18, 111, 91, 115, 25, 151, 11, 142, 9, 14228, 185, 8136, 28, 335, 33, 185, 576, 67, 106, 19, 755, 137, 18, 111, 151, 1, 4640, 282, 4296, 2, 63, 25, 118, 11, 288, 3, 594, 9, 61, 1852, 90, 23, 1376, 205, 44, 2688, 429, 43, 15, 4296, 7, 5, 2857, 528, 156, 749, 424, 54, 103, 14228, 42, 8, 18, 111, 118, 116, 1, 794, 66, 185, 576, 27, 9, 8136, 19, 680, 8136, 119, 958, 177, 9, 429, 4, 658, 65, 360, 197, 18, 481, 48, 307, 268, 14, 339, 6, 33, 887, 19, 28314, 4, 1962, 4, 9018, 1, 1376, 1166, 1280, 8136, 72, 5, 14228, 10, 41, 5, 8, 97, 142, 6757]",1308.0,27164061,Fludarabine-Busulfan Reduced-Intensity Conditioning Comparison Fludarabine-Melphalan Associated Increased Relapse Risk Spite Pharmacokinetic Dosing,0,0.0
Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC).,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2016-04-27,"Although multiple predispositions to hematologic malignancies exist, evaluations for hereditary cancer syndromes (HCS) are underperformed by most hematologist/oncologists. Criteria for initiating HCS evaluation are poorly defined, and results of genetic testing for hereditary hematologic malignancies have not been systematically reported. From April 2014 to August 2015, 67 patients were referred to the Hereditary Hematologic Malignancy Clinic (HHMC). Referral reasons included (1) bone marrow failure or myelodysplastic syndrome in patients 50 years, (2) evaluation for germ-line inheritance of identified RUNX1, GATA2, or CEBPA mutations on targeted next-generation sequencing panels, and (3) strong personal and/or family history of malignancy. Cultured skin fibroblasts were utilized for germ-line DNA in all patients with hematologic malignancy. Eight patients (12%) were clinically diagnosed with a HCS: 4 patients with RUNX1-related familial platelet disorder (FPD)/acute myeloid leukemia (AML), and 1 patient each with dyskeratosis congenita, Fanconi anemia, germ-line DDX41, and Li-Fraumeni syndrome (LFS). Two patients with concern for FPD/AML and LFS, respectively, had RUNX1 and TP53 variants of unknown significance. Additionally, 4 patients with prior HCS diagnosis (1 LFS, 3 FPD/AML) were referred for further evaluation and surveillance. In this HHMC-referred hematologic malignancy cohort, HCS was confirmed in 12 patients (18%). HCS identification provides insight for improved and individualized treatment, as well as screening/surveillance opportunities for family members. The HHMC has facilitated HCS diagnosis; with increased clinical awareness of hematologic malignancy predisposition syndromes, more patients who may benefit from evaluation can be identified. Mutation panels intended for prognostication may provide increased clinical suspicion for germ-line testing.",Journal Article,1364.0,34.0,multiple predispositions hematologic malignancies exist evaluations hereditary syndromes HCS underperformed hematologist/oncologists Criteria initiating HCS evaluation poorly defined genetic testing hereditary hematologic malignancies systematically reported April 2014 August 2015 67 patients referred Hereditary Hematologic Malignancy Clinic HHMC Referral reasons included 1 bone marrow failure myelodysplastic syndrome patients  50 years 2 evaluation germ-line inheritance identified RUNX1 GATA2 CEBPA targeted next-generation sequencing panels 3 strong personal and/or family history malignancy Cultured skin fibroblasts utilized germ-line DNA patients hematologic malignancy patients 12 clinically diagnosed HCS 4 patients RUNX1-related familial platelet disorder FPD /acute myeloid leukemia AML 1 patient dyskeratosis congenita Fanconi anemia germ-line DDX41 Li-Fraumeni syndrome LFS patients concern FPD/AML LFS respectively RUNX1 TP53 unknown significance Additionally 4 patients prior HCS diagnosis 1 LFS 3 FPD/AML referred evaluation surveillance HHMC-referred hematologic malignancy cohort HCS confirmed 12 patients 18 HCS identification provides insight improved individualized treatment screening/surveillance opportunities family members HHMC facilitated HCS diagnosis increased clinical awareness hematologic malignancy predisposition syndromes patients benefit evaluation identified panels intended prognostication provide increased clinical suspicion germ-line testing,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[242, 232, 19697, 6, 813, 441, 1923, 3816, 9, 2305, 12, 2040, 21799, 32, 39095, 20, 96, 15278, 1339, 371, 9, 2637, 21799, 451, 32, 1240, 395, 2, 99, 1, 336, 471, 9, 2305, 813, 441, 47, 44, 85, 3390, 210, 29, 2292, 1409, 6, 2480, 1483, 598, 7, 11, 1995, 6, 3, 2305, 813, 710, 1188, 41445, 2096, 2325, 159, 14, 581, 496, 15, 681, 4, 7, 1552, 212, 60, 18, 451, 9, 2280, 328, 10070, 1, 108, 6092, 12909, 15, 7667, 138, 23, 238, 1305, 914, 615, 4383, 2, 27, 1082, 3008, 2, 15, 607, 532, 1, 710, 3197, 3921, 11, 2080, 9, 2280, 328, 261, 4, 62, 7, 5, 813, 710, 659, 7, 133, 11, 505, 265, 5, 8, 21799, 39, 7, 5, 6092, 139, 2200, 1596, 2645, 25366, 286, 533, 329, 2, 14, 69, 296, 5, 27182, 35908, 8057, 1545, 2280, 328, 16588, 2, 5066, 9130, 681, 5674, 100, 7, 5, 2893, 9, 25366, 329, 2, 5674, 106, 42, 6092, 2, 1206, 839, 1, 860, 724, 1724, 39, 7, 5, 324, 21799, 147, 14, 5674, 27, 25366, 329, 11, 1995, 9, 195, 451, 2, 617, 4, 26, 41445, 1995, 813, 710, 180, 21799, 10, 557, 4, 133, 7, 203, 21799, 911, 777, 2670, 9, 231, 2, 2596, 24, 22, 149, 22, 453, 617, 2605, 9, 607, 1684, 3, 41445, 71, 4667, 21799, 147, 5, 101, 38, 3310, 1, 813, 710, 2863, 2040, 80, 7, 54, 68, 247, 29, 451, 122, 40, 108, 258, 4383, 4081, 9, 4260, 68, 377, 101, 38, 5782, 9, 2280, 328, 471]",1808.0,27210295,Evaluation Patients Families Concern Predispositions Hematologic Malignancies Hereditary Hematologic Malignancy Clinic HHMC,0,0.0
Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.,Cancer research,Cancer Res.,2016-06-10,"Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) suppress normal hematopoietic activity in part by enabling a pathogenic inflammatory milieu in the bone marrow. In this report, we show that elevation of angiopoietin-1 in myelodysplastic CD34(+) stem-like cells is associated with higher risk disease and reduced overall survival in MDS and AML patients. Increased angiopoietin-1 expression was associated with a transcriptomic signature similar to known MDS/AML stem-like cell profiles. In seeking a small-molecule inhibitor of this pathway, we discovered and validated pexmetinib (ARRY-614), an inhibitor of the angiopoietin-1 receptor Tie-2, which was also found to inhibit the proinflammatory kinase p38 MAPK (which is overactivated in MDS). Pexmetinib inhibited leukemic proliferation, prevented activation of downstream effector kinases, and abrogated the effects of TNF on healthy hematopoietic stem cells. Notably, treatment of primary MDS specimens with this compound stimulated hematopoiesis. Our results provide preclinical proof of concept for pexmetinib as a Tie-2/p38 MAPK dual inhibitor applicable to the treatment of MDS/AML. Cancer Res; 76(16); 4841-9. 2016 AACR.",Journal Article,1320.0,14.0,Myelodysplastic syndromes MDS acute myeloid leukemia AML suppress normal hematopoietic activity enabling pathogenic inflammatory milieu bone marrow report elevation angiopoietin-1 myelodysplastic CD34 stem-like associated higher risk disease reduced overall survival MDS AML patients Increased angiopoietin-1 expression associated transcriptomic signature similar known MDS/AML stem-like profiles seeking small-molecule inhibitor pathway discovered validated pexmetinib ARRY-614 inhibitor angiopoietin-1 receptor Tie-2 inhibit proinflammatory kinase p38 MAPK overactivated MDS Pexmetinib inhibited leukemic proliferation prevented activation downstream effector kinases abrogated effects TNF healthy hematopoietic stem Notably treatment primary MDS specimens compound stimulated hematopoiesis provide preclinical proof concept pexmetinib Tie-2/p38 MAPK dual inhibitor applicable treatment MDS/AML Res 76 16 4841-9 2016 AACR,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2040, 1223, 2, 286, 533, 329, 3134, 295, 1007, 128, 4, 760, 20, 5257, 8, 2806, 1291, 6795, 4, 3, 581, 4, 26, 414, 21, 514, 17, 3292, 1, 7898, 14, 4, 2215, 452, 733, 37, 16, 41, 5, 142, 43, 34, 2, 405, 63, 25, 4, 1223, 2, 329, 7, 101, 7898, 14, 55, 10, 41, 5, 8, 5983, 1651, 288, 6, 440, 1223, 329, 452, 733, 31, 1241, 4, 5734, 8, 302, 1354, 230, 1, 26, 308, 21, 2747, 2, 938, 41465, 13412, 13928, 35, 230, 1, 3, 7898, 14, 153, 10793, 18, 92, 10, 120, 204, 6, 1433, 3, 5767, 216, 3970, 1748, 92, 16, 31955, 4, 1223, 41465, 879, 2015, 457, 3902, 363, 1, 1489, 2070, 1549, 2, 3728, 3, 176, 1, 8713, 23, 1331, 1007, 452, 37, 2552, 24, 1, 86, 1223, 623, 5, 26, 2823, 2816, 5114, 114, 99, 377, 693, 3840, 1, 2545, 9, 41465, 22, 8, 10793, 18, 3970, 1748, 1828, 230, 3801, 6, 3, 24, 1, 1223, 329, 12, 1936, 846, 245, 68392, 83, 3456, 1630]",1121.0,27287719,Pexmetinib Novel Dual Inhibitor Tie2 p38 MAPK Efficacy Preclinical Models Myelodysplastic Syndromes Acute Myeloid Leukemia,15,0.02617801047120419
Time-dependent changes in mortality and transformation risk in MDS.,Blood,Blood,2016-06-22,"In myelodysplastic syndromes (MDSs), the evolution of risk for disease progression or death has not been systematically investigated despite being crucial for correct interpretation of prognostic risk scores. In a multicenter retrospective study, we described changes in risk over time, the consequences for basal prognostic scores, and their potential clinical implications. Major MDS prognostic risk scoring systems and their constituent individual predictors were analyzed in 7212 primary untreated MDS patients from the International Working Group for Prognosis in MDS database. Changes in risk of mortality and of leukemic transformation over time from diagnosis were described. Hazards regarding mortality and acute myeloid leukemia transformation diminished over time from diagnosis in higher-risk MDS patients, whereas they remained stable in lower-risk patients. After approximately 3.5 years, hazards in the separate risk groups became similar and were essentially equivalent after 5 years. This fact led to loss of prognostic power of different scoring systems considered, which was more pronounced for survival. Inclusion of age resulted in increased initial prognostic power for survival and less attenuation in hazards. If needed for practicability in clinical management, the differing development of risks suggested a reasonable division into lower- and higher-risk MDS based on the IPSS-R at a cutoff of 3.5 points. Our data regarding time-dependent performance of prognostic scores reflect the disparate change of risks in MDS subpopulations. Lower-risk patients at diagnosis remain lower risk whereas initially high-risk patients demonstrate decreasing risk over time. This change of risk should be considered in clinical decision making.",Journal Article,1308.0,46.0,myelodysplastic syndromes MDSs evolution risk disease progression death systematically investigated despite crucial correct interpretation prognostic risk scores multicenter retrospective described changes risk time consequences basal prognostic scores potential clinical implications Major MDS prognostic risk scoring systems constituent individual predictors 7212 primary untreated MDS patients International Working Group Prognosis MDS database Changes risk mortality leukemic transformation time diagnosis described Hazards mortality acute myeloid leukemia transformation diminished time diagnosis higher-risk MDS patients remained stable lower-risk patients approximately 3.5 years hazards separate risk groups similar essentially equivalent 5 years fact led loss prognostic power different scoring systems considered pronounced survival Inclusion age resulted increased initial prognostic power survival attenuation hazards needed practicability clinical management differing development risks suggested reasonable division lower- higher-risk MDS based IPSS-R cutoff 3.5 points time-dependent performance prognostic scores reflect disparate change risks MDS subpopulations Lower-risk patients diagnosis remain lower risk initially high-risk patients demonstrate decreasing risk time change risk considered clinical decision making,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 2040, 13550, 3, 2554, 1, 43, 9, 34, 91, 15, 273, 71, 44, 85, 3390, 565, 550, 486, 2653, 9, 4883, 3037, 1, 177, 43, 703, 4, 8, 1570, 459, 45, 21, 1027, 400, 4, 43, 252, 98, 3, 3255, 9, 2135, 177, 703, 2, 136, 174, 38, 1268, 458, 1223, 177, 43, 2504, 1530, 2, 136, 13832, 797, 674, 11, 311, 4, 68461, 86, 1278, 1223, 7, 29, 3, 944, 2644, 87, 9, 356, 4, 1223, 609, 400, 4, 43, 1, 282, 2, 1, 2015, 1392, 252, 98, 29, 147, 11, 1027, 1017, 666, 282, 2, 286, 533, 1392, 2849, 252, 98, 29, 147, 4, 142, 43, 1223, 7, 547, 491, 958, 585, 4, 280, 43, 7, 50, 705, 27, 33, 60, 1017, 4, 3, 2282, 43, 271, 3451, 288, 2, 11, 7257, 2017, 50, 33, 60, 26, 1991, 836, 6, 407, 1, 177, 2349, 1, 338, 2504, 1530, 515, 92, 10, 80, 3517, 9, 25, 1680, 1, 89, 627, 4, 101, 388, 177, 2349, 9, 25, 2, 299, 5349, 4, 1017, 492, 575, 9, 68462, 4, 38, 284, 3, 5276, 193, 1, 1098, 1148, 8, 3203, 5750, 237, 280, 2, 142, 43, 1223, 90, 23, 3, 8751, 668, 28, 8, 2779, 1, 27, 33, 862, 114, 74, 666, 98, 470, 528, 1, 177, 703, 2694, 3, 7985, 707, 1, 1098, 4, 1223, 4847, 280, 43, 7, 28, 147, 918, 280, 43, 547, 1625, 64, 43, 7, 608, 2777, 43, 252, 98, 26, 707, 1, 43, 257, 40, 515, 4, 38, 948, 1079]",1710.0,27335276,Time-dependent changes mortality transformation risk MDS,2,0.0034904013961605585
Long-Term Outcomes after Treatment with ClofarabineFludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2016-07-01,"Pretransplant conditioning regimens critically determine outcomes in the setting of allogeneic stem cell transplantation (allo-SCT). The use of nucleoside analogs such as fludarabine (Flu) in combination with i.v. busulfan (Bu) has been shown to be highly effective as a pretransplant conditioning regimen in acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS). Because leukemia relapse remains the leading cause of death after allo-SCT, we studied whether clofarabine (Clo), a nucleoside analog with potent antileukemia activity, can be used to complement Flu. In a preliminary report, we previously showed the safety and efficacy of CloFlu with i.v. Bu in 51 patients with high-risk AML, CML, and MDS. The study has now been completed, and we present long-term follow-up data on the entire 70-patient population, which included 49 (70%), 8 (11%), and 13 (19%) patients with AML, MDS, and CML, respectively. Thirteen patients (19%) were in complete remission, and 41 patients (59%) received matched unrelated donor grafts. Engraftment was achieved in all patients. Sixty-three patients (90%) achieved complete remission. There were no deaths reported at day +30, and the 100-day nonrelapse mortality rate was 4% (n=3). Thirty-one percent of patients (n=22) developed grades II to IV acute graft-versus-host disease, and the median overall survival and progression-free survival times were 2.4 years and .9 years, respectively. Our results confirm the safety and overall and progression-free survival advantage of the arms with higher Clo doses and lower Flu doses, which was most prominent in the AML/MDS group.",Journal Article,1299.0,6.0,Pretransplant conditioning regimens critically determine outcomes setting allogeneic stem transplantation allo-SCT use nucleoside analogs fludarabine Flu combination i.v busulfan Bu shown highly effective pretransplant conditioning regimen acute myeloid leukemia AML chronic myeloid leukemia CML myelodysplastic syndrome MDS leukemia relapse remains leading cause death allo-SCT studied clofarabine Clo nucleoside analog potent antileukemia activity complement Flu preliminary report previously showed safety efficacy Clo  Flu i.v Bu 51 patients high-risk AML CML MDS completed present long-term follow-up entire 70-patient population included 49 70 8 11 13 19 patients AML MDS CML respectively Thirteen patients 19 complete remission 41 patients 59 received matched unrelated donor grafts Engraftment achieved patients Sixty-three patients 90 achieved complete remission deaths reported day +30 100-day nonrelapse mortality rate 4 n 3 Thirty-one percent patients n 22 developed grades II IV acute graft-versus-host disease median overall survival progression-free survival times 2.4 years .9 years respectively confirm safety overall progression-free survival advantage arms higher Clo doses lower Flu doses prominent AML/MDS group,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7763, 1933, 472, 4331, 223, 123, 4, 3, 546, 1, 1063, 452, 31, 497, 2564, 1988, 3, 119, 1, 4032, 4063, 225, 22, 2027, 5119, 4, 150, 5, 70, 603, 3906, 3667, 71, 85, 443, 6, 40, 561, 323, 22, 8, 7763, 1933, 477, 4, 286, 533, 329, 442, 533, 903, 2, 681, 1223, 408, 429, 469, 3, 1049, 708, 1, 273, 50, 2564, 1988, 21, 656, 317, 4149, 7676, 8, 4032, 3497, 5, 1157, 9169, 128, 122, 40, 95, 6, 3731, 5119, 4, 8, 1676, 414, 21, 373, 224, 3, 367, 2, 209, 1, 7676, 810, 5119, 5, 70, 603, 3667, 4, 725, 7, 5, 64, 43, 329, 903, 2, 1223, 3, 45, 71, 1134, 85, 781, 2, 21, 364, 319, 337, 166, 126, 74, 23, 3, 1797, 431, 69, 266, 92, 159, 739, 431, 66, 175, 2, 233, 326, 7, 5, 329, 1223, 2, 903, 106, 3170, 7, 326, 11, 4, 236, 734, 2, 605, 7, 728, 103, 655, 2092, 1488, 4713, 2881, 10, 513, 4, 62, 7, 1746, 169, 7, 424, 513, 236, 734, 125, 11, 77, 1043, 210, 28, 218, 201, 2, 3, 394, 218, 4640, 282, 116, 10, 39, 78, 27, 977, 104, 714, 1, 7, 78, 350, 276, 2276, 215, 6, 478, 286, 1599, 185, 1204, 34, 2, 3, 52, 63, 25, 2, 91, 115, 25, 1072, 11, 18, 39, 60, 2, 83, 60, 106, 114, 99, 1843, 3, 367, 2, 63, 2, 91, 115, 25, 1874, 1, 3, 1335, 5, 142, 7676, 415, 2, 280, 5119, 415, 92, 10, 96, 3689, 4, 3, 329, 1223, 87]",1547.0,27377901,Long-Term Outcomes Treatment Clofarabine  Fludarabine Once-Daily Intravenous Busulfan Pretransplant Conditioning Therapy Advanced Myeloid Leukemia Myelodysplastic Syndrome,2,0.0034904013961605585
Ipilimumab for Patients with Relapse after Allogeneic Transplantation.,The New England journal of medicine,N. Engl. J. Med.,2016-07-01,"Loss of donor-mediated immune antitumor activity after allogeneic hematopoietic stem-cell transplantation (HSCT) permits relapse of hematologic cancers. We hypothesized that immune checkpoint blockade established by targeting cytotoxic T-lymphocyte-associated protein 4 with ipilimumab could restore antitumor reactivity through a graft-versus-tumor effect. We conducted a phase 1/1b multicenter, investigator-initiated study to determine the safety and efficacy of ipilimumab in patients with relapsed hematologic cancer after allogeneic HSCT. Patients received induction therapy with ipilimumab at a dose of 3 or 10 mg per kilogram of body weight every 3 weeks for a total of 4 doses, with additional doses every 12 weeks for up to 60 weeks in patients who had a clinical benefit. A total of 28 patients were enrolled. Immune-related adverse events, including one death, were observed in 6 patients (21%), and graft-versus-host disease (GVHD) that precluded further administration of ipilimumab was observed in 4 patients (14%). No responses that met formal response criteria occurred in patients who received a dose of 3 mg per kilogram. Among 22 patients who received a dose of 10 mg per kilogram, 5 (23%) had a complete response, 2 (9%) had a partial response, and 6 (27%) had decreased tumor burden. Complete responses occurred in 4 patients with extramedullary acute myeloid leukemia and 1 patient with the myelodysplastic syndrome developing into acute myeloid leukemia. Four patients had a durable response for more than 1 year. Responses were associated with in situ infiltration of cytotoxic CD8+ T cells, decreased activation of regulatory T cells, and expansion of subpopulations of effector T cells in the blood. Our early-phase data showed that administration of ipilimumab was feasible in patients with recurrent hematologic cancers after allogeneic HSCT, although immune-mediated toxic effects and GVHD occurred. Durable responses were observed in association with several histologic subtypes of these cancers, including extramedullary acute myeloid leukemia. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT01822509.).","Clinical Trial, Phase I",1299.0,190.0,Loss donor-mediated immune antitumor activity allogeneic hematopoietic stem-cell transplantation HSCT permits relapse hematologic hypothesized immune checkpoint blockade established targeting cytotoxic T-lymphocyte-associated 4 ipilimumab restore antitumor reactivity graft-versus-tumor effect conducted phase 1/1b multicenter investigator-initiated determine safety efficacy ipilimumab patients relapsed hematologic allogeneic HSCT Patients received induction therapy ipilimumab dose 3 10 mg kilogram body weight 3 weeks total 4 doses additional doses 12 weeks 60 weeks patients clinical benefit total 28 patients enrolled Immune-related adverse events including death observed 6 patients 21 graft-versus-host disease GVHD precluded administration ipilimumab observed 4 patients 14 responses met formal response criteria occurred patients received dose 3 mg kilogram 22 patients received dose 10 mg kilogram 5 23 complete response 2 9 partial response 6 27 decreased burden Complete responses occurred 4 patients extramedullary acute myeloid leukemia 1 patient myelodysplastic syndrome developing acute myeloid leukemia patients durable response 1 year Responses associated situ infiltration cytotoxic CD8+ decreased activation regulatory expansion subpopulations effector blood early-phase showed administration ipilimumab feasible patients recurrent hematologic allogeneic HSCT immune-mediated toxic effects GVHD occurred Durable responses observed association histologic subtypes including extramedullary acute myeloid leukemia Funded National Institutes Health ClinicalTrials.gov number NCT01822509,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[407, 1, 1488, 517, 250, 579, 128, 50, 1063, 1007, 452, 31, 497, 1703, 8504, 429, 1, 813, 163, 21, 1237, 17, 250, 986, 1189, 635, 20, 529, 759, 102, 1448, 41, 178, 39, 5, 1306, 359, 6075, 579, 4601, 298, 8, 1599, 185, 30, 254, 21, 426, 8, 124, 14, 4693, 1570, 3464, 1917, 45, 6, 223, 3, 367, 2, 209, 1, 1306, 4, 7, 5, 591, 813, 12, 50, 1063, 1703, 7, 103, 504, 36, 5, 1306, 28, 8, 61, 1, 27, 15, 79, 81, 379, 6543, 1, 642, 924, 454, 27, 244, 9, 8, 181, 1, 39, 415, 5, 402, 415, 454, 133, 244, 9, 126, 6, 335, 244, 4, 7, 54, 42, 8, 38, 247, 8, 181, 1, 339, 7, 11, 346, 250, 139, 290, 281, 141, 104, 273, 11, 164, 4, 49, 7, 239, 2, 1599, 185, 1204, 34, 1562, 17, 8035, 195, 634, 1, 1306, 10, 164, 4, 39, 7, 213, 77, 253, 17, 543, 5057, 51, 371, 489, 4, 7, 54, 103, 8, 61, 1, 27, 81, 379, 6543, 107, 350, 7, 54, 103, 8, 61, 1, 79, 81, 379, 6543, 33, 382, 42, 8, 236, 51, 18, 83, 42, 8, 450, 51, 2, 49, 428, 42, 340, 30, 892, 236, 253, 489, 4, 39, 7, 5, 5508, 286, 533, 2, 14, 69, 5, 3, 681, 931, 237, 286, 533, 294, 7, 42, 8, 1480, 51, 9, 80, 76, 14, 111, 253, 11, 41, 5, 4, 957, 2084, 1, 759, 968, 102, 37, 340, 363, 1, 1253, 102, 37, 2, 1422, 1, 4847, 1, 2070, 102, 37, 4, 3, 315, 114, 191, 124, 74, 224, 17, 634, 1, 1306, 10, 1313, 4, 7, 5, 387, 813, 163, 50, 1063, 1703, 242, 250, 517, 1812, 176, 2, 1562, 489, 1480, 253, 11, 164, 4, 248, 5, 392, 884, 814, 1, 46, 163, 141, 5508, 286, 533, 3827, 20, 3, 657, 5973, 1, 341, 2, 1749, 1252, 1239, 207, 68578]",2082.0,27410923,Ipilimumab Patients Relapse Allogeneic Transplantation,5,0.008726003490401396
Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.,"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",Mod. Pathol.,2016-07-15,"In acute erythroleukemia, erythroid/myeloid subtype, blasts usually comprise 5-19% of total bone marrow cells, similar to the myelodysplastic syndrome subtype refractory anemia with excess blasts; recent studies have raised the question if acute erythroleukemia should be considered as a myelodysplastic syndrome subtype. We reviewed 77 de novo acute erythroleukemia and 279 de novo refractory anemia with excess blasts from three large medical centers. Compared to refractory anemia with excess blasts, acute erythroleukemia patients had higher total bone marrow blasts, lower platelets, hemoglobin, and absolute neutrophil counts, with more patients being assigned a very-poor-karyotype risk and very-high Revised International Prognostic Scoring System score. Induction chemotherapy was administered to 55% of acute erythroleukemia patients, but was not associated with longer overall survival compared to acute erythroleukemia patients treated with lower-intensity therapies or supportive care (P=0.44). In multivariable analysis of all patients, Revised International Prognostic Scoring System very high (P<0.0001) or high (P=0.005) risk, but not a diagnosis of acute erythroleukemia (P=0.30), were independent risk factors for shorter overall survival. Our data show that acute erythroleukemia patients have similar risk-adjusted outcome to refractory anemia with excess blasts patients and do not appear to gain survival advantage with acute myeloid leukemia-type induction chemotherapy. These data suggest that acute erythroleukemia, erythroid/myeloid subtype with <20% blasts may be more appropriately classified as refractory anemia with excess blasts rather than as an acute myeloid leukemia subtype.",Journal Article,1285.0,16.0,acute erythroleukemia erythroid/myeloid subtype blasts usually comprise 5-19 total bone marrow similar myelodysplastic syndrome subtype refractory anemia excess blasts recent studies raised question acute erythroleukemia considered myelodysplastic syndrome subtype reviewed 77 novo acute erythroleukemia 279 novo refractory anemia excess blasts large medical centers Compared refractory anemia excess blasts acute erythroleukemia patients higher total bone marrow blasts lower platelets hemoglobin absolute neutrophil counts patients assigned very-poor-karyotype risk very-high Revised International Prognostic Scoring score Induction chemotherapy administered 55 acute erythroleukemia patients associated longer overall survival compared acute erythroleukemia patients treated lower-intensity therapies supportive care P=0.44 multivariable patients Revised International Prognostic Scoring high P 0.0001 high P=0.005 risk diagnosis acute erythroleukemia P=0.30 independent risk factors shorter overall survival acute erythroleukemia patients similar risk-adjusted outcome refractory anemia excess blasts patients appear gain survival advantage acute myeloid leukemia-type induction chemotherapy suggest acute erythroleukemia erythroid/myeloid subtype 20 blasts appropriately classified refractory anemia excess blasts acute myeloid leukemia subtype,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 286, 14661, 7839, 533, 875, 2438, 2082, 5238, 33, 326, 1, 181, 581, 37, 288, 6, 3, 681, 875, 430, 1545, 5, 2612, 2438, 435, 94, 47, 5673, 3, 2840, 492, 286, 14661, 257, 40, 515, 22, 8, 681, 875, 21, 446, 849, 1566, 2018, 286, 14661, 2, 8562, 1566, 2018, 430, 1545, 5, 2612, 2438, 29, 169, 375, 484, 1168, 72, 6, 430, 1545, 5, 2612, 2438, 286, 14661, 7, 42, 142, 181, 581, 2438, 280, 4407, 2222, 2, 1766, 2595, 1911, 5, 80, 7, 486, 896, 8, 923, 334, 3385, 43, 2, 923, 64, 4218, 944, 177, 2504, 398, 368, 504, 56, 10, 468, 6, 614, 1, 286, 14661, 7, 84, 10, 44, 41, 5, 589, 63, 25, 72, 6, 286, 14661, 7, 73, 5, 280, 837, 235, 15, 1877, 165, 19, 13, 584, 4, 658, 65, 1, 62, 7, 4218, 944, 177, 2504, 398, 923, 64, 19, 13, 488, 15, 64, 19, 13, 1614, 43, 84, 44, 8, 147, 1, 286, 14661, 19, 13, 201, 11, 306, 43, 130, 9, 985, 63, 25, 114, 74, 514, 17, 286, 14661, 7, 47, 288, 43, 586, 228, 6, 430, 1545, 5, 2612, 2438, 7, 2, 1022, 44, 1322, 6, 1803, 25, 1874, 5, 286, 533, 2647, 267, 504, 56, 46, 74, 309, 17, 286, 14661, 7839, 533, 875, 5, 179, 2438, 68, 40, 80, 4544, 1373, 22, 430, 1545, 5, 2612, 2438, 1832, 76, 22, 35, 286, 533, 875]",1627.0,27443511,Acute erythroid leukemia 20 bone marrow blasts clinically biologically similar myelodysplastic syndrome excess blasts,0,0.0
Targeting Splicing in the Treatment of Myelodysplastic Syndromes and Other Myeloid Neoplasms.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2016-12-01,"Genome sequencing of primary cells from patients with myelodysplastic syndromes (MDS) led to the identification of recurrent heterozygous mutations in gene encoding components of the spliceosome, the cellular machinery which processes pre-messenger RNA (mRNA) to mature mRNA during gene transcription. Splicing mutations are mutually exclusive with one another and collectively represent the most common mutation class in MDS, occurring in approximately 60% of patients overall and more than 80% of those with ring sideroblasts. Evidence from animal models suggests that homozygous splicing mutations are lethal, and that in heterozygously mutated models, any further disruption of splicing triggers apoptosis and cell death. MDS cells with spliceosome mutations are thus uniquely vulnerable to therapies targeting splicing, which may be tolerated by healthy cells. The spliceosome is emerging as a novel therapeutic target in MDS and related myeloid neoplasms, with the first clinical trial of a splicing modulator opening in 2016.",Journal Article,1146.0,8.0,Genome sequencing primary patients myelodysplastic syndromes MDS led identification recurrent heterozygous encoding components spliceosome cellular machinery processes pre-messenger RNA mRNA mature mRNA transcription Splicing mutually exclusive collectively represent common class MDS occurring approximately 60 patients overall 80 ring sideroblasts Evidence animal models suggests homozygous splicing lethal heterozygously models disruption splicing triggers apoptosis death MDS spliceosome uniquely vulnerable therapies targeting splicing tolerated healthy spliceosome emerging novel therapeutic target MDS related myeloid neoplasms clinical trial splicing modulator opening 2016,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[898, 615, 1, 86, 37, 29, 7, 5, 2040, 1223, 836, 6, 3, 911, 1, 387, 4167, 138, 4, 145, 2362, 1628, 1, 3, 13443, 3, 763, 6415, 92, 1849, 671, 5992, 893, 956, 6, 2908, 956, 190, 145, 866, 3895, 138, 32, 5575, 4804, 5, 104, 1809, 2, 2535, 1231, 3, 96, 186, 258, 1040, 4, 1223, 1821, 4, 705, 335, 1, 7, 63, 2, 80, 76, 493, 1, 135, 5, 4091, 23740, 241, 29, 2026, 274, 844, 17, 3189, 3895, 138, 32, 2266, 2, 17, 4, 49933, 1185, 274, 500, 195, 3220, 1, 3895, 5951, 351, 2, 31, 273, 1223, 37, 5, 13443, 138, 32, 631, 7089, 5017, 6, 235, 529, 3895, 92, 68, 40, 421, 20, 1331, 37, 3, 13443, 16, 1478, 22, 8, 229, 189, 283, 4, 1223, 2, 139, 533, 1179, 5, 3, 157, 38, 160, 1, 8, 3895, 6318, 11677, 4, 1390]",999.0,27492253,Targeting Splicing Treatment Myelodysplastic Syndromes Myeloid Neoplasms,182,0.31762652705061084
Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2016-08-04,"Analysis of the clinical characteristics of hematopoietic stem cell transplant (HSCT) donors has proven beneficial for identifying cases of heritable hematopoietic disorders. This study examines poor peripheral blood hematopoietic stem cell mobilization after granulocyte colony-stimulating factor administration among 328 donors as a potential marker for suspected familial predisposition to myeloid malignancies. Here, we present data comparing the clinical characteristics of poor-mobilizing versus nonpoor-mobilizing donors and the results of panel-based sequencing of hematopoietic genes in poor-mobilizing donors. From this analysis, we identified a novel case of a donor-derived myelodysplastic syndrome in an HSCT recipient that is consistent with clonal evolution of TET2-mutated clonal hematopoiesis of indeterminate potential (CHIP) within the donor. This study demonstrates the potential risk of using hematopoietic stem cells from a donor with CHIP and raises the question of whether there should be increased screening measures to identify such donors.",Journal Article,1265.0,13.0,clinical characteristics hematopoietic stem transplant HSCT donors proven beneficial identifying cases heritable hematopoietic disorders examines poor peripheral blood hematopoietic stem mobilization granulocyte colony-stimulating factor administration 328 donors potential marker suspected familial predisposition myeloid malignancies present comparing clinical characteristics poor-mobilizing versus nonpoor-mobilizing donors panel-based sequencing hematopoietic poor-mobilizing donors identified novel case donor-derived myelodysplastic syndrome HSCT recipient consistent clonal evolution TET2-mutated clonal hematopoiesis indeterminate potential CHIP donor demonstrates potential risk hematopoietic stem donor CHIP raises question increased screening measures identify donors,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[65, 1, 3, 38, 374, 1, 1007, 452, 31, 941, 1703, 2344, 71, 1930, 2524, 9, 1386, 140, 1, 6874, 1007, 1997, 26, 45, 4468, 334, 672, 315, 1007, 452, 31, 4030, 50, 2764, 1975, 2122, 161, 634, 107, 8584, 2344, 22, 8, 174, 952, 9, 2768, 2200, 2863, 6, 533, 441, 467, 21, 364, 74, 1430, 3, 38, 374, 1, 334, 17631, 185, 49937, 17631, 2344, 2, 3, 99, 1, 993, 90, 615, 1, 1007, 214, 4, 334, 17631, 2344, 29, 26, 65, 21, 108, 8, 229, 473, 1, 8, 1488, 526, 681, 4, 35, 1703, 5783, 17, 16, 925, 5, 1946, 2554, 1, 5038, 1185, 1946, 5114, 1, 5167, 174, 4222, 262, 3, 1488, 26, 45, 1902, 3, 174, 43, 1, 75, 1007, 452, 37, 29, 8, 1488, 5, 4222, 2, 5789, 3, 2840, 1, 317, 125, 257, 40, 101, 453, 1018, 6, 255, 225, 2344]",1039.0,27497531,Identifying Inherited Acquired Genetic Factors Involved Poor Stem Mobilization Donor-Derived Malignancy,5,0.008726003490401396
"Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination With Fludarabine and Cytarabine, in Pediatric Relapsed or Refractory Acute Leukemia.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2016-10-31,"Purpose To characterize the toxicity, pharmacokinetics, and pharmacodynamics of selinexor, a selective inhibitor of nuclear export, when combined with fludarabine and cytarabine, in children with relapsed or refractory leukemia. Patients and Methods Eighteen patients with relapsed or refractory acute leukemia were enrolled in the SELHEM (Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome) clinical trial (NCT02212561). Selinexor, initially at 30 mg/m<sup>2</sup> per dose, was given orally on days 1, 3, 8, 10, 22, and 24 and was escalated according to a rolling-six design. Fludarabine 30 mg/m<sup>2</sup> and cytarabine 2 g/m<sup>2</sup> were administered on days 15 to 19. Pharmacokinetic and pharmacodynamic studies were performed on days 1 and 22. Response evaluations were performed on day 15 and at the completion of course 1. Results Among the 17 patients who were evaluable for toxicity, three were treated at 30 mg/m<sup>2</sup>, three at 40 mg/m<sup>2</sup>, six at 55 mg/m<sup>2</sup>, and five at 70 mg/m<sup>2</sup>. The most common grade 3 nonhematologic toxicity was asymptomatic hyponatremia. Two patients who were treated at 70 mg/m<sup>2</sup> experienced reversible cerebellar toxicity, thereby defining the dose-limiting toxicity. Pharmacokinetic parameters demonstrated that plasma exposure was dose proportional. Fifteen of 16 patients demonstrated at least a twofold increase of XPO1 mRNA, indicating inhibition of the XPO1 protein. In this group of heavily pretreated, relapsed, and refractory patients, seven of 15 evaluable patients (47%) achieved complete response or complete response with incomplete count recovery. Conclusion Selinexor, in combination with fludarabine and cytarabine, is tolerable at doses up to 55 mg/m<sup>2</sup> in pediatric patients with relapsed or refractory leukemia. All patients who received selinexor at  40 mg/m<sup>2</sup> demonstrated XPO1 target inhibition. Response rates are promising and will be further explored in a phase II trial.","Clinical Trial, Phase I",1177.0,34.0,Purpose characterize toxicity pharmacokinetics pharmacodynamics selinexor selective inhibitor nuclear export combined fludarabine cytarabine children relapsed refractory leukemia Patients Methods Eighteen patients relapsed refractory acute leukemia enrolled SELHEM Selinexor Fludarabine Cytarabine Treatment Refractory Relapsed Leukemia Myelodysplastic Syndrome clinical trial NCT02212561 Selinexor initially 30 mg/m sup 2 /sup dose given orally days 1 3 8 10 22 24 escalated according rolling-six design Fludarabine 30 mg/m sup 2 /sup cytarabine 2 g/m sup 2 /sup administered days 15 19 Pharmacokinetic pharmacodynamic studies performed days 1 22 Response evaluations performed day 15 completion course 1 17 patients evaluable toxicity treated 30 mg/m sup 2 /sup 40 mg/m sup 2 /sup 55 mg/m sup 2 /sup 70 mg/m sup 2 /sup common grade 3 nonhematologic toxicity asymptomatic hyponatremia patients treated 70 mg/m sup 2 /sup experienced reversible cerebellar toxicity defining dose-limiting toxicity Pharmacokinetic parameters demonstrated plasma exposure dose proportional 16 patients demonstrated twofold increase XPO1 mRNA indicating inhibition XPO1 group heavily pretreated relapsed refractory patients seven 15 evaluable patients 47 achieved complete response complete response incomplete count recovery Selinexor combination fludarabine cytarabine tolerable doses 55 mg/m sup 2 /sup pediatric patients relapsed refractory leukemia patients received selinexor  40 mg/m sup 2 /sup demonstrated XPO1 target inhibition Response rates promising explored phase II trial,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[743, 6, 1507, 3, 155, 1159, 2, 3587, 1, 7233, 8, 1094, 230, 1, 928, 8202, 198, 397, 5, 2027, 2, 1855, 4, 541, 5, 591, 15, 430, 7, 2, 636, 3195, 7, 5, 591, 15, 430, 286, 11, 346, 4, 3, 68749, 7233, 5, 2027, 2, 1855, 9, 24, 1, 430, 15, 591, 15, 681, 38, 160, 68750, 7233, 1625, 28, 201, 81, 188, 172, 18, 172, 379, 61, 10, 447, 1428, 23, 162, 14, 27, 66, 79, 350, 2, 259, 2, 10, 2842, 768, 6, 8, 15220, 437, 771, 2027, 201, 81, 188, 172, 18, 172, 2, 1855, 18, 499, 188, 172, 18, 172, 11, 468, 23, 162, 167, 6, 326, 1456, 2, 2424, 94, 11, 173, 23, 162, 14, 2, 350, 51, 3816, 11, 173, 23, 218, 167, 2, 28, 3, 1438, 1, 906, 14, 99, 107, 3, 269, 7, 54, 11, 859, 9, 155, 169, 11, 73, 28, 201, 81, 188, 172, 18, 172, 169, 28, 327, 81, 188, 172, 18, 172, 437, 28, 614, 81, 188, 172, 18, 172, 2, 365, 28, 431, 81, 188, 172, 18, 172, 3, 96, 186, 88, 27, 3534, 155, 10, 2100, 6672, 100, 7, 54, 11, 73, 28, 431, 81, 188, 172, 18, 172, 592, 2786, 8103, 155, 2267, 2847, 3, 61, 817, 155, 1456, 1038, 264, 17, 554, 645, 10, 61, 831, 3057, 1, 245, 7, 264, 28, 506, 8, 8144, 344, 1, 9933, 956, 1716, 297, 1, 3, 9933, 178, 4, 26, 87, 1, 2447, 2193, 591, 2, 430, 7, 648, 1, 167, 859, 7, 662, 513, 236, 51, 15, 236, 51, 5, 2610, 1276, 1602, 1221, 7233, 4, 150, 5, 2027, 2, 1855, 16, 2668, 28, 415, 126, 6, 614, 81, 188, 172, 18, 172, 4, 815, 7, 5, 591, 15, 430, 62, 7, 54, 103, 7233, 28, 749, 327, 81, 188, 172, 18, 172, 264, 9933, 283, 297, 51, 151, 32, 721, 2, 303, 40, 195, 1443, 4, 8, 124, 215, 160]",1964.0,27507877,Phase Selinexor Selective Inhibitor Nuclear Export Combination Fludarabine Cytarabine Pediatric Relapsed Refractory Acute Leukemia,0,0.0
Prognosis of Primary Myelofibrosis in the Genomic Era.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2016-08-01,"Currently, prognostication in primary myelofibrosis (PMF) relies on the International Prognostic Scoring System (IPSS), dynamic IPSS (DIPSS), and DIPSS-plus, which incorporate age, blood counts, constitutional symptoms, circulating blasts, red cell transfusion need, and karyotype. Although the JAK2 V617F mutation was discovered a decade ago and MPL mutations shortly thereafter, it was the recent discovery of CALR mutations in the vast majority of JAK2/MPL-unmutated patients and recognition of the powerful impact of CALR mutations and triple-negative (JAK2/MPL/CALR-negative) status on outcome that set the stage for revision of traditional prognostic models to include molecular information. Additionally, the advent of next-generation sequencing has identified a host of previously unrecognized somatic mutations across hematologic malignancies. As in the myelodysplastic syndromes, the majority of common and prognostically informative mutations in PMF affect epigenetic regulation and mRNA splicing. Thus, a need has arisen to incorporate mutational information on genes such as ASXL1 and SRSF2 into risk stratification systems. Mutations in yet other genes appear to be important players in leukemic transformation, and new insights into disease pathogenesis are emerging. Finally, the number of prognostically detrimental mutations may affect both survival and response to ruxolitinib, which has significant implications for clinical decision making. In this review, we briefly summarize the prognostic models in use today and discuss in detail the somatic mutations commonly encountered in patients with PMF, along with their prognostic implications and role in leukemic transformation. Emerging prognostic models that incorporate new molecular information into existing systems or exclude clinical variables are also presented.",Journal Article,1268.0,6.0,Currently prognostication primary myelofibrosis PMF relies International Prognostic Scoring IPSS dynamic IPSS DIPSS DIPSS-plus incorporate age blood counts constitutional symptoms circulating blasts red transfusion need karyotype JAK2 V617F discovered decade ago MPL shortly recent discovery CALR vast majority JAK2/MPL-unmutated patients recognition powerful impact CALR triple-negative JAK2/MPL/CALR-negative status outcome set stage revision traditional prognostic models include molecular information Additionally advent next-generation sequencing identified host previously unrecognized somatic hematologic malignancies myelodysplastic syndromes majority common prognostically informative PMF affect epigenetic regulation mRNA splicing need arisen incorporate information ASXL1 SRSF2 risk stratification systems appear important players leukemic transformation new insights disease pathogenesis emerging Finally number prognostically detrimental affect survival response ruxolitinib significant implications clinical decision making review briefly summarize prognostic models use today discuss somatic commonly encountered patients PMF prognostic implications role leukemic transformation Emerging prognostic models incorporate new molecular information existing systems exclude clinical variables presented,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[694, 4260, 4, 86, 4637, 7389, 6495, 23, 3, 944, 177, 2504, 398, 8751, 2540, 8751, 16128, 2, 16128, 349, 92, 3360, 89, 315, 1911, 5962, 507, 1033, 2438, 3422, 31, 2785, 594, 2, 3385, 242, 3, 2509, 5657, 258, 10, 2747, 8, 2025, 5028, 2, 16440, 138, 6961, 3972, 192, 10, 3, 435, 1574, 1, 11222, 138, 4, 3, 4337, 686, 1, 2509, 16440, 7216, 7, 2, 2335, 1, 3, 3757, 345, 1, 11222, 138, 2, 1500, 199, 2509, 16440, 11222, 199, 156, 23, 228, 17, 916, 3, 82, 9, 5646, 1, 1847, 177, 274, 6, 643, 219, 487, 1724, 3, 4114, 1, 1305, 914, 615, 71, 108, 8, 1204, 1, 373, 6055, 1119, 138, 716, 813, 441, 22, 4, 3, 2040, 3, 686, 1, 186, 2, 7848, 4189, 138, 4, 7389, 1158, 1418, 863, 2, 956, 3895, 631, 8, 594, 71, 14255, 6, 3360, 1619, 487, 23, 214, 225, 22, 7782, 2, 9830, 237, 43, 1541, 1530, 138, 4, 1145, 127, 214, 1322, 6, 40, 305, 10996, 4, 2015, 1392, 2, 217, 1957, 237, 34, 1384, 32, 1478, 1368, 3, 207, 1, 7848, 6227, 138, 68, 1158, 110, 25, 2, 51, 6, 4894, 92, 71, 93, 1268, 9, 38, 948, 1079, 4, 26, 206, 21, 6277, 2479, 3, 177, 274, 4, 119, 5665, 2, 1139, 4, 5000, 3, 1119, 138, 841, 3903, 4, 7, 5, 7389, 1510, 5, 136, 177, 1268, 2, 200, 4, 2015, 1392, 1478, 177, 274, 17, 3360, 217, 219, 487, 237, 1692, 1530, 15, 6262, 38, 682, 32, 120, 917]",1789.0,27521306,Prognosis Primary Myelofibrosis Genomic Era,74,0.12914485165794065
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2016-08-01,"Eltrombopag used for thrombocytopenia in myelodysplastic syndrome (MDS) patients is being explored in clinical trials including those with chronic myelomonocytic leukemia (CMML). We report our experience treating patients with CMML enrolled in a sequential 2-stage dose escalation study with eltrombopag in patients with MDS after hypomethylating agent failure. Patients with CMML were compared with patients with MDS in respect to response and adverse events. Among 33 patients in the study, we treated 7 patients with CMML. Hematological improvement or better (by International Working Group 2006 criteria) was observed in 6 (23%) of 26 MDS patients and 1 (14%) of 7 patients with CMML. The responding patient with CMML had bilineage response. Two patients with CMML became platelet transfusion-independent. Five (71%) patients with CMML developed leukocytosis compared with 3 (12%) patients with MDS. Four (57%) patients with CMML showed peripheral myeloblasts after treatment compared with 11 (42%) in the MDS group. One (14%) patient with CMML developed grade 3 fibrosis from grade 0 to 1 at baseline compared with 3 (12%) patients with MDS. The rate of acute myeloid leukemia transformation was 39% and 29%, respectively, in patients with MDS and CMML. Further clinical studies are needed to identify patients with CMML who will benefit from this treatment.","Clinical Trial, Phase I",1268.0,15.0,Eltrombopag thrombocytopenia myelodysplastic syndrome MDS patients explored clinical trials including chronic myelomonocytic leukemia CMML report experience treating patients CMML enrolled sequential 2-stage dose escalation eltrombopag patients MDS hypomethylating agent failure Patients CMML compared patients MDS respect response adverse events 33 patients treated 7 patients CMML Hematological improvement better International Working Group 2006 criteria observed 6 23 26 MDS patients 1 14 7 patients CMML responding patient CMML bilineage response patients CMML platelet transfusion-independent 71 patients CMML developed leukocytosis compared 3 12 patients MDS 57 patients CMML showed peripheral myeloblasts treatment compared 11 42 MDS group 14 patient CMML developed grade 3 fibrosis grade 0 1 baseline compared 3 12 patients MDS rate acute myeloid leukemia transformation 39 29 respectively patients MDS CMML clinical studies needed identify patients CMML benefit treatment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[13462, 95, 9, 1340, 4, 681, 1223, 7, 16, 486, 1443, 4, 38, 143, 141, 135, 5, 442, 5451, 3382, 21, 414, 114, 730, 1367, 7, 5, 3382, 346, 4, 8, 1787, 18, 82, 61, 1125, 45, 5, 13462, 4, 7, 5, 1223, 50, 4931, 420, 496, 7, 5, 3382, 11, 72, 5, 7, 5, 1223, 4, 2184, 6, 51, 2, 290, 281, 107, 466, 7, 4, 3, 45, 21, 73, 67, 7, 5, 3382, 2890, 767, 15, 380, 20, 944, 2644, 87, 1324, 371, 10, 164, 4, 49, 382, 1, 432, 1223, 7, 2, 14, 213, 1, 67, 7, 5, 3382, 3, 3261, 69, 5, 3382, 42, 38636, 51, 100, 7, 5, 3382, 3451, 1596, 2785, 306, 365, 792, 7, 5, 3382, 276, 7463, 72, 5, 27, 133, 7, 5, 1223, 294, 696, 7, 5, 3382, 224, 672, 14909, 50, 24, 72, 5, 175, 595, 4, 3, 1223, 87, 104, 213, 69, 5, 3382, 276, 88, 27, 3000, 29, 88, 13, 6, 14, 28, 330, 72, 5, 27, 133, 7, 5, 1223, 3, 116, 1, 286, 533, 1392, 10, 587, 2, 462, 106, 4, 7, 5, 1223, 2, 3382, 195, 38, 94, 32, 575, 6, 255, 7, 5, 3382, 54, 303, 247, 29, 26, 24]",1282.0,27521328,Eltrombopag Use Patients Chronic Myelomonocytic Leukemia CMML Cautionary Tale,0,0.0
PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2016-08-01,"Inflammation has an essential role in the pathogenesis of myelodysplastic syndromes (MDS). Its expression is controlled by phosphodiesterase 4 (PDE4). Thus, PDE4 inhibitors might be useful therapeutic targets for MDS. We evaluated the expression of each isoform of PDE4 (A, B, C, and D) using transcriptomic profiling and examined the potential impact on the outcome of patients with MDS in terms of survival and response to hypomethylating agents. Total RNA was extracted from CD34(+) bone marrow hematopoietic cells from healthy individuals (n = 10) and patients with MDS (n = 24) or chronic myelomonocytic leukemia (n = 19). The study cohort had a median follow-up period of 21.2 months (range, 0.2-68 months) and a median overall survival of 17.6 months (95% confidence interval, 9.6-25.6). The main finding of the present study was that PDE4 mean expression was generally higher in patients with MDS than in healthy individuals. Also, upregulated PDE4 expression seemed to have a possible negative effect on survival (P > .05). Moreover, lower, compared with higher, mean PDE4A and PDE4C expression is indicative of a response to a hypomethylating agent (0.09 and 0.03 vs. 0.54 and 0.49, respectively; P > .05). These results should be confirmed in a larger patient cohort. PDE4 expression could be an effective potential prognostic factor and therapeutic target for patients with MDS and chronic myelomonocytic leukemia. The role of PDE4 inhibitors should be explored in vitro against MDS cell lines and in preclinical mouse models of MDS.",Journal Article,1268.0,1.0,Inflammation essential role pathogenesis myelodysplastic syndromes MDS expression controlled phosphodiesterase 4 PDE4 PDE4 inhibitors useful therapeutic targets MDS evaluated expression isoform PDE4 B C transcriptomic profiling examined potential impact outcome patients MDS terms survival response hypomethylating agents Total RNA extracted CD34 bone marrow hematopoietic healthy individuals n 10 patients MDS n 24 chronic myelomonocytic leukemia n 19 cohort median follow-up period 21.2 months range 0.2-68 months median overall survival 17.6 months 95 confidence interval 9.6-25.6 main finding present PDE4 mean expression generally higher patients MDS healthy individuals upregulated PDE4 expression possible negative effect survival P .05 lower compared higher mean PDE4A PDE4C expression indicative response hypomethylating agent 0.09 0.03 vs. 0.54 0.49 respectively P .05 confirmed larger patient cohort PDE4 expression effective potential prognostic factor therapeutic target patients MDS chronic myelomonocytic leukemia role PDE4 inhibitors explored vitro MDS lines preclinical mouse models MDS,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1815, 71, 35, 1452, 200, 4, 3, 1384, 1, 2040, 1223, 211, 55, 16, 1149, 20, 11624, 39, 27549, 631, 27549, 222, 822, 40, 999, 189, 637, 9, 1223, 21, 194, 3, 55, 1, 296, 3995, 1, 27549, 8, 132, 256, 2, 427, 75, 5983, 1080, 2, 409, 3, 174, 345, 23, 3, 228, 1, 7, 5, 1223, 4, 1794, 1, 25, 2, 51, 6, 4931, 183, 181, 893, 10, 2484, 29, 2215, 581, 1007, 37, 29, 1331, 869, 78, 79, 2, 7, 5, 1223, 78, 259, 15, 442, 5451, 78, 326, 3, 45, 180, 42, 8, 52, 166, 126, 727, 1, 239, 18, 53, 184, 13, 18, 806, 53, 2, 8, 52, 63, 25, 1, 269, 49, 53, 48, 307, 268, 83, 49, 243, 49, 3, 1895, 1567, 1, 3, 364, 45, 10, 17, 27549, 313, 55, 10, 1228, 142, 4, 7, 5, 1223, 76, 4, 1331, 869, 120, 2684, 27549, 55, 5025, 6, 47, 8, 899, 199, 254, 23, 25, 19, 474, 1393, 280, 72, 5, 142, 313, 68768, 2, 68769, 55, 16, 5572, 1, 8, 51, 6, 8, 4931, 420, 13, 1730, 2, 13, 680, 105, 13, 667, 2, 13, 739, 106, 19, 474, 46, 99, 257, 40, 557, 4, 8, 1077, 69, 180, 27549, 55, 359, 40, 35, 323, 174, 177, 161, 2, 189, 283, 9, 7, 5, 1223, 2, 442, 5451, 3, 200, 1, 27549, 222, 257, 40, 1443, 4, 439, 480, 1223, 31, 285, 2, 4, 693, 830, 274, 1, 1223]",1448.0,27521329,PDE4 Differential Expression Potential Prognostic Factor Therapeutic Target Patients Myelodysplastic Syndrome Chronic Myelomonocytic Leukemia,166,0.28970331588132636
"Connect MDS/AML: design of the myelodysplastic syndromes and acute myeloid leukemia disease registry, a prospective observational cohort study.",BMC cancer,BMC Cancer,2016-08-19,"Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are myeloid neoplasms in which outgrowth of neoplastic clones disrupts normal hematopoiesis. Some patients with unexplained persistent cytopenias may not meet minimal diagnostic criteria for MDS but an alternate diagnosis is not apparent; the term idiopathic cytopenia of undetermined significance (ICUS) has been used to describe this state. MDS and AML occur primarily in older patients who are often treated outside the clinical trial setting. Consequently, our understanding of the patterns of diagnostic evaluation, management, and outcomes of these patients is limited. Furthermore, there are few natural history studies of ICUS. To better understand how patients who have MDS, ICUS, or AML are managed in the routine clinical setting, the Connect MDS/AML Disease Registry, a multicenter, prospective, observational cohort study of patients newly diagnosed with these conditions has been initiated. The Connect MDS/AML Disease Registry will capture diagnosis, risk assessment, treatment, and outcomes data for approximately 1500 newly diagnosed patients from approximately 150 community and academic sites in the United States in 4 cohorts: (1) lower-risk MDS (International Prognostic Scoring System [IPSS] low and intermediate-1 risk), with and without del(5q); (2) higher-risk MDS (IPSS intermediate-2 and high risk); (3) ICUS; and (4) AML in patients aged55years (excluding acute promyelocytic leukemia). Diagnosis will be confirmed by central review. Baseline patient characteristics, diagnostic patterns, treatment patterns, clinical outcomes, health economics outcomes, and patient-reported health-related quality of life will be entered into an electronic data capture system at enrollment and quarterly for 8years. A tissue substudy to explore the relationship between karyotypes, molecular markers, and clinical outcomes will be conducted, and is optional for patients. The Connect MDS/AML Disease Registry will be the first prospective, observational, non-interventional study in the United States to collect clinical information, patient-reported outcomes, and tissue samples from patients with MDS, ICUS, or AML receiving multiple therapies. Results from this registry may provide new insights into the relationship between diagnostic practices, treatment regimens, and outcomes in patients with these diseases and identify areas for future investigation. Connect MDS/AML Disease Registry ( NCT01688011 ). Registered 14 September 2012.",Journal Article,1250.0,7.0,Myelodysplastic syndromes MDS acute myeloid leukemia AML myeloid neoplasms outgrowth neoplastic clones disrupts normal hematopoiesis patients unexplained persistent cytopenias meet minimal diagnostic criteria MDS alternate diagnosis apparent term idiopathic cytopenia undetermined significance ICUS state MDS AML occur primarily older patients treated outside clinical trial setting Consequently understanding patterns diagnostic evaluation management outcomes patients limited Furthermore natural history studies ICUS better understand patients MDS ICUS AML managed routine clinical setting Connect MDS/AML Disease Registry multicenter prospective observational cohort patients newly diagnosed conditions initiated Connect MDS/AML Disease Registry capture diagnosis risk assessment treatment outcomes approximately 1500 newly diagnosed patients approximately 150 community academic sites United States 4 cohorts 1 lower-risk MDS International Prognostic Scoring IPSS low intermediate-1 risk del 5q 2 higher-risk MDS IPSS intermediate-2 high risk 3 ICUS 4 AML patients aged  55 years excluding acute promyelocytic leukemia Diagnosis confirmed central review Baseline patient characteristics diagnostic patterns treatment patterns clinical outcomes health economics outcomes patient-reported health-related quality life entered electronic capture enrollment quarterly 8 years tissue substudy explore relationship karyotypes molecular markers clinical outcomes conducted optional patients Connect MDS/AML Disease Registry prospective observational non-interventional United States collect clinical information patient-reported outcomes tissue patients MDS ICUS AML receiving multiple therapies registry provide new insights relationship diagnostic practices treatment regimens outcomes patients diseases identify areas future investigation Connect MDS/AML Disease Registry NCT01688011 Registered 14 September 2012,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2040, 1223, 2, 286, 533, 329, 32, 533, 1179, 4, 92, 7201, 1, 2000, 2749, 7754, 295, 5114, 476, 7, 5, 8221, 1882, 5635, 68, 44, 3362, 1048, 752, 371, 9, 1223, 84, 35, 4689, 147, 16, 44, 2235, 3, 337, 7540, 8165, 1, 5206, 724, 26683, 71, 85, 95, 6, 897, 26, 1309, 1223, 2, 329, 1271, 1561, 4, 434, 7, 54, 32, 629, 73, 2513, 3, 38, 160, 546, 3244, 114, 612, 1, 3, 764, 1, 752, 451, 284, 2, 123, 1, 46, 7, 16, 383, 798, 125, 32, 1021, 1504, 532, 94, 1, 26683, 6, 380, 1640, 832, 7, 54, 47, 1223, 26683, 15, 329, 32, 2231, 4, 3, 1311, 38, 546, 3, 14290, 1223, 329, 34, 1608, 8, 1570, 482, 2495, 180, 45, 1, 7, 732, 265, 5, 46, 1298, 71, 85, 1917, 3, 14290, 1223, 329, 34, 1608, 303, 2891, 147, 43, 455, 24, 2, 123, 74, 9, 705, 7204, 732, 265, 7, 29, 705, 1577, 1714, 2, 1916, 633, 4, 3, 1088, 907, 4, 39, 736, 14, 280, 43, 1223, 944, 177, 2504, 398, 8751, 154, 2, 919, 14, 43, 5, 2, 187, 3084, 5460, 18, 142, 43, 1223, 8751, 919, 18, 2, 64, 43, 27, 26683, 2, 39, 329, 4, 7, 1032, 749, 614, 60, 3207, 286, 4300, 147, 303, 40, 557, 20, 854, 206, 330, 69, 374, 752, 764, 24, 764, 38, 123, 341, 14602, 123, 2, 69, 210, 341, 139, 372, 1, 358, 303, 40, 2836, 237, 35, 3098, 74, 2891, 398, 28, 1798, 2, 22531, 9, 66, 60, 8, 246, 13843, 6, 1645, 3, 858, 59, 6809, 219, 525, 2, 38, 123, 303, 40, 426, 2, 16, 9281, 9, 7, 3, 14290, 1223, 329, 34, 1608, 303, 40, 3, 157, 482, 2495, 220, 6182, 45, 4, 3, 1088, 907, 6, 6248, 38, 487, 69, 210, 123, 2, 246, 347, 29, 7, 5, 1223, 26683, 15, 329, 357, 232, 235, 99, 29, 26, 1608, 68, 377, 217, 1957, 237, 3, 858, 59, 752, 2634, 24, 472, 2, 123, 4, 7, 5, 46, 1342, 2, 255, 1361, 9, 508, 940, 14290, 1223, 329, 34, 1608, 68822, 1653, 213, 2636, 1195]",2414.0,27538433,Connect MDS/AML design myelodysplastic syndromes acute myeloid leukemia disease registry prospective observational cohort,124,0.2164048865619546
"Secondary malignancies in patients with multiple myeloma, Waldenstrm macroglobulinemia and monoclonal gammopathy of undetermined significance.",Leukemia & lymphoma,Leuk. Lymphoma,2016-08-22,"In recent years, the survival of patients with plasma cell dyscrasias has improved due to improvements in anticancer and supportive therapy. However, the risk of secondary malignancies has increased, thought to be due to a combination of environmental and disease-related factors, as well as treatment. In the present review, we evaluate the risk of secondary malignancies in patients with monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and Waldenstrm macroglobulinemia (WM). Patients with MGUS appear to have a higher risk of developing myeloid malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In patients with MM, the risk of AML, acute lymphoblastic leukemia and some solid tumors appears increased. Finally, in WM patients, there seems to be increased risk of AML, diffuse large B-cell lymphoma, thyroid cancer and melanoma.",Journal Article,1247.0,9.0,recent years survival patients plasma dyscrasias improved improvements anticancer supportive therapy risk secondary malignancies increased thought combination environmental disease-related factors treatment present review evaluate risk secondary malignancies patients monoclonal gammopathy undetermined significance MGUS multiple myeloma MM Waldenstrm macroglobulinemia WM Patients MGUS appear higher risk developing myeloid malignancies myelodysplastic syndromes MDS acute myeloid leukemia AML patients MM risk AML acute lymphoblastic leukemia solid appears increased Finally WM patients increased risk AML diffuse large B-cell lymphoma thyroid melanoma,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,"[4, 435, 60, 3, 25, 1, 7, 5, 554, 31, 17162, 71, 231, 520, 6, 1474, 4, 1475, 2, 1877, 36, 137, 3, 43, 1, 568, 441, 71, 101, 2739, 6, 40, 520, 6, 8, 150, 1, 3766, 2, 34, 139, 130, 22, 149, 22, 24, 4, 3, 364, 206, 21, 376, 3, 43, 1, 568, 441, 4, 7, 5, 848, 5334, 1, 5206, 724, 3226, 232, 321, 2, 3700, 3389, 1518, 7, 5, 3226, 1322, 6, 47, 8, 142, 43, 1, 931, 533, 441, 225, 22, 2040, 1223, 2, 286, 533, 329, 4, 7, 5, 321, 3, 43, 1, 329, 286, 1275, 2, 476, 537, 57, 1233, 101, 1368, 4, 1518, 7, 125, 2744, 6, 40, 101, 43, 1, 329, 1388, 375, 132, 31, 12, 2]",805.0,27546465,Secondary malignancies patients multiple myeloma Waldenstrm macroglobulinemia monoclonal gammopathy undetermined significance,0,0.0
Clostridium tertium in neutropenic patients: case series at a cancer institute.,International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,Int. J. Infect. Dis.,2016-08-26,"Clostridium tertium is considered an uncommon pathogen in humans, but is a cause of bacteremia in patients with underlying hematological malignancies and neutropenia. A case series highlighting 10 years of experience with C. tertium as a cause of bacteremia in this population is presented; the cases were seen at a National Cancer Institute designated cancer center. Institutional review board approval was obtained prior to the start of the study. All cases of C. tertium bacteremia seen at H. Lee Moffitt Cancer Center and Research Institute from 2005 to 2015 were reviewed. The study population was identified by positive blood cultures obtained from the microbiology laboratory over the same time period. Seven patients were found to have had C. tertium bacteremia. These patients had a temperature of >38.3C at the time of diagnosis and severe neutropenia. All patients had a history of hematological malignancy, five having acute myeloid leukemia and two having myelodysplastic syndrome. All of the patients' blood cultures cleared within 3 days of antibiotic therapy. The unusual susceptibility pattern of C. tertium, with resistance to beta-lactams and clindamycin, likely explains its presence in immunosuppressed patients. Vancomycin remains the drug of choice. The pathogen continues to have a low virulence and a low mortality when treated appropriately.",Journal Article,1243.0,3.0,Clostridium tertium considered uncommon pathogen humans cause bacteremia patients underlying hematological malignancies neutropenia case series highlighting 10 years experience C. tertium cause bacteremia population presented cases seen National Institute designated center Institutional review board approval obtained prior start cases C. tertium bacteremia seen H. Lee Moffitt Center Research Institute 2005 2015 reviewed population identified positive blood cultures obtained microbiology laboratory time period Seven patients C. tertium bacteremia patients temperature 38.3C time diagnosis severe neutropenia patients history hematological malignancy acute myeloid leukemia myelodysplastic syndrome patients blood cultures cleared 3 days antibiotic therapy unusual susceptibility pattern C. tertium resistance beta-lactams clindamycin likely explains presence immunosuppressed patients Vancomycin remains drug choice pathogen continues low virulence low mortality treated appropriately,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[14864, 32646, 16, 515, 35, 2052, 15956, 4, 3218, 84, 16, 8, 708, 1, 7085, 4, 7, 5, 1181, 2890, 441, 2, 778, 8, 473, 988, 4051, 79, 60, 1, 730, 5, 256, 32646, 22, 8, 708, 1, 7085, 4, 26, 266, 16, 917, 3, 140, 11, 527, 28, 8, 657, 12, 1377, 4107, 12, 574, 1115, 206, 2620, 1814, 10, 683, 324, 6, 3, 2435, 1, 3, 45, 62, 140, 1, 256, 32646, 7085, 527, 28, 555, 15635, 9054, 12, 574, 2, 389, 1377, 29, 1242, 6, 1483, 11, 446, 3, 45, 266, 10, 108, 20, 109, 315, 3231, 683, 29, 3, 26476, 1624, 252, 3, 827, 98, 727, 648, 7, 11, 204, 6, 47, 42, 256, 32646, 7085, 46, 7, 42, 8, 6882, 1, 519, 41542, 28, 3, 98, 1, 147, 2, 905, 778, 62, 7, 42, 8, 532, 1, 2890, 710, 365, 1041, 286, 533, 2, 100, 1041, 681, 62, 1, 3, 7, 315, 3231, 9266, 262, 10021, 162, 1, 5210, 36, 3, 4015, 1432, 1177, 1, 256, 32646, 5, 251, 6, 1090, 68896, 2, 49979, 322, 10558, 211, 463, 4, 12749, 7, 9013, 469, 3, 234, 1, 1866, 3, 15956, 2274, 6, 47, 8, 154, 12977, 2, 8, 154, 282, 198, 73, 4544]",1325.0,27575937,Clostridium tertium neutropenic patients case series institute,0,0.0
Precision Medicine in Myelodysplastic Syndromes and Leukemias: Lessons from Sequential Mutations.,Annual review of medicine,Annu. Rev. Med.,2016-09-07,"Precision medicine can be simply defined as the identification of personalized treatment that matches patient-specific clinical and genomic characteristics. Since the completion of the Human Genome Project in 2003, significant advances have been made in our understanding of the genetic makeup of diseases, especially cancers. The identification of somatic mutations that can drive cancer has led to the development of therapies that specifically target the abnormal proteins derived from these mutations. This has led to a paradigm shift in our treatment methodology. Although some success has been achieved in targeting some genetic abnormalities, several challenges and limitations exist when applying precision-medicine concepts in leukemia and myelodysplastic syndromes. We review the current understanding of genomics in myelodysplastic syndromes (MDS) and leukemias and the limitations of precision-medicine concepts in MDS.",Journal Article,1231.0,3.0,Precision medicine simply defined identification personalized treatment matches patient-specific clinical genomic characteristics completion Human Genome Project 2003 significant advances understanding genetic makeup diseases especially identification somatic drive led development therapies specifically target abnormal derived led paradigm shift treatment methodology success achieved targeting genetic abnormalities challenges limitations exist applying precision-medicine concepts leukemia myelodysplastic syndromes review current understanding genomics myelodysplastic syndromes MDS leukemias limitations precision-medicine concepts MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2720, 1807, 122, 40, 8908, 395, 22, 3, 911, 1, 2175, 24, 17, 13019, 69, 112, 38, 2, 572, 374, 1192, 3, 1438, 1, 3, 171, 898, 3105, 4, 1522, 93, 954, 47, 85, 1229, 4, 114, 612, 1, 3, 336, 14176, 1, 1342, 1093, 163, 3, 911, 1, 1119, 138, 17, 122, 3279, 12, 71, 836, 6, 3, 193, 1, 235, 17, 1225, 283, 3, 1668, 652, 526, 29, 46, 138, 26, 71, 836, 6, 8, 2431, 3024, 4, 114, 24, 3209, 242, 476, 1825, 71, 85, 513, 4, 529, 476, 336, 1171, 392, 1427, 2, 1939, 1923, 198, 4798, 2720, 1807, 5101, 4, 2, 2040, 21, 206, 3, 291, 612, 1, 4229, 4, 2040, 1223, 2, 2792, 2, 3, 1939, 1, 2720, 1807, 5101, 4, 1223]",879.0,27618752,Precision Medicine Myelodysplastic Syndromes Leukemias Lessons Sequential,432,0.7539267015706806
Hematopoietic Cell Transplantation for Myelodysplastic Syndromes.,Journal of oncology practice,J Oncol Pract,2016-09-01,"Allogeneic hematopoietic cell transplantation (HCT) offers the only potential cure for patients with myelodysplastic syndromes (MDS). However, with current approaches to HCT, many older patients with comorbidities are poor HCT candidates, and treatment-related morbidity and mortality may offset benefit for patients with lower-risk disease. Consequently, selection of patients with MDS for HCT should take into consideration disease risk category including mutational status, HCT comorbidity index, functional status, donor options, and available institutional resources. Formal geriatric assessment may further guide use of HCT and, if HCT is chosen, selection of conditioning intensity. Patients with higher-risk MDS should be considered for HCT at the time of diagnosis, whereas expectant nontransplant management is more appropriate for those with lower-risk disease. A high blast burden at the time of HCT increases the risk of subsequent relapse; however, the role of pretransplant cytoreductive therapy and the regimen of choice remain controversial. Patients with MDS younger than 65 years and with an HCT comorbidity index  4 may benefit from more intense conditioning regimens. The presence of complex or monosomal karyotype or mutations in TP53, DNMT3A, or other genes identify patients with poorer outcomes following HCT. Patients with TP53 mutations have particularly poor survival, and should be enrolled in clinical trials whenever possible. Several important HCT studies are ongoing and will better define the role of HCT in MDS as well as the value of pretransplant cytoreductive therapy or post-transplant relapse-prevention strategies. Given the apparent underuse of HCT in eligible patients and low enrollment in MDS HCT clinical trials to date, timely referral of patients with MDS to such trials and HCT programs is critical.",Journal Article,1237.0,4.0,Allogeneic hematopoietic transplantation HCT offers potential cure patients myelodysplastic syndromes MDS current approaches HCT older patients comorbidities poor HCT candidates treatment-related morbidity mortality offset benefit patients lower-risk disease Consequently selection patients MDS HCT consideration disease risk category including status HCT comorbidity index functional status donor options available institutional resources Formal geriatric assessment guide use HCT HCT chosen selection conditioning intensity Patients higher-risk MDS considered HCT time diagnosis expectant nontransplant management appropriate lower-risk disease high blast burden time HCT increases risk subsequent relapse role pretransplant cytoreductive therapy regimen choice remain controversial Patients MDS younger 65 years HCT comorbidity index  4 benefit intense conditioning regimens presence complex monosomal karyotype TP53 DNMT3A identify patients poorer outcomes following HCT Patients TP53 particularly poor survival enrolled clinical trials possible important HCT studies ongoing better define role HCT MDS value pretransplant cytoreductive therapy post-transplant relapse-prevention strategies Given apparent underuse HCT eligible patients low enrollment MDS HCT clinical trials date timely referral patients MDS trials HCT programs critical,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1063, 1007, 31, 497, 1085, 2339, 3, 158, 174, 1722, 9, 7, 5, 2040, 1223, 137, 5, 291, 611, 6, 1085, 445, 434, 7, 5, 1909, 32, 334, 1085, 1931, 2, 24, 139, 787, 2, 282, 68, 9500, 247, 9, 7, 5, 280, 43, 34, 3244, 881, 1, 7, 5, 1223, 9, 1085, 257, 3585, 237, 2415, 34, 43, 2169, 141, 1619, 156, 1085, 1879, 558, 583, 156, 1488, 838, 2, 390, 1115, 2892, 5057, 3914, 455, 68, 195, 1597, 119, 1, 1085, 2, 492, 1085, 16, 4695, 881, 1, 1933, 837, 7, 5, 142, 43, 1223, 257, 40, 515, 9, 1085, 28, 3, 98, 1, 147, 547, 16351, 21364, 284, 16, 80, 870, 9, 135, 5, 280, 43, 34, 8, 64, 3112, 892, 28, 3, 98, 1, 1085, 1106, 3, 43, 1, 706, 429, 137, 3, 200, 1, 7763, 2604, 36, 2, 3, 477, 1, 1866, 918, 2010, 7, 5, 1223, 773, 76, 556, 60, 2, 5, 35, 1085, 1879, 558, 1552, 39, 68, 247, 29, 80, 3933, 1933, 472, 3, 463, 1, 840, 15, 22660, 3385, 15, 138, 4, 1206, 6199, 15, 127, 214, 255, 7, 5, 1769, 123, 366, 1085, 7, 5, 1206, 138, 47, 823, 334, 25, 2, 257, 40, 346, 4, 38, 143, 8395, 899, 392, 305, 1085, 94, 32, 942, 2, 303, 380, 1107, 3, 200, 1, 1085, 4, 1223, 22, 149, 22, 3, 549, 1, 7763, 2604, 36, 15, 539, 941, 429, 1070, 422, 447, 3, 2235, 10192, 1, 1085, 4, 625, 7, 2, 154, 1798, 4, 1223, 1085, 38, 143, 6, 1244, 4225, 2096, 1, 7, 5, 1223, 6, 225, 143, 2, 1085, 2251, 16, 740]",1801.0,27621329,Hematopoietic Transplantation Myelodysplastic Syndromes,142,0.24781849912739964
"The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes.",Haematologica,Haematologica,2016-08-04,"We sought to confirm the prognostic importance of simple clinically available biomarkers of C-reactive protein, serum albumin, and ferritin prior to allogeneic hematopoietic cell transplantation. The study population consisted of 784 adults with acute myeloid leukemia in remission or myelodysplastic syndromes undergoing unrelated donor transplant reported to the Center for International Blood and Marrow Transplant Research. C-reactive protein and ferritin were centrally quantified by ELISA from cryopreserved plasma whereas each center provided pre-transplant albumin. In multivariate analysis, transplant-related mortality was associated with the pre-specified thresholds of C-reactive protein more than 10 mg/L (P=0.008) and albumin less than 3.5 g/dL (P=0.01) but not ferritin more than 2500 ng/mL. Only low albumin independently influenced overall mortality. Optimal thresholds affecting transplant-related mortality were defined as: C-reactive protein more than 3.67 mg/L, log(ferritin), and albumin less than 3.4 g/dL. A 3-level biomarker risk group based on these values separated risks of transplant-related mortality: low risk (reference), intermediate (HR=1.66, P=0.015), and high risk (HR=2.7, P<0.001). One-year survival was 74%, 67% and 56% for low-, intermediate- and high-risk groups. Routinely available pre-transplant biomarkers independently risk-stratify for transplant-related mortality and survival.",Journal Article,1265.0,24.0,sought confirm prognostic importance simple clinically available biomarkers C-reactive serum albumin ferritin prior allogeneic hematopoietic transplantation population consisted 784 adults acute myeloid leukemia remission myelodysplastic syndromes undergoing unrelated donor transplant reported Center International Blood Marrow Transplant Research C-reactive ferritin centrally quantified ELISA cryopreserved plasma center provided pre-transplant albumin multivariate transplant-related mortality associated pre-specified thresholds C-reactive 10 mg/L P=0.008 albumin 3.5 g/dL P=0.01 ferritin 2500 ng/mL low albumin independently influenced overall mortality Optimal thresholds affecting transplant-related mortality defined C-reactive 3.67 mg/L log ferritin albumin 3.4 g/dL 3-level biomarker risk group based values separated risks transplant-related mortality low risk reference intermediate HR=1.66 P=0.015 high risk HR=2.7 P 0.001 One-year survival 74 67 56 low- intermediate- high-risk groups Routinely available pre-transplant biomarkers independently risk-stratify transplant-related mortality survival,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 990, 6, 1843, 3, 177, 1187, 1, 2763, 505, 390, 582, 1, 256, 2163, 178, 524, 2799, 2, 9101, 324, 6, 1063, 1007, 31, 497, 3, 45, 266, 1695, 1, 14395, 857, 5, 286, 533, 4, 734, 15, 2040, 479, 2092, 1488, 941, 210, 6, 3, 574, 9, 944, 315, 2, 581, 941, 389, 256, 2163, 178, 2, 9101, 11, 4604, 2790, 20, 3664, 29, 10432, 554, 547, 296, 574, 1052, 671, 941, 2799, 4, 331, 65, 941, 139, 282, 10, 41, 5, 3, 671, 3575, 4634, 1, 256, 2163, 178, 80, 76, 79, 81, 805, 19, 13, 2155, 2, 2799, 299, 76, 27, 33, 499, 1826, 19, 13, 355, 84, 44, 9101, 80, 76, 11735, 997, 542, 158, 154, 2799, 1042, 2574, 63, 282, 665, 4634, 2319, 941, 139, 282, 11, 395, 22, 256, 2163, 178, 80, 76, 27, 598, 81, 805, 1066, 9101, 2, 2799, 299, 76, 27, 39, 499, 1826, 8, 27, 301, 901, 43, 87, 90, 23, 46, 1030, 4910, 1098, 1, 941, 139, 282, 154, 43, 2482, 919, 168, 14, 700, 19, 13, 3433, 2, 64, 43, 168, 18, 67, 19, 13, 144, 104, 111, 25, 10, 794, 598, 2, 664, 9, 154, 919, 2, 64, 43, 271, 3066, 390, 671, 941, 582, 1042, 43, 3570, 9, 941, 139, 282, 2, 25]",1364.0,27662010,prognostic value serum C-reactive ferritin albumin prior allogeneic transplantation acute myeloid leukemia myelodysplastic syndromes,0,0.0
When clinical heterogeneity exceeds genetic heterogeneity: thinking outside the genomic box in chronic myelomonocytic leukemia.,Blood,Blood,2016-10-05,"Exome sequencing studies in chronic myelomonocytic leukemia (CMML) illustrate a mutational landscape characterized by few somatic mutations involving a subset of recurrent gene mutations in ASXL1, SRSF2, and TET2, each approaching 40% in incidence. This has led to the clinical implementation of next-generation sequencing panels that effectively identify clonal monocytosis and complement clinical prognostic scoring systems in most patients. However, most murine models based on single gene mutations fail to recapitulate the CMML phenotype, and many gene mutations are loss of function, making the identification of traditional therapeutic vulnerabilities challenging. Further, as a subtype of the myelodysplastic/myeloproliferative neoplasms, CMML has a complex clinical heterogeneity not reflected by the mutational landscape. In this review, we will discuss the discordance between mutational homogeneity and clinical complexity and highlight novel genomic and nongenomic approaches that offer insight into the underlying clinical characteristics of CMML.",Journal Article,1203.0,21.0,Exome sequencing studies chronic myelomonocytic leukemia CMML illustrate landscape characterized somatic involving subset recurrent ASXL1 SRSF2 TET2 approaching 40 incidence led clinical implementation next-generation sequencing panels effectively identify clonal monocytosis complement clinical prognostic scoring systems patients murine models based single fail recapitulate CMML phenotype loss function making identification traditional therapeutic vulnerabilities challenging subtype myelodysplastic/myeloproliferative neoplasms CMML complex clinical heterogeneity reflected landscape review discuss discordance homogeneity clinical complexity highlight novel genomic nongenomic approaches offer insight underlying clinical characteristics CMML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2865, 615, 94, 4, 442, 5451, 3382, 4746, 8, 1619, 2801, 765, 20, 1021, 1119, 138, 1267, 8, 697, 1, 387, 145, 138, 4, 7782, 9830, 2, 5038, 296, 7773, 327, 4, 287, 26, 71, 836, 6, 3, 38, 2393, 1, 1305, 914, 615, 4383, 17, 1856, 255, 1946, 16875, 2, 3731, 38, 177, 2504, 1530, 4, 96, 7, 137, 96, 1471, 274, 90, 23, 226, 145, 138, 4373, 6, 7746, 3, 3382, 1005, 2, 445, 145, 138, 32, 407, 1, 343, 1079, 3, 911, 1, 1847, 189, 9614, 1950, 195, 22, 8, 875, 1, 3, 10589, 10857, 1179, 3382, 71, 8, 840, 38, 1144, 44, 4686, 20, 3, 1619, 2801, 4, 26, 206, 21, 303, 1139, 3, 5771, 59, 1619, 7502, 2, 38, 3082, 2, 1817, 229, 572, 2, 22042, 611, 17, 1918, 2670, 237, 3, 1181, 38, 374, 1, 3382]",1035.0,27707735,clinical heterogeneity exceeds genetic heterogeneity thinking outside genomic box chronic myelomonocytic leukemia,6,0.010471204188481676
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents.,Cancer,Cancer,2016-10-14,"The outcome of patients with higher-risk myelodysplastic syndromes (MDS) after hypomethylating agent (HMA) failure is poor. This study evaluated the safety and activity of a combination of low-dose clofarabine and cytarabine for these patients. Seventy patients with higher-risk MDS who had no response, progressed, or relapsed after at least 4 cycles of HMA therapy were treated. The median age was 72 years. Thirty-nine percent of the patients had high-risk disease according to the International Prognostic Scoring System, and 50% of the patients had poor-risk cytogenetics. Twenty-three percent of the patients had therapy-related MDS. The median number of prior cycles of HMA was 6 (range, 4-45). The overall response rate was 44%. The 6-week mortality rate was 9%. Grade 3 and higher nonhematologic toxicities were rare, but infections occurred in 52% of the patients, and fever of unknown origin occurred in 33%. The median overall survival (OS) was 10 months (95% confidence interval, 1-37 months). Thirteen percent of the patients underwent allogeneic stem cell transplantation. The responding patients had a median OS of 22 months, whereas the nonresponding patients had a median OS of 4 months. A complex karyotype was associated with worse response rates and OS. The combination of low-dose clofarabine and cytarabine is clinically active in these patients with few treatment options. Cancer 2017;123:629-637.  2016 American Cancer Society.","Clinical Trial, Phase II",1194.0,11.0,outcome patients higher-risk myelodysplastic syndromes MDS hypomethylating agent HMA failure poor evaluated safety activity combination low-dose clofarabine cytarabine patients Seventy patients higher-risk MDS response progressed relapsed 4 cycles HMA therapy treated median age 72 years Thirty-nine percent patients high-risk disease according International Prognostic Scoring 50 patients poor-risk cytogenetics Twenty-three percent patients therapy-related MDS median number prior cycles HMA 6 range 4-45 overall response rate 44 6-week mortality rate 9 Grade 3 higher nonhematologic toxicities rare infections occurred 52 patients fever unknown origin occurred 33 median overall survival OS 10 months 95 confidence interval 1-37 months Thirteen percent patients underwent allogeneic stem transplantation responding patients median OS 22 months nonresponding patients median OS 4 months complex karyotype associated worse response rates OS combination low-dose clofarabine cytarabine clinically active patients treatment options 2017 123:629-637  2016 American Society,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 228, 1, 7, 5, 142, 43, 2040, 1223, 50, 4931, 420, 7518, 496, 16, 334, 26, 45, 194, 3, 367, 2, 128, 1, 8, 150, 1, 154, 61, 4149, 2, 1855, 9, 46, 7, 2073, 7, 5, 142, 43, 1223, 54, 42, 77, 51, 1839, 15, 591, 50, 28, 506, 39, 410, 1, 7518, 36, 11, 73, 3, 52, 89, 10, 720, 60, 977, 762, 714, 1, 3, 7, 42, 64, 43, 34, 768, 6, 3, 944, 177, 2504, 398, 2, 212, 1, 3, 7, 42, 334, 43, 2510, 737, 169, 714, 1, 3, 7, 42, 36, 139, 1223, 3, 52, 207, 1, 324, 410, 1, 7518, 10, 49, 184, 39, 512, 3, 63, 51, 116, 10, 584, 3, 49, 647, 282, 116, 10, 83, 88, 27, 2, 142, 3534, 385, 11, 622, 84, 1875, 489, 4, 653, 1, 3, 7, 2, 2775, 1, 860, 1938, 489, 4, 466, 3, 52, 63, 25, 118, 10, 79, 53, 48, 307, 268, 14, 567, 53, 3170, 714, 1, 3, 7, 208, 1063, 452, 31, 497, 3, 3261, 7, 42, 8, 52, 118, 1, 350, 53, 547, 3, 13488, 7, 42, 8, 52, 118, 1, 39, 53, 8, 840, 3385, 10, 41, 5, 639, 51, 151, 2, 118, 3, 150, 1, 154, 61, 4149, 2, 1855, 16, 505, 544, 4, 46, 7, 5, 1021, 24, 838, 12, 1759, 2698, 15597, 13846, 2206, 1390, 597, 12, 1174]",1396.0,27741352,Phase 2 low-dose clofarabine plus cytarabine patients higher-risk myelodysplastic syndrome relapsed refractory hypomethylating agents,3,0.005235602094240838
KIR gene haplotype: an independent predictor of clinical outcome in MDS patients.,Blood,Blood,2016-10-19,"Myelodysplastic syndromes (MDSs) are a group of hematopoietic disorders affecting the myeloid lineage, characterized by cytopenias and clonal evolution to acute myeloid leukemia (AML). We hypothesized that natural killer (NK) cells and their activating killer immunoglobulin-like receptors (aKIRs) influence the immune surveillance and clinical outcome of patients with MDSs. Here, we first examined the distribution of aKIR genes and haplotype in 2 independent cohorts of MDS and AML patients. The median number of aKIR genes was lower in MDS patients than healthy controls (2 vs 3 genes; P = .001), and lower in patients with secondary AML (progressed from MDSs) compared with de novo AML patients (2 vs 3; P = .008) and healthy controls (2 vs 3; P = .006). In a multivariate analysis, the presence of KIR haplotype A (characterized by low aKIR content 0-1) independently predicted a higher risk of conversion to AML (relative risk [RR] with 95% confidence interval [CI], 2.67 [1.13-6.71]; P = .02) and worse adjusted progression-free survival (RR with 95% CI, 2.96 [1.59-5.52]; P = .001) and overall survival (2.25 [1.17-4.31]; P = .02), compared with KIR haplotype B (multiple aKIR genes). These novel findings may help to identify MDS patients with a high risk of disease progression who would likely benefit from adoptive NK-cell therapy.",Journal Article,1189.0,8.0,Myelodysplastic syndromes MDSs group hematopoietic disorders affecting myeloid lineage characterized cytopenias clonal evolution acute myeloid leukemia AML hypothesized natural killer NK activating killer immunoglobulin-like receptors aKIRs influence immune surveillance clinical outcome patients MDSs examined distribution aKIR haplotype 2 independent cohorts MDS AML patients median number aKIR lower MDS patients healthy controls 2 vs 3 P .001 lower patients secondary AML progressed MDSs compared novo AML patients 2 vs 3 P .008 healthy controls 2 vs 3 P .006 multivariate presence KIR haplotype characterized low aKIR content 0-1 independently predicted higher risk conversion AML relative risk RR 95 confidence interval CI 2.67 1.13-6.71 P .02 worse adjusted progression-free survival RR 95 CI 2.96 1.59-5.52 P .001 overall survival 2.25 1.17-4.31 P .02 compared KIR haplotype B multiple aKIR novel findings help identify MDS patients high risk disease progression likely benefit adoptive NK-cell therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2040, 13550, 32, 8, 87, 1, 1007, 1997, 2319, 3, 533, 2542, 765, 20, 5635, 2, 1946, 2554, 6, 286, 533, 329, 21, 1237, 17, 1504, 3458, 1765, 37, 2, 136, 1616, 3458, 2593, 733, 1186, 69209, 1054, 3, 250, 617, 2, 38, 228, 1, 7, 5, 13550, 467, 21, 157, 409, 3, 1395, 1, 36323, 214, 2, 4179, 4, 18, 306, 736, 1, 1223, 2, 329, 7, 3, 52, 207, 1, 36323, 214, 10, 280, 4, 1223, 7, 76, 1331, 535, 18, 105, 27, 214, 19, 144, 2, 280, 4, 7, 5, 568, 329, 1839, 29, 13550, 72, 5, 1566, 2018, 329, 7, 18, 105, 27, 19, 2155, 2, 1331, 535, 18, 105, 27, 19, 1861, 4, 8, 331, 65, 3, 463, 1, 6989, 4179, 8, 765, 20, 154, 36323, 2457, 13, 14, 1042, 783, 8, 142, 43, 1, 3111, 6, 329, 580, 43, 861, 5, 48, 307, 268, 58, 18, 598, 14, 233, 49, 792, 19, 588, 2, 639, 586, 91, 115, 25, 861, 5, 48, 58, 18, 921, 14, 728, 33, 653, 19, 144, 2, 63, 25, 18, 243, 14, 269, 39, 456, 19, 588, 72, 5, 6989, 4179, 132, 232, 36323, 214, 46, 229, 272, 68, 987, 6, 255, 1223, 7, 5, 8, 64, 43, 1, 34, 91, 54, 688, 322, 247, 29, 3159, 1765, 31, 36]",1250.0,27760759,KIR haplotype independent predictor clinical outcome MDS patients,27,0.04712041884816754
[Expression of miR-550a-5p in Myelodysplastic Syndrome and Its Prediction of Target Genes].,Zhongguo shi yan xue ye xue za zhi,Zhongguo Shi Yan Xue Ye Xue Za Zhi,2016-10-01,"To investigate the expression of miR-550a-5p in bone marrow of patients with myelodysplastic syndrome (MDS), and to predict its target genes and function by bioinformatics analyses, so as to provide the evidence to furthre explore the role of miR-550a-5p and its target genes in pathogenesis of MDS. Real-time PCR was used to detect the expression of miR-550a-5p in 54 MDS patients, 16 acute myeloid leukemia transformed from MDS (sfAML) and 19 healthy controls, and the correlation between the expression of miR-550a-5p and clinical pathologic characteristics of MDS, including chromosome, percentage of marrow blasts, absolute neutrophil count, platelet count and hemoglobin levels were analyzed. The sequence of miR-550 was searched in miRBase database. Target genes of miR-550a-5p were predicted by Microcosm,Miranda and Targetscan, and the predective results were collected, then the enrichment analyses of target gene function(GO) and signalling pathway(pathway of miR-550a-5p) were carried out by using gene ontology darabase and KEGG database. The expression of miR-550a-5p in bone marrow of all MDS patients was higher than that in controls: the expression level of miR-550a-5p in low risk MDS and middl risk 1 MDS was 1.7 times of controls (P=1.2310<sup>-10</sup>); the expression of miR-550a-5p in midde risk 2 MDS and high risk MDS was 1.9 times of controls (P=1.2010<sup>-10</sup>); the expression of miR-550a-5p in tAML was 2.0 times of controls (P=5.6110<sup>-10</sup>). The miR-550a-5p expression level was up-regulated gradually with the enhancement of disease risk of MDS, but there was no correlation between the expression level of miR-550a-5p and clinical pathologic characteristics of MDS(chromosome: Normal: 1.110.19, Abnormal:1.260.15, P>0.05; Percentage of Marrow Blasts: r=0.29,P=0.07; absolute neutrophil count: r=-0.02,P=0.89; hemoglobin level: r=0.09,P=0.57; platelet count: r=0.25,P=0.08). The sequence of miR-550 was conservative among different species, and the prediced results indicated that there were 19 target genes in intersection. The functions of target genes were enriched in regulation of stress-activated cascade, MAPK pathway, regulation of muscle organ development, regulation of protein homodimerization activity and other biological processes; they participated in some molecular functions including enzyme activity, combination processes of some molecules as protein, cAMP and domain existed in cell junction, synapse, coated vesicle, dendrite and other cellular components. Two of them-PDLIM2 and PSME1 were selected which might play a role in pathologic mechanism of MDS regulated by miR-550a-5p. The expression of miR-550a-5p in bone marrow of MDS patients increases specifically, and miR-550a-5p may play a role in the pathogenesis of MDS through regulation of target genes, PDLIM2 and PSME1.",Journal Article,1207.0,0.0,investigate expression miR-550a-5p bone marrow patients myelodysplastic syndrome MDS predict target function bioinformatics provide evidence furthre explore role miR-550a-5p target pathogenesis MDS Real-time PCR detect expression miR-550a-5p 54 MDS patients 16 acute myeloid leukemia transformed MDS sfAML 19 healthy controls correlation expression miR-550a-5p clinical pathologic characteristics MDS including chromosome percentage marrow blasts absolute neutrophil count platelet count hemoglobin levels sequence miR-550 searched miRBase database Target miR-550a-5p predicted Microcosm Miranda Targetscan predective collected enrichment target function signalling pathway pathway miR-550a-5p carried ontology darabase KEGG database expression miR-550a-5p bone marrow MDS patients higher controls expression level miR-550a-5p low risk MDS middl risk 1 MDS 1.7 times controls P=1.2310 sup -10 /sup expression miR-550a-5p midde risk 2 MDS high risk MDS 1.9 times controls P=1.2010 sup -10 /sup expression miR-550a-5p tAML 2.0 times controls P=5.6110 sup -10 /sup miR-550a-5p expression level up-regulated gradually enhancement disease risk MDS correlation expression level miR-550a-5p clinical pathologic characteristics MDS chromosome Normal 1.110.19 Abnormal:1.260.15 P 0.05 Percentage Marrow Blasts r=0.29 P=0.07 absolute neutrophil count r=-0.02 P=0.89 hemoglobin level r=0.09 P=0.57 platelet count r=0.25 P=0.08 sequence miR-550 conservative different species prediced indicated 19 target intersection functions target enriched regulation stress-activated cascade MAPK pathway regulation muscle organ development regulation homodimerization activity processes participated molecular functions including enzyme activity combination processes molecules cAMP domain existed junction synapse coated vesicle dendrite cellular components them-PDLIM2 PSME1 selected play role pathologic mechanism MDS regulated miR-550a-5p expression miR-550a-5p bone marrow MDS patients increases specifically miR-550a-5p play role pathogenesis MDS regulation target PDLIM2 PSME1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 963, 3, 55, 1, 722, 18716, 4534, 4, 581, 1, 7, 5, 681, 1223, 2, 6, 678, 211, 283, 214, 2, 343, 20, 6579, 318, 1743, 22, 6, 377, 3, 241, 6, 69244, 1645, 3, 200, 1, 722, 18716, 4534, 2, 211, 283, 214, 4, 1384, 1, 1223, 1589, 98, 604, 10, 95, 6, 1426, 3, 55, 1, 722, 18716, 4534, 4, 667, 1223, 7, 245, 286, 533, 2423, 29, 1223, 69245, 2, 326, 1331, 535, 2, 3, 816, 59, 3, 55, 1, 722, 18716, 4534, 2, 38, 510, 374, 1, 1223, 141, 1170, 1150, 1, 581, 2438, 1766, 2595, 1276, 1596, 1276, 2, 2222, 148, 11, 311, 3, 1532, 1, 722, 7935, 10, 3080, 4, 69246, 609, 283, 214, 1, 722, 18716, 4534, 11, 783, 20, 69247, 69248, 2, 50059, 2, 3, 69249, 99, 11, 786, 818, 3, 3020, 318, 1, 283, 145, 343, 3537, 2, 3128, 308, 308, 1, 722, 18716, 4534, 11, 2629, 1205, 20, 75, 145, 11843, 69250, 2, 21246, 609, 3, 55, 1, 722, 18716, 4534, 4, 581, 1, 62, 1223, 7, 10, 142, 76, 17, 4, 535, 3, 55, 301, 1, 722, 18716, 4534, 4, 154, 43, 1223, 2, 69251, 43, 14, 1223, 10, 14, 67, 1072, 1, 535, 19, 14, 69252, 172, 79, 172, 3, 55, 1, 722, 18716, 4534, 4, 69253, 43, 18, 1223, 2, 64, 43, 1223, 10, 14, 83, 1072, 1, 535, 19, 14, 69254, 172, 79, 172, 3, 55, 1, 722, 18716, 4534, 4, 69255, 10, 18, 13, 1072, 1, 535, 19, 33, 69256, 172, 79, 172, 3, 722, 18716, 4534, 55, 301, 10, 126, 1065, 8092, 5, 3, 2461, 1, 34, 43, 1, 1223, 84, 125, 10, 77, 816, 59, 3, 55, 301, 1, 722, 18716, 4534, 2, 38, 510, 374, 1, 1223, 1170, 295, 14, 69257, 326, 1668, 14, 69258, 167, 19, 13, 474, 1150, 1, 581, 2438, 668, 13, 462, 19, 13, 1615, 1766, 2595, 1276, 668, 13, 588, 19, 13, 887, 2222, 301, 668, 13, 1730, 19, 13, 696, 1596, 1276, 668, 13, 243, 19, 13, 1592, 3, 1532, 1, 722, 7935, 10, 4476, 107, 338, 2915, 2, 3, 69259, 99, 1103, 17, 125, 11, 326, 283, 214, 4, 15566, 3, 1681, 1, 283, 214, 11, 2220, 4, 863, 1, 1531, 735, 4678, 1748, 308, 863, 1, 1502, 1259, 193, 863, 1, 178, 27291, 128, 2, 127, 1037, 1849, 491, 3025, 4, 476, 219, 1681, 141, 1644, 128, 150, 1849, 1, 476, 1598, 22, 178, 10837, 2, 1398, 6810, 4, 31, 3322, 15533, 8248, 5608, 45578, 2, 127, 763, 1628, 100, 1, 1370, 50060, 2, 50061, 11, 715, 92, 822, 1343, 8, 200, 4, 510, 670, 1, 1223, 1065, 20, 722, 18716, 4534, 3, 55, 1, 722, 18716, 4534, 4, 581, 1, 1223, 7, 1106, 1225, 2, 722, 18716, 4534, 68, 1343, 8, 200, 4, 3, 1384, 1, 1223, 298, 863, 1, 283, 214, 50060, 2, 50061]",2745.0,27784378,Expression miR-550a-5p Myelodysplastic Syndrome Prediction Target,0,0.0
Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34<sup>+</sup> Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2016-10-24,"To evaluate the association between the hematopoietic cell transplantation-comorbidity index (HCT-CI) and the recently developed age-adjusted HCT-CI (HCT-CI/age) and transplant outcomes in the setting of CD34-selected allogeneic HCT, we analyzed a homogeneous population of patients undergoing allogeneic HCT with CD34-selected grafts for acute myeloid leukemia and myelodysplastic syndrome (n=346). Median HCT-CI and HCT-CI/age scores were 2 (percentile 25 to 75, 1 to 4) and 3 (percentile 25 to 75, 1 to 5), respectively. Higher HCT-CI and HCT-CI/age scores were associated with higher nonrelapse mortality (NRM) and lower overall survival (OS). The HCT-CI distinguished 2 risk groups (0 to 2 versus 3), whereas, with the HCT-CI/age, there was a progressive increase in NRM and decrease in OS with increasing scores in all 4 groups (0 versus 1 to 2 versus 3 to 4 versus 5). Higher scores in both models were associated with lower chronic graft-versus-host disease relapse-free survival but not with higher relapse. Both models showed a promising predictive accuracy for NRM (c-= .616 for HCT-CI and c-=.647 for HCT-CI/age). In conclusion, the HCT-CI and HCT-CI/age predict transplant outcomes in CD34-selected allo-HCT, including NRM, OS, and chronic graft-versus-host disease relapse-free survival and may be used to select appropriate patients for this approach.",Journal Article,1184.0,9.0,evaluate association hematopoietic transplantation-comorbidity index HCT-CI recently developed age-adjusted HCT-CI HCT-CI/age transplant outcomes setting CD34-selected allogeneic HCT homogeneous population patients undergoing allogeneic HCT CD34-selected grafts acute myeloid leukemia myelodysplastic syndrome n 346 Median HCT-CI HCT-CI/age scores 2 percentile 25 75 1 4 3 percentile 25 75 1 5 respectively Higher HCT-CI HCT-CI/age scores associated higher nonrelapse mortality NRM lower overall survival OS HCT-CI distinguished 2 risk groups 0 2 versus 3 HCT-CI/age progressive increase NRM decrease OS increasing scores 4 groups 0 versus 1 2 versus 3 4 versus 5 Higher scores models associated lower chronic graft-versus-host disease relapse-free survival higher relapse models showed promising predictive accuracy NRM c- .616 HCT-CI c- .647 HCT-CI/age HCT-CI HCT-CI/age predict transplant outcomes CD34-selected allo-HCT including NRM OS chronic graft-versus-host disease relapse-free survival select appropriate patients approach,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 376, 3, 248, 59, 3, 1007, 31, 497, 1879, 558, 1085, 58, 2, 3, 761, 276, 89, 586, 1085, 58, 1085, 58, 89, 2, 941, 123, 4, 3, 546, 1, 2215, 715, 1063, 1085, 21, 311, 8, 5642, 266, 1, 7, 479, 1063, 1085, 5, 2215, 715, 4713, 9, 286, 533, 2, 681, 78, 9184, 52, 1085, 58, 2, 1085, 58, 89, 703, 11, 18, 6392, 243, 6, 481, 14, 6, 39, 2, 27, 6392, 243, 6, 481, 14, 6, 33, 106, 142, 1085, 58, 2, 1085, 58, 89, 703, 11, 41, 5, 142, 4640, 282, 4296, 2, 280, 63, 25, 118, 3, 1085, 58, 4735, 18, 43, 271, 13, 6, 18, 185, 2608, 547, 5, 3, 1085, 58, 89, 125, 10, 8, 1014, 344, 4, 4296, 2, 775, 4, 118, 5, 602, 703, 4, 62, 39, 271, 13, 185, 14, 6, 18, 185, 27, 6, 39, 185, 4126, 142, 703, 4, 110, 274, 11, 41, 5, 280, 442, 1599, 185, 1204, 34, 429, 115, 25, 84, 44, 5, 142, 429, 110, 274, 224, 8, 721, 464, 1190, 9, 4296, 256, 14249, 9, 1085, 58, 2, 256, 12315, 9, 1085, 58, 89, 4, 1221, 3, 1085, 58, 2, 1085, 58, 89, 678, 941, 123, 4, 2215, 715, 2564, 1085, 141, 4296, 118, 2, 442, 1599, 185, 1204, 34, 429, 115, 25, 2, 68, 40, 95, 6, 1717, 870, 7, 9, 26, 353]",1304.0,27789361,Hematopoietic Transplantation Comorbidity Index Predicts Outcomes Patients Acute Myeloid Leukemia Myelodysplastic Syndromes Receiving CD34 sup /sup Selected Grafts Allogeneic Hematopoietic Transplantation,3,0.005235602094240838
A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.,British journal of haematology,Br. J. Haematol.,2016-10-28,"Limited therapies exist for patients with refractory and relapsed (RR) higher-risk myelodysplastic syndromes (HR-MDS) and acute myeloid leukaemia with trilineage dysplasia (AML-TD). High dose (HD) lenalidomide (50mg) has activity as frontline therapy in elderly AML but there is limited data in the RR setting. This phase II trial included patients with RR HR-MDS or AML-TD at 2 doses of lenalidomide (15 or 50mg) on days 1-28 of 42-day cycles. The primary endpoint was response rate using the 2006 International Working Group criteria. Overall survival (OS) was estimated by Kaplan-Meier methods. Of 27 patients enrolled, 59% had HR-MDS and 31% AML-TD. No patient had isolated del5q; 41% had poor-risk karyotype. Of 9 patients treated at 15mg, 56% completed 2 cycles with no responses. Of 18 patients treated at 50mg, 39% completed 2 cycles and 11% responded but all experienced grade 3/4 neutropenic fever/infection. The 60-day mortality rate was 30%. Median OS was 114days with 19% surviving 1year. The study was terminated due to lack of robust clinical activity. In conclusion, lenalidomide at 15mg is ineffective in RR myeloid malignancies. Continous high dosing schedules are poorly tolerated and minimally active. Further evaluation should be considered in upfront intensive chemotherapy-ineligible patients.","Clinical Trial, Phase II",1180.0,12.0,Limited therapies exist patients refractory relapsed RR higher-risk myelodysplastic syndromes HR-MDS acute myeloid leukaemia trilineage dysplasia AML-TD High dose HD lenalidomide 50 mg activity frontline therapy elderly AML limited RR setting phase II trial included patients RR HR-MDS AML-TD 2 doses lenalidomide 15 50 mg days 1-28 42-day cycles primary endpoint response rate 2006 International Working Group criteria Overall survival OS estimated Kaplan-Meier methods 27 patients enrolled 59 HR-MDS 31 AML-TD patient isolated del5q 41 poor-risk karyotype 9 patients treated 15 mg 56 completed 2 cycles responses 18 patients treated 50 mg 39 completed 2 cycles 11 responded experienced grade 3/4 neutropenic fever/infection 60-day mortality rate 30 Median OS 114 days 19 surviving 1 year terminated lack robust clinical activity lenalidomide 15 mg ineffective RR myeloid malignancies Continous high dosing schedules poorly tolerated minimally active evaluation considered upfront intensive chemotherapy-ineligible patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[383, 235, 1923, 9, 7, 5, 430, 2, 591, 861, 142, 43, 2040, 168, 1223, 2, 286, 533, 2001, 5, 21950, 2253, 329, 8325, 64, 61, 2701, 1288, 212, 81, 71, 128, 22, 3171, 36, 4, 1216, 329, 84, 125, 16, 383, 74, 4, 3, 861, 546, 26, 124, 215, 160, 159, 7, 5, 861, 168, 1223, 15, 329, 8325, 28, 18, 415, 1, 1288, 167, 15, 212, 81, 23, 162, 14, 339, 1, 595, 218, 410, 3, 86, 1138, 10, 51, 116, 75, 3, 1324, 944, 2644, 87, 371, 63, 25, 118, 10, 661, 20, 876, 882, 636, 1, 428, 7, 346, 728, 42, 168, 1223, 2, 456, 329, 8325, 77, 69, 42, 1355, 48944, 605, 42, 334, 43, 3385, 1, 83, 7, 73, 28, 167, 81, 664, 781, 3107, 410, 5, 77, 253, 1, 203, 7, 73, 28, 212, 81, 587, 781, 3107, 410, 2, 175, 2211, 84, 62, 592, 88, 27, 39, 3659, 2775, 930, 3, 335, 218, 282, 116, 10, 201, 52, 118, 10, 3803, 162, 5, 326, 3050, 3567, 111, 3, 45, 10, 5640, 520, 6, 926, 1, 1922, 38, 128, 4, 1221, 1288, 28, 167, 81, 16, 3957, 4, 861, 533, 441, 46954, 64, 1280, 2314, 32, 1240, 421, 2, 2144, 544, 195, 451, 257, 40, 515, 4, 2941, 1686, 56, 3773, 7]",1268.0,27790720,phase 2 trial high dose lenalidomide patients relapsed/refractory higher-risk myelodysplastic syndromes acute myeloid leukaemia trilineage dysplasia,4,0.006980802792321117
Current management of patients with chronic myelomonocytic leukemia.,Current opinion in oncology,Curr Opin Oncol,2017-01-01,"The present review will focus on the current management of patients with chronic myelomonocytic leukemia (CMML) as well as in future therapeutic perspectives. CMML is a clonal hematopoietic stem cell disorder characterized by peripheral blood monocytosis and myelodysplastic and myeloproliferative alterations in the bone marrow. Clinical behavior of the disease can be heterogeneous, with some patients having an indolent form of the disease, whereas others experience an aggressive course with decreased survival and eventual transformation to leukemia. Multiple studies have helped define the clinical, cytogenetic and mutational prognostic features of the disease. In addition, several prognostic scoring systems have been developed for patients with CMML. Incorporation of mutation data, particularly presence of frameshift and nonsense ASXL1 mutations, into these models seems to be allowing to further improve our ability to predict patient outcomes. Prognosis of patients with CMML is heterogeneous. Incorporation of mutational data into current clinical prognostic models has allowed to improve our ability to predict patient outcomes. Allogeneic stem cell transplantation remains the only potentially curative treatment for patients with CMML but is only an option for a subset of patients. For this reason, hypomethylating agents such as 5-azacitidine and decitabine have become the backbone of current therapy for patients with CMML, but new therapeutic strategies are required to improve their outcomes.",Journal Article,1115.0,3.0,present review focus current management patients chronic myelomonocytic leukemia CMML future therapeutic perspectives CMML clonal hematopoietic stem disorder characterized peripheral blood monocytosis myelodysplastic myeloproliferative alterations bone marrow Clinical behavior disease heterogeneous patients indolent form disease experience aggressive course decreased survival eventual transformation leukemia Multiple studies helped define clinical cytogenetic prognostic features disease addition prognostic scoring systems developed patients CMML Incorporation particularly presence frameshift nonsense ASXL1 models allowing improve ability predict patient outcomes Prognosis patients CMML heterogeneous Incorporation current clinical prognostic models allowed improve ability predict patient outcomes Allogeneic stem transplantation remains potentially curative treatment patients CMML option subset patients reason hypomethylating agents 5-azacitidine decitabine backbone current therapy patients CMML new therapeutic strategies required improve outcomes,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 364, 206, 303, 1222, 23, 3, 291, 284, 1, 7, 5, 442, 5451, 3382, 22, 149, 22, 4, 508, 189, 5856, 3382, 16, 8, 1946, 1007, 452, 31, 2645, 765, 20, 672, 315, 16875, 2, 2, 593, 4, 3, 581, 38, 1710, 1, 3, 34, 122, 40, 1564, 5, 476, 7, 1041, 35, 2316, 1297, 1, 3, 34, 547, 1749, 730, 35, 571, 906, 5, 340, 25, 2, 6956, 1392, 6, 232, 94, 47, 6156, 1107, 3, 38, 1266, 2, 1619, 177, 404, 1, 3, 34, 4, 352, 392, 177, 2504, 1530, 47, 85, 276, 9, 7, 5, 3382, 2838, 1, 258, 74, 823, 463, 1, 9425, 2, 9168, 7782, 138, 237, 46, 274, 2744, 6, 40, 2952, 6, 195, 401, 114, 801, 6, 678, 69, 123, 356, 1, 7, 5, 3382, 16, 1564, 2838, 1, 1619, 74, 237, 291, 38, 177, 274, 71, 2313, 6, 401, 114, 801, 6, 678, 69, 123, 1063, 452, 31, 497, 469, 3, 158, 751, 1075, 24, 9, 7, 5, 3382, 84, 16, 158, 35, 1501, 9, 8, 697, 1, 7, 9, 26, 3852, 4931, 183, 225, 22, 33, 3752, 2, 3004, 47, 1417, 3, 7066, 1, 291, 36, 9, 7, 5, 3382, 84, 217, 189, 422, 32, 616, 6, 401, 136, 123]",1438.0,27849645,Current management patients chronic myelomonocytic leukemia,1,0.0017452006980802793
Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).,Breast cancer research and treatment,Breast Cancer Res. Treat.,2016-11-19,"We examined acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) events among 9679 women treated for breast cancer on four adjuvant Alliance for Clinical Trials in Oncology trials with >90months of follow-up in order to better characterize the risk for AML/MDS in older patients receiving anthracyclines. We used multivariable Cox regression to examine factors associated with AML/MDS, adjusting for age (65 vs. <65years; separately for 70 vs. <70years), race/ethnicity, insurance, performance status, and anthracycline receipt. We also examined the effect of cyclophosphamide, the interaction of anthracycline and age, and outcomes for those developing AML/MDS. On Cancer and Leukemia Group B (CALGB) 40101, 49907, 9344, and 9741, 7290 received anthracyclines; 15% were in the age 65 and 7% were 70. Overall, 47 patients developed AML/MDS (30 AML [0.3%], 17 MDS [0.2%]); 83% of events occurred within 5years of study registration. Among those age 65 and 70, 0.8 and 1.0% developed AML/MDS (vs. 0.4% for age <65), respectively. In adjusted analyses, older age and anthracycline receipt were significantly associated with AML/MDS (adjusted hazard ratio [HR] for age 65 [vs. <65]=3.13, 95% confidence interval [CI] 1.18-8.33; HR for anthracycline receipt [vs. no anthracycline]=5.16, 95% CI 1.47-18.19). There was no interaction between age and anthracycline use. Deaths occurred in 70% of those developing AML/MDS. We observed an increased risk for AML/MDS for older patients and those receiving anthracyclines, though these events were rare. Our results help inform discussions surrounding anticipated toxicities of adjuvant chemotherapy in older patients.",Journal Article,1158.0,5.0,examined acute myeloid leukemia AML myelodysplastic syndrome MDS events 9679 women treated breast adjuvant Alliance Clinical Trials Oncology trials 90 months follow-up order better characterize risk AML/MDS older patients receiving anthracyclines multivariable Cox regression examine factors associated AML/MDS adjusting age 65 vs. 65 years separately 70 vs. 70 years race/ethnicity insurance performance status anthracycline receipt examined effect cyclophosphamide interaction anthracycline age outcomes developing AML/MDS Leukemia Group B CALGB 40101 49907 9344 9741 7290 received anthracyclines 15 age 65 7 70 Overall 47 patients developed AML/MDS 30 AML 0.3 17 MDS 0.2 83 events occurred 5 years registration age 65 70 0.8 1.0 developed AML/MDS vs. 0.4 age 65 respectively adjusted older age anthracycline receipt significantly associated AML/MDS adjusted hazard ratio HR age 65 vs. 65 3.13 95 confidence interval CI 1.18-8.33 HR anthracycline receipt vs. anthracycline 5.16 95 CI 1.47-18.19 interaction age anthracycline use Deaths occurred 70 developing AML/MDS observed increased risk AML/MDS older patients receiving anthracyclines events rare help inform discussions surrounding anticipated toxicities adjuvant chemotherapy older patients,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 409, 286, 533, 329, 2, 681, 1223, 281, 107, 47940, 117, 73, 9, 12, 23, 294, 249, 7127, 9, 38, 143, 4, 413, 143, 5, 424, 53, 1, 166, 126, 4, 1732, 6, 380, 1507, 3, 43, 9, 329, 1223, 4, 434, 7, 357, 3597, 21, 95, 658, 418, 320, 6, 1004, 130, 41, 5, 329, 1223, 1358, 9, 89, 5827, 105, 556, 60, 3582, 9, 6146, 105, 431, 60, 1047, 2091, 1935, 528, 156, 2, 2044, 1699, 21, 120, 409, 3, 254, 1, 1112, 3, 915, 1, 2044, 2, 89, 2, 123, 9, 135, 931, 329, 1223, 23, 12, 2, 87, 132, 4077, 27205, 19904, 22059, 2, 28474, 69373, 103, 3597, 167, 11, 4, 3, 89, 5827, 2, 67, 11, 6146, 63, 662, 7, 276, 329, 1223, 201, 329, 13, 27, 269, 1223, 13, 18, 852, 1, 281, 489, 262, 33, 60, 1, 45, 3169, 107, 135, 89, 5827, 2, 6146, 13, 66, 2, 14, 13, 276, 329, 1223, 105, 13, 39, 9, 89, 556, 106, 4, 586, 318, 434, 89, 2, 2044, 1699, 11, 97, 41, 5, 329, 1223, 586, 360, 197, 168, 9, 89, 5827, 105, 556, 27, 233, 48, 307, 268, 58, 14, 203, 66, 466, 168, 9, 2044, 1699, 105, 77, 2044, 33, 245, 48, 58, 14, 662, 203, 326, 125, 10, 77, 915, 59, 89, 2, 2044, 119, 1043, 489, 4, 431, 1, 135, 931, 329, 1223, 21, 164, 35, 101, 43, 9, 329, 1223, 9, 434, 7, 2, 135, 357, 3597, 2471, 46, 281, 11, 622, 114, 99, 987, 2295, 3173, 2976, 4078, 385, 1, 249, 56, 4, 434, 7]",1562.0,27866278,Risk acute myeloid leukemia myelodysplastic syndrome older women receiving anthracycline-based adjuvant chemotherapy breast Modern Cooperative Group Trials Alliance A151511,3,0.005235602094240838
Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population-Based Study.,The Prostate,Prostate,2016-11-21,"To understand the impact of radiotherapy on the development of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) among elderly prostate cancer patients. We performed a retrospective cohort study of elderly prostate cancer patients diagnosed during 1999-2011 by using the National Cancer Institute's Surveillance, Epidemiology and End Results-Medicare linked database. Competing risk analyses adjusting for patient characteristics were conducted to assess the impact of radiotherapy on the development of subsequent MDS/AML, compared with surgery. Of 32,112 prostate cancer patients, 14,672 underwent radiotherapy, and 17,440 received surgery only. The median follow-up was 4.68 years. A total of 157 (0.47%) prostate cancer patients developed subsequent MDS or AML, and the median time to develop MDS/AML was 3.30 (range: 0.16-9.48) years. Compared with prostate cancer patients who received surgery only, patients who underwent radiotherapy had a significantly increased risk of developing MDS/AML (hazard ratio [HR] =1.51, 95% confidence interval [CI]: 1.07-2.13). When radiotherapy was further categorized by modalities (brachytherapy, conventional conformal radiotherapy, and intensity-modulated radiotherapy [IMRT]), increased risk of second MDS/AML was only observed in the IMRT group (HR=1.66, 95% CI: 1.09-2.54). Our findings suggest that radiotherapy for prostate cancer increases the risk of MDS/AML, and the impact may differ by modality. Additional studies with longer follow-up are needed to further clarify the role of radiotherapy in the development of subsequent myeloid malignancies. A better understanding may help patients, physicians, and other stakeholders make more informed treatment decisions. Prostate 77:437-445, 2017.  2016 Wiley Periodicals, Inc.",Journal Article,1156.0,13.0,"understand impact radiotherapy development myelodysplastic syndromes MDS acute myeloid leukemia AML elderly prostate patients performed retrospective cohort elderly prostate patients diagnosed 1999-2011 National Institute 's Surveillance Epidemiology End Results-Medicare linked database Competing risk adjusting patient characteristics conducted assess impact radiotherapy development subsequent MDS/AML compared surgery 32,112 prostate patients 14,672 underwent radiotherapy 17,440 received surgery median follow-up 4.68 years total 157 0.47 prostate patients developed subsequent MDS AML median time develop MDS/AML 3.30 range 0.16-9.48 years Compared prostate patients received surgery patients underwent radiotherapy significantly increased risk developing MDS/AML hazard ratio HR =1.51 95 confidence interval CI 1.07-2.13 radiotherapy categorized modalities brachytherapy conventional conformal radiotherapy intensity-modulated radiotherapy IMRT increased risk second MDS/AML observed IMRT group HR 1.66 95 CI 1.09-2.54 findings suggest radiotherapy prostate increases risk MDS/AML impact differ modality Additional studies longer follow-up needed clarify role radiotherapy development subsequent myeloid malignancies better understanding help patients physicians stakeholders informed treatment decisions Prostate 77:437-445 2017  2016 Wiley Periodicals",0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 1640, 3, 345, 1, 310, 23, 3, 193, 1, 2040, 1223, 2, 286, 533, 329, 107, 1216, 12, 7, 21, 173, 8, 459, 180, 45, 1, 1216, 12, 7, 265, 190, 2043, 1132, 20, 75, 3, 657, 12, 1377, 292, 617, 1284, 2, 396, 99, 1378, 1199, 609, 2573, 43, 318, 1358, 9, 69, 374, 11, 426, 6, 423, 3, 345, 1, 310, 23, 3, 193, 1, 706, 1223, 329, 72, 5, 152, 1, 531, 3726, 12, 7, 213, 11672, 208, 310, 2, 269, 9596, 103, 152, 158, 3, 52, 166, 126, 10, 39, 806, 60, 8, 181, 1, 5311, 13, 662, 12, 7, 276, 706, 1223, 15, 329, 2, 3, 52, 98, 6, 690, 1223, 329, 10, 27, 201, 184, 13, 245, 83, 576, 60, 72, 5, 12, 7, 54, 103, 152, 158, 7, 54, 208, 310, 42, 8, 97, 101, 43, 1, 931, 1223, 329, 360, 197, 168, 14, 725, 48, 307, 268, 58, 14, 1615, 18, 233, 198, 310, 10, 195, 2320, 20, 1558, 1536, 809, 2972, 310, 2, 837, 1757, 310, 964, 101, 43, 1, 419, 1223, 329, 10, 158, 164, 4, 3, 964, 87, 168, 14, 700, 48, 58, 14, 1730, 18, 667, 114, 272, 309, 17, 310, 9, 12, 1106, 3, 43, 1, 1223, 329, 2, 3, 345, 68, 1505, 20, 1396, 402, 94, 5, 589, 166, 126, 32, 575, 6, 195, 3968, 3, 200, 1, 310, 4, 3, 193, 1, 706, 533, 441, 8, 380, 612, 68, 987, 7, 1261, 2, 127, 6990, 2378, 80, 2767, 24, 1526, 849, 12592, 9398, 1759, 2206, 1390, 4692, 5493, 3479]",1648.0,27868212,Myelodysplastic Syndromes Acute Myeloid Leukemia Radiotherapy Prostate Population-Based,7,0.012216404886561954
Genetic predisposition to leukemia and other hematologic malignancies.,Seminars in oncology,Semin. Oncol.,2016-10-25,"In this review, we provide an overview of familial myelodysplastic syndromes (MDS)/acute leukemia (AL) and bone marrow failure syndromes, as well as insights into familial myeloproliferative neoplasms (MPNs), familial multiple myeloma (MM), familial Waldenstrm macroglobulinemia (WM), familial lymphoma, and cancer predisposition syndromes with increased risk of MDS/AL. This field will continue to accelerate as next-generation sequencing (NGS) techniques identify novel predisposition alleles in families with a genetic predisposition to hematologic malignancies. Newly identified predisposition genes continue to inform the field of inherited leukemia and other hematologic malignancies. Current developments in clinical translation include techniques detailing the acquisition of appropriate germline material for patient work-ups, methods for genetic testing, and nuances essential for the treatment and clinical management of patients with a genetic predisposition to hematologic malignancies.",Journal Article,1183.0,25.0,review provide overview familial myelodysplastic syndromes MDS /acute leukemia bone marrow failure syndromes insights familial myeloproliferative neoplasms MPNs familial multiple myeloma MM familial Waldenstrm macroglobulinemia WM familial lymphoma predisposition syndromes increased risk MDS/AL field continue accelerate next-generation sequencing NGS techniques identify novel predisposition alleles families genetic predisposition hematologic malignancies Newly identified predisposition continue inform field inherited leukemia hematologic malignancies Current developments clinical translation include techniques detailing acquisition appropriate germline material patient work-ups methods genetic testing nuances essential treatment clinical management patients genetic predisposition hematologic malignancies,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 26, 206, 21, 377, 35, 2901, 1, 2200, 2040, 1223, 286, 2171, 2, 581, 496, 2040, 22, 149, 22, 1957, 237, 2200, 1179, 6880, 2200, 232, 321, 2200, 3700, 3389, 1518, 2200, 2, 12, 2863, 2040, 5, 101, 43, 1, 1223, 2171, 26, 1067, 303, 1906, 6, 5792, 22, 1305, 914, 615, 2650, 1092, 255, 229, 2863, 2558, 4, 1954, 5, 8, 336, 2863, 6, 813, 441, 732, 108, 2863, 214, 1906, 6, 2295, 3, 1067, 1, 2986, 2, 127, 813, 441, 291, 3703, 4, 38, 2691, 643, 1092, 12765, 3, 3405, 1, 870, 1009, 3692, 9, 69, 1357, 6106, 636, 9, 336, 471, 2, 15967, 1452, 9, 3, 24, 2, 38, 284, 1, 7, 5, 8, 336, 2863, 6, 813, 441]",902.0,27899193,Genetic predisposition leukemia hematologic malignancies,112,0.19546247818499127
New challenges in evaluating anemia in older persons in the era of molecular testing.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2016-12-01,"Anemia is common in older persons, and often remains unexplained despite a thorough clinical history, physical examination, and focused laboratory testing, including marrow aspiration, biopsy, and karyotyping. The advent of molecular genetic testing panels in hematology clinical practice has complicated the evaluation of older patients with unexplained anemia. While the presence of a somatic mutation provides evidence of clonal hematopoiesis and may support a diagnosis of a hematologic neoplasm such as one of the myelodysplastic syndromes (MDS), with rare exceptions, individual mutations are not strongly associated with one specific diagnosis, nor are they by themselves diagnostic of neoplasia. A clonal mutation in a patient with cytopenias and a nondiagnostic bone marrow may indicate a syndrome with a similar natural history to MDS, but at present there are no clear criteria to distinguish cytopenias coincidentally seen in association with an unrelated clonal mutation from cytopenias that are directly caused by that mutation. Ongoing and planned analyses will help define when mutation patterns alone can identify a disorder equivalent to a morphologically defined myeloid neoplasm such as MDS, further clarifying the etiology and natural history of unexplained anemia in the elderly.",Journal Article,1146.0,5.0,Anemia common older persons remains unexplained despite thorough clinical history physical examination focused laboratory testing including marrow aspiration biopsy karyotyping advent molecular genetic testing panels hematology clinical practice complicated evaluation older patients unexplained anemia presence somatic provides evidence clonal hematopoiesis support diagnosis hematologic neoplasm myelodysplastic syndromes MDS rare exceptions individual strongly associated specific diagnosis diagnostic neoplasia clonal patient cytopenias nondiagnostic bone marrow indicate syndrome similar natural history MDS present clear criteria distinguish cytopenias coincidentally seen association unrelated clonal cytopenias directly caused Ongoing planned help define patterns identify disorder equivalent morphologically defined myeloid neoplasm MDS clarifying etiology natural history unexplained anemia elderly,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1545, 16, 186, 4, 434, 4327, 2, 629, 469, 8221, 550, 8, 5506, 38, 532, 900, 1385, 2, 1649, 1624, 471, 141, 581, 3256, 411, 2, 10406, 3, 4114, 1, 219, 336, 471, 4383, 4, 6216, 38, 758, 71, 4286, 3, 451, 1, 434, 7, 5, 8221, 1545, 369, 3, 463, 1, 8, 1119, 258, 777, 241, 1, 1946, 5114, 2, 68, 538, 8, 147, 1, 8, 813, 2131, 225, 22, 104, 1, 3, 2040, 1223, 5, 622, 11084, 797, 138, 32, 44, 1327, 41, 5, 104, 112, 147, 2110, 32, 491, 20, 5374, 752, 1, 2298, 8, 1946, 258, 4, 8, 69, 5, 5635, 2, 8, 13534, 581, 68, 1008, 8, 681, 5, 8, 288, 1504, 532, 6, 1223, 84, 28, 364, 125, 32, 77, 885, 371, 6, 3081, 5635, 69437, 527, 4, 248, 5, 35, 2092, 1946, 258, 29, 5635, 17, 32, 1606, 1546, 20, 17, 258, 942, 2, 1465, 318, 303, 987, 1107, 198, 258, 764, 279, 122, 255, 8, 2645, 2017, 6, 8, 6204, 395, 533, 2131, 225, 22, 1223, 195, 14622, 3, 2855, 2, 1504, 532, 1, 8221, 1545, 4, 3, 1216]",1262.0,27913464,New challenges evaluating anemia older persons era molecular testing,1,0.0017452006980802793
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.,The New England journal of medicine,N. Engl. J. Med.,2016-11-01,"The molecular determinants of clinical responses to decitabine therapy in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) are unclear. We enrolled 84 adult patients with AML or MDS in a single-institution trial of decitabine to identify somatic mutations and their relationships to clinical responses. Decitabine was administered at a dose of 20 mg per square meter of body-surface area per day for 10 consecutive days in monthly cycles. We performed enhanced exome or gene-panel sequencing in 67 of these patients and serial sequencing at multiple time points to evaluate patterns of mutation clearance in 54 patients. An extension cohort included 32 additional patients who received decitabine in different protocols. Of the 116 patients, 53 (46%) had bone marrow blast clearance (<5% blasts). Response rates were higher among patients with an unfavorable-risk cytogenetic profile than among patients with an intermediate-risk or favorable-risk cytogenetic profile (29 of 43 patients [67%] vs. 24 of 71 patients [34%], P<0.001) and among patients with TP53 mutations than among patients with wild-type TP53 (21 of 21 [100%] vs. 32 of 78 [41%], P<0.001). Previous studies have consistently shown that patients with an unfavorable-risk cytogenetic profile and TP53 mutations who receive conventional chemotherapy have poor outcomes. However, in this study of 10-day courses of decitabine, neither of these risk factors was associated with a lower rate of overall survival than the rate of survival among study patients with intermediate-risk cytogenetic profiles. Patients with AML and MDS who had cytogenetic abnormalities associated with unfavorable risk, TP53 mutations, or both had favorable clinical responses and robust (but incomplete) mutation clearance after receiving serial 10-day courses of decitabine. Although these responses were not durable, they resulted in rates of overall survival that were similar to those among patients with AML who had an intermediate-risk cytogenetic profile and who also received serial 10-day courses of decitabine. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT01687400 .).",Clinical Trial,1176.0,276.0,molecular determinants clinical responses decitabine therapy patients acute myeloid leukemia AML myelodysplastic syndromes MDS unclear enrolled 84 adult patients AML MDS single-institution trial decitabine identify somatic relationships clinical responses Decitabine administered dose 20 mg square meter body-surface area day 10 consecutive days monthly cycles performed enhanced exome gene-panel sequencing 67 patients serial sequencing multiple time points evaluate patterns clearance 54 patients extension cohort included 32 additional patients received decitabine different protocols 116 patients 53 46 bone marrow blast clearance 5 blasts Response rates higher patients unfavorable-risk cytogenetic profile patients intermediate-risk favorable-risk cytogenetic profile 29 43 patients 67 vs. 24 71 patients 34 P 0.001 patients TP53 patients wild-type TP53 21 21 100 vs. 32 78 41 P 0.001 Previous studies consistently shown patients unfavorable-risk cytogenetic profile TP53 receive conventional chemotherapy poor outcomes 10-day courses decitabine risk factors associated lower rate overall survival rate survival patients intermediate-risk cytogenetic profiles Patients AML MDS cytogenetic abnormalities associated unfavorable risk TP53 favorable clinical responses robust incomplete clearance receiving serial 10-day courses decitabine responses durable resulted rates overall survival similar patients AML intermediate-risk cytogenetic profile received serial 10-day courses decitabine Funded National Institute ClinicalTrials.gov number NCT01687400,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 219, 3403, 1, 38, 253, 6, 3004, 36, 4, 7, 5, 286, 533, 329, 15, 2040, 1223, 32, 1200, 21, 346, 874, 780, 7, 5, 329, 15, 1223, 4, 8, 226, 731, 160, 1, 3004, 6, 255, 1119, 138, 2, 136, 2467, 6, 38, 253, 3004, 10, 468, 28, 8, 61, 1, 179, 81, 379, 3219, 8591, 1, 642, 1255, 965, 379, 218, 9, 79, 935, 162, 4, 3889, 410, 21, 173, 651, 2865, 15, 145, 993, 615, 4, 598, 1, 46, 7, 2, 2108, 615, 28, 232, 98, 862, 6, 376, 764, 1, 258, 1960, 4, 667, 7, 35, 2401, 180, 159, 531, 402, 7, 54, 103, 3004, 4, 338, 2189, 1, 3, 3790, 7, 699, 641, 42, 581, 3112, 1960, 33, 2438, 51, 151, 11, 142, 107, 7, 5, 35, 2483, 43, 1266, 800, 76, 107, 7, 5, 35, 919, 43, 15, 913, 43, 1266, 800, 462, 1, 601, 7, 598, 105, 259, 1, 792, 7, 562, 19, 13, 144, 2, 107, 7, 5, 1206, 138, 76, 107, 7, 5, 955, 267, 1206, 239, 1, 239, 394, 105, 531, 1, 833, 605, 19, 13, 144, 698, 94, 47, 2433, 443, 17, 7, 5, 35, 2483, 43, 1266, 800, 2, 1206, 138, 54, 560, 809, 56, 47, 334, 123, 137, 4, 26, 45, 1, 79, 218, 1993, 1, 3004, 2174, 1, 46, 43, 130, 10, 41, 5, 8, 280, 116, 1, 63, 25, 76, 3, 116, 1, 25, 107, 45, 7, 5, 919, 43, 1266, 1241, 7, 5, 329, 2, 1223, 54, 42, 1266, 1171, 41, 5, 2483, 43, 1206, 138, 15, 110, 42, 913, 38, 253, 2, 1922, 84, 2610, 258, 1960, 50, 357, 2108, 79, 218, 1993, 1, 3004, 242, 46, 253, 11, 44, 1480, 491, 627, 4, 151, 1, 63, 25, 17, 11, 288, 6, 135, 107, 7, 5, 329, 54, 42, 35, 919, 43, 1266, 800, 2, 54, 120, 103, 2108, 79, 218, 1993, 1, 3004, 3827, 20, 3, 657, 12, 1377, 2, 1749, 1252, 1239, 207, 69475]",2100.0,27959731,TP53 Decitabine Acute Myeloid Leukemia Myelodysplastic Syndromes,24,0.041884816753926704
The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.,Leukemia & lymphoma,Leuk. Lymphoma,2016-12-14,"TP53 gene mutations occurring in patients with myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are associated with high-risk karyotypes including 17p abnormalities, monosomal and complex cytogenetics. TP53 mutations in these disorders portend rapid disease progression and resistance to conventional therapeutics. Notably, the size of the TP53 mutant clone as measured by mutation allele burden is directly linked to overall survival (OS) confirming the importance of p53 as a negative prognostic variable. In nucleolar stress-induced ribosomopathies, such as del(5q) MDS, disassociation of MDM2 and p53 results in p53 accumulation in erythroid precursors manifested as erythroid hypoplasia. P53 antagonism by lenalidomide or other therapeutics such as antisense oligonucleotides, repopulates erythroid precursors and enhances effective erythropoiesis. These findings demonstrate that p53 is an intriguing therapeutic target that is currently under investigation in MDS and AML. This study reviews molecular advances in understanding the role of p53 in MDS and AML, and explores potential therapeutic strategies in this era of personalized medicine.",Journal Article,1133.0,16.0,TP53 occurring patients myelodysplastic syndrome MDS acute myeloid leukemia AML associated high-risk karyotypes including 17p abnormalities monosomal complex cytogenetics TP53 disorders portend rapid disease progression resistance conventional therapeutics Notably size TP53 clone measured allele burden directly linked overall survival OS confirming importance p53 negative prognostic variable nucleolar stress-induced ribosomopathies del 5q MDS disassociation MDM2 p53 p53 accumulation erythroid precursors manifested erythroid hypoplasia P53 antagonism lenalidomide therapeutics antisense oligonucleotides repopulates erythroid precursors enhances effective erythropoiesis findings demonstrate p53 intriguing therapeutic target currently investigation MDS AML reviews molecular advances understanding role p53 MDS AML explores potential therapeutic strategies era personalized medicine,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1206, 145, 138, 1821, 4, 7, 5, 681, 1223, 2, 286, 533, 329, 32, 41, 5, 64, 43, 6809, 141, 4135, 1171, 22660, 2, 840, 2510, 1206, 138, 4, 46, 1997, 11293, 1321, 34, 91, 2, 251, 6, 809, 1943, 2552, 3, 444, 1, 3, 1206, 620, 3910, 22, 644, 20, 258, 1254, 892, 16, 1606, 1199, 6, 63, 25, 118, 5030, 3, 1187, 1, 624, 22, 8, 199, 177, 1347, 4, 11328, 1531, 277, 69477, 225, 22, 3084, 5460, 1223, 40579, 1, 3277, 2, 624, 99, 4, 624, 1835, 4, 7839, 4881, 6023, 22, 7839, 20991, 624, 7537, 20, 1288, 15, 127, 1943, 225, 22, 4645, 8721, 69478, 7839, 4881, 2, 2519, 323, 10297, 46, 272, 608, 17, 624, 16, 35, 9382, 189, 283, 17, 16, 694, 669, 940, 4, 1223, 2, 329, 26, 45, 2004, 219, 954, 4, 612, 3, 200, 1, 624, 4, 1223, 2, 329, 2, 6829, 174, 189, 422, 4, 26, 1713, 1, 2175, 1807]",1120.0,27967292,role p53 myelodysplastic syndromes acute myeloid leukemia molecular aspects clinical implications,13,0.02268760907504363
Dynamics of clonal evolution in myelodysplastic syndromes.,Nature genetics,Nat. Genet.,2016-12-19,"To elucidate differential roles of mutations in myelodysplastic syndromes (MDS), we investigated clonal dynamics using whole-exome and/or targeted sequencing of 699 patients, of whom 122 were analyzed longitudinally. Including the results from previous reports, we assessed a total of 2,250 patients for mutational enrichment patterns. During progression, the number of mutations, their diversity and clone sizes increased, with alterations frequently present in dominant clones with or without their sweeping previous clones. Enriched in secondary acute myeloid leukemia (sAML; in comparison to high-risk MDS), FLT3, PTPN11, WT1, IDH1, NPM1, IDH2 and NRAS mutations (type 1) tended to be newly acquired, and were associated with faster sAML progression and a shorter overall survival time. Significantly enriched in high-risk MDS (in comparison to low-risk MDS), TP53, GATA2, KRAS, RUNX1, STAG2, ASXL1, ZRSR2 and TET2 mutations (type 2) had a weaker impact on sAML progression and overall survival than type-1 mutations. The distinct roles of type-1 and type-2 mutations suggest their potential utility in disease monitoring.",Journal Article,1128.0,115.0,"elucidate differential roles myelodysplastic syndromes MDS investigated clonal dynamics whole-exome and/or targeted sequencing 699 patients 122 longitudinally Including previous reports assessed total 2,250 patients enrichment patterns progression number diversity clone sizes increased alterations frequently present dominant clones sweeping previous clones Enriched secondary acute myeloid leukemia sAML comparison high-risk MDS FLT3 PTPN11 WT1 IDH1 NPM1 IDH2 NRAS type 1 tended newly acquired associated faster sAML progression shorter overall survival time Significantly enriched high-risk MDS comparison low-risk MDS TP53 GATA2 KRAS RUNX1 STAG2 ASXL1 ZRSR2 TET2 type 2 weaker impact sAML progression overall survival type-1 distinct roles type-1 type-2 suggest potential utility disease monitoring",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 3061, 1777, 1790, 1, 138, 4, 2040, 1223, 21, 565, 1946, 5193, 75, 902, 2865, 2, 15, 238, 615, 1, 14243, 7, 1, 953, 3285, 11, 311, 9278, 141, 3, 99, 29, 698, 1198, 21, 275, 8, 181, 1, 18, 2039, 7, 9, 1619, 3020, 764, 190, 91, 3, 207, 1, 138, 136, 3653, 2, 3910, 4131, 101, 5, 593, 746, 364, 4, 2156, 2749, 5, 15, 187, 136, 26845, 698, 2749, 2220, 4, 568, 286, 533, 8991, 4, 1155, 6, 64, 43, 1223, 1224, 8403, 3722, 2662, 4318, 4520, 2, 2845, 138, 267, 14, 3886, 6, 40, 732, 1294, 2, 11, 41, 5, 5308, 8991, 91, 2, 8, 985, 63, 25, 98, 97, 2220, 4, 64, 43, 1223, 4, 1155, 6, 154, 43, 1223, 1206, 12909, 723, 6092, 15439, 7782, 40947, 2, 5038, 138, 267, 18, 42, 8, 9087, 345, 23, 8991, 91, 2, 63, 25, 76, 267, 14, 138, 3, 834, 1790, 1, 267, 14, 2, 267, 18, 138, 309, 136, 174, 1207, 4, 34, 1315]",1064.0,27992414,Dynamics clonal evolution myelodysplastic syndromes,0,0.0
Ex Vivo CD34<sup>+</sup>-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2016-12-23,"Ex vivo CD34<sup>+</sup>-selected T cell depletion (TCD) has been developed as a strategy to reduce the incidence of graft-versus-host disease (GVHD) after allogeneic (allo) hematopoietic stem cell transplantation (HSCT). Clinical characteristics, treatment responses, and outcomes of patients developing acute (aGVHD) and chronic GVHD (cGVHD) after TCD allo-HSCT have not been well established. We evaluated 241 consecutive patients (median age, 57 years) with acute leukemia (n=191, 79%) or myelodysplastic syndrome (MDS) (n=50, 21%) undergoing CD34<sup>+</sup>-selected TCD allo-HSCT without post-HCST immunosuppression in a single institution. Cumulative incidences of grades II-IV and III-IV aGVHD at 180 days were 16% (95% confidence interval [CI], 12 to 21) and 5% (95% CI, 3 to 9), respectively. The skin was the most frequent organ involved, followed by the gastrointestinal tract. Patients were treated with topical corticosteroids, poorly absorbed corticosteroids (budesonide), and/or systemic corticosteroids. The overall day 28 treatment response was high at 82%. The cumulative incidence of any cGVHD at 3 years was 5% (95% CI, 3 to 9), with a median time of onset of 256 days (range, 95 to 1645). The 3-year transplant-related mortality, relapse, overall survival, and disease-free survival were 24% (95% CI, 18 to 30), 22% (95% CI, 17 to 27), 57% (95% CI, 50 to 64), and 54% (95% CI, 47 to 61), respectively. The 1-year and 3-year probabilities of cGVHD-free/relapse-free survival were 65% (95% CI, 59 to 71) and 52% (95% CI, 45 to 59), respectively. Our findings support the use of ex vivo CD34<sup>+</sup>-selected TCD allograft as a calcineurin inhibitor-free intervention for the prevention of GVHD in patients with acute leukemia and MDS.",Clinical Trial,1124.0,9.0,Ex vivo CD34 sup /sup -selected depletion TCD developed strategy reduce incidence graft-versus-host disease GVHD allogeneic allo hematopoietic stem transplantation HSCT Clinical characteristics treatment responses outcomes patients developing acute aGVHD chronic GVHD cGVHD TCD allo-HSCT established evaluated 241 consecutive patients median age 57 years acute leukemia n 191 79 myelodysplastic syndrome MDS n 50 21 undergoing CD34 sup /sup -selected TCD allo-HSCT post-HCST immunosuppression single institution Cumulative incidences grades II-IV III-IV aGVHD 180 days 16 95 confidence interval CI 12 21 5 95 CI 3 9 respectively skin frequent organ involved followed gastrointestinal tract Patients treated topical corticosteroids poorly absorbed corticosteroids budesonide and/or systemic corticosteroids overall day 28 treatment response high 82 cumulative incidence cGVHD 3 years 5 95 CI 3 9 median time onset 256 days range 95 1645 3-year transplant-related mortality relapse overall survival disease-free survival 24 95 CI 18 30 22 95 CI 17 27 57 95 CI 50 64 54 95 CI 47 61 respectively 1-year 3-year probabilities cGVHD-free/relapse-free survival 65 95 CI 59 71 52 95 CI 45 59 respectively findings support use ex vivo CD34 sup /sup -selected TCD allograft calcineurin inhibitor-free intervention prevention GVHD patients acute leukemia MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[2581, 386, 2215, 172, 172, 715, 102, 31, 2286, 8827, 71, 85, 276, 22, 8, 692, 6, 969, 3, 287, 1, 1599, 185, 1204, 34, 1562, 50, 1063, 2564, 1007, 452, 31, 497, 1703, 38, 374, 24, 253, 2, 123, 1, 7, 931, 286, 5873, 2, 442, 1562, 6670, 50, 8827, 2564, 1703, 47, 44, 85, 149, 635, 21, 194, 7086, 935, 7, 52, 89, 696, 60, 5, 286, 78, 6130, 842, 15, 681, 1223, 78, 212, 239, 479, 2215, 172, 172, 715, 8827, 2564, 1703, 187, 539, 50157, 3646, 4, 8, 226, 731, 967, 3981, 1, 2276, 215, 478, 2, 316, 478, 5873, 28, 3172, 162, 11, 245, 48, 307, 268, 58, 133, 6, 239, 2, 33, 48, 58, 27, 6, 83, 106, 3, 10, 3, 96, 908, 1259, 646, 370, 20, 3, 1696, 7, 11, 73, 5, 5879, 3876, 1240, 5249, 3876, 26332, 2, 15, 403, 3876, 3, 63, 218, 339, 24, 51, 10, 64, 28, 878, 3, 967, 287, 1, 500, 6670, 28, 27, 60, 10, 33, 48, 58, 27, 6, 83, 5, 8, 52, 98, 1, 1707, 1, 7162, 162, 184, 48, 6, 33843, 3, 27, 111, 941, 139, 282, 429, 63, 25, 2, 34, 115, 25, 11, 259, 48, 58, 203, 6, 201, 350, 48, 58, 269, 6, 428, 696, 48, 58, 212, 6, 660, 2, 667, 48, 58, 662, 6, 713, 106, 3, 14, 111, 2, 27, 111, 3518, 1, 6670, 115, 429, 115, 25, 11, 556, 48, 58, 728, 6, 792, 2, 653, 48, 58, 512, 6, 728, 106, 114, 272, 538, 3, 119, 1, 2581, 386, 2215, 172, 172, 715, 8827, 9568, 22, 8, 12028, 230, 115, 788, 9, 3, 1070, 1, 1562, 4, 7, 5, 286, 2, 1223]",1593.0,28017734,Ex Vivo CD34 sup /sup -Selected Cell-Depleted Peripheral Blood Stem Grafts Allogeneic Hematopoietic Stem Transplantation Acute Leukemia Myelodysplastic Syndrome Associated Low Incidence Acute Chronic Graft-versus-Host Disease High Treatment Response,5,0.008726003490401396
Ubiquitination of hnRNPA1 by TRAF6 links chronic innate immune signaling with myelodysplasia.,Nature immunology,Nat. Immunol.,2016-12-26,"Toll-like receptor (TLR) activation contributes to premalignant hematologic conditions, such as myelodysplastic syndromes (MDS). TRAF6, a TLR effector with ubiquitin (Ub) ligase activity, is overexpressed in MDS hematopoietic stem/progenitor cells (HSPCs). We found that TRAF6 overexpression in mouse HSPC results in impaired hematopoiesis and bone marrow failure. Using a global Ub screen, we identified hnRNPA1, an RNA-binding protein and auxiliary splicing factor, as a substrate of TRAF6. TRAF6 ubiquitination of hnRNPA1 regulated alternative splicing of Arhgap1, which resulted in activation of the GTP-binding Rho family protein Cdc42 and accounted for hematopoietic defects in TRAF6-expressing HSPCs. These results implicate Ub signaling in coordinating RNA processing by TLR pathways during an immune response and in premalignant hematologic diseases, such as MDS.",Journal Article,1121.0,29.0,Toll-like receptor TLR activation contributes premalignant hematologic conditions myelodysplastic syndromes MDS TRAF6 TLR effector ubiquitin Ub ligase activity overexpressed MDS hematopoietic stem/progenitor HSPCs TRAF6 overexpression mouse HSPC impaired hematopoiesis bone marrow failure global Ub screen identified hnRNPA1 RNA-binding auxiliary splicing factor substrate TRAF6 TRAF6 ubiquitination hnRNPA1 regulated alternative splicing Arhgap1 resulted activation GTP-binding Rho family Cdc42 accounted hematopoietic defects TRAF6-expressing HSPCs implicate Ub signaling coordinating RNA processing TLR pathways immune response premalignant hematologic diseases MDS,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[7445, 733, 153, 8701, 363, 2444, 6, 4343, 813, 1298, 225, 22, 2040, 1223, 19248, 8, 8701, 2070, 5, 4213, 9904, 5839, 128, 16, 1711, 4, 1223, 1007, 452, 2520, 37, 19987, 21, 204, 17, 19248, 851, 4, 830, 16490, 99, 4, 2364, 5114, 2, 581, 496, 75, 8, 1648, 9904, 2413, 21, 108, 41272, 35, 893, 791, 178, 2, 29860, 3895, 161, 22, 8, 4235, 1, 19248, 19248, 8258, 1, 41272, 1065, 1091, 3895, 1, 69565, 92, 627, 4, 363, 1, 3, 9969, 791, 5722, 607, 178, 14297, 2, 3688, 9, 1007, 2945, 4, 19248, 1046, 19987, 46, 99, 5545, 9904, 314, 4, 17428, 893, 3325, 20, 8701, 460, 190, 35, 250, 51, 2, 4, 4343, 813, 1342, 225, 22, 1223]",829.0,28024152,Ubiquitination hnRNPA1 TRAF6 links chronic innate immune signaling myelodysplasia,0,0.0
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2017-01-09,"Purpose Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition characterized by somatic mutations in the blood of otherwise healthy adults. We hypothesized that in patients undergoing autologous stem-cell transplantation (ASCT) for lymphoma, CHIP at the time of ASCT would be associated with an increased risk of myelodysplastic syndrome and acute myeloid leukemia, collectively termed therapy-related myeloid neoplasm (TMN), and other adverse outcomes. Methods We performed whole-exome sequencing on pre- and post-ASCT samples from 12 patients who developed TMN after autologous transplantation for Hodgkin lymphoma or non-Hodgkin lymphoma and targeted sequencing on cryopreserved aliquots of autologous stem-cell products from 401 patients who underwent ASCT for non-Hodgkin lymphoma between 2003 and 2010. We assessed the effect of CHIP at the time of ASCT on subsequent outcomes, including TMN, cause-specific mortality, and overall survival. Results For six of 12 patients in the exome sequencing cohort, mutations found in the TMN specimen were also detectable in the pre-ASCT specimen. In the targeted sequencing cohort, 120 patients (29.9%) had CHIP at the time of ASCT, which was associated with an increased rate of TMN (10-year cumulative incidence, 14.1% v 4.3% for those with and without CHIP, respectively; P = .002). Patients with CHIP had significantly inferior overall survival compared with those without CHIP (10-year overall survival, 30.4% v 60.9%, respectively; P < .001), including increased risk of death from TMN and cardiovascular disease. Conclusion In patients undergoing ASCT for lymphoma, CHIP at the time of transplantation is associated with inferior survival and increased risk of TMN.",Journal Article,1107.0,93.0,Purpose Clonal hematopoiesis indeterminate potential CHIP age-related condition characterized somatic blood healthy adults hypothesized patients undergoing autologous stem-cell transplantation ASCT lymphoma CHIP time ASCT associated increased risk myelodysplastic syndrome acute myeloid leukemia collectively termed therapy-related myeloid neoplasm TMN adverse outcomes Methods performed whole-exome sequencing pre- post-ASCT 12 patients developed TMN autologous transplantation Hodgkin lymphoma non-Hodgkin lymphoma targeted sequencing cryopreserved aliquots autologous stem-cell products 401 patients underwent ASCT non-Hodgkin lymphoma 2003 2010 assessed effect CHIP time ASCT subsequent outcomes including TMN cause-specific mortality overall survival 12 patients exome sequencing cohort TMN specimen detectable pre-ASCT specimen targeted sequencing cohort 120 patients 29.9 CHIP time ASCT associated increased rate TMN 10-year cumulative incidence 14.1 v 4.3 CHIP respectively P .002 Patients CHIP significantly inferior overall survival compared CHIP 10-year overall survival 30.4 v 60.9 respectively P .001 including increased risk death TMN cardiovascular disease patients undergoing ASCT lymphoma CHIP time transplantation associated inferior survival increased risk TMN,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[743, 1946, 5114, 1, 5167, 174, 4222, 16, 35, 89, 139, 2850, 765, 20, 1119, 138, 4, 3, 315, 1, 2632, 1331, 857, 21, 1237, 17, 4, 7, 479, 1028, 452, 31, 497, 1584, 9, 4222, 28, 3, 98, 1, 1584, 688, 40, 41, 5, 35, 101, 43, 1, 681, 2, 286, 533, 2535, 4183, 36, 139, 533, 2131, 17032, 2, 127, 290, 123, 636, 21, 173, 902, 2865, 615, 23, 671, 2, 539, 1584, 347, 29, 133, 7, 54, 276, 17032, 50, 1028, 497, 9, 15, 2, 238, 615, 23, 10432, 16390, 1, 1028, 452, 31, 2766, 29, 7191, 7, 54, 208, 1584, 9, 59, 1522, 2, 1120, 21, 275, 3, 254, 1, 4222, 28, 3, 98, 1, 1584, 23, 706, 123, 141, 17032, 708, 112, 282, 2, 63, 25, 99, 9, 437, 1, 133, 7, 4, 3, 2865, 615, 180, 138, 204, 4, 3, 17032, 2360, 11, 120, 2083, 4, 3, 671, 1584, 2360, 4, 3, 238, 615, 180, 2031, 7, 462, 83, 42, 4222, 28, 3, 98, 1, 1584, 92, 10, 41, 5, 35, 101, 116, 1, 17032, 79, 111, 967, 287, 213, 14, 603, 39, 27, 9, 135, 5, 2, 187, 4222, 106, 19, 1111, 7, 5, 4222, 42, 97, 1663, 63, 25, 72, 5, 135, 187, 4222, 79, 111, 63, 25, 201, 39, 603, 335, 83, 106, 19, 144, 141, 101, 43, 1, 273, 29, 17032, 2, 2179, 34, 1221, 4, 7, 479, 1584, 9, 4222, 28, 3, 98, 1, 497, 16, 41, 5, 1663, 25, 2, 101, 43, 1, 17032]",1598.0,28068180,Clonal Hematopoiesis Associated Adverse Outcomes Autologous Stem-Cell Transplantation Lymphoma,0,0.0
Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel.,Blood,Blood,2017-01-17,"An international expert panel, active within the European Society for Blood and Marrow Transplantation, European LeukemiaNet, Blood and Marrow Transplant Clinical Trial Group, and the International Myelodysplastic Syndromes Foundation developed recommendations for allogeneic hematopoietic stem cell transplantation (HSCT) in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Disease risks scored according to the revised International Prognostic Scoring System (IPSS-R) and presence of comorbidity graded according to the HCT Comorbidity Index (HCT-CI) were recognized as relevant clinical variables for HSCT eligibility. Fit patients with higher-risk IPSS-R and those with lower-risk IPSS-R with poor-risk genetic features, profound cytopenias, and high transfusion burden are candidates for HSCT. Patients with a very high MDS transplantation risk score, based on combination of advanced age, high HCT-CI, very poor-risk cytogenetic and molecular features, and high IPSS-R score have a low chance of cure with standard HSCT and consideration should be given to treating these patients in investigational studies. Cytoreductive therapy prior to HSCT is advised for patients with 10% bone marrow myeloblasts. Evidence from prospective randomized clinical trials does not provide support for specific recommendations on the optimal high intensity conditioning regimen. For patients with contraindications to high-intensity preparative regimens, reduced intensity conditioning should be considered. Optimal timing of HSCT requires careful evaluation of the available effective nontransplant strategies. Prophylactic donor lymphocyte infusion (DLI) strategies are recommended in patients at high risk of relapse after HSCT. Immune modulation by DLI strategies or second HSCT is advised if relapse occurs beyond 6 months after HSCT.",Journal Article,1099.0,66.0,international expert panel active European Society Blood Marrow Transplantation European LeukemiaNet Blood Marrow Transplant Clinical Trial Group International Myelodysplastic Syndromes Foundation developed recommendations allogeneic hematopoietic stem transplantation HSCT myelodysplastic syndromes MDS chronic myelomonocytic leukemia CMML Disease risks scored according revised International Prognostic Scoring IPSS-R presence comorbidity graded according HCT Comorbidity Index HCT-CI recognized relevant clinical variables HSCT eligibility Fit patients higher-risk IPSS-R lower-risk IPSS-R poor-risk genetic features profound cytopenias high transfusion burden candidates HSCT Patients high MDS transplantation risk score based combination advanced age high HCT-CI poor-risk cytogenetic molecular features high IPSS-R score low chance cure standard HSCT consideration given treating patients investigational studies Cytoreductive therapy prior HSCT advised patients 10 bone marrow myeloblasts Evidence prospective randomized clinical trials provide support specific recommendations optimal high intensity conditioning regimen patients contraindications high-intensity preparative regimens reduced intensity conditioning considered Optimal timing HSCT requires careful evaluation available effective nontransplant strategies Prophylactic donor lymphocyte infusion DLI strategies recommended patients high risk relapse HSCT Immune modulation DLI strategies second HSCT advised relapse occurs 6 months HSCT,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[35, 944, 2005, 993, 544, 262, 3, 1865, 1174, 9, 315, 2, 581, 497, 1865, 10631, 315, 2, 581, 941, 38, 160, 87, 2, 3, 944, 2040, 3247, 276, 883, 9, 1063, 1007, 452, 31, 497, 1703, 4, 2040, 1223, 2, 442, 5451, 3382, 34, 1098, 3179, 768, 6, 3, 4218, 944, 177, 2504, 398, 8751, 668, 2, 463, 1, 1879, 3468, 768, 6, 3, 1085, 1879, 558, 1085, 58, 11, 1904, 22, 867, 38, 682, 9, 1703, 2317, 2975, 7, 5, 142, 43, 8751, 668, 2, 135, 5, 280, 43, 8751, 668, 5, 334, 43, 336, 404, 4399, 5635, 2, 64, 2785, 892, 32, 1931, 9, 1703, 7, 5, 8, 923, 64, 1223, 497, 43, 368, 90, 23, 150, 1, 131, 89, 64, 1085, 58, 923, 334, 43, 1266, 2, 219, 404, 2, 64, 8751, 668, 368, 47, 8, 154, 3477, 1, 1722, 5, 260, 1703, 2, 2415, 257, 40, 447, 6, 1367, 46, 7, 4, 3093, 94, 2604, 36, 324, 6, 1703, 16, 9624, 9, 7, 5, 4556, 581, 14909, 241, 29, 482, 384, 38, 143, 1097, 44, 377, 538, 9, 112, 883, 23, 3, 665, 64, 837, 1933, 477, 9, 7, 5, 8511, 6, 64, 837, 6085, 472, 405, 837, 1933, 257, 40, 515, 665, 1972, 1, 1703, 1706, 3465, 451, 1, 3, 390, 323, 21364, 422, 1862, 1488, 1448, 904, 4676, 422, 32, 793, 4, 7, 28, 64, 43, 1, 429, 50, 1703, 250, 2356, 20, 4676, 422, 15, 419, 1703, 16, 9624, 492, 429, 1780, 1654, 49, 53, 50, 1703]",1776.0,28096091,Allogeneic hematopoietic stem transplantation MDS CMML recommendations international expert panel,3,0.005235602094240838
Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2017-01-17,"Allogeneic hematopoietic cell transplantation conditioning regimen intensity has varied for patients with acute myeloid leukemia and myelodysplastic syndrome. A comparative effectiveness analysis was performed to assess outcomes of busulfan and fludarabine (BuFlu) versus those of fludarabine and 400cGy total body irradiation (FluTBI) conditioning. Thirty-three subjects received BuFlu and 38 received FluTBI. The BuFlu group received more red blood cell transfusions (P=.02) and had a longer time to platelet recovery (P=.004). There were no differences between the regimens regarding incidence of acute or chronic graft-versus-host disease (GVHD), quality of life, or 2-year outcome estimates for relapse (48; 95% confidence interval [CI], 30 to 64 and 50; 95% CI, 33 to 65), nonrelapse mortality (29; 95% CI, 14 to 45 and 29; 95% CI, 15 to 44), relapse-free survival (27; 95% CI, 13 to 43 and 29; 95% CI, 16 to 44), and overall survival (35; 95% CI, 19 to 51; and 37; 95% CI, 22 to 52), respectively. These comparable outcomes have implications for health care resource utilization. Future prospective investigation comparing these regimens with larger patient cohorts and additional strategies to prevent relapse and limit toxicities as well as cost-effectiveness analyses are warranted.",Comparative Study,1099.0,0.0,Allogeneic hematopoietic transplantation conditioning regimen intensity varied patients acute myeloid leukemia myelodysplastic syndrome comparative effectiveness performed assess outcomes busulfan fludarabine BuFlu versus fludarabine 400 cGy total body irradiation FluTBI conditioning Thirty-three subjects received BuFlu 38 received FluTBI BuFlu group received red blood transfusions P .02 longer time platelet recovery P .004 differences regimens incidence acute chronic graft-versus-host disease GVHD quality life 2-year outcome estimates relapse 48 95 confidence interval CI 30 64 50 95 CI 33 65 nonrelapse mortality 29 95 CI 14 45 29 95 CI 15 44 relapse-free survival 27 95 CI 13 43 29 95 CI 16 44 overall survival 35 95 CI 19 51 37 95 CI 22 52 respectively comparable outcomes implications health care resource utilization Future prospective investigation comparing regimens larger patient cohorts additional strategies prevent relapse limit toxicities cost-effectiveness warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1063, 1007, 31, 497, 1933, 477, 837, 71, 2051, 9, 7, 5, 286, 533, 2, 681, 8, 2352, 1236, 65, 10, 173, 6, 423, 123, 1, 3906, 2, 2027, 24168, 185, 135, 1, 2027, 2, 1524, 3071, 181, 642, 1104, 50194, 1933, 977, 169, 976, 103, 24168, 2, 519, 103, 50194, 3, 24168, 87, 103, 80, 3422, 315, 31, 4987, 19, 588, 2, 42, 8, 589, 98, 6, 1596, 1602, 19, 1520, 125, 11, 77, 362, 59, 3, 472, 666, 287, 1, 286, 15, 442, 1599, 185, 1204, 34, 1562, 372, 1, 358, 15, 18, 111, 228, 1423, 9, 429, 576, 48, 307, 268, 58, 201, 6, 660, 2, 212, 48, 58, 466, 6, 556, 4640, 282, 462, 48, 58, 213, 6, 512, 2, 462, 48, 58, 167, 6, 584, 429, 115, 25, 428, 48, 58, 233, 6, 601, 2, 462, 48, 58, 245, 6, 584, 2, 63, 25, 465, 48, 58, 326, 6, 725, 2, 567, 48, 58, 350, 6, 653, 106, 46, 1279, 123, 47, 1268, 9, 341, 165, 3069, 1961, 508, 482, 940, 1430, 46, 472, 5, 1077, 69, 736, 2, 402, 422, 6, 1682, 429, 2, 2385, 385, 22, 149, 22, 835, 1236, 318, 32, 1197]",1210.0,28108271,Comparative Effectiveness Busulfan Fludarabine versus Fludarabine 400 cGy Total Body Irradiation Conditioning Regimens Acute Myeloid Leukemia/Myelodysplastic Syndrome,0,0.0
Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia.,JAMA oncology,JAMA Oncol,2017-07-01,"Therapy-related myeloid neoplasms are a potentially life-threatening consequence of treatment for autoimmune disease (AID) and an emerging clinical phenomenon. To query the association of cytotoxic, anti-inflammatory, and immunomodulating agents to treat patients with AID with the risk for developing myeloid neoplasm. This retrospective case-control study and medical record review included 40011 patients with an International Classification of Diseases, Ninth Revision, coded diagnosis of primary AID who were seen at 2 centers from January 1, 2004, to December 31, 2014; of these, 311 patients had a concomitant coded diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Eighty-six cases met strict inclusion criteria. A case-control match was performed at a 2:1 ratio. Odds ratio (OR) assessment for AID-directed therapies. Among the 86 patients who met inclusion criteria (49 men [57%]; 37 women [43%]; mean [SD] age, 72.3 [15.6] years), 55 (64.0%) had MDS, 21 (24.4%) had de novo AML, and 10 (11.6%) had AML and a history of MDS. Rheumatoid arthritis (23 [26.7%]), psoriasis (18 [20.9%]), and systemic lupus erythematosus (12 [14.0%]) were the most common autoimmune profiles. Median time from onset of AID to diagnosis of myeloid neoplasm was 8 (interquartile range, 4-15) years. A total of 57 of 86 cases (66.3%) received a cytotoxic or an immunomodulating agent. In the comparison group of 172 controls (98 men [57.0%]; 74 women [43.0%]; mean [SD] age, 72.7 [13.8] years), 105 (61.0%) received either agent (P=.50). Azathioprine sodium use was observed more frequently in cases (odds ratio [OR], 7.05; 95% CI, 2.35- 21.13; P<.001). Notable but insignificant case cohort use among cytotoxic agents was found for exposure to cyclophosphamide (OR, 3.58; 95% CI, 0.91-14.11) followed by mitoxantrone hydrochloride (OR, 2.73; 95% CI, 0.23-33.0). Methotrexate sodium (OR, 0.60; 95% CI, 0.29-1.22), mercaptopurine (OR, 0.62; 95% CI, 0.15-2.53), and mycophenolate mofetil hydrochloride (OR, 0.66; 95% CI, 0.21-2.03) had favorable ORs that were not statistically significant. No significant association between a specific length of time of exposure to an agent and the drug's category was observed. In a large population with primary AID, azathioprine exposure was associated with a 7-fold risk for myeloid neoplasm. The control and case cohorts had similar systemic exposures by agent category. No association was found for anti-tumor necrosis factor agents. Finally, no timeline was found for the association of drug exposure with the incidence in development of myeloid neoplasm.",Journal Article,934.0,26.0,Therapy-related myeloid neoplasms potentially life-threatening consequence treatment autoimmune disease AID emerging clinical phenomenon query association cytotoxic anti-inflammatory immunomodulating agents treat patients AID risk developing myeloid neoplasm retrospective case-control medical record review included 40 011 patients International Classification Diseases Ninth Revision coded diagnosis primary AID seen 2 centers January 1 2004 December 31 2014 311 patients concomitant coded diagnosis myelodysplastic syndrome MDS acute myeloid leukemia AML Eighty-six cases met strict inclusion criteria case-control match performed 2:1 ratio Odds ratio assessment AID-directed therapies 86 patients met inclusion criteria 49 men 57 37 women 43 mean SD age 72.3 15.6 years 55 64.0 MDS 21 24.4 novo AML 10 11.6 AML history MDS Rheumatoid arthritis 23 26.7 psoriasis 18 20.9 systemic lupus erythematosus 12 14.0 common autoimmune profiles Median time onset AID diagnosis myeloid neoplasm 8 interquartile range 4-15 years total 57 86 cases 66.3 received cytotoxic immunomodulating agent comparison group 172 controls 98 men 57.0 74 women 43.0 mean SD age 72.7 13.8 years 105 61.0 received agent P .50 Azathioprine sodium use observed frequently cases odds ratio 7.05 95 CI 2.35- 21.13 P .001 Notable insignificant case cohort use cytotoxic agents exposure cyclophosphamide 3.58 95 CI 0.91-14.11 followed mitoxantrone hydrochloride 2.73 95 CI 0.23-33.0 Methotrexate sodium 0.60 95 CI 0.29-1.22 mercaptopurine 0.62 95 CI 0.15-2.53 mycophenolate mofetil hydrochloride 0.66 95 CI 0.21-2.03 favorable ORs statistically significant significant association specific length time exposure agent drug 's category observed large population primary AID azathioprine exposure associated 7-fold risk myeloid neoplasm control case cohorts similar systemic exposures agent category association anti-tumor necrosis factor agents Finally timeline association drug exposure incidence development myeloid neoplasm,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[36, 139, 533, 1179, 32, 8, 751, 358, 3691, 4177, 1, 24, 9, 3445, 34, 2427, 2, 35, 1478, 38, 3936, 6, 12259, 3, 248, 1, 759, 312, 1291, 2, 13861, 183, 6, 943, 7, 5, 2427, 5, 3, 43, 9, 931, 533, 2131, 26, 459, 473, 182, 45, 2, 484, 3237, 206, 159, 327, 3651, 7, 5, 35, 944, 947, 1, 1342, 13544, 5646, 8259, 147, 1, 86, 2427, 54, 11, 527, 28, 18, 1168, 29, 1024, 14, 1131, 6, 1397, 456, 1409, 1, 46, 9521, 7, 42, 8, 1781, 8259, 147, 1, 681, 1223, 15, 286, 533, 329, 2207, 437, 140, 543, 8043, 1680, 371, 8, 473, 182, 5364, 10, 173, 28, 8, 18, 14, 197, 610, 197, 15, 455, 9, 2427, 1166, 235, 107, 3, 868, 7, 54, 543, 1680, 371, 739, 325, 696, 567, 117, 601, 313, 1270, 89, 720, 27, 167, 49, 60, 614, 660, 13, 42, 1223, 239, 259, 39, 42, 1566, 2018, 329, 2, 79, 175, 49, 42, 329, 2, 8, 532, 1, 1223, 12269, 8646, 382, 432, 67, 14648, 203, 179, 83, 2, 403, 15966, 21228, 133, 213, 13, 11, 3, 96, 186, 3445, 1241, 52, 98, 29, 1707, 1, 2427, 6, 147, 1, 533, 2131, 10, 66, 2899, 184, 39, 167, 60, 8, 181, 1, 696, 1, 868, 140, 700, 27, 103, 8, 759, 15, 35, 13861, 420, 4, 3, 1155, 87, 1, 5312, 535, 1096, 325, 696, 13, 794, 117, 601, 13, 313, 1270, 89, 720, 67, 233, 66, 60, 3263, 713, 13, 103, 361, 420, 19, 212, 18744, 4682, 119, 10, 164, 80, 746, 4, 140, 610, 197, 15, 67, 474, 48, 58, 18, 465, 239, 233, 19, 144, 4090, 84, 6761, 473, 180, 119, 107, 759, 183, 10, 204, 9, 645, 6, 1112, 15, 27, 717, 48, 58, 13, 970, 213, 175, 370, 20, 4419, 12268, 15, 18, 803, 48, 58, 13, 382, 466, 13, 2116, 4682, 15, 13, 335, 48, 58, 13, 462, 14, 350, 9223, 15, 13, 744, 48, 58, 13, 167, 18, 699, 2, 11902, 13246, 12268, 15, 13, 700, 48, 58, 13, 239, 18, 680, 42, 913, 3694, 17, 11, 44, 712, 93, 77, 93, 248, 59, 8, 112, 1318, 1, 98, 1, 645, 6, 35, 420, 2, 3, 234, 292, 2169, 10, 164, 4, 8, 375, 266, 5, 86, 2427, 18744, 645, 10, 41, 5, 8, 67, 1116, 43, 9, 533, 2131, 3, 182, 2, 473, 736, 42, 288, 403, 3401, 20, 420, 2169, 77, 248, 10, 204, 9, 312, 30, 1523, 161, 183, 1368, 77, 21670, 10, 204, 9, 3, 248, 1, 234, 645, 5, 3, 287, 4, 193, 1, 533, 2131]",2435.0,28152123,Association Therapy Autoimmune Disease Myelodysplastic Syndromes Acute Myeloid Leukemia,261,0.45549738219895286
Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma.,Transfusion,Transfusion,2017-02-10,"The goal of our study was to find predictors for the development of secondary myelodysplastic syndrome or acute myelogenous leukemia (s-MDS/AML) in patients with relapsed or refractory lymphoma who received high-dose chemotherapy and autologous stem cell transplantation (ASCT). We conducted a retrospective review of 295 patients with relapsed or refractory lymphoma who had undergone their first stem cell collection and ASCT. Patient, disease, and treatment characteristics were collected. The primary goal of this study was to analyze the association between the number of apheresis days needed to collect the requisite stem cell dose in addition to the previously described factors such as age, sex, number and type of prior chemotherapeutic regimens, disease type and status, and the risk of developing s-MDS/AML. Twenty-two patients of 295 were diagnosed with s-MDS/AML after a median follow-up of 62 months. Multivariate analysis using a classification and regression tree showed that the incidence of s-MDS/AML was lowest in patients who were not more than 55 years old at transplantation and in whom the target cell dose was collected infewer than two apheresis sessions (5-year cumulative incidence, 1%), whereas incidence was highest in patients who were more than 55 years old at transplantation and who received a transplant more than 21 months after their initial lymphoma diagnosis (5-year cumulative incidence, 20%). Our study defines a subset of relapsed or refractory lymphoma patients who should be closely monitored for development of s-MDS/AML after high-dose chemotherapy and ASCT.",Clinical Trial,1075.0,4.0,goal predictors development secondary myelodysplastic syndrome acute myelogenous leukemia s-MDS/AML patients relapsed refractory lymphoma received high-dose chemotherapy autologous stem transplantation ASCT conducted retrospective review 295 patients relapsed refractory lymphoma undergone stem collection ASCT Patient disease treatment characteristics collected primary goal association number apheresis days needed collect requisite stem dose addition previously described factors age sex number type prior chemotherapeutic regimens disease type status risk developing s-MDS/AML Twenty-two patients 295 diagnosed s-MDS/AML median follow-up 62 months Multivariate classification regression tree showed incidence s-MDS/AML lowest patients 55 years old transplantation target dose collected fewer apheresis sessions 5-year cumulative incidence 1 incidence highest patients 55 years old transplantation received transplant 21 months initial lymphoma diagnosis 5-year cumulative incidence 20 defines subset relapsed refractory lymphoma patients closely monitored development s-MDS/AML high-dose chemotherapy ASCT,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1326, 1, 114, 45, 10, 6, 2469, 674, 9, 3, 193, 1, 568, 681, 15, 286, 2194, 695, 1223, 329, 4, 7, 5, 591, 15, 430, 54, 103, 64, 61, 56, 2, 1028, 452, 31, 497, 1584, 21, 426, 8, 459, 206, 1, 7051, 7, 5, 591, 15, 430, 54, 42, 1989, 136, 157, 452, 31, 2442, 2, 1584, 69, 34, 2, 24, 374, 11, 786, 3, 86, 1326, 1, 26, 45, 10, 6, 1992, 3, 248, 59, 3, 207, 1, 9456, 162, 575, 6, 6248, 3, 15128, 452, 31, 61, 4, 352, 6, 3, 373, 1027, 130, 225, 22, 89, 1035, 207, 2, 267, 1, 324, 1573, 472, 34, 267, 2, 156, 2, 3, 43, 1, 931, 695, 1223, 329, 737, 100, 7, 1, 7051, 11, 265, 5, 695, 1223, 329, 50, 8, 52, 166, 126, 1, 744, 53, 331, 65, 75, 8, 947, 2, 320, 4899, 224, 17, 3, 287, 1, 695, 1223, 329, 10, 2101, 4, 7, 54, 11, 44, 80, 76, 614, 60, 1095, 28, 497, 2, 4, 953, 3, 283, 31, 61, 10, 786, 4, 1497, 76, 100, 9456, 4390, 33, 111, 967, 287, 14, 547, 287, 10, 1076, 4, 7, 54, 11, 80, 76, 614, 60, 1095, 28, 497, 2, 54, 103, 8, 941, 80, 76, 239, 53, 50, 136, 388, 147, 33, 111, 967, 287, 179, 114, 45, 5849, 8, 697, 1, 591, 15, 430, 7, 54, 257, 40, 3210, 2909, 9, 193, 1, 695, 1223, 329, 50, 64, 61, 56, 2, 1584]",1518.0,28185276,Patient age number apheresis days predict development secondary myelodysplastic syndrome acute myelogenous leukemia high-dose chemotherapy autologous stem transplantation lymphoma,4,0.006980802792321117
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation.,Blood,Blood,2017-02-21,"Genetic alterations, including mutations and copy-number alterations, are central to the pathogenesis of myelodysplastic syndromes and related diseases (myelodysplasia), but their roles in allogeneic stem cell transplantation have not fully been studied in a large cohort of patients. We enrolled 797 patients who had been diagnosed with myelodysplasia at initial presentation and received transplantation via the Japan Marrow Donor Program. Targeted-capture sequencing was performed to identify mutations in 69 genes, together with copy-number alterations, whose effects on transplantation outcomes were investigated. We identified 1776 mutations and 927 abnormal copy segments among 617 patients (77.4%). In multivariate modeling using Cox proportional-hazards regression, genetic factors explained 30% of the total hazards for overall survival; clinical characteristics accounted for 70% of risk. <i>TP53</i> and RAS-pathway mutations, together with complex karyotype (CK) as detected by conventional cytogenetics and/or sequencing-based analysis, negatively affected posttransplant survival independently of clinical factors. Regardless of disease subtype, <i>TP53</i>-mutated patients with CK were characterized by unique genetic features and associated with an extremely poor survival with frequent early relapse, whereas outcomes were substantially better in <i>TP53</i>-mutated patients without CK. By contrast, the effects of RAS-pathway mutations depended on disease subtype and were confined to myelodysplastic/myeloproliferative neoplasms (MDS/MPNs). Our results suggest that <i>TP53</i> and RAS-pathway mutations predicted a dismal prognosis, when associated with CK and MDS/MPNs, respectively. However, for patients with mutated <i>TP53</i> or CK alone, long-term survival could be obtained with transplantation. Clinical sequencing provides vital information for accurate prognostication in transplantation.",Journal Article,1064.0,82.0,Genetic alterations including copy-number alterations central pathogenesis myelodysplastic syndromes related diseases myelodysplasia roles allogeneic stem transplantation fully studied large cohort patients enrolled 797 patients diagnosed myelodysplasia initial presentation received transplantation Japan Marrow Donor Program Targeted-capture sequencing performed identify 69 copy-number alterations effects transplantation outcomes investigated identified 1776 927 abnormal copy segments 617 patients 77.4 multivariate modeling Cox proportional-hazards regression genetic factors explained 30 total hazards overall survival clinical characteristics accounted 70 risk TP53 /i RAS-pathway complex karyotype CK detected conventional cytogenetics and/or sequencing-based negatively affected posttransplant survival independently clinical factors Regardless disease subtype TP53 /i -mutated patients CK characterized unique genetic features associated extremely poor survival frequent early relapse outcomes substantially better TP53 /i -mutated patients CK contrast effects RAS-pathway depended disease subtype confined myelodysplastic/myeloproliferative neoplasms MDS/MPNs suggest TP53 /i RAS-pathway predicted dismal prognosis associated CK MDS/MPNs respectively patients TP53 /i CK long-term survival obtained transplantation Clinical sequencing provides vital information accurate prognostication transplantation,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[336, 593, 141, 138, 2, 1337, 207, 593, 32, 854, 6, 3, 1384, 1, 2040, 2, 139, 1342, 6128, 84, 136, 1790, 4, 1063, 452, 31, 497, 47, 44, 1910, 85, 656, 4, 8, 375, 180, 1, 7, 21, 346, 13379, 7, 54, 42, 85, 265, 5, 6128, 28, 388, 1031, 2, 103, 497, 847, 3, 6157, 581, 1488, 1243, 238, 2891, 615, 10, 173, 6, 255, 138, 4, 790, 214, 1162, 5, 1337, 207, 593, 1310, 176, 23, 497, 123, 11, 565, 21, 108, 18578, 138, 2, 18808, 1668, 1337, 5138, 107, 12379, 7, 849, 39, 4, 331, 2057, 75, 418, 831, 1017, 320, 336, 130, 3672, 201, 1, 3, 181, 1017, 9, 63, 25, 38, 374, 3688, 9, 431, 1, 43, 70, 1206, 70, 2, 1102, 308, 138, 1162, 5, 840, 3385, 4925, 22, 530, 20, 809, 2510, 2, 15, 615, 90, 65, 2723, 1424, 7346, 25, 1042, 1, 38, 130, 1583, 1, 34, 875, 70, 1206, 70, 1185, 7, 5, 4925, 11, 765, 20, 991, 336, 404, 2, 41, 5, 35, 2938, 334, 25, 5, 908, 191, 429, 547, 123, 11, 2109, 380, 4, 70, 1206, 70, 1185, 7, 187, 4925, 20, 748, 3, 176, 1, 1102, 308, 138, 9020, 23, 34, 875, 2, 11, 2902, 6, 10589, 10857, 1179, 1223, 6880, 114, 99, 309, 17, 70, 1206, 70, 2, 1102, 308, 138, 783, 8, 3929, 356, 198, 41, 5, 4925, 2, 1223, 6880, 106, 137, 9, 7, 5, 1185, 70, 1206, 70, 15, 4925, 279, 319, 337, 25, 359, 40, 683, 5, 497, 38, 615, 777, 3511, 487, 9, 1481, 4260, 4, 497]",1860.0,28223278,Genetic abnormalities myelodysplasia secondary acute myeloid leukemia impact outcome stem transplantation,40,0.06980802792321117
Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes: Registry analysis at 5 years.,Leukemia research,Leuk. Res.,2017-01-31,"Prospective data are needed to ascertain the impact of iron chelation therapy in patients with myelodysplastic syndromes. The present 5-year prospective registry analysis was conducted to compare clinical outcomes between chelated and nonchelated patients with lower-risk myelodysplastic syndromes and transfusional iron overload. In an interim analysis at 24 months, we previously reported that chelation therapy was associated with longer median overall survival and a tendency toward longer leukemia-free survival and fewer cardiac events. In the present report, we detail findings from the final analysis at 5 years. We confirm, at the conclusion of this 5-year, prospective, non-interventional study, that overall survival was significantly longer in patients who received iron chelation therapy vs those who did not. Causes of death in the overall population were predominantly myelodysplastic syndromes/acute myeloid leukemia followed by cardiac disease. Time to progression to acute myeloid leukemia was also significantly longer in patients receiving chelation therapy, and significantly fewer patients progressed to leukemia vs those not receiving chelation therapy. Limitations of the study include a potential for clinical bias, as patients with longer predicted survival may have been chosen for chelation therapy, the differences present in concomitant conditions at baseline, and the possibility that some high-risk patients were not identified due to limited cytogenetic classification.",Journal Article,1085.0,16.0,Prospective needed ascertain impact iron chelation therapy patients myelodysplastic syndromes present 5-year prospective registry conducted compare clinical outcomes chelated nonchelated patients lower-risk myelodysplastic syndromes transfusional iron overload interim 24 months previously reported chelation therapy associated longer median overall survival tendency longer leukemia-free survival fewer cardiac events present report findings final 5 years confirm 5-year prospective non-interventional overall survival significantly longer patients received iron chelation therapy vs Causes death overall population predominantly myelodysplastic syndromes/acute myeloid leukemia followed cardiac disease Time progression acute myeloid leukemia significantly longer patients receiving chelation therapy significantly fewer patients progressed leukemia vs receiving chelation therapy Limitations include potential clinical bias patients longer predicted survival chosen chelation therapy differences present concomitant conditions baseline possibility high-risk patients identified limited cytogenetic classification,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,"[482, 74, 32, 575, 6, 6040, 3, 345, 1, 4231, 19709, 36, 4, 7, 5, 2040, 3, 364, 33, 111, 482, 1608, 65, 10, 426, 6, 932, 38, 123, 59, 30470, 2, 69964, 7, 5, 280, 43, 2040, 2, 27843, 4231, 13143, 4, 35, 2914, 65, 28, 259, 53, 21, 373, 210, 17, 19709, 36, 10, 41, 5, 589, 52, 63, 25, 2, 8, 7135, 1317, 589, 2647, 115, 25, 2, 1497, 281, 4, 3, 364, 414, 21, 5000, 272, 29, 3, 1457, 65, 28, 33, 60, 21, 1843, 28, 3, 1221, 1, 26, 33, 111, 482, 220, 6182, 45, 17, 63, 25, 10, 97, 589, 4, 7, 54, 103, 4231, 19709, 36, 105, 135, 54, 205, 44, 1626, 1, 273, 4, 3, 63, 266, 11, 2117, 2040, 286, 533, 370, 20, 34, 98, 6, 91, 6, 286, 533, 10, 120, 97, 589, 4, 7, 357, 19709, 36, 2, 97, 1497, 7, 1839, 6, 105, 135, 44, 357, 19709, 36, 1939, 1, 3, 45, 643, 8, 174, 9, 38, 2947, 22, 7, 5, 589, 783, 25, 68, 47, 85, 4695, 9, 19709, 36, 3, 362, 364, 4, 1781, 1298, 28, 330, 2, 3, 2526, 17, 476, 64, 43, 7, 11, 44, 108, 520, 6, 383, 1266, 947]",1393.0,28242540,Relation chelation clinical outcomes lower-risk patients myelodysplastic syndromes Registry 5 years,0,0.0
Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells from Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.,Stem cells translational medicine,Stem Cells Transl Med,2016-11-07,"Current understanding suggests that malignant stem and progenitor cells must be reduced or eliminated for prolonged remissions in myeloid neoplasms such as acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). Multicolor flow cytometry has been widely used to distinguish stem and myeloid progenitor cells from other populations in normal and malignant bone marrow. In this study, we present a method for assessing drug sensitivity in MDS and AML patient hematopoietic stem and myeloid progenitor cell populations ex vivo using the investigational Nedd8-activating enzyme inhibitor MLN4924 and standard-of-care agent cytarabine as examples. Utilizing a multicolor flow cytometry antibody panel for identification of hematopoietic stem cells, multipotent progenitors, common myeloid progenitors, granulocyte-monocyte progenitors, and megakaryocyte-erythroid progenitors present in mononuclear cell fractions isolated from bone marrow aspirates, we compare stem and progenitor cell counts after treatment for 24 hours with drug versus diluent. We demonstrate that MLN4924 exerts a cytotoxic effect on MDS and AML stem and progenitor cell populations, whereas cytarabine has more limited effects. Further application of this method for evaluating drug effects on these populations ex vivo and in vivo may inform rational design and selection of therapies in the clinical setting. Stem Cells Translational Medicine 2017;6:840-850.",Journal Article,1170.0,3.0,Current understanding suggests malignant stem progenitor reduced eliminated prolonged remissions myeloid neoplasms acute myelogenous leukemia AML myelodysplastic syndrome MDS Multicolor flow cytometry widely distinguish stem myeloid progenitor populations normal malignant bone marrow present assessing drug sensitivity MDS AML patient hematopoietic stem myeloid progenitor populations ex vivo investigational Nedd8-activating enzyme inhibitor MLN4924 standard-of-care agent cytarabine examples Utilizing multicolor flow cytometry antibody panel identification hematopoietic stem multipotent progenitors common myeloid progenitors granulocyte-monocyte progenitors megakaryocyte-erythroid progenitors present mononuclear fractions isolated bone marrow aspirates compare stem progenitor counts treatment 24 hours drug versus diluent demonstrate MLN4924 exerts cytotoxic effect MDS AML stem progenitor populations cytarabine limited effects application evaluating drug effects populations ex vivo vivo inform rational design selection therapies clinical setting Stem Translational Medicine 2017 6:840-850,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[291, 612, 844, 17, 393, 452, 2, 2520, 37, 1642, 40, 405, 15, 6173, 9, 1069, 3166, 4, 533, 1179, 225, 22, 286, 2194, 329, 15, 681, 1223, 11920, 1412, 1914, 71, 85, 1792, 95, 6, 3081, 452, 2, 533, 2520, 37, 29, 127, 1184, 4, 295, 2, 393, 581, 4, 26, 45, 21, 364, 8, 596, 9, 1977, 234, 485, 4, 1223, 2, 329, 69, 1007, 452, 2, 533, 2520, 31, 1184, 2581, 386, 75, 3, 3093, 15031, 1616, 1644, 230, 11716, 2, 260, 1, 165, 420, 1855, 22, 4416, 2600, 8, 11920, 1412, 1914, 548, 993, 9, 911, 1, 1007, 452, 37, 16392, 4321, 186, 533, 4321, 2764, 5231, 4321, 2, 21987, 7839, 4321, 364, 4, 3041, 31, 1550, 1355, 29, 581, 7493, 21, 932, 452, 2, 2520, 31, 1911, 50, 24, 9, 259, 1459, 5, 234, 185, 37094, 21, 608, 17, 11716, 5685, 8, 759, 254, 23, 1223, 2, 329, 452, 2, 2520, 31, 1184, 547, 1855, 71, 80, 383, 176, 195, 1581, 1, 26, 596, 9, 1435, 234, 176, 23, 46, 1184, 2581, 386, 2, 4, 386, 68, 2295, 2696, 771, 2, 881, 1, 235, 4, 3, 38, 546, 452, 37, 2460, 1807, 1759, 49, 10752, 8537]",1387.0,28297583,Assessment Drug Sensitivity Hematopoietic Stem Progenitor Acute Myelogenous Leukemia Myelodysplastic Syndrome Ex Vivo,0,0.0
Improved survival after acute graft-<i>versus</i>-host disease diagnosis in the modern era.,Haematologica,Haematologica,2017-03-16,"A cute graft-<i>versus</i>-host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft-<i>versus</i>-host disease. We examined outcome following diagnosis of grade II-IV acute graft-<i>versus</i>-host disease according to time period, and explored effects according to original graft-<i>versus</i>-host disease prophylaxis regimen and maximum overall grade of acute graft-<i>versus</i>-host disease. Between 1999 and 2012, 2,905 patients with acute myeloid leukemia (56%), acute lymphoblastic leukemia (30%) or myelodysplastic syndromes (14%) received a sibling (24%) or unrelated donor (76%) blood (66%) or marrow (34%) transplant and developed grade II-IV acute graft-<i>versus</i>-host disease (n=497 for 1999-2001, n=962 for 2002-2005, n=1,446 for 2006-2010). The median (range) follow-up was 144 (4-174), 97 (4-147) and 60 (8-99) months for 1999-2001, 2002-2005, and 2006-2010, respectively. Among the cohort with grade II-IV acute graft-<i>versus</i>-host disease, there was a decrease in the proportion of grade III-IV disease over time with 56%, 47%, and 37% for 1999-2001, 2002-2005, and 2006-2012, respectively (<i>P</i><0.001). Considering the total study population, univariate analysis demonstrated significant improvements in overall survival and treatment-related mortality over time, and deaths from organ failure and infection declined. On multivariate analysis, significant improvements in overall survival (<i>P</i>=0.003) and treatment-related mortality (<i>P</i>=0.008) were only noted among those originally treated with tacrolimus-based graft-<i>versus</i>-host disease prophylaxis, and these effects were most apparent among those with overall grade II acute graft-<i>versus</i>-host disease. In conclusion, survival has improved over time for tacrolimus-treated transplant recipients with acute graft-<i>versus</i>-host disease.",Journal Article,1041.0,15.0,"cute graft- versus /i -host disease remains major threat successful outcome allogeneic hematopoietic transplantation improvements treatment supportive care occurred unknown advances resulted improved outcome specifically diagnosed acute graft- versus /i -host disease examined outcome following diagnosis grade II-IV acute graft- versus /i -host disease according time period explored effects according original graft- versus /i -host disease prophylaxis regimen maximum overall grade acute graft- versus /i -host disease 1999 2012 2,905 patients acute myeloid leukemia 56 acute lymphoblastic leukemia 30 myelodysplastic syndromes 14 received sibling 24 unrelated donor 76 blood 66 marrow 34 transplant developed grade II-IV acute graft- versus /i -host disease n=497 1999-2001 n=962 2002-2005 n=1,446 2006-2010 median range follow-up 144 4-174 97 4-147 60 8-99 months 1999-2001 2002-2005 2006-2010 respectively cohort grade II-IV acute graft- versus /i -host disease decrease proportion grade III-IV disease time 56 47 37 1999-2001 2002-2005 2006-2012 respectively P /i 0.001 Considering total population univariate demonstrated significant improvements overall survival treatment-related mortality time deaths organ failure infection declined multivariate significant improvements overall survival P /i =0.003 treatment-related mortality P /i =0.008 noted originally treated tacrolimus-based graft- versus /i -host disease prophylaxis effects apparent overall grade II acute graft- versus /i -host disease survival improved time tacrolimus-treated transplant recipients acute graft- versus /i -host disease",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[8, 70060, 1599, 70, 185, 70, 1204, 34, 469, 8, 458, 10965, 6, 8, 1401, 228, 50, 1063, 1007, 31, 497, 369, 1474, 4, 24, 2, 1877, 165, 47, 489, 192, 16, 860, 317, 46, 954, 47, 627, 4, 231, 228, 1225, 107, 135, 265, 5, 286, 1599, 70, 185, 70, 1204, 34, 21, 409, 228, 366, 147, 1, 88, 215, 478, 286, 1599, 70, 185, 70, 1204, 34, 768, 6, 98, 727, 2, 1443, 176, 768, 6, 2279, 1599, 70, 185, 70, 1204, 34, 2049, 477, 2, 689, 63, 88, 1, 286, 1599, 70, 185, 70, 1204, 34, 59, 2043, 2, 1195, 18, 13300, 7, 5, 286, 533, 664, 286, 1275, 201, 15, 2040, 213, 103, 8, 3684, 259, 15, 2092, 1488, 846, 315, 700, 15, 581, 562, 941, 2, 276, 88, 215, 478, 286, 1599, 70, 185, 70, 1204, 34, 78, 11178, 9, 2043, 1758, 78, 18823, 9, 1544, 1242, 78, 14, 9849, 9, 1324, 1120, 3, 52, 184, 166, 126, 10, 4415, 39, 5811, 1015, 39, 4961, 2, 335, 66, 1058, 53, 9, 2043, 1758, 1544, 1242, 2, 1324, 1120, 106, 107, 3, 180, 5, 88, 215, 478, 286, 1599, 70, 185, 70, 1204, 34, 125, 10, 8, 775, 4, 3, 920, 1, 88, 316, 478, 34, 252, 98, 5, 664, 662, 2, 567, 9, 2043, 1758, 1544, 1242, 2, 1324, 1195, 106, 70, 19, 70, 13, 144, 3075, 3, 181, 45, 266, 880, 65, 264, 93, 1474, 4, 63, 25, 2, 24, 139, 282, 252, 98, 2, 1043, 29, 1259, 496, 2, 930, 3054, 23, 331, 65, 93, 1474, 4, 63, 25, 70, 19, 70, 13, 1421, 2, 24, 139, 282, 70, 19, 70, 13, 2155, 11, 158, 1051, 107, 135, 5045, 73, 5, 5643, 90, 1599, 70, 185, 70, 1204, 34, 2049, 2, 46, 176, 11, 96, 2235, 107, 135, 5, 63, 88, 215, 286, 1599, 70, 185, 70, 1204, 34, 4, 1221, 25, 71, 231, 252, 98, 9, 5643, 73, 941, 2190, 5, 286, 1599, 70, 185, 70, 1204, 34]",1988.0,28302712,Improved survival acute graft- versus /i -host disease diagnosis modern era,0,0.0
Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.,Cancer,Cancer,2017-03-21,"Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment with a curative potential for myelodysplastic syndrome (MDS) patients. Allo-HSCT has substantial risks, particularly in the elderly, and its role for older MDS patients has yet to be defined. We analyzed 88 MDS patients aged60 years with allo-HSCT after reduced intensity conditioning regimens over the last decade. The study cohort had high risk features; 47 of 88 (53.4%) patients were>65 years of age, 24 (27%) patients had cytogenetic abnormalities consistent with monosomal karyotype (MKpos), 33 (38%) patients had histological subtype of RAEB-1 and RAEB-2 at diagnosis, and 45 (51%) patients had a hematopoietic cell transplantation-comorbidity index (HCT-CI) of3. The 3-year incidence of progression, transplant-related mortality (TRM), and overall survival (OS) were 26% (95% confidence interval [CI], 18%-37%), 35% (95% CI, 26%-47%), and 41% (95% CI, 30%-52%), respectively. MKpos was the only prognostic factor that increased the risk of disease progression compared with good-risk cytogenetics (hazard ratio [HR]=9.5, P=.003) as well as MKneg (HR=3.3, P=.01). For TRM, HCT-CI3, but not age >65 years, was associated with worse outcomes (HR=3.1, P=.007). Cytogenetics and HCT-CI enabled us to identify prognostic groups for OS. MKpos patients had the worst 3-year OS (17%), whereas patients with good-risk cytogenetics and HCT-CI<3 had the best OS (92%). Our results confirm that allo-HSCT can provide long-term survival in older MDS patients. Cytogenetics and HCT-CI identify prognostic risk groups and guide selection of older MDS patients who are candidates for allo-HSCT. Cancer 2017;123:2661-70.  2017 American Cancer Society.",Journal Article,1036.0,5.0,Allogeneic hematopoietic stem transplantation allo-HSCT treatment curative potential myelodysplastic syndrome MDS patients Allo-HSCT substantial risks particularly elderly role older MDS patients defined 88 MDS patients aged  60 years allo-HSCT reduced intensity conditioning regimens decade cohort high risk features 47 88 53.4 patients 65 years age 24 27 patients cytogenetic abnormalities consistent monosomal karyotype MKpos 33 38 patients histological subtype RAEB-1 RAEB-2 diagnosis 45 51 patients hematopoietic transplantation-comorbidity index HCT-CI  3 3-year incidence progression transplant-related mortality TRM overall survival OS 26 95 confidence interval CI 18 -37 35 95 CI 26 -47 41 95 CI 30 -52 respectively MKpos prognostic factor increased risk disease progression compared good-risk cytogenetics hazard ratio HR 9.5 P .003 MKneg HR 3.3 P .01 TRM HCT-CI  3 age 65 years associated worse outcomes HR 3.1 P .007 Cytogenetics HCT-CI enabled identify prognostic groups OS MKpos patients worst 3-year OS 17 patients good-risk cytogenetics HCT-CI 3 best OS 92 confirm allo-HSCT provide long-term survival older MDS patients Cytogenetics HCT-CI identify prognostic risk groups guide selection older MDS patients candidates allo-HSCT 2017 123:2661-70  2017 American Society,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1063, 1007, 452, 31, 497, 2564, 1703, 16, 3, 158, 24, 5, 8, 1075, 174, 9, 681, 1223, 7, 2564, 1703, 71, 1281, 1098, 823, 4, 3, 1216, 2, 211, 200, 9, 434, 1223, 7, 71, 1145, 6, 40, 395, 21, 311, 889, 1223, 7, 1032, 749, 335, 60, 5, 2564, 1703, 50, 405, 837, 1933, 472, 252, 3, 1060, 2025, 3, 45, 180, 42, 64, 43, 404, 662, 1, 889, 699, 39, 7, 11, 556, 60, 1, 89, 259, 428, 7, 42, 1266, 1171, 925, 5, 22660, 3385, 41709, 466, 519, 7, 42, 1831, 875, 1, 20273, 14, 2, 20273, 18, 28, 147, 2, 512, 725, 7, 42, 8, 1007, 31, 497, 1879, 558, 1085, 58, 1, 749, 27, 3, 27, 111, 287, 1, 91, 941, 139, 282, 5064, 2, 63, 25, 118, 11, 432, 48, 307, 268, 58, 203, 567, 465, 48, 58, 432, 662, 2, 605, 48, 58, 201, 653, 106, 41709, 10, 3, 158, 177, 161, 17, 101, 3, 43, 1, 34, 91, 72, 5, 1178, 43, 2510, 360, 197, 168, 83, 33, 19, 1421, 22, 149, 22, 70073, 168, 27, 27, 19, 355, 9, 5064, 1085, 58, 749, 27, 84, 44, 89, 556, 60, 10, 41, 5, 639, 123, 168, 27, 14, 19, 1999, 2510, 2, 1085, 58, 4387, 843, 6, 255, 177, 271, 9, 118, 41709, 7, 42, 3, 4066, 27, 111, 118, 269, 547, 7, 5, 1178, 43, 2510, 2, 1085, 58, 27, 42, 3, 824, 118, 937, 114, 99, 1843, 17, 2564, 1703, 122, 377, 319, 337, 25, 4, 434, 1223, 7, 2510, 2, 1085, 58, 255, 177, 43, 271, 2, 1597, 881, 1, 434, 1223, 7, 54, 32, 1931, 9, 2564, 1703, 12, 1759, 2698, 50291, 431, 2206, 1759, 597, 12, 1174]",1630.0,28324640,Cytogenetics comorbidity predict outcomes older myelodysplastic syndrome patients allogeneic stem transplantation reduced intensity conditioning,17,0.029668411867364748
"High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study.",British journal of haematology,Br. J. Haematol.,2017-03-24,"We report a single-centre, randomized study evaluating the efficacy and safety of concurrent fludarabine, mitoxantrone, dexamethasone (FND) and rituximab versus sequential FND followed by rituximab in 158 patients with advanced stage, previously untreated indolent lymphoma, enrolled between 1997 and 2002. Patients were randomized to 6-8 cycles of FND followed by 6 monthly doses of rituximab or 6 doses of rituximab given concurrently with FND. All patients who achieved at least a partial response received 12months of interferon (IFN) maintenance. Median ages were 54 and 55years. The two groups were comparable with the exception of a higher percentage of females (65% vs. 43%) and baseline anaemia (23% vs. 11%) in the FND followed by rituximab group. Complete response/unconfirmed complete response rates were 89% and 93%. The most frequent grade  3 toxicity was neutropenia (86% vs. 96%). Neutropenic fever occurred in 21% and 16%. Late toxicity included myelodysplastic syndrome (n=3) and acute myeloid leukaemia (n=5). With 125years of follow-up, no significant differences based on treatment schedule were observed. 10-year overall survival estimates were 76% and 73%. 10-year progression-free survival estimates were 52% and 51%. FND with concurrent or sequential rituximab, and IFN maintenance in indolent lymphoma demonstrated high response rates and robust survival.",Journal Article,1033.0,5.0,report single-centre randomized evaluating efficacy safety concurrent fludarabine mitoxantrone dexamethasone FND rituximab versus sequential FND followed rituximab 158 patients advanced stage previously untreated indolent lymphoma enrolled 1997 2002 Patients randomized 6-8 cycles FND followed 6 monthly doses rituximab 6 doses rituximab given concurrently FND patients achieved partial response received 12 months interferon IFN maintenance Median ages 54 55 years groups comparable exception higher percentage females 65 vs. 43 baseline anaemia 23 vs. 11 FND followed rituximab group Complete response/unconfirmed complete response rates 89 93 frequent grade  3 toxicity neutropenia 86 vs. 96 Neutropenic fever occurred 21 16 Late toxicity included myelodysplastic syndrome n 3 acute myeloid leukaemia n 5 125 years follow-up significant differences based treatment schedule observed 10-year overall survival estimates 76 73 10-year progression-free survival estimates 52 51 FND concurrent sequential rituximab IFN maintenance indolent lymphoma demonstrated high response rates robust survival,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 414, 8, 226, 5931, 384, 45, 1435, 3, 209, 2, 367, 1, 750, 2027, 4419, 1217, 13827, 2, 855, 185, 1787, 13827, 370, 20, 855, 4, 5162, 7, 5, 131, 82, 373, 1278, 2316, 346, 59, 2341, 2, 1544, 7, 11, 384, 6, 49, 66, 410, 1, 13827, 370, 20, 49, 3889, 415, 1, 855, 15, 49, 415, 1, 855, 447, 3294, 5, 13827, 62, 7, 54, 513, 28, 506, 8, 450, 51, 103, 133, 53, 1, 1688, 1256, 1146, 52, 2165, 11, 667, 2, 614, 60, 3, 100, 271, 11, 1279, 5, 3, 4188, 1, 8, 142, 1150, 1, 2451, 556, 105, 601, 2, 330, 5712, 382, 105, 175, 4, 3, 13827, 370, 20, 855, 87, 236, 51, 5971, 236, 51, 151, 11, 887, 2, 966, 3, 96, 908, 88, 749, 27, 155, 10, 778, 868, 105, 921, 3659, 2775, 489, 4, 239, 2, 245, 807, 155, 159, 681, 78, 27, 2, 286, 533, 2001, 78, 33, 5, 31967, 60, 1, 166, 126, 77, 93, 362, 90, 23, 24, 1055, 11, 164, 79, 111, 63, 25, 1423, 11, 846, 2, 803, 79, 111, 91, 115, 25, 1423, 11, 653, 2, 725, 13827, 5, 750, 15, 1787, 855, 2, 1256, 1146, 4, 2316, 264, 64, 51, 151, 2, 1922, 25]",1304.0,28340281,High ten-year remission rates following rituximab fludarabine mitoxantrone dexamethasone R-FND interferon maintenance indolent lymphoma randomized,1,0.0017452006980802793
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2017-03-28,"Purpose Most anemic patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) are treated with erythropoiesis-stimulating agents (ESAs), with a response rate of approximately 50%. Second-line treatments, including hypomethylating agents (HMAs), lenalidomide (LEN), and investigational drugs, may be used after ESA failure in some countries, but their effect on disease progression and overall survival (OS) is unknown. Here, we analyzed outcome after ESA failure and the effect of second-line treatments. Patients and Methods We examined an international retrospective cohort of 1,698 patients with non-del(5q) lower-risk MDS treated with ESAs. Results Erythroid response to ESAs was 61.5%, and median response duration was 17 months. Of 1,147 patients experiencing ESA failure, 653 experienced primary failure and 494 experienced relapse after a response. Primary failure of ESAs was associated with a higher risk of acute myeloid leukemia (AML) progression, which did not translate into an OS difference. Of 450 patients (39%) who received second-line treatment, 194 received HMAs, 148 received LEN, and 108 received other treatments (MISC), whereas 697 received RBC transfusions only. Five-year AML cumulative incidence was 20.3%, 20.3%, and 11.3% for those receiving HMAs, LEN, and MISC, respectively ( P = .05). Five-year OS for patients receiving HMA, LEN, and MISC was 36.5%, 41.7%, and 51%, respectively ( P = .21). In a multivariable analysis adjusted for age, sex, revised International Prognostic Scoring System score, and progression at ESA failure, there was no significant OS difference among the three groups. Conclusion In this large, multicenter, retrospective cohort of patients with non-del(5q) lower-risk MDS treated with ESAs, none of the most commonly used second-line treatments (HMA and LEN) significantly improved OS. Early failure of ESAs was associated with a higher risk of AML progression.",Journal Article,1029.0,26.0,"Purpose anemic patients non-deleted 5q lower-risk myelodysplastic syndromes MDS treated erythropoiesis-stimulating agents ESAs response rate approximately 50 Second-line treatments including hypomethylating agents HMAs lenalidomide LEN investigational drugs ESA failure countries effect disease progression overall survival OS unknown outcome ESA failure effect second-line treatments Patients Methods examined international retrospective cohort 1,698 patients non-del 5q lower-risk MDS treated ESAs Erythroid response ESAs 61.5 median response duration 17 months 1,147 patients experiencing ESA failure 653 experienced primary failure 494 experienced relapse response Primary failure ESAs associated higher risk acute myeloid leukemia AML progression translate OS difference 450 patients 39 received second-line treatment 194 received HMAs 148 received LEN 108 received treatments MISC 697 received RBC transfusions Five-year AML cumulative incidence 20.3 20.3 11.3 receiving HMAs LEN MISC respectively P .05 Five-year OS patients receiving HMA LEN MISC 36.5 41.7 51 respectively P .21 multivariable adjusted age sex revised International Prognostic Scoring score progression ESA failure significant OS difference groups large multicenter retrospective cohort patients non-del 5q lower-risk MDS treated ESAs commonly second-line treatments HMA LEN significantly improved OS Early failure ESAs associated higher risk AML progression",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[743, 96, 16224, 7, 5, 220, 4389, 5460, 280, 43, 2040, 1223, 32, 73, 5, 10297, 2122, 183, 3243, 5, 8, 51, 116, 1, 705, 212, 419, 328, 640, 141, 4931, 183, 12688, 1288, 6841, 2, 3093, 600, 68, 40, 95, 50, 13413, 496, 4, 476, 2115, 84, 136, 254, 23, 34, 91, 2, 63, 25, 118, 16, 860, 467, 21, 311, 228, 50, 13413, 496, 2, 3, 254, 1, 419, 328, 640, 7, 2, 636, 21, 409, 35, 944, 459, 180, 1, 14, 14072, 7, 5, 220, 3084, 5460, 280, 43, 1223, 73, 5, 3243, 99, 7839, 51, 6, 3243, 10, 713, 33, 2, 52, 51, 654, 10, 269, 53, 1, 14, 4961, 7, 2985, 13413, 496, 12567, 592, 86, 496, 2, 10919, 592, 429, 50, 8, 51, 86, 496, 1, 3243, 10, 41, 5, 8, 142, 43, 1, 286, 533, 329, 91, 92, 205, 44, 4509, 237, 35, 118, 523, 1, 5669, 7, 587, 54, 103, 419, 328, 24, 5434, 103, 12688, 4647, 103, 6841, 2, 3590, 103, 127, 640, 41719, 547, 11989, 103, 7256, 4987, 158, 365, 111, 329, 967, 287, 10, 179, 27, 179, 27, 2, 175, 27, 9, 135, 357, 12688, 6841, 2, 41719, 106, 19, 474, 365, 111, 118, 9, 7, 357, 7518, 6841, 2, 41719, 10, 511, 33, 605, 67, 2, 725, 106, 19, 239, 4, 8, 658, 65, 586, 9, 89, 1035, 4218, 944, 177, 2504, 398, 368, 2, 91, 28, 13413, 496, 125, 10, 77, 93, 118, 523, 107, 3, 169, 271, 1221, 4, 26, 375, 1570, 459, 180, 1, 7, 5, 220, 3084, 5460, 280, 43, 1223, 73, 5, 3243, 1292, 1, 3, 96, 841, 95, 419, 328, 640, 7518, 2, 6841, 97, 231, 118, 191, 496, 1, 3243, 10, 41, 5, 8, 142, 43, 1, 329, 91]",1824.0,28350519,Outcome Lower-Risk Patients Myelodysplastic Syndromes 5q Deletion Failure Erythropoiesis-Stimulating Agents,65,0.11343804537521815
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2017-02-13,"Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown. We hypothesized that lower treatment-related mortality (TRM) with reduced-intensity conditioning (RIC) would result in improved overall survival (OS) compared with myeloablative conditioning (MAC). To test this hypothesis, we performed a phase III randomized trial comparing MAC with RIC in patients with acute myeloid leukemia or myelodysplastic syndromes. Patients and Methods Patients age 18 to 65 years with HCT comorbidity index  4 and < 5% marrow myeloblasts pre-HCT were randomly assigned to receive MAC (n = 135) or RIC (n = 137) followed by HCT from HLA-matched related or unrelated donors. The primary end point was OS 18 months post-random assignment based on an intent-to-treat analysis. Secondary end points included relapse-free survival (RFS) and TRM. Results Planned enrollment was 356 patients; accrual ceased at 272 because of high relapse incidence with RIC versus MAC (48.3%; 95% CI, 39.6% to 56.4% and 13.5%; 95% CI, 8.3% to 19.8%, respectively; P < .001). At 18 months, OS for patients in the RIC arm was 67.7% (95% CI, 59.1% to 74.9%) versus 77.5% (95% CI, 69.4% to 83.7%) for those in the MAC arm (difference, 9.8%; 95% CI, -0.8% to 20.3%; P = .07). TRM with RIC was 4.4% (95% CI, 1.8% to 8.9%) versus 15.8% (95% CI, 10.2% to 22.5%) with MAC ( P = .002). RFS with RIC was 47.3% (95% CI, 38.7% to 55.4%) versus 67.8% (95% CI, 59.1% to 75%) with MAC ( P < .01). Conclusion OS was higher with MAC, but this was not statistically significant. RIC resulted in lower TRM but higher relapse rates compared with MAC, with a statistically significant advantage in RFS with MAC. These data support the use of MAC as the standard of care for fit patients with acute myeloid leukemia or myelodysplastic syndromes.","Clinical Trial, Phase III",1072.0,149.0,Purpose optimal regimen intensity allogeneic hematopoietic transplantation HCT unknown hypothesized lower treatment-related mortality TRM reduced-intensity conditioning RIC improved overall survival OS compared myeloablative conditioning MAC test hypothesis performed phase III randomized trial comparing MAC RIC patients acute myeloid leukemia myelodysplastic syndromes Patients Methods Patients age 18 65 years HCT comorbidity index  4 5 marrow myeloblasts pre-HCT randomly assigned receive MAC n 135 RIC n 137 followed HCT HLA-matched related unrelated donors primary end point OS 18 months post-random assignment based intent-to-treat Secondary end points included relapse-free survival RFS TRM Planned enrollment 356 patients accrual ceased 272 high relapse incidence RIC versus MAC 48.3 95 CI 39.6 56.4 13.5 95 CI 8.3 19.8 respectively P .001 18 months OS patients RIC arm 67.7 95 CI 59.1 74.9 versus 77.5 95 CI 69.4 83.7 MAC arm difference 9.8 95 CI -0.8 20.3 P .07 TRM RIC 4.4 95 CI 1.8 8.9 versus 15.8 95 CI 10.2 22.5 MAC P .002 RFS RIC 47.3 95 CI 38.7 55.4 versus 67.8 95 CI 59.1 75 MAC P .01 OS higher MAC statistically significant RIC resulted lower TRM higher relapse rates compared MAC statistically significant advantage RFS MAC support use MAC standard care fit patients acute myeloid leukemia myelodysplastic syndromes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[743, 3, 665, 477, 837, 348, 1063, 1007, 31, 497, 1085, 16, 860, 21, 1237, 17, 280, 24, 139, 282, 5064, 5, 405, 837, 1933, 3365, 688, 757, 4, 231, 63, 25, 118, 72, 5, 3246, 1933, 7492, 6, 412, 26, 1492, 21, 173, 8, 124, 316, 384, 160, 1430, 7492, 5, 3365, 4, 7, 5, 286, 533, 15, 2040, 7, 2, 636, 7, 89, 203, 6, 556, 60, 5, 1085, 1879, 558, 1552, 39, 2, 33, 581, 14909, 671, 1085, 11, 1108, 896, 6, 560, 7492, 78, 3978, 15, 3365, 78, 4352, 370, 20, 1085, 29, 1160, 655, 139, 15, 2092, 2344, 3, 86, 396, 741, 10, 118, 203, 53, 539, 2324, 4392, 90, 23, 35, 1697, 6, 943, 65, 568, 396, 862, 159, 429, 115, 25, 1272, 2, 5064, 99, 1465, 1798, 10, 8664, 7, 2262, 17710, 28, 6905, 408, 1, 64, 429, 287, 5, 3365, 185, 7492, 576, 27, 48, 58, 587, 49, 6, 664, 39, 2, 233, 33, 48, 58, 66, 27, 6, 326, 66, 106, 19, 144, 28, 203, 53, 118, 9, 7, 4, 3, 3365, 475, 10, 598, 67, 48, 58, 728, 14, 6, 794, 83, 185, 849, 33, 48, 58, 790, 39, 6, 852, 67, 9, 135, 4, 3, 7492, 475, 523, 83, 66, 48, 58, 13, 66, 6, 179, 27, 19, 1615, 5064, 5, 3365, 10, 39, 39, 48, 58, 14, 66, 6, 66, 83, 185, 167, 66, 48, 58, 79, 18, 6, 350, 33, 5, 7492, 19, 1111, 1272, 5, 3365, 10, 662, 27, 48, 58, 519, 67, 6, 614, 39, 185, 598, 66, 48, 58, 728, 14, 6, 481, 5, 7492, 19, 355, 1221, 118, 10, 142, 5, 7492, 84, 26, 10, 44, 712, 93, 3365, 627, 4, 280, 5064, 84, 142, 429, 151, 72, 5, 7492, 5, 8, 712, 93, 1874, 4, 1272, 5, 7492, 46, 74, 538, 3, 119, 1, 7492, 22, 3, 260, 1, 165, 9, 2975, 7, 5, 286, 533, 15, 2040]",1662.0,28380315,Myeloablative Versus Reduced-Intensity Hematopoietic Transplantation Acute Myeloid Leukemia Myelodysplastic Syndromes,28,0.04886561954624782
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.,Cancer,Cancer,2017-04-07,"The development of newer strategies to improve outcomes for older patients with secondary acute myeloid leukemia (s-AML) is a critical unmet need. Establishing baseline metrics for evaluating newer approaches is important. s-AML was defined as 1 or more of the following: a history of an antecedent hematologic disorder (AHD), a diagnosis of therapy-related acute myeloid leukemia (AML), and AML with karyotype abnormalities characteristic of myelodysplastic syndrome. Newly diagnosed s-AML patients aged 60 to 75 years were grouped into 5 treatment cohorts: 1) patients receiving high- or intermediate-dose cytarabine-based intensive chemotherapy (IC), 2) patients receiving a hypomethylating agent (HMA) or HMA combinations, 3) patients receiving low-dose cytarabine (LDAC) combinations, 4) patients receiving CPX-351, and 5) patients receiving investigational (INV) agents. Nine hundred thirty-one patients met the age and s-AML criteria. Complete remission rates were statistically lower in the HMA group (36%) versus the IC (46%), CPX-351 (45%), and LDAC groups (43%). Patients receiving less intensive regimens (the HMA and LDAC groups combined) had superior overall survival (OS) in comparison with patients receiving IC-based regimens (median 6.9 vs 5.4 months; P = .048). Only 4.3% of the IC patients proceeded to transplantation, whereas 10.3% of the patients on lower intensity regimens did (P = .001). There was no difference in median survival between patients treated with CPX-351 and patients treated with conventional lower intensity approaches (P = .75). Age > 70 years, an adverse karyotype, and a prior AHD were associated with decreased OS in a multivariate analysis. Lower intensity approaches are associated with lower early mortality rates and improved OS in comparison with intensive regimens. OS is poor with currently available therapies with a median OS of 6 months (5.4-7.6 months across regimens). Unsatisfactory outcomes with other INV agents underscore the need for more effective therapies. Cancer 2017;123:3050-60.  2017 American Cancer Society.",Journal Article,1019.0,20.0,development newer strategies improve outcomes older patients secondary acute myeloid leukemia s-AML critical unmet need Establishing baseline metrics evaluating newer approaches important s-AML defined 1 following history antecedent hematologic disorder AHD diagnosis therapy-related acute myeloid leukemia AML AML karyotype abnormalities characteristic myelodysplastic syndrome Newly diagnosed s-AML patients aged 60 75 years grouped 5 treatment cohorts 1 patients receiving high- intermediate-dose cytarabine-based intensive chemotherapy IC 2 patients receiving hypomethylating agent HMA HMA combinations 3 patients receiving low-dose cytarabine LDAC combinations 4 patients receiving CPX-351 5 patients receiving investigational INV agents thirty-one patients met age s-AML criteria Complete remission rates statistically lower HMA group 36 versus IC 46 CPX-351 45 LDAC groups 43 Patients receiving intensive regimens HMA LDAC groups combined superior overall survival OS comparison patients receiving IC-based regimens median 6.9 vs 5.4 months P .048 4.3 IC patients proceeded transplantation 10.3 patients lower intensity regimens P .001 difference median survival patients treated CPX-351 patients treated conventional lower intensity approaches P .75 Age 70 years adverse karyotype prior AHD associated decreased OS multivariate Lower intensity approaches associated lower early mortality rates improved OS comparison intensive regimens OS poor currently available therapies median OS 6 months 5.4-7.6 months regimens Unsatisfactory outcomes INV agents underscore need effective therapies 2017 123:3050-60  2017 American Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 193, 1, 2246, 422, 6, 401, 123, 9, 434, 7, 5, 568, 286, 533, 695, 329, 16, 8, 740, 3715, 594, 4431, 330, 3589, 9, 1435, 2246, 611, 16, 305, 695, 329, 10, 395, 22, 14, 15, 80, 1, 3, 366, 8, 532, 1, 35, 8775, 813, 2645, 24163, 8, 147, 1, 36, 139, 286, 533, 329, 2, 329, 5, 3385, 1171, 2037, 1, 681, 732, 265, 695, 329, 7, 1032, 335, 6, 481, 60, 11, 3706, 237, 33, 24, 736, 14, 7, 357, 64, 15, 919, 61, 1855, 90, 1686, 56, 2340, 18, 7, 357, 8, 4931, 420, 7518, 15, 7518, 1247, 27, 7, 357, 154, 61, 1855, 10714, 1247, 39, 7, 357, 12228, 7270, 2, 33, 7, 357, 3093, 6397, 183, 762, 1128, 977, 104, 7, 543, 3, 89, 2, 695, 329, 371, 236, 734, 151, 11, 712, 280, 4, 3, 7518, 87, 511, 185, 3, 2340, 641, 12228, 7270, 512, 2, 10714, 271, 601, 7, 357, 299, 1686, 472, 3, 7518, 2, 10714, 271, 397, 42, 1123, 63, 25, 118, 4, 1155, 5, 7, 357, 2340, 90, 472, 52, 49, 83, 105, 33, 39, 53, 19, 4969, 158, 39, 27, 1, 3, 2340, 7, 6406, 6, 497, 547, 79, 27, 1, 3, 7, 23, 280, 837, 472, 205, 19, 144, 125, 10, 77, 523, 4, 52, 25, 59, 7, 73, 5, 12228, 7270, 2, 7, 73, 5, 809, 280, 837, 611, 19, 481, 89, 431, 60, 35, 290, 3385, 2, 8, 324, 24163, 11, 41, 5, 340, 118, 4, 8, 331, 65, 280, 837, 611, 32, 41, 5, 280, 191, 282, 151, 2, 231, 118, 4, 1155, 5, 1686, 472, 118, 16, 334, 5, 694, 390, 235, 5, 8, 52, 118, 1, 49, 53, 33, 39, 67, 49, 53, 716, 472, 9573, 123, 5, 127, 6397, 183, 5531, 3, 594, 9, 80, 323, 235, 12, 1759, 2698, 35147, 335, 2206, 1759, 597, 12, 1174]",1963.0,28387922,Characteristics outcomes older patients secondary acute myeloid leukemia according treatment approach,12,0.020942408376963352
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).,Pediatric blood & cancer,Pediatr Blood Cancer,2017-04-14,"Plerixafor, a reversible CXCR4 antagonist, inhibits interactions between leukemic blasts and the bone marrow stromal microenvironment and may enhance chemosensitivity. A phase 1 trial of plerixafor in combination with intensive chemotherapy in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS) was performed to determine a tolerable and biologically active dose. Plerixafor was administered daily for 5 days at four dose levels (6, 9, 12, and 15 mg/m<sup>2</sup> /dose) followed 4 hr later by high-dose cytarabine (every 12 hr) and etoposide (daily). Nineteen patients (13 with AML, 5 with ALL, 1 with MDS) were treated. The most common grade 3 or greater nonhematologic toxicities attributable to plerixafor were febrile neutropenia and hypokalemia. There were no dose-limiting toxicities (DLTs). Plerixafor exposure increased with increasing dose levels and clearance was similar on days 1 and 5. Eighteen patients were evaluable for response. Two patients achieved complete remission (CR) and one patient achieved CR with incomplete hematologic recovery (CRi): all three had AML. No responses were seen in patients with ALL or MDS. Plerixafor mobilized leukemic blasts into the peripheral blood in 14 of 16 evaluable patients (median 3.4-fold increase), and the degree of mobilization correlated with surface CXCR4 expression. Plerixafor, in combination with high-dose cytarabine and etoposide, was well tolerated in children and young adults with relapsed/refractory acute leukemias and MDS. While biologic responses were observed, clinical responses in this heavily pretreated cohort were modest.","Clinical Trial, Phase I",1012.0,18.0,Plerixafor reversible CXCR4 antagonist inhibits interactions leukemic blasts bone marrow stromal microenvironment enhance chemosensitivity phase 1 trial plerixafor combination intensive chemotherapy children young adults relapsed refractory acute lymphoblastic leukemia acute myeloid leukemia AML myelodysplastic syndrome MDS performed determine tolerable biologically active dose Plerixafor administered daily 5 days dose levels 6 9 12 15 mg/m sup 2 /sup /dose followed 4 hr later high-dose cytarabine 12 hr etoposide daily Nineteen patients 13 AML 5 1 MDS treated common grade 3 greater nonhematologic toxicities attributable plerixafor febrile neutropenia hypokalemia dose-limiting toxicities DLTs Plerixafor exposure increased increasing dose levels clearance similar days 1 5 Eighteen patients evaluable response patients achieved complete remission CR patient achieved CR incomplete hematologic recovery CRi AML responses seen patients MDS Plerixafor mobilized leukemic blasts peripheral blood 14 16 evaluable patients median 3.4-fold increase degree mobilization correlated surface CXCR4 expression Plerixafor combination high-dose cytarabine etoposide tolerated children young adults relapsed/refractory acute leukemias MDS biologic responses observed clinical responses heavily pretreated cohort modest,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,"[5583, 8, 2786, 2318, 3137, 1576, 1286, 59, 2015, 2438, 2, 3, 581, 1126, 995, 2, 68, 1304, 5522, 8, 124, 14, 160, 1, 5583, 4, 150, 5, 1686, 56, 4, 541, 2, 1169, 857, 5, 591, 15, 430, 286, 1275, 62, 286, 533, 329, 2, 681, 1223, 10, 173, 6, 223, 8, 2668, 2, 2665, 544, 61, 5583, 10, 468, 391, 9, 33, 162, 28, 294, 61, 148, 49, 83, 133, 2, 167, 81, 188, 172, 18, 172, 61, 370, 39, 168, 1559, 20, 64, 61, 1855, 454, 133, 168, 2, 1934, 391, 3498, 7, 233, 5, 329, 33, 5, 62, 14, 5, 1223, 11, 73, 3, 96, 186, 88, 27, 15, 378, 3534, 385, 2971, 6, 5583, 11, 2498, 778, 2, 7799, 125, 11, 77, 61, 817, 385, 2506, 5583, 645, 101, 5, 602, 61, 148, 2, 1960, 10, 288, 23, 162, 14, 2, 33, 3195, 7, 11, 859, 9, 51, 100, 7, 513, 236, 734, 684, 2, 104, 69, 513, 684, 5, 2610, 813, 1602, 6341, 62, 169, 42, 329, 77, 253, 11, 527, 4, 7, 5, 62, 15, 1223, 5583, 7695, 2015, 2438, 237, 3, 672, 315, 4, 213, 1, 245, 859, 7, 52, 27, 39, 1116, 344, 2, 3, 1444, 1, 4030, 438, 5, 1255, 2318, 55, 5583, 4, 150, 5, 64, 61, 1855, 2, 1934, 10, 149, 421, 4, 541, 2, 1169, 857, 5, 591, 430, 286, 2792, 2, 1223, 369, 1283, 253, 11, 164, 38, 253, 4, 26, 2447, 2193, 180, 11, 1721]",1617.0,28409853,phase 1 CXCR4 antagonist plerixafor combination high-dose cytarabine etoposide children relapsed refractory acute leukemias myelodysplastic syndrome Pediatric Oncology Experimental Therapeutics Investigators Consortium POE 10-03,0,0.0
Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience.,Pediatric blood & cancer,Pediatr Blood Cancer,2017-04-18,"Children, adolescents, and young adults treated for Ewing sarcoma (ES) are at risk for disease-related and treatment-related complications. We aimed to describe early and late overall mortality, cause-specific mortality, and key adverse health outcomes in a large, single-institutional cohort of patients with ES. Patients with ES diagnosed at age less than 40 years and treated at Memorial Sloan Kettering between 1974 and 2012 were included. Overall survival was estimated using Kaplan-Meier methods. Cox proportional hazards were used to examine the association of clinical and pathologic variables with overall survival. Cause-specific mortality was evaluated with the cumulative incidence function accounting for competing risks. Three hundred patients with ES (60.3% male; median age at diagnosis: 16.8 years [range: 0.3-39]; 30.0% with metastatic disease at diagnosis) were followed for a median of 7.8 years (range: 0.2-37). Five-year overall survival was 65.2% (95% confidence interval [95% CI], 59.8-71.1%) for the entire cohort; 78.6% for those with localized disease; 40.1% for those with isolated pulmonary metastases; and 28.1% for those with extrapulmonary metastases. In multivariable analysis, older age at diagnosis, minority race/ethnicity, and metastatic disease at diagnosis were associated with inferior survival. Ten-year cumulative incidence of relapse/progression was 40.1%, with eight late relapses occurring at a median of 6.3 years after diagnosis (range: 5-14). Seventeen patients developed subsequent neoplasms (treatment-related myelodysplastic syndrome/acute myelogenous leukemia = 9; solid tumors = 6; nonmelanoma skin cancer [NMSC] = 4). Excluding NMSC and melanoma in situ, the cumulative incidence of subsequent malignant neoplasms at 25 years was 15% (95% CI, 4.8-25.1%). Patients with ES are at high risk for relapse/progression and second cancers.",Clinical Trial,1008.0,6.0,Children adolescents young adults treated Ewing sarcoma ES risk disease-related treatment-related complications aimed early late overall mortality cause-specific mortality key adverse health outcomes large single-institutional cohort patients ES Patients ES diagnosed age 40 years treated Memorial Sloan Kettering 1974 2012 included Overall survival estimated Kaplan-Meier methods Cox proportional hazards examine association clinical pathologic variables overall survival Cause-specific mortality evaluated cumulative incidence function accounting competing risks patients ES 60.3 male median age diagnosis 16.8 years range 0.3-39 30.0 metastatic disease diagnosis followed median 7.8 years range 0.2-37 Five-year overall survival 65.2 95 confidence interval 95 CI 59.8-71.1 entire cohort 78.6 localized disease 40.1 isolated pulmonary metastases 28.1 extrapulmonary metastases multivariable older age diagnosis minority race/ethnicity metastatic disease diagnosis associated inferior survival Ten-year cumulative incidence relapse/progression 40.1 late relapses occurring median 6.3 years diagnosis range 5-14 Seventeen patients developed subsequent neoplasms treatment-related myelodysplastic syndrome/acute myelogenous leukemia 9 solid 6 nonmelanoma skin NMSC 4 Excluding NMSC melanoma situ cumulative incidence subsequent malignant neoplasms 25 years 15 95 CI 4.8-25.1 Patients ES high risk relapse/progression second,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,"[541, 3101, 2, 1169, 857, 73, 9, 3011, 32, 28, 43, 9, 34, 139, 2, 24, 139, 521, 21, 1295, 6, 897, 191, 2, 807, 63, 282, 708, 112, 282, 2, 825, 290, 341, 123, 4, 8, 375, 226, 1115, 180, 1, 7, 5, 3011, 7, 5, 3011, 265, 28, 89, 299, 76, 327, 60, 2, 73, 28, 2563, 2783, 2784, 59, 10201, 2, 1195, 11, 159, 63, 25, 10, 661, 75, 876, 882, 636, 418, 831, 1017, 11, 95, 6, 1004, 3, 248, 1, 38, 2, 510, 682, 5, 63, 25, 708, 112, 282, 10, 194, 5, 3, 967, 287, 343, 3116, 9, 2573, 1098, 169, 1128, 7, 5, 3011, 335, 27, 1045, 52, 89, 28, 147, 245, 66, 60, 184, 13, 27, 587, 201, 13, 5, 113, 34, 28, 147, 11, 370, 9, 8, 52, 1, 67, 66, 60, 184, 13, 18, 567, 365, 111, 63, 25, 10, 556, 18, 48, 307, 268, 48, 58, 728, 66, 792, 14, 9, 3, 1797, 180, 833, 49, 9, 135, 5, 909, 34, 327, 14, 9, 135, 5, 1355, 1087, 196, 2, 339, 14, 9, 135, 5, 12732, 196, 4, 658, 65, 434, 89, 28, 147, 2652, 1047, 2091, 2, 113, 34, 28, 147, 11, 41, 5, 1663, 25, 1618, 111, 967, 287, 1, 429, 91, 10, 327, 14, 5, 659, 807, 3713, 1821, 28, 8, 52, 1, 49, 27, 60, 50, 147, 184, 33, 213, 3591, 7, 276, 706, 1179, 24, 139, 681, 286, 2194, 83, 537, 57, 49, 7814, 12, 7118, 39, 3207, 7118, 2, 4, 957, 3, 967, 287, 1, 706, 393, 1179, 28, 243, 60, 10, 167, 48, 58, 39, 66, 243, 14, 7, 5, 3011, 32, 28, 64, 43, 9, 429, 91, 2, 419, 163]",1758.0,28417551,Morbidity mortality treatment Ewing sarcoma single-institution experience,0,0.0
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.,International journal of molecular sciences,Int J Mol Sci,2017-04-14,"Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; <i>p</i>  0.001), but similar progression-free survival (8.0 vs. 9.4 months; <i>p</i> = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; <i>p</i> = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; <i>p</i> = 0.039). Our results support the therapeutic value of HMA in AEL.",Journal Article,1012.0,7.0,Acute erythroleukemia AEL rare disease typically associated poor prognosis median survival ranges 3-9 months initial diagnosis Hypomethylating agents HMAs shown prolong survival patients myelodysplastic syndromes MDS AML limited efficacy AEL collected 210 AEL patients treated 28 international sites Overall survival OS PFS estimated Kaplan-Meier log-rank test subgroup comparisons Survival treatment groups compared Cox proportional hazards regression model Eighty-eight patients treated HMAs 44 line 122 intensive chemotherapy ICT ICT led higher overall response rate complete partial compared first-line HMA 72 vs. 46.2 respectively p /i  0.001 similar progression-free survival 8.0 vs. 9.4 months p /i 0.342 Overall survival similar ICT vs. HMAs 10.5 vs. 13.7 months p /i 0.564 patients high-risk cytogenetics treated HMA first-line lived longer 7.5 ICT vs. 13.3 months p /i 0.039 support therapeutic value HMA AEL,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[286, 14661, 19217, 16, 8, 622, 34, 1969, 41, 5, 8, 334, 356, 3, 52, 25, 5632, 59, 27, 83, 53, 29, 388, 147, 4931, 183, 12688, 47, 85, 443, 6, 3615, 25, 4, 7, 5, 2040, 1223, 2, 329, 84, 125, 16, 383, 74, 1, 136, 209, 4, 19217, 21, 786, 74, 29, 5376, 19217, 7, 73, 28, 339, 944, 633, 63, 25, 118, 2, 300, 11, 661, 75, 3, 876, 882, 596, 2, 3, 1066, 1026, 412, 10, 95, 9, 1363, 2213, 25, 59, 24, 271, 10, 72, 75, 3, 418, 831, 1017, 320, 202, 2207, 659, 7, 11, 73, 5, 12688, 584, 3007, 328, 2, 3285, 5, 1686, 56, 10476, 10476, 836, 6, 8, 142, 63, 51, 116, 236, 15, 450, 72, 6, 157, 328, 7518, 720, 105, 641, 18, 106, 70, 19, 70, 1552, 13, 144, 84, 288, 91, 115, 25, 66, 13, 105, 83, 39, 53, 70, 19, 70, 13, 8906, 63, 25, 10, 288, 9, 10476, 105, 12688, 79, 33, 105, 233, 67, 53, 70, 19, 70, 13, 11090, 84, 7, 5, 64, 43, 2510, 73, 5, 7518, 157, 328, 4813, 589, 67, 33, 9, 10476, 105, 233, 27, 53, 70, 19, 70, 13, 5955, 114, 99, 538, 3, 189, 549, 1, 7518, 4, 19217]",1168.0,28420120,Clinical Outcomes 217 Patients Acute Erythroleukemia According Treatment Type Line Retrospective Multinational,62,0.1082024432809773
"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.",The Lancet. Oncology,Lancet Oncol.,2017-04-21,"Platinum-based chemotherapy doublets are a standard of care for women with ovarian cancer recurring 6 months after completion of initial therapy. In this study, we aimed to explore the roles of secondary surgical cytoreduction and bevacizumab in this population, and report the results of the bevacizumab component here. The multicentre, open-label, randomised phase 3 GOG-0213 trial was done in 67 predominantly academic centres in the USA (65 centres), Japan (one centre), and South Korea (one centre). Eligible patients were adult women (aged 18 years) with recurrent measurable or evaluable epithelial ovarian, primary peritoneal, or fallopian tube cancer, and a clinical complete response to primary platinum-based chemotherapy, who had been disease-free for at least 6 months following last infused cycle of platinum. Patients were randomly assigned (1:1) to standard chemotherapy (six 3-weekly cycles of paclitaxel [175 mg/m<sup>2</sup> of body surface area] and carboplatin [area under the curve 5]) or the same chemotherapy regimen plus bevacizumab (15 mg/kg of bodyweight) every 3 weeks and continued as maintenance every 3 weeks until disease progression or unacceptable toxicity. Individuals who participated in both the bevacizumab objective and surgical objective (which is ongoing) were randomly assigned (1:1:1:1) to receive either of these two chemotherapy regimens with or without prior secondary cytoreductive surgery. Randomisation for the bevacizumab objective was stratified by treatment-free interval and participation in the surgical objective. The primary endpoint was overall survival, analysed by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00565851. Between Dec 10, 2007, and Aug 26, 2011, 674 women were enrolled and randomly assigned to standard chemotherapy (n=337) or chemotherapy plus bevacizumab (n=377). Median follow-up at the end of the trial on Nov 5, 2014, was 496 months in each treatment group (IQR 415-622 for chemotherapy plus bevacizumab; IQR 408-593 for chemotherapy), at which point 415 patients had died (214 in the chemotherapy group and 201 in the chemotherapy plus bevacizumab group). Based on pretreatment stratification data, median overall survival in the chemotherapy plus bevacizumab group was 422 months (95% CI 377-462) versus 373 months (326-397) in the chemotherapy group (hazard ratio [HR] 0829; 95% CI 0683-1005; p=0056). We identified incorrect treatment-free interval stratification data for 45 (7%) patients (equally balanced between treatment groups); a sensitivity analysis of overall survival based on the audited treatment-free interval stratification data gave an adjusted HR of 0823 (95% CI 0680-0996; p=00447). In the safety population (all patients who initiated treatment), 317 (96%) of 325 patients in the chemotherapy plus bevacizumab group had at least one grade 3 or worse adverse event compared with 282 (86%) of 332 in the chemotherapy group; the most frequently reported of these in the chemotherapy plus bevacizumab group compared with the chemotherapy group were hypertension (39 [12%] vs two [1%]), fatigue (27 [8%] vs eight [2%]), and proteinuria (27 [8%] vs none). Two (1%) treatment-related deaths occurred in the chemotherapy group (infection [n=1] and myelodysplastic syndrome [n=1]) compared with nine (3%) in the chemotherapy plus bevacizumab group (infection [n=1], febrile neutropenia [n=1], myelodysplastic syndrome [n=1], secondary malignancy [n=1]; deaths not classified with CTCAE terms: disease progression [n=3], sudden death [n=1], and not specified [n=1]). The addition of bevacizumab to standard chemotherapy, followed by maintenance therapy until progression, improved the median overall survival in patients with platinum-sensitive recurrent ovarian cancer. Although the intention-to-treat analysis for overall survival was not significant, our sensitivity analysis based on corrected treatment-free interval stratification indicates that this strategy might be an important addition to the therapeutic armamentarium in these patients. National Cancer Institute and Genentech.","Clinical Trial, Phase III",1005.0,122.0,Platinum-based chemotherapy doublets standard care women ovarian recurring 6 months completion initial therapy aimed explore roles secondary surgical cytoreduction bevacizumab population report bevacizumab component multicentre open-label randomised phase 3 GOG-0213 trial 67 predominantly academic centres USA 65 centres Japan centre South Korea centre Eligible patients adult women aged 18 years recurrent measurable evaluable epithelial ovarian primary peritoneal fallopian tube clinical complete response primary platinum-based chemotherapy disease-free 6 months following infused cycle platinum Patients randomly assigned 1:1 standard chemotherapy 3-weekly cycles paclitaxel 175 mg/m sup 2 /sup body surface area carboplatin area curve 5 chemotherapy regimen plus bevacizumab 15 mg/kg bodyweight 3 weeks continued maintenance 3 weeks disease progression unacceptable toxicity Individuals participated bevacizumab objective surgical objective ongoing randomly assigned 1:1:1:1 receive chemotherapy regimens prior secondary cytoreductive surgery Randomisation bevacizumab objective stratified treatment-free interval participation surgical objective primary endpoint overall survival analysed intention treat registered ClinicalTrials.gov number NCT00565851 Dec 10 2007 Aug 26 2011 674 women enrolled randomly assigned standard chemotherapy n=337 chemotherapy plus bevacizumab n=377 Median follow-up end trial Nov 5 2014 496 months treatment group IQR 415-622 chemotherapy plus bevacizumab IQR 408-593 chemotherapy point 415 patients died 214 chemotherapy group 201 chemotherapy plus bevacizumab group Based pretreatment stratification median overall survival chemotherapy plus bevacizumab group 422 months 95 CI 377-462 versus 373 months 326-397 chemotherapy group hazard ratio HR 0829 95 CI 0683-1005 p=0056 identified incorrect treatment-free interval stratification 45 7 patients equally balanced treatment groups sensitivity overall survival based audited treatment-free interval stratification gave adjusted HR 0823 95 CI 0680-0996 p=00447 safety population patients initiated treatment 317 96 325 patients chemotherapy plus bevacizumab group grade 3 worse adverse event compared 282 86 332 chemotherapy group frequently reported chemotherapy plus bevacizumab group compared chemotherapy group hypertension 39 12 vs 1 fatigue 27 8 vs 2 proteinuria 27 8 vs 1 treatment-related deaths occurred chemotherapy group infection n=1 myelodysplastic syndrome n=1 compared 3 chemotherapy plus bevacizumab group infection n=1 febrile neutropenia n=1 myelodysplastic syndrome n=1 secondary malignancy n=1 deaths classified CTCAE terms disease progression n=3 sudden death n=1 specified n=1 addition bevacizumab standard chemotherapy followed maintenance therapy progression improved median overall survival patients platinum-sensitive recurrent ovarian intention-to-treat overall survival significant sensitivity based corrected treatment-free interval stratification indicates strategy important addition therapeutic armamentarium patients National Institute Genentech,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[828, 90, 56, 9097, 32, 8, 260, 1, 165, 9, 117, 5, 12, 6385, 49, 53, 50, 1438, 1, 388, 36, 4, 26, 45, 21, 1295, 6, 1645, 3, 1790, 1, 568, 221, 2844, 2, 599, 4, 26, 266, 2, 414, 3, 99, 1, 3, 599, 1249, 467, 3, 5761, 1020, 1756, 2827, 124, 27, 4760, 41740, 160, 10, 1822, 4, 598, 2117, 1916, 4496, 4, 3, 2706, 556, 4496, 6157, 104, 5931, 2, 5452, 10923, 104, 5931, 625, 7, 11, 780, 117, 1032, 6624, 60, 5, 387, 1884, 15, 859, 701, 86, 1639, 15, 2330, 12, 2, 8, 38, 236, 51, 6, 86, 828, 90, 56, 54, 42, 85, 34, 115, 9, 28, 506, 49, 53, 366, 1060, 4524, 417, 1, 828, 7, 11, 1108, 896, 14, 14, 6, 260, 56, 437, 27, 709, 410, 1, 490, 3300, 81, 188, 172, 18, 172, 1, 642, 1255, 965, 2, 927, 965, 669, 3, 1496, 33, 15, 3, 827, 56, 477, 349, 599, 167, 81, 503, 1, 21966, 454, 27, 244, 2, 1351, 22, 1146, 454, 27, 244, 1100, 34, 91, 15, 3215, 155, 869, 54, 3025, 4, 110, 3, 599, 461, 2, 221, 461, 92, 16, 942, 11, 1108, 896, 14, 14, 14, 14, 6, 560, 361, 1, 46, 100, 56, 472, 5, 15, 187, 324, 568, 2604, 152, 5204, 9, 3, 599, 461, 10, 1173, 20, 24, 115, 268, 2, 2599, 4, 3, 221, 461, 3, 86, 1138, 10, 63, 25, 3141, 20, 3205, 6, 943, 26, 45, 16, 1653, 5, 1252, 1239, 207, 50332, 59, 8702, 79, 1307, 2, 10497, 432, 1132, 12258, 117, 11, 346, 2, 1108, 896, 6, 260, 56, 78, 8275, 15, 56, 349, 599, 78, 8211, 52, 166, 126, 28, 3, 396, 1, 3, 160, 23, 10369, 33, 1409, 10, 50333, 53, 4, 296, 24, 87, 2245, 48947, 70253, 9, 56, 349, 599, 2245, 48918, 70254, 9, 56, 28, 92, 741, 10069, 7, 42, 1016, 6900, 4, 3, 56, 87, 2, 4766, 4, 3, 56, 349, 599, 87, 90, 23, 1194, 1541, 74, 52, 63, 25, 4, 3, 56, 349, 599, 87, 10, 70255, 53, 48, 58, 41233, 50334, 185, 70256, 53, 41234, 70257, 4, 3, 56, 87, 360, 197, 168, 70258, 48, 58, 70259, 70260, 19, 70261, 21, 108, 11774, 24, 115, 268, 1541, 74, 9, 512, 67, 7, 4142, 4115, 59, 24, 271, 8, 485, 65, 1, 63, 25, 90, 23, 3, 38454, 24, 115, 268, 1541, 74, 6421, 35, 586, 168, 1, 70262, 48, 58, 70263, 70264, 19, 70265, 4, 3, 367, 266, 62, 7, 54, 1917, 24, 7869, 921, 1, 7139, 7, 4, 3, 56, 349, 599, 87, 42, 28, 506, 104, 88, 27, 15, 639, 290, 774, 72, 5, 8219, 868, 1, 10651, 4, 3, 56, 87, 3, 96, 746, 210, 1, 46, 4, 3, 56, 349, 599, 87, 72, 5, 3, 56, 87, 11, 1824, 587, 133, 105, 100, 14, 613, 428, 66, 105, 659, 18, 2, 5381, 428, 66, 105, 1292, 100, 14, 24, 139, 1043, 489, 4, 3, 56, 87, 930, 78, 14, 2, 681, 78, 14, 72, 5, 762, 27, 4, 3, 56, 349, 599, 87, 930, 78, 14, 2498, 778, 78, 14, 681, 78, 14, 568, 710, 78, 14, 1043, 44, 1373, 5, 3898, 1794, 34, 91, 78, 27, 10643, 273, 78, 14, 2, 44, 3575, 78, 14, 3, 352, 1, 599, 6, 260, 56, 370, 20, 1146, 36, 1100, 91, 231, 3, 52, 63, 25, 4, 7, 5, 828, 745, 387, 12, 242, 3, 3205, 6, 943, 65, 9, 63, 25, 10, 44, 93, 114, 485, 65, 90, 23, 3848, 24, 115, 268, 1541, 2640, 17, 26, 692, 822, 40, 35, 305, 352, 6, 3, 189, 5543, 4, 46, 7, 657, 12, 1377, 2, 9010]",3906.0,28438473,Bevacizumab paclitaxel-carboplatin chemotherapy secondary cytoreduction recurrent platinum-sensitive ovarian NRG Oncology/Gynecologic Oncology Group GOG-0213 multicentre open-label randomised phase 3 trial,0,0.0
"Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer.",Oncotarget,Oncotarget,2017-07-01,"Olaparib is an oral inhibitor of polyadenosine 5'-diphosphoribose polymerization (PARP) that has previously shown signs of activity in patients with BRCA mutations and pancreatic ductal adenocarcinoma (PDAC). In this phase 1 dose-escalation trial in patients with unresectable PDAC, we determined the maximum tolerated dose (MTD) of olaparib (tablet formulation) in combination with irinotecan 70 mg/m2 on days 1 and 8 and cisplatin 25 mg/m2 on days 1 and 8 of a 28-day cycle (olaparib plus IC). We then studied the safety and tolerability of adding mitomycin C 5 mg/m2 on day 1 to this regimen (olaparib plus ICM). 18 patients with unresectable PDAC were enrolled. The MTD of olaparib plus IC was olaparib 100 mg twice-daily on days 1 and 8. The addition of mitomycin C to this dose level was not tolerated. Grade 3 drug-related adverse events (AEs) were encountered in 16 patients (89%). The most common grade 3 drug-related toxicities included neutropenia (89%), lymphopenia (72%), and anemia (22%). Two patients (11%), both of whom had remained on study for more than 12 cycles, developed drug-related myelodysplastic syndrome (MDS). The objective response rate (ORR) for all evaluable patients was 23%. One patient who carried a deleterious germline BRCA2 mutation had a durable clinical response lasting more than four years, but died from complications of treatment-related MDS. Olaparib had substantial toxicity when combined with IC or ICM in patients with PDAC, and this treatment combination did not have an acceptable risk/benefit profile for further study. However, durable clinical responses were observed in a subset of patients and further clinical investigation of PARP inhibitors in PDAC is warranted. This clinical trial was registered on ClinicalTrials.gov as NCT01296763.",Journal Article,934.0,,Olaparib oral inhibitor polyadenosine 5'-diphosphoribose polymerization PARP previously shown signs activity patients BRCA pancreatic ductal adenocarcinoma PDAC phase 1 dose-escalation trial patients unresectable PDAC determined maximum tolerated dose MTD olaparib tablet formulation combination irinotecan 70 mg/m2 days 1 8 cisplatin 25 mg/m2 days 1 8 28-day cycle olaparib plus IC studied safety tolerability adding mitomycin C 5 mg/m2 day 1 regimen olaparib plus ICM 18 patients unresectable PDAC enrolled MTD olaparib plus IC olaparib 100 mg twice-daily days 1 8 addition mitomycin C dose level tolerated Grade 3 drug-related adverse events AEs encountered 16 patients 89 common grade 3 drug-related toxicities included neutropenia 89 lymphopenia 72 anemia 22 patients 11 remained 12 cycles developed drug-related myelodysplastic syndrome MDS objective response rate ORR evaluable patients 23 patient carried deleterious germline BRCA2 durable clinical response lasting years died complications treatment-related MDS Olaparib substantial toxicity combined IC ICM patients PDAC treatment combination acceptable risk/benefit profile durable clinical responses observed subset patients clinical investigation PARP inhibitors PDAC warranted clinical trial registered ClinicalTrials.gov NCT01296763,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4024, 16, 35, 518, 230, 1, 70300, 7344, 70301, 12273, 2041, 17, 71, 373, 443, 3408, 1, 128, 4, 7, 5, 1555, 138, 2, 1258, 449, 1356, 4, 26, 124, 14, 61, 1125, 160, 4, 7, 5, 1468, 1356, 21, 509, 3, 689, 421, 61, 961, 1, 4024, 6977, 3583, 4, 150, 5, 1071, 431, 81, 821, 23, 162, 14, 2, 66, 2, 540, 243, 81, 821, 23, 162, 14, 2, 66, 1, 8, 339, 218, 417, 4024, 349, 2340, 21, 818, 656, 3, 367, 2, 1543, 1, 2726, 5837, 256, 33, 81, 821, 23, 218, 14, 6, 26, 477, 4024, 349, 36411, 203, 7, 5, 1468, 1356, 11, 346, 3, 961, 1, 4024, 349, 2340, 10, 4024, 394, 81, 936, 391, 23, 162, 14, 2, 66, 3, 352, 1, 5837, 256, 6, 26, 61, 301, 10, 44, 421, 88, 2608, 234, 139, 290, 281, 1477, 11, 3903, 4, 245, 7, 887, 3, 96, 186, 88, 2608, 234, 139, 385, 159, 778, 887, 3655, 720, 2, 1545, 350, 100, 7, 175, 110, 1, 953, 42, 958, 23, 45, 9, 80, 76, 133, 410, 276, 234, 139, 681, 1223, 3, 461, 51, 116, 1735, 9, 62, 859, 7, 10, 382, 104, 69, 54, 2629, 8, 3586, 1009, 1167, 258, 42, 8, 1480, 38, 51, 3443, 80, 76, 294, 60, 84, 1016, 29, 521, 1, 24, 139, 1223, 4024, 42, 1281, 155, 198, 397, 5, 2340, 15, 36411, 4, 7, 5, 1356, 2, 26, 24, 150, 205, 44, 47, 35, 1595, 43, 247, 800, 9, 195, 45, 137, 1480, 38, 253, 11, 164, 4, 8, 697, 1, 7, 2, 195, 38, 940, 1, 2041, 222, 4, 1356, 16, 1197, 26, 38, 160, 10, 1653, 23, 1252, 1239, 22, 70302]",1711.0,28454122,Olaparib combination irinotecan cisplatin mitomycin C patients advanced pancreatic,0,0.0
Risk of histological transformation and therapy-related myelodysplasia/acute myeloid leukaemia in patients receiving radioimmunotherapy for follicular lymphoma.,British journal of haematology,Br. J. Haematol.,2017-05-03,"Histological transformation (HT) of follicular lymphoma (FL) to an aggressive lymphoma after chemotherapy remains a key issue. The incidence of HT after radioimmunotherapy (RIT) is unknown. This single institution study analysed the risk of HT in FL after treatment with yttrium-90 ibritumomab tiuxetan in 115 consecutive patients treated during 1987-2012. RIT was administered for progressive FL in 111 (97%) patients and as first-line therapy in the remaining 4. 28% (n=32) had HT, occurring at a median of 60months from diagnosis and 20months after RIT. 48% (12/25) of patients who received fludarabine developed HT. The estimated 10-year risk of HT in the fludarabine and non-fludarabine groups was 67% and 26% respectively (P=0015). Only prior fludarabine was significantly associated with predicting the risk of HT after RIT. 8% (9/115) of patients developed therapy-related myelodysplastic syndrome/acute myeloid leukaemia (tMDS/AML) at a median of 414months (range, 5-89). The estimated 10-year risk of tMDS/AML in non-fludarabine treated patients (n=90) versus fludarabine treated (n=25) was 13% and 29%, respectively. The estimated overall risk of FL undergoing HT at 10years without fludarabine exposure appears similar to patients reported in the literature that have not received RIT. Patients with prior purine-analogue therapy are at significantly higher risk of HT.",Journal Article,993.0,6.0,Histological transformation HT follicular lymphoma FL aggressive lymphoma chemotherapy remains key issue incidence HT radioimmunotherapy RIT unknown single institution analysed risk HT FL treatment yttrium-90 ibritumomab tiuxetan 115 consecutive patients treated 1987-2012 RIT administered progressive FL 111 97 patients first-line therapy remaining 4 28 n 32 HT occurring median 60 months diagnosis 20 months RIT 48 12/25 patients received fludarabine developed HT estimated 10-year risk HT fludarabine non-fludarabine groups 67 26 respectively P 0015 prior fludarabine significantly associated predicting risk HT RIT 8 9/115 patients developed therapy-related myelodysplastic syndrome/acute myeloid leukaemia tMDS/AML median 414 months range 5-89 estimated 10-year risk tMDS/AML non-fludarabine treated patients n 90 versus fludarabine treated n 25 13 29 respectively estimated overall risk FL undergoing HT 10 years fludarabine exposure appears similar patients reported literature received RIT Patients prior purine-analogue therapy significantly higher risk HT,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1831, 1392, 3152, 1, 1974, 2633, 6, 35, 571, 50, 56, 469, 8, 825, 2537, 3, 287, 1, 3152, 50, 5862, 6313, 16, 860, 26, 226, 731, 45, 3141, 3, 43, 1, 3152, 4, 2633, 50, 24, 5, 7190, 424, 5251, 5294, 4, 3670, 935, 7, 73, 190, 5450, 1195, 6313, 10, 468, 9, 1014, 2633, 4, 3167, 1015, 7, 2, 22, 157, 328, 36, 4, 3, 1844, 39, 339, 78, 531, 42, 3152, 1821, 28, 8, 52, 1, 335, 53, 29, 147, 2, 179, 53, 50, 6313, 576, 133, 243, 1, 7, 54, 103, 2027, 276, 3152, 3, 661, 79, 111, 43, 1, 3152, 4, 3, 2027, 2, 220, 2027, 271, 10, 598, 2, 432, 106, 19, 27496, 158, 324, 2027, 10, 97, 41, 5, 1434, 3, 43, 1, 3152, 50, 6313, 66, 83, 3670, 1, 7, 276, 36, 139, 681, 286, 533, 2001, 50349, 329, 28, 8, 52, 1, 50350, 53, 184, 33, 887, 3, 661, 79, 111, 43, 1, 50349, 329, 4, 220, 2027, 73, 7, 78, 424, 185, 2027, 73, 78, 243, 10, 233, 2, 462, 106, 3, 661, 63, 43, 1, 2633, 479, 3152, 28, 79, 60, 187, 2027, 645, 1233, 288, 6, 7, 210, 4, 3, 789, 17, 47, 44, 103, 6313, 7, 5, 324, 5006, 4696, 36, 32, 28, 97, 142, 43, 1, 3152]",1306.0,28466487,Risk histological transformation therapy-related myelodysplasia/acute myeloid leukaemia patients receiving radioimmunotherapy follicular lymphoma,141,0.24607329842931938
Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2017-05-09,"Purpose Azacitidine is standard, first-line therapy in higher-risk myelodysplastic syndromes (MDS). Whether azacitidine-based combinations with lenalidomide or vorinostat produce superior overall response rates (ORRs) to azacitidine is not known. Patients and Methods North American Intergroup Study S1117 is a phase II/III trial that randomly assigned patients with higher-risk MDS and chronic myelomonocytic leukemia (CMML) 1:1:1 to azacitidine (75 mg/m<sup>2</sup>/day on days 1 to 7 of a 28-day cycle); azacitidine plus lenalidomide (10 mg/day on days 1 to 21); or azacitidine plus vorinostat (300 mg twice daily on days 3 to 9). The primary phase II end point was improved ORR. Results Of 277 patients from 90 centers, 92 received azacitidine, 93 received azacitidine plus lenalidomide, and 92 received azacitidine plus vorinostat. Median age was 70 years (range, 28 to 93 years), 85 patients (31%) were female, and 53 patients (19%) had CMML. Serious adverse events were similar across arms, although combination-arm patients were more likely to undergo nonprotocol-defined dose modifications ( P < .001).With a median follow-up of 23 months (range, 1 to 43 months), the ORR was 38% for patients receiving azacitidine, 49% for azacitidine plus lenalidomide ( P = .14 v azacitidine), and 27% for azacitidine plus vorinostat ( P = .16 v azacitidine). For patients with CMML, ORR was higher for azacitidine plus lenalidomide versus azacitidine (68% v 28%, P = .02) but similar for all arms across cytogenetic subgroups, as was remission duration and overall survival. ORR was higher with mutations in DNMT3A and lower for SRSF2, whereas ORR duration improved with fewer mutations. Lenalidomide dose reduction was associated with worse overall survival (hazard ratio, 1.30; P = .05). Conclusion Patients with higher-risk MDS treated with azacitidine-based combinations had similar ORR to azacitidine monotherapy, although patients with CMML benefitted from azacitidine plus lenalidomide. The efficacy of combination regimens may have been affected by dose modifications.","Clinical Trial, Phase II",987.0,81.0,Purpose Azacitidine standard first-line therapy higher-risk myelodysplastic syndromes MDS azacitidine-based combinations lenalidomide vorinostat produce superior overall response rates ORRs azacitidine known Patients Methods North American Intergroup S1117 phase II/III trial randomly assigned patients higher-risk MDS chronic myelomonocytic leukemia CMML 1:1:1 azacitidine 75 mg/m sup 2 /sup /day days 1 7 28-day cycle azacitidine plus lenalidomide 10 mg/day days 1 21 azacitidine plus vorinostat 300 mg twice daily days 3 9 primary phase II end point improved ORR 277 patients 90 centers 92 received azacitidine 93 received azacitidine plus lenalidomide 92 received azacitidine plus vorinostat Median age 70 years range 28 93 years 85 patients 31 female 53 patients 19 CMML adverse events similar arms combination-arm patients likely undergo nonprotocol-defined dose modifications P .001 .With median follow-up 23 months range 1 43 months ORR 38 patients receiving azacitidine 49 azacitidine plus lenalidomide P .14 v azacitidine 27 azacitidine plus vorinostat P .16 v azacitidine patients CMML ORR higher azacitidine plus lenalidomide versus azacitidine 68 v 28 P .02 similar arms cytogenetic subgroups remission duration overall survival ORR higher DNMT3A lower SRSF2 ORR duration improved fewer Lenalidomide dose reduction associated worse overall survival hazard ratio 1.30 P .05 Patients higher-risk MDS treated azacitidine-based combinations similar ORR azacitidine monotherapy patients CMML benefitted azacitidine plus lenalidomide efficacy combination regimens affected dose modifications,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[743, 3752, 16, 260, 157, 328, 36, 4, 142, 43, 2040, 1223, 317, 3752, 90, 1247, 5, 1288, 15, 2371, 2410, 1123, 63, 51, 151, 10767, 6, 3752, 16, 44, 440, 7, 2, 636, 2669, 597, 4839, 45, 50367, 16, 8, 124, 215, 316, 160, 17, 1108, 896, 7, 5, 142, 43, 1223, 2, 442, 5451, 3382, 14, 14, 14, 6, 3752, 481, 81, 188, 172, 18, 172, 218, 23, 162, 14, 6, 67, 1, 8, 339, 218, 417, 3752, 349, 1288, 79, 81, 218, 23, 162, 14, 6, 239, 15, 3752, 349, 2371, 2036, 81, 936, 391, 23, 162, 27, 6, 83, 3, 86, 124, 215, 396, 741, 10, 231, 1735, 99, 1, 7996, 7, 29, 424, 1168, 937, 103, 3752, 966, 103, 3752, 349, 1288, 2, 937, 103, 3752, 349, 2371, 52, 89, 10, 431, 60, 184, 339, 6, 966, 60, 772, 7, 456, 11, 1061, 2, 699, 7, 326, 42, 3382, 1762, 290, 281, 11, 288, 716, 1335, 242, 150, 475, 7, 11, 80, 322, 6, 1251, 21001, 395, 61, 2916, 19, 144, 5, 8, 52, 166, 126, 1, 382, 53, 184, 14, 6, 601, 53, 3, 1735, 10, 519, 9, 7, 357, 3752, 739, 9, 3752, 349, 1288, 19, 213, 603, 3752, 2, 428, 9, 3752, 349, 2371, 19, 245, 603, 3752, 9, 7, 5, 3382, 1735, 10, 142, 9, 3752, 349, 1288, 185, 3752, 806, 603, 339, 19, 588, 84, 288, 9, 62, 1335, 716, 1266, 1453, 22, 10, 734, 654, 2, 63, 25, 1735, 10, 142, 5, 138, 4, 6199, 2, 280, 9, 9830, 547, 1735, 654, 231, 5, 1497, 138, 1288, 61, 628, 10, 41, 5, 639, 63, 25, 360, 197, 14, 201, 19, 474, 1221, 7, 5, 142, 43, 1223, 73, 5, 3752, 90, 1247, 42, 288, 1735, 6, 3752, 1411, 242, 7, 5, 3382, 20703, 29, 3752, 349, 1288, 3, 209, 1, 150, 472, 68, 47, 85, 1424, 20, 61, 2916]",1965.0,28486043,Randomized Phase II Azacitidine Combination Lenalidomide Vorinostat Higher-Risk Myelodysplastic Syndromes Chronic Myelomonocytic Leukemia North American Intergroup SWOG S1117,0,0.0
"Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome.",Haematologica,Haematologica,2017-05-11,"Chronic eosinophilic leukemia, not otherwise specified can be difficult to distinguish from idiopathic hypereosinophilic syndrome according to the current World Health Organization guideline. To examine whether the morphological features of bone marrow might aid in the differential diagnosis of these two entities, we studied a total of 139 patients with a diagnosis of chronic eosinophilic leukemia, not otherwise specified (n=17) or idiopathic hypereosinophilic syndrome (n=122). As a group, abnormal bone marrow morphological features, resembling myelodysplastic syndromes, myeloproliferative neoplasm or myelodysplastic/myeloproliferative neoplasm, were identified in 40/139 (27%) patients: 16 (94%) of those with chronic eosinophilic leukemia and 24 (20%) of those with hypereosinophilic syndrome. Abnormal bone marrow correlated with older age (<i>P</i><0.001), constitutional symptoms (<i>P</i><0.001), anemia (<i>P</i>=0.041), abnormal platelet count (<i>P</i>=0.002), organomegaly (<i>P</i>=0.008), elevated lactate dehydrogenase concentration (<i>P</i>=0.005), abnormal karyotype (<i>P</i><0.001), as well as the presence of myeloid neoplasm-related mutations (<i>P</i><0.001). Patients with abnormal bone marrow had shorter survival (48.1 months <i>versus</i> not reached, <i>P</i><0.001), a finding which was independent of other confounding factors (<i>P</i><0.001). The association between abnormal bone marrow and shorter survival was also observed in hypereosinophilic syndrome patients alone. In summary, most patients with chronic eosinophilic leukemia, not otherwise specified and a proportion of those with idiopathic hypereosinophilic syndrome show abnormal bone marrow features similar to the ones encountered in patients with myelodysplastic syndromes, myelodysplastic/myeloproliferative neoplasm or <i>BCR-ABL1</i>-negative myeloproliferative neoplasm. Among patients who are currently considered to have idiopathic hypereosinophilic syndrome, abnormal bone marrow is a strong indicator of clonal hematopoiesis. Similar to other myeloid neoplasms, bone marrow morphology should be one of the major criteria to distinguish patients with chronic eosinophilic leukemia, not otherwise specified or clonal hypereosinophilic syndrome from those with truly reactive idiopathic hypereosinophilic syndrome.",Journal Article,985.0,12.0,Chronic eosinophilic leukemia specified difficult distinguish idiopathic hypereosinophilic syndrome according current World Health Organization guideline examine morphological features bone marrow aid differential diagnosis entities studied total 139 patients diagnosis chronic eosinophilic leukemia specified n=17 idiopathic hypereosinophilic syndrome n=122 group abnormal bone marrow morphological features resembling myelodysplastic syndromes myeloproliferative neoplasm myelodysplastic/myeloproliferative neoplasm identified 40/139 27 patients 16 94 chronic eosinophilic leukemia 24 20 hypereosinophilic syndrome Abnormal bone marrow correlated older age P /i 0.001 constitutional symptoms P /i 0.001 anemia P /i =0.041 abnormal platelet count P /i =0.002 organomegaly P /i =0.008 elevated lactate dehydrogenase concentration P /i =0.005 abnormal karyotype P /i 0.001 presence myeloid neoplasm-related P /i 0.001 Patients abnormal bone marrow shorter survival 48.1 months versus /i reached P /i 0.001 finding independent confounding factors P /i 0.001 association abnormal bone marrow shorter survival observed hypereosinophilic syndrome patients summary patients chronic eosinophilic leukemia specified proportion idiopathic hypereosinophilic syndrome abnormal bone marrow features similar ones encountered patients myelodysplastic syndromes myelodysplastic/myeloproliferative neoplasm BCR-ABL1 /i -negative myeloproliferative neoplasm patients currently considered idiopathic hypereosinophilic syndrome abnormal bone marrow strong indicator clonal hematopoiesis Similar myeloid neoplasms bone marrow morphology major criteria distinguish patients chronic eosinophilic leukemia specified clonal hypereosinophilic syndrome truly reactive idiopathic hypereosinophilic syndrome,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 9757, 44, 2632, 3575, 122, 40, 1740, 6, 3081, 29, 7540, 13967, 681, 768, 6, 3, 291, 1956, 341, 2533, 2009, 6, 1004, 317, 3, 4268, 404, 1, 581, 822, 2427, 4, 3, 1777, 147, 1, 46, 100, 4613, 21, 656, 8, 181, 1, 4929, 7, 5, 8, 147, 1, 442, 9757, 44, 2632, 3575, 78, 269, 15, 7540, 13967, 681, 78, 3285, 22, 8, 87, 1668, 581, 4268, 404, 8855, 2040, 2131, 15, 10589, 10857, 2131, 11, 108, 4, 327, 4929, 428, 7, 245, 960, 1, 135, 5, 442, 9757, 2, 259, 179, 1, 135, 5, 13967, 681, 1668, 581, 438, 5, 434, 89, 70, 19, 70, 13, 144, 5962, 507, 70, 19, 70, 13, 144, 1545, 70, 19, 70, 13, 5937, 1668, 1596, 1276, 70, 19, 70, 13, 1111, 16738, 70, 19, 70, 13, 2155, 804, 3330, 2374, 1227, 70, 19, 70, 13, 1614, 1668, 3385, 70, 19, 70, 13, 144, 22, 149, 22, 3, 463, 1, 533, 2131, 139, 138, 70, 19, 70, 13, 144, 7, 5, 1668, 581, 42, 985, 25, 576, 14, 53, 70, 185, 70, 44, 1300, 70, 19, 70, 13, 144, 8, 1567, 92, 10, 306, 1, 127, 4339, 130, 70, 19, 70, 13, 144, 3, 248, 59, 1668, 581, 2, 985, 25, 10, 120, 164, 4, 13967, 681, 7, 279, 4, 1962, 96, 7, 5, 442, 9757, 44, 2632, 3575, 2, 8, 920, 1, 135, 5, 7540, 13967, 681, 514, 1668, 581, 404, 288, 6, 3, 6737, 3903, 4, 7, 5, 2040, 10589, 10857, 2131, 15, 70, 1062, 3557, 70, 199, 2131, 107, 7, 54, 32, 694, 515, 6, 47, 7540, 13967, 681, 1668, 581, 16, 8, 1082, 3287, 1, 1946, 5114, 288, 6, 127, 533, 1179, 581, 2567, 257, 40, 104, 1, 3, 458, 371, 6, 3081, 7, 5, 442, 9757, 44, 2632, 3575, 15, 1946, 13967, 681, 29, 135, 5, 7260, 2163, 7540, 13967, 681]",2083.0,28495918,Bone marrow morphology strong discriminator chronic eosinophilic leukemia specified reactive idiopathic hypereosinophilic syndrome,0,0.0
Germline ETV6 mutations and predisposition to hematological malignancies.,International journal of hematology,Int. J. Hematol.,2017-05-29,"Patients with thrombocytopenia 5 have an autosomal dominant disorder of decreased platelet number with tendency to bleed, usually presenting in childhood, and have been found to have germline mutations in ETV6, which encodes a master hematopoietic transcription factor. Some patients who present similarly have inherited mutations in RUNX1 or ANKRD26. All three germline syndromes are also associated with a predisposition to myelodysplastic syndrome (MDS) and acute leukemia (AL). Since the first description of germline ETV6 mutations, 18 families have been reported. The common phenotype is mild to moderate thrombocytopenia with a variable predisposition to acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and MDS. This review will focus upon the role of ETV6 in hematopoiesis, especially in myeloid differentiation and maturation, and will describe the functional effects of mutant ETV6. The review will also provide an overview of common clinical features as well as recommendations for patient screening and follow-up and will debate whether additional clinical features should be included with the germline ETV6 syndrome.",Journal Article,967.0,12.0,Patients thrombocytopenia 5 autosomal dominant disorder decreased platelet number tendency bleed usually presenting childhood germline ETV6 encodes master hematopoietic transcription factor patients present similarly inherited RUNX1 ANKRD26 germline syndromes associated predisposition myelodysplastic syndrome MDS acute leukemia description germline ETV6 18 families reported common phenotype mild moderate thrombocytopenia variable predisposition acute lymphoblastic leukemia acute myeloid leukemia AML MDS review focus role ETV6 hematopoiesis especially myeloid differentiation maturation functional effects ETV6 review provide overview common clinical features recommendations patient screening follow-up debate additional clinical features included germline ETV6 syndrome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7, 5, 1340, 33, 47, 35, 6084, 2156, 2645, 1, 340, 1596, 207, 5, 7135, 6, 19502, 2082, 1656, 4, 864, 2, 47, 85, 204, 6, 47, 1009, 138, 4, 7306, 92, 4322, 8, 7561, 1007, 866, 161, 476, 7, 54, 364, 1813, 47, 2986, 138, 4, 6092, 15, 50410, 62, 169, 1009, 2040, 32, 120, 41, 5, 8, 2863, 6, 681, 1223, 2, 286, 2171, 1192, 3, 157, 5263, 1, 1009, 7306, 138, 203, 1954, 47, 85, 210, 3, 186, 1005, 16, 1980, 6, 1163, 1340, 5, 8, 1347, 2863, 6, 286, 1275, 62, 286, 533, 329, 2, 1223, 26, 206, 303, 1222, 1548, 3, 200, 1, 7306, 4, 5114, 1093, 4, 533, 910, 2, 4537, 2, 303, 897, 3, 583, 176, 1, 620, 7306, 3, 206, 303, 120, 377, 35, 2901, 1, 186, 38, 404, 22, 149, 22, 883, 9, 69, 453, 2, 166, 126, 2, 303, 5220, 317, 402, 38, 404, 257, 40, 159, 5, 3, 1009, 7306, 681]",1081.0,28555414,Germline ETV6 predisposition hematological malignancies,1,0.0017452006980802793
Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.,Blood,Blood,2017-06-02,"Chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML) are myelodysplastic syndrome (MDS)/myeloproliferative neoplasm (MPN) overlap disorders characterized by monocytosis, myelodysplasia, and a characteristic hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF). Currently, there are no available disease-modifying therapies for CMML, nor are there preclinical models that fully recapitulate the unique features of CMML. Through use of immunocompromised mice with transgenic expression of human GM-CSF, interleukin-3, and stem cell factor in a NOD/SCID-IL2R<sup>null</sup> background (NSGS mice), we demonstrate remarkable engraftment of CMML and JMML providing the first examples of serially transplantable and genetically accurate models of CMML. Xenotransplantation of CD34<sup>+</sup> cells (n = 8 patients) or unfractionated bone marrow (BM) or peripheral blood mononuclear cells (n = 10) resulted in robust engraftment of CMML in BM, spleen, liver, and lung of recipients (n = 82 total mice). Engrafted cells were myeloid-restricted and matched the immunophenotype, morphology, and genetic mutations of the corresponding patient. Similar levels of engraftment were seen upon serial transplantation of human CD34<sup>+</sup> cells in secondary NSGS recipients (2/5 patients, 6/11 mice), demonstrating the durability of CMML grafts and functionally validating CD34<sup>+</sup> cells as harboring the disease-initiating compartment in vivo. Successful engraftments of JMML primary samples were also achieved in all NSGS recipients (n = 4 patients, n = 12 mice). Engraftment of CMML and JMML resulted in overt phenotypic abnormalities and lethality in recipients, which facilitated evaluation of the JAK2/FLT3 inhibitor pacritinib in vivo. These data reveal that NSGS mice support the development of CMML and JMML disease-initiating and mature leukemic cells in vivo, allowing creation of genetically accurate preclinical models of these disorders.",Journal Article,963.0,19.0,Chronic myelomonocytic leukemia CMML juvenile myelomonocytic leukemia JMML myelodysplastic syndrome MDS /myeloproliferative neoplasm MPN overlap disorders characterized monocytosis myelodysplasia characteristic hypersensitivity granulocyte-macrophage colony-stimulating factor GM-CSF Currently available disease-modifying therapies CMML preclinical models fully recapitulate unique features CMML use immunocompromised mice transgenic expression human GM-CSF interleukin-3 stem factor NOD/SCID-IL2R sup null /sup background NSGS mice demonstrate remarkable engraftment CMML JMML providing examples serially transplantable genetically accurate models CMML Xenotransplantation CD34 sup /sup n 8 patients unfractionated bone marrow BM peripheral blood mononuclear n 10 resulted robust engraftment CMML BM spleen liver lung recipients n 82 total mice Engrafted myeloid-restricted matched immunophenotype morphology genetic corresponding patient Similar levels engraftment seen serial transplantation human CD34 sup /sup secondary NSGS recipients 2/5 patients 6/11 mice demonstrating durability CMML grafts functionally validating CD34 sup /sup harboring disease-initiating compartment vivo Successful engraftments JMML primary achieved NSGS recipients n 4 patients n 12 mice Engraftment CMML JMML resulted overt phenotypic abnormalities lethality recipients facilitated evaluation JAK2/FLT3 inhibitor pacritinib vivo reveal NSGS mice support development CMML JMML disease-initiating mature leukemic vivo allowing creation genetically accurate preclinical models disorders,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[442, 5451, 3382, 2, 7857, 5451, 16768, 32, 681, 1223, 10857, 2131, 4125, 4526, 1997, 765, 20, 16875, 6128, 2, 8, 2037, 4034, 6, 2764, 2674, 1975, 2122, 161, 2147, 1211, 694, 125, 32, 77, 390, 34, 4898, 235, 9, 3382, 2110, 32, 125, 693, 274, 17, 1910, 7746, 3, 991, 404, 1, 3382, 298, 119, 1, 7796, 399, 5, 2862, 55, 1, 171, 2147, 1211, 1603, 27, 2, 452, 31, 161, 4, 8, 7324, 4129, 27051, 172, 3505, 172, 2426, 36431, 399, 21, 608, 3813, 2881, 1, 3382, 2, 16768, 1736, 3, 157, 4416, 1, 6754, 11459, 2, 2301, 1481, 274, 1, 3382, 20362, 1, 2215, 172, 172, 37, 78, 66, 7, 15, 16341, 581, 1246, 15, 672, 315, 3041, 37, 78, 79, 627, 4, 1922, 2881, 1, 3382, 4, 1246, 4071, 2, 1, 2190, 78, 878, 181, 399, 6914, 37, 11, 533, 2016, 2, 655, 3, 5496, 2567, 2, 336, 138, 1, 3, 1734, 69, 288, 148, 1, 2881, 11, 527, 1548, 2108, 497, 1, 171, 2215, 172, 172, 37, 4, 568, 36431, 2190, 18, 33, 7, 49, 175, 399, 2219, 3, 6867, 1, 3382, 4713, 2, 3772, 6897, 2215, 172, 172, 37, 22, 2105, 3, 34, 2637, 3616, 4, 386, 1401, 36416, 1, 16768, 86, 347, 11, 120, 513, 4, 62, 36431, 2190, 78, 39, 7, 78, 133, 399, 2881, 1, 3382, 2, 16768, 627, 4, 7192, 3290, 1171, 2, 3266, 4, 2190, 92, 4667, 451, 1, 3, 2509, 1224, 230, 29404, 4, 386, 46, 74, 2396, 17, 36431, 399, 538, 3, 193, 1, 3382, 2, 16768, 34, 2637, 2, 2908, 2015, 37, 4, 386, 2952, 7560, 1, 2301, 1481, 693, 274, 1, 46, 1997]",1885.0,28576879,Robust patient-derived xenografts MDS/MPN overlap syndromes capture unique characteristics CMML JMML,297,0.518324607329843
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.,British journal of haematology,Br. J. Haematol.,2017-06-14,"Romiplostim can improve platelet counts in about 50% of patients with low- or intermediate 1-risk (lower risk) myelodysplastic syndromes (MDS) and thrombocytopenia, but its long-term toxicity and efficacy are not known. This open-label extension study evaluated the long-term safety and efficacy of romiplostim in 60 patients with lower risk MDS and platelet counts 5010<sup>9</sup> /l. The primary endpoint was adverse event (AE) incidence. Secondary endpoints were efficacy parameters, including bleeding events and platelet response. Median (range) treatment time in the extension study and the median observation times thereafter were 25 (2-181) and 57 (11-209)weeks, respectively. Treatment-related AEs and serious AEs were reported in 14/60 (23%) and 4/60 (7%) patients, respectively. Progression to acute myeloid leukaemia (AML) occurred in two patients after 44 and 46weeks. Patients (n=34, 57%) with a platelet response were further evaluated for length of response. Median (range) response duration was 33 (7-174)weeks; 28/34 (82%) patients had a continuous response. Five of 34 patients (15%) had grade 3 bleeding events; three when the platelet count was >5010<sup>9</sup> /l. There were no new safety concerns and the rate of progression to AML was low; response to romiplostim was maintained for most patients.",Clinical Trial,951.0,14.0,Romiplostim improve platelet counts 50 patients low- intermediate 1-risk lower risk myelodysplastic syndromes MDS thrombocytopenia long-term toxicity efficacy known open-label extension evaluated long-term safety efficacy romiplostim 60 patients lower risk MDS platelet counts 50 10 sup 9 /sup /l primary endpoint adverse event AE incidence Secondary endpoints efficacy parameters including bleeding events platelet response Median range treatment time extension median observation times 25 2-181 57 11-209 weeks respectively Treatment-related AEs AEs reported 14/60 23 4/60 7 patients respectively Progression acute myeloid leukaemia AML occurred patients 44 46 weeks Patients n 34 57 platelet response evaluated length response Median range response duration 33 7-174 weeks 28/34 82 patients continuous response 34 patients 15 grade 3 bleeding events platelet count 50 10 sup 9 /sup /l new safety concerns rate progression AML low response romiplostim maintained patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[19391, 122, 401, 1596, 1911, 4, 545, 212, 1, 7, 5, 154, 15, 919, 14, 43, 280, 43, 2040, 1223, 2, 1340, 84, 211, 319, 337, 155, 2, 209, 32, 44, 440, 26, 1020, 1756, 2401, 45, 194, 3, 319, 337, 367, 2, 209, 1, 19391, 4, 335, 7, 5, 280, 43, 1223, 2, 1596, 1911, 10773, 79, 172, 83, 172, 805, 3, 86, 1138, 10, 290, 774, 3633, 287, 568, 1387, 11, 209, 1038, 141, 2294, 281, 2, 1596, 51, 52, 184, 24, 98, 4, 3, 2401, 45, 2, 3, 52, 1664, 1072, 3972, 11, 243, 18, 5540, 2, 696, 175, 5941, 244, 106, 24, 139, 1477, 2, 1762, 1477, 11, 210, 4, 213, 335, 382, 2, 39, 335, 67, 7, 106, 91, 6, 286, 533, 2001, 329, 489, 4, 100, 7, 50, 584, 2, 641, 244, 7, 78, 562, 696, 5, 8, 1596, 51, 11, 195, 194, 9, 1318, 1, 51, 52, 184, 51, 654, 10, 466, 67, 5811, 244, 339, 562, 878, 7, 42, 8, 1314, 51, 365, 1, 562, 7, 167, 42, 88, 2608, 2294, 281, 169, 198, 3, 1596, 1276, 10, 212, 79, 172, 83, 172, 805, 125, 11, 77, 217, 367, 2061, 2, 3, 116, 1, 91, 6, 329, 10, 154, 51, 6, 19391, 10, 1955, 9, 96, 7]",1259.0,28616874,Romiplostim monotherapy thrombocytopenic patients myelodysplastic syndromes long-term safety efficacy,0,0.0
Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q).,Journal of hematology & oncology,J Hematol Oncol,2017-06-26,"Particularly since the advent of lenalidomide, lower-risk myelodysplastic syndromes (MDS) patients with del(5q) have been the focus of many studies; however, the impact of age on disease characteristics and response to lenalidomide has not been analyzed. We assessed the effect of age on clinical characteristics and outcomes in 286 lenalidomide-treated MDS patients with del(5q) from two multicenter trials. A total of 33.9, 34.3, and 31.8% patients were aged <65years, 65 to <75years, and 75years, respectively. Age <65years was associated with less favorable International Prognostic Scoring System (IPSS) risk and additional cytopenias at baseline versus older age groups, significantly lower cytogenetic response rates (p=0.022 vs. 65 to <75years; p=0.047 vs. 75years), and higher rates of acute myeloid leukemia (AML) progression (Gray's test, p=0.013). Lenalidomide was equally well tolerated across age groups, producing consistently high rates of red blood cell transfusion independence 26weeks. Baseline disease characteristics and AML progression appear to be more severe in younger lower-risk MDS patients with del(5q), whereas older age does not seem to compromise the response to lenalidomide. ClinicalTrials.gov NCT00065156 and NCT00179621.",Clinical Trial,939.0,4.0,Particularly advent lenalidomide lower-risk myelodysplastic syndromes MDS patients del 5q focus studies impact age disease characteristics response lenalidomide assessed effect age clinical characteristics outcomes 286 lenalidomide-treated MDS patients del 5q multicenter trials total 33.9 34.3 31.8 patients aged 65 years 65 75 years 75 years respectively Age 65 years associated favorable International Prognostic Scoring IPSS risk additional cytopenias baseline versus older age groups significantly lower cytogenetic response rates p 0.022 vs. 65 75 years p 0.047 vs. 75 years higher rates acute myeloid leukemia AML progression Gray 's test p 0.013 Lenalidomide equally tolerated age groups producing consistently high rates red blood transfusion independence 26 weeks Baseline disease characteristics AML progression appear severe younger lower-risk MDS patients del 5q older age compromise response lenalidomide ClinicalTrials.gov NCT00065156 NCT00179621,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[823, 1192, 3, 4114, 1, 1288, 280, 43, 2040, 1223, 7, 5, 3084, 5460, 47, 85, 3, 1222, 1, 445, 94, 137, 3, 345, 1, 89, 23, 34, 374, 2, 51, 6, 1288, 71, 44, 85, 311, 21, 275, 3, 254, 1, 89, 23, 38, 374, 2, 123, 4, 8302, 1288, 73, 1223, 7, 5, 3084, 5460, 29, 100, 1570, 143, 8, 181, 1, 466, 83, 562, 27, 2, 456, 66, 7, 11, 1032, 556, 60, 5827, 6, 481, 60, 2, 8999, 60, 106, 89, 556, 60, 10, 41, 5, 299, 913, 944, 177, 2504, 398, 8751, 43, 2, 402, 5635, 28, 330, 185, 434, 89, 271, 97, 280, 1266, 51, 151, 19, 13, 4773, 105, 5827, 6, 481, 60, 19, 13, 5296, 105, 8999, 60, 2, 142, 151, 1, 286, 533, 329, 91, 4163, 292, 412, 19, 13, 3612, 1288, 10, 4142, 149, 421, 716, 89, 271, 3787, 2433, 64, 151, 1, 3422, 315, 31, 2785, 5773, 32162, 244, 330, 34, 374, 2, 329, 91, 1322, 6, 40, 80, 905, 4, 773, 280, 43, 1223, 7, 5, 3084, 5460, 547, 434, 89, 1097, 44, 3233, 6, 4665, 3, 51, 6, 1288, 1252, 1239, 70681, 2, 70682]",1204.0,28651604,Clinical characteristics outcomes according age lenalidomide-treated patients RBC transfusion-dependent lower-risk MDS del 5q,0,0.0
"Co-Infections by Double-Stranded DNA Viruses after Ex Vivo T Cell-Depleted, CD34<sup>+</sup> Selected Hematopoietic Cell Transplantation.",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2017-06-28,"Recipients of ex vivo T cell-depleted (TCD) hematopoietic cell transplantation (HCT) are at risk of infection by double-stranded (ds) DNA viruses. We report rates of dsDNA viremia, end-organ disease (EOD), infection-related mortality, and overall survival (OS) in a contemporary cohort of adult TCD HCT recipients routinely monitored for cytomegalovirus (CMV), adenovirus (ADV), human herpesvirus 6 (HHV6), and Epstein-Barr virus (EBV). Healthcare utilization in the first 6 months post-HCT was compared between patients with dsDNA viremia versus no viremia. This was an observational study of adult patients with acute leukemia and myelodysplastic syndrome who received CD34<sup>+</sup> selected, peripheral blood HCT at Memorial Sloan Kettering Cancer Center from March 2012 through December 2014. Patients were prospectively monitored by quantitative PCR assays for CMV, ADV, HHV6, and EBV in whole blood or plasma. The cumulative incidence of viremia(s) at day +180, EOD at 1 year, and OS at 1 year were estimated by the Kaplan-Meier method and compared by the log-rank test among patient with and without viremia/EOD. Standardized incidence ratios were used to compare overall length of hospital stay (LOS), number of readmissions after HCT, and length of readmissions through day +180. Of 156 patients, 96 (62%) were CMV recipient seropositive. Forty-two patients received grafts from matched related (27%), 86 from matched unrelated (55%), and 28 from mismatched (18%) donors. Overall, 132 patients (85%) had 1 viremia and 52 (33%) 2 viremias by day +180. The cumulative incidences for CMV, HHV6, ADV, and EBV viremia were 44%, 61%, 7%, and 16%, respectively, with median times of onset 28 days (interquartile range [IQR], 25 to 33), 33 days (IQR, 25 to 47), 60 days (IQR, 19 to 84), and 79 days (IQR, 54 to 106) post-HCT, respectively. Twenty-eight patients (18%) developed EOD by dsDNA viruses at 1 year post-HCT. Treatment for CMV accounted for 91% total antiviral treatment-days. Compared with patients with no viremia, patients with CMV viremia, HHV6 viremia, or2 viremias experienced longer LOS (P<.001) and a higher number of readmissions (P<.001) by day +180. OS rate at 1 year was 79% and was similar between patients with or without dsDNA viremias. EOD was associated with lower 1-year OS rates (63.4%) versus without EOD (81.1%) (P=.02). Of 33 patients who died, 10 died due to infection, and 7 of these infection-related deaths were due to dsDNA viruses. Viremia by dsDNA viruses occurred in 85% of TCD HCT recipients by day +100 and 33% of patients experienced 2 viremias by day +180. CMV accounted for most antiviral use. CMV, HHV6, or 2 viremias were associated with more readmissions and longer LOS. One year OS rate was 78%. EOD by dsDNA viruses was associated with decreased 1-year OS. Infections by dsDNA viruses pose a substantial burden after TCD HCT.",Journal Article,937.0,14.0,Recipients ex vivo cell-depleted TCD hematopoietic transplantation HCT risk infection double-stranded ds DNA viruses report rates dsDNA viremia end-organ disease EOD infection-related mortality overall survival OS contemporary cohort adult TCD HCT recipients routinely monitored cytomegalovirus CMV adenovirus ADV human herpesvirus 6 HHV6 Epstein-Barr virus EBV Healthcare utilization 6 months post-HCT compared patients dsDNA viremia versus viremia observational adult patients acute leukemia myelodysplastic syndrome received CD34 sup /sup selected peripheral blood HCT Memorial Sloan Kettering Center March 2012 December 2014 Patients prospectively monitored quantitative PCR CMV ADV HHV6 EBV blood plasma cumulative incidence viremia day +180 EOD 1 year OS 1 year estimated Kaplan-Meier compared log-rank test patient viremia/EOD Standardized incidence ratios compare overall length hospital stay LOS number readmissions HCT length readmissions day +180 156 patients 96 62 CMV recipient seropositive Forty-two patients received grafts matched related 27 86 matched unrelated 55 28 mismatched 18 donors Overall 132 patients 85 1 viremia 52 33 2 viremias day +180 cumulative incidences CMV HHV6 ADV EBV viremia 44 61 7 16 respectively median times onset 28 days interquartile range IQR 25 33 33 days IQR 25 47 60 days IQR 19 84 79 days IQR 54 106 post-HCT respectively Twenty-eight patients 18 developed EOD dsDNA viruses 1 year post-HCT Treatment CMV accounted 91 total antiviral treatment-days Compared patients viremia patients CMV viremia HHV6 viremia 2 viremias experienced longer LOS P .001 higher number readmissions P .001 day +180 OS rate 1 year 79 similar patients dsDNA viremias EOD associated lower 1-year OS rates 63.4 versus EOD 81.1 P .02 33 patients died 10 died infection 7 infection-related deaths dsDNA viruses Viremia dsDNA viruses occurred 85 TCD HCT recipients day +100 33 patients experienced 2 viremias day +180 CMV accounted antiviral use CMV HHV6 2 viremias associated readmissions longer LOS year OS rate 78 EOD dsDNA viruses associated decreased 1-year OS Infections dsDNA viruses pose substantial burden TCD HCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2190, 1, 2581, 386, 102, 31, 4358, 8827, 1007, 31, 497, 1085, 32, 28, 43, 1, 930, 20, 1627, 9021, 3602, 261, 4405, 21, 414, 151, 1, 20040, 10008, 396, 1259, 34, 27623, 930, 139, 282, 2, 63, 25, 118, 4, 8, 2667, 180, 1, 780, 8827, 1085, 2190, 3066, 2909, 9, 7314, 3879, 4488, 10797, 171, 9329, 49, 32754, 2, 5212, 5190, 1450, 2672, 2819, 1961, 4, 3, 157, 49, 53, 539, 1085, 10, 72, 59, 7, 5, 20040, 10008, 185, 77, 10008, 26, 10, 35, 2495, 45, 1, 780, 7, 5, 286, 2, 681, 54, 103, 2215, 172, 172, 715, 672, 315, 1085, 28, 2563, 2783, 2784, 12, 574, 29, 2363, 1195, 298, 1397, 1409, 7, 11, 1143, 2909, 20, 1156, 604, 1013, 9, 3879, 10797, 32754, 2, 2672, 4, 902, 315, 15, 554, 3, 967, 287, 1, 10008, 695, 28, 218, 3172, 27623, 28, 14, 111, 2, 118, 28, 14, 111, 11, 661, 20, 3, 876, 882, 596, 2, 72, 20, 3, 1066, 1026, 412, 107, 69, 5, 2, 187, 10008, 27623, 1670, 287, 1137, 11, 95, 6, 932, 63, 1318, 1, 702, 2020, 3649, 207, 1, 5319, 50, 1085, 2, 1318, 1, 5319, 298, 218, 3172, 1, 5693, 7, 921, 744, 11, 3879, 5783, 9909, 1213, 100, 7, 103, 4713, 29, 655, 139, 428, 868, 29, 655, 2092, 614, 2, 339, 29, 5095, 203, 2344, 63, 4255, 7, 772, 42, 3567, 10008, 2, 653, 466, 3107, 32755, 20, 218, 3172, 3, 967, 3981, 9, 3879, 32754, 10797, 2, 2672, 10008, 11, 584, 713, 67, 2, 245, 106, 5, 52, 1072, 1, 1707, 339, 162, 2899, 184, 2245, 243, 6, 466, 466, 162, 2245, 243, 6, 662, 335, 162, 2245, 326, 6, 874, 2, 842, 162, 2245, 667, 6, 3251, 539, 1085, 106, 737, 659, 7, 203, 276, 27623, 20, 20040, 4405, 28, 14, 111, 539, 1085, 24, 9, 3879, 3688, 9, 970, 181, 6264, 24, 162, 72, 5, 7, 5, 77, 10008, 7, 5, 3879, 10008, 32754, 10008, 15, 3107, 32755, 592, 589, 3649, 19, 144, 2, 8, 142, 207, 1, 5319, 19, 144, 20, 218, 3172, 118, 116, 28, 14, 111, 10, 842, 2, 10, 288, 59, 7, 5, 15, 187, 20040, 32755, 27623, 10, 41, 5, 280, 14, 111, 118, 151, 676, 39, 185, 187, 27623, 865, 14, 19, 588, 1, 466, 7, 54, 1016, 79, 1016, 520, 6, 930, 2, 67, 1, 46, 930, 139, 1043, 11, 520, 6, 20040, 4405, 10008, 20, 20040, 4405, 489, 4, 772, 1, 8827, 1085, 2190, 20, 218, 394, 2, 466, 1, 7, 592, 3107, 32755, 20, 218, 3172, 3879, 3688, 9, 96, 6264, 119, 3879, 32754, 15, 3107, 32755, 11, 41, 5, 80, 5319, 2, 589, 3649, 104, 111, 118, 116, 10, 833, 27623, 20, 20040, 4405, 10, 41, 5, 340, 14, 111, 118, 1875, 20, 20040, 4405, 6015, 8, 1281, 892, 50, 8827, 1085]",2720.0,28668490,Co-Infections Double-Stranded DNA Viruses Ex Vivo Cell-Depleted CD34 sup /sup Selected Hematopoietic Transplantation,7,0.012216404886561954
The emerging role of immune checkpoint based approaches in AML and MDS.,Leukemia & lymphoma,Leuk. Lymphoma,2017-07-06,"The development of immune checkpoint inhibitors represents a major breakthrough in the field of cancer therapeutics. Pursuant to their success in melanoma and numerous solid tumor malignancies, these agents are being investigated in hematological malignancies including acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). Although AML/MDS have traditionally been considered to be less immunogenic than solid tumor malignancies, recent pre-clinical models suggest a therapeutic role for immune checkpoint inhibition in these diseases. CTLA-4 inhibition may be especially effective in treating late post-allogeneic stem cell transplant relapse of AML in patients with limited or no graft versus host disease. Immune checkpoint inhibition, specifically PD-1 inhibition, demonstrated limited single agent efficacy in patients with relapsed AML and with MDS post-hypomethylating therapy. Rationally designed combinations of PD-1 inhibitors with standard anti-leukemic therapy are needed. Hypomethylating agents such as azacitidine, up-regulate PD-1, PD-L1, and PD-L2 in patients with AML/MDS and up-regulation of these genes was associated with the emergence of resistance. The combination of azacitidine and PD-1/PD-L1 inhibition may be a potential mechanism to prevent or overcome resistance to 5-azacitidine. A number of such combinations are being evaluated in clinical trials with early encouraging results. Immune checkpoint inhibition is also an attractive option to improve relapse-free survival or eliminate minimal residual disease post induction and consolidation by enhancing T-cell surveillance in patients with high-risk AML. The ongoing clinical trials with checkpoint inhibitors in AML/MDS will improve our understanding of the immunobiology of these diseases and guide us to the most appropriate application of these agents in the therapy of AML/MDS.",Journal Article,929.0,23.0,development immune checkpoint inhibitors represents major breakthrough field therapeutics Pursuant success melanoma numerous solid malignancies agents investigated hematological malignancies including acute myelogenous leukemia AML myelodysplastic syndromes MDS AML/MDS traditionally considered immunogenic solid malignancies recent pre-clinical models suggest therapeutic role immune checkpoint inhibition diseases CTLA-4 inhibition especially effective treating late post-allogeneic stem transplant relapse AML patients limited graft versus host disease Immune checkpoint inhibition specifically PD-1 inhibition demonstrated limited single agent efficacy patients relapsed AML MDS post-hypomethylating therapy Rationally designed combinations PD-1 inhibitors standard anti-leukemic therapy needed Hypomethylating agents azacitidine up-regulate PD-1 PD-L1 PD-L2 patients AML/MDS up-regulation associated emergence resistance combination azacitidine PD-1/PD-L1 inhibition potential mechanism prevent overcome resistance 5-azacitidine number combinations evaluated clinical trials early encouraging Immune checkpoint inhibition attractive option improve relapse-free survival eliminate minimal residual disease post induction consolidation enhancing T-cell surveillance patients high-risk AML ongoing clinical trials checkpoint inhibitors AML/MDS improve understanding immunobiology diseases guide appropriate application agents therapy AML/MDS,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 193, 1, 250, 986, 222, 1449, 8, 458, 6022, 4, 3, 1067, 1, 12, 1943, 35365, 6, 136, 1825, 4, 2, 2331, 537, 30, 441, 46, 183, 32, 486, 565, 4, 2890, 441, 141, 286, 2194, 329, 2, 2040, 1223, 242, 329, 1223, 47, 4206, 85, 515, 6, 40, 299, 4190, 76, 537, 30, 441, 435, 671, 38, 274, 309, 8, 189, 200, 9, 250, 986, 297, 4, 46, 1342, 2127, 39, 297, 68, 40, 1093, 323, 4, 1367, 807, 539, 1063, 452, 31, 941, 429, 1, 329, 4, 7, 5, 383, 15, 77, 1599, 185, 1204, 34, 250, 986, 297, 1225, 333, 14, 297, 264, 383, 226, 420, 209, 4, 7, 5, 591, 329, 2, 5, 1223, 539, 4931, 36, 6352, 1114, 1247, 1, 333, 14, 222, 5, 260, 312, 2015, 36, 32, 575, 4931, 183, 225, 22, 3752, 126, 2288, 333, 14, 333, 729, 2, 333, 5111, 4, 7, 5, 329, 1223, 2, 126, 863, 1, 46, 214, 10, 41, 5, 3, 3397, 1, 251, 3, 150, 1, 3752, 2, 333, 14, 333, 729, 297, 68, 40, 8, 174, 670, 6, 1682, 15, 1768, 251, 6, 33, 3752, 8, 207, 1, 225, 1247, 32, 486, 194, 4, 38, 143, 5, 191, 2269, 99, 250, 986, 297, 16, 120, 35, 3059, 1501, 6, 401, 429, 115, 25, 15, 4964, 1048, 753, 34, 539, 504, 2, 2173, 20, 2430, 102, 31, 617, 4, 7, 5, 64, 43, 329, 3, 942, 38, 143, 5, 986, 222, 4, 329, 1223, 303, 401, 114, 612, 1, 3, 18842, 1, 46, 1342, 2, 1597, 843, 6, 3, 96, 870, 1581, 1, 46, 183, 4, 3, 36, 1, 329, 1223]",1824.0,28679300,emerging role immune checkpoint based approaches AML MDS,7,0.012216404886561954
High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis.,Blood,Blood,2017-07-05,"Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis that most commonly affects adults and is driven by a high frequency of mutations in <i>BRAF</i>, <i>MAP2K1</i>, and kinases promoting MAPK signaling. Because of the relative rarity of ECD, key clinical features of the disease may not be well defined. Across a multi-institutional cohort of 189 patients with ECD and ECD overlapping with Langerhans cell histiocytosis (so-called mixed histiocytosis [MH]), we identified an unexpected and heretofore undescribed frequent occurrence of myeloid neoplasms among patients with ECD and MH. Some 10.1% (19/189) of patients with ECD have an overlapping myeloid neoplasm, most commonly occurring as a myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), or mixed MDS/MPN overlap syndrome (including chronic myelomonocytic leukemia). Consistent with this, molecular analysis frequently detected hallmark driver mutations of myeloid neoplasms (such as <i>JAK2</i>V617F and <i>CALR</i> mutations) coexisting with those characteristic of histiocytosis (such as <i>BRAF</i>V600E and <i>MAP2K1</i> mutations). Histiocytosis patients diagnosed with a concomitant myeloid malignancy were significantly older at diagnosis and more commonly presented with MH than those without a myeloid malignancy. In some cases, the presence of distinct kinase mutations in the histiocytosis and myeloid neoplasm resulted in discordant and adverse responses to kinase-directed targeted therapies. These data highlight the clinical importance of evaluating adults with histiocytosis for a concomitant myeloid neoplasm.",Journal Article,930.0,20.0,Erdheim-Chester disease ECD rare non-Langerhans histiocytosis commonly affects adults driven high frequency BRAF /i MAP2K1 /i kinases promoting MAPK signaling relative rarity ECD key clinical features disease defined multi-institutional cohort 189 patients ECD ECD overlapping Langerhans histiocytosis so-called mixed histiocytosis MH identified unexpected heretofore undescribed frequent occurrence myeloid neoplasms patients ECD MH 10.1 19/189 patients ECD overlapping myeloid neoplasm commonly occurring myeloproliferative neoplasm MPN myelodysplastic syndrome MDS mixed MDS/MPN overlap syndrome including chronic myelomonocytic leukemia Consistent molecular frequently detected hallmark driver myeloid neoplasms JAK2 /i V617F CALR /i coexisting characteristic histiocytosis BRAF /i V600E MAP2K1 /i Histiocytosis patients diagnosed concomitant myeloid malignancy significantly older diagnosis commonly presented MH myeloid malignancy cases presence distinct kinase histiocytosis myeloid neoplasm resulted discordant adverse responses kinase-directed targeted therapies highlight clinical importance evaluating adults histiocytosis concomitant myeloid neoplasm,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[36084, 36085, 34, 8441, 16, 8, 622, 220, 15702, 31, 13976, 17, 96, 841, 2561, 857, 2, 16, 1621, 20, 8, 64, 675, 1, 138, 4, 70, 566, 70, 70, 11054, 70, 2, 1549, 2388, 1748, 314, 408, 1, 3, 580, 4989, 1, 8441, 825, 38, 404, 1, 3, 34, 68, 44, 40, 149, 395, 716, 8, 1414, 1115, 180, 1, 5899, 7, 5, 8441, 2, 8441, 4551, 5, 15702, 31, 13976, 1743, 3472, 1739, 13976, 17709, 21, 108, 35, 3792, 2, 18184, 13317, 908, 2291, 1, 533, 1179, 107, 7, 5, 8441, 2, 17709, 476, 79, 14, 326, 5899, 1, 7, 5, 8441, 47, 35, 4551, 533, 2131, 96, 841, 1821, 22, 8, 2131, 4125, 681, 1223, 15, 1739, 1223, 4125, 4526, 681, 141, 442, 5451, 925, 5, 26, 219, 65, 746, 530, 4683, 2228, 138, 1, 533, 1179, 225, 22, 70, 2509, 70, 5657, 2, 70, 11222, 70, 138, 8859, 5, 135, 2037, 1, 13976, 225, 22, 70, 566, 70, 2047, 2, 70, 11054, 70, 138, 13976, 7, 265, 5, 8, 1781, 533, 710, 11, 97, 434, 28, 147, 2, 80, 841, 917, 5, 17709, 76, 135, 187, 8, 533, 710, 4, 476, 140, 3, 463, 1, 834, 216, 138, 4, 3, 13976, 2, 533, 2131, 627, 4, 4570, 2, 290, 253, 6, 216, 1166, 238, 235, 46, 74, 1817, 3, 38, 1187, 1, 1435, 857, 5, 13976, 9, 8, 1781, 533, 2131]",1531.0,28679734,High prevalence myeloid neoplasms adults non-Langerhans histiocytosis,67,0.1169284467713787
Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma.,International journal of dermatology,Int. J. Dermatol.,2017-07-07,"Second hematologic cancers in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) are well documented and include Hodgkin lymphoma, therapy-related acute myeloid leukemia/myelodysplastic syndromes, and transformation to diffuse large B-cell lymphoma. Although cutaneous T-cell lymphoma (CTCL) has been reported in patients with CLL, the incidence and comparison to expected rates are unknown. We evaluated the incidence of CTCL among patients with CLL or other non-Hodgkin lymphoma (NHL) subtypes using data from the Surveillance, Epidemiology, and End Results (SEER) Program. We searched the SEER 13 registries for patients with a diagnosis of CLL and NHL between 1992 and 2008. Among patients identified, we evaluated the incidence of CTCL. Among 31,286 patients with CLL, the incidence of CTCL was not significantly higher in men than women: 104.2 (95% CI, 50.0-191.8) and 28.1 (95% CI, 3.4-101.3) per 1,000,000 person-years, respectively (P=0.06). Among 97,691 patients with NHL, the incidence of CTCL was similar in men and women (97.9 [95% CI, 62.0-146.9] and 92.0 [95% CI, 56.2-142.1] per 1,000,000 person-years, respectively; P=0.84). The incidence of CTCL among males with CLL (standardized incidence ratio [SIR], 3.0 [95% CI, 1.4-5.5]), males with NHL (SIR, 3.7 [95% CI, 2.3-5.5]), and females with NHL (SIR, 5.9 [95% CI, 3.6-9.1]) was significantly higher than expected in the general population (all P<0.001). The risk of CTCL is greater in men with CLL than in the general population. In patients with NHL, both men and women are at greater risk for CTCL than in the general population.",Journal Article,928.0,1.0,"Second hematologic patients chronic lymphocytic leukemia/small lymphocytic lymphoma CLL documented include Hodgkin lymphoma therapy-related acute myeloid leukemia/myelodysplastic syndromes transformation diffuse large B-cell lymphoma cutaneous T-cell lymphoma CTCL reported patients CLL incidence comparison expected rates unknown evaluated incidence CTCL patients CLL non-Hodgkin lymphoma NHL subtypes Surveillance Epidemiology End SEER Program searched SEER 13 registries patients diagnosis CLL NHL 1992 2008 patients identified evaluated incidence CTCL 31,286 patients CLL incidence CTCL significantly higher men women 104.2 95 CI 50.0-191.8 28.1 95 CI 3.4-101.3 1,000,000 person-years respectively P 0.06 97,691 patients NHL incidence CTCL similar men women 97.9 95 CI 62.0-146.9 92.0 95 CI 56.2-142.1 1,000,000 person-years respectively P 0.84 incidence CTCL males CLL standardized incidence ratio SIR 3.0 95 CI 1.4-5.5 males NHL SIR 3.7 95 CI 2.3-5.5 females NHL SIR 5.9 95 CI 3.6-9.1 significantly higher expected general population P 0.001 risk CTCL greater men CLL general population patients NHL men women greater risk CTCL general population",0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,"[419, 813, 163, 4, 7, 5, 442, 1193, 2647, 302, 1193, 552, 32, 149, 1405, 2, 643, 36, 139, 286, 533, 2647, 10589, 2040, 2, 1392, 6, 1388, 375, 132, 31, 242, 1486, 102, 31, 4742, 71, 85, 210, 4, 7, 5, 552, 3, 287, 2, 1155, 6, 1336, 151, 32, 860, 21, 194, 3, 287, 1, 4742, 107, 7, 5, 552, 15, 127, 1176, 814, 75, 74, 29, 3, 617, 1284, 2, 396, 99, 1605, 1243, 21, 3080, 3, 1605, 233, 3768, 9, 7, 5, 8, 147, 1, 552, 2, 1176, 59, 2846, 2, 1375, 107, 7, 108, 21, 194, 3, 287, 1, 4742, 107, 456, 8302, 7, 5, 552, 3, 287, 1, 4742, 10, 44, 97, 142, 4, 325, 76, 117, 3407, 18, 48, 58, 212, 13, 6130, 66, 2, 339, 14, 48, 58, 27, 39, 2338, 27, 379, 14, 984, 984, 2719, 60, 106, 19, 13, 1460, 107, 1015, 11661, 7, 5, 1176, 3, 287, 1, 4742, 10, 288, 4, 325, 2, 117, 1015, 83, 48, 58, 744, 13, 4909, 83, 2, 937, 13, 48, 58, 664, 18, 4785, 14, 379, 14, 984, 984, 2719, 60, 106, 19, 13, 874, 3, 287, 1, 4742, 107, 2296, 5, 552, 1670, 287, 197, 3636, 27, 13, 48, 58, 14, 39, 33, 33, 2296, 5, 1176, 3636, 27, 67, 48, 58, 18, 27, 33, 33, 2, 2451, 5, 1176, 3636, 33, 83, 48, 58, 27, 49, 83, 14, 10, 97, 142, 76, 1336, 4, 3, 1083, 266, 62, 19, 13, 144, 3, 43, 1, 4742, 16, 378, 4, 325, 5, 552, 76, 4, 3, 1083, 266, 4, 7, 5, 1176, 110, 325, 2, 117, 32, 28, 378, 43, 9, 4742, 76, 4, 3, 1083, 266]",1480.0,28685851,Risk cutaneous T-cell lymphoma patients chronic lymphocytic leukemia subtypes non-Hodgkin lymphoma,0,0.0
"A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2017-07-12,"We sought to develop a myeloablative chemotherapeutic regimen to secure consistent engraftment of T-cell depleted (TCD) hematopoietic stem cell transplantations (HSCT) without the need for total body irradiation, thereby reducing toxicity while maintaining low rates of graft-versus-host disease (GVHD) and without increasing relapse. We investigated the myeloablative combination of busulfan (Bu) and melphalan (Mel), with the immunosuppressive agents fludarabine (Flu) and rabbit antithymocyte globulin (r-ATG) as cytoreduction before a TCD HSCT. No post-transplantation immunosuppression was administered. Between April 2001 and May 2008, 102 patients (median age, 55 years) with a diagnosis of primary or secondary myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) underwent cytoreduction with Bu/Mel/Flu, followed by TCD grafts. TCD was accomplished by CD34<sup>+</sup>-selection followed by E-rosette depletion for peripheral blood stem cell grafts and, for bone marrow grafts, by soybean agglutination followed by E-rosette depletion. Donors included matched and mismatched, related and unrelated donors. Risk stratification was by American Society for Blood and Marrow Transplantation risk categorization for patients with primary disease. For patients with secondary/treatment-related MDS/AML, those in complete remission (CR) 1 or with refractory anemia were classified as intermediate risk, and all other patients were considered high risk. Neutrophil engraftment occurred at a median of 11 days in 100 of 101 evaluable patients. The cumulative incidences of grades II to IV acute and chronic GVHD at 1 year were 8.8% and 5.9%, respectively. Overall- and disease-free survival (DFS) rates at 5 years were 50.0% and 46.1%, respectively, and the cumulative incidences of relapse and treatment-related mortality were 23.5% and 28.4%, respectively. Stratification by risk group demonstrated superior DFS for low-risk patients (61.5% at 5 years) compared with intermediate- or high-risk (34.2% and 40.0%, respectively, P=.021). For patients with AML, those in CR1 had superior 5-year DFS compared with those in CR2 (60% and 30.6%, respectively, P=.01), without a significant difference in incidence of relapse (17.1% and 30.6%, respectively, P=.209). There were no differences in DFS for other patient, donor, or disease characteristics. In summary, cytoreduction with Bu/Mel/Flu and r-ATG secured consistent engraftment of TCD transplantations. The incidences of acute/chronic GVHD and disease relapse were low, with favorable outcomes in this patient population with high-risk myeloid malignancies.",Journal Article,923.0,1.0,sought develop myeloablative chemotherapeutic regimen secure consistent engraftment T-cell depleted TCD hematopoietic stem transplantations HSCT need total body irradiation reducing toxicity maintaining low rates graft-versus-host disease GVHD increasing relapse investigated myeloablative combination busulfan Bu melphalan Mel immunosuppressive agents fludarabine Flu rabbit antithymocyte globulin r-ATG cytoreduction TCD HSCT post-transplantation immunosuppression administered April 2001 2008 102 patients median age 55 years diagnosis primary secondary myelodysplastic syndrome MDS acute myeloid leukemia AML underwent cytoreduction Bu/Mel/Flu followed TCD grafts TCD accomplished CD34 sup /sup -selection followed E-rosette depletion peripheral blood stem grafts bone marrow grafts soybean agglutination followed E-rosette depletion Donors included matched mismatched related unrelated donors Risk stratification American Society Blood Marrow Transplantation risk categorization patients primary disease patients secondary/treatment-related MDS/AML complete remission CR 1 refractory anemia classified intermediate risk patients considered high risk Neutrophil engraftment occurred median 11 days 100 101 evaluable patients cumulative incidences grades II IV acute chronic GVHD 1 year 8.8 5.9 respectively Overall- disease-free survival DFS rates 5 years 50.0 46.1 respectively cumulative incidences relapse treatment-related mortality 23.5 28.4 respectively Stratification risk group demonstrated superior DFS low-risk patients 61.5 5 years compared intermediate- high-risk 34.2 40.0 respectively P .021 patients AML CR1 superior 5-year DFS compared CR2 60 30.6 respectively P .01 significant difference incidence relapse 17.1 30.6 respectively P .209 differences DFS patient donor disease characteristics summary cytoreduction Bu/Mel/Flu r-ATG secured consistent engraftment TCD transplantations incidences acute/chronic GVHD disease relapse low favorable outcomes patient population high-risk myeloid malignancies,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[21, 990, 6, 690, 8, 3246, 1573, 477, 6, 14520, 925, 2881, 1, 102, 31, 4358, 8827, 1007, 452, 31, 6779, 1703, 187, 3, 594, 9, 181, 642, 1104, 2267, 1818, 155, 369, 3284, 154, 151, 1, 1599, 185, 1204, 34, 1562, 2, 187, 602, 429, 21, 565, 3, 3246, 150, 1, 3906, 3667, 2, 2370, 7383, 5, 3, 2989, 183, 2027, 5119, 2, 11079, 11016, 7819, 668, 7168, 22, 2844, 348, 8, 8827, 1703, 77, 539, 497, 3646, 10, 468, 59, 2292, 1758, 2, 68, 1375, 2867, 7, 52, 89, 614, 60, 5, 8, 147, 1, 86, 15, 568, 681, 1223, 15, 286, 533, 329, 208, 2844, 5, 3667, 7383, 5119, 370, 20, 8827, 4713, 8827, 10, 5741, 20, 2215, 172, 172, 881, 370, 20, 563, 29408, 2286, 9, 672, 315, 452, 31, 4713, 2, 9, 581, 4713, 20, 26331, 47648, 370, 20, 563, 29408, 2286, 2344, 159, 655, 2, 5095, 139, 2, 2092, 2344, 43, 1541, 10, 20, 597, 1174, 9, 315, 2, 581, 497, 43, 8872, 9, 7, 5, 86, 34, 9, 7, 5, 568, 24, 139, 1223, 329, 135, 4, 236, 734, 684, 14, 15, 5, 430, 1545, 11, 1373, 22, 919, 43, 2, 62, 127, 7, 11, 515, 64, 43, 2595, 2881, 489, 28, 8, 52, 1, 175, 162, 4, 394, 1, 2338, 859, 7, 3, 967, 3981, 1, 2276, 215, 6, 478, 286, 2, 442, 1562, 28, 14, 111, 11, 66, 66, 2, 33, 83, 106, 63, 2, 34, 115, 25, 1010, 151, 28, 33, 60, 11, 212, 13, 2, 641, 14, 106, 2, 3, 967, 3981, 1, 429, 2, 24, 139, 282, 11, 382, 33, 2, 339, 39, 106, 1541, 20, 43, 87, 264, 1123, 1010, 9, 154, 43, 7, 713, 33, 28, 33, 60, 72, 5, 919, 15, 64, 43, 562, 18, 2, 327, 13, 106, 19, 4630, 9, 7, 5, 329, 135, 4, 4516, 42, 1123, 33, 111, 1010, 72, 5, 135, 4, 39688, 335, 2, 201, 49, 106, 19, 355, 187, 8, 93, 523, 4, 287, 1, 429, 269, 14, 2, 201, 49, 106, 19, 5941, 125, 11, 77, 362, 4, 1010, 9, 127, 69, 1488, 15, 34, 374, 4, 1962, 2844, 5, 3667, 7383, 5119, 2, 668, 7168, 23531, 925, 2881, 1, 8827, 6779, 3, 3981, 1, 286, 442, 1562, 2, 34, 429, 11, 154, 5, 913, 123, 4, 26, 69, 266, 5, 64, 43, 533, 441]",2501.0,28711727,Chemotherapy-Only Regimen Busulfan Melphalan Fludarabine Rabbit Antithymocyte Globulin Followed Allogeneic T-Cell Depleted Hematopoietic Stem Transplantations Treatment Myeloid Malignancies,3,0.005235602094240838
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome.,Haematologica,Haematologica,2017-07-20,"Vosaroxin is an anti-cancer quinolone-derived DNA topoisomerase II inhibitor. We investigated vosaroxin with decitabine in patients 60 years of age with newly diagnosed acute myeloid leukemia (n=58) or myelodysplastic syndrome (10% blasts) (n=7) in a phase II non-randomized trial. The initial 22 patients received vosaroxin 90 mg/m<sup>2</sup> on days 1 and 4 with decitabine 20 mg/m<sup>2</sup> on days 1-5 every 4-6 weeks for up to seven cycles. Due to a high incidence of mucositis the subsequent 43 patients were given vosaroxin 70 mg/m<sup>2</sup> on days 1 and 4. These 65 patients, with a median age of 69 years (range, 60-78), some of whom with secondary leukemia (22%), adverse karyotype (35%), or <i>TP53</i> mutation (20%), are evaluable. The overall response rate was 74% including complete remission in 31 (48%), complete remission with incomplete platelet recovery in 11 (17%), and complete remission with incomplete count recovery in six (9%). The median number of cycles to response was one (range, 1-4). Grade 3/4 mucositis was noted in 17% of all patients. The 70 mg/m<sup>2</sup> induction dose of vosaroxin was associated with similar rates of overall response (74% <i>versus</i> 73%) and complete remission (51% <i>versus</i> 41%, <i>P</i>=0.44), reduced incidence of mucositis (30% <i>versus</i> 59%, <i>P</i>=0.02), reduced 8-week mortality (9% <i>versus</i> 23%; <i>P</i>=0.14), and improved median overall survival (14.6 months <i>versus</i> 5.5 months, <i>P</i>=0.007). Minimal residual disease-negative status by multiparametric flow-cytometry at response ( 3 months) was achieved in 21 of 39 (54%) evaluable responders and was associated with better median overall survival (34.0 months <i>versus</i> 8.3 months, <i>P</i>=0.023). In conclusion, the combination of vosaroxin with decitabine is effective and well tolerated at a dose of 70 mg/m<sup>2</sup> and warrants randomized prospective evaluation. ClinicalTrials.gov: NCT01893320.",Journal Article,915.0,6.0,Vosaroxin anti-cancer quinolone-derived DNA topoisomerase II inhibitor investigated vosaroxin decitabine patients 60 years age newly diagnosed acute myeloid leukemia n=58 myelodysplastic syndrome 10 blasts n=7 phase II non-randomized trial initial 22 patients received vosaroxin 90 mg/m sup 2 /sup days 1 4 decitabine 20 mg/m sup 2 /sup days 1-5 4-6 weeks seven cycles high incidence mucositis subsequent 43 patients given vosaroxin 70 mg/m sup 2 /sup days 1 4 65 patients median age 69 years range 60-78 secondary leukemia 22 adverse karyotype 35 TP53 /i 20 evaluable overall response rate 74 including complete remission 31 48 complete remission incomplete platelet recovery 11 17 complete remission incomplete count recovery 9 median number cycles response range 1-4 Grade 3/4 mucositis noted 17 patients 70 mg/m sup 2 /sup induction dose vosaroxin associated similar rates overall response 74 versus /i 73 complete remission 51 versus /i 41 P /i =0.44 reduced incidence mucositis 30 versus /i 59 P /i =0.02 reduced 8-week mortality 9 versus /i 23 P /i =0.14 improved median overall survival 14.6 months versus /i 5.5 months P /i =0.007 Minimal residual disease-negative status multiparametric flow-cytometry response  3 months achieved 21 39 54 evaluable responders associated better median overall survival 34.0 months versus /i 8.3 months P /i =0.023 combination vosaroxin decitabine effective tolerated dose 70 mg/m sup 2 /sup warrants randomized prospective evaluation ClinicalTrials.gov NCT01893320,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[11529, 16, 35, 312, 12, 18448, 526, 261, 3999, 215, 230, 21, 565, 11529, 5, 3004, 4, 7, 6690, 60, 1, 89, 5, 732, 265, 286, 533, 78, 717, 15, 681, 4556, 2438, 78, 67, 4, 8, 124, 215, 220, 384, 160, 3, 388, 350, 7, 103, 11529, 424, 81, 188, 172, 18, 172, 23, 162, 14, 2, 39, 5, 3004, 179, 81, 188, 172, 18, 172, 23, 162, 14, 33, 454, 39, 49, 244, 9, 126, 6, 648, 410, 520, 6, 8, 64, 287, 1, 2606, 3, 706, 601, 7, 11, 447, 11529, 431, 81, 188, 172, 18, 172, 23, 162, 14, 2, 39, 46, 556, 7, 5, 8, 52, 89, 1, 790, 60, 184, 335, 833, 476, 1, 953, 5, 568, 350, 290, 3385, 465, 15, 70, 1206, 70, 258, 179, 32, 859, 3, 63, 51, 116, 10, 794, 141, 236, 734, 4, 456, 576, 236, 734, 5, 2610, 1596, 1602, 4, 175, 269, 2, 236, 734, 5, 2610, 1276, 1602, 4, 437, 83, 3, 52, 207, 1, 410, 6, 51, 10, 104, 184, 14, 39, 88, 27, 39, 2606, 10, 1051, 4, 269, 1, 62, 7, 3, 431, 81, 188, 172, 18, 172, 504, 61, 1, 11529, 10, 41, 5, 288, 151, 1, 63, 51, 794, 70, 185, 70, 803, 2, 236, 734, 725, 70, 185, 70, 605, 70, 19, 70, 13, 584, 405, 287, 1, 2606, 201, 70, 185, 70, 728, 70, 19, 70, 13, 588, 405, 66, 647, 282, 83, 70, 185, 70, 382, 70, 19, 70, 13, 213, 2, 231, 52, 63, 25, 213, 49, 53, 70, 185, 70, 33, 33, 53, 70, 19, 70, 13, 1999, 1048, 753, 34, 199, 156, 20, 8347, 1412, 1914, 28, 51, 810, 27, 53, 10, 513, 4, 239, 1, 587, 667, 859, 1983, 2, 10, 41, 5, 380, 52, 63, 25, 562, 13, 53, 70, 185, 70, 66, 27, 53, 70, 19, 70, 13, 4482, 4, 1221, 3, 150, 1, 11529, 5, 3004, 16, 323, 2, 149, 421, 28, 8, 61, 1, 431, 81, 188, 172, 18, 172, 2, 2782, 384, 482, 451, 1252, 1239, 70858]",1822.0,28729302,Vosaroxin combination decitabine newly diagnosed older patients acute myeloid leukemia high-risk myelodysplastic syndrome,22,0.038394415357766144
Is Disease-Specific Immunotherapy a Potential Reality for MDS?,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2017-07-01,"Myelodysplastic syndromes (MDSs) and related myeloid neoplasms represent heterogeneous diseases with overall poor outcomes related to lack of efficacious agents. Immunotherapy has revolutionized the treatment paradigm in solid malignancies and select hematologic malignancies with durable remissions in treatment-refractory populations. The initial clinical studies using immunotherapy in MDS are under way, although significant efforts are required in which to better understand their role in this disease. Likely, combinations of therapies will be required to improve outcomes in this patient population. Furthermore, identification of novel targets for antibody or T-cell modulation strategies is a matter of intensive investigation and ideally will provide treatment options in the near future for our patients.",Journal Article,934.0,3.0,Myelodysplastic syndromes MDSs related myeloid neoplasms represent heterogeneous diseases overall poor outcomes related lack efficacious agents Immunotherapy revolutionized treatment paradigm solid malignancies select hematologic malignancies durable remissions treatment-refractory populations initial clinical studies immunotherapy MDS way significant efforts required better understand role disease Likely combinations therapies required improve outcomes patient population Furthermore identification novel targets antibody T-cell modulation strategies matter intensive investigation ideally provide treatment options near future patients,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2040, 13550, 2, 139, 533, 1179, 1231, 1564, 1342, 5, 63, 334, 123, 139, 6, 926, 1, 3289, 183, 726, 71, 5746, 3, 24, 2431, 4, 537, 441, 2, 1717, 813, 441, 5, 1480, 3166, 4, 24, 430, 1184, 3, 388, 38, 94, 75, 726, 4, 1223, 32, 669, 2255, 242, 93, 1413, 32, 616, 4, 92, 6, 380, 1640, 136, 200, 4, 26, 34, 322, 1247, 1, 235, 303, 40, 616, 6, 401, 123, 4, 26, 69, 266, 798, 911, 1, 229, 637, 9, 548, 15, 102, 31, 2356, 422, 16, 8, 5090, 1, 1686, 940, 2, 8160, 303, 377, 24, 838, 4, 3, 1829, 508, 9, 114, 7]",789.0,28760299,Disease-Specific Immunotherapy Potential Reality MDS,5,0.008726003490401396
Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN.,Blood,Blood,2017-08-03,"Hypomethylating agents (HMAs) improve survival in patients with higher-risk myelodysplastic syndromes (MDS) but are less well-studied in lower-risk disease. We compared the safety and efficacy of low-dose decitabine vs low-dose azacitidine in this group of patients. Adults with low- or intermediate 1-risk MDS or MDS/myeloproliferative neoplasm (MPN), including chronic myelomonocytic leukemia, according to the International Prognostic Scoring System, were randomly assigned using a Bayesian adaptive design to receive either azacitidine 75 mg/m<sup>2</sup> intravenously/subcutaneously daily or decitabine 20 mg/m<sup>2</sup> intravenously daily for 3 consecutive days on a 28-day cycle. The primary outcome was overall response rate (ORR). Between November 2012 and February 2016, 113 patients were treated: 40 (35%) with azacitidine and 73 (65%) with decitabine. The median age was 70 years; 81% of patients were intermediate 1-risk patients. The median number of cycles received was 9. The ORRs were 70% and 49% (<i>P</i> = .03) for patients treated with decitabine and azacitidine, respectively. Thirty-two percent of patients treated with decitabine became transfusion independent compared with 16% of patients treated with azacitidine (<i>P</i> = .2). Cytogenetic response rates were 61% and 25% (<i>P</i> = .02), respectively. With a median follow-up of 20 months, the overall median event-free survival was 18 months: 20 and 13 months for patients treated with decitabine and azacitidine, respectively (<i>P</i> = .1). Treatment was well tolerated, with a 6-week mortality rate of 0%. The use of low-dose HMAs is safe and effective in patients with lower-risk MDS and MDS/MPN. Their effect on the natural history of lower-risk disease needs to be further studied. This trial was registered at clinicaltrials.gov (identifier NCT01720225).","Clinical Trial, Phase II",901.0,37.0,Hypomethylating agents HMAs improve survival patients higher-risk myelodysplastic syndromes MDS well-studied lower-risk disease compared safety efficacy low-dose decitabine vs low-dose azacitidine group patients Adults low- intermediate 1-risk MDS MDS/myeloproliferative neoplasm MPN including chronic myelomonocytic leukemia according International Prognostic Scoring randomly assigned Bayesian adaptive design receive azacitidine 75 mg/m sup 2 /sup intravenously/subcutaneously daily decitabine 20 mg/m sup 2 /sup intravenously daily 3 consecutive days 28-day cycle primary outcome overall response rate ORR November 2012 February 2016 113 patients treated 40 35 azacitidine 73 65 decitabine median age 70 years 81 patients intermediate 1-risk patients median number cycles received 9 ORRs 70 49 P /i .03 patients treated decitabine azacitidine respectively Thirty-two percent patients treated decitabine transfusion independent compared 16 patients treated azacitidine P /i .2 Cytogenetic response rates 61 25 P /i .02 respectively median follow-up 20 months overall median event-free survival 18 months 20 13 months patients treated decitabine azacitidine respectively P /i .1 Treatment tolerated 6-week mortality rate 0 use low-dose HMAs safe effective patients lower-risk MDS MDS/MPN effect natural history lower-risk disease needs studied trial registered clinicaltrials.gov identifier NCT01720225,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4931, 183, 12688, 401, 25, 4, 7, 5, 142, 43, 2040, 1223, 84, 32, 299, 149, 656, 4, 280, 43, 34, 21, 72, 3, 367, 2, 209, 1, 154, 61, 3004, 105, 154, 61, 3752, 4, 26, 87, 1, 7, 857, 5, 154, 15, 919, 14, 43, 1223, 15, 1223, 10857, 2131, 4125, 141, 442, 5451, 768, 6, 3, 944, 177, 2504, 398, 11, 1108, 896, 75, 8, 5032, 2454, 771, 6, 560, 361, 3752, 481, 81, 188, 172, 18, 172, 1672, 3928, 391, 15, 3004, 179, 81, 188, 172, 18, 172, 1672, 391, 9, 27, 935, 162, 23, 8, 339, 218, 417, 3, 86, 228, 10, 63, 51, 116, 1735, 59, 2868, 1195, 2, 3010, 1390, 4259, 7, 11, 73, 327, 465, 5, 3752, 2, 803, 556, 5, 3004, 3, 52, 89, 10, 431, 60, 865, 1, 7, 11, 919, 14, 43, 7, 3, 52, 207, 1, 410, 103, 10, 83, 3, 10767, 11, 431, 2, 739, 70, 19, 70, 680, 9, 7, 73, 5, 3004, 2, 3752, 106, 977, 100, 714, 1, 7, 73, 5, 3004, 3451, 2785, 306, 72, 5, 245, 1, 7, 73, 5, 3752, 70, 19, 70, 18, 1266, 51, 151, 11, 713, 2, 243, 70, 19, 70, 588, 106, 5, 8, 52, 166, 126, 1, 179, 53, 3, 63, 52, 774, 115, 25, 10, 203, 53, 179, 2, 233, 53, 9, 7, 73, 5, 3004, 2, 3752, 106, 70, 19, 70, 14, 24, 10, 149, 421, 5, 8, 49, 647, 282, 116, 1, 13, 3, 119, 1, 154, 61, 12688, 16, 1165, 2, 323, 4, 7, 5, 280, 43, 1223, 2, 1223, 4125, 136, 254, 23, 3, 1504, 532, 1, 280, 43, 34, 1891, 6, 40, 195, 656, 26, 160, 10, 1653, 28, 1252, 1239, 3719, 70971]",1747.0,28774880,Randomized phase 2 low-dose decitabine vs low-dose azacitidine lower-risk MDS MDS/MPN,2,0.0034904013961605585
Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.,Blood,Blood,2017-08-15,"Multiple candidate gene-association studies of non-HLA single-nucleotide polymorphisms (SNPs) and outcomes after blood or marrow transplant (BMT) have been conducted. We identified 70 publications reporting 45 SNPs in 36 genes significantly associated with disease-related mortality, progression-free survival, transplant-related mortality, and/or overall survival after BMT. Replication and validation of these SNP associations were performed using DISCOVeRY-BMT (Determining the Influence of Susceptibility COnveying Variants Related to one-Year mortality after BMT), a well-powered genome-wide association study consisting of 2 cohorts, totaling 2888 BMT recipients with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome, and their HLA-matched unrelated donors, reported to the Center for International Blood and Marrow Transplant Research. Gene-based tests were used to assess the aggregate effect of SNPs on outcome. None of the previously reported significant SNPs replicated at <i>P</i> < .05 in DISCOVeRY-BMT. Validation analyses showed association with one previously reported donor SNP at <i>P</i> < .05 and survival; more associations would be anticipated by chance alone. No gene-based tests were significant at <i>P</i> < .05. Functional annotation with publicly available data shows these candidate SNPs most likely do not have biochemical function; only 13% of candidate SNPs correlate with gene expression or are predicted to impact transcription factor binding. Of these, half do not impact the candidate gene of interest; the other half correlate with expression of multiple genes. These findings emphasize the peril of pursing candidate approaches and the importance of adequately powered tests of unbiased genome-wide associations with BMT clinical outcomes given the ultimate goal of improving patient outcomes.",Journal Article,889.0,17.0,Multiple candidate gene-association studies non-HLA single-nucleotide polymorphisms SNPs outcomes blood marrow transplant BMT conducted identified 70 publications reporting 45 SNPs 36 significantly associated disease-related mortality progression-free survival transplant-related mortality and/or overall survival BMT Replication validation SNP associations performed DISCOVeRY-BMT Determining Influence Susceptibility COnveying Related one-Year mortality BMT well-powered genome-wide association consisting 2 cohorts totaling 2888 BMT recipients acute myeloid leukemia acute lymphoblastic leukemia myelodysplastic syndrome HLA-matched unrelated donors reported Center International Blood Marrow Transplant Research Gene-based tests assess aggregate effect SNPs outcome previously reported significant SNPs replicated P /i .05 DISCOVeRY-BMT Validation showed association previously reported donor SNP P /i .05 survival associations anticipated chance gene-based tests significant P /i .05 Functional annotation publicly available shows candidate SNPs likely biochemical function 13 candidate SNPs correlate expression predicted impact transcription factor binding half impact candidate half correlate expression multiple findings emphasize peril pursing candidate approaches importance adequately powered tests unbiased genome-wide associations BMT clinical outcomes given ultimate goal improving patient outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[232, 1609, 145, 248, 94, 1, 220, 1160, 226, 1579, 1203, 1109, 2, 123, 50, 315, 15, 581, 941, 4611, 47, 85, 426, 21, 108, 431, 4463, 1760, 512, 1109, 4, 511, 214, 97, 41, 5, 34, 139, 282, 91, 115, 25, 941, 139, 282, 2, 15, 63, 25, 50, 4611, 2079, 2, 929, 1, 46, 1845, 685, 11, 173, 75, 1574, 4611, 2196, 3, 1054, 1, 1432, 26423, 839, 139, 6, 104, 111, 282, 50, 4611, 8, 149, 6855, 898, 1019, 248, 45, 2273, 1, 18, 736, 12739, 71031, 4611, 2190, 5, 286, 533, 286, 1275, 15, 681, 2, 136, 1160, 655, 2092, 2344, 210, 6, 3, 574, 9, 944, 315, 2, 581, 941, 389, 145, 90, 895, 11, 95, 6, 423, 3, 7494, 254, 1, 1109, 23, 228, 1292, 1, 3, 373, 210, 93, 1109, 6714, 28, 70, 19, 70, 474, 4, 1574, 4611, 929, 318, 224, 248, 5, 104, 373, 210, 1488, 1845, 28, 70, 19, 70, 474, 2, 25, 80, 685, 688, 40, 4078, 20, 3477, 279, 77, 145, 90, 895, 11, 93, 28, 70, 19, 70, 474, 583, 8407, 5, 6878, 390, 74, 1949, 46, 1609, 1109, 96, 322, 1022, 44, 47, 1487, 343, 158, 233, 1, 1609, 1109, 1513, 5, 145, 55, 15, 32, 783, 6, 345, 866, 161, 791, 1, 46, 1303, 1022, 44, 345, 3, 1609, 145, 1, 1333, 3, 127, 1303, 1513, 5, 55, 1, 232, 214, 46, 272, 5560, 3, 50527, 1, 71032, 1609, 611, 2, 3, 1187, 1, 4215, 6855, 895, 1, 7271, 898, 1019, 685, 5, 4611, 38, 123, 447, 3, 5768, 1326, 1, 1673, 69, 123]",1788.0,28811306,Replication validation genetic polymorphisms associated survival allogeneic blood marrow transplant,0,0.0
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.,Cancer,Cancer,2017-08-25,"Pracinostat is a potent histone deacetylase inhibitor with antitumor activity in both solid tumor and acute myeloid leukemia (AML) cell lines. Pracinostat is reported to have modest clinical activity in patients with advanced solid tumors. Given the higher preclinical sensitivity of hematologic malignancies to pracinostat, the authors conducted a phase 1 study to assess the safety, maximum tolerated dose, recommended phase 2 dose, efficacy, pharmacokinetics, and pharmacodynamics of pracinostat in patients with advanced hematological malignancies. Pracinostat was administered orally 3 times a week for 3 weeks on a 28-day cycle. Patients were assigned to 7 dose levels using a 3 + 3 dose escalation design. A total of 44 patients were enrolled, 25 of whom had AML and 14 of whom had myelodysplastic syndrome. The maximum tolerated dose was 120 mg and the recommended phase 2 dose was 60 mg. Two patients with AML achieved a response: 1 complete remission (CR) and 1 complete cytogenetic response. Despite a dose-dependent increase in the plasma concentration of pracinostat, a similar increase in histone acetylation was not observed. As an extension, 10 additional patients with myelodysplastic syndrome were enrolled to assess the safety and efficacy of pracinostat in combination with azacitidine. Six patients achieved a CR and 3 achieved a CR without platelet recovery with no added toxicity. The results of the current study demonstrate that pracinostat is safe, with modest single-agent activity in patients with hematological malignancies. Cancer 2017;123:4851-9.  2017 American Cancer Society.","Clinical Trial, Phase I",879.0,14.0,Pracinostat potent histone deacetylase inhibitor antitumor activity solid acute myeloid leukemia AML lines Pracinostat reported modest clinical activity patients advanced solid Given higher preclinical sensitivity hematologic malignancies pracinostat authors conducted phase 1 assess safety maximum tolerated dose recommended phase 2 dose efficacy pharmacokinetics pharmacodynamics pracinostat patients advanced hematological malignancies Pracinostat administered orally 3 times week 3 weeks 28-day cycle Patients assigned 7 dose levels 3 3 dose escalation design total 44 patients enrolled 25 AML 14 myelodysplastic syndrome maximum tolerated dose 120 mg recommended phase 2 dose 60 mg. patients AML achieved response 1 complete remission CR 1 complete cytogenetic response Despite dose-dependent increase plasma concentration pracinostat similar increase histone acetylation observed extension 10 additional patients myelodysplastic syndrome enrolled assess safety efficacy pracinostat combination azacitidine patients achieved CR 3 achieved CR platelet recovery added toxicity current demonstrate pracinostat safe modest single-agent activity patients hematological malignancies 2017 123:4851-9  2017 American Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[25827, 16, 8, 1157, 1508, 2732, 230, 5, 579, 128, 4, 110, 537, 30, 2, 286, 533, 329, 31, 285, 25827, 16, 210, 6, 47, 1721, 38, 128, 4, 7, 5, 131, 537, 57, 447, 3, 142, 693, 485, 1, 813, 441, 6, 25827, 3, 738, 426, 8, 124, 14, 45, 6, 423, 3, 367, 689, 421, 61, 793, 124, 18, 61, 209, 1159, 2, 3587, 1, 25827, 4, 7, 5, 131, 2890, 441, 25827, 10, 468, 1428, 27, 1072, 8, 647, 9, 27, 244, 23, 8, 339, 218, 417, 7, 11, 896, 6, 67, 61, 148, 75, 8, 27, 27, 61, 1125, 771, 8, 181, 1, 584, 7, 11, 346, 243, 1, 953, 42, 329, 2, 213, 1, 953, 42, 681, 3, 689, 421, 61, 10, 2031, 81, 2, 3, 793, 124, 18, 61, 10, 335, 81, 100, 7, 5, 329, 513, 8, 51, 14, 236, 734, 684, 2, 14, 236, 1266, 51, 550, 8, 61, 470, 344, 4, 3, 554, 1227, 1, 25827, 8, 288, 344, 4, 1508, 4145, 10, 44, 164, 22, 35, 2401, 79, 402, 7, 5, 681, 11, 346, 6, 423, 3, 367, 2, 209, 1, 25827, 4, 150, 5, 3752, 437, 7, 513, 8, 684, 2, 27, 513, 8, 684, 187, 1596, 1602, 5, 77, 1953, 155, 3, 99, 1, 3, 291, 45, 608, 17, 25827, 16, 1165, 5, 1721, 226, 420, 128, 4, 7, 5, 2890, 441, 12, 1759, 2698, 71098, 83, 2206, 1759, 597, 12, 1174]",1538.0,28841236,Phase 1 dose escalation multicenter trial pracinostat combination azacitidine patients advanced hematologic malignancies,4,0.006980802792321117
"Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.",The Lancet. Oncology,Lancet Oncol.,2017-08-24,"The hypomethylating drugs azacitidine and decitabine have shown efficacy in myelodysplastic syndromes and acute myeloid leukaemia, but complete tumour responses are infrequent and of short duration, possibly because of the short half-lives and suboptimal bone marrow exposure of the drugs. Guadecitabine, a next-generation hypomethylating drug, has a longer half-life and exposure than its active metabolite decitabine. A phase 1 study established 60 mg/m<sup>2</sup> guadecitabine for 5 days as an effective treatment schedule. In this phase 2 study, we aimed to assess the safety and activity of two doses and schedules of guadecitabine in older (65 years) patients with treatment-naive acute myeloid leukaemia who were not candidates for intensive chemotherapy. We did a multicentre, randomised, open-label, phase 1/2 study of guadecitabine in cohorts of patients with treatment-naive acute myeloid leukaemia, relapsed or refractory acute myeloid leukaemia, and myelodysplastic syndromes; here we report the phase 2 results from the cohort of treatment-naive patients with acute myeloid leukaemia. We included patients aged at least 65 years from 14 US medical centres (hospitals and specialist cancer clinics) who were not candidates for intensive chemotherapy and randomly assigned them (1:1) using a computer algorithm (for dynamic randomisation) to guadecitabine 60 or 90 mg/m<sup>2</sup> on days 1-5 (5-day schedule) of a 28-day treatment cycle. Treatment allocation was not masked. We also assigned additional patients to guadecitabine 60 mg/m<sup>2</sup> in a 10-day schedule in a 28-day treatment cycle after a protocol amendment. The primary endpoint was composite complete response (complete response, complete response with incomplete platelet recovery, or complete response with incomplete neutrophil recovery regardless of platelets). Response was assessed in all patients (as-treated) who received at least one dose of guadecitabine. We present the final analysis, although at the time of the database lock, 15 patients were still in follow-up for overall survival. This study is registered with ClinicalTrials.gov, number NCT01261312. Between Aug 24, 2012, and Sept 15, 2014, 107 patients were enrolled: 54 on the 5-day schedule (26 randomly assigned to 60 mg/m<sup>2</sup> and 28 to 90 mg/m<sup>2</sup>) and 53 were assigned to the 10-day schedule. Median age was 77 years (range 62-92), and median follow-up was 953 days (IQR 721-1040). All treated patients were assessable for a response. The number of patients who achieved a composite complete response did not differ between dose groups or schedules (13 [54%, 95% CI 328-744] with 60 mg/m<sup>2</sup> on the 5-day schedule; 16 [59%; 388-776] with 90 mg/m<sup>2</sup> on the 5-day schedule; and 26 [50%, 358-642] with 60 mg/m<sup>2</sup> on the 10-day schedule). The most frequent grade 3 or worse adverse events, regardless of relationship to treatment, were febrile neutropenia (31 [61%] of 51 patients on the 5-day schedule vs 36 [69%] of 52 patients on the 10-day schedule), thrombocytopenia (25 [49%] vs 22 [42%]), neutropenia (20 [39%] vs 18 [35%]), pneumonia (15 [29%] vs 19 [37%]), anaemia (15 [29%] vs 12 [23%]), and sepsis (eight [16%] vs 14 [27%]). The most common serious adverse events, regardless of relationship to treatment, for the 5-day and 10-day schedules, respectively, were febrile neutropenia (27 [53%] vs 25 [48%]), pneumonia (14 [27%] vs 16 [31%]), and sepsis (eight [16%] vs 14 [27%]). 23 (22%) patients died because of adverse events (mainly from sepsis, eight [8%]; and pneumonia, five [5%]); four deaths were from adverse events deemed treatment-related (pneumonia, two [2%]; multiorgan failure, one [1%]; and sepsis, one [1%], all in the 10-day cohort). More than half of older treatment-naive patients with acute myeloid leukaemia achieved a composite complete response with guadecitabine at all drug doses and schedules investigated, with tolerable toxicity. The recommended guadecitabine regimen for this population is 60 mg/m<sup>2</sup> in a 5-day schedule. A phase 3 study in this patient population is ongoing (NCT02348489) to assess guadecitabine 60 mg/m<sup>2</sup> in a 5-day schedule versus standard of care. Astex Pharmaceuticals and Stand Up To Cancer.","Clinical Trial, Phase II",880.0,53.0,hypomethylating drugs azacitidine decitabine shown efficacy myelodysplastic syndromes acute myeloid leukaemia complete tumour responses infrequent short duration possibly short half-lives suboptimal bone marrow exposure drugs Guadecitabine next-generation hypomethylating drug longer half-life exposure active metabolite decitabine phase 1 established 60 mg/m sup 2 /sup guadecitabine 5 days effective treatment schedule phase 2 aimed assess safety activity doses schedules guadecitabine older 65 years patients treatment-naive acute myeloid leukaemia candidates intensive chemotherapy multicentre randomised open-label phase 1/2 guadecitabine cohorts patients treatment-naive acute myeloid leukaemia relapsed refractory acute myeloid leukaemia myelodysplastic syndromes report phase 2 cohort treatment-naive patients acute myeloid leukaemia included patients aged 65 years 14 medical centres hospitals specialist clinics candidates intensive chemotherapy randomly assigned 1:1 algorithm dynamic randomisation guadecitabine 60 90 mg/m sup 2 /sup days 1-5 5-day schedule 28-day treatment cycle Treatment allocation masked assigned additional patients guadecitabine 60 mg/m sup 2 /sup 10-day schedule 28-day treatment cycle protocol amendment primary endpoint composite complete response complete response complete response incomplete platelet recovery complete response incomplete neutrophil recovery regardless platelets Response assessed patients as-treated received dose guadecitabine present final time database lock 15 patients follow-up overall survival registered ClinicalTrials.gov number NCT01261312 Aug 24 2012 Sept 15 2014 107 patients enrolled 54 5-day schedule 26 randomly assigned 60 mg/m sup 2 /sup 28 90 mg/m sup 2 /sup 53 assigned 10-day schedule Median age 77 years range 62-92 median follow-up 953 days IQR 721-1040 treated patients assessable response number patients achieved composite complete response differ dose groups schedules 13 54 95 CI 328-744 60 mg/m sup 2 /sup 5-day schedule 16 59 388-776 90 mg/m sup 2 /sup 5-day schedule 26 50 358-642 60 mg/m sup 2 /sup 10-day schedule frequent grade 3 worse adverse events regardless relationship treatment febrile neutropenia 31 61 51 patients 5-day schedule vs 36 69 52 patients 10-day schedule thrombocytopenia 25 49 vs 22 42 neutropenia 20 39 vs 18 35 pneumonia 15 29 vs 19 37 anaemia 15 29 vs 12 23 sepsis 16 vs 14 27 common adverse events regardless relationship treatment 5-day 10-day schedules respectively febrile neutropenia 27 53 vs 25 48 pneumonia 14 27 vs 16 31 sepsis 16 vs 14 27 23 22 patients died adverse events mainly sepsis 8 pneumonia 5 deaths adverse events deemed treatment-related pneumonia 2 multiorgan failure 1 sepsis 1 10-day cohort half older treatment-naive patients acute myeloid leukaemia achieved composite complete response guadecitabine drug doses schedules investigated tolerable toxicity recommended guadecitabine regimen population 60 mg/m sup 2 /sup 5-day schedule phase 3 patient population ongoing NCT02348489 assess guadecitabine 60 mg/m sup 2 /sup 5-day schedule versus standard care Astex Pharmaceuticals Stand,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 4931, 600, 3752, 2, 3004, 47, 443, 209, 4, 2040, 2, 286, 533, 2001, 84, 236, 770, 253, 32, 4475, 2, 1, 978, 654, 2150, 408, 1, 3, 978, 1303, 6407, 2, 3291, 581, 645, 1, 3, 600, 10779, 8, 1305, 914, 4931, 234, 71, 8, 589, 1303, 358, 2, 645, 76, 211, 544, 3379, 3004, 8, 124, 14, 45, 635, 335, 81, 188, 172, 18, 172, 10779, 9, 33, 162, 22, 35, 323, 24, 1055, 4, 26, 124, 18, 45, 21, 1295, 6, 423, 3, 367, 2, 128, 1, 100, 415, 2, 2314, 1, 10779, 4, 434, 5827, 60, 7, 5, 24, 2462, 286, 533, 2001, 54, 11, 44, 1931, 9, 1686, 56, 21, 205, 8, 5761, 2827, 1020, 1756, 124, 14, 18, 45, 1, 10779, 4, 736, 1, 7, 5, 24, 2462, 286, 533, 2001, 591, 15, 430, 286, 533, 2001, 2, 2040, 467, 21, 414, 3, 124, 18, 99, 29, 3, 180, 1, 24, 2462, 7, 5, 286, 533, 2001, 21, 159, 7, 1032, 28, 506, 556, 60, 29, 213, 843, 484, 4496, 1987, 2, 6554, 12, 4736, 54, 11, 44, 1931, 9, 1686, 56, 2, 1108, 896, 1370, 14, 14, 75, 8, 4236, 2124, 9, 2540, 5204, 6, 10779, 335, 15, 424, 81, 188, 172, 18, 172, 23, 162, 14, 33, 33, 218, 1055, 1, 8, 339, 218, 24, 417, 24, 6834, 10, 44, 7415, 21, 120, 896, 402, 7, 6, 10779, 335, 81, 188, 172, 18, 172, 4, 8, 79, 218, 1055, 4, 8, 339, 218, 24, 417, 50, 8, 1182, 11013, 3, 86, 1138, 10, 3308, 236, 51, 236, 51, 236, 51, 5, 2610, 1596, 1602, 15, 236, 51, 5, 2610, 2595, 1602, 1583, 1, 4407, 51, 10, 275, 4, 62, 7, 22, 73, 54, 103, 28, 506, 104, 61, 1, 10779, 21, 364, 3, 1457, 65, 242, 28, 3, 98, 1, 3, 609, 11517, 167, 7, 11, 1234, 4, 166, 126, 9, 63, 25, 26, 45, 16, 1653, 5, 1252, 1239, 207, 49257, 59, 10497, 259, 1195, 2, 8708, 167, 1409, 3650, 7, 11, 346, 667, 23, 3, 33, 218, 1055, 432, 1108, 896, 6, 335, 81, 188, 172, 18, 172, 2, 339, 6, 424, 81, 188, 172, 18, 172, 2, 699, 11, 896, 6, 3, 79, 218, 1055, 52, 89, 10, 849, 60, 184, 744, 937, 2, 52, 166, 126, 10, 11679, 162, 2245, 13541, 12812, 62, 73, 7, 11, 3120, 9, 8, 51, 3, 207, 1, 7, 54, 513, 8, 3308, 236, 51, 205, 44, 1505, 59, 61, 271, 15, 2314, 233, 667, 48, 58, 47824, 71105, 5, 335, 81, 188, 172, 18, 172, 23, 3, 33, 218, 1055, 245, 728, 49033, 71106, 5, 424, 81, 188, 172, 18, 172, 23, 3, 33, 218, 1055, 2, 432, 212, 41576, 71107, 5, 335, 81, 188, 172, 18, 172, 23, 3, 79, 218, 1055, 3, 96, 908, 88, 27, 15, 639, 290, 281, 1583, 1, 858, 6, 24, 11, 2498, 778, 456, 713, 1, 725, 7, 23, 3, 33, 218, 1055, 105, 511, 790, 1, 653, 7, 23, 3, 79, 218, 1055, 1340, 243, 739, 105, 350, 595, 778, 179, 587, 105, 203, 465, 3485, 167, 462, 105, 326, 567, 5712, 167, 462, 105, 133, 382, 2, 4227, 659, 245, 105, 213, 428, 3, 96, 186, 1762, 290, 281, 1583, 1, 858, 6, 24, 9, 3, 33, 218, 2, 79, 218, 2314, 106, 11, 2498, 778, 428, 699, 105, 243, 576, 3485, 213, 428, 105, 245, 456, 2, 4227, 659, 245, 105, 213, 428, 382, 350, 7, 1016, 408, 1, 290, 281, 2615, 29, 4227, 659, 66, 2, 3485, 365, 33, 294, 1043, 11, 29, 290, 281, 3779, 24, 139, 3485, 100, 18, 11760, 496, 104, 14, 2, 4227, 104, 14, 62, 4, 3, 79, 218, 180, 80, 76, 1303, 1, 434, 24, 2462, 7, 5, 286, 533, 2001, 513, 8, 3308, 236, 51, 5, 10779, 28, 62, 234, 415, 2, 2314, 565, 5, 2668, 155, 3, 793, 10779, 477, 9, 26, 266, 16, 335, 81, 188, 172, 18, 172, 4, 8, 33, 218, 1055, 8, 124, 27, 45, 4, 26, 69, 266, 16, 942, 71108, 6, 423, 10779, 335, 81, 188, 172, 18, 172, 4, 8, 33, 218, 1055, 185, 260, 1, 165, 49258, 5888, 2, 9959, 126, 6, 12]",4026.0,28844816,Guadecitabine SGI-110 treatment-naive patients acute myeloid leukaemia phase 2 multicentre randomised phase 1/2 trial,69,0.12041884816753927
Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2017-08-24,"Fluid overload (FO) commonly occurs during hospitalization for allogeneic hematopoietic stem cell transplantation. We hypothesized that FO is associated with transplantation outcomes and evaluated this complication in 2 cohorts of patients. FO was graded based on post-transplantation weight gain, symptoms, and need for treatment, scored in real time by an independent team. The first cohort (study cohort; n=145) underwent haploidentical transplantation for hematologic malignancies following a melphalan-based conditioning regimen. In univariate analysis, factors associated with day +100 nonrelapse mortality (NRM) were FO grade 2 (hazard ratio [HR],15; 95% confidence interval [CI], 4.2 to 55; P<.001), creatinine >1mg/dL (HR,4.7; 95% CI, 1.6 to 14; P=.005), and age >55 years (HR, 4.5; 95% CI, 1.5 to 13; P=.008). In multivariate analysis, factors associated with day +100 NRM were FO grade 2 (HR, 13.1; 95% CI, 3.4 to 50; P<.001) and serum creatinine level >1mg/dL at transplantation admission (HR,3.5; 95% CI, 1.1 to 11; P=.03). These findings were verified in a separate cohort (validation cohort) of patients with acute myelogenous leukemia/myelodysplastic syndrome who underwent HLA-matched transplantation with busulfan-based conditioning (n=449). In multivariate analysis, factors associated with day +100 NRM were FO grade 2 (HR, 34; 95% CI, 7.2 to 158; P<.001) and, in patients with FO grade <2, advanced disease status (HR, 5; 95% CI, 1.1 to 22; P=.03). A higher NRM translated to significantly poorer 1-year overall survival rates for patients with FO 2 than for patients without FO (70% versus 42%, P<.001 in the study cohort and 64% versus 38%, P<.001 in the validation cohort). In conclusion, FO grade 2 is strongly associated with higher NRM and shorter survival and should be considered an important prognostic factor in transplantation.",Journal Article,880.0,4.0,Fluid overload FO commonly occurs hospitalization allogeneic hematopoietic stem transplantation hypothesized FO associated transplantation outcomes evaluated complication 2 cohorts patients FO graded based post-transplantation weight gain symptoms need treatment scored real time independent team cohort cohort n 145 underwent haploidentical transplantation hematologic malignancies following melphalan-based conditioning regimen univariate factors associated day +100 nonrelapse mortality NRM FO grade 2 hazard ratio HR 15 95 confidence interval CI 4.2 55 P .001 creatinine 1 mg/dL HR 4.7 95 CI 1.6 14 P .005 age 55 years HR 4.5 95 CI 1.5 13 P .008 multivariate factors associated day +100 NRM FO grade 2 HR 13.1 95 CI 3.4 50 P .001 serum creatinine level 1 mg/dL transplantation admission HR 3.5 95 CI 1.1 11 P .03 findings verified separate cohort validation cohort patients acute myelogenous leukemia/myelodysplastic syndrome underwent HLA-matched transplantation busulfan-based conditioning n 449 multivariate factors associated day +100 NRM FO grade 2 HR 34 95 CI 7.2 158 P .001 patients FO grade 2 advanced disease status HR 5 95 CI 1.1 22 P .03 higher NRM translated significantly poorer 1-year overall survival rates patients FO 2 patients FO 70 versus 42 P .001 cohort 64 versus 38 P .001 validation cohort FO grade 2 strongly associated higher NRM shorter survival considered important prognostic factor transplantation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[2357, 13143, 15056, 841, 1780, 190, 2826, 9, 1063, 1007, 452, 31, 497, 21, 1237, 17, 15056, 16, 41, 5, 497, 123, 2, 194, 26, 1447, 4, 18, 736, 1, 7, 15056, 10, 3468, 90, 23, 539, 497, 924, 1803, 507, 2, 594, 9, 24, 3179, 4, 1589, 98, 20, 35, 306, 2870, 3, 157, 180, 45, 180, 78, 4058, 208, 5802, 497, 9, 813, 441, 366, 8, 2370, 90, 1933, 477, 4, 880, 65, 130, 41, 5, 218, 394, 4640, 282, 4296, 11, 15056, 88, 3107, 360, 197, 168, 167, 48, 307, 268, 58, 39, 18, 6, 614, 19, 144, 3177, 14, 81, 1826, 168, 39, 67, 48, 58, 14, 49, 6, 213, 19, 1614, 2, 89, 614, 60, 168, 39, 33, 48, 58, 14, 33, 6, 233, 19, 2155, 4, 331, 65, 130, 41, 5, 218, 394, 4296, 11, 15056, 88, 3107, 168, 233, 14, 48, 58, 27, 39, 6, 212, 19, 144, 2, 524, 3177, 301, 14, 81, 1826, 28, 497, 3411, 168, 27, 33, 48, 58, 14, 14, 6, 175, 19, 680, 46, 272, 11, 4815, 4, 8, 2282, 180, 929, 180, 1, 7, 5, 286, 2194, 2647, 10589, 681, 54, 208, 1160, 655, 497, 5, 3906, 90, 1933, 78, 8865, 4, 331, 65, 130, 41, 5, 218, 394, 4296, 11, 15056, 88, 3107, 168, 562, 48, 58, 67, 18, 6, 5162, 19, 144, 2, 4, 7, 5, 15056, 88, 18, 131, 34, 156, 168, 33, 48, 58, 14, 14, 6, 350, 19, 680, 8, 142, 4296, 5136, 6, 97, 1769, 14, 111, 63, 25, 151, 9, 7, 5, 15056, 3107, 76, 9, 7, 187, 15056, 431, 185, 595, 19, 144, 4, 3, 45, 180, 2, 660, 185, 519, 19, 144, 4, 3, 929, 180, 4, 1221, 15056, 88, 3107, 16, 1327, 41, 5, 142, 4296, 2, 985, 25, 2, 257, 40, 515, 35, 305, 177, 161, 4, 497]",1772.0,28844946,Impact Fluid Overload New Toxicity Category Hematopoietic Stem Transplantation Outcomes,3,0.005235602094240838
Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia.,Journal of cutaneous pathology,J. Cutan. Pathol.,2017-09-27,"Chronic myelomonocytic leukemia (CMML) is a hematopoietic stem cell neoplasm exhibiting both myelodysplastic and myeloproliferative features. Cutaneous involvement by CMML is critical to recognize as it typically is a harbinger of disease progression and an increased incidence of transformation to acute myeloid leukemia. Cutaneous lesions of CMML exhibit heterogeneous histopathologic features that can be challenging to recognize as CMML. We describe a 67-year-old man with a 3-year history of CMML who had been managed on single-agent azacitidine with stable disease before developing splenomegaly and acute onset skin lesions. Examination of these skin lesions revealed a dense infiltrate of histiocytic cells morphologically resembling Langerhans type cells (lacking frank histopathologic atypia), and with the immunophenotype of an indeterminate cell histiocytosis (S100+ CD1a+ and langerin-). Given the history of CMML, next-generation sequencing studies were performed on the skin biopsy. These revealed a KRAS (p.G12R) mutation identical to that seen in the CMML 3years prior, establishing a clonal relationship between the 2 processes. This case expands the spectrum for and underscores the protean nature of cutaneous involvement by CMML and underscores the importance of heightened vigilance when evaluating skin lesions of CMML patients.",Case Reports,846.0,6.0,Chronic myelomonocytic leukemia CMML hematopoietic stem neoplasm exhibiting myelodysplastic myeloproliferative features Cutaneous involvement CMML critical recognize typically harbinger disease progression increased incidence transformation acute myeloid leukemia Cutaneous lesions CMML exhibit heterogeneous histopathologic features challenging recognize CMML 67-year-old man 3-year history CMML managed single-agent azacitidine stable disease developing splenomegaly acute onset skin lesions Examination skin lesions revealed dense infiltrate histiocytic morphologically resembling Langerhans type lacking frank histopathologic atypia immunophenotype indeterminate histiocytosis S100+ CD1a+ langerin- Given history CMML next-generation sequencing studies performed skin biopsy revealed KRAS p.G12R identical seen CMML 3 years prior establishing clonal relationship 2 processes case expands spectrum underscores protean nature cutaneous involvement CMML underscores importance heightened vigilance evaluating skin lesions CMML patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,"[442, 5451, 3382, 16, 8, 1007, 452, 31, 2131, 4801, 110, 2, 404, 1486, 799, 20, 3382, 16, 740, 6, 4237, 22, 192, 1969, 16, 8, 24796, 1, 34, 91, 2, 35, 101, 287, 1, 1392, 6, 286, 533, 1486, 406, 1, 3382, 2239, 1564, 2630, 404, 17, 122, 40, 1950, 6, 4237, 22, 3382, 21, 897, 8, 598, 111, 1095, 3628, 5, 8, 27, 111, 532, 1, 3382, 54, 42, 85, 2231, 23, 226, 420, 3752, 5, 585, 34, 348, 931, 6364, 2, 286, 1707, 406, 1385, 1, 46, 406, 553, 8, 3076, 5172, 1, 12605, 37, 6204, 8855, 15702, 267, 37, 1941, 15252, 2630, 3598, 2, 5, 3, 5496, 1, 35, 5167, 31, 13976, 11456, 18288, 2, 50571, 447, 3, 532, 1, 3382, 1305, 914, 615, 94, 11, 173, 23, 3, 411, 46, 553, 8, 723, 19, 47723, 258, 3038, 6, 17, 527, 4, 3, 3382, 27, 60, 324, 4431, 8, 1946, 858, 59, 3, 18, 1849, 26, 473, 9365, 3, 1873, 9, 2, 6926, 3, 38764, 2202, 1, 1486, 799, 20, 3382, 2, 6926, 3, 1187, 1, 7145, 13264, 198, 1435, 406, 1, 3382, 7]",1260.0,28885734,Chronic myelomonocytic leukemia masquerading cutaneous indeterminate dendritic Expanding spectrum skin lesions chronic myelomonocytic leukemia,0,0.0
Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2017-09-14,"Allogeneic stem cell transplantation with HLA-matched donors is increasingly used for older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It remains unclear if haploidentical stem cell transplantation (haploSCT) is a suitable option for older patients with this disease. We analyzed 43 patients with AML/MDS (median age, 61 years) who underwent a haploSCT at our institution. All patients received a fludarabine-melphalan-based reduced-intensity conditioning regimen and post-transplant cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis. Except for 1 patient who had early death, the remaining 42 patients (98%) engrafted donor cells. The cumulative incidences of grades II to IV and III to IV acute GVHD at 6 months were 35% and 5%, respectively, and chronic GVHD at 2 years was 9%. After a median follow-up of 19 months, 2-year overall survival, progression-free survival (PFS), and relapse incidence were 42%, 42%, and 24%, respectively. Best PFS (74% at 2 years) was seen in patients with intermediate-/good-risk cytogenetics, in first or second remission (hazard ratio, .4; P=.05), and with a younger donor (40 years; hazard ratio, .2; P=.01). In conclusion, these data suggest that haploidentical transplantation is safe and effective for older AML/MDS patients. Disease status, cytogenetics, and younger donor age are predictors for improved survival in older patients receiving a haploidentical transplant.",Journal Article,859.0,17.0,Allogeneic stem transplantation HLA-matched donors increasingly older patients acute myeloid leukemia AML myelodysplastic syndrome MDS remains unclear haploidentical stem transplantation haploSCT suitable option older patients disease 43 patients AML/MDS median age 61 years underwent haploSCT institution patients received fludarabine-melphalan-based reduced-intensity conditioning regimen post-transplant cyclophosphamide-based graft-versus-host disease GVHD prophylaxis 1 patient early death remaining 42 patients 98 engrafted donor cumulative incidences grades II IV III IV acute GVHD 6 months 35 5 respectively chronic GVHD 2 years 9 median follow-up 19 months 2-year overall survival progression-free survival PFS relapse incidence 42 42 24 respectively Best PFS 74 2 years seen patients intermediate-/good-risk cytogenetics second remission hazard ratio .4 P .05 younger donor 40 years hazard ratio .2 P .01 suggest haploidentical transplantation safe effective older AML/MDS patients Disease status cytogenetics younger donor age predictors improved survival older patients receiving haploidentical transplant,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1063, 452, 31, 497, 5, 1160, 655, 2344, 16, 1635, 95, 9, 434, 7, 5, 286, 533, 329, 2, 681, 1223, 192, 469, 1200, 492, 5802, 452, 31, 497, 36482, 16, 8, 2884, 1501, 9, 434, 7, 5, 26, 34, 21, 311, 601, 7, 5, 329, 1223, 52, 89, 713, 60, 54, 208, 8, 36482, 28, 114, 731, 62, 7, 103, 8, 2027, 2370, 90, 405, 837, 1933, 477, 2, 539, 941, 1112, 90, 1599, 185, 1204, 34, 1562, 2049, 2187, 9, 14, 69, 54, 42, 191, 273, 3, 1844, 595, 7, 1096, 6914, 1488, 37, 3, 967, 3981, 1, 2276, 215, 6, 478, 2, 316, 6, 478, 286, 1562, 28, 49, 53, 11, 465, 2, 33, 106, 2, 442, 1562, 28, 18, 60, 10, 83, 50, 8, 52, 166, 126, 1, 326, 53, 18, 111, 63, 25, 91, 115, 25, 300, 2, 429, 287, 11, 595, 595, 2, 259, 106, 824, 300, 794, 28, 18, 60, 10, 527, 4, 7, 5, 919, 1178, 43, 2510, 4, 157, 15, 419, 734, 360, 197, 39, 19, 474, 2, 5, 8, 773, 1488, 12437, 60, 360, 197, 18, 19, 355, 4, 1221, 46, 74, 309, 17, 5802, 497, 16, 1165, 2, 323, 9, 434, 329, 1223, 7, 34, 156, 2510, 2, 773, 1488, 89, 32, 674, 9, 231, 25, 4, 434, 7, 357, 8, 5802, 941]",1383.0,28918304,Haploidentical Transplantation Older Patients Acute Myeloid Leukemia Myelodysplastic Syndrome,1,0.0017452006980802793
Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia.,International journal of molecular sciences,Int J Mol Sci,2017-07-26,"(1) Runt-related transcription factor 1 (<i>RUNX1</i>) mutations in acute myeloid leukemia (AML) are often associated with worse prognosis. We assessed co-occurring mutations, response to therapy, and clinical outcomes in patients with and without mutant <i>RUNX1</i> (<i>mRUNX1</i>); (2) We analyzed 328 AML patients, including 177 patients younger than 65 years who received intensive chemotherapy and 151 patients >65 years who received hypomethylating agents. <i>RUNX1</i> and co-existing mutations were identified using next-generation sequencing; (3) <i>RUNX1</i> mutations were identified in 5.1% of younger patients and 15.9% of older patients, and were significantly associated with increasing age (<i>p</i> = 0.01) as well as intermediate-risk cytogenetics including normal karyotype (<i>p</i> = 0.02) in the elderly cohort, and with lower lactate dehydrogenase (LDH; <i>p</i> = 0.02) and higher platelet count (<i>p</i> = 0.012) overall. Identified co-occurring mutations were primarily <i>ASXL1</i> mutations in older patients and <i>RAS</i> mutations in younger patients; FLT3-ITD and IDH1/2 co-mutations were also frequent. Younger <i>mRUNX1</i> AML patients treated with intensive chemotherapy experienced inferior treatment outcomes. In older patients with AML treated with hypomethylating agent (HMA) therapy, response and survival was independent of <i>RUNX1</i> status. Older <i>mRUNX1</i> patients with prior myelodysplastic syndrome or myeloproliferative neoplasms (MDS/MPN) had particularly dismal outcome. Future studies should focus on the prognostic implications of <i>RUNX1</i> mutations relative to other co-occurring mutations, and the potential role of hypomethylating agents for this molecularly-defined group.",Journal Article,909.0,7.0,1 Runt-related transcription factor 1 RUNX1 /i acute myeloid leukemia AML associated worse prognosis assessed co-occurring response therapy clinical outcomes patients RUNX1 /i mRUNX1 /i 2 328 AML patients including 177 patients younger 65 years received intensive chemotherapy 151 patients 65 years received hypomethylating agents RUNX1 /i co-existing identified next-generation sequencing 3 RUNX1 /i identified 5.1 younger patients 15.9 older patients significantly associated increasing age p /i 0.01 intermediate-risk cytogenetics including normal karyotype p /i 0.02 elderly cohort lower lactate dehydrogenase LDH p /i 0.02 higher platelet count p /i 0.012 overall Identified co-occurring primarily ASXL1 /i older patients RAS /i younger patients FLT3-ITD IDH1/2 co-mutations frequent Younger mRUNX1 /i AML patients treated intensive chemotherapy experienced inferior treatment outcomes older patients AML treated hypomethylating agent HMA therapy response survival independent RUNX1 /i status Older mRUNX1 /i patients prior myelodysplastic syndrome myeloproliferative neoplasms MDS/MPN particularly dismal outcome Future studies focus prognostic implications RUNX1 /i relative co-occurring potential role hypomethylating agents molecularly-defined group,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[14, 23372, 139, 866, 161, 14, 70, 6092, 70, 138, 4, 286, 533, 329, 32, 629, 41, 5, 639, 356, 21, 275, 1269, 1821, 138, 51, 6, 36, 2, 38, 123, 4, 7, 5, 2, 187, 620, 70, 6092, 70, 70, 41866, 70, 18, 21, 311, 8584, 329, 7, 141, 4699, 7, 773, 76, 556, 60, 54, 103, 1686, 56, 2, 5075, 7, 556, 60, 54, 103, 4931, 183, 70, 6092, 70, 2, 1269, 1692, 138, 11, 108, 75, 1305, 914, 615, 27, 70, 6092, 70, 138, 11, 108, 4, 33, 14, 1, 773, 7, 2, 167, 83, 1, 434, 7, 2, 11, 97, 41, 5, 602, 89, 70, 19, 70, 13, 355, 22, 149, 22, 919, 43, 2510, 141, 295, 3385, 70, 19, 70, 13, 588, 4, 3, 1216, 180, 2, 5, 280, 3330, 2374, 4592, 70, 19, 70, 13, 588, 2, 142, 1596, 1276, 70, 19, 70, 13, 3499, 63, 108, 1269, 1821, 138, 11, 1561, 70, 7782, 70, 138, 4, 434, 7, 2, 70, 1102, 70, 138, 4, 773, 7, 1224, 2837, 2, 2662, 18, 1269, 138, 11, 120, 908, 773, 70, 41866, 70, 329, 7, 73, 5, 1686, 56, 592, 1663, 24, 123, 4, 434, 7, 5, 329, 73, 5, 4931, 420, 7518, 36, 51, 2, 25, 10, 306, 1, 70, 6092, 70, 156, 434, 70, 41866, 70, 7, 5, 324, 681, 15, 1179, 1223, 4125, 42, 823, 3929, 228, 508, 94, 257, 1222, 23, 3, 177, 1268, 1, 70, 6092, 70, 138, 580, 6, 127, 1269, 1821, 138, 2, 3, 174, 200, 1, 4931, 183, 9, 26, 2372, 395, 87]",1612.0,28933735,Clinical Outcomes Co-Occurring Patients RUNX1-Mutated Acute Myeloid Leukemia,251,0.43804537521815007
NY-ESO-1 Vaccination in Combination with Decitabine Induces Antigen-Specific T-lymphocyte Responses in Patients with Myelodysplastic Syndrome.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2017-09-25,"<b>Purpose:</b> Treatment options are limited for patients with high-risk myelodysplastic syndrome (MDS). The azanucleosides, azacitidine and decitabine, are first-line therapy for MDS that induce promoter demethylation and gene expression of the highly immunogenic tumor antigen NY-ESO-1. We demonstrated that patients with acute myeloid leukemia (AML) receiving decitabine exhibit induction of NY-ESO-1 expression in circulating blasts. We hypothesized that vaccinating against NY-ESO-1 in patients with MDS receiving decitabine would capitalize upon induced NY-ESO-1 expression in malignant myeloid cells to provoke an NY-ESO-1-specific MDS-directed cytotoxic T-cell immune response.<b>Experimental Design:</b> In a phase I study, 9 patients with MDS received an HLA-unrestricted NY-ESO-1 vaccine (CDX-1401 + poly-ICLC) in a nonoverlapping schedule every four weeks with standard-dose decitabine.<b>Results:</b> Analysis of samples serially obtained from the 7 patients who reached the end of the study demonstrated induction of <i>NY-ESO-1</i> expression in 7 of 7 patients and NY-ESO-1-specific CD4<sup>+</sup> and CD8<sup>+</sup> T-lymphocyte responses in 6 of 7 and 4 of 7 of the vaccinated patients, respectively. Myeloid cells expressing NY-ESO-1, isolated from a patient at different time points during decitabine therapy, were capable of activating a cytotoxic response from autologous NY-ESO-1-specific T lymphocytes. Vaccine responses were associated with a detectable population of CD141<sup>Hi</sup> conventional dendritic cells, which are critical for the uptake of NY-ESO-1 vaccine and have a recognized role in antitumor immune responses.<b>Conclusions:</b> These data indicate that vaccination against induced NY-ESO-1 expression can produce an antigen-specific immune response in a relatively nonimmunogenic myeloid cancer and highlight the potential for induced antigen-directed immunotherapy in a group of patients with limited options. <i>Clin Cancer Res; 24(5); 1019-29. 2017 AACR</i><i>See related commentary by Fuchs, p. 991</i>.","Clinical Trial, Phase I",848.0,18.0,b Purpose /b Treatment options limited patients high-risk myelodysplastic syndrome MDS azanucleosides azacitidine decitabine first-line therapy MDS induce promoter demethylation expression highly immunogenic antigen NY-ESO-1 demonstrated patients acute myeloid leukemia AML receiving decitabine exhibit induction NY-ESO-1 expression circulating blasts hypothesized vaccinating NY-ESO-1 patients MDS receiving decitabine capitalize induced NY-ESO-1 expression malignant myeloid provoke NY-ESO-1-specific MDS-directed cytotoxic T-cell immune response. b Experimental Design /b phase 9 patients MDS received HLA-unrestricted NY-ESO-1 vaccine CDX-1401 poly-ICLC nonoverlapping schedule weeks standard-dose decitabine. b /b serially obtained 7 patients reached end demonstrated induction NY-ESO-1 /i expression 7 7 patients NY-ESO-1-specific CD4 sup /sup CD8 sup /sup T-lymphocyte responses 6 7 4 7 vaccinated patients respectively Myeloid expressing NY-ESO-1 isolated patient different time points decitabine therapy capable activating cytotoxic response autologous NY-ESO-1-specific lymphocytes Vaccine responses associated detectable population CD141 sup Hi /sup conventional dendritic critical uptake NY-ESO-1 vaccine recognized role antitumor immune responses. b Conclusions /b indicate vaccination induced NY-ESO-1 expression produce antigen-specific immune response relatively nonimmunogenic myeloid highlight potential induced antigen-directed immunotherapy group patients limited options Clin Res 24 5 1019-29 2017 AACR /i related commentary Fuchs p. 991 /i,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[132, 743, 132, 24, 838, 32, 383, 9, 7, 5, 64, 43, 681, 1223, 3, 40286, 3752, 2, 3004, 32, 157, 328, 36, 9, 1223, 17, 1290, 973, 6800, 2, 145, 55, 1, 3, 561, 4190, 30, 448, 2906, 3143, 14, 21, 264, 17, 7, 5, 286, 533, 329, 357, 3004, 2239, 504, 1, 2906, 3143, 14, 55, 4, 1033, 2438, 21, 1237, 17, 20348, 480, 2906, 3143, 14, 4, 7, 5, 1223, 357, 3004, 688, 18909, 1548, 277, 2906, 3143, 14, 55, 4, 393, 533, 37, 6, 20282, 35, 2906, 3143, 14, 112, 1223, 1166, 759, 102, 31, 250, 51, 132, 1560, 771, 132, 4, 8, 124, 70, 45, 83, 7, 5, 1223, 103, 35, 1160, 16806, 2906, 3143, 14, 1274, 12417, 30992, 2699, 18064, 4, 8, 10142, 1055, 454, 294, 244, 5, 260, 61, 3004, 132, 99, 132, 65, 1, 347, 6754, 683, 29, 3, 67, 7, 54, 1300, 3, 396, 1, 3, 45, 264, 504, 1, 70, 2906, 3143, 14, 70, 55, 4, 67, 1, 67, 7, 2, 2906, 3143, 14, 112, 1440, 172, 172, 2, 968, 172, 172, 102, 1448, 253, 4, 49, 1, 67, 2, 39, 1, 67, 1, 3, 5130, 7, 106, 533, 37, 1046, 2906, 3143, 14, 1355, 29, 8, 69, 28, 338, 98, 862, 190, 3004, 36, 11, 2787, 1, 1616, 8, 759, 51, 29, 1028, 2906, 3143, 14, 112, 102, 1594, 1274, 253, 11, 41, 5, 8, 2083, 266, 1, 71272, 172, 5910, 172, 809, 2464, 37, 92, 32, 740, 9, 3, 1135, 1, 2906, 3143, 14, 1274, 2, 47, 8, 1904, 200, 4, 579, 250, 253, 132, 2130, 132, 46, 74, 1008, 17, 1915, 480, 277, 2906, 3143, 14, 55, 122, 2410, 35, 448, 112, 250, 51, 4, 8, 1352, 19758, 533, 12, 2, 1817, 3, 174, 9, 277, 448, 1166, 726, 4, 8, 87, 1, 7, 5, 383, 838, 70, 2459, 12, 1936, 259, 33, 21118, 462, 3194, 1630, 70, 70, 3764, 139, 4662, 20, 71273, 19, 15374, 70]",1983.0,28947565,NY-ESO-1 Vaccination Combination Decitabine Induces Antigen-Specific T-lymphocyte Responses Patients Myelodysplastic Syndrome,2,0.0034904013961605585
"Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.",American journal of hematology,Am. J. Hematol.,2017-11-03,"Therapy related myeloid neoplasms (t-MN) including therapy related myelodysplastic syndromes (t-MDS) and acute myeloid leukemia (t-AML) are associated with aggressive disease biologies and poor outcomes. In this large (n=497) and informative (inclusive of molecular and cytogenetic information) chronic myelomonocytic leukemia (CMML) patient cohort, we demonstrate key biological insights and an independent prognostic impact for t-CMML. T-CMML was diagnosed in 9% of patients and occurred approximately 7 years after exposure to prior chemotherapy and/or radiation therapy. In comparison to de novo CMML, t-CMML patients had higher LDH levels, higher frequency of karyotypic abnormalities and had higher risk cytogenetic stratification. There were no differences in the distribution of gene mutations and unlike t-MDS/AML, balanced chromosomal translocations, abnormalities of chromosome 11q23 (1%) and Tp53 mutations (<2%) were uncommon. Molecularly integrated CMML prognostic models were not effective in risk stratifying t-CMML patients and responses to hypomethylating agents were dismal with no complete responses. Median overall (OS) and leukemia free survival (LFS) was shorter for t-CMML in comparison to d-CMML (Median OS 10.9 vs 26 months and median LFS 50 vs 127 months) and t-CMML independently and adversely impacted OS (P=.0001 HR 2.1 95% CI 1.4-3.0). This prognostic impact was retained in the context of the Mayo Molecular Model (P=.001, HR 2.4, 95% CI 1.5-3.7) and the GFM prognostic model (P<.0001, HR 2.15, 95% CI 1.5-3.7). In summary, we highlight the unique genetics and independent prognostic impact of t-CMML, warranting its inclusion as a separate entity in the classification schema for both CMML and t-MN.",Journal Article,809.0,16.0,Therapy related myeloid neoplasms t-MN including therapy related myelodysplastic syndromes t-MDS acute myeloid leukemia t-AML associated aggressive disease biologies poor outcomes large n 497 informative inclusive molecular cytogenetic information chronic myelomonocytic leukemia CMML patient cohort demonstrate key insights independent prognostic impact t-CMML T-CMML diagnosed 9 patients occurred approximately 7 years exposure prior chemotherapy and/or radiation therapy comparison novo CMML t-CMML patients higher LDH levels higher frequency karyotypic abnormalities higher risk cytogenetic stratification differences distribution unlike t-MDS/AML balanced chromosomal translocations abnormalities chromosome 11q23 1 Tp53 2 uncommon Molecularly integrated CMML prognostic models effective risk stratifying t-CMML patients responses hypomethylating agents dismal complete responses Median overall OS leukemia free survival LFS shorter t-CMML comparison d-CMML Median OS 10.9 vs 26 months median LFS 50 vs 127 months t-CMML independently adversely impacted OS P .0001 HR 2.1 95 CI 1.4-3.0 prognostic impact retained context Mayo Molecular Model P .001 HR 2.4 95 CI 1.5-3.7 GFM prognostic model P .0001 HR 2.15 95 CI 1.5-3.7 summary highlight unique genetics independent prognostic impact t-CMML warranting inclusion separate entity classification schema CMML t-MN,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[36, 139, 533, 1179, 102, 4691, 141, 36, 139, 2040, 102, 1223, 2, 286, 533, 102, 329, 32, 41, 5, 571, 34, 35820, 2, 334, 123, 4, 26, 375, 78, 11178, 2, 4189, 10078, 1, 219, 2, 1266, 487, 442, 5451, 3382, 69, 180, 21, 608, 825, 1037, 1957, 2, 35, 306, 177, 345, 9, 102, 3382, 102, 3382, 10, 265, 4, 83, 1, 7, 2, 489, 705, 67, 60, 50, 645, 6, 324, 56, 2, 15, 121, 36, 4, 1155, 6, 1566, 2018, 3382, 102, 3382, 7, 42, 142, 4592, 148, 142, 675, 1, 9465, 1171, 2, 42, 142, 43, 1266, 1541, 125, 11, 77, 362, 4, 3, 1395, 1, 145, 138, 2, 4246, 102, 1223, 329, 4115, 1860, 3262, 1171, 1, 1170, 7975, 14, 2, 1206, 138, 18, 11, 2052, 2372, 2102, 3382, 177, 274, 11, 44, 323, 4, 43, 5035, 102, 3382, 7, 2, 253, 6, 4931, 183, 11, 3929, 5, 77, 236, 253, 52, 63, 118, 2, 115, 25, 5674, 10, 985, 9, 102, 3382, 4, 1155, 6, 427, 3382, 52, 118, 79, 83, 105, 432, 53, 2, 52, 5674, 212, 105, 4080, 53, 2, 102, 3382, 1042, 2, 4311, 4619, 118, 19, 488, 168, 18, 14, 48, 58, 14, 39, 27, 13, 26, 177, 345, 10, 3532, 4, 3, 1533, 1, 3, 2486, 219, 202, 19, 144, 168, 18, 39, 48, 58, 14, 33, 27, 67, 2, 3, 71371, 177, 202, 19, 488, 168, 18, 167, 48, 58, 14, 33, 27, 67, 4, 1962, 21, 1817, 3, 991, 2894, 2, 306, 177, 345, 1, 102, 3382, 7643, 211, 1680, 22, 8, 2282, 2983, 4, 3, 947, 8371, 9, 110, 3382, 2, 102, 4691]",1634.0,29023992,Therapy related-chronic myelomonocytic leukemia CMML Molecular cytogenetic clinical distinctions novo CMML,1,0.0017452006980802793
"A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.",Clinical epigenetics,Clin Epigenetics,2017-10-05,"Decitabine is a deoxycytidine nucleoside derivative inhibitor of DNA-methyltransferases, which has been studied extensively and is approved for myelodysplastic syndrome in adults but with less focus in children. Accordingly, we conducted a phase 1 multicenter, randomized, open-label study to evaluate decitabine pre-treatment before standard induction therapy in children with newly diagnosed AML to assess safety and tolerability and explore a number of biologic endpoints. Twenty-four patients were fully assessable for all study objectives per protocol (10 in Arm A = epigenetic priming induction, 14 in Arm B = standard induction). All patients experienced neutropenia and thrombocytopenia. The most common grade 3 and 4 non-hematologic adverse events observed were gastrointestinal toxicities and hypophosphatemia. Plasma decitabine PK were similar to previously reported adult data. Overall CR/CRi was similar for the two arms. MRD negativity at end-induction was 85% in Arm A versus 67% in Arm B patients. DNA methylation measured in peripheral blood over the course of treatment tracked with blast clearance and matched marrow aspirates at day 0 and day 21. Unlike end-induction marrow analyses, promoter methylation in blood identified an apparent reversal of response in the lone treatment failure, 1week prior to the patient's marrow aspirate confirming non-response. Decitabine-induced effects on end-induction (day 35-43 following initiation of treatment) marrows in Arm A were reflected by changes in DNA methylation in matched paired marrow diagnostic aspirates. This first-in-pediatrics trial demonstrates that decitabine prior to standard combination chemotherapy is feasible and well tolerated in children with newly diagnosed AML. Pre-treatment with decitabine may represent a newer therapeutic option for pediatric AML, especially as it appears to induce important epigenetic alterations. The novel biological correlates studied in this trial offer a clinically relevant window into disease progression and remission. Additional studies are needed to definitively assess whether decitabine can enhance durability responses in children with AML. NCT01177540.","Clinical Trial, Phase I",838.0,8.0,Decitabine deoxycytidine nucleoside derivative inhibitor DNA-methyltransferases studied extensively approved myelodysplastic syndrome adults focus children Accordingly conducted phase 1 multicenter randomized open-label evaluate decitabine pre-treatment standard induction therapy children newly diagnosed AML assess safety tolerability explore number biologic endpoints Twenty-four patients fully assessable objectives protocol 10 Arm epigenetic priming induction 14 Arm B standard induction patients experienced neutropenia thrombocytopenia common grade 3 4 non-hematologic adverse events observed gastrointestinal toxicities hypophosphatemia Plasma decitabine PK similar previously reported adult Overall CR/CRi similar arms MRD negativity end-induction 85 Arm versus 67 Arm B patients DNA methylation measured peripheral blood course treatment tracked blast clearance matched marrow aspirates day 0 day 21 Unlike end-induction marrow promoter methylation blood identified apparent reversal response lone treatment failure 1 week prior patient 's marrow aspirate confirming non-response Decitabine-induced effects end-induction day 35-43 following initiation treatment marrows Arm reflected changes DNA methylation matched paired marrow diagnostic aspirates first-in-pediatrics trial demonstrates decitabine prior standard combination chemotherapy feasible tolerated children newly diagnosed AML Pre-treatment decitabine represent newer therapeutic option pediatric AML especially appears induce important epigenetic alterations novel correlates studied trial offer clinically relevant window disease progression remission Additional studies needed definitively assess decitabine enhance durability responses children AML NCT01177540,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3004, 16, 8, 6750, 4032, 4819, 230, 1, 261, 11494, 92, 71, 85, 656, 3576, 2, 16, 850, 9, 681, 4, 857, 84, 5, 299, 1222, 4, 541, 4705, 21, 426, 8, 124, 14, 1570, 384, 1020, 1756, 45, 6, 376, 3004, 671, 24, 348, 260, 504, 36, 4, 541, 5, 732, 265, 329, 6, 423, 367, 2, 1543, 2, 1645, 8, 207, 1, 1283, 1387, 737, 294, 7, 11, 1910, 3120, 9, 62, 45, 2409, 379, 1182, 79, 4, 475, 8, 1418, 4903, 504, 213, 4, 475, 132, 260, 504, 62, 7, 592, 778, 2, 1340, 3, 96, 186, 88, 27, 2, 39, 220, 813, 290, 281, 164, 11, 385, 2, 8021, 554, 3004, 2395, 11, 288, 6, 373, 210, 780, 74, 63, 684, 6341, 10, 288, 9, 3, 100, 1335, 2029, 6014, 28, 396, 504, 10, 772, 4, 475, 8, 185, 598, 4, 475, 132, 7, 261, 569, 644, 4, 672, 315, 252, 3, 906, 1, 24, 9331, 5, 3112, 1960, 2, 655, 581, 7493, 28, 218, 13, 2, 218, 239, 4246, 396, 504, 581, 318, 973, 569, 4, 315, 108, 35, 2235, 5933, 1, 51, 4, 3, 71387, 24, 496, 14, 647, 324, 6, 3, 69, 292, 581, 8022, 5030, 220, 51, 3004, 277, 176, 23, 396, 504, 218, 465, 601, 366, 1118, 1, 24, 13800, 4, 475, 8, 11, 4686, 20, 400, 4, 261, 569, 4, 655, 2355, 581, 752, 7493, 26, 157, 4, 12616, 160, 1902, 17, 3004, 324, 6, 260, 150, 56, 16, 1313, 2, 149, 421, 4, 541, 5, 732, 265, 329, 671, 24, 5, 3004, 68, 1231, 8, 2246, 189, 1501, 9, 815, 329, 1093, 22, 192, 1233, 6, 1290, 305, 1418, 593, 3, 229, 1037, 1871, 656, 4, 26, 160, 1918, 8, 505, 867, 5421, 237, 34, 91, 2, 734, 402, 94, 32, 575, 6, 6008, 423, 317, 3004, 122, 1304, 6867, 253, 4, 541, 5, 329, 71388]",2113.0,29034009,multicenter randomized decitabine epigenetic priming induction chemotherapy children AML,0,0.0
Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.,Gynecologic oncology,Gynecol. Oncol.,2017-10-14,"The objective of this study was to determine the overall tolerability and toxicity of olaparib capsules among older (65years) patients with recurrent ovarian cancer treated on 8 completed prospective trials of olaparib. An ancillary data analysis of 398 patients with recurrent ovarian cancer enrolled on eight prospective trials of olaparib capsules was performed. Patients aged 65years and older were stratified into age groups by 5year increments (ages 65-69, 70-74, 75years) and compared to those <65. Analysis was restricted to those patients receiving the recommended treatment dose of 400mg PO b.i.d. Of the 398 patients included, 78 were 65 (age 65-69 n=38, age 70-74 n=23, age75 n=17). The majority of elderly patients were Caucasian (n=2 Asian) and had received 5 prior lines of chemotherapy. In patients <65, 46.9% required dose reduction as compared to 44.7% of patients 65-69years, 47.8% of patients 70-74years, and 64.7% of patients 75years (p=0.62). In patients <65years 41.2% required dose interruption, as compared to 50%, 43.5%, and 64.7% of patients aged 65-69, 70-74, and 75, respectively (p=0.11). There were no occurrences of myelodysplastic syndrome or acute myeloid leukemia in any of the older cohorts. Toxicities, including grade 3/4 nausea, were similar across age groups. Tolerability and toxicity of olaparib capsules is similar between women 65years and <65years of age treated for advanced recurrent ovarian cancer. Use of olaparib should be considered in this patient population.",Journal Article,829.0,7.0,objective determine overall tolerability toxicity olaparib capsules older 65years patients recurrent ovarian treated 8 completed prospective trials olaparib ancillary 398 patients recurrent ovarian enrolled prospective trials olaparib capsules performed Patients aged 65years older stratified age groups 5year increments ages 65-69 70-74 75years compared 65 restricted patients receiving recommended treatment dose 400mg PO b.i.d 398 patients included 78 65 age 65-69 n=38 age 70-74 n=23 age75 n=17 majority elderly patients Caucasian n=2 Asian received 5 prior lines chemotherapy patients 65 46.9 required dose reduction compared 44.7 patients 65-69years 47.8 patients 70-74years 64.7 patients 75years p=0.62 patients 65years 41.2 required dose interruption compared 50 43.5 64.7 patients aged 65-69 70-74 75 respectively p=0.11 occurrences myelodysplastic syndrome acute myeloid leukemia older cohorts Toxicities including grade 3/4 nausea similar age groups Tolerability toxicity olaparib capsules similar women 65years 65years age treated advanced recurrent ovarian Use olaparib considered patient population,0,0,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 461, 1, 26, 45, 10, 6, 223, 3, 63, 1543, 2, 155, 1, 4024, 8599, 107, 434, 41044, 7, 5, 387, 12, 73, 23, 66, 781, 482, 143, 1, 4024, 35, 8496, 74, 65, 1, 8336, 7, 5, 387, 12, 346, 23, 659, 482, 143, 1, 4024, 8599, 10, 173, 7, 1032, 36462, 2, 434, 11, 1173, 237, 89, 271, 20, 40789, 8225, 2165, 556, 790, 431, 794, 41636, 2, 72, 6, 135, 556, 65, 10, 2016, 6, 135, 7, 357, 3, 793, 24, 61, 1, 14632, 4826, 132, 70, 427, 1, 3, 8336, 7, 159, 833, 11, 5827, 89, 556, 790, 78, 519, 89, 431, 794, 78, 382, 35585, 78, 269, 3, 686, 1, 1216, 7, 11, 3229, 78, 18, 2399, 2, 42, 103, 4126, 324, 285, 1, 56, 4, 7, 556, 641, 83, 616, 61, 628, 22, 72, 6, 584, 67, 1, 7, 556, 48521, 662, 66, 1, 7, 431, 48804, 2, 660, 67, 1, 7, 41636, 19, 13, 744, 4, 7, 36462, 605, 18, 616, 61, 4823, 22, 72, 6, 212, 601, 33, 2, 660, 67, 1, 7, 1032, 556, 790, 431, 794, 2, 8999, 106, 19, 13, 175, 125, 11, 77, 8781, 1, 681, 15, 286, 533, 4, 500, 1, 3, 434, 736, 385, 141, 88, 27, 39, 1218, 11, 288, 716, 89, 271, 1543, 2, 155, 1, 4024, 8599, 16, 288, 59, 117, 41044, 2, 36462, 1, 89, 73, 9, 131, 387, 12, 119, 1, 4024, 257, 40, 515, 4, 26, 69, 266]",1418.0,29037805,Tolerance toxicity PARP inhibitor olaparib older women epithelial ovarian,0,0.0
"Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2017-10-17,"Purpose Several open-label randomized studies have suggested that in vivo T-cell depletion with anti-T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) reduces chronic graft-versus-host disease (cGVHD) without compromising survival. We report a prospective, double-blind phase III trial to investigate the effect of ATLG (Neovii Biotech, Lexington, MA) on cGVHD-free survival. Patients and Methods Two hundred fifty-four patients 18 to 65 years of age with acute leukemia or myelodysplastic syndrome who underwent myeloablative HLA-matched unrelated hematopoietic cell transplantation (HCT) were randomly assigned one to one to placebo (n =128 placebo) or ATLG (n = 126) treatment at 27 sites. Patients received either ATLG or placebo 20 mg/kg per day on days -3, -2, -1 in addition to tacrolimus and methotrexate as GVHD prophylaxis. The primary study end point was moderate-severe cGVHD-free survival. Results Despite a reduction in grade 2 to 4 acute GVHD (23% v 40%; P = .004) and moderate-severe cGVHD (12% v 33%; P < .001) in ATLG recipients, no difference in moderate-severe cGVHD-free survival between ATLG and placebo was found (2-year estimate: 48% v 44%, respectively; P = .47). Both progression-free survival (PFS) and overall survival (OS) were lower with ATLG (2-year estimate: 47% v 65% [ P = .04] and 59% v 74% [ P = .034], respectively). Multivariable analysis confirmed that ATLG was associated with inferior PFS (hazard ratio, 1.55; 95% CI, 1.05 to 2.28; P = .026) and OS (hazard ratio, 1.74; 95% CI, 1.12 to 2.71; P = .01). Conclusion In this prospective, randomized, double-blind trial of ATLG in unrelated myeloablative HCT, the incorporation of ATLG did not improve moderate-severe cGVHD-free survival. Moderate-severe cGVHD was significantly lower with ATLG, but PFS and OS also were lower. Additional analyses are needed to understand the appropriate role for ATLG in HCT.","Clinical Trial, Phase III",826.0,62.0,Purpose open-label randomized studies suggested vivo T-cell depletion anti-T-lymphocyte globulin ATLG antithymocyte globulin-Fresenius reduces chronic graft-versus-host disease cGVHD compromising survival report prospective double-blind phase III trial investigate effect ATLG Neovii Biotech Lexington cGVHD-free survival Patients Methods fifty-four patients 18 65 years age acute leukemia myelodysplastic syndrome underwent myeloablative HLA-matched unrelated hematopoietic transplantation HCT randomly assigned placebo n =128 placebo ATLG n 126 treatment 27 sites Patients received ATLG placebo 20 mg/kg day days -3 -2 -1 addition tacrolimus methotrexate GVHD prophylaxis primary end point moderate-severe cGVHD-free survival Despite reduction grade 2 4 acute GVHD 23 v 40 P .004 moderate-severe cGVHD 12 v 33 P .001 ATLG recipients difference moderate-severe cGVHD-free survival ATLG placebo 2-year estimate 48 v 44 respectively P .47 progression-free survival PFS overall survival OS lower ATLG 2-year estimate 47 v 65 P .04 59 v 74 P .034 respectively Multivariable confirmed ATLG associated inferior PFS hazard ratio 1.55 95 CI 1.05 2.28 P .026 OS hazard ratio 1.74 95 CI 1.12 2.71 P .01 prospective randomized double-blind trial ATLG unrelated myeloablative HCT incorporation ATLG improve moderate-severe cGVHD-free survival Moderate-severe cGVHD significantly lower ATLG PFS OS lower Additional needed understand appropriate role ATLG HCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[743, 392, 1020, 1756, 384, 94, 47, 1148, 17, 4, 386, 102, 31, 2286, 5, 312, 102, 1448, 7819, 20942, 7350, 11016, 7819, 71392, 2389, 442, 1599, 185, 1204, 34, 6670, 187, 6102, 25, 21, 414, 8, 482, 1627, 3142, 124, 316, 160, 6, 963, 3, 254, 1, 20942, 71393, 24505, 71394, 3687, 23, 6670, 115, 25, 7, 2, 636, 100, 1128, 1461, 294, 7, 203, 6, 556, 60, 1, 89, 5, 286, 15, 681, 54, 208, 3246, 1160, 655, 2092, 1007, 31, 497, 1085, 11, 1108, 896, 104, 6, 104, 6, 619, 78, 3990, 619, 15, 20942, 78, 3927, 24, 28, 428, 633, 7, 103, 361, 20942, 15, 619, 179, 81, 503, 379, 218, 23, 162, 27, 18, 14, 4, 352, 6, 5643, 2, 2116, 22, 1562, 2049, 3, 86, 45, 396, 741, 10, 1163, 905, 6670, 115, 25, 99, 550, 8, 628, 4, 88, 18, 6, 39, 286, 1562, 382, 603, 327, 19, 1520, 2, 1163, 905, 6670, 133, 603, 466, 19, 144, 4, 20942, 2190, 77, 523, 4, 1163, 905, 6670, 115, 25, 59, 20942, 2, 619, 10, 204, 18, 111, 1191, 576, 603, 584, 106, 19, 662, 110, 91, 115, 25, 300, 2, 63, 25, 118, 11, 280, 5, 20942, 18, 111, 1191, 662, 603, 556, 19, 755, 2, 728, 603, 794, 19, 5337, 106, 658, 65, 557, 17, 20942, 10, 41, 5, 1663, 300, 360, 197, 14, 614, 48, 58, 14, 474, 6, 18, 339, 19, 4554, 2, 118, 360, 197, 14, 794, 48, 58, 14, 133, 6, 18, 792, 19, 355, 1221, 4, 26, 482, 384, 1627, 3142, 160, 1, 20942, 4, 2092, 3246, 1085, 3, 2838, 1, 20942, 205, 44, 401, 1163, 905, 6670, 115, 25, 1163, 905, 6670, 10, 97, 280, 5, 20942, 84, 300, 2, 118, 120, 11, 280, 402, 318, 32, 575, 6, 1640, 3, 870, 200, 9, 20942, 4, 1085]",1794.0,29040031,Prospective Randomized Double-Blind Phase III Clinical Trial Anti-T-Lymphocyte Globulin Assess Impact Chronic Graft-Versus-Host Disease-Free Survival Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Transplantation,2,0.0034904013961605585
MYD88 mutation status does not impact overall survival in Waldenstrm macroglobulinemia.,American journal of hematology,Am. J. Hematol.,2017-11-17,"Waldenstrm macroglobulinemia (WM) is an immunoglobulin M-associated lymphoma, with majority of cases demonstrating MYD88 locus alteration, most commonly, MYD88<sup>L265P</sup> . Owing to low prevalence of the wild-type (WT) MYD88 genotype in WM, clinically relevant data in this patient population are sparse, with one study showing nearly a 10-fold increased risk of mortality in this subgroup compared to patients with MYD88<sup>L265P</sup> mutation. We studied a large cohort of patients with MYD88<sup>L265P</sup> and MYD88<sup>WT</sup> WM, evaluated at Mayo Clinic, Rochester, between 1995 and 2016, to specifically assess the impact of these genotypes on clinical course. Of 557 patients, MYD88<sup>L265P</sup> mutation status, as determined by allele-specific polymerase chain reaction, was known in 219, and 174 (79%) of those exhibited MYD88<sup>L265P</sup> , 157 of 174 patients had active disease. Of 45 (21%) patients with MYD88<sup>WT</sup> genotype, 44 had active disease. The estimated median follow-up was 7.0 years; median overall survival was 10.2 years (95% CI: 8.4-16.5) for MYD88<sup>L265P</sup> versus 13.9 years (95% CI: 6.4-29.3) for the MYD88<sup>WT</sup> (P=0.86). The time-to-next therapy from frontline treatment and the presenting features were similar in the two patient populations. For patients with smoldering WM at diagnosis, the median time-to-progression to active disease was 2.8 years (95% CI: 2.2-3.8) in the MYD88<sup>L265P</sup> cohort and 1.9 years (95% CI: 0.7-3.1) in the MYD88<sup>WT</sup> cohort (P=0.21). The frequency of transformation to high-grade lymphoma, or the development of therapy-elated myelodysplastic syndrome was higher in the MYD88<sup>WT</sup> cohort (16% versus 4% in the MYD88<sup>L265P</sup> , P=0.009). In conclusion, MYD88<sup>L265P</sup> mutation does not appear to be a determinant of outcome, and its presence may not be a disease-defining feature in WM. Our findings warrant external validation, preferably through prospective studies.",Journal Article,795.0,16.0,Waldenstrm macroglobulinemia WM immunoglobulin M-associated lymphoma majority cases demonstrating MYD88 locus alteration commonly MYD88 sup L265P /sup Owing low prevalence wild-type WT MYD88 genotype WM clinically relevant patient population sparse showing nearly 10-fold increased risk mortality subgroup compared patients MYD88 sup L265P /sup studied large cohort patients MYD88 sup L265P /sup MYD88 sup WT /sup WM evaluated Mayo Clinic Rochester 1995 2016 specifically assess impact genotypes clinical course 557 patients MYD88 sup L265P /sup status determined allele-specific polymerase chain reaction known 219 174 79 exhibited MYD88 sup L265P /sup 157 174 patients active disease 45 21 patients MYD88 sup WT /sup genotype 44 active disease estimated median follow-up 7.0 years median overall survival 10.2 years 95 CI 8.4-16.5 MYD88 sup L265P /sup versus 13.9 years 95 CI 6.4-29.3 MYD88 sup WT /sup P 0.86 time-to-next therapy frontline treatment presenting features similar patient populations patients smoldering WM diagnosis median time-to-progression active disease 2.8 years 95 CI 2.2-3.8 MYD88 sup L265P /sup cohort 1.9 years 95 CI 0.7-3.1 MYD88 sup WT /sup cohort P 0.21 frequency transformation high-grade lymphoma development therapy-elated myelodysplastic syndrome higher MYD88 sup WT /sup cohort 16 versus 4 MYD88 sup L265P /sup P 0.009 MYD88 sup L265P /sup appear determinant outcome presence disease-defining feature WM findings warrant external validation preferably prospective studies,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3700, 3389, 1518, 16, 35, 2593, 188, 41, 5, 686, 1, 140, 2219, 3986, 2474, 2611, 96, 841, 3986, 172, 7735, 172, 3421, 6, 154, 1078, 1, 3, 955, 267, 1820, 3986, 1183, 4, 1518, 505, 867, 74, 4, 26, 69, 266, 32, 7425, 5, 104, 45, 2069, 1857, 8, 79, 1116, 101, 43, 1, 282, 4, 26, 1363, 72, 6, 7, 5, 3986, 172, 7735, 172, 258, 21, 656, 8, 375, 180, 1, 7, 5, 3986, 172, 7735, 172, 2, 3986, 172, 1820, 172, 1518, 194, 28, 2486, 1188, 5801, 59, 2323, 2, 1390, 6, 1225, 423, 3, 345, 1, 46, 2071, 23, 38, 906, 1, 12495, 7, 3986, 172, 7735, 172, 258, 156, 22, 509, 20, 1254, 112, 1451, 1260, 1329, 10, 440, 4, 6679, 2, 5811, 842, 1, 135, 1416, 3986, 172, 7735, 172, 5311, 1, 5811, 7, 42, 544, 34, 1, 512, 239, 7, 5, 3986, 172, 1820, 172, 1183, 584, 42, 544, 34, 3, 661, 52, 166, 126, 10, 67, 13, 60, 52, 63, 25, 10, 79, 18, 60, 48, 58, 66, 39, 245, 33, 9, 3986, 172, 7735, 172, 185, 233, 83, 60, 48, 58, 49, 39, 462, 27, 9, 3, 3986, 172, 1820, 172, 19, 13, 868, 3, 98, 6, 1305, 36, 29, 3171, 24, 2, 3, 1656, 404, 11, 288, 4, 3, 100, 69, 1184, 9, 7, 5, 7091, 1518, 28, 147, 3, 52, 98, 6, 91, 6, 544, 34, 10, 18, 66, 60, 48, 58, 18, 18, 27, 66, 4, 3, 3986, 172, 7735, 172, 180, 2, 14, 83, 60, 48, 58, 13, 67, 27, 14, 4, 3, 3986, 172, 1820, 172, 180, 19, 13, 239, 3, 675, 1, 1392, 6, 64, 88, 15, 3, 193, 1, 36, 71447, 681, 10, 142, 4, 3, 3986, 172, 1820, 172, 180, 245, 185, 39, 4, 3, 3986, 172, 7735, 172, 19, 13, 2376, 4, 1221, 3986, 172, 7735, 172, 258, 1097, 44, 1322, 6, 40, 8, 4372, 1, 228, 2, 211, 463, 68, 44, 40, 8, 34, 2847, 2705, 4, 1518, 114, 272, 2946, 1455, 929, 10590, 298, 482, 94]",1890.0,29080258,MYD88 status impact overall survival Waldenstrm macroglobulinemia,13,0.02268760907504363
Impact of baseline cytogenetic findings and cytogenetic response on outcome of high-risk myelodysplastic syndromes and low blast count AML treated with azacitidine.,Leukemia research,Leuk. Res.,2017-10-27,"Karyotype according to the revised IPSS is a strong independent prognostic factor for overall survival (OS) in myelodysplastic syndromes (MDS), however established in untreated patients. The prognostic impact of cytogenetics and cytogenetic response (CyR) in MDS patients receiving azacitidine (AZA) remains uncertain. We examined the prognostic value of baseline cytogenetics and CyR for overall response rate (ORR) and OS in 702 AZA-treated higher risk MDS and low blast count acute myeloid leukemia (AML), including 493 (70%) with abnormal karyotype. None of the cytogenetic abnormalities had significant impact on ORR (43.9%) or complete response (15.35%), except 3q abnormalities and complex karyotypes, which were associated with a lower ORR. OS differed significantly across all R-IPSS cytogenetic subgroups (p<10<sup>-4</sup>) but patients with non complex del(7q) had similar survival as patients with normal cytogenetics. CyR was achieved in 32% of the 281 evaluable patients with abnormal cytogenetics, was complete (CCyR) in 71 (25.3%) patients. We found no correlation between hematological response and cytogenetic response and 21% of the patients with CCyR did not achieve morphological response. In the 281 patients, we found no impact of CyR on survival, but when restricting to MDS (ie:<20% marrow blasts) achievement of CCyR was associated with better OS.",Journal Article,816.0,4.0,Karyotype according revised IPSS strong independent prognostic factor overall survival OS myelodysplastic syndromes MDS established untreated patients prognostic impact cytogenetics cytogenetic response CyR MDS patients receiving azacitidine AZA remains uncertain examined prognostic value baseline cytogenetics CyR overall response rate ORR OS 702 AZA-treated higher risk MDS low blast count acute myeloid leukemia AML including 493 70 abnormal karyotype cytogenetic abnormalities significant impact ORR 43.9 complete response 15.35 3q abnormalities complex karyotypes associated lower ORR OS differed significantly R-IPSS cytogenetic subgroups p 10 sup -4 /sup patients non complex del 7q similar survival patients normal cytogenetics CyR achieved 32 281 evaluable patients abnormal cytogenetics complete CCyR 71 25.3 patients correlation hematological response cytogenetic response 21 patients CCyR achieve morphological response 281 patients impact CyR survival restricting MDS 20 marrow blasts achievement CCyR associated better OS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3385, 768, 6, 3, 4218, 8751, 16, 8, 1082, 306, 177, 161, 9, 63, 25, 118, 4, 2040, 1223, 137, 635, 4, 1278, 7, 3, 177, 345, 1, 2510, 2, 1266, 51, 20710, 4, 1223, 7, 357, 3752, 3924, 469, 2717, 21, 409, 3, 177, 549, 1, 330, 2510, 2, 20710, 9, 63, 51, 116, 1735, 2, 118, 4, 11634, 3924, 73, 142, 43, 1223, 2, 154, 3112, 1276, 286, 533, 329, 141, 11304, 431, 5, 1668, 3385, 1292, 1, 3, 1266, 1171, 42, 93, 345, 23, 1735, 601, 83, 15, 236, 51, 167, 465, 2187, 18200, 1171, 2, 840, 6809, 92, 11, 41, 5, 8, 280, 1735, 118, 2512, 97, 716, 62, 668, 8751, 1266, 1453, 19, 79, 172, 39, 172, 84, 7, 5, 220, 840, 3084, 9723, 42, 288, 25, 22, 7, 5, 295, 2510, 20710, 10, 513, 4, 531, 1, 3, 8970, 859, 7, 5, 1668, 2510, 10, 236, 6412, 4, 792, 243, 27, 7, 21, 204, 77, 816, 59, 2890, 51, 2, 1266, 51, 2, 239, 1, 3, 7, 5, 6412, 205, 44, 1359, 4268, 51, 4, 3, 8970, 7, 21, 204, 77, 345, 1, 20710, 23, 25, 84, 198, 9998, 6, 1223, 2523, 179, 581, 2438, 5088, 1, 6412, 10, 41, 5, 380, 118]",1298.0,29112938,Impact baseline cytogenetic findings cytogenetic response outcome high-risk myelodysplastic syndromes low blast count AML treated azacitidine,0,0.0
Frailty and the management of hematologic malignancies.,Blood,Blood,2017-11-15,"The majority of blood cancers occur in the elderly. This fact conspires with an aging population in many countries to make rigorous assessment for frailty increasingly important for hematologic oncologists. In this review, we first define frailty and its relevance for patients with hematologic malignancy. Next, we review current data regarding the effect of domains of frailty on outcomes for blood cancers including myelodysplastic syndromes, acute leukemia, non-Hodgkin lymphomas such as chronic lymphocytic leukemia, and multiple myeloma. Finally, after presenting assessment and treatment options for the practicing hematologist, we propose elements of a new research agenda for geriatric hematology: the exchange of age limits for rigorous frailty screening, development of disease-specific measures, and inclusion of functional and patient-reported outcomes alongside survival.",Journal Article,797.0,33.0,majority blood occur elderly fact conspires aging population countries rigorous assessment frailty increasingly important hematologic oncologists review define frailty relevance patients hematologic malignancy review current effect domains frailty outcomes blood including myelodysplastic syndromes acute leukemia non-Hodgkin lymphomas chronic lymphocytic leukemia multiple myeloma Finally presenting assessment treatment options practicing hematologist propose elements new research agenda geriatric hematology exchange age limits rigorous frailty screening development disease-specific measures inclusion functional patient-reported outcomes alongside survival,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,"[3, 686, 1, 315, 163, 1271, 4, 3, 1216, 26, 1991, 71574, 5, 35, 4220, 266, 4, 445, 2115, 6, 2378, 6496, 455, 9, 5289, 1635, 305, 9, 813, 1339, 4, 26, 206, 21, 157, 1107, 5289, 2, 211, 2088, 9, 7, 5, 813, 710, 1305, 21, 206, 291, 74, 666, 3, 254, 1, 2703, 1, 5289, 23, 123, 9, 315, 163, 141, 2040, 286, 1557, 225, 22, 442, 1193, 2, 232, 1368, 50, 1656, 455, 2, 24, 838, 9, 3, 6734, 15278, 21, 2548, 2531, 1, 8, 217, 389, 12402, 9, 3914, 6216, 3, 6695, 1, 89, 3526, 9, 6496, 5289, 453, 193, 1, 34, 112, 1018, 2, 1680, 1, 583, 2, 69, 210, 123, 10150, 25]",816.0,29141942,Frailty management hematologic malignancies,0,0.0
The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes.,Annals of hematology,Ann. Hematol.,2017-11-22,"The prognostic value of peripheral blasts (PB) is not well-studied in patients with myelodysplastic syndromes (MDS). We evaluated the impact of PB on overall survival (OS) and transformation to acute myeloid leukemia (AML) in a large cohort. The MDS database at the Moffitt Cancer Center was retrospectively reviewed to identify patients with 1% PB (PB-MDS) and those without PB (BM-MDS). We also assessed the correlation between PB and gene mutations. One thousand seven hundred fifty-eight patients were identified, among whom 13% had PB near the time of diagnosis. PB-MDS patients were more likely to be younger with trilineage cytopenia, complex karyotype, higher-risk disease, transfusion dependence, and therapy-related MDS. The rate of AML transformation was 49 vs. 26% (p<0.005) and median OS was 16.5 vs. 45.8months (p<0.005) in the PB-MDS and BM-MDS groups, respectively. In Cox regression analysis, the presence of PB was an independent prognostic covariate for OS, HR 1.57 (95% CI 1.2-2). Among 51 patients with an available gene panel, the rate of 1 gene mutation in the PB-MDS group (n=4) was 100% compared to 81% in the BM-MDS group (n=47). The presence of PB in MDS is an adverse independent prognostic variable that refines prognostic discrimination.",Journal Article,790.0,3.0,prognostic value peripheral blasts PB well-studied patients myelodysplastic syndromes MDS evaluated impact PB overall survival OS transformation acute myeloid leukemia AML large cohort MDS database Moffitt Center retrospectively reviewed identify patients  1 PB PB-MDS PB BM-MDS assessed correlation PB thousand seven fifty-eight patients identified 13 PB near time diagnosis PB-MDS patients likely younger trilineage cytopenia complex karyotype higher-risk disease transfusion dependence therapy-related MDS rate AML transformation 49 vs. 26 p 0.005 median OS 16.5 vs. 45.8 months p 0.005 PB-MDS BM-MDS groups respectively Cox regression presence PB independent prognostic covariate OS HR 1.57 95 CI 1.2-2 51 patients available panel rate  1 PB-MDS group n 4 100 compared 81 BM-MDS group n 47 presence PB MDS adverse independent prognostic variable refines prognostic discrimination,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 177, 549, 1, 672, 2438, 3767, 16, 44, 149, 656, 4, 7, 5, 2040, 1223, 21, 194, 3, 345, 1, 3767, 23, 63, 25, 118, 2, 1392, 6, 286, 533, 329, 4, 8, 375, 180, 3, 1223, 609, 28, 3, 9054, 12, 574, 10, 894, 446, 6, 255, 7, 5, 749, 14, 3767, 3767, 1223, 2, 135, 187, 3767, 1246, 1223, 21, 120, 275, 3, 816, 59, 3767, 2, 145, 138, 104, 6161, 648, 1128, 1461, 659, 7, 11, 108, 107, 953, 233, 42, 3767, 1829, 3, 98, 1, 147, 3767, 1223, 7, 11, 80, 322, 6, 40, 773, 5, 21950, 8165, 840, 3385, 142, 43, 34, 2785, 3721, 2, 36, 139, 1223, 3, 116, 1, 329, 1392, 10, 739, 105, 432, 19, 13, 1614, 2, 52, 118, 10, 245, 33, 105, 512, 66, 53, 19, 13, 1614, 4, 3, 3767, 1223, 2, 1246, 1223, 271, 106, 4, 418, 320, 65, 3, 463, 1, 3767, 10, 35, 306, 177, 6322, 9, 118, 168, 14, 696, 48, 58, 14, 18, 18, 107, 725, 7, 5, 35, 390, 145, 993, 3, 116, 1, 749, 14, 145, 258, 4, 3, 3767, 1223, 87, 78, 39, 10, 394, 72, 6, 865, 4, 3, 1246, 1223, 87, 78, 662, 3, 463, 1, 3767, 4, 1223, 16, 35, 290, 306, 177, 1347, 17, 25346, 177, 3520]",1200.0,29167940,prognostic value circulating myeloblasts patients myelodysplastic syndromes,38,0.06631762652705062
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies.,American journal of hematology,Am. J. Hematol.,2017-12-23,"Venetoclax (VEN), a selective BCL2 inhibitor, has single-agent activity in relapsed and refractory (R/R) acute myeloid leukemia (AML), and efficacy in lower intensity combinations for treatment-nave elderly AML patients. VEN treatment combinations in R/R AML have not been previously reported. All R/R myeloid patients (including AML, myelodysplastic syndrome (MDS), and blastic plasmacytoid dendritic cell neoplasm (BPDCN)) treated with VEN combinations in the salvage setting were reviewed. Forty-three patients with median age 68 (range, 25-83) were treated for AML (91%), MDS (5%), or BPDCN (5%). Most (n=36, 84%) were  salvage-2 treatment status, including prior hypomethylating agent (HMA) in 77%. In combination with VEN, most patients received HMA therapy (n=31, 72%); eight (19%) received low-dose cytarabine (LDAC). Patients received a median of 2 treatment cycles (range, 1-4). Objective response was observed in 9 (21%) patients, including 2 complete responses (CR), 3 CRi, and 4 morphologic leukemia-free state (MLFS). Median survival was 3.0 months (range, 0.5-8.0), and estimated 6-month survival was 24%. Responses were observed in five (24%) of 21 patients with intermediate-risk cytogenetics, 3 (27%) of 11 IDH1/2-mutant, and 4 (50%) of 8 RUNX1-mutated patients. Two (20%) of 10 TP53-mutated patients responded; both had concurrent RUNX1 mutations. Of the 3 (15%) responding patients with adverse cytogenetics, all had concurrent RUNX1 mutations. Low-intensity chemotherapy, including HMAs or LDAC, in combination with VEN is a viable salvage option, even in multiply relapsed/refractory patients with AML, MDS, and BPDCN. Notable responses were identified in patients with diploid/intermediate cytogenetics, RUNX1, and/or IDH1/2 mutations.",Journal Article,759.0,68.0,Venetoclax VEN selective BCL2 inhibitor single-agent activity relapsed refractory R/R acute myeloid leukemia AML efficacy lower intensity combinations treatment-nave elderly AML patients VEN treatment combinations R/R AML previously reported R/R myeloid patients including AML myelodysplastic syndrome MDS blastic plasmacytoid dendritic neoplasm BPDCN treated VEN combinations salvage setting reviewed Forty-three patients median age 68 range 25-83 treated AML 91 MDS 5 BPDCN 5 n 36 84  salvage-2 treatment status including prior hypomethylating agent HMA 77 combination VEN patients received HMA therapy n 31 72 19 received low-dose cytarabine LDAC Patients received median 2 treatment cycles range 1-4 Objective response observed 9 21 patients including 2 complete responses CR 3 CRi 4 morphologic leukemia-free state MLFS Median survival 3.0 months range 0.5-8.0 estimated 6-month survival 24 Responses observed 24 21 patients intermediate-risk cytogenetics 3 27 11 IDH1/2-mutant 4 50 8 RUNX1-mutated patients 20 10 TP53-mutated patients responded concurrent RUNX1 3 15 responding patients adverse cytogenetics concurrent RUNX1 Low-intensity chemotherapy including HMAs LDAC combination VEN viable salvage option multiply relapsed/refractory patients AML MDS BPDCN Notable responses identified patients diploid/intermediate cytogenetics RUNX1 and/or IDH1/2,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4454, 32820, 8, 1094, 3214, 230, 71, 226, 420, 128, 4, 591, 2, 430, 668, 668, 286, 533, 329, 2, 209, 4, 280, 837, 1247, 9, 24, 2809, 1216, 329, 7, 32820, 24, 1247, 4, 668, 668, 329, 47, 44, 85, 373, 210, 62, 668, 668, 533, 7, 141, 329, 681, 1223, 2, 6529, 7978, 2464, 31, 2131, 8556, 73, 5, 32820, 1247, 4, 3, 992, 546, 11, 446, 1213, 169, 7, 5, 52, 89, 806, 184, 243, 852, 11, 73, 9, 329, 970, 1223, 33, 15, 8556, 33, 96, 78, 511, 874, 11, 749, 992, 18, 24, 156, 141, 324, 4931, 420, 7518, 4, 849, 4, 150, 5, 32820, 96, 7, 103, 7518, 36, 78, 456, 720, 659, 326, 103, 154, 61, 1855, 10714, 7, 103, 8, 52, 1, 18, 24, 410, 184, 14, 39, 461, 51, 10, 164, 4, 83, 239, 7, 141, 18, 236, 253, 684, 27, 6341, 2, 39, 2815, 2647, 115, 1309, 71760, 52, 25, 10, 27, 13, 53, 184, 13, 33, 66, 13, 2, 661, 49, 811, 25, 10, 259, 253, 11, 164, 4, 365, 259, 1, 239, 7, 5, 919, 43, 2510, 27, 428, 1, 175, 2662, 18, 620, 2, 39, 212, 1, 66, 6092, 1185, 7, 100, 179, 1, 79, 1206, 1185, 7, 2211, 110, 42, 750, 6092, 138, 1, 3, 27, 167, 3261, 7, 5, 290, 2510, 62, 42, 750, 6092, 138, 154, 837, 56, 141, 12688, 15, 10714, 4, 150, 5, 32820, 16, 8, 2663, 992, 1501, 871, 4, 14421, 591, 430, 7, 5, 329, 1223, 2, 8556, 4090, 253, 11, 108, 4, 7, 5, 6815, 919, 2510, 6092, 2, 15, 2662, 18, 138]",1627.0,29218851,Clinical experience BCL2-inhibitor venetoclax combination therapy relapsed refractory acute myeloid leukemia related myeloid malignancies,11,0.019197207678883072
Acute myeloid leukemia and myelodysplastic syndrome after adjuvant chemotherapy: A population-based study among older breast cancer patients.,Cancer,Cancer,2017-12-13,"Chemotherapy for early breast cancer is associated with a small risk of developing myelodysplastic syndrome (MDS) and/or acute myeloid leukemia (AML). The aim of this study was to determine the risk of developing AML or MDS after modern adjuvant chemotherapy in older breast cancer patients and to further define the risk of individual chemotherapy regimens. Patients diagnosed with stage I to III breast cancer from 2003 to 2009 were identified in the Surveillance, Epidemiology, and End Results-Medicare and Texas Cancer Registry-Medicare linked databases. The development of AML/MDS, chemotherapy use, and comorbidities were identified with International Classification of Diseases, Ninth Revision and Healthcare Common Procedure Coding System codes. Analyses included descriptive statistics, cumulative incidences, and Cox proportional hazards models to estimate the hazard of AML/MDS after adjustments for clinically relevant covariates. In all, 92,110 patients were included; after a median follow-up of 85 months, the overall rates per 1000 person-years were 0.65 for AML and 1.56 for MDS. Patients who received an anthracycline (A) or anthracycline and taxane (A+T) regimen were more likely to develop AML (hazard ratio [HR] for A, 1.70; 95% confidence interval [CI], 1.16-2.50; HR for A+T, 1.68; 95% CI, 1.22-2.30) or MDS (HR for A, 2.18; 95% CI, 1.70-2.80; HR for A+T, 1.62; 95% CI, 1.29-2.03) than patients who did not receive chemotherapy. Patients using docetaxel and cyclophosphamide (TC) were not at increased risk for AML or MDS. Adjuvant chemotherapy is associated with a small but significant increase in the risk of AML and MDS, especially with regimens that include A. Longer follow-up is needed to confirm that risk is not increased with the recently adopted TC regimen. Cancer 2018;124:899-906.  2017 American Cancer Society.",Journal Article,769.0,7.0,"Chemotherapy early breast associated small risk developing myelodysplastic syndrome MDS and/or acute myeloid leukemia AML aim determine risk developing AML MDS modern adjuvant chemotherapy older breast patients define risk individual chemotherapy regimens Patients diagnosed stage III breast 2003 2009 identified Surveillance Epidemiology End Results-Medicare Texas Registry-Medicare linked databases development AML/MDS chemotherapy use comorbidities identified International Classification Diseases Ninth Revision Healthcare Common Procedure Coding codes included descriptive statistics cumulative incidences Cox proportional hazards models estimate hazard AML/MDS adjustments clinically relevant covariates 92,110 patients included median follow-up 85 months overall rates 1000 person-years 0.65 AML 1.56 MDS Patients received anthracycline anthracycline taxane A+T regimen likely develop AML hazard ratio HR 1.70 95 confidence interval CI 1.16-2.50 HR A+T 1.68 95 CI 1.22-2.30 MDS HR 2.18 95 CI 1.70-2.80 HR A+T 1.62 95 CI 1.29-2.03 patients receive chemotherapy Patients docetaxel cyclophosphamide TC increased risk AML MDS Adjuvant chemotherapy associated small significant increase risk AML MDS especially regimens include Longer follow-up needed confirm risk increased recently adopted TC regimen 2018 124:899-906  2017 American Society",1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[56, 9, 191, 12, 16, 41, 5, 8, 302, 43, 1, 931, 681, 1223, 2, 15, 286, 533, 329, 3, 1130, 1, 26, 45, 10, 6, 223, 3, 43, 1, 931, 329, 15, 1223, 50, 2366, 249, 56, 4, 434, 12, 7, 2, 6, 195, 1107, 3, 43, 1, 797, 56, 472, 7, 265, 5, 82, 70, 6, 316, 12, 29, 1522, 6, 1238, 11, 108, 4, 3, 617, 1284, 2, 396, 99, 1378, 2, 2738, 12, 1608, 1378, 1199, 2348, 3, 193, 1, 329, 1223, 56, 119, 2, 1909, 11, 108, 5, 944, 947, 1, 1342, 13544, 5646, 2, 2819, 186, 1299, 3097, 398, 5271, 318, 159, 3778, 3065, 967, 3981, 2, 418, 831, 1017, 274, 6, 1191, 3, 360, 1, 329, 1223, 50, 6017, 9, 505, 867, 2489, 4, 62, 937, 3129, 7, 11, 159, 50, 8, 52, 166, 126, 1, 772, 53, 3, 63, 151, 379, 2345, 2719, 60, 11, 13, 556, 9, 329, 2, 14, 664, 9, 1223, 7, 54, 103, 35, 2044, 8, 15, 2044, 2, 1715, 8, 102, 477, 11, 80, 322, 6, 690, 329, 360, 197, 168, 9, 8, 14, 431, 48, 307, 268, 58, 14, 245, 18, 212, 168, 9, 8, 102, 14, 806, 48, 58, 14, 350, 18, 201, 15, 1223, 168, 9, 8, 18, 203, 48, 58, 14, 431, 18, 493, 168, 9, 8, 102, 14, 744, 48, 58, 14, 462, 18, 680, 76, 7, 54, 205, 44, 560, 56, 7, 75, 621, 2, 1112, 3072, 11, 44, 28, 101, 43, 9, 329, 15, 1223, 249, 56, 16, 41, 5, 8, 302, 84, 93, 344, 4, 3, 43, 1, 329, 2, 1223, 1093, 5, 472, 17, 643, 8, 589, 166, 126, 16, 575, 6, 1843, 17, 43, 16, 44, 101, 5, 3, 761, 4457, 3072, 477, 12, 2982, 2834, 16485, 8993, 2206, 1759, 597, 12, 1174]",1743.0,29236294,Acute myeloid leukemia myelodysplastic syndrome adjuvant chemotherapy population-based older breast patients,0,0.0
Reduced-Intensity Allogeneic Transplant for Acute Myeloid Leukemia and Myelodysplastic Syndrome Using Combined CD34-Selected Haploidentical Graft and a Single Umbilical Cord Unit Compared with Matched Unrelated Donor Stem Cells in Older Adults.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2017-12-27,"Haplo/cord transplantation combines an umbilical cord blood (UCB) graft with CD34-selected haploidentical cells and results in rapid hematopoietic recovery followed by durable UCB engraftment. We compared outcomes of transplants in older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) who received either HLA-matched unrelated donor (MUD) cells or haplo/cord grafts. Between 2007 and 2013, 109 adults ages 50 and older underwent similar reduced-intensity conditioning with fludarabine and melphalan and antibody-mediated T cell depletion for AML (n=83) or high-risk MDS (n=26) followed by either a MUD (n=68) or haplo/cord (n=41) graft. Patient characteristics were similar for each graft source except for more minority patients receiving a haplo/cord transplant (P=.01). One half of the AML patients were not in remission. Two-year progression-free survival (PFS), overall survival (OS), and graft-versus-host disease-free relapse-free survival were 38%, 48%, and 32.1% for MUD and 33%, 48%, and 33.8% for haplo/cord transplants (P=.62 for PFS; P=.97 for OS; P=.84), respectively. Acute grades II to IV and chronic graft-versus-host-disease rates did not differ at 19.5% and 4.9% in haplo/cord compared with 25% and 7.4% after MUD (P=.53 and P=.62, respectively). Multivariate analysis confirmed no significant differences in transplant outcomes by donor type. Haplo/cord reduced-intensity transplantation achieves similar outcomes relative to MUD in older AML and MDS patients, making this a promising option for those without matched donors.",Comparative Study,755.0,7.0,Haplo/cord transplantation combines umbilical cord blood UCB graft CD34-selected haploidentical rapid hematopoietic recovery followed durable UCB engraftment compared outcomes transplants older patients acute myeloid leukemia AML high-risk myelodysplastic syndromes MDS received HLA-matched unrelated donor MUD haplo/cord grafts 2007 2013 109 adults ages 50 older underwent similar reduced-intensity conditioning fludarabine melphalan antibody-mediated depletion AML n 83 high-risk MDS n 26 followed MUD n 68 haplo/cord n 41 graft Patient characteristics similar graft source minority patients receiving haplo/cord transplant P .01 half AML patients remission Two-year progression-free survival PFS overall survival OS graft-versus-host disease-free relapse-free survival 38 48 32.1 MUD 33 48 33.8 haplo/cord transplants P .62 PFS P .97 OS P= .84 respectively Acute grades II IV chronic graft-versus-host-disease rates differ 19.5 4.9 haplo/cord compared 25 7.4 MUD P .53 P .62 respectively Multivariate confirmed significant differences transplant outcomes donor type Haplo/cord reduced-intensity transplantation achieves similar outcomes relative MUD older AML MDS patients making promising option matched donors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6584, 1885, 497, 6705, 35, 5998, 1885, 315, 4056, 1599, 5, 2215, 715, 5802, 37, 2, 99, 4, 1321, 1007, 1602, 370, 20, 1480, 4056, 2881, 21, 72, 123, 1, 4016, 4, 434, 7, 5, 286, 533, 329, 15, 64, 43, 2040, 1223, 54, 103, 361, 1160, 655, 2092, 1488, 7070, 37, 15, 6584, 1885, 4713, 59, 1307, 2, 1346, 3486, 857, 2165, 212, 2, 434, 208, 288, 405, 837, 1933, 5, 2027, 2, 2370, 2, 548, 517, 102, 31, 2286, 9, 329, 78, 852, 15, 64, 43, 1223, 78, 432, 370, 20, 361, 8, 7070, 78, 806, 15, 6584, 1885, 78, 605, 1599, 69, 374, 11, 288, 9, 296, 1599, 2353, 2187, 9, 80, 2652, 7, 357, 8, 6584, 1885, 941, 19, 355, 104, 1303, 1, 3, 329, 7, 11, 44, 4, 734, 100, 111, 91, 115, 25, 300, 63, 25, 118, 2, 1599, 185, 1204, 34, 115, 429, 115, 25, 11, 519, 576, 2, 531, 14, 9, 7070, 2, 466, 576, 2, 466, 66, 9, 6584, 1885, 4016, 19, 744, 9, 300, 19, 1015, 9, 118, 19, 874, 106, 286, 2276, 215, 6, 478, 2, 442, 1599, 185, 1204, 34, 151, 205, 44, 1505, 28, 326, 33, 2, 39, 83, 4, 6584, 1885, 72, 5, 243, 2, 67, 39, 50, 7070, 19, 699, 2, 19, 744, 106, 331, 65, 557, 77, 93, 362, 4, 941, 123, 20, 1488, 267, 6584, 1885, 405, 837, 497, 6358, 288, 123, 580, 6, 7070, 4, 434, 329, 2, 1223, 7, 1079, 26, 8, 721, 1501, 9, 135, 187, 655, 2344]",1505.0,29288821,Reduced-Intensity Allogeneic Transplant Acute Myeloid Leukemia Myelodysplastic Syndrome Combined CD34-Selected Haploidentical Graft Single Umbilical Cord Unit Compared Matched Unrelated Donor Stem Older Adults,0,0.0
Management of older adults with myelodysplastic syndromes (MDS).,Journal of geriatric oncology,J Geriatr Oncol,2017-12-29,"The myelodysplastic syndromes (MDS) are a varied group of hematologic neoplasms that lead to bone marrow failure, and also carry a risk of progression to acute myeloid leukemia. Patients with MDS suffer significant impairments to both their quality of life and survival. Age is the dominant risk factor for the development of MDS, with a median age at diagnosis over 70years. Consequently, patients with MDS frequently have concurrent comorbidities and/or frailty which may be coincident or related to the disease itself. Disease characteristics, degree of comorbidity, and presence of frailty all impact prognosis. Treatment of MDS focuses on supportive care, with disease-modifying approaches (chemotherapy and allogeneic hematopoietic cell transplantation) reserved for fit patients with high-risk disease. Care of patients with MDS requires understanding the disease in the context of an older population, and tailoring approaches to both disease risk and patient suitability for therapy.",Journal Article,753.0,3.0,myelodysplastic syndromes MDS varied group hematologic neoplasms lead bone marrow failure carry risk progression acute myeloid leukemia Patients MDS suffer significant impairments quality life survival Age dominant risk factor development MDS median age diagnosis 70years Consequently patients MDS frequently concurrent comorbidities and/or frailty coincident related disease Disease characteristics degree comorbidity presence frailty impact prognosis Treatment MDS focuses supportive care disease-modifying approaches chemotherapy allogeneic hematopoietic transplantation reserved fit patients high-risk disease Care patients MDS requires understanding disease context older population tailoring approaches disease risk patient suitability therapy,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 2040, 1223, 32, 8, 2051, 87, 1, 813, 1179, 17, 1122, 6, 581, 496, 2, 120, 3542, 8, 43, 1, 91, 6, 286, 533, 7, 5, 1223, 6506, 93, 6948, 6, 110, 136, 372, 1, 358, 2, 25, 89, 16, 3, 2156, 43, 161, 9, 3, 193, 1, 1223, 5, 8, 52, 89, 28, 147, 252, 32318, 3244, 7, 5, 1223, 746, 47, 750, 1909, 2, 15, 5289, 92, 68, 40, 9955, 15, 139, 6, 3, 34, 4045, 34, 374, 1444, 1, 1879, 2, 463, 1, 5289, 62, 345, 356, 24, 1, 1223, 3026, 23, 1877, 165, 5, 34, 4898, 611, 56, 2, 1063, 1007, 31, 497, 6468, 9, 2975, 7, 5, 64, 43, 34, 165, 1, 7, 5, 1223, 1706, 612, 3, 34, 4, 3, 1533, 1, 35, 434, 266, 2, 7101, 611, 6, 110, 34, 43, 2, 69, 10163, 9, 36]",944.0,29290596,Management older adults myelodysplastic syndromes MDS,8,0.013961605584642234
CD34<sup>+</sup> Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2018-01-02,"Reduced-intensity conditioning (RIC) and T cell depletion (TCD) through CD34<sup>+</sup> cell selection without the use of post-transplantation immunosuppression are 2 strategies used to reduce nonrelapse mortality (NRM) in older patients after allogeneic hematopoietic cell transplantation (allo-HCT). To compare the efficacy of the RIC and TCD approaches, we evaluated the outcomes of patients age >50 years with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) who underwent allo-HCT from an HLA-matched donor with one of these strategies. Baseline characteristics were comparable in the patients receiving TCD (n=204) and those receiving RIC (n=151), except for a higher proportion of unrelated donors (68% versus 40%; P<.001) and a higher comorbidity burden (Hematopoietic Cell Transplantation Comorbidity Index [HCT-CI] 3: 51% versus 38%; P<.001) in the TCD cohort. Analysis of outcomes at 3 years showed a higher chronic graft-versus-host disease (GVHD)/relapse-free survival (CRFS) (51% versus 7%; P<.001), lower incidences of grade II-IV acute GVHD (18% versus 46% at day +180) and chronic GVHD (6% versus 55% at 3 years; P<.001), and a lower incidence of relapse (19% versus 33% at 3 years; P=.001) in the TCD group compared with the RIC group. Relapse-free survival (RFS), overall survival (OS), and NRM were similar in the 2 groups. Combining transplantation approach (RIC versus TCD) and comorbidity burden (HCT-CI 0-2 versus 3), patients with an HCT-CI score of 0-2 seemed to benefit from the TCD approach. In conclusion, in this retrospective study, the use of a CD34<sup>+</sup> cell-selected graft and a myeloablative conditioning regimen was associated with higher CRFS and similar RFS and OS compared with unmodified allo-RIC in patients age >50 years with AML and MDS.",Comparative Study,749.0,4.0,Reduced-intensity conditioning RIC depletion TCD CD34 sup /sup selection use post-transplantation immunosuppression 2 strategies reduce nonrelapse mortality NRM older patients allogeneic hematopoietic transplantation allo-HCT compare efficacy RIC TCD approaches evaluated outcomes patients age 50 years acute myelogenous leukemia AML myelodysplastic syndrome MDS underwent allo-HCT HLA-matched donor strategies Baseline characteristics comparable patients receiving TCD n 204 receiving RIC n 151 higher proportion unrelated donors 68 versus 40 P .001 higher comorbidity burden Hematopoietic Transplantation Comorbidity Index HCT-CI 3 51 versus 38 P .001 TCD cohort outcomes 3 years showed higher chronic graft-versus-host disease GVHD /relapse-free survival CRFS 51 versus 7 P .001 lower incidences grade II-IV acute GVHD 18 versus 46 day +180 chronic GVHD 6 versus 55 3 years P .001 lower incidence relapse 19 versus 33 3 years P .001 TCD group compared RIC group Relapse-free survival RFS overall survival OS NRM similar 2 groups Combining transplantation approach RIC versus TCD comorbidity burden HCT-CI 0-2 versus 3 patients HCT-CI score 0-2 benefit TCD approach retrospective use CD34 sup /sup cell-selected graft myeloablative conditioning regimen associated higher CRFS similar RFS OS compared unmodified allo-RIC patients age 50 years AML MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[405, 837, 1933, 3365, 2, 102, 31, 2286, 8827, 298, 2215, 172, 172, 31, 881, 187, 3, 119, 1, 539, 497, 3646, 32, 18, 422, 95, 6, 969, 4640, 282, 4296, 4, 434, 7, 50, 1063, 1007, 31, 497, 2564, 1085, 6, 932, 3, 209, 1, 3, 3365, 2, 8827, 611, 21, 194, 3, 123, 1, 7, 89, 212, 60, 5, 286, 2194, 329, 2, 681, 1223, 54, 208, 2564, 1085, 29, 35, 1160, 655, 1488, 5, 104, 1, 46, 422, 330, 374, 11, 1279, 4, 3, 7, 357, 8827, 78, 5996, 2, 135, 357, 3365, 78, 5075, 2187, 9, 8, 142, 920, 1, 2092, 2344, 806, 185, 327, 19, 144, 2, 8, 142, 1879, 892, 1007, 31, 497, 1879, 558, 1085, 58, 2608, 725, 185, 519, 19, 144, 4, 3, 8827, 180, 65, 1, 123, 28, 27, 60, 224, 8, 142, 442, 1599, 185, 1204, 34, 1562, 429, 115, 25, 21779, 725, 185, 67, 19, 144, 280, 3981, 1, 88, 215, 478, 286, 1562, 203, 185, 641, 28, 218, 3172, 2, 442, 1562, 49, 185, 614, 28, 27, 60, 19, 144, 2, 8, 280, 287, 1, 429, 326, 185, 466, 28, 27, 60, 19, 144, 4, 3, 8827, 87, 72, 5, 3, 3365, 87, 429, 115, 25, 1272, 63, 25, 118, 2, 4296, 11, 288, 4, 3, 18, 271, 1525, 497, 353, 3365, 185, 8827, 2, 1879, 892, 1085, 58, 13, 18, 185, 2608, 7, 5, 35, 1085, 58, 368, 1, 13, 18, 5025, 6, 247, 29, 3, 8827, 353, 4, 1221, 4, 26, 459, 45, 3, 119, 1, 8, 2215, 172, 172, 31, 715, 1599, 2, 8, 3246, 1933, 477, 10, 41, 5, 142, 21779, 2, 288, 1272, 2, 118, 72, 5, 10424, 2564, 3365, 4, 7, 89, 212, 60, 5, 329, 2, 1223]",1701.0,29305194,CD34 sup /sup Selection versus Reduced-Intensity Conditioning Unmodified Grafts Allogeneic Hematopoietic Transplantation Patients Age 50 Years Acute Myelogenous Leukemia Myelodysplastic Syndrome,0,0.0
The bone-marrow niche in MDS and MGUS: implications for AML and MM.,Nature reviews. Clinical oncology,Nat Rev Clin Oncol,2018-01-09,"Several haematological malignancies, including multiple myeloma (MM) and acute myeloid leukaemia (AML), have well-defined precursor states that precede the development of overt cancer. MM is almost always preceded by monoclonal gammopathy of undetermined significance (MGUS), and at least a quarter of all patients with myelodysplastic syndromes (MDS) have disease that evolves into AML. In turn, MDS are frequently anteceded by clonal haematopoiesis of indeterminate potential (CHIP). The acquisition of additional genetic and epigenetic alterations over time clearly influences the increasingly unstable and aggressive behaviour of neoplastic haematopoietic clones; however, perturbations in the bone-marrow microenvironment are increasingly recognized to have key roles in initiating and supporting oncogenesis. In this Review, we focus on the concept that the haematopoietic neoplasia-microenvironment relationship is an intimate rapport between two partners, provide an overview of the evidence supporting a role for the bone-marrow niche in promoting neoplasia, and discuss the potential for niche-specific therapeutic targets.",Journal Article,742.0,20.0,haematological malignancies including multiple myeloma MM acute myeloid leukaemia AML well-defined precursor states precede development overt MM preceded monoclonal gammopathy undetermined significance MGUS quarter patients myelodysplastic syndromes MDS disease evolves AML turn MDS frequently anteceded clonal haematopoiesis indeterminate potential CHIP acquisition additional genetic epigenetic alterations time clearly influences increasingly unstable aggressive behaviour neoplastic haematopoietic clones perturbations bone-marrow microenvironment increasingly recognized key roles initiating supporting oncogenesis Review focus concept haematopoietic neoplasia-microenvironment relationship intimate rapport partners provide overview evidence supporting role bone-marrow niche promoting neoplasia discuss potential niche-specific therapeutic targets,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,"[392, 5143, 441, 141, 232, 321, 2, 286, 533, 2001, 329, 47, 149, 395, 2765, 907, 17, 14074, 3, 193, 1, 7192, 12, 321, 16, 2214, 3763, 6083, 20, 848, 5334, 1, 5206, 724, 3226, 2, 28, 506, 8, 8034, 1, 62, 7, 5, 2040, 1223, 47, 34, 17, 10413, 237, 329, 4, 3854, 1223, 32, 746, 71930, 20, 1946, 25245, 1, 5167, 174, 4222, 3, 3405, 1, 402, 336, 2, 1418, 593, 252, 98, 2536, 3859, 3, 1635, 7705, 2, 571, 8173, 1, 2000, 7274, 2749, 137, 7013, 4, 3, 3417, 581, 995, 32, 1635, 1904, 6, 47, 825, 1790, 4, 2637, 2, 1912, 4503, 4, 26, 206, 21, 1222, 23, 3, 2545, 17, 3, 7274, 2298, 995, 858, 16, 35, 14894, 50803, 59, 100, 4005, 377, 35, 2901, 1, 3, 241, 1912, 8, 200, 9, 3, 3417, 581, 4385, 4, 2388, 2298, 2, 1139, 3, 174, 9, 4385, 112, 189, 637]",1085.0,29311715,bone-marrow niche MDS MGUS implications AML MM,368,0.6422338568935427
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus <sup>131</sup>I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2018-01-22,"Purpose SWOG S0016 was a phase III randomized study that compared the safety and efficacy of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) with CHOP-RIT (CHOP followed by consolidation with iodine-133-tositumomab radioimmunotherapy) for previously untreated patients with follicular lymphoma. Understanding the long-term outcome of patients provides a benchmark for novel treatment regimens for FL. Patients and Methods Between 2001 and 2008, 531 previously untreated patients with FL were randomly assigned to receive either six cycles of R-CHOP or six cycles of CHOP-RIT. Patients with advanced-stage disease (bulky stage II, III, or IV) of any pathologic grade (1, 2, or 3) were eligible. Results After a median follow-up of 10.3 years, 10-year estimates of progression-free and overall survival were 49% and 78% among all patients, respectively. Patients in the CHOP-RIT arm had significantly better 10-year progression-free survival compared with patients in the R-CHOP arm (56% v 42%; P = .01), but 10-year overall survival was not different between the two arms (75% v 81%; P = .13). There was no significant difference between the CHOP-RIT and R-CHOP arms in regard to incidence of second malignancies (15.1% v 16.1%; P = .81) or myelodysplastic syndrome or acute myeloid leukemia (4.9% v 1.8%; P = .058). The estimated 10-year cumulative incidences of death resulting from second malignancies were not different (7.1% v 3.2%; P = .16), but cumulative incidence of death resulting from myelodysplastic syndrome or acute myeloid leukemia was higher in the CHOP-RIT arm compared with the R-CHOP arm (4% v 0.9%; P = .02). Conclusion Given these outstanding outcomes, immunochemotherapy should remain the standard induction approach for patients with high-risk FL until long-term follow-up of alternative approaches demonstrates superiority.","Clinical Trial, Phase III",729.0,19.0,Purpose SWOG S0016 phase III randomized compared safety efficacy R-CHOP rituximab plus cyclophosphamide doxorubicin vincristine prednisone CHOP-RIT CHOP followed consolidation iodine-133-tositumomab radioimmunotherapy previously untreated patients follicular lymphoma Understanding long-term outcome patients provides benchmark novel treatment regimens FL Patients Methods 2001 2008 531 previously untreated patients FL randomly assigned receive cycles R-CHOP cycles CHOP-RIT Patients advanced-stage disease bulky stage II III IV pathologic grade 1 2 3 eligible median follow-up 10.3 years 10-year estimates progression-free overall survival 49 78 patients respectively Patients CHOP-RIT arm significantly better 10-year progression-free survival compared patients R-CHOP arm 56 v 42 P .01 10-year overall survival different arms 75 v 81 P .13 significant difference CHOP-RIT R-CHOP arms regard incidence second malignancies 15.1 v 16.1 P .81 myelodysplastic syndrome acute myeloid leukemia 4.9 v 1.8 P .058 estimated 10-year cumulative incidences death resulting second malignancies different 7.1 v 3.2 P .16 cumulative incidence death resulting myelodysplastic syndrome acute myeloid leukemia higher CHOP-RIT arm compared R-CHOP arm 4 v 0.9 P .02 Given outstanding outcomes immunochemotherapy remain standard induction approach patients high-risk FL long-term follow-up alternative approaches demonstrates superiority,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[743, 5462, 50825, 10, 8, 124, 316, 384, 45, 17, 72, 3, 367, 2, 209, 1, 668, 2907, 855, 349, 1112, 856, 2132, 2, 1979, 5, 2907, 6313, 2907, 370, 20, 2173, 5, 4287, 5026, 13227, 5862, 9, 373, 1278, 7, 5, 1974, 612, 3, 319, 337, 228, 1, 7, 777, 8, 7330, 9, 229, 24, 472, 9, 2633, 7, 2, 636, 59, 1758, 2, 1375, 11308, 373, 1278, 7, 5, 2633, 11, 1108, 896, 6, 560, 361, 437, 410, 1, 668, 2907, 15, 437, 410, 1, 2907, 6313, 7, 5, 131, 82, 34, 4112, 82, 215, 316, 15, 478, 1, 500, 510, 88, 14, 18, 15, 27, 11, 625, 99, 50, 8, 52, 166, 126, 1, 79, 27, 60, 79, 111, 1423, 1, 91, 115, 2, 63, 25, 11, 739, 2, 833, 107, 62, 7, 106, 7, 4, 3, 2907, 6313, 475, 42, 97, 380, 79, 111, 91, 115, 25, 72, 5, 7, 4, 3, 668, 2907, 475, 664, 603, 595, 19, 355, 84, 79, 111, 63, 25, 10, 44, 338, 59, 3, 100, 1335, 481, 603, 865, 19, 233, 125, 10, 77, 93, 523, 59, 3, 2907, 6313, 2, 668, 2907, 1335, 4, 2539, 6, 287, 1, 419, 441, 167, 14, 603, 245, 14, 19, 865, 15, 681, 15, 286, 533, 39, 83, 603, 14, 66, 19, 10189, 3, 661, 79, 111, 967, 3981, 1, 273, 1113, 29, 419, 441, 11, 44, 338, 67, 14, 603, 27, 18, 19, 245, 84, 967, 287, 1, 273, 1113, 29, 681, 15, 286, 533, 10, 142, 4, 3, 2907, 6313, 475, 72, 5, 3, 668, 2907, 475, 39, 603, 13, 83, 19, 588, 1221, 447, 46, 14565, 123, 10633, 257, 918, 3, 260, 504, 353, 9, 7, 5, 64, 43, 2633, 1100, 319, 337, 166, 126, 1, 1091, 611, 1902, 5233]",1749.0,29356608,Continued Excellent Outcomes Previously Untreated Patients Follicular Lymphoma Treatment CHOP Plus Rituximab CHOP Plus sup 131 /sup I-Tositumomab Long-Term Follow-Up Phase III Randomized SWOG-S0016,1,0.0017452006980802793
Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial.,The Lancet. Haematology,Lancet Haematol,2018-01-26,"Treatment options for thrombocytopenia in myelodysplastic syndromes are scarce. As described previously in a randomised phase 2 study (n=250), 58 weeks of romiplostim treatment in patients with International Prognostic Scoring System (IPSS)-defined lower-risk (low-risk or intermediate-1 risk) myelodysplastic syndromes led to reduced platelet transfusions (p<00001) and increased International Working Group-defined haematological improvement-platelet rates (p<00001) versus placebo. However, the study drug was discontinued because of the potential risk for progression to or incorrect diagnosis or treatment for acute myeloid leukaemia, based on an acute myeloid leukaemia interim hazard ratio (HR) of 25; the subsequent 58-week acute myeloid leukaemia HR was 12 (95% CI 04-38). This study is a 5-year follow-up of a phase 2, multicentre, double-blind trial of romiplostim treatment in patients with lower-risk myelodysplastic syndromes. Eligible patients were recruited at 109 centres in North America, Europe, Russia, and Australia, were aged 18-90 years, and had platelets of 2010<sup>9</sup> per L or less with or without a history of bleeding or 5010<sup>9</sup> platelets per L or less with a history of bleeding. Patients were randomly assigned by interactive voice response system with stratification by baseline platelet count (2010<sup>9</sup> per L or <2010<sup>9</sup> per L) and IPSS risk (low or intermediate-1) to receive either placebo or 750 g romiplostim subcutaneously once per week for 58 weeks. The primary outcomes for this long-term follow-up were survival and progression to acute myeloid leukaemia. Progression to acute myeloid leukaemia was defined as either 20% blasts or more after 4 weeks from romiplostim discontinuation; as per pathology; or by initiation of antileukaemia treatment. The primary outcome was assessed per protocol in all patients with available data. This study is registered with ClinicalTrials.gov, NCT00614523. Patients were recruited from July 21, 2008, to Dec 16, 2010. 167 patients were assigned to receive romiplostim treatment and 83 were assigned to receive placebo. 210 (84%) of 250 patients entered the 5-year long-term follow-up (139 patients in the romiplostim group and 83 in the placebo group). At the end of follow-up, proportions of patients with acute myeloid leukaemia (20 [12%] of 167 in the romiplostim group vs nine [11%] of 83 in the placebo group; HR 106 [95% CI 048-233]; p=088) and proportions who died (93 [56%] vs 54 [54%]; HR 103 [072-147]; p=089) were not significantly different between the two groups. Following the decision to stop the study drug, 5-year long-term follow-up HRs for transformation to acute myeloid leukaemia and HRs for death did not differ between patients treated with romiplostim and those treated with placebo, indicating that use of romiplostim is probably not associated with any increased risk of acute myeloid leukaemia or death, despite initial concerns. Amgen Inc.","Clinical Trial, Phase II",725.0,12.0,Treatment options thrombocytopenia myelodysplastic syndromes scarce described previously randomised phase 2 n=250 58 weeks romiplostim treatment patients International Prognostic Scoring IPSS -defined lower-risk low-risk intermediate-1 risk myelodysplastic syndromes led reduced platelet transfusions p 00001 increased International Working Group-defined haematological improvement-platelet rates p 00001 versus placebo drug discontinued potential risk progression incorrect diagnosis treatment acute myeloid leukaemia based acute myeloid leukaemia interim hazard ratio HR 25 subsequent 58-week acute myeloid leukaemia HR 12 95 CI 04-38 5-year follow-up phase 2 multicentre double-blind trial romiplostim treatment patients lower-risk myelodysplastic syndromes Eligible patients recruited 109 centres North America Europe Russia Australia aged 18-90 years platelets 20 10 sup 9 /sup L history bleeding 50 10 sup 9 /sup platelets L history bleeding Patients randomly assigned interactive voice response stratification baseline platelet count 20 10 sup 9 /sup L 20 10 sup 9 /sup L IPSS risk low intermediate-1 receive placebo 750 g romiplostim subcutaneously week 58 weeks primary outcomes long-term follow-up survival progression acute myeloid leukaemia Progression acute myeloid leukaemia defined 20 blasts 4 weeks romiplostim discontinuation pathology initiation antileukaemia treatment primary outcome assessed protocol patients available registered ClinicalTrials.gov NCT00614523 Patients recruited July 21 2008 Dec 16 2010 167 patients assigned receive romiplostim treatment 83 assigned receive placebo 210 84 250 patients entered 5-year long-term follow-up 139 patients romiplostim group 83 placebo group end follow-up proportions patients acute myeloid leukaemia 20 12 167 romiplostim group vs 11 83 placebo group HR 106 95 CI 048-233 p=088 proportions died 93 56 vs 54 54 HR 103 072-147 p=089 significantly different groups Following decision stop drug 5-year long-term follow-up HRs transformation acute myeloid leukaemia HRs death differ patients treated romiplostim treated placebo indicating use romiplostim probably associated increased risk acute myeloid leukaemia death despite initial concerns Amgen,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[24, 838, 9, 1340, 4, 2040, 32, 8113, 22, 1027, 373, 4, 8, 2827, 124, 18, 45, 78, 2039, 717, 244, 1, 19391, 24, 4, 7, 5, 944, 177, 2504, 398, 8751, 395, 280, 43, 154, 43, 15, 919, 14, 43, 2040, 836, 6, 405, 1596, 4987, 19, 4599, 2, 101, 944, 2644, 87, 395, 5143, 767, 1596, 151, 19, 4599, 185, 619, 137, 3, 45, 234, 10, 2402, 408, 1, 3, 174, 43, 9, 91, 6, 15, 11774, 147, 15, 24, 9, 286, 533, 2001, 90, 23, 35, 286, 533, 2001, 2914, 360, 197, 168, 1, 17499, 3, 706, 717, 647, 286, 533, 2001, 168, 10, 14363, 48, 58, 20759, 23912, 26, 45, 16, 8, 33, 111, 166, 126, 1, 8, 124, 18, 5761, 1627, 3142, 160, 1, 19391, 24, 4, 7, 5, 280, 43, 2040, 625, 7, 11, 2619, 28, 3486, 4496, 4, 2669, 4010, 3934, 23377, 2, 6978, 11, 1032, 203, 424, 60, 2, 42, 4407, 1, 179, 79, 172, 83, 172, 379, 805, 15, 299, 5, 15, 187, 8, 532, 1, 2294, 15, 212, 79, 172, 83, 172, 4407, 379, 805, 15, 299, 5, 8, 532, 1, 2294, 7, 11, 1108, 896, 20, 4750, 6284, 51, 398, 5, 1541, 20, 330, 1596, 1276, 8076, 79, 172, 83, 172, 379, 805, 15, 179, 79, 172, 83, 172, 379, 805, 2, 8751, 43, 154, 15, 919, 14, 6, 560, 361, 619, 15, 4506, 3802, 19391, 3928, 1059, 379, 647, 9, 717, 244, 3, 86, 123, 9, 26, 319, 337, 166, 126, 11, 25, 2, 91, 6, 286, 533, 2001, 91, 6, 286, 533, 2001, 10, 395, 22, 361, 179, 2438, 15, 80, 50, 39, 244, 29, 19391, 2007, 22, 379, 1117, 15, 20, 1118, 1, 41975, 24, 3, 86, 228, 10, 275, 379, 1182, 4, 62, 7, 5, 390, 74, 26, 45, 16, 1653, 5, 1252, 1239, 72084, 7, 11, 2619, 29, 2066, 239, 1375, 6, 8702, 245, 1120, 5431, 7, 11, 896, 6, 560, 19391, 24, 2, 852, 11, 896, 6, 560, 619, 5376, 874, 1, 2039, 7, 2836, 3, 33, 111, 319, 337, 166, 126, 4929, 7, 4, 3, 19391, 87, 2, 852, 4, 3, 619, 87, 28, 3, 396, 1, 166, 126, 4117, 1, 7, 5, 286, 533, 2001, 179, 133, 1, 5431, 4, 3, 19391, 87, 105, 762, 175, 1, 852, 4, 3, 619, 87, 168, 23926, 48, 58, 25282, 72085, 19, 18601, 2, 4117, 54, 1016, 966, 664, 105, 667, 667, 168, 19351, 16580, 41067, 19, 18072, 11, 44, 97, 338, 59, 3, 100, 271, 366, 3, 948, 6, 7142, 3, 45, 234, 33, 111, 319, 337, 166, 126, 2733, 9, 1392, 6, 286, 533, 2001, 2, 2733, 9, 273, 205, 44, 1505, 59, 7, 73, 5, 19391, 2, 135, 73, 5, 619, 1716, 17, 119, 1, 19391, 16, 4061, 44, 41, 5, 500, 101, 43, 1, 286, 533, 2001, 15, 273, 550, 388, 2061, 16736, 3479]",2855.0,29396092,Long-term follow-up 5 years risk leukaemic progression thrombocytopenic patients lower-risk myelodysplastic syndromes treated romiplostim placebo randomised double-blind trial,0,0.0
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.,Gynecologic oncology,Gynecol. Oncol.,2018-02-04,"Niraparib is an oral poly(ADP ribose) polymerase (PARP) inhibitor that is currently approved by the United States Food and Drug Administration (US FDA) as well as recently approved by the European Medicines Agency (EMA) for the maintenance treatment of women with recurrent ovarian cancer who are in complete or partial response to platinum-based chemotherapy. The mechanisms of action of niraparib include inhibition of PARP enzymatic activity as well as increased formation of PARP-DNA complexes through ""trapping"" the PARP enzyme on damaged DNA. Phase I and III studies have demonstrated activity and benefit of niraparib in both BRCA mutated (BRCAm) and BRCA wild-type (BRCAwt) cancers. Phase I testing of niraparib established the maximally tolerated dose of 300mg by mouth (PO) daily, and the phase 3 ENGOT-OV16/NOVA study demonstrated the benefit of niraparib maintenance therapy compared to placebo after completion of and response to platinum-based chemotherapy in both BRCAm and BRCAwt ovarian cancer patient populations. Toxicities seen with niraparib include hematologic, gastrointestinal, fatigue, and cardiovascular. Hematologic toxicities include thrombocytopenia, anemia, neutropenia and leukopenia; upfront dose modification to 200mg niraparib for patients with baseline weight of 77kg and/or baseline platelets of 150,000K/uL should be considered to avoid significant hematologic toxicity, especially thrombocytopenia, based on recent analyses of the ENGOT-OV16/NOVA study. Cardiovascular toxicities include hypertension, tachycardia, as well as palpitations, and patients should be monitored for hypertension. PARP inhibitors have been associated with low risks of acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS), and the overall risk of AML and MDS is 0.9% of all patients treated with niraparib. Niraparib testing is ongoing in newly diagnosed ovarian cancer patients as maintenance therapy following completion of platinum-based chemotherapy, in BRCAwt cancers as treatment, as well as in combinations with other biologic drugs such as immunotherapy and anti-angiogenic agents.",Journal Article,716.0,16.0,"Niraparib oral poly ADP ribose polymerase PARP inhibitor currently approved United States Food Drug Administration FDA recently approved European Medicines Agency EMA maintenance treatment women recurrent ovarian complete partial response platinum-based chemotherapy mechanisms action niraparib include inhibition PARP enzymatic activity increased formation PARP-DNA complexes `` trapping '' PARP enzyme damaged DNA Phase III studies demonstrated activity benefit niraparib BRCA BRCAm BRCA wild-type BRCAwt Phase testing niraparib established maximally tolerated dose 300mg mouth PO daily phase 3 ENGOT-OV16/NOVA demonstrated benefit niraparib maintenance therapy compared placebo completion response platinum-based chemotherapy BRCAm BRCAwt ovarian patient populations Toxicities seen niraparib include hematologic gastrointestinal fatigue cardiovascular Hematologic toxicities include thrombocytopenia anemia neutropenia leukopenia upfront dose modification 200mg niraparib patients baseline weight 77kg and/or baseline platelets 150,000K/uL considered avoid significant hematologic toxicity especially thrombocytopenia based recent ENGOT-OV16/NOVA Cardiovascular toxicities include hypertension tachycardia palpitations patients monitored hypertension PARP inhibitors associated low risks acute myelogenous leukemia AML myelodysplastic syndrome MDS overall risk AML MDS 0.9 patients treated niraparib Niraparib testing ongoing newly diagnosed ovarian patients maintenance therapy following completion platinum-based chemotherapy BRCAwt treatment combinations biologic drugs immunotherapy anti-angiogenic agents",0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[9147, 16, 35, 518, 2699, 3638, 3507, 1451, 2041, 230, 17, 16, 694, 850, 20, 3, 1088, 907, 1773, 2, 234, 634, 843, 2078, 22, 149, 22, 761, 850, 20, 3, 1865, 11478, 8613, 13135, 9, 3, 1146, 24, 1, 117, 5, 387, 12, 54, 32, 4, 236, 15, 450, 51, 6, 828, 90, 56, 3, 483, 1, 1578, 1, 9147, 643, 297, 1, 2041, 5226, 128, 22, 149, 22, 101, 1264, 1, 2041, 261, 3817, 298, 12140, 522, 3, 2041, 1644, 23, 9884, 261, 124, 70, 2, 316, 94, 47, 264, 128, 2, 247, 1, 9147, 4, 110, 1555, 1185, 20907, 2, 1555, 955, 267, 41976, 163, 124, 70, 471, 1, 9147, 635, 3, 6402, 421, 61, 1, 21658, 20, 5831, 4826, 391, 2, 3, 124, 27, 27665, 32840, 29881, 45, 264, 3, 247, 1, 9147, 1146, 36, 72, 6, 619, 50, 1438, 1, 2, 51, 6, 828, 90, 56, 4, 110, 20907, 2, 41976, 12, 69, 1184, 385, 527, 5, 9147, 643, 813, 613, 2, 2179, 813, 385, 643, 1340, 1545, 778, 2, 3904, 2941, 61, 2437, 6, 15316, 9147, 9, 7, 5, 330, 924, 1, 72094, 2, 15, 330, 4407, 1, 72095, 72096, 22961, 257, 40, 515, 6, 3085, 93, 813, 155, 1093, 1340, 90, 23, 435, 318, 1, 3, 27665, 32840, 29881, 45, 2179, 385, 643, 1824, 12177, 22, 149, 22, 34403, 2, 7, 257, 40, 2909, 9, 1824, 2041, 222, 47, 85, 41, 5, 154, 1098, 1, 286, 2194, 329, 2, 681, 1223, 2, 3, 63, 43, 1, 329, 2, 1223, 16, 13, 83, 1, 62, 7, 73, 5, 9147, 9147, 471, 16, 942, 4, 732, 265, 12, 7, 22, 1146, 36, 366, 1438, 1, 828, 90, 56, 4, 41976, 163, 22, 24, 22, 149, 22, 4, 1247, 5, 127, 1283, 600, 225, 22, 726, 2, 312, 2068, 183]",2017.0,29397193,poly ADP ribose polymerase inhibitor niraparib Management toxicities,0,0.0
Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome.,"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",Mod. Pathol.,2018-02-14,"The Philadelphia chromosome resulting from t(9;22)(q34;q11.2) or its variants is a defining event in chronic myeloid leukemia. It is also observed in several types of de novo acute leukemia, commonly in B lymphoblastic leukemia, and rarely in acute myeloid leukemia, acute leukemia of ambiguous lineage, and T lymphoblastic leukemia. Acquisition of the Philadelphia chromosome during therapy of acute leukemia and myelodysplastic syndrome is rare. We reported 19 patients, including 11 men and 8 women with a median age of 53 years at initial diagnosis. The diagnoses at initial presentation were acute myeloid leukemia (n=11), myelodysplastic syndrome (n=5), B lymphoblastic leukemia (n=2), and T lymphoblastic leukemia (n=1); no cases carried the Philadelphia chromosome. The Philadelphia chromosome was detected subsequently at relapse, or at refractory stage of acute leukemia or myelodysplastic syndrome. Of 14 patients evaluated for the BCR-ABL1 transcript subtype, 12 had the e1a2 transcript. In 11 of 14 patients, the diseases before and after emergence of the Philadelphia chromosome were clonally related by karyotype or shared gene mutations. Of 15 patients with treatment information available, 7 received chemotherapy alone, 5 received chemotherapy plus tyrosine kinase inhibitors, 2 received tyrosine kinase inhibitors only, and 1 patient was not treated. Twelve patients had follow-up after acquisition of the Philadelphia chromosome; all had persistent/refractory acute leukemia. Thirteen of 15 patients died a median of 3 months after the emergence of the Philadelphia chromosome. In summary, secondary Philadelphia chromosome acquired during therapy is rare, and is associated with the e1a2 transcript subtype, terminal disease stage, and poor outcome.",Journal Article,706.0,6.0,Philadelphia chromosome resulting 9 22 q34 q11.2 defining event chronic myeloid leukemia observed types novo acute leukemia commonly B lymphoblastic leukemia rarely acute myeloid leukemia acute leukemia ambiguous lineage lymphoblastic leukemia Acquisition Philadelphia chromosome therapy acute leukemia myelodysplastic syndrome rare reported 19 patients including 11 men 8 women median age 53 years initial diagnosis diagnoses initial presentation acute myeloid leukemia n 11 myelodysplastic syndrome n 5 B lymphoblastic leukemia n 2 lymphoblastic leukemia n 1 cases carried Philadelphia chromosome Philadelphia chromosome detected subsequently relapse refractory stage acute leukemia myelodysplastic syndrome 14 patients evaluated BCR-ABL1 transcript subtype 12 e1a2 transcript 11 14 patients diseases emergence Philadelphia chromosome clonally related karyotype shared 15 patients treatment information available 7 received chemotherapy 5 received chemotherapy plus tyrosine kinase inhibitors 2 received tyrosine kinase inhibitors 1 patient treated patients follow-up acquisition Philadelphia chromosome persistent/refractory acute leukemia Thirteen 15 patients died median 3 months emergence Philadelphia chromosome summary secondary Philadelphia chromosome acquired therapy rare associated e1a2 transcript subtype terminal disease stage poor outcome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 3006, 1170, 1113, 29, 102, 83, 350, 16609, 11532, 18, 15, 211, 839, 16, 8, 2847, 774, 4, 442, 533, 192, 16, 120, 164, 4, 392, 630, 1, 1566, 2018, 286, 841, 4, 132, 1275, 2, 2416, 4, 286, 533, 286, 1, 11286, 2542, 2, 102, 1275, 3405, 1, 3, 3006, 1170, 190, 36, 1, 286, 2, 681, 16, 622, 21, 210, 326, 7, 141, 175, 325, 2, 66, 117, 5, 8, 52, 89, 1, 699, 60, 28, 388, 147, 3, 2403, 28, 388, 1031, 11, 286, 533, 78, 175, 681, 78, 33, 132, 1275, 78, 18, 2, 102, 1275, 78, 14, 77, 140, 2629, 3, 3006, 1170, 3, 3006, 1170, 10, 530, 1611, 28, 429, 15, 28, 430, 82, 1, 286, 15, 681, 1, 213, 7, 194, 9, 3, 1062, 3557, 3268, 875, 133, 42, 3, 31351, 3268, 4, 175, 1, 213, 7, 3, 1342, 348, 2, 50, 3397, 1, 3, 3006, 1170, 11, 9157, 139, 20, 3385, 15, 2664, 145, 138, 1, 167, 7, 5, 24, 487, 390, 67, 103, 56, 279, 33, 103, 56, 349, 564, 216, 222, 18, 103, 564, 216, 222, 158, 2, 14, 69, 10, 44, 73, 2544, 7, 42, 166, 126, 50, 3405, 1, 3, 3006, 1170, 62, 42, 1882, 430, 286, 3170, 1, 167, 7, 1016, 8, 52, 1, 27, 53, 50, 3, 3397, 1, 3, 3006, 1170, 4, 1962, 568, 3006, 1170, 1294, 190, 36, 16, 622, 2, 16, 41, 5, 3, 31351, 3268, 875, 2158, 34, 82, 2, 334, 228]",1571.0,29449681,Secondary Philadelphia chromosome acquired therapy acute leukemia myelodysplastic syndrome,0,0.0
"Phase Ib Study of Glasdegib, a Hedgehog Pathway Inhibitor, in Combination with Standard Chemotherapy in Patients with AML or High-Risk MDS.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2018-02-20,"<b>Purpose:</b> This open-label, multicenter, dose-finding, phase Ib study (NCT01546038) evaluated the safety, pharmacokinetics, pharmacodynamics, and clinical activity of the novel Hedgehog pathway Smoothened inhibitor glasdegib (PF-04449913) in patients (<i>N</i> = 52) with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).<b>Experimental Design:</b> Glasdegib 100 or 200 mg was administered orally, once daily in 28-day cycles, in combination with low-dose cytarabine (arm A) or decitabine (arm B) to newly diagnosed patients considered not suitable for standard induction chemotherapy, and in combination with cytarabine/daunorubicin (arm C) to fit patients. The study followed a standard 3+3 dose-escalation design. The primary endpoint was dose-limiting toxicity (DLT). Ten additional patients were enrolled in expansion cohorts of arms A (<i>n</i> = 23) and C (<i>n</i> = 22) to confirm the recommended phase II dose (RP2D).<b>Results:</b> No DLTs were observed in arms A and B; 1 DLT (grade 4 neuropathy) occurred in arm C. The most common treatment-related nonhematologic adverse events were mostly grades 1 and 2 in all arms. Muscle spasms, dysgeusia, and alopecia were generally mild. Overall, 16 patients (31%) achieved a complete remission (CR)/CR with incomplete blood count recovery. Note that 100 mg daily was selected as the RP2D for glasdegib in combination with standard chemotherapies in the absence of an estimated MTD in this setting.<b>Conclusions:</b> Treatment with glasdegib in combination with standard chemotherapy was generally well-tolerated and consistent with prior findings, warranting further evaluation of glasdegib-based combinations in patients with AML or high-risk MDS. <i>Clin Cancer Res; 24(10); 2294-303. 2018 AACR</i>.","Clinical Trial, Phase I",700.0,26.0,b Purpose /b open-label multicenter dose-finding phase Ib NCT01546038 evaluated safety pharmacokinetics pharmacodynamics clinical activity novel Hedgehog pathway Smoothened inhibitor glasdegib PF-04449913 patients N /i 52 acute myeloid leukemia AML high-risk myelodysplastic syndrome MDS b Experimental Design /b Glasdegib 100 200 mg administered orally daily 28-day cycles combination low-dose cytarabine arm decitabine arm B newly diagnosed patients considered suitable standard induction chemotherapy combination cytarabine/daunorubicin arm C fit patients followed standard 3+3 dose-escalation design primary endpoint dose-limiting toxicity DLT additional patients enrolled expansion cohorts arms n /i 23 C n /i 22 confirm recommended phase II dose RP2D b /b DLTs observed arms B 1 DLT grade 4 neuropathy occurred arm C. common treatment-related nonhematologic adverse events grades 1 2 arms Muscle spasms dysgeusia alopecia generally mild Overall 16 patients 31 achieved complete remission CR /CR incomplete blood count recovery Note 100 mg daily selected RP2D glasdegib combination standard chemotherapies absence estimated MTD setting. b Conclusions /b Treatment glasdegib combination standard chemotherapy generally well-tolerated consistent prior findings warranting evaluation glasdegib-based combinations patients AML high-risk MDS Clin Res 24 10 2294-303 2018 AACR /i,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[132, 743, 132, 26, 1020, 1756, 1570, 61, 1567, 124, 3180, 45, 41990, 194, 3, 367, 1159, 3587, 2, 38, 128, 1, 3, 229, 4097, 308, 11990, 230, 15452, 3313, 20054, 4, 7, 70, 78, 70, 653, 5, 286, 533, 329, 15, 64, 43, 681, 1223, 132, 1560, 771, 132, 15452, 394, 15, 1250, 81, 10, 468, 1428, 1059, 391, 4, 339, 218, 410, 4, 150, 5, 154, 61, 1855, 475, 8, 15, 3004, 475, 132, 6, 732, 265, 7, 515, 44, 2884, 9, 260, 504, 56, 2, 4, 150, 5, 1855, 5247, 475, 256, 6, 2975, 7, 3, 45, 370, 8, 260, 27, 27, 61, 1125, 771, 3, 86, 1138, 10, 61, 817, 155, 2059, 1618, 402, 7, 11, 346, 4, 1422, 736, 1, 1335, 8, 70, 78, 70, 382, 2, 256, 70, 78, 70, 350, 6, 1843, 3, 793, 124, 215, 61, 3977, 132, 99, 132, 77, 2506, 11, 164, 4, 1335, 8, 2, 132, 14, 2059, 88, 39, 1751, 489, 4, 475, 256, 3, 96, 186, 24, 139, 3534, 290, 281, 11, 2754, 2276, 14, 2, 18, 4, 62, 1335, 1502, 18539, 13905, 2, 5691, 11, 1228, 1980, 63, 245, 7, 456, 513, 8, 236, 734, 684, 684, 5, 2610, 315, 1276, 1602, 5739, 17, 394, 81, 391, 10, 715, 22, 3, 3977, 9, 15452, 4, 150, 5, 260, 4203, 4, 3, 1127, 1, 35, 661, 961, 4, 26, 546, 132, 2130, 132, 24, 5, 15452, 4, 150, 5, 260, 56, 10, 1228, 149, 421, 2, 925, 5, 324, 272, 7643, 195, 451, 1, 15452, 90, 1247, 4, 7, 5, 329, 15, 64, 43, 1223, 70, 2459, 12, 1936, 259, 79, 39620, 9044, 4281, 1630, 70]",1681.0,29463550,Phase Ib Glasdegib Hedgehog Pathway Inhibitor Combination Standard Chemotherapy Patients AML High-Risk MDS,170,0.29668411867364747
Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes.,Leukemia,Leukemia,2018-02-22,"Immune checkpoint inhibitors, as single-agent therapy, have shown modest clinical efficacy in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). As has been successfully shown in other less immunogenic hematologic malignancies, rationally designed combination approaches may be more effective than single-agent checkpoint inhibitors, and may be the approach to pursue in AML/MDS. Hypomethylating agents (HMAs) such as azacitidine, while enhancing anti-tumor immune response, concurrently dampen immune response by upregulating inhibitory immune checkpoint molecule expression. Immune checkpoint molecule upregulation may be an important mechanism of azacitidine resistance. These findings have resulted in multiple clinical trials combining HMAs with immune checkpoint blockade. Clinical trial data have shown encouraging response rates and durable responses without resorting to stem cell transplant. In this review, we discuss preclinical data supporting the use of these agents in combination, and focus on clinical and correlative data emerging from numerous clinical trials investigating HMA-immune checkpoint inhibitor combinations in AML/MDS.",Journal Article,698.0,30.0,Immune checkpoint inhibitors single-agent therapy shown modest clinical efficacy treatment acute myeloid leukemia AML myelodysplastic syndromes MDS successfully shown immunogenic hematologic malignancies rationally designed combination approaches effective single-agent checkpoint inhibitors approach pursue AML/MDS Hypomethylating agents HMAs azacitidine enhancing anti-tumor immune response concurrently dampen immune response upregulating inhibitory immune checkpoint molecule expression Immune checkpoint molecule upregulation important mechanism azacitidine resistance findings resulted multiple clinical trials combining HMAs immune checkpoint blockade Clinical trial shown encouraging response rates durable responses resorting stem transplant review discuss preclinical supporting use agents combination focus clinical correlative emerging numerous clinical trials investigating HMA-immune checkpoint inhibitor combinations AML/MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[250, 986, 222, 22, 226, 420, 36, 47, 443, 1721, 38, 209, 4, 3, 24, 1, 286, 533, 329, 2, 2040, 1223, 22, 71, 85, 1878, 443, 4, 127, 299, 4190, 813, 441, 6352, 1114, 150, 611, 68, 40, 80, 323, 76, 226, 420, 986, 222, 2, 68, 40, 3, 353, 6, 7874, 4, 329, 1223, 4931, 183, 12688, 225, 22, 3752, 369, 2430, 312, 30, 250, 51, 3294, 19142, 250, 51, 20, 12850, 1810, 250, 986, 1354, 55, 250, 986, 1354, 2218, 68, 40, 35, 305, 670, 1, 3752, 251, 46, 272, 47, 627, 4, 232, 38, 143, 1525, 12688, 5, 250, 986, 1189, 38, 160, 74, 47, 443, 2269, 51, 151, 2, 1480, 253, 187, 72274, 6, 452, 31, 941, 4, 26, 206, 21, 1139, 693, 74, 1912, 3, 119, 1, 46, 183, 4, 150, 2, 1222, 23, 38, 2, 3679, 74, 1478, 29, 2331, 38, 143, 3103, 7518, 250, 986, 230, 1247, 4, 329, 1223]",1135.0,29487386,Hypomethylating agents combination immune checkpoint inhibitors acute myeloid leukemia myelodysplastic syndromes,1,0.0017452006980802793
<i>Sipa1</i> deficiency-induced bone marrow niche alterations lead to the initiation of myeloproliferative neoplasm.,Blood advances,Blood Adv,2018-03-01,"Mutations of signal-induced proliferation-associated gene 1 (<i>SIPA1</i>), a RAP1 GTPase-activating protein, were reported in patients with juvenile myelomonocytic leukemia, a childhood myelodysplastic/myeloproliferative neoplasm (MDS/MPN). <i>Sipa1</i> deficiency in mice leads to the development of age-dependent MPN. However, <i>Sipa1</i> expression in bone marrow (BM) microenvironment and its effect on the pathogenesis of MPN remain unclear. We here report that <i>Sipa1</i> is expressed in human and mouse BM stromal cells and downregulated in these cells from patients with MPN or MDS/MPN at diagnosis. By using the <i>Sipa1</i><sup>-/-</sup> MPN mouse model, we find that <i>Sipa1</i> deletion causes phenotypic and functional alterations of BM mesenchymal stem and progenitor cells prior to the initiation of the MPN. Importantly, the altered <i>Sipa1</i><sup>-/-</sup> BM niche is required for the development of MDS/MPN following transplantation of normal hematopoietic cells. RNA sequencing reveals an enhanced inflammatory cytokine signaling and dysregulated <i>Dicer1</i>, <i>Kitl</i>, <i>Angptl1</i>, <i>Cxcl12</i>, and <i>Thpo</i> in the <i>Sipa1</i><sup>-/-</sup> BM cellular niches. Our data suggest that <i>Sipa1</i> expression in the BM niche is critical for maintaining BM niche homeostasis. Moreover, <i>Sipa1</i> loss-induced BM niche alterations likely enable evolution of clonal hematopoiesis to the hematological malignancies. Therefore, restoring <i>Sipa1</i> expression or modulating the altered signaling pathways involved might offer therapeutic potential for MPN.",Journal Article,691.0,8.0,signal-induced proliferation-associated 1 SIPA1 /i RAP1 GTPase-activating reported patients juvenile myelomonocytic leukemia childhood myelodysplastic/myeloproliferative neoplasm MDS/MPN Sipa1 /i deficiency mice leads development age-dependent MPN Sipa1 /i expression bone marrow BM microenvironment effect pathogenesis MPN remain unclear report Sipa1 /i expressed human mouse BM stromal downregulated patients MPN MDS/MPN diagnosis Sipa1 /i sup -/- /sup MPN mouse model Sipa1 /i deletion causes phenotypic functional alterations BM mesenchymal stem progenitor prior initiation MPN Importantly altered Sipa1 /i sup -/- /sup BM niche required development MDS/MPN following transplantation normal hematopoietic RNA sequencing reveals enhanced inflammatory cytokine signaling dysregulated Dicer1 /i Kitl /i Angptl1 /i Cxcl12 /i Thpo /i Sipa1 /i sup -/- /sup BM cellular niches suggest Sipa1 /i expression BM niche critical maintaining BM niche homeostasis Sipa1 /i loss-induced BM niche alterations likely enable evolution clonal hematopoiesis hematological malignancies restoring Sipa1 /i expression modulating altered signaling pathways involved offer therapeutic potential MPN,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,"[138, 1, 1235, 277, 457, 41, 145, 14, 70, 19334, 70, 8, 14946, 9189, 1616, 178, 11, 210, 4, 7, 5, 7857, 5451, 8, 864, 10589, 10857, 2131, 1223, 4125, 70, 19334, 70, 2299, 4, 399, 1940, 6, 3, 193, 1, 89, 470, 4125, 137, 70, 19334, 70, 55, 4, 581, 1246, 995, 2, 211, 254, 23, 3, 1384, 1, 4125, 918, 1200, 21, 467, 414, 17, 70, 19334, 70, 16, 570, 4, 171, 2, 830, 1246, 1126, 37, 2, 3315, 4, 46, 37, 29, 7, 5, 4125, 15, 1223, 4125, 28, 147, 20, 75, 3, 70, 19334, 70, 172, 172, 4125, 830, 202, 21, 2469, 17, 70, 19334, 70, 1528, 1626, 3290, 2, 583, 593, 1, 1246, 1569, 452, 2, 2520, 37, 324, 6, 3, 1118, 1, 3, 4125, 1859, 3, 1495, 70, 19334, 70, 172, 172, 1246, 4385, 16, 616, 9, 3, 193, 1, 1223, 4125, 366, 497, 1, 295, 1007, 37, 893, 615, 4054, 35, 651, 1291, 1675, 314, 2, 4288, 70, 21537, 70, 70, 72320, 70, 70, 72321, 70, 70, 5807, 70, 2, 70, 72322, 70, 4, 3, 70, 19334, 70, 172, 172, 1246, 763, 8005, 114, 74, 309, 17, 70, 19334, 70, 55, 4, 3, 1246, 4385, 16, 740, 9, 3284, 1246, 4385, 4975, 1393, 70, 19334, 70, 407, 277, 1246, 4385, 593, 322, 3047, 2554, 1, 1946, 5114, 6, 3, 2890, 441, 673, 8364, 70, 19334, 70, 55, 15, 3712, 3, 1495, 314, 460, 646, 822, 1918, 189, 174, 9, 4125]",1519.0,29514790,Sipa1 /i deficiency-induced bone marrow niche alterations lead initiation myeloproliferative neoplasm,0,0.0
"Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.",The Lancet. Haematology,Lancet Haematol,2018-03-14,"Activating mutations of tyrosine kinases are common in leukaemias. Oncogenic tyrosine kinases use the growth factor receptor-bound protein 2 (Grb2) for signal transduction, leading to activation of mitogen-activated protein kinase (MAPK) 1 and MAPK3 (ERK2 and ERK1). We hypothesised that inhibition of Grb2 would suppress ERK1 and ERK2 activation and inhibit leukaemia progression. To inhibit Grb2, a liposome-incorporated antisense oligodeoxynucleotide that blocks Grb2 protein expression, BP1001, was developed. We report the first phase 1 findings of BP1001. In this single-centre, open-label, dose-escalation phase 1/1b trial, we enrolled participants (aged 18 years) with refractory or relapsed acute myeloid leukaemia, Philadelphia-chromosome-positive chronic myeloid leukaemia (in chronic, accelerated, or blast phase), acute lymphoblastic leukaemia, or myelodysplastic syndrome, at MD Anderson Cancer Center (Houston, TX, USA). We used a 3+3 dose escalation strategy, with at least three patients enrolled at each dose level. We administered BP1001 intravenously, twice weekly, for 28 days, with a starting dose of 5 mg/m<sup>2</sup>. If two or more patients developed toxic effects of grade 3 or higher, that dose level was deemed toxic. The dose was escalated if it did not produce dose-limiting toxic effects, and patients would be sequentially enrolled into cohort 2 (10 mg/m<sup>2</sup>), cohort 3 (20 mg/m<sup>2</sup>), cohort 4 (40 mg/m<sup>2</sup>), cohort 5 (60 mg/m<sup>2</sup>), or cohort 6 (90 mg/m<sup>2</sup>). After completion of monotherapy, we assessed the safety and toxicity of BP1001 (60 or 90 mg/m<sup>2</sup>) in combination with 20 mg low-dose cytarabine (twice-daily subcutaneous injections) in a phase 1b study in patients with refractory or relapsed acute myeloid leukaemia (ie, those who were refractory to at least one previous therapy regimen and no more than one previous salvage regimen). The objectives of this study were to establish the toxicity and tolerance of escalating doses of BP1001 monotherapy in patients with refractory or relapsed leukaemia, to assess the maximum tolerated dose of BP1001, and to determine the optimal biologically active dose of BP1001, defined as a 50% reduction in Grb2 expression in circulating leukaemia cells. We also aimed to assess the in-vivo pharmacokinetics of BP1001 and tumour response. The study is completed and is registered with ClinicalTrials.gov, number NCT01159028. Between July 23, 2010, and Feb 23, 2016, we enrolled and treated 39 patients, of whom 27 were assessable for dose-limiting toxicity. The first patient treated had mucositis and hand-foot syndrome, which were assessed as possibly related to BP1001 and counted as a dose-limiting toxicity. We noted no other dose-limiting toxicities, and a maximum tolerated dose was not identified. The highest tested dose of BP1001 was 90 mg/m<sup>2</sup>. The most common grade 3-4 adverse events were cardiopulmonary disorders (25 [64%] of 39 patients), and fever (including neutropenic fever) and infections (17 [44%] patients). Grade 5 adverse events were cardiopulmonary disorders (two [5%] of 39 patients), fever (including neutropenic fever) and infections (two [5%] of 39 patients), and multi-organ failure (one [3%] of 39 patients). Nine (33%) of 27 patients who had peripheral blood blasts at the start of therapy had a reduction of 50% or more in peripheral blood blasts while receiving BP1001 montherapy. Three (10%) of 29 patients who had bone marrow blasts at the start of therapy had a reduction in bone marrow blasts of 50% or more while receiving BP1001 monotherapy. Per investigator's assessment, seven (22%) of 32 patients benefited from BP1001 monotherapy and had extended cycles of treatment. Of seven patients receiving BP1001 plus low-dose cytarabine combination therapy, two had complete remission, one had complete remission with incomplete haematological recovery, and two had stable disease with no dose-limiting toxicity; one patient died and one withdrew, both because of disease progression. There were eight deaths; none were treatment related. BP1001 is well tolerated, with early evidence of anti-leukaemic activity in combination with low-dose cytarabine. To further explore this anti-leukaemic activity, the efficacy of BP1001 plus low-dose cytarabine combination is being investigated in an ongoing phase 2 study in patients with previously untreated acute myeloid leukaemia who are ineligible for intensive induction therapy. Bio-Path Holdings Inc.","Clinical Trial, Phase I",678.0,4.0,Activating tyrosine kinases common leukaemias Oncogenic tyrosine kinases use growth factor receptor-bound 2 Grb2 signal transduction leading activation mitogen-activated kinase MAPK 1 MAPK3 ERK2 ERK1 hypothesised inhibition Grb2 suppress ERK1 ERK2 activation inhibit leukaemia progression inhibit Grb2 liposome-incorporated antisense oligodeoxynucleotide blocks Grb2 expression BP1001 developed report phase 1 findings BP1001 single-centre open-label dose-escalation phase 1/1b trial enrolled participants aged 18 years refractory relapsed acute myeloid leukaemia Philadelphia-chromosome-positive chronic myeloid leukaemia chronic accelerated blast phase acute lymphoblastic leukaemia myelodysplastic syndrome MD Anderson Center Houston TX USA 3 3 dose escalation strategy patients enrolled dose level administered BP1001 intravenously twice weekly 28 days starting dose 5 mg/m sup 2 /sup patients developed toxic effects grade 3 higher dose level deemed toxic dose escalated produce dose-limiting toxic effects patients sequentially enrolled cohort 2 10 mg/m sup 2 /sup cohort 3 20 mg/m sup 2 /sup cohort 4 40 mg/m sup 2 /sup cohort 5 60 mg/m sup 2 /sup cohort 6 90 mg/m sup 2 /sup completion monotherapy assessed safety toxicity BP1001 60 90 mg/m sup 2 /sup combination 20 mg low-dose cytarabine twice-daily subcutaneous injections phase 1b patients refractory relapsed acute myeloid leukaemia refractory previous therapy regimen previous salvage regimen objectives establish toxicity tolerance escalating doses BP1001 monotherapy patients refractory relapsed leukaemia assess maximum tolerated dose BP1001 determine optimal biologically active dose BP1001 defined 50 reduction Grb2 expression circulating leukaemia aimed assess in-vivo pharmacokinetics BP1001 tumour response completed registered ClinicalTrials.gov number NCT01159028 July 23 2010 Feb 23 2016 enrolled treated 39 patients 27 assessable dose-limiting toxicity patient treated mucositis hand-foot syndrome assessed possibly related BP1001 counted dose-limiting toxicity noted dose-limiting toxicities maximum tolerated dose identified highest tested dose BP1001 90 mg/m sup 2 /sup common grade 3-4 adverse events cardiopulmonary disorders 25 64 39 patients fever including neutropenic fever infections 17 44 patients Grade 5 adverse events cardiopulmonary disorders 5 39 patients fever including neutropenic fever infections 5 39 patients multi-organ failure 3 39 patients 33 27 patients peripheral blood blasts start therapy reduction 50 peripheral blood blasts receiving BP1001 montherapy 10 29 patients bone marrow blasts start therapy reduction bone marrow blasts 50 receiving BP1001 monotherapy investigator 's assessment seven 22 32 patients benefited BP1001 monotherapy extended cycles treatment seven patients receiving BP1001 plus low-dose cytarabine combination therapy complete remission complete remission incomplete haematological recovery stable disease dose-limiting toxicity patient died withdrew disease progression deaths treatment related BP1001 tolerated early evidence anti-leukaemic activity combination low-dose cytarabine explore anti-leukaemic activity efficacy BP1001 plus low-dose cytarabine combination investigated ongoing phase 2 patients previously untreated acute myeloid leukaemia ineligible intensive induction therapy Bio-Path Holdings,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1616, 138, 1, 564, 1549, 32, 186, 4, 12160, 1302, 564, 1549, 119, 3, 129, 161, 153, 2951, 178, 18, 10967, 9, 1235, 2761, 1049, 6, 363, 1, 2625, 735, 178, 216, 1748, 14, 2, 50815, 21182, 2, 3533, 21, 11998, 17, 297, 1, 10967, 688, 3134, 3533, 2, 21182, 363, 2, 1433, 2001, 91, 6, 1433, 10967, 8, 8645, 2449, 4645, 15543, 17, 2860, 10967, 178, 55, 18128, 10, 276, 21, 414, 3, 157, 124, 14, 272, 1, 18128, 4, 26, 226, 5931, 1020, 1756, 61, 1125, 124, 14, 4693, 160, 21, 346, 776, 1032, 6624, 60, 5, 430, 15, 591, 286, 533, 2001, 3006, 1170, 109, 442, 533, 2001, 4, 442, 2241, 15, 3112, 124, 286, 1275, 2001, 15, 681, 28, 2244, 1929, 12, 574, 6212, 6614, 2706, 21, 95, 8, 27, 27, 61, 1125, 692, 5, 28, 506, 169, 7, 346, 28, 296, 61, 301, 21, 468, 18128, 1672, 936, 709, 9, 339, 162, 5, 8, 1723, 61, 1, 33, 81, 188, 172, 18, 172, 492, 100, 15, 80, 7, 276, 1812, 176, 1, 88, 27, 15, 142, 17, 61, 301, 10, 3779, 1812, 3, 61, 10, 2842, 492, 192, 205, 44, 2410, 61, 817, 1812, 176, 2, 7, 688, 40, 5455, 346, 237, 180, 18, 79, 81, 188, 172, 18, 172, 180, 27, 179, 81, 188, 172, 18, 172, 180, 39, 327, 81, 188, 172, 18, 172, 180, 33, 335, 81, 188, 172, 18, 172, 15, 180, 49, 424, 81, 188, 172, 18, 172, 50, 1438, 1, 1411, 21, 275, 3, 367, 2, 155, 1, 18128, 335, 15, 424, 81, 188, 172, 18, 172, 4, 150, 5, 179, 81, 154, 61, 1855, 936, 391, 2529, 4344, 4, 8, 124, 4693, 45, 4, 7, 5, 430, 15, 591, 286, 533, 2001, 2523, 135, 54, 11, 430, 6, 28, 506, 104, 698, 36, 477, 2, 77, 80, 76, 104, 698, 992, 477, 3, 2409, 1, 26, 45, 11, 6, 1811, 3, 155, 2, 2614, 1, 2922, 415, 1, 18128, 1411, 4, 7, 5, 430, 15, 591, 2001, 6, 423, 3, 689, 421, 61, 1, 18128, 2, 6, 223, 3, 665, 2665, 544, 61, 1, 18128, 395, 22, 8, 212, 628, 4, 10967, 55, 4, 1033, 2001, 37, 21, 120, 1295, 6, 423, 3, 4, 386, 1159, 1, 18128, 2, 770, 51, 3, 45, 16, 781, 2, 16, 1653, 5, 1252, 1239, 207, 72382, 59, 2066, 382, 1120, 2, 10128, 382, 1390, 21, 346, 2, 73, 587, 7, 1, 953, 428, 11, 3120, 9, 61, 817, 155, 3, 157, 69, 73, 42, 2606, 2, 2833, 4100, 681, 92, 11, 275, 22, 2150, 139, 6, 18128, 2, 12252, 22, 8, 61, 817, 155, 21, 1051, 77, 127, 61, 817, 385, 2, 8, 689, 421, 61, 10, 44, 108, 3, 1076, 650, 61, 1, 18128, 10, 424, 81, 188, 172, 18, 172, 3, 96, 186, 88, 27, 39, 290, 281, 11, 7744, 1997, 243, 660, 1, 587, 7, 2, 2775, 141, 3659, 2775, 2, 1875, 269, 584, 7, 88, 33, 290, 281, 11, 7744, 1997, 100, 33, 1, 587, 7, 2775, 141, 3659, 2775, 2, 1875, 100, 33, 1, 587, 7, 2, 1414, 1259, 496, 104, 27, 1, 587, 7, 762, 466, 1, 428, 7, 54, 42, 672, 315, 2438, 28, 3, 2435, 1, 36, 42, 8, 628, 1, 212, 15, 80, 4, 672, 315, 2438, 369, 357, 18128, 72383, 169, 79, 1, 462, 7, 54, 42, 581, 2438, 28, 3, 2435, 1, 36, 42, 8, 628, 4, 581, 2438, 1, 212, 15, 80, 369, 357, 18128, 1411, 379, 3464, 292, 455, 648, 350, 1, 531, 7, 7067, 29, 18128, 1411, 2, 42, 1747, 410, 1, 24, 1, 648, 7, 357, 18128, 349, 154, 61, 1855, 150, 36, 100, 42, 236, 734, 104, 42, 236, 734, 5, 2610, 5143, 1602, 2, 100, 42, 585, 34, 5, 77, 61, 817, 155, 104, 69, 1016, 2, 104, 7939, 110, 408, 1, 34, 91, 125, 11, 659, 1043, 1292, 11, 24, 139, 18128, 16, 149, 421, 5, 191, 241, 1, 312, 8871, 128, 4, 150, 5, 154, 61, 1855, 6, 195, 1645, 26, 312, 8871, 128, 3, 209, 1, 18128, 349, 154, 61, 1855, 150, 16, 486, 565, 4, 35, 942, 124, 18, 45, 4, 7, 5, 373, 1278, 286, 533, 2001, 54, 32, 3773, 9, 1686, 504, 36, 10683, 6361, 72384, 3479]",4345.0,29550383,Liposomal Grb2 antisense oligodeoxynucleotide BP1001 patients refractory relapsed haematological malignancies single-centre open-label dose-escalation phase 1/1b trial,374,0.6527050610820244
"A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2018-03-16,"With improvement in transplantation practices in the modern era, nonrelapse mortality (NRM) following allogeneic hematopoietic stem cell transplantation (HSCT) has improved, while disease relapse rates have remained unchanged. Survival outcomes are therefore driven by NRM in the modern era. Myeloablative conditioning (MAC) regimens are used to maximize disease control and facilitate engraftment; however, their use is often limited by toxicity. The commonly used MAC regimens incorporate either chemotherapy plus total body irradiation (TBI) or combination chemotherapy. Furthermore, reduced-toxicity myeloablative (RTM) regimens, such as fludarabine/busulfan (FluBu), have emerged as alternatives to traditional MAC and their impact on outcomes in the current era have not been fully investigated. In this study, we compare outcomes following HSCT, using the chemotherapy only RTM MAC regimens FluBu with the chemoradiotherapy regimen cyclophosphamide/TBI (CyTBI), for patients with hematologic malignancies who underwent MAC HSCT at the Dana-Farber Cancer Institute. We hypothesized that the chemotherapy-only regimen would fare better, primarily due to improved NRM. A retrospective cohort analysis was performed on 387 patients with myeloid or lymphoid hematologic malignancies who underwent HLA-matched related (8/8), matched unrelated (8/8), or single-antigen mismatched unrelated (7/8) HSCT following myeloablative conditioning. Patients received FluBu (n=158) or CyTBI (n=229). The primary outcome was overall survival (OS) and all other outcomes were regarded as secondary. A subset analysis was performed for patients <55 years of age and for acute myelogenous leukemia/myelodysplastic syndrome patients of age<55 years. For the whole cohort, 3-year OS was similar for FluBu compared with CyTBI in unadjusted analysis. However, in multivariable analysis, FluBu resulted in superior OS compared with CyTBI (3-year adjusted estimate: 65% versus 55%, respectively; HR for death, .62; 95% CI, .40 to .97; P=.036). While relapse rates were similar between the 2 regimens, NRM and acute graft-versus-host disease (GVHD) (grade II to IV) were significantly worse with CyTBI compared with FluBu. Rates of chronic GVHD were similar between 2 regimens. These results were consistent in a subset of patients <55 years of age and in acute myelogenous leukemia/myelodysplastic syndrome patients below 55 years of age. The RTM chemotherapy-only regimen FluBu appears to be as effective and more tolerable than the chemoradiotherapy regimen CyTBI, leading to better OS driven by better NRM. The improvement in NRM was attributable chiefly to lower rates of grade II to IV acute GVHD. Relapse rates were not increased with FluBu. In the absence of randomized data, FluBu appears to be the optimal regimen for myeloablative HSCT in patients of all age groups.",Comparative Study,676.0,3.0,improvement transplantation practices modern era nonrelapse mortality NRM following allogeneic hematopoietic stem transplantation HSCT improved disease relapse rates remained unchanged Survival outcomes driven NRM modern era Myeloablative conditioning MAC regimens maximize disease control facilitate engraftment use limited toxicity commonly MAC regimens incorporate chemotherapy plus total body irradiation TBI combination chemotherapy Furthermore reduced-toxicity myeloablative RTM regimens fludarabine/busulfan FluBu emerged alternatives traditional MAC impact outcomes current era fully investigated compare outcomes following HSCT chemotherapy RTM MAC regimens FluBu chemoradiotherapy regimen cyclophosphamide/TBI CyTBI patients hematologic malignancies underwent MAC HSCT Dana-Farber Institute hypothesized chemotherapy-only regimen fare better primarily improved NRM retrospective cohort performed 387 patients myeloid lymphoid hematologic malignancies underwent HLA-matched related 8/8 matched unrelated 8/8 single-antigen mismatched unrelated 7/8 HSCT following myeloablative conditioning Patients received FluBu n 158 CyTBI n 229 primary outcome overall survival OS outcomes regarded secondary subset performed patients 55 years age acute myelogenous leukemia/myelodysplastic syndrome patients age 55 years cohort 3-year OS similar FluBu compared CyTBI unadjusted multivariable FluBu resulted superior OS compared CyTBI 3-year adjusted estimate 65 versus 55 respectively HR death .62 95 CI .40 .97 P .036 relapse rates similar 2 regimens NRM acute graft-versus-host disease GVHD grade II IV significantly worse CyTBI compared FluBu Rates chronic GVHD similar 2 regimens consistent subset patients 55 years age acute myelogenous leukemia/myelodysplastic syndrome patients 55 years age RTM chemotherapy-only regimen FluBu appears effective tolerable chemoradiotherapy regimen CyTBI leading better OS driven better NRM improvement NRM attributable chiefly lower rates grade II IV acute GVHD Relapse rates increased FluBu absence randomized FluBu appears optimal regimen myeloablative HSCT patients age groups,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[5, 767, 4, 497, 2634, 4, 3, 2366, 1713, 4640, 282, 4296, 366, 1063, 1007, 452, 31, 497, 1703, 71, 231, 369, 34, 429, 151, 47, 958, 4639, 25, 123, 32, 673, 1621, 20, 4296, 4, 3, 2366, 1713, 3246, 1933, 7492, 472, 32, 95, 6, 4116, 34, 182, 2, 1876, 2881, 137, 136, 119, 16, 629, 383, 20, 155, 3, 841, 95, 7492, 472, 3360, 361, 56, 349, 181, 642, 1104, 4889, 15, 150, 56, 798, 405, 155, 3246, 42009, 472, 225, 22, 2027, 3906, 17063, 47, 2054, 22, 6295, 6, 1847, 7492, 2, 136, 345, 23, 123, 4, 3, 291, 1713, 47, 44, 85, 1910, 565, 4, 26, 45, 21, 932, 123, 366, 1703, 75, 3, 56, 158, 42009, 7492, 472, 17063, 5, 3, 1464, 477, 1112, 4889, 19524, 9, 7, 5, 813, 441, 54, 208, 7492, 1703, 28, 3, 4932, 4979, 12, 1377, 21, 1237, 17, 3, 56, 158, 477, 688, 11470, 380, 1561, 520, 6, 231, 4296, 8, 459, 180, 65, 10, 173, 23, 9513, 7, 5, 533, 15, 2303, 813, 441, 54, 208, 1160, 655, 139, 66, 66, 655, 2092, 66, 66, 15, 226, 448, 5095, 2092, 67, 66, 1703, 366, 3246, 1933, 7, 103, 17063, 78, 5162, 15, 19524, 78, 7584, 3, 86, 228, 10, 63, 25, 118, 2, 62, 127, 123, 11, 7217, 22, 568, 8, 697, 65, 10, 173, 9, 7, 614, 60, 1, 89, 2, 9, 286, 2194, 2647, 10589, 681, 7, 1, 89, 614, 60, 9, 3, 902, 180, 27, 111, 118, 10, 288, 9, 17063, 72, 5, 19524, 4, 4487, 65, 137, 4, 658, 65, 17063, 627, 4, 1123, 118, 72, 5, 19524, 27, 111, 586, 1191, 556, 185, 614, 106, 168, 9, 273, 744, 48, 58, 327, 6, 1015, 19, 5395, 369, 429, 151, 11, 288, 59, 3, 18, 472, 4296, 2, 286, 1599, 185, 1204, 34, 1562, 88, 215, 6, 478, 11, 97, 639, 5, 19524, 72, 5, 17063, 151, 1, 442, 1562, 11, 288, 59, 18, 472, 46, 99, 11, 925, 4, 8, 697, 1, 7, 614, 60, 1, 89, 2, 4, 286, 2194, 2647, 10589, 681, 7, 2736, 614, 60, 1, 89, 3, 42009, 56, 158, 477, 17063, 1233, 6, 40, 22, 323, 2, 80, 2668, 76, 3, 1464, 477, 19524, 1049, 6, 380, 118, 1621, 20, 380, 4296, 3, 767, 4, 4296, 10, 2971, 25694, 6, 280, 151, 1, 88, 215, 6, 478, 286, 1562, 429, 151, 11, 44, 101, 5, 17063, 4, 3, 1127, 1, 384, 74, 17063, 1233, 6, 40, 3, 665, 477, 9, 3246, 1703, 4, 7, 1, 62, 89, 271]",2772.0,29555313,Comparison Myeloablative Conditioning Regimen Fludarabine/Busulfan Cyclophosphamide/Total Body Irradiation Allogeneic Stem Transplantation Modern Era Cohort,27,0.04712041884816754
RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia.,Nature communications,Nat Commun,2018-03-21,"The roles of RNA 5-methylcytosine (RNA:m<sup>5</sup>C) and RNA:m<sup>5</sup>C methyltransferases (RCMTs) in lineage-associated chromatin organization and drug response/resistance are unclear. Here we demonstrate that the RCMTs, namely NSUN3 and DNMT2, directly bind hnRNPK, a conserved RNA-binding protein. hnRNPK interacts with the lineage-determining transcription factors (TFs), GATA1 and SPI1/PU.1, and with CDK9/P-TEFb to recruit RNA-polymerase-II at nascent RNA, leading to formation of 5-Azacitidine (5-AZA)-sensitive chromatin structure. In contrast, NSUN1 binds BRD4 and RNA-polymerase-II to form an active chromatin structure that is insensitive to 5-AZA, but hypersensitive to the BRD4 inhibitor JQ1 and to the downregulation of NSUN1 by siRNAs. Both 5-AZA-resistant leukaemia cell lines and clinically 5-AZA-resistant myelodysplastic syndrome and acute myeloid leukaemia specimens have a significant increase in RNA:m<sup>5</sup>C and NSUN1-/BRD4-associated active chromatin. This study reveals novel RNA:m<sup>5</sup>C/RCMT-mediated chromatin structures that modulate 5-AZA response/resistance in leukaemia cells, and hence provides a new insight into treatment of leukaemia.",Journal Article,671.0,11.0,roles RNA 5-methylcytosine RNA sup 5 /sup C RNA sup 5 /sup C methyltransferases RCMTs lineage-associated chromatin organization drug response/resistance unclear demonstrate RCMTs NSUN3 DNMT2 directly bind hnRNPK conserved RNA-binding hnRNPK interacts lineage-determining transcription factors TFs GATA1 SPI1/PU.1 CDK9/P-TEFb recruit RNA-polymerase-II nascent RNA leading formation 5-Azacitidine 5-AZA -sensitive chromatin structure contrast NSUN1 binds BRD4 RNA-polymerase-II form active chromatin structure insensitive 5-AZA hypersensitive BRD4 inhibitor JQ1 downregulation NSUN1 siRNAs 5-AZA-resistant leukaemia lines clinically 5-AZA-resistant myelodysplastic syndrome acute myeloid leukaemia specimens significant increase RNA sup 5 /sup C NSUN1-/BRD4-associated active chromatin reveals novel RNA sup 5 /sup C/RCMT-mediated chromatin structures modulate 5-AZA response/resistance leukaemia provides new insight treatment leukaemia,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1790, 1, 893, 33, 14943, 893, 188, 172, 33, 172, 256, 2, 893, 188, 172, 33, 172, 256, 11494, 50944, 4, 2542, 41, 2287, 2533, 2, 234, 51, 251, 32, 1200, 467, 21, 608, 17, 3, 50944, 5046, 72408, 2, 72409, 1606, 4060, 50945, 8, 5547, 893, 791, 178, 50945, 5528, 5, 3, 2542, 2196, 866, 130, 7335, 17662, 2, 50946, 10882, 14, 2, 5, 11333, 19, 30565, 6, 8973, 893, 1451, 215, 28, 15915, 893, 1049, 6, 1264, 1, 33, 3752, 33, 3924, 745, 2287, 2772, 4, 748, 42011, 3333, 8141, 2, 893, 1451, 215, 6, 1297, 35, 544, 2287, 2772, 17, 16, 7422, 6, 33, 3924, 84, 14077, 6, 3, 8141, 230, 10635, 2, 6, 3, 2475, 1, 42011, 20, 8006, 110, 33, 3924, 436, 2001, 31, 285, 2, 505, 33, 3924, 436, 681, 2, 286, 533, 2001, 623, 47, 8, 93, 344, 4, 893, 188, 172, 33, 172, 256, 2, 42011, 8141, 41, 544, 2287, 26, 45, 4054, 229, 893, 188, 172, 33, 172, 256, 72410, 517, 2287, 2414, 17, 3319, 33, 3924, 51, 251, 4, 2001, 37, 2, 3665, 777, 8, 217, 2670, 237, 24, 1, 2001]",1150.0,29563491,RNA cytosine methylation methyltransferases mediate chromatin organization 5-azacytidine response resistance leukaemia,127,0.22164048865619546
Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations.,The American journal of surgical pathology,Am. J. Surg. Pathol.,2018-06-01,"A subset of patients with chronic myelomonocytic leukemia (CMML) presents with significance myelofibrosis. In myelodysplastic syndromes, significant myelofibrosis has been associated with adverse outcomes and p53 dysregulation. However, in CMML the clinical and molecular correlates of significant myelofibrosis at presentation remain poorly understood. From a cohort of 651 CMML patients, we identified retrospectively 20 (3.1%) cases with moderate to severe reticulin fibrosis (CMML-F) detected at diagnosis, and we compared them to CMML patients without fibrosis (n=631) seen during the same period. Patients with CMML-F had a median age of 69.8 years (range, 24.8 to 91.2y) and most (13; 65%) were men. Patients with CMML-F differed significantly from other CMML patients across the following parameters: white blood count, absolute monocyte count, serum lactate dehydrogenase level, splenomegaly, and bone marrow blast percentage. Notably, the frequency of JAK2 p.V617F mutation was higher in CMML-F patients compared with other CMML patients (P<0.001). Most CMML-F patients (12/20; 60%) had myeloproliferative CMML. Dysregulation of p53 was uncommon in CMML-F. CMML-F patients tended to have a shorter median overall survival compared with other CMML patients (P=0.079). Multivariate analysis using the Cox proportional hazards model showed an independent association between CMML-F and overall survival (P=0.047). In summary, unlike typical CMML, CMML-F is commonly associated with JAK2 p.V617F. The high frequency of myeloproliferative features and JAK2 p.V617F mutation, and the low frequency of p53 dysregulation, suggest that fibrosis in the context of CMML has a different pathogenesis from that previously reported in myelodysplastic syndrome.",Comparative Study,599.0,10.0,subset patients chronic myelomonocytic leukemia CMML presents significance myelofibrosis myelodysplastic syndromes significant myelofibrosis associated adverse outcomes p53 dysregulation CMML clinical molecular correlates significant myelofibrosis presentation remain poorly understood cohort 651 CMML patients identified retrospectively 20 3.1 cases moderate severe reticulin fibrosis CMML-F detected diagnosis compared CMML patients fibrosis n=631 seen period Patients CMML-F median age 69.8 years range 24.8 91.2 13 65 men Patients CMML-F differed significantly CMML patients following parameters white blood count absolute monocyte count serum lactate dehydrogenase level splenomegaly bone marrow blast percentage Notably frequency JAK2 p.V617F higher CMML-F patients compared CMML patients P 0.001 CMML-F patients 12/20 60 myeloproliferative CMML Dysregulation p53 uncommon CMML-F. CMML-F patients tended shorter median overall survival compared CMML patients P=0.079 Multivariate Cox proportional hazards model showed independent association CMML-F overall survival P=0.047 summary unlike typical CMML CMML-F commonly associated JAK2 p.V617F high frequency myeloproliferative features JAK2 p.V617F low frequency p53 dysregulation suggest fibrosis context CMML different pathogenesis previously reported myelodysplastic syndrome,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[8, 697, 1, 7, 5, 442, 5451, 3382, 2740, 5, 724, 4637, 4, 2040, 93, 4637, 71, 85, 41, 5, 290, 123, 2, 624, 3935, 137, 4, 3382, 3, 38, 2, 219, 1871, 1, 93, 4637, 28, 1031, 918, 1240, 1784, 29, 8, 180, 1, 13114, 3382, 7, 21, 108, 894, 179, 27, 14, 140, 5, 1163, 6, 905, 19464, 3000, 3382, 1068, 530, 28, 147, 2, 21, 72, 1370, 6, 3382, 7, 187, 3000, 78, 14576, 527, 190, 3, 827, 727, 7, 5, 3382, 1068, 42, 8, 52, 89, 1, 790, 66, 60, 184, 259, 66, 6, 970, 18, 2055, 2, 96, 233, 556, 11, 325, 7, 5, 3382, 1068, 2512, 97, 29, 127, 3382, 7, 716, 3, 366, 1038, 886, 315, 1276, 1766, 5231, 1276, 524, 3330, 2374, 301, 6364, 2, 581, 3112, 1150, 2552, 3, 675, 1, 2509, 19, 5657, 258, 10, 142, 4, 3382, 1068, 7, 72, 5, 127, 3382, 7, 19, 13, 144, 96, 3382, 1068, 7, 133, 179, 335, 42, 3382, 3935, 1, 624, 10, 2052, 4, 3382, 1068, 3382, 1068, 7, 3886, 6, 47, 8, 985, 52, 63, 25, 72, 5, 127, 3382, 7, 19, 13, 12510, 331, 65, 75, 3, 418, 831, 1017, 202, 224, 35, 306, 248, 59, 3382, 1068, 2, 63, 25, 19, 13, 5296, 4, 1962, 4246, 3476, 3382, 3382, 1068, 16, 841, 41, 5, 2509, 19, 5657, 3, 64, 675, 1, 404, 2, 2509, 19, 5657, 258, 2, 3, 154, 675, 1, 624, 3935, 309, 17, 3000, 4, 3, 1533, 1, 3382, 71, 8, 338, 1384, 29, 17, 373, 210, 4, 681]",1621.0,29596070,Chronic Myelomonocytic Leukemia Fibrosis Distinct Disease Subset Myeloproliferative Features Frequent JAK2 p.V617F,4,0.006980802792321117
Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation.,Blood,Blood,2018-04-02,"Although survival outcomes have significantly improved, up to 40% of patients die within 1 year of HLA-matched unrelated-donor blood and marrow transplantation (BMT). To identify non-HLA genetic contributors to mortality after BMT, we performed the first exome-wide association study in the DISCOVeRY-BMT cohorts using the Illumina HumanExome BeadChip. This study includes 2473 patients with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome and 2221 10/10 HLA-matched donors treated from 2000 to 2011. Single-variant and gene-level analyses were performed on overall survival (OS), transplantation-related mortality (TRM), and disease-related mortality (DRM). Genotype mismatches between recipients and donors in a rare nonsynonymous variant of testis-expressed gene <i>TEX38</i> significantly increased risk of TRM, which was more dramatic when either the recipient or donor was female. Using the SKAT-O test to evaluate gene-level effects, variant genotypes of <i>OR51D1</i> in recipients were significantly associated with OS and TRM. In donors, 4 (<i>ALPP</i>, <i>EMID1</i>, <i>SLC44A5</i>, <i>LRP1</i>), 1 (<i>HHAT</i>), and 2 genes (<i>LYZL4</i>, <i>NT5E</i>) were significantly associated with OS, TRM, and DRM, respectively. Inspection of NT5E crystal structures showed 4 of the associated variants affected the enzyme structure and likely decreased the catalytic efficiency of the enzyme. Further confirmation of these findings and additional functional studies may provide individualized risk prediction and prognosis, as well as alternative donor selection strategies.",Journal Article,659.0,4.0,survival outcomes significantly improved 40 patients die 1 year HLA-matched unrelated-donor blood marrow transplantation BMT identify non-HLA genetic contributors mortality BMT performed exome-wide association DISCOVeRY-BMT cohorts Illumina HumanExome BeadChip includes 2473 patients acute myeloid leukemia acute lymphoblastic leukemia myelodysplastic syndrome 2221 10/10 HLA-matched donors treated 2000 2011 Single-variant gene-level performed overall survival OS transplantation-related mortality TRM disease-related mortality DRM Genotype mismatches recipients donors rare nonsynonymous testis-expressed TEX38 /i significantly increased risk TRM dramatic recipient donor female SKAT-O test evaluate gene-level effects genotypes OR51D1 /i recipients significantly associated OS TRM donors 4 ALPP /i EMID1 /i SLC44A5 /i LRP1 /i 1 HHAT /i 2 LYZL4 /i NT5E /i significantly associated OS TRM DRM respectively Inspection NT5E crystal structures showed 4 associated affected enzyme structure likely decreased catalytic efficiency enzyme confirmation findings additional functional studies provide individualized risk prediction prognosis alternative donor selection strategies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 25, 123, 47, 97, 231, 126, 6, 327, 1, 7, 3384, 262, 14, 111, 1, 1160, 655, 2092, 1488, 315, 2, 581, 497, 4611, 6, 255, 220, 1160, 336, 9680, 6, 282, 50, 4611, 21, 173, 3, 157, 2865, 1019, 248, 45, 4, 3, 1574, 4611, 736, 75, 3, 7457, 72501, 16111, 26, 45, 1920, 39392, 7, 5, 286, 533, 286, 1275, 15, 681, 2, 72502, 79, 79, 1160, 655, 2344, 73, 29, 1081, 6, 1132, 226, 1142, 2, 145, 301, 318, 11, 173, 23, 63, 25, 118, 497, 139, 282, 5064, 2, 34, 139, 282, 26786, 1183, 11828, 59, 2190, 2, 2344, 4, 8, 622, 10233, 1142, 1, 7697, 570, 145, 70, 72503, 70, 97, 101, 43, 1, 5064, 92, 10, 80, 3079, 198, 361, 3, 5783, 15, 1488, 10, 1061, 75, 3, 36265, 1990, 412, 6, 376, 145, 301, 176, 1142, 2071, 1, 70, 72504, 70, 4, 2190, 11, 97, 41, 5, 118, 2, 5064, 4, 2344, 39, 70, 72505, 70, 70, 72506, 70, 70, 72507, 70, 70, 16997, 70, 14, 70, 72508, 70, 2, 18, 214, 70, 72509, 70, 70, 50975, 70, 11, 97, 41, 5, 118, 5064, 2, 26786, 106, 11746, 1, 50975, 9197, 2414, 224, 39, 1, 3, 41, 839, 1424, 3, 1644, 2772, 2, 322, 340, 3, 4784, 2904, 1, 3, 1644, 195, 3551, 1, 46, 272, 2, 402, 583, 94, 68, 377, 2596, 43, 1590, 2, 356, 22, 149, 22, 1091, 1488, 881, 422]",1517.0,29610366,Exome chip identify affecting mortality HLA-matched unrelated-donor blood marrow transplantation,0,0.0
Characterization of IDH1 p.R132H Mutant Clones Using Mutation-specific Antibody in Myeloid Neoplasms.,The American journal of surgical pathology,Am. J. Surg. Pathol.,2018-05-01,"Isocitrate dehydrogenase 1 (IDH1) and IDH2 mutations occur in a variety of myeloid neoplasms. Immunohistochemistry (IHC)-based direct visualization of mutant clones of hematopoietic cells can be useful for rapid diagnostic screening and for monitoring treatment response. In this study, we first evaluated the sensitivity and specificity of the IDH1 p.R132H mutation-specific antibody by IHC. All IDH1 wild type cases (n=11) and IDH1 mutant cases with a non-p.R132H mutation (n=30) were negative by IHC, demonstrating 100% antibody specificity. All the initial diagnostic specimens with IDH1 p.R132H mutation including acute myeloid leukemia (n=30), myelodysplastic syndromes (MDS) (n=10), MDS/myeloproliferative neoplasms (MPN) (n=4), and MPN (n=5) were positive by IHC, demonstrating 100% antibody sensitivity. Both immature and mature myeloid cells showed immunoreactivity. Erythroid precursors, lymphoid cells, endothelial cells, and osteoblasts were consistently negative by IHC. We then evaluated the follow-up specimens with a known IDH1 mutation status including acute myeloid leukemia (n=23), MDS (n=2), MDS/MPN (n=2), and MPN (n=2). Thirty-three IDH1 p.R132H mutant cases were positive by IHC and 12 IDH1 mutation negative cases were negative by IHC. However, IHC reactivity in up to 25% of bone marrow cells was noted in 8 of 20 polymerase chain reaction-negative cases, all from patients with a known history of IDH1 p.R132H mutation indicating sampling error or a sensitivity issue with molecular tests. These data indicate that IHC is a highly specific and sensitive tool to detect IDH1 p.R132H mutation in bone marrow involved by myeloid neoplasms. In addition, IDH1 p.R132H IHC also allows localization and assessment of the maturation stage of the clones carrying the mutation.",Journal Article,630.0,2.0,Isocitrate dehydrogenase 1 IDH1 IDH2 occur variety myeloid neoplasms Immunohistochemistry IHC -based direct visualization clones hematopoietic useful rapid diagnostic screening monitoring treatment response evaluated sensitivity specificity IDH1 p.R132H mutation-specific antibody IHC IDH1 wild type cases n=11 IDH1 cases non-p.R132H n=30 negative IHC demonstrating 100 antibody specificity initial diagnostic specimens IDH1 p.R132H including acute myeloid leukemia n=30 myelodysplastic syndromes MDS n=10 MDS/myeloproliferative neoplasms MPN n=4 MPN n=5 positive IHC demonstrating 100 antibody sensitivity immature mature myeloid showed immunoreactivity Erythroid precursors lymphoid endothelial osteoblasts consistently negative IHC evaluated follow-up specimens known IDH1 status including acute myeloid leukemia n=23 MDS n=2 MDS/MPN n=2 MPN n=2 Thirty-three IDH1 p.R132H cases positive IHC 12 IDH1 negative cases negative IHC IHC reactivity 25 bone marrow noted 8 20 polymerase chain reaction-negative cases patients known history IDH1 p.R132H indicating sampling error sensitivity issue molecular tests indicate IHC highly specific sensitive tool detect IDH1 p.R132H bone marrow involved myeloid neoplasms addition IDH1 p.R132H IHC allows localization assessment maturation stage clones carrying,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[5795, 2374, 14, 2662, 2, 4520, 138, 1271, 4, 8, 1362, 1, 533, 1179, 888, 1289, 90, 1196, 6234, 1, 620, 2749, 1, 1007, 37, 122, 40, 999, 9, 1321, 752, 453, 2, 9, 1315, 24, 51, 4, 26, 45, 21, 157, 194, 3, 485, 2, 1121, 1, 3, 2662, 19, 9312, 258, 112, 548, 20, 1289, 62, 2662, 955, 267, 140, 78, 175, 2, 2662, 620, 140, 5, 8, 220, 19, 9312, 258, 78, 201, 11, 199, 20, 1289, 2219, 394, 548, 1121, 62, 3, 388, 752, 623, 5, 2662, 19, 9312, 258, 141, 286, 533, 78, 201, 2040, 1223, 78, 79, 1223, 10857, 1179, 4125, 78, 39, 2, 4125, 78, 33, 11, 109, 20, 1289, 2219, 394, 548, 485, 110, 5733, 2, 2908, 533, 37, 224, 4900, 7839, 4881, 2303, 37, 845, 37, 2, 5965, 11, 2433, 199, 20, 1289, 21, 818, 194, 3, 166, 126, 623, 5, 8, 440, 2662, 258, 156, 141, 286, 533, 78, 382, 1223, 78, 18, 1223, 4125, 78, 18, 2, 4125, 78, 18, 977, 169, 2662, 19, 9312, 620, 140, 11, 109, 20, 1289, 2, 133, 2662, 258, 199, 140, 11, 199, 20, 1289, 137, 1289, 4601, 4, 126, 6, 243, 1, 581, 37, 10, 1051, 4, 66, 1, 179, 1451, 1260, 1329, 199, 140, 62, 29, 7, 5, 8, 440, 532, 1, 2662, 19, 9312, 258, 1716, 2874, 3444, 15, 8, 485, 2537, 5, 219, 895, 46, 74, 1008, 17, 1289, 16, 8, 561, 112, 2, 745, 1515, 6, 1426, 2662, 19, 9312, 258, 4, 581, 646, 20, 533, 1179, 4, 352, 2662, 19, 9312, 1289, 120, 2333, 2145, 2, 455, 1, 3, 4537, 82, 1, 3, 2749, 2934, 3, 258]",1693.0,29635257,Characterization IDH1 p.R132H Clones Mutation-specific Antibody Myeloid Neoplasms,0,0.0
"Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.",Cancer,Cancer,2018-04-16,"Indisulam possesses anticancer properties through down-regulation of various cell-cycle checkpoint molecules, thereby blocking the phosphorylation of retinoblastoma protein and inducing p53 and p21. Indisulam exhibits synergy with nucleoside analogs and topoisomerase inhibitors. The authors designed a phase 2 study of indisulam in combination with idarubicin and cytarabine in patients who had relapsed/refractory acute myeloid leukemia AML and high-risk myelodysplastic syndrome. In stage 1, patients received intravenous indisulam at 400mg/m<sup>2</sup> on days 1 and 8 of a 28-day cycle. If they had no response, then patients received same dose schedule of indisulam followed by intravenous idarubicin 8mg/m<sup>2</sup> daily for 3 days and cytarabine 1.0g/m<sup>2</sup> over 24 hours daily on days 9 through 12 (for those aged<60 years) or days 9 through 11 (for those aged>60 years) of a 28-day cycle. Primary endpoints included the overall response rate, and secondary objectives included overall survival. Forty patients were enrolled. Of the 37 evaluable patients, 31 received indisulam with chemotherapy. Of these, 11 (35%) responded for a median duration of 5.3 months. The estimated 1-year overall survival rate was 51% for responders compared with 8 % for nonresponders (P<.001). The most common grade 3 nonhematologic toxicities were electrolyte abnormalities (50%) and febrile neutropenia (28%). The combination of indisulam with idarubicin and cytarabine yielded a 35% response rate in heavily pretreated patients with AML. With emerging data identifying the expression of DCAF15 (DDB1 and CUL4-associated factor 15) as a potential biomarker for activity, the combination of indisulam with idarubicin and cytarabine should be studied in a biomarker-driven trial or in patients who have splicing factor mutations. Cancer 2018;124:2758-65.  2018 American Cancer Society. Cancer 2018;124:2758-2765.  2018 American Cancer Society.","Clinical Trial, Phase II",645.0,7.0,Indisulam possesses anticancer properties down-regulation cell-cycle checkpoint molecules blocking phosphorylation retinoblastoma inducing p53 p21 Indisulam exhibits synergy nucleoside analogs topoisomerase inhibitors authors designed phase 2 indisulam combination idarubicin cytarabine patients relapsed/refractory acute myeloid leukemia AML high-risk myelodysplastic syndrome stage 1 patients received intravenous indisulam 400 mg/m sup 2 /sup days 1 8 28-day cycle response patients received dose schedule indisulam followed intravenous idarubicin 8 mg/m sup 2 /sup daily 3 days cytarabine 1.0 g/m sup 2 /sup 24 hours daily days 9 12 aged 60 years days 9 11 aged 60 years 28-day cycle Primary endpoints included overall response rate secondary objectives included overall survival patients enrolled 37 evaluable patients 31 received indisulam chemotherapy 11 35 responded median duration 5.3 months estimated 1-year overall survival rate 51 responders compared 8 nonresponders P .001 common grade 3 nonhematologic toxicities electrolyte abnormalities 50 febrile neutropenia 28 combination indisulam idarubicin cytarabine yielded 35 response rate heavily pretreated patients AML emerging identifying expression DCAF15 DDB1 CUL4-associated factor 15 potential biomarker activity combination indisulam idarubicin cytarabine studied biomarker-driven trial patients splicing factor 2018 124:2758-65  2018 American Society 2018 124:2758-2765  2018 American Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[25857, 9857, 1475, 1571, 298, 1328, 863, 1, 747, 31, 417, 986, 1598, 2267, 2521, 3, 982, 1, 178, 2, 1958, 624, 2, 2657, 25857, 4273, 3439, 5, 4032, 4063, 2, 3999, 222, 3, 738, 1114, 8, 124, 18, 45, 1, 25857, 4, 150, 5, 5684, 2, 1855, 4, 7, 54, 42, 591, 430, 286, 533, 329, 2, 64, 43, 681, 4, 82, 14, 7, 103, 1262, 25857, 28, 1524, 81, 188, 172, 18, 172, 23, 162, 14, 2, 66, 1, 8, 339, 218, 417, 492, 491, 42, 77, 51, 818, 7, 103, 827, 61, 1055, 1, 25857, 370, 20, 1262, 5684, 66, 81, 188, 172, 18, 172, 391, 9, 27, 162, 2, 1855, 14, 13, 499, 188, 172, 18, 172, 252, 259, 1459, 391, 23, 162, 83, 298, 133, 9, 135, 1032, 335, 60, 15, 162, 83, 298, 175, 9, 135, 1032, 335, 60, 1, 8, 339, 218, 417, 86, 1387, 159, 3, 63, 51, 116, 2, 568, 2409, 159, 63, 25, 1213, 7, 11, 346, 1, 3, 567, 859, 7, 456, 103, 25857, 5, 56, 1, 46, 175, 465, 2211, 9, 8, 52, 654, 1, 33, 27, 53, 3, 661, 14, 111, 63, 25, 116, 10, 725, 9, 1983, 72, 5, 66, 9, 4498, 19, 144, 3, 96, 186, 88, 2608, 3534, 385, 11, 10834, 1171, 212, 2, 2498, 778, 339, 3, 150, 1, 25857, 5, 5684, 2, 1855, 2178, 8, 465, 51, 116, 4, 2447, 2193, 7, 5, 329, 5, 1478, 74, 1386, 3, 55, 1, 72579, 32290, 2, 72580, 41, 161, 167, 22, 8, 174, 901, 9, 128, 3, 150, 1, 25857, 5, 5684, 2, 1855, 257, 40, 656, 4, 8, 901, 1621, 160, 15, 4, 7, 54, 47, 3895, 161, 138, 12, 2982, 2834, 42022, 556, 2206, 2982, 597, 12, 1174, 12, 2982, 2834, 42022, 44516, 2206, 2982, 597, 12, 1174]",1862.0,29660836,Final phase 2 open-label indisulam idarubicin cytarabine patients relapsed refractory acute myeloid leukemia high-risk myelodysplastic syndrome,19,0.03315881326352531
Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.,Blood advances,Blood Adv,2018-05-01,"Optimal donor selection is critical for successful allogeneic hematopoietic cell transplantation (HCT). Donor sex and parity are well-established risk factors for graft-versus-host disease (GVHD), with male donors typically associated with lower rates of GVHD. Well-matched unrelated donors (URDs) have also been associated with increased risks of GVHD as compared with matched sibling donors. These observations raise the question of whether male URDs would lead to more (or less) favorable transplant outcomes as compared with parous female sibling donors. We used the Center for International Blood and Marrow Transplant Research registry to complete a retrospective cohort study in adults with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome, who underwent T-cell replete HCT from these 2 donor types (parous female sibling or male URD) between 2000 and 2012. Primary outcomes included grade 2 to 4 acute GVHD (aGVHD), chronic GVHD (cGVHD), and overall survival. Secondary outcomes included disease-free survival, transplant-related mortality, and relapse. In 2813 recipients, patients receiving male URD transplants (n = 1921) had 1.6 times higher risk of grade 2 to 4 aGVHD (<i>P</i> < .0001). For cGVHD, recipient sex was a significant factor, so donor/recipient pairs were evaluated. Female recipients of male URD grafts had a higher risk of cGVHD than those receiving parous female sibling grafts (relative risk [RR] = 1.43, <i>P</i> < .0001), whereas male recipients had similar rates of cGVHD regardless of donor type (RR = 1.09, <i>P</i> = .23). Donor type did not significantly affect any other end point. We conclude that when available, parous female siblings are preferred over male URDs.",Clinical Trial,630.0,2.0,Optimal donor selection critical successful allogeneic hematopoietic transplantation HCT Donor sex parity well-established risk factors graft-versus-host disease GVHD male donors typically associated lower rates GVHD Well-matched unrelated donors URDs associated increased risks GVHD compared matched sibling donors observations raise question male URDs lead favorable transplant outcomes compared parous female sibling donors Center International Blood Marrow Transplant Research registry complete retrospective cohort adults acute myeloid leukemia acute lymphoblastic leukemia myelodysplastic syndrome underwent T-cell replete HCT 2 donor types parous female sibling male URD 2000 2012 Primary outcomes included grade 2 4 acute GVHD aGVHD chronic GVHD cGVHD overall survival Secondary outcomes included disease-free survival transplant-related mortality relapse 2813 recipients patients receiving male URD transplants n 1921 1.6 times higher risk grade 2 4 aGVHD P /i .0001 cGVHD recipient sex significant factor donor/recipient pairs evaluated Female recipients male URD grafts higher risk cGVHD receiving parous female sibling grafts relative risk RR 1.43 P /i .0001 male recipients similar rates cGVHD regardless donor type RR 1.09 P /i .23 Donor type significantly affect end point conclude available parous female siblings preferred male URDs,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[665, 1488, 881, 16, 740, 9, 1401, 1063, 1007, 31, 497, 1085, 1488, 1035, 2, 5754, 32, 149, 635, 43, 130, 9, 1599, 185, 1204, 34, 1562, 5, 1045, 2344, 1969, 41, 5, 280, 151, 1, 1562, 149, 655, 2092, 2344, 15979, 47, 120, 85, 41, 5, 101, 1098, 1, 1562, 22, 72, 5, 655, 3684, 2344, 46, 2172, 5008, 3, 2840, 1, 317, 1045, 15979, 688, 1122, 6, 80, 15, 299, 913, 941, 123, 22, 72, 5, 10191, 1061, 3684, 2344, 21, 95, 3, 574, 9, 944, 315, 2, 581, 941, 389, 1608, 6, 236, 8, 459, 180, 45, 4, 857, 5, 286, 533, 286, 1275, 15, 681, 54, 208, 102, 31, 11151, 1085, 29, 46, 18, 1488, 630, 10191, 1061, 3684, 15, 1045, 5847, 59, 1081, 2, 1195, 86, 123, 159, 88, 18, 6, 39, 286, 1562, 5873, 442, 1562, 6670, 2, 63, 25, 568, 123, 159, 34, 115, 25, 941, 139, 282, 2, 429, 4, 72725, 2190, 7, 357, 1045, 5847, 4016, 78, 49670, 42, 14, 49, 1072, 142, 43, 1, 88, 18, 6, 39, 5873, 70, 19, 70, 488, 9, 6670, 5783, 1035, 10, 8, 93, 161, 1743, 1488, 5783, 2773, 11, 194, 1061, 2190, 1, 1045, 5847, 4713, 42, 8, 142, 43, 1, 6670, 76, 135, 357, 10191, 1061, 3684, 4713, 580, 43, 861, 14, 601, 70, 19, 70, 488, 547, 1045, 2190, 42, 288, 151, 1, 6670, 1583, 1, 1488, 267, 861, 14, 1730, 70, 19, 70, 382, 1488, 267, 205, 44, 97, 1158, 500, 127, 396, 741, 21, 2060, 17, 198, 390, 10191, 1061, 2758, 32, 2514, 252, 1045, 15979]",1635.0,29739773,Graft-versus-host disease recipients male unrelated donor compared parous female sibling donor transplants,0,0.0
Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study.,The Journal of infection,J. Infect.,2018-05-07,"To compare the effectiveness and tolerability of micafungin versus posaconazole during chemotherapy-induced neutropenia in acute leukemia (AL) and myelodysplastic syndrome (MDS). Patients with AL or MDS undergoing chemotherapy were randomized to open-label micafungin 100mg intravenously daily or posaconazole suspension 400mg orally twice daily until neutrophil recovery, up to 28 days. Patients were followed for 12 weeks. The primary endpoint was prophylaxis failure (premature discontinuation due to infection, intolerance, adverse event, or death). Time to failure and survival were calculated by Kaplan-Meier analysis. From March 2011 to May 2016, 113 patients who received at least 2 doses of prophylaxis were analyzed (58 patients randomized to micafungin and 55 to posaconazole). Prophylaxis failure occurred in 34.5% and 52.7% of patients on micafungin and posaconazole, respectively (P=0.0118). The median number of days on prophylaxis was 16 [interquartile range (IQR) 12-20] for micafungin and 13 [IQR 6-16] for posaconazole (P=0.01). Micafungin failures were largely due to antifungal treatment; posaconazole failures were mostly due to gastrointestinal intolerance or adverse effects. IFI incidence and survival were similar between study arms. Our data support micafungin as alternative antifungal prophylaxis in patients with AL and MDS.",Comparative Study,624.0,6.0,compare effectiveness tolerability micafungin versus posaconazole chemotherapy-induced neutropenia acute leukemia myelodysplastic syndrome MDS Patients MDS undergoing chemotherapy randomized open-label micafungin 100 mg intravenously daily posaconazole suspension 400 mg orally twice daily neutrophil recovery 28 days Patients followed 12 weeks primary endpoint prophylaxis failure premature discontinuation infection intolerance adverse event death Time failure survival calculated Kaplan-Meier March 2011 2016 113 patients received 2 doses prophylaxis 58 patients randomized micafungin 55 posaconazole Prophylaxis failure occurred 34.5 52.7 patients micafungin posaconazole respectively P 0.0118 median number days prophylaxis 16 interquartile range IQR 12-20 micafungin 13 IQR 6-16 posaconazole P 0.01 Micafungin failures largely antifungal treatment posaconazole failures gastrointestinal intolerance adverse effects IFI incidence survival similar arms support micafungin alternative antifungal prophylaxis patients MDS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 932, 3, 1236, 2, 1543, 1, 17479, 185, 10886, 190, 56, 277, 778, 4, 286, 2171, 2, 681, 1223, 7, 5, 2171, 15, 1223, 479, 56, 11, 384, 6, 1020, 1756, 17479, 394, 81, 1672, 391, 15, 10886, 9348, 1524, 81, 1428, 936, 391, 1100, 2595, 1602, 126, 6, 339, 162, 7, 11, 370, 9, 133, 244, 3, 86, 1138, 10, 2049, 496, 5682, 2007, 520, 6, 930, 5266, 290, 774, 15, 273, 98, 6, 496, 2, 25, 11, 981, 20, 876, 882, 65, 29, 2363, 1132, 6, 68, 1390, 4259, 7, 54, 103, 28, 506, 18, 415, 1, 2049, 11, 311, 717, 7, 384, 6, 17479, 2, 614, 6, 10886, 2049, 496, 489, 4, 562, 33, 2, 653, 67, 1, 7, 23, 17479, 2, 10886, 106, 19, 13, 44989, 3, 52, 207, 1, 162, 23, 2049, 10, 245, 2899, 184, 2245, 133, 179, 9, 17479, 2, 233, 2245, 49, 245, 9, 10886, 19, 13, 355, 17479, 3368, 11, 1733, 520, 6, 8606, 24, 10886, 3368, 11, 2754, 520, 6, 5266, 15, 290, 176, 24192, 287, 2, 25, 11, 288, 59, 45, 1335, 114, 74, 538, 17479, 22, 1091, 8606, 2049, 4, 7, 5, 2171, 2, 1223]",1276.0,29746955,Micafungin versus posaconazole prophylaxis acute leukemia myelodysplastic syndrome randomized,0,0.0
The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34<sup>+</sup>CD123<sup>+</sup> cells from acute myeloid leukemia/myelodysplastic syndrome patients and healthy donors.,Haematologica,Haematologica,2018-05-17,"Diseases with clonal hematopoiesis such as myelodysplastic syndrome and acute myeloid leukemia have high rates of relapse. Only a small subset of acute myeloid leukemia patients are cured with chemotherapy alone. Relapse in these diseases occurs at least in part due to the failure to eradicate leukemic stem cells or hematopoietic stem cells in myelodysplastic syndrome. CD123, the alpha chain of the interleukin-3 receptor heterodimer, is expressed on the majority of leukemic stem cells and myelodysplastic syndrome hematopoietic stem cells and in 80% of acute myeloid leukemia. Here, we report indiscriminate killing of CD123<sup>+</sup> normal and acute myeloid leukemia / myelodysplastic syndrome cells by SL-401, a diphtheria toxin interleukin-3 fusion protein. SL-401 induced cytotoxicity of CD123<sup>+</sup> primary cells/blasts from acute myeloid leukemia and myelodysplastic syndrome patients but not CD123<sup>-</sup> lymphoid cells. Importantly, SL-401 was highly active even in cells expressing low levels of CD123, with minimal effect on modulation of the CD123 target in acute myeloid leukemia. SL-401 significantly prolonged survival of leukemic mice in acute myeloid leukemia patient-derived xenograft mouse models. In addition to primary samples, studies on normal cord blood and healthy marrow show that SL-401 has activity against normal hematopoietic progenitors. These findings indicate potential use of SL-401 as a ""bridge-to-transplant"" before allogeneic hematopoietic cell transplantation in acute myeloid leukemia / myelodysplastic syndrome patients.",Journal Article,614.0,8.0,Diseases clonal hematopoiesis myelodysplastic syndrome acute myeloid leukemia high rates relapse small subset acute myeloid leukemia patients cured chemotherapy Relapse diseases occurs failure eradicate leukemic stem hematopoietic stem myelodysplastic syndrome CD123 alpha chain interleukin-3 receptor heterodimer expressed majority leukemic stem myelodysplastic syndrome hematopoietic stem 80 acute myeloid leukemia report indiscriminate killing CD123 sup /sup normal acute myeloid leukemia myelodysplastic syndrome SL-401 diphtheria toxin interleukin-3 fusion SL-401 induced cytotoxicity CD123 sup /sup primary cells/blasts acute myeloid leukemia myelodysplastic syndrome patients CD123 sup /sup lymphoid Importantly SL-401 highly active expressing low levels CD123 minimal effect modulation CD123 target acute myeloid leukemia SL-401 significantly prolonged survival leukemic mice acute myeloid leukemia patient-derived xenograft mouse models addition primary studies normal cord blood healthy marrow SL-401 activity normal hematopoietic progenitors findings indicate potential use SL-401 `` bridge-to-transplant '' allogeneic hematopoietic transplantation acute myeloid leukemia myelodysplastic syndrome patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1342, 5, 1946, 5114, 225, 22, 681, 2, 286, 533, 47, 64, 151, 1, 429, 158, 8, 302, 697, 1, 286, 533, 7, 32, 3733, 5, 56, 279, 429, 4, 46, 1342, 1780, 28, 506, 4, 760, 520, 6, 3, 496, 6, 5650, 2015, 452, 37, 15, 1007, 452, 37, 4, 681, 8849, 3, 950, 1260, 1, 3, 1603, 27, 153, 15819, 16, 570, 23, 3, 686, 1, 2015, 452, 37, 2, 681, 1007, 452, 37, 2, 4, 493, 1, 286, 533, 467, 21, 414, 26618, 3003, 1, 8849, 172, 172, 295, 2, 286, 533, 681, 37, 20, 6570, 7191, 8, 15853, 8848, 1603, 27, 1212, 178, 6570, 7191, 277, 1408, 1, 8849, 172, 172, 86, 37, 2438, 29, 286, 533, 2, 681, 7, 84, 44, 8849, 172, 172, 2303, 37, 1859, 6570, 7191, 10, 561, 544, 871, 4, 37, 1046, 154, 148, 1, 8849, 5, 1048, 254, 23, 2356, 1, 3, 8849, 283, 4, 286, 533, 6570, 7191, 97, 1069, 25, 1, 2015, 399, 4, 286, 533, 69, 526, 1330, 830, 274, 4, 352, 6, 86, 347, 94, 23, 295, 1885, 315, 2, 1331, 581, 514, 17, 6570, 7191, 71, 128, 480, 295, 1007, 4321, 46, 272, 1008, 174, 119, 1, 6570, 7191, 22, 8, 7728, 6, 941, 522, 348, 1063, 1007, 31, 497, 4, 286, 533, 681, 7]",1383.0,29773600,interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity CD34 sup /sup CD123 sup /sup acute myeloid leukemia/myelodysplastic syndrome patients healthy donors,21,0.03664921465968586
Consequences of mutant TET2 on clonality and subclonal hierarchy.,Leukemia,Leukemia,2018-05-24,"Somatic mutations in TET2 are common in myelodysplastic syndromes (MDS), myeloproliferative, and overlap syndromes. TET2 mutant (TET2<sup>MT</sup>) clones are also found in asymptomatic elderly individuals, a condition referred to as clonal hematopoiesis of indeterminate potential (CHIP). In various entities of TET2<sup>MT</sup> neoplasia, we examined the phenotype in relation to the strata of TET2 hits within the clonal hierarchy. Using deep sequencing, 1781 mutations were found in 1205 of 4930 patients; 40% of mutant cases were biallelic. Hierarchical analysis revealed that of TET2<sup>MT</sup> cases >40% were ancestral, e.g., representing 8% of MDS. Higher (earlier) TET2 lesion rank within the clonal hierarchy (greater clonal burden) was associated with impaired survival. Moreover, MDS driven by ancestral TET2<sup>MT</sup> is likely derived from TET2<sup>MT</sup> CHIP with a penetrance of ~1%. Following ancestral TET2 mutations, individual disease course is determined by secondary hits. Using multidimensional analyses, we demonstrate how hits following the TET2 founder defect induces phenotypic shifts toward dysplasia, myeloproliferation, or progression to AML. In summary, TET2<sup>MT</sup> CHIP-derived MDS is a subclass of MDS that is distinct from de novo disease.",Journal Article,607.0,7.0,Somatic TET2 common myelodysplastic syndromes MDS myeloproliferative overlap syndromes TET2 TET2 sup MT /sup clones asymptomatic elderly individuals condition referred clonal hematopoiesis indeterminate potential CHIP entities TET2 sup MT /sup neoplasia examined phenotype relation strata TET2 hits clonal hierarchy deep sequencing 1781 1205 4930 patients 40 cases biallelic Hierarchical revealed TET2 sup MT /sup cases 40 ancestral e.g. representing 8 MDS Higher earlier TET2 lesion rank clonal hierarchy greater clonal burden associated impaired survival MDS driven ancestral TET2 sup MT /sup likely derived TET2 sup MT /sup CHIP penetrance ~1 Following ancestral TET2 individual disease course determined secondary hits multidimensional demonstrate hits following TET2 founder defect induces phenotypic shifts dysplasia myeloproliferation progression AML summary TET2 sup MT /sup CHIP-derived MDS subclass MDS distinct novo disease,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1119, 138, 4, 5038, 32, 186, 4, 2040, 1223, 2, 4526, 2040, 5038, 620, 5038, 172, 4875, 172, 2749, 32, 120, 204, 4, 2100, 1216, 869, 8, 2850, 1995, 6, 22, 1946, 5114, 1, 5167, 174, 4222, 4, 747, 4613, 1, 5038, 172, 4875, 172, 2298, 21, 409, 3, 1005, 4, 2191, 6, 3, 5758, 1, 5038, 12397, 262, 3, 1946, 12517, 75, 2369, 615, 32592, 138, 11, 204, 4, 29362, 1, 72834, 7, 327, 1, 620, 140, 11, 6435, 4466, 65, 553, 17, 1, 5038, 172, 4875, 172, 140, 327, 11, 15165, 563, 499, 2861, 66, 1, 1223, 142, 1677, 5038, 1180, 1026, 262, 3, 1946, 12517, 378, 1946, 892, 10, 41, 5, 2364, 25, 1393, 1223, 1621, 20, 15165, 5038, 172, 4875, 172, 16, 322, 526, 29, 5038, 172, 4875, 172, 4222, 5, 8, 4792, 1, 14, 366, 15165, 5038, 138, 797, 34, 906, 16, 509, 20, 568, 12397, 75, 7002, 318, 21, 608, 832, 12397, 366, 3, 5038, 7243, 5398, 1516, 3290, 5906, 1317, 2253, 32883, 15, 91, 6, 329, 4, 1962, 5038, 172, 4875, 172, 4222, 526, 1223, 16, 8, 12352, 1, 1223, 17, 16, 834, 29, 1566, 2018, 34]",1209.0,29795413,Consequences TET2 clonality subclonal hierarchy,15,0.02617801047120419
"Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.",The Lancet. Oncology,Lancet Oncol.,2018-05-31,"Old age and FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations in patients with acute myeloid leukaemia are associated with early relapse and poor survival. Quizartinib is an oral, highly potent, and selective next-generation FLT3 inhibitor with clinical antileukaemic activity in relapsed or refractory acute myeloid leukaemia. We aimed to assess the efficacy and safety of single-agent quizartinib in patients with relapsed or refractory acute myeloid leukaemia. We did an open-label, multicentre, single-arm, phase 2 trial at 76 hospitals and cancer centres in the USA, Europe, and Canada. We enrolled patients with morphologically documented primary acute myeloid leukaemia or acute myeloid leukaemia secondary to myelodysplastic syndromes and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 into two predefined, independent cohorts: patients who were aged 60 years or older with relapsed or refractory acute myeloid leukaemia within 1 year after first-line therapy (cohort 1), and those who were 18 years or older with relapsed or refractory disease following salvage chemotherapy or haemopoietic stem cell transplantation (cohort 2). Patients with an FLT3-ITD allelic frequency of more than 10% were considered as FLT3-ITD positive, whereas all other patients were considered as FLT3-ITD negative. Patients received quizartinib once daily as an oral solution; the initial 17 patients received 200 mg per day but the QTcF interval was prolonged for more than 60 ms above baseline in some of these patients. Subsequently, doses were amended for all patients to 135 mg per day for men and 90 mg per day for women. The co-primary endpoints were the proportion of patients who achieved a composite complete remission (defined as complete remission+complete remission with incomplete platelet recovery+complete remission with incomplete haematological recovery) and the proportion of patients who achieved a complete remission. Efficacy and safety analyses included all patients who received at least one dose of quizartinib (ie, the intention-to-treat population). Patients with a locally assessed post-treatment bone marrow aspirate or biopsy were included in efficacy analyses by response; all other patients were considered to have an unknown response. This study is registered with ClinicalTrials.gov, number NCT00989261, and with the European Clinical Trials Database, EudraCT 2009-013093-41, and is completed. Between Nov 19, 2009, and Oct 31, 2011, a total of 333 patients were enrolled (157 in cohort 1 and 176 in cohort 2). In cohort 1, 63 (56%) of 112 FLT3-ITD-positive patients and 16 (36%) of 44 FLT3-ITD-negative patients achieved composite complete remission, with three (3%) FLT3-ITD-positive patients and two (5%) FLT3-ITD-negative patients achieving complete remission. In cohort 2, 62 (46%) of 136 FLT3-ITD-positive patients achieved composite complete remission with five (4%) achieving complete remission, whereas 12 (30%) of 40 FLT3-ITD-negative patients achieved composite complete remission with one (3%) achieving complete remission. Across both cohorts (ie, the intention-to-treat population of 333 patients), grade 3 or worse treatment-related treatment-emergent adverse events in 5% or more of patients were febrile neutropenia (76 [23%] of 333), anaemia (75 [23%]), thrombocytopenia (39 [12%]), QT interval corrected using Fridericia's formula (QTcF) prolongation (33 [10%]), neutropenia (31 [9%]), leucopenia (22 [7%]), decreased platelet count (20 [6%]), and pneumonia (17 [5%]). Serious adverse events occurring in 5% or more of patients were febrile neutropenia (126 [38%] of 333; 76 treatment related), acute myeloid leukaemia progression (73 [22%]), pneumonia (40 [12%]; 14 treatment related), QTcF prolongation (33 [10%]; 32 treatment related), sepsis (25 [8%]; eight treatment related), and pyrexia (18 [5%]; nine treatment related). Notable serious adverse events occurring in less than 5% of patients were torsades de pointes (one [<1%]) and hepatic failure (two [1%]). In total, 125 (38%) of 333 patients died within the study treatment period, including the 30-day follow-up. 18 (5%) patients died because of an adverse event considered by the investigator to be treatment related (ten [6%] of 157 patients in cohort 1 and eight [5%] of 176 in cohort 2. Single-agent quizartinib was shown to be highly active and generally well tolerated in patients with relapsed or refractory acute myeloid leukaemia, particularly those with FLT3-ITD mutations. These findings confirm that targeting the FLT3-ITD driver mutation with a highly potent and selective FLT3 inhibitor is a promising clinical strategy to help improve clinical outcomes in patients with very few options. Phase 3 studies (NCT02039726; NCT02668653) will examine quizartinib at lower starting doses. Ambit Biosciences/Daiichi Sankyo.","Clinical Trial, Phase II",600.0,62.0,Old age FMS-like tyrosine kinase 3 internal tandem duplication FLT3-ITD patients acute myeloid leukaemia associated early relapse poor survival Quizartinib oral highly potent selective next-generation FLT3 inhibitor clinical antileukaemic activity relapsed refractory acute myeloid leukaemia aimed assess efficacy safety single-agent quizartinib patients relapsed refractory acute myeloid leukaemia open-label multicentre single-arm phase 2 trial 76 hospitals centres USA Europe Canada enrolled patients morphologically documented primary acute myeloid leukaemia acute myeloid leukaemia secondary myelodysplastic syndromes Eastern Cooperative Oncology Group ECOG performance status 0-2 predefined independent cohorts patients aged 60 years older relapsed refractory acute myeloid leukaemia 1 year first-line therapy cohort 1 18 years older relapsed refractory disease following salvage chemotherapy haemopoietic stem transplantation cohort 2 Patients FLT3-ITD allelic frequency 10 considered FLT3-ITD positive patients considered FLT3-ITD negative Patients received quizartinib daily oral solution initial 17 patients received 200 mg day QTcF interval prolonged 60 ms baseline patients Subsequently doses amended patients 135 mg day men 90 mg day women co-primary endpoints proportion patients achieved composite complete remission defined complete remission complete remission incomplete platelet recovery complete remission incomplete haematological recovery proportion patients achieved complete remission Efficacy safety included patients received dose quizartinib intention-to-treat population Patients locally assessed post-treatment bone marrow aspirate biopsy included efficacy response patients considered unknown response registered ClinicalTrials.gov number NCT00989261 European Clinical Trials Database EudraCT 2009-013093-41 completed Nov 19 2009 Oct 31 2011 total 333 patients enrolled 157 cohort 1 176 cohort 2 cohort 1 63 56 112 FLT3-ITD-positive patients 16 36 44 FLT3-ITD-negative patients achieved composite complete remission 3 FLT3-ITD-positive patients 5 FLT3-ITD-negative patients achieving complete remission cohort 2 62 46 136 FLT3-ITD-positive patients achieved composite complete remission 4 achieving complete remission 12 30 40 FLT3-ITD-negative patients achieved composite complete remission 3 achieving complete remission cohorts intention-to-treat population 333 patients grade 3 worse treatment-related treatment-emergent adverse events 5 patients febrile neutropenia 76 23 333 anaemia 75 23 thrombocytopenia 39 12 QT interval corrected Fridericia 's formula QTcF prolongation 33 10 neutropenia 31 9 leucopenia 22 7 decreased platelet count 20 6 pneumonia 17 5 adverse events occurring 5 patients febrile neutropenia 126 38 333 76 treatment related acute myeloid leukaemia progression 73 22 pneumonia 40 12 14 treatment related QTcF prolongation 33 10 32 treatment related sepsis 25 8 treatment related pyrexia 18 5 treatment related Notable adverse events occurring 5 patients torsades pointes 1 hepatic failure 1 total 125 38 333 patients died treatment period including 30-day follow-up 18 5 patients died adverse event considered investigator treatment related 6 157 patients cohort 1 5 176 cohort 2 Single-agent quizartinib shown highly active generally tolerated patients relapsed refractory acute myeloid leukaemia particularly FLT3-ITD findings confirm targeting FLT3-ITD driver highly potent selective FLT3 inhibitor promising clinical strategy help improve clinical outcomes patients options Phase 3 studies NCT02039726 NCT02668653 examine quizartinib lower starting doses Ambit Biosciences/Daiichi Sankyo,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1095, 89, 2, 5516, 733, 564, 216, 27, 2329, 2905, 4616, 1224, 2837, 138, 4, 7, 5, 286, 533, 2001, 32, 41, 5, 191, 429, 2, 334, 25, 10379, 16, 35, 518, 561, 1157, 2, 1094, 1305, 914, 1224, 230, 5, 38, 20016, 128, 4, 591, 15, 430, 286, 533, 2001, 21, 1295, 6, 423, 3, 209, 2, 367, 1, 226, 420, 10379, 4, 7, 5, 591, 15, 430, 286, 533, 2001, 21, 205, 35, 1020, 1756, 5761, 226, 475, 124, 18, 160, 28, 846, 1987, 2, 12, 4496, 4, 3, 2706, 3934, 2, 4740, 21, 346, 7, 5, 6204, 1405, 86, 286, 533, 2001, 15, 286, 533, 2001, 568, 6, 2040, 2, 35, 2118, 1690, 413, 87, 2351, 528, 156, 1, 13, 18, 237, 100, 5944, 306, 736, 7, 54, 11, 1032, 335, 60, 15, 434, 5, 591, 15, 430, 286, 533, 2001, 262, 14, 111, 50, 157, 328, 36, 180, 14, 2, 135, 54, 11, 203, 60, 15, 434, 5, 591, 15, 430, 34, 366, 992, 56, 15, 21685, 452, 31, 497, 180, 18, 7, 5, 35, 1224, 2837, 3861, 675, 1, 80, 76, 79, 11, 515, 22, 1224, 2837, 109, 547, 62, 127, 7, 11, 515, 22, 1224, 2837, 199, 7, 103, 10379, 1059, 391, 22, 35, 518, 5829, 3, 388, 269, 7, 103, 1250, 81, 379, 218, 84, 3, 11340, 268, 10, 1069, 9, 80, 76, 335, 2307, 2090, 330, 4, 476, 1, 46, 7, 1611, 415, 11, 7595, 9, 62, 7, 6, 3978, 81, 379, 218, 9, 325, 2, 424, 81, 379, 218, 9, 117, 3, 1269, 86, 1387, 11, 3, 920, 1, 7, 54, 513, 8, 3308, 236, 734, 395, 22, 236, 734, 236, 734, 5, 2610, 1596, 1602, 236, 734, 5, 2610, 5143, 1602, 2, 3, 920, 1, 7, 54, 513, 8, 236, 734, 209, 2, 367, 318, 159, 62, 7, 54, 103, 28, 506, 104, 61, 1, 10379, 2523, 3, 3205, 6, 943, 266, 7, 5, 8, 795, 275, 539, 24, 581, 8022, 15, 411, 11, 159, 4, 209, 318, 20, 51, 62, 127, 7, 11, 515, 6, 47, 35, 860, 51, 26, 45, 16, 1653, 5, 1252, 1239, 207, 72942, 2, 5, 3, 1865, 38, 143, 609, 14681, 1238, 72943, 605, 2, 16, 781, 59, 10369, 326, 1238, 2, 5137, 456, 1132, 8, 181, 1, 9616, 7, 11, 346, 5311, 4, 180, 14, 2, 5800, 4, 180, 18, 4, 180, 14, 676, 664, 1, 3726, 1224, 2837, 109, 7, 2, 245, 511, 1, 584, 1224, 2837, 199, 7, 513, 3308, 236, 734, 5, 169, 27, 1224, 2837, 109, 7, 2, 100, 33, 1224, 2837, 199, 7, 1785, 236, 734, 4, 180, 18, 744, 641, 1, 4829, 1224, 2837, 109, 7, 513, 3308, 236, 734, 5, 365, 39, 1785, 236, 734, 547, 133, 201, 1, 327, 1224, 2837, 199, 7, 513, 3308, 236, 734, 5, 104, 27, 1785, 236, 734, 716, 110, 736, 2523, 3, 3205, 6, 943, 266, 1, 9616, 7, 88, 27, 15, 639, 24, 139, 24, 4348, 290, 281, 4, 33, 15, 80, 1, 7, 11, 2498, 778, 846, 382, 1, 9616, 5712, 481, 382, 1340, 587, 133, 9283, 268, 3848, 75, 24040, 292, 7986, 11340, 4464, 466, 79, 778, 456, 83, 10317, 350, 67, 340, 1596, 1276, 179, 49, 2, 3485, 269, 33, 1762, 290, 281, 1821, 4, 33, 15, 80, 1, 7, 11, 2498, 778, 3927, 519, 1, 9616, 846, 24, 139, 286, 533, 2001, 91, 803, 350, 3485, 327, 133, 213, 24, 139, 11340, 4464, 466, 79, 531, 24, 139, 4227, 243, 66, 659, 24, 139, 2, 8417, 203, 33, 762, 24, 139, 4090, 1762, 290, 281, 1821, 4, 299, 76, 33, 1, 7, 11, 42076, 1566, 42077, 104, 14, 2, 939, 496, 100, 14, 4, 181, 1731, 519, 1, 9616, 7, 1016, 262, 3, 45, 24, 727, 141, 3, 201, 218, 166, 126, 203, 33, 7, 1016, 408, 1, 35, 290, 774, 515, 20, 3, 3464, 6, 40, 24, 139, 1618, 49, 1, 5311, 7, 4, 180, 14, 2, 659, 33, 1, 5800, 4, 180, 18, 226, 420, 10379, 10, 443, 6, 40, 561, 544, 2, 1228, 149, 421, 4, 7, 5, 591, 15, 430, 286, 533, 2001, 823, 135, 5, 1224, 2837, 138, 46, 272, 1843, 17, 529, 3, 1224, 2837, 2228, 258, 5, 8, 561, 1157, 2, 1094, 1224, 230, 16, 8, 721, 38, 692, 6, 987, 401, 38, 123, 4, 7, 5, 923, 1021, 838, 124, 27, 94, 72944, 50696, 303, 1004, 10379, 28, 280, 1723, 415, 72945, 39386, 39804, 39805]",4645.0,29859851,Quizartinib FLT3 inhibitor monotherapy patients relapsed refractory acute myeloid leukaemia open-label multicentre single-arm phase 2 trial,0,0.0
Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall.,The American Journal of dermatopathology,Am J Dermatopathol,2018-11-01,"Myeloid sarcoma is a rare extramedullary hematologic malignancy. Accurate and timely diagnosis may be challenging because myeloid sarcoma is known to mimic solid tumors, including hepatobiliary, nasopharyngeal, and breast carcinomas. We report a case of myeloid sarcoma that developed in the primary tumor lymphatic drainage field of a previously treated intermediate-thickness cutaneous melanoma, clinically and radiographically mimicking an in-transit metastasis, in a patient with myelodysplastic syndrome. The diagnosis of myeloid sarcoma was achieved after surgical excision of the mass and pathological examination that included extensive immunohistochemical studies. Awareness of such an unusual clinical presentation can help reduce diagnostic delay and ensure that adequate tissue is obtained for pathological examination and ancillary studies that are critical for accurate diagnosis and appropriate patient management.",Case Reports,446.0,0.0,Myeloid sarcoma rare extramedullary hematologic malignancy Accurate timely diagnosis challenging myeloid sarcoma known mimic solid including hepatobiliary nasopharyngeal breast carcinomas report case myeloid sarcoma developed primary lymphatic drainage field previously treated intermediate-thickness cutaneous melanoma clinically radiographically mimicking in-transit metastasis patient myelodysplastic syndrome diagnosis myeloid sarcoma achieved surgical excision mass pathological examination included extensive immunohistochemical studies Awareness unusual clinical presentation help reduce diagnostic delay ensure adequate tissue obtained pathological examination ancillary studies critical accurate diagnosis appropriate patient management,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[533, 16, 8, 622, 5508, 813, 710, 1481, 2, 4225, 147, 68, 40, 1950, 408, 533, 16, 440, 6, 5356, 537, 57, 141, 4718, 2, 826, 21, 414, 8, 473, 1, 533, 17, 276, 4, 3, 86, 30, 2936, 3528, 1067, 1, 8, 373, 73, 919, 2903, 1486, 505, 2, 5770, 8191, 35, 4, 6432, 278, 4, 8, 69, 5, 681, 3, 147, 1, 533, 10, 513, 50, 221, 1366, 1, 3, 782, 2, 1301, 1385, 17, 159, 1344, 1382, 94, 3310, 1, 225, 35, 4015, 38, 1031, 122, 987, 969, 752, 1984, 2, 3478, 17, 1658, 246, 16, 683, 9, 1301, 1385, 2, 8496, 94, 17, 32, 740, 9, 1481, 147, 2, 870, 69, 284]",840.0,29863571,Case Report Myeloid Sarcoma Masquerading In-Transit Metastasis Previous Melanoma Site Avoiding Diagnostic Pitfall,0,0.0
CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2018-06-20,"Relapse is the main cause of treatment failure after allogeneic stem cell transplant (alloSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Injectable azacitidine can improve post-transplant outcomes but presents challenges with exposure and compliance. Oral CC-486 allows extended dosing to prolong azacitidine activity. We investigated use of CC-486 maintenance therapy after alloSCT. Adults with MDS or AML in morphologic complete remission at CC-486 initiation (42 to 84 days after alloSCT) were included. Patients received 1 of 4 CC-486 dosing schedules per 28-day cycle for up to 12 cycles. Endpoints included safety, pharmacokinetics, graft-versus-host disease (GVHD) incidence, relapse/progression rate, and survival. Of 30 patients, 7 received CC-486 once daily for 7 days per cycle (200 mg, n=3; 300 mg, n=4) and 23 for 14 days per cycle (150 mg, n=4; 200 mg, n=19 [expansion cohort]). Grades 3 to 4 adverse events were infrequent and occurred with similar frequency across regimens. Standard concomitant medications did not alter CC-486 pharmacokinetic parameters. Three patients (10%) experienced grade III acute GVHD and 9 experienced chronic GVHD. Of 28 evaluable patients, 6 (21%) relapsed or had progressive disease: 3 of 7 patients (43%) who had received 7-day dosing and 3 of 23 (13%) who had received 14-day dosing. Transplant-related mortality was 3%. At 19 months of follow-up, median overall survival was not reached. Estimated 1-year survival rates were 86% and 81% in the 7-day and 14-day dosing cohorts, respectively. CC-486 maintenance was generally well tolerated, with low rates of relapse, disease progression, and GVHD. CC-486 maintenance may permit epigenetic manipulation of the alloreactive response postallograft. Findings require confirmation in randomized trials. (ClinicalTrials.gov NCT01835587.).",Clinical Trial,580.0,13.0,Relapse main cause treatment failure allogeneic stem transplant alloSCT acute myeloid leukemia AML myelodysplastic syndromes MDS Injectable azacitidine improve post-transplant outcomes presents challenges exposure compliance Oral CC-486 allows extended dosing prolong azacitidine activity investigated use CC-486 maintenance therapy alloSCT Adults MDS AML morphologic complete remission CC-486 initiation 42 84 days alloSCT included Patients received 1 4 CC-486 dosing schedules 28-day cycle 12 cycles Endpoints included safety pharmacokinetics graft-versus-host disease GVHD incidence relapse/progression rate survival 30 patients 7 received CC-486 daily 7 days cycle 200 mg n 3 300 mg n 4 23 14 days cycle 150 mg n 4 200 mg n 19 expansion cohort Grades 3 4 adverse events infrequent occurred similar frequency regimens Standard concomitant medications alter CC-486 pharmacokinetic parameters patients 10 experienced grade III acute GVHD 9 experienced chronic GVHD 28 evaluable patients 6 21 relapsed progressive disease 3 7 patients 43 received 7-day dosing 3 23 13 received 14-day dosing Transplant-related mortality 3 19 months follow-up median overall survival reached Estimated 1-year survival rates 86 81 7-day 14-day dosing cohorts respectively CC-486 maintenance generally tolerated low rates relapse disease progression GVHD CC-486 maintenance permit epigenetic manipulation alloreactive response postallograft Findings require confirmation randomized trials ClinicalTrials.gov NCT01835587,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[429, 16, 3, 1895, 708, 1, 24, 496, 50, 1063, 452, 31, 941, 7253, 4, 286, 533, 329, 2, 2040, 1223, 11652, 3752, 122, 401, 539, 941, 123, 84, 2740, 1427, 5, 645, 2, 3336, 518, 1951, 7582, 2333, 1747, 1280, 6, 3615, 3752, 128, 21, 565, 119, 1, 1951, 7582, 1146, 36, 50, 7253, 857, 5, 1223, 15, 329, 4, 2815, 236, 734, 28, 1951, 7582, 1118, 595, 6, 874, 162, 50, 7253, 11, 159, 7, 103, 14, 1, 39, 1951, 7582, 1280, 2314, 379, 339, 218, 417, 9, 126, 6, 133, 410, 1387, 159, 367, 1159, 1599, 185, 1204, 34, 1562, 287, 429, 91, 116, 2, 25, 1, 201, 7, 67, 103, 1951, 7582, 1059, 391, 9, 67, 162, 379, 417, 1250, 81, 78, 27, 2036, 81, 78, 39, 2, 382, 9, 213, 162, 379, 417, 1577, 81, 78, 39, 1250, 81, 78, 326, 1422, 180, 2276, 27, 6, 39, 290, 281, 11, 4475, 2, 489, 5, 288, 675, 716, 472, 260, 1781, 2679, 205, 44, 2688, 1951, 7582, 1456, 1038, 169, 7, 79, 592, 88, 316, 286, 1562, 2, 83, 592, 442, 1562, 1, 339, 859, 7, 49, 239, 591, 15, 42, 1014, 34, 27, 1, 67, 7, 601, 54, 42, 103, 67, 218, 1280, 2, 27, 1, 382, 233, 54, 42, 103, 213, 218, 1280, 941, 139, 282, 10, 27, 28, 326, 53, 1, 166, 126, 52, 63, 25, 10, 44, 1300, 661, 14, 111, 25, 151, 11, 868, 2, 865, 4, 3, 67, 218, 2, 213, 218, 1280, 736, 106, 1951, 7582, 1146, 10, 1228, 149, 421, 5, 154, 151, 1, 429, 34, 91, 2, 1562, 1951, 7582, 1146, 68, 5634, 1418, 6239, 1, 3, 13831, 51, 51132, 272, 1353, 3551, 4, 384, 143, 1252, 1239, 73097]",1762.0,29933073,CC-486 Maintenance Stem Transplantation Patients Acute Myeloid Leukemia Myelodysplastic Syndromes,26,0.04537521815008726
Paramount therapy for young and fit patients with mantle cell lymphoma: strategies for front-line therapy.,Journal of experimental & clinical cancer research : CR,J. Exp. Clin. Cancer Res.,2018-07-13,"The natural history of mantle cell lymphoma (MCL) is a continuous process with the vicious cycle of remission and recurrence. Because MCL cells are most vulnerable before their exposure to therapeutic agents, front-line therapy could eliminate MCL cells at the first strike, reduce the chance for secondary resistance, and cause long-term remissions. If optimized, it could become an alternative to cure MCL. The key is the intensity of front-line therapy. Both the Nordic 2 and the MD Anderson Cancer Center HCVAD trials, with follow-up times greater than 10years, achieved long-term survivals exceeding 10years. But the Achilles heel in both trials were the severe toxicities, such as secondary malignancies including myelodysplastic syndromes /leukemia. Therefore, intensive therapies can act as a double-edged sword providing long term survival at the cost of severe toxicities. In our opinion, although intensive chemotherapy can cause detrimental side effects, it is indispensable given that we run the risk of sacrificing long-term survivals in these young and fit patients. We must seek for a powerful alternative at the front-line. Furthermore, minimal residual disease negativity should be the optimal therapeutic goal to achieve before and after autologous stem cell transplantation. Some novel therapeutic strategies have shown to improve outcomes, but it is not yet clear as to how these results translate in population. Of note, MCL patients need to be stratified at diagnosis and be provided with different intensities of front-line regimen. In this review, we discuss current strategies for the treatment of young patients with newly diagnosed MCL.",Journal Article,557.0,0.0,natural history mantle lymphoma MCL continuous process vicious cycle remission recurrence MCL vulnerable exposure therapeutic agents front-line therapy eliminate MCL strike reduce chance secondary resistance cause long-term remissions optimized alternative cure MCL key intensity front-line therapy Nordic 2 MD Anderson Center HCVAD trials follow-up times greater 10 years achieved long-term survivals exceeding 10 years Achilles heel trials severe toxicities secondary malignancies including myelodysplastic syndromes /leukemia intensive therapies act double-edged sword providing long term survival cost severe toxicities opinion intensive chemotherapy cause detrimental effects indispensable given run risk sacrificing long-term survivals young fit patients seek powerful alternative front-line Furthermore minimal residual disease negativity optimal therapeutic goal achieve autologous stem transplantation novel therapeutic strategies shown improve outcomes clear translate population note MCL patients need stratified diagnosis provided different intensities front-line regimen review discuss current strategies treatment young patients newly diagnosed MCL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1504, 532, 1, 2757, 31, 1308, 16, 8, 1314, 1129, 5, 3, 21300, 417, 1, 734, 2, 146, 408, 1308, 37, 32, 96, 5017, 348, 136, 645, 6, 189, 183, 3007, 328, 36, 359, 4964, 1308, 37, 28, 3, 157, 38317, 969, 3, 3477, 9, 568, 251, 2, 708, 319, 337, 3166, 492, 4039, 192, 359, 1417, 35, 1091, 6, 1722, 1308, 3, 825, 16, 3, 837, 1, 3007, 328, 36, 110, 3, 20680, 18, 2, 3, 2244, 1929, 12, 574, 14372, 143, 5, 166, 126, 1072, 378, 76, 79, 60, 513, 319, 337, 3794, 5178, 79, 60, 84, 3, 21442, 24994, 4, 110, 143, 11, 3, 905, 385, 225, 22, 568, 441, 141, 2040, 2647, 673, 1686, 235, 122, 2559, 22, 8, 1627, 73234, 73235, 1736, 319, 337, 25, 28, 3, 835, 1, 905, 385, 4, 114, 3564, 242, 1686, 56, 122, 708, 6227, 1152, 176, 192, 16, 13338, 447, 17, 21, 7726, 3, 43, 1, 14886, 319, 337, 3794, 4, 46, 1169, 2, 2975, 7, 21, 1642, 6606, 9, 8, 3757, 1091, 28, 3, 3007, 328, 798, 1048, 753, 34, 6014, 257, 40, 3, 665, 189, 1326, 6, 1359, 348, 2, 50, 1028, 452, 31, 497, 476, 229, 189, 422, 47, 443, 6, 401, 123, 84, 192, 16, 44, 1145, 885, 22, 6, 832, 46, 99, 4509, 4, 266, 1, 5739, 1308, 7, 594, 6, 40, 1173, 28, 147, 2, 40, 1052, 5, 338, 11565, 1, 3007, 328, 477, 4, 26, 206, 21, 1139, 291, 422, 9, 3, 24, 1, 1169, 7, 5, 732, 265, 1308]",1612.0,30005678,Paramount therapy young fit patients mantle lymphoma strategies front-line therapy,3,0.005235602094240838
Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes.,JCI insight,JCI Insight,2018-07-26,"Germline SAMD9 and SAMD9L mutations cause a spectrum of multisystem disorders that carry a markedly increased risk of developing myeloid malignancies with somatic monosomy 7. Here, we describe 16 siblings, the majority of which were phenotypically normal, from 5 families diagnosed with myelodysplasia and leukemia syndrome with monosomy 7 (MLSM7; OMIM 252270) who primarily had onset of hematologic abnormalities during the first decade of life. Molecular analyses uncovered germline SAMD9L (n = 4) or SAMD9 (n = 1) mutations in these families. Affected individuals had a highly variable clinical course that ranged from mild and transient dyspoietic changes in the bone marrow to a rapid progression of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with monosomy 7. Expression of these gain-of-function SAMD9 and SAMD9L mutations reduces cell cycle progression, and deep sequencing demonstrated selective pressure favoring the outgrowth of clones that have either lost the mutant allele or acquired revertant mutations. The myeloid malignancies of affected siblings acquired cooperating mutations in genes that are also altered in sporadic cases of AML characterized by monosomy 7. These data have implications for understanding how SAMD9 and SAMD9L mutations contribute to myeloid transformation and for recognizing, counseling, and treating affected families.",Journal Article,544.0,10.0,Germline SAMD9 SAMD9L cause spectrum multisystem disorders carry markedly increased risk developing myeloid malignancies somatic monosomy 7 16 siblings majority phenotypically normal 5 families diagnosed myelodysplasia leukemia syndrome monosomy 7 MLSM7 OMIM 252270 primarily onset hematologic abnormalities decade life Molecular uncovered germline SAMD9L n 4 SAMD9 n 1 families Affected individuals highly variable clinical course ranged mild transient dyspoietic changes bone marrow rapid progression myelodysplastic syndrome MDS acute myeloid leukemia AML monosomy 7 Expression gain-of-function SAMD9 SAMD9L reduces cycle progression deep sequencing demonstrated selective pressure favoring outgrowth clones lost allele acquired revertant myeloid malignancies affected siblings acquired cooperating altered sporadic cases AML characterized monosomy 7 implications understanding SAMD9 SAMD9L contribute myeloid transformation recognizing counseling treating affected families,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1009, 36644, 2, 36645, 138, 708, 8, 1873, 1, 17333, 1997, 17, 3542, 8, 2195, 101, 43, 1, 931, 533, 441, 5, 1119, 7521, 67, 467, 21, 897, 245, 2758, 3, 686, 1, 92, 11, 8495, 295, 29, 33, 1954, 265, 5, 6128, 2, 681, 5, 7521, 67, 73318, 73319, 73320, 54, 1561, 42, 1707, 1, 813, 1171, 190, 3, 157, 2025, 1, 358, 219, 318, 5601, 1009, 36645, 78, 39, 15, 36644, 78, 14, 138, 4, 46, 1954, 1424, 869, 42, 8, 561, 1347, 38, 906, 17, 1869, 29, 1980, 2, 2473, 73321, 400, 4, 3, 581, 6, 8, 1321, 91, 1, 681, 1223, 15, 286, 533, 329, 5, 7521, 67, 55, 1, 46, 1803, 1, 343, 36644, 2, 36645, 138, 2389, 31, 417, 91, 2, 2369, 615, 264, 1094, 3738, 6238, 3, 7201, 1, 2749, 17, 47, 361, 3009, 3, 620, 1254, 15, 1294, 42913, 138, 3, 533, 441, 1, 1424, 2758, 1294, 11413, 138, 4, 214, 17, 32, 120, 1495, 4, 1928, 140, 1, 329, 765, 20, 7521, 67, 46, 74, 47, 1268, 9, 612, 832, 36644, 2, 36645, 138, 1248, 6, 533, 1392, 2, 9, 5842, 2011, 2, 1367, 1424, 1954]",1313.0,30046003,Germline SAMD9 SAMD9L associated extensive genetic evolution diverse hematologic outcomes,0,0.0
Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories.,Blood advances,Blood Adv,2018-08-01,"The 2017 revision of the World Health Organization (WHO) classification includes substantial changes to the subclassification of chronic myelomonocytic leukemia (CMML): (1) a 3-tiered blast-based scheme including a novel ""CMML-0"" category replacing a 2-tiered system in place since 2001 and (2) 2 CMML subtypes, myelodysplastic (MDS-CMML) and myeloproliferative (MP-CMML), based on a white blood cell count cutoff of 13  10<sup>9</sup>/L. The clinical utility of this subclassification scheme, particularly the expansion of blast-based subgroups, has not been validated. In this study, a large single-institution CMML patient cohort (n = 629) was used to assess the prognostic impact of the newly proposed categories. Patients were risk stratified according to the CMML-specific Prognostic Scoring System (CPSS) and the MD Anderson Prognostic Scoring System. MP-CMML patients had significantly shorter overall survival (OS; <i>P</i> < .0001; hazard ratio: 0.53, 95% confidence interval: 0.42-0.65) and median duration to acute myeloid leukemia (AML) transformation (<i>P</i> < .0001; 15.2 vs 22.0 months) compared with MDS-CMML patients. The CMML-0 group included 36.4% patients with higher risk CPSS categories and 11.2% of patients with high-risk cytogenetics. Among treatment-nave patients (n = 499), there was a marginal difference in OS between the CMML-0 and CMML-1<sup>2017</sup> subgroups (<i>P</i> = .0552). The WHO 2017 blast-based categories were not associated with AML-free survival. Incorporation of the WHO 2017 blast-based subgroups in a modified CPSS scheme had a neutral effect and did not improve its prognostic strength. Our data support the inclusion of MP-CMML and MDS-CMML subtypes in the WHO 2017 revision. Although of some utility in MP-CMML, the 3-tiered blast-based system is not well supported in this study.",Clinical Trial,538.0,6.0,2017 revision World Health Organization classification includes substantial changes subclassification chronic myelomonocytic leukemia CMML 1 3-tiered blast-based scheme including novel `` CMML-0 '' category replacing 2-tiered place 2001 2 2 CMML subtypes myelodysplastic MDS-CMML myeloproliferative MP-CMML based white blood count cutoff 13 10 sup 9 /sup /L clinical utility subclassification scheme particularly expansion blast-based subgroups validated large single-institution CMML patient cohort n 629 assess prognostic impact newly proposed categories Patients risk stratified according CMML-specific Prognostic Scoring CPSS MD Anderson Prognostic Scoring MP-CMML patients significantly shorter overall survival OS P /i .0001 hazard ratio 0.53 95 confidence interval 0.42-0.65 median duration acute myeloid leukemia AML transformation P /i .0001 15.2 vs 22.0 months compared MDS-CMML patients CMML-0 group included 36.4 patients higher risk CPSS categories 11.2 patients high-risk cytogenetics treatment-nave patients n 499 marginal difference OS CMML-0 CMML-1 sup 2017 /sup subgroups P /i .0552 2017 blast-based categories associated AML-free survival Incorporation 2017 blast-based subgroups modified CPSS scheme neutral effect improve prognostic strength support inclusion MP-CMML MDS-CMML subtypes 2017 revision utility MP-CMML 3-tiered blast-based supported,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 1759, 5646, 1, 3, 1956, 341, 2533, 54, 947, 1920, 1281, 400, 6, 3, 9341, 1, 442, 5451, 3382, 14, 8, 27, 14526, 3112, 90, 4633, 141, 8, 229, 3382, 13, 522, 2169, 9574, 8, 18, 14526, 398, 4, 3536, 1192, 1758, 2, 18, 18, 3382, 814, 1223, 3382, 2, 4545, 3382, 90, 23, 8, 886, 315, 31, 1276, 2779, 1, 233, 79, 172, 83, 172, 805, 3, 38, 1207, 1, 26, 9341, 4633, 823, 3, 1422, 1, 3112, 90, 1453, 71, 44, 85, 938, 4, 26, 45, 8, 375, 226, 731, 3382, 69, 180, 78, 15597, 10, 95, 6, 423, 3, 177, 345, 1, 3, 732, 1587, 1996, 7, 11, 43, 1173, 768, 6, 3, 3382, 112, 177, 2504, 398, 19332, 2, 3, 2244, 1929, 177, 2504, 398, 4545, 3382, 7, 42, 97, 985, 63, 25, 118, 70, 19, 70, 488, 360, 197, 13, 699, 48, 307, 268, 13, 595, 13, 556, 2, 52, 654, 6, 286, 533, 329, 1392, 70, 19, 70, 488, 167, 18, 105, 350, 13, 53, 72, 5, 1223, 3382, 7, 3, 3382, 13, 87, 159, 511, 39, 7, 5, 142, 43, 19332, 1996, 2, 175, 18, 1, 7, 5, 64, 43, 2510, 107, 24, 2809, 7, 78, 11673, 125, 10, 8, 3450, 523, 4, 118, 59, 3, 3382, 13, 2, 3382, 14, 172, 1759, 172, 1453, 70, 19, 70, 73333, 3, 54, 1759, 3112, 90, 1996, 11, 44, 41, 5, 329, 115, 25, 2838, 1, 3, 54, 1759, 3112, 90, 1453, 4, 8, 1230, 19332, 4633, 42, 8, 6338, 254, 2, 205, 44, 401, 211, 177, 3671, 114, 74, 538, 3, 1680, 1, 4545, 3382, 2, 1223, 3382, 814, 4, 3, 54, 1759, 5646, 242, 1, 476, 1207, 4, 4545, 3382, 3, 27, 14526, 3112, 90, 398, 16, 44, 149, 2708, 4, 26, 45]",1716.0,30054307,Validation 2017 revision chronic myelomonocytic leukemia categories,569,0.9930191972076788
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.,Leukemia research,Leuk. Res.,2018-07-19,"Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). 9028 recipients of hematopoietic cell autotransplants (1995-2010) for Hodgkin lymphoma (HL; n=916), non-Hodgkin lymphoma (NHL; n=3546) and plasma cell myeloma (PCM; n=4566), reported to the CIBMTR, were analyzed for risk of subsequent AML or MDS. 335 MDS/AML cases were diagnosed posttransplant (3.7%). Variables associated with an increased risk for AML or MDS in multivariate analyses were: (1) conditioning with total body radiation versus chemotherapy alone for HL (HR=4.0; 95% confidence interval [1.4, 11.6]) and NHL (HR=2.5 [1.1, 2.5]); (2) 3 versus 1 line of chemotherapy for NHL (HR=1.9 [1.3, 2.8]); and (3) subjects with NHL transplanted in 2005-2010 versus 1995-1999 (HR=2.1 [1.5, 3.1]). Using Surveillance, Epidemiology and End Results (SEER) data, we found risks for AML/MDS in HL, NHL and PCM to be 5-10 times the background rate. In contrast, relative risks were 10-50 for AML and approximately 100 for MDS in the autotransplant cohort. There are substantial risks of AML and MDS after autotransplants for HL, NHL and PCM.",Clinical Trial,551.0,4.0,Exposures DNA-damaging drugs ionizing radiations increase risks acute myeloid leukemia AML myelodysplastic syndrome MDS 9028 recipients hematopoietic autotransplants 1995-2010 Hodgkin lymphoma HL n 916 non-Hodgkin lymphoma NHL n 3546 plasma myeloma PCM n 4566 reported CIBMTR risk subsequent AML MDS 335 MDS/AML cases diagnosed posttransplant 3.7 Variables associated increased risk AML MDS multivariate 1 conditioning total body radiation versus chemotherapy HL HR 4.0 95 confidence interval 1.4 11.6 NHL HR 2.5 1.1 2.5 2 3 versus 1 line chemotherapy NHL HR 1.9 1.3 2.8 3 subjects NHL transplanted 2005-2010 versus 1995-1999 HR 2.1 1.5 3.1 Surveillance Epidemiology End SEER risks AML/MDS HL NHL PCM 5-10 times background rate contrast relative risks 10-50 AML approximately 100 MDS autotransplant cohort substantial risks AML MDS autotransplants HL NHL PCM,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3401, 6, 261, 4904, 600, 2, 4341, 38385, 344, 1098, 1, 286, 533, 329, 2, 681, 1223, 73341, 2190, 1, 1007, 31, 28841, 2323, 1120, 9, 1718, 78, 19860, 1176, 78, 37318, 2, 554, 31, 12450, 78, 40194, 210, 6, 3, 11203, 11, 311, 9, 43, 1, 706, 329, 15, 1223, 9286, 1223, 329, 140, 11, 265, 7346, 27, 67, 682, 41, 5, 35, 101, 43, 9, 329, 15, 1223, 4, 331, 318, 11, 14, 1933, 5, 181, 642, 121, 185, 56, 279, 9, 1718, 168, 39, 13, 48, 307, 268, 14, 39, 175, 49, 2, 1176, 168, 18, 33, 14, 14, 18, 33, 18, 2608, 185, 14, 328, 1, 56, 9, 1176, 168, 14, 83, 14, 27, 18, 66, 2, 27, 976, 5, 1176, 4600, 4, 1242, 1120, 185, 2323, 2043, 168, 18, 14, 14, 33, 27, 14, 75, 617, 1284, 2, 396, 99, 1605, 74, 21, 204, 1098, 9, 329, 1223, 4, 1718, 1176, 2, 12450, 6, 40, 33, 79, 1072, 3, 2426, 116, 4, 748, 580, 1098, 11, 79, 212, 9, 329, 2, 705, 394, 9, 1223, 4, 3, 28704, 180, 125, 32, 1281, 1098, 1, 329, 2, 1223, 50, 28841, 9, 1718, 1176, 2, 12450]",1040.0,30055822,Risk acute myeloid leukemia myelodysplastic syndrome autotransplants lymphomas plasma myeloma,79,0.13787085514834205
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.,American journal of hematology,Am. J. Hematol.,2018-09-09,"Glasdegib is a Hedgehog pathway inhibitor. This ongoing, open-label, phase 2 study (NCT01546038) evaluated glasdegib plus cytarabine/daunorubicin in patients with untreated acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS). Patients received glasdegib 100 mg orally, once daily in continuous 28-daycycles from day -3, with intravenous cytarabine 100mg/m<sup>2</sup> on days 1-7 and daunorubicin 60mg/m<sup>2</sup> on days 1-3. Patients in remission then received consolidation therapy (2-4 cycles of cytarabine 1 g/m<sup>2</sup> twice daily on days 1, 3, 5 of each cycle), followed by maintenance glasdegib (maximum 6 cycles). Primary endpoint was complete remission (CR) in patients aged 55years. Secondary endpoints included overall survival (OS), safety and outcome by mutational status. Patients had a median (range) age of 64.0 (27-75) years, 60.0% were male, and 84.5% were white. In 69 evaluable patients, 46.4% (80% confidence interval [CI]: 38.7-54.1) achieved investigator-reported CR. Among patients 55years old (n =60), 40.0% (80% CI 31.9-48.1) achieved CR. Among all 69 patients, median OS was 14.9 (80% CI 13.4-19.3) months, with 12-month survival probability 66.6% (80% CI 58.5-73.4). The most common treatment-related adverse events (50% patients) were diarrhea and nausea. There were no significant associations between mutational status (12 genes) and clinical response, suggesting potential benefit across diverse molecular profiles. Glasdegib plus cytarabine/daunorubicin was well tolerated and associated with clinical activity in patients with untreated AML or high-risk MDS. A randomized phase 3 trial of glasdegib in combination with chemotherapy (7 + 3 schedule) is ongoing.","Clinical Trial, Phase II",499.0,22.0,Glasdegib Hedgehog pathway inhibitor ongoing open-label phase 2 NCT01546038 evaluated glasdegib plus cytarabine/daunorubicin patients untreated acute myeloid leukemia AML high-risk myelodysplastic syndromes MDS Patients received glasdegib 100 mg orally daily continuous 28-day cycles day -3 intravenous cytarabine 100 mg/m sup 2 /sup days 1-7 daunorubicin 60 mg/m sup 2 /sup days 1-3 Patients remission received consolidation therapy 2-4 cycles cytarabine 1 g/m sup 2 /sup twice daily days 1 3 5 cycle followed maintenance glasdegib maximum 6 cycles Primary endpoint complete remission CR patients aged 55 years Secondary endpoints included overall survival OS safety outcome status Patients median range age 64.0 27-75 years 60.0 male 84.5 white 69 evaluable patients 46.4 80 confidence interval CI 38.7-54.1 achieved investigator-reported CR patients 55 years old n 60 40.0 80 CI 31.9-48.1 achieved CR 69 patients median OS 14.9 80 CI 13.4-19.3 months 12-month survival probability 66.6 80 CI 58.5-73.4 common treatment-related adverse events 50 patients diarrhea nausea significant associations status 12 clinical response suggesting potential benefit diverse molecular profiles Glasdegib plus cytarabine/daunorubicin tolerated associated clinical activity patients untreated AML high-risk MDS randomized phase 3 trial glasdegib combination chemotherapy 7 3 schedule ongoing,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[15452, 16, 8, 4097, 308, 230, 26, 942, 1020, 1756, 124, 18, 45, 41990, 194, 15452, 349, 1855, 5247, 4, 7, 5, 1278, 286, 533, 329, 15, 64, 43, 2040, 1223, 7, 103, 15452, 394, 81, 1428, 1059, 391, 4, 1314, 339, 218, 410, 29, 218, 27, 5, 1262, 1855, 394, 81, 188, 172, 18, 172, 23, 162, 14, 67, 2, 5247, 335, 81, 188, 172, 18, 172, 23, 162, 14, 27, 7, 4, 734, 818, 103, 2173, 36, 18, 39, 410, 1, 1855, 14, 499, 188, 172, 18, 172, 936, 391, 23, 162, 14, 27, 33, 1, 296, 417, 370, 20, 1146, 15452, 689, 49, 410, 86, 1138, 10, 236, 734, 684, 4, 7, 1032, 15425, 60, 568, 1387, 159, 63, 25, 118, 367, 2, 228, 20, 1619, 156, 7, 42, 8, 52, 184, 89, 1, 660, 13, 428, 481, 60, 335, 13, 11, 1045, 2, 874, 33, 11, 886, 4, 790, 859, 7, 641, 39, 493, 307, 268, 58, 519, 67, 667, 14, 513, 3464, 210, 684, 107, 7, 15425, 60, 1095, 78, 335, 327, 13, 493, 58, 456, 83, 576, 14, 513, 684, 107, 62, 790, 7, 52, 118, 10, 213, 83, 493, 58, 233, 39, 326, 27, 53, 5, 133, 811, 25, 1320, 700, 49, 493, 58, 717, 33, 803, 39, 3, 96, 186, 24, 139, 290, 281, 5660, 7, 11, 1172, 2, 1218, 125, 11, 77, 93, 685, 59, 1619, 156, 133, 214, 2, 38, 51, 802, 174, 247, 716, 1867, 219, 1241, 15452, 349, 1855, 5247, 10, 149, 421, 2, 41, 5, 38, 128, 4, 7, 5, 1278, 329, 15, 64, 43, 1223, 8, 384, 124, 27, 160, 1, 15452, 4, 150, 5, 56, 67, 27, 1055, 16, 942]",1624.0,30074259,Glasdegib combination cytarabine daunorubicin patients AML high-risk MDS Phase 2,0,0.0
Upper gastrointestinal acute graft-<i>versus</i>-host disease adds minimal prognostic value in isolation or with other graft-<i>versus</i>-host disease symptoms as currently diagnosed and treated.,Haematologica,Haematologica,2018-08-03,"Upper gastrointestinal acute graft-<i>versus</i>-host disease is reported in approximately 30% of hematopoietic stem cell transplant recipients developing acute graft-<i>versus</i>-host disease. Currently classified as Grade II in consensus criteria, upper gastrointestinal acute graft-<i>versus</i>-host disease is often treated with systemic immunosuppression. We reviewed the Center for International Blood and Marrow Transplant Research database to assess the prognostic implications of upper gastrointestinal acute graft-<i>versus</i>-host disease in isolation or with other acute graft-<i>versus</i>-host disease manifestations. 8567 adult recipients of myeloablative allogeneic hematopoietic stem cell transplant receiving T-cell replete grafts for acute leukemia, chronic myeloid leukemia or myelodysplastic syndrome between 2000 and 2012 were analyzed. 51% of transplants were from unrelated donors. Reported upper gastrointestinal acute graft-<i>versus</i>-host disease incidence was 12.1%; 2.7% of recipients had isolated upper gastrointestinal acute graft-<i>versus</i>-host disease, of whom 95% received systemic steroids. Patients with isolated upper gastrointestinal involvement had similar survival, disease-free survival, transplant-related mortality, and relapse as patients with Grades 0, I, or II acute graft-<i>versus</i>-host disease. Unrelated donor recipients with isolated upper gastrointestinal acute graft-<i>versus</i>-host disease had less subsequent chronic graft-<i>versus</i>-host disease than those with Grades I or II disease (<i>P</i>=0.016 and <i>P</i>=0.0004, respectively). Upper gastrointestinal involvement added no significant prognostic information when present in addition to other manifestations of Grades I or II acute graft-<i>versus</i>-host disease. If upper gastrointestinal symptoms were reclassified as Grade 0 or I, 425 of 2083 patients (20.4%) with Grade II disease would be downgraded, potentially impacting the interpretation of clinical trial outcomes. Defining upper gastrointestinal acute graft-<i>versus</i>-host disease as a Grade II entity, as it is currently diagnosed and treated, is not strongly supported by this analysis. The general approach to diagnosis, treatment and grading of upper gastrointestinal symptoms and their impact on subsequent acute graft-<i>versus</i>-host disease therapy warrants reevaluation.",Journal Article,536.0,0.0,Upper gastrointestinal acute graft- versus /i -host disease reported approximately 30 hematopoietic stem transplant recipients developing acute graft- versus /i -host disease Currently classified Grade II consensus criteria upper gastrointestinal acute graft- versus /i -host disease treated systemic immunosuppression reviewed Center International Blood Marrow Transplant Research database assess prognostic implications upper gastrointestinal acute graft- versus /i -host disease isolation acute graft- versus /i -host disease manifestations 8567 adult recipients myeloablative allogeneic hematopoietic stem transplant receiving T-cell replete grafts acute leukemia chronic myeloid leukemia myelodysplastic syndrome 2000 2012 51 transplants unrelated donors Reported upper gastrointestinal acute graft- versus /i -host disease incidence 12.1 2.7 recipients isolated upper gastrointestinal acute graft- versus /i -host disease 95 received systemic steroids Patients isolated upper gastrointestinal involvement similar survival disease-free survival transplant-related mortality relapse patients Grades 0 II acute graft- versus /i -host disease Unrelated donor recipients isolated upper gastrointestinal acute graft- versus /i -host disease subsequent chronic graft- versus /i -host disease Grades II disease P /i =0.016 P /i =0.0004 respectively Upper gastrointestinal involvement added significant prognostic information present addition manifestations Grades II acute graft- versus /i -host disease upper gastrointestinal symptoms reclassified Grade 0 425 2083 patients 20.4 Grade II disease downgraded potentially impacting interpretation clinical trial outcomes Defining upper gastrointestinal acute graft- versus /i -host disease Grade II entity currently diagnosed treated strongly supported general approach diagnosis treatment grading upper gastrointestinal symptoms impact subsequent acute graft- versus /i -host disease therapy warrants reevaluation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1726, 286, 1599, 70, 185, 70, 1204, 34, 16, 210, 4, 705, 201, 1, 1007, 452, 31, 941, 2190, 931, 286, 1599, 70, 185, 70, 1204, 34, 694, 1373, 22, 88, 215, 4, 1391, 371, 1726, 286, 1599, 70, 185, 70, 1204, 34, 16, 629, 73, 5, 403, 3646, 21, 446, 3, 574, 9, 944, 315, 2, 581, 941, 389, 609, 6, 423, 3, 177, 1268, 1, 1726, 286, 1599, 70, 185, 70, 1204, 34, 4, 5019, 15, 5, 127, 286, 1599, 70, 185, 70, 1204, 34, 4282, 73365, 780, 2190, 1, 3246, 1063, 1007, 452, 31, 941, 357, 102, 31, 11151, 4713, 9, 286, 442, 533, 15, 681, 59, 1081, 2, 1195, 11, 311, 725, 1, 4016, 11, 29, 2092, 2344, 210, 1726, 286, 1599, 70, 185, 70, 1204, 34, 287, 10, 133, 14, 18, 67, 1, 2190, 42, 1355, 1726, 286, 1599, 70, 185, 70, 1204, 34, 1, 953, 48, 103, 403, 4580, 7, 5, 1355, 1726, 799, 42, 288, 25, 34, 115, 25, 941, 139, 282, 2, 429, 22, 7, 5, 2276, 13, 70, 15, 215, 286, 1599, 70, 185, 70, 1204, 34, 2092, 1488, 2190, 5, 1355, 1726, 286, 1599, 70, 185, 70, 1204, 34, 42, 299, 706, 442, 1599, 70, 185, 70, 1204, 34, 76, 135, 5, 2276, 70, 15, 215, 34, 70, 19, 70, 13, 3820, 2, 70, 19, 70, 13, 5295, 106, 1726, 799, 1953, 77, 93, 177, 487, 198, 364, 4, 352, 6, 127, 4282, 1, 2276, 70, 15, 215, 286, 1599, 70, 185, 70, 1204, 34, 492, 1726, 507, 11, 7864, 22, 88, 13, 15, 70, 8544, 1, 49723, 7, 179, 39, 5, 88, 215, 34, 688, 40, 16006, 751, 8661, 3, 3037, 1, 38, 160, 123, 2847, 1726, 286, 1599, 70, 185, 70, 1204, 34, 22, 8, 88, 215, 2983, 22, 192, 16, 694, 265, 2, 73, 16, 44, 1327, 2708, 20, 26, 65, 3, 1083, 353, 6, 147, 24, 2, 3452, 1, 1726, 507, 2, 136, 345, 23, 706, 286, 1599, 70, 185, 70, 1204, 34, 36, 2782, 15828]",2120.0,30076185,Upper gastrointestinal acute graft- versus /i -host disease adds minimal prognostic value isolation graft- versus /i -host disease symptoms currently diagnosed treated,0,0.0
Association Between Renal Cell Carcinoma and Myelodysplastic Syndromes: Epigenetic Underpinning?,Clinical genitourinary cancer,Clin Genitourin Cancer,2018-06-28,"Renal cell carcinoma (RCC) and certain myeloid malignancies are both characterized by widespread aberrant DNA hypermethylation. After clinical observations of patients with a personal history of both malignancies, we sought to explore a potential association, and to describe the clinical characteristics of these patients. Mayo Clinic's 'Advanced Cohort Explorer' database was used to identify patients with a history of both malignancies. Clinical features and long-term outcome were abstracted. Prevalence of myelodysplastic syndromes (MDSs) in patients 65 years with a personal history of nephrectomy for RCC was then compared with the prevalence of MDSs in the Dusseldorf MDS registry and the general patient population at Mayo Clinic, using 1-sample test of proportions. A total of 59 patients with a diagnosis of both RCC and myeloid malignancy were identified. The myeloid malignancies included 38 MDSs, 12 acute myelogenous leukemia, and 9 myeloproliferative neoplasms. The cohort was characterized by marked male predominance (4.4:1). The median age at RCC diagnosis was 64 years (range, 37-87 years), and for myeloid malignancy was 75 years (range, 44-90 years). Prevalence of MDS in patients >65 years with a personal history of nephrectomy for RCC was  8.4 times that of the age-concordant general population based on the Dusseldorf registry (28/6490 or 395/100,000 vs.  47/100,000; P< .001), and 3.07 times that of the age-concordant patient population at Mayo Clinic (28/6490 or 395/100,000 vs. 128.4/100,000; P< .001). We observed a strong association between RCC and MDS. Patients with a history of RCC appear to have a substantially increased risk of developing MDS compared with the general population.",Journal Article,572.0,0.0,"Renal carcinoma RCC certain myeloid malignancies characterized widespread aberrant DNA hypermethylation clinical observations patients personal history malignancies sought explore potential association clinical characteristics patients Mayo Clinic 's 'Advanced Cohort Explorer database identify patients history malignancies Clinical features long-term outcome abstracted Prevalence myelodysplastic syndromes MDSs patients  65 years personal history nephrectomy RCC compared prevalence MDSs Dusseldorf MDS registry general patient population Mayo Clinic 1-sample test proportions total 59 patients diagnosis RCC myeloid malignancy identified myeloid malignancies included 38 MDSs 12 acute myelogenous leukemia 9 myeloproliferative neoplasms cohort characterized marked male predominance 4.4:1 median age RCC diagnosis 64 years range 37-87 years myeloid malignancy 75 years range 44-90 years Prevalence MDS patients 65 years personal history nephrectomy RCC  8.4 times age-concordant general population based Dusseldorf registry 28/6490 395/100,000 vs.  47/100,000 P .001 3.07 times age-concordant patient population Mayo Clinic 28/6490 395/100,000 vs. 128.4/100,000 P .001 observed strong association RCC MDS Patients history RCC appear substantially increased risk developing MDS compared general population",0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[31, 134, 796, 2, 1840, 533, 441, 32, 110, 765, 20, 3029, 1898, 261, 2575, 50, 38, 2172, 1, 7, 5, 8, 3008, 532, 1, 110, 441, 21, 990, 6, 1645, 8, 174, 248, 2, 6, 897, 3, 38, 374, 1, 46, 7, 2486, 1188, 292, 73368, 180, 24943, 609, 10, 95, 6, 255, 7, 5, 8, 532, 1, 110, 441, 38, 404, 2, 319, 337, 228, 11, 4106, 1078, 1, 2040, 13550, 4, 7, 749, 556, 60, 5, 8, 3008, 532, 1, 1738, 9, 796, 10, 818, 72, 5, 3, 1078, 1, 13550, 4, 3, 51182, 1223, 1608, 2, 3, 1083, 69, 266, 28, 2486, 1188, 75, 14, 1000, 412, 1, 4117, 8, 181, 1, 728, 7, 5, 8, 147, 1, 110, 796, 2, 533, 710, 11, 108, 3, 533, 441, 159, 519, 13550, 133, 286, 2194, 2, 83, 1179, 3, 180, 10, 765, 20, 2003, 1045, 7593, 39, 39, 14, 3, 52, 89, 28, 796, 147, 10, 660, 60, 184, 567, 912, 60, 2, 9, 533, 710, 10, 481, 60, 184, 584, 424, 60, 1078, 1, 1223, 4, 7, 556, 60, 5, 8, 3008, 532, 1, 1738, 9, 796, 10, 19267, 66, 39, 1072, 17, 1, 3, 89, 3610, 1083, 266, 90, 23, 3, 51182, 1608, 339, 51183, 15, 10300, 394, 984, 105, 19267, 662, 394, 984, 19, 144, 2, 27, 1615, 1072, 17, 1, 3, 89, 3610, 69, 266, 28, 2486, 1188, 339, 51183, 15, 10300, 394, 984, 105, 3990, 39, 394, 984, 19, 144, 21, 164, 8, 1082, 248, 59, 796, 2, 1223, 7, 5, 8, 532, 1, 796, 1322, 6, 47, 8, 2109, 101, 43, 1, 931, 1223, 72, 5, 3, 1083, 266]",1635.0,30077464,Association Renal Carcinoma Myelodysplastic Syndromes Epigenetic Underpinning,0,0.0
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.,The Lancet. Haematology,Lancet Haematol,2018-08-13,"Front-line therapy for elderly or unfit patients with acute myeloid leukaemia (AML) remains unsatisfactory with poor outcomes and excessive toxicity. We studied a new low-intensity regimen of cladribine combined with low-dose cytarabine alternating with decitabine, aimed at improving outcomes in this population. Based on our previous experience, we hypothesised that this combination would be safe and more effective than current approaches with hypomethylating agents. In this single-arm, open-label, single-centre phase 2 study, we enrolled patients aged 60 years or older with previously untreated AML or high-risk myelodysplastic syndrome who had adequate organ function and an Eastern Cooperative Oncology Group performance status of 2 or less. Patients were treated with cladribine plus low-dose cytarabine for two 28-day cycles alternating with decitabine for two 28-day cycles, for up to 18 cycles. Induction therapy (cycle 1) consisted of cladribine 5 mg/m<sup>2</sup> intravenously over 1-2 h on days 1-5 and cytarabine 20 mg subcutaneously twice daily on days 1-10. Patients who had remission during this induction regimen moved on to consolidation therapy (cladribine 5 mg/m<sup>2</sup> intravenously over 1-2 h on days 1-3 and cytarabine 20 mg twice daily on days 1-10, alternating with decitabine 20 mg/m<sup>2</sup> intravenously on days 1-5). The primary outcome measure was disease-free survival. Secondary outcomes were overall survival, proportion of patients achieving complete response, proportion of patients achieving response, toxicity, and induction mortality. All treated patients were included in the analyses. This trial is ongoing and is registered with ClinicalTrials.gov, number NCT01515527. Between Feb 17, 2012, and July 6, 2017, 118 patients were enrolled and treated, among whom 48 (41%) had an adverse karyotype, 20 (17%) had therapy-related AML, 18 (15%) had treated secondary AML, and 20 (17%) had TP53 mutations. Median disease-free survival was 108 months (IQR 54-259). 80 (68%) patients achieved objective response: 69 (58%) achieved a complete response and 11 (9%) patients had complete response with incomplete count recovery. The median overall survival was 138 months (69-286). The regimen was well tolerated, with one (1%) death within the first 4 weeks and eight (7%) deaths within the first 8 weeks. The most common non-haematological adverse events of grade 3 or worse were infection (88 [75%] patients), elevated total bilirubin (26 [22%] patients), rash (13 [11%] patients), and nausea (13 [11%] patients). The combination of cladribine and low-dose cytarabine alternating with decitabine appears to be a safe and highly effective regimen for the treatment of elderly or unfit patients with newly diagnosed AML. Further testing of this regimen is warranted, and could help to provide a new, effective option for reduced-intensity therapy in this population. Part supported by the National Institutes of Health.","Clinical Trial, Phase II",526.0,7.0,Front-line therapy elderly unfit patients acute myeloid leukaemia AML remains unsatisfactory poor outcomes excessive toxicity studied new low-intensity regimen cladribine combined low-dose cytarabine alternating decitabine aimed improving outcomes population Based previous experience hypothesised combination safe effective current approaches hypomethylating agents single-arm open-label single-centre phase 2 enrolled patients aged 60 years older previously untreated AML high-risk myelodysplastic syndrome adequate organ function Eastern Cooperative Oncology Group performance status 2 Patients treated cladribine plus low-dose cytarabine 28-day cycles alternating decitabine 28-day cycles 18 cycles Induction therapy cycle 1 consisted cladribine 5 mg/m sup 2 /sup intravenously 1-2 h days 1-5 cytarabine 20 mg subcutaneously twice daily days 1-10 Patients remission induction regimen moved consolidation therapy cladribine 5 mg/m sup 2 /sup intravenously 1-2 h days 1-3 cytarabine 20 mg twice daily days 1-10 alternating decitabine 20 mg/m sup 2 /sup intravenously days 1-5 primary outcome measure disease-free survival Secondary outcomes overall survival proportion patients achieving complete response proportion patients achieving response toxicity induction mortality treated patients included trial ongoing registered ClinicalTrials.gov number NCT01515527 Feb 17 2012 July 6 2017 118 patients enrolled treated 48 41 adverse karyotype 20 17 therapy-related AML 18 15 treated secondary AML 20 17 TP53 Median disease-free survival 108 months IQR 54-259 80 68 patients achieved objective response 69 58 achieved complete response 11 9 patients complete response incomplete count recovery median overall survival 138 months 69-286 regimen tolerated 1 death 4 weeks 7 deaths 8 weeks common non-haematological adverse events grade 3 worse infection 88 75 patients elevated total bilirubin 26 22 patients rash 13 11 patients nausea 13 11 patients combination cladribine low-dose cytarabine alternating decitabine appears safe highly effective regimen treatment elderly unfit patients newly diagnosed AML testing regimen warranted help provide new effective option reduced-intensity therapy population supported National Institutes Health,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3007, 328, 36, 9, 1216, 15, 9681, 7, 5, 286, 533, 2001, 329, 469, 9573, 5, 334, 123, 2, 4529, 155, 21, 656, 8, 217, 154, 837, 477, 1, 8251, 397, 5, 154, 61, 1855, 5181, 5, 3004, 1295, 28, 1673, 123, 4, 26, 266, 90, 23, 114, 698, 730, 21, 11998, 17, 26, 150, 688, 40, 1165, 2, 80, 323, 76, 291, 611, 5, 4931, 183, 4, 26, 226, 475, 1020, 1756, 226, 5931, 124, 18, 45, 21, 346, 7, 1032, 335, 60, 15, 434, 5, 373, 1278, 329, 15, 64, 43, 681, 54, 42, 1658, 1259, 343, 2, 35, 2118, 1690, 413, 87, 528, 156, 1, 18, 15, 299, 7, 11, 73, 5, 8251, 349, 154, 61, 1855, 9, 100, 339, 218, 410, 5181, 5, 3004, 9, 100, 339, 218, 410, 9, 126, 6, 203, 410, 504, 36, 417, 14, 1695, 1, 8251, 33, 81, 188, 172, 18, 172, 1672, 252, 14, 18, 555, 23, 162, 14, 33, 2, 1855, 179, 81, 3928, 936, 391, 23, 162, 14, 79, 7, 54, 42, 734, 190, 26, 504, 477, 13329, 23, 6, 2173, 36, 8251, 33, 81, 188, 172, 18, 172, 1672, 252, 14, 18, 555, 23, 162, 14, 27, 2, 1855, 179, 81, 936, 391, 23, 162, 14, 79, 5181, 5, 3004, 179, 81, 188, 172, 18, 172, 1672, 23, 162, 14, 33, 3, 86, 228, 1463, 10, 34, 115, 25, 568, 123, 11, 63, 25, 920, 1, 7, 1785, 236, 51, 920, 1, 7, 1785, 51, 155, 2, 504, 282, 62, 73, 7, 11, 159, 4, 3, 318, 26, 160, 16, 942, 2, 16, 1653, 5, 1252, 1239, 207, 73422, 59, 10128, 269, 1195, 2, 2066, 49, 1759, 4002, 7, 11, 346, 2, 73, 107, 953, 576, 605, 42, 35, 290, 3385, 179, 269, 42, 36, 139, 329, 203, 167, 42, 73, 568, 329, 2, 179, 269, 42, 1206, 138, 52, 34, 115, 25, 10, 25437, 53, 2245, 17493, 41431, 493, 806, 7, 513, 461, 51, 790, 717, 513, 8, 236, 51, 2, 175, 83, 7, 42, 236, 51, 5, 2610, 1276, 1602, 3, 52, 63, 25, 10, 18674, 53, 18024, 35969, 3, 477, 10, 149, 421, 5, 104, 14, 273, 262, 3, 157, 39, 244, 2, 659, 67, 1043, 262, 3, 157, 66, 244, 3, 96, 186, 220, 5143, 290, 281, 1, 88, 27, 15, 639, 11, 930, 889, 481, 7, 804, 181, 5009, 432, 350, 7, 1641, 233, 175, 7, 2, 1218, 233, 175, 7, 3, 150, 1, 8251, 2, 154, 61, 1855, 5181, 5, 3004, 1233, 6, 40, 8, 1165, 2, 561, 323, 477, 9, 3, 24, 1, 1216, 15, 9681, 7, 5, 732, 265, 329, 195, 471, 1, 26, 477, 16, 1197, 2, 359, 987, 6, 377, 8, 217, 323, 1501, 9, 405, 837, 36, 4, 26, 266, 760, 2708, 20, 3, 657, 5973, 1, 341]",2846.0,30115541,Cladribine low-dose cytarabine alternating decitabine front-line therapy elderly patients acute myeloid leukaemia phase 2 single-arm trial,0,0.0
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2018-08-25,"The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), but there are limited data comparing efficacy of the 2 regimens. We evaluated 1564 adult patients who underwent RIC alloHCT for acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS) from 2000 to 2013 using HLA-identical sibling (matched related donor [MRD]) or unrelated donor (URD) peripheral blood graft and received CYSP or TAC with MTX or MMF for GVHD prophylaxis. Primary outcomes of the study were acute and chronic GVHD and overall survival (OS). The study divided the patient population into 4 cohorts based on regimen: MMF-TAC, MMF-CYSP, MTX-TAC, and MTX-CYSP. In the URD group, MMF-CYSP was associated with increased risk of grade II to IV acute GVHD (relative risk [RR], 1.78; P < .001) and grade III to IV acute GVHD (RR, 1.93; P = .006) compared with MTX-TAC. In the URD group, use of MMF-TAC (versus MTX-TAC) lead to higher nonrelapse mortality. (hazard ratio, 1.48; P = .008). In either group, no there was no difference in chronic GVHD, disease-free survival, and OS among the GVHD prophylaxis regimens. For RIC alloHCT using MRD, there are no differences in outcomes based on GVHD prophylaxis. However, with URD RIC alloHCT, MMF-CYSP was inferior to MTX-based regimens for acute GVHD prevention, but all the regimens were equivalent in terms of chronic GVHD and OS. Prospective studies, targeting URD recipients are needed to confirm these results.",Clinical Trial,514.0,2.0,combination calcineurin inhibitor CNI tacrolimus TAC cyclosporine CYSP methotrexate MTX mycophenolate mofetil MMF commonly graft-versus-host disease GVHD prophylaxis reduced-intensity conditioning RIC allogeneic hematopoietic transplantation alloHCT limited comparing efficacy 2 regimens evaluated 1564 adult patients underwent RIC alloHCT acute myelogenous leukemia AML acute lymphoblastic leukemia chronic myelogenous leukemia CML myelodysplastic syndrome MDS 2000 2013 HLA-identical sibling matched related donor MRD unrelated donor URD peripheral blood graft received CYSP TAC MTX MMF GVHD prophylaxis Primary outcomes acute chronic GVHD overall survival OS divided patient population 4 cohorts based regimen MMF-TAC MMF-CYSP MTX-TAC MTX-CYSP URD group MMF-CYSP associated increased risk grade II IV acute GVHD relative risk RR 1.78 P .001 grade III IV acute GVHD RR 1.93 P .006 compared MTX-TAC URD group use MMF-TAC versus MTX-TAC lead higher nonrelapse mortality hazard ratio 1.48 P .008 group difference chronic GVHD disease-free survival OS GVHD prophylaxis regimens RIC alloHCT MRD differences outcomes based GVHD prophylaxis URD RIC alloHCT MMF-CYSP inferior MTX-based regimens acute GVHD prevention regimens equivalent terms chronic GVHD OS Prospective studies targeting URD recipients needed confirm,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 150, 1, 8, 12028, 230, 16942, 225, 22, 5643, 7364, 15, 9112, 29992, 5, 2116, 3453, 15, 5, 11902, 13246, 9889, 71, 85, 841, 95, 9, 1599, 185, 1204, 34, 1562, 2049, 50, 405, 837, 1933, 3365, 1063, 1007, 31, 497, 5514, 84, 125, 32, 383, 74, 1430, 209, 1, 3, 18, 472, 21, 194, 73484, 780, 7, 54, 208, 3365, 5514, 9, 286, 2194, 329, 2, 286, 1275, 62, 442, 2194, 903, 2, 681, 1223, 29, 1081, 6, 1346, 75, 1160, 3038, 3684, 655, 139, 1488, 2029, 15, 2092, 1488, 5847, 672, 315, 1599, 2, 103, 29992, 15, 7364, 5, 3453, 15, 9889, 9, 1562, 2049, 86, 123, 1, 3, 45, 11, 286, 2, 442, 1562, 2, 63, 25, 118, 3, 45, 2176, 3, 69, 266, 237, 39, 736, 90, 23, 477, 9889, 7364, 9889, 29992, 3453, 7364, 2, 3453, 29992, 4, 3, 5847, 87, 9889, 29992, 10, 41, 5, 101, 43, 1, 88, 215, 6, 478, 286, 1562, 580, 43, 861, 14, 833, 19, 144, 2, 88, 316, 6, 478, 286, 1562, 861, 14, 966, 19, 1861, 72, 5, 3453, 7364, 4, 3, 5847, 87, 119, 1, 9889, 7364, 185, 3453, 7364, 1122, 6, 142, 4640, 282, 360, 197, 14, 576, 19, 2155, 4, 361, 87, 77, 125, 10, 77, 523, 4, 442, 1562, 34, 115, 25, 2, 118, 107, 3, 1562, 2049, 472, 9, 3365, 5514, 75, 2029, 125, 32, 77, 362, 4, 123, 90, 23, 1562, 2049, 137, 5, 5847, 3365, 5514, 9889, 29992, 10, 1663, 6, 3453, 90, 472, 9, 286, 1562, 1070, 84, 62, 3, 472, 11, 2017, 4, 1794, 1, 442, 1562, 2, 118, 482, 94, 529, 5847, 2190, 32, 575, 6, 1843, 46, 99]",1659.0,30153491,Comparative Calcineurin Inhibitor-Based Methotrexate Mycophenolate Mofetil-Containing Regimens Prevention Graft-versus-Host Disease Reduced-Intensity Conditioning Allogeneic Transplantation,2,0.0034904013961605585
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.,Hematological oncology,Hematol Oncol,2018-12-05,"Trabectedin is an FDA-approved DNA minor groove binder that has activity against translocation-associated sarcomas. Lurbinectedin is a next-generation minor groove binder with preclinical activity against myeloid leukemia cells. A dose-finding phase 1 clinical trial was performed in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) with further assessment of safety and tolerability. Forty-two patients with relapsed/refractory AML/MDS received lurbinectedin administered as a 1-hour intravenous infusion in a 3+3 study design. Two dosing schedules were used: 3.5, 5, 7, or 6mg on days 1 and 8 or 2, 3, 1, or 1.5mg for 3 consecutive days on days 1 to 3. Three patients experienced dose-limiting toxicities of rhabdomyolysis (grade 4), hyperbilirubinemia (grade 3), and oral herpes (grade 3) with the day 1 and 8 schedule. Otherwise, adverse events mainly consisted of gastrointestinal manifestations (n=11), febrile neutropenia/infections (n=4), pulmonary toxicity (n=2), and renal failure (n=2). The most common laboratory abnormalities observed were an increase in creatinine (93%) and anemia, neutropenia, and thrombocytopenia (100%). Overall, 33 of 42 patients (79%) had reduction in blasts in peripheral blood or bone marrow. One patient achieved a partial response and 2 patients a morphologic leukemia-free state. Most (n=30, 71%) were discontinued due to progressive disease. Early deaths occurred from disease-related causes that were not attributable to lurbinectedin. Four patients with a chromosome 11q21-23 abnormality had significantly greater bone marrow blast reduction than those without such abnormality, with decrease of 3114% (n=4) vs 88% (n=16), respectively (P=.04). Overall, lurbinectedin was safe and tolerated using the schedules and dose levels tested. While no sustained remissions were observed, single-agent lurbinectedin was transiently leukemia suppressive for some patients.",Journal Article,412.0,2.0,Trabectedin FDA-approved DNA minor groove binder activity translocation-associated sarcomas Lurbinectedin next-generation minor groove binder preclinical activity myeloid leukemia dose-finding phase 1 clinical trial performed patients acute myeloid leukemia AML myelodysplastic syndrome MDS assessment safety tolerability Forty-two patients relapsed/refractory AML/MDS received lurbinectedin administered 1-hour intravenous infusion 3 3 design dosing schedules 3.5 5 7 6 mg days 1 8 2 3 1 1.5 mg 3 consecutive days days 1 3 patients experienced dose-limiting toxicities rhabdomyolysis grade 4 hyperbilirubinemia grade 3 oral herpes grade 3 day 1 8 schedule adverse events mainly consisted gastrointestinal manifestations n 11 febrile neutropenia/infections n 4 pulmonary toxicity n 2 renal failure n 2 common laboratory abnormalities observed increase creatinine 93 anemia neutropenia thrombocytopenia 100 Overall 33 42 patients 79 reduction blasts peripheral blood bone marrow patient achieved partial response 2 patients morphologic leukemia-free state n 30 71 discontinued progressive disease Early deaths occurred disease-related causes attributable lurbinectedin patients chromosome 11q21-23 abnormality significantly greater bone marrow blast reduction abnormality decrease 31  14 n 4 vs 8  8 n 16 respectively P .04 Overall lurbinectedin safe tolerated schedules dose levels tested sustained remissions observed single-agent lurbinectedin transiently leukemia suppressive patients,0,0,1,0,0,0,1,0,0,1,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[5110, 16, 35, 2078, 850, 261, 2278, 17860, 28810, 17, 71, 128, 480, 2006, 41, 1479, 15792, 16, 8, 1305, 914, 2278, 17860, 28810, 5, 693, 128, 480, 533, 37, 8, 61, 1567, 124, 14, 38, 160, 10, 173, 4, 7, 5, 286, 533, 329, 2, 681, 1223, 5, 195, 455, 1, 367, 2, 1543, 1213, 100, 7, 5, 591, 430, 329, 1223, 103, 15792, 468, 22, 8, 14, 2583, 1262, 904, 4, 8, 27, 27, 45, 771, 100, 1280, 2314, 11, 95, 27, 33, 33, 67, 15, 49, 81, 23, 162, 14, 2, 66, 15, 18, 27, 14, 15, 14, 33, 81, 9, 27, 935, 162, 23, 162, 14, 6, 27, 169, 7, 592, 61, 817, 385, 1, 20398, 88, 39, 7236, 88, 27, 2, 518, 4716, 88, 27, 5, 3, 218, 14, 2, 66, 1055, 2632, 290, 281, 2615, 1695, 1, 4282, 78, 175, 2498, 778, 1875, 78, 39, 1087, 155, 78, 18, 2, 496, 78, 18, 3, 96, 186, 1624, 1171, 164, 11, 35, 344, 4, 3177, 966, 2, 1545, 778, 2, 1340, 394, 63, 466, 1, 595, 7, 842, 42, 628, 4, 2438, 4, 672, 315, 15, 581, 104, 69, 513, 8, 450, 51, 2, 18, 7, 8, 2815, 2647, 115, 1309, 96, 78, 201, 792, 11, 2402, 520, 6, 1014, 34, 191, 1043, 489, 29, 34, 139, 1626, 17, 11, 44, 2971, 6, 15792, 294, 7, 5, 8, 1170, 30355, 382, 3698, 42, 97, 378, 581, 3112, 628, 76, 135, 187, 225, 3698, 5, 775, 1, 456, 810, 213, 78, 39, 105, 66, 810, 66, 78, 245, 106, 19, 755, 63, 15792, 10, 1165, 2, 421, 75, 3, 2314, 2, 61, 148, 650, 369, 77, 2275, 3166, 11, 164, 226, 420, 15792, 10, 9235, 3707, 9, 476, 7]",1794.0,30153704,Safety tolerability lurbinectedin PM01183 patients acute myeloid leukemia myelodysplastic syndrome,1,0.0017452006980802793
Characteristics and Predictors for Secondary Leukemia and Myelodysplastic Syndrome in Ewing and Osteosarcoma Survivors.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2018-08-28,"Long-term survivors of Ewing sarcoma (ES) and osteosarcoma may be at risk for therapy-related acute leukemia or myelodysplastic syndrome (t-AL/MDS). We retrospectively reviewed the clinicopathologic characteristics of 1071 patients with osteosarcoma (n=757) and ES (n=314) who were treated between 1985 and 2014. Multivariable competing risk analysis was used to analyze predictors of t-AL/MDS, including a radiation dose (55.8Gy vs <55.8Gy)disease site (pelvis/spine vs other) interaction term. A supplemental nested case-control study was conducted to assess the association between cumulative chemotherapy dose and t-AL/MDS. The median follow-up for surviving patients was 97months (range, 0.03-380). Twenty patients developed t-AL/MDS, all of whom received chemotherapy and 15 of whom were treated with radiation therapy. Radiation therapy to 55.8Gy was associated with development of t-AL/MDS (adjusted hazard ratio, 2.89; 95% confidence interval [CI], 1.23-6.80; P=.015), and there was a significant radiation dosedisease site interaction term (adjusted hazard ratio, 6.70; 95% CI, 2.71-16.53; P<sub>interaction</sub><.001). The 5-year cumulative incidence of t-AL/MDS in patients receiving 55.8Gy radiation therapy to the pelvis or spine was 5.0% (95% CI,0.9-14.9) for osteosarcoma and 10.7% for ES (95% CI, 3.3-23.2). In our nested case-control study, cumulative doses of ifosfamide and etoposide were associated with development of t-AL/MDS. Patients with osteosarcoma and ES receiving 55.8Gy of radiation therapy to the pelvis or spine appear to be at increased risk for t-AL/MDS. Treatment with high cumulative doses of chemotherapy may further augment this risk.",Journal Article,511.0,1.0,Long-term survivors Ewing sarcoma ES osteosarcoma risk therapy-related acute leukemia myelodysplastic syndrome t-AL/MDS retrospectively reviewed clinicopathologic characteristics 1071 patients osteosarcoma n 757 ES n 314 treated 1985 2014 Multivariable competing risk predictors t-AL/MDS including radiation dose 55.8 Gy vs 55.8 Gy disease site pelvis/spine vs interaction term supplemental nested case-control conducted assess association cumulative chemotherapy dose t-AL/MDS median follow-up surviving patients 97 months range 0.03-380 patients developed t-AL/MDS received chemotherapy 15 treated radiation therapy Radiation therapy 55.8 Gy associated development t-AL/MDS adjusted hazard ratio 2.89 95 confidence interval CI 1.23-6.80 P .015 significant radiation dose disease site interaction term adjusted hazard ratio 6.70 95 CI 2.71-16.53 P sub interaction /sub .001 5-year cumulative incidence t-AL/MDS patients receiving 55.8 Gy radiation therapy pelvis spine 5.0 95 CI 0.9-14.9 osteosarcoma 10.7 ES 95 CI 3.3-23.2 nested case-control cumulative doses ifosfamide etoposide associated development t-AL/MDS Patients osteosarcoma ES receiving 55.8 Gy radiation therapy pelvis spine appear increased risk t-AL/MDS Treatment high cumulative doses chemotherapy augment risk,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,"[319, 337, 332, 1, 3011, 2, 68, 40, 28, 43, 9, 36, 139, 286, 15, 681, 102, 2171, 1223, 21, 894, 446, 3, 1399, 374, 1, 30302, 7, 5, 78, 15631, 2, 3011, 78, 9391, 54, 11, 73, 59, 4675, 2, 1409, 658, 2573, 43, 65, 10, 95, 6, 1992, 674, 1, 102, 2171, 1223, 141, 8, 121, 61, 15425, 66, 381, 105, 614, 66, 381, 34, 606, 3270, 2342, 105, 127, 915, 337, 8, 6303, 4789, 473, 182, 45, 10, 426, 6, 423, 3, 248, 59, 967, 56, 61, 2, 102, 2171, 1223, 3, 52, 166, 126, 9, 3050, 7, 10, 1015, 53, 184, 13, 680, 8389, 737, 7, 276, 102, 2171, 1223, 62, 1, 953, 103, 56, 2, 167, 1, 953, 11, 73, 5, 121, 36, 121, 36, 6, 15425, 66, 381, 10, 41, 5, 193, 1, 102, 2171, 1223, 586, 360, 197, 18, 887, 48, 307, 268, 58, 14, 382, 49, 493, 19, 3433, 2, 125, 10, 8, 93, 121, 61, 34, 606, 915, 337, 586, 360, 197, 49, 431, 48, 58, 18, 792, 245, 699, 19, 551, 915, 551, 144, 3, 33, 111, 967, 287, 1, 102, 2171, 1223, 4, 7, 357, 15425, 66, 381, 121, 36, 6, 3, 3270, 15, 2342, 10, 33, 13, 48, 58, 13, 83, 213, 83, 9, 2, 79, 67, 9, 3011, 48, 58, 27, 27, 382, 18, 4, 114, 4789, 473, 182, 45, 967, 415, 1, 3157, 2, 1934, 11, 41, 5, 193, 1, 102, 2171, 1223, 7, 5, 2, 3011, 357, 15425, 66, 381, 1, 121, 36, 6, 3, 3270, 15, 2342, 1322, 6, 40, 28, 101, 43, 9, 102, 2171, 1223, 24, 5, 64, 967, 415, 1, 56, 68, 195, 4369, 26, 43]",1538.0,30165126,Characteristics Predictors Secondary Leukemia Myelodysplastic Syndrome Ewing Osteosarcoma Survivors,7,0.012216404886561954
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation.,Leukemia research,Leuk. Res.,2018-09-14,"Therapeutic options for patients with lower-risk myelodysplastic syndrome (MDS) who have failed prior therapies are limited particularly after hypomethylating agent. Several studies have indicated that deregulation of innate immunity signaling is critical in the pathogenesis of MDS. This process involves Toll-like receptor stimulation, cytokine overexpression, and nuclear factor-kB (NF-kB) activation. Since ruxolitinib, a JAK1/JAK2 inhibitor, suppresses NF-kB expression, we conducted a phase 1 dose-escalation study to determine the safety and efficacy of ruxolitinib in previously treated lower-risk MDS patients with evidence of NF-kB activation. Nineteen patients, 8 with chronic myelomonocytic leukemia and 11 with MDS, were enrolled. No dose limiting toxicity was observed and the maximum tolerated dose was 20mg twice daily. Responses were restricted to MDS patients with an overall response rate of 22% [hematological improvement in platelets (HI-P)=2, hematological improvement in erythrocytes (HI-E)=1, partial cytogenetic response (PCyR)=1]. Of these patients, 2 relapsed (HI-P and PCyR) and 2 continue to be in HI-P and HI-E, respectively, with ongoing therapy. Meaningful improvement in bone marrow dysplasia was only seen in a patient who achieved HI-E. Phosphorylated p65 (pp65) decreased in 6 of 15 patients (40%) including the 2 patients with continued response to treatment and increased in a patient who relapsed after a short-lived HI-P. This suggests potential correlation between reduction in pp65 expression and response duration. In conclusion, ruxolitinib was well-tolerated in previously treated lower-risk MDS patients with evidence of NF-kB activation and resulted in low but significant frequency of responses. (NCT01895842).","Clinical Trial, Phase I",494.0,1.0,Therapeutic options patients lower-risk myelodysplastic syndrome MDS failed prior therapies limited particularly hypomethylating agent studies indicated deregulation innate immunity signaling critical pathogenesis MDS process involves Toll-like receptor stimulation cytokine overexpression nuclear factor-kB NF-kB activation ruxolitinib JAK1/JAK2 inhibitor suppresses NF-kB expression conducted phase 1 dose-escalation determine safety efficacy ruxolitinib previously treated lower-risk MDS patients evidence NF-kB activation Nineteen patients 8 chronic myelomonocytic leukemia 11 MDS enrolled dose limiting toxicity observed maximum tolerated dose 20 mg twice daily Responses restricted MDS patients overall response rate 22 hematological improvement platelets HI-P 2 hematological improvement erythrocytes HI-E 1 partial cytogenetic response PCyR 1 patients 2 relapsed HI-P PCyR 2 continue HI-P HI-E respectively ongoing therapy Meaningful improvement bone marrow dysplasia seen patient achieved HI-E. Phosphorylated p65 pp65 decreased 6 15 patients 40 including 2 patients continued response treatment increased patient relapsed short-lived HI-P suggests potential correlation reduction pp65 expression response duration ruxolitinib well-tolerated previously treated lower-risk MDS patients evidence NF-kB activation resulted low significant frequency responses NCT01895842,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[189, 838, 9, 7, 5, 280, 43, 681, 1223, 54, 47, 1551, 324, 235, 32, 383, 823, 50, 4931, 420, 392, 94, 47, 1103, 17, 4765, 1, 3939, 1604, 314, 16, 740, 4, 3, 1384, 1, 1223, 26, 1129, 2921, 7445, 733, 153, 2503, 1675, 851, 2, 928, 161, 5116, 1365, 5116, 363, 1192, 4894, 8, 8075, 2509, 230, 4079, 1365, 5116, 55, 21, 426, 8, 124, 14, 61, 1125, 45, 6, 223, 3, 367, 2, 209, 1, 4894, 4, 373, 73, 280, 43, 1223, 7, 5, 241, 1, 1365, 5116, 363, 3498, 7, 66, 5, 442, 5451, 2, 175, 5, 1223, 11, 346, 77, 61, 817, 155, 10, 164, 2, 3, 689, 421, 61, 10, 179, 81, 936, 391, 253, 11, 2016, 6, 1223, 7, 5, 35, 63, 51, 116, 1, 350, 2890, 767, 4, 4407, 5910, 19, 18, 2890, 767, 4, 18561, 5910, 563, 14, 450, 1266, 51, 20284, 14, 1, 46, 7, 18, 591, 5910, 19, 2, 20284, 2, 18, 1906, 6, 40, 4, 5910, 19, 2, 5910, 563, 106, 5, 942, 36, 2538, 767, 4, 581, 2253, 10, 158, 527, 4, 8, 69, 54, 513, 5910, 563, 2365, 6781, 22108, 340, 4, 49, 1, 167, 7, 327, 141, 3, 18, 7, 5, 1351, 51, 6, 24, 2, 101, 4, 8, 69, 54, 591, 50, 8, 978, 4813, 5910, 19, 26, 844, 174, 816, 59, 628, 4, 22108, 55, 2, 51, 654, 4, 1221, 4894, 10, 149, 421, 4, 373, 73, 280, 43, 1223, 7, 5, 241, 1, 1365, 5116, 363, 2, 627, 4, 154, 84, 93, 675, 1, 253, 73642]",1682.0,30245189,Phase ruxolitinib previously treated patients low intermediate-1 risk myelodysplastic syndrome evidence NF-kB activation,103,0.17975567190226877
Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.,The Journal of clinical investigation,J. Clin. Invest.,2018-11-05,"Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are associated with disease-initiating stem cells that are not eliminated by conventional therapies. Transcriptomic analysis of stem and progenitor populations in MDS and AML demonstrated overexpression of STAT3 that was validated in an independent cohort. STAT3 overexpression was predictive of a shorter survival and worse clinical features in a large MDS cohort. High STAT3 expression signature in MDS CD34+ cells was similar to known preleukemic gene signatures. Functionally, STAT3 inhibition by a clinical, antisense oligonucleotide, AZD9150, led to reduced viability and increased apoptosis in leukemic cell lines. AZD9150 was rapidly incorporated by primary MDS/AML stem and progenitor cells and led to increased hematopoietic differentiation. STAT3 knockdown also impaired leukemic growth in vivo and led to decreased expression of MCL1 and other oncogenic genes in malignant cells. These studies demonstrate that STAT3 is an adverse prognostic factor in MDS/AML and provide a preclinical rationale for studies using AZD9150 in these diseases.",Journal Article,442.0,6.0,Acute myeloid leukemia AML myelodysplastic syndromes MDS associated disease-initiating stem eliminated conventional therapies Transcriptomic stem progenitor populations MDS AML demonstrated overexpression STAT3 validated independent cohort STAT3 overexpression predictive shorter survival worse clinical features large MDS cohort High STAT3 expression signature MDS CD34+ similar known preleukemic signatures Functionally STAT3 inhibition clinical antisense oligonucleotide AZD9150 led reduced viability increased apoptosis leukemic lines AZD9150 rapidly incorporated primary MDS/AML stem progenitor led increased hematopoietic differentiation STAT3 knockdown impaired leukemic growth vivo led decreased expression MCL1 oncogenic malignant studies demonstrate STAT3 adverse prognostic factor MDS/AML provide preclinical rationale studies AZD9150 diseases,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[286, 533, 329, 2, 2040, 1223, 32, 41, 5, 34, 2637, 452, 37, 17, 32, 44, 6173, 20, 809, 235, 5983, 65, 1, 452, 2, 2520, 1184, 4, 1223, 2, 329, 264, 851, 1, 1439, 17, 10, 938, 4, 35, 306, 180, 1439, 851, 10, 464, 1, 8, 985, 25, 2, 639, 38, 404, 4, 8, 375, 1223, 180, 64, 1439, 55, 1651, 4, 1223, 2215, 37, 10, 288, 6, 440, 19788, 145, 2210, 3772, 1439, 297, 20, 8, 38, 4645, 4727, 24210, 836, 6, 405, 2120, 2, 101, 351, 4, 2015, 31, 285, 24210, 10, 1755, 2449, 20, 86, 1223, 329, 452, 2, 2520, 37, 2, 836, 6, 101, 1007, 910, 1439, 1563, 120, 2364, 2015, 129, 4, 386, 2, 836, 6, 340, 55, 1, 8132, 2, 127, 1302, 214, 4, 393, 37, 46, 94, 608, 17, 1439, 16, 35, 290, 177, 161, 4, 1223, 329, 2, 377, 8, 693, 1728, 9, 94, 75, 24210, 4, 46, 1342]",1076.0,30252677,Antisense STAT3 inhibitor decreases viability myelodysplastic leukemic stem,3,0.005235602094240838
"Hereditary Myelodysplastic Syndrome and Acute Myeloid Leukemia: Diagnosis, Questions, and Controversies.",Current hematologic malignancy reports,Curr Hematol Malig Rep,2018-12-01,"To review the diagnosis of individuals with hereditary hematopoietic malignancies (HHMs) that predispose to myelodysplastic syndrome and acute myeloid leukemia, barriers to HHM diagnosis, and unaddressed questions and controversies within the HHM field. Pathogenic germline mutations in approximately a dozen genes predispose to HHMs, and many more genes are likely to be involved. Many of these HHM genes have only been identified recently. HHM phenotypes are diverse, but may be categorized as ""purely"" myeloid syndromes, syndromes with abnormal platelet number/function, and HHMs with additional organ system involvement. A number of questions remain unanswered in this emerging field, including the ideal diagnostic approach for patients at risk for HHMs, the optimal surveillance of unaffected carriers, and how to personalize care for individuals with HHMs. The field of HHMs is evolving rapidly. Ongoing research in this area will eventually inform the care of patients with both somatic and hereditary cancer syndromes, but much work remains to be done.",Journal Article,416.0,5.0,review diagnosis individuals hereditary hematopoietic malignancies HHMs predispose myelodysplastic syndrome acute myeloid leukemia barriers HHM diagnosis unaddressed questions controversies HHM field Pathogenic germline approximately dozen predispose HHMs likely involved HHM identified recently HHM phenotypes diverse categorized `` purely '' myeloid syndromes syndromes abnormal platelet number/function HHMs additional organ involvement number questions remain unanswered emerging field including ideal diagnostic approach patients risk HHMs optimal surveillance unaffected carriers personalize care individuals HHMs field HHMs evolving rapidly Ongoing research area eventually inform care patients somatic hereditary syndromes work remains,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[6, 206, 3, 147, 1, 869, 5, 2305, 1007, 441, 24337, 17, 6043, 6, 681, 2, 286, 533, 2160, 6, 36676, 147, 2, 29248, 1937, 2, 6613, 262, 3, 36676, 1067, 2806, 1009, 138, 4, 705, 8, 20512, 214, 6043, 6, 24337, 2, 445, 80, 214, 32, 322, 6, 40, 646, 445, 1, 46, 36676, 214, 47, 158, 85, 108, 761, 36676, 2618, 32, 1867, 84, 68, 40, 2320, 22, 13033, 522, 533, 2040, 2040, 5, 1668, 1596, 207, 343, 2, 24337, 5, 402, 1259, 398, 799, 8, 207, 1, 1937, 918, 7550, 4, 26, 1478, 1067, 141, 3, 3662, 752, 353, 9, 7, 28, 43, 9, 24337, 3, 665, 617, 1, 4585, 1316, 2, 832, 6, 8346, 165, 9, 869, 5, 24337, 3, 1067, 1, 24337, 16, 3276, 1755, 942, 389, 4, 26, 965, 303, 3124, 2295, 3, 165, 1, 7, 5, 110, 1119, 2, 2305, 12, 2040, 84, 1802, 1357, 469, 6, 40, 1822]",1021.0,30259338,Hereditary Myelodysplastic Syndrome Acute Myeloid Leukemia Diagnosis Questions Controversies,13,0.02268760907504363
"Peripheral Blood versus Bone Marrow from Unrelated Donors: Bone Marrow Allografts Have Improved Long-Term Overall and Graft-versus-Host Disease-Free, Relapse-Free Survival.",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2018-10-03,"Peripheral blood (PB) and bone marrow (BM) from unrelated donors can serve as a graft source for hematopoietic cell transplantation (HCT). Currently, PB is most commonly used in roughly 80% of adult recipients. Determining the long-term impact of graft source on outcomes would inform this decision. Data collected by the Center for International Blood and Marrow Transplant Research from 5200 adult recipients of a first HCT from an 8/8 or 7/8 HLA antigen-matched unrelated donor for treatment of acute leukemia, chronic myelogenous leukemia, or myelodysplastic syndrome between 2001 and 2011 were analyzed to determine the impact of graft source on graft-versus-host disease (GVHD) relapse-free survival (GRFS), defined as freedom from grade III/IV acute GVHD, chronic GVHD requiring immunosuppressive therapy, relapse, and death, and overall survival. GRFS at 2 years was superior in BM recipients compared with PB recipients (16%; 95% confidence interval [CI], 14% to 18% versus 10%; 95% CI, 8% to 11%; P <.0001) in the 8/8 HLA-matched cohort and 7/8 HLA-matched cohort (11%; 95% CI, 8% to 14% versus 5%; 95% CI, 4% to 7%; P=.001). With 8/8 HLA-matched unrelated donors, overall survival at 5 years was superior in recipients of BM (43%; 95% CI, 40% to 46% versus 38%; 95% CI, 36% to 40%; P=.014). The inferior 5-year survival in the PB cohort was attributable to a higher frequency of deaths while in remission compared with the BM cohort. For recipients of 7/8 HLA-matched grafts, survival at 5 years was similar in BM recipients and PB recipients (32% versus 29%; P=.329). BM grafts are associated with improved long-term GRFS and overall survival in recipients of matched unrelated donor HCT and should be considered the unrelated allograft of choice, when available, for adults with acute leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome.",Clinical Trial,475.0,2.0,Peripheral blood PB bone marrow BM unrelated donors serve graft source hematopoietic transplantation HCT Currently PB commonly roughly 80 adult recipients Determining long-term impact graft source outcomes inform decision collected Center International Blood Marrow Transplant Research 5200 adult recipients HCT 8/8 7/8 HLA antigen-matched unrelated donor treatment acute leukemia chronic myelogenous leukemia myelodysplastic syndrome 2001 2011 determine impact graft source graft-versus-host disease GVHD relapse-free survival GRFS defined freedom grade III/IV acute GVHD chronic GVHD requiring immunosuppressive therapy relapse death overall survival GRFS 2 years superior BM recipients compared PB recipients 16 95 confidence interval CI 14 18 versus 10 95 CI 8 11 P .0001 8/8 HLA-matched cohort 7/8 HLA-matched cohort 11 95 CI 8 14 versus 5 95 CI 4 7 P .001 8/8 HLA-matched unrelated donors overall survival 5 years superior recipients BM 43 95 CI 40 46 versus 38 95 CI 36 40 P .014 inferior 5-year survival PB cohort attributable higher frequency deaths remission compared BM cohort recipients 7/8 HLA-matched grafts survival 5 years similar BM recipients PB recipients 32 versus 29 P .329 BM grafts associated improved long-term GRFS overall survival recipients matched unrelated donor HCT considered unrelated allograft choice available adults acute leukemia chronic myelogenous leukemia myelodysplastic syndrome,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[672, 315, 3767, 2, 581, 1246, 29, 2092, 2344, 122, 1833, 22, 8, 1599, 2353, 9, 1007, 31, 497, 1085, 694, 3767, 16, 96, 841, 95, 4, 7954, 493, 1, 780, 2190, 2196, 3, 319, 337, 345, 1, 1599, 2353, 23, 123, 688, 2295, 26, 948, 74, 786, 20, 3, 574, 9, 944, 315, 2, 581, 941, 389, 29, 73743, 780, 2190, 1, 8, 157, 1085, 29, 35, 66, 66, 15, 67, 66, 1160, 448, 655, 2092, 1488, 9, 24, 1, 286, 442, 2194, 15, 681, 59, 1758, 2, 1132, 11, 311, 6, 223, 3, 345, 1, 1599, 2353, 23, 1599, 185, 1204, 34, 1562, 429, 115, 25, 36678, 395, 22, 3060, 29, 88, 316, 478, 286, 1562, 442, 1562, 1888, 2989, 36, 429, 2, 273, 2, 63, 25, 36678, 28, 18, 60, 10, 1123, 4, 1246, 2190, 72, 5, 3767, 2190, 245, 48, 307, 268, 58, 213, 6, 203, 185, 79, 48, 58, 66, 6, 175, 19, 488, 4, 3, 66, 66, 1160, 655, 180, 2, 67, 66, 1160, 655, 180, 175, 48, 58, 66, 6, 213, 185, 33, 48, 58, 39, 6, 67, 19, 144, 5, 66, 66, 1160, 655, 2092, 2344, 63, 25, 28, 33, 60, 10, 1123, 4, 2190, 1, 1246, 601, 48, 58, 327, 6, 641, 185, 519, 48, 58, 511, 6, 327, 19, 3618, 3, 1663, 33, 111, 25, 4, 3, 3767, 180, 10, 2971, 6, 8, 142, 675, 1, 1043, 369, 4, 734, 72, 5, 3, 1246, 180, 9, 2190, 1, 67, 66, 1160, 655, 4713, 25, 28, 33, 60, 10, 288, 4, 1246, 2190, 2, 3767, 2190, 531, 185, 462, 19, 8766, 1246, 4713, 32, 41, 5, 231, 319, 337, 36678, 2, 63, 25, 4, 2190, 1, 655, 2092, 1488, 1085, 2, 257, 40, 515, 3, 2092, 9568, 1, 1866, 198, 390, 9, 857, 5, 286, 442, 2194, 2, 681]",1707.0,30292009,Peripheral Blood versus Bone Marrow Unrelated Donors Bone Marrow Allografts Improved Long-Term Overall Graft-versus-Host Disease-Free Relapse-Free Survival,5,0.008726003490401396
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents.,American journal of hematology,Am. J. Hematol.,2018-11-15,"The outcome of patients with myelodysplastic syndromes (MDSs) after failure of hypomethylating agents (HMAs) failure is poor with a median overall survival (OS) of only 4-6 months. Omacetaxine mepesuccinate (OM) is safe and effective in myeloid malignancies but has not been studied in MDS with HMA failure. We conducted a phase II study of OM in patients with MDS or chronic myelomonocytic leukemia (CMML) who had previously failed or been intolerant to HMAs. Patients received OM at a dose of 1.25 mg/m<sup>2</sup> subcutaneously every 12 hours for 3 consecutive days on a 4- to 7-week schedule. The primary endpoints were the overall response rate (ORR) and OS. A total of 42 patients were enrolled with a median age of 76 years. The ORR was 33%. Patients with diploid cytogenetics were more likely to respond to OM than were those with cytogenetic abnormalities (58% vs 23%, respectively; P = .03). Overall, the median OS was 7.5 months and 1-year OS rate was 25%. Patients with diploid cytogenetics had superior OS to those with cytogenetic abnormalities (median OS 14.8 vs 6.8 months, respectively; P = .01). Two patients had ongoing response to OM of 2 years or longer (both MDS with diploid cytogenetics and RUNX1 mutation). The most common grade  3 adverse events were infections in 11 patients (26%), febrile neutropenia in 4 (10%), and hemorrhage in 3 (7%). Overall, OM was safe and active in patients with MDS or CMML who experienced HMA failure. These results support the further development of OM in this setting.","Clinical Trial, Phase II",432.0,0.0,outcome patients myelodysplastic syndromes MDSs failure hypomethylating agents HMAs failure poor median overall survival OS 4-6 months Omacetaxine mepesuccinate OM safe effective myeloid malignancies studied MDS HMA failure conducted phase II OM patients MDS chronic myelomonocytic leukemia CMML previously failed intolerant HMAs Patients received OM dose 1.25 mg/m sup 2 /sup subcutaneously 12 hours 3 consecutive days 4- 7-week schedule primary endpoints overall response rate ORR OS total 42 patients enrolled median age 76 years ORR 33 Patients diploid cytogenetics likely respond OM cytogenetic abnormalities 58 vs 23 respectively P .03 Overall median OS 7.5 months 1-year OS rate 25 Patients diploid cytogenetics superior OS cytogenetic abnormalities median OS 14.8 vs 6.8 months respectively P .01 patients ongoing response OM 2 years longer MDS diploid cytogenetics RUNX1 common grade  3 adverse events infections 11 patients 26 febrile neutropenia 4 10 hemorrhage 3 7 Overall OM safe active patients MDS CMML experienced HMA failure support development OM setting,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 228, 1, 7, 5, 2040, 13550, 50, 496, 1, 4931, 183, 12688, 496, 16, 334, 5, 8, 52, 63, 25, 118, 1, 158, 39, 49, 53, 15787, 35902, 7435, 16, 1165, 2, 323, 4, 533, 441, 84, 71, 44, 85, 656, 4, 1223, 5, 7518, 496, 21, 426, 8, 124, 215, 45, 1, 7435, 4, 7, 5, 1223, 15, 442, 5451, 3382, 54, 42, 373, 1551, 15, 85, 4944, 6, 12688, 7, 103, 7435, 28, 8, 61, 1, 14, 243, 81, 188, 172, 18, 172, 3928, 454, 133, 1459, 9, 27, 935, 162, 23, 8, 39, 6, 67, 647, 1055, 3, 86, 1387, 11, 3, 63, 51, 116, 1735, 2, 118, 8, 181, 1, 595, 7, 11, 346, 5, 8, 52, 89, 1, 846, 60, 3, 1735, 10, 466, 7, 5, 6815, 2510, 11, 80, 322, 6, 1892, 6, 7435, 76, 11, 135, 5, 1266, 1171, 717, 105, 382, 106, 19, 680, 63, 3, 52, 118, 10, 67, 33, 53, 2, 14, 111, 118, 116, 10, 243, 7, 5, 6815, 2510, 42, 1123, 118, 6, 135, 5, 1266, 1171, 52, 118, 213, 66, 105, 49, 66, 53, 106, 19, 355, 100, 7, 42, 942, 51, 6, 7435, 1, 18, 60, 15, 589, 110, 1223, 5, 6815, 2510, 2, 6092, 258, 3, 96, 186, 88, 749, 27, 290, 281, 11, 1875, 4, 175, 7, 432, 2498, 778, 4, 39, 79, 2, 3599, 4, 27, 67, 63, 7435, 10, 1165, 2, 544, 4, 7, 5, 1223, 15, 3382, 54, 592, 7518, 496, 46, 99, 538, 3, 195, 193, 1, 7435, 4, 26, 546]",1445.0,30328139,phase II omacetaxine mepesuccinate patients higher-risk myelodysplastic syndrome chronic myelomonocytic leukemia failure hypomethylating agents,0,0.0
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy.,Cell stem cell,Cell Stem Cell,2018-11-01,"Clonal hematopoiesis (CH), in which stem cell clones dominate blood production, becomes increasingly common with age and can presage malignancy development. The conditions that promote ascendancy of particular clones are unclear. We found that mutations in PPM1D (protein phosphatase Mn<sup>2+</sup>/Mg<sup>2+</sup>-dependent 1D), a DNA damage response regulator that is frequently mutated in CH, were present in one-fifth of patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome and strongly correlated with cisplatin exposure. Cell lines with hyperactive PPM1D mutations expand to outcompete normal cells after exposure to cytotoxic DNA damaging agents including cisplatin, and this effect was predominantly mediated by increased resistance to apoptosis. Moreover, heterozygous mutant Ppm1d hematopoietic cells outcompeted their wild-type counterparts invivo after exposure to cisplatin and doxorubicin, but not during recovery from bone marrow transplantation. These findings establish the clinical relevance of PPM1D mutations in CH and the importance of studying mutation-treatment interactions. VIDEO ABSTRACT.",Journal Article,446.0,30.0,Clonal hematopoiesis CH stem clones dominate blood production increasingly common age presage malignancy development conditions promote ascendancy particular clones unclear PPM1D phosphatase Mn sup 2+ /sup /Mg sup 2+ /sup -dependent 1D DNA damage response regulator frequently CH present one-fifth patients therapy-related acute myeloid leukemia myelodysplastic syndrome strongly correlated cisplatin exposure lines hyperactive PPM1D expand outcompete normal exposure cytotoxic DNA damaging agents including cisplatin effect predominantly mediated increased resistance apoptosis heterozygous Ppm1d hematopoietic outcompeted wild-type counterparts vivo exposure cisplatin doxorubicin recovery bone marrow transplantation findings establish clinical relevance PPM1D CH importance studying mutation-treatment interactions VIDEO ABSTRACT,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[1946, 5114, 6557, 4, 92, 452, 31, 2749, 18953, 315, 1529, 5366, 1635, 186, 5, 89, 2, 122, 73910, 710, 193, 3, 1298, 17, 1617, 73911, 1, 1454, 2749, 32, 1200, 21, 204, 17, 138, 4, 16732, 178, 2577, 4691, 172, 18, 172, 81, 172, 18, 172, 470, 13371, 8, 261, 1350, 51, 2452, 17, 16, 746, 1185, 4, 6557, 11, 364, 4, 104, 5780, 1, 7, 5, 36, 139, 286, 533, 15, 681, 2, 1327, 438, 5, 540, 645, 31, 285, 5, 11802, 16732, 138, 4082, 6, 35652, 295, 37, 50, 645, 6, 759, 261, 4904, 183, 141, 540, 2, 26, 254, 10, 2117, 517, 20, 101, 251, 6, 351, 1393, 4167, 620, 16732, 1007, 37, 36388, 136, 955, 267, 3953, 4, 386, 50, 645, 6, 540, 2, 856, 84, 44, 190, 1602, 29, 581, 497, 46, 272, 1811, 3, 38, 2088, 1, 16732, 138, 4, 6557, 2, 3, 1187, 1, 4559, 258, 24, 1286, 4139, 8161]",1096.0,30388424,PPM1D Drive Clonal Hematopoiesis Response Cytotoxic Chemotherapy,255,0.44502617801047123
A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer.,Pediatric blood & cancer,Pediatr Blood Cancer,2018-12-11,"Bacillus species are known to cause severe infection in immunocompromised hosts. The incidence of Bacillus bloodstream infections and characteristics of infection among children with cancer or indication for hematopoietic cell transplant (HCT) is unknown. We performed a retrospective medical record review of all cases of Bacillus bacteremia between January 1, 2005, and December 31, 2014, at Boston Children's Hospital. We report average incidences from 2012 to 2014. We performed a detailed review of infections among children with cancer or undergoing HCT and a case-control study to evaluate whether neutropenia at diagnosis caries higher risk of Bacillus infection for children with acute lymphoblastic leukemia (ALL). One hundred fourteen children developed Bacillus bacteremia during the study period, with an estimated incidence of 0.27/1,000 patients. Among children treated for cancer or undergoing HCT, there were 37 bloodstream infections (2.0/1,000 patients). Of the 37 oncology/HCT patients, oncologic diagnoses included ALL (18), acute myeloid leukemia (3), myelodysplastic syndrome (1), solid tumors (8), and 7 children were undergoing HCT. The incidence of infection among children with ALL was 34/1,000 patients and all central nervous system (CNS) infections (6) and deaths (3) occurred in this population. Neutropenia at time of diagnosis in children with ALL was not associated with risk of infection (P=0.17). We report the first hospital-wide analysis of Bacillus infection and found that immunocompromised children experience a significant proportion of Bacillus infections. Children with ALL have a high incidence of infection and are at higher risk of CNS involvement and death.",Journal Article,406.0,0.0,"Bacillus species known cause severe infection immunocompromised hosts incidence Bacillus bloodstream infections characteristics infection children indication hematopoietic transplant HCT unknown performed retrospective medical record review cases Bacillus bacteremia January 1 2005 December 31 2014 Boston Children 's Hospital report average incidences 2012 2014 performed detailed review infections children undergoing HCT case-control evaluate neutropenia diagnosis caries higher risk Bacillus infection children acute lymphoblastic leukemia fourteen children developed Bacillus bacteremia period estimated incidence 0.27/1,000 patients children treated undergoing HCT 37 bloodstream infections 2.0/1,000 patients 37 oncology/HCT patients oncologic diagnoses included 18 acute myeloid leukemia 3 myelodysplastic syndrome 1 solid 8 7 children undergoing HCT incidence infection children 34/1,000 patients central nervous CNS infections 6 deaths 3 occurred population Neutropenia time diagnosis children associated risk infection P 0.17 report hospital-wide Bacillus infection immunocompromised children experience significant proportion Bacillus infections Children high incidence infection higher risk CNS involvement death",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4947, 2915, 32, 440, 6, 708, 905, 930, 4, 7796, 9867, 3, 287, 1, 4947, 10210, 1875, 2, 374, 1, 930, 107, 541, 5, 12, 15, 3607, 9, 1007, 31, 941, 1085, 16, 860, 21, 173, 8, 459, 484, 3237, 206, 1, 62, 140, 1, 4947, 7085, 59, 1024, 14, 1242, 2, 1397, 456, 1409, 28, 7026, 541, 292, 702, 21, 414, 1011, 3981, 29, 1195, 6, 1409, 21, 173, 8, 2455, 206, 1, 1875, 107, 541, 5, 12, 15, 479, 1085, 2, 8, 473, 182, 45, 6, 376, 317, 778, 28, 147, 29155, 142, 43, 1, 4947, 930, 9, 541, 5, 286, 1275, 62, 104, 1128, 3225, 541, 276, 4947, 7085, 190, 3, 45, 727, 5, 35, 661, 287, 1, 13, 428, 14, 984, 7, 107, 541, 73, 9, 12, 15, 479, 1085, 125, 11, 567, 10210, 1875, 18, 13, 14, 984, 7, 1, 3, 567, 413, 1085, 7, 1998, 2403, 159, 62, 203, 286, 533, 27, 681, 14, 537, 57, 66, 2, 67, 541, 11, 479, 1085, 3, 287, 1, 930, 107, 541, 5, 62, 10, 562, 14, 984, 7, 2, 62, 854, 1880, 398, 1025, 1875, 49, 2, 1043, 27, 489, 4, 26, 266, 778, 28, 98, 1, 147, 4, 541, 5, 62, 10, 44, 41, 5, 43, 1, 930, 19, 13, 269, 21, 414, 3, 157, 702, 1019, 65, 1, 4947, 930, 2, 204, 17, 7796, 541, 730, 8, 93, 920, 1, 4947, 1875, 541, 5, 62, 47, 8, 64, 287, 1, 930, 2, 32, 28, 142, 43, 1, 1025, 799, 2, 273]",1627.0,30537106,single institutional review pediatric Bacillus spp bloodstream infections demonstrates increased incidence children,0,0.0
Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.,Advances in experimental medicine and biology,Adv. Exp. Med. Biol.,,"In the past few years, our improved understanding of the pathogenesis of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) has led to remarkable advances in the development of novel therapeutic approaches for these diseases. This chapter summarizes the available clinical data with immune-based therapeutic modalities in AML and MDS, focusing on monoclonal antibodies, T cell engager antibodies, chimeric antigen receptor (CAR)-T cells, and checkpoint blockade via blockade of PD-1/PD-L1 or CTLA4. Numerous clinical trials are currently ongoing in patients with AML and MDS, both in the frontline and relapsed refractory setting. Given the natural diversity of AML blasts, it became apparent that the best responses would be achieved with rationally designed combination strategies of immunetherapy, moleculartherapy, and chemotherapy. A number of such combinations are enrolling patients with AML in variousclinical settings. Biomarkers to select the optimal combination regimen for individual patients are critical.",Journal Article,,4.0,past years improved understanding pathogenesis acute myeloid leukemia AML myelodysplastic syndrome MDS led remarkable advances development novel therapeutic approaches diseases chapter summarizes available clinical immune-based therapeutic modalities AML MDS focusing monoclonal antibodies engager antibodies chimeric antigen receptor CAR -T checkpoint blockade blockade PD-1/PD-L1 CTLA4 Numerous clinical trials currently ongoing patients AML MDS frontline relapsed refractory setting Given natural diversity AML blasts apparent best responses achieved rationally designed combination strategies immune therapy molecular therapy chemotherapy number combinations enrolling patients AML clinical settings Biomarkers select optimal combination regimen individual patients critical,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[4, 3, 1219, 1021, 60, 114, 231, 612, 1, 3, 1384, 1, 286, 533, 329, 2, 681, 1223, 71, 836, 6, 3813, 954, 4, 3, 193, 1, 229, 189, 611, 9, 46, 1342, 26, 6366, 2869, 3, 390, 38, 74, 5, 250, 90, 189, 1558, 4, 329, 2, 1223, 3312, 23, 848, 890, 102, 31, 19374, 890, 2897, 448, 153, 1881, 102, 37, 2, 986, 1189, 847, 1189, 1, 333, 14, 333, 729, 15, 5427, 2331, 38, 143, 32, 694, 942, 4, 7, 5, 329, 2, 1223, 110, 4, 3, 3171, 2, 591, 430, 546, 447, 3, 1504, 3653, 1, 329, 2438, 192, 3451, 2235, 17, 3, 824, 253, 688, 40, 513, 5, 6352, 1114, 150, 422, 1, 250, 36, 219, 36, 2, 56, 8, 207, 1, 225, 1247, 32, 6280, 7, 5, 329, 4, 747, 38, 1947, 582, 6, 1717, 3, 665, 150, 477, 9, 797, 7, 32, 740]",989.0,30539507,Update Immunotherapy AML MDS Monoclonal Antibodies Checkpoint Inhibitors Paving Road Clinical Practice,0,0.0
Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome.,Leukemia,Leukemia,2018-12-16,"Glasdegib is a Hedgehog pathway inhibitor. This phase II, randomized, open-label, multicenter study (ClinicalTrials.gov,NCT01546038) evaluated the efficacy of glasdegib plus low-dose cytarabine (LDAC) in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome unsuitable for intensive chemotherapy. Glasdegib 100mg (oral, QD) was administered continuously in 28-day cycles; LDAC 20mg (subcutaneous, BID) was administered for 10 per 28 days. Patients (stratified by cytogenetic risk) were randomized (2:1) to receive glasdegib/LDAC or LDAC. The primary endpoint was overall survival. Eighty-eight and 44 patients were randomized to glasdegib/LDAC and LDAC, respectively. Median (80% confidence interval [CI]) overall survival was 8.8 (6.9-9.9) months with glasdegib/LDAC and 4.9 (3.5-6.0) months with LDAC (hazard ratio, 0.51; 80% CI, 0.39-0.67, P=0.0004). Fifteen (17.0%) and 1 (2.3%) patients in the glasdegib/LDAC and LDAC arms, respectively, achieved complete remission (P<0.05). Nonhematologic grade 3/4 all-causality adverse events included pneumonia (16.7%) and fatigue (14.3%) with glasdegib/LDAC and pneumonia (14.6%) with LDAC. Clinical efficacy was evident across patients with diverse mutational profiles. Glasdegib plus LDAC has a favorable benefit-risk profile and may be a promising option for AML patients unsuitable for intensive chemotherapy.","Clinical Trial, Phase II",401.0,46.0,Glasdegib Hedgehog pathway inhibitor phase II randomized open-label multicenter ClinicalTrials.gov NCT01546038 evaluated efficacy glasdegib plus low-dose cytarabine LDAC patients acute myeloid leukemia AML high-risk myelodysplastic syndrome unsuitable intensive chemotherapy Glasdegib 100 mg oral QD administered continuously 28-day cycles LDAC 20 mg subcutaneous BID administered 10 28 days Patients stratified cytogenetic risk randomized 2:1 receive glasdegib/LDAC LDAC primary endpoint overall survival Eighty-eight 44 patients randomized glasdegib/LDAC LDAC respectively Median 80 confidence interval CI overall survival 8.8 6.9-9.9 months glasdegib/LDAC 4.9 3.5-6.0 months LDAC hazard ratio 0.51 80 CI 0.39-0.67 P 0.0004 17.0 1 2.3 patients glasdegib/LDAC LDAC arms respectively achieved complete remission P 0.05 Nonhematologic grade 3/4 all-causality adverse events included pneumonia 16.7 fatigue 14.3 glasdegib/LDAC pneumonia 14.6 LDAC Clinical efficacy evident patients diverse profiles Glasdegib plus LDAC favorable benefit-risk profile promising option AML patients unsuitable intensive chemotherapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[15452, 16, 8, 4097, 308, 230, 26, 124, 215, 384, 1020, 1756, 1570, 45, 1252, 1239, 41990, 194, 3, 209, 1, 15452, 349, 154, 61, 1855, 10714, 4, 7, 5, 286, 533, 329, 15, 64, 43, 681, 12277, 9, 1686, 56, 15452, 394, 81, 518, 5419, 10, 468, 4285, 4, 339, 218, 410, 10714, 179, 81, 2529, 2793, 10, 468, 9, 79, 379, 339, 162, 7, 1173, 20, 1266, 43, 11, 384, 18, 14, 6, 560, 15452, 10714, 15, 10714, 3, 86, 1138, 10, 63, 25, 2207, 659, 2, 584, 7, 11, 384, 6, 15452, 10714, 2, 10714, 106, 52, 493, 307, 268, 58, 63, 25, 10, 66, 66, 49, 83, 83, 83, 53, 5, 15452, 10714, 2, 39, 83, 27, 33, 49, 13, 53, 5, 10714, 360, 197, 13, 725, 493, 58, 13, 587, 13, 598, 19, 13, 5295, 3057, 269, 13, 2, 14, 18, 27, 7, 4, 3, 15452, 10714, 2, 10714, 1335, 106, 513, 236, 734, 19, 13, 474, 3534, 88, 27, 39, 62, 10107, 290, 281, 159, 3485, 245, 67, 2, 613, 213, 27, 5, 15452, 10714, 2, 3485, 213, 49, 5, 10714, 38, 209, 10, 2853, 716, 7, 5, 1867, 1619, 1241, 15452, 349, 10714, 71, 8, 913, 247, 43, 800, 2, 68, 40, 8, 721, 1501, 9, 329, 7, 12277, 9, 1686, 56]",1294.0,30555165,Randomized comparison low dose cytarabine glasdegib patients newly diagnosed acute myeloid leukemia high-risk myelodysplastic syndrome,18,0.031413612565445025
Novel EZH2 mutation in a patient with secondary B-cell acute lymphocytic leukemia after deletion 5q myelodysplastic syndrome treated with lenalidomide: A case report.,Medicine,Medicine (Baltimore),2019-01-01,"The gene deletion (5)(q22q35) is reported in 10-20% of myelodysplastic syndrome (MDS) cases and is associated with response to lenalidomide and favorable prognosis. The authors report here a clinical case of MDS transformation to B-cell acute lymphocytic leukemia (B-ALL) with an associated accrual of an additional mutation following treatment with lenalidomide. A 69-year-old man presented with progressive anemia, normal white blood cell count, and thrombocytopenia consistent with MDS. He was administered lenalidomide for 27 months, then developed acute B-cell lymphocytic leukemia and acquired a previously unreported mutation in the gene enhancer of zeste homolog 2 (EZH2). After 27 months of therapy with lenalidomide, a surveillance bone marrow aspiration (BMA) revealed 90% cellularity with persistent multilineage dysplasia and a population of blasts comprising 54% of all bone marrow elements by morphology, consistent with B-ALL, even though the patient was asymptomatic. Conventional karyotype showed no signs of del(5)(q22q35) MDS, however bone marrow next-generation sequencing (NGS) demonstrated the accrual of a nonsense mutation (c.211del pL71*) in exon 3 of EZH2. A confirmatory BMA yielded 70% blasts and clinical features indicative of B-ALL. Mini-hyper-CVD (cyclophosphamide and dexamethasone at 50% dose reduction, no anthracycline, methotrexate at 75% dose reduction, cytarabine at 0.5g/m4 doses) was administered for 21 days. A follow-up BMA was performed 2 months after mini-hyper-CVD therapy, showing dysplastic features with 25% ring sideroblasts, but no evidence of B-ALL. The patient is currently receiving monthly-low dose decitabine, ofatumumab, and dexamethasone, and is transfusion independent and asymptomatic after 7 cycles. The present study shows an extremely rare progression of del(5)(q22q35) MDS to B-ALL with accompanying NGS data and a newly described acquisition of an EZH2 frameshift mutation. This case highlights the importance of NGS as a diagnostic and surveillance tool for MDS.",Case Reports,385.0,3.0,deletion 5 q22q35 reported 10-20 myelodysplastic syndrome MDS cases associated response lenalidomide favorable prognosis authors report clinical case MDS transformation B-cell acute lymphocytic leukemia B-ALL associated accrual additional following treatment lenalidomide 69-year-old man presented progressive anemia normal white blood count thrombocytopenia consistent MDS administered lenalidomide 27 months developed acute B-cell lymphocytic leukemia acquired previously unreported enhancer zeste homolog 2 EZH2 27 months therapy lenalidomide surveillance bone marrow aspiration BMA revealed 90 cellularity persistent multilineage dysplasia population blasts comprising 54 bone marrow elements morphology consistent B-ALL patient asymptomatic Conventional karyotype showed signs del 5 q22q35 MDS bone marrow next-generation sequencing NGS demonstrated accrual nonsense c.211del pL71* exon 3 EZH2 confirmatory BMA yielded 70 blasts clinical features indicative B-ALL Mini-hyper-CVD cyclophosphamide dexamethasone 50 dose reduction anthracycline methotrexate 75 dose reduction cytarabine 0.5 g/m 4 doses administered 21 days follow-up BMA performed 2 months mini-hyper-CVD therapy showing dysplastic features 25 ring sideroblasts evidence B-ALL patient currently receiving monthly-low dose decitabine ofatumumab dexamethasone transfusion independent asymptomatic 7 cycles present shows extremely rare progression del 5 q22q35 MDS B-ALL accompanying NGS newly described acquisition EZH2 frameshift case highlights importance NGS diagnostic surveillance tool MDS,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 145, 1528, 33, 42232, 16, 210, 4, 79, 179, 1, 681, 1223, 140, 2, 16, 41, 5, 51, 6, 1288, 2, 913, 356, 3, 738, 414, 467, 8, 38, 473, 1, 1223, 1392, 6, 132, 31, 286, 1193, 132, 62, 5, 35, 41, 2262, 1, 35, 402, 258, 366, 24, 5, 1288, 8, 790, 111, 1095, 3628, 917, 5, 1014, 1545, 295, 886, 315, 31, 1276, 2, 1340, 925, 5, 1223, 3174, 10, 468, 1288, 9, 428, 53, 818, 276, 286, 132, 31, 1193, 2, 1294, 8, 373, 10046, 258, 4, 3, 145, 4239, 1, 11270, 3412, 18, 3755, 50, 428, 53, 1, 36, 5, 1288, 8, 617, 581, 3256, 22315, 553, 424, 6363, 5, 1882, 12471, 2253, 2, 8, 266, 1, 2438, 3538, 667, 1, 62, 581, 2531, 20, 2567, 925, 5, 132, 62, 871, 2471, 3, 69, 10, 2100, 809, 3385, 224, 77, 3408, 1, 3084, 33, 42232, 1223, 137, 581, 1305, 914, 615, 2650, 264, 3, 2262, 1, 8, 9168, 258, 256, 74266, 74267, 4, 1725, 27, 1, 3755, 8, 5697, 22315, 2178, 431, 2438, 2, 38, 404, 5572, 1, 132, 62, 7313, 4855, 5264, 1112, 2, 1217, 28, 212, 61, 628, 77, 2044, 2116, 28, 481, 61, 628, 1855, 28, 13, 33, 499, 188, 39, 415, 10, 468, 9, 239, 162, 8, 166, 126, 22315, 10, 173, 18, 53, 50, 7313, 4855, 5264, 36, 2069, 6461, 404, 5, 243, 4091, 23740, 84, 77, 241, 1, 132, 62, 3, 69, 16, 694, 357, 3889, 154, 61, 3004, 5732, 2, 1217, 2, 16, 2785, 306, 2, 2100, 50, 67, 410, 3, 364, 45, 1949, 35, 2938, 622, 91, 1, 3084, 33, 42232, 1223, 6, 132, 62, 5, 9503, 2650, 74, 2, 8, 732, 1027, 3405, 1, 35, 3755, 9425, 258, 26, 473, 2527, 3, 1187, 1, 2650, 22, 8, 752, 2, 617, 1515, 9, 1223]",1927.0,30608448,Novel EZH2 patient secondary B-cell acute lymphocytic leukemia deletion 5q myelodysplastic syndrome treated lenalidomide case report,0,0.0
"Mutation, drift and selection in single-driver hematologic malignancy: Example of secondary myelodysplastic syndrome following treatment of inherited neutropenia.",PLoS computational biology,PLoS Comput. Biol.,2019-01-07,"Cancer development is driven by series of events involving mutations, which may become fixed in a tumor via genetic drift and selection. This process usually includes a limited number of driver (advantageous) mutations and a greater number of passenger (neutral or mildly deleterious) mutations. We focus on a real-world leukemia model evolving on the background of a germline mutation. Severe congenital neutropenia (SCN) evolves to secondary myelodysplastic syndrome (sMDS) and/or secondary acute myeloid leukemia (sAML) in 30-40%. The majority of SCN cases are due to a germline ELANE mutation. Acquired mutations in CSF3R occur in >70% sMDS/sAML associated with SCN. Hypotheses underlying our model are: an ELANE mutation causes SCN; CSF3R mutations occur spontaneously at a low rate; in fetal life, hematopoietic stem and progenitor cells expands quickly, resulting in a high probability of several tens to several hundreds of cells with CSF3R truncation mutations; therapeutic granulocyte colony-stimulating factor (G-CSF) administration early in life exerts a strong selective pressure, providing mutants with a growth advantage. Applying population genetics theory, we propose a novel two-phase model of disease development from SCN to sMDS. In Phase 1, hematopoietic tissues expand and produce tens to hundreds of stem cells with the CSF3R truncation mutation. Phase 2 occurs postnatally through adult stages with bone marrow production of granulocyte precursors and positive selection of mutants due to chronic G-CSF therapy to reverse the severe neutropenia. We predict the existence of the pool of cells with the mutated truncated receptor before G-CSF treatment begins. The model does not require increase in mutation rate under G-CSF treatment and agrees with age distribution of sMDS onset and clinical sequencing data.",Journal Article,379.0,0.0,development driven series events involving fixed genetic drift selection process usually includes limited number driver advantageous greater number passenger neutral mildly deleterious focus real-world leukemia model evolving background germline Severe congenital neutropenia SCN evolves secondary myelodysplastic syndrome sMDS and/or secondary acute myeloid leukemia sAML 30-40 majority SCN cases germline ELANE Acquired CSF3R occur 70 sMDS/sAML associated SCN Hypotheses underlying model ELANE causes SCN CSF3R occur spontaneously low rate fetal life hematopoietic stem progenitor expands quickly resulting high probability tens hundreds CSF3R truncation therapeutic granulocyte colony-stimulating factor G-CSF administration early life exerts strong selective pressure providing growth advantage Applying population genetics theory propose novel two-phase model disease development SCN sMDS Phase 1 hematopoietic tissues expand produce tens hundreds stem CSF3R truncation Phase 2 occurs postnatally adult stages bone marrow production granulocyte precursors positive selection chronic G-CSF therapy reverse severe neutropenia predict existence pool truncated receptor G-CSF treatment begins model require increase rate G-CSF treatment agrees age distribution sMDS onset clinical sequencing,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[12, 193, 16, 1621, 20, 988, 1, 281, 1267, 138, 92, 68, 1417, 1959, 4, 8, 30, 847, 336, 19901, 2, 881, 26, 1129, 2082, 1920, 8, 383, 207, 1, 2228, 10650, 138, 2, 8, 378, 207, 1, 16917, 6338, 15, 9443, 3586, 138, 21, 1222, 23, 8, 1589, 1956, 202, 3276, 23, 3, 2426, 1, 8, 1009, 258, 905, 6711, 778, 25341, 10413, 6, 568, 681, 24344, 2, 15, 568, 286, 533, 8991, 4, 201, 327, 3, 686, 1, 25341, 140, 32, 520, 6, 8, 1009, 51399, 258, 1294, 138, 4, 15024, 1271, 4, 431, 24344, 8991, 41, 5, 25341, 6243, 1181, 114, 202, 32, 35, 51399, 258, 1626, 25341, 15024, 138, 1271, 6459, 28, 8, 154, 116, 4, 6698, 358, 1007, 452, 2, 2520, 37, 9365, 7325, 1113, 4, 8, 64, 1320, 1, 392, 27097, 6, 392, 9035, 1, 37, 5, 15024, 11944, 138, 189, 2764, 1975, 2122, 161, 499, 1211, 634, 191, 4, 358, 5685, 8, 1082, 1094, 3738, 1736, 3423, 5, 8, 129, 1874, 4798, 266, 2894, 6386, 21, 2548, 8, 229, 100, 124, 202, 1, 34, 193, 29, 25341, 6, 24344, 4, 124, 14, 1007, 742, 4082, 2, 2410, 27097, 6, 9035, 1, 452, 37, 5, 3, 15024, 11944, 258, 124, 18, 1780, 38075, 298, 780, 1153, 5, 581, 1529, 1, 2764, 4881, 2, 109, 881, 1, 3423, 520, 6, 442, 499, 1211, 36, 6, 1772, 3, 905, 778, 21, 678, 3, 5335, 1, 3, 6545, 1, 37, 5, 3, 1185, 6502, 153, 348, 499, 1211, 24, 12811, 3, 202, 1097, 44, 1353, 344, 4, 258, 116, 669, 499, 1211, 24, 2, 29197, 5, 89, 1395, 1, 24344, 1707, 2, 38, 615, 74]",1758.0,30615612,drift selection single-driver hematologic malignancy Example secondary myelodysplastic syndrome following treatment inherited neutropenia,13,0.02268760907504363
The role of TGF in hematopoiesis and myeloid disorders.,Leukemia,Leukemia,2019-02-28,"The role of transforming growth factor- (TGF) signaling in embryological development and tissue homeostasis has been thoroughly characterized. Its canonical downstream cascade is well known, even though its true complexity and other non-canonical pathways are still being explored. TGF signaling has been described as an important pathway involved in carcinogenesis and cancer progression. In the hematopoietic compartment, the TGF pathway is an important regulator of proliferation and differentiation of different cell types and has been implicated in the pathogenesis of a diverse variety of bone marrow disorders. Due to its importance in hematological diseases, novel inhibitors of this pathway are being developed against a number of hematopoietic disorders, including myelodysplastic syndromes (MDS). In this review, we provide an overview of the TGF pathway, focusing on its role in hematopoiesis and impact on myeloid disorders. We will discuss therapeutic interventions with promising results against MDS.",Journal Article,327.0,1.0,role transforming growth factor- TGF signaling embryological development tissue homeostasis thoroughly characterized canonical downstream cascade known true complexity non-canonical pathways explored TGF signaling described important pathway involved carcinogenesis progression hematopoietic compartment TGF pathway important regulator proliferation differentiation different types implicated pathogenesis diverse variety bone marrow disorders importance hematological diseases novel inhibitors pathway developed number hematopoietic disorders including myelodysplastic syndromes MDS review provide overview TGF pathway focusing role hematopoiesis impact myeloid disorders discuss therapeutic interventions promising MDS,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[3, 200, 1, 3621, 129, 161, 1458, 5960, 314, 4, 31912, 193, 2, 246, 4975, 71, 85, 11576, 765, 211, 4471, 1489, 4678, 16, 149, 440, 871, 2471, 211, 2501, 3082, 2, 127, 220, 4471, 460, 32, 1234, 486, 1443, 5960, 314, 71, 85, 1027, 22, 35, 305, 308, 646, 4, 1719, 2, 12, 91, 4, 3, 1007, 3616, 3, 5960, 308, 16, 35, 305, 2452, 1, 457, 2, 910, 1, 338, 31, 630, 2, 71, 85, 1771, 4, 3, 1384, 1, 8, 1867, 1362, 1, 581, 1997, 520, 6, 211, 1187, 4, 2890, 1342, 229, 222, 1, 26, 308, 32, 486, 276, 480, 8, 207, 1, 1007, 1997, 141, 2040, 1223, 4, 26, 206, 21, 377, 35, 2901, 1, 3, 5960, 308, 3312, 23, 211, 200, 4, 5114, 2, 345, 23, 533, 1997, 21, 303, 1139, 189, 1151, 5, 721, 99, 480, 1223]",982.0,30816330,role TGF hematopoiesis myeloid disorders,0,0.0
"Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies.",Blood,Blood,2019-06-05,"This study aimed to evaluate whether gait speed and grip strength predicted clinical outcomes among older adults with blood cancers. We prospectively recruited 448 patients aged 75 years and older presenting for initial consultation at the myelodysplastic syndrome/leukemia, myeloma, or lymphoma clinic of a large tertiary hospital, who agreed to assessment of gait and grip. A subset of 314 patients followed for 6 months at local institutions was evaluated for unplanned hospital or emergency department (ED) use. We used Cox proportional hazard models calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for survival, and logistic regression to calculate odds ratios (ORs) for hospital or ED use. Mean age was 79.7 ( 4.0 standard deviation) years. After adjustment for age, sex, Charlson comorbidity index, cognition, treatment intensity, and cancer aggressiveness/type, every 0.1-m/s decrease in gait speed was associated with higher mortality (HR, 1.20; 95% CI, 1.12-1.29), odds of unplanned hospitalizations (OR, 1.33; 95% CI, 1.16-1.51), and ED visits (OR, 1.34; 95% CI, 1.17-1.53). Associations held among patients with good Eastern Cooperative Oncology Group performance status (0 or 1). Every 5-kg decrease in grip strength was associated with worse survival (adjusted HR, 1.24; 95% CI, 1.07-1.43) but not hospital or ED use. A model with gait speed and all covariates had comparable predictive power to comprehensive validated frailty indexes (phenotype and cumulative deficit) and all covariates. In summary, gait speed is an easily obtained ""vital sign"" that accurately identifies frailty and predicts outcomes independent of performance status among older patients with blood cancers.",Journal Article,230.0,6.0,aimed evaluate gait speed grip strength predicted clinical outcomes older adults blood prospectively recruited 448 patients aged 75 years older presenting initial consultation myelodysplastic syndrome/leukemia myeloma lymphoma clinic large tertiary hospital agreed assessment gait grip subset 314 patients followed 6 months local institutions evaluated unplanned hospital emergency department ED use Cox proportional hazard models calculated hazard ratios HRs 95 confidence intervals CIs survival logistic regression calculate odds ratios ORs hospital ED use Mean age 79.7  4.0 standard deviation years adjustment age sex Charlson comorbidity index cognition treatment intensity aggressiveness/type 0.1-m/s decrease gait speed associated higher mortality HR 1.20 95 CI 1.12-1.29 odds unplanned hospitalizations 1.33 95 CI 1.16-1.51 ED visits 1.34 95 CI 1.17-1.53 Associations held patients good Eastern Cooperative Oncology Group performance status 0 1 5-kg decrease grip strength associated worse survival adjusted HR 1.24 95 CI 1.07-1.43 hospital ED use model gait speed covariates comparable predictive power comprehensive validated frailty indexes phenotype cumulative deficit covariates summary gait speed easily obtained `` vital sign '' accurately identifies frailty predicts outcomes independent performance status older patients blood,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[26, 45, 1295, 6, 376, 317, 11841, 5051, 2, 16562, 3671, 783, 38, 123, 107, 434, 857, 5, 315, 163, 21, 1143, 2619, 15302, 7, 1032, 481, 60, 2, 434, 1656, 9, 388, 2981, 28, 3, 681, 2647, 15, 1188, 1, 8, 375, 2557, 702, 54, 4681, 6, 455, 1, 11841, 2, 16562, 8, 697, 1, 9391, 7, 370, 9, 6258, 53, 28, 293, 1764, 10, 194, 9, 5851, 702, 15, 4605, 4271, 3880, 119, 21, 95, 418, 831, 360, 274, 981, 360, 1137, 2733, 2, 48, 307, 1582, 1927, 9, 25, 2, 812, 320, 6, 3232, 610, 1137, 3694, 9, 702, 15, 3880, 119, 313, 89, 10, 842, 67, 810, 39, 13, 260, 3348, 60, 50, 1852, 9, 89, 1035, 4670, 1879, 558, 8130, 24, 837, 2, 12, 3908, 267, 454, 13, 14, 188, 695, 775, 4, 11841, 5051, 10, 41, 5, 142, 282, 168, 14, 179, 48, 58, 14, 133, 14, 462, 610, 1, 5851, 4888, 15, 14, 466, 48, 58, 14, 245, 14, 725, 2, 3880, 2690, 15, 14, 562, 48, 58, 14, 269, 14, 699, 685, 4033, 107, 7, 5, 1178, 2118, 1690, 413, 87, 528, 156, 13, 15, 14, 454, 33, 503, 775, 4, 16562, 3671, 10, 41, 5, 639, 25, 586, 168, 14, 259, 48, 58, 14, 1615, 14, 601, 84, 44, 702, 15, 3880, 119, 8, 202, 5, 11841, 5051, 2, 62, 2489, 42, 1279, 464, 2349, 6, 949, 938, 5289, 11480, 1005, 2, 967, 6819, 2, 62, 2489, 4, 1962, 11841, 5051, 16, 35, 4697, 683, 3511, 7636, 522, 17, 2141, 2953, 5289, 2, 2623, 123, 306, 1, 528, 156, 107, 434, 7, 5, 315, 163]",1623.0,31167800,Gait speed grip strength clinical outcomes older patients hematologic malignancies,4,0.006980802792321117
"Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study.",The Lancet. Haematology,Lancet Haematol,2019-08-07,"Outcomes for younger patients with acute myeloid leukaemia have moderately improved over the past two decades owing to better supportive care and recent introduction of novel targeted agents. Blocking PD-1 and its ligand's pathways enhances antileukaemia responses by enabling T cells in murine models. We aimed to assess the addition of nivolumab to frontline therapy with idarubicin and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome. This single-arm, phase 2 part of the phase 1-2 study of nivolumab in combination with idarubicin and cytarabine was done at the University of Texas MD Anderson Cancer Center (Houston, TX, USA). Eligible patients were aged 18-60 years (or >60 years if suitable for intensive chemotherapy), and had newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome, and an Eastern Cooperative Oncology Group performance status of 0-2. Induction included cytarabine 15 g/m<sup>2</sup> by 24-h continuous infusion daily on days 1-4 (3 days in patients >60 years) and idarubicin 12 mg/m<sup>2</sup> daily on days 1-3. Nivolumab 3 mg/kg was started on day 24 (range 22-26) and continued every 2 weeks for up to a year in responders. Responders received either up to five consolidation cycles of attenuated doses of idarubicin and cytarabine, or allogeneic stem cell transplantation if eligible. The primary endpoint was event-free survival. Efficacy and safety analyses were done in all patients who received at least one dose of study treatment. Secondary endpoints were relapse-free survival and overall survival. This ongoing trial is registered with ClinicalTrials.gov, number NCT02464657. Between Aug 7, 2015, and June 2, 2018, 44 patients were enrolled of whom 22 (50%) had adverse genetic risk by European Leukaemia Network classification. All patients were evaluable for safety and efficacy. At a median follow-up of 1725 months (IQR 050-3040), median event-free survival was not reached (95% CI 793-NR). Median relapse-free survival of responders was 1854 months (95% CI 820-2322). The median overall survival was 1854 months (95% CI 1081-2881). Six patients had seven grade 3-4 immune-related adverse events with two cases of rash, two of colitis, and one each of transaminitis, pancreatitis, and cholecystitis. 19 (43%) of 44 patients achieved a response and proceeded to allogeneic stem cell transplantation, with grade 3-4 graft-versus-host disease observed in five (26%). No treatment related deaths were attributed to nivolumab. Addition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome. Post-transplant severe graft-versus-host disease could be improved, and earlier initiation of checkpoint inhibitor therapy is warranted in future studies. The MD Anderson Cancer Center Support Grant CA016672, and the MD Anderson Cancer Center Leukaemia SPORE CA100632 from the National Cancer Institute, Bristol Myers Squibb.","Clinical Trial, Phase II",167.0,3.0,Outcomes younger patients acute myeloid leukaemia moderately improved past decades owing better supportive care recent introduction novel targeted agents Blocking PD-1 ligand 's pathways enhances antileukaemia responses enabling murine models aimed assess addition nivolumab frontline therapy idarubicin cytarabine patients newly diagnosed acute myeloid leukaemia high-risk myelodysplastic syndrome single-arm phase 2 phase 1-2 nivolumab combination idarubicin cytarabine University Texas MD Anderson Center Houston TX USA Eligible patients aged 18-60 years 60 years suitable intensive chemotherapy newly diagnosed acute myeloid leukaemia high-risk myelodysplastic syndrome Eastern Cooperative Oncology Group performance status 0-2 Induction included cytarabine 15 g/m sup 2 /sup 24-h continuous infusion daily days 1-4 3 days patients 60 years idarubicin 12 mg/m sup 2 /sup daily days 1-3 Nivolumab 3 mg/kg started day 24 range 22-26 continued 2 weeks year responders Responders received consolidation cycles attenuated doses idarubicin cytarabine allogeneic stem transplantation eligible primary endpoint event-free survival Efficacy safety patients received dose treatment Secondary endpoints relapse-free survival overall survival ongoing trial registered ClinicalTrials.gov number NCT02464657 Aug 7 2015 June 2 2018 44 patients enrolled 22 50 adverse genetic risk European Leukaemia Network classification patients evaluable safety efficacy median follow-up 1725 months IQR 050-3040 median event-free survival reached 95 CI 793-NR Median relapse-free survival responders 1854 months 95 CI 820-2322 median overall survival 1854 months 95 CI 1081-2881 patients seven grade 3-4 immune-related adverse events cases rash colitis transaminitis pancreatitis cholecystitis 19 43 44 patients achieved response proceeded allogeneic stem transplantation grade 3-4 graft-versus-host disease observed 26 treatment related deaths attributed nivolumab Addition nivolumab induction chemotherapy idarubicin cytarabine feasible patients newly diagnosed acute myeloid leukaemia high-risk myelodysplastic syndrome Post-transplant severe graft-versus-host disease improved earlier initiation checkpoint inhibitor therapy warranted future studies MD Anderson Center Support Grant CA016672 MD Anderson Center Leukaemia SPORE CA100632 National Institute Bristol Myers Squibb,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,"[123, 9, 773, 7, 5, 286, 533, 2001, 47, 3508, 231, 252, 3, 1219, 100, 1968, 3421, 6, 380, 1877, 165, 2, 435, 2456, 1, 229, 238, 183, 2521, 333, 14, 2, 211, 1232, 292, 460, 2519, 41975, 253, 20, 5257, 102, 37, 4, 1471, 274, 21, 1295, 6, 423, 3, 352, 1, 1636, 6, 3171, 36, 5, 5684, 2, 1855, 4, 7, 5, 732, 265, 286, 533, 2001, 15, 64, 43, 681, 26, 226, 475, 124, 18, 760, 1, 3, 124, 14, 18, 45, 1, 1636, 4, 150, 5, 5684, 2, 1855, 10, 1822, 28, 3, 1652, 1, 2738, 2244, 1929, 12, 574, 6212, 6614, 2706, 625, 7, 11, 1032, 203, 335, 60, 15, 335, 60, 492, 2884, 9, 1686, 56, 2, 42, 732, 265, 286, 533, 2001, 15, 64, 43, 681, 2, 35, 2118, 1690, 413, 87, 528, 156, 1, 13, 18, 504, 159, 1855, 18648, 499, 188, 172, 18, 172, 20, 259, 555, 1314, 904, 391, 23, 162, 14, 39, 27, 162, 4, 7, 335, 60, 2, 5684, 133, 81, 188, 172, 18, 172, 391, 23, 162, 14, 27, 1636, 27, 81, 503, 10, 3461, 23, 218, 259, 184, 350, 432, 2, 1351, 454, 18, 244, 9, 126, 6, 8, 111, 4, 1983, 1983, 103, 361, 126, 6, 365, 2173, 410, 1, 2656, 415, 1, 5684, 2, 1855, 15, 1063, 452, 31, 497, 492, 625, 3, 86, 1138, 10, 774, 115, 25, 209, 2, 367, 318, 11, 1822, 4, 62, 7, 54, 103, 28, 506, 104, 61, 1, 45, 24, 568, 1387, 11, 429, 115, 25, 2, 63, 25, 26, 942, 160, 16, 1653, 5, 1252, 1239, 207, 74942, 59, 10497, 67, 1483, 2, 1924, 18, 2982, 584, 7, 11, 346, 1, 953, 350, 212, 42, 290, 336, 43, 20, 1865, 2001, 1801, 947, 62, 7, 11, 859, 9, 367, 2, 209, 28, 8, 52, 166, 126, 1, 74943, 53, 2245, 25606, 74944, 52, 774, 115, 25, 10, 44, 1300, 48, 58, 74945, 5677, 52, 429, 115, 25, 1, 1983, 10, 51560, 53, 48, 58, 74946, 74947, 3, 52, 63, 25, 10, 51560, 53, 48, 58, 74948, 74949, 437, 7, 42, 648, 88, 27, 39, 250, 139, 290, 281, 5, 100, 140, 1, 1641, 100, 1, 4132, 2, 104, 296, 1, 8181, 4535, 2, 18305, 326, 601, 1, 584, 7, 513, 8, 51, 2, 6406, 6, 1063, 452, 31, 497, 5, 88, 27, 39, 1599, 185, 1204, 34, 164, 4, 365, 432, 77, 24, 139, 1043, 11, 3073, 6, 1636, 352, 1, 1636, 6, 504, 56, 5, 5684, 2, 1855, 16, 1313, 4, 7, 5, 732, 265, 286, 533, 2001, 15, 64, 43, 681, 539, 941, 905, 1599, 185, 1204, 34, 359, 40, 231, 2, 1677, 1118, 1, 986, 230, 36, 16, 1197, 4, 508, 94, 3, 2244, 1929, 12, 574, 538, 11041, 41660, 2, 3, 2244, 1929, 12, 574, 2001, 15948, 74950, 29, 3, 657, 12, 1377, 8116, 8117, 8118]",2947.0,31400961,Idarubicin cytarabine nivolumab patients newly diagnosed acute myeloid leukaemia high-risk myelodysplastic syndrome single-arm phase 2,0,0.0
